<SEC-DOCUMENT>0001104659-23-126113.txt : 20231215
<SEC-HEADER>0001104659-23-126113.hdr.sgml : 20231215
<ACCEPTANCE-DATETIME>20231214214022
ACCESSION NUMBER:		0001104659-23-126113
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		206
FILED AS OF DATE:		20231215
DATE AS OF CHANGE:		20231214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TriSalus Life Sciences, Inc.
		CENTRAL INDEX KEY:			0001826667
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				853009869
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274292
		FILM NUMBER:		231488640

	BUSINESS ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031
		BUSINESS PHONE:		415 336 8917

	MAIL ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedTech Acquisition Corp
		DATE OF NAME CHANGE:	20200930
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>tlsi-20230630xs1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:tlsi="http://trisaluslifesci.com/20230630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_hEWHjdpaqEmDJ8rJJtuMSg">http://fasb.org/srt/2023#OfficerMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_0uAmhLx37kmMeu6JYwSpdQ">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_wC5tKaPCI02xKBFgae0GHg">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_srz1yOgJk0yT6Oi9nTltqw">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_IHOqsN5VBE2fYTqDamTD_g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_4Rb3HZ7YJUO-talCZjeiIQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_OJYM0hi69UmtMbvo15SFqA">6250000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_b6ImW9IeQUasGJKmmhoIyA">6250000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_pk70F63lqki1D9grphKNIQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_5SPZGeCxe0S-tXPBv0ErJA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_E2BSRmatsEOoepPdjWNoDQ">6250000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_-TYIfX8tYUq6QGwvbRq2KQ">6250000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_PGeoap2kbES85OLJxH3XvQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Wpt77xBz9kWEzY7OiYMTMg">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="Hidden_jz_e7WblyE-1Bl5cl61WeA">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_GmdJagC4QEqR94i1L7BnQg">5331943</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_fMqDHJuZfkKsjkdzOr-5PA">5331943</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_PdbO3qeysEm9BeCQ1HyZjA">5331943</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_lZ1wbBR_AEqRNTeQ2eNi_A">5331943</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_d9HmYbhmUEql5W0hyfnOjw">23307464</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_yVozK5movEyUEipRcm_skg">23307464</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_NNRfWnBCw0eJNjdjreMURQ">23307464</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_84VBOMPLm0-dL0j-3ECVwQ">23307464</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_udhlawH-MUKOYrDpM2aydg">24792020</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_dsSoj5LstEuFvQsmenN0xw">24792020</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_3cOPFsYw70aXK0x_YY5ibg">24792020</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_ePMPpDq6v0CK7s_8g3honA">24792020</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_bLf7M8D1zE2rC3pxfJMSLA">5169690</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_voFa5pe7DUypjGRp8OQjew">5169690</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_9V6TE6x1wEauvuI-rrDxyQ">5169690</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_PmLSRxbUwE2QryRQulmbxg">5169690</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_4sUcCQK9wEyjFzRHLObDBw">29545455</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_7KYGLEay5EibqsGMIE89vA">29545455</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_MZUlS2GiW0G7nLTHy5Zcxw">32391000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_M6HJZyLV9U26_Ok0b0Uy2Q">32391000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_XJ_7vamH80anLN9UOIzRgA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_RC5nkNkWiUaAYNYHOZbyPw">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntityCentralIndexKey" id="Tc_ICBlboi8H0Ov3ke1Ktbj1w_2_1">0001826667</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:AmendmentFlag" id="Tc__ZoB-TK--UGkBJrMb2YdXw_3_1">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:AmendmentDescription" id="Hidden_Pz3-aZKVPEagACyzY8ZLrg">AMENDMENT NO. 3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:DocumentType" id="Hidden_xWgaFrhPg0G0LJX8EzlMuw">S-1/A</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_6NASHxsNhUWqUIlF6AmGRw">http://fasb.org/srt/2023#OfficerMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_iNvGd1yKm0-3yMIN_CTOsw">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" name="us-gaap:LiabilitiesCurrent" id="Hidden_mJe2zsZH4kOfjy-NS1oSag">3842998</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" xs:nil="true" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" name="us-gaap:CommonStockValue" id="Hidden__l_n-zwG9EeRbMmLFtmXMw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" xs:nil="true" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" name="us-gaap:CommonStockValue" id="Hidden_2f0FE7DwkUujpx4HM72l_w"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:RedemptionPeriodUponClosure" id="Hidden_8o7rIpLqL0adL1dGev6vwQ">P10D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="4" name="tlsi:NumberOfWarrantsIssuedPerUnit" id="Hidden_MkCiTlqYpkyh8SfuJUz1DA">0.0033</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_vkr2IKtEfkK2saNonouWWA" decimals="4" name="tlsi:BusinessCombinationsOfWarrantToPurchase" id="Hidden_tErA0HV8TUSeW-q1gHsPXg">0.0033</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_gXPw_HPigEaLTrob0MTpMA">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_2rj7F36mjUqkt3ooiJGgKw">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:CommonStockValue" id="Hidden__lATSp_YGkqaGlHAuRVnnA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Ik-aY2A_jE63wIuR7UyzxQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_E4ll_gLBaEKReg0u9L57fA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_KK59tWCaEUuJB54qaw6hYw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_6PBZ3tLP70iHvRVOg6SEvw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_mStXdH1f4ki5O4OxCGWhIA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_9ja8HteS90a0p7WpZcVgWw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Ev_u3OXaCUWJcSjZ4HGqRg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_NzkeQmyzwEqzGAZViRfbSw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_rORiQd8xoUiQi4Bgch3EXg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_P_r4of4hd0KZsZrm_28PQQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_O8EyWJtM2kqmmJRUvl-qlA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_bjBXccsdxkSy45ztWFjM-Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_wkeHRludRkq2fuu18Uz84Q">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww" name="tlsi:CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" id="Hidden_3ei8mRKxXUqQjdtfqOZDNA">P3D</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_COg4MMgPikKQtsRGe2ldbw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_TGerLk0gnEGuJJZj4XcYiQ">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_TpLPz4TCh0OaDlbyebwvQw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_n3iyYUo2ik-Sz0AnGN46Zg">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_10_8_2023_-N_ZHqE3nU2aqMlyR4MjcQ" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Hidden_Lb4zgAF5e0CJPYvsKdE9Yw">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Hidden_V-mQW-qQIUa1vQtlrdyyEg">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Hidden_2n4YMje6bU2yQX9mVj9haw">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Hidden_tM-2Y2RyQUOzCJbuqMIVTw">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Hidden_i6irmobClEimgYt4sNAgmg">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw" name="tlsi:PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" id="Hidden_5hLzbZ6A6U-WazkWaQSF7A">P10D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" id="Hidden_MGlu3JgwP0qQ1n5yi83_7Q">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" id="Hidden_6Tz5Z9c8bUyOeKGuhhUwgw">142000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:LiabilitiesCurrent" id="Hidden_gI9YjpVWsES8mrCJx_zz-A">32357000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:Liabilities" id="Hidden_G_sKOz3pS0e7k4l56q5hag">34319000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_aaQdiWrtqEOASK7EYWjkdA">347926</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_xTDCpcpvCUOG0LVU4dkrTA">264977</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:AdditionalPaidInCapital" id="Hidden_F9yMPOv05EiBNsMwQ9IylA">10028000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" sign="-" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_M1dWk5e9m0KG5yLnLGB_PA">176330000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_X5CnAy8BbkqdT58gfX2FcQ">6738000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" sign="-" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" name="us-gaap:StockholdersEquity" id="Hidden_NaQHkAWSzk2neGw_XEl-TQ">129604000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" id="Hidden_ZCuk_ZdpA0SUrfc6xIvFJg">113796000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="Hidden_b16GYIIPRE-ojj7RlH_rdQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA" decimals="2" name="us-gaap:PreferredStockConvertibleConversionPrice" id="Hidden_PxxmfclgUkWgfznbDZcazQ">0.35</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg" decimals="2" name="us-gaap:PreferredStockConvertibleConversionPrice" id="Hidden_qYvtfI9-2EK0FA_smo_g4g">0.05</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember__BRrOWeWS02G7DSzlPGD0Q" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" id="Hidden_RXte8gIJ0UWW5BmmCYcnHg">52878539</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_5m-lXEUUKkGjcNnQvX8_4Q" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_huQWM8PukUiNaHCwSJKzHA">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_9Uda4Ka9V0W5_fLKlUaijw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_RgKa1fvyFki-3G_4NLjGcA">P4Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wfMDLkDNqEO3xSkwvmaxgA" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Hidden_0XVq7K5E4EaVAxzq8BPz2g">7200000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-JQHw6enTUqU0PtNBY6i1A" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Hidden_PCQ3iCsu6kiybYaKiTQPcQ">2237414</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_IhjA9SxPWke_WdT-YL8OYQ">P8Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" id="Hidden_QpMaoZ2rLEe3kuE2nEwMHQ">0.081</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_2BqQnWUrKUS-sNcB_hxrKQ" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_b4QB_34hYkSQy8m2zvvSVA">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_rHR-FeR1skyizmwP_cj_wA" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_mW0ye0ape0K0u7SnjgQyTg">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kfYB5YdzlU25J8QBvIS-0A" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_D1tTYpAKD0mwadhIRhVubw">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_d8SWm3qiNEy8rA1CdxgJzw" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_Wp2d5AfagUeiDJyLPZ20iQ">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_pkty5j8Sy0Go5dYfRJilQQ" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_F187q8J5AkCMoKigjnNSmw">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_4OU6RNLQI0m02PWitPh6_A" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_s43EmyAlY0-5J-sKfRJXGg">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e_Hw10IjjUGLlhJfGUN8KA" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_iGujevr0gUmbUx_6BKltrg">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_kucXttDDKkm2baEp3zUfTw" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_IoB8wHCgok2nthhVpcAt4w">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w_J4gh8nE0iBqb1LS2a64w" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" id="Hidden_7EvRLYEDcEumV76exoXIWA">0.001</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tlsi-20230630.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_25lDX06in0-qNkGhQyvfQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Rp9zrLRlm0CYZN74Ck2XNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_m13ANPolnkC_TrigPHT8kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_0Joxy8nL_k6rabaYjK9iOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_nHo1vJsJrkKTnWl_TCasMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_G8V4djaCEkCway9XsOM4DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Xpnlw4k0NkuO1sNJfiAs9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_MB7pT5iLf0uF_V9jm7PXzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputInceptionDiscountRateMember_mzUQ236JO0anFu5jzI22tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_Wce1nzVCUkqX390MzkZu9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Qppm2hRKWU60ummLMBfT1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_iVlKykJbaEi1jw6dwN8Bmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WdW_HNNUdE21vIAEvcd5UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_a8ra3C8AWUOIDlIdA4ccMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_Rf1rpKHlWkavH2VB0BmDhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_n9CPBSe_t0CIf2MEce1Hbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_X-8bVslRMUid_3Y3ZJ4oPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_cJo1v1yvJ0KPv470OFqLQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_YRX9eNe2yk2VIn3MFun3YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_lounZVZfw0O8AKj7iHFE-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_hN-8AGcFuEuZnr2HwF1cJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_v8JMAlK36k2t47JlYo0chg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w_J4gh8nE0iBqb1LS2a64w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_kucXttDDKkm2baEp3zUfTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e_Hw10IjjUGLlhJfGUN8KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_4OU6RNLQI0m02PWitPh6_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_pkty5j8Sy0Go5dYfRJilQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_d8SWm3qiNEy8rA1CdxgJzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kfYB5YdzlU25J8QBvIS-0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_rHR-FeR1skyizmwP_cj_wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_2BqQnWUrKUS-sNcB_hxrKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dVErUypF_kmGT88HG0br_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mxqu6HErZkefO1cAxk8GhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_iTZWPgkZoEq7CXYI1m6Ohg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_SwY35kQgfk2dbaaXKgOEjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_yR9f-JPIGUujVs37FEydrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_az5NgdPmYEyG5PMwrX8MQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_n2Hy7mytPUCwfCaVDdp1yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0AcI-Ohrv0KOD6jjNcyFJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_p1P46KnXQEWJ8sMTS1L0LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_j-5jcvWtPkWU5cOve1Ihkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UBHriL6i-U6Bz3QKMBjg8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_lAPd1qaSFUOkNSYqELJ4Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_GkzygEWdwkGIA2Hdptj-cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AtUfw1J3o0mUu0fWLK3F2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_SpKOv8seVEehXwRiUfpyGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Ud_kLyd8f0OBg8UKavOv8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_FovQYveUg0eH1LzMQqa8QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_L9vZuhgzoEacaBLEGmOqKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_B4SIjbwX80epv50y8th_fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_j2yRaHhWpkeOdK0kZMluwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bssbHLSzMUK2YenLYRNChw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_w6jktUReSU6j4r6UpAQFPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_cea7kamFTU22C8ALOM0GOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Zc1cKHOFuE287fqlH5Vrlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_gjy8I8__kk2j4tbbvWuraA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_TPmSEZHn3kuue57QJjzxuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_no3I2F75LU6zm401jb81jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_Odw8LxLv6U6EdXprDOfRGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_u1kddxNyJUmK6bKY3LELxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Z9YkJw2n8E-yk3Qt_1NPmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_AQay36hQlke0WUBpyZbKSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_VQjBztCgREimLMoQNXlNZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_H2sJkceQxk2-u0Rxe759jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_3a3-tw6PskK-JRJJsHXixQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kPXiLC6i0kmzr0XFHhfPLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_WsB6XkUK_EudysZ944qZNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_94WSWWTYZ0-oiPrmTAHAog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9ph7-9habkWVkrJfwFcs6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_V6c578Z9dUakm48y3fS_Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_tlsi_ConvertibleNotesAndWarrantsMember_w8EJUYCkGEaDC6o1zmBY8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tlsi:ConvertibleNotesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mOezHh-BNkaD4qPijc7hSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-MRJe6VGPUipa0NC3BILAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4B_cIF7e5UODEBv68U8L3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Adumul5f_Emd_SmbobiJGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-11</xbrli:startDate><xbrli:endDate>2020-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wLjUOHJXF0auOVXVpPAl0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YYKvXH4qESsBarliMaTVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PI-ObqYFzUCIPTC8H9DIcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J5RUj6hZ_kW5XH1lPZrp9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_b5EJjukOmUCZShWroteuUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gAe7cbk-Ik2xnUHTe-lZNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VwGAxYqj30auZ7FoL0bSaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_daSSC4kDIUWJG6OwMuYQ7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NSmQJB__l0yYnVCxzz6oDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gBMde9-vjEq-B-QzZmmW9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gexd2UdIVEm-wcSYwLDc0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZZNP8UD0GUO6uzjHEM33Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_Bf2tptIPOU6oGPVXVUCTjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_c6idVF-ySEuT1HSIivSjLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iOL4HjdfO0Km7gzdEnTioA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_OYgjx4XmSkGPAAF-Re-xWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jSD5X1FfwUGwejMu7znIQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vK2xj6_BxUyXDij_MHIdJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jrQIVcWI-069v0ykyuASTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_polfWIhfYU6ib1Sd0a3R4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0kAqZczoU06tzJG4_2vBug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_GRTEC4z9hku2SFFVuuuxUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_aQAt3IxfvU6l-oEcuIHn0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tc_V7gDSeUmpSxYMDtGWdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_8YJDeE11cE2EQ4ztbjcPYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.09To0.46Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.005Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.004Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.001Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember__BRrOWeWS02G7DSzlPGD0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wfMDLkDNqEO3xSkwvmaxgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OCE06-VX20WwiST2nFqLhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-JQHw6enTUqU0PtNBY6i1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_xHLJVJ8VWkiIevSmCiWZ6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_8_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_eJO2ISwMrkCXvzy18ph9pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_FJuc69Mu_0KlSo6eQPUexg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_mmQ5QRZtFUmMijBSylDvfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_20_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_C40yv7V3Uk-CTwQZSf-3fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_23_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_SEb9zumk50CCxQ_gl3sqTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_2_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_hYo6l3T-EkW_DjtHSivOsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_-vVRuuYOS0yFk8mPXLMGtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Ewnc-WVz9ku_b5ftkI7wMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_EbEeXi4j7EGJVYkS9xiwOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_5m-lXEUUKkGjcNnQvX8_4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_9Uda4Ka9V0W5_fLKlUaijw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vVJ6K-dKOUaqNkzDlxnlNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_y-7dsjtGUkKm-ryLp0va2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FcaQ3gGcXUGxDiS7u2MNxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_8Jq5kxQISkum-Rv6Ika4FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_cg1NyxPfCkWCdJlnSrnvrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TJoHaLkdN0KmClA53sXJgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gIaBMU-_LU6xAQZ8ZjYntA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_gSf4GXYVD0WuBgBuDWBn0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">tlsi:AccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_ffngkVT0QkSB0YxjNIwPKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Mnxv0wTYjEKdigU5lNSyow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Bd5mwUEb0keN4-RoxS7_YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">tlsi:AccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_R6XCzzcbnUOZXAK4sUOmgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Ss29-0arFEmgdC-qVRGyZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_COg4MMgPikKQtsRGe2ldbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_TpLPz4TCh0OaDlbyebwvQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Yy4qomYWEumToz2Q3IF5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_grIe4j2NjUW8eovYdmDsAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ANvX6KP4G0CXL1ffGVduvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_Yzsv-OD0SkGrA-t5QrzSQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ekxf6NMJqU2o-owseUO9jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_8jVm0JgFSkq10jUH1ZLKNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4rbUCoNCLkiKBrrFNhgp2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dnZOErz2JUevW3yh4sbChw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_5abH1QNeh0GMJn5kZVJQ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_GWy7uUXZB0aOm-obxy2m_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_NkH9eTFLRkK7c-mjvyXwSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_0iOOdQCvqky-8LHpNIwfpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_e-IRiyeUokWhELXaV-4wUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_1_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_LqmQyedzNEqB45yzduiYgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:PaycheckProtectionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_V-j5MOfUwUGyMV160Ndygg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_PDIZOYv6rka-K3_56EQVNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_6hORdNW_yE623vRVLJelFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_10_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f8UN7L2qYEiwdyhrpna6mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_JxTqOZ5zzEWxBqVPHktsLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_9_30_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_2DKAccvY4ESMxGwfCcxgEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_9_2023_To_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_EQp5eTc6Nk61dCNahJBvFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_jVhbJpAu0kG_D4Un6eb0-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_rmbLcmOtAU-0t0vs9Lj3pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dQMI2sHi4EGNCkXWwNvsLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3grY9SX1cEWH0kR90lBaDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_tfAYqXS-rkCNMjlKTM0Vmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-z57Xm8kCEOcnn9iDm5FJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NYFdJrTKuU2AdqrUK_6Juw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kHWGZ6RfI0-CW2KwDqzmJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUa9pt6UYU2qKZU1q7KGtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BHFAAUN4h0mbBW1Dpe_8vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wivqVnmy-EKDR9DGDZZYDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_1lqC9l63wEiuJzSe6Hi-cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2021_To_3_11_2021__-g4Qp5Pyka4gA7LbeyrTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-11</xbrli:startDate><xbrli:endDate>2021-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_srt_StatementScenarioAxis_tlsi_SecondInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XU3a0ehnaEO_Yn_QEfUcqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:SecondInstallmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2021_To_11_18_2021_srt_StatementScenarioAxis_tlsi_FirstInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Lr-_cbK0CE6ccIYutbIUoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:FirstInstallmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-18</xbrli:startDate><xbrli:endDate>2021-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2021_To_11_15_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NTqWL_rATUeGsMWY1n5tKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_8_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_I5SxmOgITEqkvbLNanEY2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:PromissoryNote2022ThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aZgwMCP6sEuHAa1-q5dwCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8QPxAWLYn0eSa29pAZk5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:PromissoryNote2022ThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_LongtermDebtTypeAxis_tlsi_ExtensionNoteMember_tiwUkSJfkE-HqTQAgDXx9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tlsi:ExtensionNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_jb_q390JZkiH38PyUwE9zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_rS227lpA-0ato7P2m7Pn8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_wbUeBXlixU2vDzFtryoUTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_J6vJujbvTU-jEUmIjkq0yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_OKx8PR3Il0avdary9MaUKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_UfT8ljsnjEiwXR-Eomw_NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_4mN-bA9Uz0yu-SCx5mjf4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_UO7Dm79BGEGf58YUPTUeig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_om9EAvh6fk-yKmSCpi6WYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_nogwz9gxqU-ku2Q36qb4nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:PrincipalAdministrativeAndProductionFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_Wpnc4LkhDkOnH49fJmT_-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:LeaseForOfficeSpaceAtHalfDayRoadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_CWI5Bga8AE2e_En3lvUg6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:PrincipalAdministrativeAndProductionFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w0DdgmyjNEGACAuQcuscQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_4rgr5dtwgkOc8kEvgOYxOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:CopierInWestminsterFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_oBhuknZam0qxfv5h_KKCBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_UH_cOo5McUeHvPGUA75elg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_0h9HVSfBy0CDyP55pbIu_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_-mgXyb38JkOXu9Btsyc7MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_prO-azAGCkKvlOGQ87zRuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_0GubflhbPUawUpS7hbiulg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_wRJ1i4W4p0yQRHB5YvbGBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB3WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_7kh5ioPPCU2NcXnDWvOSDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_5m4IloO620mxYhPYECQr_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_4e0nEOiYy0GXKQ8LC542oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_HJefUCEOC0ila6lDpRZnrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_t0-7UkxO_EO65rt0UdRyZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_z7ZUYrej5U-HRCyTPGR3Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9FstVZm760uM_Oiv3BV2pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_mON5gWTp7EKirtCszFVuWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lDZmpqyvbUGnBpoWYEe-5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_NpeQJRDSdU60CDOOsBwD5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WJzJV0pqcEuaZ1x08vBwUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_ZC3gPhsLq0C-Ql-nVHkpag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_7fyqcBdnXkWyRm6NSBBkYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:PutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dOs7dd0euEGpMogpANdTlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XjvP2qF1UUWER7JjNd59jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_4G4-51YVe0-W2QwDgj40EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB3WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_5bX39y7wV06kY0hYQDIn6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9tvbOtUSfE2CdGMRe7SRBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:PutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_peL04lSM_U-U4I3kzipk2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_YldtoLvAcESUUN65IvBRSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_zWZM6-KBpkui8gyBIKU0hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_DAgjRnDA-kiGIHGiIR6buA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_T7Li9gpr_0G4t4E0kCavKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Wub9s-eMQkCXY7--e9OtAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LjBcrN9xrU2acLCoC3csdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_UBk3dK2cpk-EifzkXC7RPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:ValuationReverseRecapitalizationApproachEnterpriseValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yQXpaQmMKkOs4sGjRq4fiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_U3Mfr4KP40avhKdtSM8eCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_tK0vLXJF0k6IM1QbPso1tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lJ2gu3Wxtka5YhLPEJVNXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_79RwHeAEqk6ErcJTlraR9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_bjN6UWcFCUm13QmQZ585Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BinomialTrancheModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_gJ1cZLTqKkOyAt34WAIZFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BinomialTrancheModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_xf9JNaLZckaWeYpqmrjafw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:ValuationReverseRecapitalizationApproachEnterpriseValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_o6rFJS2RUEmPlThbUoOgeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_ljGYthGmzESwFy_58hlCQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputExerciseSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_HEqBbWgIskKT23W1Znx3WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputExerciseSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_ValuationTechniqueAxis_tlsi_BlackScholesModelMember_Bc0NkOT9wEihH_2yOvMkbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_jRIu7P7O9kCs7H6PMq9I4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_bGF1dz-8s06ozP-Wejxjuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_D-d-uo6wjU6j8DmtuRLnlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_YfJXZ7psnU-0gET12ACfMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_yQOpRc5_AUSFptkZf40mhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1gIIWYB_SU-WziuVHJK-DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember__2jiobm5aUuVXVU4BFopyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_djynE7y46UuGJtBrPjxTbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_MdOc8gt9DkG_ANRSNF1Feg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_vLPoVC9kzEqm61EhV_wbdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_7-Ei6pQlX0-G_ZB2qY5krg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_kVRrUl0H3EKb1JhB7W02Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_u3QAPFO_gkSJ1bhVwH2ETQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_p0n0zYd2Y0m3WvEBclIL9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_TN5C51PNT0GEkx_dOCvSqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_0y-vFKCdP0GBKfV2QNnuaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_VNbM6PPC7Ui-DQUvI1KgNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionUptoThreePercentMember_cv3StuhiV0WTIiY4lV9S9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionUptoThreePercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_Fo9HbOq37U21cbLPB6-3eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionBetweenThreeAndFourPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenFourAndFivePercentMember_aGOIseMil0e-w33qyFfkww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionBetweenFourAndFivePercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_oBl1u_pQM06egIcZ8MCY8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_8Tcmoc6fkkCSZMerDheLAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_MiWZm6fBjEKUajPVpCkIUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_HS9G4zEpn0eaK4XwwKWnBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_30_2021_us-gaap_DebtInstrumentAxis_tlsi_TermLoanAndSupplementalTermLoanMember_K5TX_Dl3_UOXwI1TQxgdow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:TermLoanAndSupplementalTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_Jzm_A_jvhUqwLkEpaKybUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:RelatedPartyLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_IJINUXuw9ECauZXpwrbGYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2021_To_4_19_2021_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_SAPDdK4uLkukkpYiynrn7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:PaycheckProtectionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-19</xbrli:startDate><xbrli:endDate>2021-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_JJrctF3Ss0aVYnhFS_75uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_Z3lUDqKSpU2d131KWzDy6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_QnfyiZ486EqFzaXxwbOqWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_o2D8Am3EA0qP-aO4LNlnsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_n7C8O3tfnEa9PI51Rt_RTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_c8vgoPz11Emp9qsaEJDkKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_unAxPM_nUkazhDm3agcBLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ciY8mEnJHkKZYJWWeE3zcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_spU-CoGWskCTi4k7rsFi5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o17RMY4e1kCnffIskGGRgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_chTyyFWls023GE6-jbCH2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_WarrantMember_IqC1qJJSQUWIbrrHEeO5HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_EmployeeStockOptionMember_3KKxG7YSZUSyqE0uG1rr9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_ConvertiblePreferredStockMember__NAecSCB_kCj1haUJLi3OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_IUEdiusOq0Ggfdrn4ZnVkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantToPurchaseSeriesSixPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_kmZ2EGx-bE20yy95aA1umQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantToPurchaseSeriesFivePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_FH-Sf7Hf3EiGk-qmzaSrtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantsToPurchaseSeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_ZQxUbocD4UC-2DmmXP5A4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantsToPurchaseSeriesB3PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsOutstandingMember_Qeaap63POUSl7kq016l15Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:StockOptionsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsAvailableForFutureGrantMember_x-OjXsG_GU2kREkY5w2Tfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:StockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesBConvertiblePreferredStockMember_YcYnzFlBjEak37oDh3RW8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_ubWSfyc1rESSfcBRziTGkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_R3C848oe2UKgjk229Eov0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_L9okU4WLpk-102h2M_xYYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JfpRQYxY-UKeBky1qs6kyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_78cDcL2q8UmHmCn5D2OBjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_CMG6zRmmJk-DrVcCs784UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_D2982Aa3FUev4xmNbgrmLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AbCmIlVGwU2jFoD1_oyB1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ly_yjlxk9kaGKN3_pao1QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_-wdfKUjnDUyvvNS1vvWscg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_TqnHEEX_6U2SUQQnKIvWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_RdkVFV-BmUiRk_p7buc6iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember__XDMheCIA0mYIUNydTkduw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lE_mD9hOd0STU9O_pFbkxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dqYj144kIECijtd5V_e50g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_5P40y196CUq_heFGRG6Rdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_CMmCuzre6E-tcEDvHRTyuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OXuKzykTU0aBwch15YAXNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_g1Y_0bPfVUeHvgx_nTS4NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_Q_kjqMAvdUaQjRHDJ3DK2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_JNDGtibE0E6YxR5fvB4Kuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ilNvF-LtlEuM40NvOR74NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DMJEIP8fGUaGXbZBbwD0BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_pSuIgL5MgkW3Hup01vec-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_P_hbBZGvG0SAPWdr9iTosQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1sI5wKqJ1kuQbBSeQbH8aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tt5jNBG_Ik2_dw16N9eu5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_ApO8mJ0Y8k2llY2j78FSwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_CounterpartyNameAxis_tlsi_TrisalusMember_us-gaap_TypeOfArrangementAxis_tlsi_MergerAgreementMember_ZN8XEh8o7U6Eq1INZQlX_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tlsi:TrisalusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_LyZj3LV5jUiUFferyoGtMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_M4z_mBalEE6paS3q3L0Vjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Hdz3D5qVJE2TxNezwlDqVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantMember_nusetr3QVEyFrcC8HvKhQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_MMnEXq3f5UuA9b_f9X_bWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember__tC8H3YIX0S5r6g2u5BcaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_sFPUIoXf4E6S5yFU1jhaWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_bEObA7CvVkWwdUC6J69fXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RlRaDCvakUCj5EZrtYDWeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantMember_OZsWLbb_CUea_sEX2DVygw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_SXG7MYzIGUCgqGneHO46ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_tO2ji53wmU-1qqLGxMnwug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_egZnUbZL7UuFABnCiYNEEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantsMember_XSIPBticd0u3pNKbWJTJMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvBwoibMpE-Z98sDm4_9Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s45KCdyGNkGuDVWgIQ86KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_ycMhMOSauU-qDs_XF5sQ8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lGYh6vgZNkWoq1VwMwVVnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_siP3YoYtZU2LiMLvWdN7xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kVYk9im19EGexCFAmViCqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ebJaNhnAhkKomsCxm4SEeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pILTs-HrB0uQSMTr-D17nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_06c-BVDZVUSTkxyfqRQpPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_RBw78ON9SUGlT5g_SudELQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_21ZnY62BB0aviR0_y6NS1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_jzrdTKUMPkaJYvHWOVu7LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_nysdtTEnvUyJymOGjXTL2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendPaymentMember_Tw6UZ9TXRk2sGpM7oFAZCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UK6sekRvOEe_2GBgz560wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_3b9pYLI57U2CBSFmckSYmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_zcWk9JPUm0aHGEFVscgstQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_PWoqiQtqAEGjuMjXT5sw3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_G42a6weQT06upXOSAO8LBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_0r7I6QWZA0GsYAkditjprg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Fall2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Fall2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:March2021FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RT4r_FWuwky0MaFoh-QwIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CzvQjMCE50yLWqH7Ft3yaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_26RYOBDJd0m4B-qQpNBrnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2022_To_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_71ivAMN5WEaesHqSjeTrwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.09To0.46Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.005Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.004Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.001Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jdMJ3tTPVki2UbZF3EKNtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_uj5I6WUTUkaK0xF0RTcbcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_wobYTtCwpU6MS4kEO9U9KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_6MR-PsP6QE615ZeUhGehHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_aUCSUO5VHk6A6DggrcFYYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_II1Zn2a3G0K5tjXGFPo3uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_GF-K_2uVu02v02J0fL-JeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_gKTiACbSCUajmar_Jm_ALg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_OZVZQrBqCEGgs_ptg5yGoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:IssuanceOfPromissoryNote2022ToSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_srt_CounterpartyNameAxis_tlsi_MedTechAcquisitionCorporationMember_Nh62w64sX0GFn1hFJJgndg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tlsi:MedTechAcquisitionCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_wJYhKnteSUeKXfPhHtBzkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_BhA3ZSO6j0m1LCmgkuwIQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RCz63iBnwEquUzALofbf-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3-ZqQhxZkGHRMDML9MFaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_rezUy1wqukqJitR5qGefCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_LAf8O94CsUeODp-5oXER8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_tKNgd2GCgESsCQV33cAzXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_xbC97N33okWvF9zYFtzwMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_y3jzsSpPn06F9ea0zBxkMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:MtacClassCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierEquipmentMember_yN9PhUZ9oUmQbLbfhyWOVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:CopierEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_XOapO_xAxkSVGyKMkyZktQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:AnalyticalEquipmentInLaboratoryFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LVK9Ysk-RU6dEwdwJdOHYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_TmWc_b8zrkOoESGM-nlcbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pP0da2xH7UW_LfRCdr8p5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xh7u3lp9k0iiIeQaqMuClw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_A5ZRtG0Mp0KDhqGdsKvyPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_lt1UpQkALESaPZXbSwBQZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_XlqBY_bMDkKgTAzVoxZklQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_Vt3SPP67yUGmnpcjM2X0Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2021_To_11_15_2021_b3QxwyefQ0edxXCsFdJSjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_XOPnCg0EYEC20KqnpImsyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:AnalyticalEquipmentInLaboratoryFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_xbdsgc83CU-hmC04QM8BBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_HwXyrgNF9kSQ67jpRCw_4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyOnePromissoryNoteMember_rhZTQ658W0at8bOMTC8FaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyOnePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_8_2023_To_10_8_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_b2HZiZvawEOx8-1-aQfYAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-08</xbrli:startDate><xbrli:endDate>2023-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_Pqp-qsKfKUquIRMTUTshbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_QW7EfoeCZUGUfloNheRNUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_S0Lcn3b7qUysLIF0lPwnmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_cmpIjKVmEEiX0-ssByWUEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_wfMBzSQGZkKbDc2aHYdY9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_cjlWfxkjMkGCwnUKknuA_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-10</xbrli:startDate><xbrli:endDate>2023-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_QkCtTzY3sU-AQnJ_aipXPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_Kkt3ckHCjEGBa9C6I-e57g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_bzhbnoR9okG4s-q-sw9axQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_k5WzB7ynsUKBqdgC_-pE5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_8_2023_-N_ZHqE3nU2aqMlyR4MjcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_1J2ClcRDUUC7d2IrxMQFMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wbWlcEUxYUS1rDanZQ4z-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jGJ8x1reCEyfHu4lILMFaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_Kxpz0qSUe0mhCS0fzXQnrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2009-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember__otGtNiDqUS3D-2IJAK-XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_dsiZTjMLTEKnTS_3xuMRbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_qmSmw3DpY0WjaiDXUJYiOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_qO_tJd7jHECOCsFdPPXStg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:RelatedPartyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn11202018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn10272016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn08262015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn06302017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_RHMSaTNJIEmzTCVVY75WyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7GgzZHKQ-Em17ealfdPxcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_vkr2IKtEfkK2saNonouWWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:MtacClassCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_HDWwXtuDDUqAhelDAH9-9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3VDT5dIz0yqR_H8-7yMPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestoneFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone500000AnnualSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone250000AnnualSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone1000000AnnualSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_1pk8tgoJY0SRZ1kWItulfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_xsabo2n52UilLgijgS19aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:AggregateAnnualNetSalesGreaterThan1000000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf500000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf250000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf1000000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:AggregateAnnualNetSalesLessThanOrEqualTo1000000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_wGOWYsCQ5ku3FPlY92CUbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ"><xbrli:measure>tlsi:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg"><xbrli:measure>tlsi:patent</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg"><xbrli:measure>tlsi:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q"><xbrli:measure>tlsi:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA"><xbrli:measure>tlsi:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ"><xbrli:measure>tlsi:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg"><xbrli:measure>tlsi:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg"><xbrli:measure>tlsi:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_0xHPpLFYGkuxngV0kCBNoQ"><xbrli:measure>tlsi:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">As filed with the U.S. Securities and Exchange Commission on December 14, 2023.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registration No.&#160;333-274292</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 5pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_63b8025e_54a6_4e05_9fe0_6a07a5bbbba6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="-sec-ix-hidden:Hidden_Pz3-aZKVPEagACyzY8ZLrg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">AMENDMENT NO. 3</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><span style="-sec-ix-hidden:Hidden_xWgaFrhPg0G0LJX8EzlMuw;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">S-1</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">THE SECURITIES ACT OF 1933</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntityRegistrantName" id="Narr_NQf-KsZ-9kinBavKdve4jQ"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of registrant as specified in its charter)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:31.59%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br/>incorporation or organization)</p></td><td style="vertical-align:top;width:2.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">3841</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Primary Standard Industrial<br/>Classification Code Number)</p></td><td style="vertical-align:top;width:2.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">85-3009869</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer<br/>Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">6272 W. 91st Ave.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Westminster, Colorado 80031</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><b style="font-weight:bold;">(888) 321-5212</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><span style="font-size:5pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Mary Szela</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">6272 W. 91st Ave.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Westminster, Colorado 80031</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><b style="font-weight:bold;">(888) 321-5212</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><span style="font-size:5pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><span style="font-size:5pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Copy to:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Matt Browne</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Carlos Ramirez</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Alexander Gefter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Cooley LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">10265 Science Center Dr</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">San Diego, California 92121</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0.5pt;"><b style="font-weight:bold;">(858) 550-6000</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Approximate date of commencement of proposed sale to the public:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">From time to time on or after this registration statement is declared effective.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box. <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(c)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_9fecac8b_c25d_4976_9123_fc30fc0f8243"></a><div style="padding-left:18pt;"><a id="Tc_e0Yz4cdkwkqTn4SIBqbyYg_1_0"></a><a id="Tc_aIs_HSS4_UWpNPtLuKWxbQ_1_1"></a><a id="Tc_rVIpeand4kWfiuKnQsPeUg_1_2"></a><a id="Tc_zi2UW6XDkECG3QJfQeSVlg_1_3"></a><a id="Tc_IRGfAOC2w0WqhG81xKBGCQ_2_1"></a><a id="Tc_iIk386wBFUyR8eCJ498EOQ_2_2"></a><a id="Tc_RgQeQfmHNUyowRftEBJBDw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.69%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:24.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.69%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:31.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:24.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.69%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntityFilerCategory" id="Tc_zH-nGDeMp0SfOA19lCcsnA_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:31.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:24.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntitySmallBusiness" id="Tc_u6eOerWhPkSmi1EMT-Ltfw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.69%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:24.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntityEmergingGrowthCompany" id="Tc_6qWV2U1M4kewShRnQSiZ_A_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.</span><span style="font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="dei:EntityExTransitionPeriod" id="Narr_hLHZpn-AQUC6RoGqLYusRA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:606pt;left:0pt;position:absolute;top:34.8pt;width:33.03pt;z-index:251658240;"><div style="height:604.8pt;left:0pt;padding-bottom:1.2pt;position:relative;top:0pt;width:31.93pt;"><div style="height:604.8pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:31.93pt;"><div style="left:0pt;max-height:100%;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:31.93pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;width:100%;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">The information in this preliminary prospectus is not complete and may be changed. Neither we nor the selling security holders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:670.8pt;"><a id="_2dd65013_bcf2_45f2_8b58_f0642c0a4b4b"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><b style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-weight:bold;">Subject to Completion, Dated December 14, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">PRELIMINARY PROSPECTUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><img src="tlsi-20230630xs1a002.jpg" alt="Graphic" style="display:inline-block;height:36.24pt;width:144pt;"/></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Times New Roman','Times','serif';">This prospectus relates to the issuance by us of an aggregate of up to 13,215,112 shares of our common stock, $0.0001 par value per share (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common Stock</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), issuable upon the exercise of warrants, which consists of (a) up to 4,933,333 shares of Common Stock that are issuable upon the exercise of 4,933,333 warrants (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Private Placement Warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) held by MedTech Acquisition Sponsor LLC, a Delaware limited liability company (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sponsor</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), originally issued in a private placement in connection with the initial public offering of MedTech Acquisition Corporation (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MTAC</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) by the holders thereof and (b) up to 8,281,779 shares of Common Stock that are issuable upon the exercise of 8,281,779 warrants (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Public Warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) originally issued in the initial public offering of MTAC by the holders thereof.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Times New Roman','Times','serif';">This prospectus also relates to the offer and sale, from time to time, by the Selling Securityholders named in this prospectus or their permitted transferees (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Selling Securityholders</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) of (i) up to 36,772,040 shares of Common Stock consisting of (a) up to 25,237,094 shares of Common Stock that are issuable upon the conversion of the 4,015,002 shares of Preferred Stock originally issued to investors in a private placement pursuant to those certain Subscription Agreements (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PIPE Shares</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) at a price of $10.00 per share, (b) up to 4,062,500 shares of Common Stock (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Founder Shares</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) originally issued in a private placement to the Sponsor prior to MTAC&#8217;s initial public offering at a price of approximately $0.006 per share, including 3,125,000 Founder Shares subject to vesting and forfeiture, (c) up to 1,452,965 shares of Common Stock issuable upon exercise of outstanding options that were initially granted by Legacy TriSalus, at a weighted average price of $2.51 per share, and assumed by the Company and converted into options to purchase Common Stock pursuant to the Agreement and Plan of Merger (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merger Agreement</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), dated as of November 11, 2022, as amended on April 4, 2023, May 13, 2023 and July 5, 2023, by and among MTAC, MTAC Merger Sub, Inc. and TriSalus Operating Life Sciences, Inc. (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Legacy TriSalus</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Assumed Options</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), (d) up to 86,148 shares of Common Stock issuable upon the settlement of restricted stock units that were initially granted by Legacy TriSalus and assumed by the Company and converted into restricted stock units with respect to the Common Stock pursuant to the Merger Agreement, which were granted at no cost to the recipients thereof (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Assumed RSUs</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), (e) up to 4,933,333 shares of Common Stock issuable upon exercise of the Private Placement Warrants at a price of $11.50 per share and (f) up to 1,000,000 shares of Common Stock that are issuable upon the exercise of conversion warrants issued upon the conversion of the promissory note issued by MTAC to the Sponsor for working capital requirements and payment of certain expenses in connection with a potential business combination transaction by the holders thereof (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Conversion Warrants</b><span style="font-family:'Times New Roman','Times','serif';"> and, together with the Private Placement Warrants and the Public Warrants, the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;)) at a price of $11.50 per share and (ii) up to 5,933,333 warrants consisting of (a) up to 4,933,333 Private Placement Warrants and (b) up to 1,000,000 Conversion Warrants. We will receive the proceeds from any exercise of any Warrants for cash. However, we will not receive any proceeds from the sale of shares of Common Stock or Warrants by the Selling Securityholders pursuant to this prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f9bd6eb_f9a8_43be_a19d_d437f8ecaba1"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Common Stock being offered for resale pursuant to this prospectus by the Selling Securityholders would represent approximately 54.6% of our outstanding Common Stock as of December 8, 2023 (after giving effect to the issuance of the shares issuable upon exercise of the Warrants, the acquisition of certain shares acquirable upon the exercise of assumed options and settlement of assumed restricted stock units, and the issuance of the PIPE Shares (assuming conversion at the initial conversion price of $10.00)). Given the substantial number of shares of Common Stock being registered for potential resale by Selling Securityholders pursuant to this prospectus, the sale of shares by the Selling Securityholders of a large number of shares, or the perception in the market that the Selling Securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock. Even if our trading price is significantly below $10.00, the offering price for the units offered in the initial public offering of MTAC, the purchasers of which exchanged their MTAC shares for our Common Stock in the business combination described in this prospectus, the Selling Securityholders may still have an incentive to sell our shares of our Common Stock because they purchased the shares at prices that are significantly lower than the purchase prices paid by our public investors or the current trading price of our Common Stock. While certain of the Selling Securityholders may experience a positive rate of return on their investment in our Common Stock as a result, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in their purchase prices and the trading price. For example, based on the closing price of our Common Stock of $4.00 as of December 8, 2023, assuming all shares held by the Sponsor that are subject to vesting and forfeiture are fully vested, the original holder of the Founder Shares would experience a potential profit of up to approximately $4.00 per share that they purchased prior to the initial public offering of MTAC, or up to approximately $16.25 million in the aggregate (not giving effect to the issuance of Common Stock issuable upon exercise of the Warrants held by them).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Certain of the Selling Securityholders and their affiliates are contractually restricted to sell or transfer certain of their shares of Common Stock beginning at the Closing and ending on the earliest of (i)&#160;one year after the completion of the Closing; (ii)&#160;the first day after the date on which the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150&#160;days after the date of the Closing; or (iii)&#160;the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Selling Securityholders may sell the securities being offered for resale through various methods, as described in the section titled &#8220;<i style="font-style:italic;">Plan of Distribution</i>.&#8221; These sales may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. In connection with any sales of securities offered hereunder, the Selling Securityholders and any underwriters, agents, brokers or dealers participating in such sales may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act of 1933, as amended. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of Common Stock or Warrants. See the section titled &#8220;<i style="font-style:italic;">Plan of Distribution</i>.&#8221; We will not receive any of the proceeds from such sales of the shares of Common Stock or Warrants, except with respect to amounts received by us upon exercise of the Warrants. We believe the likelihood that holders of the Warrants will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. The exercise price of our outstanding Warrants is $11.50 per share, which exceeds the trading price of our Common Stock as of the date of this prospectus. So long as the trading price for our Common Stock is less than $11.50 per share, meaning the Warrants are &#8220;out of the money&#8221;, we believe holders of our Warrants will be unlikely to exercise their warrants on a cash basis. In addition, to the extent the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. The Private Placement Warrants and Conversion Warrants may be exercised for cash or on a &#8220;cashless basis.&#8221; The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of common stock issuable upon the exercise of such warrants. If there is not a then-effective registration statement, then such warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act of 1933, as amended.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Common Stock and Public Warrants are listed on the Nasdaq Global Market under the ticker symbols &#8220;TLSI&#8221; and &#8220;TLSIW,&#8221; respectively. On December 8, 2023, the last reported sales price of our Common Stock was $4.00 per share and the last reported sales price of our Warrants was $0.24 per warrant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company. We are incorporated in Delaware.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#8220;</b><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Risk Factors</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221; beginning on page&#160;</b><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> of this prospectus, and under similar headings in any amendments or supplements to this prospectus.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Prospectus dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c3f8ec0d_a690_4cb4_8f21_bd98f1275982"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ABOUTTHISPROSPECTUS_543667"><span style="font-style:normal;font-weight:normal;">ABOUT THIS PROSPECTUS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">ii</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SPECIALNOTEREGARDINGFORWARDLOOKINGSTATEM"><span style="font-style:normal;font-weight:normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">iii</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FREQUENTLYUSEDTERMS_814153"><span style="font-style:normal;font-weight:normal;">FREQUENTLY USED TERMS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">v</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PROSPECTUSSUMMARY_85644"><span style="font-style:normal;font-weight:normal;">PROSPECTUS SUMMARY</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TheOffering_845069"><span style="font-style:normal;font-weight:normal;">THE OFFERING</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RISKFACTORS_119991"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#USEOFPROCEEDS_881566"><span style="font-style:normal;font-weight:normal;">USE OF PROCEEDS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DETERMINATIONOFOFFERINGPRICE_183680"><span style="font-style:normal;font-weight:normal;">DETERMINATION OF OFFERING PRICE</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MARKETINFORMATIONFORSECURITIESANDDIVIDEN"><span style="font-style:normal;font-weight:normal;">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MANAGEMENTSDISCUSSIONANDANALYSISOF"><span style="font-style:normal;font-weight:normal;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OURBUSINESS_994987"><span style="font-style:normal;font-weight:normal;">OUR BUSINESS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MANAGEMENT_315555"><span style="font-style:normal;font-weight:normal;">MANAGEMENT</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">125</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EXECUTIVECOMPENSATION_739960"><span style="font-style:normal;font-weight:normal;">EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">137</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">152</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PRINCIPALSECURITYHOLDERS_381529"><span style="font-style:normal;font-weight:normal;">PRINCIPAL SECURITYHOLDERS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">160</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SELLINGSECURITYHOLDERS_482651"><span style="font-style:normal;font-weight:normal;">SELLING SECURITYHOLDERS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">164</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DESCRIPTIONOFOURSECURITIES_872750"><span style="font-style:normal;font-weight:normal;">DESCRIPTION OF OUR SECURITIES</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">173</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MATERIALUNITEDSTATESFEDERALINCOMETAXCONS"><span style="font-style:normal;font-weight:normal;">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">183</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PLANOFDISTRIBUTION_937583"><span style="font-style:normal;font-weight:normal;">PLAN OF DISTRIBUTION</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">188</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LEGALMATTERS_293236"><span style="font-style:normal;font-weight:normal;">LEGAL MATTERS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">191</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EXPERTS_3359"><span style="font-style:normal;font-weight:normal;">EXPERTS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">191</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CHANGEINREGISTRANTSCERTIFYINGACCOUNTANT_"><span style="font-style:normal;font-weight:normal;">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">191</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_144649"><span style="font-style:normal;font-weight:normal;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">192</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"><span style="font-style:normal;font-weight:normal;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">193</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOFINANCIALSTATEMENTS_415916"><span style="font-style:normal;font-weight:normal;">INDEX TO FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;). Neither we, nor the Selling Securityholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the SEC. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Securityholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For investors outside of the United States: Neither we, nor the Selling Securityholders, have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_771277b3_a3b2_4638_a0f3_784d54ecc119"></a><a id="ABOUTTHISPROSPECTUS_543667"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ABOUT THIS PROSPECTUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus is part of a registration statement on Form S-1 that we filed with the SEC using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of any Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;10, 2023, Legacy TriSalus, MTAC and Merger Sub consummated the transactions contemplated by the Merger Agreement (as such terms are defined below), following the approval by MTAC&#8217;s stockholders at an extraordinary general meeting held on August&#160;2, 2023. Pursuant to the terms of the Merger Agreement, a Business Combination (as defined below) of Legacy TriSalus and MTAC was effected through, among other transactions, the merger of Merger Sub with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing. In connection with the consummation of the Merger on August&#160;10, 2023, MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc. and Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;TriSalus,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to TriSalus Life Sciences,&#160;Inc. (f/k/a MedTech Acquisition Corporation) and its consolidated subsidiaries (including Legacy TriSalus). References to &#8220;MTAC&#8221; refer to the predecessor company prior to the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_715c799e_9345_413f_ba1e_e7fa4ef5c0f3"></a><a id="SPECIALNOTEREGARDINGFORWARDLOOKINGSTATEM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Some of the statements contained in this prospectus constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These forward-looking statements include statements regarding our intentions, beliefs and current expectations and projections concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which we operate. In some cases, you can identify these forward-looking statements by the use of terminology such as &#8220;outlook,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;approximately,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;anticipates&#8221; or the negative version of these words or other comparable words or phrases.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The forward-looking statements contained in this prospectus reflect our current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. There are no guarantees that the transactions and events described will happen as described (or that they will happen at all). As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recognize the anticipated benefits of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain the listing of our Common Stock and warrants on the Nasdaq Global Market, and the potential liquidity and trading of such securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise financing in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain or recruit, or changes required in, our officers, key employees or directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize any product candidates that we successfully develop and that are approved by applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations for the timing and results of data from clinical trials and regulatory approval applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business, operations and financial performance including:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our history of operating losses and expectations of significant expenses and continuing losses for the foreseeable future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to execute our business strategy, including the growth potential of the markets for our products and our ability to serve those markets;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to grow market share in our existing markets or any new markets we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop and maintain our brand and reputation;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to partner with other companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the addressable markets for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manage our growth effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of any legal proceedings that may be instituted against us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable conditions in our industry, the global economy or global supply chain, including financial and credit market fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare and terrorist attacks.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, statements that &#8220;TriSalus believes,&#8221; &#8220;the Company believes&#8221; or &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subjects. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. Except to the extent required by applicable law, we are under no obligation (and expressly disclaim any such obligation) to update or revise their forward-looking statements whether as a result of new information, future events, or otherwise. For a further discussion of these and other factors that could cause our future results, performance or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>.&#8221; You should not place undue reliance on any forward-looking statements, which are based only on information currently available to us (or to third parties making the forward-looking statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_36a3b001_c668_4c64_a927_c41801d93639"></a><a id="FREQUENTLYUSEDTERMS_814153"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FREQUENTLY USED TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">A&amp;R Registration Rights Agreement</b>&#8221; means that certain Amended and Restated Registration Rights Agreement entered into at Closing by and among TriSalus, the members of Sponsor, certain former stockholders of Legacy TriSalus, attached hereto as Exhibit 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Business Combination</b>&#8221; means the transactions contemplated by the Merger Agreement, including, among other things, the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Closing</b>&#8221; means the closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Closing Date</b>&#8221; means August&#160;10, 2023, the date on which the Closing occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Common Stock</b>&#8221; means the shares of our common stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Conversion Warrants</b>&#8221; means the 1,000,000 warrants issued upon the conversion of the promissory note issued by MTAC to the Sponsor for working capital requirements and payment of certain expenses in connection with the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">DGCL</b>&#8221; means the General Corporation Law of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Founder Shares</b>&#8221; means the 4,062,500 shares of Common Stock issued to the members of the Sponsor that were not forfeited at Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Legacy TriSalus</b>&#8221; means TriSalus Operating Life Sciences,&#160;Inc., a Delaware corporation which, pursuant to the Business Combination, became a direct, wholly owned subsidiary of TriSalus Life Sciences,&#160;Inc., and, unless the context otherwise requires, its consolidated subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Merger</b>&#8221; means the merger of Merger Sub, a direct, wholly owned subsidiary of MTAC, with and into Legacy TriSalus, with Legacy TriSalus continuing as the surviving entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Merger Agreement</b>&#8221; means that certain Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023, with Merger Sub and Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Merger Sub</b>&#8221; means MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">MTAC</b>&#8221; means MedTech Acquisition Corporation (which was renamed &#8220;TriSalus Life Sciences, Inc&#8221; in connection with the consummation of the Business Combination).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">MTAC IPO</b>&#8221; means MTAC&#8217;s initial public offering, consummated on December&#160;22, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">MTAC</b><b style="font-weight:bold;"> Units</b>&#8221; means equity securities of us, each consisting of one share of Class&#160;A Common Stock and one-third of one Public Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">PIPE Shares</b>&#8221; means the shares of Common Stock that are issuable upon the conversion of the shares of Preferred Stock originally issued to investors in a private placement pursuant to those certain Subscription Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Preferred Stock PIPE Investors</b>&#8221; means the investors with whom MTAC has entered into the Subscriptions Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Private Placement Warrants</b>&#8221; means the 4,933,333 warrants purchased by the Sponsor in connection with the MTAC IPO in a private placement transaction occurring simultaneously with the closing of the MTAC IPO.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">v</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Public Warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221; means the 8,281,779 outstanding warrants included as a component of the MTAC Units sold in the MTAC IPO, each of which is exercisable, at an exercise price of $11.50, for one share of Common Stock, in accordance with its terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Sponsor</b>&#8221; means MedTech Acquisition Sponsor LLC, a Delaware limited liability company, which liquidated and distributed its holdings to its ultimate beneficiaries prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Subscription Agreements</b>&#8221; means those certain subscription agreements, dated June&#160;7, 2023 and July&#160;4, 2023, by and among MTAC and the Preferred Stock PIPE Investors pursuant to, and on the terms and subject to the conditions of which, the Preferred Stock PIPE Investors have collectively subscribed for and agreed to purchase in private placements an aggregate of 4,015,002 shares of Series&#160;A Convertible Preferred Stock at a purchase price of $10.00 per share, resulting in an aggregate purchase price of $40,150,020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Warrants</b>&#8221; means the Conversion Warrants, the Private Placement Warrants and the Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">vi</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8738090f_f4ab_42a3_800a_daff4a4a9278"></a><a id="PROSPECTUSSUMMARY_85644"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROSPECTUS SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth in the sections titled &#8220;Risk Factors,&#8221; &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the notes thereto included elsewhere in this prospectus, before deciding to invest in our shares of common stock. For purposes of this section, unless otherwise indicated or the context otherwise requires, all references to &#8220;TriSalus,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; or similar terms refer to TriSalus Life Sciences,&#160;Inc. and its consolidated subsidiaries after the Closing.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an oncology company integrating standard-of-care treatments and our investigational immunotherapeutic with disruptive delivery technology with the goal of transforming the treatment paradigm for patients battling liver and pancreatic tumors. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of immunotherapeutics in these difficult-to-treat diseases: (i)&#160;high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii)&#160;the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve checkpoint inhibitor response and enable improved patient outcomes. Our business is a Delaware corporation. We were incorporated in 2009 as Surefire Medical,&#160;Inc. We began doing business as TriSalus Life Sciences in 2018, and changed our name to TriSalus Life Sciences,&#160;Inc. in August&#160;2021. The mailing address of our principal executive office is 6272 W. 91st Ave., Westminster, Colorado 80031.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Implications of Being an Emerging Growth Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, as amended, and therefore we intend to take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in this prospectus, our periodic reports and our proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal&#160;year in which the market value of our Common Stock that is held by non-affiliates equals or exceeds $700&#160;million as of the end of that&#160;year&#8217;s second fiscal quarter, (ii)&#160;the last day of the fiscal&#160;year in which we have total annual gross revenue of $1.235&#160;billion or more during such fiscal&#160;year (as indexed for inflation), (iii)&#160;the date on which we have issued more than $1.00&#160;billion in non-convertible debt in the prior three-year period or (iv)&#160;December&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; in this prospectus. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should carefully consider the risks and uncertainties described under the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; as part of your evaluation of an investment in our securities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, have incurred significant losses since our inception and anticipate incurring increasing expenses and continuing losses for the foreseeable future. Our independent registered public accountants and management have expressed substantial doubt as to our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Asset Purchase Agreement, dated July&#160;31, 2020, we entered into with Dynavax Technologies Corporation (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Dynavax</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in connection with our purchase of SD-101 requires us to make potentially significant payments to Dynavax before we will have regulatory approval of SD-101 and be able to generate revenue from sales of SD-101.</span></td></tr></table></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Until we are able to generate significant revenues or achieve profitability through product sales, we will require substantial additional capital to finance our operations and continue development of our product candidates. We cannot be certain that such additional financing will be available on terms favorable to us, or at all, which could limit our ability to grow and jeopardize our ability to continue our business operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our revenue is primarily generated from sales of our TriNav device and we are therefore highly dependent on it for our success. Failure to achieve continued market acceptance of TriNav for any reason will harm our business and future prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TriNav is subject to an uncertain reimbursement environment, and any change to TriNav&#8217;s reimbursement status that reduces our level of reimbursement could cause TriNav revenue to materially decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have a limited marketing, sales and distribution organization. If we are unable to successfully grow our marketing, sales and distribution capabilities, then our product revenues related to TriNav, results of operations and financial condition will suffer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are early in our pharmaceutical development efforts and have only one pharmaceutical product candidate, SD-101, in early clinical development. If we are unable to advance our product candidates, including SD-101, in clinical development for any reason (including due to lack of funding), obtain regulatory approval and ultimately commercialize our product candidates, or experiences significant delays in doing so, our business, results of operations, financial condition and prospects may be materially adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical development is a lengthy and expensive process with an uncertain outcome. In addition, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials. Failure can occur at any stage of clinical development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in existing third-party coverage or our inability to secure advantageous reimbursement codes may impact our ability to sell our products, which would materially and adversely impact our business, results of operations, financial condition and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The business and industry in which we participate in are highly competitive. If we are unable to compete effectively, we will not be able to establish our products in the marketplace or grow our products&#8217; market share in the marketplace, and as a result, our business and results of operations will be adversely impacted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to numerous complex regulatory requirements and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The complexity of a combination product that includes a drug and a medical device, presents additional, unique development and regulatory challenges, which may adversely impact our development plans and our ability to obtain regulatory approval or clearance of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to obtain, adequately protect, maintain or enforce our intellectual property rights could substantially harm our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The expiration or loss of patent protection may adversely affect our future revenues.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience operating as a United States public company and may not be able to adequately develop and implement the governance, compliance, risk management and control infrastructure and culture required for a public company, including compliance with the Sarbanes Oxley Act.</span></td></tr></table></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our management has identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future. If we fail to remediate the material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, it may adversely affect our ability to accurately and timely report our financial results, and may adversely affect investor confidence and business operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our Common Stock and Public Warrants has been and may continue to be volatile.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Please see the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';">&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';">7</span><span style="font-family:'Times New Roman','Times','serif';"> of this prospectus for a discussion of these and other factors you should consider in evaluating our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 6272 W. 91st Ave., Westminster, Colorado 80031 and our telephone number is (888) 321-5212. Our corporate website address is www.trisaluslifesci.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and our subsidiaries own or have rights to trademarks, trade names and service marks that they use in connection with the operation of their business. Other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to in this prospectus are listed without the applicable <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, &#8482; and SM symbols.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f0377e8f_b8a8_4167_8fd6_75fafdc4e5de"></a><a id="TheOffering_845069"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Offering</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">Issuance of Common Stock</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Shares of Common Stock offered by us</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Up to 13,215,112 shares of Common Stock, including shares of Common Stock issuable upon exercise of the Private Placement Warrants and Public Warrants, consisting of (i) up to 4,933,333 shares of Common Stock that are issuable upon the exercise of up to 4,933,333 Private Placement Warrants by the holders thereof and(ii) up to 8,281,779 shares of Common Stock that are issuable upon the exercise of up to 8,281,779 Public Warrants by the holders thereof.</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Shares of Common Stock outstanding prior to the exercise of all Warrants</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26,387,321 shares (as of December 8, 2023).</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Shares of Common Stock outstanding assuming exercise of all Warrants</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">40,602,433 shares (based on total shares outstanding as of December 8, 2023).</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Exercise price of Warrants</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$11.50 per share, subject to adjustment as described herein.</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Use of proceeds</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We will receive up to an aggregate of approximately $163.8 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants, if any, for general corporate purposes. Due to the uncertainty regarding the exercise of the Warrants, none of our projected liquidity requirements discussed in this prospectus assume the receipt of any proceeds from the exercise of the Warrants. The exercise price of our Warrants is $11.50 per warrant, which exceeds the trading price of our Common Stock as of the date of this prospectus. We believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. So long as the trading price for our Common Stock is less than $11.50 per share, meaning the Warrants are &#8220;out of the money,&#8221; we believe holders of our Warrants will be unlikely to exercise their warrants. In addition, to the extent that our Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of such Warrants will decrease. The Private Placement Warrants and Conversion Warrants may be exercised for cash or on a &#8220;cashless basis.&#8221; The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of Common Stock issuable upon the exercise of such Warrants. If there is not a then-effective registration statement, then such Warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;). See the section titled &#8220;<i style="font-style:italic;">Use of Proceeds.</i>&#8221;</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Resale of Common Stock and Warrants</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Shares of Common Stock offered by the Selling Securityholders</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;">We are registering the resale by the Selling Securityholders named in this prospectus, or their permitted transferees, an aggregate of 36,772,040 shares of Common Stock, consisting of:</p><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 25,237,094 PIPE Shares issuable upon conversion of 4,015,022 shares of preferred stock originally issued to investors in a private placement at a price of $10.00 per share;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 4,062,500 Founder Shares originally issued in a private placement to the Sponsor prior to MTAC&#8217;s initial public offering, at a price of approximately $0.006 per share, including 3,125,000 Founder Shares subject to vesting and forfeiture;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 1,452,965 shares of Common Stock issuable upon exercise of the Assumed Options, initially granted by Legacy TriSalus at a weighted average price of $2.51 per share;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 86,148 shares of Common Stock issuable upon the Assumed RSUs, which were granted at no cost to the recipients thereof;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 4,933,333 shares of Common Stock issuable upon the exercise of the Private Placement Warrants at a price of $11.50 per share; and</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 1,000,000 shares of Common Stock issuable upon the exercise of the Conversion Warrants at a price of $11.50 per share.</span></div></div></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Given the substantial number of shares of Common Stock being registered for potential resale by Selling Securityholders pursuant to this prospectus, the sale of shares by the Selling Securityholders of a large number of shares, or the perception in the market that the Selling Securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock. Even if our trading price is significantly below $10.00 per share, the offering price for the units offered in the initial public offering of MTAC, the purchasers of which exchanged their MTAC shares for our Common Stock in the Business Combination, the Selling Securityholders may still have an incentive to sell our shares of our Common Stock because they purchased the shares at prices that are significantly lower than the purchase prices paid by our public investors or the current trading price of our </p></td></tr></table></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:15.6pt 5.22% 32pt 5.22%;padding:6pt 0.65% 4pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Common Stock. While certain of the Selling Securityholders may experience a positive rate of return on their investment in our Common Stock as a result, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in their purchase prices and the trading price. For example, based on the closing price of our Common Stock of $4.00 as of December 8, 2023, assuming all shares held by the Sponsor that are subject to vesting and forfeiture are fully vested, the original holder of the Founder Shares would experience a potential profit of up to approximately $4.00 per share that they purchased prior to the initial public offering of MTAC, or up to approximately $16.25 million in the aggregate (not giving effect to the issuance of Common Stock issuable upon exercise of the Warrants held by them).</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Warrants offered by the Selling Securityholders</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Up to 5,933,333 warrants consisting of (a) up to 4,933,333 Private Placement Warrants and (b) up to 1,000,000 Conversion Warrants.</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Redemption</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The Public Warrants are redeemable in certain circumstances. See the section titled &#8220;<i style="font-style:italic;">Description of Our Securities&#8201;&#8212;&#8201;Warrants.</i>&#8221;</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Lock-up agreements</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Certain of our securityholders are subject to certain restrictions on transfer until the termination of applicable lock-up periods. See the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions&#8201;&#8212;&#8201;Lock-up Agreements.</i>&#8221;</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Terms of the offering</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The Selling Securityholders will determine when and how they will dispose of the securities registered for resale under this prospectus.</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Use of proceeds</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">We will not receive any proceeds from the sale of shares of Common Stock or Warrants by the Selling Securityholders.</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Risk factors</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Before investing in our securities, you should carefully read and consider the information set forth in the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page 7.</p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Nasdaq ticker symbols</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8220;TLSI&#8221; and &#8220;TLSIW&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">For additional information concerning the offering, see the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Plan of Distribution</i><span style="font-family:'Times New Roman','Times','serif';">&#8221; beginning on page&#160;</span><span style="font-family:'Times New Roman','Times','serif';">188</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a9d9c3b0_1202_4905_878b_89835895691c"></a><a id="RISKFACTORS_119991"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under &#8220;Special Note&#160;Regarding Forward-Looking Statements,&#8221; you should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our securities. If any of the events or developments described below were to occur, our business, prospects, operating results, and financial condition could suffer materially, the trading price of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RISKS RELATED TO OUR BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history, have incurred significant losses since our inception and anticipate incurring increasing expenses and continuing losses for the foreseeable future. Our independent registered public accountants and management have expressed substantial doubt as to our ability to continue as a going concern.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are a commercial-stage medical device and Phase I clinical-stage pharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have incurred significant losses since inception, including net losses of $23.5 million and $47.2 million for the nine months ended September 30, 2023, and the year ended December 31, 2022, respectively. As of September 30, 2023, we had an accumulated deficit of $212.9 million. We anticipate incurring increasing research and development and general and administrative expenses related to our operations and transition into a public company for the foreseeable future. Losses will likely continue and may increase in the future as we continue to incur significant expenses related to drug development. We may find that these efforts are more expensive than we currently anticipate or that these efforts may not result in revenues, which would further increase our losses. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by clinical-stage pharmaceutical companies. If we are unable to achieve and/or sustain profitability, or if we are unable to achieve the growth that we expect from these efforts, it could have a material adverse effect on our business, financial condition or results of operations. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, the Report of Independent Registered Public Accounting Firm to our December 31, 2022, financial statements includes an explanatory paragraph that expressed substantial doubt about our ability to continue as a going concern. Additionally, our management has independently determined that there is substantial doubt about our ability to continue as a going concern because we have incurred significant operating losses and expect to continue incurring losses for the foreseeable future. Our financial statements were prepared assuming that we will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty. Although we have raised additional cash in connection with the Closing of the Business Combination and received cash proceeds from the exercise of warrants to purchase series B-3 preferred stock in July 2023, without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents as of September 30, 2023 will be insufficient to fund our projected liquidity requirements for the next 12 months, creating substantial doubt about our ability to continue as a going concern, and we may be unable to realize assets and discharge liabilities in the ordinary course of operations. If we are unable to obtain sufficient funding, we may be forced to delay, scale back, or eliminate some or all of our research and development activities, our financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future financial statements may include similar qualifications about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern; investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Dynavax Agreement entered into by Legacy TriSalus in connection with its purchase of SD-101 requires us to make potentially significant payments to Dynavax before we will have regulatory approval of SD-101 and be able to generate revenue from sales of SD-101.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Dynavax Agreement, we and Legacy TriSalus have paid Dynavax $12 million to date and we may be required to pay Dynavax up to an additional $158 million upon the achievement of certain development and regulatory milestones with respect to SD-101. We will also be required to pay up to $80 million upon achieving certain commercial milestones once sales of SD-101 have begun. The Dynavax Agreement also obligates us to pay royalties based on potential future net sales of products containing SD-101 compound on a product-by-product and country-by-country basis during the applicable royalty term. Such royalties are subject to reduction by up to 50% in certain circumstances. Our failure to satisfy these payment obligations or other obligations under the Dynavax Agreement could result in penalties or litigation, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Until we are able to generate significant revenues or achieve profitability through product sales, we will require substantial additional capital to finance our operations and continue development of our product candidates. We cannot be certain that such additional financing will be available on terms favorable to us, or at all, which could limit our ability to grow and jeopardize our ability to continue our business operations.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Based on our sales, operations, and research and development plans, we expect that our existing cash and cash equivalents as of September 30, 2023 will be sufficient to fund operations into early 2024. However, we expect to incur significant expenses and operating losses for the foreseeable future as we continue to invest in the commercialization of SD-101, clinical trials and other development, manufacturing and regulatory activities for TriNav, SD-101 and our other product candidates, and discovery research and development. Based on our history of losses, we do not expect that we will be able to fund our longer-term capital and liquidity needs through our cash balances and operating cash flow alone.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Until we can generate a sufficient amount of revenue, we will need to finance our operations through strategic alliance and licensing arrangements and/or public or private debt and equity financings. We will need to obtain substantial additional funding in connection with our continuing operations and planned activities, including to continue the clinical development of, and seek regulatory approval for, SD-101 in any indication, to expand our business, to respond to competitive pressure and to make acquisitions. The amount of capital we will need may change depending on, among other things, the success of our efforts to grow revenue, our efforts to continue to effectively manage expenses, the results of our research and development and clinical trials for product candidates, and costs arising from seeking regulatory approvals. We may not succeed in raising additional funds in a timely manner. The timing of our need for additional funds will depend on many factors, which are difficult to predict or may be outside of our control, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue received from sales of TriNav;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of research and development programs, including for additional Pressure-Enabled Drug Delivery (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">PEDD</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results, resources, time and costs of preclinical development, laboratory testing and clinical trials for our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of the regulatory review and approval of SD-101 and any future product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of any milestone payments or royalties due to Dynavax; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our estimates and predictions relating to any of these factors are incorrect, we may need to modify our business plans. Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales for SD-101 or any of our product candidates. In addition, SD-101 and any future product candidates, if approved, may not achieve commercial success. Our commercial revenues from TriNav will not be sufficient to fund our planned research activities in the near term, if ever. Accordingly, we may try to raise additional funds through public or private financings, strategic relationships, or other arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to raise additional capital in the equity and debt markets, should we choose to do so, will depend upon many factors, including but not limited to, the market demand for Common Stock, which itself is subject to a number of development and business risks and uncertainties, as well as investor perception of our creditworthiness and prospects. It will also depend on a number of factors, including market conditions, interest rates, our operating performance and our credit rating. If we are unable to raise funds on acceptable terms, we may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements. This may seriously harm our business, financial condition and results of operations. If we are not able to continue operations, investors may suffer a complete loss of their investments in our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of Common Stock. Any debt financing that we may secure in the future could involve significant fixed payment obligations and restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when needed, we may need to delay, reduce the scope of or put on hold one or more research and development programs or commercialization efforts while we seek strategic alternatives, and our ability to continue to support our business growth and to respond to business challenges and opportunities could be significantly impaired.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We may also need to seek collaborators for SD-101 and any future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to SD-101 and any future product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. If we otherwise raise funds through collaborations, strategic alliances or licensing agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. Any of the above events could significantly harm our business, prospects, financial condition, and results of operations and cause the price of Common Stock to decline. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, and the continued disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from geopolitical events, including the wars in Ukraine and Israel, and disruptions to the U.S. banking system due to bank failures, particularly in light of the recent events that have occurred with respect to Silicon Valley Bank, Signature Bank, and First Republic Bank. Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry, or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy and business development efforts, which could jeopardize our ability to continue our business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future capital needs may require us to sell additional equity or debt securities that may dilute our stockholders, adversely affect the market price of our Common Stock or introduce covenants that may restrict our operations or our ability to pay dividends.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, such offerings may reduce the market price of the Common Stock, and the terms may include a preference on liquidating distributions or a preference on dividend payments liquidation or other preferences that adversely affect your rights as a stockholder. Thus, existing holders of our Common Stock bear the risk of our future offerings reducing the market price of our Common Stock and diluting their shareholdings in us. For instance, in October 2023, we entered into </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">a standby equity purchase agreement (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Yorkville Purchase Agreement</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) with YA II PN, LTD., a Cayman Islands exempt limited partnership (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Yorkville</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), whereby we have the right, but not the obligation, to sell to Yorkville up to $30.0 million of our Common Stock at our request, subject to terms and conditions specified in the Yorkville Purchase Agreement. We expect to opportunistically seek access to additional funds by utilizing the Yorkville Purchase Agreement. In addition, the incurrence of indebtedness would result in increased fixed or variable payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business, including grants of security interests in our intellectual property. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because our decision to issue additional equity or debt securities in any future offering or to enter into any strategic partnership or licensing arrangement will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, nature or success of our future capital raising efforts or partnership and licensing arrangements. In addition, our ability to raise additional capital through the sale of equity or convertible debt securities could be significantly impacted by the resale of our securities by the Selling Securityholders pursuant to the registration statement of which this prospectus forms a part, which could result in a significant decline in the trading price of our Common Stock and potentially hinder our ability to raise capital at terms that are acceptable to us or at all. In addition, a significant decline in the trading price of our Common Stock could potentially impact our ability to use equity securities as consideration in acquisitions. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, or grant rights to develop and market products or product candidates that we would otherwise develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may issue additional Common Stock from time to time, including under our equity incentive plans. Any such issuances would dilute the interest of our stockholders and likely present other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may issue additional Common Stock from time to time, including under our equity incentive plans or as part of an acquisition. Common Stock reserved for future issuance under our equity incentive plans will become eligible for sale in the public market once those shares are issued, subject to provisions relating to time-based and performance-based vesting conditions, lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. We have filed a registration statement on Form S-8 under the Securities Act to register additional shares we may issue pursuant to our 2023 Equity Incentive Plan (the &#8220;<b style="font-weight:bold;">2023 Plan</b>&#8221;) and 2023 Employee Stock Purchase Plan (&#8220;<b style="font-weight:bold;">ESPP</b>&#8221;). In addition, we may file one or more registration statements on Form S-8 under the Securities Act to register additional Common Stock or securities convertible into or exchangeable for Common Stock issued pursuant to our equity incentive plans. Any future Form S-8 registration statements will automatically become effective upon filing. Accordingly, Common Stock registered under such registration statements may be immediately available for sale in the open market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders if we issue equity securities, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of our equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and related regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, which could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to TriNav</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our revenue is primarily generated from sales of our TriNav device and we are therefore highly dependent on it for our success. Failure to achieve continued market acceptance of TriNav for any reason will harm our business and future prospects.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We began selling TriNav in 2020 in the United States, and sales of TriNav accounted for substantially all of revenue for the three and nine months ended September 30, 2023, and the year ended December 31, 2022. Sales of TriNav are expected to continue to account for primarily all of our revenue going forward. Our ability to execute our growth strategy and become profitable will therefore depend upon the adoption of TriNav by physicians and hospitals, among others.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav is a relatively new drug delivery platform designed to overcome the barriers of the high pressure tumor microenvironment (&#8220;<b style="font-weight:bold;">TME</b>&#8221;). As a result, physician awareness of TriNav, and experience with TriNav, is limited. A number of factors that are outside of our control may contribute to fluctuations in our financial results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physician experience and hospital demand for our products and the extent of adoption of TriNav, including the rate at which physicians recommend TriNav for use on their patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in, or failure to supply product, component and material deliveries by our third-party suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">positive or negative media coverage, or public, patient and/or physician perception, of TriNav or competing products and procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any safety or effectiveness concerns that arise regarding TriNav;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of reimbursement by CMS for purchases of TriNav; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products or procedures for delivering drugs into the tumor microenvironment that compete with TriNav.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no assurance that TriNav will achieve broad market acceptance among physicians and hospitals. Any failure of TriNav to satisfy physician or hospital demand or to achieve meaningful market acceptance will harm our business and future prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business is dependent upon the continued adoption of TriNav by hospitals and physicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our future growth and profitability largely depend on our ability to increase physician awareness and adoption of TriNav and on the willingness of physicians to recommend the device to more of their patients. Physicians may not use our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our product provides a safe and effective treatment alternative for drug delivery. Even if we are able to raise awareness and increase adoption of TriNav </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">among physicians, physicians tend to be slow in changing their medical treatment practices and may be hesitant to select TriNav for recommendation to patients for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long-standing relationships with competing companies and distributors that sell competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Competitive response and negative selling efforts from providers of alternative catheter products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Perceived liability risk generally associated with the use of new products and procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lack of sufficient clinical evidence, including long-term data, supporting the clinical benefits of TriNav;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reluctance to change to or use new products and procedures; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Time commitment and skill development that may be required to gain familiarity and proficiency with TriNav.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Physicians play a significant role in determining the course of a patient&#8217;s treatment and, as a result, the type of treatment that will be recommended or provided to a patient. We focus our sales, marketing, and education efforts primarily on interventional radiologists with the goal of educating these physicians regarding the patient population that we believe would benefit from TriNav. However, we cannot assure you that we will achieve broad education or market acceptance among these practitioners. For example, if treating physicians are not made aware of TriNav, they may not treat patients using our product, and those patients may instead not seek treatment at all or may be treated with alternative products or procedures. In addition, some physicians may choose to utilize TriNav on only a subset of their total patient population or may not adopt TriNav at all. If a physician experiences an adverse event in one or more of their TriNav patients or if any issues with the safety or efficacy of TriNav develop, physicians may not continue offering TriNav as a drug delivery method at the same rate or at all. If we are not able to effectively demonstrate that TriNav is beneficial in a broad range of patients, adoption of TriNav will be limited and may not occur as rapidly as we anticipate, which would have a material adverse effect on our business, financial condition, and results of operations. We cannot assure you that TriNav will achieve broad market acceptance among hospitals and physicians. Any failure of TriNav to satisfy demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the medical device industry&#8217;s interactions and relationships with physicians are under increasing scrutiny by the Health and Human Services Office of the Inspector General (&#8220;<b style="font-weight:bold;">OIG</b>&#8221;), the Department of Justice (&#8220;<b style="font-weight:bold;">DOJ</b>&#8221;), state attorneys general, and other foreign and domestic government agencies. Our failure to comply with laws, rules&#160;and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general or other government agencies, could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In most cases, before physicians can use our products for the first time, our products must be approved for use by a hospital&#8217;s new product or value analysis committee, or the staff of a hospital or health system. Following such approval, we may be required to enter into purchase contracts with such hospital or health system. Such approvals or requirements to enter into a purchase contract could deter or delay the use of our products by physicians. We cannot provide assurance that our efforts to obtain such approvals, enter into purchase contracts, or generate adoption will be successful or increase the use of our products, and if we are not successful, it could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">TriNav is currently subject to an uncertain reimbursement environment, and any change to TriNav&#8217;s reimbursement status that reduces our level of reimbursement could cause TriNav revenue to materially decline and impede market adoption.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We presently benefit from various reimbursement codes in the United States, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare Common Procedure Coding System Code (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HCPCS</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;): C1982; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current Procedural Terminology (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CPT</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) for physicians to support reimbursement for physician-rendered healthcare services Codes: 37242 Mapping and 37243 Treatment.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our approved TPT payment for TriNav was extended on December 29, 2022, through the Consolidated Appropriations Act of 2023 and allows for reimbursement payments in the amount of $7,750 for each catheter through December 31, 2023. The TPT allows for temporary payments above the standard prospective payment rate paid for the procedure (rather than as a cost included in the standard payment). The American Medical Association (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AMA</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) routinely creates these codes for emerging technology, services and procedures. On June 1, 2023, we applied for a new technology APC code with CMS and met with them on June 26, 2023, to review the application. In December 2023, CMS granted a New Technology HCPCS for procedures involving TriNav. This new code, HCPCS C9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 - Level 4 Endovascular Procedures. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers, but there can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Any reduction in the amount of the reimbursement for TriNav will negatively impact the revenue we are able to generate from the sale of TriNav and may hinder our ability to recoup our total investment in TriNav notwithstanding regulatory approval of the product. If we are unable to promptly obtain coverage and profitable payment rates from hospital budgets or government-funded and private purchasers for TriNav or any future products, we may sell fewer units or need to sell them at a lower price. Such changes in revenues would have a material adverse effect on our operating results and our overall financial condition.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">We currently have a limited marketing, sales and distribution organization. If we are unable to successfully grow our marketing, sales and distribution capabilities, then our product revenues related to TriNav, our results of operations and financial condition will suffer.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We currently have limited in-house sales and marketing capabilities. In the past, we have contracted with a limited number of third-party distributors for a significant portion of our commercial sales of TriNav. Our revenues and results of operations were adversely impacted after we discontinued our distributor agreement with Advanced Critical Devices (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ACD</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) in December&#160;2022. Although we continue to further develop an in-house marketing organization and sales force with technical expertise and supporting distribution capabilities to commercialize TriNav, which will require significant capital expenditures, management resources and time, we may be unable to accurately predict the future level of demand for TriNav that will be generated by our existing or potential customers, or the future demand for our medical device products by these customers or new customers. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. We may not be able to build an effective sales and marketing organization with supporting distribution capabilities in the United States, the European Union (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EU</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) or other key global markets in compliance with applicable legal requirements. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact our revenues, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, if we decide to re-enter into arrangements with third parties to perform sales, marketing, and distribution services, our product revenues related to TriNav may be lower than if we were to market, sell and distribute TriNav ourselves. We also would face competition in our search for third parties to assist with the sales, marketing and distribution efforts of TriNav.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Increases in costs, disruption of supply or shortage of materials could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We manufacture TriNav internally, and certain materials necessary to produce our products are sourced from a limited number of suppliers. Any disruption in the supply of materials from such suppliers could disrupt production of our products until such time as a different supplier is fully qualified. As a result, we may experience an increase in costs or inability to meet customer demand. Furthermore, shortages or increased demand of such materials and other economic conditions, like inflation, may cause us to experience significant increases in the cost of materials. In the case of TriNav, substantial increases in the prices for materials used in our production would increase our operating costs and could reduce our margins if we cannot recoup any such increased costs through increased product pricing. Any attempts to increase product prices in response to increased material costs could result in cancellations of product orders and therefore materially and adversely affect our brand, business, prospects and results of operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to SD-101 and Product Development</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">We are early in our pharmaceutical development efforts and we have only one pharmaceutical product candidate, SD-101, in early clinical development. If we are unable to advance our product candidates, including SD-101, in clinical development for any reason (including due to lack of funding), obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business, results of operations, financial condition and prospects may be materially adversely affected.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are in the early stages of our development efforts and have only one product candidate, SD-101, in early clinical development. We have initiated Phase 1 and Phase 1b clinical trials for this product candidate, each of which are focused on a different target indication, specifically: uveal melanoma, intrahepatic cholangiocarcinoma and hepatocellular carcinoma. We will need to progress any early product candidates through IND-enabling studies and submit Investigational New Drug applications (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INDs</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) to the FDA prior to initiating their clinical development. Our ability to generate product revenues from our pharmaceutical candidates, which we do not expect will occur for several&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of these product candidates will depend on several factors, including the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clearance of INDs by the FDA or similar regulatory filings by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrating the safety and efficacy in the proposed indications for use of our product candidates to the satisfaction of applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities, including New Drug Applications (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NDAs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) from the FDA and maintaining such approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining an acceptable safety profile of our products following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">building and maintaining an organization of people who can successfully develop our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of our business depends in part on the successful development, regulatory approval, and commercialization of our product candidate, SD-101, as well as any other future product candidates, which may never occur. We have not yet succeeded in, and we may not succeed in, obtaining marketing approval for SD-101. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate any revenue from our pharmaceutical development efforts and this may have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials of our product candidates or potential product candidates may fail to produce results necessary to support regulatory clearance or authorization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We incur substantial expense for, and devote significant time to, clinical trials but cannot be certain that the trials will ever result in commercial gains. We may experience significant setbacks in clinical trials, even after earlier clinical trials showed promising results, and failure can occur at any time during the clinical development process. Our products may produce undesirable adverse effects that could cause us, institutional review boards (&#8220;<b style="font-weight:bold;">IRBs</b>&#8221;) or regulatory authorities to interrupt, delay or halt clinical trials. We, IRBs, the FDA, or another regulatory authority may suspend or terminate clinical trials at any time to avoid exposing trial participants </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to unacceptable health risks. Our clinical trials may produce negative or inconclusive results or may demonstrate a lack of effect of our product candidates. Additionally, the FDA may disagree with our interpretation of the data from our pilot studies and clinical trials, or may find the clinical trial design, conduct or results inadequate to demonstrate safety or effectiveness, and may require us to pursue additional clinical trials, which could further delay the clearance or authorization of our product candidates. If we are unable to demonstrate the safety and effectiveness of product candidates in our clinical trials, we will be unable to obtain the regulatory clearances or authorizations we need to commercialize new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim, &#8220;topline&#8221; and preliminary data from clinical trials of our product candidates may change as more patient data becomes available and are subject to confirmation, audit, and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data is available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical development is a lengthy and expensive process with an uncertain outcome. In addition, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials. Failure can occur at any stage of clinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many&#160;years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process and may result from a multitude of factors both within and outside our control, including flaws in formulation, adverse safety or efficacy profiles and flaws in trial design, among others. To obtain the requisite regulatory approvals or clearances to market and sell any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans for use in each target indication. The results of preclinical studies and early clinical trials of SD-101 and any future drug candidates may not be predictive of the results of later-stage clinical trials, making it impossible to predict when or if any of our product candidates will prove safe or effective in humans or receive regulatory approval or clearance. The results generated to date in preclinical studies for our product candidates do not ensure that later preclinical studies or clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and earlier-stage clinical trials. In later-stage clinical trials, we will likely be subject to more rigorous statistical analyses than in completed earlier-stage clinical trials. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval or clearance of these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other clinical trial protocols, and the rate of dropout among clinical trial participants. If the trials result in negative or inconclusive results, we or our collaborators or partners may decide, or regulators may require them, to discontinue trials of our drug candidates or conduct additional clinical trials or preclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. For these reasons, our future clinical trials may not be successful. If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval or clearance and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Also, we cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including challenges resulting from COVID-19, labor shortages, and global supply chain interruptions. Any inability to timely and successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to achieve regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">additional testing to bridge our modified product candidate to earlier versions. Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals or clearances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and could jeopardize or delay our ability to obtain regulatory approval and commence future product sales. We may also find it difficult to enroll patients in our clinical trials, which could delay or prevent the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in clinical trials of our drug candidates. Planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to raise or delays in raising funding necessary to initiate or continue a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement with the FDA on final trial design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective contract manufacturing organizations (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CMOs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), or contract research organizations (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CROs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and clinical trial sites, or failure by such CMOs to complete the manufacturing of clinical trial materials or CROs to follow and carry out the clinical study protocol at each site in accordance with the terms of our agreements with them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining required IRB, approval at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties or delays in having patients&#8217; complete participation in a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites electing to terminate their participation in one of our clinical trials, which would likely have a detrimental effect on subject enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time required to add new clinical sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays by prospective CMOs to produce and deliver sufficient supply of clinical trial materials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If initiation or completion of our planned clinical trials is delayed for any of the above reasons or other reasons, our development costs may increase, our regulatory approval process could be delayed and our ability to commercialize and commence sales of our drug candidates could be materially harmed, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, identifying and qualifying patients to participate in clinical trials of our drug candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our drug candidates as well as completion of required follow-up periods. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics or to complete our clinical trials in a timely manner. Patient enrollment is and completion of the trials are affected by a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity and prevalence of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria for the trial in question;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of the drug candidate under trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of competing therapies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to monitor patients adequately during and after treatment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">SD-101 relies on oligonucleotide TLR agonists. Serious adverse event data relating to TLR agonists may require us to reduce the scope of or discontinue certain of our pre-clinical or clinical activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SD-101 is composed, in part, of TLR9 agonist CpG oligonucleotides. If SD-101 or any of our future product candidates in clinical trials or similar products from competitors produce serious adverse event data, we may be required to delay, discontinue, or modify many of our clinical trials or our clinical trial strategy. If a safety risk based on mechanism of action or the molecular structure were identified, it may hinder our ability to develop our product candidates or enter into potential collaboration or commercial arrangements. Rare diseases and a numerical imbalance in cardiac adverse events have been observed in patients in our clinical trials. If adverse event data are found to apply to our TLR agonist and/or inhibitor technology as a whole, we may be required to significantly reduce the scope of or discontinue certain of our pre-clinical or clinical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our long-term prospects are dependent on the success of our development-stage products including SD-101, which depend on regulatory approval. Failure to maintain or obtain regulatory approvals would materially and adversely impact us and our business prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our long-term prospects are dependent on SD-101, currently our sole development-stage immune-oncology product candidate, and early-stage development is inherently risky. Even if we have early indications of success in clinical development, in order to be able to market SD-101 in the United States, we must obtain approval from the FDA, and corresponding applications to foreign regulatory agencies must be approved by those agencies before we may sell the product in respective geographic areas. Obtaining FDA marketing approval and corresponding foreign applications is highly uncertain and we may fail to obtain approval, or might obtain approval in a more limited indication than sought. The FDA review process is extensive, lengthy, expensive and uncertain, and the FDA or foreign regulatory agencies may delay, limit or deny approval of our application for many reasons, including: whether the data from our clinical trials or the development program are satisfactory to the FDA or foreign regulatory agency; disagreement with the number, design, size, conduct or implementation of our clinical trials or proposed post-marketing study, or a conclusion that the data fails to meet statistical or clinical significance or safety requirements; acceptability of data generated at our clinical trial sites that are monitored by third-party CROs; and deficiencies in our manufacturing processes or facilities or those of our third-party contract manufacturers and suppliers, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that we determine to commercialize SD-101 outside the United States, such as in Europe, whether we can do so successfully will depend upon us receiving regulatory approval, which can be costly and time-consuming, and there is a risk that one or more regulatory bodies may require that we conduct additional clinical trials and/or take other measures which will take time and require us to incur significant additional expense. In addition, there is the risk that we may not receive approval in one or more jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we obtain guidance from regulatory authorities on certain aspects of our clinical development activities and seek to comply with written guidelines provided by such authorities. These discussions and written guidelines are not binding obligations on the part of the regulatory authorities and the regulatory authorities may require additional patient data or studies to be conducted. Regulatory authorities may revise or retract previous guidance during the course of a clinical trial or after the completion of the trial. The authorities may also disqualify a clinical trial from consideration in support of approval of a potential product if they deem the guidelines have not been met. The FDA or foreign regulatory agencies may determine our clinical trials or other data regarding safety, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">efficacy or consistency of manufacture or compliance with GMP regulations are insufficient for regulatory approval. Failure to maintain or obtain regulatory approvals would materially and adversely impact us and our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community, which could materially adversely impact our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our sole pharmaceutical product candidate, SD-101, may never be approved for marketing as a potential cancer treatment. To the extent SD-101 is approved for marketing as a potential cancer treatment, it may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether SD-101 is accepted in the market, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which SD-101 is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians, hospitals, cancer treatment centers and patients considering SD-101 as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of SD-101 over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate the advantages of SD-101 over other cancer medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of SD-101 as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If SD-101 is approved by the FDA but fails to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, our business and prospects will be adversely affected. Even if SD-101 achieves market acceptance, it may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than SD-101, are more cost-effective or render SD-101 obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, although SD-101 differs in certain ways from other approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our products do not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community, this could materially adversely impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in existing third-party coverage or our inability to secure advantageous reimbursement codes may impact our ability to sell our products, which would materially and adversely impact our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maintaining and growing sales of TriNav, and any future product candidates, depends, in part, on the availability of coverage and adequate reimbursement from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs. The process for determining whether a third-party payor will provide coverage for a product or procedure may be separate from the process for establishing the reimbursement rate that such a payor will pay for the product or procedure. A payor&#8217;s decision to provide coverage for a product or procedure does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product or procedure does not assure that other payors will also provide such coverage. Adequate third-party reimbursement may not be available to enable us to achieve profitability. We may be unable to sell our products on a profitable basis if third-party payors deny coverage or reduce any existing levels of payment, or if our costs of production increase faster than increases in reimbursement levels.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For example, our TPT payment for TriNav was extended on December 29, 2022, through the Consolidated Appropriations Act of 2023 and allows for reimbursement payments in the amount of $7,750 for each catheter through December 31, 2023. On June 1, 2023, we applied for a new technology APC code with CMS. We met with CMS on June 26, 2023 to review the application. In December 2023, CMS granted a New Technology HCPCS for procedures involving TriNav. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers, but there can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all. If TriNav does not receive adequate reimbursement, this would materially and adversely impact our business, results of operations, financial conditions, and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the reimbursement process is complex and can involve lengthy delays. Also, third-party payors may reject, in whole or in part, requests for reimbursement based on determinations that certain amounts are not reimbursable under plan coverage, that services provided were not medically necessary, that additional supporting documentation is necessary, or for other reasons. Retroactive adjustments by third-party payors may be difficult or cost-prohibitive to appeal, and such changes could materially reduce the actual amount we receive. Delays and uncertainties in the reimbursement process may be out of our control and could have a material adverse effect on our business, prospects, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the reimbursement by third-party payors for our product and the amount that we may receive in payment for our products may be materially and adversely affected by factors we do not control, including federal or state regulatory or legislative changes, and cost-containment decisions and changes in reimbursement schedules of third-party payors or product purchasers (such as hospitals). Lack of reimbursement or any reduction or elimination of these payments could have a material adverse effect on our business, prospects, results of operations and financial condition. Furthermore, the healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Therefore, we cannot be certain that the procedures using our products will be reimbursed at a cost-effective level. Nor can we be certain that third-party payors using a methodology that sets amounts based on the type of procedure performed, such as those utilized by government programs and in many privately managed care systems, will view the cost of our products to be justified so as to incorporate such costs into the overall cost of the procedure. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to achieve profitability. Moreover, we are unable to predict what changes will be made to the reimbursement methodologies used by third-party payors in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The business and industry in which we participate are highly competitive. If we are unable to compete effectively, we will not be able to establish our products in the marketplace or maintain or grow our products&#8217; market share in the marketplace, and as a result, our business and results of operations will be adversely impacted.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The biopharmaceutical and medical device industries are characterized by intense competition and rapid innovation. Our competitors may be able to develop other devices or drugs that are able to achieve similar or better results. Potential competitors for </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriNav and SD-101 include major multinational medical device and pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of these competitors have substantially greater financial, technical, and other resources than we do, such as larger research and development staff, experienced marketing and manufacturing organizations, well-established sales forces, and name recognition. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than SD-101 or may develop proprietary technologies or secure patent protection that we may need for the development of our drug delivery technologies and products or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The availability and price, and in the case of SD-101, if approved, its FDA-approved labeling versus that of competitors of our competitors&#8217; products could limit the demand and the price we are able to charge for TriNav and SD-101, if approved. We may not be able to implement our business plan if the acceptance of TriNav or SD-101 is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment, or if physicians switch to other new drug or biologic products or drug delivery systems or choose to reserve TriNav and/or SD-101 for use in limited circumstances. For additional information regarding our competition, see the section titled &#8220;<i style="font-style:italic;">Our Business&#8201;&#8212;&#8201;Competition</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may, in the future, enter into material collaborations, in-licensing arrangements, joint ventures, or strategic alliances with third parties that may not result in the development of commercially viable products or the generation of significant or any future revenues. Alternatively, part of our strategy is to enter into such kinds of relationships with third parties involving our products and product candidates, and we may not be able to do so on acceptable terms or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, or strategic alliances to develop and/or commercialize our products or product candidates and/or to pursue new markets. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, and strategic alliances may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenues or otherwise achieve their goals and could be terminated prior to developing any products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and growth strategy depend on the continued ability of TriNav to remain a preferred product among a community of established, board-certified physicians and other provider specialists and to expand such community. If we are unable to do so, our future growth would be limited and our business would be harmed.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our success is dependent upon the continued ability of TriNav to remain a preferred product among a community of independent, established, board-certified physicians and other provider specialists who choose to use TriNav in their medical practice. Fulfilling our </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">clinical and customer service obligations requires a robust supply of physicians. If we are unable to attract and engage with board-certified physicians and other healthcare professionals to expand our community, it would harm our business and ability to grow and would adversely affect our results of operations. In any particular market, the hospitals that purchase TriNav for use by these providers could demand higher payments or take other actions that could result in higher costs or difficulty meeting regulatory or accreditation requirements. Our ability to develop and maintain satisfactory relationships with these providers, and to attract and engage with new providers, also may be negatively impacted by other factors not associated with us, such as changes in Medicare and/or Medicaid reimbursement levels and other pressures on healthcare providers and consolidation activity among hospitals, physician groups and healthcare providers. The failure to maintain or to secure new cost-effective contracts with the hospitals may result in a loss of or inability to grow our customer base, higher costs and/or healthcare provider community disruptions, any of which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We generally do not have long-term contractual commitments from our customers, and our customers may choose not to enter into new agreements with us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We generally do not have long-term contractual commitments with our customers. Our TriNav customers can terminate many of our consignment agreements with or without cause, in some cases subject only to 30&#160;days&#8217; prior notice in the case of termination without cause. Although a substantial majority of our revenue is typically generated from existing customers, our engagements with our customers are typically for orders that are singular in nature. Large consignment orders may involve multiple deliveries or stages, and a customer may choose not to replace inventory with TriNav devices or may cancel or delay additional planned orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we successfully deliver on contracted orders and maintain close relationships with our customers, a number of factors outside of our control could cause the loss of or reduction in business or revenue from our existing customers. The loss or diminution in business from any of our major customers could have a material adverse effect on our business, financial condition, results of operations and prospects. The ability of our customers to terminate agreements exacerbates the uncertainty of our future revenue. We may not be able to replace any customer that elects to terminate or not renew its contract with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to effectively manage our growth or achieve anticipated growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of our future operating activities will depend upon our ability to expand our support system to meet the demands of our growing business. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and marketing, research, drug development and regulatory affairs. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. We will be required to manage multiple relationships with various customers, clinical investigators, manufacturers and suppliers, consultants and other third parties. This expansion and these expanded relationships will require us to significantly improve or replace our existing managerial, operational and financial systems, procedures and controls; to improve the coordination between our various corporate functions; and to manage, train, motivate and maintain a growing employee base. The time and costs to effectuate these steps may significantly strain our management personnel, systems and resources, particularly given the limited amount of financial resources and skilled employees that may be available at the time. We may not be able to institute, in a timely manner or at all, the improvements to our managerial, operational and financial systems, procedures and controls necessary to support our anticipated increased levels of operations and to coordinate our various corporate functions, or that we will be able to properly manage, train, motivate and retain our anticipated increased employee base. Any failure by our management to effectively anticipate, implement, and manage changes required to sustain our growth would have a material adverse effect on our business, financial condition, and results of operations. We cannot assure you that we will be able to successfully operate acquired businesses, if any, become profitable in the future, or effectively manage any other change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our future performance depends to a large extent on the continued services of members of our current management including, in particular, our Chief Executive Officer, Chief Medical Officer and Chief Financial Officer. If any of these key executive officers were to leave us, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in both a delay in the implementation of our business plan and the diversion of limited working capital. The unique knowledge and expertise of these individuals would be difficult to replace. In the event that we lose the continued services of such key personnel for any reason, this could have a material adverse effect on our business, operations and prospects. In addition, we will be required over the longer-</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">term to hire highly skilled managerial, scientific and administrative personnel to fully implement our business plan and growth strategies. Due to the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified scientific, technical and managerial personnel. If we cannot attract and retain such personnel, we will be unable to develop our product candidates and achieve regulatory clearance for them, which would have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of October 16, 2023,we had approximately 106 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and marketing, research, drug development and regulatory affairs. Competition for skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, in a timely manner or at all. In particular, we have experienced a very competitive hiring environment. Many of the other biotechnology and medical device companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity incentive awards that vest over time. The value to employees of stock options or other equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams are at-will employees and may terminate their employment with us on short notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Given the stage of our programs and our plans to expand operations, our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior personnel across the organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Workforce shortages may continue to negatively impact our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Workforce shortages have resulted in staffing challenges experienced by us and by third parties that we utilize, including but not limited to manufacturing and testing organizations, CROs and clinical trial sites. If these challenges continue for any period of time, our anticipated timing of clinical trials and product development may be delayed and our product inventory may not meet demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to promote, protect, and maintain our brand in a cost-effective manner, we may lose market share and our ability to commercialize our products and revenues will suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to further develop our business depends on our ability to build a strong and trusted brand. We are in the process of building our brand, and once achieved, we believe that developing, protecting, and maintaining awareness of our brand in a cost-effective manner will be critical to continuing to develop our business. Successful promotion of our brand will entail broadening our brand among physicians and hospitals and will depend largely on the effectiveness of our marketing efforts and the experience of physicians who use our products and product candidates in treating their patients. Our efforts to build our brand have involved significant expense, and we expect to increase our marketing spend in the near term. These brand promotion activities may not result in increased revenue and, even if they do, any increases may not offset the expenses incurred. Additionally, the successful protection and maintenance of our brand will depend on our ability to obtain, maintain, protect and enforce trademark and other intellectual property protection for our brand. If we fail to successfully promote, protect and maintain our brand, or if we incur substantial expenses in an unsuccessful attempt to promote, protect and maintain our brand, we may be unable to broaden the use of our products and product candidates among physicians and hospitals, which would have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The medical device and drug development industries are characterized by rapid, continuous innovation, and if we cannot keep pace with rapid innovation in those industries, our products and product candidates will become less competitive and our ability to commercialize our products and revenues will suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The medical device and drug development industries are highly competitive and characterized by rapid and significant change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete or less competitive. Many of our current and potential competitors have substantially greater financial, manufacturing, marketing and technical resources than we do. Larger competitors may have substantially larger sales and marketing operations than we have or plan to have and may </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">have greater name recognition. This may allow those competitors to spend more time with potential customers and to focus on a larger number of potential customers, which would give them a significant advantage over the sales and marketing team we would use in making sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Larger competitors may also have broader product lines, which enable them to offer customers bundled purchase contracts and quantity discounts. These competitors may have more experience than we have in research and development, marketing, manufacturing, preclinical testing, conducting clinical studies, obtaining FDA and foreign regulatory approvals or certifications and marketing approved or certified products. Our competitors may discover technologies and techniques, or enter into partnerships and collaborations, to develop competing products that are more effective or less costly than our products or the products we may develop. There can be no assurance that other companies will not succeed in developing or marketing products that are more effective than our products or product candidates or that would render our products or product candidates obsolete or noncompetitive. Academic institutions, government agencies, and other public and private research organizations may seek patent protection regarding potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors. Our competitors may be better equipped than we are to respond to competitive pressures. Competition will likely intensify.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, many healthcare provider systems are consolidating to create new companies with greater market power, and we expect that to continue. As the healthcare provider systems consolidate, competition among suppliers to healthcare provider systems will become more intense. Healthcare provider systems may try to use their market power to negotiate price concessions or reductions for our products. If we reduce our prices because of consolidation in the healthcare industry, our revenue would decrease and our results of operations and financial condition would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The manufacturing of our product candidates may require outsourced, custom manufacturing, and we may encounter difficulties in production, particularly with respect to formulation, process development or scaling up of our manufacturing capabilities. If our third-party manufacturers or suppliers encounter such difficulties, our ability to provide supply of product candidates for preclinical studies, clinical trials or products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of developing our product candidates, we expect that various aspects of the development program, such as manufacturing methods, may be altered along the way to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned preclinical studies or future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If either we or any third-party we rely on for materials used in the production of our product candidates is adversely affected by ongoing supply chain constraints, we and our third-party manufacturers may be unable to timely manufacture product candidates for our clinical trials. Although we are working to develop commercially viable manufacturing processes, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale up or formulation, process reproducibility, stability issues, lot consistency and timely availability of reagents or raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these challenges could delay completion of preclinical studies or clinical trials, require bridging studies or trials, or the repetition of one or more studies or trials, increase development costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently rely on, and may in the future rely on, third-party contractors, including certain sole-source suppliers and manufacturers, to supply and manufacture preclinical, clinical and commercial drug supplies for SD-101 and any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not currently have the internal infrastructure to supply or manufacture preclinical, clinical or commercial quantities of our drug candidate, SD-101. While we have a supply of SD-101 sufficient for our ongoing clinical trials, we do not currently have a supplier for SD-101. If we are not able to establish a reliable supplier for SD-101 before our supply is exhausted, our clinical trials may be delayed.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be unable to establish agreements and validate third-party manufacturers and suppliers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers and suppliers entails additional risks, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for sufficient quantity and quality;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing or supply agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to manufacture or supply SD-101 according to our specifications, schedule or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or comparator not being properly identified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">misappropriation of our proprietary information, including our trade secrets and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reliance on the third party for regulatory compliance, quality assurance and safety reporting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thus, our current and anticipated future dependence upon others for the manufacture or supply of SD-101 or other product candidates and materials may adversely affect our development timeline, our future profit margins or our ability to commercialize SD-101 or any future product candidates that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture. We may also have sole-source suppliers for one or more of our other product candidates. Some of the active pharmaceutical ingredients (&#8220;<b style="font-weight:bold;">APIs</b>&#8221;) and other substances and materials used in our product candidates are currently available only from one or a limited number of domestic or foreign suppliers and foreign manufacturers and certain of our finished product candidates are manufactured by one or a limited number of contract manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event an existing supplier or manufacturer fails to supply or manufacture, as applicable, product or product candidate on a timely basis or in the requested amount, fails to meet regulatory requirements or our specifications, becomes unavailable through business interruption or financial insolvency or loses regulatory status as an approved source, or if we or our manufacturers are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we likely would incur added costs and delays in identifying or qualifying replacement suppliers, manufacturers and materials and there can be no assurance that replacements would be available to us on a timely basis, on acceptable terms or at all. In certain cases, we may be required to get regulatory approval to use alternative suppliers and manufacturers, and this process of approval could delay the production of our products or development of product candidates indefinitely. We and our manufacturers do not currently maintain inventory of these APIs and other substances and materials. Any interruption in the supply of an API or other substance or material or in the manufacture of a finished product could have a material adverse effect on our business, financial condition, operating results and prospects.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Although we are ultimately responsible for ensuring compliance with regulatory requirements such as current Good Manufacturing Practices (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">cGMPs</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), we are dependent on our contract suppliers and manufacturers for day-to-day compliance with cGMPs for production. Facilities used by our contract suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. Our contract suppliers and manufacturers must comply with cGMP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information. If our contract suppliers or manufacturers fail to achieve and maintain compliance with applicable laws and regulatory requirements, our business could be adversely affected in a number of ways, and cause, among other things:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to initiate or continue clinical trials of our product candidates under development;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party manufacturing facilities or our own facilities to be subjected to additional inspections by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to cease distribution or to recall batches of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of manufacturing of our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revocation of obtained approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to meet commercial demands for our products or product candidates in the event of approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, if the safety of any product or product candidate or component is compromised due to a failure to adhere to applicable laws and regulatory requirements, or for other reasons, we may not be able to successfully commercialize or obtain regulatory approval for the affected product or product candidate, and we may be held liable for injuries sustained as a result. Any of these factors could cause a delay or termination of preclinical studies, clinical trials or regulatory submissions or approvals of our product candidates and could entail higher costs or result in us being unable to effectively commercialize our approved products on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future, but supply and manufacturing arrangements do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. We and our contract suppliers and manufacturers may attempt to improve production processes, certain aspects of which are complex and unique, and we may encounter difficulties with new or existing processes. While we attempt to build in certain contractual obligations on such third-party suppliers and manufacturers, we may not be able to ensure that such third parties comply with these obligations. Depending on the extent of any difficulties encountered, we could experience an interruption in clinical or commercial supply, with the result that the development, regulatory approval or commercialization of our products or product candidates may be delayed or interrupted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our risk management processes and procedures may not be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we have dedicated resources to develop risk management processes and procedures intended to identify, measure, monitor and control the types of risk we are subject to, including liquidity risk, strategic risk, operational risk, cybersecurity risk, healthcare regulatory compliance risk, product liability risk, and reputational risk, those procedures may not be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risk is inherent in our business, and therefore, despite our efforts to manage risk, there can be no assurance that we will not sustain unexpected losses. We could incur substantial losses and our business operations could be disrupted to the extent our business model, operational processes, control functions, technological capabilities, risk analyses, and business/product knowledge do not adequately identify and manage potential risks associated with our business operations and strategic initiatives. There also may be risks that exist, or that develop in the future, that we have not appropriately anticipated, identified or mitigated, including when processes are changed or new products are introduced. If our risk management framework does not effectively identify and control our risks, we could suffer unexpected losses or be adversely affected, which could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the ordinary course of our business, we and the third parties upon which we rely may process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, which could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications and electrical failures, earthquakes, fires, floods, and other similar threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks and other threats to our business operations. We may rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business, including clinical trial sites and investigators, contractors, manufacturers, suppliers, and consultants. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the information security measures we have adopted will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, including government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm (including but not limited to damage to our patient, partner, or employee relationships); monetary fund diversions; interruptions in our operations (including availability of data and interruptions to our clinical trial operations); financial loss; delay in the development and commercialization of our products and product candidates; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Natural or man-made disasters and other similar events may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to make, move and sell products in coordination with our suppliers, manufacturers and business partners is critical to our success. Damage or disruption to our collective supply, manufacturing or distribution capabilities resulting from weather, any potential effects of climate change, natural disasters, pandemics or other outbreaks of contagious diseases, fire, explosion, cyber-attacks, terrorism, strikes, repairs or enhancements at facilities manufacturing or delivering TriNav or other reasons could impair our ability to manufacture, sell or timely deliver TriNav to customers and patients. Further, such damage or disruption to the supply, manufacturing, or trial sites of SD-101 could impair our ability to complete our clinical trials on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on a limited number of third-party suppliers and manufacturers. Adverse events affecting such suppliers or manufacturers may limit our ability to obtain the materials they supply or manufacture for us, or alternatives at competitive prices, or at all. Competitors can be affected differently by weather conditions and natural disasters depending on the location of their suppliers and operations. Failure to take adequate steps to reduce the likelihood or mitigate the potential impact of such events, or to effectively manage such events if they occur, particularly when materials are sourced from a single location or supplier or produced by a single manufacturer, could adversely affect our business, financial condition, results of operations and/or require additional resources to restore our supply chain or manufacturing capabilities, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any acquisitions, strategic investments, entries into new businesses, joint ventures, divestitures, and other transactions could fail to achieve strategic objectives, disrupt our ongoing operations, result in operating difficulties, liabilities and expenses, harm our business, or negatively impact our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate and consider strategic transactions, combinations, acquisitions, dispositions, joint ventures or similar transactions. These transactions could be material to our financial condition and results of operations if consummated. If we are able to identify an appropriate business opportunity, we may not be successful in negotiating favorable terms and/or consummating the transaction and, even if we do consummate such a transaction, we may be unable to obtain the benefits or avoid the difficulties and risks of such transaction. Any strategic transaction, combination, acquisition, disposition, joint venture or similar transaction will involve risks encountered in business relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in assimilating and integrating the operations, personnel, systems, data, technologies, products and services of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability of the acquired technologies, products or businesses to achieve expected levels of revenue, profitability, productivity or other benefits;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in retaining, training, motivating and integrating key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s time and resources from our normal daily operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in successfully incorporating licensed or acquired technology and rights into our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in maintaining uniform standards, controls, procedures, and policies within the combined organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in retaining relationships with customers, employees, and suppliers of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks of entering markets in which we have no or limited prior experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory risks, including remaining in good standing with existing regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with oversight over an acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumption of contractual obligations that contain terms that are not beneficial to us, require us to license or waive intellectual property rights, or increase our liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully further develop any acquired product candidates or technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability for activities of the acquired or disposed of business before the acquisition or disposition, including patent and trademark infringement claims, violations of laws, regulatory actions, commercial disputes, tax liabilities, assumed debt and other known and unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in separating assets and replacing shared services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential disruptions to our ongoing businesses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected costs and unknown risks and liabilities associated with the specific transaction.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not make any strategic transactions, combinations, acquisitions, dispositions, joint ventures or similar transactions, or any future transactions, combinations, acquisitions, dispositions, joint ventures or similar transactions may not be successful, may not benefit our business strategy, may not generate sufficient revenue to offset the associated costs, or may not otherwise result in the intended benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It may take us longer than expected to fully realize the anticipated benefits and synergies of these transactions, including the Business Combination, and those benefits and synergies may ultimately be smaller than anticipated or may not be realized at all, which could adversely affect our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any strategic transactions, combinations, acquisitions, dispositions, joint ventures or similar transactions may also require us to issue additional equity securities, spend our cash, or incur debt (and increase our interest expense), liabilities, and amortization expenses related to intangible assets or write-offs of goodwill, which could adversely affect our results of operations and the interests of holders of our indebtedness and dilute the economic and voting rights of our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we cannot assure you that any future acquisition of new businesses, products, product candidates or technologies will lead to the successful integration of any products, product candidates or technologies acquired with our existing operations or the successful development of new or enhanced products or that any new or enhanced products, if developed, will achieve market acceptance or prove to be profitable. Further, we may also choose to divest certain businesses or product lines that no longer fit with our strategic objectives. If we decide to sell assets or a business, we may have difficulty obtaining terms acceptable to us in a timely manner, or at all. Additionally, the terms of such potential transactions may expose us to ongoing obligations and liabilities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Legal and Regulatory Environment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to numerous complex regulatory requirements, and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research, pre-clinical testing, clinical trials, manufacturing, marketing and distribution of medical devices, human drugs and biologics and combination products are subject to regulation by numerous governmental authorities in the United States and other jurisdictions, if we desire to export the resulting products to such other jurisdictions. These regulations govern or affect the testing, manufacture, safety, effectiveness, labeling, storage, record-keeping, approval or clearance, distribution, advertising and promotion of product candidates, as well as safe working conditions. In some cases, the FDA requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the United States. The FDA and foreign regulatory authorities have substantial discretion to require additional testing, to delay or withhold registration and marketing approval or clearance and to otherwise preclude distribution and sale of a product. In addition, regulatory approval or clearance could impose limitations on the indicated or intended uses for which product candidates may be marketed, and impose post-approval requirements. Our failure to obtain approval or clearance, significant delays in the approval or clearance process, or our failure to maintain approval or clearance in any jurisdiction will prevent us from selling any applicable products in that jurisdiction. We would not be able to realize revenues for those new products in any jurisdiction where we do not have approval or clearance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even after a product candidate has been approved, the FDA and comparable governmental authorities subject such product to continuing review and regulatory requirements including, for example, the reporting of safety issues or adverse events associated with use of an approved drug or cleared or approved device. These authorities may, in certain circumstances, require us to conduct and report the results of certain clinical studies or trials and to commit to voluntarily conducting additional clinical trials. Developments following regulatory approval or clearance may adversely affect sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with, or changes to applicable regulatory requirements may result in a variety of consequences, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on our products or the manufacturing processes of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters and cyber letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of a product from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voluntary or mandatory recall of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of regulatory approvals or clearances for a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">denial of permission to file an application or supplement in a jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">debarment, exclusion from participation in federal healthcare programs, exclusion or debarment from government contracting, consent decrees, or corporate integrity agreements;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seizure or detention of products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties against us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More stringent oversight by the FDA and other agencies in recent&#160;years has resulted in increased enforcement activity, which increases our compliance risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we or our partners do not perform particular regulated functions themselves but contract out to third parties, including contract manufacturers, contract research organizations, clinical trial sites, and laboratories, we or our partners may be held responsible for such third parties&#8217; failure to follow the applicable regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The complexity of a combination product that includes a drug and a medical device presents additional, unique development and regulatory challenges, which may adversely impact our development plans and our ability to obtain regulatory approval or clearance of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may decide to pursue marketing authorization for a combination product comprised of drug candidates and medical devices. A combination product includes, among other possibilities, a combination of a drug and device intended to be used together, according to their proposed labeling where both are required to achieve the intended use, indication or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developing and obtaining regulatory approval or clearance for combination products pose unique challenges because they involve components that are regulated by the FDA pursuant to different regulatory frameworks and by different FDA centers. As a result, such products raise regulatory, policy and review management challenges. For example, because divisions from both FDA&#8217;s Center for Drug Evaluation and Research and FDA&#8217;s Center for Devices and Radiological Health must review submissions concerning product candidates that are combination products comprised of drug and devices, the regulatory review and approval or clearance process for these products may be lengthened. In addition, differences in regulatory pathways for each component of a combination product can impact the regulatory processes for all aspects of product development and management, including clinical investigation, marketing applications, manufacturing and quality control, adverse event reporting, promotion and advertising, user fees and post-approval modifications. Similarly, the device components of our product candidates will require any necessary approvals or clearances or other marketing authorizations or certifications in other jurisdictions, which may prove challenging to obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to use the FDA&#8217;s expedited drug development programs for SD-101 but may not be able to achieve expedited development or approval for this product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has established various expedited drug development programs to facilitate more rapid and efficient development, review and approval of certain types of drugs. Such programs include fast track designation, breakthrough therapy designation, accelerated approval, and priority review. We intend to use one or more expedited drug development programs for SD-101. The FDA has broad discretion on whether or not to admit a drug candidate for these programs, so even if we believe a particular product candidate is eligible for an expedited drug development program, we cannot assure you that the FDA would agree. Even if any of our product candidates is admitted to any of the expedited drug development programs, we may not experience a faster development process, review or approval compared to conventional FDA approval timelines, and the FDA may still decline to approve such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast track designation is designed to facilitate the development and expedite the review of therapies for serious conditions that fill an unmet medical need. Programs with fast track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. If any of our product candidates receive fast track designation but do not continue to meet the criteria for fast track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply or due to other issues, we will not receive the benefits associated with the fast track program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">FDA may award breakthrough therapy designation to a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Designation as a breakthrough therapy is within the discretion of the FDA. Even if one or more of our product candidates qualify as breakthrough therapies pursuant to FDA standards, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we may seek breakthrough therapy designation for one or more of our current or future product candidates, there can be no assurance that we will receive breakthrough therapy designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our programs or product candidates receive fast track or breakthrough therapy designation by the FDA or similar designations by other regulatory authorities, there is no assurance that we will receive any benefits from such programs or that we will continue to meet the criteria to maintain such designation. Even if we obtain such designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track or breakthrough therapy designation does not ensure that a product candidate will receive marketing approval or that approval will be granted within any particular time frame. In addition, the FDA may withdraw any such designation if it believes that the designation is no longer supported by data from our clinical development program upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of SD-101 or any future product candidates. Any marketing approval we or our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive orphan drug designation for any of our product candidates, we may be unable to maintain the benefits associated with such designation, including the potential for market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the EU, may also designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products evaluates orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers, and it may entitle the therapeutic to exclusivity. Regulatory authorities may not grant our requests for orphan designation or may require submission of additional data before making such determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we receive orphan drug designation for any of our product candidates, there is no guarantee that it will obtain approval or orphan drug exclusivity for such product candidates. Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product candidates from competition because different therapies can be approved for the same condition and the same therapy could be approved for different conditions. Even after an orphan drug is approved, the FDA can subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease for which it received orphan designation. On January 24, 2023, the FDA announced its intention to apply its existing regulations and long-standing approach to grant orphan drug exclusivity based on the indications for which the drug is approved rather than granting the exclusivity for the entire rare disease or condition that was the subject of the orphan drug designation, in response to the U.S. Court of Appeals for the Eleventh Circuit&#8217;s September 30, 2021, decision in <i style="font-style:italic;">Catalyst Pharms., Inc. v. Becerra</i>. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, under the Inflation Reduction Act of 2022 (&#8220;<b style="font-weight:bold;">IRA</b>&#8221;), orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA, SEC and other government agencies (e.g., CMS) caused by funding shortages or global health concerns could hinder our ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new medical devices, drugs or biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the United States government has shut down several times, certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, in response to the COVID-19 pandemic, the FDA had to postpone inspections of foreign and domestic manufacturing facilities and products. While such inspections have resumed, the FDA may use remote interactive evaluations where in-person inspections are not feasible or may defer action due to factors including travel restrictions. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, if we or any future collaborators experience delays in obtaining approval or clearance or if we or they fail to obtain approval or clearance of SD-101 or any future product candidates, the commercial prospects for these product candidates may be harmed, and our ability to generate revenues will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval or clearance process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals or clearances for the commercialization of SD-101 or any future product candidates. If we or any future collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals or clearances, we or they will not be able to commercialize SD-101, and our ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The activities associated with SD-101 or other product candidates&#8217; development and commercialization, including testing, manufacturing, safety, efficacy, record keeping, labeling, storage, approval or clearance, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States. Additionally, in order to commercialize, develop, market and sell our products in the European Union, Canada, the United Kingdom, China or other countries and many other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals or clearances and comply with numerous and varying regulatory requirements for comparable regulatory authorities in these other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to obtain marketing approval or clearance for SD-101 or any future product candidates will prevent us from commercializing them. We have not received approval to market SD-101 from regulatory authorities in any jurisdiction. We have limited experience in the designing of clinical trials, in obtaining authorization and in conducting clinical trials in various countries and expect to rely on third-party CROs to assist us in this process. Securing marketing approval or clearance requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SD-101 or any future product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or clearance or prevent or limit commercial use. The success of our product candidates will depend on several additional factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful initiation of, patient enrollment in, and completion of clinical trials that demonstrate their safety and efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receiving marketing approvals or clearances from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property rights and regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing any post-marketing studies required by applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making and maintaining arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our product candidates by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following approval or clearance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing effectively with other cancer therapies, including with respect to the sales and marketing of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining licenses to any third-party intellectual property we deem necessary or desirable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining any necessary third-party agreements to register SD-101 as part of a combination therapy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of these factors are beyond our control, including the time needed to adequately complete preclinical studies, clinical testing and the regulatory submission process, our ability to obtain and protect intellectual property rights and changes in the competitive landscape. It is possible that none of our product candidates will ever obtain regulatory approval or clearance, even if we expend substantial time and resources seeking such approval or clearance. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We or any future third-party collaborators may not obtain approvals or clearances from regulatory authorities outside the United States on a timely basis, if at all. Approvals or clearances by the FDA does not ensure approval or clearance by regulatory authorities in other countries or jurisdictions, and approval or clearance by one regulatory authority outside the United States does not ensure approval or clearance by regulatory authorities in other countries or jurisdictions or by the FDA. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete clinical trials, obtain regulatory approval or clearance or, if approved, commercialize our product candidates, which would materially harm our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may in the future develop product candidates in combination with other therapies and that may expose us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may develop future product candidates for use in combination with one or more currently approved therapies. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate our product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell our product candidates we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA or similar foreign regulatory authorities do not approve or revoke the approval of these other drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs that we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval or clearance for SD-101 or any future product candidates, such product candidates will remain subject to ongoing regulatory oversight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval or clearance for any of our product candidates, they will be subject to extensive and ongoing regulatory requirements for manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations and GCPs, for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals or clearances that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval or clearance, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, that may require surveillance requirements regarding monitoring the safety and efficacy of the product candidate. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval or clearance for any future product candidates we may develop, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. However, if we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA may also require a Risk Evaluation and Mitigation Strategies (&#8220;<b style="font-weight:bold;">REMS</b>&#8221;) as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval or clearance of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability. Moreover, if there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuing warning or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking an injunction or imposing civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or imposition of restrictions on operations, including product manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seizure or detention of products, refusal to permit the import or export of products or request that we initiate a product recall;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of our marketing authorizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to applications submitted by us; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular for TriNav and the pancreatic retrograde venous infusion (&#8220;<b style="font-weight:bold;">PRVI</b>&#8221;) device and any future medical device product candidate, we and our third-party suppliers are required to comply with the FDA&#8217;s Quality System Regulation (&#8220;<b style="font-weight:bold;">QSR</b>&#8221;). These FDA regulations cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA. If we or our manufacturers fail to adhere to QSR requirements in the United States, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA assesses compliance with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in any of the enforcement actions listed above. Any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our product candidates receives marketing approval or clearance and we or others later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the product could be compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval or clearance, and we or others later discover that such product candidates are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal or limitation by regulatory authorities of approvals or clearances of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seizure of the product by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing of the product or the manufacturing process for any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commitment to expensive additional safety studies prior to approval or clearance or post-marketing studies required by regulatory authorities of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse impact on the product&#8217;s competitiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of legal action against us to hold us liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm to our reputation and resulting harm to physician or patient acceptance of our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, the commercial success of our products or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the U.S. and in certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, or collectively the Affordable Care Act (&#8220;<b style="font-weight:bold;">ACA</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect that there will be additional challenges and amendments to the ACA in the future. For example, the former Trump administration issued various Executive Orders which eliminated cost-sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. Further, on December&#160;20, 2019, the Further Consolidated Appropriations Act (H.R. 1865), which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax, was signed into law. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what effect further changes to the ACA would have on our business, especially under the Biden administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach the required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal&#160;year, and, due to subsequent legislative amendments, will remain in effect through 2032 unless additional congressional action is taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There has been increasing legislative and enforcement interest in the U.S. with respect to prescription-pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. The HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. It is unclear what effect such legislative and enforcement interest may have on prescription devices. Further, it is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify the prior administration&#8217;s executive and administrative actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on reimbursement price that we receive for any cleared, authorized, or approved device, which could have an adverse effect on patients for our products or product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory clearance, authorization, or approval and that may affect our overall financial condition and ability to develop product candidates. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates that we may develop may lose any regulatory clearance, authorization, or approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">TriNav and the PRVI device must be manufactured in accordance with federal and foreign regulations, and we or any of our suppliers or third-party manufacturers could be forced to recall the products or terminate production if we fail to comply with these regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The design, manufacture and marketing of medical devices involve certain inherent risks. Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure of risks or other information relating to the use of our products can lead to injury or other serious adverse events. The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. For the FDA, the authority to require a recall must be based on a finding that there is reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working&#160;days after the recall is initiated. A government-mandated or voluntary recall by us or one of our international distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA or another third-country competent authority. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA or another third-country competent authority. If the FDA disagrees with our determinations, the FDA could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report recalls. We are also required to follow detailed recordkeeping requirements for all firm-initiated medical device corrections and removals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If treatment guidelines for the cancer indications that we are targeting change or the standard of care evolves, we may need to redesign our preclinical or clinical trials of, or seek new marketing authorization from, the FDA for any approved products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If treatment guidelines for the cancer indications that we are targeting change or the standard of care evolves, We may need to redesign TriNav, the PRVI device or any product candidates and seek new clearances or approvals from the FDA for any approved products. Our 510(k)&#160;clearances from the FDA for TriNav, TriNav Large and the PRVI device are based on current treatment guidelines. If treatment guidelines change so that different treatments become desirable, the clinical utility of TriNav and the PRVI device could be diminished, and our business could suffer. Competition by other forms of cancer treatment, for example, the development of new and more efficacious systemic therapies, could reduce the use of regional therapy as a standard of care in certain indications. Changes in treatment guidelines or standard of care may also impact product coverage and/or reimbursement by payers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval or clearance and commercialization, it is common that various aspects of the development activities, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any of these changes could cause SD-101 or any future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">require additional testing, including comparability testing, to bridge earlier clinical data obtained from SD-101 produced under earlier manufacturing methods or formulations, and regulatory authorities may disagree on the interpretation of results from this testing. This could delay the completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of SD-101 or any future product candidates and jeopardize our ability to commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, including physicians and third-party payors in the United States and elsewhere, will play a primary role in the recommendation of TriNav and the PRVI device and prescription of any product candidates for which we obtain marketing approval or clearance. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws, data privacy and security laws, transparency laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute TriNav and the PRVI device, and any other any future products candidates once they have obtained marketing authorization. We are also subject to healthcare regulation and enforcement by the U.S. federal government and the states and any other countries in which we conduct our business, including our research, and the sales, marketing and distribution of TriNav, the PRVI device or any future products candidates once they have obtained marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the physicians or other providers or entities with whom we do, or expect to do, business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We could be subject to litigation that could have an adverse effect on our business and operating results.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are, from time to time, involved in litigation. The numerous operating hazards inherent in our business increase our exposure to litigation, which may involve, among other things, contract disputes, personal injury, environmental, employment, warranty and product liability claims, tax and securities litigation, patent infringement and other intellectual property claims and litigation that arises in the ordinary course of business. Our management cannot predict with certainty the outcome or effect of any claim or other litigation matter. Litigation may have an adverse effect on us because of potential negative outcomes such as monetary damages or restrictions on future operations, the costs associated with defending the lawsuits, the diversion of management&#8217;s resources and other factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are developing additional sizes of, and uses for, the TriNav device. Our product candidates may be used in connection with medical procedures in which it is important that those products function with precision and accuracy. If our existing TriNav device or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our product candidates, if approved, do not function as designed, or are designed improperly, we may be forced by regulatory agencies to withdraw such products from the market. In addition, the use of our product candidates in clinical trials, the sale of any products for which we obtain marketing approval, and other liability risks that are inherent in the testing, manufacturing, marketing and sale of medical devices exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. Claims or losses in excess of any product liability insurance coverage that we may obtain could have a material adverse effect on our business, financial condition and results of operations. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation and related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources, and the inability to commercialize any product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for a product candidate, if approved for commercial sale; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we currently carry clinical trial insurance and product liability insurance which we believe to be reasonable, such insurance may not be adequate to cover all liability that we may incur. An inability to renew our policies or to obtain sufficient insurance at an acceptable cost could prevent or inhibit the commercialization of pharmaceutical products that we develop, alone or with collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;<b style="font-weight:bold;">processing</b>&#8221;) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information and patient data (collectively, &#8220;<b style="font-weight:bold;">sensitive data</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our data processing activities may subject us to data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;<b style="font-weight:bold;">HIPAA</b>&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;<b style="font-weight:bold;">HITECH</b>&#8221;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states also exempt some data processed in the context of clinical trials through laws like the California Consumer Privacy Act, these developments may further complicate compliance efforts, and may increase legal risk and compliance costs to us and the third parties upon whom we rely. Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;<b style="font-weight:bold;">EU GDPR</b>&#8221;) imposes strict requirements for processing personal data, and, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#8220;<b style="font-weight:bold;">EEA</b>&#8221;) and the United Kingdom (&#8220;<b style="font-weight:bold;">UK</b>&#8221;) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, we could face significant adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages&#160;in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax law and differences in interpretation of tax laws and regulations may adversely impact our financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We operate in multiple jurisdictions and are subject to tax laws and regulations of the U.S. federal, state and local and non-U.S. governments. U.S. federal, state and local and non-U.S. tax laws and regulations are complex and subject to change and varying interpretations. U.S. federal, state and local and non-U.S. tax authorities may interpret tax laws and regulations differently than we do and challenge tax positions that we have taken. This may result in differences in the treatment of revenues, deductions, credits and/or differences in the timing of these items. The differences in treatment may result in payment of additional taxes, interest or penalties that could have an adverse effect on our financial condition and results of operations. Further, future changes to U.S. federal, state and local and non-U.S. tax laws and regulations could increase our tax obligations in jurisdictions where we do business or require us to change the manner in which we conduct some aspects of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes is limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have incurred financial losses during our history. Unused federal net operating losses (&#8220;<b style="font-weight:bold;">NOLs</b>&#8221;) for taxable&#160;years beginning before January&#160;1, 2018, may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under current law, federal NOLs incurred in taxable&#160;years beginning after December&#160;31, 2017, can be carried forward indefinitely, but the deductibility of such federal NOLs in taxable&#160;years beginning after December&#160;31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50&#160;percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and may experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. These factors could limit our ability to use our NOLs and other tax attributes, which could adversely affect our future cash flows or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain, adequately protect, maintain or enforce our intellectual property rights could substantially harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our ability to obtain and maintain protection for our owned and in-licensed intellectual property rights and proprietary technology. We rely on a combination of patents, trademarks, trade secret protection and confidentiality agreements, including in-licenses of intellectual property rights of others, to protect our current or future platform technologies, products, product candidates, methods used to manufacture our current or future product candidates and methods for treating patients using our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We own or in-license patents and patent applications relating to our platform technologies, products and product candidates. There is no guarantee that any patents covering our platform technologies or product candidates will issue from the patent applications we own, in-license or may file in the future, or, if they do, that the issued claims will provide adequate protection for our platform technologies or product candidates, or any meaningful competitive advantage. Further, there cannot be any assurance that such patents issued will not be infringed, designed around, invalidated by third parties or effectively prevent others from commercializing competitive technologies, products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents, and, even if patents are issued, such patents may not cover our current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We do not have exclusive control over the preparation, filing and prosecution of patent applications under certain of our in-license agreements, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents that we out-licenses to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, although we make reasonable efforts to ensure patentability of our inventions, we cannot guarantee that all of the potentially relevant prior art relating to our owned or in-licensed patents and patent applications has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, and in some cases not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates, or the use of our technologies. We thus cannot know with certainty whether we or our licensors were the first to file for patent protection of such inventions. In addition, the United States Patent and Trademark Office (&#8220;<b style="font-weight:bold;">USPTO</b>&#8221;) might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. There is no assurance that all potentially relevant prior art relating to our owned or in-licensed patent applications has been found. For this reason, and because there is no guarantee that any prior art search is correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent our owned or in-licensed patent applications from issuing as patents. Invalidation of any of our patent rights, including in-licensed patent rights, could materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the patent positions of biotechnology and medical device companies like us are generally uncertain because they may involve complex legal and factual considerations that have, in recent&#160;years, been the subject of legal development and change. The relevant patent laws and their interpretation, both inside and outside of the United States, are also uncertain. Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our platform technology or product candidates and could affect the value of such intellectual property. Our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe, misappropriate or otherwise violate our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our platform technology, product candidates, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications we may file or license in the future, nor can we be sure that any patents that may be granted to us or our licensors in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Additionally, third parties, including our former employees and collaborators, may challenge the ownership or inventorship of our patent rights to claim that they are entitled to ownership and inventorship interest, and we may not be successful in defending against such claims. However, we are not currently facing any such challenges. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block&#8201;&#8212;&#8201;in some cases&#8201;&#8212;&#8201;potential competitors from practicing the claimed inventions of the issued patents.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The issuance, scope, validity, enforceability and commercial value of our pending patent rights are uncertain. The standards applied by the USPTO and foreign patent offices in granting patents are not always certain and moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or in-licensed patent applications or narrow the scope of any patent protection we may obtain from our owned or in-licensed patent applications. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, patents and other intellectual property rights in the pharmaceutical, biotechnology and medical device space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and any future product candidates and practicing our proprietary technology, and any issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our products, product candidates and any future </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors or other parties with similar technology. Additionally, our competitors may initiate legal proceedings, such as declaratory judgment actions in federal court or reexaminations or an <i style="font-style:italic;">inter partes</i> review at the USPTO in an attempt to invalidate or narrow the scope of our patents. However, we are not currently facing any such proceedings. Furthermore, our competitors or other parties may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our products, product candidates and any future product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product candidate may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if patents do successfully issue from our owned or in-licensed patent application, and even if such patents cover our current or any future products or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any current or future products or product candidates that we may develop. Likewise, if patent applications we own or have in-licensed with respect to our development programs and current or future products or product candidates fail to issue, if their breadth or strength is threatened, or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future products or product candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain or any loss of patent protection could have a material adverse impact on our business and ability to achieve profitability may be unable to prevent competitors from entering the market with a product that is similar or identical to any of our products or current or potential future product candidates or from utilizing technologies similar to those in our products or current product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The filing of a patent application or the issuance of a patent is not conclusive as to our ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by our licensors, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings. By further example, any issued patents that may result from our owned or in-licensed patent applications may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our owned or in-licensed patent rights, result in the loss of exclusivity, limit our ability to stop others from using or commercializing similar or identical products and product candidates, or allow third parties to compete directly with us without payment to us. In addition, if the breadth or strength of protection provided by any patents that might result from our owned or in-licensed patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we currently co-own certain patents and patent applications with third parties and may in the future co-own additional patents and patent applications with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent application, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such co-owners to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our in-licensed patent rights may be subject to a reservation of rights by one or more third parties, such as the U.S. government. In addition, our rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The expiration or loss of patent protection may adversely affect our future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on patent, trademark, trade secret and other intellectual property protection in the discovery, development, manufacturing and sale of our products and product candidates. In particular, patent protection is important in the development and eventual commercialization of our product candidates. Patents covering our product candidates normally provide market exclusivity, which is important in order to improve the probability that our product candidates are able to become profitable. Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other countries with respect to our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology and medical device companies generally are highly uncertain, involve complex legal and factual questions and have in recent&#160;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patents that issue are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the U.S. Further, the examination process may require us to narrow the claims of pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our products and product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our products and product candidates may be impaired.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December 8, 2023, we owned at least 122 registered patents. Our issued U.S. patents expire between 2023 and 2040. All of our solely-owned granted U.S. and foreign patents that relate to composition of matter for SD-101 will expire in December&#160;2023. Upon expiration of the patents covering SD-101, third parties, including other biopharmaceutical companies, will be able to obtain or use SD-101 other than to the extent we have other patent protection, including through our method of use patents for pressure controlled therapeutic delivery. In addition, certain of our patents relating to the use of TriNav will expire beginning in 2031, with additional patents relating to TriNav expiring in 2036 and 2038. While we are seeking additional patent coverage, there can be no assurances that such additional patent protection will be granted, or if granted, that these patents will not be infringed upon or otherwise held enforceable. Even if we are successful in obtaining a patent, patents have a limited lifespan. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. We also intend to apply for orphan drug designation and orphan designation in the U.S. and EU, respectively, which, if granted, would extend the exclusivity period beyond the initial five&#160;years of regulatory exclusivity from the date of approval in the U.S. and beyond the eight&#160;years of data exclusivity from the date of approval in Europe; however, there can be no assurance that we will ever obtain approval or orphan drug exclusivity for such product candidates. Without patent protection of our product candidates, we may be open to competition from generic versions of such methods and compositions. As of December 8, 2023, we have at least 69 pending patent applications and four U.S. provisional patent applications. We do not know whether any of our patent applications will result in issued patents or, if any of our patent applications do issue, whether such patents will protect our technology and drugs, in whole or in part, or whether such patents will effectively prevent others from commercializing competitive technologies and products. Even if we are successful in obtaining a patent, patents have a limited lifespan. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection of our product candidates, we may be open to competition from generic versions of such methods and compositions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no guarantee that any of our issued or granted patents will not later be found invalid or unenforceable. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to our product candidates. Furthermore, as our issued patents expire, the risk that competitors may be able to circumvent our remaining patents by developing similar or alternate technologies or products in a non-infringing manner is increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our products and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or shortly after such candidates begin to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;<b style="font-weight:bold;">Hatch-Waxman Amendments</b>&#8221;). The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following expiration of our regulatory exclusivity and our patent expiration, and launch their product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents covering our products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of some foreign countries do not protect intellectual property rights, especially those relating to life sciences, to the same extent as federal and state laws in the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does and novel formulations of existing drugs and manufacturing processes may not be patentable in certain jurisdictions. Further, future licensing partners may not prosecute patents in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products or product candidates and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and medical device products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while it intends to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products and product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our products and product candidates in all of our expected significant foreign markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, the requirements for patentability may differ in certain countries. Generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensees or any </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">future licensors to engage in complex, lengthy and costly litigation or other proceedings. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensees or any future licensors may have limited remedies if patents are infringed or if we and our licensees or any future licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights in some regions of the world may be inadequate to obtain a significant commercial advantage from our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that we or our employees, consultants, contractors or advisors have infringed, misappropriated or otherwise violated the intellectual property of a third party, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of the contributors to our intellectual property, including patents and applications, were previously employed at universities or other biotechnology, pharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the intellectual property and other proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these employees have used or disclosed such intellectual property or other proprietary information. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. To the extent that we fail to obtain such assignments, such assignments do not contain a self-executing assignment of intellectual property rights, or if such assignments are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our products or product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business model may require reliance on third parties and the need to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed, and if we are unable to protect the confidentiality of our trade secrets, the value of our intellectual property could be materially adversely affected and our business would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for some of our products and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, in seeking to develop and maintain a competitive position. Because we rely on third parties to manufacture our product candidates and we may collaborate with third parties on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, corporate collaborators, outside scientific collaborators, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have sought to contract with manufacturers to supply commercial quantities of pharmaceutical formulations. As a result, we have disclosed, under confidentiality agreements, various aspects of our technology with potential manufacturers and suppliers. We believe that these disclosures, while necessary for our business, may result in the attempt by potential manufacturers and suppliers to improperly assert ownership claims to our technology in an attempt to gain an advantage in negotiating manufacturing and supplier rights.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade secrets and know-how can be difficult to protect as trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If we fail to prevent material disclosure of the know-how, trade secrets and other intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. Even if we are able to adequately protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently discovered by our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, in the absence of patent protection, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be able to prevent misappropriation of our trade secrets or other proprietary and confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our competitors may seek to market generic versions of SD-101 or any other product candidate for which we may in the future obtain approval by submitting abbreviated new drug applications (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ANDAs</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) or biosimilar applications to the FDA or new products that use our approved products as the reference listed drug (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLD</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), in each case where our competitors claim that our patents are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products that are the same as, similar to or otherwise competitive with SD-101 and any future product candidates we may develop. In these circumstances, we may need to defend or assert our patents, by means including filing lawsuits alleging patent infringement requiring us to engage in complex, lengthy and costly litigation or other proceedings. In any of these types of proceedings, a court or government agency with jurisdiction may find our patents invalid, unenforceable or not infringed. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if patents are valid and enforceable, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Furthermore, as our issued patents expire, the risk that competitors may be able to circumvent our remaining patents by developing similar or alternate technologies or products in a non-infringing manner is increased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, competitors could purchase TriNav or our other products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have in the past been, and may in the future be, subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The issuance of a patent is not conclusive as to our inventorship, scope, validity or enforceability, and our owned and licensed patents have in the past been, and in the future may be, challenged in the courts or patent offices in the United States and abroad. For example, in October&#160;2017, an individual filed a suit against Legacy TriSalus in the United States District Court, District of Colorado asserting joint inventorship of six patents assigned to Legacy TriSalus. The individual sought to be added as a co-inventor and co-owner of the patents in question. A stipulated dismissal order was entered in June&#160;2021 with the court dismissing the plaintiff&#8217;s case with prejudice. In the future, we may face similar or other challenges by third parties, former employees or collaborators with respect to ownership interest in the patents and intellectual property that we own or license at the time. We could be subject to ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our products or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates. While it is our policy to require employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as Legacy-TriSalus owned. To the extent that we license intellectual property from a third party, such licensors may face similar obstacles. In addition, we have not updated the records in certain foreign patent offices to reflect our ownership of certain foreign patents relating to SD-101, but have recorded our ownership for at least the unexpired foreign patents acquired from Dynavax relating to composition of matter for SD-101 in Australia, Canada, Austria, Germany, Denmark, Estonia, United Kingdom, Hong Kong, Ireland, Luxembourg, Portugal, New Zealand, and Singapore. Failure to update such ownership may result in a purchaser potentially acquiring rights in such patents that are adverse to our interests. Litigation may be necessary to defend against any claims challenging inventorship or ownership and such litigation may be costly. If we fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent undertaken, we cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of our products and product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, certain United States patent applications can remain confidential until patents issue. Therefore, patent applications covering our products and product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our products and product candidates.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products and product candidates. We may incorrectly determine that our products or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products and product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products or product candidates that are held to be infringing. We might, if possible, also be forced to redesign products or product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. Disputes may arise between us and any of these counterparties regarding intellectual property rights that are subject to such agreements, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patent and other rights to third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to transfer or assign our license; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of termination.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any agreements, we may be required to pay damages and could lose intellectual property rights that are necessary or useful for developing and protecting our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dynavax has represented to us that we were given all intellectual property rights related to SD-101 pursuant to the Dynavax Agreement. Pursuant to the Dynavax Agreement, we are obligated to pay up to $250 million upon the achievement of certain development, regulatory, and commercial milestones and low double-digit royalties based on potential future net sales of products containing the SD-101 compound. Additionally, we are responsible for prosecution and maintenance of the acquired patents with obligations to keep Dynavax reasonably informed of the status thereof. Any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any such material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and any licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology, or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor to gain access to the licensed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make formulations that are similar to our product candidates or other formulations but that are not covered by the claims of our patents that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties may have an adverse effect on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any current or future strategic partners and/or collaborators might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our current or future strategic partners and/or collaborators might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we may own or that we exclusively license in the future may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in the United States and in other countries that provide a safe harbor from patent infringement claims for such activities, as well in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our existing or intended commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties performing manufacturing or testing for us using our product candidates could use the intellectual property of others without obtaining a proper license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent application for certain technologies, trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The validity, scope and enforceability of any of our patents can be challenged by third parties and any lawsuits to protect or enforce our patents could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors or other third parties may infringe our patents or the patents of any party from whom we may license patents from in the future. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In a patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. A court may decide that a patent of ours or of any of our future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In addition, to the extent that we have to file patent litigation in a federal court against a U.S. patent holder, we would be required to initiate the proceeding in the state of incorporation or residency of such entity. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found unenforceable, or interpreted narrowly, and it could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain product candidates or aspects of the TriNav or other technology. Such a loss of patent protection could compromise our ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents and patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology or to attempt to license rights from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone, with our licensees, or with any of our future licensors, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or other foreign patent offices, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology, products or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize our products or product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future products or product candidates.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non-infringement. For example, if a third party submits an application under Section&#160;505(b)(2)&#160;or an ANDA, for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the FDA&#8217;s publication Approved Drug Products with Therapeutic Equivalence Evaluations, which we refer to as the Orange Book, with respect to our New Drug Application (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NDA</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) for the applicable approved product candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid or unenforceable, is called a &#8220;paragraph IV certification.&#8221; If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us within 20&#160;days once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30&#160;months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, a third party may challenge the current patents, or patents that may be issued in the future, within our portfolio which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our product candidates. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our product candidates, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing the applicable product candidate. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our product candidates. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will largely depend on our ability to retain with respect to TriNav and other device technologies, and obtain with respect to SD-101 and other product candidates, market exclusivity in the United States and other countries. Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, certain of our product candidates may be eligible for marketing exclusivity.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Federal Food, Drug and Cosmetic Act (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FDC Act</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA or Section&#160;505(b)(2)&#160;NDA for a new chemical entity, or NCE. An NCE is a drug that contains no active moiety (the molecule or ion responsible for the action of the drug substance) that has been approved by FDA in any other NDA submitted under section 505(b)&#160;of the FDC Act. During the five-year NCE exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application, or ANDA, or a Section&#160;505(b)(2)&#160;NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a paragraph IV certification of patent invalidity, unenforceability, or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDC Act also provides three&#160;years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations for a previously-approved active moiety, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages, dosage forms or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and prohibits the FDA from approving an ANDA, or a Section&#160;505(b)(2)&#160;NDA submitted by another company with overlapping conditions associated with the new clinical investigations for the three-year period. Three-year exclusivity does not prohibit the FDA from approving ANDAs for drugs containing the original conditions of use, i.e., original indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain such marketing exclusivity for our product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our approval to obtain approval of competing products and launch their product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on trademarks as one means to distinguish any of our products or product candidates that are approved for marketing from the products of our competitors. TriNav&#174; and Pressure-Enabled Drug Delivery&#8482; (PEDD&#8482;) are our trademarks and, in the United States, our trademarks may be challenged, infringed, circumvented or declared descriptive or generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks, we may not be able to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related the Ownership of Our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited experience operating as a United States public company and may not be able to adequately develop and implement the governance, compliance, risk management and control infrastructure and culture required for a public company, including compliance with the Sarbanes Oxley Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited experience operating as a United States public company. Certain of our executive officers lack experience in managing a United States public company, which makes their ability to comply with applicable laws, rules&#160;and regulations uncertain. Our failure to comply with all laws, rules&#160;and regulations applicable to United States public companies could subject us and our management to regulatory scrutiny or sanction, which could harm our reputation and share price.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited experience preparing and filing periodic or other reports with the SEC or complying with the other requirements of United States federal securities laws applicable to public companies. We also have limited experience establishing and maintaining the disclosure controls and procedures and internal controls over financial reporting applicable to a public company in the United States, including the Sarbanes-Oxley Act. Although we are in the process of developing and implementing our governance, compliance, risk management and control framework and culture required for a public company, we may not be able to meet the requisite standards expected by the SEC and/or our investors. We may also encounter errors, mistakes and lapses in processes and controls resulting in failures to meet the requisite standards expected of a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a United States public reporting company, we incur significant legal, accounting, insurance, compliance, and other expenses. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. Compliance with reporting, internal control over financial reporting and corporate governance obligations requires members of our management and our finance and accounting staff to divert time and resources from other responsibilities to ensure these new regulatory requirements are fulfilled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to adequately implement the required governance and control framework, we could be at greater risk of failing to comply with the rules&#160;or requirements associated with being a public company. Such failure could result in the loss of investor confidence, could harm our reputation, and cause the market price of our securities to decline. Other challenges in complying with these regulatory requirements may arise because we may not be able to complete our evaluation of compliance and any required remediation in a timely fashion. Furthermore, any current or future controls may be considered as inadequate due to changes or increased complexity in regulations, our operating environment or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to inadequate governance and internal control policies, misstatements or omissions due to error or fraud may occur and may not be detected, which could result in failures to make required filings in a timely manner and make filings containing incorrect or misleading information. Any of these outcomes could result in SEC enforcement actions, monetary fines or other penalties, as well as damage to our reputation, business, financial condition, operating results and share price.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management now devotes substantial time to new compliance initiatives and corporate governance practices. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would adversely impact our business.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we incur significant legal, accounting, and other expenses that we did not incur as a private company, including costs resulting from public company reporting obligations under the Securities Act and the Exchange Act, and regulations regarding corporate governance practices. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the rules&#160;of the SEC, the listing requirements of the Nasdaq Stock Market, and other applicable securities rules&#160;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have begun to hire additional accounting, finance, and other personnel in connection with becoming a public company, and our management and other personnel devotes a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are currently evaluating these rules&#160;and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We cannot predict or estimate the amount of additional costs we will incur as a result of becoming a public company or the timing of such costs. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules&#160;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the Board of Directors (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Board</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) or committees of the Board or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to Sarbanes-Oxley Act Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting beginning with the filing of our Annual Report on Form&#160;10-K with the SEC for the&#160;year ending December&#160;31, 2023. In order to continue to maintain effective internal controls to support growth and public company requirements, we will need additional financial personnel, systems and resources. However, while we remain an emerging growth company, we are not required </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 of the Sarbanes-Oxley Act within the prescribed period, we are engaged in a process to enhance our documentation and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our internal control over financial reporting is effective as required by Sarbanes-Oxley Act Section&#160;404. Our management has identified material weaknesses and, in the future, our management may identify one or more material weaknesses, which could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Our management has identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future. If we fail to remediate the material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, it may adversely affect our ability to accurately and timely report our financial results, and may adversely affect investor confidence and business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the financial statements would not be prevented or detected on a timely basis.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with our audited consolidated financial statements for the years ended December 31, 2021 and December 31, 2022, management identified material weaknesses in its internal control over financial reporting with respect (i) to a lack of sufficient number of trained resources with the appropriate skills and knowledge and with assigned responsibilities and accountability for the design and operation of internal controls over financial reporting and (ii) to inadequate internal controls over the valuation of the warrant and tranche rights and obligations and liabilities resulting from the series B-2 preferred stock financing, each described in more detail under the heading Part I &#8212; Item 4. Controls and Procedures in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity and quantity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over our Exchange Act reporting disclosures. Our management developed a remediation plan, and we are taking steps to remediate each of the material weaknesses described above. The material weaknesses will be considered remediated when our management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. Our management will continue to monitor the effectiveness of the remediation plan and will make the changes it determines to be appropriate. Although our management intends to complete this remediation process as quickly as practicable, it cannot at this time estimate how long it will take, and initiatives may not prove to be successful in remediating the material weaknesses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we cannot assure you that the remediation measures taken to date, and the actions we may take in the future, will be sufficient to remediate the control deficiencies that led to the material weaknesses in our internal controls over financial reporting described above or that we will prevent or avoid potential future material weaknesses. Further, additional weaknesses in our disclosure controls and internal controls over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in material errors in our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to the listing requirements of Nasdaq, investors may lose confidence in our financial reporting and our stock price may decline as a result. In addition, we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities as well as shareholder litigation which would require additional financial and management resources, and investors may lose confidence in our financial reporting and our stock price may decline as a result. As a result, our ability to obtain financing, or financing on favorable terms, could be materially and adversely affected, which in turn, could materially and adversely affect our business, financial condition and the market value of our common stock and require us to incur additional costs to improve our internal control systems and procedures. In addition, perceptions of us among customers, partners, investors, securities analysts and others could also be adversely affected.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, we are required to comply with the requirements of the Sarbanes-Oxley Act, including, among other things, maintaining effective disclosure controls and procedures and internal control over financial reporting. We continue to develop and refine our disclosure controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file with the SEC is recorded, processed, summarized, and reported within the time periods specified in SEC rules&#160;and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We must continue to improve our internal control over financial reporting. Our management will be required to make a formal assessment of the effectiveness of our internal control over financial reporting pursuant to Sarbanes-Oxley Act Section&#160;404(a), and we may in the future be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with these requirements within the prescribed time period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that we will not be able to conclude, within the prescribed time period or at all, that our internal control over financial reporting is effective as required by Section&#160;404 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any failure to implement and maintain effective disclosure controls and procedures and internal control over financial reporting, including the identification of one or more material weaknesses, could cause investors to lose confidence in the accuracy and completeness of our financial statements and reports, which would likely adversely affect the market price of our Common Stock. In addition, we could be subject to sanctions or investigations by the stock exchange on which our Common Stock is listed, the SEC and other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our Common Stock and Public Warrants has been and may continue be volatile.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The price of our Common Stock and Public Warrants has been and may continue to be volatile. From August 11, 2023, the date our Common Stock and Public Warrants began trading on Nasdaq following the Business Combination, through December 8, 2023, the closing price of our Common Stock has fluctuated from a low of $3.62 to a high of $12.00 per share, and the closing price of our Public Warrants has fluctuated from a low of $0.12 to a high of $0.41 per Public Warrant. The price of our Common Stock and Public Warrants may continue to fluctuate in the future due to a variety of factors, including, without limitation:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volume and timing of sales of TriNav or other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products or product enhancements by us or others in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and results of clinical trials of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of existing or new competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment or termination of collaborations for our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or discontinuation of any of our development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of product candidates of our competitors;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results or development timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our quarterly or annual operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports by securities analysts about us or our competitors or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the public&#8217;s reaction to our press releases, our other public announcements and our filings with the SEC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions and departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws and regulations affecting our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement of, or involvement in, litigation involving us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volume of shares of Common Stock available for public sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and political conditions, such as recessions, interest rates, social, political and economic risks and acts of war or terrorism; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the information we are required to disclose in the reports that we file with the SEC is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These market and industry factors may materially reduce the market price of our Common Stock and Warrants regardless of our operating performance. It is also possible that an active trading market will not be sustained. Any of these effects would make it difficult for you to sell shares of our Common Stock or our Warrants at an attractive price or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to maintain the listing of our securities on Nasdaq in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that our securities will continue to be listed on Nasdaq. If we fail to meet the requirements of the applicable listing rules, such failure may result in a suspension of the trading of our shares or delisting in the future. This may further result in legal or regulatory proceedings, fines and other penalties, legal liability for us, the inability for our stockholders to trade their shares and negatively impact our share price, reputation, operations and financial position, as well as our ability to conduct future fundraising activities. If Nasdaq delists our securities and we are not able to list our securities on another national securities exchange, we expect that our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for our securities;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced liquidity for our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news and analyst coverage for the company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, Russia&#8217;s ongoing incursion of Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets; it is possible that the war in Israel may have similar effects. There have also recently been disruptions to the U.S. banking system due to bank failures, particularly in light of the recent events that have occurred with respect to Silicon Valley Bank, Signature Bank, and First Republic Bank. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, higher inflation could also increase customers&#8217; operating costs, which could result in reduced budgets for customers and potentially less demand for our products and services. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our operating and financial performance in any given period does not meet the guidance provided to the public or the expectations of investment analysts, the market price of Common Stock may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may, but are not obligated to, provide public guidance on our expected operating and financial results for future periods. Any such guidance will consist of forward-looking statements, subject to the risks and uncertainties described in this filing and in our public filings and public statements. The ability to provide this public guidance, and the ability to accurately forecast our results of operations, will be impacted by a number of factors, many of which are out of our control. Actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic or regulatory uncertainty. If, in the future, our operating or financial results for a particular period do not meet any guidance provided or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of Common Stock may decline as well. Even if we issue public guidance, there can be no assurance that we will continue to do so in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of our securities. This risk is especially relevant for us because life sciences companies have experienced significant stock price volatility in recent&#160;years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Securities research analysts may establish and publish their own periodic projections of us. These projections may vary widely and may not accurately predict the results that we actually achieve. Our share price may decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, our share price could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, our share price or trading volume could decline. While we expect research analyst coverage to continue, if analysts cease to continue coverage of us, the market price and volume for our securities could be adversely affected.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of our Common Stock and/or Warrants or the perception of such sales, by us or the selling securityholders pursuant to this prospectus, in the public market or otherwise, could cause the market price for our securities to decline, even though the selling securityholders would still realize a profit on sales at lower prices. Resales of the securities offered by this prospectus may cause the market price of such securities to drop significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">The sale of our Common Stock in the public market or otherwise, including sales pursuant to this prospectus, or the perception that such sales could occur, could harm the prevailing market price of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Resales of our Common Stock may cause the market price of our securities to drop significantly, even if our business is doing well.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Certain of the selling securityholders named in this prospectus acquired securities at prices that are significantly less than the current trading price of our Common Stock. Accordingly, certain of the Selling Securityholder could still realize a profit on sales at lower prices.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, the selling securityholders named in this prospectus hold a disproportionately large portion of our outstanding Common Stock. The Common Stock being offered for resale pursuant to this prospectus by the Selling Securityholders would represent approximately 54.6% of our outstanding Common Stock as of December 8, 2023 (after giving effect to the issuance of the shares issuable upon exercise of the Warrants, the acquisition of certain shares acquirable upon the exercise of assumed options and settlement of assumed restricted stock units, and the issuance of the PIPE Shares (assuming conversion at the initial conversion price of $10.00)). Given the substantial number of shares of Common Stock being registered for potential resale by Selling Securityholders pursuant to this prospectus, the sale of shares by the Selling Securityholders of a large number of shares, or the perception in the market that the Selling Securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock. Even if our trading price is significantly below $10.00 per share, the offering price for the units offered in the initial public offering of MTAC, the purchasers of which exchanged their MTAC shares for our Common Stock in the Business Combination, the Selling Securityholders may still have an incentive to sell our shares of our Common Stock because they purchased the shares at prices that are significantly lower than the purchase prices paid by our public investors or the current trading price of our Common Stock. While certain of the Selling Securityholders may experience a positive rate of return on their investment in our Common Stock as a result, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in their purchase prices and the trading price. For example, based on the closing price of our Common Stock of $4.00 as of December 8, 2023, assuming all shares held by the Sponsor that are subject to vesting and forfeiture are fully vested, the original holder of the Founder Shares would experience a potential profit of up to approximately $4.00 per share that they purchased prior to the initial public offering of MTAC, or up to approximately $16.25 million in the aggregate (not giving effect to the issuance of Common Stock issuable upon exercise of the Warrants held by them).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our stockholders will be able to sell all of their securities held and registered for resale under the registration statement of which this prospectus forms a part for so long as such registration statement is in effect, subject to any applicable lock-up restrictions. Such restrictions began at the Closing and end on the earliest of (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their Common Stock for cash, securities or other property. Even if the trading price of our Common Stock falls to or significantly below the current trading price, the selling securityholders may still have an incentive to sell and profit due to the nominal purchase prices paid by such selling securityholders, which are significantly lower than the purchase prices paid by the public securityholders. Certain of our selling securityholders acquired the Common Stock at prices that are significantly lower than the current trading price of our Common Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Warrants are exercisable for Common Stock, the exercise of which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Public Warrants, Private Placement Warrants and Conversion Warrants became exercisable on September 10, 2023 in accordance with the terms of that certain warrant agreement, dated December 17, 2020 by and between us and Continental Stock Transfer &amp; Trust Company, as warrant agent (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Warrant Agreement</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). The exercise price of the Warrants is $11.50 per share, or </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">approximately $163.8 million in the aggregate, assuming none of the Warrants are exercised through &#8220;cashless&#8221; exercise. We believe the likelihood that warrant holders will exercise their warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. So long as the trading price for our Common Stock is less than $11.50 per share, meaning the Warrants are &#8220;out of the money,&#8221; we believe holders of our Warrants that were issued will be unlikely to exercise their warrants on a cash basis. On December 8, 2023, the last reported sales price of our Common Stock was $4.00 per share and the last reported sales price of our Public Warrants was $0.24 per warrant, both of which are lower than the exercise price of the Warrants. To the extent such Warrants are exercised, additional Common Stock will be issued, which will result in dilution to the holders of Common Stock and will increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of Common Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are an emerging growth company as well as a smaller reporting company within the meaning of the Securities Act and, if we take advantage of certain exemptions from disclosure requirements available to &#8220;emerging growth companies,&#8221; our securities may be less attractive to investors and it may be more difficult to compare our performance with other public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We qualify as an emerging growth company under SEC rules. As an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These provisions include: (1)&#160;presenting only two&#160;years of audited financial statements; (2)&#160;presenting only two&#160;years of related selected financial data and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; (3)&#160;an exemption from compliance with the auditor attestation requirement in the assessment of internal control over financial reporting pursuant to Section&#160;404 of Sarbanes-Oxley; (4)&#160;not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; (5)&#160;reduced disclosure obligations regarding executive compensation arrangements in periodic reports, registration statements, and proxy statements; and (6)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide will be different than the information that is available with respect to other public companies that are not emerging growth companies. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for the Common Stock, and its market price may be more volatile. We will remain an emerging growth company until the earlier of: (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of MTAC&#8217;s initial public offering (i.e., December&#160;31, 2025), (b)&#160;in which we have total annual gross revenue of at least $1.235 billion or (c)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules&#160;of the SEC, which means the market value of our common equity that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal&#160;year&#8217;s second fiscal quarter; and (2)&#160;the date on which we will have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we qualify as a &#8220;smaller reporting company&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal&#160;year in which (1)&#160;the market value of our Common Stock held by non-affiliates exceeds $250 million as of the end of that&#160;year&#8217;s second fiscal quarter, or (2)&#160;our annual revenues exceeded $100 million during such completed fiscal&#160;year and the market value of Common Stock held by non-affiliates equals or exceeds $700 million as of the end of that&#160;year&#8217;s second fiscal quarter. To the extent that we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Warrants may not be exercised at all or may be exercised on a cashless basis and we may not receive any cash proceeds from the exercise of the Warrants.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The exercise price of the Warrants may be higher than the prevailing market price of the underlying shares of Common Stock. The exercise price of the Warrants is subject to market conditions and may not be advantageous if the prevailing market price of the underlying shares of Common Stock is lower than the exercise price. The cash proceeds associated with the exercise of Warrants to purchase our Common Stock are contingent upon our stock price. The value of our Common Stock will fluctuate and may not align with the exercise price of the Warrants at any given time. As of December 8, 2023, the last reported sales price of our Common Stock was $4.00 per share. So long as the trading price of our Common Stock is less than $11.50, meaning the Warrants are &#8220;out of the money,&#8221; meaning the exercise price is higher than the market price of our Common Stock, we believe that holders of the Warrants are unlikely to choose to exercise their Warrants. As a result, we may not receive any proceeds from the exercise of the Warrants. </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Furthermore, to the extent that the Private Placement Warrants or Conversion Warrants are exercised on a &#8220;cashless basis,&#8221; we may not receive cash upon their exercise. A cashless exercise allows holders of such Warrants to convert the Warrants into shares of our Common Stock without the need for a cash payment. Instead of paying cash upon exercise, the warrant holder would receive a reduced number of shares based on a predetermined formula. As a result, the number of shares issued through a cashless exercise will be lower than if the Private Placement Warrants or Conversion Warrants were exercised on a cash basis, which could impact the cash proceeds we receive from the exercise of such Warrants. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of Common Stock issuable upon the exercise of such Warrants. If there is not a then-effective registration statement, then such Public Warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions contained in our Certificate of Incorporation and Bylaws, as well as provisions of Delaware law, could limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws contain provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. These provisions could also make it difficult for stockholders to take certain actions, including electing directors who are not nominated by the Board or taking other corporate actions, including effecting changes in our management. We are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control. Together these provisions may discourage transactions that otherwise could involve the payment of a premium over prevailing market prices for our securities. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the right of the Board to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death or removal of a director in certain circumstances, which prevents stockholders from being able to fill vacancies on the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement that a special meeting of stockholders may only be called by a majority of the Board, the chairperson of the Board, or our chief executive officer which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the Board to issue shares of preferred stock, including &#8220;blank check&#8221; preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitation of the liability of, and the indemnification of, our directors and officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the Board to amend our Bylaws, which may allow the Board to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice procedures with which stockholders must comply to nominate candidates to the Board or to propose matters to be acted upon at a stockholders&#8217; meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in the Board, and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the potential acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control of us or changes in our Board and our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the General Corporation Law of the State of Delaware (the &#8220;<b style="font-weight:bold;">DGCL</b>&#8221;), which prevents some stockholders who hold more than 15% of our outstanding Common Stock from engaging in certain business combinations without approval of the holders of substantially all of our Common Stock. Any provision of our Certificate of Incorporation and Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for stockholders to receive a premium for their shares of Common Stock and could also affect the price that some investors are willing to pay for Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Certificate of Incorporation designates the Delaware Court of Chancery or Delaware state or United States federal district courts as the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit such stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, other employees or other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for state law claims for (i)&#160;any derivative claim or cause of action brought on behalf of us; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, other employees or stockholders, us or our stockholder; (iii)&#160;any action against us or any of our current or former directors, officers or other employees asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or Bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v)&#160;any claim or cause of action as to which the DGCL confers jurisdiction on the Delaware Court of Chancery; and (vi)&#160;any action asserting a claim against us or any of our current or former directors, officers or other employees governed by the internal affairs doctrine or otherwise related to our internal affairs. The foregoing provisions will not apply to any claims as to which the Delaware Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of such court, which is rested in the exclusive jurisdiction of a court or forum other than such court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules or regulations promulgated thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such Securities Act claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any person or entity purchasing or otherwise acquiring, holding or owning (or continuing to hold or own) any interest in any of our securities shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation. Although we believe these exclusive forum provisions will benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum provision contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. Furthermore, investors cannot waive compliance with the federal securities laws and rules and regulations promulgated thereunder.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Certificate of Incorporation, to the extent permitted by applicable law, contains provisions renouncing our interest and expectation to participate in certain corporate opportunities identified or presented to our non-employee directors or stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our officers and directors and their respective affiliates may hold, and may, from time to time in the future, acquire interests in or provide advice to businesses that directly or indirectly compete with certain areas of our business. Our Certificate of Incorporation provides that we renounce, to the fullest extent permitted by Delaware or other applicable law, any expectancy that any of our non-employee directors, stockholders or the affiliates of such stockholders will offer any corporate opportunity of which such director or stockholder may become aware to us except with respect to a corporate opportunity that was offered to a director solely in his or her capacity as our director and (i)&#160;such opportunity is one we are legally and contractually permitted to undertake and (ii)&#160;the director is permitted to refer that opportunity to us without violating any legal obligation. As a result, these arrangements could adversely affect our business, results of operations, financial condition or prospects if attractive business opportunities are allocated to any of our non-employee directors, stockholders or the affiliates of such stockholders instead of to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fd8ca013_880c_4a9d_ad12_7dc983df2d93"></a><a id="USEOFPROCEEDS_881566"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">All of the shares of Common Stock and Warrants offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from these sales. We will pay certain expenses associated with the registration of the securities as described in the &#8220;<i style="font-style:italic;">Plan of Distribution</i>&#8221; section in this prospectus.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We will receive up to an aggregate of approximately $163.8 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants, if any, for general corporate purposes. Due to the uncertainty regarding the exercise of the Warrants, none of our projected liquidity requirements discussed in this prospectus assume the receipt of any proceeds from the exercise of the Warrants. We will have broad discretion over the use of proceeds from the exercise of the Warrants. There is no assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. We believe the likelihood that holders of the Warrants will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. So long as the trading price for our Common Stock is less than $11.50 per share, meaning the Warrants are &#8220;out of the money,&#8221; we believe holders of our Warrants will be unlikely to exercise their Warrants on a cash basis. In addition, to the extent that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. The Private Placement Warrants and Conversion Warrants may be exercised for cash or on a &#8220;cashless basis.&#8221; The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of Common Stock issuable upon the exercise of such Warrants. If there is not a then- effective registration statement, then such Warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aaaa3a6c_fc81_4513_beb0_9f295cc2e542"></a><a id="DETERMINATIONOFOFFERINGPRICE_183680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DETERMINATION OF OFFERING PRICE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The offering price of the shares of Common Stock underlying the Warrants offered hereby is determined by reference to the exercise price of the Warrants of $11.50 per share. The Public Warrants are listed on Nasdaq under the symbol &#8220;TLSIW.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot currently determine the price or prices at which shares of Common Stock or Warrants may be sold by the Selling Securityholders under this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e1a0ead0_d82b_4105_9134_46f001514dc2"></a><a id="MARKETINFORMATIONFORSECURITIESANDDIVIDEN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Common Stock and Public Warrants are currently listed on Nasdaq Global Market under the symbols &#8220;TLSI&#8221; and &#8220;TLSIW,&#8221; respectively. Prior to the Closing, MTAC&#8217;s units, Class&#160;A and Class&#160;B Common Stock and Public Warrants were historically quoted on the Nasdaq Capital Market under the symbols &#8220;MTACU,&#8221; &#8220;MTAC&#8221; and &#8220;MTACW,&#8221; respectively. As of December&#160;8, 2023, there were 272 holders of record of the Common Stock and 1 holder of record of our Public Warrants. We currently do not intend to list the Private Placement Warrants on any stock exchange or stock market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not declared or paid any dividends on shares of Common Stock to date. We anticipate that we will retain our future earnings to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of the Board and will depend on our financial condition, results of operations, capital requirements and future agreements and financing instruments, business prospects, and such other factors as the Board deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e62775a_754d_4bb6_a837_f010ab7b3c8b"></a><a id="MANAGEMENTSDISCUSSIONANDANALYSISOF"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements and the related notes thereto as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, included elsewhere in this prospectus and our audited consolidated financial statements as of and for the fiscal year ended December 31, 2022, included elsewhere in this prospectus. This discussion and analysis contains forward-looking statements, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;will,&#8221; &#8220;continue,&#8221; &#8220;project,&#8221; and the like, and/or future tense or conditional constructions (&#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those we describe under sections titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">For purposes of this discussion, &#8220;TriSalus,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to TriSalus Life Sciences, Inc. (which changed its name to TriSalus Operating Life Sciences, Inc. in connection with the Business Combination) and its subsidiaries prior to the consummation of the Business Combination and TriSalus Life Sciences, Inc. (formerly known as MedTech Acquisition Corporation) and its subsidiaries after the Business Combination was consummated, unless the context otherwise requires.</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Overview</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines: Pressure Enabled Drug Delivery (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PEDD</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) infusion systems, in use today, and an investigational agent, called SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other solid tumors in the liver. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical)</span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';">is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In 2020, we also launched TriNav&#8482;, which is the newest delivery device with SmartValve technology for our proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TPT</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) approval from the Centers for Medicare &amp; Medicaid Services (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CMS</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), which allows hospitals to cover the cost of using TriNav. The approval began in January 2020 and is scheduled to expire at the end of 2023. On June 1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">APC</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) code with CMS and met with CMS on June 26, 2023, to review the application. In December 2023, CMS granted a New Technology Healthcare Common Procedure Coding System code for procedures involving TriNav. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers. There can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T-cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are currently in our early stage of development and have yet to generate revenues sufficient to drive positive cash flows from operations. Beginning in 2020, we began a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices are marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation led us to acquire our first immune-oncology drug, SD-101, in July 2020, and to begin clinical development of SD-101 for the treatment of liver and pancreatic cancers.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The Business Combination</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On November 11, 2022, pursuant to the Merger Agreement, Legacy TriSalus merged with and into Merger Sub, with Legacy TriSalus surviving the merger and becoming a wholly owned subsidiary of MTAC. The aggregate consideration payable to the stockholders of Legacy TriSalus was $220.0 million, payable in 22,000,000 shares of our Common Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August 8, 2023, the stockholders of MTAC approved the Business Combination, and the Business Combination closed on August 10, 2023. Pursuant to the Merger Agreement, 890,020,482 shares of TriSalus common stock (after conversion of all outstanding shares of preferred stock and all in-the-money warrants) were exchanged for approximately 22,000,000 shares of MTAC common stock, reflecting an exchange ratio of approximately 0.02471853. All share and per share amounts of our Common Stock and our preferred stock have been retrospectively adjusted for the exchange ratio in the following discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Following the consummation of the Business Combination, we were deemed the accounting acquirer and we are accounting for the Business Combination as a reverse recapitalization. See the unaudited pro forma condensed combined financial information included elsewhere in this prospectus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Factors Affecting Our Performance</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We believe that our performance and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including liquidity and those discussed below and in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';">.&#8221; In particular, our performance is affected by:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The continued acceptance and growth of TriNav in the marketplace</i><span style="font-family:'Times New Roman','Times','serif';">. While we believe TriNav to be a superior technology for the delivery of therapies to tumors, particularly high-density tumors, there are other technologies with which we compete. Our ability to grow TriNav sales depends on the skills of our sales force and the willingness of the marketplace to use TriNav.</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">2)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Our ability to maintain our current TriNav pricing and gross margins to help fund the rest of our activities. </i><span style="font-family:'Times New Roman','Times','serif';">Our current pricing allows us to generate a substantial gross margin, which provides funds to support our growth and our research and development (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">R&amp;D</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) for both TriNav and SD-101. TriNav sells at a significant premium to competitive products. Our higher price is currently supported by the TPT payment program from CMS; however, the current TPT authorization expires on December 31, 2023. On June 1, 2023, we applied for a new technology APC code with CMS and met with them on June 26, 2023, to review the application. </span><span style="font-family:'Times New Roman','Times','serif';">In December 2023, CMS granted a New Technology Healthcare Common Procedure Coding System code for procedures involving TriNav. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers. There can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all. If we are unable to obtain continuing reimbursement at similar reimbursement rates or at all, we may be forced to reduce our price to compete, which may materially and adversely impact our margins.</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">3)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The success and cost of our clinical trials of SD-101</i><span style="font-family:'Times New Roman','Times','serif';">. SD-101 is in Phase 1 human trials to determine if, when delivered via TriNav, it is safe and effective in treating certain cancers. As with all drug candidates, the cost of operating clinical trials can be substantial, with no guarantee that the trials will result in favorable data.</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">4)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Obtaining FDA approval of SD-101 for sale</i><span style="font-family:'Times New Roman','Times','serif';">. Our clinical trials are still in early stages, and there is no certainty that we will generate favorable data or that, upon review, the FDA will approve SD-101 for sale.</span></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Recent Developments</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Preferred Stock Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In October 2022, we sold 706,243 shares of Series B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of $14.16 per share (raising approximately $9.8 million, net of issuance costs) (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Initial Preferred Stock Financing</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). For each share sold, we also issued a warrant to purchase four shares of Series B-3 preferred stock for no additional consideration (warrants to purchase an aggregate of 2,824,974 shares of Series B-3 preferred stock were issued in the Initial Preferred Stock </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Financing). The strike price of the warrants issued was $2.03 per share. The Initial Preferred Stock Financing included, at the unilateral option of the Company's Audit Committee, a second tranche for to the sale of up to 518,854 shares of Series B-2 preferred stock for approximately $7.3 million (which could be increased up to an aggregate of 706,243 shares of Series B-2 preferred stock for approximately $10.0 million), with each such share of Series B-2 preferred stock accompanied by a warrant to purchase four shares of Series B-3 preferred stock at a strike price of $2.03 per share (warrants to purchase up to an aggregate of 2,075,417 shares of Series B-3 preferred stock may be issued in closings of the second tranche of the Initial Preferred Stock Financing assuming the full $10.0 million is sold); and a third tranche, at the unilateral election of investors who participated in the second tranche, for the sale of up to 306,053 shares of Series B-2 preferred stock, for approximately $4.3 million (which could be increased up to an aggregate of 353,121 shares of Series B-2 preferred stock for approximately $5.0 million), with each such share of Series B-2 preferred stock accompanied by a warrant to purchase eight shares of Series B-3 preferred stock at a strike price of $2.03 per share (warrants to purchase up to an aggregate of 2,824,974 shares of Series B-3 preferred stock may be issued in the third tranche closing assuming the full $5.0 million is sold). We made offers to participate in the Series B-2 preferred stock financing to all of our existing preferred stockholders (representing approximately 99.2% of our then outstanding shares on an as converted to common stock basis) to continue to fund our operations through the Closing of our Business Combination, including our expenses in connection with the Business Combination and readying ourselves to be a public company.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March 2023, we effectuated closings (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Second Tranche Closings</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) of a portion of the second tranche of the Series B-2 preferred stock financing (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">B-2 Preferred Stock Financing</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) whereby (i) 207,541 shares of Series B-2 preferred stock and accompanying warrants to purchase 830,167 shares of Series B-3 preferred stock, representing 40% of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $2.9 million, net of execution costs, and (ii) 17,656 shares of Series B-2 preferred stock and accompanying warrants to purchase 70,624 shares of Series B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of $250. As a result of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock were adjusted. The conversion prices were further adjusted as a result of the June 2023 exercise of a portion of the second tranche of the B-2 Preferred Stock Financing described below, which represent the conversion prices in effect on the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May 2023, we amended the Series B-2 preferred stock agreement and warrant agreement to purchase Series B-3 preferred stock to extend the expiration date for the second tranche from February 28, 2023, to May 31, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June 2023, we effectuated closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i) 257,779 shares of Series B-2 preferred stock and accompanying warrants to purchase 1,031,116 shares of Series B-3 preferred stock, representing approximately 49.7% of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $3.7 million, and (ii) 165,967 shares of Series B-2 preferred stock and accompanying warrants to purchase 663,868 shares of Series B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of $2,350. As a result of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock (i) were adjusted to $38.84 for Series A-1 preferred stock, $12.14 for Series A-2 preferred stock, $13.36 for Series A-3 preferred stock, $12.55 for Series A-4 preferred stock, $13.36 for Series A-5 preferred stock, $14.97 for Series A-6 preferred stock, $9.71 for Series B preferred stock, and $10.93 for Series B-1 preferred stock and (ii) remained the same for Series B-2 preferred stock $14.16 and Series B-3 preferred stock $2.03, which correlate to approximate (in each case rounded to three decimals) exchange ratios of 1.275 to 1 for Series A-1 preferred stock, 1.290 to 1 for Series A-2 preferred stock, 1.303 to 1 for Series A-3 preferred stock, 1.277 to 1 for Series A-4 preferred stock, 1.333 to 1 for Series A-5 preferred stock, 1.351 to 1 for Series A-6 preferred stock, 1.250 to 1 for Series B preferred stock, 1.296 to 1 for Series B-1 preferred stock, 1 to 1 for Series B-2 preferred stock and 1 to 1 for Series B-3 preferred stock. These conversion prices remained in effect at the Closing Date. Any portion of the Series B-3 Warrants (as defined below) that remained unexercised at the time the Business Combination was consummated were automatically net settled for shares of Legacy TriSalus Common Stock immediately prior to the closing of the Business Combination (see Note 3 &#8220;Financial Instruments&#8221; in the unaudited condensed consolidated financial statements included elsewhere in this prospectus) and exchanged into shares of our Common Stock at the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July 2023, holders of warrants to purchase 2,239,977 shares of Series B-3 preferred stock exercised their purchase rights for proceeds of approximately $4.5 million.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Warrant Repurchase Program</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In August 2023, our Board approved a warrant repurchase program, authorizing the repurchase of some or all of the Public Warrants (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Warrant Repurchase Program</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). The Board authorized an aggregate expenditure of up to $4.0 million for such repurchases. The repurchases may be made from time to time in open market or privately negotiated transactions. We may adopt one or more purchase plans pursuant to Rule 10b5-1 under the Exchange Act, in order to implement the Warrant Repurchase Program. The Warrant Repurchase Program does not obligate us to purchase any Public Warrants and may be terminated, increased or decreased by the Board in its discretion at any time. We adopted a purchase plan in October 2023. Through October 31, 2023, we had repurchased 28,502 Public Warrants for $9,900.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Standby Equity Purchase Agreement</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On October 2, 2023, we entered into a Standby Equity Purchase Agreement (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Yorkville Purchase Agreement</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) with YA II PN, Ltd. (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Yorkville</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Yorkville Purchase Agreement, we shall have the right, but not the obligation, to sell to Yorkville up to $30.0 million of our Common Stock at our request any time during the commitment period commencing on October 2, 2023 (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effective Date</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), and terminating on the first day of the month following the 24-month anniversary of the Effective Date. Each issuance and sale by us to Yorkville under the Yorkville Purchase Agreement (an &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Advance</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) is subject to a maximum limit equal to the greater of: (i) an amount equal to 100% of the average of the daily volume traded of our Common Stock on the Nasdaq Stock Market (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Nasdaq</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) for the 10 trading days immediately preceding an Advance notice, or (ii) 1,000,000 shares of Common Stock. The shares will be issued and sold to Yorkville at a per share price equal to, at our election as specified in the relevant Advance notice: (i) 96% of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on </span><span style="font-family:'Times New Roman','Times','serif';">4:00</span><span style="font-family:'Times New Roman','Times','serif';"> p.m. New York City time on the applicable Advance notice date (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option 1 Pricing Period</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), and (ii) 97% of the Market Price for any three consecutive trading days commencing on the Advance notice date (the &#8220;Option 2 Pricing Period,&#8221; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Pricing Period</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Market Price</b><span style="font-family:'Times New Roman','Times','serif';">&#8221; is defined as, for any Option 1 Pricing Period, the daily volume weighted average price (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">VWAP</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than 4.99% of our outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than 19.99% of our outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following discussion sets forth certain components of our consolidated statements of operations as well as factors that impact those items.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We currently operate in one reportable segment and revenue is generated from sales of PEDD infusion systems to our customers, principally related to TriNav. Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which we expect to be entitled in exchange for those products or services.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The primary end-user customers for our products are hospitals, clinics and physicians. We had certain arrangements with our distributors under which they purchase our products and then resell them in geographic markets where we do not have a sales presence. These arrangements provided for a discount on the invoice when the distributor resold our units at our normal sales price. Such sales are recorded net of the discounts. All such arrangements were terminated on or before December 31, 2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Cost of Goods Sold</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cost of goods sold primarily consists of raw materials, direct labor and manufacturing overhead costs related to sales of TriNav.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Gross Profit and Gross Margin</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Gross profit represents revenue less cost of goods sold. Gross margin is gross profit expressed as a percentage of revenue. Our gross margin and overall profitability may in the future fluctuate from period to period based on a number of factors, such as the innovation initiatives we undertake, and manufacturing costs and efficiencies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our operating expenses consist of R&amp;D, sales and marketing and general and administrative expenses.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research and Development</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">R&amp;D expenses include engineering, drug supply, regulatory, pre-clinical and clinical activities. We expense R&amp;D costs as incurred. We recognize expenses for certain development activities, such as preclinical studies and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in R&amp;D activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">R&amp;D activities account for a significant portion of our operating expenses. We expect our R&amp;D expenses to increase significantly in future periods as we continue to implement our business strategy, which includes advancing our manufacturing technologies into and through clinical development of SD-101, expanding our R&amp;D efforts, including hiring additional personnel to support our R&amp;D efforts, and seeking regulatory approvals for our drug candidates that successfully complete clinical trials. In addition, drug candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, although we expect our R&amp;D expenses to increase as SD-101 advances into later stages of clinical development, we do not believe that it is possible at this time to accurately project total program-specific expenses through to commercialization.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales and Marketing</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Sales and marketing expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">General and Administrative</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">General and administrative expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. General and administrative costs also include corporate facility costs, including rent, utilities, depreciation and maintenance, not otherwise included in production or R&amp;D expenses, as well as regulatory and professional fees for legal, patent, accounting and other consulting services.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Loss on Equity Issuance</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Loss on equity issuance represents the excess of the fair value of the warrants to purchase Series B-3 preferred stock and the Series B-2 tranche liabilities over the proceeds received from the Initial Preferred Stock Financing and subsequent tranche closings.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Tranche and Warrant Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Change in fair value of warrant and tranche liabilities represents the change in fair value of the warrants to purchase Series B-3 preferred stock and the Series B-2 tranche liabilities at each reporting period that were issued as part of the Initial Preferred Stock Financing, and changes in the fair value of the Public Warrants and Private Placement Warrants in this line.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Contingent Earnout Liability</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Change in fair value of contingent earnout liability represents the change recorded as a result of remeasurement of the fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Deemed dividend related to Series B-2 preferred stock down round provision</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The deemed dividend represents the value attributed to the increase in shares of Legacy TriSalus Common Stock that preferred stockholders would receive upon conversion to Legacy TriSalus Common Stock as a result of the Series B-2 preferred stock financing rounds in October 2022 and March 2023, which was deemed to be a down round and triggered the anti-dilution provisions associated with our preferred stock. The resulting increase in value of the preferred stock was deemed to be a dividend to the preferred stockholders and was recognized as a non-cash adjustment to additional paid-in-capital.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Income Tax Benefit (Expense)</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our income tax provision consists primarily of U.S. federal and state income taxes. We maintain a full valuation allowance for our federal and state deferred tax assets, including net operating loss carryforwards, as we have concluded that it is not more likely than not that the deferred tax assets will be realized.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Results of Operations:</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table sets forth our consolidated statements of operations data for each of the periods indicated (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,172</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">701</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,442</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,730</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,091</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,881</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,425</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(18,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,111)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(40,032)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24,667)</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of tranche and warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(71)</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(23,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24,642)</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(23,529)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24,645)</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deemed dividend related to Series B-2 preferred stock down round provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Undeclared dividends on Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(458)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,744)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(26,968)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24,645)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table sets forth our consolidated statements of operations data expressed as a percentage of revenue:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">82.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">180.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">122.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">171.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">164.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">77.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">173.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">136.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(355.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(206.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(313.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(268.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(32.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of tranche and warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(54.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of earnout liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">383.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(206.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(183.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(268.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(24.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(206.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(184.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(268.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deemed dividend related to Series B-2 preferred stock down round provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(23.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Undeclared dividends on Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(33.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(206.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(210.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(268.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Comparison of the Three Months Ended September 30, 2023, and 2022</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Revenue increased by $1.3 million or 32.4% for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase in revenue was primarily due to an increase of $1.1 million in units of TriNav sold as our launch of the product, begun in 2020, recovered from the impact of the Covid-19 pandemic. In addition, we realized a reduction in sales discounts of $0.2 million as we terminated the distributor agreements that required the discounts.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Cost of Goods Sold and Gross Profit</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cost of goods sold decreased by $0.1 million, or 16.0%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The decrease in cost of goods sold was primarily due to increased manufacturing efficiencies driven by additional production of TriNav to support our sales growth.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Gross profit increased by $1.4 million or 42.9%, and gross margin increased to 88.7% from 82.1% for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase in gross profit was due primarily to the increase in revenue. The increase in gross margin percentage was driven principally by increased manufacturing efficiencies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">R&amp;D expenses increased by $4.6 million, or 94.8%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was primarily driven by a $3.4 million increase in expense for our three clinical trials of our drug candidate, SD-101, and a $0.5 million increase in expense for development of manufacturing for SD-101, along with increases in headcount related expenses and travel of $0.7 million.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Sales and Marketing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Sales and marketing expenses increased by $1.7 million or 54.8%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was primarily driven by a $1.9 million increase for payroll and travel expenses due to increased headcount of sales and marketing personnel to support our sales of TriNav. The increase was partially offset by a reduction in professional services of $0.2 million, reflecting lower expenditures after completing development of our web site and social media platforms.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General and Administrative</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">General and administrative expenses increased by $5.5 million, or 158.2%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was primarily due to a $4.8 million increase for professional services, principally for legal, consulting and auditing work in connection with the Business Combination, and a $0.7 increase in payroll and travel expenses related to additional personnel.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Interest income increased by $67 thousand for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was due to higher interest received from the investment of our excess cash in short-term money market funds in three months ended September 30, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Tranche and Warrant Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The change in fair value of tranche and warrant liabilities resulted in a loss of $2.8 million in the three months ended September 30, 2023, due to the increase in the trading price of the Public Warrants.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Earnout Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The change in fair value of earnout liability resulted in a gain of $19.9 million in the three months ended September 30, 2023, due to the decrease in the market price of the underlying common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Comparison of the Nine Months Ended September 30, 2023, and 2022</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Revenue increased $3.6 million, or 39.4%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily due to higher sales volume of TriNav, amounting to $3.1 million, and a reduction in discounts of $0.5 million as a result of the shift away from sales to distributors.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Cost of Goods Sold and Gross Profit</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cost of goods sold increased by $0.6 million, or 40.3%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase in cost of goods sold was primarily due to the higher volume of TriNav produced in the period to support the higher sales volume.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Gross profit increased by $3.0 million, or 39.3%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, and gross margin decreased from 84.3% to 84.2%. The increase in gross profit was driven primarily by higher sales volume. The decrease in gross margin was driven primarily by higher overhead costs, principally labor.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">R&amp;D expenses increased by $6.8 million, or 44.9%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily due to a $5.2 million increase in spending on our clinical trials, an increase of $1.0 million for development of manufacturing of SD-101, and an increase of $0.6 million in payroll expense as we increased our headcount.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Sales and Marketing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Sales and marketing expenses increased by $2.5 million, or 28.7%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily driven by a $2.6 million increase for additional payroll expenses due to an increase in headcount of sales and marketing personnel, and $0.7 million of additional travel expense, partially offset by a $0.8 million decrease in marketing expense, reflecting lower expenditures after completing development of our web site and social media platforms.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">General and administrative expenses increased by $9.1 million, or 107.7%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily due to a $7.7 million increase in professional service fee due to additional legal, consulting, and audit-related expenditures incurred leading up to the Business Combination, and a $1.4 million increase for payroll, personnel, and travel expenses due to increased headcount of general and administrative personnel.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Interest income increased by $112.0 thousand, or 149.3%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily due to a combination of higher surplus cash balances invested in money market funds and higher interest rates during the nine months ended September 30, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Loss on Equity Issuance</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">A loss on equity issuance of $4.2 million was recorded in the nine months ended September 30, 2023, attributable to the issuance of Series B-2 preferred stock and the accompanying warrants to purchase Series B-3 preferred stock and related tranche obligations, which were valued in excess of the proceeds received as part of the transaction. The fair value exceeded proceeds primarily due to the issuance of warrants to purchase four shares of Series B-3 preferred stock for every one share of Series B-2 preferred stock purchased in the Initial Preferred Stock Financing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Tranche and Warrant Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The change in fair value of tranche and warrant liabilities resulted in a gain of $0.7 million in the nine months ended September 30, 2023, due to reductions in the measured fair value of the tranche and warrant liabilities. There were no tranche or warrant liabilities in the nine months ended September 30, 2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change in Fair Value of Earnout Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The change in fair value of earnout liability resulted in a gain of $19.9 million in the nine months ended September 30, 2023, due to a decrease in the market price of the underlying common stock. There was no earnout liability in the nine months ended September 30, 2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Deemed dividend related to Series B-2 preferred stock down round provision</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The deemed dividend is related to the Initial Preferred Stock Financing, which was deemed to be a down round and triggered the anti-dilution provisions associated with our preferred stock. As a result, the conversion prices of all prior series of preferred stock were </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">adjusted such that the holders would receive more shares of Legacy TriSalus Common Stock upon conversion than previously. The resulting increase in value of the preferred stock was deemed to be a dividend to the preferred stockholders and we recognized a $3.0 million, non-cash adjustment to additional paid-in-capital for the nine months ended September 30, 2023. There was no such adjustment recorded in the nine months ended September 30, 2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future due to the investments we will continue to make in R&amp;D and sales and marketing, and due to additional general and administrative costs we expect to incur as a public company. We incurred net losses of $23.5 million for the nine months ended September 30, 2023. We had cash and cash equivalents of approximately $21.4 million at September 30, 2023. Since inception, we have financed operations primarily through the issuance of preferred stock, convertible notes, and term loans. We are still in our early stages of development and have yet to generate revenues sufficient to fund cash flows from operations. Our ability to fund future operations and execute our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or debt. There can be no assurance that we will be able to raise such additional financing on satisfactory terms. If additional capital is not secured when required, we may need to delay or curtail our operations until such funding is received. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected. As a result, we have concluded that there is substantial doubt of our ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our ability to continue as a going concern is dependent upon obtaining additional capital and financing. Our financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should we be unable to continue as a going concern. In connection with the consummation of the Business Combination on August 10, 2023, we raised an additional $36.9 million of cash (net of expenses related to closing the Business Combination). In addition, as described below, we received $4.5 million in cash proceeds from the exercise of warrants to purchase Series B-3 preferred stock in July 2023.As of September 30, 2023, we had approximately $21.4 million in cash and cash equivalents. Based on our sales, operations and research and development plans, we do not currently expect that our cash and cash equivalents as of September 30, 2023, will be sufficient to fund our projected liquidity requirements for the next 12 months, creating substantial doubt about our ability to continue as a going concern. We have based these estimates on assumptions that may prove to be wrong and we could use our available capital resources sooner than we currently expect, and future capital requirements and the adequacy of available funds will depend on many factors, including those described in the section titled &#8220;Risk Factors&#8221; in this prospectus. See also &#8220;Funding Requirements&#8221; below.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In October 2022, we raised $9.8 million, net of issuance costs, through the issuance of Series B-2 preferred stock and warrants to purchase Series B-3 preferred stock. This issuance also included, at our option, a second tranche of Series B-2 preferred stock and warrants to purchase Series B-3 preferred stock (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Series B-3 Warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) for up to approximately $7.4 million (which could be increased to $10 million) and a third tranche, at the election of investors in the second tranche, of up to $4.3 million (which could be increased to $5 million) of Series B-2 preferred stock and warrants to purchase Series B-3 preferred stock, subject, in all respects, to the covenants in the Merger Agreement prohibiting us from issuing additional securities during the Interim Period without MTAC&#8217;s prior consent. We offered the Series B-2 preferred stock to all of our preferred stockholders at the time of the Initial Preferred Stock Financing (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In January through July 2023, holders of warrants to purchase 4,771,642 shares of Series B-3 preferred stock exercised their purchase right, for proceeds of approximately $9.6 million. In March 2023, we effectuated (i) a closing of a portion of the second tranche of the Initial Preferred Stock Financing whereby 207,541 shares of Series B-2 preferred stock and accompanying warrants to purchase 830,167 shares of Series B-3 preferred stock, representing 40% of the shares committed in the second tranche, were sold for an aggregate purchase price of $2.9 million, and (ii) an additional closing under the purchase agreement for the Initial Preferred Stock </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Financing whereby 17,656 shares of Series B-2 preferred stock and accompanying warrants to purchase 70,624 shares of Series B-3 preferred stock were sold for an aggregate purchase price of $0.2 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June 2023, we effectuated (i) a closing of a portion of the second tranche of the Initial Preferred Stock Financing whereby 257,779 shares of Series B-2 preferred stock and accompanying warrants to purchase 1,031,116 shares of Series B-3 preferred stock, representing approximately 49.7% of the shares committed in the second tranche, were sold for an aggregate purchase price of $3.7 million, and (ii) an additional closing under the purchase agreement for the Initial Preferred Stock Financing whereby 165,967 shares of Series B-2 preferred stock and accompanying warrants to purchase 663,868 shares of Series B-3 preferred stock were sold for an aggregate purchase price of $2.3 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">In July 2023, holders of warrants to purchase 90,619,356 shares of Series B-3 preferred stock exercised their purchase rights for proceeds of approximately $4.5 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Any Series B-3 Warrants that were not exercised for cash were automatically net settled for shares of Legacy TriSalus Common Stock immediately prior to the Closing of the Business Combination and exchanged into shares of the combined company Common Stock at Closing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">In September 2023, our Board approved the Warrant Repurchase Program. The Board authorized an aggregate expenditure of up to $4.0 million for such repurchases. The Warrant Repurchase Program does not obligate us to purchase any Public Warrants and may be terminated, increased or decreased by the Board in its discretion at any time.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">In October 2023, we entered into the Yorkville Purchase Agreement with Yorkville, whereby we have the right, but not the obligation, to sell to Yorkville up to $30.0 million of shares of Common Stock at our request any time during the 24 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">In addition, we will receive the proceeds from any exercise of any Warrants in cash. Each Warrant entitles the holder thereof to purchase one share of Common Stock at a price of $11.50 per share. The aggregate amount of proceeds could be up to approximately $152.2 million if all such Warrants are exercised for cash. We believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. So long as the trading price for our Common Stock is less than $11.50 per share, meaning the Warrants are &#8220;out of the money,&#8221; we believe holders of our Warrants will be unlikely to exercise their Warrants. In addition, to the extent that our Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of such Warrants will decrease. The Private Placement Warrants and Conversion Warrants may be exercised for cash or on a &#8220;cashless basis.&#8221; The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of Common Stock issuable upon the exercise of such warrants. If there is not a then-effective registration statement, then such warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act. We expect to use any such proceeds for general corporate purposes. Due to the uncertainty regarding the exercise of the Warrants, none of our projected liquidity requirements discussed in this prospectus assume the receipt of any proceeds from the exercise of the Warrants.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">As of December 8, 2023, the price of our Common Stock was $4.00 per share. We believe the likelihood that warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the market price of our Common Stock. So long as the market price for our Common Stock is less than $11.50 per share and the Warrants are &#8220;out of the money,&#8221; we believe holders will be unlikely to exercise their Warrants on a cash basis. To the extent the Warrants are exercised by holders, ownership interest of our stockholders will be diluted as a result of such issuances. Moreover, the resale of shares of Common Stock issuable upon the exercise of such Warrants, or the perception of such sales, may cause the market price of our Common Stock to decline and impact our ability to raise additional financing on favorable terms. See &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">Risk Factors &#8212; Until we are able to generate significant revenues or achieve profitability through product sales, we will require substantial additional capital to finance our operations and continue development of our product candidates. We cannot be certain that such additional financing will be available on terms favorable to us, or at all, which could limit our ability to grow and jeopardize our ability to continue our business operations</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">.&#8221; and &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">Risk Factors &#8212; Risks Related the Ownership of Our Securities</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">&#8221; for more details.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">The shares of Common Stock being offered for resale pursuant to this prospectus by the Selling Securityholders would represent approximately 54.6% of our outstanding Common Stock as of December 8, 2023 (after giving effect to the issuance of the shares issuable upon exercise of the Warrants, the acquisition of certain shares acquirable upon the exercise of assumed options and </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">settlement of assumed restricted stock units, and the issuance of the PIPE Shares (assuming conversion at the initial conversion price of $10.00)). Furthermore, excluding the Company&#8217;s affiliates, there are three beneficial owners of more than 5% of its Common Stock, which together hold an aggregate of 4,329,931 shares of Common Stock as of August 10, 2023, will be able to sell a maximum aggregate of 7,553,271 shares of Common Stock, assuming that all Series A Convertible Preferred Stock held is converted into the maximum number of shares of Common Stock such shares are convertible into following the floor price reset on the 47th month anniversary of August 10, 2023 and so long as the registration statement of which this prospectus forms a part is available for use. Given the substantial number of shares of Common Stock being registered for potential resale by Selling Securityholders pursuant to this prospectus, the sale of shares by the Selling Securityholders of a large number of shares, or the perception in the market that the Selling Securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Comparison of the Nine Months Ended September 30, 2023, and September 30, 2022</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table presents net cash from operating, investing, and financing activities (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(41,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(24,003)</p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(1,421)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(1,514)</p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">54,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">7,554</p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net increase / (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">11,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">(17,963)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash Used in Operating Activities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For the nine months ended September 30, 2023, net cash used in operating activities was $41.2 million. The net cash used in operating activities consisted of net loss of $23.5 million, adjusted for non-cash charges totaling $15.4 million, primarily related to a gain on the adjustment of the fair value of the contingent earnout liability of $19.9 million, and a gain on the adjustment of the fair value of warrants to purchase preferred stock of $0.7 million, partially offset by a loss on equity issuance of $4.2 million, depreciation of $0.5 million and share-based compensation of $0.4 million. Net operating assets and liabilities decreased $3.2 million, due primarily to an increase in accounts receivable and a decrease in accounts payable.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For the nine months ended September 30, 2022, net cash used in operating activities was $24.0 million. The net cash used in operating activities consisted of net loss of $24.6 million, adjusted for non-cash charges totaling $0.7 million, primarily related to depreciation and amortization of $0.5 million and stock-based compensation expense of $0.3 million. In addition, there was a net increase of $1.1 million in our net operating assets and liabilities. The increase in our net operating assets and liabilities was driven by an increase in prepaid expenses of $1.3 million and accounts receivable of $0.9 million, and a decrease in trade payable, accrued expenses and other current liabilities of $1.1 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash Used in Investing Activities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Net cash used in investing activities of $1.4 million for the nine months ended September 30, 2023, was due to purchases of property and equipment of $0.2 million, payments of $0.2 million to acquire or maintain intellectual property, and a milestone payment of $1.0 million to Dynavax.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Net cash used in investing activities of $1.5 million for the nine months ended September 30, 2022, was primarily due to purchases of property and equipment of $0.4 million, payments of $0.1 million to acquire or maintain intellectual property, and a milestone payment of $1.0 million to Dynavax.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash Used in Financing Activities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Net cash provided by financing activities of $54.6 million for the nine months ended September 30, 2023, consisted principally of proceeds from the merger of $36.9 million, proceeds from the issuance of Series B-2 preferred stock of $9.2 million, and proceeds </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">from the exercise of warrants to purchase Series B-3 preferred stock of $9.6 million, partially offset by expenses incurred related to the Business Combination of $1.1 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Net cash provided by financing activities of $7.6 million for the nine months ended September 30, 2022, consisted of prepayments of $4.0 million for Series B-2 preferred stock that was issued in the fourth quarter of 2022 and proceeds from the sale of Series B-1 preferred stock of $3.5 million.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our primary use of cash is to fund operating expenses, which consist of research, development and clinical expenses related to our lead product candidate SD-101, and preclinical programs, sales and marketing expenses related to the growth of TriNav, as well as general and administrative expenses. We plan to advance the development of SD-101, initiate new research and pre-clinical development efforts and seek marketing approval for product candidates that we successfully develop. If we obtain approval for our product candidates, we expect to incur commercialization expenses, which may be significant, related to establishing sales, marketing, manufacturing capabilities, distribution and other commercial infrastructure to commercialize such products. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Inflation and rising interest rates may result in an economic recession globally or in the U.S., which could lead to a reduction in product demand, a decrease in corporate capital expenditures, prolonged unemployment, labor shortages, reduction in consumer confidence, adverse geopolitical and macroeconomic events, or any similar negative economic condition. Economic conditions in some parts of the world have been worsening, with disruptions to, and volatility and uncertainty in, the credit and financial markets in the U.S. and worldwide resulting from the effects of inflation and rising interest rates. These conditions have been further exacerbated by recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, the wars in Ukraine and Israel and the lingering effects of the COVID-19 pandemic. It is not possible at this time to estimate the long-term impact that these and related events could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. If these conditions persist and deepen, we could experience an inability to access additional capital, or our liquidity could otherwise be impacted. If we are unable to raise capital when needed and on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs and/or other efforts. A recession or additional market corrections resulting from the impact of difficult macroeconomic conditions, disruptions in the banking system, and the lingering effects of the COVID-19 pandemic could materially affect our business and the value of our securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We also expect to continue to incur significant expenses in connection with our ongoing activities related to TriNav, including sales and marketing expenses and expenditures to support expansion of our production capacity to support our expected sales growth. Our future capital requirements, both near and long-term, will depend on many factors, including but not limited to: the success of our commercialization of TriNav including, among other things, continued patient and physician adoption of TriNav and our ability to maintain adequate reimbursement for TriNav; the cost of commercialization activities for TriNav, including manufacturing, distribution, marketing and sales; net product revenues received from sales of TriNav; the outcome, timing and cost of the regulatory approval process for SD-101 by the FDA, including the potential for the FDA to require that we perform more studies and clinical trials than those that we currently expect; the costs involved in preparing, filing and prosecuting patent applications and annuity fees relating to issued patents; the cost of maintaining and enforcing our intellectual property rights, as well as the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; the initiation, progress, timing, costs and results of clinical trials and other research and development related to our product candidates; and the extent to which we in-license, acquire or otherwise partner in development or commercialization of other products, product candidates or technologies; the achievement of milestones or occurrence of other developments that trigger payments under the Dynavax Agreement or any other collaboration or other agreements; the number of future product candidates that we may pursue and their development requirements; the costs of commercialization activities for any of our product candidates that may receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; the amount and timing of future revenue, if any, received from commercial sales of our current and future product candidates upon any marketing approvals; and the costs of operating as a public company.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing ownership interest in our company may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the price of our </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">common shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September 30, 2023, we had approximately $21.4 million in cash and cash equivalents. Based on our sales, operations, and research and development plans, we do not currently expect that our cash and cash equivalents as of September 30, 2023, will be sufficient to fund our projected liquidity requirements for the next 12 months, creating substantial doubt about our ability to continue as a going concern. We will likely require additional capital in the near term in order to continue to fund our operations through equity or debt financings, partnerships, collaborations, or other sources which may not be available on a timely basis, on favorable terms, or at all, and such capital, if obtained, may not be sufficient to enable us to continue to implement our long-term business strategy. See factors discussed above and in the section titled &#8220;Risk Factors.&#8221; As further discussed above in the section titled "Recent Developments," in October 2023, we entered into the Yorkville Purchase Agreement, whereby we have the right, but not the obligation, to sell to Yorkville up to $30.0 million of shares of Common Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Additionally, we may never become profitable, or if we do, may not be able to sustain profitability on a recurring basis. If we cannot capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected and we may need to delay or curtail our operations until such funding is received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, or other sources to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. As discussed in Note 1 to our unaudited consolidated financial statements accompanying this prospectus, there is substantial doubt regarding our ability to continue as a going concern as of September 30, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Contractual Obligations and Commitments</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our contractual obligations as of September 30, 2023, include lease obligations of $1.7 million, reflecting the minimum commitments for our principal administrative and production facility and other office spaces.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Asset Purchase Agreement, dated July 31, 2020, between TriSalus and Dynavax, we have paid Dynavax $12 million as of September 30, 2023, and may be required to pay Dynavax up to an additional $158 million upon the achievement of certain development and regulatory milestones with respect to SD-101. We will also be required to pay up to $80 million upon achieving certain commercial milestones once sales of SD-101 have begun. The Dynavax Agreement also obligates us to pay low double-digit royalties based on potential future net sales of product containing SD-101 compound on a product-by-product and country-by-country basis during the applicable royalty term. Such royalties are subject to reduction by up to 50% in certain circumstances.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Proceeds from Warrants</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We will not receive any of the proceeds from sales of Warrants, except with respect to amounts we may receive upon the cash exercise of the Warrants. Whether warrantholders will exercise their Warrants, and therefore the amount of cash proceeds we would receive upon exercise, is dependent upon the trading price of the Common Stock, the last reported sales price for which was $4.00 per share on December 8, 2023. Each Warrant is exercisable for one share of Common Stock at an exercise price of $11.50. Therefore, if and when the trading price of the Common Stock is less than $11.50 per share, we expect that warrantholders would not exercise their Warrants. To the extent the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. The Private Placement Warrants and Conversion Warrants may be exercised for cash or on a &#8220;cashless basis.&#8221; The Public Warrants may only be exercised for cash provided there is then an effective registration statement registering the </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">shares of Common Stock issuable upon the exercise of such Warrants. If there is not a then-effective registration statement, then such Warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant to an available exemption from registration under the Securities Act.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We could receive up to an aggregate of approximately $152.2 million if all of the Warrants are exercised for cash, but we would only receive such proceeds if and when the warrantholders exercise their Warrants, which, based on the current trading price of our Common Stock, is unlikely unless there is a significant increase in the trading price of our Common Stock. The Warrants may not be, or remain, in the money during the period they are exercisable and prior to their expiration and, therefore, it is possible that the Warrants may not be exercised prior to their maturity, even if they are in the money, and as such, may expire worthless with minimal proceeds received by us, if any, from the exercise of the Warrants. To the extent that any of the Warrants are exercised on a &#8220;cashless basis,&#8221; we will not receive any proceeds upon such exercise. As a result, we do not expect to rely on the cash exercise of Warrants to fund our operations. Instead, we intend to rely on other sources of cash discussed elsewhere in this prospectus to continue to fund our operations.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We did not have during the periods presented, and we do not currently have, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities, which were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Critical Accounting Policies and Estimates:</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our significant accounting policies are summarized in Note 2 &#8220;Summary of Significant Accounting Policies&#8221; in the unaudited condensed consolidated financial statements included elsewhere in this prospectus. While all of these significant accounting policies affect the reporting of our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require us to use a greater degree of judgment and/or estimates. Actual results may differ from those estimates. Additionally, changes in accounting estimates could occur in the future from period to period.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from shipments of our TriNav infusion devices to our customers which are generally comprised of hospitals, clinics and physicians, and is recognized in accordance with the provisions of the Financial Accounting Standards Board, ASC 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue from Contracts with Customers</i><span style="font-family:'Times New Roman','Times','serif';">, and all related applicable guidance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i) identify the contract; (ii) identify the performance obligation; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We contract with our customers based on customer purchase orders. For each contract, we consider the promise to transfer products, each of which is distinct, to be the identified performance obligation. As part of our performance obligation, products are delivered in accordance with the terms of the purchase order and we do not have any on-going service obligation after delivery.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We maintain a single, discrete transaction price for each of the products, with no adjustments since the price is approved by CMS. We do not have multiple performance obligations to complete when a purchase order is fulfilled, hence the transaction price is always allocated fully to the units being sold.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Revenue is recognized when the units for a purchase order have been shipped and control of the units has been transferred to the customer. Ex-works shipment is followed, wherein we recognize revenue when the shipment leaves our premises. In certain cases where purchase orders specify alternate shipping terms, usually delivery at place, revenue recognition is deferred until we are assured the units are delivered.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances. We do not have a history of any refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We had certain arrangements with distributors under which the distributors purchased and then resold our products in geographic markets where we did not have sales presence. These arrangements provided for a discount on the invoice. When the distributor resold our units at our normal sales price, the discount served to compensate the distributor for their efforts. We recorded these sales net of the discounts. One of our distributors, ACD, accounted for approximately 20% of our sales for the year ended December 31, 2022. We discontinued the distributor agreement with ACD in December 2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We provide certain customers with rebates that are explicitly stated in our contracts and are recorded as a reduction of revenue in the period the conditions for the rebates are achieved. The rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Contingent Earnout Liability</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination, the Sponsor received shares that will vest upon the achievement of certain share price targets and change in control events. In accordance with ASC 815-40, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, the earnout shares were classified as a liability as they do not qualify as being indexed to the Company&#8217;s own stock and therefore are measured at fair value at each reporting date with changes in fair value recorded in the unaudited condensed consolidated statements of operations included elsewhere in this prospectus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The estimated fair value of the earnout liability was determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes. The inputs and assumptions utilized in the calculation require management to apply judgment and make estimates including:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected volatility, which is based on the historical equity volatility of publicly traded peer companies for a term equal to the expected term of the earnout period;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected term, which we based on the earnout period per the agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time periods commensurate with the expected term of the earnout period; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected dividend yield, which we estimate to be zero based on the fact that we have never paid or declared dividends.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">R&amp;D costs include our engineering, drug supply, regulatory, pre-clinical and clinical activities. R&amp;D costs are expensed as incurred. Approximately 12% of our R&amp;D costs are headcount-related; the balance is external services we purchase, such as pre-clinical supplies and materials, clinical study management and supplies, and consulting related to our R&amp;D.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Warrant and Tranche Rights and Obligation Liabilities</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We classified the Public Warrants and Private Placement Warrants as liabilities on the unaudited condensed consolidated balance sheets included elsewhere in this prospectus. We measured the warrants at fair value at August 10, 2023, when we assumed them in the Business Combination, and at September 30, 2023. The fair value of the Public Warrants is based on their trading price; we used the price of the Public Warrants as the fair value of the Private Placement Warrants, as the rights and characteristics of the warrants are the same.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We classified the Series B-2 tranche rights and obligations (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Series B-2 Tranche Rights</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) and Series B-3 Warrants as liabilities on the unaudited condensed consolidated balance sheets included elsewhere in this prospectus. We measured the Series B-2 Tranche Rights and Series B-3 Warrants at fair value upon issuance in October 2022, March 2023, and June 2023, and remeasured the liabilities to fair value at December 31, 2022, March 31, 2023, June 30, 2023, and August 10, 2023, with changes in the fair value at each measurement date recognized in change in fair value of tranche and warrant liabilities in the consolidated statements of operations. The Series B-2 Tranche Rights and series B-3 Warrants were extinguished in the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series B-2 tranche liabilities was determined using a Binomial Tranche Model. The fair value of the Series B-3 Warrants was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on Legacy TriSalus&#8217;s expectation of each occurring: (1) a status quo scenario whereby Legacy TriSalus would continue as a private company and (2) a scenario where the Business Combination would close. Under the status quo scenario, the Series B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series B-2 tranche liabilities and Series B-3 Warrants used various inputs and assumptions that required management to apply judgment and make estimates, including:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the equity value under the status quo scenario, which was determined using the Guideline Public Company method within the market approach to estimate the fair value of equity on a minority, marketable basis using selected publicly traded peer companies and valuation multiples based on size, growth, profitability, and other relevant factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fair value of underlying Series B-2 preferred stock, which was determined using the Option Pricing Model to allocate Legacy TriSalus&#8217;s equity value among its various classes of equity securities under the status quo scenario;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance and exercise price, which was based on the terms of the purchase agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected term, which we based on the expiry periods as defined in the purchase agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected volatility, which was based on the historical equity volatility of publicly traded peer companies for a term equal to the expected term of the warrants and tranche liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time periods commensurate with the expected terms of the warrants and tranche liabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected dividend yield, which we estimate to be zero based on the fact that we have never paid or declared dividends.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision. The scenario probability is the most sensitive estimated input into the calculation of the fair value of the Series B-3 Warrants. The risk of exposure is estimated using a sensitivity analysis of potential changes in the significant unobservable inputs, primarily the scenario probability input that is the most susceptible to valuation risk.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Emerging Growth Company Status</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. MTAC previously elected to avail itself of the extended transition period, and following the Closing of the Business Combination, we are an emerging growth company and will take advantage of the benefits of the extended transition period that the emerging growth company status permits. During the extended transition period, it may be difficult or impossible to compare our financial results with the financial results of another public company that complies with public company effective dates for accounting standard updates because of the potential differences in accounting standards used.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We will remain an emerging growth company under the JOBS Act until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of MTAC&#8217;s initial public offering (i.e., December 31, 2025), (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common equity that is held by non-affiliates exceeds $700.0 million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Note 2(q) to our unaudited condensed consolidated financial statements included elsewhere in this prospectus includes more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one, of their potential impact on our financial condition and our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b1fcd66e_44c1_4c9e_bc32_1b10ec141cb5"></a><a id="OURBUSINESS_994987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">OUR BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion reflects the business of TriSalus Life Sciences,&#160;Inc., as currently embodied by each of </i><i style="font-style:italic;">Legacy TriSalus and TriSalus after the Closing of the Business Combination. As used in this section, &#8220;TriSalus</i>,<i style="font-style:italic;">&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to Legacy TriSalus prior to the Closing of the Business Combination and TriSalus following the Closing of the Business Combination unless the context specifically indicates otherwise.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an oncology company integrating standard-of-care treatments and our investigational immunotherapeutic with disruptive delivery technology with the goal of transforming the treatment paradigm for patients battling liver and pancreatic tumors. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of immunotherapeutics in these difficult-to-treat diseases: (i)&#160;high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii)&#160;the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve checkpoint inhibitor (&#8220;<b style="font-weight:bold;">CPI</b>&#8221;) response and enable improved patient outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liver and pancreatic cancers are among the world&#8217;s most lethal diseases. Depending on the disease stage, many patients have no curative treatment options and have poor outcomes, with 5-year survival rates ranging from 8-20% for patients with advanced disease. While immunotherapy represents one of the greatest advancements in cancer treatment over the past 50&#160;years, patients with primary or secondary tumors in the liver or pancreas are less likely to respond to treatment relative to most other cancer types that do not involve these sites of disease. These patients need new treatment options designed to address the unique challenges specific to liver and pancreatic tumors that limit the success of immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The Opportunity: Changing the Treatment Paradigm with an Innovative Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have developed a platform approach to address the unique challenges of treating tumors in the liver and pancreas by integrating our investigational immunotherapeutic, SD-101, with our innovative drug delivery technology with the goal of overcoming the two primary barriers that inhibit treatment success: intratumoral pressure and immunosuppression, both of which limit therapeutic delivery and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our delivery method&#8201;&#8212;&#8201;Pressure-Enabled Drug Delivery (PEDD</span><span style="font-size:7.5pt;">TM</span><span style="font-size:10pt;">) (&#8220;</span><b style="font-size:10pt;font-weight:bold;">PEDD</b><span style="font-size:10pt;">&#8221;)&#8201;&#8212;&#8201;modulates pressure and flow within blood vessels to improve the intravascular therapeutic delivery and is designed to increase the likelihood of tumor response in ways traditional approaches currently do not. In addition, we are studying the ability of SD-101, an investigational class C toll-like receptor 9 (&#8220;</span><b style="font-size:10pt;font-weight:bold;">TLR9</b><span style="font-size:10pt;">&#8221;) agonist, to reactivate the immune system within the liver and pancreas by broadly reprograming immune cells and reducing myeloid derived suppressor cells (&#8220;</span><b style="font-size:10pt;font-weight:bold;">MDSCs</b><span style="font-size:10pt;">&#8221;) which we believe will enable more durable responses to CPIs, thereby improving patient outcomes. SD-101 has previously been shown in both clinical and non-clinical studies to broadly induce interferon production, dendritic cell activation, and B cell activation. Through pre-clinical experiments and early clinical experience in patients with liver tumors, we have recently demonstrated that SD-101 may reduce MDSCs, which are important mediators of immunosuppression in liver and pancreas tumors, while also stimulating immunity systemically. SD-101 delivered via the PEDD method is designed to promote responsiveness to systemic checkpoint inhibition by:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reducing or eliminating liver MDSCs by inducing apoptosis and favorably reprogramming them to M1 macrophages; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enhancing innate immunity (e.g., DC and NK cells), directly stimulating B cells, and promoting T-cell infiltration and cytotoxic T-cell programming to create an immuno-responsive environment stimulating greater responses to checkpoint inhibition.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the combination of PEDD with SD-101 creates a platform approach with the potential to address common therapeutic barriers across numerous cancer indications affecting the liver and pancreas and that this approach could provide a meaningful benefit to patients. There is also the potential that this platform may not only enable CPIs, but other classes of immunotherapy as well, such as cell therapeutics.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PEDD component of our platform currently comprises two FDA-cleared devices that use our proprietary method to enhance delivery of therapeutics: (i)&#160;TriNav for liver tumors used during hepatic artery infusion procedures and (ii)&#160;the pancreatic retrograde venous infusion (&#8220;<b style="font-weight:bold;">PRVI</b>&#8221;) device for pancreatic tumors using a novel delivery approach designed to address anatomic limitations of arterial infusion for the pancreas. The TriNav device is currently in use with standard-of-care therapeutics for patients with primary and metastatic liver tumors. PEDD has been used in over 18,000 procedures, primarily for transarterial chemoembolization (&#8220;<b style="font-weight:bold;">TACE</b>&#8221;) and transarterial radioembolization (&#8220;<b style="font-weight:bold;">TARE</b>&#8221;) delivery during routine outpatient interventional radiology procedures. The PRVI device, is currently being studied in a clinical trial for SD-101 delivery into pancreatic tumors. Although FDA-cleared, the PRVI device has not yet been commercialized and commercial sale is not anticipated before 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently we are studying our platform approach in three clinical trials, which include four indications, in leading academic oncology centers across the United States (&#8220;<b style="font-weight:bold;">U.S.</b>&#8221;). In these trials, PEDD devices are used to administer our investigational immunotherapy candidate, SD-101, through a regional intravascular approach for patients with liver and pancreatic tumors alone or in combination with intravenous systemic CPI infusions. We believe this approach will maximize TLR9 stimulation within the liver and pancreas and eliminate immunosuppressive cells to broadly reprogram the tumor microenvironment (&#8220;<b style="font-weight:bold;">TME</b>&#8221;) with the goal of enabling improved efficacy of systemic immunotherapies like CPIs or cell therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Strategic Acquisition of SD-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2020, we acquired SD-101, a class C TLR9 agonist, from Dynavax Technologies Corporation. Prior to acquiring SD-101, we embarked on a comprehensive landscape assessment evaluating assets currently or formerly in clinical development that would fit the criteria for optimal immunomodulation of the TME in the liver and pancreas. Our selection criteria included the identification of an immunotherapeutic with a potential mechanism of action to specifically address immunosuppressive mechanisms in the liver and/or pancreas; the potential to enable systemic checkpoint inhibition in patients with liver or pancreatic tumors to the extent observed in other indications, and the ability to broadly reprogram the TME while addressing MDSCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We concluded that the greatest value creation and cancer patient impact opportunity for the PEDD devices, including TriNav, would be to demonstrate clinical efficacy in difficult to treat &#8220;cold tumors&#8221; such as those affecting the liver and pancreas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, we chose to focus on TLR agonists since they are well known to have broad TME modulating effects with induction of immunity at distal sites. Many have been in clinical development with varying results, most often using needle injection strategies which limit the ability to treat multiple or large tumors. TLR agonists are generally not safe to be administered intravenously due to concerns related to excessive immune cell activation. Within the TLR agonist space, TLR9 targeting assets were particularly attractive given our hypothesis that MDSC may be eliminated in the liver via TLR9 engagement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We acquired SD-101 from Dynavax based on Phase&#160;2 study data that demonstrated improved responsiveness to pembrolizumab with acceptable tolerability in stage IV cutaneous melanoma. In particular, Dynavax conducted the Synergy-001/KEYNOTE&#160;184 Phase&#160;1b/2 study (the &#8220;<b style="font-weight:bold;">Synergy study</b>&#8221;) to assess the safety and preliminary efficacy of the combination of intratumoral SD-101 and intravenous (&#8220;<b style="font-weight:bold;">IV</b>&#8221;) pembrolizumab for cutaneous melanoma and head and neck cancer. In the Synergy study, SD-101 + pembrolizumab was associated with a serious adverse event rate on par with that of pembrolizumab alone, and a response rate of 78% was achieved in treatment na&#239;ve patients. It was also studied in the I-SPY2 Trial for patients with high-risk, Stage II/III breast cancer. In the melanoma and head and neck carcinoma studies, SD-101 in combination with anti-programmed cell death protein 1 (&#8220;<b style="font-weight:bold;">PD-1</b>&#8221;) therapy produced response rates that are higher than those reported for anti-PD 1 therapy alone. See Note&#160;8&#8201;&#8212;&#8201;&#8221;Dynavax Purchase&#8221; to our consolidated financial statements included elsewhere in this prospectus for more information. We believed that we could substantially enhance SD-101&#8217;s profile to create new liver and pancreas opportunities via PEDD administration to optimize its delivery while minimizing systemic exposure, thereby enhancing the therapeutic index and bringing SD-101 and PEDD into clinical testing as a platform approach. Our goal is to achieve a similar response rate for SD-101 with checkpoint inhibition as reported in stage IV melanoma across a wide array of liver and pancreatic indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since acquiring the worldwide rights to SD-101, we have initiated three Phase&#160;1/1b Pressure Enabled Regional Immuno-oncology (PERIOTM) (&#8220;<b style="font-weight:bold;">PERIO</b>&#8221;) studies which are focused on four indications within the primary liver cancer, metastatic liver cancer, and locally advanced pancreatic cancer categories. We are testing the ability of the SD-101/PEDD therapeutic platform to enable systemic CPIs in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Uveal melanoma with liver metastases (PERIO-01, NCT04935229);</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Intrahepatic cholangiocarcinoma (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ICC</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and hepatocellular carcinoma (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HCC</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (PERIO-02, NCT05220722); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Locally advanced pancreatic carcinoma (PERIO-03, NCT05607953).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also planning on testing the SD-101/PEDD therapeutic platform in patients with liver metastases from colorectal carcinoma. We are collaborating with leading cancer centers across the country to help leverage our deep immuno-oncology expertise and our unique, proprietary platform to improve patient responses to CPI therapy and potentially allow a greater number of cancer patients to benefit from immunotherapy advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe our approach in combination with CPI therapy has the potential to extend and improve the lives of patients battling liver and pancreatic tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current Treatment and Limitations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the 1990s, researchers discovered that cancer cells can block the immune system from attacking the tumor through immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (&#8220;<b style="font-weight:bold;">CTLA-4</b>&#8221;) and PD-1. These drugs, known as &#8220;checkpoints,&#8221; normally control immune responses to infections or other stimuli, to mitigate collateral tissue damage. Cancer cells can exploit these checkpoint molecules to escape detection and elimination by immune cells. CPIs work by blocking the interaction of checkpoint proteins found on T cells and the associated receptor proteins found on other cells, including tumor cells. When these proteins bind together, an &#8220;off&#8221; signal in T cells is blocked, enabling a potential anti-tumor immune response. These seminal discoveries enabled researchers to focus on developing CPI therapies, which spurred the approval in the last decade of several CPIs including PD-1 and programmed death-ligand 1 (&#8220;<b style="font-weight:bold;">PD-L1</b>&#8221;) blocking antibodies (often referred together as &#8220;<b style="font-weight:bold;">PD-(L)1</b>&#8221;). Importantly, for CPIs to work, tumors require the presence of a sufficient number of CPI targets within them&#8201;&#8212;&#8201;activated or exhausted T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Two critical barriers have historically hindered immunotherapy success in patients with intrahepatic and pancreatic malignancies: (1)&#160;delivery of immunotherapy agents into high-pressure liver tumors is inefficient with conventional approaches and (2)&#160;specific immunosuppression pathways hinder immunotherapy responsiveness. In the majority of liver and pancreatic cancers, the tumors are not infiltrated by T cells and the TME overall is suppressed. An accumulation of suppressive immune cells, such as MDSCs, further limit the ability of T cells to enter into tumors and remain in an activated state. For immunostimulatory drugs like SD-101 to enable CPIs and other forms of immunotherapy, successful delivery into tumors is necessary. Intratumoral pressure in the TME may result in subtherapeutic drug concentrations at the site of disease. With systemic intravenous (IV)&#160;infusion, it is difficult to achieve therapeutic levels within the tumor due to distribution of cardiac output and high intratumoral pressures, and off-target toxicity is common. Local needle injection, the traditional approach for TLR agonists since they typically cannot be administered systemically, is highly localized at the point of insertion, not uniformly distributed throughout the tissue (particularly in patients with large or multiple tumors), and physically impractical for most tumors, including liver and pancreas. Importantly, regional intravascular delivery with standard microcatheters does not address the intra-tumoral pressure barrier, while balloon catheters cause a cessation of forward blood flow, which may eliminate the ability to augment baseline intravascular pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite progress in other cancer treatments with CPIs, tumors in the liver and pancreas remain challenging to treat and patients have extremely poor outcomes. Few patients with liver or pancreatic cancers demonstrate benefit from CPIs and other immunotherapy approaches. Enabling immunotherapy in liver and pancreas cancer patients requires not only optimization of therapeutic delivery, but also a therapeutic with a mechanism of action appropriate for the specific biologic barriers in the liver and pancreatic tumors. This may be particularly important for CPIs as an emerging body of literature indicates that the presence of tumors in the liver may be among the most significant determinants of poor outcomes in patients receiving anti-PD-1 and/or anti-CTLA-4 agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overcoming Barriers to Effective Drug Delivery with PEDD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Systemic delivery of cancer therapeutics presents two critical challenges for patients with liver tumors. First, based on the normal distribution of cardiac output, the liver will receive a small fraction of the dose. Second, intratumoral solid stresses compress the interior of the tumor and deform blood vessels, reducing the delivery of drugs. Hypoperfusion and interstitial hypertension pose major barriers to the systemic administration of chemotherapeutic agents and nanomedicines to tumors, reducing treatment efficacies. In particular, vessel leakiness together with vascular compression cause elevated interstitial fluid pressure that hinders delivery of therapeutic agents and limits efficacy.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:262.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As such, a technological solution to the intratumoral pressure barrier may enable more effective delivery of therapeutic agents to liver and pancreas tumors. PEDD devices are engineered to overcome high intratumoral pressure through creation of a favorable pressure gradient, while at the same time minimizing systemic exposure and decreasing toxicity. In small trials and retrospective studies, the capability of PEDD to modulate pressure during infusion has been shown to overcome the infusion barriers of the TME and improve therapeutic delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Treating Immunosuppression in the Liver and Pancreas</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The immunosuppressive properties of liver immune cells protect humans from excessive responses to foreign antigens but limit the ability of human immune systems to fight intrahepatic neoplasia. The propensity of primary and metastatic tumors to thrive in the liver is in part reflective of the tolerogenic nature of the intrahepatic milieu. T-cell suppression caused by MDSCs is mediated in part by L-arginine depletion by arginase 1 or by reactive oxygen species. Liver MDSCs expand in response to granulocyte-macrophage colony-stimulating factor (&#8220;<b style="font-weight:bold;">GM-CSF</b>&#8221;) secreted by tumor cells and GM-CSF enhances their capacity to suppress immunotherapeutic cells through exploitation of signal transducer and activator of transcription 3 (&#8220;<b style="font-weight:bold;">STAT3</b>&#8221;) signaling, indoleamine 2,3-dioxygenase (&#8220;<b style="font-weight:bold;">IDO</b>&#8221;) and PD-L1 to suppress anti-tumor immunity. At the same time, PEDD has been shown to significantly improve therapeutic delivery to liver tumors using a regional intravascular approach and SD-101 has demonstrated enhanced response rates to CPI therapy in cutaneous melanoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">SD-101 mechanism of action</i>.&#160;As a class C TLR9 agonist, SD-101 has the capacity to stimulate a broad array of immune cells and induce numerous cytokines. In addition, SD-101 may be able to reduce myeloid suppressor cells in the liver and pancreas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tlsi-20230630xs1a003.jpg" alt="Graphic" style="display:inline-block;height:261.9pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:382.48pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Uveal Melanoma Liver Metastases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">With fewer than 3,000 new diagnoses per&#160;year in the United States, uveal melanoma is a rare solid organ malignancy in which metastatic spread to the liver results in rapidly progressive and often fatal disease. Uveal melanoma, however, is the most common primary intraocular malignancy accounting for 3% to 5% of all melanoma cases. Uveal melanoma arises from melanocytes within the uveal tract, but it is a unique disease with distinct genetic, chromosomal, and biologic features not observed in cutaneous melanoma. Although primary uveal melanoma tumors can be managed effectively with surgical or radiation therapy, metastatic disease occurs in more than 50% of patients and involves the liver in up to 90% of patients. The disease course of uveal melanoma that has metastasized </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to the liver is well understood, with a 1-year overall survival (&#8220;<b style="font-weight:bold;">OS</b>&#8221;) rate of 43% and approximately 90% of patients not surviving beyond 24&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CPIs that target CTLA-4, such as ipilimumab, and those that target PD-1, such as nivolumab and pembrolizumab, while highly effective in cutaneous melanoma, have only had limited efficacy in metastatic uveal melanoma. An important contributor to the failure of current therapies to effectively treat uveal melanoma is the profoundly immunosuppressive intrahepatic environment. The liver contains an abundance of immunosuppressive cell types, including liver sinusoidal endothelial cells, regulatory T cells, and MDSCs. In the setting of liver metastases, MDSC are critical drivers of intrahepatic immunosuppression, enabling growth and progression of malignant tumors and limiting the efficacy of immune-oncology therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The recent regulatory approval of tebentafusp, a bispecific T-cell receptor engager, which had a 1-year OS rate of 73% offers promise for patients with stage IV uveal melanoma and demonstrates that immunotherapy has potential application in addressing this disease. However, approximately 50% of patients are ineligible due to human leukocyte antigen (&#8220;<b style="font-weight:bold;">HLA</b>&#8221;) type. While the OS data was positive, the response rate was only 9% and progression-free survival at one&#160;year only approximately 19%. Despite representing a crucial clinical advance, the unmet need in the stage IV uveal melanoma space persists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Primary Liver Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HCC and ICC are the most common primary liver tumors, with HCC representing approximately 90% of cases. While the underlying reasons for the biologic aggressiveness of HCC and ICC are not fully understood, the profoundly immunosuppressive intrahepatic environment is likely an important contributor to both disease progression and failure of current therapies. Given limited success of single agent CPI therapy for HCC and ICC, these drugs have been used in this patient population, but with less success than other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Encouraging results have been reported in carefully selected HCC patients with CPI combination therapies, although these are tempered by limited response rates and clinical outcomes, a result that we believe to be associated with the immunosuppression in the liver and the delivery barrier imposed by high intra-tumoral pressure. In the Checkmate-040 study, HCC patients treated with nivolumab + ipilimumab had an overall response rate (&#8220;<b style="font-weight:bold;">ORR</b>&#8221;) of 32% (5% CR) with a median OS time of 22.8&#160;months. The IMbrave 150 trial tested the combination of atezolizumab + bevacizumab in HCC patients, with the reported ORR being 27.3% (CR 5.5%), median progression-free survival (&#8220;<b style="font-weight:bold;">PFS</b>&#8221;) of 6.8&#160;months, and median OS of 19.2&#160;months. Data on the use of CPI in ICC is more limited, but suggests significant challenges related to the TME. A study of biliary tract cancers, including ICC, demonstrated an ORR of 22% and median PFS of 3.7&#160;months following treatment with nivolumab + ipilimumab. In a transcriptome study which categorized 566 cases of ICC, only 11% displayed &#8220;hot&#8221; phenotype required for CPI responsiveness, whereas 45% showed a &#8220;cold&#8221; phenotype, which has been associated with CPI failure. For both HCC and ICC, improvements in CPI responsiveness are needed. A recent first-line approval based on the TOPAZ-1 trial, which evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer, brings checkpoint therapy into standard-of-care for ICC, but the ORR was 26.7% and incidence of grade 3 or 4 adverse events was 75.7%. Several checkpoint inhibitor regimens are approved for first- and second-line HCC treatment, but recent data published in the Journal of Clinical Oncology indicates the real-world response rates may be lower than observed in the pivotal trials. As with the uveal melanoma immunotherapy landscape, further advances are required to address the remaining significant unmet clinical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Locally Advanced Pancreatic Adenocarcinoma (&#8220;LA-PDAC&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LA-PDAC is associated with rapid progression, resistance to conventional therapies, deterioration in quality of life, significant morbidity, and a high mortality rate. PDAC tumors are characterized by dense desmoplastic stroma with a paucity of effector immune cells, rendering both drug delivery and stimulation of immune responses very challenging. Immuno-oncology approaches in general and CPI therapy have been highly successful in other malignancies, but PDAC is a particularly aggressive disease which has proven resistant to 100envat-oncology regimens. Poor responses to CPI therapy in PDAC patients may be due to the presence of suppressive immune mediators such as MSDCs, scarcity of effector T cells, and drug delivery challenges due to a highly desmoplastic stroma creating high tumor pressures. Response rates to CPI in patients with PDAC are routinely below 10% and new therapeutic options capable of addressing the delivery and immunologic barriers are urgently needed. Like uveal melanoma liver metastases, HCC, and ICC, LA-PDAC immunotherapy success may be limited due to challenges with drug delivery and a deeply immunosuppressive TME driven by MDSC. The PERIO programs are designed to test a delivery technology and class C TLR9 agonist with the potential to enhance immunotherapy performance in intrapancreatic indications.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Treatment of Liver Tumors with Transarterial Radioembolization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radioembolization is a treatment option for HCC patients that are not candidates for resection with intermediate to advanced stage hepatocellular carcinoma as characterized by the Barcelona Clinic Liver Cancer (&#8220;<b style="font-weight:bold;">BCLC</b>&#8221;) staging system. Radioembolization is used in BCLC stage A disease as an alternate to ablation. TACE is an alternative to radioembolization in patients with intermediate-stage disease. However, radioembolization is preferred by many because, relative to TACE, radioembolization is better tolerated and is associated with a longer time to progression, though no survival benefit has been demonstrated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The PEDD approach may provide a reliable method to maximize the tumor to normal liver ratio (&#8220;</span><b style="font-size:10pt;font-weight:bold;">T/N ratio</b><span style="font-size:10pt;">&#8221;). PEDD devices are designed to not only increase therapeutic delivery to target tumors but also to provide anti-reflux protection to minimize off-target delivery of radioactive microspheres and potential complications associated with undesired normal tissue exposure. A pilot study of the anti-reflux catheter not only demonstrated reduced hepatic nontarget embolization but also found a significant increase in tumor deposition of </span><span style="font-size:7.5pt;">99m</span><span style="font-size:10pt;">Tc-MAA by a factor of 1.68 (range 1.33 to 1.90, p &lt; 0.05). At least one study at the Saint Luc University Hospital and King Albert II Cancer Institute in Brussels, Belgium has also confirmed the superiority of PEDD devices in improving tumor deposition in liver radioembolization with resin microspheres.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the above benefits of the PEDD approach, the valve on the PEDD device works to provide a fixed centro-luminal catheter position compared to a standard microcatheter where the position of the catheter is in a random off-centered position. This more reproducible catheter positioning has been associated with a more homogeneous particle distribution in an in vivo hepatic arterial model. Augmenting the T/N ratio for the delivery of therapeutic microspheres has the potential to increase therapeutic response as a direct positive relationship between adsorbed dose and tumor response has been shown in patients undergoing radioembolization. In addition to the potential for improved response, an increased T/N ratio reduces radiation exposure to normal liver parenchyma and reduces the risk of associated liver toxicity. The objective of a current study underway at Massachusetts General Hospital is to determine if delivery via a PEDD device increases the T/N ratio of radiotracer in the mapping procedure relative to the standard microcatheter. The reproducibility of catheter positioning between the mapping and treatment procedures, as well as the ability of each catheter type to be centered in the vessel during delivery, are also being looked at in this study. A second study recently opened at the MD Anderson Cancer Center is investigating how a PEDD device may improve the concordance between mapping and treatment procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Treatment of Liver Tumors with Transarterial Chemoembolization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TACE is an image-guided locoregional therapy that involves hepatic artery embolization with intra-arterial infusion of a chemotherapeutic agent and is a commonly used treatment for HCC in the U.S. TACE exploits the vascular biology of HCC, which derives its blood supply from the hepatic artery, to deprive tumors of oxygen and essential nutrients, leading to growth arrest and/or necrosis; however, only a limited number of treated lesions demonstrate extensive or complete pathological necrosis. The mechanisms by which tumor cells survive are thought to be related to their ability to develop an adaptive response to nutrient deprivation<b style="font-weight:bold;">.</b> This adaptive response is reflected by the presence of viable tumor cells adjacent to necrotic regions on histopathology and is consistent with the clinical phenomenon of local recurrence observed on follow-up imaging after a brief latency period. These findings emphasize the importance of improving lipiodol TACE delivery to enhance induced ischemia to overcome cell survival mechanisms because poor delivery leads to therapeutic not reaching these areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Augmenting lipiodol deposition with hypervascular tumors requires overcoming the interstitial pressure within the tumors. One previously described method of overcoming the relatively high and often heterogenous pressures in the TME could be the PEDD using the 510(k)&#160;FDA-cleared TriNav device. TriNav alters downstream hepatic arterial blood pressure and may reduce resistance in tumor microvasculature. In clinical trials, the use of PEDD devices for radioembolization and embolization with drug-coated microspheres to treat HCC has demonstrated improved microsphere deposition, tumor necrosis, and imaging response compared to delivery with conventional end-hole catheters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform Solution: Addressing the Limitations of Current Approaches in Cancer Immunotherapy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our proprietary platform approach seeks to address immune dysfunction in liver and pancreatic tumors by combining our drug delivery technology with immunotherapeutics. In small prospective and retrospective studies, PEDD has shown the ability to overcome intra-tumoral pressure and enable delivery of therapeutics intravascularly into liver tumors relative to conventional regional </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">delivery. By broadly stimulating the TME and making it susceptible to checkpoint inhibition, we aim to enable immunotherapy responsiveness and increase anti-tumor immune activity which may slow disease progression in liver and pancreatic cancer patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Platform Components</p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">PEDD Devices:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;Launched in 2020, TriNav is a commercial-stage, FDA-cleared device that is designed to administer therapeutics. TriNav, using the PEDD method, delivers SD-101 to tumors in the liver, with the ability to deliver the therapeutic throughout the entire organ. The improvements in therapeutic delivery with TriNav relative to standard devices is supported by clinical data from multiple peer-reviewed studies conducted at various clinical sites and more than 17,000 PEDD device cases performed to-date for liver tumors. TriNav uses the proprietary PEDD method of administration of therapeutics to liver tumors. It is designed to overcome intra-tumoral pressure through modulation of pressure and flow to increase therapeutic agent delivery and improve patient outcomes. TriNav is currently reimbursed by CMS through TPT payments with TPT status extended by the Consolidated Appropriations Act of 2023 through December&#160;31, 2023. TriSalus has been granted a New Technology Ambulatory Payment Classifications (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">APC</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) code from CMS effective January 1, 2024, and intends to work toward a Category I CPT code. A second FDA-cleared device, the PRVI device, is designed for therapeutic delivery into pancreatic tumors. The PRVI device has not yet been commercialized and commercial sale is not anticipated before 2025. PEDD devices have been demonstrated in multiple independent clinical studies to increase delivery of chemotherapy beads, enhance response rates to chemotherapy beads, improve tumor targeting with Y-90 products, and enhance cell therapy delivery to liver tumors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">SD-101:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;In July&#160;2020, we acquired SD-101, a class C TLR9 agonist, from Dynavax and are investigating SD-101 as a therapeutic candidate delivered by PEDD to reactivate the immune system within the liver and pancreas with the goal of enabling deeper, more durable responses to other immunotherapeutics (e.g., CPIs) in a range of liver and pancreatic cancers for which limited therapeutic options currently exist. Broad immune suppression driven by MDSCs leads to failure of systemic immunotherapeutics in liver and pancreas tumors. It is believed that activating TLR9 primes immune cells to promote anti-tumor T-cell function, induces interferon pathways, reduces MDSCs and broadly activates the local tumor immune system to reverse immunosuppression in the liver and pancreas.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Opportunity for TriNav Delivery Technology and Investigational Therapeutic SD-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TriNav Market Opportunity</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The incidence of primary and metastatic liver tumors is steadily increasing, presenting a large opportunity for developing technologies and therapeutics. According to the American Cancer Society, primary liver tumors, including ICC and HCC, currently represent more than 41,000 cases annually in the U.S. The liver is also one of the most common sites for metastases, which is cancer that has spread from another site, and according to the National Cancer Institute, there are at least 96,000 individuals diagnosed annually with liver metastases, primarily from colorectal cancer or non-small cell lung cancer, for a total of more than 137,000 new liver cancer diagnoses per&#160;year. We estimate that approximately 40% of these patients are eligible for TACE or TARE procedures and that between 25% and 30% are appropriate candidates for our current TriNav device, representing a potential market opportunity of approximately 37,000&#160;units, or approximately $286&#160;million, based on our current TPT payment rate of $7,750 issued by CMS for hospital purchases of TriNav. If TriNav Large, a larger version of TriNav capable of being used in larger vessel size 3.0-5.0 mm, is successfully launched, we expect that our addressable market will increase by approximately 25%, resulting in an aggregate opportunity of 47,500&#160;units or approximately $368&#160;million, based on an assumption that TriNav's current reimbursement rate will be comparable to its new permanent reimbursement rate that will take effect beginning January 1, 2024. Currently, TriNav is used for either TACE or TARE, both of which entail localized delivery to HCC or metastatic liver tumors using standard interventional radiology techniques. We are also exploring additional indications for use, which fall within the present 510(k)&#160;clearance. Potential market impact of additional indications will be determined after clinical data become available.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">SD-101 Market Opportunity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">According to the American Cancer Society and National Cancer Institute, there are approximately 145,000 relevant new cases of cancer diagnosed annually in the U.S. alone, of which more than 80,000 may be addressable through our SD-101/PEDD platform for liver and pancreas. Assuming an average cost per course of therapy of $200,000, we estimate that the total annual addressable market </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.58pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in the U.S. alone for SD-101 could be in excess of $15&#160;billion. Additionally, there is a high global incidence in key targeted indications, such as HCC and ICC, providing an additional opportunity outside the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tlsi-20230630xs1a004.jpg" alt="Graphic" style="display:inline-block;height:234.58pt;width:449.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">SD-101 Potential Indications: Uveal Melanoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Melanoma is a malignant tumor derived from melanocytes. Despite similarities between cutaneous and uveal melanoma with respect to cell of origin, the genetic, molecular, and clinical features are entirely distinct. In particular, uveal melanoma has a unique metastatic pattern, with the liver being the dominant site of spread. Uveal melanoma is more aggressive and resistant to current therapies than cutaneous melanoma. Up to 50% of patients develop metastatic disease, with 90% of stage IV patients developing liver metastases. The highly suppressive immune environment in the liver may prevent immunotherapies such as CPIs from achieving success in this patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently, there are limited treatments for uveal melanoma. Dual agent checkpoint inhibition can achieve an 18% ORR, providing indication that checkpoint therapy can be responsive. This ORR was reported in a September&#160;2020 study published in the Journal of Clinical Oncology where MD Anderson reported via a Phase&#160;2 trial of 35 patients a median PFS of 5.5&#160;months and median OS of 19.1&#160;months. The cold immune TME may limit the extent of activity of checkpoint therapy in this population. The recent regulatory approval of tebentafusp offers promise for patients with stage IV uveal melanoma and demonstrates that immunotherapy has potential application in addressing this disease. However, approximately 50% of patients are ineligible due to HLA type.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are seeking to create a TME more amenable to checkpoint inhibition, which we believe may potentially be achievable due to direct delivery of SD-101 to the liver with PEDD, the dual mechanism effect of broad intratumoral immune stimulation coupled with elimination of MDSCs, and the absence of HLA restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">SD-101 Potential Indications: Intrahepatic Cholangiocarcinoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cholangiocarcinoma (&#8220;<b style="font-weight:bold;">CCA</b>&#8221;) is a rare and aggressive form of primary bile duct cancer that may arise at any point in the biliary tree. ICC is located within the liver&#8217;s bile ducts and, therefore, can be targeted with TriNav in the same manner as liver metastases or HCC. ICC is the second most common primary intrahepatic malignancy after HCC comprising approximately 15% of all liver tumors. ICC has a poor prognosis since it is typically diagnosed when the disease is already in advanced stages. Despite growing awareness and education of the disease, outcomes have not improved substantially in the last decade, with a 5-year survival rate of 7-20% and tumor recurrence rates after resection.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Locoregional therapies are appropriate for selected ICC patients depending on the location of ICC within the liver. Like HCC, ICC tumors are supplied predominantly by the hepatic artery. In patients with localized, unresectable ICC, TACE is a treatment option and associated with median OS durations of 6-20&#160;months. Radioembolization using yttrium-90 microspheres is an alternative treatment option for unresectable ICC (median OS duration of 11-22&#160;months).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For patients with advanced or metastatic disease, systemic chemotherapy with gemcitabine + cisplatin (&#8220;<b style="font-weight:bold;">gem/cis</b>&#8221;) has been the standard-of-care with FOLFOX or FOLFIRI chemotherapy regimens for later line therapy. Recently, the FDA approved the PD-L1 inhibitor, durvalumab, in combination with gem/cis, for the treatment of first-line patients with advanced or metastatic biliary tract cancers, including ICC. In this trial of first-line patients, median OS for durvalumab + gem/cis was 12.8&#160;months, as compared to 11.5&#160;months for gem/cis alone. In 2021, the FDA approved fibroblast growth factor receptor 2 and isocitrate dehydrogenase-1 (&#8220;<b style="font-weight:bold;">IDH1</b>&#8221;) inhibitors for second line and third line treatment in CCA, but less than 15% of the patients are eligible. The results from CPI in microsatellite instability-high CCA (&lt;10% of CCA patients) may suggest the potential for immunotherapy to work if the TME in microsatellite instability-stable patients can be reprogrammed effectively. Since ICC is typically a desmoplastic tumor with a &#8220;cold&#8221; TME, direct tumor administration of SD-101 via PEDD has the potential to enhance patient outcomes. We will initially seek a second-line and beyond indication for ICC for which the current standard of care is systemic chemotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">SD-101 Potential Indications: Hepatocellular Carcinoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HCC remains a significant health challenge and is among the most prevalent and deadly cancers. Unique features of HCC include the liver-only or liver-dominant disease location, in addition to the presence of underlying liver disease or cirrhosis in most patients. While HCC may be immunogenic in some cases as demonstrated by limited responsiveness to CPI, the pro-inflammatory conditions enhance the underlying immunosuppression in the liver which drives both disease progression and resistance to immunotherapy. The poor outcomes of HCC primarily stem from: (1)&#160;late-stage presentation, (2)&#160;liver fibrosis and dysfunction, (3)&#160;challenges with systemic drug delivery for a liver-centric disease, and (4)&#160;baseline immunosuppression in the liver exacerbated by chronic injury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite effective management of early-stage disease through liver transplantation and surgical resection or ablation, most patients with HCC will recur and more than 50% present with advanced disease. For patients with recurrent or advanced disease, embolization and systemic therapies may offer disease control in subgroups. Stable disease control or cure remain out of reach for most HCC patients. While tyrosine kinase and CPIs have offered improvements relative to historical benchmarks in HCC patients with recurrent or advanced disease, response rates remain low. We will initially seek a second-line and beyond indication for HCC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">SD-101 Potential Indications: Pancreatic Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pancreatic ductal adenocarcinoma (&#8220;<b style="font-weight:bold;">pancreatic cancer</b>&#8221; or &#8220;<b style="font-weight:bold;">PDAC</b>&#8221;) is a prevalent, highly lethal cancer, with a five-year survival rate of 11%. Systemic first-line therapies for advanced pancreatic carcinoma currently provide short-term disease control. Both locally advanced and metastatic PDAC face similar challenges with respect to drug delivery and deep immunosuppression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite advances in systemic therapy and surgical care, the outcomes for PDAC patients have remained poor highlighting the need for novel approaches. The National Comprehensive Cancer Network recommends consideration of clinical trials as the preferred option in the first-line setting for metastatic and locally advanced PDAC, emphasizing the broad recognition that current therapies are failing. First-line therapy for advanced or recurrent disease patients involves either FOLFIRINOX, a chemotherapy regimen that includes four drugs, or Gemcitabine-Abraxane. Immunotherapy and CPIs have minimally impacted PDAC. A hallmark of PDAC TME is the abundance of noncancer cell components, collectively designated as the stroma, including MDSCs, which can account for up to 90% of the tumor mass. The stroma has been shown to inhibit both spontaneous and therapeutically inducted antitumor immunity making it difficult to treat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Higher CPI response rates in mismatch repair (&#8220;<b style="font-weight:bold;">MMR</b>&#8221;) deficient PDAC patients suggest promise for CPI in combination with immune reprograming agents, although fewer than 5% of PDAC patients are MMR deficient. The success of immunotherapy in PDAC may hinge on successful management of two critical barriers: (1)&#160;PDAC tumors are densely desmoplastic, with the stroma and high tumor pressures posing a major barrier to drug delivery and (2)&#160;PDAC tumors foster deep immunosuppression, which is driven in part by MDSCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are initially focusing on locally advanced PDAC due to the potential of the PRVI device to deliver SD-101 into pancreatic tumors with the PRVI approach. Drug delivery to pancreatic tumors is more challenging than to the liver, given the more complicated </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">arterial anatomy for the pancreas. We believe that the potential to administer an immunomodulatory drug, such as SD-101, into pancreatic tumors with PEDD creates a highly differentiated clinical approach and significant value creation opportunity. Following the initial safety trials in PERIO-03, we plan to move into the neoadjuvant setting for PDAC where patients are typically treated earlier in their disease course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Two critical barriers, high intra-tumoral pressure and broad immune suppression driven by MDSCs, limit the delivery and efficacy of immunotherapies in tumors of the liver and pancreas. Notably, less than 1% of therapeutic may be delivered into a tumor with systemic infusion. We believe that comprehensively addressing these two barriers has the potential to enable patients with liver and pancreatic tumors to benefit more reliably from CPIs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the strength of our therapeutic platform is the combination with, and potential to enable, systemic immunotherapies like CPIs and cell therapy. Our proprietary platform approach seeks to address immune dysfunction in liver and pancreatic tumors by combining its drug delivery technology with immunotherapeutics.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Fast-Growing Device Business</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;While we are pursuing commercialization of additional technologies leveraging the PEDD approach, such as the PRVI device, TriNav is already a commercial-stage, high margin, and FDA-cleared drug delivery device. The PEDD approach has undergone peer-reviewed studies at multiple clinical sites and been performed in more than 17,000 cases to date. Longer term, if our platform is validated and approved by the FDA, TriNav is expected to support the growth and effectiveness of SD-101 in addition to SD-101 utilization supporting increased TriNav demand. TriNav achieved $8.4&#160;million in revenue in 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Significant Potential Upside From SD-101 Program in Development</span>:&#160;&#160;&#160;We are investigating SD-101 as a therapeutic candidate to re-activate the immune system within the liver and pancreas and to enable deeper and more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) with the goal of achieving better patient outcomes. We are initially evaluating SD-101 for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe delivering SD-101 through our proprietary FDA cleared PEDD technology creates a potential opportunity to change the paradigm of how liver and pancreatic cancer is treated. We are currently enrolling uveal melanoma patients with liver metastases in the PERIO-01 clinical trial administering SD-101 via our PEDD technology in combination with systemic CPIs (&#8220;<b style="font-weight:bold;">PERIO-01</b>&#8221;), ICC and HCC patients in a similarly designed trial, PERIO-02 (&#8220;<b style="font-weight:bold;">PERIO-02</b>&#8221;), and locally advanced pancreatic adenocarcinoma patients in PERIO-03 (&#8220;<b style="font-weight:bold;">PERIO-03</b>&#8221;). Our current pipeline focuses on liver and pancreas cancer, which represents a market opportunity of more than $15&#160;billion based on multiple indications in these organs, and multiple settings within these indications. Phase&#160;1/1b early response data for the uveal melanoma and ICC indications was received in the first quarter of 2023, with additional data presented in June&#160;2023 at the American Society of Clinical Oncology (&#8220;<b style="font-weight:bold;">ASCO</b>&#8221;). More mature efficacy data at the highest dose levels for the uveal melanoma and ICC and HCC indications is expected in the fourth quarter of 2023. As described below, in July 2023, we received written responses from the FDA in reference to a Type B meeting request related to our PERIO-01 clinical program. Based on the FDA&#8217;s feedback, we will wait for Phase 1 to complete enrollment and for efficacy data to mature before initiating any further studies for this program. The initiation and timing of Phase 2 trials and related data milestones are dependent on multiple factors, including prioritization of availablecapital, interactions with regulatory authorities, enrollment rates, and external events which may impact operations at clinical sites. In connection with our development plan for HCC, we are also considering a separate study for advanced second line and beyond HCC with SD-101 in combination with Y-90 radioembolization. HCC study prioritization will be based on data expected to be available in the fourth quarter of 2023.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Unique Platform Approach Combining Drug Delivery Technology with Immunotherapeutic</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;PEDD is designed to overcome infusion barriers of the TME and improve therapy penetration. In small prospective and retrospective studies, PEDD has shown the ability to overcome intra-tumoral pressure and enable higher intra-tumoral drug concentrations, with less therapy delivered to non-target tissue than standard microcatheters.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Multi-Layered Intellectual Property Protection</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;We aim to interweave patents and exclusivity to increase the long-term protection of our intellectual property. By layering multiple levels of intellectual property protection&#8201;&#8212;&#8201;from process to our platform intellectual property to methods of treatment, all of which surround TriNav and SD-101 product-specific intellectual </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property&#8201;&#8212;&#8201;we believe that, notwithstanding the expiration of certain of our patents in December&#160;2023, we have effectively created long-term exclusivity for our most critical intellectual property.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Successful Track Record of Value Creation:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;Our team&#8217;s deep clinical expertise and strategic partnerships and collaborations with leading cancer centers and strong track record of value creation across an array of medical device companies provides us with the potential to successfully develop and bring to market life-saving cancer treatments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Growth Strategies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our goal is to target the significant unmet medical needs of patients with liver and pancreatic cancers by transforming immunotherapy treatment through using our PEDD method to administer our investigational class C TLR9 agonist, SD-101. We intend to achieve this goal by: (1)&#160;advancing our PEDD technology to additional liver and pancreatic indications as well as other organs in the body, (2)&#160;expanding the TriNav sales organization in the U.S., (3)&#160;expanding internationally through distributors and (4)&#160;completing development and obtaining approval of SD-101.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance the Pipeline</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;We believe there is a significant opportunity to continue to advance our PEDD technology to additional liver and pancreatic indications as well as other organs in the body. Additionally, we will continue to progress our clinical evidence of PEDD through TriSalus-sponsored and investigator-sponsored research.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">TriNav</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The next product that we plan to commercialize is TriNav Large, a larger version of TriNav capable of being used in larger vessel sizes, 3.0-5.0 mm, which was 510(k)&#160;cleared by the FDA in May&#160;2023. We intend to launch the product commercially in 2024. Also in development is a smaller version of TriNav, designed to enable access to much smaller vessel sizes, 1.0-2.0 mm. We believe that by offering a full range of sizes to address vessels encountered on TACE and TARE procedures, there is a potential that TriNav and our next-generation of PEDD products could be positioned to be utilized across the wide range of procedural approaches, disease stages, and patient vasculatures that interventional radiologists encounter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also intend to embed advanced pressure sensing within our devices to aid in detecting vascular pressure at the site of disease. This information, in addition to tumor size and flow rate, is intended to provide the necessary components to optimize infusions and create clear endpoints for drug delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;font-weight:normal;">PRVI</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we are advancing our PRVI device, which is currently 510(k)&#160;cleared by the FDA and in the safety run-in period of a Phase&#160;1 clinical trial in locally advanced pancreatic cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our PRVI approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors. The pancreas&#8217; arterial system is composed of numerous small, collateralized vessels that make targeted delivery challenging. Additionally, pancreatic tumors exhibit a dense, desmoplastic stroma that limits the delivery of therapeutics. Certain cell types within the stroma construct an immunologically suppressed microenvironment that prevents the local immune system from clearing the tumor. We believe our PRVI device may address these challenges by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accessing the pancreatic vasculature via the venous system, which allows the clinician access to larger vessels and a greater ability to isolate the tumor region of the pancreas;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Embedding real-time pressure sensing capability to optimize the pressure and flow to fully perfuse the tumor vasculature;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Elevating venous pressure sufficiently during infusion to enable retrograde flow and thereby overcome intra-tumoral pressure and distribute therapy within the tumor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Delivering a 3.5 to a 7-fold higher dose of therapeutics to the pancreas tumor compared to systemic administration; and</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enabling a therapeutic index that is efficacious while limiting toxicity compared to systemic dosing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our near-term pipeline focus is to improve outcomes with TARE and TACE for patients, while concurrently investigating how SD-101 may allow more patients with liver tumors to benefit from immunotherapy. Current evidence for the efficacy of specific locoregional therapies is primarily based on retrospective reports as there are few prospective clinical trials, some of which only have the best supportive therapy as the control arm. Given this landscape, along with our PERIO clinical program, we are supporting multiple investigator-initiated trials comparing PEDD with standard catheters for TACE and TARE procedures with respect to therapeutic delivery. Our goal for our PEDD technology is to create enhanced technologies that can assist the clinician in optimizing the pressure range needed to fully open collapsed vessels and to deliver the optimal flow rate to infuse the entire vasculature of the tumor and clear endpoints to reduce the impact of physician technique variability.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand TriNav Sales Organization in the U.S.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;We sell TriNav through our direct sales organization in the U.S. Our sales team has in-depth knowledge of the markets in which we compete and in which we seek to compete. However, we currently can only adequately cover approximately 45% of the high procedure hospitals and high-procedure physicians due to our size and resources. Our intent is to expand our specialized sales organization across the U.S. to provide broader hospital coverage and increased time for the representative to expand utilization within hospital targets from which we expect to foster deep relationships with physicians and drive revenue growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand Internationally Through Distributors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;In addition to growing our direct sales organization in the U.S., we intend to sell to distributors in Europe, where we believe that selling through third-party distributors is the best way to optimize our opportunities and resources. We plan to select distribution partners who have deep experience in our markets, have strong customer relationships, and have a demonstrated track record of launching innovative products. In addition, certain Asian markets have a very high incidence of both HCC and ICC, and TACE procedures are the standard of care for many patient types. We currently have a distribution relationship with Hangzhou Ruizhen Therapeutics Co.,&#160;Ltd. (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Hangzhou</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in China. In collaboration with Hangzhou, TriNav has been submitted for National Medical Products Administration (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NMPA</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) approval and we expect a final determination regarding such approval by the end of 2023. If approved, Hangzhou is expected to have the responsibility to launch in the Chinese market with support from us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Complete Development and Obtain Approval of SD-101</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;Currently, our uveal melanoma liver metastasis, HCC and ICC clinical programs are studying the delivery of SD-101 deep into the vasculature of the liver tumors using our proprietary, FDA-cleared TriNav device. Phase&#160;1/1b early response data for the uveal melanoma and ICC indications was received in the first quarter of 2023. Additional response data for the uveal melanoma program was presented at the ASCO meeting in June&#160;2023. Additional response data at the highest dose levels for the uveal melanoma and ICC and HCC indications is expected in the fourth quarter of 2023. Traditionally, TLR9 agonists like SD-101 have not been administered intravenously but by direct injection into superficial tumors, making treatment of large or multiple tumors, or tumors in deep locations, such as the liver and pancreas very difficult. Infusion by the TriNav device using the PEDD method improves targeted delivery of therapy into high-pressure tumors using a standard intraarterial procedure that allows us to distribute the drug to tumors within the organ, irrespective of size, number and location of tumors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Seek Potential Accelerated Approval Regulatory Pathway</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;Our targeting of orphan indications and rare disease creates an opportunity for expedited development and the potential for an accelerated path to approval and commercialization. Our clinical development is designed to test the ability of SD-101 to enable CPI therapy in liver and pancreas tumors across a broad array of both orphan and ultra-orphan indications, providing potential to access expedited development and approval pathways. SD-101 is being studied for the treatment of ICC, uveal melanoma and HCC, diseases for which potential therapies have previously received orphan drug designations. However, TriSalus does not currently have orphan designation, nor has it discussed possible use of the accelerated approval pathway for any indication from the FDA or other comparable regulatory agencies and it is possible that TriSalus may never be granted orphan designation or pursue accelerated approval. For approval of new medicines, the regulatory standard for proving &#8220;substantial evidence of efficacy&#8221; normally requires the execution of two randomized, well-controlled clinical trials. In orphan and ultra-orphan indications with unmet medical need, including many cancer indications, there is significant precedent for FDA approval based on a single pivotal clinical trial. Further, certain drugs in development that have received orphan drug designation have been approved via the accelerated approval regulatory pathway. It is also possible, however, that in the context of either orphan or non-orphan drug development, the FDA may require more than one clinical study and/or may not accept certain clinical data.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Pursue Potential Relationships with Companies Advancing Checkpoint Inhibition</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;&#160;&#160;The global current immunotherapy market represents the highest growth therapeutic sector in the pharmaceutical industry. This growth has been led, and we anticipate that this growth will continue to be led, by the continuing growth of CPIs, innovative new classes and an expanding patient pool. While immunotherapy targeting CTLA-4 and PD-1/PD-L1 in many cancer types has been introduced, response rates remain low in uveal melanoma, HCC, ICC and pancreatic cancer leaving significant unmet need in these patient groups. According to a 2022 IQVIA publication, PD-(L)1 inhibitors represent one of the most dynamic segments of the current immunotherapy market with global sales of approximately $36&#160;billion in 2021, which is expected to reach approximately $58&#160;billion by 2025. PD-(L)1 therapy has been transformational for a number of cancer types but outcomes with respect to the liver and pancreas have lagged in comparison. ORR among leading PD-(L)1 therapies for liver indications have ranged from 17-35%. Despite this performance, we believe that PD-(L)1 companies remain focused on hepatobiliary cancers given the high unmet need and large global market size. PD-(L)1 companies have significant clinical programs studying various novel combinations of their PD-(L)1 inhibitors with both on-market and investigational drugs, including investigational immmunotherapeutics in hepatobiliary cancers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">CPI companies are open to a wide range of approaches to improve outcomes through novel combinatorial regimens. Based on a 2022 IQVIA publication, nearly 300 separate targets and pathways are being studied in combination with PD-(L)1s. In this competitive environment, we are focused on developing mutually beneficial collaborations with one or more PD-(L)1 companies. We believe collaborating with PD-(L)1 companies to enhance outcomes compared to the current standard of care in our key indications has the potential to provide such companies with significant growth opportunities and act as a differentiator from competitors. We intend to initiate discussions with pharmaceutical companies with CPIs to determine opportunities for collaboration, clinical development and licensing.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Potential Partnerships with Companies Advancing Chimeric Antigen Receptor T Cells (&#8220;CAR-T&#8221;) and Other Cell Therapies:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;Six FDA approved CAR-T cell therapies are currently commercially available, with none for solid tumors. We believe that these therapies are potentially attractive targets for collaboration, partnership and acquisition because of the promise of cell therapy has yet to be realized in the treatment of solid tumors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">As with CPIs, the immunosuppressive tumor environment in the liver and pancreas combined with high intratumoral pressure has been shown to limit performance of cell therapies in pre-clinical models. Regional delivery via PEDD has the potential to reduce systemic toxicity and has been proven to increase therapeutic delivery to tumor tissue. In clinical trials, PEDD has been reported to improve CAR-T delivery to liver tumors more than 5-fold across two single-arm studies and induced a durable complete positron emission tomography response in a patient with liver metastases. Pre-clinical animal model work has also shown improved cell therapy delivery to liver metastases using PEDD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Combining SD-101 and PEDD with cell therapy has the potential to facilitate the realization of the full potential of cell therapy in select solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development Program for SD-101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table sets forth information pertaining to the clinical trials for SD-101 with our initial focus on advancing PERIO-01, PERIO-02 and PERIO-03. <span style="color:#231f20;">Initiation and timing of Phase 2 programs and data milestones are subject to change and </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:148.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">dependent on multiple factors including interactions with regulatory authorities, enrollment rates, and external events which may impact operations at clinical sites.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="tlsi-20230630xs1a005.jpg" alt="Graphic" style="display:inline-block;height:148.34pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:315.97pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our anticipated upcoming milestones (which are subject to change based on enrollment, competitive environment, and regulatory feedback) include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">release of PERIO-01 Phase 1 data and PERIO-03 SD-101 initial monotherapy safety data in the fourth quarter of 2023;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of SD-101 + Y-90 Phase 1b cohort in PERIO-02 in the first half of 2024; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of PERIO-03 Phase 1b (SD-101 + anti-PD-1) in the first half of 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Progress to Date Using Our Therapeutic Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PEDD With Standard of Care Therapies</i>:&#160;&#160;&#160;In clinical and pre-clinical studies, improved therapy delivery has been demonstrated with PEDD across therapeutic classes. Clinical studies have directly compared standard catheters to PEDD devices. For instance, such studies have shown that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PEDD has improved tumor targeting in liver radioembolization with resin microspheres and significantly increased both T/N ratio and dose delivery compared to a standard endhole microcatheter in head-to-head comparisons between PEDD devices and standard catheters in two studies summarized below:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A prospective company sponsored study included 9 patients with a variety of tumor types who were referred for Y-90 radioembolization treatment of their liver tumors. Prior to treatment via PEDD, each patient received two same-day sequential lobar infusions of macroaggregated albumin (MAA) via endhole microcatheter and PEDD. Differences in MAA distribution within the tumors and non-target sites were evaluated and the results showed: a 33% to 90% (mean=68%; p&lt;0.05) increase in tumor deposition; a 24% to 89% (mean=42%; p&lt;0.05) decrease in nontarget embolization; and increased on-target deposition in 100% of the tumors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A retrospective independent study of 61 patients with liver cancer (190 lesions) treated with resin Y-90 radioembolization. All patients in the study underwent an MAA planning procedure delivered via a standard endhole (EH) catheter. Resin Y-90 was then delivered via either an EH catheter (control group) or via PEDD, followed by PET/CT imaging. Each patient&#8217;s post-Y-90 PET/CT was co-registered to their post- MAA SPECT/CT to compare the tumor to normal liver ratio (T/N) and tumor dose (TD). The results showed that across all tumor types, PEDD increased the T/N by a median of 24%, and the TD by a median of 23%, (p&lt;0.001) with no significant difference seen in the standard EH catheter (control) group. The results showed that PEDD significantly improved both tumor targeting and dose delivery across multiple tumor types.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PEDD achieved greater on-target distribution of chemotherapy eluting beads, delivering a significantly higher concentration of therapy in the tumor as compared to standard endhole microcatheters in association with higher radiographic and </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pathologic response rates in a head-to-head comparison between the PEDD device and standard catheter in a study summarized below; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A retrospective, single-center study, included 88 treatment-naive with solitary HCC tumors &lt;6.5cm who underwent treatment using either PEDD (n = 18) or a standard EH microcatheter (n = 70). PEDD patients exhibited lower aspartate aminotransferase (p = 0.003) and alanine aminotransferase (p = 0.044) at 6&#160;months. Blinded radiological evaluation showed that PEDD achieved a significantly higher objective response rate, compared to the EH catheter (100% vs 76.5%; p=0.019). Following liver explant, a blinded review of the liver specimens found that PEDD achieved improved pathological response compared to the standard EH catheter (88.8% vs 33.8%; p=0.026) as well as a significantly higher concentration of therapy in tumor compared to the standard EH catheter (88.7 &#177; 10.6% vs 55.3 &#177; 32.7 %; p=0.002).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-clinical pancreatic cancer model experiments indicated that using the PRVI method of PEDD improved drug delivery 3.6-7.0-fold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We studied PRVI in an orthotopic murine model of PDAC and demonstrated that PRVI delivery of gemcitabine increased intra-tumoral drug concentrations and enhanced the subsequent tumor responses to treatment. PRVI infusion of gemcitabine resulted in more than 100-fold greater tumor concentrations compared with systemic delivery (127 vs 19 ng/mg; P &lt; .01) and lesser tumor volume compared with both systemic gemcitabine and saline via PRVI (274 vs 857 vs 629 mm3; P &lt; .01). The same mouse model was employed to assess the impact of pancreatic retrograde venous infusion (PRVI) on tumor uptake and response to oxaliplatin. It was found that PRVI administration of a 2mg dose of oxaliplatin resulted in a significant decrease in tumor size while preserving nerve conduction velocity and nerve tissue morphology as compared to standard delivery methods under histopathological analysis.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PEDD with SD-101</i><i style="font-style:italic;">:</i>&#160;&#160;&#160;As of May&#160;12, 2023, across three clinical trials, 204 infusions of SD-101 have been delivered at multiple dose levels as monotherapy and in combination with CPIs in 51 patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Sites and Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MD Anderson Cancer Center</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have been engaged with top academic sites and leading clinicians in the liver and pancreas cancer spaces. All three PERIO programs are centered on a 5-year Alliance Program with the University of Texas MD Anderson Cancer Center (&#8220;<b style="font-weight:bold;">MDACC</b>&#8221;) which we entered into in March&#160;2021 (the &#8220;<b style="font-weight:bold;">MDACC Agreement</b>&#8221;). Pursuant to the MDACC Agreement, investigators at MDACC agreed to serve as the lead clinicians for the PERIO-01, PERIO-02, and PERIO-03 studies and we agreed to pay $10.0&#160;million in collaboration funding to MDACC to conduct preclinical and clinical studies as mutually agreed by the parties. To date, we have paid an aggregate of $4.0&#160;million towards these studies and will pay an additional $2.0&#160;million following the consummation of the business combination and on each of the third and fourth anniversaries of the MDACC Agreement. The term of the agreement is for the later of (i)&#160;five&#160;years or (ii)&#160;until the applicable studies are completed. Prior to the expiration of the term of the MDACC Agreement, either party may terminate the MDACC Agreement if the other party commits a material breach of the agreement and fails to cure such breach within 30&#160;days of receiving notice of such breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have the right to terminate a study (and the corresponding study order) upon 30&#160;days prior notice to MDACC, provided that the joint steering committee (which is composed of three representatives of each party and oversees the collaboration) has approved such termination and that all reasonable study costs and fees associated with wind-down activities and final monitoring visit shall be paid by us. Termination of one or more study orders will not automatically result in the termination of the MDACC Agreement or termination of any other study orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the terms of the MDACC Agreement, each party retains all right, title and interest in and to its own background intellectual property and no license to use such background intellectual property is granted to the other party except for MDACC&#8217;s use of the study drug and study devices, as applicable, in a study as set forth in the MDACC Agreement. Within fifteen&#160;days after our receipt of an invention disclosure covering any invention, representatives from each party shall meet to assess whether, taking into consideration the intellectual property limits outlined in the MDACC Agreement, the applicable invention in which MDACC has an ownership interest can be assigned to us in full and exclusive ownership. If such assignment would not violate the intellectual property limits agreed to, MDACC assigns to us the sole and exclusive ownership in and to the applicable invention and we shall reimburse MDACC </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">for reasonable patent costs, if any, incurred by MDACC prior to the date of assignment. No intellectual property has been developed or transferred to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Clinic Sites</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other active clinical sites for the PERIO programs include: University of Colorado Anschutz Medical School, Columbia University, Massachusetts General Hospital, Thomas Jefferson University Hospitals, University of Pittsburgh Medical Center, Stanford University, University of California&#8201;&#8212;&#8201;Los Angeles, University of Miami and University of Washington Medical Center. We also recently entered into an agreement with Lifespan to open the TriSalus Translational Immunotherapy Lab, which is part of a comprehensive, integrated, academic health system with The Warren Alpert Medical School of Brown University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SD-101 is currently in three Phase&#160;1/1b PERIO studies for primary liver cancer (ICC and HCC), metastatic liver cancer (uveal melanoma), and locally advanced pancreatic cancer. TriSalus is testing the ability of the SD-101/PEDD platform to enable systemic CPIs in the following indications:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Uveal melanoma with liver metastases (PERIO-01, NCT04935229),</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Intrahepatic cholangiocarcinoma and hepatocellular carcinoma (PERIO-02, NCT05220722), and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Locally advanced pancreatic adenocarcinoma (PERIO-03, NCT05607953).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Response data for PERIO-01 at the lowest SD-101 dose levels was presented at the ASCO meeting in June 2023, with more mature data expected to be released in November 2023. We expect to have further Phase 1/1b efficacy and immunologic data across the dose range for the PERIO-01 and PERIO-02 trials in the fourth quarter of 2023 and to establish the optimal biologic dose in preparation for later phase studies in multiple indications. We are also planning on testing the SD-101/PEDD therapeutic platform in patients with liver metastases from colorectal carcinoma, and possibly other indications as well. We are collaborating with leading cancer centers across the country, to help leverage our deep-immuno-oncology expertise and inventive technology development, to improve patient response rates to checkpoint therapy and improve overall outcomes. Our initial trials are heavily focused on determining the optimal biologic dose for SD-101 to align with FDA Project Optimus guidance, minimize uncertainty or risk for further SD-101 development, and develop a deep understanding of SD-101 efficacy signals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PERIO-01 and PERIO-02&#8201;&#8212;&#8201;Primary and Metastatic Liver Tumors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, we initiated our clinical development program by enrolling the first patients in the PERIO-01 clinical study evaluating the TriSalus platform in adults with uveal melanoma with liver metastases. PERIO-01 is an open-label first-in human Phase&#160;1 trial of SD-101 given by hepatic arterial infusion (&#8220;<b style="font-weight:bold;">HAI</b>&#8221;) using PEDD in metastatic uveal melanoma (NCT04935229).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We followed with PERIO-02, which is studying SD-101 for the treatment of HCC and ICC. PERIO-02 is an open-label, Phase&#160;1b/2 study of the pressure-enabled hepatic artery infusion of SD-101 alone or in combination with intravenous checkpoint blockade in adults with HCC and ICC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of May&#160;12, 2023, 204 infusions of SD-101 have been administered to 51 patients in the PERIO trials, with no grade 3 or higher cytokine adverse events related to SD-101 or other serious adverse events related to TriNav or PEDD. Preliminary findings include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pooled data from 36 patients in the PERIO-01 trial and 12 patients from the PERIO-02 trial that received SD-101 delivered via TriNav showed evidence of induction of immunostimulatory cytokines in the blood as determined by Luminex assays. These pooled data demonstrated a trend toward a dose-related increase in serum cytokines.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:160.53pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As of May&#160;12, 2023, 39 patients were enrolled in the PERIO-01 trial, with 36 having received at least one dose of SD-101. Of the patients with available data, five patients were treatment-na&#239;ve and approximately 81% had failed at least one prior line of therapy, including three patients on their sixth-line of treatment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the PERIO-01 study, the treatment-related serious adverse event rate reported at the ASCO meeting in June&#160;2023 was 5%.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pharmacokinetic data indicate that the strategy of delivering a toll-like receptor-9 agonist with the PEDD method results in high drug levels in the liver, while the drug is undetectable after four hours in the serum in 97% of patients with available data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There are no HLA-type restrictions for this treatment regimen.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Concordant with the predicted mechanism of action, PEDD HAI administered SD-101 resulted in decreases in liver tumor monocytic MDSC levels in 5 of 5 patients as determined by multiplex immunofluorescence data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased levels of circulating tumor DNA (&#8220;ctDNA&#8221;) levels were observed within eight out of 13 evaluable patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stable disease was noted as the best on-treatment response for target lesions in 15 out of 25 patients, with one partial response.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tlsi-20230630xs1a006.jpg" alt="Graphic" style="display:inline-block;height:159.98pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:467.99pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ctDNA and CTCs were quantified at baseline and after two or three infusions of SD-101. (A) Change in ctDNA levels as determined by NGS. (B) Change in CTC levels as determined using the CellSearch. ctDNA has been reported to be a surrogate of survival in this population and imaging can be unreliable at times due to immune mediated tumor swelling or pseudoprogression.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">92% of procedures required a single TriNav device to infuse to all target locations. The average infusion time reported was 40 minutes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There were no procedure-related serious adverse events reported, and 15 procedure-related adverse events were reported, including minor adverse events such as puncture site pain, bruising, or hematoma.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thirteen immune-related adverse events were reported, including fever and chills during the infusion procedures which were all grade 1 or 2. There were no severe (CTCAE &gt; 3) immune-related events in the procedure rooms or during follow-up, with 1 grade 2 cytokine related event. No other severe adverse events related to SD-101 were noted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pharmacokinetic data from tissue and serum specimens is consistent with the hypothesis that TriNav can achieve high SD-101 levels in the liver (&gt;2000 ng/gm at 8 mg SD-101) with limited systemic exposure (&lt;4 hour detection in serum across all dose levels) using the PEDD method.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are hopeful that the TME reprogramming demonstrated thus far in the PERIO-01 and&#160;-02 trials, as assessed by NanoString, flow cytometry, and immunofluorescence analyses, including a reduction in MDSC and MDSC-associated genes, may support better immune checkpoint inhibitor performance in metastatic uveal melanoma and other intrahepatic indications presently under study.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Early data from PERIO-01 subjects, based on liver tumor biopsies taken before SD-101 infusion and then again 57&#160;days later, indicates that gene expression changes, as assessed by NanoString, are induced consistent with our hypothesis regarding liver TME stimulation and MDSC reduction. The NanoString platform was used to measure changes in RNA levels before and after treatment, which indicates which genes are being activated or suppressed, as RNA is produced from the DNA in genes when a cell receives the appropriate signal. Specifically, in pooled analyses from subjects with available biopsy data (n=14) we have documented increased activation of genes associated with cytokine production, TLR signaling, and broad immune cell activation in liver tumors. Evidence of reduction in genes associated with MDSC in liver tumors was also shown. We have also examined gene expression changes in peripheral blood immune cells at multiple time points post SD-101 infusion, and have detected signals of immune cell activation outside of the liver as well.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We received PERIO-01 and PERIO-02 Phase-1 response data in May&#160;2023. The studies continue to enroll at higher SD-101 dose levels in combination with checkpoint inhibitors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July 2023, we received written responses from the FDA in reference to a Type B meeting request for our PERIO-01 clinical program. The FDA acknowledged that preliminary data from the PERIO-01 program suggests a tolerable safety profile of SD-101 delivered by PEDD in combination with systemic checkpoint inhibition in metastatic uveal melanoma patients, and that there were no concerns raised with respect to delivery of SD-101 via PEDD with the TriNav device. The FDA has asked for additional exploration of the optimal SD-101 dose, in a smaller study prior to proceeding with a registrational trial. We currently expect to have Phase 1 more mature efficacy data at the multiple SD-101 doses for its PERIO-01 clinical trial in the fourth quarter of 2023. Based on the FDA&#8217;s feedback, we will wait for Phase 1 to complete enrollment and for efficacy data to mature before initiating any further studies for this program. The initiation and timing of Phase 2 trials and related data milestones are dependent on multiple factors, including prioritization of available capital, interactions with regulatory authorities, enrollment rates, and external events which may impact operations at clinical sites.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to present updated PERIO-01 efficacy and immunologic data in November 2023.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PERIO-03&#8201;&#8212;&#8201;Locally Advanced Pancreatic Carcinoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PERIO-03 is a study of the SD-101/PEDD therapeutic platform to enable systemic CPIs among locally advanced pancreatic carcinoma (NCT05607953) (&#8220;<b style="font-weight:bold;">PERIO-03</b>&#8221;) and is currently enrolling patients in a three patient safety run-in. See &#8220;&#8212; <i style="font-style:italic;">Development Plan for SD-101 For Use in Locally Advanced Pancreatic Adenocarcinoma with the Pancreatic Retrograde Venous Infusion Approach&#8201;&#8212;&#8201;PERIO 03</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Development Plan for Uveal Melanoma with Liver Metastases Following PERIO-01</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PERIO clinical program is exploring SD-101, a class C TLR9 agonist delivered intrahepatically via PEDD in combination with systemic CPI therapy. Enrollment and follow-up is ongoing in Phase 1 for determination of potential clinical benefit in this indication and optimal dose for other liver programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Development Plan for Intrahepatic Cholangiocarcinoma Following PERIO-02</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We plan to progress toward registration for the treatment of ICC with SD-101 delivered via PEDD in combination with systemic CPI. While ICC and HCC have been combined for the safety and dose finding Phase&#160;1b study (PERIO-2), we recognize the need for separate, later-stage efficacy trials. The design of the ICC study is predicated on the FDA accepting our proposal of a single-arm potentially pivotal Phase&#160;2 trial given the very high unmet need in this patient population, which includes second or later line patients. The study <span style="color:#231f20;">is anticipated to open</span> at clinical sites in the U.S. with the currently planned co-primary endpoints of PFS and ORR. Secondary endpoints may include the determination of the duration of response, safety, PFS, OS, pharmacokinetics, and pharmacodynamics.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Development Plan for Hepatocellular Carcinoma Following PERIO-02</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also contemplating, subject to FDA feedback, to conduct a Phase 2 expansion study in anticipation of a Phase 3 randomized, active-controlled, open-label study of PEDD administered SD-101 in combination with intravenous CPI therapy, potentially with the addition of Y-90. Based on data from all Phase 1b cohorts, including a cohort in which patients will receive SD-101 + Y-90, we will select the regimen for further study in later phases. The total number of patients required will be determined based on Phase 1b data and regulatory interactions, when appropriate. We anticipate opening sites in Asia for the Phase 3 study. We are also considering a separate study for advanced second line and beyond HCC with SD-101 in combination with Y-90 radioembolization based on previous combination data, both delivered via PEDD. HCC study prioritization will be based on data emerging in the fourth quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Development Plan for SD-101 For Use in Locally Advanced Pancreatic Adenocarcinoma with the Pancreatic Retrograde Venous Infusion Approach&#8201;&#8212;&#8201;PERIO-03</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our priority for pancreatic carcinoma patients is to advance the use of our PRVI device in combination with SD-101 and CPI therapy for the treatment of locally advanced pancreatic cancer. The PRVI device is currently 510(k) cleared while also in use in a 3 patient safety run-in portion of a Phase 1 clinical trial open at MD Anderson Cancer Center to validate technical performance in locally advanced pancreatic cancer patients. Once completed, we plan to progress to a full Phase 1 clinical program trial in combination with SD-101 with the goal of evaluating the safety and preliminary efficacy and a further goal to initiate a Phase 1b study in the fourth quarter of 2023. The Phase 1 program will focus on single-agent SD-101 safety (and optimal dose determination), while Phase 1b will test safety (and optimal dose determination) for SD-101 in combination with pembrolizumab. Progression free survival will be the primary endpoint for efficacy based on our experience in the other PERIO programs. For Phase 1, 9-18 patients are anticipated to enroll depending on dose-limiting events, and 6-12 subjects are expected for the Phase 1b portion. A subsequent Phase 2 design and endpoints will be determined following review of Phase 1/1b data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Development Plan for SD-101 For Use in Patients with Colorectal Cancer with Liver Metastases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should data from PERIO-01 and PERIO-02 be supportive of further development of SD-101 with PEDD, we will pursue additional indications as we believe the platform has the potential to address immunosuppression and intratumoral pressure in multiple liver cancer types. We believe the TriSalus platform can play a meaningful role in the treatment of colorectal cancer with liver metastases (&#8220;<b style="font-weight:bold;">CRCLM</b>&#8221;) since the liver is the dominant site of failure in colorectal cancer. Overall, about 70% of colorectal cancer patients will develop liver metastases, and 30-40% of patients with advanced disease may have liver-only metastatic disease. Even though resection of CRCLM is potentially curative, a majority of patients develop recurrent disease, and for patients who are not eligible for resection, no therapy options that provide long-term survival exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our intention is to initially use our platform in the 3L+ metastatic colorectal cancer setting for patients who are ineligible for targeted therapies and have liver metastases. Our anticipated approach is based on the low benchmarks and high unmet need in this setting. Additionally, there is potential for accelerated approval here if SD-101 can outperform the low benchmarks set by trifluridine-tipiracil or regorafenib. As a future development pathway, we also believe our platform has the potential to improve outcomes in the neoadjuvant setting for CRCLM patients undergoing surgical resection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TriSalus&#8217; Currently Marketed Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">TriNav Use</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TACE and TARE are minimally invasive, image-guided procedures used to infuse a high dose of chemotherapy or radiation particles into liver tumors. They are an important treatment modality in the management of HCC and liver metastases. The procedures involve gaining catheter access into the arterial system of the hepatic arteries and delivering therapeutics directly to blood vessels supplying the tumor. By administering therapy directly to the tumor, physicians can minimize exposure to healthy parts of the liver while maximizing the dose directed at the tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">These outpatient procedures are performed by interventional radiologists in an interventional suite. During the procedures, the physician uses real-time fluoroscopic guidance to place TriNav into the blood vessels feeding the tumors in the liver, through a small </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:193.81pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">incision in the groin or the wrist. The physician will then infuse the chemotherapy and embolic materials through TriNav. By using TriNav, the physician is able to optimize therapeutic delivery and tumor targeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">TriNav Design</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav is a flexible microcatheter that can be used to deliver diagnostic and therapeutic agents into peripheral vasculature beds, with its main clinical use being TACE or TARE for liver tumors. It is equipped with a one-way microvalve (&#8220;<b style="font-weight:bold;">SmartValve</b>&#8221;) capable of generating infusion pressure greater than mean arterial pressure to help overcome intratumoral pressure and improve distribution of therapeutics. The SmartValve is designed to provide reflux protection and to maintain a centroluminal position during infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unique ability of TriNav in generating infusion pressure to drive therapy deeper into solid tumors is driven by the SmartValve at the distal end of the catheter. It is made of ultra-thin nitinol fibers laid out in a precise braid geometry, that is then overlaid with nanofilaments made of composite polymers&#8201;&#8212;&#8201;creating a filter valve that allows particles &gt;10&#181;m (for example, red blood cells) to pass through. The exact geometry of the braid and composition of the polymers have been calibrated to create a soft, pliable valve that can react dynamically to varying pressure and flow conditions in vasculatures, yet that is strong enough to prevent reflux of material and generate sufficient pressure without imposing too much radial force on the vessel walls. TriNav&#8217;s dimensional specifications are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:bottom;width:100%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dimensional Specifications</b></p></td></tr><tr><td style="vertical-align:middle;width:48.34%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parameter</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Specification (nominal)</b></p></td></tr><tr><td style="vertical-align:middle;width:48.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Usable Length</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">120 cm, 150 cm</p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outer Diameter (max)</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.038 in (0.97 mm)</p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inner Diameter (Infusion Lumen)</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.021 in (0.53 mm)</p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expandable Tip Outer Diameter</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.7 mm</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The catheter shaft is made of composite polymer (Pebax) segments of varying softness and reinforced with stainless-steel braid. The design and material of the shaft have been optimized to provide strength, kink resistance, ease of tracking and flexibility&#8201;&#8212;&#8201;all of which are important to enable navigation of the catheter over microwires in tortuous vasculature. At the distal end of the catheter, there are two radiopaque marker bands to help physicians locate the distal end of the catheter as it is being threaded through the vasculature. The inner lumen of the catheter shaft is lined with polytetrafluoroethylene, a highly inert and lubricious polymer, to minimize friction and maximize compatibility with microwires, chemotherapy, cell therapy products, and other agents used during the procedure. Finally, the device is coated with a hydrophilic formulation that is thin yet durable, making it even more trackable and capable of accessing the most tortuous vasculature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tlsi-20230630xs1a007.jpg" alt="Graphic" style="display:inline-block;height:193.81pt;width:339pt;"/></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We aim to interact closely with all of our key stakeholders to ensure a patient&#8217;s experience with our platform is a success. We view our customers as including the interventional radiologists, oncology providers, nursing support, procedural staff, pharmacy staff, and value analysis committee staff, who use our products and recommend the purchase of such products to hospitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our goal is to establish a high level of engagement and trust with the various clinicians and support individuals in the hospital. Additionally, we believe that many hospitals are under cost pressure and need education on, and assistance to support and embrace, the use of new technology. We have reimbursement, clinical and technical support to ensure each clinician and support individual feels confident in using our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equally important is educating the broader community including patients, oncologists and support organizations so they understand and appreciate the value and benefits of our platform approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have established a commercial infrastructure designed to drive the adoption of TriNav among interventional radiologists, oncologists and hospital clinicians. Our commercial strategy for TriNav targets hospitals through direct sales engagements with their clinicians and medical staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We market our products to U.S. hospitals whose interventional radiologists and oncologists treat patients with liver cancer. We have direct sales capability in the U.S. that targets hospitals with the highest number of TACE and TARE procedures. We plan to expand our sales organization to reach a broader array of hospitals and clinicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our sales representatives and sales managers have substantial and applicable medical device experience, specifically in the interventional radiology space, and market our products directly to interventional radiologists who perform TACE and TARE procedures. We are focused on developing strong relationships with our physicians and hospital customers in order to educate them on the use and benefits of our products. Similarly, our marketing team has a significant amount of domain expertise and a strong track record of success. Our sales and marketing team totals 37 professionals as of July&#160;13, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that TriNav is simple, intuitive, and easy to use. This provides value to our customers and makes our sales model a source of competitive advantage. Lower service burden means we can develop a cost-efficient sales model by optimizing a mix of clinical specialists and salespeople. In the U.S., TriNav can be provided to hospitals on a consignment basis whereby title is transferred when the technology is used in clinical procedures. Other hospitals purchase TriNav directly, and TriNav is sold for a predetermined set fee for each catheter via a predetermined contract or purchase order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the U.S., hospitals are the primary purchasers of our products. Hospitals bill various third-party payors, which include commercial payors, Medicare and Medicaid. Since there is not a uniform policy for coverage and reimbursement for medical procedures in the U.S., commercial payors may use Medicare coverage policy as key inputs to setting their own rates. However, their processes and methods are separate from Medicare and can differ significantly from payor to payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Both TARE and TACE procedures have coding, coverage and payment in all settings of care. TriNav, which is a novel drug delivery technology, uses current endovascular codes for billing. Reimbursement is determined by Medicare&#8217;s comprehensive APC, which is a smaller bundle than a Diagnosis Related Group, more specifically related to a single procedure. Hospitals receive a Medicare outpatient payment based on the APC group assigned to the physician service or procedure performed, which are described by Current Procedure Terminology (&#8220;</span><b style="font-size:10pt;font-weight:bold;">CPT</b><b style="font-size:7.5pt;font-weight:bold;">&#174;</b><span style="font-size:10pt;">&#8221;) codes. CPT</span><span style="font-size:7.5pt;">&#174;</span><span style="font-size:10pt;"> codes are specific to the approach, the technique used and the specific anatomy in which the procedure is performed. TriNav is generally billed under CPT</span><span style="font-size:7.5pt;">&#174;</span><span style="font-size:10pt;"> 37242 and CPT</span><span style="font-size:7.5pt;">&#174;</span><span style="font-size:10pt;"> 37243.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Transitional Pass-Through Payment Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Medicare operates the TPT payment program in order to facilitate patient access to new and innovative products that have shown substantial clinical improvement. TPT allows CMS to gather the necessary cost and utilization data for a product and assign </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">appropriate codes and rates for long-term payment purposes. Medicare makes this special TPT payment while it is collecting data to foster use of new technologies in the outpatient setting amid facility cost concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Criteria needed to receive TPT designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medicare applied its three-part test&#8201;&#8212;&#8201;(1)&#160;newness, (2)&#160;cost impact, and (3)&#160;substantial clinical improvement&#8201;&#8212;&#8201;and determined that TriNav qualified for pass-through payment in hospital outpatient and ASC settings starting January&#160;1, 2020. In support of substantial clinical improvement, CMS considered a number of clinical studies that demonstrated increased intratumoral therapy uptake and improved tumor response in HCC and liver metastases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Transitional Pass-Through Status</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We received approval for TPT payments for TriNav beginning on January 1, 2020, based on CMS&#8217;s assessment of clinical evidence demonstrating improved therapeutic delivery and the highly differentiating, innovative nature of TriNav technology. On December 29, 2022, the Consolidated Appropriations Act of 2023 (H.R. 2617) was signed into law and includes an extension of TPT status for certain devices, including TriNav, through December 31, 2023. In December 2023, CMS granted a New Technology Healthcare Common Procedure Coding System code for procedures involving TriNav. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers. There can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Industry and Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TriNav Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary competition for TriNav is the standard microcatheter, which is frequently used in minimally invasive procedures for delivering therapeutics or devices. However, standard microcatheters do not have the ability to modulate pressure and flow and do not have data on improving therapeutic delivery to tumors.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.79pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Microcatheters are manufactured by a wide range of medical device manufacturers. Besides the standard microcatheter, there are two other competitive products: Embolix&#8217;s Sniper and Guerbet&#8217;s SeQure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="tlsi-20230630xs1a008.jpg" alt="Graphic" style="display:inline-block;height:280.79pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:466.01pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our competitors are large, well-capitalized companies with significantly larger market shares and resources than we have. As a consequence, they are able to spend more money on product development, marketing, sales, and other products. We also compete with smaller, niche players that have less resources and more limited influence in the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">SD-101 Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect SD-101 to compete primarily with a number of therapeutics that are now, or will soon be, approved for use in uveal melanoma with liver metastases, cholangiocarcinoma HCC, ICC, and locally advanced PDAC. These therapeutics include a range of immunotherapeutics (e.g., tebentafusp for HLA-A*02:01 positive metastatic uveal melanoma patients, atezolizumab in combination with bevacizumab for HCC patients), chemotherapeutics (e.g., gemcitabine combined with cisplatin for cholangiocarcinoma) and a limited number of targeted therapies (e.g., sorafenib or lenvatinib for HCC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Uveal Melanoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uveal melanoma has only one FDA-approved therapy, tebentafusp (KIMMTRAK). Tebentafusp is a bispecific fusion protein that recognizes two targets, with one target present on melanoma cells, and the second target present on T cells. As with all T-cell receptor products, only patients with specific HLA types are eligible for treatment. As a result, only approximately 50% of stage IV uveal melanoma patients are eligible to receive tebentafusp, and a significant unmet need still remains. We believe that SD-101 delivered with PEDD to the site of disease with its believed dual mechanism effect of broad intratumoral immune stimulation coupled with elimination of MDSCs, has the potential to outperform the current treatment option. Moreover, SD-101, if approved, would address the entire stage IV uveal melanoma patient population, with no limitations based on HLA typing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Intrahepatic Cholangiocarcinoma (ICC)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Most patients at initial presentation of ICC are poor candidates for surgical resection and, in those that undergo surgical resection, recurrence rates are high. Chemotherapy is the primary treatment approach, although the recent approval of the PD-L1 inhibitor </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">durvalumab in combination with gemcitabine + cisplatin for first-line ICC is likely to lead to this regimen becoming the standard of care. FGFs and IDH1 inhibitors have been approved by the FDA, but fewer than 15% of ICC patients are eligible to receive such treatment based on mutation presence. Initially, we will seek approval in previously-treated patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Hepatocellular Carcinoma (HCC)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although there are a number of therapeutics and therapeutic combinations approved by FDA, there is still a substantial unmet need for this disease due to poor clinical outcomes. Advanced stage HCC includes heterogeneous groups of patients with different clinical conditions and radiological features. Keytruda&#174;, Opdivo + Yervoy, Tecentriq&#174; + bevacizumab and Imfinzi&#174; + Imjudo&#174; are FDA approved checkpoint-based therapies for use in HCC, although the combinations of Tecentrq + bevacizumab or Imfinzi + Imjudo are considered the preferred first-line therapies. Tyrosine kinase inhibitors such as sorafenib and lenvatinib are also regularly used to treat HCC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe we have a unique value proposition in HCC due to the potential importance of MDSCs in driving HCC disease progressions, a low level of serious adverse events, and previous confirmation of SD-101&#8217;s ability to augment checkpoint inhibitor responses. We believe key competitive factors affecting the commercial success of SD-101 and any other product candidates we may develop are likely to be efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dynavax Asset Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2020, we entered into an Asset Purchase Agreement with Dynavax pursuant to which we purchased from Dynavax (i)&#160;SD-101 intellectual property and product know-how, together with any and all goodwill, rights to royalties, profits, compensation, license fees and all rights to obtain renewals, reissues and extensions of registrations, (ii)&#160;all permits related to SD-101, (iii)&#160;all regulatory documentation related to SD-101, (iv)&#160;the SD-101 investigational new drug and (v)&#160;all clinical trial data associated with SD-101 (the &#8220;<b style="font-weight:bold;">Dynavax Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dynavax Agreement, we made an upfront payment to Dynavax of $5&#160;million, and on December&#160;30, 2020, made an additional payment of $4&#160;million to reimburse Dynavax for clinical trial expenses incurred. Dynavax may also receive certain development milestone consideration dependent on the results of (a)&#160;certain clinical studies, (b)&#160;the dosing of patients in clinical trials, (c)&#160;what phase of clinical trial SD-101 reaches, and (d)&#160;regulatory approval. The development milestones are valued up to $170&#160;million. Dynavax may also receive certain commercial milestone payments based on (a)&#160;first commercial sale and (b)&#160;net sales in a fiscal&#160;year. Such commercial milestone payments are valued up to $80&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also are obligated to pay Dynavax certain royalty payments equal to 10% of aggregate net sales of products containing the SD-101 compound acquired during each fiscal&#160;year up to and including $1&#160;billion and 12% for the portion of aggregate net sales during a fiscal&#160;year greater than $1&#160;billion, subject to certain adjustments. Our royalty payment obligations shall expire on the latest to occur of: (i)&#160;expiration of the last-to-expire claim of an issued and unexpired patent relating to SD-101 that claims such product (or compound contained therein) or the manufacture or use thereof in the applicable country of sale, or (ii)&#160;10&#160;years after the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing and Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We manufacture TriNav at our facility in Westminster, Colorado, and have adequate capacity to meet anticipated commercial and clinical demands through the approval of SD-101, at which point we plan to re-evaluate our manufacturing capacity. We are continually strengthening our supply chain and are currently qualifying additional third-party suppliers for select components of TriNav. These alternate third-party suppliers of TriNav components are subject to qualification and approval from the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We contract with third parties for the manufacture, testing, and storage of SD-101. In our experience, contract manufacturers (&#8220;<b style="font-weight:bold;">CMOs</b>&#8221;) are generally cost-efficient and reliable, and therefore, we currently have no plans to build our own manufacturing capabilities for SD-101. Because we rely on CMOs, we employ personnel with extensive technical, manufacturing, analytical, and quality experience to oversee contract manufacturing and testing activities and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control, and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective January&#160;1, 2023, we are the exclusive distributor in the U.S. for TriNav, which we now distribute directly to our customers. Previously, we contracted with third party distributors for a significant portion of our commercial sales of TriNav. One of our former distributors, Advanced Critical Devices,&#160;Inc. (&#8220;<b style="font-weight:bold;">ACD</b>&#8221;), previously served as the third party intermediary between TriSalus and customers who accounted for approximately 20% of our sales for the&#160;year ended December&#160;31, 2022, and approximately 25% for the&#160;year ended December&#160;31, 2021. The&#160;year-over-year decrease in sales through ACD reflects the beginning of our transition to an internal distribution model. As we continue to expand the commercialization of TriNav, we have expanded our direct distribution capabilities to work directly with hospitals across the U.S., including by further expanding our internal sales team to increase our overall sales output.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, we entered into a Distribution and Collaboration Agreement with Hangzhou (the &#8220;<b style="font-weight:bold;">Hangzhou Agreement</b>&#8221;) pursuant to which Hangzhou was granted an exclusive, non-transferable and non-sublicensable right to distribute PEDD devices and to develop and commercialize PEDD combination products, if any, in China, Taiwan, Hong Kong and Macau (the &#8220;<b style="font-weight:bold;">Territory</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We shall collaborate with Hangzhou with the development, manufacture and commercialization of PEDD combination therapies. We must provide Hangzhou with sufficient quantities of PEDD devices to conduct clinical trials to obtain regulatory approval for each PEDD combination therapy in the Territory and use commercially reasonable best efforts to meet all supply needs to support the commercialization plan (if implemented). Hangzhou is responsible for (i)&#160;developing a commercialization plan, (ii)&#160;the cost of development activities to obtain regulatory approval for each PEDD combination therapy in the Territory, (iii)&#160;securing all rights to each of its drug candidates as necessary to execute the applicable plan and grant the corresponding U.S. option to TriSalus, and (iv)&#160;developing, commercializing and obtaining regulatory approvals for each PEDD combination therapy for the applicable indication in the Territory. To date, no clinical trials have commenced nor do we believe such commencement is imminent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with entering into the agreement, we issued a convertible promissory note (which has been subsequently fully converted to TriSalus common stock) to an affiliate of Hangzhou for gross proceeds of $10 million. No other amounts have been paid or received under the Hangzhou Agreement to date. In collaboration with Hangzhou, we submitted TriNav for NMPA approval and we expect a final determination by the end of 2023. The Hangzhou Agreement also requires Hangzhou to deliver to us a marketing plan no less than 12&#160;months prior to the first distribution of any PEDD device. Such marketing plan has not been delivered to us as of the date of this prospectus and accordingly no PEDD devices have been sold pursuant to this agreement or are expected to be sold in the immediate future. The agreement further includes an obligation for Hangzhou to pay us a milestone payment in the amount of $2.5 million for each PEDD combination therapy that receives regulatory approval in the covered jurisdictions and low-single digit royalties for any subsequent sales of such PEDD combination therapy on a country-by-country basis for the later of (i)&#160;ten&#160;years after the first commercial sale of such therapy in such country or (b)&#160;the first commercial sale of a generic version of such therapy by a third party. No submission for regulatory approval has been made as of the date of this prospectus and none is expected to be made in the immediate future. Under the terms of the Hangzhou Agreement, we will own all intellectual property that is discovered or generated in the course of performance of the collaboration that relates primarily and directly to any PEDD device, including any method of making or using any of the foregoing. Hangzhou shall own all intellectual property generated in the course of performance of the collaboration that relates primarily and directly to a Hangzhou drug candidate, including the composition, salt, polymorph, formulation of or any method of making or using the foregoing; except that TriSalus has the option to obtain an exclusive, non-transferable license under the Hangzhou intellectual property to develop, manufacture and commercialize Hangzhou drug candidates as PEDD combination therapies in the United States. The exercise of such option, or lack thereof, will result in further payment obligations of ours, if exercised, ranging from $0 to $10.0 million dependent on the timing of the exercise, and of Hangzhou in the amount of up to $10.0 million if unexercised. In the event of a material breach, the Hangzhou Agreement can be terminated by the non-breaching party effective upon (i)&#160;90&#160;days written notice of the breach if uncured, (ii)&#160;30&#160;days written notice if the alleged breach related to failure to make payments under the Hangzhou Agreement and is uncured, or (iii)&#160;immediately if such notice pertains to the willful and intentional breach related to compliance with anti-corruption laws, confidentiality obligations, distribution of competing PEDD devices, or violation of material intellectual property rights of the non-breaching party.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to protect our proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and technologies that are important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, as well as know-how, trademarks, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We internally developed our intellectual property related to TriNav and related technologies. We have sought and intend to continue to seek appropriate patent protection for our product candidates, as well as other proprietary technologies and their uses by filing patent applications in the U.S. and other select countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Patents</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December 8, 2023, we owned at least 122 registered patents expiring between 2023 and 2040, with at least an additional 69 pending patent applications and four&#160;provisional applications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For our TriNav device, we are the sole owner of five (5)&#160;granted U.S. patents, seven (7)&#160;pending U.S. patent applications, one (1)&#160;granted patent in Japan and four (4)&#160;pending foreign patent applications in Canada, China, Europe, and Hong Kong relating to a dynamic reconfigurable microvalve protection device and the PEDD method for infusing an immunotherapy agent to a solid tumor and method for selective pressure-controlled therapeutic delivery. The five (5)&#160;granted U.S. patents expire between 2031 and 2038. The one (1)&#160;granted patent in Japan expires in 2038. Any patents issuing from the pending patent applications (or in the case of priority applications, if issued from future non-provisional applications that we file) are expected to expire between 2030 and 2041, without accounting for potential terminal disclaimers or potentially available patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For SD-101, we are the sole owner of five (5)&#160;granted U.S. patents, four (4)&#160;pending U.S. patent applications, three&#160;(3)&#160;pending U.S. provisional patent applications, two (2)&#160;pending PCT patent applications, twenty-three (23)&#160;pending foreign patent applications, and 61 granted foreign patents in Australia, Canada, China, Europe (counting national validations), Hong Kong, Japan, South Korea, New Zealand and Singapore relating to immunostimulatory sequence oligonucleotides and methods of using the oligonucleotides and specifically SD-101. All of the granted US and foreign patents that relate to composition of matter for SD-101 expire in December&#160;2023. Currently, we do not solely own any granted US or foreign patents relating to SD-101 that expire past December&#160;2023. However, we jointly own with Merck Sharp&#160;&amp; Dohme LLC one&#160;(1)&#160;granted US, seven (7)&#160;granted foreign patents, and two (2)&#160;pending foreign applications that relate to SD-101, which is a CPG-C type oligonucleotide, as discussed further below. We also jointly own a pending U.S. patent application with the Regents of the University of California and H. Lee Moffitt Cancer Center and Research Institute,&#160;Inc. The jointly owned patents and applications are directed to combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer and are listed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any patents issuing from the pending patent applications (if issued from future national phase applications that we file) are expected to expire between 2023 and 2043, without accounting for potential terminal disclaimers or potentially available patent term adjustments or extensions. The following pending patent applications relating to the composition of matter for SD-101 or methods of using SD-101, that if issued or if issued from future national phase applications that we file, are expected to expire between 2023 and 2043, without accounting for potential terminal disclaimers or potentially available patent term adjustments or extensions:</p><a id="_Hlk144171732"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:34.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Title/Subject Matter</b></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Country</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Application No.</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:23.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expected Expiration </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(if granted)</b></p></td></tr><tr><td style="vertical-align:top;width:34.99%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/713,718 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">WO</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US2021/051378 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">18/027,883 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">AU</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021347154 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3196273 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021800749390 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">DE</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">112021004999.2 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">21873296.4 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023-518828 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">KR</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10-2023-0121995 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SG</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11202302204S </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">WO</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US2021/051384 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">18/027,895 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">AU</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021347690 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3196274 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021800730445 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">DE</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">112021004970.4 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">21873298.0 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023-518829 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">KR</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10-2023-7013610 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SG</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11202302205V </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">WO</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US2022/022801 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 (if national phase application(s) are filed and granted)</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in US </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">AU </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2022249092 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in CA </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in CN </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">22782201.2 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in JP </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">KR </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in KR </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SG </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">National Phase in SG </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2042 </p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unpublished U.S. Provisional Patent Application filed on 11/6/2022 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unpublished U.S. Provisional Patent Application filed on 11/20/2022 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cancer Therapy Using Toll-Like Receptor Agonists</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">WO</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">PCT/US2023/061035 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2043 (if national phase application(s) are filed and granted)</p></td></tr><tr><td style="vertical-align:top;width:34.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Methods of Treating Uveal Melanoma Liver Metastases with a Therapeutically Effective Combination of One or More Checkpoint Inhibitors and a Toll-Like Receptor 9 Agonist</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unpublished U.S. Provisional Patent Application filed on 6/2/2023 </p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">N/A</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also jointly own with third parties one (1)&#160;granted U.S. patent, two (2)&#160;pending U.S. patent applications, and seven (7)&#160;granted foreign patents in China, Europe (counting national validations), Hong Kong and Japan and two (2)&#160;pending foreign applications relating to combinations with CPG-C type oligonucleotides for treating cancer. The one (1)&#160;granted U.S. patent and seven (7)&#160;granted foreign patents in China, Europe (counting national validations), Hong Kong and Japan all expire in 2036. Any patents issuing from the two (2)&#160;pending U.S. patent applications and the two (2)&#160;pending foreign patent applications (or in the case of priority applications, if issued from future non-provisional applications that we file) are expected to expire between 2036 and 2039, without accounting for potential terminal disclaimers or potentially available patent term adjustments or extensions. A listing of the jointly owned granted patents and pending applications relating to combinations with CPG-C type oligonucleotides for treating cancer, along with expiration dates for granted patents is provided below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Title/Subject Matter</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Country</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Application&#160;No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent&#160;No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:37.49%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combination of a PD-1 Antagonist and CPG-C Type Oligonucleotide for Treating Cancer</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15/577,369</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10,751,412</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/8/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17/000,149</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">201680043989.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">108025018</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16804054.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3302501</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Validated&#160;in:</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DE</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FR</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">GB</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">21159163.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">HK</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">18111959.6</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">1252652</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">HK</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">42022051138.0</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">2017561621</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">6893608</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;">2021041014</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">7236483</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/26/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combination Including a CPG-C Type Oligonucleotide and a PD-1 Antagonist for Treating Breast Cancer</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17/229,856</p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon regulatory approval of SD-101 in the U.S., we expect to be granted five (5)&#160;years of regulatory exclusivity in the U.S. We also intend to apply for orphan drug designation which, if granted, would extend the exclusivity period for an additional two (2)&#160;years. In addition, upon regulatory approval of SD-101 in the EU we expect to be granted eight (8)&#160;years of data exclusivity in the EU. We also intend to apply for orphan designation in the EU which, if granted, would provide ten (10)&#160;year of regulatory exclusivity starting from the date of approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SD-101 is currently undergoing clinical trials using pressure enabled drug delivery of SD-101 using TriNav and the TriSalus Infusion System in various cancers, and in combination with systemic checkpoint inhibitor therapy. Some of the patents and applications described with respect to TriNav and the TriSalus Infusion System are expected to be relevant to the manner SD-101 is administered in clinical development, and post-marketing if SD-101 is approved by regulatory authorities to be used in combination with TriNav and the TriSalus Infusion System.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the TriSalus Infusion System, we are the sole owner of five (5)&#160;granted U.S. patents, seven (7)&#160;pending U.S. patent applications, twelve (12) granted foreign patents (counting national validations in Europe) and four (4)&#160;pending foreign patent applications in China, Europe, Hong Kong, and India relating to closed tip dynamic microvalve protection device, atraumatic occlusive system with compartment for measurement of vascular pressure change, method for selective pressure-controlled therapeutic delivery and the PRVI method for pressure-controlled retrograde venous therapeutic delivery. The five (5)&#160;granted U.S. patents expire between 2035 to 2038. The twelve (12) granted foreign patents expire between 2035 and 2040. Any patents issuing from the pending patent applications (or in the case of priority applications, if issued from future non-provisional applications that we file) are expected to expire between 2035 and 2041, without accounting for potential terminal disclaimers or potentially available patent term adjustments or extensions. Some patents and applications relating to the TriSalus Infusion System overlap with those identified for the TriNav device.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus&#8217; patent portfolio is a dynamic portfolio that continues to evolve. Currently, we believe the following listing of patents and applications, along with expiration dates for granted patents, comprises all of TriSalus&#8217; patents and applications relating to TriNav, the TriSalus Infusion System, PEDD and PRVI:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Title/Subject Matter</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Country</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.28%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Application No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent No.</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(if granted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:29.03%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dynamic Microvalve Protection Device</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">15/804,839</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">10,813,739</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/26/2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/356,270</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Closed Tip Dynamic Microvalve Protection Device</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">14/259,293</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">9,770,319</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10/7/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">14/330,456</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">9,968,740</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10/7/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">15/970,797</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">11,135,361</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2/17/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/874,144</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/474,633</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">2015236464</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">2015236464</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">2,941,706</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">2,941,706</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">201580015967.X</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">106456868</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">15768764.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">3122399</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Validated in:</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">CH</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">DE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">FR</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">GB</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">IE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">IN</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">201647035398</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2020-082002</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">6982811</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SG</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11201607272Q</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11201607272Q</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/20/2035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td rowspan="2" style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/219,738</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">11,090,460</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">7/4/2036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="display:none;vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/376,115</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">System and Method for Selective Pressure-Controlled Therapeutic Delivery</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">15/703,951</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">10,780,250</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">6/28/2038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">15/871,326</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">11,400,263</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4/23/2038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/671,296</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/886,350</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Dynamic Reconfigurable Microvalve Protection Device</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">15/464,036</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">10,588,636</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4/7/2038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/116,790</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">3056079</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">202111184263.9</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">18770345.9</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">HK</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">42022053999.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2019-551584</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">7234131</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3/13/2038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Systems And Methods for Pressure-Facilitated Therapeutic Agent Delivery</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/408,266</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Atraumatic Occlusive System With Compartment for Measurement of Vascular Pressure Change</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">16/431,547</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">17/236,446</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">3,139,118</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">3,139,118</p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">5/27/2040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">CN</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">202080041227.4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">20819412.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">HK</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 3pt 0pt 0pt;">62022053890.9</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">JP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2021-572025</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Related to Pressure Directed Therapy</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unpublished U.S. non-provisional<br/>application filed 6/14/2021</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Related to Retrograde Venous Therapy</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:23.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unpublished U.S. non-provisional<br/> application filed 7/14/2021</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Trade Secrets and Other Proprietary Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention provisions. Further, we generally require confidentiality agreements from business partners and other third parties that receive our confidential information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also rely on 16 registered trademarks and trade designs to develop and maintain our competitive position. TriNav, SmartValve, and TRISALUS LIFE SCIENCES are registered trademarks of ours in the U.S, and we have pending applications for U.S. trademarks for TRISALUS, SMARTSENSE, TRIGUIDE, TRISALUS CLINICAL ESSENTIALS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act (the &#8220;<b style="font-weight:bold;">FD&amp;C Act</b>&#8221;) and the FDA&#8217;s implementing regulations set forth, among other things, requirements for the testing, development, including clinical trials, manufacture, quality control, safety, effectiveness, approval/clearance, labeling, storage, record-keeping, reporting, distribution, import, export, sale, advertising and promotion of our products and product candidates. Although the discussion below focuses on regulation in the U.S. because that is currently our primary focus, we may seek approval/clearance for, and market, our products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect the global regulatory environment will continue to evolve, which could impact the cost, the time needed to approve, and ultimately, our ability to maintain existing approvals or obtain future approvals for our products. Regulations of the FDA and other regulatory agencies in and outside the U.S. impose extensive compliance and monitoring obligations on our business. These agencies review our design and manufacturing practices, labeling, record keeping, and manufacturers&#8217; required reports of adverse experiences and other information to identify potential problems with marketed products. We are also subject to periodic inspections for compliance with applicable manufacturing and quality system regulations, which govern the methods used in, and the facilities and controls used for, the design, manufacture, packaging, and servicing of finished drugs and medical devices intended for human use. In addition, the FDA and other regulatory bodies, both within and outside the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the U.S. Department of Justice, and various state attorneys general), monitor the promotion and advertising of our products. Any adverse regulatory action, depending on its magnitude, may limit our ability to effectively market and sell our products, limit our ability to obtain future pre-market approvals or result in a substantial modification to our business practices and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Medical Device Development and Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k)&#160;premarket notification submission, granting of a de novo request, or premarket application (&#8220;<b style="font-weight:bold;">PMA</b>&#8221;) approval. Under the FD&amp;C Act, medical devices are classified into one of three classes, Class&#160;I, Class&#160;II, or Class&#160;III, depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and includes those devices for which safety and effectiveness can be assured by adherence to the FDA&#8217;s general controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (&#8220;<b style="font-weight:bold;">QSR</b>&#8221;), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Some Class&#160;I devices may require premarket notification to the FDA.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Class&#160;II devices are moderate risk devices and are subject to the FDA&#8217;s general controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries, and FDA guidance documents. While most Class&#160;I devices are exempt from the 510(k)&#160;premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to the FDA a premarket notification under Section&#160;510(k)&#160;of the FD&amp;C Act requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k)&#160;premarket notification is generally known as 510(k)&#160;clearance. Under the 510(k)&#160;process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221; to either a device that was legally marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, or another commercially available device that was cleared to through the 510(k)&#160;or de novo process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&#160;III, requiring approval of a PMA. For a device that is Class&#160;III by default (because it is a novel device that was not previously classified and has no predicate), the device manufacturer may request that FDA reclassify the device into Class&#160;II or Class&#160;I via a de novo request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">510(k)&#160;Marketing Clearance</i>.&#160;To obtain 510(k)&#160;clearance by the FDA, a premarket notification submission must be submitted to the FDA demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&#160;28, 1976, and for which a PMA is not required, a device that has been reclassified from Class&#160;III to Class&#160;II or I (e.g., via the de novo classification process), or a device that was previously cleared through the 510(k)&#160;process. The FDA&#8217;s 510(k)&#160;review process usually takes from three to six&#160;months, but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. If the FDA agrees that the device is substantially equivalent to a predicate device, it will grant 510(k)&#160;clearance to market the device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After a device receives 510(k)&#160;marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k)&#160;marketing clearance or, depending on the modification, a de novo request or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), de novo or a PMA in the first instance, but the FDA can review that decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until FDA has cleared or approved a 510(k), de novo or PMA for the change. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">De Novo Process</i>.&#160;If a previously unclassified new medical device does not qualify for the 510(k)&#160;pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class&#160;III. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class&#160;III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class&#160;III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class&#160;III to request down-classification of its medical device into Class&#160;I or Class&#160;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class&#160;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k)&#160;or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. If the FDA agrees with the down-classification, the de novo applicant will then receive authorization to market the device, and a classification regulation will be established for the device type. The device can then be used as a predicate device for future 510(k)&#160;submissions by the manufacturer or a competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Premarket Approval Process</i>.&#160;Class&#160;III devices require submission through the PMA process before they can be marketed. The PMA process is more demanding than the 510(k)&#160;premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain, among other things, a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission, the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days under the FD&amp;C Act to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer and can take up to several&#160;years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. In addition, the FDA will generally conduct a preapproval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing facility or facilities to ensure compliance with the QSR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA application constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA application with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of&#160;years and to make periodic reports to FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i>.&#160;Clinical trials are almost always required to support de novo or a PMA and are sometimes required to support a 510(k)&#160;submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational Device Exemption (&#8220;<b style="font-weight:bold;">IDE</b>&#8221;) regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA, unless the FDA notifies the manufacturer that the investigation may not begin or is subject to a clinical hold. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;<b style="font-weight:bold;">IRB</b>&#8221;) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the trial. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During a clinical trial, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA, or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Drug Development and Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the FD&amp;C Act, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs require extensive studies and submission of a large amount of data by the applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Testing.</i>&#160;Before testing any compound in human patients in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product. Certain animal studies must be performed in compliance with the FDA&#8217;s Good Laboratory Practice (&#8220;<b style="font-weight:bold;">GLP</b>&#8221;) regulations and the U.S. Department of Agriculture&#8217;s Animal Welfare Act. Some nonclinical testing can happen during the clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IND Application.</i>&#160;Human clinical trials in the U.S. cannot commence until an investigational new drug (&#8220;<b style="font-weight:bold;">IND</b>&#8221;) application is submitted and becomes effective. A company must submit preclinical testing results to the FDA as part of the IND, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30&#160;days following its receipt by the FDA, and the clinical trial proposed in the IND may begin. Either before or after human clinical trials commence, the FDA may stop a clinical trial by placing it on &#8220;clinical hold&#8221; because of concerns about the safety of the product being tested or for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials.</i>&#160;Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulations, including compliance with the FDA&#8217;s Good Clinical Practice (&#8220;<b style="font-weight:bold;">GCP</b>&#8221;) requirements, which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate and that the rights, safety, and well-being of study participants are protected. The conduct of clinical trials is subject to the FDA&#8217;s Bioresearch Monitoring (&#8220;<b style="font-weight:bold;">BIMO</b>&#8221;) program, a comprehensive program of on-site inspections, data audits, and remote regulatory assessments. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board (&#8220;<b style="font-weight:bold;">IRB</b>&#8221;) for each clinical site. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events (&#8220;<b style="font-weight:bold;">AEs</b>&#8221;). Foreign studies conducted under an IND must meet the same or comparable requirements as those that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with GCP and U.S. regulations and the FDA is able to validate the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A study sponsor is required to publicly post specified details about certain clinical trials and clinical trial results on government or independent websites (e.g., http://clinicaltrials.gov). Human clinical trials typically are conducted in three sequential phases, although the phases may overlap, be combined, or be subdivided. In some cases, particularly in the development of therapies to treat orphan or rare disease or diseases with unmet medical need, development is limited to one or two phases.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase&#160;1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population, and are designed to develop initial data regarding the product&#8217;s effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential AEs.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug&#8217;s overall risk-benefit profile and to provide a basis for physician labeling. Generally, Phase&#160;3 clinical development programs consist of expanded, multi-site, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen. Phase&#160;3 data often form the core basis on which the FDA evaluates a drug&#8217;s safety and effectiveness when considering the product application.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The sponsoring company, the FDA or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NDA Submission and Review.</i>&#160;The FD&amp;C Act provides two pathways for the approval of new drugs through an NDA. An NDA under Section&#160;505(b)&#160;of the FD&amp;C Act is a comprehensive application to support approval of a product candidate that includes, among other things, data and information to demonstrate that the proposed drug is safe and effective for its proposed uses, that production methods are adequate to ensure its identity, strength, quality, and purity of the drug, and that proposed labeling is appropriate and contains all necessary information. A 505(b)(1)&#160;NDA contains results of the full set of preclinical studies and clinical trials conducted by or on behalf of the applicant to characterize and evaluate the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;505(b)(2)&#160;of the FD&amp;C Act provides an alternate regulatory pathway to obtain FDA approval that permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We plan to seek FDA approval of SD-101 through a 505(b)(1)&#160;regulatory approval pathway, as part of a combination regimen with checkpoint inhibitor(s). A combination regimen requires data demonstrating the contribution of each drug in the regimen to the treatment of the disease under study. For SD-101 to obtain approval, we will be required to produce data to confirm its contribution to the regimen improves the efficacy of the therapeutic regimen. There is FDA precedent for this data to be obtained from a number of sources, including, a comparator in a controlled trial, prior FDA approvals, historic data from other clinical trials or meta-analysis of clinical practice or &#8220;real world&#8221; data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to a combined therapy, the inclusion of a drug (SD-101) and a cleared device component (TriNav) in the platform may be considered a &#8220;combination product&#8221; under FDA regulations. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. For SD-101, we expect that the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;<b style="font-weight:bold;">CDER</b>&#8221;) will have primary jurisdiction for review of the NDA, and the drug and cleared device will be reviewed as a combination product under one marketing application. For a drug-device combination product, CDER typically consults with the FDA&#8217;s Center for Devices and Radiological Health in the NDA review process. For TriNav to become part of a combination product, we may be required to produce data supporting TriNav or PEDD&#8217;s contribution to the efficacy of SD-101 in the targeted indications beyond the original data used in support of 510(k)&#160;clearance of the TriNav device. In addition, our PRVI device is currently being studied in combination with SD-101 in the PERIO-03 trial. The PRVI device has received 510(k)&#160;clearance and may in the future also meet the definition of a &#8220;combination product&#8221; under FDA regulations. For the PRVI device to become part of a combination product, we may be required to produce data supporting PRVI or PEDD&#8217;s contribution to the efficacy of SD-101 in the targeted indications beyond the original data used in support of 510(k)&#160;clearance of the PRVI device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The submission of an NDA generally requires payment of a substantial user fee to the FDA. The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#8217;s identity, strength, quality, and purity. For some NDAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the FDA considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additional regulatory requirements may be implicated. The FDA may determine that a Risk Evaluation and Mitigation Strategy (&#8220;<b style="font-weight:bold;">REMS</b>&#8221;) is necessary to ensure that the benefits of a new product outweigh its risks prior to approving a new product. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. Under the Pediatric Research Equity Act, as </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">amended by the FDA Reauthorization Act of 2017, certain molecularly targeted oncology drugs require early evaluation. Specifically, if an original NDA or Biologics License Application for a new active ingredient for adults is directed at a molecular target FDA determines to be substantially relevant to the growth or progression of a pediatric cancer, study of the molecularly targeted pediatric cancer must be submitted with the marketing application, unless FDA waives or defers the requirement. FDA also inspects the facility or facilities where the product is manufactured prior to approving an NDA. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice (&#8220;<b style="font-weight:bold;">cGMP</b>&#8221;) requirements and an adequate quality system to assure consistent production of the product within required specifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the FDA accepts an NDA submission&#8201;&#8212;&#8201;which occurs, if at all, within 60&#160;days after submission of the NDA&#8201;&#8212;&#8201;the FDA&#8217;s goal for a non-priority review of an NDA is ten&#160;months. The review process can be and often is significantly extended, however, by FDA requests for additional information, studies, or clarification. After review of an NDA and the facilities where the product is manufactured, the FDA either issues an approval letter or a complete response letter (&#8220;<b style="font-weight:bold;">CRL</b>&#8221;) outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor. FDA&#8217;s goal for the review of an application granted priority review is six&#160;months after the 60-day acceptance period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developing a drug and obtaining regulatory approval often takes a number of&#160;years, involves the expenditure of substantial resources, and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including the completion within a specified time period of additional clinical studies, which often are referred to as &#8220;Phase&#160;4&#8221; or &#8220;post-marketing&#8221; studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Post-approval modifications to the drug or its use, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical studies or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once approved, drug and medical device products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met, or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval/clearance or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Good Manufacturing Practices.</i>&#160;Companies engaged in manufacturing drug products or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. Compliance with cGMP includes adhering to requirements relating to organization and training of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, quality control and quality assurance, packaging and labeling controls, holding and distribution, laboratory controls, and records and reports. The FDA regulates and inspects equipment, facilities, and processes used in manufacturing pharmaceutical products prior to approval. If, after receiving approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to take enforcement action or seek sanctions, including fines, issuance of warning letters, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution. Although we periodically monitor the FDA compliance of our third-party manufacturers, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP and other applicable FDA regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We also need to comply with some of the FDA&#8217;s manufacturing and safety regulations for devices. In addition to cGMP, the FDA requires that devices or drug-device combination products comply with the QSR, which sets forth the FDA&#8217;s manufacturing quality </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">standards for medical devices. The FDA also requires that we comply with certain device safety reporting requirements for device or a drug-device combination product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advertising and Promotion.</i>&#160;The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs and medical devices through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#8201;&#8212;&#8201;that is, uses not approved by the FDA and not described in the product&#8217;s labeling&#8201;&#8212;&#8201;because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers&#8217; communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. In addition to FDA restrictions on marketing of pharmaceutical products, state and federal fraud and abuse laws have been applied to restrict certain marketing practices in the pharmaceutical industry. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug or medical device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Requirements. </i>&#160;Drug and medical device market authorization holders must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse experiences, and maintaining certain records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RLD Patents. </i>&#160;In an NDA, a sponsor must identify patents that claim the drug substance or drug product or a method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication <i style="font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</i> which is referred to as the <i style="font-style:italic;">Orange Book</i>. Following a drug&#8217;s approval, a sponsor wishing to submit an Abbreviated New Drug Application (&#8220;<b style="font-weight:bold;">ANDA</b>&#8221; or &#8220;<b style="font-weight:bold;">generic</b>&#8221;) NDA or 505(b)(2)&#160;application seeking to rely on the originally approved product as the reference-listed drug (&#8220;<b style="font-weight:bold;">RLD</b>&#8221;) for its ANDA or 505(b)(2)&#160;must make one of several certifications regarding each listed patent. A &#8220;Paragraph I&#8221; certification is the sponsor&#8217;s statement that patent information has not been filed for the RLD. A &#8220;Paragraph II&#8221; certification is the sponsor&#8217;s statement that the RLD&#8217;s patents have expired. A &#8220;Paragraph III&#8221; certification is the sponsor&#8217;s statement that it will wait for the patent to expire before obtaining approval for its product. A &#8220;Paragraph IV&#8221; certification is an assertion that the patent does not block approval of the later product, either because the patent is invalid or unenforceable or because the patent, even if valid, is not infringed by the new product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulatory Exclusivities. </i>&#160;The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as RLDs for an ANDA or 505(b)(2)&#160;application. If a product is a &#8220;new chemical entity&#8221;, commonly referred to as an &#8220;NCE&#8221;, which generally indicates that the active moiety has never before been approved in any drug, there is a period of five&#160;years from the product&#8217;s approval during which the FDA may not accept for filing any ANDA or 505(b)(2)&#160;application for a drug with the same active moiety. An ANDA or 505(b)(2)&#160;application may be submitted after four&#160;years, however, if the sponsor of the application makes a Paragraph IV certification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data, other than bioavailability studies, derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2)&#160;application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2)&#160;application until three&#160;years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Once the FDA accepts for filing an ANDA or 505(b)(2)&#160;application containing a Paragraph IV certification, the applicant must within 20&#160;days provide notice to the RLD or listed drug NDA holder and patent owner that the application has been submitted and provide the factual and legal basis for the applicant&#8217;s assertion that the patent is invalid or not infringed. If the NDA holder or patent owner files suit against the ANDA or 505(b)(2)&#160;applicant for patent infringement within 45&#160;days of receiving the Paragraph IV notice, the FDA is prohibited from approving the ANDA or 505(b)(2)&#160;application for a period of 30&#160;months or the resolution of the underlying suit, whichever is earlier. If the RLD has NCE exclusivity and the notice is given and suit is filed during the fifth&#160;year of exclusivity, the regulatory stay extends until 7.5&#160;years after the RLD approval. The FDA may approve the proposed product before the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration. </i>&#160;A portion of the patent term lost during product development and FDA review of an NDA may be restored if approval of the application is the first permitted commercial marketing of a drug containing the active ingredient. The patent term restoration period is generally one-half the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. The maximum period of restoration is five&#160;years, and the patent cannot be extended to more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The U.S. Patent and Trademark Office in consultation with the FDA reviews and approves the application for patent term restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Exclusivities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity. </i>&#160;Section&#160;505A of the FD&amp;C Act provides for six&#160;months of additional exclusivity or patent protection if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show that the product is effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or <i style="font-style:italic;">Orange Book</i> listed patent protection that cover the drug are extended by six&#160;months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2)&#160;application owing to regulatory exclusivity or listed patents. When any product is approved, we will evaluate seeking pediatric exclusivity as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Exclusivity</i>. &#160;The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the U.S. If a sponsor demonstrates that a drug product qualifies for orphan drug designation, the FDA grants orphan drug designation to the product for that use. The benefits of orphan drug designation include research and development tax credits and exemption from user fees. A drug that is approved for the orphan drug designated indication generally is granted seven&#160;years of orphan drug exclusivity (to run concurrently with any other granted exclusivities). During that period, the FDA generally may not approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expedited Development and Review Programs</i>. &#160;The FDA has various programs, including Fast Track Designation, Priority Review Designation, Accelerated Approval Program and Breakthrough Therapy Designation, which are intended to expedite or simplify the process for reviewing product candidates. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will be lengthened. Generally, product candidates that are eligible for these programs are those for serious or life- threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track Designation is a process designed to facilitate the development and expedite the review of product candidates to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Priority Review Designation is designed to give a product candidate that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness, an initial review within eight&#160;months as compared to a standard review time of within ten&#160;months of the date the FDA files the NDA. Although Fast Track Designation and Priority Review Designation do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track Designation product candidate and expedite review of the application for a Priority Review Designation product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the U.S., there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;<b style="font-weight:bold;">Affordable Care Act</b>&#8221;) was passed in March&#160;2010, which substantially </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been judicial, congressional and executive branch challenges to certain aspects of the Affordable Care Act. For example, on June&#160;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the individual mandate was repealed by Congress. In addition, there have been a number of health reform initiatives by the Biden administration that have impacted the Affordable Care Act. On August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;<b style="font-weight:bold;">IRA</b>&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan&#160;year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to legal challenges and additional health reform measures in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, in August&#160;2011, the Budget Control Act of 2011 was signed into law which, among other things, led to aggregate reductions of Medicare payments to providers up to 2% per fiscal&#160;year, and, due to subsequent legislative amendments, will remain in effect until 2031 unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal&#160;year of this sequester.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There has been increasing legislative and enforcement interest in the U.S. with respect to prescription-pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, in July&#160;2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September&#160;9, 2021, the U.S. Department of Health and Human Services (&#8220;<b style="font-weight:bold;">HHS</b>&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1)&#160;directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare, (2)&#160;imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price increases that outpace inflation and (3) protects orphan drugs with a single indication label from drug price negotiation but causes an orphan drug to lose the exclusion from price negotiation once it gains additional indications. These provisions will take effect progressively starting in fiscal&#160;year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October&#160;14, 2022, directing HHS to submit a report within 90&#160;days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that other healthcare reform measures may be adopted in the future, which may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of our products and any product candidates for which we may obtain regulatory approval. Sales of any of our products and product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government healthcare programs such as Medicare and Medicaid, and private payors, such as commercial health insurers and managed care organizations. Third-party payors determine which drugs they will cover and the amount of reimbursement they will provide for a covered drug. In the U.S., there is no uniform system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for our products we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals. Even if we conduct pharmacoeconomic studies, our products and product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Furthermore, the healthcare industry in the U.S. has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Therefore, we cannot be certain that the procedures using our products will be reimbursed at a cost-effective level. Nor can we be certain that third-party payors using a methodology that sets amounts based on the type of procedure performed, such as those utilized by government programs and in many privately managed care systems, will view the cost of our products to be justified so as to incorporate such costs into the overall cost of the procedure. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to achieve profitability. Moreover, we are unable to predict what changes will be made to the reimbursement methodologies used by third-party payors in the future. For example, CMS awarded TPT payments for TriNav for the two-year period through December&#160;31, 2022. On December&#160;29, 2022, the Consolidated Appropriations Act of 2023 (H.R. 2617) was signed into law and includes an extension of TPT status for certain devices, including TriNav, through December&#160;31, 2023. In December 2023, CMS granted a New Technology HCPCS code for procedures involving TriNav. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments and ambulatory surgical centers. There can be no assurance that continuing reimbursement will be available at similar reimbursement rates or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional legislative changes, regulatory changes and judicial challenges related to the Affordable Care Act remain possible, as discussed above under the subheading &#8220;U.S. Healthcare Reform.&#8221; In addition, there likely will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payors to contain healthcare costs. Thus, even if we obtain favorable coverage and reimbursement status for our products and any product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Fraud and Abuse Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA restrictions on marketing of pharmaceutical products, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These laws include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate in order to commit a violation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal civil and criminal false claims laws, including the False Claims Act, which can be enforced by private individuals on behalf of the government through civil whistleblower or qui tam actions, and civil monetary penalty laws prohibit individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the U.S. federal government.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HIPAA</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">HITECH</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and its implementing regulations, imposes obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; and their subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also increased the civil and criminal penalties that may be imposed under HIPAA and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers. Other states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with such laws and regulations requires substantial resources. Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to legal challenge and enforcement actions. In the event governmental authorities conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, they may impose sanctions under these laws, which are potentially significant and may include civil monetary penalties, damages, exclusion of an entity or individual from participation in government health care programs, criminal fines and imprisonment, additional reporting requirements if we become subject to a corporate integrity agreement or other settlement to resolve allegations of violations of these laws, as well as the potential curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Corrupt Practices Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. Foreign Corrupt Practices Act of 1997 prohibits corporations and their intermediaries from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal office is located in Westminster, Colorado, where we lease approximately 21,000 square feet of office, manufacturing, and warehouse space pursuant to a lease that expires on December 31, 2026 with the option of extension for an additional five-year term. We also lease office facilities in Bannockburn, Illinois, and Cranston, Rhode Island. We also lease laboratory space at Brown University in Providence, Rhode Island. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Team</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of October 16, 2023, we had approximately 106 full-time employees. None of our employees is represented by a labor union or covered under collective bargaining agreement. We have not experienced any material work stoppages&#160;and we consider our relationship with our employees to be good, healthy and transparent. We actively engage with managers to collect feedback and ideas on how to improve our working environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining incentivizing and integrating our existing and new employees, advisors and consultants. The principal purpose of our equity and cash incentive plans is to attract, retain, and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of TriSalus by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be subject to legal proceedings. We are not currently party to or aware of any active legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_daaf9a72_915c_4f15_8315_5f868075f5b8"></a><a id="MANAGEMENT_315555"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">MANAGEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Directors and Executive Officers</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table sets forth the names, ages and positions of our directors and executive officers as of December 8, 2023:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:39.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers and Directors</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mary Szela</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President; Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sean Murphy</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer; Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Katz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bryan Cox</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific and Manufacturing Officer</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jennifer Stevens</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Regulatory Officer</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Richard Marshak</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Corporate Development &amp; Strategy</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jodi Devlin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Commercial Operations</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mats Wahlstr&#246;m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew von Eschenbach</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">George Kelly Martin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David J. Matlin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Arjun Desai</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Kerry Hicks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Anil Singhal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mary Szela</span><b style="font-weight:bold;">. </b>&#160;Ms.&#160;Szela is our Chief Executive Officer and President and a member of our Board and, prior to the Business Combination, had served as the Chief Executive Officer and a director of Legacy TriSalus since January&#160;2018. Prior to joining Legacy TriSalus, Ms.&#160;Szela was CEO of Novelion Therapeutics, a biopharmaceutical company, from January&#160;2016 through November&#160;2017 where she led the company through regulatory compliance and legal difficulties to a successful merger and expansion. Prior to that, Ms.&#160;Szela served as CEO of Melinta Therapeutics, a biopharmaceutical company, from August&#160;2013 through August&#160;2015. From 1987 to 2012, Ms.&#160;Szela held progressive leadership roles with Abbott Laboratories, a multinational medical devices and health care company, including Vice President, U.S. Commercial Operations, President of U.S. Pharmaceuticals, and culminating as Senior Vice President of Global Strategic Market and Services. In addition to her executive experience, Ms.&#160;Szela currently sits on the boards of directors of Kura Oncology, a public company, Omega Therapeutics, a public company, and Senda BioSciences. Ms.&#160;Szela received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that Ms.&#160;Szela is qualified to serve on our Board based on her substantial business, leadership and management experience in the biotechnology sector.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sean Murphy. </span>&#160;Mr.&#160;Murphy is our Chief Financial Officer and a member of our Board and, prior to the Business Combination, had served as the Chief Financial Officer of Legacy TriSalus since June&#160;2022. He was also a director of Legacy TriSalus since August&#160;2020 and served as the chairman of its audit committee from August&#160;2020 through June&#160;2022. Prior to joining Legacy TriSalus, Mr.&#160;Murphy was Executive Vice President at Malin PLC, a publicly listed company investing in life sciences companies, from April&#160;2016 through June&#160;2021. Mr.&#160;Murphy was a senior advisor at Evercore, an independent investment banking advisory firm, from August&#160;2011 to June&#160;2018. Prior to that, he held numerous positions over a 30-year career with Abbott Laboratories, a multinational medical devices and health care company, culminating as Vice President of Business Development and Licensing. Mr.&#160;Murphy has had extensive Board experience as well. He currently serves on the boards of directors of Xenex, and Prenosis. In addition, Mr.&#160;Murphy previously served on the public company board of directors of Radius Health, where he sat on the audit committee, and Poseida, where he was a member of the compensation and governance committee. Mr.&#160;Murphy received his BBA in Finance and Accounting from Western Illinois University and his M.S. in Finance from University of Illinois. He is a Certified Public Accountant, State of Illinois.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Mr.&#160;Murphy is qualified to serve on our Board based on his corporate finance experience and his previous experience on boards of directors.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Steven Katz. </span>&#160;Dr.&#160;Steven Katz is our Chief Medical Officer and, prior to the Business Combination, had served as Chief Medical Officer of Legacy TriSalus since September&#160;2020 and is Chairman of the Scientific Advisory Board, which includes leadership of our Translational Immunotherapy Laboratory. Previously, Dr.&#160;Katz served as an advisor to Legacy TriSalus from June&#160;2014 to August&#160;2020, and Chief Medical Advisor from January&#160;2019 to August&#160;2020. Since 2016, Dr.&#160;Katz also has served as a consultant for several companies developing cell therapies for solid tumors. In Dr.&#160;Katz&#8217;s academic work, he is an Associate Professor of Surgery at Brown University and has been with Brown Surgical Associates in a part-time role since February&#160;2022. From 2009 to 2021, Dr.&#160;Katz led the creation of a solid tumor immunotherapy program at CharterCare Health Partners, serving as the Director of the Office of Therapeutic Development and Complex Surgical Oncology Program Director during that time. While at CharterCare, he led a translational immunotherapy laboratory focused on immunosuppression and immunotherapy development, while serving as principal investigator for multiple immunotherapy trials which integrated novel delivery approaches. Dr.&#160;Katz received his B.A. in Government&#160;&amp; Biochemistry from Wesleyan University and his M.D. from New York University, followed by completion of a general surgery residency at New York University. He completed Immunology Research and Surgical Oncology fellowships at the Memorial Sloan-Kettering Cancer Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bryan Cox. </span>&#160;Bryan Cox is our Chief Scientific and Manufacturing Officer and, prior to the Business Combination, had served as Chief Scientific and Manufacturing Officer of Legacy TriSalus since June&#160;2020. Dr.&#160;Cox has also served as the Chief Executive Officer of Nephraegis Therapeutics, a biotechnology company, since November&#160;2018. Prior to joining Legacy TriSalus, Dr.&#160;Cox served as a consultant for CoPharm Global Consulting, a boutique consultancy focuses on providing guidance for biotechnology companies, from May&#160;2013 to June&#160;2020. Prior to that, Dr.&#160;Cox served as the Director of Integrative Pharmacology for Abbott Laboratories, a multinational medical devices and health care company, from 1996 to 2013. Dr.&#160;Cox has served on the board of directors for Nephraegis Therapeutics since November&#160;2018. Dr.&#160;Cox received his B.S. in Biological Sciences from North Carolina University and his Ph.D. in Pharmacology from the University of Iowa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jennifer Stevens. </span>&#160;Jennifer Stevens is our Chief Regulatory Officer and also serves as our Head of Quality for Devices and Drugs. Prior to the Business Combination, she had served as Chief Regulatory Officer of Legacy TriSalus since March&#160;2022. Previously, Ms.&#160;Stevens served as Legacy TriSalus&#8217; Senior Vice President of Regulatory Affairs from March&#160;2021 to March&#160;2022. Prior to joining of Legacy TriSalus, Ms.&#160;Stevens held several progressive leadership roles with EMD Serono&#160;Inc., a division of Merck KGaA focused on biopharmaceuticals, from January&#160;2016 through March&#160;2021, including as Acting Head of US Oncology Hub &#8212;&#8201; Regulatory Affairs. Previously, Ms.&#160;Stevens was Regulatory Counsel for the U.S. Food and Drug Administration from July&#160;2008 to December&#160;2012. Earlier in her career, Ms.&#160;Stevens was a practicing attorney at several global law firms, achieving partnership at Kirkland&#160;&amp; Ellis&#160;LLP. Ms.&#160;Stevens received her B.A. in Political Sciences from the University of Illinois and her J.D. from George Washington University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Richard Marshak, VMD. </span>&#160;Dr.&#160;Richard Marshak is our Senior Vice President, Corporate Development and Strategy and, prior to the Business Combination, had served as Senior Vice President, Corporate Development and Strategy of Legacy TriSalus since June&#160;2022. Prior to joining of Legacy TriSalus, Dr.&#160;Marshak was Managing Principal of LF Consulting, a consulting firm for biotechnology companies, from June&#160;2013 to June&#160;2022. Dr.&#160;Marshak also co-founded Nephraegis Therapeutics, a biotechnology company, in September&#160;2018 and served as its Chief Business Officer. Previously, Dr.&#160;Marshak served as the Chief Executive Officer of Mount Tam Biotechnologies from May&#160;2016 to October&#160;2019. Prior to these roles, Dr.&#160;Marshak held several progressive leadership roles in Abbott Laboratories, a multinational medical devices and health care company, from 1999 to 2013, culminating as the Head of Global Strategic Pricing. Dr.&#160;Marshak has served on the board of directors of Nephraegis Therapeutics since August&#160;2018 and previously served on the board of Mount Tam Biotechnologies from May&#160;2016 to October&#160;2019. Dr.&#160;Marshak received his B.A. in Psychology and VMD in Veterinary Medicine from the University of Pennsylvania, and his MBA from the University of Chicago.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jodi Devlin. </span>Jodi Devlin is our President, Commercial Operations and joined our team in August 2023 as President, Therapeutics. She has more than 30 years in the biotech and pharmaceutical industry. Previously, Ms. Devlin served as CEO of AltaThera Pharmaceuticals, a specialized, hospital pharmaceutical company, where she executed a turnaround where she raised funding, obtained a new FDA indication, built a commercial and clinical team, completed two new clinical trials, and significantly accelerated revenue. Prior to that, Ms. Devlin spent 21 years at Abbott/AbbVie where she held leadership roles in pipeline planning, global launches, and management of numerous commercial organizations. Ms. Devlin also serves as Chairman of the board of directors of Fitabeo Therapeutics. Before her time in the biotech industry, she worked as a hospital nurse in New York and Missouri. Ms. Devlin received her B.S. in Nursing from University of Oklahoma and her MBA from Washington University, Olin School of Business.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-Employee Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The size of our Board is nine directors, each of whom was voted upon by MTAC&#8217;s stockholders an extraordinary general meeting held on August&#160;2, 2023. In addition to Ms.&#160;Szela and Mr.&#160;Murphy (who are listed above), our Board members are listed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mats Wahlstr&#246;m. </span>&#160;Mats Wahlstr&#246;m is the Chairman of our Board and, prior to the Business Combination, had served as chairman of the board of directors of Legacy TriSalus since January&#160;2017. He has also served as the Co-Chairman of HW Investment Partners, LLC since July&#160;2016 and as Partner and Executive Chairman of KMG Capital Partners, LLC since April&#160;2012, both investment funds focused on investments in the healthcare industry. In addition, Mr.&#160;Wahlstr&#246;m has served as the Chairman of the board of directors of Triomed AB since October&#160;2016, as the lead independent director of Coherus Biosciences,&#160;Inc., a public biotech company, since January&#160;2012 and as Chairman of Caduceus Medical Holdings,&#160;Inc. since August&#160;2010. Mr.&#160;Wahlstr&#246;m has served on the boards of directors of Alteco Medical AB since October&#160;2012, Circuit Clinical Solutions,&#160;Inc. since July&#160;2016 and PCI | HealthDev since August&#160;2010. He served as a director of Health Grades,&#160;Inc. a Nasdaq-listed healthcare ratings company, from March&#160;2009 through its sale to a private equity firm in October&#160;2010, as a director of Getinge AB, a Swedish Stock Exchange-listed medical device company, from March&#160;2012 to March&#160;2017, and as a director of Zynex&#160;Inc. an over-the-counter medical device manufacturer, from October&#160;2010 through January&#160;2014. From January&#160;2004 to December&#160;2009, Mr.&#160;Wahlstr&#246;m served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG&#160;&amp; Co. KGaA. From November&#160;2002 to December&#160;2009, Mr.&#160;Wahlstr&#246;m served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mr.&#160;Wahlstr&#246;m held various positions at Gambro AB in Sweden from January&#160;1983 to February&#160;2000, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare&#160;Inc. as well as Chief Financial Officer of the Gambro Group. Mr.&#160;Wahlstr&#246;m has a B.S. degree in Economics and Business Administration from the University of Lund, Sweden.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe Mr.&#160;Wahlstr&#246;m is qualified to serve on our Board based on his extensive management and director experience in the life sciences and healthcare sectors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Andrew von Eschenbach. </span>&#160;&#160;Dr.&#160;von Eschenbach has been a member of our Board since August 2023. Dr.&#160;von Eschenbach is the President and founder of Samaritan Health Initiatives,&#160;Inc., a health care policy consultancy, a role which he has held since 2010. He is also an Adjunct Professor at the University of Texas M.D. Anderson Cancer Center (&#8220;<b style="font-weight:bold;">MDACC</b>&#8221;), a position he has held since 2009. Dr.&#160;von Eschenbach holds advisory roles as the Senior Advisor at Target RWE, a biotechnology company, since September&#160;2020, and Medical Advisor at Datavant, a health information technology company, since January&#160;2020. From October&#160;2017 to June&#160;2019, Dr.&#160;von Eschenbach served as Chief Medical Advisor at Malin Corporation PLC, a life sciences company. From 2009 to 2021, he worked on the International Advisory Council of Chugai Pharmaceutical Co.,&#160;Ltd., a Japanese drug manufacturer. From 2012 to 2016, Dr.&#160;von Eschenbach was a Senior Fellow and Director of the FDA Project at the Manhattan Institute, a think tank. From 2009 to 2018, he served on the GE Healthymagination Advisory Board, a GE Healthcare initiative to provide better healthcare for more people around the world. From 2012 to 2016, he served as a global council member of Eli Lilly and Company, PACE, a global collaboration that encourages public policies and healthcare decisions that speed the development of new medicines. From September&#160;2005 to January&#160;2009, Dr.&#160;von Eschenbach served as Commissioner of the FDA. Previously, Dr.&#160;von Eschenbach served as Director of the National Cancer Institute at the National Institutes of Health from January&#160;2002 to June&#160;2006. As a researcher, clinician and administrator, Dr.&#160;von Eschenbach served in a variety of roles at MDACC, including as Director, Genitourinary Cancer Center, Vice President for Academic Affairs, and Executive Vice President and Chief Academic Officer. Dr.&#160;von Eschenbach currently serves on the boards of directors of Bausch and Lomb Corporation and Celularity,&#160;Inc. In addition, Dr.&#160;von Eschenbach previously served on the boards of directors of Bausch Health Companies and Radius Health,&#160;Inc. Dr.&#160;von Eschenbach received his B.S. in biology from St. Joseph&#8217;s University and his M.D. in medicine from Georgetown University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Dr.&#160;von Eschenbach is qualified to serve on our Board based on his extensive experience in the pharmaceutical and healthcare industries, as well as his service as Commissioner of the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">George Kelly Martin. </span>&#160;&#160;Mr.&#160;Martin has been a member of our Board since August 2023. Mr.&#160;Martin currently serves as Chairman of Transition Bio,&#160;Inc., a molecular condensates discovery company, a role which he has held since 2020, and as Vice Chairman of Ride Therapeutics,&#160;Inc., a molecular logistics company, a role which he has held since 2022. He has also served as Chairman of WaveBreak (formerly Wren Therapeutics,&#160;Inc.), a company that utilizes physical science and kinetics to create therapeutic solutions for protein misfolding diseases, since 2018. Mr.&#160;Martin previously served as President and Chief Executive Officer of Radius Health,&#160;Inc., a bone and women&#8217;s health company, from 2020 to 2022. Prior to that, Mr.&#160;Martin served as Chief Executive Officer of Novan,&#160;Inc., a development-stage dermatology company, from 2018 to 2020. Prior to joining Novan,&#160;Inc., Mr.&#160;Martin was the Chief </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Executive Officer of Malin Corporation PLC, a life sciences investment company, from 2015 to 2017. Mr.&#160;Martin also served as Chief Executive Officer of Elan Corporation plc, an Ireland-based neurodegeneration research and development company, from 2003 to 2013. Mr.&#160;Martin&#8217;s business career started in finance and capital markets, having spent 21&#160;years at Merrill Lynch&#160;&amp; Co.&#160;Inc. At the time of his departure from Merrill Lynch in 2002, he was a member of the company&#8217;s Executive Operating Committee and his tenure included leadership oversight of four global divisions (debt markets, international equities, Information Technology, and International Private Banking). While at Merrill Lynch, Mr.&#160;Martin served multi-year assignments in both Tokyo and London. He previously served on the boards of directors of Questcor Pharmaceuticals, Immunocore Holdings, plc, and Kymab&#160;Ltd. Mr.&#160;Martin received his B.A. in Politics from Princeton University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Mr.&#160;Martin is qualified to serve on our Board based on his extensive executive experience in the biopharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">David J. Matlin. </span>&#160;Mr.&#160;Matlin has been a member of our Board since August 2023. Mr.&#160;Matlin previously served as the Chief Financial Officer and has served as director of MTAC since September&#160;2020. Mr.&#160;Matlin was also the co-founder and Chief Executive Officer of MatlinPatterson Global Advisers LLC (&#8220;<b style="font-weight:bold;">MatlinPatterson</b>&#8221;), a distressed securities investment manager, which he co-founded in July&#160;2002, through 2021. Mr.&#160;Matlin was also Chief Executive Officer of MatlinPatterson Asset Management&#160;L.P. and its operating joint venture affiliates that managed non-distressed credit strategies, from 2015 to 2018. In 2017, MatlinPatterson began winding down its investment activities and its various funds began to return the investment proceeds to their respective investors. In conjunction with this wind-down process and to protect their investors from foreign litigation, two of the MatlinPatterson funds (Matlin Global Opportunities Partners II&#160;L.P. and Matlin Global Opportunities Partners (Cayman) II&#160;L.P.) that had been unable to settle foreign litigation, filed, along with MatlinPatterson, voluntary petitions for relief under Chapter&#160;11 of the U.S. Bankruptcy Code in July&#160;2021. Prior to forming MatlinPatterson, Mr.&#160;Matlin was a Managing Director at Credit Suisse, and headed their Global Distressed Securities Group upon its inception in 1994. Mr.&#160;Matlin was also a Managing Director and a founding partner of Merrion Group,&#160;L.P., an investment advisory firm, from 1988 to 1994. He began his career as a securities analyst at Halcyon Investments from 1986 to 1988. Until its November&#160;2022 sale, Mr.&#160;Matlin also served on the board of directors of US Well Services&#160;Inc. (Nasdaq: USWS) (formerly Matlin&#160;&amp; Partners Acquisition Corporation) and was Chief Executive Officer and Chairman of the company prior to its business combination with US Well Services&#160;LLC. He also serves on the boards of directors of Dermasensor,&#160;Inc. and Pristine Surgical LLC, which are medical device manufacturers. Mr.&#160;Matlin has served on the board of directors of Clene,&#160;Inc. (Nasdaq: CLNN), a biopharmaceutical manufacturer, since December&#160;2020, and has served as the Chairman of its Board of Directors since May&#160;2021. Since 2020, he has served on the board of Traffk, LLC, an insurance-based data analytics company, and since July&#160;2021, he has served on the board of Empyrean Neuroscience, a biotechnology company. Previously, he served on the board of directors of Flagstar Bank FSB, a federally charted savings bank, and Flagstar Bancorp,&#160;Inc. (NYSE: FBC), a savings and loan holding company from 2009 to May&#160;2021, CalAtlantic Group,&#160;Inc. (NYSE: CAA), a U.S. homebuilder, from 2009 to 2018, Global Aviation Holdings,&#160;Inc., an air charter company, from 2006 to 2012, and Huntsman Corporation (NYSE: HUN), a U.S. chemicals manufacturer, between 2005 and 2007 and Orthosensor,&#160;Inc. until the sale of the company to Stryker Corporation in December&#160;2020. Mr.&#160;Matlin holds a JD degree from the Law School of the University of California at Los Angeles and a BS in Economics from the Wharton School of the University of Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Mr.&#160;Matlin&#8217;s significant public company board experience qualifies him to serve as a member of our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Arjun Desai. </span>&#160;Dr.&#160;Desai has been a member of our Board since August 2023. Dr.&#160;Desai has served as the Chief Strategic Innovation Officer at Insightec, a medical device company, since 2018. From 2016 to 2018, he served as the Global Vice President and Chief Operating Officer of Johnson&#160;&amp; Johnson Innovation, a company that collaborates with innovators to incorporate science into healthcare solutions. Additionally, Dr.&#160;Desai currently serves on the boards of directors of Obvius Robotics,&#160;Inc., Tympa Health TechnologiesLtd, Pathology Watch, Openwater Software,&#160;Inc., and Wesper. Dr.&#160;Desai received his B.S. degree in Economics from the University of Oklahoma and his M.D. from the University of Miami. He also completed his residency and advanced training in Anesthesiology at Stanford University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Dr.&#160;Desai is qualified to serve on our Board based on his extensive experience in the biotech industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Anil Singhal. </span>&#160;Dr.&#160;Singhal has been a member of our Board since August 2023. Dr.&#160;Singhal has served as the President and Chief Executive Officer of Trishula Therapeutics, a biotechnology company, since January&#160;2021. From May&#160;2019 to September&#160;2020, he served as President and Chief Executive Officer of Adicet Bio, a publicly-traded biotechnology company, and from September&#160;2020 to February&#160;2021, he served as an advisor to Adicet. Dr.&#160;Singhal also served as Vice President, Early Oncology Development, of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AbbVie&#160;Inc., a publicly-traded pharmaceutical company, from January&#160;2013 to March&#160;2018. Dr.&#160;Singhal is a member of the American Association of Cancer Research, which he joined in 2005, and a member of the American Society of Clinical Oncology, which he joined in 2007. Dr.&#160;Singhal has been a member of the board of directors of Legacy TriSalus since 2018. Dr.&#160;Singhal received his B.Sc&#160;Honours degree in Biochemistry from Panjab University in India, his MBA in Business Administration from the University of Washington and his PhD in Biochemistry from Rutgers University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Dr.&#160;Singhal is qualified to serve on our Board based on his extensive experience cancer research and development and his extensive experience in the biotechnology and pharmaceutical industries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Kerry Hicks. </span>&#160;&#160;Mr.&#160;Hicks has been a member of our Board since August 2023. Mr.&#160;Hicks has served as Partner, Chief Executive Officer, and President of KMG Capital Partners LLC, a boutique healthcare venture capital company, since April&#160;2012. He also currently serves as Executive Chairman of Circuit Clinical, an integrated research organization, and Co-Chairman and Partner of HW Investment Partners, LLC, a venture capital firm that focuses on investing in healthcare companies, both positions which he has held since 2016. Prior to joining KMG Capital Partners, Mr.&#160;Hicks served as Chief Executive Officer of Healthgrades, a healthcare information and services company, from 2000 to 2012, Chairman of Healthgrades from 2000 to 2010 and 2012 to 2013, and as President, Chief Executive Officer and Chairman of Specialty Care Network, a predecessor company to Healthgrades, from 1995 to 2000. Mr.&#160;Hicks has been a member of the board of directors of Legacy TriSalus since April&#160;2021. Mr.&#160;Hicks received his B.S. degree in Management and his MBA in Business Administration from Colorado State University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that Mr.&#160;Hicks is qualified to serve on our Board based on his extensive experience in the healthcare industry and knowledge regarding TriSalus and its products and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Family Relationships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are no family relationships among our directors and executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Composition of the Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business and affairs are organized under the direction of the Board. Our Board is comprised of nine members. Mats Wahlstr&#246;m is the Chairman of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to our management. The Board meets on a regular basis and additionally as required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the terms of our certificate of incorporation (the &#8220;<b style="font-weight:bold;">Certificate of Incorporation</b>&#8221;), our Board is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with one class of directors being elected in each&#160;year and each class serving a three-year term. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. The Board is divided among the following classes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;I, which consists of Anil Singhal, Kerry Hicks, and Sean Murphy, whose terms will expire at the annual meeting of stockholders to be held in 2024;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;II, which consists of David Matlin, Mats Wahlstr&#246;m, and Andrew von Eschenbach, whose terms will expire at the annual meeting of stockholders to be held in 2025; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;III, which consists of Mary Szela, Arjun &#8220;JJ&#8221; Desai, and George Kelly Martin, whose terms will expire at the annual meeting of stockholders to be held in 2026.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified, or their earlier resignation, removal, retirement or death. This classification of the Board may have the effect of delaying or preventing changes in our control or management. Our directors may be removed for cause by the affirmative vote of the holders of at least 66</span>2<span style="font-size:10pt;">&#8725;</span>3<span style="font-size:10pt;">% of our voting stock.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of our common stock being listed on the Nasdaq Stock Exchange (&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221;), we are required to comply with the applicable rules&#160;of such exchange in determining whether a director is independent. Prior to the completion of Closing, the Board reviewed the independence of the individuals named above. The Board determined that each of the directors on the current Board, other than Mary Szela and Sean Murphy, qualify as independent directors, as defined under the Nasdaq Stock Exchange listing rules&#160;(the &#8220;<b style="font-weight:bold;">Nasdaq listing rules</b>&#8221;) and that the Board consists of a majority of &#8220;independent directors,&#8221; as defined under the rules&#160;of the SEC and Nasdaq listing rules&#160;relating to director independence requirements. In addition, we are subject to the rules&#160;of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Role of the Board in Risk Oversight</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One of the key functions of the Board is informed oversight of our risk management process. The Board does not anticipate having a standing risk management committee, but rather anticipates administering this oversight function directly through the Board as a whole, as well as through various standing committees of the Board that address risks inherent in their respective areas of oversight. In particular, the Board is responsible for monitoring and assessing strategic risk exposure and the audit committee will have the responsibility to consider and discuss our major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. The compensation committee will assess and monitor whether our compensation plans, policies and programs comply with applicable legal and regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Committees of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board will direct the management of its business and affairs, as provided by Delaware law, and will conduct its business through meetings of the board of directors and standing committees. We have a standing audit committee, compensation committee and nominating and corporate governance committee. We have adopted a charter for each of these committees, which complies with the applicable requirements of current Nasdaq rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, from time to time, special committees may be established under the direction of the Board when the Board deems it necessary or advisable to address specific issues. Following the Business&#160;Combination, current copies of our committee charters were posted on its website, https://investors.trisaluslifesci.com/governance/governance-overview, as required by applicable SEC and Nasdaq rules. The information on or available through any of such website is not deemed incorporated in this prospectus and does not form part of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Audit Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit committee was appointed promptly after Closing and consists of David Matlin, Kerry Hicks, and George Kelly Martin. The Board has determined that each of the members of the audit committee will satisfy the independence requirements of Nasdaq listing rules&#160;and Rule&#160;10A-3 under the Exchange Act. Each member of the audit committee can read and understand fundamental financial statements in accordance with applicable audit committee requirements. In arriving at this determination, the Board examined each audit committee member&#8217;s scope of experience and the nature of their prior and/or current employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Matlin serves as the chair of the audit committee. The Board has determined that Mr.&#160;Matlin qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of Nasdaq listing rules. In making this determination, the Board considered Mr.&#160;Matlin&#8217;s formal education and previous experience in financial roles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both our independent registered public accounting firm and management periodically meet privately with our audit committee. The primary purposes of the audit committee of the Board are, among other things, to assist the Board in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our financial reporting processes and disclosure controls;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the adequacy and effectiveness of our internal control policies and procedures, including reviewing, with the independent auditors, management&#8217;s plans with respect to the responsibilities, budget, staffing and effectiveness of our internal audit function, and reviewing and approving our head of internal audit (if established);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with the independent auditors the annual audit plan, including the scope of audit activities and all critical accounting policies and practices we use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and reviewing at least annually (if required by applicable stock exchange listing requirements) or as otherwise determined, a report by our independent auditors describing the independent auditors&#8217; internal quality-control procedures and any material issues raised by the most recent internal quality-control review, peer review, or any inquiry or investigation by governmental or professional authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring the rotation of partners of our independent auditors on our engagement team as required by law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing relationships that may reasonably be thought to bear on the independence of the committee, receiving and reviewing a letter from the independent auditor affirming their independence, discussing the potential effects of any such relationship, and assessing and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> otherwise taking the appropriate action to oversee the independence of our independent auditor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our annual and quarterly financial statements and reports, including the disclosures contained in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors&#8221; and discussing the statements and reports with our independent auditors and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls and critical accounting policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with management and our independent auditors any earnings announcements, disclosures and other financial information and guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing procedures for the review, retention and investigation of complaints we receive regarding financial controls, accounting, auditing or other matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the report that the SEC requires in our annual proxy statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and providing oversight of any related party transactions in accordance with our related party transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing with management risks related to data privacy, technology and information security, including cybersecurity, back-up of information systems, and policies and procedures that we have in place to monitor and control such exposures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing any analyses prepared by management or the independent auditors setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial statements, including analyses of the effects of alternative GAAP methods on the financial statements;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with management and the independent auditors any disagreement between them regarding financial reporting, accounting practices or policies, or other matters, that individually or in the aggregate could be significant to our financial statements or the independent auditor&#8217;s report, reviewing management&#8217;s response, and resolving any other conflicts or disagreements regarding financial reporting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considering and reviewing with management, the independent auditors, and outside advisors or accountants any correspondence with regulators or governmental agencies and any published reports that raise material issues regarding our financial statements or accounting policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with management legal and regulatory compliance and any material current, pending or threatened legal matters; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The composition and function of the audit committee complies with all applicable requirements of the Sarbanes-Oxley Act, SEC rules&#160;and regulations and Nasdaq listing rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation committee was appointed promptly after Closing and consists of George Kelly Martin, Arjun &#8220;JJ&#8221; Desai, and Anil Singhal. Mr.&#160;Martin serves as the chair of the compensation committee. The Board has determined that each of the members of the compensation committee will be a non-employee director, as defined in Rule&#160;16b-3 promulgated under the Exchange Act, and will satisfy the independence requirements of Nasdaq. The primary purposes of the compensation committee of the Board are, among other things, to assist the Board in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the corporate objectives that pertain to our overall compensation strategy and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving annually the compensation and other terms of employment of our executive officers and other members of senior management, in the compensation committee&#8217;s discretion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the type and amount of compensation to be paid or awarded to our non-employee Board members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">administering our equity incentive plans and other benefit plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections, indemnification agreements and any other material arrangements with our executive officers and other members of senior management, in the compensation committee&#8217;s discretion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and establishing appropriate insurance coverage for our directors and officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing with management our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing an annual report on executive compensation that the SEC requires in our annual proxy statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our practices and policies for employee compensation as related to risk management and risk-taking incentives to determine if such compensation policies and practices are reasonably likely to have a material adverse effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and monitoring stock ownership guidelines for our directors and executive officers, if and as determined to be necessary or appropriate;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing recommendations to the Board on compensation-related proposals to be considered at our annual meeting of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing with management, if appropriate, the independence of and any conflicts of interest raised by the work of a compensation consultant, outside legal counsel, or advisor hired by the compensation committee or management and how such conflict is being addressed for disclosure in the appropriate filing or report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">annually reviewing and discussing with management our human capital management practices with respect to its employees and, where applicable, independent contractors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving and modifying, as needed, clawback policies allowing us to recoup improper compensation paid to employees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and evaluating on an annual basis the performance of the compensation committee and recommending such changes as deemed necessary with the Board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The composition and function of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act, SEC rules&#160;and regulations and Nasdaq listing rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nominating and Governance Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our nominating and corporate governance committee was appointed promptly after Closing and consists of Kerry&#160;Hicks, Mats Wahlstr&#246;m, Andrew von Eschenbach and David Matlin. Mr.&#160;Hicks serves as the chair of the nominating and corporate governance committee. The Board has determined that each of the members of our nominating and corporate governance committee satisfies the independence requirements of Nasdaq. The primary purposes of the nominating and governance committee of the Board are, among other things, to assist the Board in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determining the qualifications, qualities, skills and other expertise required to be a director of the Board</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and developing and recommending to the Board for approval criteria to be considered in selecting nominees for director;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, reviewing and making recommendations of candidates to serve on the Board, including incumbent directors for reelection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the performance of the Board, committees of the Board and individual directors and determining whether continued service on the Board is appropriate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">periodically reviewing and making recommendations to the Board regarding our process for stockholder communications with the Board, and making such recommendations to the Board with respect thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating nominations by stockholders of candidates for election to the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the structure and organization of the Board and its committees and making recommendations to the Board for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considering possible conflicts of interest of officers and directors as set forth in our code of business conduct and ethics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and considering environmental, social responsibility and sustainability and governance matters as it determines appropriate and making recommendations to the Board regarding, or taking action with respect to, such matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">periodically reviewing our corporate governance guidelines and code of business conduct and ethics and recommending to the Board any changes to such policies and principles;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and periodically reviewing with our Chief Executive Officer the plans for succession for our Chief Executive Officer and other executive officers, as it sees fit, and making recommendations to the Board with respect to the selection of appropriate individuals to succeed to these positions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considering the Board&#8217;s leadership structure, including the separation of the roles of chairperson of the Board and the Chief Executive Officer and/or the appointment of a lead independent director;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">periodically reviewing our processes and procedures to provide information to the Board and its committees and the scope of such information and making recommendations to the Board and management for improvement as appropriate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing periodically the nominating and corporate governance committee charter and recommending any proposed changes to the Board, including undertaking an annual review of its own performance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The composition and function of the nominating and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act, SEC rules&#160;and regulations and Nasdaq listing rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Science and Technology Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our science and technology committee was appointed promptly after Closing and consists of Andrew Von Eschenbach, Anil Singhal and Arjun Desai. Mr.&#160;Von Eschenbach serves as the chair of the science and technology committee. The primary purposes of the science and technology committee of the Board are, among other things, to assist the Board in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing, evaluating and advising the Board and management on matters relating </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to the overall strategy, direction, and effectiveness of our research and development strategy and related investments and on our progress in achieving its long-term strategic research and development goals and objectives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our planned or ongoing research activities and plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating and monitoring, on its own or in conjunction with external experts engaged by the committee, plans as well as individual project progress and performance of our research and development pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating and advising the Board and management on the opportunities and risks associated with the products, programs and technologies in which we are, or are considering, investing its research and development efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing the Board with strategic advice on emerging regulatory, clinical and scientific issues that are relevant to us and in alignment with our strategy and on areas that are important to the success of our R&amp;D activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess and advise our Board, from time to time, on the committee&#8217;s view of the overall quality and expertise of medical and scientific talent in our R&amp;D organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assisting the Board in understanding our intellectual property position in connection with the foregoing and otherwise.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation Committee Interlocks and Insider Participation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of the members of our compensation committee has ever been one of our executive officers or employees. None of our executive officers currently serve, or has served during the last completed fiscal&#160;year, on the compensation committee or board of directors of any other entity that has one or more executive officers that will serve as a member of our Board or compensation committee.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitation on Liability and Indemnification of Directors and Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation limits a director&#8217;s or an officer&#8217;s liability to the fullest extent permitted under the DGCL. The DGCL provides that, if provided in the certificate of incorporation as we have done, directors and officers of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any transaction from which the director derives an improper personal benefit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any unlawful payment of dividends or redemption of shares; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for any breach of a director&#8217;s or an officer&#8217;s duty of loyalty to the corporation or its shareholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of officers and directors, then the liability of our officers and directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our bylaws (the &#8220;<b style="font-weight:bold;">Bylaws</b>&#8221;) require that we indemnify and advance expenses to, to the fullest extent permitted by applicable law, our directors, officers and agents. We plan to maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. Finally, our Certificate of Incorporation prohibits any retroactive changes to the rights or protections or increase the liability of any officer or director in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we have entered into separate indemnification agreements with our directors and officers, the form of which is attached hereto as Exhibit&#160;10.25 to the registration statement of which this prospectus forms a part. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services to at our request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe these provisions in our Certificate of Incorporation, Bylaws, and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Code of Business Conduct and Ethics for Employees, Executive Officers and Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a Code of Business Conduct and Ethics (the &#8220;<b style="font-weight:bold;">Code of Conduct</b>&#8221;) that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at <i style="font-style:italic;">www.investors.trisaluslifesci.com/governance/governance-overview</i>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. The nominating and corporate governance committee of the Board will be responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We plan to disclose any amendments to the Code of Conduct, or any waivers of its requirements, on our website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-Employee Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board expects to review director compensation periodically to ensure that director compensation remains competitive such that we are able to recruit and retain qualified directors. In August 2023, our Board approved a non-employee director compensation policy (the &#8220;<b style="font-weight:bold;">Non-Employee Director Policy</b>&#8221;) consisting of annual cash retainers of $50,000 for each non-employee director and an additional $30,000 for the chairperson of the Board; an additional $20,000 and $7,500 for the chairperson and each other member of the audit committee of the Board, respectively; an additional $15,000 and $7,500 for the chairperson and each other member of the compensation committee of the Board, respectively; an additional $15,000 and $7,500 for the chairperson and each other member of the nominating and corporate governance committee of the Board, respectively; and an additional $25,000 and $7,500 for the chairperson and each other member of the science and technology committee of the Board, respectively. The Non-Employee Director Policy also provides for an initial grant of a stock option for 35,000 shares on the date an eligible director is first elected or appointed to the Board and an annual stock option grant for 15,000 shares on the date of each annual stockholder meeting for each eligible director who continues to serve as a non-employee member of the Board as of such date. The non-employee directors also received a one-time stock option grant for 35,000 shares immediately following the Closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Non-Employee Director Policy was developed with input from an independent compensation consultant regarding practices and compensation levels at comparable companies. It is designed to align compensation with our business objectives and the creation of stockholder value, while enabling us to attract, retain, incentivize and reward directors who contribute to our long-term success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_7136bbd3_0c99_4cd2_be6b_b5a4120a5761"></a><a id="EXECUTIVECOMPENSATION_739960"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MTAC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Closing of the Business Combination, MTAC did not enter into any employment agreements with its executive officers and did not make any agreements to provide benefits upon termination of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Executive Officers and Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No MTAC executive officers or directors received any cash compensation for services rendered to MTAC. Executive officers and directors, or any of their respective affiliates, were reimbursed for any out-of-pocket expenses incurred in connection with activities on MTAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TriSalus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">As used in this section, &#8220;TriSalus&#8221; refers to Legacy TriSalus prior to the Closing of the Business Combination and TriSalus after the closing of the Business Combination. Upon the Closing of the Business Combination, the executive officers of Legacy TriSalus became executive officers of TriSalus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Throughout this section, unless otherwise noted, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; and similar terms refer to TriSalus and its subsidiaries prior to the Closing and to TriSalus and its subsidiaries after the Business Combination. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations, and determinations regarding future compensation programs.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus&#8217; named executive officers for the&#160;year ended December&#160;31, 2022 were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mary Szela, Chief Executive Officer and President;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jennifer Stevens, Chief Regulatory Officer; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Steven Katz, Chief Medical Officer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary Compensation Table</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below shows compensation of TriSalus&#8217; named executive officers for the&#160;year ended December&#160;31, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incentive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name, Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Salary</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Bonus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mary Szela</b><b style="font-weight:bold;"><br/></b><i style="font-style:italic;">CEO and President</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 463,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 52,841</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 340,819</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,612</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 860,902</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jennifer Stevens</b><b style="font-weight:bold;"><br/></b><i style="font-style:italic;">Chief Regulatory Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 398,670</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 190,405</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,920</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 652,027</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Steven Katz</b><b style="font-weight:bold;"><br/></b><i style="font-style:italic;">Chief Medical Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 468,197</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 85,720</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 342,461</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 936,078</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Salary amounts represent actual amounts earned during fiscal&#160;year 2022, whether or not paid in 2022. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">See </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;&#8212;Narrative Disclosure to Summary Compensation Table&#8201;&#8212;&#8201;Base Salaries</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This column reflects the aggregate grant date fair value of the option awards granted during fiscal&#160;year 2022 computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amounts are included in the notes to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">See &#8220;&#8212; Narrative Disclosure to Summary Compensation Table &#8212; Non-Equity Incentive Plan Compensation&#8221; below for a description of the material terms of the non-equity incentive plan for fiscal&#160;year 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This column reflects the aggregate value of other categories of payment, including (i)&#160;for Dr.&#160;Katz, $16,479 for 401(k)&#160;plan employer matching contributions and (ii)&#160;for Ms.&#160;Stevens, $13,486 for 401(k)&#160;plan employer matching contributions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Narrative Disclosure to Summary Compensation Table</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Base Salaries</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our named executive officers receive an annual base salary to compensate them for the services they provide to the Company. The annual base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, Ms.&#160;Szela, Ms.&#160;Stevens and Dr.&#160;Katz had annual base salaries of $466,875, $400,010 and $469,125, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, on August&#160;11, 2023, TriSalus approved annual base salaries of $412,000 and $515,000 for Ms.&#160;Stevens and Dr.&#160;Katz, respectively. On August&#160;14, 2023, TriSalus approved an annual base salary of $600,000 for Ms.&#160;Szela. These salary adjustments were approved in connection with the transition from operating a private corporation to a publicly-traded corporation. These salary adjustments were effective beginning as of August&#160;10, 2023, and were not retroactive to any period prior to such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Bonuses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus has at times provided, and may in the future provide, cash bonuses to certain members of its executive team on an ad hoc basis as deemed appropriate, in the form of spot bonuses or for achievement of certain milestones or as individually negotiated in a named executive officer&#8217;s employment agreement or offer letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Non-Equity Incentive Plan&#160;Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We develop a performance-based cash bonus program annually. Under the 2022 program, each named executive officers was eligible to be considered for an annual performance bonus based on (1)&#160;the individual&#8217;s target bonus, as a&#160;percentage of base salary pursuant to their respective employment agreements, which are described in &#8220;&#8212; <i style="font-style:italic;">Employment Arrangements with Executive Officers</i>&#8221; below and (2)&#160;the&#160;percentage attainment of 2022 corporate goals established by the Board in its sole discretion and communicated to each officer. Each named executive officer is assigned a maximum target performance bonus expressed as a&#160;percentage of their base salary, which for 2022 was 50% for each of Ms.&#160;Szela and Dr.&#160;Katz and 40% for Ms.&#160;Stevens. For the fiscal&#160;year ended December&#160;31, 2022, the Board determined that each of Ms.&#160;Szela and Dr.&#160;Katz was entitled to receive 150% of his or her target bonus and that Ms.&#160;Stevens was entitled to 120% of her target bonus. The bonuses are conditioned upon the consummation of the Business Combination and were paid on the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Board approved bonuses in an aggregate amount of approximately $2.8 million to TriSalus&#8217; executive officers and other employees, including bonuses of $340,819, $342,461 and $190,405 to Ms.&#160;Szela, Dr.&#160;Katz and Ms.&#160;Stevens, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, on August 11, 2023, TriSalus approved post-merger target bonuses of 40% and 50% for Ms. Stevens and Dr. Katz, respectively. On August 14, 2023, TriSalus approved a a post-merger target bonus of 55% for Ms. Szela. These target bonus adjustments were approved in connection with the transition from operating a private corporation to a publicly-traded corporation. The adjustments were effective beginning as of August 10, 2023, and were not retroactive to any period prior to such date.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Equity-Based Incentive Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our equity award program is the primary vehicle for offering long-term incentives to our executives. We believe that equity awards provide our executive officers with a strong link to long-term performance, create an ownership culture and help to align the interests of our executive officers with our stockholders. TriSalus has historically granted both incentive stock options and nonstatutory stock options to executive officers. We believe that equity awards are an important retention tool for our executive officers, as well as for our other employees. We grant equity awards broadly to our employees, including to our nonexecutive employees. The Board is responsible for approving equity grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently maintain the 2023 Plan, which our Board and stockholders approved in connection with the Business Combination for purposes of granting equity-based incentive awards to our employees and consultants, including our named executive officers. See &#8220;&#8212;<i style="font-style:italic;">2023 Equity Incentive Plan</i>&#8221; below for further information. Prior to the Business Combination, TriSalus granted equity incentive awards under the 2009 Amended and Restated Equity Incentive Plan (the &#8220;<b style="font-weight:bold;">2009 Plan</b>&#8221;). The 2009 Plan will not be used following the Business Combination. See &#8220;&#8212;<i style="font-style:italic;">2009 Equity Incentive Plan</i>&#8221; below for further information. Historically, we have used options as an incentive for long-term compensation to our executive officers because options allow our executive officers to realize value from this form of equity compensation only if the value of the underlying equity securities increase relative to the option&#8217;s exercise price, which exercise price is set at the fair market value of the underlying equity securities on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;20, 2022, Ms.&#160;Szela was granted an option to purchase 55,616 shares of TriSalus Common Stock at an exercise price of $2.43 per share, Mr.&#160;Katz was granted an option to purchase 90,222 shares of TriSalus Common Stock at an exercise price of $2.43 per share, and Ms.&#160;Stevens was granted an option to purchase 24,718 shares of TriSalus Common Stock at an exercise price of $2.43 per share. The options vest as described below in &#8220;&#8212;<i style="font-style:italic;">Outstanding Equity Awards as of December&#160;31, 2022</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;19, 2023, TriSalus approved grants of 279,351 options to new hires and current executives of the Company, including to Ms.&#160;Szela, Mr.&#160;Katz and Ms.&#160;Stevens in the amounts of 58,409,31,040, and 8,391, respectively, at an exercise price of $10.00 (the per share value of each share of our Common Stock as set forth in Merger Agreement). The options must satisfy both time-based and performance-based requirements in order to vest. The time-based requirement is satisfied as follows: one fourth (1/4th) of the total number of options will satisfy time-based requirement on the vesting start date, which is May&#160;19, 2023, for each of Ms.&#160;Szela, Mr.&#160;Katz and Ms.&#160;Stevens, and one forty-eighth (1/48th) of the total number of options will satisfy the time-based requirement each&#160;month thereafter over the following three&#160;years. The options satisfied the performance-based requirement upon TriSalus&#8217; consummation of the Business Combination prior to the termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;19, 2023, TriSalus approved awards of RSUs to certain of its employees in the aggregate amount of 184,031 including to Ms.&#160;Szela, Mr.&#160;Katz and Ms.&#160;Stevens in the amounts of 36,775, 16,644 and 4,127, respectively. The RSUs must satisfy both time-based and performance-based requirements in order to vest. The time-based requirement is satisfied as follows: one fourth (1/4th) of the total number of RSUs will satisfy time-based requirement on each anniversary of the vesting start date, which is October&#160;5, 2022, for each of Ms.&#160;Szela, Mr.&#160;Katz and Ms.&#160;Stevens. The RSUs satisfied the performance-based requirement upon TriSalus&#8217; consummation of the Business Combination prior to the termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, on August&#160;11, 2023, TriSalus approved awards of 288,000 options to current executives of the Company, including to Mr.&#160;Katz and Ms.&#160;Stevens in the amounts of 62,500 and 40,000, respectively, at an exercise price of $12.00. On August&#160;14, 2023, TriSalus approved an award of 172,500 options to Ms.&#160;Szela at an exercise price of $11.51. Each of these options have a vesting schedule as follows: one-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of August&#160;10, 2023, and 1/36th of the remaining shares shall vest each&#160;month thereafter on the same day of the&#160;month as August&#160;10, 2023, subject to the optionee&#8217;s Continuous Service (as defined in the 2023 Plan) through each such vesting date. TriSalus approved these option grants in connection with the transition from operating a private corporation to a publicly-traded corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Health and Welfare and Retirement Benefits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of TriSalus&#8217; named executive officers are eligible to participate in TriSalus&#8217; employee benefit plans, including medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of TriSalus&#8217; other full-time employees. TriSalus pays approximately 80% of the premiums for medical, dental, vision, group term life, disability and accidental death and dismemberment insurance for all of its employees, including its named executive officers. TriSalus generally does not provide perquisites or personal benefits to its named executive officers, except in limited circumstances.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">401(k)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus&#8217; named executive officers are eligible to participate in a defined contribution retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax-advantaged basis. Eligible employees may defer eligible compensation on a pre-tax or after-tax (Roth) basis, up to the statutorily prescribed annual limits on contributions under the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;). Contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k)&#160;plan is intended to be qualified under Section&#160;401(a)&#160;of the Code with the 401(k)&#160;plan&#8217;s related trust intended to be tax exempt under Section&#160;501(a)&#160;of the Code. As a tax-qualified retirement plan, contributions to the 401(k)&#160;plan (except for Roth contributions) and earnings on those contributions are not taxable to the employees until distributed from the 401(k)&#160;plan. In 2022, contributions made by participants, including the named executive officers, to the 401(k)&#160;plan were matched by TriSalus up to a specified&#160;percentage of the employees&#8217; contribution. These matching contributions are fully vested when made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Outstanding Equity Awards at December&#160;31, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents information regarding outstanding equity awards held by TriSalus&#8217; named executive officers as of December&#160;31, 2022. All awards were granted pursuant to the 2009 Plan. See the section titled &#8220;<i style="font-style:italic;">&#8212; Equity Incentive Plans&#8201;&#8212;&#8201;2009 Plan</i>&#8221; below for additional information.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:43.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option&#160;Awards</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mary Szela</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/30/18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 177,973</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/29/28</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10/06/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,302</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,930</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10/05/30</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/21/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 101,345</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/20/31</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11/03/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 58,577</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 157,709</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11/02/31</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/20/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55,616</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/19/32</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Steven Katz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">07/14/14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 593</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.62</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">07/13/24</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">05/17/16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 593</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">05/16/26</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/18/17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,471</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/17/27</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/18/18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,471</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/17/28</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/22/19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 154</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">01/21/29</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10/06/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,071</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 550,611</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10/05/30</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11/03/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,850</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,827</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11/02/31</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/20/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90,222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/19/32</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jennifer Stevens</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/21/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,856</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (8)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/20/31</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/20/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,718</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (9)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">04/19/32</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month following the vesting commencement date (October&#160;1, 2020) on the same day of the&#160;month as the vesting commencement date, subject to Ms.&#160;Szela&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">54,071 of the shares underlying this option were vested as of November&#160;3, 2022, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month on the same day of the&#160;month as the vesting commencement date (November&#160;3, 2021), subject to Ms.&#160;Szela&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One twelfth (1/12) of the shares subject to this option will vest each&#160;month following the first anniversary of the vesting commencement date (April&#160;20, 2022) on the same day of the&#160;month as the vesting commencement date, subject to Ms.&#160;Szela&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month following the vesting commencement date (January&#160;22, 2019) on the same day of the&#160;month as the vesting commencement date, subject to Dr, Katz&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28,920 of the shares underlying this option were vested as of September&#160;21, 2021, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month on the same day of the&#160;month as the vesting commencement date (September&#160;21, 2020), subject to Dr.&#160;Katz&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,169 of the shares underlying this option were vested as November&#160;3, 2022, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month on the same day of the&#160;month as the vesting commencement date (November&#160;3, 2021), subject to Dr.&#160;Katz&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One twelfth (1/12) of the shares subject to this option will vest each&#160;month following the first anniversary of the vesting commencement date (April&#160;20, 2022) on the same day of the&#160;month as the vesting commencement date, subject to Dr.&#160;Katz&#8217;s continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9,269 of the shares underlying this option were vested as March&#160;22, 2022, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month on the same day of the&#160;month as the vesting commencement date (March&#160;22, 2021), subject to Ms.&#160;Stevens&#8217; continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Twenty-five&#160;percent (25%) shares underlying this option will vest on the first anniversary of the vesting commencement date (April&#160;20, 2022) and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each&#160;month on the same day of the&#160;month as the vesting commencement date subject to Ms.&#160;Stevens&#8217; continuing to be a Service Provider (as defined in the 2009 Plan) through each such date, subject to continued service at each vesting date. Please see &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Employment Arrangements with Executive Officers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for more information regarding severance benefits applicable to this option grant.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Arrangements with Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of TriSalus&#8217; named executive officers is an at-will employee. TriSalus entered into amended and restated executive employment agreements with each of its named executive officers in November&#160;2022, which are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Mary Szela</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November&#160;2022, TriSalus entered into an amended and restated executive employment agreement with Ms.&#160;Szela. Pursuant to the amended and restated executive employment agreement, Ms.&#160;Szela&#8217;s annual base salary was $466,875 and she was eligible to receive an annual performance bonus of a target amount equal up to 50% of her base salary, based upon certain profitability or other financial objectives of the Company, business initiatives and other criteria to be determined by the Board, with such bonus subject to review and adjustment by the Board. Following the Business Combination, TriSalus approved an increase of Ms. Szela&#8217;s annual base </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">salary to $600,000 and a revised post-merger target bonus of 55% of her base salary. Ms.&#160;Szela is also eligible to participate in TriSalus&#8217; benefit plans generally available to similarly situated employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ms.&#160;Szela is entitled to certain severance benefits as described below in &#8220;&#8212;<i style="font-style:italic;">Potential Payments Upon Termination or Change in Control</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Jennifer Stevens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2022, TriSalus entered into an executive employment agreement with Ms.&#160;Stevens. Pursuant to the executive employment agreement, Ms.&#160;Stevens&#8217;s annual base salary was $400,010 and she was eligible to receive an annual performance bonus of a target amount equal to up to 55% of her base salary, based upon certain profitability or other financial objectives of the Company, business initiatives and other criteria to be determined by the Board, with such bonus subject to review and adjustment by the Board. Following the Business Combination, TriSalus approved an increase of Ms. Stevens&#8217; annual base salary to $412,000 and a revised post-merger target bonus of 40% of her base salary. Ms.&#160;Stevens is also eligible to participate in TriSalus&#8217; benefit plans generally available to similarly situated employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ms.&#160;Stevens is entitled to certain severance benefits as described below in &#8220;&#8212;<i style="font-style:italic;">Potential Payments Upon Termination or Change in Control</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Steven Katz</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2022, TriSalus entered into an amended and restated executive employment agreement with Dr.&#160;Katz. Pursuant to the amended and restated executive employment agreement, Dr.&#160;Katz&#8217;s annual base salary was $469,125 and he was eligible to receive an annual performance bonus of a target amount equal to up to 50% of his base salary, based upon certain profitability or other financial objectives of the Company, business initiatives and other criteria to be determined by the Board, with such bonus subject to review and adjustment by the Board. Following the Business Combination, TriSalus approved an increase of Dr. Katz&#8217;s annual base salary to $515,000 and his post-merger target bonus remained at 50% of his base salary. Dr.&#160;Katz is also eligible to participate in TriSalus&#8217; benefit plans generally available to similarly situated employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Katz&#8217;s executive employment agreement also provides that he is eligible for two cash payments of $500,000 each, which are payable upon achievement of certain corporate milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Katz is entitled to certain severance benefits as described below in &#8220;&#8212;<i style="font-style:italic;">Potential Payments Upon Termination or Change in Control</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential Payments Upon Termination or Change in Control</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Ms.&#160;Szela, Ms.&#160;Stevens and Dr.&#160;Katz are entitled to the following severance benefits under their employment agreements if their employment is terminated by TriSalus pursuant to a &#8220;Discharge Without Cause&#8221; (as such term is defined in each of their respective employment agreements), and provided such executive officer timely executes and does not revoke a release of claims in TriSalus&#8217; favor: (a)&#160;continuing payments of the executive&#8217;s then-current annual base salary for 12&#160;months for both Ms.&#160;Szela and Dr.&#160;Katz and six&#160;months for Ms.&#160;Stevens, (b)&#160;any accrued obligations, which include accrued but unpaid salary through the date of termination, unreimbursed expenses, and benefits owed to such executive officer under retirement or health plans in which such executive officer was a participant (&#8220;<b style="font-weight:bold;">Accrued Benefits</b>&#8221;), and (c)&#160;if Ms.&#160;Szela&#8217;s, Ms.&#160;Stevens&#8217;s or Dr.&#160;Katz&#8217;s &#8220;Discharge Without Cause&#8221; occurs in the fourth calendar quarter of a&#160;year and the Company achieves it financial objectives on which such executive&#8217;s bonus for that&#160;year is based, such executive would also be entitled to a pro-rata annual bonus for such&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Ms.&#160;Szela, Ms.&#160;Stevens or Dr.&#160;Katz experiences a &#8220;Resignation For Good Reason&#8221; (as such term is defined in each of their respective employment agreements), and provided such executive officer timely executes and does not revoke a release of claims in TriSalus&#8217; favor, the executive is entitled to: (a)&#160;continuing payments of the executive&#8217;s then-current annual base salary for 12&#160;months for both Ms.&#160;Szela and Dr.&#160;Katz and six&#160;months for Ms.&#160;Stevens, (b)&#160;the Accrued Benefits, and (c)&#160;if such termination is in the fourth calendar quarter of a&#160;year and the Company achieves it financial objectives on which such executive&#8217;s bonus for that&#160;year is based, such executive would also be entitled to a pro-rata annual bonus for such&#160;year.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, Dr.&#160;Katz is also entitled to receive an applicable Milestone Payment(s)&#160;if he experiences a &#8220;Discharge Without Cause&#8221; or a &#8220;Resignation For Good Reason&#8221; within 60&#160;days of the achievement of the applicable qualifying milestone or milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alternatively, if Ms.&#160;Szela, Ms.&#160;Stevens or Dr.&#160;Katz experiences a &#8220;Discharge Without Cause&#8221; or a &#8220;Resignation For Good Reason&#8221; within the one-year period following a &#8220;Change in Control&#8221; (as such term is defined in each of their respective employment agreements) and provided each executive officer timely executes and does not revoke a release of claims in TriSalus&#8217; favor, they will instead be entitled to a lump sum payment equal to: (a)&#160;12&#160;months of their annual base salary, (b)&#160;their annual bonus for the&#160;year of termination, assuming performance was met at the &#8220;target&#8221; level, and (c)&#160;the cost of one&#160;year of continued medical, dental and vision benefits. Additionally, if Ms.&#160;Szela&#8217;s, Ms.&#160;Stevens&#8217;s and Dr.&#160;Katz&#8217;s stock options and other non-performance based equity incentives remain unvested at the time of termination, they shall vest in full and become immediately exercisable when the release of claims is effective and becomes irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2023 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2023 our Board adopted and in August&#160;2023 our stockholders approved the 2023 Plan. The 2023 Plan became effective immediately upon the Closing. A summary description of the material features of the 2023 Plan is set forth below. This summary is not a complete description of all provisions of the 2023 Plan and is qualified in its entirety by reference to the 2023 Plan, the form of which is attached as an exhibit to the registration statement of which this prospectus forms a part and incorporated by reference in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility</i>. &#160;Any individual who is our employee or any of our affiliates, or any person who provides services to us or our affiliates, including members of our Board, is eligible to receive awards under the 2023 Plan at the discretion of the plan administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Awards</i>. &#160;The 2023 Plan provides for the grant of incentive stock options (&#8220;<b style="font-weight:bold;">ISOs</b>&#8221;), within the meaning of Section&#160;422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;<b style="font-weight:bold;">NSOs</b>&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares</i>. &#160;Initially, the maximum number of shares of Common Stock that may be issued under the 2023 Plan will not exceed a number of shares of Common Stock equal to the product of (i)&#160;12%, multiplied by (ii)&#160;the total number of shares of the Fully Diluted Common Stock determined as of immediately following the Closing (the &#8220;<b style="font-weight:bold;">Share Reserve</b>&#8221;). The TriSalus Options assumed as part of the Business Combination and converted into options to purchase shares of Common Stock are not counted in the Share Reserve. In addition, the Share Reserve will automatically increase on January&#160;1 of each&#160;year for a period of ten&#160;years, commencing on January&#160;1, 2024, and ending on January&#160;1, 2033, in an amount equal to (1)&#160;five&#160;percent (5%) of the total number of shares of the Fully Diluted Common Stock determined on December&#160;31 of the preceding&#160;year, or (2)&#160;a lesser number of shares of Common Stock determined by our Board prior to January&#160;1 of a given&#160;year. The maximum number of shares of Common Stock that may be issued on the exercise of ISOs under the 2023 Plan is equal to 300% of the initial Share Reserve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares subject to stock awards granted under the 2023 Plan that expire or terminate without being exercised or otherwise issued in full or that are paid out in cash rather than in shares do not reduce the Share Reserve. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax withholding obligation do not reduce the Share Reserve. If any shares of Common Stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us (1)&#160;because of the failure to meet a contingency or vest, (2)&#160;to satisfy the exercise, strike or purchase price of an award, or (3)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert back to the Share Reserve and will again become available for issuance under the 2023 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Employee Director Compensation Limit</i>. &#160;The aggregate value of all compensation granted or paid to any non-employee director with respect to any period commencing on the date of our Annual Meeting of Stockholders for a particular&#160;year and ending on the day immediately prior to the date of our Annual Meeting of Stockholders for the next subsequent&#160;year, including awards granted under the 2023 Plan and cash fees paid to such non-employee director, will not exceed (1)&#160;$750,000 in total value or (2)&#160;if such non-employee director is first appointed or elected to our Board during such annual period, $1,000,000 in total value, in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Plan&#160;Administration. </i>&#160;Our Board, or a duly authorized committee thereof, administers the 2023 Plan and is referred to as the &#8220;plan administrator&#8221; herein. Our Board may also delegate to one or more of our officers the authority to, among other things, (1)&#160;designate employees (other than officers) to receive specified stock awards and (2)&#160;determine the number of shares subject to such stock awards. Under the 2023 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value and exercise price, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award, subject to the limitations of the 2023 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2023 Plan, the Board also generally has the authority to effect, without the approval of stockholders but with the consent of any materially adversely affected participant, (1)&#160;the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right; (2)&#160;the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration; or (3)&#160;any other action that is treated as a repricing under generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Options</i>. &#160;ISOs and NSOs are granted under stock option agreements approved by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2023 Plan, provided that the exercise price of a stock option cannot be less than 100% of the fair market value of a share of Common Stock on the date of grant. Options granted under the 2023 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator determines the term of stock options granted under the 2023 Plan, up to a maximum of 10&#160;years. Unless the terms of a participant&#8217;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the participant may generally exercise any vested options for a period of three&#160;months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. Unless the terms of a participant&#8217;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary of the participant may generally exercise any vested options for a period of 18&#160;months following the date of death. Unless the terms of a participant&#8217;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested options for a period of 12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator will determine the manner of payment of the exercise of a stock option, which may include (1)&#160;cash, check, bank draft or money order, (2)&#160;a broker-assisted cashless exercise, (3)&#160;the tender of shares of Common Stock previously owned by the participant, (4)&#160;a net exercise of the option if it is an NSO or (5)&#160;other legal consideration approved by the plan administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tax Limitations on ISOs</i>. &#160;The aggregate fair market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar&#160;year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (1)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&#160;the term of the ISO does not exceed five&#160;years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Unit Awards</i>. &#160;Restricted stock unit awards are granted under restricted stock unit award agreements approved by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock&#160;units awards, including vesting and forfeiture terms, as well as the manner of settlement, which may be by cash, delivery of shares of Common Stock, a combination of cash and shares of Common Stock, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement or by the plan administrator, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Restricted Stock Awards</i>. &#160;Restricted stock awards are granted under restricted stock award agreements approved by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, services to us, or any other form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. The plan </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may reacquire any or all of the shares of Common Stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Appreciation Rights</i>. &#160;Stock appreciation rights are granted under stock appreciation right agreements approved by the plan administrator. The plan administrator determines the strike price for a stock appreciation right, which cannot be less than 100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the 2023 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. Stock appreciation rights may be settled in cash or shares of Common Stock or in any other form of payment, as determined by the plan administrator and specified in the stock appreciation right agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator determines the term of stock appreciation rights granted under the 2023 Plan, up to a maximum of 10&#160;years. Unless the terms of a participant&#8217;s stock appreciation rights agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three&#160;months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. Unless the terms of a participant&#8217;s stock appreciation rights agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12&#160;months in the event of disability and 18&#160;months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Performance Awards</i>. &#160;The 2023 Plan permits the plan administrator to grant performance awards, which may be settled in stock, cash or other property. Performance awards may be structured so that the stock, cash or a combination of stock and cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period as determined by the plan administrator. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Stock Awards</i>. &#160;The plan administrator may grant other awards based in whole or in part by reference to the Common Stock. The plan administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Changes to Capital Structure</i>. &#160;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1)&#160;the class and maximum number of shares reserved for issuance under the 2023 Plan, (2)&#160;the class of shares by which the share reserve may increase automatically each&#160;year, (3)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs (4)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards, and (5)&#160;the performance goals of any award if the change in the capital structure affects such goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate Transactions</i>. &#160;The following applies to stock awards under the 2023 Plan in the event of a Corporate Transaction (as defined in the 2023 Plan), unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the event of a Corporate Transaction, stock awards outstanding under the 2023 Plan may be assumed or continued, or substitute awards may be issued, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to our successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or issue substitute awards for such stock awards, then (i)&#160;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the Corporate Transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level unless otherwise provided in the award agreement) to a date prior to the effective time of the Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction), and such stock awards will terminate if not </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the Corporate Transaction), and (ii)&#160;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event a stock award will terminate if not exercised prior to the effective time of a Corporate Transaction, the plan administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&#160;the value of the property the holder would have received upon the exercise of the award (including, at the discretion of the plan administrator, any unvested portion of such award), over (ii)&#160;any per share exercise price payable by such holder, if applicable, provided that the plan administrator may also determine that the payment to be made to the holder with respect to such award shall be made in the same form, at the same time and subject to the same conditions as the payments to be made to our stockholders in connection with the Corporate Transaction to the extent permitted by Section&#160;409A of the Code. If the amount so determined for any award is $0, then such award shall be automatically cancelled at the effective time for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Control</i>. &#160;Awards granted under the 2023 Plan may be subject to acceleration of vesting and exercisability upon or after a change in control (as defined in the 2023 Plan) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transferability</i>. &#160;A participant may not transfer stock awards under the 2023 Plan other than by will, the laws of descent and distribution, or as otherwise provided under the 2023 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recoupment</i>. &#160;Awards granted under the 2023 Plan are subject to recoupment in accordance with any clawback policy adopted by our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Plan&#160;Amendment or Termination. </i>&#160;Our Board has the authority to amend, suspend, or terminate the 2023 Plan at any time, provided that such action does not materially impair (within the meaning of the 2023 Plan) the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date that the Board adopts the 2023 Plan. No stock awards may be granted under the 2023 Plan while it is suspended or after it is terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ESPP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2023 our Board adopted and in August&#160;2023 our stockholders approved the ESPP. The ESPP became effective immediately upon the Closing. A summary description of the material features of the ESPP is set forth below. This summary is not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP, the form of which is attached as an exhibit to the registration statement of which this prospectus forms a part and incorporated by reference in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the ESPP is to provide a means by which our eligible employees and certain designated companies may be given an opportunity to purchase shares of Common Stock, to assist us in retaining the services of eligible employees, to secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for our success. The ESPP includes two components: a 423 Component and a Non-423 Component. We intend that the share purchase rights under the 423 Component will qualify as options issued under an &#8220;employee stock purchase plan&#8221; as that term is defined in Section&#160;423(b)&#160;of the Code. The share purchase rights under the Non-423 Component will not qualify as options that are subject to Section&#160;423(b)&#160;of the Code. Except as otherwise provided in the ESPP or determined by the Board, the Non-423 Component will operate and be administered in the same manner as the 423&#160;Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Share Reserve</i>. &#160;The maximum number of shares of Common Stock that may be issued under the ESPP will not exceed the number of shares of Common Stock equal to three&#160;percent (3%) of the Fully Diluted Common Stock (as defined in the ESPP) determined as of immediately following the closing of the Business Combination. This number is referred to herein as the &#8220;Initial Share Reserve&#8221;, subject to adjustment for specified changes in our capitalization. Additionally, the number of shares of Common Stock reserved for issuance under the ESPP will automatically increase on January&#160;1 of each&#160;year for a period of up to ten&#160;years, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">beginning on January&#160;1, 2024, and continuing through and including January&#160;1, 2033, by an amount equal to the lesser of (x)&#160;two&#160;percent (2%) of the total number of shares of the Fully Diluted Common Stock determined on December&#160;31 of the preceding&#160;year, and (y)&#160;200% of the Initial Share Reserve. Notwithstanding the foregoing, the Board may act prior to January&#160;1</span><span style="font-size:7.5pt;">st</span><span style="font-size:10pt;"> of a given&#160;year to provide that the increase for such&#160;year will be a lesser number of shares. Shares issuable under the ESPP may be shares of authorized but unissued or reacquired Common Stock, including shares purchased by us on the open market. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Administration</i>. &#160;Our Board, or a duly authorized committee thereof, administers the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility</i>. &#160;Our employees and the employees of any of our designated affiliates, are eligible to participate in the ESPP, provided they may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by the administrator: (1)&#160;customary employment with us or one of our affiliates for more than 20 hours per week and more than five&#160;months per calendar&#160;year or (2)&#160;continuous employment with us or one of our affiliates for a minimum period of time, not to exceed two&#160;years, prior to the first date of an offering. In addition, the Board may also exclude from participation in the ESPP or any offering, employees who are &#8220;highly compensated employees&#8221; (within the meaning of Section&#160;423(b)(4)(D)&#160;of the Code) or a subset of such highly compensated employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An employee may not be granted rights to purchase stock under the 423 Component of the ESPP (a)&#160;if such employee immediately after the grant would own stock (including stock issuable upon exercise of all such employee&#8217;s purchase rights) possessing 5% or more of the total combined voting power or value of all classes of Common Stock or (b)&#160;to the extent that such rights would accrue at a rate that exceeds $25,000 worth of Common Stock for each calendar&#160;year that the rights remain outstanding. The Board may approve different eligibility rules&#160;for the Non-423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Offerings</i>. &#160;The 423 Component of the ESPP is intended to qualify as an employee stock purchase plan under Section&#160;423 of the Code. The administrator may specify offerings under the 423 Component with a duration of not more than 27&#160;months and may specify one or more shorter purchase periods within each offering. For the Non-423 Component, the administrator may specify offerings, and purchase periods within each offering, as determined by the administrator. Each offering will have one or more purchase dates on which shares of Common Stock will be purchased for the employees who are participating in the offering. The administrator, in its discretion, will determine the other terms of offerings under the ESPP. The administrator has the discretion to structure an offering so that if the fair market value of a share of Common Stock on any purchase date during the offering period is less than or equal to the fair market value of a share of Common Stock on the first day of the offering period, then that offering will terminate immediately, and the participants in such terminated offering will be automatically enrolled in a new offering that begins immediately after such purchase date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A participant may not transfer purchase rights under the ESPP other than by will, the laws of descent and distribution, or as otherwise provided under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Payroll Deductions</i>. &#160;The ESPP permits participants to purchase shares of Common Stock through payroll deductions, subject to such limitations as the administrator specifies. The administrator may limit a participant&#8217;s payroll deductions to a certain&#160;percentage or amount of pay, or by limiting the number of shares that may be purchased during the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Purchase Price</i>. &#160;Unless otherwise determined by the administrator, the purchase price of the shares will be 85% of the lesser of the fair market value of Common Stock on the first day of an offering or on the applicable date of purchase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Withdrawal</i>. &#160;Participants may withdraw from an offering by delivering a withdrawal form to us and terminating their contributions. Such withdrawal may be elected at any time prior to the end of an offering, except as otherwise provided by the administrator. Upon such withdrawal, we will distribute to the employee such employee&#8217;s accumulated but unused contributions without interest (unless otherwise required by law), and such employee&#8217;s right to participate in that offering will terminate. However, an employee&#8217;s withdrawal from an offering does not affect such employee&#8217;s eligibility to participate in any other offerings under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Termination of Employment</i>. &#160;A participant&#8217;s rights under any offering under the ESPP will terminate immediately if the participant either (i)&#160;is no longer employed by us or any of our parent or subsidiary companies (subject to any post-employment </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">participation period required by law) or (ii)&#160;is otherwise no longer eligible to participate. In such event, we will distribute to the participant such participant&#8217;s accumulated but unused contributions, without interest (unless otherwise required by law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate Transactions</i>. &#160;In the event of certain specified significant corporate transactions, such as a merger or change in control, a successor corporation may assume, continue, or substitute each outstanding purchase right. If the successor corporation does not assume, continue, or substitute for the outstanding purchase rights, the offering in progress will be shortened and a new purchase date will be set. The participants&#8217; purchase rights will be exercised on the new purchase date and such purchase rights will terminate immediately thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment and Termination</i>. &#160;The Board has the authority to amend, suspend, or terminate the ESPP, at any time and for any reason, provided certain types of amendments will require the approval of our stockholders. Any benefits, privileges, entitlements and obligations under any outstanding purchase rights granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&#160;with the consent of the person to whom such purchase rights were granted, (ii)&#160;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations, or (iii)&#160;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. The ESPP will remain in effect until terminated by our Board in accordance with the terms of the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2009 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2009 Plan was originally adopted by the TriSalus Board in July&#160;2009 and last approved by the stockholders of TriSalus on July&#160;19, 2022. Immediately prior to the Business Combination, the 2009 Plan was terminated, and no further grants may be made under the 2009 Plan. Any awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan and the applicable award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Awards</i>. &#160;The 2009 Plan provided for the grant of ISOs, NSOs, restricted stock, restricted stock&#160;units, and stock appreciation rights to TriSalus&#8217; employees, directors, and consultants who provided services to TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares</i>. &#160;Subject to certain capitalization adjustments, as of December 31, 2022, the aggregate number of Shares of Common Stock that may be issued pursuant to non-qualified stock awards under the 2009 Plan was 12,020,875 shares. The maximum number of shares of TriSalus Common Stock that could be issued pursuant to the exercise of ISOs under the 2009 Plan was 55,583,282 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Plan&#160;Administration</i>. &#160;A committee designated by the Board, or if no such committee is designated by the Board, the Board, referred to herein as the plan administrator, administers the 2009 Plan. The plan administrator has the authority to construe and interpret the terms of the 2009 Plan and awards granted under it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Options</i>. &#160;As of December&#160;31, 2022, options to purchase 67,604,157 shares of TriSalus Common Stock were outstanding under the 2009 Plan. ISOs and NSOs were granted under stock option agreements adopted by the administrator. The administrator determined the exercise price for stock options, within the terms and conditions of the 2009 Plan, provided that the exercise price of a stock option cannot be less than 100% of the fair market value of TriSalus Common Stock on the date of grant. Options granted under the 2009 Plan vested at the rate specified in the stock option agreement as determined by the administrator. The standard form of option award agreement under the 2009 Plan provided that options would vest 25% on the first anniversary of the vesting commencement date with the remainder vesting ratably over the next 36&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tax Limitations on ISOs. </i>&#160;The aggregate fair market value, determined at the time of grant, of TriSalus Common Stock with respect to ISOs that were exercisable for the first time by an option holder during any calendar&#160;year under all of TriSalus&#8217; stock plans could not exceed $100,000. Options or portions thereof that exceed such limit would generally be treated as NSOs. No ISO could be granted to any person who, at the time of the grant, owned or were deemed to own stock possessing more than 10% of TriSalus&#8217; total combined voting power or that of any of its affiliates unless (i)&#160;the option exercise price was at least 110% of the fair market value of the stock subject to the option on the date of grant and (ii)&#160;the term of the ISO did not exceed five&#160;years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Changes to Capital Structure</i>. &#160;In the event there was a specified type of change in TriSalus&#8217; capital structure, such as a recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, combination, repurchase, or exchange </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of shares, appropriate adjustments would be made to the number and class of shares that may be delivered under the 2009 Plan and/or number, class, and the exercise price of shares covered by each outstanding award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger or Change in Control</i>. &#160;The 2009 Plan provided that in the event of a merger or change in control awards would be treated as the administrator determines, and the administrator could take one or more of the following actions with respect to such awards:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">arrange for the assumption or substitution of an award by a surviving or acquiring corporation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate the awards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerate the vesting of the award and, to the extent the administrator determines, provide for termination if not exercised (if applicable) at or before the effective time of the merger or change in control; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate the award in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such award or realization of the participant&#8217;s rights as of the date of the occurrence of the transaction or the replacement of such award with other rights or property selected by the administrator in its sole discretion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The administrator would not be obligated to treat all awards or portions of awards in the same manner and would not be obligated to treat all participants in the same manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the successor corporation did not assume or substitute for the award, the participant would fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, including shares as to which such awards would not have otherwise been vested or exercisable, all restrictions on restricted stock and restricted stock&#160;units would lapse, and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met. In addition, if an option or stock appreciation right was not assumed or substituted in the event of a merger or change in control, the administrator would notify the participant in writing or electronically that the option or stock appreciation right would be exercisable for a period of time determined by the administrator in its sole discretion, and the option or stock appreciation right would terminate upon the expiration of such period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2009 Plan, a change in control means the occurrence of any of the following events: (i)&#160;a change in ownership of TriSalus, which occurs on the date that any one person, or more than one person acting as a group, acquires ownership of the stock of TriSalus that constitutes more than 50% of the total voting power of the stock of TriSalus, except that any changes in the ownership of the stock of TriSalus as a result of a private financing of TriSalus that is approved by the Board will not be considered a change in control, (ii)&#160;a change in the effective control of TriSalus, which occurs on the date the majority of the members of the Board is replaced during any twelve&#160;month period by directors whose appointment or election is not endorsed by a majority of members of the Board prior to the date of the appointment or election, or (iii)&#160;a change in the ownership of a substantial portion of TriSalus&#8217; assets, which occurs on the date that any person acquires (or has acquired during the twelve&#160;month period ending on the date of the most recent acquisition by such person) assets from TriSalus that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of TriSalus immediately prior to such acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Plan&#160;Amendment or Termination</i>. &#160;The Board had the authority to amend, alter, suspend, or terminate the 2009 Plan, provided that such action did not impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also required the approval of TriSalus stockholders. No stock awards could be granted under the 2009 Plan while it was suspended or after its termination and no further awards will be made under the 2009 Plan following the Closing of the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2022 Director Compensation Table</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information concerning the compensation of TriSalus&#8217; directors for fiscal&#160;year 2022. Ms.&#160;Szela, our Chief Executive Officer, did not receive additional compensation for her service as a director in fiscal&#160;year 2022, and therefore is not included in the Director Compensation table below. All compensation paid to Ms.&#160;Szela is reported above in the &#8220;<i style="font-style:italic;">Summary Compensation Table</i>.&#8221;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option&#160;Awards</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All&#160;Other&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Simone Song</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">John L. Tullis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gene McGrevin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Kerry Hicks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 42,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57,132</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Diane Parks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,137</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,137</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Anil Singhal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mats Wahlstr&#246;m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 78,056</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 228,056</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sean Murphy</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 47,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 122,067</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 207,462</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 377,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This column reflects the aggregate grant date fair value of the stock options granted to the directors during fiscal&#160;year 2022. The aggregate grant date fair value is computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our financial statements and related notes appearing at the end of this prospectus. In accordance with ASC Topic 718, recognition of compensation expense was deferred until the Closing of the Business Combination. This amount does not reflect the actual economic value that may be realized by the director.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of option awards granted to Mr.&#160;Murphy for his service as (i)&#160;a director, with an aggregate grant date fair value $10,172 and (ii)&#160;as the Chief Financial Officer of TriSalus, with an aggregate grant date fair value of $111,895.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amount shown reflects Mr.&#160;Murphy&#8217;s compensation for serving as the Chief Financial Officer of TriSalus since July&#160;2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus&#8217; policy is to reimburse directors for reasonable and necessary out-of-pocket expenses incurred in connection with attending Board and committee meetings or performing other services in their capacities as directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below shows shares underlying options that are vested and unvested for each director who was serving, and held outstanding equity awards, as of December&#160;31, 2022. Ms.&#160;Szela, our Chief Executive Officer, did not receive equity awards for her service as a director in fiscal&#160;year 2022, and therefore is not included in the table below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;Underlying&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;Underlying</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Vested)&#160;at&#160;Fiscal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unvested)&#160;at&#160;Fiscal&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;End</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;End</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Simone Song</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,874</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">John L. Tullis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,874</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gene McGrevin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,874</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Kerry Hicks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,148</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,075</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Diane Parks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,986</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Anil Singhal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,518</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,763</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mats Wahlstr&#246;m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,801</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 101,151</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sean Murphy</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,274</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 136,621</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 123,593 shares granted in an incentive stock option when Mr.&#160;Murphy accepted the role of Chief Financial Officer in July&#160;2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Historically, TriSalus did not have a formalized non-employee director compensation program; however, it granted certain of non-employee directors equity awards upon commencement of service and for fiscal&#160;years 2021 and 2022. It also compensated non-</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">employee directors in cash for their board service and service on committees. The stock options awarded to directors generally had a&#160;percentage that vested upon grant, with the remaining shares vesting over four&#160;years, subject to continued service, and accelerated vesting upon a change of control (as defined in the grant agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;19, 2022, TriSalus granted to each of Ms.&#160;Song, Mr.&#160;Tullis, Mr.&#160;McGrevin, Mr.&#160;Hicks, Mr.&#160;Singhal, and Mr.&#160;Murphy an option to purchase 12,359 shares of TriSalus Common Stock, and to Ms.&#160;Parks an option to purchase 9,887 shares of TriSalus Common Stock, each at an exercise price of $2.43 per share. One-forty eighth (1/48th) of the shares underlying their respective option vest each&#160;month following the vesting commencement date on the same day of the&#160;month as the vesting commencement date. On July&#160;13, 2022, TriSalus granted to Mr.&#160;Hicks an option to purchase 4,943 shares of TriSalus Common Stock, to Mr.&#160;Wahlstr&#246;m an option to purchase 86,514 shares of TriSalus Common Stock, and to Mr.&#160;Murphy an option to purchase 123,592 shares of TriSalus Common Stock, each at an exercise price of $2.43 per share. Twenty-five&#160;percent (25%) of the shares underlying their respective option vest one&#160;year following the vesting commencement date on the same day of the&#160;year, and one-thirty sixth (1/36th) of the remainder of the shares subject to this option vest each&#160;month following the vesting commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Closing Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, the Board approved a non-employee director compensation policy consisting of annual cash retainers of $50,000 for each non-employee director and an additional $30,000 for the chairperson of the Board; an additional $20,000 and $7,500 for the chairperson and each other member of the audit committee of the Board, respectively; an additional $15,000 and $7,500 for the chairperson and each other member of the compensation committee of the Board, respectively; an additional $15,000 and $7,500 for the chairperson and each other member of the nominating and corporate governance committee of the Board, respectively; and an additional $25,000 and $7,500 for the chairperson and each other member of the science and technology committee of the Board, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The policy also provides for an initial grant of a stock option for 35,000 shares on the date an eligible director is first elected or appointed to the Board and an annual stock option grant for 15,000 shares on the date of each annual stockholder meeting for each eligible director who continues to serve as a non-employee member of the Board as of such date. The directors also received a one-time stock option grant for 35,000 shares immediately following the Closing of the Business Combination, pursuant to the Non-Employee Director Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an emerging growth company, we are exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our chief executive officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and is entitled to take advantage of certain other &#8220;scaled&#8221; disclosure rules, such as only being required to report the compensation of three named executive officers rather than five.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_88b73d10_3049_49e0_80b0_b976ff0fa412"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than the compensation arrangements for TriSalus&#8217; directors and executive officers, which are described in the section titled &#8220;<i style="font-style:italic;">Executive Compensation</i>,&#8221; below is a description of transactions since January&#160;1, 2021 to which TriSalus was a party, in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed $120,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of TriSalus&#8217; directors, executive officers or holders of more than 5% of TriSalus&#8217; capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MTAC&#8217;s Transactions and Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Founder Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On September 11, 2020, the Sponsor purchased 5,750,000 shares of Class B common stock for an aggregate purchase price of $25,000 to cover certain offering and formation costs. In December 2020, we effected a stock dividend of 0.1 shares for each share of Class B common stock outstanding, resulting in 6,325,000 Founder Shares outstanding. As a result of the partial over-allotment exercised by the underwriters in the IPO, 75,000 shares of Class B common stock were forfeited, and no shares of Class B common stock remain subject to forfeiture, except as provided in the Sponsor Support Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be sold, pledged, or otherwise disposed until the earlier of (i) twelve months after the Closing Date or (ii) the date on which the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Closing Date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On June 26, 2023, the Sponsor elected to convert 6,249,999 shares of Class B common stock into 6,249,999 shares of Class A common stock, leaving the Sponsor with 1 remaining Founder Share as Class B common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On August 10, 2023, in connection with the Closing of the Business Combination, the Sponsor forfeited 2,187,500 of its Founder Shares pursuant to the terms of the Sponsor Support Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Private Placement Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the MTAC IPO, the Sponsor purchased an aggregate of 4,933,333 Private Placement Warrants at a price of $1.50 per whole warrant, for an aggregate purchase price of $7,400,000. Each Private Placement Warrant entitles the holder to purchase one share of Common Stock at $11.50 per share, subject to adjustment. The Private Placement Warrants are identical to the Public Warrants except that the Private Placement Warrants, so long as they are held by the Sponsor, the underwriters or their permitted transferees: (i)&#160;will not be redeemable by us; (ii)&#160;may not (including the Common Stock issuable upon exercise of the Private Placement Warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof until 30&#160;days after the Closing Date; (iii)&#160;may be exercised by the holders thereof on a cashless basis; and (iv)&#160;will be entitled to registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Promissory Notes&#8201;&#8212;&#8201;Related Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, we issued an unsecured promissory note to the Sponsor (as amended, the &#8220;<b style="font-weight:bold;">2021 Promissory Note</b>&#8221;), pursuant to which we could borrow up to an aggregate principal amount of $544,000. The 2021 Promissory Note was non-interest bearing. On December 2, 2022, the 2021 Promissory Note was amended to clarify that no amount shall be due under the note if a business combination is not consummated on or before the outside date to consummate a business combination pursuant to the Existing Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 28, 2022, we issued an unsecured promissory note to the Sponsor (as amended, the &#8220;<b style="font-weight:bold;">January 2022 Promissory Note</b>&#8221;) in principal amount of up to $400,000. The January 2022 Promissory Note was non-interest bearing. On December 2, 2022, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the January 2022 Promissory Note was amended to clarify that no amount shall be due under the note if a business combination is not consummated on or before the outside date to consummate a business combination pursuant to the Existing Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 24, 2022, we issued a promissory note in the principal amount of up to $1,500,000 to the Sponsor for working capital requirements and payment of certain expenses in connection with a potential business combination transaction (the &#8220;<b style="font-weight:bold;">Convertible Sponsor Note</b>&#8221;). The Convertible Sponsor Note was non-interest bearing and became payable on the date of the Closing of the Business Combination. At any time prior to payment in full of the principal balance of the Convertible Sponsor Note, the Sponsor was permitted to elect to convert all or any portion of the unpaid principal balance into that number of warrants, each exercisable for one share of Common Stock (the &#8220;<b style="font-weight:bold;">Conversion Warrants</b>&#8221;), equal to: (x) the portion of the principal amount of the Convertible Sponsor Note being converted, <i style="font-style:italic;">divided by </i>(y) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_qO_tJd7jHECOCsFdPPXStg" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_6D4waJPNBUmtZOPrxadgiA">1.50</ix:nonFraction>, rounded up to the nearest whole number of warrants. Each Conversion Warrant entitles the holder to purchase one share of Common Stock at $11.50 per share, subject to adjustment. The Conversion Warrants and their underlying securities are entitled to certain demand and piggyback registration rights as set forth in the Convertible Sponsor Note. On August 10, 2023, the Convertible Sponsor Note was converted into 1,000,000 Conversion Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, we issued an unsecured promissory note to the Sponsor (the &#8220;<b style="font-weight:bold;">December 2022 Promissory Note</b>&#8221;, together with the 2021 Promissory Note and the January 2022 Promissory Note, the &#8220;<b style="font-weight:bold;">Sponsor Promissory Notes</b>.&#8221;) in principal amount of up to $1,000,000. The December 2022 Promissory Note was non-interest bearing. At the Closing of the Business Combination, we repaid the Sponsor Promissory Notes out of the proceeds of the Trust Account released to us (subject to the MTAC Transaction Expenses Cap (as defined in the Merger Agreement)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Working Capital Loans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to fund working capital deficiencies or finance transaction costs in connection with negotiating and consummating an initial business combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors loaned to us additional funds as may be required (&#8220;<b style="font-weight:bold;">Working Capital Loans</b>&#8221;). At the Closing of the Business Combination, we repaid the Working Capital Loans out of the proceeds of the Trust Account released to us (subject to the MTAC Transaction Expenses Cap).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Promissory Notes&#8201;&#8212;&#8201;Related Party Extension Loans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the special meeting of MTAC stockholders held on December 12, 2022 (the &#8220;<b style="font-weight:bold;">First Extension Meeting</b>&#8221;), the stockholders approved an amendment to MTAC&#8217;s then-current charter (the &#8220;<b style="font-weight:bold;">First Extension Amendment</b>&#8221;), which extended the date by which MTAC was required to (i) consummate an initial business combination or (ii) dissolve and liquidate, from December 22, 2022 to June 22, 2023. In connection with the First Extension Amendment, the Sponsor agreed to, among other things, deposit, or cause the deposit of, $0.04 for each of the 1,953,422 public shares that were not redeemed in connection with the First Extension Meeting, for a monthly contribution into the Trust Account of $78,136.88 and an aggregate contribution of $468,821.28.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the special meeting of MTAC stockholders held on June 12, 2023 (the &#8220;<b style="font-weight:bold;">Second Extension Meeting</b>&#8221;), the stockholders approved an amendment to MTAC&#8217;s then-current charter (the &#8220;<b style="font-weight:bold;">Second Extension Amendment</b>&#8221;), which extended the date by which MTAC was required to (i) consummate an initial business combination or (ii) dissolve and liquidate, from June 22, 2023 to September 22, 2023. In connection with the Second Extension Amendment, the Sponsor agreed to, among other things, deposit, or cause the deposit of, $0.04 for each of the 1,144,794 public shares that were not redeemed in connection with the Second Extension Meeting, for a monthly contribution into the Trust Account of $45,791.76 and an aggregate contribution of $91,583.52.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, Legacy TriSalus agreed to pay for, as a transaction expense and not as a loan, 50% of the Sponsors contributions into the Trust Account until the earliest to occur of (i) the Closing and (ii) the valid termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When we completed the Business Combination, we repaid the Sponsor Notes (representing the Sponsor&#8217;s allocable 50% portion of the contributions into the Trust Account) out of the proceeds of the Trust Account released to us (subject, in the case of the Business Combination, to the MTAC Transaction Expenses Cap).</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sponsor Support Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the execution of the Merger Agreement, on November 11, 2022, we, the Sponsor, and Legacy TriSalus entered into the Sponsor Support Agreement (the &#8220;<b style="font-weight:bold;">Sponsor Support Agreement</b>&#8221;) pursuant to which the Sponsor agreed, among other things, to (i) vote or cause to be voted (or express consent or dissent in writing, as applicable) all its shares of Common Stock that were entitled to vote to approve and adopt the Merger Agreement and the Business Combination and (ii) to forfeit 2,187,500 of its shares of Common Stock (which represented 35% of the shares of Common Stock held by Sponsor as of November 11, 2022). The Sponsor Support Agreement also provides that 3,125,000 of the shares of Common Stock held by Sponsor immediately after the Closing are subject to vesting and potential forfeiture if certain share price-based triggering events are not achieved prior to August 10, 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lock-up Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the execution of the Merger Agreement, certain Legacy TriSalus stockholders entered into lockup agreements with us, pursuant to which such stockholders agreed, subject to certain customary exceptions, to not transfer any shares of Common Stock held by them prior to the earliest of (x) the date that is 365 days after the Closing Date, (y) the date following the Closing Date on which the last sales price of Common Stock equals or exceeds $12.00 per share, subject to adjustment as provided therein, for any 20 trading days within any 30-consecutive-day trading period commencing at least 150 days after the Closing Date, and (z) the date following the Closing Date on which the Company consummates a liquidation, merger, tender offer, or similar transaction resulting in all of its stockholders having the right to exchange their shares of Common Stock for cash, securities, or other property. The Sponsor is subject to a lockup on substantially similar terms pursuant to the terms of a letter agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Subscription Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;7, 2023 and July&#160;4, 2023, MTAC and the Preferred Stock PIPE Investors entered into the Subscription Agreements pursuant to, and on the terms and subject to the conditions of which, the Preferred Stock PIPE Investors have collectively subscribed for and agreed to purchase in private placements an aggregate of 4,015,002 shares of Series&#160;A Convertible Preferred Stock at a purchase price of $10.00 per share, resulting in an aggregate purchase price of $40,150,020. Leonard Capital LLC (&#8220;<b style="font-weight:bold;">Leonard Capital</b>&#8221;), an affiliate of Mr.&#160;Wahlstr&#246;m, the chairman of the Board, subscribed to purchase 50,000 shares of Series&#160;A Convertible Preferred Stock in the Preferred Stock PIPE Investment. In addition, Frankenius Equity AB (&#8220;<b style="font-weight:bold;">Frankenius</b>&#8221;), a 10% or greater holder of our current company, subscribed to purchase 230,000 shares of Series&#160;A Convertible Preferred Stock in the Preferred Stock PIPE Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Backstop Letter Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 7, 2023, Sponsor and we entered into the Backstop Letter Agreement, pursuant to which the Sponsor agreed that, to the extent that the Sponsor&#8217;s members, or their respective affiliates, related parties or designees, did not collectively subscribed to purchase an aggregate of $2 million worth of Series A Convertible Preferred Stock (excluding for such purposes, the subscriptions to purchase $3 million of Series A Convertible Preferred Stock by certain members of the Sponsor pursuant to those Initial Subscription Agreements executed on June 7, 2023 and described above) (any such shortfall, the &#8220;<b style="font-weight:bold;">Sponsor Commitment Amount</b>&#8221;), the Sponsor shall execute and deliver to us a Subscription Agreement providing for a subscription by the Sponsor in an amount equal to the Sponsor Commitment Amount to purchase shares of Series A Convertible Preferred Stock on the same terms and conditions as the other Preferred Stock PIPE Investors who have executed Subscription Agreements as of such date. On July 4, 2023, we and the Sponsor formalized the termination of the Backstop Letter Agreement in a letter agreement to confirm that the Backstop Letter Agreement terminated in accordance with its terms as an additional $2 million of Series A Convertible Preferred Stock were collectively subscribed for by Sponsor&#8217;s members and their respective affiliates, related parties and designees pursuant to the Additional Subscription Agreements executed on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Placement Agent Services from Ceros</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We engaged Ceros, an SEC registered broker/dealer and FINRA member firm, to act as our placement agent for the noninstitutional equity financing component of the Future PIPE Investment that resulted in our entry into the Subscription Agreements as part of the Preferred Stock PIPE Investment. Christopher Dewey, our former Chief Executive Officer and director, as well as a Managing Member of the Sponsor, is a Managing Director of Ceros. In consideration for its services as placement agent, Ceros received a fee from the Sponsor equal to 10% of the gross proceeds received by us in the Preferred Stock PIPE Investment (excluding </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">amounts raised from stockholders or members of the Company, the Sponsor, Legacy TriSalus, or their affiliates and certain designees) plus expense reimbursement. As part of the engagement, the Sponsor paid the entirety of such placement agent fees and Ceros has agreed that we shall not be responsible or liable for any portion of such payment. Ceros&#8217; placement agent fees were contingent upon the completion of the Preferred Stock PIPE Investment, which closed in connection with the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legacy TriSalus&#8217; Transactions and Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Note&#160;Financings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In multiple closings during March, May&#160;and June&#160;2020, Legacy TriSalus sold $10 million in aggregate principal amount of its convertible promissory notes, increasing the aggregate principal amount of convertible notes to be issued and sold in the offering to $30 million from $20 million approved previously in 2018 and 2019. Purchasers of the notes included: Frankenius, in the aggregate principal amount of $2.5 million; Gene McGrevin, a principal stockholder of Legacy and current TriSalus and a former member of the Legacy TriSalus board of directors, in the aggregate principal amount of $1.5 million; Leonard Capital in the amount of $0.3 million; HW Investment Partners, LLC, a principal stockholder of Legacy TriSalus and an affiliate of (i)&#160;Mr.&#160;Wahlstr&#246;m and (ii)&#160;Kerry Hicks, a member of the Legacy TriSalus and our current board of directors, in the aggregate principal amount of $1.4 million (&#8220;<b style="font-weight:bold;">HW Investment</b>&#8221;); KMG TriSalus Investments LLC, an affiliate of Mr.&#160;Wahlstr&#246;m, in the aggregate amount of $2.0 million; and Mr.&#160;Hicks, in the amount of $1.1 million. The convertible securities accrued interest at an annual rate of 8.0%. In March&#160;2021, the principal amount of the convertible securities, including accrued interest, was exchanged for shares of Legacy TriSalus series B preferred stock at a purchase price of $0.30 per share in connection with the financings described below under &#8220;&#8212; <i style="font-style:italic;">Series&#160;B Preferred Stock Financing</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In multiple closing during July&#160;and August&#160;2020, pursuant to note subscription agreements, Legacy TriSalus issued and sold to certain investors convertible promissory notes having an aggregate principal amount of up to $15 million and warrants (collectively, the &#8220;<b style="font-weight:bold;">Summer 2020 Notes</b>&#8221;). Purchasers of the notes included: Frankenius, in the aggregate principal amount of $2.0 million; Messrs.&#160;McGrevin and Hicks in the aggregate principal amount of $1.0 million and $2.4 million, respectively; Mary Szela, Legacy TriSalus&#8217; and our current Chief Executive Officer and President, in the aggregate principal amount of $0.4 million; Leonard Capital in the aggregate principal amount of $2.2 million; and Lord Alpha Investments Limited (&#8220;<b style="font-weight:bold;">Ori Capital</b>&#8221;), a principal stockholder of Legacy TriSalus affiliated with Simone Song, a member of the Legacy TriSalus board of directors, in the aggregate principal amount of $5.0 million. The convertible securities accrued interest at an annual rate of 8.0%. In March&#160;2021, the principal amount of the convertible securities, including accrued interest, was exchanged for shares of Legacy TriSalus series B preferred stock at a purchase price of $0.30 per share in connection with the financings described below under &#8220;&#8212; <i style="font-style:italic;">Series&#160;B Preferred Stock Financing</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;and December&#160;2020, Legacy TriSalus amended the Summer 2020 Notes&#160;to increase the aggregate principal amount of convertible securities to up to $16 million. In multiple closings, Legacy TriSalus sold convertible promissory notes and warrants to certain purchasers, including: Bryan Cox, one of Legacy TriSalus&#8217; and our current executive officers, in the aggregate principal amount of $35,000; Ms.&#160;Szela in the aggregate principal amount of $146,000; and HW Investment in the aggregate principal amount of $0.5 million. The convertible securities accrued interest at an annual rate of 8.0%. In March&#160;2021, the principal amount of the convertible securities, including accrued interest, was exchanged for shares of Legacy TriSalus series B preferred stock at a purchase price of $0.30 per share in connection with the financings described below under &#8220;&#8212; <i style="font-style:italic;">Series&#160;B Preferred Stock Financing</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B Preferred Stock Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2021, with subsequent closings through July&#160;2021, Legacy TriSalus entered into a Stock Purchase Agreement, as amended, with a group of investors (the &#8220;<b style="font-weight:bold;">Series&#160;B SPA</b>&#8221;) pursuant to which it issued and sold an aggregate of 2,648,349 shares of its series B preferred stock (the &#8220;<b style="font-weight:bold;">Series&#160;B Stock</b>&#8221;) to such investors at a purchase price of $12.14 per share, for aggregate gross proceeds of approximately $32.1 million (the &#8220;<b style="font-weight:bold;">Series&#160;B Financing</b>&#8221;). In connection with the Series&#160;B Financing, the aggregate value of principal and interest of all then outstanding notes were converted into shares of Series&#160;B Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B SPA, Legacy TriSalus issued and sold to Frankenius an aggregate of 700,358 shares of Series&#160;B Stock, resulting in aggregate gross proceeds of approximately $8.5 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the Series&#160;B SPA, Legacy TriSalus issued and sold shares to various entities associated with Mr.&#160;Wahlstr&#246;m, including 123,592 shares of Series&#160;B Stock to Leonard Capital and an aggregate of 416,097 shares of Series&#160;B Stock to HW </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Investment, a principal stockholder of Legacy TriSalus and an affiliate of (i)&#160;Mr.&#160;Wahlstr&#246;m and (ii)&#160;Mr.&#160;Hicks, resulting in aggregate gross proceeds of approximately $6.6 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B SPA, Legacy TriSalus issued and sold shares to various entities associated with Mr.&#160;McGrevin, including 82,395 shares of Series&#160;B Stock to the Eugene R McGrevin Roth Contributory IRA, resulting in aggregate gross proceeds of approximately $1.0 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B SPA, Legacy TriSalus issued and sold to Steven Katz, one of its executive officers, 4,119 shares of Series&#160;B Stock, resulting in aggregate gross proceeds of approximately $50,000 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B SPA, Legacy TriSalus issued and sold shares to various entities associated with Mr.&#160;Hicks, including an aggregate of 416,097 shares of Series&#160;B Stock to HW Investment, resulting in aggregate gross proceeds of approximately $5.1 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B-1 Preferred Stock Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, with subsequent closings through July&#160;2022, Legacy TriSalus entered into a Stock Purchase Agreement, as amended, with a group of investors (the &#8220;<b style="font-weight:bold;">Series&#160;B-1 SPA</b>&#8221;) pursuant to which it issued and sold an aggregate of 1,659,672 shares of its series B-1 preferred stock (&#8220;<b style="font-weight:bold;">Series&#160;B-1 Stock</b>&#8221;) to such investors at a purchase price of $14.16 per share, for aggregate gross proceeds of approximately $23.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-1 SPA, Legacy TriSalus issued and sold to Frankenius 1,059,365 shares of Series&#160;B-1 Stock, resulting in aggregate gross proceeds of approximately $15.0 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B-2/B-3 Preferred Stock Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, Legacy TriSalus entered into a Preferred Stock and Warrant Purchase Agreement (the &#8220;<b style="font-weight:bold;">Series&#160;B-2/B-3 Purchase Agreement</b>&#8221;) pursuant to which it issued and sold an aggregate of 706,243 shares of its series B-2 preferred shares (&#8220;<b style="font-weight:bold;">Series&#160;B-2 Stock</b>&#8221;) to investors at a purchase price of $14.16 per share, for aggregate gross proceeds of approximately $10 million. For each such share of Series&#160;B-2 Stock sold under the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus also issued a warrant to purchase four shares of its series B-3 preferred stock (&#8220;<b style="font-weight:bold;">Series&#160;B-3 Stock</b>&#8221;) for no additional consideration (for an aggregate of 2,824,974 warrants issued in connection with the initial issuance of Series&#160;B-2 Stock). The strike price of the warrants issued in the financing was $2.02 per share. The Series&#160;B-2/B-3 Purchase Agreement included, at the option of Legacy TriSalus, a second tranche for the sale of up to 518,854 shares of Series&#160;B-2 Stock for approximately $7.3 million (which could be increased up to an aggregate of 706,243 shares of Series&#160;B-2 Stock for approximately $10.0 million), with each such share of Series&#160;B-2 Stock accompanied by a warrant to purchase four shares of Series&#160;B-3 Stock at a strike price of $2.02 per share (warrants to purchase up to an aggregate of 2,824,974 shares of Series&#160;B-3 Stock may be issued in second tranche closings assuming the full $10.0 million is sold); and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to 306,053 shares of Series&#160;B-2 Stock for approximately $4.3 million (which could be increased up to an aggregate of 353,121 shares of Series&#160;B-2 Stock for approximately $5.0 million), with each such share of Series&#160;B-2 Stock accompanied by a warrant to purchase eight shares of Series&#160;B-3 Stock at a strike price of $2.02 per share (warrants to purchase up to an aggregate of 2,824,974 shares of Series&#160;B-3 Stock may be issued in the third tranche closing assuming the full $5.0 million is sold).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, Legacy TriSalus effectuated two closings of the second tranche under the Series&#160;B-2/B-3 Purchase Agreement whereby (i)&#160;207,541 shares of Series&#160;B-2 Stock and accompanying warrants to purchase 830,167 shares of Series&#160;B-3 Stock, representing 40% of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $2.9 million, and (ii)&#160;17,656 shares of Series&#160;B-2 Stock and accompanying warrants to purchase 70,624 shares of Series&#160;B-3 Stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of $0.2 million. The series B-2/B-3 preferred stock financing was deemed to be non-compensatory to the participating directors and officers because (i)&#160;the issuance was not associated to services, (ii)&#160;the participating directors and officers participated on the same terms as all parties, and (iii)&#160;the participating parties who were non-insiders (i.e., non-service providers) represented greater than 50% of the participation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In June&#160;2023, Legacy TriSalus effectuated two closings of the second tranche under the Series&#160;B-2/B-3 Purchase Agreement whereby (i)&#160;257,779 shares of Series&#160;B-2 Stock and accompanying warrants to purchase 1,031,116 shares of Series&#160;B-3 Stock, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">representing approximately 49.7% of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $3.7 million, and (ii)&#160;165,967 shares of Series&#160;B-2 Stock and accompanying warrants to purchase 663,868 shares of Series&#160;B-3 Stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of approximately $2.3 million. The Series&#160;B-2/B-3 preferred stock financing was deemed to be non-compensatory to the participating directors and officers because (i)&#160;the issuance was not associated to services, (ii)&#160;the participating directors and officers participated on the same terms as all parties, and (iii)&#160;the participating parties who were non- insiders (i.e., non-service providers) represented greater than 50% of the participation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Frankenius an aggregate of 655,909 shares of Series&#160;B-2 Stock and warrants purchase 2,623,637 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of $9.3 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold shares to various entities associated with Mr.&#160;Wahlstr&#246;m, one of its directors, including (i)&#160;104,742 shares of Series&#160;B-2 Stock and warrants to purchase 418,970 shares of Series&#160;B-3 Stock to Leonard Capital and (ii)&#160;109,470 shares of Series&#160;B-2 Stock and warrants to purchase 437,882 shares of Series&#160;B-3 Stock to HW Investment, resulting in aggregate gross proceeds of approximately $3.1 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold shares to various entities associated with Mr.&#160;Hicks, including (i)&#160;71,902 shares of Series&#160;B-2 Stock and warrants to purchase 287,608 shares of Series&#160;B-3 Stock to Mr.&#160;Hicks in his individual capacity and (ii)&#160;109,470 shares of Series&#160;B-2 Stock and warrants to purchase 437,882 shares of Series&#160;B-3 Stock to HW Investment, resulting in aggregate gross proceeds of approximately $2.6 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to various entities associated with Sean Murphy, one of its executive officers, including (i)&#160;87,397 shares of Series&#160;B-2 Stock and warrants to purchase 349,590 shares of Series&#160;B-3 Stock to the Murphy Family Trust 2012 and (ii)&#160;17,656 shares of Series&#160;B-2 Stock and warrants to purchase 70,624 shares of Series&#160;B-3 Stock to the Sean E Murphy TTEE U/A 2/4/2004, resulting in aggregate gross proceeds of approximately $1.5 million to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Ms.&#160;Szela, one of its executive officers, 32,116 shares of Series&#160;B-2 Stock and warrants to purchase 128,466 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of approximately $454,754 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Mr.&#160;McGrevin 33,490 shares of Series&#160;B-2 Stock and warrants to purchase 133,961 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of approximately $474,205 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Dr.&#160;Katz, one of its executive officers, 2,411 shares of Series&#160;B-2 Stock and warrants to purchase 9,645 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of $34,143 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Dr.&#160;Cox, one of its executive officers, 1,674 shares of Series&#160;B-2 Stock and warrants to purchase 6,698 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of $23,710 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Series&#160;B-2/B-3 Purchase Agreement, Legacy TriSalus issued and sold to Richard Marshak, one of its executive officers, 1,674 shares of Series&#160;B-2 Stock and warrants to purchase 6,698 shares of Series&#160;B-3 Stock, resulting in aggregate gross proceeds of $23,710 to Legacy TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2023, holders of warrants to purchase 2,306,471 shares of Series B-3 Stock exercised their warrants, resulting in gross proceeds of approximately $4.5 million. The list below sets forth the number of shares of Series B-3 Stock purchased by related parties pursuant to the exercise of warrants to purchase Series B-3 Stock.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Leonard Capital, associated with Mr. Wahlstr&#246;m, purchased 249,471 shares of Series B-3 Stock for $504,625.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sean E Murphy TTEE U/A 2/4/2004, associated with Mr. Murphy, purchased 134,186 shares of Series B-3 Stock for $271,428.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HW Investment, associated with Mr. Wahlstr&#246;m and Mr. Hicks, purchased 122,680 shares of series B-3 Stock for $248,155.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr. McGrevin purchased 63,337 shares of Series B-3 Stock for $128,118.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Cox purchased 3,166 shares of Series B-3 Stock for $6,406.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr. Marshak purchased 3,166 shares of Series B-3 Stock for $6,406.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TriSalus Stockholder Support Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the execution of the Merger Agreement, MTAC, Legacy TriSalus and certain stockholders of Legacy TriSalus, constituting each of Legacy TriSalus&#8217; officers, directors (and their affiliates), and the holders of 5% or more of Legacy TriSalus&#8217; capital stock, who collectively hold approximately 70% of Legacy TriSalus&#8217; shares of capital stock outstanding as of the date of the Merger Agreement, entered into the Stockholder Support Agreements, pursuant to which, among other things and subject to the terms and conditions therein, such Legacy TriSalus stockholders agreed to, among other things, (a)&#160;vote or provide their written consent for the approval and adoption of the Merger Agreement and the Business Combination, subject to certain customary exceptions, (b)&#160;not to transfer any of their shares of Legacy TriSalus capital stock (or enter into any arrangement with respect thereto) prior to the Closing, subject to certain customary exceptions, and (c)&#160;waive any dissenters&#8217; or approval rights under applicable law in connection with the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consulting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2019, Legacy TriSalus entered into a consulting agreement with SCKMD Consulting,&#160;Inc. (the &#8220;<b style="font-weight:bold;">Katz Consulting Agreement</b>&#8221;) pursuant to which Dr.&#160;Katz, as President of SCKMD Consulting,&#160;Inc., was compensated for his consulting services as chair of the company&#8217;s Scientific Advisory Board. The Katz Consulting Agreement was terminated in November&#160;2020 and is superseded by our employment agreement with Dr.&#160;Katz described in the section titled &#8220;<i style="font-style:italic;">Executive Compensation&#8201;</i><i style="font-style:italic;letter-spacing:0.2pt;">&#8212;</i><i style="font-style:italic;">&#8201;Employment Arrangements with Executive Officers</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation Arrangements and Stock Option Grants for Executive Officers and Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Legacy TriSalus had employment arrangements with its named executive officers that, among other things, provide for certain change in control benefits, as well as severance benefits. For a description of these agreements, see &#8220;<i style="font-style:italic;">Executive Compensation</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Legacy TriSalus had granted stock options to its executive officers and certain of its directors. For a description of these equity awards, see &#8220;<i style="font-style:italic;">Executive Compensation&#8201;&#8212;&#8201;Employment Arrangements with Executive Officers</i>&#8221; and &#8220;<i style="font-style:italic;">Executive Compensation &#8201;&#8212;&#8201;Outstanding Equity Awards as of December&#160;31, 2022</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amended and Restated Registration Rights Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the Closing Date, in connection with the consummation of the Business Combination and as contemplated by the Merger Agreement, TriSalus, Sponsor, the members of the Sponsor, and the directors and officers and certain former stockholders of Legacy TriSalus entered into an amended and restated registration rights agreement (the &#8220;<b style="font-weight:bold;">Amended and Restated Registration Rights Agreement</b>&#8221;). Pursuant to the Amended and Restated Registration Rights Agreement, the Company agreed to file, not later than 45&#160;days after the Closing Date, a registration statement to register for resale, pursuant to Rule&#160;415 under the Securities Act, certain TriSalus securities that are held by the parties thereto (the &#8220;<b style="font-weight:bold;">Registrable Securities</b>&#8221;). Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registration and will indemnify the parties thereto against certain liabilities related to such registration. The Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto, on the date that such party no longer holds any Registrable Securities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into indemnification agreements with our executive officers and directors. The indemnification agreements require us to indemnify our executive officers and directors to the fullest extent permitted by Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also entered into an indemnification agreement with Dr.&#160;Katz with respect to legal fees, judgments and awards in relation to third party claims arising out of the prior consulting services on behalf of our company pursuant to the Katz Consulting Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Related Person Transaction Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board has adopted a written related person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related person transactions.&#8221; For purposes of this policy only, a &#8220;related person transaction&#8221; will be considered a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds $120,000, in which any &#8220;related person&#8221; has a material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions involving compensation for services provided to our company as an employee, consultant or director will not be considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including our Common Stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the policy, the related person in question or, in the case of transactions with an entity holding more than 5% of any class of our voting securities, an officer with knowledge of a proposed transaction, must present information regarding the proposed related person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our Board) for review. To identify related person transactions in advance, we will rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related person transactions, our audit committee will take into account the relevant available facts and circumstances, which may include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risks, costs, and benefits to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms of the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of other sources for comparable services or products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms available to or from, as the case may be, unrelated third parties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit committee will approve only those transactions that it determines are fair and in our best interests. All of the transactions described above were entered into prior to the adoption of such policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_083fa0cb_a768_4ca5_9a87_cbe550fd00e5"></a><a id="PRINCIPALSECURITYHOLDERS_381529"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PRINCIPAL SECURITYHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding the beneficial ownership of shares of Common Stock as of August&#160;10, 2023, after giving effect to the Closing, by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person known by the Company to be the beneficial owner of more than 5% of Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of the Company&#8217;s named executive officers and directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of the Company&#8217;s executive officers and directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with SEC rules, which generally provides that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power with respect to the security. Under SEC rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through exercise of stock options or warrants, within 60&#160;days and are deemed to be outstanding and beneficially owned by the persons holding those options or warrants for the purpose of computing the number of shares beneficially owned and the&#160;percentage ownership of that person. They are not, however, deemed to be outstanding and beneficially owned for the purpose of computing the&#160;percentage ownership of any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The beneficial ownership percentages set forth in the table below are based on 26,316,681 shares of Common Stock issued and outstanding as of the Closing Date and other than as noted below, do not take into account the issuance of any shares of Common Stock upon the exercise of 8,281,779 Public Warrants, each exercisable for one share of Common Stock at a price of $11.50 per share to purchase an aggregate of 8,281,779 shares of Common Stock, the 5,933,333 Private Placement Warrants and Conversion Warrants (referred to in the footnotes below as the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">private warrants</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;), each exercisable for one share of Common Stock at a price of $11.50 per share to purchase an aggregate of 5,933,333 shares of Common Stock or the unexercised stock options and unvested RSUs held by the individuals, except as noted below. Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned Common Stock.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beneficially&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Directors and Named Executive Officers</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mary Szela<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">652,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sean Murphy<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">580,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Steven Katz, MD, FACS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">132,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jennifer Stevens<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,958</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mats Wahlstr&#246;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,744,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Andrew von Eschenbach</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">George Kelly Martin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">247,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">David J. Matlin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,272,421</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Arjun &#8220;JJ&#8221; Desai<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 449,794</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Anil Singhal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,278</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Kerry Hicks<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,310,022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">All executive officers and directors as a group (14 individuals)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,405,646</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Five Percent Holders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Frankenius Equity AB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,397,776</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unique Diamond Investments Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,546,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Christopher Dewey<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,522,789</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Michael Stansky<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,449,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gene R. McGrevin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(14)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,403,130</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">HW Investment Partners, LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(15)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,370,028</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lombard International<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(16)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,358,013</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than 1%</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unless otherwise noted, the business address of each of the following entities or individuals is c/o TriSalus Life Sciences, Inc., 6272 W. 91st Avenue, Westminster, Colorado 80031.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 243,189 shares held directly by Ms. Szela and (ii) 409,450 shares of Common Stock issuable pursuant to options or restricted stock units that are exercisable within 60 days.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 357,535 shares held by Murphy Family Trust 2012, (ii) 167,732 shares held by Sean E Murphy TTEE U/A 2/4/2004 (&#8220;<b style="font-weight:bold;">Sean Murphy Trust</b>&#8221;) and (iii) 55,038 shares of Common Stock issuable pursuant to options or restricted stock units that are exercisable within 60 days. Lisa Murphy, Mr. Murphy&#8217;s spouse, has voting and investment discretion with respect to the shares held directly by Murphy Family Trust 2012 and thus Mr. Murphy may be deemed to have beneficial ownership of the shares held directly by Murphy Family Trust 2012. Mr. Murphy is the trustee of the Sean Murphy Trust and thus Mr. Murphy may be deemed to have beneficial ownership of the shares held directly by the Sean Murphy Trust.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 17,799 shares held directly by Mr. Katz and (ii) 114,587 shares of Common Stock issuable pursuant to options that are exercisable within 60 days.</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 13,904 shares held directly by Ms. Stevens and (ii) 19,054 shares of Common Stock issuable pursuant to options or restricted stock units that are exercisable within 60 days.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 1,254,259 shares held by Leonard Capital LLC, (ii) 50,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Leonard Capital LLC as a Preferred Stock PIPE Investor, (iii) 1,370,028 shares held by HW Investment and (iv) 70,255 shares of Common Stock issuable pursuant to options that are exercisable within 60 days. Mr. Wahlstr&#246;m has sole voting and investment discretion with respect to the shares held directly by Leonard Capital LLC and shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(7)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of 247,185 shares of Common Stock held by Varka LLC. Mr. Martin may be deemed to have beneficial ownership of the shares held directly by the Varka LLC.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(8)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 931,903 shares held directly by Mr. Matlin of which 215,055 shares are vested and 716,848 shares are subject to vesting and forfeiture pursuant to the Sponsor Support Agreement, (ii) 1,240,518 shares underlying private warrants, which are exercisable for shares of Common Stock commencing 30 days after the closing of the Business Combination and (iii) 100,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Matlin as a Preferred Stock PIPE Investor.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(9)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 203,127 shares held directly by Dr. Desai of which 46,875 shares are vested and 156,252 shares are subject to vesting and forfeiture pursuant to the Sponsor Support Agreement and (ii) 246,667 shares underlying private warrants, which are exercisable for shares of Common Stock commencing 30 days after the Closing of the Business Combination.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(10)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 514,589 shares held directly by Mr. Hicks, (ii) 1,370,028 shares held by HW Investment, (iii) 81,845 shares held by the Millennium Trust Company, LLC, as custodian FBO Kerry Hicks IRAT, (iv) 322,737 shares held by The Kerry Raymond Hicks Dynasty Trust, for which Mr. Hicks serves as trustee and (v) 20,823 shares of Common Stock issuable pursuant to options that are exercisable within 60 days. Mr. Hicks has shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(11)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 6,167,776 shares held by Frankenius Equity AB (&#8220;<b style="font-weight:bold;">Frankenius Equity</b>&#8221;) and (ii) 230,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Frankenius Equity as a Preferred Stock PIPE Investor. Frankenius Equity&#8217;s principal place of business is Box 984, 501 10 Boras, Sweden. Paul Frankenius has sole voting and investment discretion with respect to the shares held directly by Frankenius Equity and may be deemed to have beneficial ownership of the shares held by Frankenius Equity.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(12)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 573,690 shares held directly by the Christopher C Dewey Trust DTD 5/3/18, (ii) 881,599 shares underlying private warrants, which are exercisable for shares of Common Stock commencing 30 days after the Closing of the Business Combination held by the Christopher C Dewey Trust DTD 5/3/18 and (iii) 67,500 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by the Christopher C Dewey Trust DTD 5/3/18. Mr. Dewey is the trustee of the Christopher C Dewey Trust DTD 5/3/18 and thus Mr. Dewey may be deemed to have beneficial ownership of the shares held directly by the Christopher C Dewey Trust DTD 5/3/18.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(13)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 521,539 shares held directly by Mr. Stansky, (ii) 827,590 shares underlying private warrants, which are exercisable for shares of Common Stock commencing 30 days after the closing of the Business Combination, (iii) 75,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Stansky as a Preferred Stock PIPE Investor and (iv) 25,000 shares of Series A Convertible Preferred Stock held by Skyview Investments LLC (&#8220;<b style="font-weight:bold;">Skyview</b>&#8221;) as a Preferred Stock PIPE Investor. Mr. Stansky is the managing member of Skyview, has voting and investment discretion with respect to the shares held directly by Skyview and, as result, may be deemed to have beneficial ownership of the shares held by each of them.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(14)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 1,287,481 shares of Common Stock held directly by Mr. McGrevin, (ii) 102,993 shares of Common Stock held directly by Mr. McGrevin through his IRA and (iii) 12,656 shares of Common Stock issuable pursuant to options that are exercisable within 60 days.</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(15)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of 1,370,028 shares held by HW Investment. Messrs. Wahlstr&#246;m and Hicks have shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(16)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i) 41,197 shares held directly by Lombard International Assurance S.A. &#8212; P47082 and 33,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. &#8212; P47082 as a Preferred Stock PIPE Investor, (ii) 360,478 shares held directly by Lombard International Assurance S.A. &#8212; P47083 and 365,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. &#8212; P47083 as a Preferred Stock PIPE Investor, (iii) 113,293 shares held directly by Lombard International Assurance S.A. &#8212; P47084 and 110,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. &#8212; P47084 as a Preferred Stock PIPE Investor, (iv) 237,389 shares held directly by Lombard International Assurance S.A. &#8212; P47472, (v) 28,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. &#8212; P47473 as a Preferred Stock PIPE Investor, (vi) 52,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. &#8212; P69562 as a Preferred Stock PIPE Investor and (vii) 17,656 shares held directly by Lombard International Assurance S.A., policy number 2304-150035<span style="font-size:8pt;">.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9df0de66_ddb8_46be_8812_56cb3577fdf1"></a><a id="SELLINGSECURITYHOLDERS_482651"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">SELLING SECURITYHOLDERS</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">This prospectus relates to the resale by the Selling Securityholders from time to time of up to 36,772,040 shares of Common Stock (including (i) up to 25,237,094 PIPE Shares, (ii) up to 4,062,500 Founder Shares originally issued in a private placement to the Sponsor prior to MTAC&#8217;s initial public offering, including 3,125,000 Founder Shares subject to vesting and forfeiture, (iii) up to 1,452,965 shares of Common Stock issuable upon exercise of the Assumed Options, (iv) up to 86,148 shares of Common Stock issuable upon the Assumed RSUs, (v) up to 4,933,333 shares of Common Stock that may be issued upon exercise of the Private Placement Warrants and (vi) up to 1,000,000 shares of Common Stock issuable upon the exercise of the Conversion Warrants) and up to 5,933,333 warrants (including (i) up to 4,933,333 Private Placement Warrants and (ii) up to 1,000,000 Conversion Warrants). The Selling Securityholders may from time to time offer and sell any or all of the Common Stock, Private Placement Warrants and Conversion Warrants (referred to in the footnotes below as the &#8220;private warrants&#8221;) set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Selling Securityholders</b><span style="font-family:'Times New Roman','Times','serif';">&#8221; includes the persons listed in the table below, together with any additional Selling Securityholders listed in a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the Selling Securityholders&#8217; interests in the Common Stock, Private Placement Warrants or Conversion Warrants other than through a public sale.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of the Selling Securityholders listed below entered into a lock-up agreement with us with respect to certain of the shares of Common Stock that may be sold by it, from time to time, pursuant to the registration statement of which this prospectus forms part. Such restrictions began at the Closing of the Business Combination and end on the earliest to occur of (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their Common Stock for cash, securities or other property. See the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions&#8201;-&#8201;Lock-up Agreements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as set forth in the footnotes below, the following table sets forth, based on written representations from the Selling Securityholders, certain information as of August 10, 2023, regarding the beneficial ownership of our Common Stock and Warrants by the Selling Securityholders and the shares of Common Stock and Warrants being offered by the Selling Securityholders. The applicable percentage ownership of Common Stock is based on approximately 26,316,681 shares of Common Stock outstanding as of August 10, 2023. Information with respect to shares of Common Stock, Private Placement Warrants or Conversion Warrants owned beneficially after the offering assumes the sale of all of the shares of Common Stock, Private Placement Warrants or Conversion Warrants. The Selling Securityholders may offer and sell some, all or none of their shares of Common Stock, Private Placement Warrants or Conversion Warrants, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined beneficial ownership in accordance with the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security or the right to acquire such power within 60 days. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the Selling Securityholders have sole voting and investment power with respect to all shares of Common Stock and Warrants that they beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the Selling Securityholders, no Selling Securityholders is a broker-dealer or an affiliate of a broker dealer.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Relating to shares of Series A Convertible Preferred Stock held by the Selling Securityholders, the floor prices applicable to the conversion of Series A Convertible Preferred Stock into PIPE Shares are not in effect as of the date of this prospectus. As of 60 days from August 10, 2023, a holder of a share of Series A Convertible Preferred Stock is entitled to receive, upon conversion of such shares of Series A Convertible Preferred Stock, a number of shares of Common Stock equal to the quotient of $10.00 plus accrued dividends to date on such share of Series A Convertible Preferred Stock divided by the initial conversion price of $10.00.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Relating to shares of Series A Convertible Preferred Stock held by the Selling Securityholders, the number of corresponding shares of Common Stock registered for resale to each Selling Securityholder is the maximum number of shares of Common Stock such shares are convertible into following the floor price reset on the 47th month anniversary of August 10, 2023. See section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of Our Securities&#8201;-&#8201;Series A Convertible Preferred Stock&#8201;-&#8201;Anti-dilution Provisions</i><span style="font-family:'Times New Roman','Times','serif';">.&#8221;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Please see the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Plan of Distribution</i><span style="font-family:'Times New Roman','Times','serif';">&#8221; for further information regarding the Selling Securityholders&#8217; method of distributing these shares.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;to&#160;Purchase&#160;Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Selling Securityholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">PIPE Investors</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">2010 Eisenberg Legacy Trust III</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">3700 Bigelow Boulevard LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Aegis Special Situations Fund LLC&#8201;&#8211;&#8201;Series Medtech XII</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">340,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,137,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Albert Vu</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Alden Thomas Leith</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Allen Schacher Living Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Andres R. Lamas</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Andrew John Shoorlemmer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Angelo Paparella</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">188,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Armando Codina</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,194,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Barbara R. Soldwedel</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Barry D. Chandler and Diane E. Chandler</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Barry Donner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">188,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Benjamin Dagley</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">47,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">BG Holding Group Ltd.</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Bradley Hanus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Bradley T and Tara Johnson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Charles Du Pont</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Charles Hill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Charles K. Eby Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by Christopher Dewey</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,522,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,879,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">881,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">881,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by Christina Dewey</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">32,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">204,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Clayton A. Struve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Daniel &amp; Annette Pietro</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Daniel M. Carney Living Trust U/A 6/22/06</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">110,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">David E. Hall Living Trust U/A 6/18/09</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">David J. Matlin</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,272,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,800,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,240,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,240,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">David M. Sweeney</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Shares held by Dennis L. Ross and Ann Marie Ross</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(14)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">22,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">138,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Donald W. Pearson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Edward H. Bradbury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">44,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Edwin John Gerik, Jr.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Elizabeth Nicole Hanley Pickett 2002 Descendants Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(15)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">157,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Eric O. Tyler and Fran T. Tyler</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">47,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ernest Riling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Erwin L. Gonzalez</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Federico A. Morano, Jr.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Five Talents LP</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(16)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">188,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Frankenius Equity AB</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(17)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,397,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,445,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,167,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares held by Frederic H. Moll</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(18)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,111,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">835,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">540,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">540,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Gary D. Wilson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Gerald A. Tomsic 1995 Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(19)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Shares held by Gerald T. Aaron and Janis L. Aaron</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(20)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">62,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;to&#160;Purchase&#160;Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Selling Securityholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Greg R. Boxberger</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Gregory P. Hayden</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Hanta Yo LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(21)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">157,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Harvey Greenspan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Herbert D. Iverson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Huestis Revocable Living Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(22)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">James Edwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">James Field</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">James Regan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">James Tomlin</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jason H. Gould</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jerald A. Koering Trust Dtd. 12/29/2022</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(23)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jody Bardash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Joel Pruzansky</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John A. &amp; Wendy Cotter</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John A. Barlow</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John C. Geraci</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">78,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John Duffy</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John Foster</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John H. &amp; Jyl E. Pomeroy</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John J. Todd</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">188,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John M. Guynn</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John Olsen</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John S. Mendicino</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">John V. &amp; Michelle Kay Family Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(24)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jonathan E. Martinez</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jonathan Singer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">94,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jose Alberto Ferre</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jose Luis Ferre</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jose Remigio Lamas Bejos Revocable Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(25)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">628,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Joseph Trobunella</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Justin Pieper</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">KC Venture Holdings LLC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,885,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Kenneth Ray</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Kent Mitchell</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Kerry W. Phelan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">94,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Kevin Kearney</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Kyle Bratton</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Larry Kellner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Lee Merrill Hanley Curtis 2002 Descendants Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(26)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">157,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lee Michael Bank Revocable Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(27)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lies Holdings LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(28)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Shares held by Lombard International Assurance S.A.</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(29)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,358,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,695,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">770,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lucina Green</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares held by Manuel E. Aguero</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(30)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">150,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">414,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mark Bunselmeyer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;to&#160;Purchase&#160;Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Selling Securityholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mark D. Kellam</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mark Sullivan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mats L. Wahlstrom</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(31)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,744,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">450,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,624,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Michael &amp; Marilyn Bernstein</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Michael A. Parimucha</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Michael L. &amp; Melanie B. Tyler</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Michael P. Driscoll</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Michael Stansky</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(32)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,449,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,977,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">827,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">827,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mike J. &amp; Evelyn Schaublin</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">MTAC Investment LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(33)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,257,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Okema Corporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Pamela Goldman</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Paul Montaneralla</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Portofino Ventures LP</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(34)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Randall B. Hall</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard Brafford</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard Bush</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard C. Eden</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">125,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard J. Hall Trust U/A 11/23/2010</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(35)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard J. Kavanagh III Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(36)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard McLean</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert B. &amp; Barbara U. Tomes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert J. Bargar &amp; Elinor Nelson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert J. Reutter</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert Kipperman</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert Korn</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">78,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert Perry</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ronald Dagley</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ronald E. &amp; Debbie M. Bratton</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ronald H. White</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ronald L. Asher</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">103,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Sands Point LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(37)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,142,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Scott R. Brown</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Steven Paul &amp; Martina Rodi</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Steven Wietsma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Susan Ann Swanson</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Tamberlaine Harris</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">The Alice H. Hanley Revocable Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(38)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">314,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Thomas D. Siciliano Jr.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Thomas Duffy</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Thomas J. Rutherford</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Thomas Kennedy</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">T J Brown Living Trust</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(39)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Tosh D. &amp; Ashley M. Grebenik</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Garner W. Mcnett</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Wilfred L. Alcorn</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">William C. Loveless</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;to&#160;Purchase&#160;Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prior&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">After</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Selling Securityholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b><sup style="font-size:5.25pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b><sup style="font-size:5.25pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Hereby</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Offering</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">William Scott Miller</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(40)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">203,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">188,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">173,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Holders of Registration Rights Pursuant to the Registration Rights Agreement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Anil Singhal</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(41)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Antonia F. Ferre</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(42)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Arjun Desai</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(43)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">449,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">449,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">246,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">246,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Bryan Cox</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(44)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">72,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Camila M. Ferre</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(45)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Chateau Caroline LLC</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(46)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">David L. Treadwell</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Diane Parks</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(47)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Isabella M. Ferre</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(48)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Ivan Delevic</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(49)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">362,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">362,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">258,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">258,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jennifer Stevens</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(50)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">60,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Karim Karti</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(51)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">318,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">318,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">162,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">162,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lisa Matlin</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(52)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">530,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">530,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">270,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Manmeet Singh Ahluwalia</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Martin W. Roche</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(53)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">309,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">309,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">231,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">231,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Mary T. Szela</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(54)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">652,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">663,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">243,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Maurice E. Ferre</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(55)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Maurice R. Ferre</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(56)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,040,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,040,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">529,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">529,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Richard Marshak</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(57)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Robert H. Weiss</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(58)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">403,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">403,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">266,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">266,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Roman Bensen</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by Kerry Hicks</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(59)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,310,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,289,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by Sean Murphy</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(60)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">580,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">188,825</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">525,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by Simone Song</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(61)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,567,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,546,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Steven Katz</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(62)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">132,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">294,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shares owned by John Tullis</b><sup style="font-size:6pt;font-weight:bold;letter-spacing:-0.1pt;line-height:100%;top:0pt;vertical-align:top;">(63)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">851,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">830,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="display:inline-block;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Less than one percent.</p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As 60 days from August 10, 2023, the floor prices applicable to the conversion of Series A Convertible Preferred Stock into shares of Common Stock and each share of Series A Convertible Preferred Stock is entitled to receive, upon conversion of such share of Series A Convertible Preferred Stock, a number of shares of Common Stock equal to the quotient of $10.00 plus accrued dividends to date on such share of Series A Convertible Preferred Stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The number of shares of Common Stock registered for resale hereby assumes that each selling securityholder&#8217;s Series A Convertible Preferred Stock is convertible into the maximum number of shares of Common Stock following the floor price reset on the 47th month anniversary of August 10, 2023. See section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Description of Our Securities&#8201;&#8212;&#8201;Series A Convertible Preferred Stock&#8201;&#8212;&#8201;Anti-dilution Provisions</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#8221;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Glenn M. Eisenberg, as Trustee of 2010 Eisenberg Legacy Trust III, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thomas Kopff, as Managing Member of 3700 Bigelow Boulevard LLC, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cosme Ordonez, as Manager of the Manager of Aegis Special Situations Fund LLC&#8201;&#8212;&#8201;Series Medtech XII, has voting and/or dispositive power over the holdings of such entity. Managers of the Manager of Aegis Special Situations Fund LLC&#8201;&#8212;&#8201;Series Medtech XII, Aegis Special Situations Management LLC, are affiliates of Aegis Capital Corp, which is a registered broker dealer with the SEC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allen Shacher, as Trustee of the Allen Schacher Living Trust, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rodolfo Batres has voting and/or dispositive power over the shares held by BG Holding Group Ltd.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Charles K. Eby and Jean C. Eby, each as Trustee of Charles K. Eby Trust, each have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 573,690 shares held by the Christopher C Dewey Trust DTD 5/3/18, (ii) 881,599 private warrants held by the Christopher C Dewey Trust DTD 5/3/18, (iii) 881,599 shares of Common Stock underlying such private warrants and (iv) 424,285 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by the Christopher C Dewey Trust DTD 5/3/18 (with 67,000 shares convertible within 60 days). Mr. Dewey is the trustee of the Christopher C Dewey Trust DTD 5/3/18 and thus Mr. Dewey may be deemed to have beneficial ownership of the shares held directly by the Christopher C Dewey Trust DTD 5/3/18.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 56,571 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Christopher C. Dewey Family Trust Dated 9/7/07 (with 9,000 shares convertible within 60 days) and (ii) 147,714 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Dewey Family Properties LLC (with 23,500 shares convertible within 60 days). Christina Dewey has voting and/or dispositive power over the holdings of Christopher C. Dewey Family Trust Dated 9/7/07 and Dewey Family Properties LLC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Daniel M. Carney, as Trustee of the Daniel M. Carney Living Trust U/A 6/22/06, has voting and/or dispositive power over the shares held by such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">David E. Hall and Diane A. Hall, each as Trustee of David E. Hall Living Trust U/A 6/18/09, each have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 931,903 shares held directly by Mr. Matlin, (ii) 1,240,518 private warrants, (iii) 1,240,518 shares of Common Stock underlying such private warrants and (iv) 628,571 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Matlin (with 100,000 shares convertible within 60 days). Mr. Matlin is a member of our board of directors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(14)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 37,714 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Ross Real Estate Co., LC (with 6,000 shares convertible within 60 days) and (ii) 100,571 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Dennis Ross Living Trust (with 16,000 shares convertible within 60 days). Dennis L. Ross and Ann Marie Ross are each a Member of Ross Real Estate Co., LC and have voting and/or dispositive power over the holdings of such entity. Dennis L. Ross and Ann Marie Ross are each a Trustee of Dennis Ross Living Trust and have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(15)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Elizabeth Nicole Hanley Pickett has voting and/or dispositive power over the shares held by the Elizabeth Nicole Hanley Pickett 2002 Descendants Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(16)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">James Traweek has voting and/or dispositive power over the shares held by Five Talents LP.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(17)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent 1,445,714 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Frankenius (with 230,000 shares convertible within 60 days). In addition, 6,167,776 shares of Common Stock held by Frankenius are not registered for resale by this prospectus. Frankenius&#8217; principal place of business is Box 984, 501 10 Boras, Sweden. Paul Frankenius has sole voting and investment discretion with respect to the shares held directly by Frankenius and may be deemed to have beneficial ownership of the shares held by Frankenius</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(18)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 521,539 shares of Common Stock held directly by MLB Growth Fund LLC, (ii) 314,285 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by The Frederic H. Moll Revocable Trust (with 50,000 shares convertible within 60 days), (iii) 540,090 private warrants held directly by Mr. Moll and (iv) 540,090 shares of Common Stock underlying such private warrants. Frederic H. Moll has voting and/or dispositive power over the holdings of MLB Growth Fund LLC and The Frederic H. Moll Revocable Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(19)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gerald A Tomsic has voting and/or dispositive power over the holdings of Gerald A. Tomsic 1995 Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(20)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gerald T. Aaron and Janis L. Aaron, as trustees of Gerald T. Aaron Living Trust U/A 8/1/07, each have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(21)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kristin Johnson has voting and/or dispositive power over the holdings of Hanta Yo LLC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(22)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Richard J. Huestis, as Trustee of the Huestis Revocable Living Trust, has voting and/or dispositive power over the shares held by such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(23)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jerald Koering, as Trustee of the Jerald A. Koering Trust Dtd. 12/29/2022, has voting and/or dispositive power over the shares held by such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(24)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">John V. Kay and Michelle F. Kay are each a Trustee of John V. &amp; Michelle Kay Family Trust and have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(25)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jose Antonio Lamas, Alejandra Lamas Berliner and Maria Guadalupe Lamas are each a Trustee of Jose Remigio Lamas Bejos Revocable Trust and each have voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(26)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lee Merrill Hanley Curtis has voting and/or dispositive power over the holdings of Lee Merrill Hanley Curtis 2002 Descendants Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(27)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lee M. Bank, as Trustee of the Lee Michael Bank Revocable Trust, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(28)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Michael Lies, as Manager of Lies Holdings LLC, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(29)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 207,428 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47082 (with 33,000 shares convertible within 60 days), (ii) 2,294,285 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47083 (with 365,000 shares convertible within 60 days), (iii) 691,428 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47084 (with 110,000 shares convertible within 60 days), (iv) 176,000 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47473 (with 28,000 shares convertible within 60 days) and (v) 326,857 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P69562 (with 52,000 shares convertible within 60 days). In addition, the following shares beneficially owned by Lombard International Assurance S.A. are not registered for resale by this prospectus: (i) 41,197 shares of Common Stock held directly by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47082, (ii) 360,478 shares of Common Stock held directly by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P4708, (iii) 113,293 shares of Common Stock held directly by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47084, (iv) 17,656 shares of Common Stock held directly by Lombard International Assurance S.A., policy number 2304-150035 and (v) 237,389 shares of Common Stock held directly by Lombard International Assurance S.A.&#8201;&#8212;&#8201;P47472.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(30)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 314,285 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Aguero Ventures, LLLP (with 50,000 shares convertible within 60 days), (ii) 100,000 private warrants held directly by Manuel E. Aguero and (iii) 100,000 shares of Common Stock underlying such private warrants. Manuel E. Aguero has voting and/or dispositive power over the holdings of Aguero Ventures, LLLP.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(31)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 314,285 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Leonard Capital LLC (with 50,000 shares convertible within 60 days) and (ii) 135,945 shares of Common Stock issuable upon exercise of Assumed Options (70,255 of which are exercisable within 60 days). In addition, 1,254,259 shares of Common Stock held by Leonard Capital LLC and 1,370,028 shares of Common Stock held by HW Investment Partners, LLC (&#8220;HW Investment&#8221;) are not registered for resale by this prospectus. Mr. Wahlstr&#246;m has sole voting and investment discretion with respect to the shares held directly by Leonard Capital LLC and shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(32)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 521,539 shares of Common Stock held directly by Mr. Stansky, (ii) 827,590 private warrants held directly by Mr. Stansky, (iii) 827,590 shares of Common Stock underlying such private warrants, (iii) 471,428 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Stansky (with 75,000 shares convertible within 60 days) and (iv) 157,142 shares of Series A Convertible Preferred Stock held by Skyview Investments LLC (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Skyview</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (with 25,000 shares convertible within 60 days). Mr. Stansky is the managing member of Skyview, has voting and investment discretion with respect to the shares held directly by Skyview and, as result, may be deemed to have beneficial ownership of the shares held by each of them.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(33)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 1,257,142 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by MTAC Investment LLC, a Delaware limited liability company (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">MTAC Investment</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (with 200,000 shares convertible within 60 days). MTAC Manager LLC (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">MTAC Manager</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is the managing member of MTAC Investment, has the power to vote and dispose of the shares held by MTAC Investment and, as a result, may be deemed to beneficially own the securities owned by MTAC Investment. MTAC Manager disclaims any beneficial ownership of the securities held by MTAC Investment, other than to the extent of any pecuniary interest it may have therein, directly or indirectly. Michael Viola has voting and/or dispositive power over the holdings of MTAC Investment LLC. MTAC Investment LLC is affiliated with Virtu Americas LLC, which is a registered broker dealer with the Commission.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(34)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Michael Knudsen, as President of Portofino Management, Inc., the General Partner of Portofino Ventures LP, has voting and/or dispositive power over the holdings of Portofino Ventures LP.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(35)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Richard Hall, as Trustee of the Richard J. Hall Trust U/A 11/23/2010, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(36)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Richard J. Kavanagh III, as Trustee of the Richard J. Kavanagh III Trust, has voting and/or dispositive power over the holdings of Richard J. Kavanagh III Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(37)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kenneth G. Langone, as Manager, Sole Member and President of Sands Point LLC, has voting and/or dispositive power over the holdings of such entity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(38)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alice H. Hanley has voting and/or dispositive power over the holdings of The Alice H. Hanley Revocable Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(39)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Toliver J. Brown Jr has voting and/or dispositive power over the holdings of T J Brown Living Trust.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(40)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent 188,571 shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by William Scott Miller (with 30,000 shares convertible within 60 days). In addition, the following shares beneficially owned by Mr. Miller are not registered for resale by this prospectus: (i) 101,747 shares of Common Stock held directly and (ii) 71,394 shares of Common Stock held by Mr. Miller through his IRA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(41)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 19,278 shares of Common Stock issuable upon exercise of Assumed Options (19,278 of which are exercisable within 60 days).</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(42)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 13,037 shares of Common Stock held directly by Ms. Antonia Ferre, (ii) 13,502 private warrants held directly by Ms. Ferre and (iii) 13,502 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(43)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 203,127 shares of Common Stock held directly by Dr. Desai, (ii) 246,667 private warrants held directly by Dr. Desai and (iii) 246,667 shares of Common Stock underlying such private warrants. Dr. Desai is a member of our board of directors.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(44)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 14,454 shares of Common Stock issuable upon exercise of Assumed Options (3,536 of which are exercisable within 60 days) and (ii) 4,127 shares of Common Stock issuable upon settlement of Assumed RSUs (1,031 of which can settle within 60 days). Mr. Cox also holds 67,817 shares of Common Stock not registered for resale by this prospectus. Dr. Cox is our Chief Scientific and Manufacturing Officer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(45)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 23,468 shares of Common Stock held directly by Ms. Camila Ferre, (ii) 24,304 private warrants held directly by Ms. Ferre and (iii) 24,304 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(46)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thierry Thaure has voting and/or dispositive power over the holdings of Chateau Caroline LLC.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(47)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 18,536 shares of Common Stock issuable upon exercise of Assumed Options (18,536 of which are exercisable within 60 days) and (ii) 1,235 shares of Common Stock issuable upon settlement of Assumed RSUs (1,235 of which can settle within 60 days).</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(48)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 13,037 shares of Common Stock held directly by Ms. Isabella Ferre, (ii) 13,502 private warrants held directly by Ms. Ferre and (iii) 13,502 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(49)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 104,307 shares of Common Stock held directly by Mr. Delevic, (ii) 258,018 private warrants held directly by Mr. Delevic and (iii) 258,018 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(50)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 56,282 shares of Common Stock issuable upon exercise of Assumed Options (18,023 of which are exercisable within 60 days) and (ii) 4,127 shares of Common Stock issuable upon settlement of Assumed RSUs (1,031 of which can settle within 60 days). Ms. Stevens also holds 13,904 shares of Common Stock not registered for resale by this prospectus. Ms. Stevens is our Chief Regulatory Officer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(51)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 156,462 shares of Common Stock held by Mr. Karti, (ii) 162,027 private warrants held directly by Mr. Karti and (iii) 162,027 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(52)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 260,769 shares of Common Stock held directly by Ms. Matlin, (ii) 270,045 private warrants held directly by Ms. Matlin and (iii) 270,045 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(53)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 78,229 shares of Common Stock held directly by Dr. Roche, (ii) 231,014 private warrants held directly by Dr. Roche and (iii) 231,014 shares of Common Stock underlying such private warrants.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(54)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 626,932 shares of Common Stock issuable upon exercise of Assumed Options (400,257 of which are exercisable within 60 days) and (ii) 36,774 shares of Common Stock issuable upon settlement of Assumed RSUs (9,193 of which can settle within 60 days). Ms. Szela also holds 243,189 shares of Common Stock not registered for resale by this prospectus. Ms. Szela is our Chief Executive Officer and a member of our board of directors.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(55)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 13,037 shares of Common Stock held directly by Mr. Maurice E. Ferre, (ii) 13,502 private warrants held directly by Mr. Ferre and (iii) 13,502 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(56)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 511,108 shares of Common Stock held directly by Mr. Maurice R. Ferre, (ii) 529,288 private warrants held directly by Mr. Ferre and (iii) 529,288 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(57)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The shares registered for resale hereby represent (i)  70,187 shares of Common Stock issuable upon exercise of Assumed Options (34,760 of which are exercisable within 60 days) and (ii) 4,127 shares of Common Stock issuable upon settlement of Assumed RSUs (1,031 of which can settle within 60 days). Mr. Marshak also holds 8,372 shares of Common Stock not registered for resale by this prospectus. Mr. Marshak is our Senior Vice President, Corporate Development and Strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(58)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 137,248 shares of Common Stock held directly by Mr. Weiss, (ii) 266,667 private warrants held directly by Mr. Weiss and (iii) 266,667 shares of Common Stock underlying such private warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(59)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent 24,222 shares of Common Stock issuable upon exercise of Assumed Options (20,823 of which are exercisable within 60 days). In addition, the following shares beneficially owned by Mr. Hicks are not registered for resale by this prospectus: (i) 514,589 shares of Common Stock held directly by Mr. Hicks, (ii) 1,370,028 shares of Common Stock held by HW Investment, (iii) 81,845 shares of Common Stock held by the Millennium Trust Company, LLC, as custodian FBO Kerry Hicks IRAT and (iv) 322,737 shares of Common Stock held by The Kerry Raymond Hicks Dynasty Trust, for which Mr. Hicks serves as trustee. Mr. Hicks has shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them. Mr. Hicks is a member of our board of directors.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(60)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 172,181 shares of Common Stock issuable upon exercise of Assumed Options (50,877 of which are exercisable within 60 days) and (ii) 16,644 shares of Common Stock issuable upon settlement of Assumed RSUs (4,161 of which can settle within 60 days). In addition, the following shares beneficially owned by Sean Murphy are not registered for resale by this prospectus: (i) 357,535 shares of Common Stock held by Murphy Family Trust 2012 and (ii) 167,732 shares of Common Stock held by Sean E Murphy TTEE U/A 2/4/2004 (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Sean Murphy Trust</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Lisa Murphy, Mr. Murphy&#8217;s spouse, has voting and investment discretion with respect to the shares held directly by Murphy Family Trust 2012 and thus Mr. Murphy may be deemed to have beneficial ownership of the shares held directly by Murphy Family Trust 2012. Mr. Murphy is the trustee of the Sean Murphy Trust and thus Mr. Murphy may be deemed to have beneficial ownership of the shares held directly by the Sean Murphy Trust. Mr. Murphy is our Chief Financial Officer and a member of our board of directors.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(61)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i) 19,278 shares of Common Stock issuable upon exercise of Assumed Options (19,278 of which are exercisable within 60 days) and (ii) 1,235 shares of Common Stock issuable upon settlement of Assumed RSUs (1,235 of which can settle within 60 days). Ms. Song also beneficially owns 1,546,569 shares of Common Stock held by Unique Diamond Investments Limited that are not registered for resale by this prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(62)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 277,627 shares of Common Stock issuable upon exercise of Assumed Options (110,426 of which are exercisable within 60 days) and (ii) 16,644 shares of Common Stock issuable upon settlement of Assumed RSUs (4,161 of which can settle within 60 days). Dr. Katz also holds 17,799 shares of Common Stock not registered for resale by this prospectus. Dr. Katz is our Chief Medical Officer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(63)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares registered for resale hereby represent (i) 19,278 shares of Common Stock issuable upon exercise of Assumed Options (19,278 of which are exercisable within 60 days) and (ii) 1,235 shares of Common Stock issuable upon settlement of Assumed RSUs (1,235 of which can settle within 60 days). In addition, the following shares beneficially owned by Mr. Tullis are not registered for resale by this prospectus: (i) 440,917 shares of Common Stock held by Tullis Growth Fund II, L.P. and (ii) 389,865 shares of Common Stock held by Tullis Growth Fund. James L.L. Tullis, John L. Tullis and Nora Mende have shared voting and/or dispositive power over the holdings of Tullis Growth Fund II, L.P. and Tullis Growth Fund, L.P.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d386957_a0c2_4e80_91b4_67ff04fe22d5"></a><a id="DESCRIPTIONOFOURSECURITIES_872750"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DESCRIPTION OF OUR SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, our Bylaws and the Warrants described herein, which are exhibits to the registration statement of which this prospectus is a part. We urge you to read each of our Certificate of Incorporation, our Bylaws, and the Warrants-related documents described herein in their entirety for a complete description of the rights and preferences of our securities.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Authorized and Outstanding Stock</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation authorizes the issuance of 410,000,000 shares of our capital stock, consisting of (a)&#160;400,000,000 shares of Common Stock, having a par value per share of $0.0001, and (b)&#160;10,000,000 shares of preferred stock, having a par value per share of $0.0001 (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;). As of December 8, 2023, there were approximately 26,387,321 shares of our Common Stock and an aggregate of 4,015,002 shares of preferred stock, par value $0.0001 per share, designated as Series&#160;A Convertible Preferred Stock (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Series&#160;A Convertible Preferred Stock</b><span style="font-family:'Times New Roman','Times','serif';">&#8221;) issued and outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Voting Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each holder of Common Stock is entitled to one (1) vote for each share of Common Stock held of record by such holder on all matters submitted to a vote of our stockholders, provided, however, that, except as otherwise required in our Certificate of Incorporation or by applicable law, the holders of Common Stock shall not be entitled to vote on any amendment to our Certificate of Incorporation or any certificate of designation filed with respect to any series of our preferred stock that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of our preferred stock (including the Series A Convertible Preferred Stock) if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to our Certificate of Incorporation (including any certificate of designation relating to any series of preferred stock) or pursuant to the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to applicable law and the rights of the holders of any outstanding class of our preferred stock, including the Series&#160;A Convertible Preferred Stock, and the provisions of our Certificate of Incorporation, holders of Common Stock are entitled to receive such dividends and other distributions in cash, stock or property of the Company when, as and if declared thereon by our Board, in its sole discretion, from time to time out of assets or funds of the Company legally available therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rights upon Liquidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to applicable law and the rights and preferences of the holders of any outstanding class of preferred stock, including the Series&#160;A Convertible Preferred Stock, in the event of any liquidation, dissolution or winding up of our affairs, whether voluntary or involuntary, after payment or provision for payment of our debts and any other payments required by law and amounts payable upon shares of preferred stock ranking senior to the shares of Common Stock upon such dissolution, liquidation or winding up, if any, our remaining net assets will be distributed to the holders of Common Stock and the holders of any other class or series of capital stock ranking equally with the Common Stock upon such dissolution, liquidation or winding up, equally on a per share basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preemptive or Other Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of Common Stock do not have preemptive or other subscription rights and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of holders of the Common Stock are subject to those of the holders of the Series&#160;A Convertible Preferred Stock and any other series of preferred stock that we may issue in the future.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Election of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three-year terms with only one class of directors being elected in each&#160;year. There is no cumulative voting with respect to the election of directors. Under the Bylaws, the election of directors is determined by plurality vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not paid any cash dividends on our Common Stock to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, general financial condition, contractual restrictions and other factors that the Board may deem relevant and will be within the discretion of the Board at such time. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness that we or our subsidiaries incur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Founder Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Founder Shares are identical to the shares of our Common Stock, and holders of Founder Shares have the same stockholder rights as public stockholders, except that (i)&#160;the Founder Shares are subject to certain transfer restrictions, as described in more detail below and (ii)&#160;are entitled to registration rights. With certain limited exceptions, the Founder Shares are not transferable, assignable or salable (except to officers and directors and other persons or entities affiliated with the Sponsor, each of whom will be subject to the same transfer restrictions) until the earlier of&#8201; (A)&#160;August&#160;10, 2024, (B)&#160;if the reported closing price of our Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after August&#160;10, 2023 or (C)&#160;the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation authorizes 10,000,000 shares of Preferred Stock and provides that shares of Preferred Stock may be issued, from time to time, in one or more series. The Board is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Board is able to, without stockholder approval, issue Preferred Stock with voting and other rights that could adversely affect the voting power and other rights of the holders of Common Stock and could have anti-takeover effects. The ability of the Board to issue Preferred Stock without stockholder approval could have the effect of delaying, deferring, or preventing a change of control of us or the removal of existing management. As of December 8, 2023, there were </span><span style="font-family:'Times New Roman','Times','serif';">4,015,002</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Preferred Stock outstanding. Although we do not currently intend to issue any additional shares of Preferred Stock, circumstances in which we might issue other series of Preferred Stock in the future could include, among others, offerings of Preferred Stock undertaken for capital raising purposes, issuances in connection with acquisitions we might make in the future, or issuances in connection with potential change of control or strategic transactions involving us. Any determination by us to issue shares of Preferred Stock in the future will be dependent on the facts and circumstances at the time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;A Convertible Preferred Stock</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December 8, 2023, there were 4,015,002 shares of Series&#160;A Convertible Preferred Stock outstanding.</span><span style="font-family:'Times New Roman','Times','serif';"> Our Certificate of Designations, Preferences and Rights of Series&#160;A Convertible Preferred Stock</span><span style="font-family:'Times New Roman','Times','serif';"> (the &#8220;Certificate of Designations&#8221;) </span><span style="font-family:'Times New Roman','Times','serif';">establishes</span><span style="font-family:'Times New Roman','Times','serif';"> the voting powers, designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of </span><span style="font-family:'Times New Roman','Times','serif';">our</span><span style="font-family:'Times New Roman','Times','serif';"> Series&#160;A Convertible Preferred Stock. The following description of our Series&#160;A Convertible Preferred Stock is intended as a summary only and does not purport to be complete, and is qualified in its entirety by reference to the Certificate of Designations, </span><span style="font-family:'Times New Roman','Times','serif';">which is attached hereto as Exhibit&#160;3.3 to the registration statement of which this prospectus forms a part</span><span style="font-family:'Times New Roman','Times','serif';">, and to the applicable provisions of Delaware law. We urge you to read the Certificate of Designations because it, and not this description, defines the rights of holders of shares of Series&#160;A Convertible Preferred Stock.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Ranking</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With respect to any payment of dividends and distribution of assets upon our liquidation, dissolution or winding up, the Series&#160;A Convertible Preferred Stock ranks: (i)&#160;junior to any class or series of our capital stock hereafter created which expressly ranks senior to the Series&#160;A Convertible Preferred Stock; (ii)&#160;on parity with any class or series of our capital stock hereafter created that expressly ranks pari passu with the Series&#160;A Convertible Preferred Stock; and (iii)&#160;senior to the Common Stock or any class or series of our capital stock hereafter created that expressly ranks junior to the Series&#160;A Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Optional Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Convertible Preferred Stock are convertible at any time at the option of the holder thereof into the number of shares of our Common Stock determined by the quotient of (i)&#160;the sum of $10.00 (as adjusted for any stock dividend, stock split, reverse stock split, combination or similar event affecting the Series&#160;A Convertible Preferred Stock) (the &#8220;<b style="font-weight:bold;">Liquidation Preference</b>&#8221;) and if we have not elected to otherwise pay the accrued Annual Dividends (as defined below) in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price (as defined in the Certificate of Designations) of such shares in effect at the time of conversion. See section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions&#160;&#8212;</i><i style="font-style:italic;"> Subscription Agreements</i>&#8221; for a further description of the Conversion Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Automatic Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the four&#160;year anniversary of the Closing, all then outstanding shares of Series&#160;A Convertible Preferred Stock shall automatically convert into the number of shares of our Common Stock equal to the quotient of (i)&#160;the sum of the Liquidation Preference and if we had not elected to otherwise pay the accrued Annual Dividends in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price of such shares in effect at the time of conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Series&#160;A Convertible Preferred Stock are entitled to participate equally in any dividends declared to holders of Common Stock (the &#8220;<b style="font-weight:bold;">Participating Dividends</b>&#8221;). In addition, each holder of the Series&#160;A Convertible Preferred Stock is entitled to receive, when, as and if authorized and declared by our Board, annual dividends that accrue and accumulate on a daily basis at a rate per annum (calculated on the basis of an actual 365- or 366-day&#160;year, as applicable) equal to 8.0% of the Liquidation Preference, which will be either paid in cash, paid by issuing fully paid and nonassessable shares of Common Stock, or a combination thereof (the &#8220;<b style="font-weight:bold;">Annual Dividends</b>&#8221;). So long as any shares of Series&#160;A Convertible Preferred Stock remain outstanding, unless all Annual Dividends on all outstanding shares of Series&#160;A Convertible Preferred Stock have been declared and paid in cash, we will be prohibited from declaring any dividends on, or making any distributions relating to, other classes of our preferred stock ranking junior to the Series&#160;A Convertible Preferred Stock, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-dilution Provisions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Conversion Price is subject to customary adjustments in the case of certain distributions to holders of our Common Stock payable in shares of our Common Stock, subdivisions, splits or combinations of the shares of our Common Stock and distributions to all holders of shares of our Common Stock of any convertible securities or options or any other assets for which there is no corresponding distribution in respect of the Series&#160;A Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial Conversion Price will automatically reset upon each of February&#160;10, 2025 and July&#160;10, 2027, the eighteen (18)&#160;month and forty-seven (47)&#160;month anniversaries of the Closing Date, to be equal to the lower of (i)&#160;the then-current Conversion Price and (ii)&#160;the VWAP of our Common Stock for the ten trading&#160;days immediately prior to, but excluding, the applicable reset date, on the Nasdaq Stock Market LLC (subject to the&#160;Floor Price (as defined in the Certificate of Designations)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Voting Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Holders of the Series&#160;A Convertible Preferred Stock are entitled to vote with the holders of our Common Stock on all matters submitted to a vote of our stockholders, except as otherwise provided in the Certificate of Designations or as required by applicable </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">law, voting together with the holders of our Common Stock as a single class. Each holder is entitled to a number of votes in respect of the shares of Series&#160;A Convertible Preferred Stock owned as of the record date by it, or if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, equal to the quotient of (i)&#160;$10.00 divided by (ii)&#160;the Minimum Price (as defined in Nasdaq Listing Rule&#160;5635(d)) of our Common Stock as determined at Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As long as any shares of Series&#160;A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series&#160;A Convertible Preferred Stock, (i)&#160;amend, alter, repeal or otherwise modify any provision of our certificate of incorporation or the Certificate of Designations in a manner that would alter or change the terms or the powers, preferences, rights or privileges of the Series&#160;A Convertible Preferred Stock as to affect them adversely; (ii)&#160;authorize, create, increase the authorized amount of, or issue any class or series of senior to the Series&#160;A Convertible Preferred Stock; (iii)&#160;increase the authorized number of shares of Series&#160;A Convertible Preferred Stock or (iv)&#160;enter into any agreement with respect to the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon any liquidation, dissolution or winding-up by us, whether voluntary or involuntary (excluding any mergers, consolidations, reorganizations or other changes of control), after payment or provision for payment of our debts and other liabilities, the holders of the Series&#160;A Convertible Preferred Stock are entitled to receive, before the holders of any of our Common Stock or other classes of our preferred stock ranking junior thereto, out of our remaining net assets, the amount equal to the greater of (i)&#160;the sum of (A)&#160;the Liquidation Preference, and (B)&#160;the aggregate accrued Annual Dividends of such shares as of the date of the liquidation, and (ii)&#160;the amount such holder would have received had such shares of Series&#160;A Convertible Preferred Stock, immediately prior to such liquidation, been converted into shares of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the assets available for distribution to our stockholders upon a liquidation are insufficient to pay in full the amounts payable with respect to all outstanding shares of Series&#160;A Convertible Preferred Stock, such assets, or the proceeds thereof, shall be distributed among the holders of the Series&#160;A Convertible Preferred Stock ratably in proportion to the full respective liquidating distributions to which each holder would otherwise be entitled upon such liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fundamental Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon any sale of all or substantially all of our assets, any merger, consolidation, reorganization, change of control or other similar transaction (each a &#8220;<b style="font-weight:bold;">Fundamental Transaction</b>&#8221;), holders of Series&#160;A Convertible Preferred Stock shall have the right to receive, for each share of our Common Stock that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the number of shares of our Common Stock (if we are the surviving entity), or common stock of the successor or acquiring corporation (if it is the surviving entity), and any additional consideration receivable as a result of such Fundamental Transaction by a holder of the number of shares of our Common Stock for which the Series&#160;A Convertible Preferred Stock is convertible immediately prior to such Fundamental Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to timely deliver shares of our Common Stock upon conversion of the Series&#160;A Convertible Preferred Stock within the time period specified in the Certificate of Designations, then we are obligated to (A)&#160;pay to the holder, in cash, the amount, if any, by which (x)&#160;such holder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of our Common Stock that such holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such holder, either reissue (if surrendered) the shares of Series&#160;A Convertible Preferred Stock equal to the number of shares of Series&#160;A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such holder the number of shares of our Common Stock that would have been issued if we had timely complied with its delivery requirements.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public Stockholders&#8217; Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each whole Public Warrant entitles the registered holder to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as discussed below. The Public Warrants will expire five&#160;years on August&#160;10, 2028, at 5:00&#160;p.m., New York City time, or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will not be obligated to deliver any shares of Common Stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No Public Warrant will be exercisable and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Public Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any Public Warrant. In the event that a registration statement is not effective for the exercised Public Warrants, the purchaser of a unit of MTAC containing such warrant, if not cash settled, will have paid the full purchase price for the unit of MTAC solely for the share of Common Stock underlying such unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have agreed that as soon as practicable, but in no event later than 15 business days following the Closing, we will use our reasonable best efforts to file with the SEC a registration statement registering the issuance of the shares of Common Stock issuable upon exercise of the Public Warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Common Stock until the Public Warrants expire or are redeemed, as specified in the Warrant Agreement. If a registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrants is not effective by the 60th business day after the Closing Date or within a specified period following the consummation of the Business Combination, warrantholders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their Public Warrants on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the Public Warrants become exercisable, we may call the warrants for redemption:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of $0.01 per warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than 30&#160;days&#8217; prior written notice of redemption (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">30-day redemption period</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) to each warrantholder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the reported closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading&#160;days within a 30-trading day period ending three business&#160;days before we send the notice of redemption to the warrantholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the Public Warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. We will use our reasonable best efforts to register or qualify such shares of Common Stock under the blue sky laws of the state of residence in those states in which the Public Warrants were initially offered by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have established the last of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Public Warrants, each warrantholder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the Common Stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">dividends, reorganizations, recapitalizations and the like), as well as the $11.50 warrant exercise price after the redemption notice is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we call the Public Warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise its warrant to do so on a cashless basis. In determining whether to require all holders to exercise their Public Warrants on a cashless basis, our management will consider, among other factors, our cash position, the number of warrants that are outstanding and the dilutive effect on our stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our warrants. If our management takes advantage of this option, all holders of Public Warrants would pay the exercise price by surrendering their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;<span style="white-space:pre-wrap;">the product of the number of shares of Common Stock underlying the Public Warrants multiplied by the excess of the &#8220;fair market value&#8221;  (defined below) over the exercise price of the Public Warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported closing price of the Common Stock for the 10 trading&#160;days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Public Warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Common Stock to be received upon exercise of the Public Warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the Public Warrants after the Business Combination. If we call our warrants for redemption and our management does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their Private Placement Warrants for cash or on a cashless basis using the same formula described above that other warrantholders would have been required to use had all warrantholders been required to exercise their Public Warrants on a cashless basis, as described in more detail below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of a Public Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify) of the shares of Common Stock outstanding immediately after giving effect to such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise of each Public Warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering to holders of Common Stock entitling holders to purchase shares of Common Stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Common Stock equal to the product of&#8201; (i)&#160;the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Common Stock) and (ii)&#160;one minus the quotient of&#8201; (x)&#160;the price per share of Common Stock paid in such rights offering divided by (y)&#160;the fair market value. For these purposes (i)&#160;if the rights offering is for securities convertible into or exercisable for Common Stock, in determining the price payable for Common Stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;fair market value means the volume weighted average price of Common Stock as reported during the 10 trading day period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we, at any time while the Public Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Common Stock on account of such shares of Common Stock (or other shares of our capital stock into which the warrants are convertible), other than (a)&#160;as described above or (b)&#160;certain ordinary cash dividends, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Common Stock in respect of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the number of outstanding shares of our Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Public Warrant will be decreased in proportion to such decrease in outstanding shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Whenever the number of shares of Common Stock purchasable upon the exercise of the Public Warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the Public Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of our Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their Public Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Common Stock in such a transaction is payable in the form of Common Stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Public Warrant properly exercises the warrant within 30&#160;days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes value (as defined in the Warrant Agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Public Warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants. This formula is to compensate the warrantholder for the loss of the option value portion of the Public Warrant due to the requirement that the warrantholder exercise the warrant within 30&#160;days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Public Warrants were issued in registered form under the Warrant Agreement. The description of the Public Warrants set forth herein is a summary and does not purport to be complete. The Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, and that all other modifications or amendments require the vote or written consent of the holders of at least a majority of the then outstanding public warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants, a majority of the then outstanding Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Public Warrants being exercised. The warrantholders do not have the rights or privileges of holders of Common Stock or any voting rights until they exercise their Public Warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares will be issued upon exercise of the Public Warrants. If, upon exercise of the Public Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued to the warrantholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Private Placement Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as described below, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants. Holders of our Private Placement Warrants are entitled to certain registration rights and the Private Placement Warrants will not be redeemable by us so long as they are held by Sponsor or its permitted transferees. Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in MTAC&#8217;s initial public offering. Any amendment to the terms of the Private Placement Warrants or any provision of the Warrant Agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock&#160;underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) over the exercise price of the warrants by (y)&#160;the fair market value. For these purposes, the &#8220;fair market value&#8221; means the average reported closing price of the Common Stock for the 10 trading&#160;days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain Anti-Takeover Provisions of Delaware Law and our Certificate of Incorporation and Bylaws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an affiliate of an interested stockholder; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an associate of an interested stockholder, for three&#160;years following the date that the stockholder became an interested stockholder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;business combination&#8221; includes a merger or sale of more than 10% of our assets. However, the above provisions of Section&#160;203 do not apply if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Board approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of Common Stock; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on or subsequent to the date of the transaction, the initial business combination is approved by our Board and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides that the Board is classified into three classes of directors, each of which will generally serve for a term of three&#160;years with only one class of directors being elected in each&#160;year. As a result, in most circumstances, a person can gain control of our Board only by successfully engaging in a proxy contest at two or more annual meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The authorized but unissued Common Stock and Preferred Stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved shares of Common Stock and Preferred Stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exclusive Forum for Certain Lawsuits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the fact that our Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law, Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act, or the rules&#160;and regulations thereunder. As a result, the exclusive forum provision does not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the rules&#160;and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules&#160;and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Special Meeting of Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Bylaws provide that special meetings of our stockholders may be called only by a majority vote of our Board, by our Chief Executive Officer or by our Chairman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&#8217;s notice will need to be received by our secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day prior to the anniversary date of the immediately preceding annual meeting of stockholders. Pursuant to Rule&#160;14a-8 of the Exchange Act, proposals seeking inclusion in our annual proxy statement must comply with the notice periods contained therein. Our Bylaws also specify certain requirements as to the form and content of a stockholders&#8217; meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Action by Written Consent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any action required or permitted to be taken by holders of our Common Stock must be effected by a duly called annual or special meeting of such stockholders and may not be effected by written consent of the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations on Liability and Indemnification of Officers and Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under our Certificate of Incorporation, none of our directors or officers will be liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director or officer, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or may be amended. We have entered into customary indemnification agreements, the form of which is attached hereto as Exhibit&#160;10.25, with each of our officers and directors that provide them, in general, with customary indemnification in connection with their service to us or on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Transfer Agent and Warrant Agent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transfer agent for our Common Stock and the warrant agent for our Warrants is Continental Stock Transfer&#160;&amp; Trust Company. Continental Stock Transfer&#160;&amp; Trust Company&#8217;s address is One State Street Plaza, 30&#160;Floor New York, New York 10004.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Registration Rights Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing, we, Sponsor and certain stockholders of Legacy TriSalus who received shares of Common Stock pursuant to the Merger Agreement entered into the Amended and Restated Registration Rights Agreement (which amended and restated the Registration Rights Agreement between us and Sponsor, dated as of December 17, 2020). Pursuant to the Amended and Restated Registration Rights Agreement, among other things, we are obligated to file, not later than 45 days after the Closing Date, a registration statement covering the re-sale of the Registrable Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, we will also grant piggyback registration rights and demand registration rights to the Sponsor and Legacy TriSalus stockholders that are parties thereto, will pay certain expenses related to such registration and will indemnify the Sponsor and Legacy TriSalus stockholders that are parties thereto against certain liabilities related to such registration. The Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto, on the date that such party no longer holds any Registrable Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exchange Listing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Common Stock and Public Warrants are listed on Nasdaq Global Market under the symbols &#8220;TLSI&#8221; and &#8220;TLSIW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0dc3a5b6_e636_494a_9e1e_921c57bf2ffd"></a><a id="MATERIALUNITEDSTATESFEDERALINCOMETAXCONS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of material U.S. federal income tax considerations generally applicable to the purchase, ownership and disposition of our Common Stock and the purchase, exercise, disposition and lapse of our Warrants. The Common Stock and the Warrants are collectively referred to herein as our securities. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local, and non-U.S. tax consequences of the purchase, ownership, and disposition of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating to the purchase, ownership, and disposition of our securities. This summary is based upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements, and rulings of the U.S. Internal Revenue Service (the &#8220;<b style="font-weight:bold;">IRS</b>&#8221;), and judicial decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership, or disposition of our securities. We assume in this discussion that a holder holds our securities as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#8217;s individual circumstances, nor does it address the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code, any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or non-U.S. taxes, or any other U.S. federal tax laws. This discussion also does not address consequences relevant to holders subject to special tax rules, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, governmental organizations, banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities, commodities or currencies, regulated investment companies or real estate investment trusts, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, tax-qualified retirement plans, holders who hold or receive our securities pursuant to the exercise of employee stock options or otherwise as compensation, holders holding our securities as part of a hedge, straddle, or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our securities under the constructive sale provisions of the Code, passive foreign investment companies, controlled foreign corporations, and certain former U.S. citizens or long-term residents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold our securities through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; means a beneficial owner of our securities (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is, for U.S. federal income tax purposes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust if (a)&#160;a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all of the trust&#8217;s substantial decisions or (b)&#160;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, a &#8220;non-U.S. Holder&#8221; is a beneficial owner of our securities that is neither a U.S. Holder nor a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Tax Considerations Applicable to U.S. Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Taxation of Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to U.S. Holders &#8212; U.S. Holders &#8212; Gain or Loss on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gain or Loss on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange, or other taxable disposition of our Common Stock. Any such gain or loss will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of exceeds one&#160;year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such Common Stock (or, in the case of Common Stock received upon exercise of a Warrant, the U.S. Holder&#8217;s initial basis for such Common Stock, as discussed below), less any prior distributions treated as a return of capital. Long-term capital gains recognized by non-corporate U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one&#160;year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exercise of a Warrant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as discussed below with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss upon exercise of a Warrant for cash. The U.S. Holder&#8217;s initial tax basis in the share of our Common Stock received upon exercise of the Warrant will generally be an amount equal to the sum of the U.S. Holder&#8217;s acquisition cost of the Warrant and the exercise price of such Warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock received upon exercise of the Warrant would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In certain circumstances, the Warrants may be exercised on a cashless basis. The U.S. federal income tax treatment of an exercise of a warrant on a cashless basis is not clear and could differ from the consequences described above. It is possible that a cashless exercise could be a taxable event. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a Warrant on a cashless basis, including with respect to their holding period and tax basis in the Common Stock received upon exercise of the Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale, Exchange, Redemption or Expiration of a Warrant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon a sale, exchange (other than by exercise), redemption, or expiration of a Warrant, a U.S. Holder will recognize taxable gain or loss in an amount equal to the difference between (1)&#160;the amount realized upon such disposition or expiration and (2)&#160;the U.S. </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Holder&#8217;s adjusted tax basis in the Warrant. A U.S. Holder&#8217;s adjusted tax basis in its Warrants will generally equal the U.S. Holder&#8217;s acquisition cost, increased by the amount of any constructive distributions included in income by such U.S. Holder (as described below under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to U.S. Holders &#8212; Possible Constructive Distributions</i>&#8221;). Such gain or loss generally will be treated as long-term capital gain or loss if the Warrant is held by the U.S. Holder for more than one&#160;year at the time of such disposition or expiration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to such holder&#8217;s adjusted tax basis in the Warrant. Any such loss generally will be a capital loss and will be long-term capital loss if the Warrant is held for more than one&#160;year. Because the term of the Warrants is more than one&#160;year, a U.S. Holder&#8217;s capital loss will be treated as a long-term capital loss. The deductibility of capital losses is subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Possible Constructive Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section titled &#8220;<i style="font-style:italic;">Description of our Securities &#8212; Warrants</i>.&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a U.S. Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise or an adjustment to the exercise price of the Warrant) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to U.S. Holders &#8212; Taxation of Distributions</i>&#8221; in the same manner as if such U.S. Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Information Reporting and Backup Withholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition of our shares of Common Stock and Warrants, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number (or furnishes an incorrect taxpayer identification number) or a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules&#160;will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Taxpayers should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Tax Considerations Applicable to Non-U.S. Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Taxation of Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In general, any distributions (including constructive distributions) we make to a non-U.S. Holder of shares on our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the non-U.S. Holder&#8217;s conduct of a trade or business within the United&#160;States or, if an applicable tax treaty so requires, are not attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form&#160;W-8BEN or W-8BEN-E, as applicable). In the case of any constructive dividend (as described below under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to Non-U.S. Holders &#8212; Possible Constructive Distributions</i>&#8221;), it is possible that this tax would be withheld from any amount owed to a non-U.S. Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from Warrants or other property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the non-U.S. Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the non-U.S. Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which will be treated as described under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to Non-U.S. Holders &#8212; Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock and Warrants</i>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding corporation&#8221; (see the section titled &#8220;<i style="font-style:italic;">Tax Considerations Applicable to Non-U.S. Holders &#8212; Gain on Sale, Exchange, or Other Taxable Disposition of Common Stock and Warrants</i>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends we pay to a non-U.S. Holder that are effectively connected with such non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder) will generally not be subject to U.S. withholding tax, provided such non-U.S. Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form&#160;W-8ECI). Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same individual or corporate rates applicable to U.S. Holders. If the non-U.S. Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exercise of a Warrant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal income tax treatment of a non-U.S. Holder&#8217;s exercise of a Warrant will generally correspond to the U.S. federal income tax treatment of the exercise of a Warrant by a U.S. Holder, as described under &#8220;<i style="font-style:italic;">Tax Considerations Applicable to U.S. Holders &#8212; Exercise of a Warrant</i>&#8221; above, although to the extent a cashless exercise results in a taxable exchange, the tax consequences to the non-U.S. Holder would be the same as those described below in &#8220;<i style="font-style:italic;">Tax Considerations Applicable to Non-U.S. Holders &#8212; Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock or Warrants or an expiration or redemption of our Warrants, unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the non-U.S. Holder is an individual who is present in the United States for 183&#160;days or more in the taxable&#160;year of disposition and certain other conditions are met; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our Common Stock or Warrants and, in the case where shares of our Common Stock are regularly traded on an established securities market, (i)&#160;the non-U.S. Holder is disposing of our Common Stock and has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder&#8217;s holding period for the shares of our Common Stock or (ii), in the case where our Warrants are regularly traded on an established securities market, the non-U.S. Holder is disposing of our Warrants and has owned, directly or constructively, more than 5% of our Warrants at any time within the within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder&#8217;s holding period for the shares of our Warrants. There can be no assurance that our Common Stock or Warrants will be treated as regularly traded or not regularly traded on an established securities market for this purpose.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the non-U.S. Holder were a U.S. resident. Any gains described in the first bullet point above of a non-U.S. Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. Non-U.S. Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the third bullet point above applies to a non-U.S. Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock or Warrants, as applicable, will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock or Warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. We do not believe we currently are or will become a United States real property holding corporation, however there can be no assurance in this regard. Non-U.S. Holders are urged to consult their tax advisors regarding the application of these rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Possible Constructive Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section titled &#8220;<i style="font-style:italic;">Description of our Securities &#8212; Warrants.</i>&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a non-U.S. Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise or an adjustment to the exercise price of the Warrant) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. A non-U.S. Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<i style="font-style:italic;">Non-U.S. Holders &#8212; Taxation of Distributions</i>&#8221; under that section in the same manner as if such non-U.S. Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Foreign Account Tax Compliance Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Provisions of the Code and Treasury Regulations and administrative guidance promulgated thereunder commonly referred as the &#8220;Foreign Account Tax Compliance Act&#8221; (&#8220;<b style="font-weight:bold;">FATCA</b>&#8221;) generally impose withholding at a rate of 30% in certain circumstances on dividends (including constructive dividends) in respect of our securities which are held by or through certain foreign financial institutions (including investment funds), unless any such institution (1)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain non-U.S. entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (2)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which our securities are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of our securities held by an investor that is a non-financial non-U.S. entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (1)&#160;certifies to us or the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (2)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. Withholding under FATCA was scheduled to apply to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source interest or dividends, however, the IRS released proposed regulations that, if finalized in their proposed form, would eliminate the obligation to withhold on such gross proceeds. Although these proposed Treasury Regulations are not final, taxpayers generally may rely on them until final Treasury Regulations are issued. Prospective investors should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Information Reporting and Backup Withholding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our Common Stock and Warrants. A non-U.S. Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c73ab3db_c41b_496a_a647_a0ddc5ade85c"></a><a id="PLANOFDISTRIBUTION_937583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PLAN OF DISTRIBUTION</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are registering the issuance by us of an aggregate of up to 13,215,112 shares of Common Stock, consisting of up to (a) 4,933,333 shares of Common Stock that are issuable upon the exercise of the equivalent number of Private Placement Warrants by the holders thereof and (b) 8,281,779 shares of Common Stock that are issuable upon the exercise of the equivalent number of Public Warrants by the holders thereof.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are also registering the resale by the Selling Securityholders or their permitted transferees from time to time of (i) up to 36,772,040 shares of Common Stock, consisting of (a) up to 25,237,094 PIPE Shares that are issuable upon the conversion of the 4,015,002 shares of Series A Convertible Preferred Stock; (b) up to 4,062,500 Founder Shares originally issued in a private placement to the Sponsor prior to MTAC&#8217;s initial public offering, including 3,125,000 Founder Shares subject to vesting and forfeiture; (c) up to 1,452,965 shares of Common Stock issuable upon exercise of Assumed Options; (d) up to 86,148 shares of Common Stock issuable upon the settlement of Assumed RSUs; (e) up to 4,933,333 shares of Common Stock that are issuable upon the exercise of the equivalent number of Private Placement Warrants by the holders thereof; and (f) up to 1,000,000 shares of Common Stock that are issuable upon the exercise of the equivalent number of Conversion Warrants by the holders thereof, (ii) up to 5,933,333 warrants, consisting of (a) up to 4,933,333 Private Placement Warrants and (b) up to 1,000,000 Conversion Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to pay all fees and expenses incident to the registration of the securities to be offered and sold pursuant to this prospectus, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws.. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sale of securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will not receive any of the proceeds from the sale of the securities by the Selling Securityholders. We will receive proceeds from Warrants exercised in the event that such Warrants are exercised for cash. The aggregate proceeds to the Selling Securityholders will be the purchase price of the securities less any discounts and commissions borne by the Selling Securityholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The securities beneficially owned by the Selling Securityholders covered by this prospectus may be offered and sold from time to time by the Selling Securityholders. The term &#8220;Selling Securityholders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a Selling Securityholders as a gift, pledge, partnership distribution or other transfer. The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise. These sales may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selling Securityholders may sell their securities by one or more of, or a combination of, the following methods:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ordinary brokerage transactions and transactions in which the broker solicits purchasers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an over-the-counter distribution in accordance with the rules of Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through trading plans entered into by a Selling Securityholder pursuant to Rule 10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">short sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution to employees, members, limited partners or securityholders of the Selling Securityholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by pledge to secured debts and other obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delayed delivery arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to or through underwriters or broker-dealers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in privately negotiated transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in options transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through a combination of any of the above methods of sale; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other method permitted pursuant to applicable law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, any securities that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the securities or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with selling securityholder. The Selling Securityholders may also sell the securities short and redeliver the securities to close out such short positions. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Selling Securityholder may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In effecting sales, broker-dealers or agents engaged by the Selling Securityholder may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with any sales of securities offered hereunder, the Selling Securityholders and any underwriters, agents, brokers or dealers participating in such sales may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act. Any profits realized by Selling Securityholder and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. If any Selling Securityholder is an &#8220;underwriter&#8221; within the meaning of Section 2(11) of the Securities Act, then the Selling Securityholder will be subject to the prospectus delivery requirements of the Securities Act. At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have advised the Selling Securityholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of securities in the market and to the activities of the Selling Securityholders and their affiliates. In addition, we will make copies of this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of Warrants may exercise their Warrants in accordance with the Warrant on or before the expiration date set forth therein by surrendering, at the office of the Warrant Agent, Continental Stock Transfer &amp; Trust Company, the certificate evidencing such Warrant, with the form of election to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes due in connection with the exercise of the Warrant, subject to any applicable provisions relating to cashless exercises in accordance with the Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify the Selling Securityholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the Warrants or shares offered by this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended and Restated Registration Rights Agreement, we have agreed to keep the registration statement of which this prospectus constitutes a part effective until such time as (A) a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities have been sold, transferred, disposed of or exchanged in accordance with such registration statement; (B) such securities have been otherwise transferred, new certificates or book entry provisions for such securities not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities Act; (C) such securities have ceased to be outstanding; (D) such securities may be sold without registration pursuant to Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the SEC) without limitation as to volume and manner of sale or other public information requirements; or (E) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Subscription Agreements, we have agreed to keep the registration statement of which this prospectus constitutes a part effective with respect to each Subscriber (as defined in the Subscription Agreements) until the earliest to occur of (i) two (2) years from the effective date of such registration statement, (ii) the date on which Subscriber ceases to hold any Company Shares issued pursuant to the Subscription Agreement and covered by such registration statement and (iii) the first date on which such Subscriber can sell all of its Conversion Shares underlying the Preferred Shares issued pursuant to the Subscription Agreement (or securities received in exchange therefor) and covered by such registration statement under Rule 144 without limitation as to the manner of sale or the amount of such securities that may be sold and without the requirement for the Company to be in compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if applicable). For purposes of this paragraph, capitalized terms not otherwise defined shall have the meanings given to them in the Subscription Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2e1e185d_66de_47eb_be21_57e7f4bbdc1c"></a><a id="LEGALMATTERS_293236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">LEGAL MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The validity of the securities offered hereby will be passed upon for us by Cooley&#160;LLP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_12ad6733_982f_4da7_90d5_a4e7776ef200"></a><a id="EXPERTS_3359"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXPERTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of TriSalus Life Sciences,&#160;Inc. as of December&#160;31, 2022 and 2021, and for the&#160;years then ended, have been included in this Prospectus and Registration Statement in reliance upon the report of KPMG LLP (&#8220;<b style="font-weight:bold;">KPMG</b>&#8221;), independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December&#160;31, 2022, consolidated financial statements contains an explanatory paragraph that states that TriSalus Life Sciences,&#160;Inc.&#8217;s recurring losses from operations and net capital deficiency raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements of MedTech Acquisition Corporation as of December&#160;31, 2022 and 2021, and for the&#160;years then ended, appearing in this Prospectus and Registration Statement have been audited by WithumSmith+Brown, PC (&#8220;<b style="font-weight:bold;">Withum</b>&#8221;), independent registered public accounting firm, as set forth in their report thereon (which includes an explanatory paragraph relating to MedTech Acquisition Corporation&#8217;s ability to continue as a going concern), appearing elsewhere in this Prospectus and Registration Statement, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><a id="_1abecdc3_8474_4bbb_815e_e9f5552e30d5"></a><a id="CHANGEINREGISTRANTSCERTIFYINGACCOUNTANT_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;10, 2023, the Board approved the engagement of KPMG as our independent registered public accounting firm for the&#160;year ending December&#160;31, 2023. KPMG previously served as the independent registered public accounting firm of Legacy TriSalus prior to the Business Combination. Accordingly, Withum, MTAC&#8217;s independent registered public accounting firm prior to the Business Combination, was informed on the Closing Date that it would be replaced by KPMG as our independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Withum&#8217;s report on our consolidated balance sheets as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the&#160;years ended December&#160;31, 2022 and 2021, and the related notes to the financial statements (collectively, the &#8220;<b style="font-weight:bold;">financial statements</b>&#8221;) did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except for the substantial doubt about our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the period from September&#160;11, 2020 (inception) through December&#160;31, 2022, and the subsequent interim period through August&#160;9, 2023, there were no: (i)&#160;disagreements with Withum on any matter of accounting principles or practices, financial statement disclosures or audited scope or procedures, which disagreements if not resolved to Withum&#8217;s satisfaction would have caused Withum to make reference to the subject matter of the disagreement in connection with its report or (ii)&#160;reportable events as defined in Item&#160;304(a)(1)(v)&#160;of Regulation S-K under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the period from September&#160;11, 2020 (inception) through December&#160;31, 2022, and the interim period through August&#160;9, 2023, we did not consult KPMG with respect to either (i)&#160;the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on our financial statements, and no written report or oral advice was provided to us by KPMG that KPMG concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii)&#160;any matter that was either the subject of a disagreement, as that term is described in Item&#160;304(a)(1)(iv)&#160;of Regulation S-K under the Exchange Act and the related instructions to Item&#160;304 of Regulation S-K under the Exchange Act, or a reportable event, as that term is defined in Item&#160;304(a)(1)(v)&#160;of Regulation S-K under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have provided Withum with a copy of the disclosures we made in response to Item&#160;4.01 of our Current Report on Form&#160;8-K filed on August&#160;16, 2023, and have requested that Withum furnish us with a letter addressed to the SEC stating whether it agrees with the statements made by us in response to Item&#160;4.01 of Current Report on Form&#160;8-K and, if not, stating the respects in which it does not agree. A letter from Withum is attached hereto as Exhibit&#160;16.1 of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_29735aa6_fc29_447c_8bb4_112d706d5042"></a><a id="WHEREYOUCANFINDMOREINFORMATION_144649"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">WHERE YOU CAN FIND MORE INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have filed with the SEC a registration statement on Form&#160;S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement, over the internet at the SEC&#8217;s website at www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the information reporting requirements of the Exchange Act, and we file reports, proxy statements, and other information with the SEC. These reports, proxy statements, and other information will be available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at www.trisaluslifesci.com. Through our website, we make available, free of charge, the following documents as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC, including our Annual Reports on Form&#160;10-K; our proxy statements for our annual and special stockholder meetings; our Quarterly Reports on Form&#160;10-Q; our Current Reports on Form&#160;8-K; Forms 3, 4, and 5 and Schedules 13D with respect to our securities filed on behalf of our directors and our executive officers; and amendments to those documents. The information contained on, or that may be accessed through, our website is not a part of, and is not incorporated into, this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e182aa60_a95f_4ab1_8a42_a360f85ab14f"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this prospectus.</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Introduction</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following unaudited pro forma condensed combined financial information presents the combination of the financial information of MTAC and TriSalus adjusted to give effect to the Business Combination and related transactions. The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X and should be read in conjunction with the accompanying notes. Defined terms included below have the same meaning as terms defined and included in the prospectus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The effects of the Business Combination are reflected in the unaudited condensed consolidated balance sheet of TriSalus as of September 30, 2023 included elsewhere in this prospectus. Accordingly, an unaudited pro forma condensed combined balance sheet is not presented. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023 and the year ended December 31, 2022, give pro forma effect to the Business Combination and Preferred Stock PIPE Investment as if it had occurred on January 1, 2022, the beginning of the earliest period presented.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information was derived from the following historical financial statements and the accompanying notes:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The historical unaudited condensed consolidated financial statements of TriSalus as of and for the nine months ended September 30, 2023, included elsewhere in this prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The historical audited consolidated financial statements of Legacy TriSalus as of and for the year ended December 31, 2022, included elsewhere in this prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The historical unaudited condensed financial statements of MTAC for the period from January 1, 2023 to August 10, 2023; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The historical audited financial statements of MTAC as of and for the year ended December 31, 2022, included elsewhere in this prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The foregoing historical financial statements have been prepared in accordance with GAAP. The unaudited pro forma condensed combined financial information has been prepared based on the aforementioned historical financial statements and the assumptions and adjustments as described in the notes to the unaudited pro forma condensed combined financial information. The pro forma adjustments reflect transaction accounting adjustments related to the Business Combination and Preferred Stock PIPE Investment, which is discussed in further detail below. The unaudited pro forma condensed combined financial statements are presented for illustrative purposes only and do not purport to represent the consolidated results of operations or consolidated financial position that would actually have occurred had the Business Combination and Preferred Stock PIPE Investment been consummated on the dates assumed or to project consolidated results of operations or consolidated financial position for any future date or period. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed combined financial information.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information should also be read together with the section entitled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of MTAC</i><span style="font-family:'Times New Roman','Times','serif';">,&#8221; and the other financial information relating to MTAC included in the Current Report on Form 8-K filed on August 16, 2023, and the section entitled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i><span style="font-family:'Times New Roman','Times','serif';">,&#8221; and other financial information related to TriSalus included elsewhere in this prospectus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Description of the Business Combination</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">On the Closing Date, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Legacy TriSalus, with Legacy TriSalus surviving the merger as a wholly-owned subsidiary of MTAC. Upon the close of the Business Combination, each </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">share of MTAC&#8217;s Class&#160;A Common Stock and each share of MTAC&#8217;s Class&#160;B Common Stock that was outstanding was reclassified into a single class of common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to Closing, shares of Legacy TriSalus Preferred Stock converted into shares of Legacy TriSalus Common Stock based on the applicable Exchange Ratio. In addition, each outstanding warrant of Legacy TriSalus (&#8220;Legacy TriSalus Warrant&#8221;) to purchase shares of Legacy TriSalus Preferred Stock or Legacy TriSalus Common Stock that was in-the-money and would have been exercised or otherwise exchanged in full in accordance with its terms by virtue of the occurrence of the Business Combination, was automatically exercised for shares of Legacy TriSalus Common Stock. Legacy TriSalus Warrants that were out-of-the-money and automatically expired worthless in accordance with their terms were cancelled for no consideration. Following the Legacy TriSalus Preferred Stock Conversion and the exercise of the Legacy TriSalus Warrants, the Legacy TriSalus Common Stock was converted into the right to receive such number of shares of TriSalus Common Stock as was equal to (i)&#160;the number of shares of TriSalus Common Stock </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">multiplied by </i><span style="font-family:'Times New Roman','Times','serif';">(ii)&#160;the Exchange Ratio (subject to rounding mechanisms as described in the Merger Agreement). The total shares of TriSalus Common Stock issued to holders of Legacy TriSalus Common Stock was 21,999,886, which includes the issuance of Legacy TriSalus Common Stock resulting from the Legacy TriSalus Preferred Stock Conversion and exercise of Legacy TriSalus Warrants. At Closing, each outstanding option to purchase shares of Legacy TriSalus Common Stock, whether or not then vested and exercisable, was assumed and converted into an option to purchase such number of shares of TriSalus Common Stock as was equal to (i)&#160;the number of shares of Legacy TriSalus Common Stock subject to such option prior to the Closing </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">multiplied by </i><span style="font-family:'Times New Roman','Times','serif';">(ii)&#160;the Exchange Ratio (subject to rounding mechanisms described in the Merger Agreement), with a per share exercise price equal to the exercise price prior to the Closing </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">divided by </i><span style="font-family:'Times New Roman','Times','serif';">the Exchange Ratio. The Exchange Ratio was 0.02471853.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination, the Preferred Stock PIPE Investment closed with the Preferred Stock PIPE Investors purchasing 4,015,002 shares of Series&#160;A Convertible Preferred Stock at a purchase price of $10.00 per share, for an aggregate purchase price of approximately $40.2 million.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.96%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total Capitalization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">TriSalus Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21,999,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">72.6</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">MTAC Public Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">254,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.8</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Preferred Stock PIPE Investors<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,015,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13.2</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Holders of founder shares<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,062,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13.4</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">30,331,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes the 4,015,002 shares of Series&#160;A Convertible Preferred Stock issued at $10.00 per share in the Preferred Stock PIPE Investment are converted into shares of TriSalus Common Stock at the initial conversion price of $10.00 per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 3,125,000 Sponsor Earnout Shares that are subject to vesting and forfeiture if the TriSalus Common Stock does not meet certain price thresholds following the Closing Date. While unvested, holders of the Sponsor Earnout Shares will have full ownership rights to the Sponsor Earnout Shares, including the right to vote such shares. The founder shares (including Sponsor Earnout Shares) were distributed pro rata to the members of the Sponsor in connection with the consummation of the Business Combination.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting for the Business Combination</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Business Combination has been accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, MTAC has been treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, the Legacy TriSalus stockholders have a majority of the voting power of TriSalus, Legacy TriSalus comprises all of the ongoing operations of TriSalus, Legacy TriSalus has appointed a majority of the governing body of TriSalus, and Legacy TriSalus&#8217; senior management comprises all of the senior management of TriSalus. Accordingly, for accounting purposes, the Business Combination has been treated as the equivalent of Legacy TriSalus issuing shares for the net assets of MTAC, accompanied by a recapitalization. The net assets of MTAC have been stated at historical cost, with no goodwill or other intangible assets recorded. The financial statements of TriSalus represent a continuation of the financial statements of Legacy TriSalus.</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting for the Sponsor Earnout Shares</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriSalus has restructured the 6,250,000 shares of common stock previously outstanding and held by the Sponsor (the &#8220;Sponsor Shares&#8221;), with such Sponsor Shares reclassified into shares of TriSalus Common Stock as of the Closing. Thirty-five percent (35%), or 2,187,500 shares, of the Sponsor Shares have been forfeited and canceled as of the Closing; fifteen percent (15%), or 937,500 shares, of the Sponsor Shares have fully vested and are free from forfeiture; and fifty percent (50%), or 3,125,000 shares, of the Sponsor Shares are subject to vesting and forfeiture if the TriSalus Common Stock does not meet certain price thresholds prior to the fifth anniversary of the Closing Date. One-fourth of the Sponsor Earnout Shares will vest when the volume-weighted average price (&#8220;VWAP&#8221;) of the TriSalus Common Stock price equals or exceeds $15.00 per share for at least 20 trading days during any 30 trading-day period, one- fourth of the Sponsor Earnout Shares will vest when the VWAP of the TriSalus Common Stock price equals or exceeds $20.00 for at least 20 trading days during any 30 trading-day period, one- fourth of the Sponsor Earnout Shares will vest when the VWAP of the TriSalus Common Stock price equals or exceeds $25.00 for at least 20 trading days during any 30 trading-day period, and the remaining one-fourth will vest when the VWAP equals or exceeds $30.00 for at least 20 trading days during any 30 trading-day period. Additionally, the Sponsor Earnout Shares will vest if there is a change in control of TriSalus on or before the 5th anniversary of the Closing Date that results in the holders of TriSalus Common Stock receiving a price per share equal to or in excess of the applicable earnout targets.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accounting for the Sponsor Earnout Shares was evaluated under ASC Topic 480, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Distinguishing Liabilities from Equity</i><span style="font-family:'Times New Roman','Times','serif';">, and ASC Subtopic 815-40, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own</i><span style="font-family:'Times New Roman','Times','serif';"> </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Equity</i><span style="font-family:'Times New Roman','Times','serif';">, to determine if the Sponsor Earnout Shares should be classified as a liability or within equity. The analysis concluded that the Sponsor Earnout Shares subject to vesting are freestanding from other shares of common stock held by the Sponsor and do not meet the criteria in ASC 815-40 to be considered indexed to the TriSalus Common Stock. As a result, the Sponsor Earnout Shares was classified as a liability.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting for the Preferred Stock PIPE Investment</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with closing of the Business Combination, MTAC issued 4,015,002 shares of TriSalus&#8217; Series A Convertible Preferred Stock, with a par value of $0.0001 per share (the &#8220;Series A Convertible Preferred Stock&#8221;), at a purchase price of $10.00 per share, for gross proceeds of approximately $40.2 million. The Series A Convertible Preferred Stock will initially be convertible into shares of TriSalus Common Stock at $10.00 per share, subject to customary adjustments and a conversion price reset feature, at any time at the option of the holder. The Series A Convertible Preferred Stock will also automatically convert into shares of TriSalus Common Stock, at the then-applicable conversion price, upon the four- year anniversary of the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;A Convertible Preferred Stock accrues cumulative dividends at 8.0% per annum, which will be paid upon declaration by the board of directors, upon liquidation, or upon conversion. It will also participate in any dividends or distributions (other than dividends paid in the form of TriSalus Common Stock, convertible securities, or options) made to the common stockholders on an as-converted basis. Dividends may be paid in cash or, at the election of the TriSalus, by delivery of shares of the TriSalus Common Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accounting for the Series A Convertible Preferred Stock was performed whereby ASC Topic 480, Distinguishing Liabilities from Equity, ASC Subtopic 815-15, Derivatives and Hedging&#8201;&#8212;&#8201;Embedded Derivatives and ASC Subtopic 815-40, Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity were considered in determining whether the Series A Convertible Preferred Stock should be classified as a liability or within equity. As part of that analysis, it was determined that the Series A Convertible Preferred Stock does not meet the criteria in ASC 480 to be classified as a liability, rather, it meets the criteria in ASC 815-40 to be considered indexed to the TriSalus Common Stock and classified as equity. Further, it was determined that there aren&#8217;t any embedded features that require bifurcation or result in a classification outside of permanent equity. As a result, the Series A Convertible Preferred Stock was classified as equity.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Financing and Related Events</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-weight:normal;">MTAC&#160;&#8212; Final Redemption</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in the proxy statement/prospectus, MTAC provided holders of its shares of Class&#160;A Common Stock with the opportunity to have all or a portion of their shares redeemed for cash upon the closing of the Business Combination. On August&#160;8, 2023, MTAC held a special meeting of stockholders, at which, holders of an aggregate of 890,499 shares of MTAC&#8217;s Class&#160;A </span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Common Stock elected to exercise their right to redeem their shares for a pro rata portion of the funds in the Company&#8217;s trust account (the &#8220;</span><span style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account</span><span style="font-family:'Times New Roman','Times','serif';">&#8221;).&#160;As a result, approximately $9.4 million (approximately $10.58 per redeemed share) was removed from the Trust Account to pay such holders.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Basis of Pro Forma Presentation</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The historical financial information has been adjusted to give pro forma effect to the transaction accounting required for the Business Combination. The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an accurate understanding of the post-combination entity upon the Closing. A pro forma condensed combined balance sheet has been omitted from the pro forma condensed combined financial information presented given the Company&#8217;s balance sheet data as September 30, 2023 included elsewhere in this prospectus already reflects the Closing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information is for illustrative purposes only.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the post-combination entity will experience. Legacy TriSalus and MTAC have not had any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting Policies</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Following consummation of the Business Combination, management is performing a comprehensive review of Legacy TriSalus&#8217; and MTAC&#8217;s accounting policies. As a result of the review, management may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of TriSalus. Based on its initial analysis, management did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro forma condensed combined financial information does not assume any differences in accounting policies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_348975c3_3878_43dc_a250_f448de940572"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Unaudited Pro Forma Condensed Combined Statement of Operations</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">For the Nine&#160;Months Ended September&#160;30, 2023</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TriSalus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MTAC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,790</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,023</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">10,767</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">10,767</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,871</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,430</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,600</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(40,032</b>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(4,102)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(44,134)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(A)</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">187</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(13)</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,171)</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of warrant and tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(B)</p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(4,177)</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gain on conversion of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income and expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(56)</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(Loss) income before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(23,521)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(3,664)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(3,955)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(31,141)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">78</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;"><b style="font-weight:bold;">Net (loss) income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(23,529)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(3,734)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(3,955)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(31,219)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net (loss) income per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares outstanding of Class A common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,025,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted net income per share, Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares outstanding of Class B common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,954,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted net income per share, Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average shares outstanding of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,749,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,191,681</p></td></tr><tr><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted net loss per share, common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(5.68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.45)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The period presented for MTAC is from January 1, 2023, through August 10, 2023, prior to the completion of the Business Combination.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f38d1d5d_2139_45ba_99cc_7d0290de9b35"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Unaudited Pro Forma Condensed Combined Statement of Operations</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">For the&#160;Year Ended December&#160;31, 2022</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in thousands, except share and per share data)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TriSalus</b><br/><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MTAC</b><br/><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><br/><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;width:3.91%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma</b><br/><b style="font-weight:bold;">Combined</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Revenue</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">12,398</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">12,398</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Cost of goods sold</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">2,258</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">2,258</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">10,140</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">10,140</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Operating expenses:</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Research and development</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">21,358</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">21,358</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Sales and marketing</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">12,738</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">12,738</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">General and administrative</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">12,483</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">2,746</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">15,229</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(36,439)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(2,746)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.94%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:7.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(39,185)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Interest income</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">180</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">3,019</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(3,019)</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#221f1f;">(C)</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">180</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Interest expense</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(1)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(1)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Change in fair value of warrant and tranche liabilities</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(2,186)</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">5,837</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">2,186</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(D)</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">5,837</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Loss on equity issuance</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">(8,312)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(8,312)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Other income and expense, net</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">(420)</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(420)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(Loss) income before income taxes</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(47,178)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">6,110</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.94%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:7.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(833)</b></p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(41,901)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Income tax expense</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">9</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">571</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">&#8212;</span></p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">580</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">Net (loss) income</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(47,187)</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="color:#221f1f;font-weight:bold;">5,539</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:7.7%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(833)</b></p></td><td style="vertical-align:bottom;width:3.91%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.87%;border-bottom:2.25pt double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#221f1f;font-weight:bold;">(42,481)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Net (loss) income per share:</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Weighted average shares outstanding of Class&#160;A common stock, basic and diluted</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">23,358,326</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Basic and diluted net income per share, Class&#160;A common stock</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">0.19</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Weighted average shares outstanding of Class&#160;B common stock, basic and diluted</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">6,250,000</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Basic and diluted net income per share, Class&#160;B common stock</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">0.19</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Weighted average shares outstanding of common stock, basic and diluted</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">309,609&#160;</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="color:#221f1f;">23,191,681</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="color:#221f1f;">Basic and diluted net loss per share, common stock</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(161.55)</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#221f1f;">$</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#221f1f;">(1.97)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2560685b_7c8b_4e84_8987_055f0716744b"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOTES&#160;TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Basis of Presentation</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The pro forma adjustments have been prepared as if the Business Combination had been consummated on January 1, 2022, the beginning of the earliest period presented, in the case of the unaudited pro forma condensed combined statements of operations. A pro forma condensed combined balance sheet has been omitted from the pro forma condensed combined financial information presented given the Company&#8217;s balance sheet data as September 30, 2023 included elsewhere in this prospectus already reflects the Closing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information has been prepared assuming the following methods of accounting in accordance with GAAP.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of TriSalus issuing stock for the net assets of MTAC, accompanied by a recapitalization. The net assets of MTAC was stated at historical cost, with no goodwill or other intangible assets recorded. The financial statements of TriSalus represents a continuation of the financial statements of Legacy TriSalus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial statements were prepared in accordance with Article&#160;11 of SEC Regulation S-X, as amended by the final rule, Release No.&#160;33-10786, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Amendments to Financial Disclosures about Acquired and Disposed Businesses</i><span style="font-family:'Times New Roman','Times','serif';">. Release No.&#160;33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the Business Combination and related transactions (&#8220;Transaction Accounting Adjustments&#8221;). The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information does not give effect to any tax impacts associated with the pro forma adjustments as such pro forma adjustments result in the generation of additional net operating losses offset by a full valuation allowance recorded on such net operating losses as it is more likely than not that the net operating losses will not be utilized.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The pro forma adjustments reflecting the completion of the Business Combination and related transactions are based on currently available information and assumptions and methodologies that management believes are reasonable under the circumstances. The pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the difference may be material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Business Combination and related transactions based on information available to management at the current time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination and related transactions taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of TriSalus. They should be read in conjunction with the historical financial statements and notes thereto of Legacy TriSalus and MTAC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_43478ddd_a176_4bf8_8502_5ec89b15bcd2"></a><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transaction Accounting Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Statement of Operations for the Nine Months Ended September 30, 2023</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The adjustments included in the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023, are as follows:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(A)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the elimination of interest earned on investments held in the Trust Account.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(B)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the elimination of the change in fair value of Legacy TriSalus warrant and tranche liabilities as a result the settlement of the Legacy TriSalus Warrants and expiration of the tranche rights at or immediately prior to the Closing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3736cd30_8594_464d_847e_b6522720070f"></a><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">Transaction Accounting Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended December 31, 2022</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022, are as follows:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">(C)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Reflects the elimination of interest earned on investments held in the Trust Account.</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">(D)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';">Reflects the elimination of the change in fair value of Legacy TriSalus warrant and tranche liabilities as a result the settlement of the Legacy TriSalus Warrants and expiration of the tranche rights at or immediately prior to the Closing.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a37fc645_ebb6_4f4f_b432_2f0e98ccc527"></a><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Net Loss per Share</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The pro forma weighted average shares calculations have been calculated for the nine&#160;months ended September&#160;30, 2023 using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the Business Combination occurred on January&#160;1, 2022. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding for both basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. Holders of Legacy TriSalus Common Stock received shares of TriSalus Common Stock in an amount determined by application of the Exchange Ratio.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The 3,125,000 Sponsor Earnout Shares are not considered outstanding from an accounting perspective. Further, due to the fact that the Sponsor Earnout Shares are contingently issuable for accounting purposes based upon TriSalus Common Stock share price reaching specified thresholds that have not yet been achieved, the Sponsor Earnout Shares have been excluded from basic and diluted pro forma net loss per share.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potential outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because their effect would have been anti-dilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sponsor Earnout Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">3,125,000</p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock Options (formerly TriSalus Options)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">1,759,366</p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted Stock Units (&#8220;RSU&#8217;s&#8221;) (formerly TriSalus RSU&#8217;s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">184,018</p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">8,333,272</p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">5,933,333</p></td></tr><tr><td style="vertical-align:bottom;width:81.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">4,015,002</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The unaudited pro forma condensed combined net loss per share has been prepared for the nine months ended September 30, 2023 and the year ended December 31, 2022 (in thousands, except for share and per share data):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Nine Months</b> <b style="font-weight:bold;">Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Year Ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:19.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined Pro Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:19.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined Pro Forma</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro forma net loss &#8211; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(31,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(42,481)</p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less: Annual 8% cumulative dividend for Convertible Preferred Shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,409)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,212)</p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to common Stockholder</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(33,628)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(45,693)</p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro forma weighted average shares of common stock outstanding &#8211; basic and diluted<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,191,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,191,681</p></td></tr><tr><td style="vertical-align:bottom;width:56.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Pro forma basic and diluted net loss per share</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1.97)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Excludes the effects of potentially dilutive shares from Sponsor Earnout Shares, Series&#160;A Convertible Preferred Stock, stock options, public warrants, and Private Placement Warrants from the computation of diluted net loss per share because including them would have had an antidilutive effect.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_459fb305_acdd_42c0_9cd5_0b914f81dd90"></a><a id="INDEXTOFINANCIALSTATEMENTS_415916"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AUDITED FINANCIAL STATEMENTS:</b></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm (WithumSmith+Brown, PC)</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEET_801827"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTOFOPERATIONS_447144"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTOFCHANGESINSTOCKHOLDERSEQUITY_5"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Deficit for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTOFCASHFLOWS_886732"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AuditedNOTE1DESCRIPTIONOFORGANIZATIONAND"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TRISALUS LIFE SCIENCES,&#160;INC.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">UNAUDITED FINANCIAL STATEMENTS:</b></p></td><td style="vertical-align:bottom;width:6.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Balancesheet2"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022</span></a></p></td><td style="vertical-align:bottom;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-25</p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Statementofoperations_2"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2023 and 2022 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-26</p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholdersEquity_2"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Deficit for the Nine Months Ended September 30, 2023 and 2022 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-27</p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CashFlow_2"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-29</p></td></tr><tr><td style="vertical-align:bottom;width:93.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notes_2"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-30</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AUDITED FINANCIAL STATEMENTS:</b></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudReportofIndependentRegisteredPubli"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm (KPMG LLP)</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-52</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudCONSOLIDATEDBALANCESHEETS_592299"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-53</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudCONSOLIDATEDSTATEMENTSOFOPERATIONS"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-54</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudCONSOLIDATEDSTATEMENTSOFSTOCKHOLDE"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Deficit for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-55</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudCONSOLIDATEDSTATEMENTSOFCASHFLOWS_"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-56</p></td></tr><tr><td style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TriAudNOTESTOCONSOLIDATEDFINANCIALSTATEM"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-57</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_331f188c_8b1b_4d3b_9687_d81b029fddc4"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and the Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Medtech Acquisition Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying balance sheets of Medtech Acquisition Corporation (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations, changes in stockholders&#8217; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs and complete a business combination by June&#160;22, 2023 then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ WithumSmith+Brown, PC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, New York</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">March 22, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PCAOB Number 100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d67c90c7_957a_4588_9030_a1548fe1364f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><a id="_48698_0"></a><a id="BALANCESHEET_801827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1cd372f8_e2c4_455a_9500_467e06612961"></a><a id="Tc_01WJ5D9z20qShUfMW5SwAg_1_2"></a><a id="Tc_Xow2A_7wq0uSUR9Z1QX3bQ_2_2"></a><a id="Tc_o_VmsI0n30uUjijiGVUCTg_2_5"></a><a id="Tc_FT1CF2c_UE6o21tg6bA1Fg_3_0"></a><a id="Tc_vxIRoodeQ0W6K-Nva5te6g_4_0"></a><a id="Tc_1XmckQPpJUmELYTBYsvNQQ_5_0"></a><a id="Tc_BNcQ5ryldEaWtMcKeCfQag_5_2"></a><a id="Tc_r6U0n7JQ6k64SRn49132CQ_5_5"></a><a id="Tc_Y5mtiFrjH0K6shhxXIs43g_6_0"></a><a id="Tc_Cc2JUeAczkyp5qwGUniGFA_7_0"></a><a id="Tc_HuBcVH6NF0y_sU1dCD_u3g_8_0"></a><a id="Tc_1yLgKCWbQ06W4-KbS_vRFA_9_0"></a><a id="Tc_sXu8x8tQcEqDwdXCDOekhA_9_2"></a><a id="Tc__PY0Dx9Bok68YfGJMSAstA_9_5"></a><a id="Tc_gTnF2swEWEGatMEd9x1xmQ_10_0"></a><a id="Tc_6fqLIDkKokuXcOztQL1h8A_11_0"></a><a id="Tc_OD56pViDA0CGuynTdmu1Sw_12_0"></a><a id="Tc_JOUWuSPNh0-YsAaMXCsjxA_13_0"></a><a id="Tc_8eCRgU8jmkqh6sFXGrSkOQ_13_2"></a><a id="Tc_ChKiRH7W7UW1aWd9QNMiVw_13_5"></a><a id="Tc_fGlSK1DiRkmXnygEnHp-Pg_14_6"></a><a id="Tc_0aYEzBiOlkazf2R8ymQHYA_15_0"></a><a id="Tc_SmhoDP62kUSaHIFy8ls-Fw_15_6"></a><a id="Tc_x0JgKU0RdkS5g7FtOtBWUA_16_0"></a><a id="Tc_CmoNu3gEFkO5crQQHEHczw_16_6"></a><a id="Tc_i-5oWpln1UOY3QuerJbKbA_18_0"></a><a id="Tc_eW4C77ZxkUyoAEO6S7ykUA_19_0"></a><a id="Tc_7dVGa-5SqUiJIojHXWY32w_20_0"></a><a id="Tc_FwWFbNcA80CaXyJ07gz4qw_20_6"></a><a id="Tc_mycM6JpH_EC_LF1lXDt0Ug_21_0"></a><a id="Tc_VoF7YT3R2kq8BukolOSZKQ_22_0"></a><a id="Tc_v2uUO1QWmUmk-AP1qQX88g_23_0"></a><a id="Tc_pRllNEfRjEmC8hkcJ6taCg_24_0"></a><a id="Tc_Y9Up_ZfwmEO-4yjIC4F1zw_25_0"></a><a id="Tc_4avRPg-vHES_GOZgHgIURA_26_0"></a><a id="_470e89cc_7e11_44c4_bc19_d7bf438559d2"></a><a id="_470e89cc_7e11_44c4_bc19_d7bf438559d2_2"></a><a id="_470e89cc_7e11_44c4_bc19_d7bf438559d2_3"></a><a id="Tc_KU0YKp4nIUesATwIQXKrVg_26_3"></a><a id="Tc_3-piCS0fT0KxvNgo8Klw-w_26_6"></a><a id="Tc_RfRine6E0UuLfsIesYgNNg_27_0"></a><a id="_6baa6aeb_5fa3_499e_aa5e_ca491201f7ed"></a><a id="_6baa6aeb_5fa3_499e_aa5e_ca491201f7ed_2"></a><a id="_6baa6aeb_5fa3_499e_aa5e_ca491201f7ed_3"></a><a id="Tc_tqIQ-6MuCkG9rj05glanAw_28_0"></a><a id="_df459343_8f42_4469_a123_81b70e792514"></a><a id="_df459343_8f42_4469_a123_81b70e792514_2"></a><a id="_df459343_8f42_4469_a123_81b70e792514_3"></a><a id="Tc_8alkm7eImkivj2PNZmvmxg_29_0"></a><a id="Tc_JB4sIDxWZ0i33FL4AHiAmg_29_3"></a><a id="Tc_wQ0VB7yBd0m3WPGa6IZLKQ_29_6"></a><a id="Tc_TsqiIrL1yU-KBQSxVwnEyw_30_0"></a><a id="Tc_xWB8jLKOyUGuiD6VowiN2g_31_0"></a><a id="Tc_3sYrDdDSek6vIGQ8YXVG-g_32_0"></a><a id="Tc_xu95VmGtxUy1i_hwcoC5SQ_32_2"></a><a id="Tc_OgIS7h8htkG5IpmcAyZTDw_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_x0dUB3ew-0yUGkZevDm5Eg_5_3">153,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_rZo0p5aG_0yhCRPY07BJEw_5_6">200,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_sxjyX8MHvUOUnE4u35DXSQ_6_3">206,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_cIxroCf06kmBeL4RmPuHiQ_6_6">325,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_swoR3bwu_kaZdXxIPZmI8g_7_3">359,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_LGoYiGhaGkKtK2dXXYa4Yg_7_6">525,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Tc_89uUqth8UUSYaMc6zEBSmg_8_3">19,827,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Tc_XKxLJB6H8EKeVF0umFksog_8_6">250,007,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_-cJJZq1Q20mUibKmU5OQ7w_9_3">20,187,776</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_NOxhBxpHq0KSTa3rQ6oHiQ_9_6">250,533,179</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES, CLASS A COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_QBoqo2l0qUikTt0vdhllfw_13_3">1,442,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_JsWm48ij0EicXa-tH7Q6yw_13_6">1,057,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_6NASHxsNhUWqUIlF6AmGRw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to stockholders</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_BejHiuQgCU69i7rHrcjkeg_14_3">48,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" id="Tc_PqzxRfK6-U-Nc7BNCPrsjQ_15_3">27,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Extension Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:ExtensionNotesPayableCurrent" scale="0" id="Tc_SuSYIrSaD0Sn36YJWCSvqw_16_3">39,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iNvGd1yKm0-3yMIN_CTOsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Promissory note &#8211; related party</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_zEWg2RfbcEmQx3Wfmn1PVw_17_3">944,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_cBS-D1_tDkiHDiu2_aRjoQ_17_6">544,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_mJe2zsZH4kOfjy-NS1oSag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2,501,998</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_4ThZ1Eq4zU2FXKlTiy2UKA_18_6">1,601,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_wCj6nAF7oEW7IXdE-SizHg_19_3">1,061,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_1pA6jIKIlEaLIDz0X7UGXQ_19_6">6,898,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Convertible Promissory Note &#8211; related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent" scale="0" id="Tc_FXmmh-oYxUC3_nN730y0IA_20_3">1,341,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred underwriting fee payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredOfferingCostsNoncurrent" scale="0" id="Tc_lMZz1d8NPEuDxTfAX9JWOw_21_3">8,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredOfferingCostsNoncurrent" scale="0" id="Tc_DUzfIbbKj0yo5glcqTcW5w_21_6">8,750,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_KypFHsXMS0ayMg6apUcw9w_22_3">13,654,332</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_rdak905SxE--g21BpnToYQ_22_6">17,250,282</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and Contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock subject to possible redemption, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_Y_yhmdr71E--bX7qX83Nog">1,953,422</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_h_vlZdstsEG9iuG-9-BaGQ">25,000,000</ix:nonFraction> shares at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_6KKYnwqYHUKzw91JDi8wbA">10.14</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_ZUGASeT5C0mBew4874_1HA">10.00</ix:nonFraction> per share redemption value as of December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_vli6dic-PkGlhmL-zOliVQ_24_3">19,800,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Ny9vWmOp_E226wGcsC3npw_24_6">250,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_GWxX8VER5U2UjbRjYBT9HQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_M82xDr6GLE2-nYsEGBPRgg">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_zL2ndLzyMEWsYbI5bXQv5g"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_EXlIZxwq50Ko8RnDx2VHNg">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_obvS9J01YEG7bd87grKN8A"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_xE5Vw63KSU2qLoEOnmBWGg">none</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_fA3JhCbA-0icWvDz_u-5Bg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4jQV-f3t902kv0rCHr4KJg">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_LGlOR82muUiO_whfVA_VJg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_TA6UlvTiUUW0egly3GAjmw">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_VHfe_ZajkkK_AzrqAD684g"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_HwsEIJ9Lr0-hOBcvxYY10g">none</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__l_n-zwG9EeRbMmLFtmXMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2f0FE7DwkUujpx4HM72l_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Class B common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_LuwY8nUJPEqjwlEwgv9drw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_8rqva54S2Uqhmh9j9Hhv6g">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_B9CyYkjJpUiuBXt_JxhFPA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bcJoZEAtrEmI_rp0R2Hhww">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_R2G78H41gEqG85uKOjPCxg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_lAPmT4AoJ0yA3XPN9H_IFw">6,250,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_Duavmn9x20O4awbQx4vPkg_28_3">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_mLohlHD1e0-vSs0hdMqJJQ_28_6">625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_RLQP9LcEGk6C-omcVMf_4w_30_3">13,267,211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_zBCEB2CSC0KMWuPsQ1jjEQ_30_6">16,717,728</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ToaEEhHFpkaRc25W0upe7w_31_3">13,266,586</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_RztVn65v7EO5xRJeiuwNXQ_31_6">16,717,103</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES, CLASS A COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_nH7ngSD-G06ysf2JLL3D7w_32_3">20,187,776</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_kN9udw-gS0Osqb8p7CzCBQ_32_6">250,533,179</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6a260aef_61f3_43f0_b4c7_bef765f21be4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><a id="_862950_0"></a><a id="STATEMENTOFOPERATIONS_447144"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_dfc88694_d3c5_4739_9bf3_a06553ffe13a"></a><a id="_a31867a4_29ff_496e_b4d2_24df5a9a9f9b"></a><a id="Tc_X_d9ePDgcUOirG9_ECD_NA_1_2"></a><a id="Tc_wMjiNCocuE-6oG3vlsUz3g_2_2"></a><a id="Tc_3l-BLX1mu0mbNkJF5pRAsA_3_2"></a><a id="Tc_v_u3Xq40EUu9NFNLuDadVQ_3_5"></a><a id="Tc_XPXmt7xv9ESrOsxoUQWpWw_4_0"></a><a id="Tc_xjnzmgmSyEKTMowt24WYGw_4_2"></a><a id="Tc_UcLeT5RwrUmtrJCoe__Pkw_4_5"></a><a id="Tc_YIXXQ5zeaUiWZa9q9n9N0A_5_0"></a><a id="Tc_D_qnM0bZCU2b11oVMPZSTA_6_0"></a><a id="Tc_KNZ2kYFaMEG5d1ee6UadBA_7_0"></a><a id="Tc_qfhPrftPpE2nsNZIwBLjKg_8_0"></a><a id="Tc_RyPWKtt6iUyEv1zw_ko7DA_9_0"></a><a id="Tc_-POhsW3BJ0uVCRSRe3G_mQ_10_0"></a><a id="Tc_cUniNNYMhEq4bdivL3D6rw_11_0"></a><a id="Tc_cprCVj9eqEiDXEIPQf4Pqg_11_6"></a><a id="Tc_hLuaaogQoku0EWCXoT31JA_12_0"></a><a id="Tc_c37IE1XUN0SVY1YF3Q-VfQ_12_2"></a><a id="Tc_WHnaOiugV02xkYrJgUBDnQ_12_5"></a><a id="Tc_nQKNmW4bokabFiRPpgwtLw_13_0"></a><a id="Tc_c0d5aykDzEuEIyWCNN8sqA_14_0"></a><a id="Tc_gPeh2v3CFUmGOeHE4A1IJQ_14_2"></a><a id="Tc_dGdSVc-y1kmTxR1CJYNxYg_14_5"></a><a id="Tc_vesAIppLbkGS5ax2uGQgVw_15_0"></a><a id="Tc_9ITjpzlM1EOaQ5bxu3MLYQ_16_0"></a><a id="Tc_MlIdPRdcR06TaKEQwdcSYw_16_2"></a><a id="Tc_W9kvbdHfbEiV8lTz09RB7A_16_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_8Sca9tTpJUm9j1iPeGzIUg_4_3">2,746,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_kp9wUOysn0660TnYeUAPqQ_4_6">3,040,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_BIzYqst5lEKrb2Azi9oOdg_5_3">2,746,125</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_HBg7awgH10aVdpV4TfWlSw_5_6">3,040,714</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_1XZwOds3I0qF9Zd1U5fVZg_7_3">5,837,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_rUBhijw9VkGNM6ybBa78kA_7_6">7,744,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest earned on cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_-aJ_ZYLKuk-MnfSOkhBiyQ_8_3">3,018,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_7G2jQmF4FUCjA_qibn2LhA_8_6">63,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Total other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_KbSmuGcqw0myc87Exc_U3w_9_3">8,856,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_1AlPwgz740KWs451LBsdww_9_6">7,807,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income before provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_tOFALvz-70CU3bVNd4YYcw_10_3">6,109,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_l7RN4GmhvUWqj8SFT4OgSA_10_6">4,767,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_AWIUcZJ_Gk6ddKftBEGPpg_11_3">570,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Net income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_QY-yEJRpMU2MItxWXLnDYw_12_3">5,539,079</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_5wVomSSuC0-_hlvQzLA6Dw_12_6">4,767,283</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding of Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6p0-Q8tbEk6axrpvD3d37w_13_3"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6p0-Q8tbEk6axrpvD3d37w_13_3_2">23,358,326</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EevRoZWFA0eUZwTfB0a71g_13_6"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_EevRoZWFA0eUZwTfB0a71g_13_6_2">25,000,000</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Basic and diluted net income per share, Class A common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_jXeNqKWEAUaga38gOQbp-w_14_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_jXeNqKWEAUaga38gOQbp-w_14_3_2">0.19</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_LdTQR3rDGkO3kKBzfFNT7A_14_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_LdTQR3rDGkO3kKBzfFNT7A_14_6_2">0.15</ix:nonFraction></ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding of Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ZHkShQ6y50CNavdSOhiPhA_15_3"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ZHkShQ6y50CNavdSOhiPhA_15_3_2">6,250,000</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NhKo7w3E0kukoZNrXGIeXw_15_6"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_NhKo7w3E0kukoZNrXGIeXw_15_6_2">6,250,000</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Basic and diluted net income per share, Class B common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_8eXDDkV0z0Cvh63bEG1QQw_16_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_8eXDDkV0z0Cvh63bEG1QQw_16_3_2">0.19</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_Jf8EdWMAtU-wFr5oCSj6GQ_16_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_Jf8EdWMAtU-wFr5oCSj6GQ_16_6_2">0.15</ix:nonFraction></ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_566b2b2a_fe24_43ea_8cf4_a258b0a9afe0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_803524_0"></a><a id="STATEMENTOFCHANGESINSTOCKHOLDERSEQUITY_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_165a2417_2f68_4f46_b7bf_7621725fc90d"></a><a id="Tc_28y6aL6e2Ey3MhMNsodPgQ_1_2"></a><a id="Tc_CanRI6fNTUGmWNx4n7EmJg_1_7"></a><a id="Tc_NTVR9ZQulkmBfQrlw3bGGw_1_13"></a><a id="Tc_Sa70U5I5k0Kk5CPfvLB9HQ_2_2"></a><a id="Tc_7BgB_3sdV0OSWhF_Dj2k4w_2_7"></a><a id="Tc_qGKYA4I0_kyk-hVWcryBMg_2_10"></a><a id="Tc_2t9Uoz7P3kCahcbhTORKFA_2_13"></a><a id="Tc_IU0BBI9p_0qS_s6pZlcSkg_3_2"></a><a id="Tc_pNOFgnrsbUi6dHI7bSHuzA_3_4"></a><a id="Tc_fS3U8oNQY0qZhtJ0lsUakw_3_7"></a><a id="Tc_9PLC06cTF0a62HLm-fn8cA_3_10"></a><a id="Tc_715XftptG0mqu8l9NLS8Zg_3_13"></a><a id="Tc_Xy89eTxQsUig1w_ylYWMBw_4_0"></a><a id="Tc_tNrqNkq5IkqeESIJiw-9ZA_4_4"></a><a id="Tc_xeLnGRnnVES8mX7UtAKXJA_4_7"></a><a id="Tc_ZSRKlEYuNEu_2Jms_1SClg_4_8"></a><a id="Tc_hGTP5LBxLk22Udobcsxbpw_4_10"></a><a id="Tc_5OfXhzuF8E2sb8CkVT1UuA_4_13"></a><a id="Tc_1J-p63vnhESBKarWG_tf9w_5_0"></a><a id="Tc_EYpfzWlxkEqhOGEZW9o9Jg_5_2"></a><a id="Tc_uBXHFkP3QEe1UQ7MOGzzQQ_5_5"></a><a id="Tc_sG9OCheU602j4qztQHB7XA_5_8"></a><a id="Tc_Oa_mIo_GNE-688_C6hLwoQ_6_0"></a><a id="Tc_bOuLjU85fEu0Vs4y6g9qTw_6_8"></a><a id="Tc_alu9na-I5k2krot9FJX0yw_7_0"></a><a id="Tc_I6Wk1S85BEeyA3L_qSfB4Q_7_2"></a><a id="Tc_cHDDqqlJ4kOZsysYoQWY4g_7_5"></a><a id="Tc_NJF0GJe640WQYfWr8vI5Bg_7_11"></a><a id="Tc_ntb3OqvZ0kKxJhOCj_BXKg_8_0"></a><a id="Tc_G90ApE66iEWaviyGbX6SNA_8_2"></a><a id="Tc_bf59zb7tmEC7dN5nObZn2g_8_5"></a><a id="Tc_1rL2mgjcCUC2ktDlqhpLdg_9_0"></a><a id="Tc_pKfrfSfKqEq3SK7GtU0UoA_9_2"></a><a id="Tc_9rMmTFhnKECXa6ur0lQZRw_9_5"></a><a id="Tc_dtT1iLHWJk618R2tovD3-A_9_8"></a><a id="Tc_loTmcasQkkezlhyzwOTWxg_10_0"></a><a id="Tc_ktpGLEwoV0O0VQwjC42_Qw_10_4"></a><a id="Tc_tTNrdK_EIEi8Z2nwY28HxQ_10_7"></a><a id="Tc_co0tcFNRk0q6pUVep9CEjQ_10_8"></a><a id="Tc_JaskYzAB9UaksSmfmzkwrA_10_10"></a><a id="Tc_e-70pZq-qUWPibEsyjRb3w_10_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;&#8211; January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_UVmivPCUcU646KXwQvHugg_4_2">6,250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" scale="0" id="Tc_fjc6sBsxVUuRinMVa84oXg_4_5">625</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_26RYOBDJd0m4B-qQpNBrnA" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_5KhIQyYNWUKitCp_Ha6mzw_4_11">21,485,011</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_PTSD97EW-kmWUsNiYEIWUQ_4_14">21,484,386</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BHFAAUN4h0mbBW1Dpe_8vg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_DC2hL3q76EmslnZfpAnWAw_5_11">4,767,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_-Cf_sHKilUutkvVRDEtxWg_5_14">4,767,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;&#8211; December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_Y4S9j9PgvkCzsuA3Mp4bEw_6_2">6,250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" scale="0" id="Tc_cm6eTwXffEC_BxSRRTYkmw_6_5">625</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CzvQjMCE50yLWqH7Ft3yaQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_lcmku5nfDEKoe9QNLuKByw_6_11">16,717,728</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_Fq44kBmYakOu8P8ysYRtPg_6_14">16,717,103</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Investment pursuant to business combination agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w" decimals="0" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" sign="-" scale="0" id="Tc_qxDOI4mGGUehnfM6ThjBDg_7_8">82,741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" sign="-" scale="0" id="Tc_0kn2P8_tFUCzzwMr1rn7ng_7_14">82,741</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion for Class A common stock to redemption amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_FpNEsDV90Eya9mYeXvnd9g_8_8">82,741</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_0HidGjrgAku46BRFLOzb0A_8_11">2,088,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_8CL0XzXZFUWJHcRu8zhOKA_8_14">2,171,303</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_vZVbYpoGnkab9ap7y1kEtQ_9_11">5,539,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_JfasDfUOp0GnFN-OjWKRSw_9_14">5,539,079</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;&#8211; December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_2ZSF7k8TikO6wIrXF_lgVw_10_2">6,250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" scale="0" id="Tc_rnQdDMrEhEWqxbyU-200bg_10_5">625</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RT4r_FWuwky0MaFoh-QwIA" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_pZO2Fe0YRkaj1Kl4Or8-Cg_10_11">13,267,211</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:StockholderEquity" sign="-" scale="0" id="Tc_9hywFJuoW0WMebTTVJa8QQ_10_14">13,266,586</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b9cacec3_2aa6_45e0_8f95_22ef8b3c757a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_676047_0"></a><a id="STATEMENTOFCASHFLOWS_886732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_367c528c_67a6_4b63_a0e9_bd12f9f324a1"></a><a id="Tc__82kbT2KC0mtiYabrUGRSw_1_2"></a><a id="Tc_XYrBHVCT80e18wmdLePPeQ_2_2"></a><a id="Tc_G_8zBy4whE-Wo3bb7hICWg_2_5"></a><a id="Tc_xH3GTAyWfkGID_yr7io6rg_3_0"></a><a id="Tc_N5WGLSOuN0erAyW6u5_Qhw_4_0"></a><a id="Tc_FFG9I_GAcUeoHd_-IG-Qew_4_2"></a><a id="Tc_9BuT4w9tQUaxmWVHvQx9_A_4_5"></a><a id="Tc_RZUyYGjZN0ebtCign5VOtw_5_0"></a><a id="Tc_rtiwLdggT0OdKnmwbrdR-g_6_0"></a><a id="Tc_x3ARJ8ZXtUqt04E4T_CvbA_7_0"></a><a id="Tc_4QqAmQdL7ky5wEjRc6z8ow_8_0"></a><a id="Tc_hc28zIvf30aec3P9bnXK7Q_9_0"></a><a id="Tc_1u6PVk7St0WCE_FhXK7g8Q_10_0"></a><a id="Tc_alrjfL7S7k-rDxUVLs9MuQ_11_0"></a><a id="Tc_tv5j0UP3PkK40EytCEgtKg_11_6"></a><a id="Tc_icODOY1pDUmUMLqo-HLAVg_12_0"></a><a id="Tc_DMff3TbV2kqxTVOkBTYN9A_12_6"></a><a id="Tc_tDTBrdyFY0aVMAq4z2ZdYg_13_0"></a><a id="Tc_TWtDS7ztaEO166M9NBUAew_14_0"></a><a id="Tc_ZchWlutf00aGhIAq_LpaHQ_15_0"></a><a id="Tc_Xdq_fV11h0KiWWzxWBeYUw_15_6"></a><a id="Tc_aK7Mz77UEkehP4E2xPJtQA_16_0"></a><a id="Tc_sxc3mC0qOEezYTWdYkNjew_17_0"></a><a id="Tc_jBmrC_LrCkKzkH281AXoqw_17_6"></a><a id="Tc_BDRUvU6nSESYnoOGBLL2kA_18_0"></a><a id="Tc_LnCU5_H6EkSg_sUTJOo2RA_19_0"></a><a id="Tc_wNeKK1ntFkKtdDla4puHLw_20_0"></a><a id="Tc_dHcbyaAuO0ipjrMKHrceIw_20_6"></a><a id="Tc_6M-s7CnNfke-uPN4tC-XFA_21_0"></a><a id="Tc_yWj2J4ok0U-v3XuwHkzVag_22_0"></a><a id="Tc_MN_f42ns_0ecYbwmHCBWTg_22_6"></a><a id="Tc_1wD5rvxhq0WLk7TGpwBQKg_23_0"></a><a id="Tc_K4ILxgRJpECdsJZs5oX3bg_23_6"></a><a id="Tc_-d1tasoLwUmWDpsIa6Z7hQ_24_0"></a><a id="Tc_CJp_RaJ8cE6PKtgNs2RRXA_24_6"></a><a id="Tc_P_JrF3bQxEK7ghXEmdlYFg_25_0"></a><a id="Tc_cGuR0-vXa06Fv1z1MEgLkg_26_0"></a><a id="Tc_EZUBAMDCX0u5Igoucgb4Vw_27_0"></a><a id="Tc_KlGFU0vCv0i7VZQPpullaQ_28_0"></a><a id="Tc_QJGHG78NhEmXD-FXsHUlsg_28_2"></a><a id="Tc_KkzAw97d00qjgIfM0wxA2A_28_5"></a><a id="Tc_kFtrVDzmH0SZ-uU6GNoi6w_29_0"></a><a id="Tc_iMf6vI27-EWMnwqTs74V7Q_30_0"></a><a id="Tc_ttsabgncQ0q8Liv7VeZfpw_30_2"></a><a id="Tc_kwSWjyOSU0S8P-N81gc7AA_30_5"></a><a id="Tc_r122t_TNVESVlZqJczWhKg_30_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_lHC6G8xyGUqZKbt9qZGJTA_4_3">5,539,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_pxsJ3aAZIUuP0dq2t3DgAg_4_6">4,767,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net income to net cash used in operating activities:</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_ZYZ6bw3JnkCjjSIqb6K9xg_6_3">5,837,332</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_nvT4SVQGBkOT0IV34mLHcw_6_6">7,744,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest earned on cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_ydvSDK9qeECb1Excp9BnOQ_7_3">3,018,726</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_x98wRKqwcUOhdBGlgu4rIA_7_6">63,997</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_QXM-L2tT4UmAtLllT2ucQA_9_3">118,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_vxd-azam3UKOAMpCr0Olzw_9_6">348,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_FnBe3GJDXEqVuPR3g2p89g_10_3">385,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_EiYgyKHD2ECs9EQahIskqg_10_6">954,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Due to stockholders</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders" scale="0" id="Tc_P3gD8QS_G0u8IkD7CmDkCg_11_3">48,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="Tc_wNOAyT7hfkudp1MFrsakYg_12_3">27,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_DiDFs-OGDEq-cDJ8HaIxfg_13_3">2,736,994</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_fy4eDsZGz0OPsIbRFl5J8g_13_6">1,738,114</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment of cash into Trust Account</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:PaymentForInvestmentOfCashInTrustAccount" scale="0" id="Tc_5W2oSlB0dk-dgMhihi-uEg_15_3">78,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash withdrawn from Trust Account to pay franchise and income taxes</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" scale="0" id="Tc_VJCn8DLqz0eG1Y36Ocd7FA_16_3">905,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" scale="0" id="Tc_0CZMZmcSpEeVfFXBRz2Y6Q_16_6">60,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash withdrawn from Trust Account in connection with redemptions</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ProceedsFromTrustAccountInConnectionWithRedemption" scale="0" id="Tc_tKDMbdCCEkqQMVREFPngNA_17_3">232,371,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Net cash provided by investing activities</b></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_gy09Cko74EugKnZMdYI4uQ_18_3">233,198,137</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_-ltDpmoRX0e-SKUbbmHk5g_18_6">60,000</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from promissory note</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="Tc_eaKCCi1NcECELM-o0G3X2w_20_3">39,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from promissory note &#8211; related party</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" id="Tc_iBZuyObXCUOOKtdqpR9jsg_21_3">400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" id="Tc_KMXR1iAhfkKz1hE0vPO9LA_21_6">544,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from Convertible Promissory Note &#8211; related party</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" scale="0" id="Tc_3tb3RjCjPk2RLhPyNo3BJg_22_3">1,341,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Extension capital contribution from TriSalus </p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ProceedsFromExtensionNote" scale="0" id="Tc_d0-sASJ8802KYJWW7Z8LCw_23_3">82,741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Redemptions of Class A common stock</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="Tc_o26nXyuaEU2LV_0PfMzk6A_24_3">232,371,273</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Net cash (used in) provided by financing activities</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="0" id="Tc_xrEdOItMME-sQR-Qm33TXw_25_3">230,508,464</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_eso-ZJz33EeaZ7HAqWEZlw_25_6">544,000</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Change in Cash</b></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_ECWZtPsoC0OMZEYg7pEkag_26_3">47,321</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_bej3I4eUp0mlsjJkL5CYKA_26_6">1,134,114</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash &#8211; Beginning of year</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_mLH_NcBkvEO8mKYtJ2M_pQ_27_3">200,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_tNkY8WYFgEq0MN1_qFsuHA_27_6">1,334,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash &#8211; End of year</b></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_JdJSegtKt0OfPBsVhPiwbg_28_3">153,563</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ExjP7_5ncUWOgvcCsiyPbA_28_6">200,884</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_ioAylDLZQkSSpm3kkKH2yQ_30_3">543,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of the financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_df06fd85_d22c_4df4_9522_4d0165b5710f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MEDTECH ACQUISITION CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DECEMBER 31, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="AuditedNOTE1DESCRIPTIONOFORGANIZATIONAND"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:NatureOfOperations" id="Tb_tbJXgmlLxEWNGzAkbA81hw" continuedAt="Tb_tbJXgmlLxEWNGzAkbA81hw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MedTech Acquisition Corporation (the &#8220;Company&#8221;) was incorporated in Delaware on September 11, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with <ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" scale="0" id="Narr_ZSpz9DQ9SEyIIyuO_UVYbg">one</ix:nonFraction> or more businesses (the &#8220;Business Combination&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. The Company has one wholly-owned subsidiary that was created on November 9, 2022, MTAC Merger Sub, Inc, a Delaware corporation (&#8220;Merger Sub&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had not commenced any operations. All activity from inception through December 31, 2022, relates to the Company&#8217;s formation, the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination, including the terminated Memic Business Combination and the Merger Agreement with TriSalus (as defined and more fully described in Note 6). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statements for the Company&#8217;s Initial Public Offering were declared effective on December 17, 2020. On December 22, 2020, the Company consummated the Initial Public Offering of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_2VFn_JVHvU-rJLaSV0e3cg">25,000,000</ix:nonFraction> units (the &#8220;Units&#8221; and, with respect to the Class A common stock included in the Units sold, the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriter of its over-allotment option in the amount of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_fQkWhGeKpkawZsBIgwJtxg">3,000,000</ix:nonFraction> Units, at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_y4BghahNREqlPO7aNF5CiQ">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Narr_un297zLIK0-bPaZpcYP7_Q">250,000,000</ix:nonFraction> which is described in Note&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_frWlGOdE-EuzekMjxOqN-Q">4,933,333</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_7WTwyYo-fUCzoe7WAcw8zg">1.50</ix:nonFraction> per Private Placement Warrant in a private placement to MedTech Acquisition Sponsor LLC (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_n_c6ldt--EaVq7XO9CKXXA">7,400,000</ix:nonFraction>, which is described in Note&#160;4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on December 22, 2020, an amount of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg" decimals="0" format="ixt:numdotdecimal" name="tlsi:PaymentsForInvestmentOfCashInTrustAccount" scale="0" id="Narr_CEENtxdYt0m-XNxrYC3xFA">250,000,000</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tc_V7gDSeUmpSxYMDtGWdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_9Uci8XBbk0y4HxPuzqPOqg">10.00</ix:nonFraction> per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="0" format="ixt:numdotdecimal" name="tlsi:TransactionCosts" scale="0" id="Narr_zMqKSFVvp0ajCaPS9bSVBA">14,161,525</ix:nonFraction>, consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="0" format="ixt:numdotdecimal" name="tlsi:SaleOfStockUnderwritingFees" scale="0" id="Narr_G6Nsf9T6-0qKD3PfxKmpLw">5,000,000</ix:nonFraction> in cash underwriting fees, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_0tlwTHS4FEuOw29tQlTbmw">8,750,000</ix:nonFraction> of deferred underwriting fees and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="0" format="ixt:numdotdecimal" name="tlsi:SaleOfStockOtherOfferingCosts" scale="0" id="Narr_AOsZfKkEM0m3T1ZN7S0meA">411,525</ix:nonFraction> of other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConditionForFutureBusinessCombinationUseOfProceedsPercentage" scale="0" id="Narr_WKw0aArYzkSDhuKcP5FAyg">80</ix:nonFraction>% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held in trust and net of taxes payable). The Company will only complete a Business Combination if the post-transaction company owns or acquires <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConditionForFutureBusinessCombinationThresholdPercentageOwnership" scale="0" id="Narr_bEkcAS5SaE-CJCEPld-tXA">50</ix:nonFraction>% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tbJXgmlLxEWNGzAkbA81hw_cont1" continuedAt="Tb_tbJXgmlLxEWNGzAkbA81hw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide the holders of the outstanding Public Shares (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_lF-epmnUWU6-1BmHVSjyKA">10.00</ix:nonFraction> per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will only proceed with a Business Combination if the Company has net tangible assets of at least $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" scale="0" id="Narr_eFUhwp8y2EuS_P91AOB3cA">5,000,001</ix:nonFraction> following any related redemptions and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:RedemptionLimitPercentageWithoutPriorConsent" scale="0" id="Narr_HEK3tRu7fUu_Y6YWyEx9rw">15</ix:nonFraction>% of the Public Shares, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (b) to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination by June 22, 2023 (or such earlier date as determined by the board of directors of the Company (the &#8220;Board&#8221;)) and (c) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company&#8217;s obligation to allow redemptions in connection with a Business Combination or to redeem <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" scale="-2" id="Narr_0Tqtk9Tjf06OxGuJdIeAsw">100</ix:nonFraction>% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders&#8217; rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will have until June 22, 2023 (or such earlier date as determined by the Board) to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_8o7rIpLqL0adL1dGev6vwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:MaximumAllowedDissolutionExpenses" scale="0" id="Narr_NGSahLccYk2e7wTAN0_TBw">100,000</ix:nonFraction> of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining stockholders and the Board, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders. At the meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tbJXgmlLxEWNGzAkbA81hw_cont2" continuedAt="Tb_tbJXgmlLxEWNGzAkbA81hw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;Extension Amendment&#8221;) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of&#8201; (i)&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Gp05lJBb1UuZbEf6kSCSng">10.00</ix:nonFraction> per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_SPLXJ8CHPkCERab1sNxaxw">10.00</ix:nonFraction> per public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:OperatingBankAccounts" scale="0" id="Narr_72gQ8HtKTkGIad-j9kkmuQ">153,563</ix:nonFraction> in its operating bank account and working capital deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:WorkingCapital" scale="0" id="Narr_40ODIDpWgkqYI4GKYzTsLA">2,114,252</ix:nonFraction>, which excludes $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_HwXyrgNF9kSQ67jpRCw_4w" decimals="0" format="ixt:numdotdecimal" name="tlsi:DueToSponsorForCertainReimbursableExpenses" scale="0" id="Narr_dDBVyidioEOt4PD9xZ2pOQ">27,854</ix:nonFraction> of income taxes payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company issued an unsecured promissory note to the Sponsor in the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyOnePromissoryNoteMember_rhZTQ658W0at8bOMTC8FaA" decimals="0" format="ixt:numdotdecimal" name="tlsi:DueToSponsorForCertainReimbursableExpenses" scale="0" id="Narr_WG01BWZn-E-ClwDNgVqfgw">544,000</ix:nonFraction> (the &#8220;2021 Promissory Note&#8221;). The 2021 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#8217;s initial Business Combination. As of December 31, 2022 and 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_tfAYqXS-rkCNMjlKTM0Vmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_aP6FhkbZFEGe3_OggOW7uw"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_-nqPaUNo5Ee7PeXVTcABRA">544,000</ix:nonFraction></ix:nonFraction> outstanding under the 2021 Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2022, the Company issued an unsecured promissory note in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="0" id="Narr_qyTnFqapeUqJwL2Aqj9rvw">400,000</ix:nonFraction> to the Sponsor (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#8217;s initial Business Combination. As of December 31, 2022 and 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_5JazsVAuJ0mtYVoCGdH2xA">400,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_tfJF3hmSsESDs-veTRNR0Q">0</ix:nonFraction> outstanding under the 2022 Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 24, 2022, the Company issued the Convertible Promissory Note (as defined in Note 5) in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_IJINUXuw9ECauZXpwrbGYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_f3RQbcTgzUK-VRW39hEUWA">1,500,000</ix:nonFraction> to the Sponsor. As of December 31, 2022 and 2021, there were amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent" scale="0" id="Narr_z25sOGIM20ifmLNdRoZCYw">1,341,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent" scale="0" id="Narr_io7-LZGwqkeYmvKK6-eVYQ">0</ix:nonFraction> outstanding under the Convertible Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued a promissory note in the aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="0" id="Narr_D-v5Fy2i6UmeaDptTrynvA">468,821</ix:nonFraction> to the Sponsor (the &#8220;Extension Note&#8221;), pursuant to which the Sponsor agreed to loan to the Company up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg" decimals="0" format="ixt:numdotdecimal" name="tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" scale="0" id="Narr_bNYEeuHv-0ybY657xj-OFw">468,821</ix:nonFraction> (the &#8220;Extension Funds&#8221;) to deposit into the Company&#8217;s trust account (the &#8220;Trust Account&#8221;) for the shares of Class A common stock of the Company (the &#8220;Public Shares&#8221;) that were not redeemed in connection with the extension of the Company&#8217;s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the Board (the &#8220;Extension&#8221;). The Extension Note, as described in Note 5, does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there were the amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_P2ijqYguiEq-WixRVlnIpg">39,068</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_l3ErAACBpU2OU_rUwLBMbw">0</ix:nonFraction> outstanding under Extension Note, respectively.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tbJXgmlLxEWNGzAkbA81hw_cont3" continuedAt="Tb_tbJXgmlLxEWNGzAkbA81hw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will deposit $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_qng7JWcC0EiNZ2Np7W3ZDQ">0.04</ix:nonFraction> per share into the Trust Account for each month (commencing on December 23, 2022 and ending on the 22nd day of each subsequent month) (the &#8220;Extension Deposit&#8221;), or portion thereof, that is needed by the Company to complete an initial business combination until June 22, 2023 or such earlier date as determined by the Board (the &#8220;Extension&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, TriSalus has agreed to pay, as a transactional expense and not as a loan, for <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentageOfTransactionalFeePaid" scale="-2" id="Narr_cZf3UFfCYkGWe3wUe3TL2w">50</ix:nonFraction>% of the costs incurred by the Company in connection with the preparation and filing of applicable proxy materials and the holding of the Meeting (as defined below) (TriSalus&#8217; portion of such fees, the &#8220;TriSalus Extension Fees&#8221;), in addition to <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentageOfAmountDepositedInTrustAccount" scale="-2" id="Narr_7aTDH6wyQUymAVSKGvE-3A">50</ix:nonFraction>% of the amounts deposited into the Trust Account in connection with the Extension, with the remainder to be funded by the Sponsor and/or its designee in the form of a loan to the Company; provided that TriSalus&#8217; obligation to pay the TriSalus Extension Fees and its portion of the deposits for the Extension will terminate immediately at the earliest to occur of (i) the closing date of the TriSalus Business Combination and (ii) the valid termination of the Merger Agreement. Upon such termination, the Company will have no obligation to repay the TriSalus Extension Fees or any portion of the Extension Funds paid by TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_MiWZm6fBjEKUajPVpCkIUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="0" id="Narr_31AZFI-zVE66HGQ-MhOu8Q">1,000,000</ix:nonFraction> (the &#8220;Working Capital Note&#8221;) to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its amendment and restated certificate of incorporation, as amended from time to time. As of December 31, 2022 and 2021, there was no outstanding amount under the Working Capital Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) Topic 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; the Company has until June 22, 2023, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management plans to consummate a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 22, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inflation Reduction Act of 2022</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tbJXgmlLxEWNGzAkbA81hw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, a vote by the stockholders to extend the period of time to complete the Company&#8217;s initial Business Combination (the &#8220;extension vote&#8221;) or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any &#8220;PIPE&#8221; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company&#8217;s ability to complete a Business Combination.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_A1kFE1uOcE6ixb7a2UYb6Q" continuedAt="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_hL2crN-aKkO0XWsicblMZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;)<i style="font-style:italic;">.</i></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_rUCWDfahIkWeafAJx3ueUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which were formed on November 9, 2022. All significant intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:EmergingGrowthCompanyPolicyTextBlock" id="Tb_vqi_aGZwb0-KdKeKigf7sQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:UseOfEstimates" id="Tb_OWKkorqfkk-zfGt3fo9JhQ" continuedAt="Tb_OWKkorqfkk-zfGt3fo9JhQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont1" continuedAt="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont2"><ix:continuation id="Tb_OWKkorqfkk-zfGt3fo9JhQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_D5EPrqmacEyGQHDxKL6mXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Narr_TlFjrrnkTEaLoPmwEn6Axw">153,563</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Narr_GKjnvH-XKka1GMqCAO9Nbw">200,884</ix:nonFraction> of cash as of December 31, 2022 and 2021, respectively, and <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_3m-48D6GA0OElvse4Fke4A"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" id="Narr_gIq_PVAv2EWnR-KiGl0cjA">no</ix:nonFraction></ix:nonFraction> cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:AssetsHeldInTrustAccountPolicyPolicyTextBlock" id="Tb_8-zSUlW0f0qdgp0s-gNpNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Investments Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its U.S. Treasury and equivalent securities as held to maturity in accordance with FASB Accounting Standard Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities.&#8221; Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, substantially all of the assets held in the Trust Account were held in a demand deposit account held by Continental Stock Transfer &amp; Trust Company. At December 31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest primarily in U.S. Treasury securities. The money market funds are presented at fair value within the accompanying consolidated balance sheets, and fair value of the investments in the Trust Account is equal to the amortized cost basis of the money market funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:TemporaryEquityPolicyPolicyTextBlock" id="Tb_Rsnn70bGCEuGCYmlY1RNIQ" continuedAt="Tb_Rsnn70bGCEuGCYmlY1RNIQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Shares of Class A common stock subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; equity. The Company&#8217;s Class A common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the special meeting in lieu of the 2022 annual meeting of stockholders held by the Company on December 12, 2022, stockholders holding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" scale="0" id="Narr_ipnKcXGqUUa74E7-2e55nA">23,046,578</ix:nonFraction> Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg" decimals="-4" format="ixt:numdotdecimal" name="tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" scale="6" id="Narr_dgK9dzpLuUCQQhoH4grwBA">232.37</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_12_12_2022_To_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_71ivAMN5WEaesHqSjeTrwQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" scale="0" id="Narr_J7AYLByhdE6_kZ_xw-NOgg">10.08</ix:nonFraction> per Public Share) was removed from the Trust Account to pay such holders and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg" decimals="-4" format="ixt:numdotdecimal" name="tlsi:ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" scale="6" id="Narr_UgCouH0Y1UKS8PaB3wanTg">19.70</ix:nonFraction> million remains in the Trust Account. Following redemptions, the Company has <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Narr_vBfNBoX3EEGfvb8pEDrtLg">1,953,422</ix:nonFraction> Public Shares outstanding. $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:AmountDepositedIntoTrustAccount" scale="0" id="Narr_fC2oE0sEqUyHfsza6_t_bw">78,137</ix:nonFraction> was deposited into the Trust Account of which <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_OZVZQrBqCEGgs_ptg5yGoA" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentOfDepositsIntoTrustAccountDrawnDown" scale="-2" id="Narr_PETSa-zoHUq_DjqiU5wvZA">50</ix:nonFraction>% was be drawn down under the Extension Note and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentOfDepositsIntoTrustAccountFundedByAcquiree" scale="-2" id="Narr_dvN2CO4jRkeh0f3MY0ZUkw">50</ix:nonFraction>% was funded by TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, at December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_qykoVvaASUS7WM_Wwc7VNg">1,953,422</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_LcniZ9J3sU--Rpq2BaoKdg">25,000,000</ix:nonFraction> shares of Class A common stock subject to possible redemption are presented at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_cJmLkb7uqEmrqPzaz3uu-Q">10.14</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_2TPHBwl9GkWtrC__8V8Osg">10.00</ix:nonFraction> redemption value, respectively, as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares of common stock to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_5BII9CCG1kS9gvR6FMI4vQ_1_0"></a><a id="Tc_4Pexw1T6ckGE2VcTqeB-eA_1_2"></a><a id="Tc_xcTCka8r30uxuF7VBMD5gw_2_0"></a><a id="Tc_gSlY7zsdEEiWMUnDSdj0AQ_3_0"></a><a id="Tc_IG7zdqMdOU6XmRFOLmnrUw_4_0"></a><a id="Tc_0ZscMOt5Y0W0KFVXwthwaw_5_0"></a><a id="Tc_5_7PzMCvMkKgRvLw_pfupw_6_0"></a><a id="Tc_NAn2nxowVEu_UVr9bplxNQ_7_0"></a><a id="Tc_52u48iMW0kqTb3YO8vCPkg_8_0"></a><a id="Tc_b5GAnhcHHUeXhOkWnLY8PA_9_0"></a><a id="Tc_s_hy5SJ9-kKtrKZ5Y-tHQA_10_0"></a><a id="Tc_UW-JERiogk6kqVJkmVgJTw_10_2"></a><ix:continuation id="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont2" continuedAt="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont3"><ix:continuation id="Tb_Rsnn70bGCEuGCYmlY1RNIQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2022 and 2021, the Class A common stock subject to possible redemption reflected in the consolidated balance sheets is reconciled in the following table:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_UyF2zaZ3mkmr4qlKvGJhwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock subject to possible redemption, January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_AQay36hQlke0WUBpyZbKSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_gde5vugi1E2Ycuq_mpxC-g_1_3">250,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_2Na5uq1SqUyKwtQcg62MfQ_4_3">250,000,000</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Redemptions of Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A" decimals="0" format="ixt:numdotdecimal" name="tlsi:ProceedsFromTrustAccountInConnectionWithRedemption" scale="0" id="Tc_VPCstSdQyEu2Zh-n-L6_0A_6_3">232,371,273</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" sign="-" scale="0" id="Tc_a9p-eu7RvECHxRNclWHgdg_8_3">2,093,167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Extension Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A" decimals="0" format="ixt:numdotdecimal" name="tlsi:ExtensionDeposit" scale="0" id="Tc_enBFIb25nUmEvgHLPG9WIw_9_3">78,136</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_iIUopaUey0OU5V-L-_Laqw_10_3">19,800,030</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_5TJK_TT7rE-U1F2GH8ychQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A common stock issued were initially charged to temporary equity and then accreted to common stock subject to redemption upon the completion of the Initial Public Offering. A total of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_HITddlXY6k6ICDRsA6ienw">14,161,525</ix:nonFraction> in offering costs was incurred. Of these offering costs, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_F6KCm3FBHUyT8Te0cuEOxg">13,638,664</ix:nonFraction> was related to the Initial Public Offering and charged to Class A Common Stock subject to possible redemption. Offering costs allocable to Public Warrants (as defined below) and Private Placement Warrants were $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_oBl1u_pQM06egIcZ8MCY8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_maDLA_dZSE6a8RNBIWHORw">514,106</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_8Tcmoc6fkkCSZMerDheLAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_UGVoJLE-KEm6wbXiISA0RQ">8,755</ix:nonFraction>, respectively, and expensed at the date of Initial Public Offering.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:WarrantLiabilitiesPolicyTextBlock" id="Tb_tKjFtV4OAEGk2X6OJl4giA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the Public Warrants and Private Placement Warrants (together with the Public Warrants, the &#8220;Warrants&#8221;) in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model. The Public Warrants for periods where no observable traded price was available were also valued using a Monte Carlo simulation Model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_I5-vYhQLQkq0bUkhat7XiA" continuedAt="Tb_I5-vYhQLQkq0bUkhat7XiA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_316fa38d_5656_4c59_afd3_a4c8d2937aa2"></a><a id="_49a78a71_8478_4b4d_959c_bb1fe05f23f0"></a><a id="Tc_zlOtVelg-U6JDSrHxmIxxA_1_2"></a><a id="Tc_hm0n3ciO4E-VGhnFu3sCOA_2_2"></a><a id="Tc_GHoKqJX-AkWtY2o5JnxgSw_2_8"></a><a id="Tc_J8lWfbpD-kCUbzpkkVylQw_3_2"></a><a id="Tc_1vazKPPAFESVxJ3GsYtmUA_3_5"></a><a id="Tc_nuDSZBDqU060_I28gjC2ag_3_8"></a><a id="Tc_Nv9chYAUI0OE7q_zvubejw_3_11"></a><a id="Tc_NPI6QwHjBkmjPgsd2zTwAg_4_0"></a><a id="Tc_7lUpIi58YUWn7p_mFjs0QQ_5_0"></a><a id="Tc_IplDgvqZcUaCltNCu4gvmA_6_0"></a><a id="Tc_NxdkW0PLlkeKTrVVV_YoVg_6_2"></a><a id="Tc_u0m8iesycE2fPJQtnHYABQ_6_5"></a><a id="Tc_L486z-HeMkm6kD4ODzfjtw_6_8"></a><a id="Tc_W6wr00ZsU0CK8djQ6oZCJQ_6_11"></a><a id="Tc_MTTaZ6hVyUu_97imjKdoTw_7_0"></a><a id="Tc_SYPrtM4kfkKdt-H-4fFrxw_8_0"></a><a id="Tc_PrIIs5cM70qijXrZHY3X1g_9_0"></a><a id="Tc_4zfZZ4COPUOraV1a9TOiaA_9_2"></a><a id="Tc_2ObL1ZcFskms9v53uQlgmw_9_5"></a><a id="Tc_NFmGvnGiWEGGKD1gyfeYZw_9_8"></a><a id="Tc_pKZlwrQvwE2LOPwdw6aDVg_9_11"></a><ix:continuation id="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont3" continuedAt="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont4"><ix:continuation id="Tb_I5-vYhQLQkq0bUkhat7XiA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in interim periods under ASC 740-270-30-5. As of December 31, 2022 and 2021, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it. The Company&#8217;s effective tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_huAN_J8lLUeRDOF2mXqgbw">9.34</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_FKqcLFBoAkm9Am-RT1IbSg">0</ix:nonFraction>% for the years ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_wis7oCuiI0imwC_WGWu_eg"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_QtgN_hr_-ku3vt6sW6HZsA">21</ix:nonFraction></ix:nonFraction>% for the years ended December 31, 2022 and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_wGBQNtMBlkC7pynxqB8wmg"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_b9SX4xD9ykSB93AAUXFL2w">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits and <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_x-ms3kcaQE6gT8iA5zixOA"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_7Yk8mYP6QUuEa--2cWRcXg">no</ix:nonFraction></ix:nonFraction> amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has been subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_FENWmKOtDUyFoPvG_jIvaA" continuedAt="Tb_FENWmKOtDUyFoPvG_jIvaA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Income per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per share of common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. The Company has two classes of common stock, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock, which assumes a business combination as to be the most likely outcome. Accretion associated with the redeemable shares of Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_Qjv8IDhFrkSSuhS9bsrtzw">13,266,666</ix:nonFraction> shares of Class A common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income per common stock is the same as basic net income per common stock for the periods presented.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_JfQilB6MkEeOa0QeyfI2nw" continuedAt="Tb_JfQilB6MkEeOa0QeyfI2nw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basic and diluted net income per share of common stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allocation of net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="Tc_VRBcQ9UhY0OO4dMps49dwQ_6_3">4,369,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="Tc_PC5cgcdg7kS9E665gW1quw_6_6">1,169,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="Tc_CQyd8hqkwEipYjzUmCQTEA_6_9">3,813,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="Tc_OXK97vxb6kehl0sFuoXEPA_6_12">953,457</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ZokKaf3S7EOH0ZXCHVqL6A_8_3"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ZokKaf3S7EOH0ZXCHVqL6A_8_3_2">23,358,326</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_85DCpX2o6kGnegiKXAc4Ig_8_6"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_85DCpX2o6kGnegiKXAc4Ig_8_6_2">6,250,000</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_TMsPqP6ADki4ZOVvzk-8DQ_8_9"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_TMsPqP6ADki4ZOVvzk-8DQ_8_9_2">25,000,000</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_P74xhmyjoU6KZ2gjpzsorQ_8_12"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_P74xhmyjoU6KZ2gjpzsorQ_8_12_2">6,250,000</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net income per share of common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_AOpnt1PcRESUFY1awVUK5w_9_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_AOpnt1PcRESUFY1awVUK5w_9_3_2">0.19</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_SSc7jurvKku5iYhHgTZYzQ_9_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_SSc7jurvKku5iYhHgTZYzQ_9_6_2">0.19</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_BYO9mvwN0U6AjRRy5kDaUA_9_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_BYO9mvwN0U6AjRRy5kDaUA_9_9_2">0.15</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_J339RXykX0-X5pbdlwK3YQ_9_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_J339RXykX0-X5pbdlwK3YQ_9_12_2">0.15</ix:nonFraction></ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_A1kFE1uOcE6ixb7a2UYb6Q_cont4"><ix:continuation id="Tb_FENWmKOtDUyFoPvG_jIvaA_cont1"><ix:continuation id="Tb_JfQilB6MkEeOa0QeyfI2nw_cont1"></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_IPWQnC45l0SMZ8dwqyOILA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations and cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_jQCpxA1Ws0uWRIfm3x_iqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the Warrant Liabilities (See Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_J1YNnz2YO0SmOfl5RUDd0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU Topic 2020-06, &#8220;Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8221; (&#8220;ASU 2020-06&#8221;), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:InitialPublicOfferingTextBlock" id="Tb_nPShHRVDbkeF7Kr2a2Chgg" continuedAt="Tb_nPShHRVDbkeF7Kr2a2Chgg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 3. PUBLIC OFFERING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Initial Public Offering, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_w96krJG7p0ykqTkmiz1CwQ">25,000,000</ix:nonFraction> Units, which includes a partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_m5mgNlw8BUK70ilHui2npg">3,000,000</ix:nonFraction> Units, at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_3k3AIYP7vk2PnNOkZ__ojA">10.00</ix:nonFraction> per Unit. Each Unit consists of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_xbC97N33okWvF9zYFtzwMA" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfSharesIssuedPerUnit" scale="0" id="Narr_SYs39qv0xEituO1oS71kyw">one</ix:nonFraction> share of Class A common stock and <span style="-sec-ix-hidden:Hidden_MkCiTlqYpkyh8SfuJUz1DA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OXuKzykTU0aBwch15YAXNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_SLxoG7aubk63EH3yJwFYoQ">one</ix:nonFraction> share of Class A common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ilNvF-LtlEuM40NvOR74NA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8ANmTNIXB0y5-A2v5HrRpw">11.50</ix:nonFraction>&#160;per share, subject to adjustment (see Note 8).</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nPShHRVDbkeF7Kr2a2Chgg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:PrivatePlacementTextBlock" id="Tb_KehyZ8-uKESa9cyV09ZDbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 4. PRIVATE PLACEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_B-_jPg6zL0W-NM-N9X59kA">4,933,333</ix:nonFraction> Private Placement Warrants at a price of&#8201;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_QjkNF1FfDU6MRB2Ec-Wndw">1.50</ix:nonFraction> per Private Placement Warrant ($<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_47ObvDojhUa37P35BxZ0fA">7,400,000</ix:nonFraction>) from the Company in a private placement. Each Private Placement Warrant will be exercisable to purchase <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_P1eNNREBkU20Ar7pmgecbQ">one</ix:nonFraction> share of Class A common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DMJEIP8fGUaGXbZBbwD0BQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_p1hrJM7Wgk6tGQ8Vq_C2Yg">11.50</ix:nonFraction> per share, subject to adjustment (see Note 7). The proceeds from the sale of the Private Placement Warrants were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_msfYcro5okO9tOYpUZy_1w" continuedAt="Tb_msfYcro5okO9tOYpUZy_1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5. RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 11, 2020, the Sponsor purchased <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kCOToJAFfkqBH6HAMm3T7Q">5,750,000</ix:nonFraction> shares (the &#8220;Founder Shares&#8221;) of the Company&#8217;s Class B common stock for an aggregate price of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_h5smdKF280qqRRNp-1YLXw">25,000</ix:nonFraction>. In December 2020, the Company effected a stock dividend for <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_1_2020_To_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_chTyyFWls023GE6-jbCH2A" decimals="1" format="ixt:numdotdecimal" name="us-gaap:CommonStockDividendsShares" scale="0" id="Narr_9Mu6A9Ehoki1s4x7c01EkQ">0.1</ix:nonFraction> shares for each share of Class B common stock outstanding,resulting in <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_wGOWYsCQ5ku3FPlY92CUbw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:AggregateNumberOfSharesOwned" scale="0" id="Narr_McfyxwIs3E-m3SRg3e9hYg">6,325,000</ix:nonFraction> Founder Shares outstanding. As a result of the partial over-allotment exercised by the underwriters, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w" decimals="INF" format="ixt:numdotdecimal" name="tlsi:NumberOfSharesSubjectToForfeiture" scale="0" id="Narr_4q4SxLFX5kO9vyn0-n25lg">75,000</ix:nonFraction> shares of Class B common stock were forfeited, and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfSharesNoLongerSubjectToForfeiture" scale="0" id="Narr_4n7neVYvT02kligFNwdt9A">no</ix:nonFraction> shares remain subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of (A)&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg" format="ixt-sec:durwordsen" name="tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" id="Narr_64W6-wCy0USCjiOvENB1Hg">one year</ix:nonNumeric>&#160;after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the reported closing price of the Class A common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg" decimals="2" format="ixt:numdotdecimal" name="tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" scale="0" id="Narr_H0vzIFfK_0q2DGsjJ8IzPg">12.00</ix:nonFraction> per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" scale="0" id="Narr_fPXRfFAHwk2Oc5330aDpIw">20</ix:nonFraction> trading&#160;days within any <ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" scale="0" id="Narr_DOzRdJHUEk2k-jSEnM9QBA">30</ix:nonFraction>-trading day period commencing at least <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg" format="ixt-sec:durwordsen" name="tlsi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" id="Narr_hn6FJGBxGEqJa5yKEjt6mA">150&#160;days</ix:nonNumeric> after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of common stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement, commencing on December 22, 2020, to pay the Sponsor an amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_aUCSUO5VHk6A6DggrcFYYw" decimals="0" format="ixt:numdotdecimal" name="tlsi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" scale="0" id="Narr_vtRINIsYKUGC9XeYzQtiLA">10,000</ix:nonFraction> per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Mnxv0wTYjEKdigU5lNSyow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_WJMNAiUMpky5vPOVmjm_LQ">120,000</ix:nonFraction>, in fees for these services. For the year ended December 31, 2021, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Ss29-0arFEmgdC-qVRGyZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_7ntPLtlD0kuD7zYZEY1e9w">120,000</ix:nonFraction>, in fees for these services. There were $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_gSf4GXYVD0WuBgBuDWBn0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_ZmeiVV5ls0SPMsJvmgqkSQ">240,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Bd5mwUEb0keN4-RoxS7_YA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_cmy-bodhLEKPcV_ZzF_9Yg">120,000</ix:nonFraction> included in accrued expenses for these services in the accompanying consolidated balance sheets at December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Note&#8201;&#8212;&#8201;Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company issued the 2021 Promissory Note to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_Vt3SPP67yUGmnpcjM2X0Eg" decimals="0" format="ixt:numdotdecimal" name="tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" scale="0" id="Narr_g3SgDUQO_02RlddM3i13DA">544,000</ix:nonFraction>. The 2021 Promissory Note is non-interest bearing. No amount shall be due under the 2021 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_vZdUHoDFX0qFuJtpne0MMQ">544,000</ix:nonFraction> outstanding under the 2021 Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2022, the Company issued the 2022 Promissory Note I in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="0" id="Narr_cwRZJGWkvUqC1fLYroVK9A">400,000</ix:nonFraction> to the Sponsor. The 2022 Promissory Note is non-interest bearing. No amount shall be due under 2022 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there were amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_S473jYSQc02m_lmoUr_ZLA">400,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_rGzouwhmu0aG-_cT9NC0ow">0</ix:nonFraction> outstanding under the 2022 Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued the Extension Note, a promissory note in the aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_XlqBY_bMDkKgTAzVoxZklQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" scale="0" id="Narr_rFVDa6Zr00G3Ke-osMtlgQ">468,821</ix:nonFraction> to the Sponsor, pursuant to which the Sponsor agreed to loan to the Company the Extension Funds to deposit into the Trust Account for the Public Shares that were not redeemed in connection with the Extension. The Extension Note does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_YONUEau-vEGjLZLEvVptjg">39,068</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Narr_c7UtyyJb6UmUBjc4QyYp7g">0</ix:nonFraction> outstanding under Extension Note, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_msfYcro5okO9tOYpUZy_1w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued the 2022 Promissory Note I, an unsecured promissory note in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_HS9G4zEpn0eaK4XwwKWnBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="0" id="Narr_G9wTsM4-6UKdvDfkY1da9g">1,000,000</ix:nonFraction> to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the Combination Period. As of December 31, 2022 and 2021, there was <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3grY9SX1cEWH0kR90lBaDQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NotesPayable" scale="0" id="Narr_8ZnaKBIrE0-AtiXRvHdThA"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dQMI2sHi4EGNCkXWwNvsLA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NotesPayable" scale="0" id="Narr_pUWDu6qODUmnFHbWtjePfw">no</ix:nonFraction></ix:nonFraction> outstanding under Working Capital Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:MaximumLoansConvertibleIntoWarrants" scale="0" id="Narr_-VatKJgPjEmUNQn2P2oqYg">1,500,000</ix:nonFraction> of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_XfL8uPIat0KgIufUb_Q-nQ">1.50</ix:nonFraction> per warrant. The warrants would be identical to the Private Placement Warrants as described in Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On May 24, 2022, the Company issued a promissory note in the principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_Jzm_A_jvhUqwLkEpaKybUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_JtDcJZii9kyLJnkWe7i8Fw">1,500,000</ix:nonFraction> to the Sponsor for working capital requirements and payment of certain expenses in connection the Company&#8217;s initial Business Combination (&#8220;Convertible Promissory Note&#8221;). The Convertible Promissory Note is non-interest bearing and payable on the earlier of (i) the date of the initial Business Combination or (ii) the winding up of the Company. At any time prior to payment in full of the principal balance of the Convertible Promissory Note, the Sponsor may elect to convert all or any portion of the unpaid principal balance into that number of warrants, each exercisable for one share of Class A common stock of the Company (the &#8220;Conversion Warrants&#8221;), equal to (x) the portion of the principal amount of this Note being converted, divided by (y) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_G8PrpEED9k22iXWcwxeAqg">1.50</ix:nonFraction>, rounded up to the nearest whole number of warrants. The Conversion Warrants and their underlying securities are entitled to certain demand and piggyback registration rights as set forth in the Convertible Promissory Note. The Company determined that the fair value of the Convertible Promissory Note was par value. As of December 31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_ffngkVT0QkSB0YxjNIwPKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_awXpii3I00OMK6KkE30M9g">1,341,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_R6XCzzcbnUOZXAK4sUOmgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_wLflIDP7gEaCZPLbXtN2PA">0</ix:nonFraction>, respectively, borrowings under the Working Capital Loans.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_EzGzZBZgcU-WdFfJbS3hZQ" continuedAt="Tb_EzGzZBZgcU-WdFfJbS3hZQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;6. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a registration rights agreement entered into on December 17, 2020, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will have registration rights to require the Company to register a sale of any of the securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering. These holders of these securities will be entitled to make up to <ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:MaximumNumberOfDemandsForRegistrationOfSecurities" scale="0" id="Narr_w-SHwMHuNkGZ_jYL3cG67Q">three</ix:nonFraction> demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have &#8220;piggy-back&#8221; registration rights to include their securities in other registration statements filed by the Company, subject to certain limitations. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raymond James Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;) was originally engaged by the Company to act as sole manager for the Initial Public Offering and would be entitled to a deferred underwriting fee of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_1J2ClcRDUUC7d2IrxMQFMg" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredUnderwritingFeesUponConsummationOfBusinessCombination" scale="0" id="Narr_5Zzgt7mwpUOB9PUmvLwtRg">8,750,000</ix:nonFraction> upon the consummation of a Business Combination. In connection with the entry into the Merger Agreement with TriSalus, on November 11, 2022, the Company and Raymond James amended that certain Underwriting Agreement, dated December 17, 2020, pursuant to which, Raymond James agreed </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_EzGzZBZgcU-WdFfJbS3hZQ_cont1" continuedAt="Tb_EzGzZBZgcU-WdFfJbS3hZQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to waive the foregoing deferred underwriting fee in its entirety if the proposed Business Combination between the Company and TriSalus is consummated. Raymond James was separately engaged by the Company to act as its investment banking advisor in connection with a Business Combination, and will receive customary fees for its services in that role if the Business Combination with TriSalus is consummated. The Company also engaged Raymond James to act as sole placement agent for an institutional debt financing that resulted in the Company&#8217;s entry into the non-binding term sheet with Magnetar Capital LLC (&#8220;Magnetar&#8221;). In consideration for its services as the Company&#8217;s investment banking advisor and its services as placement agent, Raymond James will be entitled to receive an aggregate fee ranging between $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_V-j5MOfUwUGyMV160Ndygg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromFeesReceived" scale="6" id="Narr_8KwwO3NyLkeKa2tepMmstw">3</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_PDIZOYv6rka-K3_56EQVNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromFeesReceived" scale="6" id="Narr_I7DetgjDAEKeQU5HtI_jOA">4.5</ix:nonFraction> million from the Company at the closing of the Business Combination with TriSalus plus expense reimbursements, depending on the amount raised in the institutional debt financing with Magnetar and/or other institutional investors, excluding any incremental fee consideration for exercise of the greenshoe. If the Company is unable to consummate the Business Combination with TriSalus or is unable to obtain private financing in connection with the Business Combination with TriSalus, then Raymond James will not receive any compensation for its investment banking advisory or placement agent services, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Professional Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company incurred legal fees of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:LegalFeeContingentUponConsummationOfBusinessCombination" scale="0" id="Narr_fcaQv_yfY0KVxq2dMDpwOA">508,525</ix:nonFraction> and investment advisory fees of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" scale="0" id="Narr_SYSer_RvL0y5fKrDqvyvHw">400,000</ix:nonFraction>, which were contingent upon the consummation of the Memic Business Combination. On March 12, 2022, the Memic Business Combination was terminated, as such, the incurred contingent legal and investment advisory fees are no longer due. These fees were not recorded on the Company&#8217;s consolidated balance sheets, therefore no reversal was required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The company incurred legal fees of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" scale="0" id="Narr__DwEtU8ZKEyq501VB4pGPg">479,262</ix:nonFraction>, which are contingent on the consummation of the Merger with TriSalus. These fees were not recorded on the Company&#8217;s consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 12, 2021, the Company entered into the Business Combination Agreement (the &#8220;Memic Business Combination Agreement&#8221;) with Memic Innovative Surgery Ltd., a private company organized under the laws of the State of Israel (&#8220;Memic&#8221;), and Maestro Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Memic (&#8220;Merger Sub&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of Business Combination Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2022, the Company, Memic and Merger Sub entered into a Termination of Business Combination Agreement (the &#8220;Termination Agreement&#8221;), pursuant to which the parties agreed to mutually terminate the Business Combination Agreement. The termination of the Business Combination Agreement was effective as of March 9, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the termination of the Business Combination Agreement, the Business Combination Agreement, along with any Transaction Agreement (as defined in the Business Combination Agreement) entered into in connection therewith, are void and there is no liability under either of the Business Combination Agreement or any Transaction Agreement on the part of any party thereto (including, without limitation, under the SPAC Sponsor Letter Agreement by and among Memic, the Sponsor, and the other parties signatory thereto dated August 12, 2021). Pursuant to the Termination Agreement, subject to certain exceptions, the Company, Memic and Merger Sub have also agreed, on behalf of themselves and their respective related parties, to a release of claims relating to the business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company (herein referred to as &#8220;MTAC&#8221; in this Note 6), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (&#8220;Merger Sub&#8221;), and TriSalus Life Sciences, Inc., a Delaware corporation (&#8220;TriSalus&#8221;), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the &#8220;Merger&#8221;), with TriSalus surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of MTAC (the transactions contemplated by the Merger Agreement and the related ancillary agreements, the &#8220;TriSalus Business Combination&#8221;). The TriSalus Business Combination is subject to certain closing conditions. Upon consummation of the TriSalus Business Combination, MTAC will be renamed &#8220;TriSalus Life Sciences, Inc.&#8221;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_EzGzZBZgcU-WdFfJbS3hZQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aggregate consideration payable to the stockholders of TriSalus at the closing of the TriSalus Business Combination (the &#8220;Closing&#8221;) is $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_P_hbBZGvG0SAPWdr9iTosQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="0" id="Narr_xKlMPZGV1EmB4y3q9aDhWw">220,000,000</ix:nonFraction>, payable solely in shares of MTAC common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Q4gCJc9vTUOLucx6xlIHaw">0.0001</ix:nonFraction> per share (&#8220;Common Stock&#8221;), valued at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="Narr_DX59ujkaWUm3aTRfGkbDeA">10.00</ix:nonFraction> per share (the &#8220;Closing Merger Consideration&#8221;). Immediately prior to the Closing, the shares of Class A Common Stock of MTAC and the warrants to purchase shares of Class A Common Stock of MTAC issued to the public that comprise each issued and outstanding Unit will be automatically separated, if not already separated prior to such time, and the holder thereof shall be deemed to hold <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_y3jzsSpPn06F9ea0zBxkMQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfHoldings" scale="0" id="Narr_bmBwCZwCbkOLhdy56NjGHQ">one</ix:nonFraction> share of Class A Common Stock of MTAC and <span style="-sec-ix-hidden:Hidden_tErA0HV8TUSeW-q1gHsPXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third of one warrant to purchase Class A Common Stock; provided that any fractional warrants issuable to a holder upon the separation of the Units will be rounded down to the nearest whole number of warrants. Following the separation of the Units but prior to the Closing, the Class B Common Stock of MTAC will automatically convert into Class A Common Stock, and pursuant to the proposed amended and restated certificate of incorporation of MTAC to be effective immediately prior to the effective time of the Merger, if approved by MTAC&#8217;s stockholders, Class A Common Stock and Class B Common Stock will be reclassified into a single class of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately prior to the Closing, each share of TriSalus&#8217; issued and outstanding preferred stock will automatically convert into shares of TriSalus common stock (the &#8220;Preferred Conversion&#8221;), and all in-the-money TriSalus warrants that would be exercised or otherwise exchanged in full in accordance with their terms by virtue of the occurrence of the TriSalus Business Combination will be exercised for shares of TriSalus common stock, such that the holders thereof will receive Closing Merger Consideration as holders of TriSalus common stock. TriSalus warrants that are out-of-the-money will be cancelled for no consideration immediately prior to the Closing. At the time of the TriSalus Business Combination, the outstanding options for shares of TriSalus common stock under TriSalus&#8217; equity plan will be assumed by MTAC and converted into options to purchase Common Stock (the &#8220;Assumed Equity&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Representations, Warranties and Covenants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations, warranties and covenants by the parties thereto, including, among other things, covenants with respect to the conduct of MTAC and TriSalus during the period between execution of the Merger Agreement and the Closing, including the parties&#8217; agreement not to solicit or enter into any inquiry, proposal or offer, or any indication of interest in making an offer or proposal for an alternative competing transactions. The representations, warranties and covenants made under the Merger Agreement will not survive the Closing; provided, however, that any covenants that are to be performed at or after the Closing shall survive until such covenant has been performed or satisfied pursuant to their terms. Each of MTAC and TriSalus have agreed to use their commercially reasonable efforts to cause the TriSalus Business Combination to be consummated as soon as practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be terminated prior to the Closing under certain circumstances, including, among others, (i) by written consent of TriSalus and MTAC, (ii) by written notice from either MTAC or TriSalus, if (A) the Closing has not occurred on or before December 22, 2022, as such date may be extended to match the extension of the last date for MTAC to consummate a Business Combination under its certificate of incorporation (currently June 22, 2023) obtained by MTAC stockholder approval (the &#8220;Outside Date&#8221;), unless the terminating party&#8217;s failure to comply in any material respect with its obligations under the Merger Agreement shall have contributed to the failure of the Closing to have occurred on or prior to the Outside Date, (B) the consummation of the TriSalus Business Combination is permanently enjoined, (C) MTAC does not obtain stockholder approval of the TriSalus Business Combination at the special meeting at which such approval shall be voted upon, or (D) by March 31, 2023, MTAC shall not have obtained commitments for private financing of at least $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="0" id="Narr_frFkjPXujEqyCGSDsM9GUA">40,000,000</ix:nonFraction> in support of the TriSalus Business Combination, (iii) by written notice from either MTAC or TriSalus, in the event that the other party breaches any of its representations, warranties, covenants or other agreements under the Merger Agreement that would result in the failure of the conditions to MTAC&#8217;s or TriSalus&#8217; obligation to consummate the TriSalus Business Combination and such breach has not been cured by the breaching party within <ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:NumberOfTrading" scale="0" id="Narr_ilLhr9dZxkKZgCx1jRE36g">30</ix:nonFraction> days after receiving notice of such breach, (iv) by TriSalus at any time prior to the approval of the TriSalus Business Combination by MTAC&#8217;s public stockholders, if the board of directors of MTAC has made a change in recommendation to its stockholders regarding the TriSalus Business Combination, and (v) by written notice to TriSalus from MTAC, if TriSalus does not obtain stockholder approval within <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" format="ixt-sec:durwordsen" name="tlsi:StockholderApprovalAfterDeliveringBusinessCombinationDays" id="Narr_KjJhK5JMokiBHqHXUZpI8g">25 days</ix:nonNumeric> after delivering an information statement regarding the TriSalus Business Combination to its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For additional information, refer to MTAC&#8217;s Current Report on Form 8-K, as filed with the SEC on November 14, 2022.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_96dfbe01_d870_454c_bb31_d61a930b2f04"></a><a id="_96dfbe01_d870_454c_bb31_d61a930b2f04_2"></a><a id="_96dfbe01_d870_454c_bb31_d61a930b2f04_3"></a><a id="_be176711_5732_4c05_8523_5c398da26796"></a><a id="_be176711_5732_4c05_8523_5c398da26796_2"></a><a id="_be176711_5732_4c05_8523_5c398da26796_3"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb__T7BkZ_nwU6DIMtzu4G0kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;7. STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock &#8212; </span>The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_FMBPSG5p-ky3kPb2AH1oag"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_xahw9v-N40O2yNMSba-qHQ">1,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hWBWxXa7g0WZoMnWgbyKUA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_2ws_r22n0UGa3Do6ioERPQ">0.0001</ix:nonFraction></ix:nonFraction> per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ngFY_8HcEEuQEEAl2NbNZA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_dDze9KqAakGyGsIcEnsfqQ">no</ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;A Common Stock &#8212; </span>The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_2Sz9jWvS3U-AyYL13SEDCg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_a5AI8q9AA0GPAcw7lEiROA">100,000,000</ix:nonFraction></ix:nonFraction> shares of Class A common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_RQx3d5NvI0SslmQE-yJwLw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_FcZD3e1cbku0c8J3PltdvA">0.0001</ix:nonFraction></ix:nonFraction> per share. Holders of Class A common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_lhqKJQSjDk-C5KalHbqqUg">one</ix:nonFraction> vote for each share. At December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_JegcenqVz0epmh1lF4opTw">1,953,422</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_RWoqMkojzECnu7FaRAov4A">25,000,000</ix:nonFraction> shares of Class&#160;A common stock subject to possible redemption which are presented as temporary equity, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;B Common Stock &#8212; </span>The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Gd7htElxmkC0xtUxILbzJg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HMnMMJ_9nEShBegxBMPR8w">10,000,000</ix:nonFraction></ix:nonFraction> shares of Class B common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ou5F3YoozUa6bOXGHPWXWA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_RkaSsxSYdEGeAQcZN5ljOw">0.0001</ix:nonFraction></ix:nonFraction> per share. Holders of Class B common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_dK8-qchhFEW_i6LjGTi0IA">one</ix:nonFraction> vote for each share. At December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_HZ2N4zgF00WQ9mQbsREwBA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_-Zt243UdGE2YmQpbMX8_0A">6,250,000</ix:nonFraction></ix:nonFraction> shares of Class B common stock issued and outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company&#8217;s stockholders except as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination on a <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_5b9JOHIeIkeRFSwQZRH0hQ">one</ix:nonFraction>-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with a Business Combination, the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA" decimals="0" format="ixt:numdotdecimal" name="tlsi:ConvertibleStockConversionRatio" scale="0" id="Narr_3olLDo0H-0-L1uxxpZgrog">20</ix:nonFraction>% of the sum of the total number of all shares of common stock outstanding upon the completion of the Initial Public Offering, plus the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any shares of Class A common stock or equity-linked securities exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in a Business Combination and any private placement-equivalent warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans; provided that such conversion of Founder Shares will never occur on a less than one for one basis. The Company cannot determine at this time whether a majority of the holders of Class B common stock at the time of any future issuance would agree to waive such adjustment to the conversion ratio.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock" id="Tb_uwuC6cNrN0-N87vr11Lb5Q" continuedAt="Tb_uwuC6cNrN0-N87vr11Lb5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 8. WARRANT LIABILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_-wdfKUjnDUyvvNS1vvWscg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_cfEphI6eHEa2NdKnRUCYaw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_h6I6CvWv4U2qbZkhLMGIsQ">8,333,333</ix:nonFraction></ix:nonFraction> Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a)&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" format="ixt-sec:durwordsen" name="tlsi:WarrantExercisePeriodConditionOne" id="Narr_VE19MU405EWLboJ7lubg9A">30 days</ix:nonNumeric>&#160;after the completion of a Business Combination and (b)&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" format="ixt-sec:durwordsen" name="tlsi:WarrantExercisePeriodConditionTwo" id="Narr_Lldfh3NWY0-I1s5B3r0pkw">12 months</ix:nonNumeric>&#160;from the closing of the Initial Public Offering. The Public Warrants will expire <ix:nonNumeric contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_fS97UZyQiUCR4iNqdVRInQ">five years</ix:nonNumeric>&#160;after the completion of a Business Combination or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any shares of Class&#160;A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class&#160;A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class&#160;A common stock upon exercise of a warrant unless Class&#160;A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA" format="ixt-sec:durday" name="tlsi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" id="Narr_RIJrIzsJU06F0ZEHr2_weg">15</ix:nonNumeric> business days after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement registering the issuance of the shares of Class A common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA" format="ixt-sec:durday" name="tlsi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" id="Narr_88hSwZcZkUmqohTqr3rrqA">60</ix:nonNumeric><span style="font-size:8pt;">th</span>&#160;business day after the closing of a Business Combination or within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uwuC6cNrN0-N87vr11Lb5Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" id="Narr_75nzNJm3aEiGypsOe-yOKg">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per Public Warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" format="ixt-sec:durwordsen" name="tlsi:RedemptionPeriod" id="Narr_qGZmUebVfUK2bsO6iWL8JQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the reported closing price of the Class A common stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:WarrantRedemptionConditionMinimumSharePrice" scale="0" id="Narr_DuFpLshRl0akvYgc6Aoqng">18.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" scale="0" id="Narr_ysi6mlX9hUuzVqRNkjCqvA">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" scale="0" id="Narr_t39xScKWcEW3sUKlHbVyjA">30</ix:nonFraction>-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading day period ending </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" scale="0" id="Narr_-vIfGFeuPUCjNxd8me8a8Q">three</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> business days before the Company sends the notice of redemption to the warrant holders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of Class&#160;A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of Class&#160;A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if&#8201; (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag" decimals="2" format="ixt:numdotdecimal" name="tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_DQaCYcHKaUSPYIAKVr8CXA">9.20</ix:nonFraction> per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" decimals="0" format="ixt:numdotdecimal" name="tlsi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" scale="0" id="Narr_ULWw-fF5JE6wjqq5Bi9big">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of the Company&#8217;s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company&#8217;s common stock during the <ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" scale="0" id="Narr_fhQpjpRMnkGQLqbcBJ-60Q">20</ix:nonFraction> trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag" decimals="2" format="ixt:numdotdecimal" name="tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_cLu5o_Bm8k247KHpyhJS6w">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" decimals="0" format="ixt:numdotdecimal" name="tlsi:WarrantExercisePriceAdjustmentMultiple" scale="0" id="Narr_0XnWv8HQSUWHkGX-Gz4ufA">115</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price and the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:WarrantRedemptionConditionMinimumSharePrice" scale="0" id="Narr_vaJR6TJwC02WjgetjAb0Tw">18.00</ix:nonFraction> per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA" decimals="0" format="ixt:numdotdecimal" name="tlsi:WarrantRedemptionPriceAdjustmentMultiple" scale="0" id="Narr_4GEjc4jFmEOnbJcxDKX5_A">180</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_X-8bVslRMUid_3Y3ZJ4oPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_JG8DMUz3ikakXJ40BihrLA"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_n9CPBSe_t0CIf2MEce1Hbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_2IpKA3q3bE2Ewc3T7Dpffw">4,933,333</ix:nonFraction></ix:nonFraction> Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_6MR-PsP6QE615ZeUhGehHg" format="ixt-sec:durwordsen" name="tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" id="Narr_1GXTq_kRU0mqT7fhf4bvNg">30 days</ix:nonNumeric>&#160;after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_rIcktcnwLE6CkFaZd2Zn0g_1_2"></a><a id="Tc_-hPDkXspBUyn25T4JVW3lw_1_5"></a><a id="Tc_Jd-7i3SY9UScTH4fI6uE3g_2_2"></a><a id="Tc_3tDB9Yi90keArJ2387fjtw_2_5"></a><a id="Tc_KlyYKRlls0m_RuSHGG6aaA_3_0"></a><a id="Tc_HtW9OqULR06FRznw79gVnw_4_0"></a><a id="Tc_y-VXunlKjk2XRoYrgqGkuA_4_2"></a><a id="Tc_19L_UFvSLE2fMn0XAkoJ4Q_4_5"></a><a id="Tc_mNj_vaPKQkWyhSGAmIS5PA_5_0"></a><a id="Tc_kfOv8_8p0EaqoXDkbGpUKQ_6_0"></a><a id="Tc_pykj9ESibU2jrPQdcvuIcQ_7_0"></a><a id="Tc_Iq78C0FXOUy8qadIDox2mg_8_0"></a><a id="Tc_xraPvMcL_UCJaIi33gLPjg_8_2"></a><a id="Tc_Lc8WPBWVDEyCakdHJeZWBw_8_5"></a><a id="Tc_IsmSe23yTUO3iz99wLjlNw_1_2"></a><a id="Tc_obb6F5y8v0i8ZyjQOMg87w_2_2"></a><a id="Tc_nIpGS_qGP0uwggayM86arg_2_5"></a><a id="Tc_0MksazCCrUq20YiL1SfNjA_3_0"></a><a id="Tc_uj7C3u7COU-TdzbwNElyug_4_0"></a><a id="Tc_mM1m-BWok06AVV3nefAhtQ_4_2"></a><a id="Tc_aWJEmf3jzkWRdtDQDTdMdw_4_5"></a><a id="Tc_V-AOnMRnjkOdpC_Bb9Lq1A_5_0"></a><a id="Tc_zRj5okumzECNQ3eIdlkCCA_6_0"></a><a id="Tc_h4DcxR9It0qYyyHzpvGf_Q_7_0"></a><a id="Tc_H66F5BQGUUirt6YUGp7hiQ_7_3"></a><a id="Tc_9WpCxKYtZkmoUycNhhHVPw_7_6"></a><a id="Tc_NygPJ-_vfESt4N32Rr8nCA_8_0"></a><a id="Tc_fvcnvWUL10CoRlytjhMBgw_8_3"></a><a id="Tc_1axExu4rLE6dBKHZQIfNcg_8_6"></a><a id="Tc_XT9L_NyUJECxuwdEkSLmLQ_9_0"></a><a id="Tc_E-B4HZlGYEu5oTt7T84feQ_10_0"></a><a id="Tc_8I3DjMhs2EOEOAkVb2YyaA_10_2"></a><a id="Tc_esWyL43OckGIoqQh1P7A9A_10_5"></a><a id="Tc__PbtCNcy9Um74zWDSr9Q4g_10_6"></a><a id="Tc_kvwvim1l7E2lF6pPjPpfxQ_1_2"></a><a id="Tc_fOxkhz3220KgkmDi5KSJHw_1_4"></a><a id="Tc_nNaG9mYWJU6TVWzSdB83iA_2_2"></a><a id="Tc_boqvo456A0GDa7W1co-jkw_2_4"></a><a id="Tc_j5T4BytX3Ei2QqfP9xh13A_3_0"></a><a id="Tc_ht7kGdgWoEeWiSEuDQbg1A_3_3"></a><a id="Tc_Bc3GEUC2Ykul8yDaLKg1xA_3_5"></a><a id="Tc_vtiOqEY_Gk2ERL7tNDj7Lg_4_0"></a><a id="Tc_v3YkTWFWkUO4sYaAm_VbgQ_4_3"></a><a id="Tc_2MrqwqD0WEmfDxD7sew3zQ_4_5"></a><a id="Tc_3T5uu9bCbUq9DwjmslqBBw_5_0"></a><a id="Tc_kpGdqg1-xEmtjuxz2GBFmA_5_3"></a><a id="Tc_tZk-0HLIDkyxQ9not7H63A_5_5"></a><a id="Tc_uPHZTr46q0q5NtlH-2aVeQ_6_0"></a><a id="Tc_lySxY2_hh02iiUAHWxIsuQ_6_3"></a><a id="Tc_i5tutoD5bEuNL1k1hmAI4w_6_5"></a><a id="Tc_d8CdEAIi_E6ubI9Uzkp4cg_7_0"></a><a id="Tc_E0sDm13UV0GPWoqzbmETxQ_7_3"></a><a id="Tc_sm8eIsdHnkykXxpd7KGwbQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_US-yiEmGJEq00ozTsVHY6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;9. INCOME TAX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s net deferred tax assets for the year ended December 31, 2022 and 2021 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_GT0l1CfR5EOigCcmJUWAYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_peeH7xmihk6B18-CtGtP2A_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_lvGIbIoQ8EaOlPf9wnyqAA_4_6">40,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Organizational costs/start-up expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" scale="0" id="Tc_YJ5rkIQsdkK_C1RCbGpkXg_5_3">1,160,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" scale="0" id="Tc_KsqxRuudZEKd7Cfhv1K3Kg_5_6">606,383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_pXMxGG1aRkaSp8YG8bwspA_6_3">1,160,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_M4xlxDqit06WZMoc8se4TQ_6_6">647,202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_kChYhdCvQUCXN-Mjd8ibOw_7_3">1,160,666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_NL_uROErXk-zmjY4AqCHWg_7_6">647,202</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets, net of allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_96yGiroYtUmj0N5jQeQRQA_8_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_a1-2V8fAY0SPG6TYevBAsg_8_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The income tax provision for the years ended December 31, 2022 and 2021 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_12FACrNjaECTzzXJy6hr8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Tc_3K8yOxe_502xbh-n7n3wJQ_4_3">570,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Tc_t9az2f9ryk--UgmB7ioLEQ_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_1jDXPz7QsEG4bJvgDqQFhw_5_3">513,464</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_CCkgw80cr0eWQlFusRV2RQ_5_6">625,111</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:IncreaseDecreaseInValuationAllowance" scale="0" id="Tc_bOrElSfKMUOR8SC67XuxxA_9_3">513,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="tlsi:IncreaseDecreaseInValuationAllowance" scale="0" id="Tc_qXsfyR_iF0q5aQNn3EauiQ_9_6">625,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_W0Us2RffDkOCw-FdZrscjw_10_3">570,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, the Company had a U.S. federal net operating loss carryover of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_zg_BX-o7LkyJGWcjZbc2TA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_vZ-VGcSYeEWQWAjwyJfcSw">194,000</ix:nonFraction> available to offset future taxable income, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended December 31, 2022 and 2021, the change in the valuation allowance was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt:numdotdecimal" name="tlsi:IncreaseDecreaseInValuationAllowance" scale="0" id="Narr_oeKyLPEtj02gaBAlOLSaVA">513,464</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="0" format="ixt:numdotdecimal" name="tlsi:IncreaseDecreaseInValuationAllowance" scale="0" id="Narr_gkqX43r-QUixRgC5i4q6aQ">625,111</ix:nonFraction>,respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate at December 31, 2022 and 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_XBwKOntoGUWbD2V--XUeww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_oSE9qMdtAUC3chfiOqo1Kg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_S_pq0ndPSUShpiCPQfST4Q_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_AM_3NCi78USfe0PgWVJDDA_4_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_455F2n8XzkKs9aPywsjv_g_4_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="3" format="ixt:numdotdecimal" name="tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities" sign="-" scale="-2" id="Tc_iXTrJEQZ4UiYtB-4tLIuew_5_2">20.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="3" format="ixt:numdotdecimal" name="tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities" sign="-" scale="-2" id="Tc_loMMSttceEGTWu8vp1C5aA_5_4">34.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc__ICtDchwoEGhm2USNVoTpw_6_2">8.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_HrSstvoks02YmJqlccDmDg_6_4">13.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_J5WQ0pyWp0qY_vB7Xz221w_7_2">9.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_4iRrn2r660ye-yX5v1ZHww_7_4">0.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_wPstuwF0A0uoK825p4JEcQ_1_4"></a><a id="Tc_8RwQueyY2kmzoKgw3AsrLQ_1_7"></a><a id="Tc_Yon66sC2skKjkmpyclG4EA_2_2"></a><a id="Tc_9ejj3CoJ4ECdagtHo5mUxw_2_4"></a><a id="Tc__w2QrtBDG02F3bCqsvrPhw_2_7"></a><a id="Tc_RFET5FUkn0q4RQl5t2f7rg_3_0"></a><a id="Tc_GAXuQcwGXUeoi_Jz7viN8Q_4_0"></a><a id="Tc_1NuwJUnnsUK1qVdYYtIS3g_4_2"></a><a id="Tc_k7kRt-OBFkOjVMdM_gl77A_4_4"></a><a id="Tc_yvE3g1AXrk6-TjmkOgrWxg_4_7"></a><a id="Tc_zWtLrrfUyUCbyhJVvUiZhA_5_0"></a><a id="Tc_EgbI_mFYMUOsDnrQiJ-v1g_6_0"></a><a id="Tc_AwlraZkPWUyYhAb-U4PgQQ_6_2"></a><a id="Tc_REdlwdAMWECHu5p6waiRng_6_4"></a><a id="Tc_ylIAIFfxIk2O1txixlCl5w_6_7"></a><a id="Tc_kXGQe0ZDLk-59sojV82L_g_7_0"></a><a id="Tc_YVNC2wEOg02tuOwwx0xK2w_7_2"></a><a id="Tc_PWgk24Ho_kakpVDVVw0bhQ_7_4"></a><a id="Tc_v7lLoARFmU20ltQ-sStheA_7_7"></a><a id="Tc_4Fkf0FwZSUCGV400KM2jUg_1_2"></a><a id="Tc_h0d-pI-QOkSnR900cF9lSA_1_5"></a><a id="Tc_ReRiDs__vkehnFuqxQjZWg_2_2"></a><a id="Tc_auEmWlmEB06c_k8NsJmNwA_2_5"></a><a id="Tc_KYkjPCh44EixRfity108Tg_3_0"></a><a id="Tc_M06b3V8EDEqUPIQ5QcylNw_3_2"></a><a id="Tc_sqPz_KY32E6JL_L3IAz_6Q_3_5"></a><a id="Tc_zV5nPswUjkWf3uUaXNcURw_4_0"></a><a id="Tc_nZoMpMeJBEisvZDjzF8O2g_4_2"></a><a id="Tc_xFco2h4f9Ua1IYvEol5vFA_4_5"></a><a id="Tc_fFF1anGUyE69byVnld9ZVg_5_0"></a><a id="Tc_edPshentRUeDWbFsEldbPw_5_4"></a><a id="Tc_YtIt9JfCSkiF8TUp4xhtcw_5_7"></a><a id="Tc_2JKTCug7akmnqlARxmfF4Q_6_0"></a><a id="Tc__1TLVWk0GEWi4SjFt8NnjQ_7_0"></a><a id="Tc_u26E4p6YyEKRBGJmjHzarg_7_4"></a><a id="Tc_PrqIuOwluEm-6aRHPB7RnA_7_7"></a><a id="Tc_K7Tki4XZiUGBtbDXMXwPSQ_8_0"></a><a id="Tc_esZU1p60NUW5RE66mK7X0Q_8_4"></a><a id="Tc_JhJJwdNdnkaSVZFfnpMpCw_8_7"></a><a id="_69922d6b_874e_45d0_9954_1a8c9e37538b"></a><a id="Tc_FGuIz2FS6UKV_BZRbqQd8w_1_2"></a><a id="Tc_sMc55YxVJkyFli-IADNPZQ_1_8"></a><a id="Tc_-pYSh8Hd0Ui-yWPOTq9zWQ_2_2"></a><a id="Tc_q5Z9ThKCIkCT8SfmiXA97A_2_5"></a><a id="Tc_3tVYw4JpUUS8ExHMeTW3KQ_2_8"></a><a id="Tc_HARSkVoYfUqdoKkYDSKmeQ_3_0"></a><a id="Tc_XrcvKR9_nkKvBW3rPBihpw_3_2"></a><a id="Tc_uP_m5APTYEyO9idy2fP1Uw_3_5"></a><a id="Tc_kNy5zy4-OkKp4fZGW7YnHQ_3_6"></a><a id="Tc_T6ztwov9oUKA2qhYpbgR8g_3_8"></a><a id="Tc_rbZQyR81tkK3tDbMKTIvNQ_4_6"></a><a id="Tc_BCMVg3nCXEG7IEDj3xIM7Q_5_0"></a><a id="Tc_zoPFCthCL0WxSV_mZ3RMSA_5_2"></a><a id="Tc_3ckLzgLS20m4zze7QdQjLQ_5_5"></a><a id="Tc_mR4l5MXgIE-ad7w03BgLpQ_5_6"></a><a id="Tc_4hSXOKF_RUitm2IZviFF0Q_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_JsXbDQWh40mGzfLbeYjRcQ" continuedAt="Tb_JsXbDQWh40mGzfLbeYjRcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;10. FAIR VALUE MEASUREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, assets held in the Trust Account were comprised of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_pSuIgL5MgkW3Hup01vec-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Narr_zwfTeJsakUWoviYqvGQ02w">19,827,884</ix:nonFraction> in cash. During the year ended December 31, 2022, the Company withdrew $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w" decimals="0" format="ixt:numdotdecimal" name="tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" scale="0" id="Narr_-RksQlhqL0WxvVDEh4N2oQ">905,000</ix:nonFraction> of interest income from the Trust Account to pay for taxes and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w" decimals="0" format="ixt:numdotdecimal" name="tlsi:ProceedsFromTrustAccountInConnectionWithRedemption" scale="0" id="Narr_SlJceyRenkeiVDwR8KrLLg">232,371,273</ix:nonFraction> in connection with redemptions of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, assets held in the Trust Account were comprised of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_ApO8mJ0Y8k2llY2j78FSwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Narr_dORJ69w63karfVGJ7S511w">250,007,295</ix:nonFraction> in money market funds. During the year ended December 31, 2021, the Company withdrew $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7GgzZHKQ-Em17ealfdPxcw" decimals="0" format="ixt:numdotdecimal" name="tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" scale="0" id="Narr_9yONw7Gp40e4RKYCY6HKTw">60,000</ix:nonFraction> of interest income from the Trust Account to pay for taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2022 and 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. The gross holding loss and fair value of the Trust Account at December 31, 2022 and 2021, are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_8dBzeY_VHE2Trnp4nwoh_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1sI5wKqJ1kuQbBSeQbH8aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Tc_sA_vpdA8F027sM8zeDkPzg_4_5">19,827,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tt5jNBG_Ik2_dw16N9eu5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Tc_ecC882wxwkq4SbUJqaNUOA_4_8">250,007,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vK2xj6_BxUyXDij_MHIdJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_b0Ni2ckJcUeNhymocwQlvg_6_5">666,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_polfWIhfYU6ib1Sd0a3R4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_lZos9YI0REqo9bx8JFWpVA_6_8">4,333,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jrQIVcWI-069v0ykyuASTw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_sApU8x_VOUqgqlUbnGMV0g_7_5">394,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0kAqZczoU06tzJG4_2vBug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_6Q4PoD_YlUK7L0Iz2d6IFA_7_8">2,565,333</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrants in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model, which is considered to be a Level 3 fair value measurement. The Monte Carlo Simulation model&#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. Significant increases (decreases) in the expected volatility in isolation would result in a significantly higher (lower) fair value measurement. The expected volatility as of the Initial Public Offering date and subsequent was derived from observable Public Warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified target. A Monte Carlo simulation methodology was used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The key inputs into the Monte Carlo Simulation for the Private Placement Warrants as of December 31, 2022 and 2021, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_ZjyY6cp84EOYjHwjgT6_kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_CJLtKJK7qUergetVoiFMww_3_3">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_Rf1rpKHlWkavH2VB0BmDhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_GOQoKJ42AUSJpomhkk1WiA_3_6">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_25lDX06in0-qNkGhQyvfQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_CVmnXCqPe0WwKBsclQr0mQ_4_3">10.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_Wce1nzVCUkqX390MzkZu9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_oPCOuwDbT0-NUnsTebo4zg_4_6">9.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_m13ANPolnkC_TrigPHT8kQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_eiHlzpxlUU6iQ_KNAOHBYg_5_3">6.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_iVlKykJbaEi1jw6dwN8Bmg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_3p5u4IThx0aY2MzRIMZD8w_5_6">9.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_0Joxy8nL_k6rabaYjK9iOA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_ZiVE65t9GEKkhgEcflNkWQ_6_3">5.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WdW_HNNUdE21vIAEvcd5UQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_bIxVqNT2ek2sr79MzLJTsA_6_6">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Rp9zrLRlm0CYZN74Ck2XNw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_f6eV9l5TGkaNm7FUn6DFlA_7_3">3.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Qppm2hRKWU60ummLMBfT1w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_rijD24maKUaumkvvSdW6Vw_7_6">1.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_nHo1vJsJrkKTnWl_TCasMA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_XoTWNkJEvEe9yRgVRHblQQ_8_3">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_a8ra3C8AWUOIDlIdA4ccMw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_LE9Pgy7c5kqtmIKfH9QCew_8_6">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents the changes in the Level 3 fair value of warrant liabilities during the years ended December 31, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_IogKnMMNX0uzLtWgLHXI7Q" continuedAt="Tb_IogKnMMNX0uzLtWgLHXI7Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_sRNj3c2rZkSn5DefVsyP_g_3_3">2,565,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_2we1WgDOqkGRwMYrsb_nNg_3_9">2,565,333</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gXPw_HPigEaLTrob0MTpMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XjvP2qF1UUWER7JjNd59jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_Cngb9ZfmFEqlAxZh-81y8Q_4_3">2,170,666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dOs7dd0euEGpMogpANdTlQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_x3piW-1bYEuUbhe-o5Sc2A_4_9">2,170,666</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_0GubflhbPUawUpS7hbiulg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_DbvdrStsu0muN6sBmCM3xw_5_3">394,667</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_prO-azAGCkKvlOGQ87zRuw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_PFrHTld_V0Wyxs_kADDu3g_5_9">394,667</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0152871a_48e9_4303_9a93_1433c21bc0ae"></a><a id="Tc_LTTd2VRp1kSjNOyqSgUbmw_1_2"></a><a id="Tc_eq68KYox5Uymv_d1d57vnQ_1_8"></a><a id="Tc_bsL01k2YVEWXQ14-_A99cg_2_2"></a><a id="Tc_lPk5bIQZB0ekbgyCZjFVdQ_2_5"></a><a id="Tc_bzgA-sE0GkCAjFxzXqmWPQ_2_8"></a><a id="Tc_t4NPbVjj8U6GoWCh8nvnkw_3_0"></a><a id="Tc__06KG40beE6gJIYoGFNMNw_3_2"></a><a id="Tc_aLd51gF38UWHa8EKgkq3_g_3_5"></a><a id="Tc_6z21VYgbHkWviT6aJAH6iQ_3_8"></a><a id="Tc_hXrPXpxtp0S3pvSbKmW9Jw_5_0"></a><a id="Tc_VzoCWcGAR026eBM5BxcdbA_5_3"></a><a id="Tc_F5aN9YTFOUqwMqE-o1m7rQ_6_0"></a><a id="Tc_m89sXjde9UaYU9MfH8UU-w_6_2"></a><a id="Tc_WXKtJekw30CvwJ6lUjiKWQ_6_5"></a><a id="Tc_2-111hhZB02fstOICkpiZA_6_8"></a><ix:continuation id="Tb_JsXbDQWh40mGzfLbeYjRcQ_cont1"><ix:continuation id="Tb_IogKnMMNX0uzLtWgLHXI7Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WJzJV0pqcEuaZ1x08vBwUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_IPATj5Dq_0ySkViG9l9mBw_3_3">5,476,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_NpeQJRDSdU60CDOOsBwD5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_RgvC6NUU6ESdA8qJwRQaIQ_3_6">9,166,666</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lDZmpqyvbUGnBpoWYEe-5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc__u5bWo-h50q4pZsQo6Z2Zg_3_9">14,642,666</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2rj7F36mjUqkt3ooiJGgKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_5bX39y7wV06kY0hYQDIn6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_Vox7ocTi4kiXMMqAB-xZaw_4_3">2,910,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_w5xrwltERku_gc-cgbBHXg_4_6">4,833,333</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_SPw4q8hKZEW-qpYCbkrU_w_4_9">7,744,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transfer to level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" sign="-" scale="0" id="Tc_g1QviIZdyUq-s39_rRPuUA_5_6">4,333,333</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" sign="-" scale="0" id="Tc_BPDF3nkep0mf5mCBLIOrPQ_5_9">4,333,333</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_R8iRIidU7kCfycGaLQx7Kw_6_3">2,565,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9FstVZm760uM_Oiv3BV2pg" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_Yd_WuJRcKE-Yf4LO1fo9Iw_6_6">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_w9LGdZuMdEOeqY17iDJ5tA_6_9">2,565,333</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the year ended December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9tvbOtUSfE2CdGMRe7SRBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="Narr_kzavE-a5JU--5EFqqfcZMA">4,333,333</ix:nonFraction>, when the Public Warrants were separately listed and traded. There were <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="0" id="Narr_qcjD5SB6REq8Hgvnh5UI1Q">no</ix:nonFraction> transfers in or out of Level 3 from other levels in the fair value hierarchy during the year ended December 31, 2022.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="NOTE11SUBSEQUENTEVENTS_8220"></a><a id="Endbookmark"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_EyxPqvVoE0CnzZzBAPRssw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 11. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than the below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_LongtermDebtTypeAxis_tlsi_ExtensionNoteMember_tiwUkSJfkE-HqTQAgDXx9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_jGSGW8oskEeJG7Tl5Ucqfw">78,136</ix:nonFraction> was drawn on the Extension Note, as described in Note 5 and deposited into the Trust Account. In addition, TriSalus deposited $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_CounterpartyNameAxis_tlsi_TrisalusMember_us-gaap_TypeOfArrangementAxis_tlsi_MergerAgreementMember_ZN8XEh8o7U6Eq1INZQlX_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrust" scale="0" id="Narr_gZRoIkUh3EeFAOJBgYkNIg">78,136</ix:nonFraction> in the Trust Account pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023, the Company drew an additional $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aZgwMCP6sEuHAa1-q5dwCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_ZuuGw60rZkyS8_8SXN4PWg">159,000</ix:nonFraction> on the Convertible Promissory Note as described in Note 5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023 and February 8, 2023, the Company drew an additional $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8QPxAWLYn0eSa29pAZk5ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_7Pd7-IjNDUeW8GF2moYDDQ">215,222</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_2_8_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_I5SxmOgITEqkvbLNanEY2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_v-aG3LDiyk6QBoee0li4fw">200,000</ix:nonFraction> on the 2022 Promissory Note III as described in Note 5, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2023, the Company and the Sponsor engaged Ceros Financial Services, Inc. to render certain advisory and placement services to the Company. Pursuant to such engagement, the Sponsor (and not the Company) would be solely responsible for any and all fees and expenses payable to Ceros Financial Services, Inc., if any, that would arise or accrue prior to, or in connection with, the closing of an initial Business Combination.<br/><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;background:#ffffff;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_aa0accfe_a71e_451b_8aa9_0a5ee5a10434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Balancesheet2"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONDENSED </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in thousands except share and per share data)</b></p><a id="_42c129fe_38cb_40a8_a5ce_ed177ae40223"></a><a id="Tc_Sp9sDZsEvE6Au7Px8qFEBw_1_2"></a><a id="Tc_rLBqGvfuyU6GFz61CZwL7w_1_5"></a><a id="Tc_L9xZy5FpSE-ZEXP4M-r2SA_2_2"></a><a id="Tc_oEJ9joith02jcrWO1FBKSw_3_0"></a><a id="Tc_mS3YM5gJfkiugHjOFTQJRQ_4_0"></a><a id="Tc_olG_IMGdtki2iiQDBW3gCA_5_0"></a><a id="Tc_UtXvK9z5JE6OLIIHYGA9fg_5_2"></a><a id="Tc_72LBJVF62kW9kX888ZD-MA_5_5"></a><a id="Tc_USu0OIkcFkuqZ8ic9YkaCQ_6_0"></a><a id="Tc_DJ6OPI7VxEG4XiSxybwn-Q_7_0"></a><a id="Tc_EjAYIwdPYEGJLyWGrXHgYw_8_0"></a><a id="Tc_9DQiiBDB4k-q7YJkKYELfQ_9_0"></a><a id="Tc_4HfoTPkopECOFrp1UUGlxw_10_0"></a><a id="Tc_UmR9ZrpIVU2NuQHwdMrhzg_11_0"></a><a id="Tc_16OxgSMWLES6-41B2vcBxg_12_0"></a><a id="Tc_JhOg5bLiyE-9P8sLCwOZSw_13_0"></a><a id="Tc_ZVeABlXiTEuHd79IPiQPpQ_14_0"></a><a id="Tc_SwrWQ81NXkWGiweBbNHC4g_14_2"></a><a id="Tc_Rw6Hsfpr3keen-UwOL5n4w_14_5"></a><a id="Tc_PuHpzX0Ur0yl5nhIM8X3yA_15_0"></a><a id="Tc_lV0OgsC1W02YbhGGhWx7Rg_16_0"></a><a id="Tc_7h2hyU_f4Ey8jKp_VCR4VA_17_0"></a><a id="Tc__ELvQ0PB0UmCnaUiyyJrdQ_17_2"></a><a id="Tc_-yih_AblakSxW2UmI8MDkA_17_5"></a><a id="Tc_fCUUFgzbkEyD59x_OpG73A_18_0"></a><a id="Tc_1kOrlEe52kWk6yQ0WHGXqQ_19_0"></a><a id="Tc_zr_jODNYH0uxUgoZORQBfQ_19_3"></a><a id="Tc_j0TgwK9xFEqAK-Fk-A3QJg_20_0"></a><a id="Tc_PPC8RQbkJUS75yW7WZbzAg_20_3"></a><a id="Tc_qo-XPIItskqT_rYmjhQL3w_21_0"></a><a id="Tc_bhJyv-2qCUGPOSeapPbwdA_22_0"></a><a id="Tc_hFbLNTc5AkqjOM0Kc9i-SQ_23_0"></a><a id="Tc_qjnHB8vTIUmgi5q0gkJmIA_24_0"></a><a id="Tc_StVqgkgZB0ylYKqf4ulr0w_25_0"></a><a id="Tc_SmjHAK1Lz0uASra8S4hgMQ_25_6"></a><a id="Tc_-sVGGp2yEk-e1aVVaMRqHg_26_0"></a><a id="Tc_IsUGyNkwwkSA68_FlYSNCw_27_0"></a><a id="Tc_XiMcHFhp2U21Qu5QhelB8A_28_0"></a><a id="Tc__DagaxvuH0SfxBI8pk7hoQ_29_0"></a><a id="Tc_maxvQ7LPAkOvspYtbI781A_29_3"></a><a id="Tc_vHqaAGk2z0iBe1WsbXPBAQ_30_0"></a><a id="Tc_zqLf1h3sA0Wjp_cNdG1SfQ_31_0"></a><a id="Tc_ULfvtfZ9Y0eYwZDhrmHjAQ_31_6"></a><a id="Tc_FTNBjzoDw0alp_OQVFPGcw_32_0"></a><a id="Tc_4_VrEf7y2U6aJer2EgEvtg_33_0"></a><a id="Tc_9tTaJo331US8x5GwznB1Jw_34_0"></a><a id="Tc_jy02tQBXVUqALpW20oVAiA_35_0"></a><a id="Tc_O-hXJqslh06Dt7Eq49ZHGg_36_0"></a><a id="Tc_MnEyFdYfW02mY5LG9G5aqw_36_2"></a><a id="Tc_jX-GKd8XQkiaDFKOO5ajCA_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LdkZGq5LRk2UG4KiMC9o_w_5_3">21,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8QWkNHA0vkWJ01DhrRCgOA_5_6">9,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_pL5FiF7EJUmVNDCdbl_whA_6_3">3,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_LDSBiRVXy0KzJh18QVr1ng_6_6">1,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_fUA6eAFtZEqhGFkEheModg_7_3">1,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_crH9iFSqHUi5qfTPHjG03w_7_6">1,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_atDmrYjdTEuzYkIKkE3PlQ_8_3">2,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_7azYVc8GsEKj0U0eu-AAfg_8_6">4,772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_lT-Hcz4i-0Sd9pQW-o4pBg_9_3">29,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_aBXeyt9LQ0GmSuYWMjegcg_9_6">17,214</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_BIsDZtrFXUqoVqO3TGfp3Q_10_3">1,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Xj1HXC6bvkqTX1I8q6KmYg_10_6">2,231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_7jW9rB2rskSh0RWSjky3gg_11_3">1,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_OmUHwaL7lkiQHGy7hytIew_11_6">1,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_DOTZbWCePECMxdd0kTQtiw_12_3">997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_fvmbP5aiCkKhnxxXi-cOTQ_12_6">802</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_XNeQMwn0Hku0y05l-7t_fA_13_3">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_8ovwzcZG0UmS3Mma44oQWQ_13_6">367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12.25pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_y2MiQnehNkmgwWZ1DztC3A_14_3">33,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_SFeaGi4CrEmbvFdUiLjERA_14_6">21,995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8217;</b><b style="font-weight:bold;"> Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_0z-dESqgiEKW7TSG-RHqGQ_17_3">1,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_TsZyU6DrZkiPDbzPnRU_OQ_17_6">4,947</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_VbsSSh3ZUUuPmdp3CLdHHA_18_3">6,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Yvw9mi0cTEmFhlyxOxxLHA_18_6">6,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="Tc_ybt2RdAR3EKaXcU1V11gMA_19_6">4,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_7-Ei6pQlX0-G_ZB2qY5krg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="Tc_pXANtf26hE2BQJdtlmZ53A_20_6">15,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityCurrent" scale="3" id="Tc_npyyCPmr9EydP6ngejISNA_21_3">379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityCurrent" scale="3" id="Tc_6AY_NHiewU6Kuf17LpqWNg_21_6">370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_3UeXXR_5HE-uifZlrf7qQw_22_3">427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_O52VQmzLSkqw0u9kFlHLpw_22_6">142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_0ckZaTIfpkOnWZdEv_RnMA_23_3">9,305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_K1KgOKQ5rkCBC-dn2_pHkA_23_6">32,357</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Long-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityNoncurrent" scale="3" id="Tc_tBhkeYbnZ0K9rLlFTfyrIg_24_3">1,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityNoncurrent" scale="3" id="Tc_DkQnESWpY0GNvLLw2tbN8w_24_6">1,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_iQIJIdexski4TllYsG6NWw_25_3">9,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_Mv0sKiTaQE-_9a7LRSTmqA_26_3">5,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_djynE7y46UuGJtBrPjxTbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_Z5BKY1njJkGUgKb_KX9IPQ_26_6">369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_nvdkejMI10Kkh-8ikQ6XoQ_27_3">25,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_hE__nxZZg0CUDEa-CKOdVQ_27_6">34,319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Vl95CsaHzkeodosTc0tw-A_29_6">164,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span> equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, Series A, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_qXNTsmBJckSI6GoAVaCTmw">0.0001</ix:nonFraction> par value per share, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_iRG2NtnTH0i9Zqbl0q76QQ">10.00</ix:nonFraction> liquidation value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_9XTbgl3mUEmogKtzyP47Sw">10,000,000</ix:nonFraction> and 0 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_9_1X5zXjg0uOJOCqiorANg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_FoxGdjXrtk6lSjYm44Mprw">4,015,002</ix:nonFraction></ix:nonFraction> and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_oUsG1eehwk6NnrNnc53HtA_31_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7Gy582q5nUKr1ZWZGCZ9Hw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_as7upiRgd0e27KdEHqYJDQ">0.0001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4FurbMzBWkK3NDaVMyTWsg">400,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bqnx8EfHME-hRjrBq0m9sw">30,898,162</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_H-1oDNV3uUmZx1gQ5pS2PQ"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_-ll8B2FRMkqlpVWNZ5vezA">26,316,681</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_mSUfA0jMFkmQcIE77N4iVw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_o5dIWReGykGjaAIK2-O_6w">347,926</ix:nonFraction></ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_krk23REpVkCXpYF6jNmbPA_32_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__lATSp_YGkqaGlHAuRVnnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_57b5Nv9zAE2dSxOUeUS_iA_33_3">221,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_z73BU1TppUCxocPEi7XyGg_33_6">10,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_-JKyo8ysqUSfflYiWXBJVg_34_3">212,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_qw9aZ_7j7UWVIwkkyDAt_g_34_6">186,358</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span> equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_veskGXe2ZU6iwXuUuERXUA_35_3">8,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Cqf7dZod0E-sU4exBmsgTw_35_6">176,330</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span> equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_LQGjSQphg0GmS1gxOUz6Bg_36_3">33,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_bdzcoXSzhEueFv_c8dykJQ_36_6">21,995</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See accompanying notes to condensed consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_566b0afb_10e4_4c19_af51_c872f5cb7ee4"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="Statementofoperations_2"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONDENSED CONSOLIDATED </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">STATEMENTS OF OPERATIONS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(unaudited, in thousands except share and per share data)</b></p><a id="_1ce508cf_993a_4891_a3eb_2620eefd92f8"></a><a id="_857599d4_c893_4d00_89bf_b58c2a8b0030"></a><a id="Tc_ylwC1_QtHk2d0Mn98qvfFA_3_2"></a><a id="Tc_8XdkIxyvA0-_HP083wYNUw_3_8"></a><a id="Tc_c0_BOKRGPEmCAQSHuaqZHw_4_2"></a><a id="Tc_KLlx1_x2oEOPLi56y2w1_w_4_5"></a><a id="Tc_C4bPIG4x-Em9U5oWO5vRog_4_8"></a><a id="Tc_xUUwOHIdBUmc_N5FyIkC3Q_4_11"></a><a id="Tc_vUw59zbX80SLUOXHfTt3RQ_5_0"></a><a id="Tc_zPgbXF6LPEy82a0-BbBIcA_5_2"></a><a id="Tc_doDgygD2TE-gNblKslbX3g_5_5"></a><a id="Tc_YT5w5RYXTUW3JYB7kERicg_5_8"></a><a id="Tc_IrrwlLsqLkqcravz6Gi23Q_5_11"></a><a id="Tc_UhzSgbgSQkiVVeXaSInWyQ_6_0"></a><a id="Tc_pWVd_jCA5Uecf_Oj9c-qfQ_7_0"></a><a id="Tc_f1Ltu2CPAkSkkTMHXTnD5Q_8_0"></a><a id="Tc_hM_IkgbodEq0OT_y6Jr7qg_9_0"></a><a id="Tc_0eb0VrKR9USLLZa3YilA3A_10_0"></a><a id="Tc_Si1-B1wFREKZCkFh1DEW7A_11_0"></a><a id="Tc_XBReNNdGh0Gihov2N8Z5TA_12_0"></a><a id="Tc_3IzCF0Xg30S8s2pUVWDgpA_13_0"></a><a id="Tc_-cNxoNvCvEe7wHHpI74WoQ_14_0"></a><a id="Tc_NHzdl9G2Ok2PpaDzOBmhSA_15_0"></a><a id="Tc_iXcWDl7L10WKDblydUJvjA_16_0"></a><a id="Tc_d6UtURD-K0exixKVjgcntA_17_0"></a><a id="Tc_n6SMyK65YkWPeiNOTiG38g_18_0"></a><a id="Tc_DtD98Ojo0Ee0jEv9vSrS_A_19_0"></a><a id="Tc_AuKVuIWG9Ey0Yssdw6XHYA_20_0"></a><a id="Tc_O4bm9FAsBEOnyXk-t8lbGQ_21_0"></a><a id="Tc_JB0WACRTjkO6bpHzeH4wWw_21_2"></a><a id="Tc_HkvJ6UAWLUmjbVtjR9O3AQ_21_5"></a><a id="Tc_DX-PiXG0gE-BDYmmkgegVQ_21_8"></a><a id="Tc_roLO5Ukc8EmVDT281phm0w_21_11"></a><a id="Tc_M37AOtDGHU-O4g2vATUUtg_22_0"></a><a id="Tc_yaDw7NFOn02414M2fukFvQ_22_2"></a><a id="Tc_nchXqrKZ-kizXdkeC17n_g_22_5"></a><a id="Tc_40d-ZoGXJkGjI9H_s9W0Gg_22_8"></a><a id="Tc_qcPF3D0cKkOXytGaTZj-8w_22_11"></a><a id="Tc_Et3NnPrB80OKxiIvhj0aaw_23_0"></a><a id="Tc_nfyf6-wMw0qDW5kIyfHA8g_23_2"></a><a id="Tc_NaTVr8Kkg0GxC7E-6pgeCg_23_5"></a><a id="Tc_SRWS-CQz3UCJ3JNVMuKWig_23_8"></a><a id="Tc_CcAK7Tjy10Cnfg04BBu-Rw_23_11"></a><a id="Tc_4ufrbQmO90yrAyWgkudeYA_24_0"></a><a id="Tc_WtmwAs7ya0KRE6MQPqqGpQ_24_2"></a><a id="Tc_MJRFlZfaR0yLAzuFJpB8AQ_24_5"></a><a id="Tc_6YONoBT2t0C_E4dwz4H1Og_24_8"></a><a id="Tc_YLd600Yock6KWRGVCnQ7Cw_24_11"></a><a id="Tc_YnfK-guB8EuLxWdIm6CdNg_25_0"></a><a id="Tc_l-v4ps5zIUeHYihGYakWcA_25_2"></a><a id="Tc_PEXDuUF5AUSGXKB3gNOL2w_25_5"></a><a id="Tc_YiBqFH9P3k23W2i1OXAGlQ_25_8"></a><a id="Tc_6JI_oJ708ku6ONO5VNnfCQ_25_11"></a><a id="Tc_Ji5KBcljiEKR2qLWHJBA_w_26_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;September&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</b></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_NYdo0uAZH0CcLQhUN6sYSg_5_3">5,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_c1PdJH7v-0iO-pflJAzPUg_5_6">3,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_uV2Tgdz130ew6Tmaxu19LQ_5_9">12,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_6O71_rBQ2EGpCeDYrJ3tjQ_5_12">9,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_Kt-nk8muV0mGq6obgqXGAg_6_3">589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_mAyxdMjP6ky398jmYT7B9w_6_6">701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_C86YI1BB-U6lzNGBCYuNUA_6_9">2,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_kFZm2fq36kS0Cao-DZevcg_6_12">1,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_OKkiGqJ5ykSTZ6S6zHMrPA_7_3">4,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_2RbBNvBmaEqUocG8a04FYw_7_6">3,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_voVcMvmf0kiOsv657Brisw_7_9">10,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_urOIF4KCm0-tC57jpIi3SA_7_12">7,730</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_7TtjEML_PEax6jyXxGSJJQ_9_3">9,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Zc9fuG01ZkupqNYx_Q3NFw_9_6">4,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_tYGDlqLs0kC0NRp_ZRmGZA_9_9">21,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_56bp4Yxo90OhYboeLPRtGg_9_12">15,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_l7lDGeG8TkiLsAmJOlPU0g_10_3">4,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_8tZY4lzlNkitjNxE5vPMhg_10_6">3,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_TQtloQ-Tl0qrS-wglZk69w_10_9">11,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_xG_d9vwk4U2xaqETz2ASaA_10_12">8,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_0yHQCFbgGUynQCITxbu2TQ_11_3">9,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_apjWn9P4rEi96AmZ75D4Fw_11_6">3,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_2hXFFDY-0km9YALSUtZylg_11_9">17,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_MWU35pnbeEa6-ZAYmrKuaQ_11_12">8,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_ADCyzjjMCUOwBNgQDmr7BQ_12_3">18,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_DK5Wd7e0Gk-U23LTDQetTw_12_6">8,111</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_15LqtN10cEuN3s1RcMAUfA_12_9">40,032</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Ccksevz2REeszHgCVTFuAA_12_12">24,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_wHPjlJ0ml0OeKCNF6_-JQg_13_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_WhBcseAWpEGiHjLcQ30WPA_13_6">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc__PL5Jd-Fi0WvwvC90BxOIw_13_9">187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_5B9eqfGCwEeFA_cOz9-IvA_13_12">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_JJgAvkWbkEmVGfSacjo3gQ_14_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="Tc_lfPx-Hq37kStq_uCMOpv4g_14_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_XLjB4pBwNEGpnY22z2ApCA_14_9">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="Tc_ktL0BhEwWkuRRjhFWVYzpQ_14_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:zerodash" name="tlsi:GainLossOnEquityIssuance" scale="3" id="Tc_wKYejvcOH0y_LVNc5JwIaQ_15_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:zerodash" name="tlsi:GainLossOnEquityIssuance" scale="3" id="Tc_wyXGuu-cbEiVPFvazraOLg_15_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Tc_mYZLM8kmVkq8mTfCpX82KA_15_9">4,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="tlsi:GainLossOnEquityIssuance" scale="3" id="Tc_NUQ8WKnJ8EqLfH0d6ZsKSQ_15_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of tranche and warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_u3QAPFO_gkSJ1bhVwH2ETQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Tc_OkKDNAJf3UGLLAmoK1FLag_16_3">2,812</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_0y-vFKCdP0GBKfV2QNnuaw" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_bKOrYOd25EWS_Rd0ITu7dA_16_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_L4irDd9BxUmfXsQRfT-kPw_16_9">660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_6n6dane990u68QIyNJeL2w_16_12">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in fair value of contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_MnsxK1ekK0Oa1gT6eVi82A_17_3">19,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_VNbM6PPC7Ui-DQUvI1KgNg" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_GwJbS1TwRk68XSacM-NhSA_17_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_q4ROv0TWiky4XkC8LhztlQ_17_9">19,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_HLmyF__iWUaMbnQZU053WA_17_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Y4sxXoHiC0We7SrQcqCEsA_18_3">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_5GyNfqrRqUSxPY8gstPjkA_18_6">31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_kc26FXlIRkGyZaIDC8jFGQ_18_9">56</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_H45rN8Yao0CMLsosfcieFA_18_12">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_VgNDvlXc30aWcclT5vvr9w_19_3">1,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_QFRnNktx0U6AfL34RBlI_g_19_6">8,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_rGLvlNwtnUOXoZp4gNrwxQ_19_9">23,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_7HyGEp6vKkOMsAO5uglACg_19_12">24,642</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_sNfHZclCnUWhqw1ZrryzOQ_20_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_EKbxvVltn0yai1mN3Opf8w_20_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_D3PiMPqVEEW1tiWwiAFVkw_20_9">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_HM_wMONvCkqZMcMu5grTNQ_20_12">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uPXyiLQp0EGZ0V6wwf838w_21_3">1,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BVONEZHOr0yKopAItLj83A_21_6">8,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_u7HB-dtYnEWYRsVBFuc99A_21_9">23,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_IjgOh4QavkGIeZaHlFcm1g_21_12">24,645</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deemed dividend related to Series B-2 preferred stock down round provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Tc_ndTIGJhRRESqwwkxmnUyww_22_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Tc_xkRysL0h_UCOoztdla_f0A_22_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Tc_AsF-jXgo8EeRrVCYjHZ6cw_22_9">2,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Tc_EwF8q2bbD0i-Ahsvuf5B0g_22_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Undeclared dividends on Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_AWRZVV0_LEar5DbQqxAl4w_23_3">458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_7oTKwxX00UGVMJxiOhk8iw_23_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_HxdICK2fP0-mgQOcHvzU9A_23_9">458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_nd-6lERLFkud5RTARpY-BQ_23_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_sg4eXuniakeXQ2oqLDcg8g_24_3">1,744</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_Ur6hmw2hoUm1395ke03GAw_24_6">8,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_0fHV6Ur0TkqIbtYoVTTTuA_24_9">26,968</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_OCyRxeHpwEyPKPqEF5rd6w_24_12">24,645</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_hUlS3ava60qRTX0wWnwOGA_25_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hUlS3ava60qRTX0wWnwOGA_25_3_2">0.13</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_UROfL39YFkyQnBp1LfLZ-A_25_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UROfL39YFkyQnBp1LfLZ-A_25_6_2">25.95</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_K9F_iEyit0KFTqEerrmhug_25_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_K9F_iEyit0KFTqEerrmhug_25_9_2">5.68</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Q3pNx1zcCEa7g8B4FLjMPQ_25_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Q3pNx1zcCEa7g8B4FLjMPQ_25_12_2">82.17</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_NhLfPD4WdEeBHrrRXMoARg_26_3"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NhLfPD4WdEeBHrrRXMoARg_26_3_2">13,173,422</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_bJHKb_JplUar2RCHLnUJPg_26_6"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_bJHKb_JplUar2RCHLnUJPg_26_6_2">311,823</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_x343sDrPikaQmNA5x7K0VA_26_9"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_x343sDrPikaQmNA5x7K0VA_26_9_2">4,749,849</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc__i2-ma8H70iHJqa8BVaiHg_26_12"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__i2-ma8H70iHJqa8BVaiHg_26_12_2">299,936</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See accompanying notes to condensed consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3a9fcce_af5d_4fd1_94c0_725ccd4de259"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="StockholdersEquity_2"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(unaudited, in thousands except share data)</b></p><a id="_56806048_b9d9_4c31_906a_d5ea66511143"></a><a id="Tc_ztisxnqtzUW22UXCCdcGIA_1_2"></a><a id="Tc_QQA_R3a-rE2QYDm7Cjn4Ag_2_2"></a><a id="Tc_kATq2CTLCUmhcnxV-vfA-Q_2_7"></a><a id="Tc_DOxaZzzONEGswzTxdgyOaw_2_12"></a><a id="Tc_d3jDE7z9xkekgMaqNxKfGw_2_15"></a><a id="Tc_cCQjKMwhvUejo6KpDgiC3A_3_2"></a><a id="Tc_wvixiJ-R0kqTXuNuh6Bhcw_3_4"></a><a id="Tc_9X07cYV9JUqi8sWb1G9mfQ_3_7"></a><a id="Tc_krglqeegDkyhm1npApGMvg_3_9"></a><a id="Tc_sjwTEG8iaEijEihAb5-LeA_3_12"></a><a id="Tc_CzCGOPOs6ECaoYeQQAn6Lg_3_15"></a><a id="Tc_62aRp-PLqkGsPeppYUg8tA_3_18"></a><a id="Tc_XE8ScR4j1kGd2kTbCTwILg_4_0"></a><a id="Tc_WRztT8jJ70qdJyg1CKWtOw_4_4"></a><a id="Tc_HmTdjYt4OU6i2FoL1mQ_uQ_4_9"></a><a id="Tc_pL1IqCeibE6KOl_MUbwhcQ_4_12"></a><a id="Tc_7_nl5B0Pj064f1EERyipAA_4_15"></a><a id="Tc_t8jzEbrhS0KHPObiYRmD6w_4_18"></a><a id="Tc_NJBxfHTZskmLP2-EEL5TXg_5_0"></a><a id="Tc_UXV1cpNPfEajbrpu1u7BGw_5_2"></a><a id="Tc_Qe6qYWGKOkGBDSSBXyPOdQ_5_5"></a><a id="Tc_cToqwAOsa0yJ2bjb2wQKfA_5_10"></a><a id="Tc_d0ePk1oLNUKncYaL2g2jBQ_5_16"></a><a id="Tc_Qi4AvisPyUazVnhZvUttgg_6_0"></a><a id="Tc_hTrx-vPaMkO2egkUbrX5_g_6_2"></a><a id="Tc_fjq0eJYXpk-CdCbNM2Ir9g_6_5"></a><a id="Tc_2A_zRxzDeUuYqzho_kce7Q_6_7"></a><a id="Tc_HLEVIfK3Q0SngjXVvM6itw_6_10"></a><a id="Tc_0BrR1YQrX0aqlTlJj81D5Q_6_16"></a><a id="Tc_gVLC6HQi6k60pvzVF9beEg_7_0"></a><a id="Tc_a7jLe8WvCkCcA9ZDVPja4A_7_2"></a><a id="Tc_hfJfT6TPmUmyzWySfF3BKw_7_5"></a><a id="Tc_iuqY8nI2rkqGTAvrzIgzQQ_7_7"></a><a id="Tc__CbskAhgaUyoPu1NHRWUuA_7_10"></a><a id="Tc_T6UhRejNWEan9ElUtTNKuA_7_19"></a><a id="Tc_XXL2XqzWIkSkR5ZjNGdUSQ_8_0"></a><a id="Tc_rGg6afR5I0eywuOg4RbZNQ_8_2"></a><a id="Tc_pMMkgADISUqZqhSmXGW1ng_8_5"></a><a id="Tc_PLAdko1nQUSnzGJzj2b9jw_8_7"></a><a id="Tc_z0XNlzUEWkalm0TG6dY_ag_8_10"></a><a id="Tc_XSfXPwDBd0SCaWQKlwx80Q_8_13"></a><a id="Tc_qICPTn2jvUCdjDVlVHelug_9_0"></a><a id="Tc_J9pLZoUrbEeXBDQjnG0IOQ_10_0"></a><a id="Tc_9KpYCXI6kUmC8WpdzhY-VA_10_2"></a><a id="Tc_hy4tLuqgGES7MOIfksQibA_10_5"></a><a id="Tc_DiwFcQZbRUCC-NzJDuXkVg_10_10"></a><a id="Tc_xnzofmEcXkqosR6pJdWFvw_10_16"></a><a id="Tc_aQLV_j4-R0-xhgrjWUs1kQ_11_0"></a><a id="Tc_iV7fwwGHqU2mM6WvrKqKBA_11_2"></a><a id="Tc_6_utPD4Krk6fTNyEB71jLQ_11_5"></a><a id="Tc_Z0QYOUJtnUeDslQ7lZoJVQ_11_7"></a><a id="Tc_DJ9bXJLQEEWuF5YM_T3pqQ_11_10"></a><a id="Tc_JkcbrFtmckisI1T07r_A7w_11_16"></a><a id="Tc_Fp2q2KKVzE20J7MbQcMnzQ_12_0"></a><a id="Tc_lYYanK2pZUe2qoMDxSEM7A_12_2"></a><a id="Tc_QfcgAvMFj0yv4XBKDH7pSA_12_5"></a><a id="Tc_uoYC4Rj_wUaUByYDFoWzqg_12_7"></a><a id="Tc_J-uAR7FUzEKz6DWVMCiHAw_12_10"></a><a id="Tc_x4fFf3yZ30COUZwwPmN7Og_12_19"></a><a id="Tc_NrR65MN4kUqSwZl4cyiwkw_13_0"></a><a id="Tc_4-8lFP9JVkCIC22OpGl-xg_13_2"></a><a id="Tc_mGPz2qSOz0OlyoWT-RBKBQ_13_5"></a><a id="Tc_GR-yKkzAZEGrb0Sb1El4ww_13_7"></a><a id="Tc_1uPlWpjfyUao7DED5OzsBA_13_10"></a><a id="Tc_21P_289WoUS8pSn7_3U9Qg_13_13"></a><a id="Tc_uHS-2_lYZEivBt6WOhTklQ_14_0"></a><a id="Tc_mYVtzX6wNUSrtezXYljAOA_15_0"></a><a id="Tc_nS44IqlLI0W1xhF_Zu9TRw_15_2"></a><a id="Tc_ypHHPhHtDEup7lkkwRsuBA_15_5"></a><a id="Tc_LqiKR5Wtakq5OvfaGwzyEA_15_10"></a><a id="Tc_2I6eqHwppkmclS2Zp1lCLw_15_16"></a><a id="Tc_HW_lbPBZeEqeF5LiST3rBA_16_0"></a><a id="Tc_RYBaCyerfUeqKsJeiDLPWg_16_2"></a><a id="Tc_j2fjAGbQgkeYHkYDj5SRWA_16_5"></a><a id="Tc_ztB1Fbrgdkex5UjkK_eehQ_16_7"></a><a id="Tc_63-PnrzX4Ue3zN8LR2or3g_16_10"></a><a id="Tc_udz6vitsH0ukBgQcnWf1aQ_16_16"></a><a id="Tc_kPaDxt1VIECyt1MNrhZ96Q_17_0"></a><a id="Tc_T_23HWDN_U-dTaA56DOf7A_18_0"></a><a id="Tc_0gn8-f61fUONAkaOLwlRqg_18_2"></a><a id="Tc_wNqgWidHOU2ELeMTHw-TQQ_18_5"></a><a id="Tc_3dLUkSN-F0yggwMwY87xHQ_18_16"></a><a id="Tc_hOnCb26SnEinw3C0a4hfSw_19_0"></a><a id="Tc_pOEh8Rfs00yzG3t0g6Nzgw_19_2"></a><a id="Tc_wsMakd9C1EmMdpdUuuKMSw_19_5"></a><a id="Tc_VmuZ11kjJ0q6ArKwpRYwTA_19_7"></a><a id="Tc_4NBboXfONkeN5fEXcYr6lA_19_10"></a><a id="Tc_uGLDb_r7HEu1XleD6wpEXw_19_16"></a><a id="Tc_zEiXSqy3ME-Ci4IdR7i5Yw_20_0"></a><a id="Tc_rQpw5LRsCE-q9K4JJJ0Oaw_20_2"></a><a id="Tc_MgDGFGLBOUq84uFbYWym8A_20_5"></a><a id="Tc_pdLmfYvwdEu-XSWY-1lpvA_20_10"></a><a id="Tc_dWydHBjev0md0r4vXBu4pQ_20_16"></a><a id="Tc_fC0uUpPOEke3ljaEEXr0Mg_21_0"></a><a id="Tc_x_Cg2mGamEGD-UmiWR-Ybw_21_2"></a><a id="Tc_7dB-XLzP9kOQkBSmkkSDKg_21_5"></a><a id="Tc_zszJo2lqVk-7FGJa_DxxeQ_21_7"></a><a id="Tc_r6CuxQpIOkWRRHwCB6Vv3A_21_10"></a><a id="Tc_IJiVhObioEWRfp5IP77ciw_21_16"></a><a id="Tc_E8bpj8LM8E-tWMSF65nnlQ_22_0"></a><a id="Tc_riht4JXP9E6fUOdRbU9S2Q_22_7"></a><a id="Tc_Rd05nya7OEGCz3iukHI1vg_22_10"></a><a id="Tc_7O_BfETt4k-qMyPqkdd1ug_22_16"></a><a id="Tc_p2KXa-i3_0-_gnuhOxRYLg_23_0"></a><a id="Tc_bNL0ikUElkecYb_Yx00DLw_23_2"></a><a id="Tc_WI0B8YhWZ0y7bIaoAa11Ww_23_5"></a><a id="Tc_v29lbmRcoEe8uIr5SeevdQ_23_7"></a><a id="Tc_YSqR480l9kubH2FAdFuheQ_23_10"></a><a id="Tc_MWBSWdNaHUyiBLtbVqzq0g_23_13"></a><a id="Tc_yYrMlDk7h0WT5vcgF558vQ_24_0"></a><a id="Tc_nLqLtU4kMUCFIACbKAzD8A_24_4"></a><a id="Tc_QLOFaggCOUaxqOyjvSl4UQ_24_9"></a><a id="Tc_DjHgRLBr5kWOKDqb1qS_aA_24_12"></a><a id="Tc_SmvcrITSKkiy9UyccpUq6g_24_15"></a><a id="Tc_75uDnszTv0iNl8TMl711Dw_24_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="18" style="vertical-align:bottom;white-space:normal;width:67.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">months</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">ended</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:normal;width:19.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">stock</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:normal;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">stock</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">At December 31, 2022</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ik-aY2A_jE63wIuR7UyzxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E4ll_gLBaEKReg0u9L57fA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_0g2ys7O-IEytJb4va4p1eA_4_7">347,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_KK59tWCaEUuJB54qaw6hYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QyASKvv4vkmnDNTTOcajIQ_4_13">10,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vvWax9PUtkqFhvN55bVT4A_4_16">186,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gg3RatWsykGUZBoSJAJYCA_4_19">176,330</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mOezHh-BNkaD4qPijc7hSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_AlazJ7rNsUGDgZ24IJvrdg_5_7">95,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_BJVr7cf_tECca4yQBfgN2Q_5_13">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_HvjhXEbDA06xCELNGusyrA_5_19">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BiHrQw8cdEeAu51zRaGKDw_6_13">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_R5gK4wxIPkKQfPU2U4XDIg_6_19">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deemed dividend</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_WJBriMIX2U-D4L35WyIPOQ_7_13">959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" sign="-" scale="3" id="Tc_YkPZujt2V0mpgH4D5O6wQw_7_16">959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jj_GrxwkxEiDpwUkXkRxmg_8_16">8,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ujSY0-XPvU6tJsqUxk-rEQ_8_19">8,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_6PBZ3tLP70iHvRVOg6SEvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_mStXdH1f4ki5O4OxCGWhIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_qf6D7ow8SUuGTSvcbjDVXQ_9_7">443,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_9ja8HteS90a0p7WpZcVgWw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VwGAxYqj30auZ7FoL0bSaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VTcXzgB6sES47zHBGoY3kg_9_13">11,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gAe7cbk-Ik2xnUHTe-lZNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5OBxTygttECoLhun9Kpqaw_9_16">195,585</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_daSSC4kDIUWJG6OwMuYQ7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bgefJwkGcUihmi9h1NCgAw_9_19">184,475</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9ph7-9habkWVkrJfwFcs6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ahDgu_LmxEeHT7k1EOGBCA_10_7">4,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fWQ6JH0XakmvgGcIDO9Icg_10_13">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_aav9S7fTfkeqVS0Pr4aAUw_10_19">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_m8WkX74WWEKO6BFyDXvRFA_11_13">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_a9ExlCw2uEiXe3ubCDtX-g_11_19">69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deemed dividend</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_8stM-BRKcUyvfPr-xSnZxg_12_13">2,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" sign="-" scale="3" id="Tc_nvGdMsWZA06P2XXC0TD6Eg_12_16">2,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oTs26iKcCEC2dQ4-0YPwBg_13_16">13,974</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wyXEpwf44UWf5V0dceK7AQ_13_19">13,974</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">At June 30, 2023</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ev_u3OXaCUWJcSjZ4HGqRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NzkeQmyzwEqzGAZViRfbSw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_-1mj77RXX0Cdn_8IV724mw_14_7">448,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_rORiQd8xoUiQi4Bgch3EXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J5RUj6hZ_kW5XH1lPZrp9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__sDopmZeW0GYlIH5D-NEhA_14_13">13,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PI-ObqYFzUCIPTC8H9DIcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Yq9WzNzReE2Dch_2_aceuA_14_16">211,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_b5EJjukOmUCZShWroteuUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zsf-TF9GPUqPAlwxAG394w_14_19">198,364</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_hzkwkxTfEkGwkOiLDlrBXw_15_7">50,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_UqK-XDhrt0G2Zd-LfPwGOw_15_13">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fKvvQcf0Xkib_mfYMAzENg_15_19">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wLQ8QsBgs0K9IVSCBvpkQA_16_13">259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_nNPjapI6Xk6dx0kijRxuwg_16_19">259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Impact of Business Combination</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_S-Bb9NHkyUOCUJ63T-66kw_18_7">21,500,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_MxIpFFa2vUORuXMcCd43Pg_18_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_qYcoibvE90eFCRSmQnVpVw_18_13">204,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_eIykxy4XG0CiMseMChDLhA_18_19">204,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Assumption of warrants to purchase common stock in connection with the Business Combination</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" scale="3" id="Tc_xuON8vw5sk6EZtCwkvBE-g_19_13">2,568</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" scale="3" id="Tc_Bjz_Gs4J4UmFJ1-_bO0Kjg_19_19">2,568</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock upon closing the Business Combination, net of expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StockIssuedDuringPeriodSharesReverseRecapitalization" scale="0" id="Tc_3tVSlOSG9UW8wRs3WnP0Pw_20_7">4,316,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:StockIssuedDuringPeriodValueReverseRecapitalization" scale="3" id="Tc_p8uDGcWBPU2n7J73kpVBRQ_20_13">957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:StockIssuedDuringPeriodValueReverseRecapitalization" scale="3" id="Tc_tQ4H6CjsCk-lj4rsF6r-eg_20_19">957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Contingent earnout liability recognized upon closing of the Business Combination</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" scale="3" id="Tc_BEc363TbnEqn52LEWui7_A_21_13">28,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" scale="3" id="Tc_7AtFAtqK60K2xp8yyBUkJw_21_19">28,927</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Assumption of preferred stock in connection with the Business Combination</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_CWW4_4SQH0K6yYYYCCx_LQ_22_2">4,015,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_gJeXgNuX7UKpRUhT3vui7g_22_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_mJUviHATNEq-RieF2y_P2g_22_13">34,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_xq7vc9wzbECyfVN2v03NOA_22_19">34,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-z57Xm8kCEOcnn9iDm5FJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0QbkkUATUEaEbEHNWJtI4Q_23_16">1,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_npOayvHb30aGCptC-vN0og_23_19">1,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:30.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">At September 30, 2023</p></td><td style="vertical-align:bottom;white-space:normal;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Tc_uKVlo85zoUaE_7mU7f67JQ_24_2">4,015,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_F5ewbBZZ00q3kuRqzIXOkQ_24_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_k2rjXmd_kU2rWVSfc3DeHA_24_7">26,316,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:4.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QllQXzH4eU6UuX6jKeAJiQ_24_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.96%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YYKvXH4qESsBarliMaTVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MjuAKVKu3EOzVczLuG3-cQ_24_13">221,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wLjUOHJXF0auOVXVpPAl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6ij5am30HEyRwH0EV00Qkw_24_16">212,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.82%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.17%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YN7S-Ccdg0O29xXuyl3ObA_24_19">8,487</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">See accompanying notes to condensed consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES, INC.</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(DEFICIT)&#8201;(continued)</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(unaudited, in thousands except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_14cc052d_a7aa_4eaf_8b23_0c78576bc522"></a><a id="Tc_YxoTxlVVvE2SpmhHwe3WSQ_1_2"></a><a id="Tc_j5HWk7aow0e_Gj47gpbCGg_2_2"></a><a id="Tc_WBBJtsMV3UeyDtGRxk-Z6w_2_7"></a><a id="Tc_gayLNQxOEkOd5CMxHgHxlg_2_10"></a><a id="Tc_bs3olfvk7Uak_xuPhZVJ0g_3_2"></a><a id="Tc_Js-Hpu7YKUiPjVVwYwr8Jw_3_4"></a><a id="Tc_oKSekTnl1EW55-CG9h6yWg_3_7"></a><a id="Tc_qa96j2mU20SsTRC-ZhIHfA_3_10"></a><a id="Tc_0BQXC-OkmkG1NLH9hWe5DQ_3_13"></a><a id="Tc_oM1vS_v_dk-AvIW8jxtXaA_4_0"></a><a id="Tc_boroJX94y0qeAYru2kA-Fw_4_4"></a><a id="Tc_yisJOp8PokWJqMM4TF96rw_4_7"></a><a id="Tc_Hr--RoUQQU-549NwWf_4Bg_4_10"></a><a id="Tc_8r1IVPL5UkGgVsmnpoU8Jw_4_13"></a><a id="Tc_mZczB6XkekuPaQlaD-dkzw_5_0"></a><a id="Tc_ggWSspFbx0qGE3suTugW6w_5_5"></a><a id="Tc_oMvZI0O47kyMHpuaUMgm6Q_5_11"></a><a id="Tc_ekXG-9alA0aDxE2MSrPjDw_6_0"></a><a id="Tc_UwWWy6o1G0CYy3Yqb7T77A_6_2"></a><a id="Tc_l9b_4r-4JkCYyyMmKToOAw_6_5"></a><a id="Tc_Jl1c4l5S6k6cMQYpW7D43w_6_11"></a><a id="Tc_mijAI0bmtk21c5tbc9n3kg_7_0"></a><a id="Tc_yUSVWe-g0E-N22QhQk3bZw_7_2"></a><a id="Tc_CLrnLcebikKMeI4qz_1aLA_7_5"></a><a id="Tc_ii72OO3hP0ChBZAsgp3IVw_7_8"></a><a id="Tc_pvIWWgAGlUe4CEIRtGf0oQ_8_0"></a><a id="Tc_qwugMoGwRkKxx1TWldET9A_8_4"></a><a id="Tc_DS3GAK_ixk2NPAX9DnptTQ_8_7"></a><a id="Tc_re1qilIuGUqMXpHLNcVzdg_8_10"></a><a id="Tc_9NzACBwL4kSB-2HLaClLhw_8_13"></a><a id="Tc_qcen4SbxF0GdutERzkxC0w_9_0"></a><a id="Tc__KIf5_31S0WUQtZInKzFBA_9_5"></a><a id="Tc_TxUX8IsDoUmrBX8ilnQjTA_9_11"></a><a id="Tc_dmFROH5isU2N5NH-K6k7HQ_10_0"></a><a id="Tc_wU6OKukDtE2tj3Ys5nTZsQ_10_2"></a><a id="Tc_G7Jh4ErQgkGlB1oG-I7Yrw_10_5"></a><a id="Tc_Og2dauGPXUWxIJXX4iaqRw_10_11"></a><a id="Tc_uFAKxNArtkO406pBIm9mmg_11_0"></a><a id="Tc_9LNBUHxdKkGTjAMRQDgfrA_11_2"></a><a id="Tc_wRjnAaEtBkeU1zhYtjyJ1g_11_5"></a><a id="Tc_ptkVUW5Ei02PraieUjRm5A_11_8"></a><a id="Tc_ITEvqOCqaUikyLU6QNROjg_12_0"></a><a id="Tc_VmXADsZS6kS6hs_GOzlqxA_12_4"></a><a id="Tc_VightQI5QkWGdkEmw11tlw_12_7"></a><a id="Tc_AP4Eahdu00-Z7CjytVAAmA_12_10"></a><a id="Tc_4XiNxJ8JeUqRSmzaho-SlQ_12_13"></a><a id="Tc_ZvRApccY_Ua4YHtL7XOXAw_13_0"></a><a id="Tc_WCCAFAKAb0G1nyyUzwor4w_13_5"></a><a id="Tc_37Ro9jpPREmpbWNfXYdvUw_13_11"></a><a id="Tc_A2uZ97LkrUaJFkmNCwePBA_14_0"></a><a id="Tc_rhcaG3vOXUuQp_tsyQY2cQ_14_2"></a><a id="Tc_5JSCFD_400CoesnwLrsgcg_14_5"></a><a id="Tc_RyUegZBkZ0S_oyMMjUAkcQ_14_11"></a><a id="Tc_hZObvT3SSUmQ-LWRyIlPvg_15_0"></a><a id="Tc_CkNoJf2q_UOF0Nd6J_JdYw_15_2"></a><a id="Tc_j71FESncake7wr7lmGJtGQ_15_5"></a><a id="Tc_K-rYPDXom0K_tlYwuodz5A_15_8"></a><a id="Tc_D8AVL_f3206cqSgK-nGJZA_16_0"></a><a id="Tc_h4Vwm0fez0y615cZK-DMOg_16_4"></a><a id="Tc_KMr6_kiClki4W8W-dGrPag_16_7"></a><a id="Tc_wFA1jpVKEUe2NEjHdNKEzw_16_10"></a><a id="Tc_DVrovnfRKUaF2Q6CO5NlSg_16_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:48.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">months</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">ended</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_5heNRyPxXUKfrORV-N70sQ_4_2">264,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P_r4of4hd0KZsZrm_28PQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2N01Opu_TUyP3qMlmQfP8g_4_8">6,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YRpoZtwp30S36lbi5W7pVQ_4_11">136,342</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YKF6MorbPUqcKbwFWkljIw_4_14">129,604</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Adumul5f_Emd_SmbobiJGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_hEvmOjS0aUafWgfNPd7fLQ_5_2">33,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_RmNxqB61OEWSKxgJbYoabg_5_8">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_mdkklA23-EqEedgjhH4DQw_5_14">61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Q6l8AR1owEKrxBRA76nnSA_6_8">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_tBDSm4OP8065-wlsOIzUcg_6_14">62</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUa9pt6UYU2qKZU1q7KGtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8Nl5vDDTtUq8v9AcBJEBXA_7_11">7,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rxcKRScqXEy-Tm5ovX6qrg_7_14">7,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_jOfXygYvckq4krlTC_kgrA_8_2">298,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_O8EyWJtM2kqmmJRUvl-qlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iOL4HjdfO0Km7gzdEnTioA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GeB4rpe3iUmP_gsYRTAjiw_8_8">6,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_c6idVF-ySEuT1HSIivSjLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AIozaA52a0a-vouKFCrGtA_8_11">144,215</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2022_OYgjx4XmSkGPAAF-Re-xWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_S5j5wMJX_kCvkZWtaKfWKQ_8_14">137,354</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4B_cIF7e5UODEBv68U8L3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_1ieEXeMYdk6_M44ZcNxKsg_9_2">9,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XGfT7SuWC0K2vunWvhlwaQ_9_8">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_gjLa5sctAEGcKg3V2xl_9g_9_14">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_gk-yNDzvGU-7UzmIuSJxYQ_10_8">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_pyRShoCksk-vRKkXJPc4OA_10_14">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kHWGZ6RfI0-CW2KwDqzmJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WDjzPTF34kqwDWtt2UMBOA_11_11">8,679</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_e9uWmTUju0as1XknjpLz7A_11_14">8,679</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_EzQ4QU6GpUaN6nfI0aY70Q_12_2">308,118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_bjBXccsdxkSy45ztWFjM-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZZNP8UD0GUO6uzjHEM33Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7TT7Ii-05Ui-gAqlLiGgzA_12_8">6,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gexd2UdIVEm-wcSYwLDc0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jrba9F2pAEm533XwwCpQZQ_12_11">152,894</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2022_Bf2tptIPOU6oGPVXVUCTjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KyPk0MM3c02gjeGaQK63Mg_12_14">145,958</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-MRJe6VGPUipa0NC3BILAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_sH_PKqjJnEKBN8eDY9XJvA_13_2">12,128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XcEMQGqMP0qTV8U3rTyZ7w_13_8">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_79AXRlla9ku3E3HOU9XNfw_13_14">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BbeNPNpubEW-YJXwMor7HQ_14_8">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_sBUqImn0rUqi8b3a_doYAQ_14_14">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NYFdJrTKuU2AdqrUK_6Juw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fuNfo-K0dU6Y4P-hZgqq3Q_15_11">8,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0WxyFYVNEE2Obyn54JERgA_15_14">8,093</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_ZZzVkIfCCkOAJYBjh9QhUw_16_2">320,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_wkeHRludRkq2fuu18Uz84Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gBMde9-vjEq-B-QzZmmW9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RrKjao-_P0u-W9Iu_AaT0Q_16_8">7,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NSmQJB__l0yYnVCxzz6oDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Gysu31sr9EyjVq-EnO2r-Q_16_11">160,987</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_sPDGSvgCNEavcGTVOfj7QQ_16_14">153,925</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See accompanying notes to condensed consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_994c336b_4b8e_47f3_addf_83c7d6c8a364"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="CashFlow_2"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONDENSED CONSOLIDATED </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">STATEMENTS OF CASH FLOWS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(UNAUDITED, IN THOUSANDS)</b></p><a id="_f33971c3_6ec1_4446_b433_adc13a228b8a"></a><a id="Tc_YfSIlnat2kmnNCYAZoSUSA_1_2"></a><a id="Tc_nlOfJqpfWk65JkjVLNNi8w_2_2"></a><a id="Tc_0uMOI0BDSEWcbZKfBLrbAQ_2_5"></a><a id="Tc_aKJ5KijTeECHbVpCzq4H4g_3_0"></a><a id="Tc_VwnT-YRmHE-SjtH7CKDF5g_4_0"></a><a id="Tc_zYOD88qx40yn1xOL5RQJ3g_4_2"></a><a id="Tc_aFcaWNnHgUG2pV-0N3-veg_4_5"></a><a id="Tc_tYjXPB-xkkODIStKQm5-IA_5_0"></a><a id="Tc_6FtK_ubLbUWkWicBXWw0vQ_6_0"></a><a id="Tc_loXdlNbYP0Otfy47p_nRHg_7_0"></a><a id="Tc_RNTEKEiJSU2tLjkDXOL3ZA_8_0"></a><a id="Tc_pjDWW10NP0G9tjrexy5zKg_9_0"></a><a id="Tc_j6BiSrcJEUWMVzO70-WzVA_10_0"></a><a id="Tc_ysMI--VZDE24Olf4FA2vtA_11_0"></a><a id="Tc_qT9RO2nhuUGKdTPHt6eZLA_12_0"></a><a id="Tc_IAT9wHbDy02KS9PsQ8CTEw_13_0"></a><a id="Tc_RH-87EtZAkS_hwezHsMreg_14_0"></a><a id="Tc_JbQxSrONJkqWfJDwLJxSWg_15_0"></a><a id="Tc_kFdj5Oo_K0-kHjEaxpFBOg_16_0"></a><a id="Tc_RxkDklreX0CqyP-PZyaKLg_17_0"></a><a id="Tc_ewlAaBE8aUuFo34j0RKS1w_18_0"></a><a id="Tc_PLI6Jighi0mZXgSqSFPltQ_19_0"></a><a id="Tc_NxSP6FLdF0CYcO3wekrjcw_20_0"></a><a id="Tc_yFbkJ8ZsD0uQrHzoaALsMA_21_0"></a><a id="Tc_BNzAp7pxI0mjUAqLtd8AMQ_22_0"></a><a id="Tc_HnhWE1t8PkiKldv3wBmnXg_23_0"></a><a id="Tc_QNYP74DiSEy4dcRokZ7Ctg_24_0"></a><a id="Tc_m-ItrMujU0uYcCjRyRE93Q_25_0"></a><a id="Tc_0QZsCfIFCEujqoBuqaqF0g_26_0"></a><a id="Tc_XahU013WvUWn5nt9xLCW3g_27_0"></a><a id="Tc_srEKSBhlJ06h0UeD5cEguA_28_0"></a><a id="Tc_UKx7ScuY70i2u-4APPYX9w_29_0"></a><a id="Tc_wyUAdJZg_kaqdfnsCoDQxg_30_0"></a><a id="Tc_TPb2cYonXk2xLKG3bNIE_Q_31_0"></a><a id="Tc_y9d2fBjWqUaWSjd-ArV9ZA_32_0"></a><a id="Tc_KQaVhhNe6k-I0mBq3Z_4OQ_33_0"></a><a id="Tc_Pgn6GHBovE-yqpcv7xyz7Q_34_0"></a><a id="Tc_2mZAfPHZEUmxC94VooWStQ_35_0"></a><a id="Tc_pvgQceAP6U-ZQvqxyqWSuA_36_0"></a><a id="Tc_1YD0zM2g7ECUd-9myahTCg_36_2"></a><a id="Tc__-sy1vzk5kKAItY6SP3f-g_36_5"></a><a id="Tc_BxATRgyPGkeEcrrZUWhxhQ_37_0"></a><a id="Tc_D5FQ9OEQdEmwXaLYVM5c-g_38_0"></a><a id="Tc_u6x-cMAQu0atFAzOPM0z3A_39_0"></a><a id="Tc_Y57sw78vvUqwbmq4QujWNw_39_2"></a><a id="Tc_70CHZcAk5Uum4sBWM-bo5w_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Months</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Ended</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7kZ5WYU65EWW3hPc2cla6Q_4_3">23,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5xks-Ly1fEOmeCzoL3PzSg_4_6">24,645</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_IGI9NhomDkiKW0qp3ZNNVw_6_3">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_J21awQJd5UWC_XZI1C5H1A_6_6">452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant and tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_2KmDtD-1pEqtX_JrbLReVg_7_3">660</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_yRrvLF_SI0q3MSmFuX49VQ_7_6">21</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_9l00ipe5JUSvyCYYGEbr3w_8_3">19,904</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_H3eZn64Z8UeE79GkwIYopw_8_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Tc_ing-_qS4yUSmxFNUQBEcuw_9_3">4,171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="tlsi:GainLossOnEquityIssuance" scale="3" id="Tc_7gUfV4jdPECIt8_cnGr-Fw_9_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_1cHhsMby902oD9YFwgLpRQ_10_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gekngVpMI06SdOwMaUK6mg_10_6">251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_GEW1ULfDakKeNsa34PRZdw_11_3">60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_J6B_MQef2k2NnDVxFgJENg_11_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Milestone payments to Dynavax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnMilestonePaymentForAssetAcquistion" sign="-" scale="3" id="Tc_DIudcViUx0ON2fYnNNDoWw_12_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnMilestonePaymentForAssetAcquistion" sign="-" scale="3" id="Tc_4mk2P_smJU2dXJN-WGzBMA_12_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_DvY5AuB9K0y8WSVjrvhkSg_14_3">1,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_u5rCU2pZXE6EEY04xiQM4Q_14_6">936</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_nk8zxaDSz02MfLj4rVWYzA_15_3">158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_ZUu7BJIruUmmtU9mvvOmbw_15_6">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_Ojqtpw5asEOMrUh4Pidemw_16_3">1,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_X-0Tld64HUe907bRaSa9zQ_16_6">1,306</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_VRhFwMc5ukW3m629atYW5g_17_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_XkYN_p925EerXZDnyxhnuw_17_6">38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Trade payables, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_6gfVQvU43kKhBAPfs-2SnA_18_3">2,772</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_mO3PN4n5HEiqyufC1pMDoQ_18_6">1,108</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_yOTWg-D5ZkOHg4cl4pkQmQ_19_3">41,196</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_nCnf7tciakmsmtx_ZWBrcQ_19_6">24,003</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_nS-VGbGgO06d7stVWHM-Pg_21_3">216</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_-DaV4AvX9EWSHU_SKsqJlA_21_6">451</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Milestone payments to Dynavax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetsAcquisitionMilestone" scale="3" id="Tc_VypP8Q65GUiLYqNjh9udug_22_3">1,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetsAcquisitionMilestone" scale="3" id="Tc_FMjL4qOdxEGgfECGnl1R6w_22_6">1,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for intellectual property and licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_nB_O-YUlH0Wy7v8xq0mxQw_23_3">205</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_rAeNqEHJgESHj1Nom2EjZg_23_6">63</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_aNDMrOT9LEifu4yxar9rAg_24_3">1,421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_FS2Yvj8a5k2eCVkpZMWAjg_24_6">1,514</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from the issuance of preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc__rsAWKVcQEub5YTdvnHkPQ_26_3">9,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_W9utDHz5dUO8iPk6iWr4oA_26_6">3,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Refundable prepayments for Series B-2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:zerodash" name="tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock" scale="3" id="Tc_vZwQMztmuE-ezWlSYvwVOQ_27_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock" scale="3" id="Tc_nb-XQmxU0EiHlcYaBx0lvg_27_6">3,986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_-jOdeltSJ0i5BDqwfyWDhg_28_3">9,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_c9knsxDv90qdylpeAq3TEA_28_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromReverseRecapitalization" scale="3" id="Tc_NV81dUHSJEq1JtFcKEcKTw_29_3">36,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="tlsi:ProceedsFromReverseRecapitalization" scale="3" id="Tc_fc32muH-MUGFguYi021o9A_29_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Offering costs related to Business Combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsOfReverseRecapitalizationTransactionCosts" scale="3" id="Tc_STUnXBQm9UW7ARVMvF-3wQ_30_3">1,116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="tlsi:PaymentsOfReverseRecapitalizationTransactionCosts" scale="3" id="Tc_CHBFR-rQGE2B-csIt2QZQA_30_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payments on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_HRrry_Ab8kidZSRBa7NYmA_31_3">65</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_aiNOIRmEIEe5rgae2j7bVQ_31_6">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash proceeds from the exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_2qnLZZcekEmOJSp3tZKp9g_32_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_YWV4H9sVFkChLiF7i4rUQw_32_6">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_UqIp49goVUOMX8j-7QdhYQ_33_3">54,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_-MICMvks70qINal5KNlSiA_33_6">7,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_aXvK_7JdT0aHpw2L2GHh5Q_34_3">11,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_EMdk31hJckO-2u2fRyXz3Q_34_6">17,963</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_LwfGSpkWi0-jRl2vvJMT5Q_35_3">9,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YKxu5lmcokyR_uojDGhjEQ_35_6">30,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_1yv1ShDeVEiPkU-mY3E8oQ_36_3">21,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_TGyqBWxlo0WtVQMQGsNkfg_36_6">12,338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosure of noncash items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Transfer of warrant liability to preferred stock upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" scale="3" id="Tc_Lebo3-n--ECzyY6rSANqNg_39_3">25,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:zerodash" name="tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" scale="3" id="Tc_ig74gCtI-UmkUr_9N-lhng_39_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See accompanying notes to condensed consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7a37f1dd_9f31_4018_9137_00a2a7f2a84b"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="Notes_2"></a><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOTES&#160;TO CONDENSED </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Unaudited)</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:NatureOfOperations" id="Tb_j4VhpNJppU21ITvEiKTi8w" continuedAt="Tb_j4VhpNJppU21ITvEiKTi8w_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Nature of Business</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023 (the "Closing Date"), TriSalus Life Sciences,&#160;Inc., a Delaware corporation (the &#8220;Company,&#8221; &#8220;TriSalus,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), formerly known as MedTech Acquisition Corporation (&#8220;MTAC&#8221;), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023 (as amended, the &#8220;Merger Agreement&#8221;), by and between MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (&#8220;Merger Sub&#8221;) and TriSalus Operating Life Sciences,&#160;Inc. (formerly known as TriSalus Life Sciences,&#160;Inc.), a Delaware corporation (&#8220;Legacy TriSalus&#8221;), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and TriSalus Life Sciences,&#160;Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as &#8220;the Closing.&#8221; In connection with the consummation of the Merger, on August&#160;10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc., the surviving company ("New TriSalus&#8221;). As further described in Note&#160;3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of the Business</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfProductLinesInDevelopment" scale="0" id="Narr_ECSJi_RjbEa_wiTwHZfPkQ">two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June&#160;1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC&#8221;) code with CMS and met with CMS on June&#160;26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January&#160;1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_j4VhpNJppU21ITvEiKTi8w_cont1" continuedAt="Tb_j4VhpNJppU21ITvEiKTi8w_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September&#160;30, 2023, we have issued for cash </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_V6c578Z9dUakm48y3fS_Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Narr_CPa8fMW0AESOwBk5qBEs9Q">164,364</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> of preferred stock (of which </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromReverseRecapitalization" scale="3" id="Narr_e5Qt_y1YokWjMwpgtZpC8g">36,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was raised at the closing of the Business Combination, including issuance of Series&#160;A convertible preferred stock), which, along with </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Narr_t4I2eBPw_UKJp3mdZf18_g">551</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> from common stock and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_tlsi_ConvertibleNotesAndWarrantsMember_w8EJUYCkGEaDC6o1zmBY8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Narr_i73WgkjP3E-p-QMTZgBh8w">44,692</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> from convertible notes and warrants, has funded our accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_wV08Ar1aqkGrPBlvjfF8Bw">212,867</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. During the nine&#160;months ended September&#160;30, 2023, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Narr_Uof0l7IEhE6opTkV-B3e2Q">9,189</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_YxlNQctQ7ECaOjMEuLfZUA">9,630</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_jva_HcfXLkaAW8p8tB4zfg">94</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> from the exercise of stock options, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromReverseRecapitalization" scale="3" id="Narr_gng7WCNysky0seR7jtVpIg">36,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> from the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had cash and cash equivalents of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_nyr-eGrJTU-uKVZjV3x7Aw">21,383</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_1yTSJLFT4EyM94jgOQJ2Tg">212,867</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12&#160;months.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In accordance with ASC Topic 205-40,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i><span style="font-family:'Times New Roman','Times','serif';">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management&#8217;s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management&#8217;s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_j4VhpNJppU21ITvEiKTi8w_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On October&#160;2, 2023, we entered into a Standby Equity Purchase Agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN,&#160;Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SaleOfStockAuthorizedAmountValue" scale="3" id="Narr_1E902mz29Uul1wOt2YfVQA">30,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> of common stock, par value </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_uCtjCcPEF0qcbGQrVC4sKg">0.0001</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share of the Company (the &#8220;Common Stock&#8221;), at the Company&#8217;s request any time during the commitment period commencing on October&#160;2, 2023 (the &#8220;Effective Date&#8221;), and terminating on the first day of the&#160;month following the </span><ix:nonNumeric contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww" format="ixt-sec:durmonth" name="tlsi:StandbyEquityPurchaseAgreementTerm" id="Narr_eVZIxCb6IE26B_oaHg6B_g"><span style="font-family:'Times New Roman','Times','serif';">24</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';">-</span><span style="font-family:'Times New Roman','Times','serif';">month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an &#8220;Advance&#8221;) is subject to a maximum limit equal to the greater of: (i)&#160;an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:CommonStockSharePricePercentageOfAverageDailyVolume" scale="0" id="Narr_8gybkS02bk-5ghHbnamApw">100</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the average of the daily volume traded of the Company&#8217;s Common Stock on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) for the </span><ix:nonNumeric contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ" format="ixt-sec:durday" name="tlsi:CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" id="Narr_CJraqTrRaEqB_UStq9y2hA"><span style="font-family:'Times New Roman','Times','serif';">10</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days immediately preceding an Advance notice, or (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" scale="0" id="Narr_K30qIuiLuEueAnASULaepQ">1,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg" decimals="0" format="ixt:numdotdecimal" name="tlsi:SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" scale="0" id="Narr_dRUKmXLD20aWGYFgIVRFjw">96</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on 4:00&#160;p.m. New York City time on the applicable Advance notice date (the &#8220;Option 1 Pricing Period&#8221;), and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg" decimals="0" format="ixt:numdotdecimal" name="tlsi:SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" scale="0" id="Narr_iXkuetSPfUWXnZZY8ywd1Q">97</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price for any </span><span style="-sec-ix-hidden:Hidden_3ei8mRKxXUqQjdtfqOZDNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days commencing on the Advance notice date (the &#8220;Option 2 Pricing Period,&#8221; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#8220;Pricing Period&#8221;). &#8220;Market Price&#8221; is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (&#8220;VWAP&#8221;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA" decimals="2" format="ixt:numdotdecimal" name="tlsi:PurchaseAgreementOwnershipLimitation" scale="0" id="Narr_t-a4m3PhD0iq0mmQYXgVrA">4.99</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA" decimals="2" format="ixt:numdotdecimal" name="tlsi:PurchaseAgreementExchangeCap" scale="0" id="Narr_uAseic8j7kW0-4Dmmd0Hdw">19.99</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_59cnX9xJg0uDnepKCWrbsQ" continuedAt="Tb_59cnX9xJg0uDnepKCWrbsQ_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_xMSvDUguNk2YqSjNxW4iTA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_BaZrq7FWvUWZeYY__QXN7A" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_1lqC9l63wEiuJzSe6Hi-cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="Narr_Ki22CHU8F0akYx238BfOMg">8,617</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_G0H1gCuA5Uu2xr5BL9skcA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(b)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accounts Receivable</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_Ndbth8LlWE6zH7AXd6GnvQ" continuedAt="Tb_Ndbth8LlWE6zH7AXd6GnvQ_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(c)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Inventory</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#8212; including direct labor and manufacturing overhead&#160;&#8212; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59cnX9xJg0uDnepKCWrbsQ_cont1" continuedAt="Tb_59cnX9xJg0uDnepKCWrbsQ_cont2"><ix:continuation id="Tb_Ndbth8LlWE6zH7AXd6GnvQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_MZa7oSBS1ESXf8hJKb0yUg" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(d)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Property and Equipment</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_Nxd_qGDkY0OvImNXarzy4Q" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(e)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Impairment and Disposal of Long-Lived Assets</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows</span><span style="font-family:'Times New Roman','Times','serif';"> expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_UVdN6vX7fEKu6jT-jH23SQ" continuedAt="Tb_UVdN6vX7fEKu6jT-jH23SQ_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(f)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i><span style="font-family:'Times New Roman','Times','serif';">. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#8220;ROU&#8221;) representing the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59cnX9xJg0uDnepKCWrbsQ_cont2" continuedAt="Tb_59cnX9xJg0uDnepKCWrbsQ_cont3"><ix:continuation id="Tb_UVdN6vX7fEKu6jT-jH23SQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_tVWCaXUlJkyICbEIetyWkg" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(g)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Warrant and Tranche Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockConversionPercentageOfOutstandingShares" scale="0" id="Narr_kBEv0EaKmkCD6eOj6IBXHA">99.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(h)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Contingent Earnout Liability</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#8220;Sponsor Support Agreement&#8221;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#8221;), Legacy TriSalus and MTAC&#8217;s directors and officers (the Sponsor and MTAC&#8217;s directors and officers, collectively, the &#8220;Sponsor Holders&#8221;). Pursuant to the Sponsor Support Agreement, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_8_2023_To_10_8_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_b2HZiZvawEOx8-1-aQfYAw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares" scale="0" id="Narr_HksUTk6pLEqfeJCCxdT_9w">3,125,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#8220;Sponsor Earnout Shares&#8221;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date (the &#8220;Earnout Period&#8221;). The Sponsor Earnout Shares are classified as a liability in the Company&#8217;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:UseOfEstimates" id="Tb_bvAgD8z-fEy-4u7l7BJfoA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_fp0bbi-bREq_oXqN314lvA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(j)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Concentrations of Credit Risk and Other Risks and Uncertainties</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_q4lkPhsAeUOd1Iy_21TwcA" continuedAt="Tb_q4lkPhsAeUOd1Iy_21TwcA_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(k)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Share-Based Compensation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59cnX9xJg0uDnepKCWrbsQ_cont3" continuedAt="Tb_59cnX9xJg0uDnepKCWrbsQ_cont4"><ix:continuation id="Tb_q4lkPhsAeUOd1Iy_21TwcA_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_riVPdDWkTEOlmNhwhPV2Qg" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(l)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have determined, in accordance with ASC Topic 280, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i><span style="font-family:'Times New Roman','Times','serif';">, that we operate under </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_jAbKSGgmb0GUlqxnH_dsTg">one</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> operating segment, and therefore </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_YqJQeXajGke6jpt2DqdcLA">one</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_632XL7DfGk2_5-DOKxrA6g" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(m)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i><span style="font-family:'Times New Roman','Times','serif';">, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#160;&#8212; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#160;&#8212; We recognize revenue at the point</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_7KHkQ8jMskeTWBGt8WsCew" continuedAt="Tb_7KHkQ8jMskeTWBGt8WsCew_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59cnX9xJg0uDnepKCWrbsQ_cont4"><ix:continuation id="Tb_7KHkQ8jMskeTWBGt8WsCew_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="tlsi:ReverseRecapitalizationDisclosureTextBlock" id="Tb_1zI7Frd_JUGVx4M0lMwkUg" continuedAt="Tb_1zI7Frd_JUGVx4M0lMwkUg_cont1" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(3)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Business Combination</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023, we consummated the previously announced merger pursuant to the Merger Agreement by and among MTAC, Merger Sub,&#160;Inc., and TriSalus Life Sciences,&#160;Inc. Upon the closing of the transactions contemplated by the Merger Agreement, Merger Sub merged with and into Legacy TriSalus (the &#8220;Business Combination&#8221;) with Legacy TriSalus surviving the merger as a wholly-owned subsidiary of MTAC, renamed &#8220;TriSalus Operating Life Sciences,&#160;Inc.&#8221; In addition, in connection with the consummation of the Business Combination, MTAC was renamed &#8220;TriSalus Life Sciences,&#160;Inc.&#8221;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to the effective time of the Merger, each in-the-money warrant of Legacy TriSalus that was unexercised and unexpired was automatically net exercised into the respective series of preferred stock of Legacy TriSalus. Each share of preferred stock of Legacy TriSalus (&#8220;Legacy TriSalus Preferred Stock&#8221;) that was issued and outstanding was then automatically converted into shares of common stock of Legacy TriSalus (&#8220;Legacy TriSalus Common Stock&#8221;) in accordance with the Amended and Restated Certificate of Incorporation of Legacy TriSalus at the then current conversion price, such that each converted share of Legacy TriSalus Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy TriSalus Preferred Stock thereafter ceased to have any rights with respect to such securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, by virtue of the Business Combination and without any action on the part of MTAC, Merger Sub, Legacy TriSalus or the holders of any of the following securities:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each share of Legacy TriSalus Common Stock (including shares of Legacy TriSalus Common Stock resulting from the conversion of shares of TriSalus Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time were exchanged at an exchange ratio of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="8" format="ixt:numdotdecimal" name="tlsi:RecapitalizationExchangeRatio" scale="0" id="Narr_A6wDVXETWUOzvyHdNRa6Xg">0.02471853</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;Exchange Ratio&#8221;) for an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StockConvertedReverseRecapitalization" scale="0" id="Narr_xgPZlcKNNEifIvSIDyqeKA">21,999,886</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of our Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each option to purchase shares of Legacy TriSalus Common Stock, whether vested or unvested, converted into an option to purchase shares of our Common Stock (&#8220;TriSalus Assumed Option&#8221;), with each TriSalus Assumed Option subject to the same terms and conditions as were applicable to the original Legacy TriSalus option and with the resulting exercise price and number of shares of TriSalus Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each Legacy TriSalus restricted stock unit (&#8220;RSU&#8221;) award converted into a restricted stock unit award to receive shares of our Common Stock (&#8220;TriSalus Assumed RSU Award&#8221;), with each TriSalus Assumed RSU Award subject to the same terms and conditions as were applicable to the original Legacy TriSalus restricted stock unit award, and with the number of shares of TriSalus Common Stock to which the TriSalus Assumed RSU Award relates being based on the Exchange Ratio and other terms contained in the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, MTAC was treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, the Legacy TriSalus stockholders have a majority of the voting power of TriSalus, Legacy TriSalus comprises all of our ongoing operations, Legacy TriSalus has appointed a majority of our governing body, and Legacy TriSalus&#8217; senior management comprises all of our senior management. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy TriSalus with the business combination being treated as the equivalent of Legacy TriSalus issuing stock for the net assets of MTAC, accompanied by a recapitalization. Operations prior to the Business Combination are those of Legacy TriSalus. Reported shares and earnings per share available to holders of the Company&#8217;s common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination (1.0 share of Legacy TriSalus for approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="8" format="ixt:numdotdecimal" name="tlsi:RecapitalizationExchangeRatio" scale="0" id="Narr_hA3TFnIhHkGb-q3UsZe6jg">0.02471853</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of TriSalus).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Proceeds from this transaction totaled </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromReverseRecapitalizationTransaction" scale="3" id="Narr_uMM8lGATYUOSjx0A9wKMug">42,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. These proceeds were comprised of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromContributedCapital" scale="3" id="Narr_9hikV5KHZ0eycA3Ln-d4tQ">2,704</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> from the MTAC trust account, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="Narr_rm2tdjipAE-56WcAcQ0Sow">40,150</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> received from the assumption of a concurrent private investment in public equity financing (&#8220;PIPE Financing&#8221;). Pursuant to the terms of the Merger Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_srt_CounterpartyNameAxis_tlsi_MedTechAcquisitionCorporationMember_Nh62w64sX0GFn1hFJJgndg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsOfReverseRecapitalizationTransactionCosts" scale="3" id="Narr_mpQ2Wb6MvUu3R5p00dMkkg">6,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> of the proceeds were used to pay expenses incurred by MTAC related to the merger, resulting in net cash proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromReverseRecapitalization" scale="3" id="Narr_AOqWd4z6YUuJNdp3Nv9xKw">36,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The Company incurred </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ReverseRecapitalizationTransactionCostsIncurred" scale="3" id="Narr_uni4iFyaVUuCCJ3s7QnORg">6,069</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in transaction costs relating to the merger with MTAC, of which </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsOfReverseRecapitalizationTransactionCosts" scale="3" id="Narr_Zz8g5cHQJk-9XLuuKVKAUg">1,742</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as a reduction of equity and the balance of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ReverseRecapitalizationTransactionCostsPaid" scale="3" id="Narr_MLjGfj5ZYEaY9CbLah_j9Q">4,327</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was recorded in general and administrative expense.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1zI7Frd_JUGVx4M0lMwkUg_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy TriSalus exchanged their interests for shares of common stock of TriSalus. In addition, MTAC had previously issued public warrants and private placement warrants (collectively, the &#8220;MTAC Warrants&#8221;) as part of its initial public offering in November&#160;2020. None of the terms of the MTAC Warrants were modified as a result of the Business Combination. On the Closing Date, the Company recorded a liability related to the MTAC Warrants of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_UMIz0OMwo0Ow-mU2_7en1Q">2,568</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. During the period from August&#160;10, 2023, to September&#160;30, 2023, the fair value of the MTAC Warrants increased to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_vXafRp9NMki44aH7Q7shoA">5,421</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, resulting in a loss on the change in fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_YldtoLvAcESUUN65IvBRSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLossOnDerivative" scale="3" id="Narr_ZomDKz3UqUW7KsjnU2UvJQ">2,853</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and a gain of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_kVRrUl0H3EKb1JhB7W02Wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainOnDerivative" scale="3" id="Narr_gKuirC-YN0GGp7xGQcm4Iw">660</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in the Condensed Consolidated Statements of Operations for the three and nine&#160;months ended September&#160;30, 2023, respectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately following the Business Combination, there were </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_fxSuvEZEWUmk1LryBKdO9A">26,316,681</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of our Common Stock outstanding, options and RSUs to purchase an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_JYladCbATEW8vaNJdEZi3A">2,816,224</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock and warrants outstanding to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_98MiLwy3qUirRTBedHnwkg">14,266,605</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">PIPE Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On the Closing Date, certain investors agreed to purchase an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_1GddLHy4N0u5cwyGHakZ2w">4,015,002</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> newly-issued shares of Series&#160;A Convertible Preferred Stock at a purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_M296iw47A0WExRQ7IhA_0A">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_pCqecvAnAk2rWQIchf8CeQ">40,150</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, pursuant to separate subscription agreements dated June&#160;7, 2023, and July&#160;4, 2023 (collectively, the &#8220;Subscription Agreements&#8221;). See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sponsor Earnout</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement. Pursuant to the Sponsor Support Agreement, the </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_Pqp-qsKfKUquIRMTUTshbQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares" scale="0" id="Narr_o89m4IQqOU6re3UWQLG7ew">3,125,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> Sponsor Earnout Shares became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" format="ixt-sec:duryear" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Narr_dMux_ykGJkazLZYlk6-R1A"><span style="font-family:'Times New Roman','Times','serif';">5</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date. Pursuant to the Sponsor Support Agreement, (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_wfMBzSQGZkKbDc2aHYdY9Q" decimals="0" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" scale="0" id="Narr_nE9y9M1byU-ZAOn7DjLKjw">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_V-mQW-qQIUa1vQtlrdyyEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_bzhbnoR9okG4s-q-sw9axQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" scale="0" id="Narr_v6dctT0Uzk2mZeqyH8HtxQ">15.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" scale="0" id="Narr_ygQGq2NShkS-a3XGLJDM1Q">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" scale="0" id="Narr_nQt2q-CCe02SPKCkqVKPDw">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days, (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_S0Lcn3b7qUysLIF0lPwnmw" decimals="0" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" scale="0" id="Narr_CYve8Kwa6Ey_Dr2M9n5IiA">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_2n4YMje6bU2yQX9mVj9haw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_QkCtTzY3sU-AQnJ_aipXPw" decimals="2" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" scale="0" id="Narr_hAsXeEHMBEumaWGR5WGFPw">20.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" scale="0" id="Narr_BqZiu-iSRUW2vbGPTFsEFg">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" scale="0" id="Narr_MH2ElKgGokKPIk-XW8qF8w">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days, (iii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_cmpIjKVmEEiX0-ssByWUEg" decimals="0" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" scale="0" id="Narr_SqyA-W2HrU2pxv_7SD2JTw">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor</span><span style="font-family:'Times New Roman','Times','serif';"> Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_tM-2Y2RyQUOzCJbuqMIVTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_Kkt3ckHCjEGBa9C6I-e57g" decimals="2" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" scale="0" id="Narr_jtiz-40zUEWHIqBWX058qg">25.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" scale="0" id="Narr_fizJLc6AmUuWzuDoZKq2MQ">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" scale="0" id="Narr_VlBCV1uCzEmIEKwzG_B8CQ">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days; and (iv)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_cjlWfxkjMkGCwnUKknuA_w" decimals="0" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" scale="0" id="Narr_dGOz9H1YPUKS7aMaS91qdQ">25</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_i6irmobClEimgYt4sNAgmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_k5WzB7ynsUKBqdgC_-pE5w" decimals="2" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" scale="0" id="Narr_3crwZ29r3US7EZMmLkaVGQ">30.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" scale="0" id="Narr_QvSnf06tCEOUX36oqktGRQ">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" scale="0" id="Narr_i8KIfIxan06dvziwLOpcIw">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days. Additionally, the Sponsor Earnout Shares will vest if there is a change in control of our company on or before the </span><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" format="ixt-sec:duryear" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Narr_J5rcS5YJaEiU2fQ7_KQGRw"><span style="font-family:'Times New Roman','Times','serif';">5</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date that results in the holders of our Common Stock receiving a price per share equal to or in excess of the applicable earnout targets. Any such shares held by the Sponsor Holders that remain unvested after the </span><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" format="ixt-sec:duryear" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" id="Narr_MnteuQH7vkyxh8KcrFfz7w"><span style="font-family:'Times New Roman','Times','serif';">5</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing will be forfeited.</span></p></ix:continuation><a id="_4886437c_810a_4e51_a555_cad58b1aafa1"></a><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(4)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Instruments</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_cp3cQ4BmE0yDwyd_EGVWUQ" continuedAt="Tb_cp3cQ4BmE0yDwyd_EGVWUQ_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, contingent earnout liability, and warrants to purchase preferred and common stock. The carrying values of these financial instruments (other than warrants and tranche liabilities, which are held at fair value) approximate fair value at September&#160;30, 2023, and December&#160;31, 2022. In general, asset and liability fair values are determined using the following categories:</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;1&#8201;&#8212;&#8201;Inputs utilize quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;2&#8201;&#8212;&#8201;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;3&#8201;&#8212;&#8201;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#8217;s own assumptions about the assumptions that a market participant would use.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrant, tranche and earnout liabilities are measured at fair value on a recurring basis.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c7af709_4132_409e_b781_7566d0502e2f"></a><a id="Tc_aaN9FGHjpEquIF9uHDiQAQ_1_2"></a><a id="Tc_ZkPpbPKAYkyNvikX3DSKtw_1_5"></a><a id="Tc_qYHl1MuC9U2XIewab7JchQ_1_11"></a><a id="Tc_g1hdci-YX0q6zvcMySusuQ_1_14"></a><a id="Tc_dhVxhcmI5UqUobzgXpoX_w_2_0"></a><a id="Tc_91ZbDAQ3Iki3u2qVTLudjQ_2_2"></a><a id="Tc_V_bzwcentEaAWRnvJCemNA_2_5"></a><a id="Tc_cG58LdvcO0-zAtg1SRYFng_2_8"></a><a id="Tc_mxBgeiIJXUmZLD2-z1pEsQ_2_11"></a><a id="Tc_V2np68C210aB0SeelQMJlw_2_14"></a><a id="Tc_Ivsb6G2uMkiAXdrq_ZgwXQ_3_0"></a><a id="Tc_qMqKRQ0_V0q3wZX1ILKWHg_3_2"></a><a id="Tc_WS-kji44wkiuI8T5MAzYew_3_5"></a><a id="Tc_p2B19R0LJEG_jAZ3WZq1GA_3_8"></a><a id="Tc_PBgztliJj0uhiLCeO_HPJQ_3_11"></a><a id="Tc_vdw8ij6Uu0OJD3wBhVix3Q_3_14"></a><a id="Tc_zlXzJFtxz0u0wDmvJGZOgw_4_0"></a><a id="Tc_F1DXwJL2gUikPEWBPfvyaA_4_2"></a><a id="Tc_1vADPbrGvE2dZDz7b0NUGQ_4_5"></a><a id="Tc_r59cuP0CbUKeZjKQUoD8sg_4_8"></a><a id="Tc_yIhZVl1yKUefdXzcIc8YMQ_4_11"></a><a id="Tc_W52wLonfDEWpbAMbd2LqKg_4_14"></a><ix:continuation id="Tb_cp3cQ4BmE0yDwyd_EGVWUQ_cont1" continuedAt="Tb_cp3cQ4BmE0yDwyd_EGVWUQ_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments After Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The carrying amount of our outstanding MTAC warrants liabilities was </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_eQs6v3ICbkSDNRLasIsTmg">5,421</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. The carrying amount of outstanding earnout liability was </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_FlTPQCmPcUu1fXuinF9wmQ">9,023</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. These carrying values of the warrant liabilities represent the remeasurement to fair value each reporting period based on Level 1 inputs for the publicly traded MTAC Warrants and Level 2 inputs for the private placement MTAC Warrants. The carrying amounts of the contingent earnout liability represent the remeasurement to fair value each reporting period based on unobservable, or Level 3, inputs, using assumptions made by us, including the market price of our common stock and the observed volatility of a peer group of companies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we assumed warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_ZH4caqhdqU2kcQ3RThO0nA">14,266,605</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WSz9xgGh-0awui3E-6uptw">11.50</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (see Note&#160;9). Of these, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_ANxEjcLOfEenO7ZZICFoNQ">8,333,272</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> are traded publicly and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_Y-tAHk4ARkmzr2jGYRuL-A">5,933,333</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> are privately held. At the Closing Date, we determined the fair value of all the warrants to be </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_5vrM1Cc2RUyHU2I3EC7eHg">2,568</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> based on the closing price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_5SoPOebGtkWCpPA3MCyxhg">0.18</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the publicly traded warrants (Level 1).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we determined the fair value of the earnout liability to be </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_gOsR8R5VA0CEVTan0luU7w">28,927</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> based on a Monte Carlo simulation of future trading prices for our common stock. See Note&#160;8 for further discussion.</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Group_Vs0kxX3OOkatbgPr-wFJKw" continuedAt="Group_Vs0kxX3OOkatbgPr-wFJKw_2" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_5m4IloO620mxYhPYECQr_w" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_pUZJu8XJmk6X9yXFEcHsqg_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="3" id="Tc_eOt051wPskmDB3kX_poX_w_4_6">19,904</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" id="Tc_ECzU_yUNLU6h28ATqiBLYA_4_9">28,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="3" id="Tc_2Qjc3Em0HUiw2EgmUWJRcA_4_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_oBhuknZam0qxfv5h_KKCBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_1WK_FxJCqU2xyBnL6k1gCA_4_15">9,023</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments Prior to the Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrants and tranche liabilities are measured at fair value on a recurring basis. The carrying amount of outstanding warrant liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Narr_gCF57fEhRE2zmytqtvYPow">16,188</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. The carrying amount of outstanding tranche liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="Narr_qeP2RaQrQUiKA4KpIZg-Gg">4,702</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. These carrying values represent the remeasurement to fair value each reporting period based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to a status quo scenario and the potential closing of the Business Combination (see Note&#160;3) scenario, the value of the Series&#160;B-3 Warrants (as defined below) upon closing of the Business Combination, the fair value of the Company, the fair value of the underlying preferred stock, the Company&#8217;s volatility, discount rate, and expected term of the related instrument.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See Note&#160;9 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_vLPoVC9kzEqm61EhV_wbdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="Narr_SOhWRLiEJUWFqG-5sWWVdQ">4,654</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_TN5C51PNT0GEkx_dOCvSqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Narr_GjN_aqIXXUqQpKkAbuEdWA">584</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_MdOc8gt9DkG_ANRSNF1Feg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="Narr_UIjZ9bkZI06eD2mIDhoN0g">10,047</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_p0n0zYd2Y0m3WvEBclIL9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Narr_SV27rHXY5kePlKNbpS9kPg">3,425</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to the exercise of the warrants to purchase Series&#160;B-3 preferred stock in February, March, June&#160;and July&#160;2023, the associated liabilities were remeasured to fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2023, warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_TqnHEEX_6U2SUQQnKIvWrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ogJjAvwloE-OFezTr9HegA">2,239,309</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock were exercised for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_DU9c7TXJSUCF55hor5hngA">4,530</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were remeasured to fair value, net-exercised, converted to shares of common stock of Legacy TriSalus, and then exchanged for shares of TriSalus common stock at the Exchange Ratio. Out-of-the-money warrants expired, resulting in a gain on expiration of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_XOPnCg0EYEC20KqnpImsyw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnWarrantExpirations" sign="-" scale="3" id="Narr_9oFZq1mtOkSzl4eHdRoIZA">18</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_90b98296_2913_4dc4_b0c5_ede668db7886"></a><a id="Tc_YauadxQJDUKaaLFcwqV-lw_1_2"></a><a id="Tc_dDNf6GlokkORfdj-BS5aRA_1_5"></a><a id="Tc_30ghXn_tTEKn5Ze9Bcar0g_1_11"></a><a id="Tc_0vb-nzyhsE-_RQAYMqpSEA_1_14"></a><a id="Tc_k5bopnYXhk-kjYW4rliC3Q_2_0"></a><a id="Tc_35VH4vzpjU-wKKzHvaoQLw_2_2"></a><a id="Tc_t_Y_E1UNmEaXOoZ1icVf2Q_2_5"></a><a id="Tc_F4H15-YW4kWWzGM-wmYTVQ_2_8"></a><a id="Tc_BYNdjLmYnkGY_GNKYYoqfA_2_11"></a><a id="Tc_F8Xb_nQ-CkyT-MM760Y22g_2_14"></a><a id="Tc_CM6so28TTkCAB5LbLtqSxw_3_0"></a><a id="Tc_rM1XMs9e4kKN1lX1drs-AQ_3_2"></a><a id="Tc_SIOEFvbLUUOlCE23LRu20A_3_5"></a><a id="Tc_WCsAAxdlV0i2R5pM_Sjrmg_3_8"></a><a id="Tc_czJicC1hBU-fSOi5hz22vg_3_11"></a><a id="Tc__fGJMkJh-EeSQyVypFXqjg_3_14"></a><a id="Tc_bhOoy8nhEk-M4LUCJMmOOw_4_0"></a><a id="Tc_u7GjFyKkhkCUFmM25UzTIQ_4_2"></a><a id="Tc_Feaqg3yNK0yX11O79iJTVg_4_5"></a><a id="Tc_iXPT138jA0yC8vla7dDenw_4_8"></a><a id="Tc__y-JAtNHekWs9GRxXc68DA_4_11"></a><a id="Tc_BQ-wWG0pJUeuwrqIgnWEoA_4_14"></a><a id="_0114f14b_55dd_40e6_8af4_e0a11a3b12dd"></a><a id="Tc_PTu9d2sEfUGAQXXnOWiY_w_1_2"></a><a id="Tc_S8IcbCBQ6kCeVwtrhrAeVw_1_5"></a><a id="Tc_1eq3Ekx0b020YWvVIlDX-Q_1_11"></a><a id="Tc_pva31Mhx6Eq2WFUdovA3lA_1_14"></a><a id="Tc_e0y6-LL0ikWKi6l0JVR3QQ_2_0"></a><a id="Tc_Z9MFRrvUIEOl1NObfgGihw_2_2"></a><a id="Tc_Pa16_916J0qNSGOcwzoYfA_2_5"></a><a id="Tc__yV6D2soX06NMaUEoUYFHA_2_8"></a><a id="Tc_tleFI7-16EOr3noOQHVVIw_2_11"></a><a id="Tc_nxXwSMp70kCWx8Mz_T9SvA_2_14"></a><a id="Tc_bZDalZbTCEq2TFYG31d_xA_3_0"></a><a id="Tc_9xmSq8lWqkit-mlBCT05lw_3_2"></a><a id="Tc_tC7KK2JBaES2wiIE4olsCw_3_5"></a><a id="Tc_7wyPVvOeZESC51EeY7H-rg_3_8"></a><a id="Tc_xCkDxOGDDU6e4UO4v-xaig_3_11"></a><a id="Tc_IC1SfPNfMka53UmtSijD3A_3_14"></a><a id="Tc__a3oMnx4WEet1blaJS7oow_4_0"></a><a id="Tc_4rpYwKKycUqXc4kdLn0S1g_4_2"></a><a id="Tc_5hu8aBZFwk21D5kghFTAQw_4_5"></a><a id="Tc_tYyuPV7kG0GEBEjI2JoYXA_4_8"></a><a id="Tc_6ML4YtldvkW5uK9Nh49Ifg_4_11"></a><a id="Tc_j0yfuMcqYU-7zEjFnF74zQ_4_14"></a><a id="Tc_e55MtTqYj0q5RF3f5Ssl0g_5_0"></a><a id="Tc_4LP_TToO4UaTD7K3yRp1gA_5_2"></a><a id="Tc_w8osuvL3SEOMBepjhA8vBA_5_5"></a><a id="Tc_kirrzg2jGUqPGdk288WVmA_5_8"></a><a id="Tc_gsA5EyHjaE6Z3cMW8PVqfA_5_11"></a><a id="Tc_HJPUfpool0e6cYvWX9bMWA_5_14"></a><a id="Tc_g6Vo8Ub0_0aCS4OcrpCrPA_6_0"></a><a id="Tc_2SJxutm-dkS3rfJWQhr8gA_6_2"></a><a id="Tc_G37224xYX0a-Iiiem3pn6A_6_5"></a><a id="Tc_NyBQlitKfkGocCT0powEJQ_6_8"></a><a id="Tc_oaYStn5T5E67c-osCrdwfQ_6_10"></a><a id="Tc_Z11uFz5JZUuGVHFp9D4Jxw_6_11"></a><a id="Tc_PQIID-edqUSCxAc4PMp_2g_6_14"></a><ix:continuation id="Tb_cp3cQ4BmE0yDwyd_EGVWUQ_cont2"><ix:continuation id="Group_Vs0kxX3OOkatbgPr-wFJKw_2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_mON5gWTp7EKirtCszFVuWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_GFIUPOZprk6epKTEkPb6LQ_4_3">391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="3" id="Tc_8xzA2Nmrikm-8gPA9PrOOA_4_6">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" id="Tc_yVjX3BrpxEW1Z8xmHcY4TA_4_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="3" id="Tc_0ayHzAzlW0egVtowWx9NZg_4_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_z7ZUYrej5U-HRCyTPGR3Zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_D5bQGTtiEE2lvNUXzoOHnw_4_15">372</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_4e0nEOiYy0GXKQ8LC542oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_QmaBYK_LvUOsPdy3Y9Tviw_4_3">369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="3" id="Tc_pxeYBTO7f0aBT9uraAaBmw_4_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" sign="-" scale="3" id="Tc_cnKDtD6J60i4GAvTpNayLw_4_9">369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="3" id="Tc_a7TC__6jwkmVx4f4gW1fzw_4_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_UH_cOo5McUeHvPGUA75elg" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_jGnYh4h2HEayy1fvNGccVw_4_15">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_HJefUCEOC0ila6lDpRZnrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_3zlAlG_PeEOPC0g7tKbFRw_5_3">4,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="3" id="Tc_viPRfzEgW0ab9KIK7BRwsA_5_6">3,200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" sign="-" scale="3" id="Tc_VCaWchvyh0OzdQp7TwWz6w_5_9">1,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="3" id="Tc_veF3qI-YYkef7HGo3crR5g_5_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_0h9HVSfBy0CDyP55pbIu_A" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_slf0IxkoHEKb8OsnXXV27g_5_15">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_t0-7UkxO_EO65rt0UdRyZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_H0iz9xpRg0yPHzlsS27bwA_6_3">15,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" scale="3" id="Tc_7A57i6gqGUCYV0lqB-N5qg_6_6">311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" sign="-" scale="3" id="Tc_-tlUUi3u80O5DWvbcj-T9g_6_9">15,508</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="3" id="Tc_-dzxAJsM-UyQ97yR0-cg8Q_6_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_-mgXyb38JkOXu9Btsyc7MA" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_KHF_FwtQE0m0_nsOJAmzXA_6_15">&#8212;</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Narr_Y33p3hr0LUGpNiKzOz0Cmw">25,409</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="Narr_qnksrUX6fUSfE2qKtXblJw">4,800</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Narr_jxoBMk-yDkSgnV-RcqX-Jw">14,701</ix:nonFraction></span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.2pt;text-indent:-16.2pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_e063df28_8fa5_457c_a29c_3bf7ffbb24fe"></a><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(5)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Cash, cash equivalents and restricted cash</b></p></td></tr></table><a id="_4d32c834_66be_4a65_be5b_9408ca472df2"></a><a id="Tc_Yim9-cmVi0aDiGGYAlytZQ_1_2"></a><a id="Tc_MhwL8HnCaECNFrZyYuQ6Zw_1_5"></a><a id="Tc_0PxkzR4Gh0eRWXQ-fTiBMA_2_2"></a><a id="Tc_phK3_UkCD0WXu-BcXBd0pQ_2_5"></a><a id="Tc_prkQeKpcSkyN7l9Z5Cs1iw_3_0"></a><a id="Tc__PVv2DH_WkGssNCPhoIefw_3_2"></a><a id="Tc__JyHbDM0g0yZmXOHVQ4fBA_3_5"></a><a id="Tc_rYE5dB3it0iJQZPtagsBdg_4_0"></a><a id="Tc_8Vcz8_JbUkiXkS6tfUhoAA_5_0"></a><a id="Tc_0zEQafygWUeEWGpcF9NMJw_5_2"></a><a id="Tc_yLfo7kVzLUuQgDnbdCqGbg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="Tb_hApBuAD9mE2j4fFF-nVVmA" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_0weMS52kpU-do90Tp2to7A" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_5ZDbBaNi9kSOxXutGUjlHA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BNEBo75kWUCLa5s0kqC84g_3_3">21,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FKUXn3kljkuoJZvzvTNa8A_3_6">9,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_073p7SiLAUOf0CtMnysi9w_4_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_A2VHY6w8PkCDkGcCxrFrWg_4_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_B6q_KeJP70ir3ASH63rOjg_5_3">21,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_SOXlMnP4S0i49NFVtlAMyQ_5_6">9,664</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Restricted cash is </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Narr_-ZGfr1VHCk6ORmjLj7zpkg">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> held by our bank to support our corporate credit card program.</span></p></ix:nonNumeric><a id="_343bbcfa_e145_44d2_8e26_f72a31645b5c"></a><a id="Tc_4YBVfa7L8UaGtSquDZoUqQ_1_2"></a><a id="Tc_48Wj2EIdikWm3RFGJqbsQQ_1_5"></a><a id="Tc_i8HN6dFZuUuhK1EwcvOf8w_2_2"></a><a id="Tc_TsWM797W0k2EbdRTEbx9YQ_2_5"></a><a id="Tc_x-JGUiOFfEKnm1MyAiV4tw_3_0"></a><a id="Tc_GhiOn-EXN06Q9bxm-IKnUw_3_2"></a><a id="Tc_xdSjjyRyS0SmNj7HNTRmKw_3_5"></a><a id="Tc_T7GUJhZy7UCCj4zb2eob2A_4_0"></a><a id="Tc_I2E5BaFzp06yghHXs7GnMA_5_0"></a><a id="Tc_nRJdvWCAX0eiP4vMMcBarg_5_2"></a><a id="Tc__P4CUQr47UmCLXCgDaG-Og_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_VpygLjGHL0OdGlO7oCPNLQ" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_iPLiUv-SiEiZdzlxV-3wBA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The components of inventory are summarized as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_JEL7IcDzxEiJm6FeEIE5Dw_3_3">289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_KiL0X8-yxkO0VF48YPEvaA_3_6">753</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_-UdhjSt-2Uu5HN6FbRmVkQ_4_3">1,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_FvZwqIsNKEuLL76w6PbV0g_4_6">718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_G_5-n7ugUEy-phYumLw0Zw_5_3">1,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_9g0BJ1s9X0WbEKGAPrQmMA_5_6">1,471</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Finished goods amounts include a reserve for excess or obsolete inventory of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:InventoryValuationReserves" scale="3" id="Narr_OauPt8mvwUWMudca1qguQg">nil</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="3" id="Narr_-Ru3VoFU002zWQRa_OCGzw">43</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023, and December&#160;31, 2022.</span></p></ix:nonNumeric><a id="_09235ba5_4db4_4938_baec_d8824cd57c47"></a><a id="Tc_LJZN-OEbQEqV7zYCfe2hHw_1_2"></a><a id="Tc_zL5NON11FkaEffKRZpb4zQ_1_5"></a><a id="Tc_NtOLmC4DSEyXjrUQb319Yg_2_2"></a><a id="Tc_QzIlFga6nUKsr752pOKr6w_2_5"></a><a id="Tc_YyRvKf1znEagNZN4mcKifA_3_0"></a><a id="Tc_NUqWmHw6VUy2fJeC6Br6kw_3_2"></a><a id="Tc_4erktKb8-kOn_uHraF2lQA_3_5"></a><a id="Tc_SqU1JpG4nUWcrovzCRe4cw_4_0"></a><a id="Tc_SoYDCWahuECYm6xqW2ERRA_5_0"></a><a id="Tc_Ene1V3RGS0iQra9SKZ9k0g_6_0"></a><a id="Tc_Ulq71puDkE-1M8D45EY0Og_7_0"></a><a id="Tc_lltG11rrQ02kpBZEzxtaIQ_7_2"></a><a id="Tc_ACmOEFrvPE2f_nexOfdN2w_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_YGfi3A7zDEC2JzjYJWQOFw" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accrued Liabilities</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_6Dt_vbDw_0WWXnVlCp5LyA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accrued Liabilities consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_vej69PDPGEuRb3z87sm3bQ_3_3">3,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_QdWd2qkmbkuXmefrCyuv9g_3_6">2,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_LKYUs83nEECscFllijtFpA_4_3">2,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_rDcvZEeo7U6dpIYr9GGgdQ_4_6">2,896</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_doQVThRuQ06zdLyGaAcZ4w_5_3">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_1n-yiwELc0--PsLkXW-TsQ_5_6">329</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_O8gEYfLbe0utu65tVjJFDw_6_3">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_S-fof5oqDUSZbQZTpkyLgA_6_6">247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_h-W9I7dJYEWPHBFhExrIgg_7_3">6,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_V8TzkTlguEKYM2ehjzB6AA_7_6">6,377</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ca183611_9b91_4b1d_9faa_585c1b609ce2"></a><a id="Tc_tG8Uu7r8TU22BZf2Vy5XRA_1_2"></a><a id="Tc_M6sgfS6ki0aCHmaBqf5LNw_1_5"></a><a id="Tc_H528z_aV106nEAFVVphiaw_2_2"></a><a id="Tc_cPZDk0HROESyCmcvYyXpvA_2_5"></a><a id="Tc_REQzqsvPFEivRoUPE2_BLQ_3_0"></a><a id="Tc_LKiyxC6rYkG9j6AH8C8uBw_3_2"></a><a id="Tc_Z_qS1r5bs0yDSp5w3Vzmdw_3_5"></a><a id="Tc_1_NctA21c0ugNBsHwI6PAA_4_0"></a><a id="Tc_P0Fd2-uPQkCjUCluWc9sTQ_4_4"></a><a id="Tc_7-S-fKeYgEu_Srw6FQ3LPQ_4_7"></a><a id="Tc_bQERPZSQf0WPA_nMzEVVkQ_5_0"></a><a id="Tc_BLLMYu3_u06_zsG9WiGiAg_5_4"></a><a id="Tc_AYd_2n0oM0uP9BzDUk0MuA_5_7"></a><a id="Tc_9-TmGSnl3UiP5-j_evMBGA_6_0"></a><a id="Tc_2-vwuXXoHUWhPciSwci_bg_7_0"></a><a id="Tc_KRBweSY9_0-RxMkHygu8bg_7_4"></a><a id="Tc_Py1EquJWSEuxfxwyYBY-3w_7_7"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_2gmCQV_mjkOxe3Y4DArR4Q" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(8)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Contingent Earnout Liability</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;2 and Note&#160;3, in connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement with the Sponsor Holders and Legacy TriSalus, pursuant to which, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_QW7EfoeCZUGUfloNheRNUg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares" scale="0" id="Narr_miGCW357f0KB9LGQQW_N-A">3,125,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor immediately after the Closing Date became unvested and subject to potential forfeiture if certain triggering events are not achieved during the Earnout Period. The earnout shares are classified as a liability and were initially measured at fair value at the Closing Date and will subsequently be remeasured at the end of each reporting period with the change in fair value of the earnout liability recorded in the Condensed Consolidated Statements of Operations.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The estimated fair value of the total contingent earnout liability at the closing on August&#160;10, 2023, was </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_xX8qBpS53UOLcOzeN-gu8w">28,927</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> based on a Monte Carlo simulation valuation model. The liability was remeasured to its fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_LerLiJRoXEC3rcs3ysRR4A">9,023</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. This remeasurement resulted in the recording of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Narr_falOt-3VWEuRwf-PW2SoZQ">19,904</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the three and nine&#160;months ended September&#160;30, 2023, classified as change in fair value of contingent earnout liability in the Condensed Consolidated Statements of Operations. Assumptions used in the valuation are described below:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_zWZM6-KBpkui8gyBIKU0hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_8Q0Om5D-S06_l2NA4sssgQ_3_3">5.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yQXpaQmMKkOs4sGjRq4fiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_4EgLNzPxekWBpt1NNm0XAQ_3_6">11.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected share price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_T7Li9gpr_0G4t4E0kCavKg" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_x9DqjiuzJUGefgVOqqgCEw_4_3">65.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_tK0vLXJF0k6IM1QbPso1tQ" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_grbvlIghEUuqdBHGe0ZwaA_4_6">65.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_DAgjRnDA-kiGIHGiIR6buA" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_O0GLEgGMC0-HB0YLnEFETQ_5_3">4.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_U3Mfr4KP40avhKdtSM8eCg" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_I2xRrJDCBkCbbu7ApxW37Q_5_6">4.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Wub9s-eMQkCXY7--e9OtAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_eUtYEq9F40qyl4AmpnEm-w_6_3">4.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lJ2gu3Wxtka5YhLPEJVNXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_fO6_zj1HBEiO1YOgdNhxYg_6_6">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LjBcrN9xrU2acLCoC3csdQ" decimals="2" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_eSY3NsBHn0yJROr991ME8A_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_79RwHeAEqk6ErcJTlraR9A" decimals="2" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_fGNqhLtYa0Czki9-VEmcpw_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The estimated fair value of the liability was determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes. The inputs and assumptions utilized in the calculation require management to apply judgment and make estimates including:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected volatility, which is based on the historical equity volatility of publicly traded peer companies for a term equal to the expected term of the earnout period;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected term, which we based on the earnout period per the agreement;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time periods commensurate with the expected term of the earnout period; and</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected dividend yield, which we estimate to be </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_SCl9YgPpEUOC4yNBJt6Thw">zero</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> based on the fact that we have never paid or declared dividends.</span></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision.</span></p></ix:nonNumeric><a id="_65c7988e_e1a5_46de_89f2_c804f5e22aa6"></a><a id="Tc_jjfaXi8W60Gwg6tHj-0uLA_1_2"></a><a id="Tc_VkealZ6XwU2mMpxCwTqshw_1_4"></a><a id="Tc_gMm7G77mg0OwCa27liYPTA_2_2"></a><a id="Tc_vTCG8mVSI0u_7d5TqQP4ZQ_2_4"></a><a id="Tc_BWiOYdcqoU-nXhKVsYov-g_3_0"></a><a id="Tc_mwUqR-DXvEK6YRV_WYs9Kg_3_4"></a><a id="Tc_156yJBZjc02MtQyTS7UzQg_4_0"></a><a id="Tc_qRU1hGBRM06Hn-OTiArc5Q_4_4"></a><a id="Tc_z5vzGHoqAkqtLpFBaWjNSA_5_0"></a><a id="Tc_NrN4RkgAVkqaH8DRNfxEuQ_5_2"></a><a id="Tc_yT0H19hVVUCtedJRj_Y72g_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="tlsi:WarrantsLiabilitiesTextBlock" id="Tb_wKnyi7HHv0imwZKhgjTIeA" continuedAt="Tb_wKnyi7HHv0imwZKhgjTIeA_cont1" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(9)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Warrants</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Group_DqtoymI-ok6sSmCYeH7lqg" continuedAt="Group_DqtoymI-ok6sSmCYeH7lqg_2" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Cmf-IP0xbUCF-S1EcyvcFA_3_2">8,333,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_b4vraasYukyXcoFhgsFKzg_4_2">5,933,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Series B-3 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_tTMI_mJSY0aVudzs6Thybg_5_4">15,819,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Pdpul-ppJUuXfqqiA_DVeg_6_2">14,266,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_AGFj7b-2JEy_-IGW6Ot-fA_6_4">15,819,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Public and Private Placement Warrant Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with consummation of the Business Combination, the Company assumed the warrant liabilities associated with </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_2hz7BfEs002wZUeVU-SOfQ">8,333,272</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> MTAC Public Warrants. Each Public Warrant is exercisable to purchase one share of common stock at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_EvwSPWi9MUebZrI-klp4iA">11.50</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, subject to adjustment. As of September&#160;30, 2023, there were </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_u0xVG9dfrUWhHudbdqX_Sg">8,333,272</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> Public Warrants outstanding.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wKnyi7HHv0imwZKhgjTIeA_cont1" continuedAt="Tb_wKnyi7HHv0imwZKhgjTIeA_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Public Warrants will become exercisable </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA" format="ixt-sec:durwordsen" name="tlsi:ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" id="Narr_nIhXR2EzYEm5qs0DgA3pJg"><span style="font-family:'Times New Roman','Times','serif';">30&#160;days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination. The Public Warrants expire </span><ix:nonNumeric contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_KUzUl0D8FEmuIBsJrug-PQ"><span style="font-family:'Times New Roman','Times','serif';">5&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination or earlier upon redemption or liquidation.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;31, 2023, the Company filed an amended registration statement on Form&#160;S-1 a(as may be amended from time to time) with the SEC registering the issuance of the shares of common stock issuable upon exercise of the warrants and will use its best efforts to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed, as specified in the warrant agreement.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">a.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">in whole and not in part;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">b.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">at a price of $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightRedemptionPrice" scale="0" id="Narr_fjlxRs2DukyuK97XwRe1LQ">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per Public Warrant;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">c.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_RHMSaTNJIEmzTCVVY75WyQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionDaysNotice" scale="0" id="Narr_y7O_mUZhXES9YXw_8gL88g">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> days&#8217; prior written notice of redemption to each warrant holder; and</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">d.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">if, and only if, the reported closing price of the Common Stock equals or exceeds $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionStockPriceThreshold" scale="0" id="Narr_SLooJbiyz0O0LugBoEQd1A">18.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionTermsThresholdTradingDays" scale="0" id="Narr_XnaytNiPE0yq9UgkspPwig">20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" scale="0" id="Narr_qvd1_UO9rkyeCv4felMmTA">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.</span></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis.&#8221; The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. Accordingly, the warrants may expire worthless.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition to the Public Warrants, the Company assumed the warrant liabilities associated with </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_iUzVz3nSvkmMuRD6Ys8Lpw">5,933,333</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> MTAC Private Placement Warrants. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" format="ixt-sec:durwordsen" name="tlsi:ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" id="Narr_oU_dWTYlQ0avTZlHVX4LCQ"><span style="font-family:'Times New Roman','Times','serif';">30&#160;days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. As of September&#160;30, 2023, there were </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_H0pCYSs4fUGdmBhg28UZZw">5,933,333</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> Private Placement Warrants outstanding.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the Public and Private placement Warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. As a result, the Private and Public Warrants do not meet the criteria for equity classification.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the close of the Business Combination, the fair values of the Public Warrants and Private Placement Warrants were </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_cfcG06OqrUSv8b0oq8McUA">1,500</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_M4CDa-1olEetC4CFUHmfXw">1,068</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively. As of September&#160;30, 2023, the fair values of the Public Warrants and Private Placement Warrants were </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_3YTcyIdAXEmZMQhnuP67qg">3,166</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_9Sxtip3EUUSeR9cOHurQEw">2,255</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively. The fair value of the Public Warrants has been measured based on the quoted price of such warrants on the Nasdaq Global Market. The transfer of Private Placement Warrants to anyone outside of a small group of individuals who are permitted transferees would result in the Private Placement Warrants having substantially the same terms as the Public Warrants. Therefore, we determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wKnyi7HHv0imwZKhgjTIeA_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Series&#160;B-3 Warrants</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-3 Warrants were issued in conjunction with shares of Series&#160;B-2 preferred stock in October&#160;2022, March&#160;2023 and May&#160;2023. Each warrant allowed the holder to purchase one share of Series&#160;B-3 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_JNDGtibE0E6YxR5fvB4Kuw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_L29IaNRPEEaFk_pUcinoUw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_Q_kjqMAvdUaQjRHDJ3DK2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_O7qLLwpn50KNCyPlXZZ4cQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_5_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_g1Y_0bPfVUeHvgx_nTS4NQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_KBUamnW95km4gaZc0ISLKg">0.05</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;B-3 Warrants expired at the earlier of October&#160;5, 2028, or the closing date of a change of control transaction. All in-the-money warrants that were outstanding at a change of control transaction would automatically net exercise.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2023, Series&#160;B-3 Warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_7_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_RdkVFV-BmUiRk_p7buc6iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HZjxrj-TO0iMR_dqkGIpqQ">2,239,309</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock were exercised for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_f39JFztaOUONTwOxzh44ug">4,530</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were net-exercised and converted to shares of common stock of Legacy TriSalus, then exchanged for shares of TriSalus common stock. Out-of-the-money warrants for other classes of preferred stock expired. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event: Warrant Repurchase Program</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In August&#160;2023, our Board approved a warrant repurchase program, authorizing the repurchase of some or all of the Public Warrants (the &#8220;Warrant Repurchase Program&#8221;). The Board authorized an aggregate expenditure of up to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_1_2023_To_8_31_2023_qmSmw3DpY0WjaiDXUJYiOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" scale="3" id="Narr_5PhUmXRYQUWFcjKF7E8HYQ">4,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for such repurchases. The repurchases may be made from time to time in open market or privately negotiated transactions. We may adopt one or more purchase plans pursuant to Rule&#160;10b5-1 under the Exchange Act, in order to implement the Warrant Repurchase Program. The Warrant Repurchase Program does not obligate us to purchase any Public Warrants and may be terminated, increased or decreased by the Board in its discretion at any time. We adopted a purchase plan in October&#160;2023. Through October&#160;31, 2023, we had repurchased </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightNumberOfWarrantsRepurchased" scale="0" id="Narr_v3VnbqZCh0KB71vKG5tyCw">28,502</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> Public Warrants for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="Narr_Jt7KcwaRSU6o4u7J2aFATA">10</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_QglO07lewkm1gVw93BiuPw" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(10)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Income Taxes</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full calendar&#160;year and use that rate to provide for income taxes on a current&#160;year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the annual effective tax rate, including use of the actual effective rate for the&#160;year-to-date. The impact of the discrete items is recorded in the quarter in which they occur.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We utilize the balance sheet method of accounting for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings, forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Based on our full valuation allowance against the net deferred tax assets, our effective federal tax rate for the calendar&#160;year is </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_NCEJx4laAkKgmB6Kzf-yow">zero</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and we recorded an immaterial income tax expense in the nine&#160;months ended September&#160;30, 2023 and 2022.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:PreferredStockTextBlock" id="Tb_qpFZA5LJL0O_uDqNOzuSWA" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont1" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(11)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Series&#160;A Convertible Preferred Stock</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we issued </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_e6tFgRkHrUOpriQ2o9HSDw">4,015,002</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A Convertible Preferred Stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Narr_kHIDvh-kBUmFmFGP44w14w">40,150</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, the Company is authorized to issue up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Qh5vZeweaE2HPzcq2HTx2g">10,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of preferred stock with </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_PrJ46V1dvkCVSrf-h1yfzQ">5,984,998</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares available for issuance. The original issue price of the Series&#160;A Convertible Preferred Stock was </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockIssuedPricePerShare" scale="0" id="Narr_JWg1ZyR3dUuigPtA7eIsIg">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;A Convertible Preferred Stock accrues cumulative dividends at the rate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_jVhbJpAu0kG_D4Un6eb0-g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_PaF1tV7tDE6ZbEzC_QKpkQ">8.00</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> per annum on the original issue price. As of September&#160;30, 2023, total undeclared cumulative dividends were </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Narr__quI-UF7vU6wObiC6Q4MHA">458</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. We have not recorded the undeclared dividends in our condensed consolidated financial statements.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont1" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">All shares of Series&#160;A Convertible Preferred Stock had the following rights:</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion</i></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">(a)</i></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Optional Conversion</i></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;A Convertible Preferred Stock are convertible at any time at the option of the holder thereof into the number of shares of our Common Stock determined by the quotient of (i)&#160;the sum of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockIssuedPricePerShare" scale="0" id="Narr_xMLGjeEhUESFVGKM4yCZIQ">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (as adjusted for any stock dividend, stock split, reverse stock split, combination or similar event affecting the Series&#160;A Convertible Preferred Stock) (the &#8220;Liquidation Preference&#8221;) and, if we have not elected to otherwise pay the accrued Annual Dividends (as defined below) in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price (as defined in our Certificate of Designations, Preferences, and Rights of Series&#160;A Convertible Preferred Stock (the "Certificate of Designations")) of such shares in effect at the time of conversion.</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">(b)</i></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">Automatic </i><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion</i></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">On the </span><ix:nonNumeric contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" format="ixt-sec:durwordsen" name="tlsi:PreferredStockAutomaticConversionPeriod" id="Narr_kcAdTVOQyk2eyHa6L5t6gA"><span style="font-family:'Times New Roman','Times','serif';">four-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> anniversary of the Closing, all then outstanding shares of Series&#160;A Convertible Preferred Stock shall automatically convert into the number of shares of our Common Stock equal to the quotient of (i)&#160;the sum of the Liquidation Preference and if we had not elected to otherwise pay the accrued Annual Dividends in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price of such shares in effect at the time of conversion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(ii)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Voting Rights</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Holders of the Series&#160;A Convertible Preferred Stock are entitled to vote with the holders of our Common Stock on all matters submitted to a vote of our stockholders, except as otherwise provided in the Certificate of Designations or as required by applicable law, voting together with the holders of our Common Stock as a single class. Each holder is entitled to a number of votes in respect of the shares of Series&#160;A Convertible Preferred Stock owned as of the record date by it, or if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, equal to the quotient of (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockIssuedPricePerShare" scale="0" id="Narr_YiWEsUVkN0ShZ4djHcxbKQ">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> divided by (ii)&#160;the Minimum Price (as defined in Nasdaq Listing Rule&#160;5635(d)) of our Common Stock as determined at Closing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As long as any shares of Series&#160;A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the Holders of a majority of the then-outstanding shares of the Series&#160;A Convertible Preferred Stock, (i)&#160;amend, alter, repeal or otherwise modify any provision of our certificate of incorporation or the Certificate of Designations in a manner that would alter or change the terms or the powers, preferences, rights or privileges of the Series&#160;A Convertible Preferred Stock as to affect them adversely; (ii)&#160;authorize, create, increase the authorized amount of, or issue any class or series of capital stock senior to the Series&#160;A Convertible Preferred Stock; (iii)&#160;increase the authorized number of shares of Series&#160;A Convertible Preferred Stock or enter into any agreement with respect to the foregoing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iii)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dividends</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Holders of the Series&#160;A Convertible Preferred Stock are entitled to participate equally in any dividends declared to holders of Common Stock. In addition, each holder of the Series&#160;A Convertible Preferred Stock is entitled to receive cumulative annual dividends that accrue and accumulate on a daily basis at a rate per annum (calculated on the basis of an actual 365- or 366-day&#160;year, as applicable) equal to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_8_9_2023_To_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_EQp5eTc6Nk61dCNahJBvFw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_CA6ii2NXMkK5y1Yu-gVdMw">8.00</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the original issue price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockIssuedPricePerShare" scale="0" id="Narr_61egRqKzn02PURDx4OjGXQ">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share (the "Annual Dividends&#8221;). The Annual Dividends will be either paid in cash, paid by issuing fully paid and nonassessable shares of Common Stock, or a combination thereof when, as and if authorized and declared by our Board. Upon conversion or a change of control, any unpaid Annual Dividends will be paid to the holders, either in the form of common stock upon a conversion, or in cash upon a change of control. So long as any shares of Series&#160;A Convertible Preferred Stock remain outstanding, unless all Annual Dividends on all outstanding shares of Series&#160;A Convertible Preferred Stock have been declared and paid in cash, we will be prohibited from declaring any dividends on, or making any distributions relating to, other classes of our capital stock ranking junior to the Series&#160;A Convertible Preferred Stock, subject to certain exceptions.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont2" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont3"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Anti-dilution Provisions</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The initial Conversion Price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_0R1eIjV3EUubTlQwrMBxsw">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> is subject to customary adjustments in the case of certain distributions to holders of our Common Stock payable in shares of our Common Stock, subdivisions, splits or combinations of the shares of our Common Stock and distributions to all holders of shares of our Common Stock of any convertible securities or options or any other assets for which there is no corresponding distribution in respect of the Series&#160;A Convertible Preferred Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Conversion Price will automatically reset upon each of February&#160;10, 2025, and July&#160;10, 2027, the </span><ix:nonNumeric contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw" format="ixt-sec:durwordsen" name="tlsi:PreferredStockConversionPriceAutomaticResetDurationFirstReset" id="Narr_X7tk81K90EGUxCSBJcFU_g"><span style="font-family:'Times New Roman','Times','serif';">eighteen-month</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> and </span><ix:nonNumeric contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw" format="ixt-sec:durwordsen" name="tlsi:PreferredStockConversionPriceAutomaticResetDurationSecondReset" id="Narr_QO9VFTYmaEKePjw3vUb8Ww"><span style="font-family:'Times New Roman','Times','serif';">forty-seven-month</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> anniversaries of the Closing Date, to be equal to the lowest of:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initial Conversion Price, subject to adjustments for stock dividends and distributions or other distributions made to common stockholders for which there is no corresponding distribution for Preferred Stock,</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the then-current Conversion Price, and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the higher of 1) the&#160;Floor Price (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw" decimals="2" format="ixt:numdotdecimal" name="tlsi:PreferredStockConversionPriceFloor" scale="0" id="Narr_QT_Iq30TmESmqQs1Vj8pNA">2.10</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share) or 2) the trailing </span><span style="-sec-ix-hidden:Hidden_5hLzbZ6A6U-WazkWaQSF7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-Trading Day VWAP of the Common Stock determined as of the date of such reset.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Liquidation Preferences</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The terms of the Series&#160;A Convertible Preferred Stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a &#8220;Liquidation Event&#8221;), none of which were deemed probable as of September&#160;30, 2023. The Liquidation Preferences of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_lRkAnltKA0qFpwejhqPINA">10.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, plus all unpaid dividends, are payable prior to payment to any class of capital stock that is junior to the Series&#160;A Convertible Preferred Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment of the full Liquidation Preferences to all holders of Series&#160;A Convertible Preferred Stock, then such assets will be distributed ratably to the holders of Series&#160;A Convertible Preferred Stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned Liquidation Preferences, any remaining proceeds from a Liquidation Event will be distributed to all classes of capital stock that are junior to the Series&#160;A Convertible Preferred Stock pro&#160;rata on an as-if converted basis.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Legacy TriSalus Preferred Stock</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Since inception, we have issued various series of preferred stock as described below. As described in Note&#160;3, all of the Legacy TriSalus Preferred Stock was converted to Legacy TriSalus Common Stock immediately prior to the Merger and, upon consummation of the Merger, were exchanged for shares of our Common Stock. In accordance with the terms of the Legacy TriSalus Preferred Stock, upon an acquisition of the Company, the proceeds would be used to first pay the liquidation preferences on the preferred stock prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our Board and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#8201;&#8212;&#8201;and thereby redeem the convertible preferred stock&#8201;&#8212;&#8201;was deemed to be outside of our control. As a result, the Legacy TriSalus Preferred Stock has been classified as temporary equity in the accompanying Condensed Consolidated Balance Sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments were not currently redeemable and we believed it was not probable that the instruments would become redeemable.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2455c3ee_41a8_499a_81e2_b7b0120972d0"></a><a id="Tc_UgvUPhvh4UebT1yywd80Kg_1_2"></a><a id="Tc_-jHIt3qV7UaoSygfCQ-EZQ_1_5"></a><a id="Tc_pG9voejwnUybp4JiLcM4aQ_1_8"></a><a id="Tc_Wq1xS4EcR0ezKPpvTyK4Qw_2_0"></a><a id="Tc_-in-uS2mlk2RmNjMwESdqA_2_2"></a><a id="Tc_Cx22o6-MM02sf9q2bLvUzQ_2_5"></a><a id="Tc_nVhDQ_Jy3k2P2fFd5LDtUw_2_8"></a><a id="Tc_GIe5t2tb7UKi6KgIKAfQOw_3_0"></a><a id="Tc_0dDVmyLXmEK9dhBcuFQFvA_3_2"></a><a id="Tc_fZxJc2aMVEaXiCzXo1xJCg_3_3"></a><a id="Tc_tpo7Zn8Q-k-_HW1nURsPKg_3_5"></a><a id="Tc_ObqVdxRrVk-RGYxFg-bIHw_3_8"></a><a id="Tc_TfXB-MpcQ062s4JwrdAv_w_4_0"></a><a id="Tc_77rfOFZtnkGCeyGONSZx9A_4_3"></a><a id="Tc_uIcCmAsGREiVL_HO2y2A6g_5_0"></a><a id="Tc_olv94TLAm0a6WoxHLdIyFQ_5_3"></a><a id="Tc_zz3nCZuLRUWUvQ4csvgxrg_6_0"></a><a id="Tc_SybBlhS6kkOblo4yNYUvhA_6_3"></a><a id="Tc_IFwCZXchkkGWtbWfepmzqw_7_0"></a><a id="Tc_5A8aBu6w9EKUbAXt_xEwEw_7_3"></a><a id="Tc_7KJ1Tc78Xk2E89GEn0WbMg_8_0"></a><a id="Tc_Oz1daXlJkEe17MOycmx6mA_8_3"></a><a id="Tc_6l-S4rA79ESRIZZPyl7UFg_9_0"></a><a id="Tc_7VJk_4zRM0ykb8jsHmg7uA_9_3"></a><a id="Tc_2RQ6YSkJQkSsGOObu9wdcw_10_0"></a><a id="Tc_qtOhJB-A9kGWhBJn62mPjQ_10_3"></a><a id="Tc_ajHHnFGPO067ueo0GDeL3A_11_0"></a><a id="Tc_hEHF9twtO0SgjnnmLJX15A_11_3"></a><a id="Tc_FhIN_43YSUKFLwSxcZaj8g_11_6"></a><a id="Tc_i_gvkNDP0kqDVt40Q0q6WQ_11_9"></a><a id="Tc_mLPlfdZPdUyV5FfSZAcWog_12_0"></a><a id="Tc_9A2vOGFUTEOrr2JuMAg3Jg_12_3"></a><a id="Tc_kU7QJHnRxES3S9m3fWOPlw_12_9"></a><a id="Tc_VWDR2PruN0el5B028sG8NA_13_0"></a><a id="Tc_BXpcadOfy0mJzjJ90C_Yhw_13_2"></a><a id="Tc_NbvxxCpqWEa2pjTIzgq6kQ_13_3"></a><a id="Tc_W37eir7PRkKtAWlr-8WYSw_13_5"></a><a id="Tc_JwgJ3ZBu0km3KdddsuYd6A_13_8"></a><a id="_d2845005_42a9_4eda_86fc_0bbce4250d44"></a><a id="Tc_BWAwU-dXmE2ELcKb-1gn_w_1_2"></a><a id="Tc_ZA60_v1KMUygMc1RhBu2EA_1_8"></a><a id="Tc_nDWWvVecuE2XdSAyOehWeg_1_11"></a><a id="Tc_gZmiX7p1W0qCh81ZmKH8bA_2_0"></a><a id="Tc_r5mC5RW34ECNkd9HSDwEnw_2_2"></a><a id="Tc_g_eprMzZzkmf_FYtpHfAtA_2_5"></a><a id="Tc_506TgSQre0m-xs0uuVg6Dw_2_8"></a><a id="Tc_q-dNwi5mWk6UakqOolbHnQ_2_11"></a><a id="Tc_ufCYZJc4xE2gRyJbj1Ef3g_3_0"></a><a id="Tc_miSJn4NmYk6vOIvDcuE2JA_3_2"></a><a id="Tc_8y0lAtPWE0qofYcc8ti21Q_3_5"></a><a id="Tc_NYnqrPxR60-jdif7duh1kg_3_6"></a><a id="Tc_2eU3t0rzIk-Uu17tLVWbfg_3_8"></a><a id="Tc_ewapwPCXtEWraMvGchAfEA_3_11"></a><a id="Tc_bYWvXwNuAEK2A5Uc3weCzg_3_12"></a><a id="Tc_ReIjKibZFkCGMp4f4B8Blw_4_0"></a><a id="Tc_fdM2Hr4ggUmy2tKSjnrXcw_4_6"></a><a id="Tc_2r_aDprYOEWQlo4YV6ORPg_4_12"></a><a id="Tc_GAi4lma2F025pZ-kj6027A_5_0"></a><a id="Tc_5GN2Gn_HS0OrpAKUlEVuaA_5_6"></a><a id="Tc_OVQSolRUxk6068_AXWQkIA_5_12"></a><a id="Tc_Ra11aQ_GtEybjxCRwltH2g_6_0"></a><a id="Tc_C373qBITzEi_CRQ68986SQ_6_6"></a><a id="Tc_753qK99XMEKcVQVh7ifoWA_6_12"></a><a id="Tc_daBm-HeDI0CuH2NNOIBCUA_7_0"></a><a id="Tc_EaSlPKsaBk-1ZdxtffEAMg_7_6"></a><a id="Tc_I2iu4TtvX0GKooyH1gflKQ_7_12"></a><a id="Tc_f58qgkm2z0im6zT2tITb1g_8_0"></a><a id="Tc_5oklosUpHUK-7I_r4WFkhw_8_6"></a><a id="Tc_vmKqN0Z67UCpie7fLcRP4g_8_12"></a><a id="Tc_5mNa2REM10C9jOFJQa-uKQ_9_0"></a><a id="Tc_iqbAo-OxDkahz0G2Ptt7dQ_9_12"></a><a id="Tc_jK6xdF0fl06aG6NPfZgE2A_10_0"></a><a id="Tc_oMoUG4ZNyEeBvCTMvE8Ejw_10_12"></a><a id="Tc_jMeJcw8fqky30kPtYWSa7A_11_0"></a><a id="Tc_deuZkOMJiked8VkHCAJK-w_11_3"></a><a id="Tc_Uny5XTm18kC744BHhqpboA_11_6"></a><a id="Tc_drmUI3srFk6VORlnXGGK6w_11_9"></a><a id="Tc_YDZfMwV910-3Eg5Xjutghg_11_12"></a><a id="Tc_hjaO8SFpI0C0U9ZvpQ5J1w_12_0"></a><a id="Tc_QA_f3byQcEWilEeBcl6SJQ_12_3"></a><a id="Tc_JbM4pAj_8EWJyjl0625UGQ_12_12"></a><a id="Tc_smK402WxWkynsca0910T9Q_13_0"></a><a id="Tc_9ELLGc8iT0CIC05B0UnfqA_13_2"></a><a id="Tc__N3sOOU2r0qHm0Dty25wew_13_5"></a><a id="Tc_VHl5gHJd902axd29h7HUAA_13_8"></a><a id="Tc_oy015Toz7Em89LAqw_30bg_13_11"></a><a id="Tc_pNccXe0us0qx4XDNpMqCMw_13_12"></a><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont3" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont4"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_GnsCzGj9q0KbYbHqKAGjPg" continuedAt="Tb_GnsCzGj9q0KbYbHqKAGjPg_cont1" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-1 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_9JGnGHK1pUOEmLMcNYKx3A">0.001</ix:nonFraction> par value per share. Issued, and outstanding 0 and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_W6cvkYPAG0SDf2gMFU7AMg">131,797</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_p1P46KnXQEWJ8sMTS1L0LQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_3uj0SOH0UkSdWSFSen25RQ_3_6">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_NbGfjJ_8K0aN3UKfyA7MWQ_3_9">6,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-2 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_uu1krdvpSkqg3Pm6Ueojpg">0.001</ix:nonFraction> par value per share. Issued, and outstanding 0 and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_alC7IAKjiUuc49ZXKbpaFA">576,126</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0AcI-Ohrv0KOD6jjNcyFJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_SktNu7WJwEqysocidL3sXw_4_6">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_v81-JLetYkaTUXHSI4huBA_4_9">8,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-3 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_fhVHbioT6U23prrETSQarQ">0.001</ix:nonFraction> par value per share. Issued, and outstanding 0 and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_ndJRQOjJUkiCvrPRf0PlGg">612,822</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_n2Hy7mytPUCwfCaVDdp1yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc__5r0GhgNeEO2JFMTBnb2nw_5_6">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_8Cwd1uMdmUy4cboKJGnOlQ_5_9">10,611</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-4 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_8EJFKbCNTk-7AcBridUGDA">0.001</ix:nonFraction> par value per share. Issued, and outstanding 0 and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_wC69y0K4iEqsT8Wa87kZuQ">127,787</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_az5NgdPmYEyG5PMwrX8MQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_65MIoEa1cEGA1CPlrqNVig_6_6">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_rBpiRuSBnUOEAuLueOLDnA_6_9">1,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_tx-URdNDSUCUnyIkcHUMHA">0.001</ix:nonFraction> par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_A485uUOxFkmARK8JorceQg">734,533</ix:nonFraction>, issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_HrJWNJEO-EexFVI5j6R05w">730,320</ix:nonFraction> and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_yR9f-JPIGUujVs37FEydrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_RO0w8LH6J0aDBDSQOxWifw_7_6">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_UlCv7rFGK0-nTrrydvbaMQ_7_9">12,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_C8RIvdj1uU63xtOB39ZHbg">0.001</ix:nonFraction> par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_TA61s2LxgE2BHJjJ-Kkkiw">805,848</ix:nonFraction>, issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_MKuITITD4kqQsY5Gvkr58Q">800,657</ix:nonFraction> at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_SwY35kQgfk2dbaaXKgOEjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_B3QRtZJAA0OZ3rNUmOfK6A_8_6">15,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_PDEB-E38dUSzMnVRo4ZmVA_8_9">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_nsSkDDroeE65kxzTlq_Zjw">0.001</ix:nonFraction> par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_njAkuEk8k0W0WfXMt9LkTw">7,021,678</ix:nonFraction>, issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_lX74RLaaNkaWnfNupq-hvg">6,984,971</ix:nonFraction> at December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dVErUypF_kmGT88HG0br_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_sDdQRIYQIEKAc246Tqge_Q_9_6">84,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_d9jtOFxZwEiO8vhnhtypww_9_9">84,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-1 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_VdVYUAXaKkG8srtvzc-JZA">0.001</ix:nonFraction> par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_8MpDuY2CN0iN-QH7KYNEcA">1,659,672</ix:nonFraction> at and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_iTZWPgkZoEq7CXYI1m6Ohg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_tDrk0xyxbkSnxJCupUZqbA_10_6">23,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_R5Ton_qfpUWp2F4roCJHVw_10_9">23,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-2 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_KeU9QqTrS0e9njYFB29tDA">0.001</ix:nonFraction> par value per share. Issued and outstanding 0 and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_k-gKCB0hgk-3b5Q7sQ7RIQ">706,243</ix:nonFraction> shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_hCRH8jlnj0eZcHYow9nEaA">0.001</ix:nonFraction> par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mxqu6HErZkefO1cAxk8GhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_P_GJp6JGDUqlSMT7TJtyug_12_6">39,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_tjgLXpDcWkO1PFkQ-ztzig_13_6">203,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_SkCjl3PfT0-0tXqUGrGO9Q_13_9">164,006</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements / </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AtUfw1J3o0mUu0fWLK3F2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_4KrPnnXQekC4mW0C7LLBSQ_3_3">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_PWoqiQtqAEGjuMjXT5sw3Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_i-grYBMrvEGEIzSTj11cvQ_3_9">6,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_GkzygEWdwkGIA2Hdptj-cA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_xY22yT66nUe8PunA1Km0LQ_4_3">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_zcWk9JPUm0aHGEFVscgstQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_Yt_LgW4qika6jmp7VDI-3A_4_9">8,976</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_lAPd1qaSFUOkNSYqELJ4Zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_TGLrkNRFSEKwhGsLBOYSzw_5_3">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_3b9pYLI57U2CBSFmckSYmw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_m4t0f4hkSEuyO52FKYGr8g_5_9">10,611</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UBHriL6i-U6Bz3QKMBjg8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_yepHyhzwO06uF6Jp5fSu-Q_6_3">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UK6sekRvOEe_2GBgz560wQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_NcCfzexFyEuBzi8Aqs0mDw_6_9">1,993</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_fiLbapa0rkm1Wsy4sSa9Gw_7_3">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_-ea-KX8KWUiHPiNyinS0jw_7_9">12,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_fiUN8jXknE6iFLl2C9MozQ_8_3">15,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_9t2yf5DWS0u2gNUKIOb_og_8_9">15,476</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_ztbn6lVO5ECMI2XBAMp_Cw_9_3">84,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_W290GjzTPk6sV2S78vFFtw_9_6">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_MnJ03puxPUubSPMhIpL14A_9_9">84,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_j-5jcvWtPkWU5cOve1Ihkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_fRBYfweRDkuGwFDyut85WA_10_3">23,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Nx4QF2i8n024GoRDelaHcQ_10_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_RnW1ANi3jEeYrSPOZBRgkw_10_9">23,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_svxyRopoWUOrTxX2YHjehw_12_6">39,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_Bz2gXeB5hU6T-EBixS3n6g_12_9">39,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_yj1a0pkL10-SzH4LrUcE6w_13_3">164,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_uZGQsYcfnE6EAOK7oWXIRA_13_6">39,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="Tc_DxzzRJPu2kuhOx5nEhEpnQ_13_9">203,974</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4f658094_f34a_4301_a18b_bbf80e01c501"></a><a id="Tc_e0bfx6ZKaEOvOg3DgmK4BQ_1_2"></a><a id="Tc_cJfI1bU_60ydVEBu2GTVGg_1_8"></a><a id="Tc_fZ2D_Ix5pU66Yfi62Vk1dQ_2_0"></a><a id="Tc_5YUjYp8RaEu4QWuBlC7fsg_2_2"></a><a id="Tc_nYy-mf_zc0e0YOs9_JTiVw_2_5"></a><a id="Tc_MfxQtxTUK0mPxhHwQkiKOA_2_8"></a><a id="Tc_RUCuLWNTgkeZ8NhUoTkuAQ_3_0"></a><a id="Tc_yv2il3pE8U2FoazdRNP9Og_3_2"></a><a id="Tc_o_mPJ5WUg0OxHA-jIP6apA_3_5"></a><a id="Tc_CnjmOAO9NUuCMH8EwI5Dpw_3_6"></a><a id="Tc_PTv0PJL6DkqaeNYwoQw2Wg_3_8"></a><a id="Tc_nCiQv9ZdDUSbdZKp-uRfCw_4_0"></a><a id="Tc_ko8x6MUzcUatNsyj5H9COQ_4_6"></a><a id="Tc_b2lXJ8scekmLvtgyO_IvcA_5_0"></a><a id="Tc_ROu0Fhnjfku_PNpsvDXoPw_5_6"></a><a id="Tc_3ciWBXDucE64tnwm5L3dnA_6_0"></a><a id="Tc_m3n5h91PiUe1VmXo-QCqcg_6_6"></a><a id="Tc_uGar6ZAgBkajiUD-7wFDLg_7_0"></a><a id="Tc_EXFx7Jc2CkG9TUcTdPLIeA_7_6"></a><a id="Tc_I6NKex-EMEatAAKGdtWK1w_8_0"></a><a id="Tc_X7TUeCr9nk2Or_zT5YYSGA_8_6"></a><a id="Tc_rEiAG5Z5ZUuc5MTdIaMNsQ_9_0"></a><a id="Tc_nFe848RbCkaF1JRTBEH_YA_9_6"></a><a id="Tc_uGSWXV3XTEu3CzzzKewZjw_10_0"></a><a id="Tc_lEiY_mZ-8UCveGd84cXi2Q_11_0"></a><a id="Tc_l3jqhZ9f10eB_4RweT-f9A_11_2"></a><a id="Tc_Ui6-5TTvD0SK9Q2Tb7nSaw_11_5"></a><a id="Tc_ysRxonsDxkeNFy3hLtiq-Q_11_8"></a><a id="_b40296b1_a9b4_4c35_a3e1_f1ce502a10ea"></a><a id="Tc_vEfx4Y70wEa9BCGgfzFtNw_1_2"></a><a id="Tc_0mdmtLFKl0uy5OzmSVgYJQ_1_4"></a><a id="Tc_E2KO_O95EEuMUH5H1CI_5g_2_0"></a><a id="Tc_a9jP46rAtESfD-v4S8A1aQ_2_2"></a><a id="Tc_c4gJFWjsWECyJAUYWlby7g_2_4"></a><a id="Tc_ChMl-nLHZEqla9df-ZLQaA_3_0"></a><a id="Tc_QxVAmjkn6U6zNsh9sO774A_3_2"></a><a id="Tc_IWM1n3W39U6S-UzFX2FFJQ_4_0"></a><a id="Tc_eoZIvDBCTkq-Zam6eVQdDQ_4_2"></a><a id="Tc_epi5svcRekehodUNQgNwJg_5_0"></a><a id="Tc_sbhRLtNA5E-JBz93IP6tfg_5_2"></a><a id="Tc_zTUwaVAlNkGOukehYLtv8w_6_0"></a><a id="Tc_WnnIQqlX7kCybtd8_uJNcQ_6_2"></a><a id="Tc_pcIHIopllke2gN4dyLlyUw_7_0"></a><a id="Tc_PjQtvi9eWkajee3U9361ZQ_7_2"></a><a id="_15da807c_e84a_4fbc_bd06_d1f32be1ced8"></a><a id="Tc_XP2UqqkpDU2TBDYC_Yz9cg_1_2"></a><a id="Tc_O9kWi-yeDk6tAHGLMW7cCg_1_8"></a><a id="Tc_WZ2hjG_KDk2CuASCXbss-Q_1_10"></a><a id="Tc_YubhPuglSEKe5u60zJTdhw_2_0"></a><a id="Tc_GTcFCLGdKEemG-a1tMcB2g_2_2"></a><a id="Tc_tb2hF4gpDkSdv4yKYIrk-g_2_4"></a><a id="Tc_hTfG7YNba0SJ7gM1HoGevw_2_6"></a><a id="Tc_yjUb6EvIwU-Zsc5E9E8oDA_2_8"></a><a id="Tc_RiSJbESh_0GW6VNTRS0S3Q_2_10"></a><a id="Tc_g6TsF_y1Y0Kn2X_zago8bA_3_0"></a><a id="Tc_Yr4MyrrPbkG0UGEmAEJTDQ_3_4"></a><a id="Tc_8BwNOa_UTE2IOFks8MJRpw_3_6"></a><a id="Tc_EqLY7C7ov0iP1D_zexmvfw_3_10"></a><a id="Tc_0TDeKvN2BU-zdmnbQPKiiw_4_0"></a><a id="Tc_yXcTE4-ctkqeDgXN4Mv0kQ_4_4"></a><a id="Tc_LkjauZVOpEyH8kP9eDLmUw_4_6"></a><a id="Tc_-OysApNzU0WwmCG70gWMcg_4_10"></a><a id="Tc_1CzKwW8U9kuHSHuvJ5LQQw_5_0"></a><a id="Tc_eubHI7weGE-FWC1L6IZzGg_5_6"></a><a id="Tc_NdZs3Q_dokKWQOWhvzjFnw_5_10"></a><a id="Tc_IajirINI9U6er2NV9plzRw_6_0"></a><a id="Tc_lcDR7D_vQ0aD7_UFDfPqDA_6_10"></a><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont4" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont5"><ix:continuation id="Tb_GnsCzGj9q0KbYbHqKAGjPg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Z9YkJw2n8E-yk3Qt_1NPmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_vOUZFhbgNkSxeyOCXCyu5w_3_3">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_w6jktUReSU6j4r6UpAQFPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_V3tPP-MYzEazcJjNDri6zw_3_9">6,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_u1kddxNyJUmK6bKY3LELxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_YH0S8aA09kG8wQzBtGg_pw_4_3">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bssbHLSzMUK2YenLYRNChw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_7XkkYHZryEW-GOwhLvRIVA_4_9">8,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_Odw8LxLv6U6EdXprDOfRGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_RYhTbR9z0ESn_K1dAfe4hQ_5_3">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_j2yRaHhWpkeOdK0kZMluwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Vac0QpJRWEC9Z1cqIU4LFg_5_9">10,611</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_no3I2F75LU6zm401jb81jQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_JgKiFtFXnUm7DJQMpnNxkg_6_3">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_B4SIjbwX80epv50y8th_fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_yDQE2htO70aJdfAinX23HQ_6_9">1,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_TPmSEZHn3kuue57QJjzxuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_9NpRPnU5Iku5ToLtPKVPsg_7_3">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_L9vZuhgzoEacaBLEGmOqKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_j53OvK_EukGOsrVn2BY2Vw_7_9">12,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_gjy8I8__kk2j4tbbvWuraA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_jV6ufyDVNE6FE7AuvAyzYA_8_3">15,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_FovQYveUg0eH1LzMQqa8QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_KvKmOz3VnUqGrNgD09VlXg_8_9">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_cea7kamFTU22C8ALOM0GOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_O2Xeipimc02SYWgixqSFIQ_9_3">84,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_SpKOv8seVEehXwRiUfpyGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_8O1OfyNAQ0OdcDKA3q_9_w_9_9">84,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Zc1cKHOFuE287fqlH5Vrlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_dAb14nOJmk-C69aQ5klX8g_10_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_cJo1v1yvJ0KPv470OFqLQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_LWwuQYmga0C5kjJvt5Sdkw_10_6">3,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Ud_kLyd8f0OBg8UKavOv8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_jndfN-5mrEmmTlHQ715fdA_10_9">23,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_eC-cr6C3UUGyTI_rFnutzw_11_3">160,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_6Fn8rgK_QkOeGFaU4zLevw_11_6">3,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_AfpA9sBfb02V1M4NdFyU8w_11_9">164,006</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:continuation id="Group_DqtoymI-ok6sSmCYeH7lqg_2"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_E0LxqvMzOk2zspV-PNr1NQ">17.81</ix:nonFraction> exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_TWZQrttP30i8mhrs6XTBqg_3_4">4,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_YE__CuwfiUGBUMHLSDjtfA">20.23</ix:nonFraction> exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_OJZ3govFBUOnlo8cUeGTJQ_4_4">5,190</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_FKBnwMlYQUS1Agaleoy3Kw">0.41</ix:nonFraction> exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Cxsyi2g5yEaeIqyi3-QfoQ_5_4">36,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_T6kb4kX_x0S9ZgRG1dJLcA">2.03</ix:nonFraction> exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_yjQgM9WUDUKvCOvjttQ77Q_6_4">2,824,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_yBhgCZo2jEK2TrrxlFuE0w_7_4">2,871,084</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercises</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gOhsWZRlH0KRDlxD3f1Msw_3_2">4,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities" scale="0" id="Tc_XkZ5aUI9J0GQ9SbeABUdFg_3_8">4,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_vmALJGT1cU68IHIbOt1eEA_4_2">5,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities" scale="0" id="Tc_2NzHHHkyiESXMO2_DJSbEA_4_8">5,190</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_6geRXd70wk2F983Ymo0oQQ_5_2">36,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightWarrantsExercised" scale="0" id="Tc_fPBQUzeM_UOQ6OluHCTJAw_5_4">11,123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities" scale="0" id="Tc_yUHSzdhEmUmM0xHN7bgCvg_5_8">25,584</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_2dFlqhAJZESHp00KQ_b-dQ_6_2">2,824,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightWarrantsExercised" scale="0" id="Tc_WFsWRxkyxUit59vhYonG1w_6_4">4,771,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" scale="0" id="Tc_BUcs-UazBkCm_4EUNpQADQ_6_6">2,595,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities" scale="0" id="Tc_mWNzBw7FUU6rdR0o3s1OOA_6_8">649,109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;A-5 and A-6 warrants were retired at the Closing Date as they were out-of-the money. The Series&#160;B and B-3 warrants were net-converted to shares of Legacy TriSalus Common Stock, then exchanged for shares of our Common Stock at the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The rights associated with the Legacy TriSalus Preferred Stock are described in our December&#160;31, 2022, financial statements included in MTAC&#8217;s definitive proxy statement filed with the SEC on July&#160;18, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">October&#160;2022 Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In early October&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" scale="0" id="Narr_PfH040V_YU2t8ZDx5Bm3Eg">706,243</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vVJ6K-dKOUaqNkzDlxnlNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_61d28YQSqUadGbHDoG-i9g">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" scale="3" id="Narr_AoCPjPyTkEGQN4Z3lFXj6w">9,755</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds (the &#8220;B-2 Preferred Stock Financing&#8221;). For each share sold, we also issued a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_WTDsxf3WwEGrIUfkK99-sg">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock (with total warrants issued being for </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ly_yjlxk9kaGKN3_pao1QA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_edL1npK5WUmaKwB0MLl2Ig">2,824,974</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock) with a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_dsiZTjMLTEKnTS_3xuMRbA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" scale="0" id="Narr_Nr4ITjTOTEyOmk-vPuifOg">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share. The B-2 Preferred Stock Financing included, at our audit committee&#8217;s option, a second tranche for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_bJ0vellW1E6kWX7Xb3ygbw">518,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_h5LGBug5xEulPhmhI2l-qA">7,347</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_wobYTtCwpU6MS4kEO9U9KA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" scale="3" id="Narr_i5f_apwHTkS88ID1LVT4qA">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_ho0gRHtjKk2phGSmW1ua5Q">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" scale="0" id="Narr_XaMxELzO2kiMkUIiiHUafA">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TJoHaLkdN0KmClA53sXJgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr__JvzdV40XkyN93mZdIMOIw">2,075,417</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_tv_b59peZUeE5WTNhEZ6vA">306,053</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_VO7dkNeSY0uNJU4Qvn8qyQ">4,334</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" scale="0" id="Narr_0qmxiEC8YEGF3lQbR6AIeQ">353,121</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" scale="3" id="Narr_6qNjjnK56UOqboNQKzN5YA">5,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_pML8Hm70h0-23rXFaRAVuw">eight</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" scale="0" id="Narr_d7kJnMP1xESkKhn9qdaCWA">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gIaBMU-_LU6xAQZ8ZjYntA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_35IAOr7nXkCj3AFJU5hr-g">2,448,428</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock to immediately convert to common stock and any warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont5" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont6"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_ZmJzDgf-D0-BbNQlElviCw">1.06</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_HcsVgL-vQUKHWWQJbEt1dw">0.33</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_EX9XrSEePEuRJZaejLu5OA">0.37</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_uqATAjW8CkODtxCkaygPAw">0.34</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_f9wvkHkvWU2wkE7cszAh1g">0.37</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_gdi9OYMZZUODgW24EUrltw">0.42</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_A4zdAZkQj0uQaTHp7FSzMw">0.26</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_1K2F4BdhjUCHcuueoK4-Pg">0.30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;set to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_t-Q-zDFDiEiOafiKMY4XRg">0.35</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_UAbun1yjv06m2kEmsHBFXQ">0.05</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_ACacmRC9sEGDzLC7ckSwpg">1.155</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_-H1ZkjNyHEqWJ-mKlS07cw">1.173</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_5aq-VkRCIk-eD3JmBQrOuw">1.162</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_qBz5tY8hIEKc6izKdbjBzw">1.165</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_xA-qm3JiuUattMeHy-myog">1.189</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_Td7QR_vLG0afeMouNEXz1g">1.190</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_J1J1OwGNv0GBPhLZ6qyLlg">1.154</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_55t39TGWKUyQotf--AkhEw">1.167</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_dMpxh7pZPEaF5bIdEWpKCA">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_sg2e0oI40EWinGEE7it-Jw">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_gKTiACbSCUajmar_Jm_ALg" decimals="1" format="ixt:numdotdecimal" name="tlsi:PreferredStockConversionPercentageOfOutstandingShares" scale="0" id="Narr_Qspke79Uk0S3h7e2383uSg">99.2</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;11), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other holders who do not provide services. As such, the Company concluded the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The warrants to purchase Series&#160;B-3 preferred stock (&#8220;Series&#160;B-3 Warrants&#8221;) represent freestanding financial instruments that should be recognized as a liability as we are required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Tranche Liability&#8221;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of our control, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the accompanying Condensed Consolidated Balance Sheets at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">2023 Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In January&#160;through September&#160;2023, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_5abH1QNeh0GMJn5kZVJQ3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_Ot5SKhIv9UC_2FrjsvmibQ">4,771,642</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_mk3BivT8k0SRnXR4ccWB5g">9,630</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. In addition, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" scale="3" id="Narr_ywY09sKJbEOIABjnWcFUbQ">25,409</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> of warrant liabilities was transferred to Series&#160;B-3 preferred stock. Also, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightWarrantsExercised" scale="0" id="Narr_8y_aWkQGIEa2_sDu8FGV1Q">11,123</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock exercised their purchase rights, for proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_PtZTKga030yglatR7g-hYw">4</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, plus the transfer of warrant liabilities of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" scale="3" id="Narr_909IjRxLLEmGeKWgpKY8dw">106</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to Series&#160;B preferred stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we effectuated closings (&#8220;Second Tranche Closings&#8221;) of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_b4UEWJ203EyKkVLRGkEwkg">207,541</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_8Jq5kxQISkum-Rv6Ika4FA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_YyMVlzQB_E-Fm7IkmXZEyw">830,167</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_GF-K_2uVu02v02J0fL-JeQ" decimals="0" format="ixt:numdotdecimal" name="tlsi:PreferredStockPercentageOfSharesCommitted" scale="0" id="Narr_346lrS0RTUGeXOUE3FLjHA">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_Zwx8xuxh_0Ot6JUVRz4wfQ">2,932</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, net of execution costs, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_dPMQ0sCBVEiQTmdjstB91Q">17,656</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_cg1NyxPfCkWCdJlnSrnvrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_MeN7KA3HtkqxeMj9WWpYDA">70,624</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_Gua6mOkHGkCw5XshKgtrUg">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock&#160;were adjusted. The conversion prices were further adjusted as a result of the June&#160;2023 exercise of a portion of the second tranche of the B-2 Preferred Stock Financing described below, which represent the conversion prices in effect on the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2023, we effectuated closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_vaE354unmEaZ9mHmUw_irA">257,779</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_y-7dsjtGUkKm-ryLp0va2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_KxzEtmzToU6o8tf0u9fXOg">1,031,116</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_II1Zn2a3G0K5tjXGFPo3uw" decimals="1" format="ixt:numdotdecimal" name="tlsi:PreferredStockPercentageOfSharesCommitted" scale="0" id="Narr_thuaqYVbJEGBrYsbB2gMyw">49.7</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e8066985_14ef_413c_9409_28119b8a6777"></a><a id="Tc_HfBYr_Dpk0mTcqQoGC62ig_1_2"></a><a id="Tc_1eXsDDJo-EuLHnqljZtfMA_2_2"></a><a id="Tc_g1p50DYfCEaWnZ32rtKIiQ_3_0"></a><a id="Tc_c7b5mpKG1kehjP2Td3CB-Q_3_2"></a><a id="Tc_MRph9XDuEEqF0weyezMrqQ_4_0"></a><a id="Tc_Ka3t96K5H02kYM772uBUbw_4_2"></a><a id="Tc_tJdKaNJn0k6P-m0CAd_4DQ_5_0"></a><a id="Tc_ZNhHkeAyAEqmQ3eVlHEKgw_5_2"></a><a id="Tc_7RXhYY0eDE2EWgwXkxf7NA_6_0"></a><a id="Tc_IW1tTcPC-Umv78QT7T6itA_6_2"></a><a id="Tc_vitC9IiMkkKAC7dqk8NHFQ_7_0"></a><a id="Tc_VpBy7rpg6EaeOI-mHwkcMQ_7_3"></a><a id="Tc_aEOuzEI1BUOM-L8mxal9gg_8_0"></a><a id="Tc_G-ykCAFE3EGMEeEmNJa8Mw_8_3"></a><a id="Tc_tIHDL_iwQUaXI43C_NCzUw_9_0"></a><a id="Tc_PjarzEIR10mjN0Sz7-1zbA_9_3"></a><a id="Tc_ERSsqOAdl06-884bQiTLNg_10_0"></a><a id="Tc_-eAER-NarkGuXyxGhL_D_A_10_3"></a><a id="Tc_KUzbAgWz0Uujb80njV2poQ_11_0"></a><a id="Tc_AraPAi62sU2uROi3QbP8TQ_11_3"></a><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont6" continuedAt="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont7"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_q_ETKKHzzU-TI2ZI1890WQ">3,650</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_oyvSYvbvAEiXM7lUC0qRfQ">165,967</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FcaQ3gGcXUGxDiS7u2MNxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_SLJIjfJv8E29NKzTjzWHTQ">663,868</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_c9wkNC3VQkuURuapANuzIg">2,350</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the closings of a portion of the second tranche of the B-2&#160;Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_qQ8jM6oBMUipeavnAdQEeg">38.84</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_G3NMckn90EGFWV-Qm-qizw">12.14</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_veWaagNasESe9O6X9KFOfw">13.36</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_9OcYTcIJi0OwFGqMTdELqA">12.55</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_-5V5eGUeL0aYjDdi6zL2Tg">13.36</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_XjOb6fy2YECOzlYjgyhjgQ">14.97</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_CxWoxhjRY0ePHhttDrSRiw">9.71</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_aP4JwDelqEuFSfVdFwEtoA">10.93</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_RP2Wt6GS9EmJAp_UvElmyw">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and Series&#160;B-3 preferred stock </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_FYTFxS6HVEyPP9JvTVVsKg">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_TmJsZRrm8EWxo2qvVrQ75A">1.275</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_CM29zq2kH0eRFSUVI5K1Vg">1.290</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_4F3OyeT3hEi2SovYkCRCpA">1.303</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_k8YbsRYkBUqnb49D5U44OQ">1.277</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_ZTU8piC3EkWVuiYli7dBtg">1.333</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_k8IRP2fWGkq1rinsGKiikw">1.351</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_xfEgKr5pE0mMtgN0lT0_Pw">1.250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_ndRbrvIFdEKyNkizrLhIQA">1.296</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_8Uyxbu0bK0m1Kns4e1p7Zw">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_Ne-ISMP7_EiWi9aTno9_fw">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;to 1 for Series&#160;B-3 preferred stock. These conversion prices remained in effect at the Closing Date. Any portion of the Series&#160;B-3 Warrants that remained unexercised at the time the Business Combination is consummated were automatically net settled for shares of Legacy TriSalus Common Stock immediately prior to the closing of the Business Combination (see Note&#160;3) and exchanged into shares of our Common Stock at the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#8217;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. The fair value of the Series&#160;B-3 Warrants as of August&#160;10, 2023, was determined solely using the scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Group_Q8TBgG2ARUOAI-LluY2qDQ" escape="true"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 preferred stock fair value per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_ljGYthGmzESwFy_58hlCQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_ath2thKzpkmfXFlmA7n3mA_3_3">14.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 preferred stock exercise price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputExerciseSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_HEqBbWgIskKT23W1Znx3WA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_fLSl2Nw6OUOcIlxtMbLhOg_4_3">14.16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 preferred stock fair value per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_o6rFJS2RUEmPlThbUoOgeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_V_rF3WVvn0GU3dqNnExs1g_5_3">3.24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrants exercise price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_ValuationTechniqueAxis_tlsi_BlackScholesModelMember_Bc0NkOT9wEihH_2yOvMkbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_WiyLTzbqzkuRGQ3pulocPA_6_3">2.03</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_YfJXZ7psnU-0gET12ACfMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_P5bLVMnSDkmE0361szcl3g">50.0</ix:nonFraction>%<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1gIIWYB_SU-WziuVHJK-DA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_9nTvzqRkTE6CsdRe88If0w">65.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_D-d-uo6wjU6j8DmtuRLnlQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_AaWVB7XZ60es5p4JW3YKpw">4.0</ix:nonFraction>%<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_yQOpRc5_AUSFptkZf40mhw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_ntUYKftaG0aVsm-lwqRrUQ">4.7</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 Tranche Liability expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_bjN6UWcFCUm13QmQZ585Iw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_pEmSfZkCTkqwKAB1eL-gyw">0.2</ix:nonFraction><span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_gJ1cZLTqKkOyAt34WAIZFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_BlVjsn_GiUeiTe6NC_NgrA">0.4</ix:nonFraction> years</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrants expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_jRIu7P7O9kCs7H6PMq9I4A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_eW2W0fp7RUGFWsn49xnTDw">5.8</ix:nonFraction><span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_bGF1dz-8s06ozP-Wejxjuw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_l8hIJ1xbFkGL9Pfiqq1DrA">6.0</ix:nonFraction> years</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the underlying shares of Series&#160;B-2 preferred stock and the Series&#160;B-3 Warrants used in these models were derived from estimates of the Company&#8217;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#8217;s forecasted 2023 and</span><span style="font-family:'Times New Roman','Times','serif';"> 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_UBk3dK2cpk-EifzkXC7RPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_OVLjfOGEGkCZwsivHrqN7w">9.31</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_xf9JNaLZckaWeYpqmrjafw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_DyNcmHSPy0i2fRpsP0GUcg">10.93</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, as of August&#160;10, 2023, and December&#160;31, 2022, respectively, which is based upon the enterprise value stated in the Merger Agreement of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ReverseRecapitalizationStockValueIfConvertedAmount" scale="3" id="Narr_EACFwOGaWk2HdYPIH3eg5A">220,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, and for the December&#160;31, 2022 valuation, discounted at </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember__2jiobm5aUuVXVU4BFopyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_WNYz1xJ6l0m-YIiofFoEig">30</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> from the expected Business Combination Closing Date. The Business Combination scenario as of August&#160;10, 2023, and December&#160;31, 2022, assumed there would be no additional exercises of the second and third tranches, and thus no value was assigned to the outstanding tranche rights and obligations, as the Company would not exercise its right to call the remaining second tranche.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrant Liabilities at issuance resulting from the completion of the Second Tranche Closings was estimated at </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2023_To_6_1_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_LqmQyedzNEqB45yzduiYgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Narr_cShqI7bPDUClzvqINZt4nQ">14,701</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. The excess of the warrant liability&#8217;s fair value compared to the proceeds received in the Second Tranche Closings resulted in a charge to loss on equity issuance in the Condensed Consolidated statements of operations of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Narr_m1sIOlZ7wkilsdZwBq8t8Q">4,171</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the nine&#160;months ended September&#160;30, 2023.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qpFZA5LJL0O_uDqNOzuSWA_cont7"></ix:continuation><a id="_d5f28f5b_a3c3_4fec_92e1_f4382349063f"></a><a id="Tc_SHkGJd0r1EuhKOJaqdmgIQ_1_2"></a><a id="Tc_qLclEw9G6kOkXvmKmyK5LQ_2_2"></a><a id="Tc_jNXM6eysxUCTYjhGoSKH6Q_2_4"></a><a id="Tc_bR6lmNlhtkaVUAd8TZ2fqA_3_0"></a><a id="Tc_ijHBLGKUQESrBD3jVaXOZw_4_0"></a><a id="Tc_1WzG3GHSCkGnNT34l3qQpw_4_2"></a><a id="Tc_SJ9-CewabUucAGoFgXd-wg_5_0"></a><a id="Tc_DOuyPjMdwECM2vG3v9vvtw_5_4"></a><a id="Tc_S43jLrSaq024KZDE-xW8zA_6_0"></a><a id="Tc_Jo99gGQAdUW5kRAB37oekw_6_4"></a><a id="Tc_b36sDkC2UkGOcwvP8uHN4g_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_K8HrkewmgUeCN0A2TMVPCA" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(12)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Loss per Share</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the nine-month periods ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb__mplDanh3UaJWPoSasAOcA" escape="true"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_M4z_mBalEE6paS3q3L0Vjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8mNLeXVCSkKOt1yeuZyvtw_3_2">4,015,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_bEObA7CvVkWwdUC6J69fXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_lJUCCvVLqkCEH_xOm1ROxw_3_4">11,624,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantMember_OZsWLbb_CUea_sEX2DVygw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FFZwv3ak7Eu1LWmz5QKdWw_4_4">46,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantMember_nusetr3QVEyFrcC8HvKhQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Ml6DJDEkzkiTSNy0jkkWhA_5_2">14,266,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_LyZj3LV5jUiUFferyoGtMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_s-DMPR2Sb0uIMjoSTV0URA_6_2">184,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Hdz3D5qVJE2TxNezwlDqVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_S3lXxAUbyU6Z-PRgHBIf8g_7_2">2,632,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RlRaDCvakUCj5EZrtYDWeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5rBsdUzLeUeJ-XhcfK7CdA_7_4">1,710,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_asvotkr09E-kTTsTiBJhVw_8_2">21,097,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Y6TgxjckLUyLjWtsyypTHw_8_4">13,381,126</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;9, the triggering of the anti-dilution feature resulting from the closing of the second tranche of the Initial Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Narr_T49qL1FH9kemF9p8GEXyPA">2,981</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common stockholders reflected in our unaudited Condensed Consolidated Statements of Operations for the nine&#160;months ended September&#160;30, 2023. The deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt:numdotdecimal" name="tlsi:IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" scale="0" id="Narr_HigrmBU_TUSxMaZL2NzkTA">0.72</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the nine&#160;months ended September&#160;30, 2023.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_bkW4gfdUjk6OhcACWzo_NQ" continuedAt="Tb_bkW4gfdUjk6OhcACWzo_NQ_cont1" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(13)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Share-Based Compensation</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We currently maintain the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which our Board of Directors and stockholders approved in connection with the Business Combination for purposes of granting equity-based incentive awards to our employees and consultants, including our executive officers and directors. Prior to the Business Combination, TriSalus granted equity incentive awards under the 2009 Amended and Restated Equity Incentive Plan (the &#8220;2009 Plan&#8221;). The 2009 Plan will not be used following the Business Combination. However, any awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan and the applicable award agreement. Historically, we have used options as an incentive for long-term compensation to our executive officers because options allow our executive officers to realize value from this form of equity compensation only if the value of the underlying equity securities increase relative to the option&#8217;s exercise price, which exercise price is set at the fair market value of the underlying equity securities on the grant date.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Q1xHabGlOEiklbNu97DQDQ_1_2"></a><a id="Tc_qr3jJDSSKk6YW0dy_ghOTA_2_2"></a><a id="Tc_3M0qB4PCOkekfBOegFO5kQ_2_4"></a><a id="Tc_RIwih7rKG0e1jH5bWvoqHw_2_6"></a><a id="Tc_jgvD1W6cxkChk28sLahrgA_3_0"></a><a id="Tc_brNu0m20QESesrcRlMtEVA_3_6"></a><a id="Tc_EehlYbDSMU-GTwV7U0Eoyg_4_0"></a><a id="Tc_YS-FKZmvZEWuJnPuuuB2gw_5_0"></a><ix:continuation id="Tb_bkW4gfdUjk6OhcACWzo_NQ_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Under the 2023 Plan, the Company&#8217;s Board may grant equity-based incentive awards to employees, consultants and other service providers of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. Initially, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_8_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_eJO2ISwMrkCXvzy18ph9pg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ZhASKkQSIEiPaCIqGmXyOg">5,585,008</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares were authorized under the 2023 Plan. In addition, the share reserve will automatically increase on January&#160;1 of each&#160;year for a period of </span><span style="-sec-ix-hidden:Hidden_MGlu3JgwP0qQ1n5yi83_7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10&#160;years</span></span><span style="font-family:'Times New Roman','Times','serif';">, commencing on January&#160;1, 2024, and ending on January&#160;1, 2033, in an amount equal to (1)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_uj5I6WUTUkaK0xF0RTcbcQ" decimals="0" format="ixt-sec:numwordsen" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" scale="0" id="Narr_MHkYA866MkiqMbPFHU7E2g">five</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;percent of the total number of shares of the fully diluted Common Stock determined on December&#160;31 of the preceding&#160;year, or (2)&#160;a lesser number of shares of Common Stock determined by our Board prior to January&#160;1 of a given&#160;year. During the nine&#160;months ended September&#160;30, 2023, we granted </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_6AxkZysWl0WQQRPt7qOOyg">1,179,480</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> options with a weighted average fair value of $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_UDJ6wP5OC06029JulO2sTA">2.66</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_FFuLUN7Gq0ufn38n2YzhHw">184,018</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> restricted stock units with a weighted average fair value of $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_-DRiWtJty0yYzbpgH8XDag">2.43</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. As of September&#160;30, 2023, the balances under the </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:ShareBasedCompensationArrangementNumberOfPlans" scale="0" id="Narr_edSSpImG_kysBzP0o_O9kg">two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> plans are below.</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="Tb_jr7TAwLfLEu81W9rZS1FsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available for Issue</b></p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2009 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Tc_x5NCLdc8GkSNmCEpyvQItw_3_2">1,915,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" scale="0" id="Tc_3WAHgaLYBUuP3TF5piT1gw_3_4">1,915,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Tc_MMlHZQjkpUm8FUn61oD22g_4_2">5,585,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" scale="0" id="Tc_Bdi6rV_P806gqGFtCGKuag_4_4">900,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_m1YrA3Tx-0uD4IqhyE5gOA_4_6">4,684,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Tc_CdbTFNpLSECYkChIoFrBcA_5_2">7,500,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" scale="0" id="Tc_OCoCPvAa40iH4B6Q5snJLQ_5_4">2,816,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_7c9dOCO5c0S32-R8n5ZKuQ_5_6">4,684,508</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had unrecognized compensation expense of $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_78jR3Opgy0-_dTAcTV-mtA">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_zNMTOZzMMkWavAix_LUtMw">337</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively, for options and RSUs granted under the 2009 Plan, and $</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_ESYuKRZNCE-vSGLqtPWhqA">3,002</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for options granted under the 2023 Plan.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Board, or a duly authorized committee thereof, administers the 2023 Plan. Our Board may also delegate to one or more of our officers the authority to, among other things, (1)&#160;designate employees (other than officers) to receive specified stock awards and (2)&#160;determine the number of shares subject to such stock awards. Under the 2023 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value and exercise price, and the provisions of each stock award, including the exercise period and the vesting schedule applicable to a stock award, subject to the limitations of the 2023 Plan.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Stock options are granted with an exercise price no less than </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jdMJ3tTPVki2UbZF3EKNtw" decimals="0" format="ixt:numdotdecimal" name="tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" scale="0" id="Narr_Ac_BmWJCdEWbsDNmTjw7Mw">100</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">% of the estimated fair value of a share of Common Stock at the date of grant.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:AssetAcquisitionTextBlock" id="Tb_xteGQAPQbESvIxATJtuYAQ" continuedAt="Tb_xteGQAPQbESvIxATJtuYAQ_cont1" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(14)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dynavax Purchase</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#8220;Dynavax&#8221;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#8220;IPR&amp;D&#8221;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#8220;TLR9&#8221;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells (&#8220;MDSCs&#8221;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" id="Narr_3g57X8u49UuMBakeMnaArw">9,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> that was split into two payments (</span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_rezUy1wqukqJitR5qGefCQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetAcquisition" scale="3" id="Narr_BjTmksDj_UaYrvEstc8khQ">5,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3-ZqQhxZkGHRMDML9MFaQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetAcquisition" scale="3" id="Narr_CFBFE4mRR0KqvG0N0JlorQ">4,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The milestone payments range from </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_BhA3ZSO6j0m1LCmgkuwIQw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetAcquisitionMilestoneAmount" scale="3" id="Narr_Fqla51dZkUWu1gRiAfWcXQ">1,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RCz63iBnwEquUzALofbf-g" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetAcquisitionMilestoneAmount" scale="3" id="Narr_pPn93N07KkKPHUgwrGXfXw">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, triggered by development achievements for each of up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:AssetAcquisitionNumberOfCommercialMilestones" scale="0" id="Narr_MVWRaeTLpUyY2TNbWDQ3MA">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> indications. The development milestone payments cannot exceed </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMaximumMilestoneAmount" scale="3" id="Narr_XEZOOV2dsUGxe2Mlx0yLZA">170,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. We have made milestone payments of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_9_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_wJYhKnteSUeKXfPhHtBzkw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentsForAssetAcquisitionMilestoneAmount" scale="3" id="Narr_acrcWRl6oEaWlA-8mIQjrg">1,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in September&#160;2021, after initiating our clinical study of uveal melanoma liver metastases, June&#160;2022, after initiating our clinical study for primary liver tumors, and August&#160;2023, after initiating our clinical study for pancreatic cancer.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, we will have to pay up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:AssetAcquisitionNumberOfCommercialMilestones" scale="0" id="Narr_btYxmdejC0SfqOfKRkcdHw">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> commercial milestones, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3VDT5dIz0yqR_H8-7yMPQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMilestoneAmount" scale="3" id="Narr_uuKLMFpudUqAfu1LC6XYvw">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> upon first commercial sale of the product; </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMilestoneAmount" scale="3" id="Narr_JhRVbMIFKUuq5WAqJbGlew">20,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionSalesMilestone" scale="3" id="Narr_FofJDZWDukuTxNVWQCOSng">250,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales; </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMilestoneAmount" scale="3" id="Narr_pqtHWmgTOEiqc8h5Z1Rs7w">20,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionSalesMilestone" scale="3" id="Narr_iopQGOyLnkegfgGiZ843Rw">500,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales; and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMilestoneAmount" scale="3" id="Narr_Z3ld7uM-zkGmrbWIOJ5xOw">30,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionSalesMilestone" scale="3" id="Narr_pbaJ7OCFW0qbRMiW1K7aPQ">1,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales. In aggregate, the commercial milestones shall not exceed </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_1pk8tgoJY0SRZ1kWItulfQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionMaximumMilestoneAmount" scale="3" id="Narr_WMEuGGoKrkOSccHFdZdpDA">80,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xteGQAPQbESvIxATJtuYAQ_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We will also pay annual royalties at the rate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="0" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" scale="0" id="Narr_uOZ5LPv1I0q98YC-H88XuA">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> for aggregate annual net sales less than or equal to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionRoyaltiesSalesThresholdAmount" scale="3" id="Narr_QvLnnJgmX0mwCfST0wPgrg">1,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw" decimals="0" format="ixt:numdotdecimal" name="tlsi:AssetAcquisitionRoyaltyPercentageOverThresholdAmount" scale="0" id="Narr_GsWZQDoBakOAXQf1Zj87jw">12</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> for aggregate annual net sales above that amount.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We record the milestone payments in R&amp;D expense when they are incurred. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb__qkc_NeWUU-xhlDkEjC0gw" escape="true"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(15)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commitments and Contingencies</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registrations and will indemnify the parties thereto against certain liabilities related to such registrations. The Company&#8217;s registration obligations under the Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto on the date that such party no longer holds any Registrable Securities (as defined in the Amended and Restated Registration Rights Agreement). The Amended and Restated Registration Rights Agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2d951acd_7895_4f3a_ab18_ed0b3ae984c0"></a><a id="TriAudReportofIndependentRegisteredPubli"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TriSalus Life Sciences,&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Opinion on the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of TriSalus Life Sciences,&#160;Inc. and subsidiaries (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, stockholders&#8217; deficit, and cash flows for the&#160;years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis for Opinion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ KPMG LLP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denver, Colorado</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">April 21, 2023, except for Note 2a, as to which the date is December 14, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5910f6f1_3fa3_4655_85af_0e270f6c73d0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="TriAudCONSOLIDATEDBALANCESHEETS_592299"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><a id="_a64fe169_52c6_4344_b222_60503267a5a0"></a><a id="Tc_zYiIc8W_IUCzx71xKOjGaw_1_2"></a><a id="Tc_3LOcTMCd3Eu3uXmXrVm38Q_1_5"></a><a id="Tc_KmdoGBK7zka-XO4KMCuKQw_2_0"></a><a id="Tc_ZLoQGd_eWUmfJdRXuSR6-A_3_0"></a><a id="Tc_z5VpXXMQqE6sCKP_n3Gd2g_4_0"></a><a id="Tc_S9RcMjCe3E-aahqWJ0culw_4_2"></a><a id="Tc_ymzGCeGyVUedKYgQRhBO-Q_4_5"></a><a id="Tc_HlJSSSbTNEGQ1KGgPutVpw_5_0"></a><a id="Tc_uxktoLstbUOX7hHsi2VqEQ_6_0"></a><a id="Tc_eOfIKWiUe0e3NVvPg3S4yg_7_0"></a><a id="Tc_uNbeEQcFDUKWYFMQH9Ci0Q_8_0"></a><a id="Tc_pGKZ3KmgFkuGbIIanjkAtQ_9_0"></a><a id="Tc_H8hLZ9zoO02yjWJ5zpdRvw_10_0"></a><a id="Tc_Aqh69ViKxUagkCp3efiOFA_10_6"></a><a id="Tc_C40-BF1YkkSXxRry9KRhgQ_11_0"></a><a id="Tc_ImxxfsO5aUekFeAbbbAlAw_12_0"></a><a id="Tc_mTMugBllnE2JHpBAA6U69A_13_0"></a><a id="Tc_aEY4fo6eBkCVt_c-iD2Y9w_13_2"></a><a id="Tc_IYaFLo4LPUGgLMIzv6rKdw_13_5"></a><a id="Tc_-g5EsNv32EKbV41Otpiilg_14_0"></a><a id="Tc_PVWetpMt10mbJFR1HxQwEA_15_0"></a><a id="Tc_krFDrT9YgkylomSDpGFPeg_16_0"></a><a id="Tc_wIBIWtyZMkaYE3QSZM6uyQ_16_2"></a><a id="Tc_thKmSWA4OUm_wPPCENk9FQ_16_5"></a><a id="Tc_P_q3Konk8kCc8iul1PH90g_17_0"></a><a id="Tc_SyWWl4_u7k6VABpsED1jWA_18_0"></a><a id="Tc_HDd6XQ6C0kKYjtEWRzCYaQ_18_6"></a><a id="Tc_ontcX4kerEO8pbKmO1nJuA_19_0"></a><a id="Tc_jfn0RteGfkC1Kts1Pl_dMA_19_6"></a><a id="Tc_m-l2d0k8GEi5WmqNsPcqCg_20_0"></a><a id="Tc_pN_PqT9PZU6RLfYoPRnTbg_20_6"></a><a id="Tc_RnKw52ryjUa0G_k8NEjo1A_21_0"></a><a id="Tc_WwArlFopO0esxu-EMFXuDA_22_0"></a><a id="Tc_rzHTvljhmEK1yGHtPhATnw_23_0"></a><a id="Tc_iDtB6GKIMEKtj-9BLfFBgg_23_6"></a><a id="Tc_MOTVHAYN1kyQ4VEnJrglhw_24_0"></a><a id="Tc_FOjVXuyjHUCzE2_EtXn5IA_25_0"></a><a id="Tc_wGpPRBtiCUiqyrAwcv4Rcg_26_0"></a><a id="Tc_4JEt5shCO0CO5g6YUZZSzw_27_0"></a><a id="Tc_aKqLwexWQEayGvTNpr8iHA_28_0"></a><a id="Tc_TBRLWadnmEGD_GGlLrbXfw_29_0"></a><a id="Tc_ID-DqOkbfUGxKg-eV0sr7g_29_3"></a><a id="Tc_ko4_TTUE0kaBoVR7Bopi5A_29_6"></a><a id="Tc_J01Irw3E9EGt__dJrI6-Hg_30_0"></a><a id="Tc_o3gNUjU1b06crKCpxtc0bQ_31_0"></a><a id="Tc_TkV7Zi53T0Sd5Tu4t4zPfA_32_0"></a><a id="Tc_wwi5u3JBDESXvrQ1y8K6XQ_33_0"></a><a id="Tc_2Q5mkNqnZ06YA_wQy7cNbQ_33_2"></a><a id="Tc_L21VpVRYjkmLpLNUgc39jQ_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_urCvNJslvUyDMpEMNkdOaw_4_3">9,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1Llet6lZ60q268ZxD-eBiw_4_6">30,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_3XBoI_DpJ0OOKKT8PqeMLg_5_3">1,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_gENhdteOdEysYDZAQ_KAlg_5_6">1,357</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_pvBrETptsEWWeRf6TCzP_w_6_3">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_W9mbx40nXkK_-uau81BapA_6_6">1,292</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_3Rby1iyEQk-DxNpRTVCBhA_7_3">4,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_PgG1aixt_k-HCV8iVZKzUg_7_6">2,181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_t2OIlqdQuUKyI4MBaZiKlQ_8_3">17,214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_uK51CD50AUqhHrpdsYvOVg_8_6">35,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_zxl7L7SY2kCSsjDIKyZ4IQ_9_3">2,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZTi9IMFT1E-7r1zV7PBbaA_9_6">1,797</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Ibv0dSdhhEm6Q-liv78Dxg_10_3">1,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_i92E0ltb7kazpSx7PmWpEg_11_3">802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_2wGHzY9N5EuDcaztHq2Xdg_11_6">794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_J_PaA4nXzUiG-QWZQv88pw_12_3">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_fai5h8egREuPzmYNK4aGfA_12_6">115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_zNAfde_RYUS6yzQgO7tiyQ_13_3">21,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_wJFkoK007EepOARbE2kcaQ_13_6">37,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_A3Dgy0GQjUmVIxTrTFMQqA_16_3">4,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_5gjyN8F0WEiV7EqO-Tj2Tg_16_6">1,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_x3tQ2JXNFkWOXWZUaSm9sA_17_3">6,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_4OuYfcQWOUyTnEdYTYfjaw_17_6">4,969</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series&#160;B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SeriesBTwoTrancheLiabilityCurrent" scale="3" id="Tc_hp5b1C76CEq56FyLep_46Q_18_3">4,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series&#160;B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:SeriesBThreeTrancheLiabilityCurrent" scale="3" id="Tc_XneBmU0e7kqMNxRtb4cKVQ_19_3">15,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityCurrent" scale="3" id="Tc_yR9qSomfNki6D8BqgFb1XQ_20_3">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6Tz5Z9c8bUyOeKGuhhUwgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 141</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_rzJ-UVohukGxhFpuyLXn2Q_21_6">104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gI9YjpVWsES8mrCJx_zz-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 32,356</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_hSt-fittCkSZaMa6kH7ZOg_22_6">6,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Long-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:LeaseLiabilityNoncurrent" scale="3" id="Tc_lS5Zcb6XkkGWGLxKHNEDDw_23_3">1,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities and other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" scale="3" id="Tc_4wrxzfLKh023giAbamQ-MQ_24_3">369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" scale="3" id="Tc_wbFUGgQNnUKU3hngyOZDYw_24_6">561</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_G_sKOz3pS0e7k4l56q5hag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 34,318</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_r1__ITgUK0SCp0dUO0ZYWA_25_6">6,934</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_7judIPKu_UGmF2fXe9Nkog_27_3">164,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_b1toPWYXXk2teN0W4wrzpw_27_6">160,507</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_nVK8GYrlM0yEF8UBOzzNzA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_c-79td-73UuNirGDcnGyzw">0.0001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_rNXHCiGBV0WLmyqRWKxtJw">30,898,162</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Ck8dwXQ5EkWMQs6PFffjLg">15,696,266</ix:nonFraction> shares at December&#160;31, 2022 and 2021, respectively; <span style="-sec-ix-hidden:Hidden_aaQdiWrtqEOASK7EYWjkdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_xTDCpcpvCUOG0LVU4dkrTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_BMHQsXPUxUuUx3oq6VESFQ">347,926</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_x9y9ruezOE-7jjaVogaWQg">264,977</ix:nonFraction> shares at December&#160;31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_F9yMPOv05EiBNsMwQ9IylA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 10,029</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_fMf3Gn0zDEOz9Ur9q8IiUg_30_6">6,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_RK8rlUtP7UKX2n7ebnRi6Q_31_3">186,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_rDCeTlRu8UKYNnHbRVgA-w_31_6">136,342</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_M1dWk5e9m0KG5yLnLGB_PA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (176,329)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_I-yWvv7SL0SBAH4bydzfbw_32_6">129,604</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc__dReN1pwJEilUanOIpPBqA_33_3">21,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Mc4K6e-WB0OE7cXHyjvdYw_33_6">37,837</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_901432f5_716d_426e_8b42_963e7e1e36d9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="TriAudCONSOLIDATEDSTATEMENTSOFOPERATIONS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><a id="_3b77a96d_fa23_4577_b1a2_81d755d2c181"></a><a id="_d8383cfe_9179_4b4d_ab9d_6c959f22cc7c"></a><a id="Tc_-uCoK8k-bkiOr4rTSfmVTw_1_2"></a><a id="Tc_C1oHcWHguka_zszMY5dI3A_1_5"></a><a id="Tc_Y1JOkgNadk6P6zKjy2FrMA_2_0"></a><a id="Tc_HhLITp1F6keBdyZU-rPo2g_2_2"></a><a id="Tc_N5pZb65YJkGsFURGBjtcTA_2_5"></a><a id="Tc_QNs2kzvq7UqCPf6QZs1gjA_3_0"></a><a id="Tc_-4FOWIatr0qP-PQhOTW55Q_4_0"></a><a id="Tc_Fd5QNEsAZ0a3CmKcj8e5Fg_5_0"></a><a id="Tc_a4271TTw0E-TdtQ9TGRCZA_6_0"></a><a id="Tc_hGKbxYx3oUCiKtYexxZCVQ_7_0"></a><a id="Tc_dU-uy7dnzE-YTG8NH4y5ZQ_8_0"></a><a id="Tc_Wv_GSy8K9kyEitCF5OJw1w_9_0"></a><a id="Tc_6FoKI6WdA069baY-8wT1eA_10_0"></a><a id="Tc_N1025C4ky0OcpD54r9KM_g_10_6"></a><a id="Tc_Cf9PjlbNFkiCb_KJvaTxeg_11_0"></a><a id="Tc_7P6j62SZMk-9-19WM3chhg_12_0"></a><a id="Tc_4F4LFXiFp0OFha7B_8mZJA_12_3"></a><a id="Tc__lyY6tkdFEKG8w2sg2Fc3w_13_0"></a><a id="Tc_nVmcA1-ZwEu3FwciJ0aEJw_13_6"></a><a id="Tc_plAey0_p3EacY9ohrVAPHg_14_0"></a><a id="Tc_XwMXtMsLa0mek-7f4WTJLQ_15_0"></a><a id="Tc_au9ZRFqUAka-Q8pvEsMnSg_16_0"></a><a id="Tc_TcJIO6OvqESLA9jeisUCxg_17_0"></a><a id="Tc_wwwbuxpS3UKnxX79gK3M_Q_18_0"></a><a id="Tc_7rnnNNdSfkiwWLJJGLjNxg_18_2"></a><a id="Tc_MO5IRlfAQUujBkjqOgtL6g_18_5"></a><a id="Tc_eFngt3sb-UKKRBM56qMBOA_19_0"></a><a id="Tc_XYFZ0ihx706M4ZK0IwwJ4A_19_2"></a><a id="Tc_QDiEcCWMIEqeIdx6KhrgPQ_19_5"></a><a id="Tc_FUX-NjhXvUaNL7vnxQ0q1g_19_6"></a><a id="Tc_xjtaUXZefkO3vXvOBhOtTg_20_0"></a><a id="Tc_FerLhzwdvE-3Ejk6nRU8uw_20_2"></a><a id="Tc_rKG_7RFv2USeGf7gG6L_fQ_20_5"></a><a id="Tc_IisXKlXelkqQ63gpJNUBEg_21_0"></a><a id="Tc_RAjJpT0DokOEXnfxcGkeeQ_21_2"></a><a id="Tc_9BLO6VNVlUWq-USvCZQwfQ_21_5"></a><a id="Tc_SDy0Si1PQEKfbCoz65JNRg_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_4Z42LLBNb0ugLqOlidfsmQ_2_3">12,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_nDXC6Fut40qfHJR917wu6A_2_6">8,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_d9xKad2AEECEd9Bc2yiF4Q_3_3">2,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_pCEi-X95yUCNKv4UZCA01g_3_6">1,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12.25pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_2f1KgrGd70WPgx_4HuGGVA_4_3">10,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_UqqOX5k-_E-8VswpC-7DMg_4_6">7,208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_KCVjRRAO_0KNAFVSuyPFIg_6_3">21,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_BRR9MsH6TkGGmXx1P2yWvg_6_6">14,224</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_AjiTttCUMUGGPJo3LyjHtA_7_3">12,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_ybEUIBfqGUKYFTIwef0Ydw_7_6">8,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ugmp6_FuLU6XLUjODKiRgA_8_3">12,483</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_UIcJ92XjME2oQyaZSFYC_Q_8_6">8,753</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12.25pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_1DQF9vv4bU6kmSIXIQlx0w_9_3">36,439</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Cn1cl59nk0CJEG41jMn5mw_9_6">24,032</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_0GQ0EBDt4UqFOMom1puKRQ_10_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_YmeCTCIwxkSy3wrAVTtm9Q_11_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_buIKeogy0kWan0UsHmZlSg_11_6">1,761</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on conversion of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnConversionOfConvertibleNotes" sign="-" scale="3" id="Tc_avhBdanTkEW1yAD9MLeEPw_12_6">3,416</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Tc_ejjrVpPBvEau_X_QQHGBoA_13_3">8,312</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of tranche and warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities" scale="3" id="Tc_4O5OP6tCVUeASVxtIS9myA_14_3">2,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities" scale="3" id="Tc_IE3jSuFznE-xINVnesCyVQ_14_6">379</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income and expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_pcyI7rzmsEG6QYIx1Kqu0g_15_3">420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_yPxl8bMr006wOw2pOVZWAw_15_6">746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_TwjwT2iKXEa2PprJMFXBVA_16_3">47,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_HvppRhA8wE6cIrg-Erzdzw_16_6">28,842</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_QDKVDDwAeUOw7ynOhF1Auw_17_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_Wq0h4fdTz0aMjyuMLxLtmg_17_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GI7BC1zu_k2Rnqg1mY66Fw_18_3">47,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gHg2IUzJMU2O5E-Dwmad5w_18_6">28,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deemed dividend related to Series&#160;B-2 preferred stock down round provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" scale="3" id="Tc_8aj14JpklEmwvt0kcnanyA_19_3">2,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_K63TVQ-UlkG27atxldSnAw_20_3">50,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_0RH843Qz3EWsrIREpSilRQ_20_6">28,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_sWNVEB2ThkWz0dGFHUk7LQ_21_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_sWNVEB2ThkWz0dGFHUk7LQ_21_3_2">161.55</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_gkzgEWWeXkq0V8oMT-W90g_21_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_gkzgEWWeXkq0V8oMT-W90g_21_6_2">131.65</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_tOGJ8_X-2UyNcMkjkT2giw_22_3"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_tOGJ8_X-2UyNcMkjkT2giw_22_3_2">309,609</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2XTDSbm_PU25YpMTN0iANw_22_6"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_2XTDSbm_PU25YpMTN0iANw_22_6_2">219,100</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bd297f03_aa00_45a9_8861_7101d22c426d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="TriAudCONSOLIDATEDSTATEMENTSOFSTOCKHOLDE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><a id="_7e6ea649_6e31_402a_9f46_3b3756972967"></a><a id="Tc_exdTO4xwlkOvisw1skU2Xw_1_7"></a><a id="Tc_Oz_FvhwbpUCNuN_CkJVQeA_1_13"></a><a id="Tc_GA3hpA6MGUasRAWtAwr_Tw_2_2"></a><a id="Tc_arZnRXYlpEuQ0Pt2UIY4qA_2_7"></a><a id="Tc_dohS8v_QT0esoYq_K5OX7w_2_10"></a><a id="Tc_9YIsL86qJUiUA2DF3LsXLA_2_13"></a><a id="Tc_sqttWL2qFEavslaNu73wQw_3_2"></a><a id="Tc_Ahc_DYmEbkqUARcyZYyuGQ_3_4"></a><a id="Tc_utdJp9xtKEO9zWHFFnON0g_3_7"></a><a id="Tc_v9vP-d9PDkuOPOH5yOIXzQ_3_10"></a><a id="Tc_2TDloXUbSkuUEc2d5jfSTA_3_13"></a><a id="Tc_ScpEOfpyZEaigy7vnCUeQg_4_0"></a><a id="Tc_sNYHbIWU20ihFp4VmK85WQ_4_4"></a><a id="Tc_0HF7nVyXwUy8M4EIPkNa7w_4_5"></a><a id="Tc_WgqmPLHobk2CH6HejsdJfw_4_7"></a><a id="Tc_LkohwJCNxUeXYY7n1izHjA_4_10"></a><a id="Tc_V3tgRMQT30SZJJSjbIexxg_4_13"></a><a id="Tc_USnMS_wwqke8nfIJHSptxQ_5_0"></a><a id="Tc_fkx8RXfm5UukBXMXjyKxLg_5_5"></a><a id="Tc_Pagh5WyxPUaIQasOR2upxw_5_11"></a><a id="Tc_2SgU7J43WESAyaPEfENJVA_6_0"></a><a id="Tc_b29FFva_dkmCAu-m2R1Phg_6_2"></a><a id="Tc_sYs9bnK9WUqy4sxtFILPJA_6_5"></a><a id="Tc_EV2ghhSGkk-QKTBXlhZQWQ_6_11"></a><a id="Tc_r4_4qCsr8EqTOk0uDtFokw_7_0"></a><a id="Tc_XcnSt6yI2E2Z7XLj0d1j5A_7_5"></a><a id="Tc_1WQSZk5RJ0GD5JQ2Y2tBHg_7_8"></a><a id="Tc_H3b6xzIz5EaOJgqDV1fMdw_7_11"></a><a id="Tc_wFt9AN6C4E-zDiPNuxTlVA_7_14"></a><a id="Tc_jxsCuYK5I067mani_9lRvA_8_0"></a><a id="Tc_q_WRw3CrskWKkOROy8updA_8_2"></a><a id="Tc_m8GxuRapiE2jSjvxDMTdNQ_8_5"></a><a id="Tc_U93A27UHEkyqkVS-KldVTg_8_11"></a><a id="Tc_kgqkPyP2k0iCBn52M8tjGQ_9_0"></a><a id="Tc_6qrcYNF8d0uMM6ynzpwOIg_9_2"></a><a id="Tc_ZISESKP0ukaBBVB-h2zO1A_9_5"></a><a id="Tc_IUK-oU8ojEeovkgGCgsa-Q_9_8"></a><a id="Tc_HmFrQKUXjEu-OBaheFkaEw_10_0"></a><a id="Tc_1Q8dSEPeA0OgZtabVOL7TA_10_4"></a><a id="Tc_CsBjRv3x3EuZfK_YK5T9sw_10_5"></a><a id="Tc_8Dn4oFWyCk2K5JaLl4gUMw_10_7"></a><a id="Tc_HEbGwtGF5EGGaewLkb7yeg_10_10"></a><a id="Tc_JTtgtL-72U6DAX7_yyYJ_g_10_13"></a><a id="Tc_JKflzoUou0qTVWVxZn7aiw_11_0"></a><a id="Tc_8JqAXQi7HE2uSgL8nXxwBw_11_5"></a><a id="Tc_lw8uFREN7Ue-zbnSwvpUxA_11_11"></a><a id="Tc_C6UXIIuGzUyIpMjLr5Zl_Q_12_0"></a><a id="Tc_pF6yex7jTkygcq28-KBZcg_12_5"></a><a id="Tc_nIxPJwpMmkus6mzr-HuoHQ_12_8"></a><a id="Tc_N0fK9i1xZE--V54zwzmdrQ_12_11"></a><a id="Tc_O6Lvvds8PEWwwR_OayQIEA_12_14"></a><a id="Tc_XLYhNBN8s0K9_ZCPG6R15A_13_0"></a><a id="Tc_c-lgsLSelkabD_u5DgHcXQ_13_2"></a><a id="Tc_wai6_BYOLEyQGc6V-0aNsA_13_5"></a><a id="Tc_Qf0cqndy802JAJ971llQEQ_13_11"></a><a id="Tc_VzepFgHAX0e6IuVHDAa01A_14_0"></a><a id="Tc_h7dzl6ggW0yIf579mLwbRA_14_2"></a><a id="Tc_EQn6TBUs60iMbSNyF4flBQ_14_5"></a><a id="Tc_JZXaKKMPqU6zmIo_VyYlMg_14_14"></a><a id="Tc_IF3q68GccU6Zr-2QNhSnoQ_15_0"></a><a id="Tc_OVhZMVETlEOm0NrbWZ6Ezg_15_2"></a><a id="Tc_0Ia3G0IUqEax8T6OZXKbVw_15_5"></a><a id="Tc_SDI8zAASnE-MfKMCtB4wsA_15_8"></a><a id="Tc_ts_B4m0AQU61EVe8cqCk4A_16_0"></a><a id="Tc_Lo2OiuDWqEmUJrdGnNOwng_16_4"></a><a id="Tc_z2yvfH99CkqCmYuPH7FKHA_16_5"></a><a id="Tc_Y0KQSBqeCUWjunUzVY6A2g_16_7"></a><a id="Tc_ZME-xy4xUk-9DLQ2OaEgiQ_16_10"></a><a id="Tc_Eswo_lqkt0GfjwVWOuKKTg_16_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b>&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o17RMY4e1kCnffIskGGRgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_IeHg80drNEO0CVx3JvNanw_4_2">193,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6Ur9zgF7wkywVIZmS7rNew_4_8">1,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jSD5X1FfwUGwejMu7znIQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ssjHJ0kYpUevpM0V8BH9dw_4_11">107,497</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_fJMthFnmeESuzQbRTQrjZw_4_14">106,133</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_9B32Czhin0mLbluUiXSsVA_5_2">71,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XFwwq2LKSECRAsl31exRpw_5_8">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_34TTIeNgGUGADADP9-JNQw_5_14">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Modification of convertible debt to remove conversion discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" scale="3" id="Tc_doEYtaLPyEKLGlKTLlKsHw_6_8">5,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" scale="3" id="Tc_SDd1AioS8UKLrxTJfMsVJQ_6_14">5,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" scale="0" id="Tc_2Oi27CmYPUGqDbWBOe5N1Q_7_2">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="Tc__b4ahBBnjk6GZIvVVZO0Tw_8_8">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="Tc_XogeVbmpHkGV3640uyaLGg_8_14">109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wivqVnmy-EKDR9DGDZZYDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_A7xOiSbRPUiNV2Pkpf3Deg_9_11">28,845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_agUxxESaV0-x7R5aD8ryMw_9_14">28,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_5lCUujh8hUeMPjTMAPTLsw_10_2">264,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_X5CnAy8BbkqdT58gfX2FcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 6,737</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CXoyK3e1fEWaITWBNqelFQ_10_11">136,342</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NaQHkAWSzk2neGw_XEl-TQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (129,605)</span></span></p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_cjgB_WHiP06Re9bbPCXT2Q_11_2">82,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 36pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OoBUwaRz60auKxrHan4I4w_11_8">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OOLx5MyL0EKnhAEjRkAusQ_11_14">94</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w" decimals="INF" format="ixt:numdotdecimal" name="tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" scale="0" id="Tc_sflc5RWxxE6kAwtiqOMPsQ_12_2">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="Tc_li_s-HW3ukKcW5jCwANMwg_13_8">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="Tc_VDF8TgdVu0-eenxyJII0JA_13_14">368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deemed dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" scale="3" id="Tc_szBfYpzHhE26J-NQKQb7fw_14_8">2,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" sign="-" scale="3" id="Tc_Edb23gLgq0uzthg_Ksv8HQ_14_11">2,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ymiq2nENbkqdWcBi9iBgkg_15_11">47,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_smApB81hY0eNKxbpsSNetg_15_14">47,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:50.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_nqORHBWXJke2vjq6eAY8XQ_16_2">347,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0E7ZYfrmKU6ZNsH3IlzcHg_16_8">10,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bLWhGpELNUCV7q_sr0defw_16_11">186,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_51_5DbmTSk28W1Upq7pdNQ_16_14">176,330</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_875e97bb_499d_4fcc_8022_dc0c6a84c241"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="TriAudCONSOLIDATEDSTATEMENTSOFCASHFLOWS_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_0adca8a3_e7be_4cbc_9b39_0e09e3154090"></a><a id="Tc_3M7ZDdQI8U-Kz8csUjMOtw_1_2"></a><a id="Tc_Xua1WJtNDEyuXaTNqxA9iw_1_5"></a><a id="Tc_XgifMyqT0E6baMO-sqxAwQ_2_0"></a><a id="Tc_wIgmguI4aUSOi_tbbLNdqg_3_0"></a><a id="Tc_dh0w-T92UE-M-dmCP9uVJA_3_2"></a><a id="Tc_G8d1xuoQD0m2KMg4H4B7Fw_3_5"></a><a id="Tc_QLBy1s1-jUyrQ0_n-ovu5g_4_0"></a><a id="Tc_yiSGOvAfsUiiBCG1WK5VCg_5_0"></a><a id="Tc_R8gSwY2_CUCVGFYTVIdyLw_6_0"></a><a id="Tc_tKbtehGhpUeNs2a_fodonQ_6_3"></a><a id="Tc_3xyUxs3X2UGVjkl9kD5MsQ_7_0"></a><a id="Tc__NoCGxulDU-rqXXWdX569w_7_3"></a><a id="Tc_pinBDxh6LkOWjeLBZWbeoA_8_0"></a><a id="Tc_YDzIB1blAECm5R9QpBh8Gw_8_6"></a><a id="Tc_86XAfuwsiUO7z3_bWiO4IA_9_0"></a><a id="Tc_5rVMsp_-_kiX-LjvFIJLyA_10_0"></a><a id="Tc_1Qdm6rDesUqG7KWk2zYkgw_10_3"></a><a id="Tc_bVeiFCK4VE-9otdqf-XUOg_11_0"></a><a id="Tc_Xf4u9lz7YUWY8GUI_Acw8w_12_0"></a><a id="Tc_o7ZSDiE9o0ezfgZA356DKQ_13_0"></a><a id="Tc_jGulvXIV20mJOxA3mFhUgQ_14_0"></a><a id="Tc_zb-DHdYHGk2naQfgBCKIbw_15_0"></a><a id="Tc_bOnapYlbJkCDmB0grEDhvQ_16_0"></a><a id="Tc_lhQYoe3VR0CfuMbzScniSw_17_0"></a><a id="Tc_5lMpwhQOrUuZ1jdHBTrD7g_18_0"></a><a id="Tc_7qpOtdI3d0WQH5mV8KVCog_18_6"></a><a id="Tc_SnD_hU1BH0edaDB5PQcRXQ_19_0"></a><a id="Tc_Thm-y8-U3kqtLCAqJpsA3w_19_6"></a><a id="Tc_hwqaDy0UN0GDhkACep3QZw_20_0"></a><a id="Tc_sIA3thHbpkWcT7rfMolfig_21_0"></a><a id="Tc_NTD_adBvs0-OqIdpQHn8Tg_22_0"></a><a id="Tc_kU1b0fqdOUuWvTj9BKVuwQ_23_0"></a><a id="Tc_lZUdUhCFMUmY1As2Dl1XBA_24_0"></a><a id="Tc_XxlqRQCbOUO_0bYrQz0HzQ_25_0"></a><a id="Tc_M3pQM8SS5EK9dloqyeycow_26_0"></a><a id="Tc_dTzufaqaqke6unQ1xJli_g_27_0"></a><a id="Tc_kHGUEEuJpEyPGJvdwU8x0A_28_0"></a><a id="Tc_m0xugbTQlk61KAlL3GUo8A_29_0"></a><a id="Tc_gMhF7mvz5U-057NabXp8nQ_29_3"></a><a id="Tc_7Zo3jSyMikOSBL9nAI2YWg_30_0"></a><a id="Tc_qpurawGET0aSXV_DFV9UGw_30_6"></a><a id="Tc_Fp1Fi3kl5kmTtwBnYr--dw_31_0"></a><a id="Tc_hWmhQY2REkaLzDFspWqKVw_31_3"></a><a id="Tc_e6uDtJmm2ECOljylDziLgw_32_0"></a><a id="Tc_R0iKwzSizUyGje_7e0RIQw_32_3"></a><a id="Tc_qElvcK6tyUGkRPdvyL-8VA_33_0"></a><a id="Tc_FdR1Jm5Hh02NbIllTQZPQQ_34_0"></a><a id="Tc_Xbq2BCfzvUGJRu6usMj9Qw_35_0"></a><a id="Tc_faBnqDSJa0e4EcLgzh7rfg_36_0"></a><a id="Tc_R2Us4KKtzkeafs-31zndKQ_37_0"></a><a id="Tc_fPTZNDUSrESSyS6FfrXsrQ_37_2"></a><a id="Tc_CqhLmqE_oEGCHNRRlg6cUw_37_5"></a><a id="Tc_xHcmhtnag0-zPO7xYzpxSA_38_0"></a><a id="Tc_YN04QVTlL0CpEJr16AEswQ_39_0"></a><a id="Tc_GtzW2Nb0REe3g_bmWwqasA_40_0"></a><a id="Tc_vIfgFp_XkUWnvo28LiQleA_40_2"></a><a id="Tc_TjK-H-JGTU60AcrBLb5O2A_40_3"></a><a id="Tc_o-wzJ7N9UUqKoIIOy7VDtg_40_5"></a><a id="Tc_KI1wLu-WFEeeRl23YcMW4A_41_0"></a><a id="Tc_8XppCxBhZUycKpmLU0id9w_42_0"></a><a id="Tc_UZFz8lQuGUqtLw-43NsdOw_43_0"></a><a id="Tc_sRc4_aJjn0e1oZ3gadGoyw_43_2"></a><a id="Tc_e9u6dvG9ekGwtJmINcHRzA_43_3"></a><a id="Tc_OW-GjOCtvk6orpBYBJR6BA_43_5"></a><a id="Tc_YpFinHl_ykCMUZHXK44POg_44_0"></a><a id="Tc_leXSrE21XUyOh_d_kAQcNg_44_3"></a><a id="Tc_Ytcn8SkV0U2htTy9gRgXvg_45_0"></a><a id="Tc_o-8u_K_xF0qaFqz4unSybA_45_6"></a><a id="Tc_tI2W3DzfGUqS6D0W20uvjw_46_0"></a><a id="Tc_6q9olq9bvkisK3znJsl7cQ_46_3"></a><a id="Tc_R3MsUTDlhkC2AF4XaRfq8Q_47_0"></a><a id="Tc_jSP8ev38vUyfMRzI0cZdkw_47_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8vMTfkYTdUq1B_hC38Uk3A_3_3">47,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UTTT-9MrXU-PmwZoCuzRXg_3_6">28,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="Tc_1tFMBPkbxU6SU9rIoy1Dtg_5_3">398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="Tc_J_ZhIT_gbUy6HR1pHW0khQ_5_6">464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Gain on PPP loan forgiveness</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainOnPppLoanForgiveness" scale="3" id="Tc_iL59EN5LN0eZRaiV3PyJXA_6_6">828</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Loss on conversion of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnConversionOfConvertibleNotes" sign="-" scale="3" id="Tc_WaucMeYDdkCTzFWrQQu9Ug_7_6">3,416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Loss on equity issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Tc_cdy7bFbQukmR2Q5PBBdXWA_8_3">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Change in fair value of tranche and warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities" scale="3" id="Tc_G4hu6WtmG0easaGE3sexxg_9_3">2,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities" scale="3" id="Tc_hrgmRf2K_E2rf_qtzlW87A_9_6">379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Discount amortization and amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_MmkK-1qzs0-acMHT19YbJA_10_6">1,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_TSA0TTA0gE6TOR8cqrudPA_11_3">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gT_HSRTMQ0Wov2IUFXT4jQ_11_6">109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Gain (loss) on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_qK1TsBsMI0aef2e4xH0Q9Q_12_3">310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_qxaHx1YZWEW9sPD_H7fQ8Q_12_6">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Milestone payment to Dynavax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxOperatingActivity" scale="3" id="Tc_6ZVvjUNAVkiHm5Oq8JlkUw_13_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxOperatingActivity" scale="3" id="Tc_T6kgIBPJ3UyRlIuvNOlpTA_13_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_LhDfY1XGa063h1kdOS4PGw_15_3">200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_xLCPe5PvuEKrOF0hxOKNgw_15_6">741</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_FVQYSWH_0UCNxdpcDCl3-w_16_3">179</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_v7T6bbzpmUCKneSPAgQv4Q_16_6">725</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_HT0TnITIZ0KHrwmCDmnWng_17_3">2,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_LdSzCtMYr0eVisV1KzsIVA_17_6">1,840</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_nrZZ9E-HEkC_f4qOLDzmlA_18_3">112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_boCyw9dKRUmtuOxDeknyMQ_19_3">87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Trade payables, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_PAkqhVBaOU--kjmABOxEUQ_20_3">5,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_WEnrORr0cEu1UdP3YfP5yQ_20_6">3,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_29StP5pKAEGGwRDcjx5q5A_21_3">32,313</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_qkslZztK1k20EDbgGiXaeQ_21_6">22,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_aYHstM1C8UGyyofhOXnCag_23_3">655</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_torMeXDUbUiV4-e6AiPX9A_23_6">1,097</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Milestone payment to Dynavax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxInvestingActivity" scale="3" id="Tc_DbbUhpOXrEKcW0IlRtSC4A_24_3">1,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxInvestingActivity" scale="3" id="Tc_jK4_gMmLkkatsnprrsL1ug_24_6">1,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for intellectual property and licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_RisUrdjvA0OYtGLj_ATf0A_25_3">131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_mmXrXFivrUaYFnRneE4Zew_25_6">161</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_P23-KkOXKEiIuooBKMyBYg_26_3">1,786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_g1TLA3hbZUGoopGz-wmMBQ_26_6">2,258</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from the issuance of preferred stock, net of costs of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_tiHFD8d49UOmS-TqcQ4WVw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_v6jV-QRGEkyn3LrqNz7yyg">242</ix:nonFraction>, in the&#160;years ended December&#160;31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_iHuk5c3U_kyeNlB5nOBdnQ_28_3">13,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_lTLt-69ieEKt0CtR4B0ziA_28_6">51,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of Series&#160;B preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_tEIfWxa200m7v5lBkjwBWA_29_6">117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Payments on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_SAsymQ3xcUS8uXLuxDbszA_30_3">131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Repayments on term loan (including $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="3" id="Narr_pMD_G96oKk-fD1ixkfk_yQ"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="3" id="Narr_OBBWJ5WDfk279mzC0X5_ng">254</ix:nonFraction></ix:nonFraction> balloon payment)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfBankDebt" scale="3" id="Tc_LoQX3lapqkmwfmkMI5eHoA_31_6">1,348</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net proceeds from issuance of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Tc_zvzUfWfbJUSOWIUyPshl1Q_32_6">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash proceeds from the exercise of stock options and warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" scale="3" id="Tc_4oYHVAeSdUC0jFVZZx1LDg_33_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" scale="3" id="Tc_lUXMim4n_kuCN7lZeq3SSw_33_6">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_x6igB39_l0O5ZPa2B4xlMQ_34_3">13,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_rtvuepKELEya6-OxETeW_w_34_6">50,768</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_UyIfTZu5IUamwmf9bIl1AQ_35_3">20,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_DvUx7JatDESqhw9SqGCOgQ_35_6">25,813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_nEUeIeLY6ESN38egotVNxg_36_3">30,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__Vkr9Bp1_0OmnGGMyBU-cQ_36_6">4,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_l09nIsWme0-8pygg09wmMQ_37_3">9,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_zwvWHrRSREC-Jl1PESz-dw_37_6">30,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid during the year for:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_5CGJk_vQyEueeDt0PKImRg_40_6">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_ysGGRzNTUk2wAza93H0IOw_41_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_I4uWRWTxv0iccoqgwJrXKQ_41_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of noncash items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Value of warrants issued with convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:ValueOfWarrantsIssuedWithConvertibleNotes" scale="3" id="Tc_Xz0wqht4qEGXow56ig2fOw_43_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Transfer of warrant liability to preferred stock upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" scale="3" id="Tc_NZf_rgAS_0aDtDSi04npyQ_44_6">3,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed asset purchases included in trade payables and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" scale="3" id="Tc_mwevurUV2EGnrxwknsHbVw_45_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Put option liability transferred to Additional paid-In capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PutOptionLiabilityTransferredToAdditionalPaidInCapital" scale="3" id="Tc_52e0V0eWRUO2DfBBBUZ19w_46_6">5,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Carrying value of convertible notes and accumulated interest transferred to preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" scale="3" id="Tc_zEgABnR8v0-qpHeWNh1pJA_47_6">49,118</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_60eb007d_0d6e_419f_b7dd_2fc17445b5de"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES,&#160;INC.</b></p><a id="TriAudNOTESTOCONSOLIDATEDFINANCIALSTATEM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(amounts in thousands, except share and per share data)</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:NatureOfOperations" id="Tb_qURQqBhA90--5ocY13LH9Q" continuedAt="Tb_qURQqBhA90--5ocY13LH9Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus Life Sciences,&#160;Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), a Delaware corporation, was incorporated in 2009 as Surefire Medical,&#160;Inc. The Company began doing business as TriSalus Life Sciences (&#8220;TriSalus&#8221;) in 2018, and changed its name to TriSalus Life Sciences, Inc, in August&#160;2021. We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;&#8221;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav infusion System, introduced in 2020, the Surefire Medical infusion System and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023; we are actively seeking an extension of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded operations to date principally with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009 through December&#160;31, 2022, we have issued for cash <span style="-sec-ix-hidden:Hidden_ZCuk_ZdpA0SUrfc6xIvFJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$108,664</span></span> of preferred stock, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_P6Qe-rVn2k2Jk6Q17yn6mg">458</ix:nonFraction> of common stock and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_zRL2Bt5Snk-kHTcFjCsiHQ">57,466</ix:nonFraction> of convertible notes and warrants, which has funded the cumulative net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CumulativeIncomeLoss" scale="3" id="Narr_ZjYOa42QsEGg-M08Yt1wjA">186,358</ix:nonFraction>. During the&#160;year ended December&#160;31, 2022, we raised $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Narr_kT04EDtU2UOEU-d8V1Jn-g">13,499</ix:nonFraction> in cash through the issuance of Series&#160;B-1 and Series&#160;B-2 preferred stock and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_oD15EJjtsECCCg512y0sdg">94</ix:nonFraction> from the exercise of stock options. In March&#160;2021, all of the then outstanding principle amount of convertible notes, with accumulated interest, converted to shares of Series&#160;B preferred stock in accordance with the terms contained in the note agreements; the note conversion did not raise any cash. See notes 10 and 11 for further discussion of the convertible debt, warrants and the 2022 financing rounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had cash, cash equivalents and restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Narr_OnijvPUTI0ycBMVsY-9j3Q">9,664</ix:nonFraction>. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_xzrSqpooEEyLVKbDAihRqg">186,358</ix:nonFraction> as of December&#160;31, 2022. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC Topic 205-40,&#160;<i style="font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qURQqBhA90--5ocY13LH9Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_5M9lEVI-qkKq-87DJ2-H2w" continuedAt="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_ZcVqojG4HkCmda8yMq7W2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_YKLw0Y9530-3CGjRzdVo8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" id="Tb_gBTlOfqGDkiR08b5JEzFfg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(c)</span></span><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_LOF6JpGiRUe1ry9wu3NutQ" continuedAt="Tb_LOF6JpGiRUe1ry9wu3NutQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Accounts Receivable and Customer Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont1" continuedAt="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont2"><ix:continuation id="Tb_LOF6JpGiRUe1ry9wu3NutQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, <ix:nonFraction unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ" contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_TmWc_b8zrkOoESGM-nlcbw" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfCustomer" scale="0" id="Narr_LhoZaWIfR0WzLJVJ1eLLPw">one</ix:nonFraction> distributor customer constituted <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_unAxPM_nUkazhDm3agcBLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_YodGdtDTzUy120h5Iw4tbw">19</ix:nonFraction>% of our accounts receivable balance. As of December&#160;31, 2021, <ix:nonFraction unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xh7u3lp9k0iiIeQaqMuClw" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfCustomer" scale="0" id="Narr_wG4TvuzFiUSQaHus9Y8_Dw">one</ix:nonFraction> distributor customer constituted <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_spU-CoGWskCTi4k7rsFi5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_QMPof6c0QEaw9YTVGf7jVA">34</ix:nonFraction>% of our accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had <ix:nonFraction unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pP0da2xH7UW_LfRCdr8p5w" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfCustomer" scale="0" id="Narr_d6cvFnRXQ0-YoYc5hDe1OQ"><ix:nonFraction unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ" contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LVK9Ysk-RU6dEwdwJdOHYQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfCustomer" scale="0" id="Narr_D5_LR0rJc0SXI9CE1NlGiQ">one</ix:nonFraction></ix:nonFraction> distributor customer which constituted <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_c8vgoPz11Emp9qsaEJDkKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_luSZR93hX0OX4-_la0XI6Q">20</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ciY8mEnJHkKZYJWWeE3zcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_YwAk9_rk8UyxiRYOdzWHJw">25</ix:nonFraction>% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_RupvBSuCeUyLMfpI16pI_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(e)</span></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,&#160;<i style="font-style:italic;">Leases</i>. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:InventoryPolicyTextBlock" id="Tb_AaRvAGpxPkSUrYAPEsZzxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(f)</span></span><span style="font-style:italic;font-weight:bold;">Inventory</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#8201;&#8212;&#8201;including direct labor and manufacturing overhead&#8201;&#8212;&#8201;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:UseOfEstimates" id="Tb_N3LwdqLHWUyvnRk0rPHiAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_VFt6rIB28ECdru7lfR3rDQ" continuedAt="Tb_VFt6rIB28ECdru7lfR3rDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(h)</span></span><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont2" continuedAt="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont3"><ix:continuation id="Tb_VFt6rIB28ECdru7lfR3rDQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_4xtsiBc_R0GeIR-9T-o_Gg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(i)</span></span><span style="font-style:italic;font-weight:bold;">Impairment and Disposal of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_L-GyQrEU006Um48SEtDkrg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(j)</span></span><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_V8aQp4AtlEewFj2v0-8l3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(k)</span></span><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined, in accordance with ASC Topic 280,&#160;<i style="font-style:italic;">Segment Reporting</i>, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_jDnVZqXllkq35st_PTF4Pw" continuedAt="Tb_jDnVZqXllkq35st_PTF4Pw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(l)</span></span><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;<i style="font-style:italic;">Revenue Recognition</i>, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price&#8201;&#8212;&#8201;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#8201;&#8212;&#8201;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#8201;&#8212;&#8201;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order </span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont3" continuedAt="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont4"><ix:continuation id="Tb_jDnVZqXllkq35st_PTF4Pw_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_SK9MXE0yqECeIvfPQaCHTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(m)</span></span><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;D costs are expensed as incurred and included milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxOperatingActivity" scale="3" id="Narr_7q0ECVOhiUCg5q21Gd-9yg"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentToDynavaxOperatingActivity" scale="3" id="Narr_YEwvW3VS4UGubYtgoOuL8w">1,000</ix:nonFraction></ix:nonFraction> to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="Tb_42iqh7WF3kS-vFJfqvuJAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(n)</span></span><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="3" id="Narr_pCs8C58etke2iQci41L5gw">2,201</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="3" id="Narr_598Jn1GCCEqy6QLY8i13Ng">1,400</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_sEBXygPRJUGWlmZlKb2fcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(o)</span></span><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes pursuant to ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#8217;s income tax liabilities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" id="Tb_LIRNO4NOaUeTMcQ3b_mvYQ" continuedAt="Tb_LIRNO4NOaUeTMcQ3b_mvYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(p)</span></span><span style="font-style:italic;font-weight:bold;">Warrant and Tranche Rights and Obligation Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="tlsi:PercentageOfSharesOutstanding" scale="-2" id="Narr_kY4yQks4k0eF2V1ntIOakA">99.2</ix:nonFraction>% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5M9lEVI-qkKq-87DJ2-H2w_cont4"><ix:continuation id="Tb_LIRNO4NOaUeTMcQ3b_mvYQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_KxN24Ol8JUKwVQ5Yh-PSDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_1_1_2022_4rgr5dtwgkOc8kEvgOYxOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingAssets" scale="3" id="Narr_agh1SAvB2EeLLfyk5n2acg">1,512</ix:nonFraction> (net of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRentCurrent" scale="3" id="Narr_ll422Rub6kCK9xMm49diWQ">320</ix:nonFraction> of accrued rent and unamortized tenant improvement allowances), current liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Narr_xG5uWF1I4UmNWXxQiyRndw">236</ix:nonFraction>, and long-term liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Narr_VDGCrvyhKUyiXINC9wTILQ">1,596</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="Tb_HwYbNpHRsUW21V8MoEiiiw" continuedAt="Tb_HwYbNpHRsUW21V8MoEiiiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial instruments consist of cash, accounts receivable, trade accounts payable, tranche and warrant liabilities to purchase preferred stock, long-term debt and convertible notes. The carrying values of these financial instruments (other than tranche liabilities and warrant liabilities, which are held at fair value) approximate fair value for the&#160;years ended December&#160;31, 2022 and 2021. In general, asset and liability fair values are determined using the following categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;1&#8201;&#8212;&#8201;Inputs utilize quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;2&#8201;&#8212;&#8201;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;3&#8201;&#8212;&#8201;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#8217;s own assumptions about the assumptions that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our financial instruments, including tranche liabilities and warrant liabilities, are measured at fair value on a recurring basis, including immediately prior to exercise. The carrying amount of outstanding warrant liabilities was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_jb_q390JZkiH38PyUwE9zQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_L4p9jRWjskiZPQWGnf8znw">16,188</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_UO7Dm79BGEGf58YUPTUeig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_t2IW0NAOOEmk2n5ytfi6GA">391</ix:nonFraction> at </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_cfdf8282_1e4a_4215_9ec9_84746375993d"></a><a id="Tc_cqTEd1SpDEC4mC7LCa9xOw_1_2"></a><a id="Tc_7o_hRxn6OEGHC4Fo9ncmsQ_1_5"></a><a id="Tc_6TN3WFW8fkGYcQYfKI6n3Q_1_11"></a><a id="Tc_yYrmXG8n90aXfrRcYjtozg_1_14"></a><a id="Tc_rIvzLdUyG0e1A0sHk9RRTQ_2_0"></a><a id="Tc_FeB9P-5dJ06vTzRDFxjSXg_2_2"></a><a id="Tc_O5MuhyACKEi1JUYubNFUjw_2_5"></a><a id="Tc_kJZd7rm9xUmrR15rfwAYGA_2_8"></a><a id="Tc_6kl2LTwfekSx_A7hKzHfpw_2_11"></a><a id="Tc_Y7nZp0kgGESgJtdstCU2Mw_2_14"></a><a id="Tc__f-OQVVlXku1Ypmcr8vvyg_3_0"></a><a id="Tc_fMAV351keEy68AWnA8DjbA_3_2"></a><a id="Tc_1JDUSY2A4k6a5JZive-rOw_3_5"></a><a id="Tc_RgZLjdvEOkahOXdRxZAYHA_3_8"></a><a id="Tc_QSjHONpjoEOF9j07xCqTOQ_3_11"></a><a id="Tc_Wu6a9CEtfUOEkks6r_BDMw_3_14"></a><a id="Tc_4gqGd5f3gUWY_GaT19G_zQ_4_0"></a><a id="Tc_rC71PNZaqEuh6aaDRa5h8g_4_2"></a><a id="Tc_3JQyaYkI0EW2FEjCNlMzqA_4_5"></a><a id="Tc_RVjcfSfJPkuBCma-hnEsuw_4_8"></a><a id="Tc_Amt1jHMaNUOwog5Iwg5FiA_4_10"></a><a id="Tc_eljdLeP3R0utucJfDdObmA_4_11"></a><a id="Tc_dp72uaFwxkyHOAZptsg10w_4_12"></a><a id="Tc_jLLVNJXbvEmsEUojHjPMCw_4_14"></a><a id="Tc_pGRtDNA_ckGy3CFRyOGZZg_5_0"></a><a id="Tc_j0ICJ94SlUWoj26JtEiApw_5_2"></a><a id="Tc_lvOA7f6v90ClbNdSKpQiqA_5_5"></a><a id="Tc_uJO1BRZ0JU-aJDti4dLWOQ_5_8"></a><a id="Tc_1TEYAm0GiUyK-mgAxKMy7A_5_11"></a><a id="Tc_a7NSCbrtukCx9UypudCIOg_5_12"></a><a id="Tc_m9Jzi9GPMUK-hKK6iONY-g_5_14"></a><a id="Tc_MKloYqB7q0afWkCASFj7bw_5_15"></a><a id="_895bac51_b8f3_43e1_b789_8e54d8a14ba5"></a><a id="Tc_Ucu2dYmLfE-D2BkpLueTBw_1_2"></a><a id="Tc_K0SspIE18EWkqHYEQrQ2-g_1_5"></a><a id="Tc_Y1TWpC3ic0CfGstzQtGEBA_1_11"></a><a id="Tc_862ostn1Dky6yBeg0A0EIw_1_14"></a><a id="Tc_Gr5-zE12XUm0vLJ7epBxZw_2_0"></a><a id="Tc_3JVuzgoXqkyNrVpBzSXQyg_2_2"></a><a id="Tc_dT8pWEJfPE6lJx_v_ZTJjw_2_5"></a><a id="Tc_CDbHA9immE2WEUdWSAF7OA_2_8"></a><a id="Tc__wAjca1GqUeDLq7yNQ0R4A_2_11"></a><a id="Tc_8TgRggFoXUa20ED8Ip_xog_2_14"></a><a id="Tc_LHS-PvXKRk2JtX4tzzW7jQ_3_0"></a><a id="Tc_WUm6eXDZ90ilJ5Cc37qXqw_3_2"></a><a id="Tc_HeD0MAIvq0eG7LIe6F542g_3_5"></a><a id="Tc_cvZXRN6CfkCNd8fIm1ZFdw_3_8"></a><a id="Tc_d9AXsyux2ECf6k6H18rU6g_3_11"></a><a id="Tc_zkhnrbUy90WxRxcmYa6uxA_3_14"></a><a id="Tc_FPZVk_E2M0GMG3wD6sRE8g_4_0"></a><a id="Tc_9ZW2ocJlLUSi1xXjDEu4fA_4_2"></a><a id="Tc_Cfym9UNj70a_yyKdDeh-gg_4_5"></a><a id="Tc_K1EDTXuT7EC8EvbwTdJ54w_4_8"></a><a id="Tc_UnDYiYxbq0K7JLJ5yPtmxw_4_9"></a><a id="Tc_41HE1u3BUEeJfGmT-vUmAA_4_11"></a><a id="Tc_hforRdhML0G7_kE2dBNxSg_4_12"></a><a id="Tc_toprPhFgFUuigv8Zi18uXw_4_14"></a><a id="Tc_VjmEjxcpmke4_RD7X6XJiQ_5_0"></a><a id="Tc_e6DGQWahlkOGk_rC9I9gFg_5_2"></a><a id="Tc_SPGKR2yx5EqbhXxqt6OAug_5_3"></a><a id="Tc_gL5BC2xV2EOeH4-qjtKrcg_5_5"></a><a id="Tc_i_1nNvW8xk-YPU_bPMG0UQ_5_8"></a><a id="Tc_qCHygNJCfkOrvzl1UUv3hg_5_11"></a><a id="Tc_TyaG6ww1uU6mXAhYkgmViw_5_12"></a><a id="Tc_fm1KMSDHIkeFvly5e2aW0A_5_14"></a><a id="Tc_n__sqwZKCUGVseEJqnI1pQ_6_0"></a><a id="Tc_b5Swkf1McUGzFqMKKdlLxw_6_2"></a><a id="Tc_zBxrWVEVh0qV5_Rg37ktyw_6_3"></a><a id="Tc_ed1t3SNV6Uu1_h7SSIxQ6g_6_5"></a><a id="Tc_zv2c8b9qmEeG38nSTrJWtg_6_8"></a><a id="Tc_bfDS6tmrR0atkvf7coZvdQ_6_11"></a><a id="Tc_m1MkN9NHrEyRn1e9OBPgUQ_6_12"></a><a id="Tc_eKTxqJ9BUEadXeCHeR-pPQ_6_14"></a><ix:continuation id="Tb_HwYbNpHRsUW21V8MoEiiiw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">December&#160;31, 2022 and 2021, respectively, and the carrying amount of outstanding tranche liabilities was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_rS227lpA-0ato7P2m7Pn8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_ED0vcNKvXk6lnKv5KzBYhw">4,702</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_om9EAvh6fk-yKmSCpi6WYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_EFtYhff3A0yztiTOS9_sng">0</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. These carrying values approximate fair value based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the fair value of the underlying preferred stock, volatility, discount rate, and expected term. The put option liability was retired in March&#160;2021 in conjunction with the conversion of all convertible notes to Series&#160;B preferred stock; see note 11 for further discussion. There were <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt-sec:numwordsen" name="tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount" scale="3" id="Narr_o7gN0kEnC0eM_ijN-F5YtA"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt-sec:numwordsen" name="tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount" scale="3" id="Narr_5dYdjmbrN0ie5eTatgjxXA">no</ix:nonFraction></ix:nonFraction> transfers between levels for the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock (see Note&#160;12). This also included rights and obligations exercisable for additional Series&#160;B-2 preferred stock and Series&#160;B-3 warrants through a second and third tranche. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g" decimals="3" format="ixt:numdotdecimal" name="tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" scale="-2" id="Narr_cx8MMogFnEKKb7h8GmCQKQ">99.2</ix:nonFraction>% of our then outstanding shares on an as-converted to common stock basis). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_LiJykRWkS0KhUlbL1p6Hgw">11,966</ix:nonFraction> (remeasured to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_4kwyEyFqtUy8Xv94Fsromg">15,819</ix:nonFraction> at December&#160;31, 2022), the tranche rights and obligations associated with the second tranche had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_UfT8ljsnjEiwXR-Eomw_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_bbcDXJOHkU-fyaPzD6jW2Q">3,109</ix:nonFraction> (remeasured to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_J6vJujbvTU-jEUmIjkq0yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_KMbEzXSpJkKQYNYrj5fJhA">2,250</ix:nonFraction> at December&#160;31, 2022), and the tranche rights and obligations associated with the third tranche had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_OKx8PR3Il0avdary9MaUKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_kGCteG7BWkOl0MbYQIqw9A">3,238</ix:nonFraction> (remeasured to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_wbUeBXlixU2vDzFtryoUTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_GJ2qWw-xIk6IY0kMCHX0HA">2,452</ix:nonFraction> at December&#160;31, 2022), all of which have been classified as liabilities. The fair value is determined based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to both a status quo scenario and the potential closing of the Business Combination (see Note&#160;16), the value of the Series&#160;B-3 warrants upon closing of the Business Combination, the fair value of the Company and resulting fair value of the underlying preferred stock, volatility, and expected term; see note 12 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities for the&#160;years ended December&#160;31, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_wYA1YoehDESgNRFA4k4OAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;(Out)&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains)&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_ZC3gPhsLq0C-Ql-nVHkpag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_nJ8st4Kmsk2EvfNdE59qDA_4_3">3,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_utH6VCbZnEiAJ7s0IDoLWQ_4_6">379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" sign="-" scale="3" id="Tc_bRsOS82oLEmj-Fgl5g4krg_4_9">3,387</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_Idxqiz-cXk-lCU4pWK4Mtw_4_15">391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Put option liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_7fyqcBdnXkWyRm6NSBBkYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_OSF-_1GkDUu0cK4sc2OE1A_5_3">5,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_4q2LYqyz5kKYkeygJdd8PA_5_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" sign="-" scale="3" id="Tc_KiwzJHMNgEe4jaMSjRfqTA_5_9">5,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_Ft2PGgabo0GDRMXqRrnMOQ_4_3">391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_4G4-51YVe0-W2QwDgj40EQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_uIclSO9I5UeplyGQ8lsiIA_4_6">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_J3dY44gNN0iTa4AVy9Cxvw_4_15">369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_W2yRU-GJI0WiCkdD71pfog_5_6">1,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" id="Tc_Pti5enyhaUS_Rf80lDf9PQ_5_9">6,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_7kh5ioPPCU2NcXnDWvOSDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_CIaJVvdLiUi5mTv-ZJqRKw_5_15">4,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_RsMQOyoDf0i4gHSH-MvQUg_6_6">3,853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" id="Tc_iYwODIF4S06WXFmarcESXg_6_9">11,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_wRJ1i4W4p0yQRHB5YvbGBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_lu4WlyGZ7EaTPVQE9Kko_w_6_15">15,819</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>This amount includes settlements of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Narr_oFmPs4VxM0e8VeGkN_-aLw">3,397</ix:nonFraction>, reduced by issuances of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Narr_6zY3enybYEKw7JbJBP8SWA">10</ix:nonFraction>.</p></ix:nonNumeric></ix:continuation><a id="_9d37b706_8e40_48e0_ae0c_50faf7fe358b"></a><a id="Tc_aDwSa66ETkyRH5U1Bu-x9g_1_2"></a><a id="Tc_Ae3w9gRPE02EbOogLUfvkw_1_5"></a><a id="Tc_i_piMDeRD0CzoxPc5QFKbQ_2_2"></a><a id="Tc_EaHMQ-g370GSaxxmcJSxrQ_2_5"></a><a id="Tc_638AhdaX4kqHs7poOku4Rg_3_0"></a><a id="Tc_joqarGLE90aozOiTnS8W1g_3_2"></a><a id="Tc_hJlTXhby_EGMz_SvgqBxow_3_5"></a><a id="Tc_tNUUoeFaiU2Q3OhMRbvHDA_4_0"></a><a id="Tc_W1f-oR9dFEydtKO6C06mvQ_4_6"></a><a id="Tc_zf8YoImh4UCAQ2hISOhc0w_5_2"></a><a id="Tc_S-VqZ8X34U-xY2dm2MWpyA_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="Tb_D1_hUWwPrUyoXXZX6bqOEg" continuedAt="Tb_D1_hUWwPrUyoXXZX6bqOEg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_cTkYeIQK9U2eLP7lYausFg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_iqABfrutGUClrk7CGHzTbg_3_3">9,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_XSmtlMhcgkyP4fwUyLkIEQ_3_6">30,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="Tc_-yc8rnX710-8WbeqLtcKbA_4_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0TKNXlY5FEqaFHedv0d4-A_5_3">9,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YEOQ--_eWEO_fFnh9z8qAQ_5_6">30,301</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash is $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="Narr_GnMLcpg1S0S3J3gxI6S7vw">250</ix:nonFraction> held by our bank to support our corporate credit card program.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_D1_hUWwPrUyoXXZX6bqOEg_cont1"></ix:continuation><a id="_b634ed1c_31ac_4581_b1f6_f00e4889941c"></a><a id="_c40fc0b1_00b6_4b35_8d07_d44c4129bfca"></a><a id="Tc_VxWKaa6FzkKX5gyUVAFT3g_1_2"></a><a id="Tc__00hFphfcEeCdzBTCKLuZA_1_5"></a><a id="Tc_IdNfGt64r0mRVfib5Tu6OA_2_0"></a><a id="Tc_6KRJauxOxUiCQ3GH2DO8PQ_2_2"></a><a id="Tc_IsKa6Oi6_kKRSVKN5qw8gg_2_5"></a><a id="Tc__QhtO7j6CESRtq46CS_JuA_3_0"></a><a id="Tc_63KpK6wQ5Ueu3SQDAHI80Q_4_0"></a><a id="Tc_A_AwdchMokGKCUIPpP667w_4_2"></a><a id="Tc_dhZj1Ogh-0iOOAjnJGuIeA_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_q25N343E8UqJElJvMS_LOQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of inventory at December&#160;31 are summarized as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_DVN1ri3XEEWPOuo-CEDdDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_a4G4K0cWt0y05Rs8AUsrHg_2_3">753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_jK6AeLHRuUutQ4ryOUDI3A_2_6">646</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_KYbrSUPiOkKAq8w8_0pyWw_3_3">718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_L6xmd99xHEeP4LoN6voOig_3_6">646</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Hob8Ww0HXEaZ8vUtt2_Qjg_4_3">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ZCatLj5jmUyX9a-InevPYg_4_6">1,292</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The finished goods amounts in the table above include a reserve for excess inventory of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryAdjustments" scale="3" id="Narr_nhnRstolYkOHsYz1OJrk6w">43</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryAdjustments" scale="3" id="Narr_i7r4SD1oekqQTrSSLR5KYA">97</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively.</p></ix:nonNumeric><a id="_e15202df_0a0c_4f0a_a05b_c4454f150e6b"></a><a id="Tc_9NihKNe6QU2WrHGgANhehQ_1_2"></a><a id="Tc_JWQma0NAMECN5AXaDCJY_A_2_2"></a><a id="Tc_G0AtcLwXrEqR8hHEbXLuDA_2_4"></a><a id="Tc_ed58FbhwWEWdtAElAFiVtA_2_7"></a><a id="Tc_-N_2tnZgPk-qIW4AkoOvtw_3_0"></a><a id="Tc_LHGt8Dgiak-hAhdVFFNrtw_3_2"></a><a id="Tc_TzbGXzGWCki5cYkCfaVq1Q_3_4"></a><a id="Tc_t4V_vqm_NkCqQwe1Memlqw_3_7"></a><a id="Tc_gq1ZTuDp1EO2c3wT0vkheg_4_0"></a><a id="Tc_zlExyRlDmU2BbMXRlziw2A_5_0"></a><a id="Tc__48W8Z_7yESMFDEVCSqoRQ_6_0"></a><a id="Tc_3HsRbg7lekSDh8kMK6mk_Q_7_0"></a><a id="Tc_9_SgLRf4iEWYVcAiPg6MxQ_9_0"></a><a id="Tc_bOVbV76dkkOAdnxoUdMEkw_10_4"></a><a id="Tc_jmjiUbgZEU-We2VgiU3z-g_10_7"></a><a id="Tc_gA1V5elvGUKz-njhMt_YvQ_1_0"></a><a id="Tc_cXkRT2U40Eq5m5YP7i8IOw_2_0"></a><a id="Tc_dCPD7ZGWLUSsj6HfpzidYQ_3_0"></a><a id="Tc_Pd23yffpz0Gwg6ue85BSIQ_4_0"></a><a id="Tc_HjKP0mXEFEa_uZDKSfoZtQ_5_0"></a><a id="Tc_qKl9IomvtESG2fSetXDenA_6_0"></a><a id="Tc_6xjB9xj-ykaIgKJ7Wi8y2w_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:LongLivedAssetsDisclosureTextBlock" id="Tb_b49v-0hztUKWibZGE4S3aQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Long-Lived Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_DuTWEFJ4zEi3gvu1mtC7Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December&#160;31 consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Yy4qomYWEumToz2Q3IF5A" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_mfLrmWqpsEmge1l1mlDkDw">5</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_grIe4j2NjUW8eovYdmDsAQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_BEDSUlekYk6ZIMpc8YqFvA">7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ANvX6KP4G0CXL1ffGVduvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_yc9Sw1MRKkmuM0PH2-0MGg_3_5">2,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ekxf6NMJqU2o-owseUO9jQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GTXAjH8WQEuZVmtVVFXzpQ_3_8">2,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_4qS60Fjc40SpRE97x8bKHw_4_2">2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_y2nMUnXi5EKoqZLQFCJeLw_4_5">602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dnZOErz2JUevW3yh4sbChw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_5YAkrqmWxUGnFCzSv3kK2Q_4_8">672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_PO4OmUsPV02ctk_x69f1VQ_5_2">5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aIEwKzaODU-PJLXDxbDDog_5_5">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4rbUCoNCLkiKBrrFNhgp2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_gSnHjyXsg06LYVoE_RqhUg_5_8">448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_hWMM4IECIUmbRVsnBjds6A_6_2">5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6cN2wGoPTUCpfDrHEofAcw_6_5">772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_8jVm0JgFSkq10jUH1ZLKNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_D7NDC5Dk50-RcqZjYMHcHw_6_8">783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other property</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_jCy5V8O5CkSGoJvxlTGCNw_7_2">7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_CmC0W4nFB0uGvNvLWdW_UA_7_5">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_Yzsv-OD0SkGrA-t5QrzSQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Dd9eRvizi0OCmHX2Yb8YPg_7_8">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Hrb_ptmzik69uktLnL6llw_8_5">4,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_OX35ToCYDki0pdlRGH5kFg_8_8">3,946</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_IKXhHBsRsUqgLFS_hA_h6w_9_5">2,425</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_xrFE_QeL8Ue649H2STeLYA_9_8">2,149</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_yE77C_4Ky0iwd5727rkFwg_10_5">2,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_fNuPt1zg-EWIoh2lKAph9A_10_8">1,797</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for property and equipment for the&#160;years ended December&#160;31, 2022 and 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_Id83Xzt5U0Crt1IzTLoRlQ">276</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_QvLbjMH7cUWLDzkiLI0bvA">361</ix:nonFraction>, respectively. The Company did not recognize any impairment losses for the&#160;years ended December&#160;31, 2022 and 2021, other than a loss on disposal of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Narr_zjU8THEr4EWBUIPXE3BE6w">310</ix:nonFraction> in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Intangible assets consist entirely of patent costs that provide the Company with rights, titles, and interests in the development of certain processes, discoveries, and inventions with the right to commercialize that are probable of future economic benefits. Patent costs associated with pharmaceutical intellectual property are expensed as incurred as future economic benefits are not deemed to be probable. Intangible assets are recorded at cost and are amortized over the estimated life of the patents, based on the approval and expiration dates applicable to each patent&#8201;&#8212;&#8201;typically <ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_sB7vGY0qnEy2K3AKcAbp_Q">20&#160;years</ix:nonNumeric>&#8201;&#8212;&#8201;on a straight-line basis. Amortization expense related to intellectual property for 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_uyXebUyZW0ijIpgkuI-sAw">122</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_VnKnhp8wEU2S-sBenxdEjA">103</ix:nonFraction>, respectively. We did not record any impairment losses in 2022 or 2021. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal&#160;years is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="Tb_BPpX71UPxEeRuJCPOZzaMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_-xza3WJvE0G3Oh-PxwWtwQ_1_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_n7Z7lX0HIEGJkjOaIEyd1g_2_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_nDELfuQUSUqjv7zopACtcA_3_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_lvZI9fVcgEW_SNeQmCBYUw_4_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_7xyDCEspFk-muwAG153WEw_5_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_AI91zDdW8E2w7YvjjJ2pDg_6_3">477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_VHsnO8gBMkWOfBsoP-pHDQ_7_3">802</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Y6L0u5SwTEWK0GHSeoyEVQ_1_2"></a><a id="Tc_38nZX623g0CSpmh848je0g_2_2"></a><a id="Tc_bNXfy627YEekkTIs_4FwaQ_2_5"></a><a id="Tc_1tqR_YpGMU-Q8LhdVvoR0g_3_0"></a><a id="Tc_lgl8fGiyf0-PO86Kl5R64Q_3_2"></a><a id="Tc_G-LyStsiu0i-dcQ0faFIdw_3_5"></a><a id="Tc_NJDRzx4ip0ukxAgjxH5kNA_4_0"></a><a id="Tc_lbJuUXevjEW3lGwDdIjKXg_5_0"></a><a id="Tc_0H6EYOu5Zk2y-VvJTvKZ0w_6_0"></a><a id="Tc_1r4l7T6_aEKd5xpWbBv62Q_7_2"></a><a id="Tc_Vkhws95iyEauBM2bT5t_tw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_wT5eyRvvvk-a_YaCf81GNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb__zOCNAI7iUaLM9lCNPgl7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_4n1LF1xfEUKV2tjXfTNYCg_3_3">2,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_LcfK8H7XTUyr_GyUpOlwKw_3_6">2,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AccruedIncentiveCurrent" scale="3" id="Tc_0xLjB7BNvUy5rMYwfTX-xA_4_3">2,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AccruedIncentiveCurrent" scale="3" id="Tc_rgGuFmhS7k6NsUWXkl_y6Q_4_6">1,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_6WS6yllQwEykI7xQv83EQw_5_3">329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_JGodAjXit0i_HRmJCmIN9g_5_6">271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="Tc_NpONSPiHSkqqTZCTB48PtQ_6_3">247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="Tc_FpcMEMr1Lkyla7V4CnYRcw_6_6">226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_26Bxxa1vo0CNiolLLwBCkw_7_3">6,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_xADfxCfDA0mAJ5GoAgCjrA_7_6">4,969</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b348438f_aa22_4539_8ebd_99ed39d1582b"></a><a id="Tc_i9BE40UUUEu1zbF43mZgtg_1_2"></a><a id="Tc_JPsvSv9PTUSLYNO6E7aKHg_1_5"></a><a id="Tc_1gWGxrjnF0mlwx9Q5Bg_-Q_2_0"></a><a id="Tc_Jd53WL7GjEqQmz4CHCGcWA_3_0"></a><a id="Tc_NGwp2hHcw0GPtDS-SHy7YQ_3_2"></a><a id="Tc_n72nwvwEBk-DTHmQkw_dYQ_3_3"></a><a id="Tc_e6DBYIVQTUyWiVUUZNW3aA_3_5"></a><a id="Tc_UgHE5st_aEW5NxsXT-Ogqw_3_6"></a><a id="Tc_4DMR269vnkeNpIc-cfbY1Q_4_0"></a><a id="Tc_AWY6DoRFY0eGTjvPkHqo8A_4_3"></a><a id="Tc_bZcSBFByPkuSUPPKLBQJIg_4_6"></a><a id="Tc_61TQgeCtbUCpLTl6n2CPvA_5_3"></a><a id="Tc_u-9zac-anU6nItImdNGAug_5_6"></a><a id="Tc_BQq6RIPGpUie4RhyROTPCQ_6_0"></a><a id="Tc_FmccnwUfFEGPvTwsqWEFRg_7_0"></a><a id="Tc_UiTRtnuuHUeBmPS9ymiQ6g_8_0"></a><a id="Tc_1EeikcRyIkiYD1sIHMTUtg_8_3"></a><a id="Tc_LcnxdQf8eE-QG80Gy7wjLw_8_6"></a><a id="Tc_hqrdlaI2bEWgqJyXk7koQw_10_0"></a><a id="Tc_WHkLXLmuZk-pBZFyXvExPg_10_2"></a><a id="Tc_NWxA3Zz27ki24U5usPMTnQ_10_5"></a><a id="_89ace75a_30f6_4a72_abaa_b1cfaf44ae1d"></a><a id="Tc_Tpff_jyBO0q09WhlY7Z94A_1_2"></a><a id="Tc_Vv58OdBtO0S9iHhjLAvCZg_1_4"></a><a id="Tc_RIHcyHBhfUqiLeUk7hd5Ew_2_0"></a><a id="Tc_X9mf66Vg2ky0yKW_wzgJqg_2_3"></a><a id="Tc_8VRjWoJXRk6eqL1cE_Q2lA_2_5"></a><a id="Tc_X-G800YYp0iH8wJ5Mcr2RA_3_0"></a><a id="Tc_8NXpvxBlYEqDv-u32xUjzg_4_0"></a><a id="Tc_Md-TQQ4sv02kAQbFuFhfbA_5_0"></a><a id="Tc_5j2CzyEx_UqVaYaRz0Gzbw_6_0"></a><a id="Tc_g_OONfDVBkWK-UjhEZWn0Q_7_2"></a><a id="Tc_V5Sk2GXEp0SKGTNDyIEHSQ_7_3"></a><a id="Tc_13V1csV5Q0yreattCW9lFA_7_4"></a><a id="Tc_ouAYCVgOiE2nPzXGOjaXbg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Xgg-ffIrNUGh-g-GnYuuEg" continuedAt="Tb_Xgg-ffIrNUGh-g-GnYuuEg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Income Taxes</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_P1xZBIpWLkyIJ0tW1Y2H7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_uYo08aIeLkKXnu717tiG4g_7_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_-ZIiVlBbWUW6L7nN85S0pg_7_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="Tc_aEfVoPX7tkGOgU36rQEdkQ_9_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="Tc_iK1_vMrzyEKuDaZ_Uh5gYA_9_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_1WbI4JEdtkKagK-vcQb5xQ_10_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_rZ2PD1RwJ0CBXmAHI9lLOQ_10_6">3</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_LL8p4K9F9UOB0Vml9sOmGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_7om0mlzf10WGndjNPiIQeA_2_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_IIKVp4XtU0Wjc4uerZwS2g_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_YV4UmjcJVkGZuH3UhqnaCw_3_2">2.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_FqXz-3kBOU-Pa7KDwCWuNg_3_4">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_gKjhaG8W0U2PwMlT7dPPTw_4_2">19.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_V01UOPS8K0Cb2uwd-NjP_A_4_4">20.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_AunLTJZKZEqaNJc5mNGlkA_5_2">1.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_R95tCUobdUOXflltUGAr4w_5_4">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="3" format="ixt:numdotdecimal" name="tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_onNaxV7YrEyEaL-zm8NxDQ_6_2">5.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="3" format="ixt:numdotdecimal" name="tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_8rTAK0gNkky95kiZlgDFsw_6_4">3.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_90bbeb28_5136_42ea_bb66_720f93a1983f"></a><a id="Tc_OEr-ti0bI0ST_5gkbLXnyA_1_2"></a><a id="Tc_6KbxXepNS0uNvwcqVr117Q_1_5"></a><a id="Tc_dmpzssAtYUuzGFFfCIRZMw_2_0"></a><a id="Tc_WduVo9jW1Eqp2uswJz9VLg_3_0"></a><a id="Tc_aSaKDIMKNEGfq8Ow7ZkO7A_3_2"></a><a id="Tc_-yaF515kT0iy931cetNizw_3_5"></a><a id="Tc_Q7t7Kba2hUewslOzvosNYg_4_0"></a><a id="Tc_Z8ZyVRezJkiOFLeHZmKaOA_5_0"></a><a id="Tc_tv_J3RHp10-yvrd8Nlklkg_6_0"></a><a id="Tc_bpgGzztx1UyHd6Q4_ZJ9nw_7_0"></a><a id="Tc_uTjzrH5Y4Eu2gj3JaOY_-A_7_6"></a><a id="Tc_FEyrkG7iIEyStt2BXOvFOw_8_0"></a><a id="Tc_FAAon7rkgUGXMxvOaPME8Q_8_6"></a><a id="Tc_M13Jz3AdQk6XzHdOJgCHNw_9_0"></a><a id="Tc_Z_hpwblAxUilR7FZsyy60Q_10_0"></a><a id="Tc_VJiqqAuBnkShw-u1M5yO9g_11_0"></a><a id="Tc_5TiSOmqCKkq3G7Hq0duwLg_12_0"></a><a id="Tc_DD6dV42f40esrkyP8nBLLA_13_0"></a><a id="Tc_dkGmUum3vUqTBqPzTGT_ZA_14_0"></a><a id="Tc_PZKyDG_9vEOMcaY2Uet18A_15_0"></a><a id="Tc_xf8Pq4_68ki0PtYOD9fe7g_15_2"></a><a id="Tc_KI1Yey00K06FrgCe2gwaEA_15_3"></a><a id="Tc_vXFdHiRrtU-SGlgl8eWpVA_15_5"></a><a id="Tc_Cdbpy1E0IUWBm8-KRYDmvg_15_6"></a><a id="Tc_Pxzk_l5IPUC7pXZaqrOa-A_1_2"></a><a id="Tc_jTjdEw8MS0qp3K5qYLEkXw_2_2"></a><a id="Tc_KHpfjB28OEibowsPsF5QeA_2_5"></a><a id="Tc_wayELfvK-kGptk0mkBlmTw_3_0"></a><a id="Tc_q2PZUIbzfESWCVK6NuTwwQ_3_2"></a><a id="Tc_dRiyu188lEyD6hLg39av2w_3_5"></a><a id="Tc__9dXM1CwTUGl6nBYPpKtzg_4_0"></a><a id="Tc_XZoSFmLFckeNBkamPl7noA_5_0"></a><a id="Tc_Qv8g38LGaEuTsITCbqcvrw_5_2"></a><a id="Tc_VWMUdoG52EG57sCHkFARdw_5_5"></a><ix:continuation id="Tb_Xgg-ffIrNUGh-g-GnYuuEg_cont1"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_CTjj49HBuEOossp9-O4Y6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_YMazCPvSZUeJc5Xbhx-sPg_3_3">30,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_rnWLZEvpRECP1He_4NLhHA_3_6">27,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeferredTaxAssetsFixedAssetsAndIntangible" scale="3" id="Tc_xL2KH3QxD0upCSRL2uN7EA_4_3">2,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeferredTaxAssetsFixedAssetsAndIntangible" scale="3" id="Tc_mIVA9KbFw0Sk6C9lOJ-zNw_4_6">2,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="Tc_UBpBCyELY02nCutxgGJNGQ_5_3">815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="Tc_UDB5XV_4f0GifZ3ZoHCFFA_5_6">108</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_DB8vDxeP4k6mjd72V4OsNg_6_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_YFBv8Aj7oEmKKT88SSVNmQ_6_6">229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_TCp0ci7fpU6ax9vpG9tVqw_7_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_ObUUkgzzskOftyK203iZTA_8_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_vPI2AfRYKEeOuUH8BD5zVw_9_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_P5sgFNAMrkWscCPM9wyD-Q_9_6">63</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_b9Lk3PbfsUSc2QMatvDZ7g_10_3">38,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_yJYgX_gD3ky7SStjPoUShw_10_6">29,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_oyAVpxYJdU2EC00YlGk1iw_12_3">101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_a1N3ugHsoUCIcUEWuXt2IA_12_6">78</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_fgozKmc_aUOH2TQtrYg9PQ_13_3">38,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_8lh2f_zggUWDSkDMK-BcCg_13_6">29,630</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_4msNSaAeWkihsYdybwRkLQ_14_3">38,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_yHfCvaj8BEaOczyEbx0mKw_14_6">29,630</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of our deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As we do not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, we do not believe it is more likely than not that we will realize the benefits of the net deferred tax assets and, accordingly, have established a valuation allowance equal to <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="tlsi:NetDeferredTaxAssetsChangeInValuationPercentage" scale="-2" id="Narr_kUvNiK8vdEutX1IexakhUg">100</ix:nonFraction>% of net deferred tax assets. The change in the valuation allowance for the&#160;years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_Sv9ixvU_nU6parPNu5nMNQ">8,728</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_7kkIwCZFwUqHQjjN3MW3cQ">5,779</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had net operating losses (&#8220;NOLs&#8221;) as follows (the NOLs which do not expire are subject to an annual utilization limitation of 80% of taxable income):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Tb_VXF4wdnBck2G8tNrFM9Xqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Federal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">State</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs expiring between 2029 and 2037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" id="Tc_gxk35Kw4kkSVYBrpuOQqcA_3_3">43,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" id="Tc_B1l_XnvDok-pUm0lg6rw1Q_3_6">67,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs which do not expire</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="3" id="Tc_2XuvOyWu4ECfA7zDN7OarQ_4_3">82,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="3" id="Tc_cZT7APlOh0KQqWkUzGmPxw_4_6">18,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total NOLs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Gt9Wblhww0q2halzq5m2QQ_5_3">125,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_s7wqASYZD0q3_z08zCWukQ_5_6">85,778</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Internal Revenue Code contains provisions that may further limit the net operating loss carryovers available to be used in any one&#160;year if certain events occur, including significant changes in ownership interests. Utilization of net operating loss and tax credit carryforwards are subject to a substantial annual limitation due to the ownership change limitations set forth in Section&#160;382 of the Code and similar state provisions. We prepared an Internal Revenue Code 382 analysis to determine the annual limitations on our consolidated net operating loss carryforwards. All of our tax attributes are subject to an annual limitation. Such annual limitations could result in the expiration of the net operating loss and tax credit carryforwards before utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, we did <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_7rKX0x8pqEmHPvYAjvtrEg"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_1y7KbGaJZEmypCCh5fMUdg">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12&#160;months. Our accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our federal and state returns for all&#160;years remain open to examination by tax authorities.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_IJQ9NRGb70m4kY_3HymqOg" continuedAt="Tb_IJQ9NRGb70m4kY_3HymqOg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Dynavax Purchase</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#8220;Dynavax&#8221;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#8220;IPR&amp;D&#8221;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#8220;TLR9&#8221;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IJQ9NRGb70m4kY_3HymqOg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(&#8220;MDSCs&#8221;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:UpfrontPaymentAmount" scale="3" id="Narr_0zFWB9LdF0iudnGtrY68DQ">9,000</ix:nonFraction> that was split into two payments ($<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentOfUpfrontAmount" scale="3" id="Narr_eRtqwonc2U-KhihNPCyI6w">5,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_LAf8O94CsUeODp-5oXER8g" decimals="-3" format="ixt:numdotdecimal" name="tlsi:PaymentOfUpfrontAmount" scale="3" id="Narr_UKBdTd0va0eooUhrNgctgA">4,000</ix:nonFraction>, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The milestone payments range from $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MinimumMilestonePaymentAmount" scale="3" id="Narr_fBDy9Qjx4kKRH6wSVfFDKA">1,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MaximumMilestonePaymentAmount" scale="3" id="Narr_hxwzdZfkHUq6wdCQkqZkDg">10,000</ix:nonFraction>, triggered by development achievements for each of up to four indications. The development milestone payments cannot exceed $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MaximumDevelopmentMilestonePayments" scale="3" id="Narr_9QYZxVX-akaOpBJJkUxLtA">170,000</ix:nonFraction>. We made a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_lt1UpQkALESaPZXbSwBQZw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentsMade" scale="3" id="Narr_g5BPp0qdske3SdYmA9_MPw">1,000</ix:nonFraction> in September&#160;2021 after initiating our clinical study of uveal melanoma liver metastases. We made an additional $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_A5ZRtG0Mp0KDhqGdsKvyPA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MilestonePaymentsMade" scale="3" id="Narr__JVqsdgnlkOhoB0k7ifGpQ">1,000</ix:nonFraction> milestone payment in June&#160;2022 after initiating our clinical study for primary liver tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we will have to pay up to <ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfCommercialMilestoneToBeMade" scale="0" id="Narr_gJrH1D37PUy7S3mKZFoTFA">four</ix:nonFraction> commercial milestones, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember__otGtNiDqUS3D-2IJAK-XQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CommercialMilestonePaymentAmount" scale="3" id="Narr_fDBLP4jcW06-9Ovpd1tjjA">10,000</ix:nonFraction> upon first commercial sale of the product; $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CommercialMilestonePaymentAmount" scale="3" id="Narr_64PGZiDl_kSHjBlvuXHnjw">20,000</ix:nonFraction> upon the first occurrence of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AnnualNetSales" scale="3" id="Narr_6-06xzL22kizmJw8oR-b3w">250,000</ix:nonFraction> in annual net sales; $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CommercialMilestonePaymentAmount" scale="3" id="Narr_tnDacvbXgESKI-yWWj3C-g">20,000</ix:nonFraction> upon the first occurrence of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AnnualNetSales" scale="3" id="Narr_HDsbXnuXJUa0foRIECTYhQ">500,000</ix:nonFraction> in annual net sales; and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g" decimals="-3" format="ixt:numdotdecimal" name="tlsi:CommercialMilestonePaymentAmount" scale="3" id="Narr_Sk6JOzHmLEuCBSOuUfevJg">30,000</ix:nonFraction> upon the first occurrence of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AnnualNetSales" scale="3" id="Narr_OO5_mYBMNk6mOnTdUXJWOQ">1,000,000</ix:nonFraction> in annual net sales. In aggregate, the commercial milestones shall not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MaximumCommercialMilestonePayments" scale="3" id="Narr_IFtBwR_3a02gKb061dlLpw">80,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will also pay annual royalties at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg" decimals="2" format="ixt:numdotdecimal" name="tlsi:AnnualRoyaltyRate" scale="-2" id="Narr_bX2bi_7Ei0q6oVktQXCPPA">10</ix:nonFraction>% for aggregate annual net sales less than or equal to $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AnnualNetSales" scale="3" id="Narr_9KyyLmOD6ESoW5cjufAMrA">1,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_xsabo2n52UilLgijgS19aQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:AnnualRoyaltyRate" scale="-2" id="Narr_26oqyzG9PkCdwgqwgI8VsQ">12</ix:nonFraction>% for aggregate annual net sales above that amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recorded the first and second development milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_rmbLcmOtAU-0t0vs9Lj3pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="3" id="Narr_UclupzQKtU6MyipMnYlBzw"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="3" id="Narr__pu4bQurm0mLeTWUbUkERA">1,000</ix:nonFraction></ix:nonFraction> in R&amp;D in 2022 and 2021. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.</p></ix:continuation><a id="Tc_s-XTT0AXaESQTaThWKCBBg_1_0"></a><a id="Tc_DRV3v9S7VEalXrP4flAVJQ_1_2"></a><a id="Tc_B2YA6XcRyUqywMIPUIvEPw_1_4"></a><a id="Tc_gj5zHYs-zU-Y0BS5lRvbbg_1_6"></a><a id="Tc_nmfpOywkak2QT6ojEQknyw_1_9"></a><a id="Tc_kJ85Yc9a-UGePlOv3_wbpA_2_0"></a><a id="Tc_QPpmLmKw5k2kl-4bVEjw9w_2_2"></a><a id="Tc_tW4y1NCjE029O7Nf3GinmQ_2_6"></a><a id="Tc_lIAPX3VD-E6be8smOcXyeQ_2_9"></a><a id="Tc_xSZzTD8lekuWAClYNinp1w_3_0"></a><a id="Tc_91in0Rwom0-EFSGrSgbUTg_3_2"></a><a id="Tc_P51ZJzXNFk66fZ5LYty5Ow_3_6"></a><a id="Tc_jP7tN59IskqycmjA1E2dhg_3_9"></a><a id="Tc_81cyfGARa0eY53xJl61LWQ_4_0"></a><a id="Tc_JOI7VrUY_kuIInxqqb7cyg_4_2"></a><a id="Tc_xFChUWU5M0S5lmh5XjJfTg_4_6"></a><a id="Tc_hAQBYDjYwEW0nIZfpqreKw_4_9"></a><a id="Tc_rXh_lYB94Eu03sBitLVzYw_5_0"></a><a id="Tc_XJWo31yar0ajcFEplxmsDg_5_2"></a><a id="Tc_QupGW0xzg0Wo2EV0utlikw_5_6"></a><a id="Tc_clpbVbieK0-gnlb9ivRr8A_5_9"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:DebtDisclosureTextBlock" id="Tb_IzZKdkHvJEq2iWKex8nKZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, we applied for, and received, a loan of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="Narr_hzKXHUKa1EWlKM-duz1VfQ">828</ix:nonFraction> under the Small Business Administration (&#8220;SBA&#8221;) Paycheck Protection Program (&#8220;PPP&#8221;) program. Under the terms of the program, the loan was used to fund retention of employees and facility expenses. The program provides for forgiveness of the loan after a period of time if the loan was used for approved expenditures. On April&#160;19, 2021, we received notice that the SBA had forgiven the loan. We recorded the forgiveness as a $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_4_19_2021_To_4_19_2021_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_SAPDdK4uLkukkpYiynrn7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="3" id="Narr_QsLjTMiTbE6tAFGox36fYQ">828</ix:nonFraction> gain included in other income and expense, net, in 2021 in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Term Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The term loan and supplemental term loan matured on November&#160;30, 2021, and were paid in full, with a final payment of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_DebtInstrumentAxis_tlsi_TermLoanAndSupplementalTermLoanMember_K5TX_Dl3_UOXwI1TQxgdow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="Narr_2DV5MSfEakm3-vu1Tgoo_w">1,348</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the term loan, we issued the following warrants. All the warrants expire <ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_eY8Sd4knlkW8tUGMvbUTVw">10&#160;years</ix:nonNumeric> after the issuance date. The warrant liabilities are carried at fair value; the initial fair values listed below were recorded as debt discount at the time of issuance and amortized as additional interest expense.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_34UTSUtsg0qsC0cvxA-1tg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial&#160;Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">08&#8209;26&#8209;2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Tc_zPCEk--olkefHZeUAg3cZw_2_4">3,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_0A6iQrfUlEuhE2ZPWLv3cg_2_7">17.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Tc_MKhrncsMp0ec9EDRsNdhWw_2_10">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">10&#8209;27&#8209;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Tc_TQ-443VvV0GcyCXku93EcA_3_4">842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_IdZTEB5j-kuF4rLwyASIuw_3_7">17.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Tc_dX-47yEjw0uHKLP0Kdc-Og_3_10">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">06&#8209;30&#8209;2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Tc_JoqVjqfS1EOTM7s7PUEQ2A_4_4">4,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_goHW2Hnbx0C30peL4nuaoA_4_7">20.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Tc_G3lu_0fqb0mVBxAtiKUDeQ_4_10">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">11&#8209;20&#8209;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Tc_DHKwLApHMUurVJDB5dZGZg_5_4">741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_EQtqcxcQzUOmx6v9_O3hnA_5_7">20.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Tc_kE8H6WHcGUSrlU2Hp8WSLg_5_10">12</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ConvertibleDebtDisclosureTextBlock" id="Tb_xgQQefXGJk2SW3KOvp0daw" continuedAt="Tb_xgQQefXGJk2SW3KOvp0daw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-weight:bold;">Convertible Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;and September&#160;2018, we issued convertible notes for aggregate cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_1_2018_To_9_30_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_2DKAccvY4ESMxGwfCcxgEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_SNiat9stw0GOjSwfNylSEA">5,000</ix:nonFraction>, which had an original maturity date of December&#160;31, 2019. The maturity date for the convertible notes was revised in 2019 to be December&#160;31, 2020, and in 2020 to be December&#160;31, 2021. The extension of maturity dates in each case were determined to be modifications to the debt instruments. Between May&#160;and September&#160;2019, we issued additional convertible notes for aggregate cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_5_1_2019_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_JxTqOZ5zzEWxBqVPHktsLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_w0VUQ7-ZX0CwSmHiTaYxYw">15,000</ix:nonFraction>, with a maturity date of December&#160;31, 2020, which was also modified to December&#160;31, 2021. Between March&#160;and October&#160;2020, we issued convertible notes for aggregate cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2020_To_10_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f8UN7L2qYEiwdyhrpna6mA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_4LjeKJ-1akmEZPWpvhKn_g">9,102</ix:nonFraction>, with a maturity date of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The convertible notes accrued interest at <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_0CJ_pzz0lUmi7opab-kWyA">8</ix:nonFraction>% and could only be prepaid upon the favorable vote of the majority holders. When and if we complete a &#8220;qualified financing&#8221; on or prior to the maturity date, the unpaid principal and accrued interest on the convertible notes are automatically convertible into the same class of preferred stock offered in the qualified financing at the lesser of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_6vSyDrzYAEa8bCqilq9-Ow">0.50</ix:nonFraction> per share or <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA" decimals="2" format="ixt:numdotdecimal" name="tlsi:DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" scale="-2" id="Narr_bc6YMkZmE0aV_nRVA1Cnmg">85</ix:nonFraction>% of the price per share paid by cash purchasers for the preferred stock issued in the qualified financing. (This discount on the price per share paid by cash purchasers was subsequently modified in 2021, see below.) A &#8220;qualified financing&#8221; is a preferred stock financing transaction for the purpose of raising capital with gross proceeds of at least $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:QualifiedFinancingMinimumProceeds" scale="3" id="Narr_ZayNdoz1k0CL98W0hA5W3A">5,000</ix:nonFraction>, excluding all proceeds from convertible notes that convert into preferred stock in connection with the financing. This conversion upon a qualified financing feature essentially provides the holder with a fixed return that is settled in a variable number of shares. As such, it qualified to be accounted for as an embedded derivative, a put option liability, at fair value. The put option liability was initially recorded as a debt discount and subsequently remeasured at its fair value each period end. We estimated the fair value of the put option liability based upon the <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" scale="-2" id="Narr_nkRhgx3Lak2jdnzLEOnpfw">90</ix:nonFraction>% probability of a qualified financing occurring multiplied by the value to be received by the holder (Level&#160;3 inputs). (We estimated a <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA" decimals="2" format="ixt:numdotdecimal" name="tlsi:ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" scale="-2" id="Narr_DiXwgC4GKU2npdG0i3SmmA">10</ix:nonFraction>% probability that the convertible notes would convert at maturity.) The put option liabilities associated with the 2018, 2019 and 2020 convertible notes were initially measured at $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_n7C8O3tfnEa9PI51Rt_RTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="3" id="Narr_icl_n570D0KOuoo8jjRjRw">794</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_o2D8Am3EA0qP-aO4LNlnsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="3" id="Narr_UinwBJ5o00aQO_p2LpqWBQ">2,382</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_QnfyiZ486EqFzaXxwbOqWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="3" id="Narr_2uY-VCH4cECTwj3v0q4-Lw">1,446</ix:nonFraction>, respectively. The fair value of the put liabilities did not change at December&#160;31, 2019, 2020 or 2021, as management&#8217;s estimate of the probability of a qualified financing did not change. Through December&#160;31, 2021, additional put option liability was recorded for the conversion feature applied to the accumulating accrued interest balance of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Narr_BuAFRsYgiEC4M_zSIjK6HA">303</ix:nonFraction>, which was recorded as additional put option liability and debt discount. The discounts on the debt as a result of recording the initial put liabilities was amortized to interest expense over the term of the loans using the effective interest method.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Between March&#160;2020 and December&#160;2020, we also issued convertible notes for aggregate cash proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_6hORdNW_yE623vRVLJelFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_eZvYQ2pHp0GC-o2HmLOOLw">15,545</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. An additional convertible note for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Narr_ZjHNGsQBQUieTKH9UPxzvQ">45</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was issued in January&#160;2021. These notes differed from the other notes issued during 2018 through 2020 in that they did not contain the conversion discount of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jGJ8x1reCEyfHu4lILMFaw" decimals="2" format="ixt:numdotdecimal" name="tlsi:DebtInstrumentConversionDiscountPercentage" scale="-2" id="Narr_XxEQ0KJTjESQq2Tkcm4UUw"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg" decimals="2" format="ixt:numdotdecimal" name="tlsi:DebtInstrumentConversionDiscountPercentage" scale="-2" id="Narr_2ZmyeQ9Y-UOQNLg0_a_OkA"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wbWlcEUxYUS1rDanZQ4z-A" decimals="2" format="ixt:numdotdecimal" name="tlsi:DebtInstrumentConversionDiscountPercentage" scale="-2" id="Narr_RK3kZgmGeEW4br6ZVWUEgw">15</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';">. Instead, they were accompanied by warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_MJ9W3dmsEk6qy7Ek7cQ_vw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_CMzjeV9K-U-hWP2yd39gXQ"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_SefCuqd2PUqLPsySyGLVJg">385,361</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> Series&#160;A-6 preferred shares at </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_R-OjogEUQ0GdNG1HDmSuFA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_I5T1IqKa3EWip4j9AegEGw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vRL2IfFpO0u7cVCe4hneZQ">0.01</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share initially, which upon issuance of the Series&#160;B Preferred Stock in 2021, were automatically converted into warrants to purchase Series&#160;B Preferred Stock. The warrants expire on the fifth anniversary of the issue date. All other terms of the notes were the same. Since the warrants are for preferred stock that were initially redeemable, they were recorded as a liability in the accompanying balance sheet at December&#160;31, 2020. The initial value of the warrant liability of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:InitialWarrantLiability" scale="3" id="Narr_lR88djeyOkSoAka2w4PVuw">3,887</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (</span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:WarrantIssued" scale="3" id="Narr_KGImDPbHuU-0LUk-LA3adA">3,877</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the warrants issued in 2020; </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:WarrantIssued" scale="3" id="Narr_4KUuVLQHnkeMmyfp8bxGzQ">10</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the warrant issued in 2021) was determined using the Black-Scholes method and resulted in an additional debt discount that was being amortized to interest expense using the effective interest method.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The convertible notes also included a provision whereby upon a change in control prior to the conversion or repayment in full of the principal amount of the convertible notes, the Company would be obligated, at each holder&#8217;s option, to either (A)&#160;pay such holder in cash an amount equal to (is) the outstanding principal and interest accrued to that date, plus (ii)&#160;a premium equal to 100% of the unpaid principal and accrued interest, or (B)&#160;convert the outstanding principal and interest accrued to date into Series&#160;A-6 preferred stock at a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_JJrctF3Ss0aVYnhFS_75uQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_3kEwp6Igr0SqUkmRvnq1rg">0.50</ix:nonFraction> per share. This change in control prepayment and conversion provision qualifies as an embedded derivative and has been included in the fair value of the embedded derivative noted above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, the convertible notes also included a provision whereby the unpaid principal and accrued interest would convert at maturity, at the option of the holders of at least 2/3 of the outstanding principal amount of the outstanding convertible notes, into shares of the Company&#8217;s Series&#160;A-6 preferred stock at a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_Z3lUDqKSpU2d131KWzDy6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_I5phJSu5MEmFiWJ2HKrVmA">0.25</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest expense related to convertible notes was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w0DdgmyjNEGACAuQcuscQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Narr_x2Srf1ogh0CGdNJkvdLojA">1,773</ix:nonFraction> for the&#160;year ended December&#160;31, 2021, which included the <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_MG6ESS3k-kOnez8ZgJ4H2w">8</ix:nonFraction>% stated interest and amortization of the debt discounts associated with the embedded put liabilities and attached warrants.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2021, the Company&#8217;s board and note holders (many of whom are also stockholders) agreed to eliminate the </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A" decimals="2" format="ixt:numdotdecimal" name="tlsi:EliminationOfOccurrenceOfDiscountPercentage" scale="-2" id="Narr_DfDtblZ9xk-H-dmxgruapg">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> discount in the next qualified round of financing attached to the 2018, 2019 and 2020 issuances of convertible notes. We determined the elimination of the </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A" decimals="2" format="ixt:numdotdecimal" name="tlsi:EliminationOfOccurrenceOfDiscountPercentage" scale="-2" id="Narr_T0M44rwwp02amFKtLpDivg">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> discount was a modification of the convertible notes with related parties and, as a result, we recorded the impact of removing the put option liability associated with the convertible notes of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" scale="3" id="Narr_jIkLa_6ke0SuqPB-AO6YHg">5,210</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to Additional Paid-in Capital in the </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xgQQefXGJk2SW3KOvp0daw_cont1"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">accompanying consolidated balance sheet for the&#160;year ended December&#160;31, 2021. Also in March&#160;2021, the issuance of Series&#160;B preferred stock was determined to be a qualified financing event. Accordingly, all of the convertible notes, with a notional amount of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_3_31_2021_peL04lSM_U-U4I3kzipk2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="3" id="Narr_5H0BrmDqUk2-KjoYljakeA">44,692</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, were converted, with accumulated interest of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Narr_fp6tHzX5H0OUcmOSUg1swA">4,426</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, into </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_KsvlqYy--EiWOn8_HmhiTQ">4,047,069</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at a conversion price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_1dgD9UgSsUOUT0C3-2EgTQ">0.30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share. Upon the conversion of the convertible notes to Series&#160;B preferred stock, we also recognized the remaining unamortized debt discounts associated with the conversion features and warrants in the aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnConversionOfConvertibleNotes" scale="3" id="Narr_6LTPlEjQR0G553HBryGErQ">3,416</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> as a loss on conversion of convertible notes in the accompanying consolidated statements of operations.</span></p></ix:continuation><a id="_5be4e566_2385_415e_878e_d33afb70502c"></a><a id="Tc_CmbpHbhwdUyWGDvgDvQ0DA_1_2"></a><a id="Tc_b55RIfyCTUGX11YEaJtdyg_2_0"></a><a id="Tc_pJ-9dl-9802JR12rfwUhxQ_2_2"></a><a id="Tc_r4UG-6pEa0K4Ztt2od7T8A_2_5"></a><a id="Tc_vVi1HNHktki6GsNNR9pbtA_3_0"></a><a id="_7d38f6bf_b421_42d5_b8e1_60fc6d81dfdb"></a><a id="_7d38f6bf_b421_42d5_b8e1_60fc6d81dfdb_2"></a><a id="_7d38f6bf_b421_42d5_b8e1_60fc6d81dfdb_3"></a><a id="_446d6d4f_329a_4986_a5a7_ebeebdefa878"></a><a id="_446d6d4f_329a_4986_a5a7_ebeebdefa878_2"></a><a id="_446d6d4f_329a_4986_a5a7_ebeebdefa878_3"></a><a id="Tc_oCCbvee9P0SzHxB-lI-Drw_3_2"></a><a id="Tc_lNyQaGiGyU-rYp7B40psSA_3_5"></a><a id="Tc_BHPKJWRut0GuAO5OeYcNRg_4_0"></a><a id="_c4613bad_3dfc_46a4_babc_b63108cd37d7"></a><a id="_c4613bad_3dfc_46a4_babc_b63108cd37d7_2"></a><a id="_c4613bad_3dfc_46a4_babc_b63108cd37d7_3"></a><a id="_986bc222_391c_4ccf_a766_aba901aacb6b"></a><a id="_986bc222_391c_4ccf_a766_aba901aacb6b_2"></a><a id="_986bc222_391c_4ccf_a766_aba901aacb6b_3"></a><a id="Tc_LB01fb9o2kmfvfH9rV_G9Q_5_0"></a><a id="_413b1170_0db0_4e7c_91ea_ca92785030ae"></a><a id="_413b1170_0db0_4e7c_91ea_ca92785030ae_2"></a><a id="_413b1170_0db0_4e7c_91ea_ca92785030ae_3"></a><a id="_a8f91a64_3a36_44e0_915d_13c61d769931"></a><a id="_a8f91a64_3a36_44e0_915d_13c61d769931_2"></a><a id="_a8f91a64_3a36_44e0_915d_13c61d769931_3"></a><a id="Tc_RHnREX5ROkuzs2QlrwV2Ag_6_0"></a><a id="_e3e340e8_6c87_4d4b_aaac_826416caaec2"></a><a id="_e3e340e8_6c87_4d4b_aaac_826416caaec2_2"></a><a id="_e3e340e8_6c87_4d4b_aaac_826416caaec2_3"></a><a id="_51b236bb_a4d1_4629_8868_bea02271e5d3"></a><a id="_51b236bb_a4d1_4629_8868_bea02271e5d3_2"></a><a id="_51b236bb_a4d1_4629_8868_bea02271e5d3_3"></a><a id="Tc_uvuw3hTn70qzRGXmIOuNfQ_7_0"></a><a id="_8190db6d_0774_424d_8ac8_e675dca45c78"></a><a id="_8190db6d_0774_424d_8ac8_e675dca45c78_2"></a><a id="_8190db6d_0774_424d_8ac8_e675dca45c78_3"></a><a id="Tc_5XyCYRfTZEeQjc2fTZxLWw_8_0"></a><a id="_f366dc3b_3b70_40b0_a1f2_97eb0aa427be"></a><a id="_f366dc3b_3b70_40b0_a1f2_97eb0aa427be_2"></a><a id="_f366dc3b_3b70_40b0_a1f2_97eb0aa427be_3"></a><a id="Tc_MrIiJ41k6UalREBlXKEt5A_9_0"></a><a id="Tc_cRkxrnQjIkGU1qYSql5VMA_10_0"></a><a id="Tc_O5m3d6kT9EybBhK_qiG4aA_11_0"></a><a id="Tc_HP9tipOKwUGwvWRn69gmdg_11_3"></a><a id="Tc_qjiucrqBikWg21lSzAKPmg_11_6"></a><a id="Tc_epsyNXZh50SCqjfk-U2Osg_12_0"></a><a id="_8b431a35_d43d_4af9_a690_a09354d6eaf5"></a><a id="_8b431a35_d43d_4af9_a690_a09354d6eaf5_2"></a><a id="_8b431a35_d43d_4af9_a690_a09354d6eaf5_3"></a><a id="Tc_qXbbYFbRvUSxmTFETQHPGw_12_3"></a><a id="Tc_n3SmPvuZkku5fqJdtauw3Q_12_6"></a><a id="Tc_UDMEeoPtm02-axo8vkvY4Q_13_0"></a><a id="Tc_83ONo-SwnUy4B-LZETmEjQ_13_2"></a><a id="Tc_GjODBVhdK0GQ22vHnruBXg_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ConvertiblePreferredStockDisclosureTextBlock" id="Tb_ePYxzYjjoUCHHIX78Ei6qQ" continuedAt="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(12)</b></span><b style="font-weight:bold;">Convertible Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have issued various series of preferred stock as more fully described below. Prior to March&#160;2021, the preferred stock was redeemable at any time after February&#160;21, 2022, upon the affirmative vote of two thirds of the then outstanding shares of preferred stock. In March&#160;2021, the redemption feature was eliminated, however, the in-substance redemption feature described below is still in place. Upon an acquisition of the Company, the proceeds will be used to first pay the liquidation preferences on the preferred stock, as defined below, prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our board of directors and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#8201;&#8212;&#8201;and thereby redeem the convertible preferred stock&#8201;&#8212;&#8201;is deemed to be outside of our control. As a result, our convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments are currently not redeemable and we believe it is not probable that the instruments will become redeemable at this point in time. Adjustments to increase the carrying values of the respective liquidation preferences will be made if and when it becomes probable that an event would occur obligating us to pay such amounts.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_ZNSVlOFotU-PiDjRmPOAFA" continuedAt="Tb_ZNSVlOFotU-PiDjRmPOAFA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_Ox5JoLyNRUex-6P4P9cCTA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_QHjN0JdJckmHuA2DbFLEuQ">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized, issued, and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_HxeFLiP48kGKY7H5KEYWcg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_laz41fKv4UyF1aXbKwmmtQ">131,797</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_nI4mMcg87U-Mv_vA6qFPOQ_3_3">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_H1EDHADeu0WV20kewvK9Sg_3_6">6,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_1zycMJTvj0i3fwcsot--yQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_PXqYwKW9tUqpKiyHf2ETbA">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized, issued, and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_XbfwEg1qvUCMcuu6SsNAEA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_ZtFNrrCoN0aH34e5OpF_xw">576,126</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Kcy88n1-bEOoPvj0kqh5Bg_4_3">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_ZzLYbA9SMUCAAoEBP9Fm5Q_4_6">8,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_oV4PKcrOMkq4RnbAh0A_sQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_kHIToVUDr0-ujAwZq0XBpg">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized, issued, and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_05ZT2eJ0BkKDQqxiVmUk7g"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_nYOBJ0X1dE2g9ZosLy8fLg">612,822</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_8U3-2Vj5gkKLdqHngnscqg_5_3">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_bjtnVIJQrk2I7uNw6Uttkg_5_6">10,611</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_c-aZjRABuEKY4kO9mZQu-w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_f5DOSnRE_k2vWKnUucnkeg">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized, issued, and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_bb6M-nkh50GtQjCOvKAWqA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_1lW0KcHUgUO1lkUU7arZ1A">127,787</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_l1ATchiFBkyckne1elHT0A_6_3">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_UdFKCeP_Vkmxl_Cnn0DuxQ_6_6">1,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_iT-WIrLSK02zsjMMTZw35Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_AHxpXJ9ikUaH1klmVzlaQQ">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_t9fTedoXu0-dcLHJ-vBEnw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_1db3fwFQHkqe_fHIo_NDDw">734,533</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_WMFfd8KVVE2gUvV-C97nUQ"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_C4DIRbwa40CSAuk5vuys8g">730,320</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_zGEUSsEHAkyFAfwSkqHRfQ_7_3">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_dwynKVfbKEWEGMqm9vTojA_7_6">12,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_WEf3711DaE6pzBbKZW3crw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_hDY9LeOdFUSqCWSjUP8q9w">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_gh7eM3GFQUW1IFhM08Okng"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_AVR3iuQRck2QDwyeXOvDUg">805,848</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_wjH5EbOl-UCPAv4nNR9Wfg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_XPBWstTTnE-QZijcSEZc8Q">800,657</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_xGEgerm-CEuLy37cn_eWIQ_8_3">15,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Ae8oD3Izo0mVAgJdp4RE4w_8_6">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_FvRCkzRJPUmwAAusJtLdQg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_q3t8qCo8Gk2zRHm-rdAxhA">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_i657U6JLIk6x33Kpn1SoeA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_bTQHaAz75USoQiQv2j4shA">7,021,678</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_3Sux7uI2gkCN6KKTYvZZvg">6,984,971</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_DVdjV39RPE6l53fcaCkx4w">6,984,971</ix:nonFraction> shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_g-dbb-Y34UGqV1rZoiy1Pg_9_3">84,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_DmrgXnvWvk-XpEBzda9Ttg_9_6">84,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_s7hv50y0vUGcguzop5cS8g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_LmS72rySrU-NaX2kPIg2rw">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_twQnf1KIzkS28EDEVLcidw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_NNho6G4hIkC-xav9z6MUtA">1,659,672</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_2LchdvFvrUiTfp0RkP0ETg">1,659,672</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_SXsj0oij5E-sIrlquQgAbA">1,412,487</ix:nonFraction> shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_xLB886tS9UOsTBwhbvYQYw_10_3">23,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Ugj15VXfkEm9hecbAXjKow_10_6">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_UgEGEnUtK0Kq3bQafHiucQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr__5utx0Kxx0WbsnxwkB5Ihg">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr__pbUIQ4f706tC1dUbGMpEg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_44MzKmr_3k6AdmJ8Dk_i_g">1,765,609</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_7qBInBUlmEGRwMLaJY_qQg">706,243</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_58r3zl_Ou0ueNK6GWjHXzQ">0</ix:nonFraction> shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_kgV4oHA5EkeB_G9fctQr7A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_2tMiln59s0q9ufQU4uIMpg">0.001</ix:nonFraction></ix:nonFraction> par value per share. Authorized <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_W0pP7nL-kUKoqmXG9OndpA"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_u7I-ISpK8EideEDRBuZCHg">8,474,924</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_R-tGGS1uC0yuUg_GBvanbg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_Na_4x6j8CEWXiB29Gu-D9g">0</ix:nonFraction></ix:nonFraction> at shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_h0bUSXb1UUWjxamhyvVFuQ_13_3">164,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_iJbV8WHBUUSiHtm7r90eaQ_13_6">160,507</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a1fe0514_32eb_486e_9af3_4b057fc0dc69"></a><a id="Tc_xDv3ZoZ8-k64pajrxARb6g_1_2"></a><a id="Tc_mT7ip-PvLkqsZ8jqM80qfA_1_8"></a><a id="Tc_HPFvwLwuvU-43oUN6jDoKA_2_0"></a><a id="Tc_U3o196Qa2U-0s19MVKdeAw_2_2"></a><a id="Tc_wHK3Xjrr_0W3rzOgPSqvmQ_2_5"></a><a id="Tc_igJrvCcjBEeUephbOOZCtQ_2_8"></a><a id="Tc_YehG0Pxll0emhiTB0SOj-w_3_0"></a><a id="Tc_k_mOXQykYEaXMk96CPtgNw_3_2"></a><a id="Tc_Lslv41dLv0uH-v_XuDVF7g_3_5"></a><a id="Tc_xsbC2GXxqEe0pCntqEZ9qQ_3_6"></a><a id="Tc_8qYbit4NBU-gzPPG6b_v9Q_3_8"></a><a id="Tc_ocJXrKr-BEio3FkR7EXqnA_4_0"></a><a id="Tc_H0xa1bGtn0qSkUOt82rGTw_4_6"></a><a id="Tc_Txnq39ySe0628wDdLXG8Ww_5_0"></a><a id="Tc_qCanvK-DNkGvkIlFxzZmcA_5_6"></a><a id="Tc_C4PCnFqwi0Wb2PGLwCblQA_6_0"></a><a id="Tc_mR-sMAzNgUSwaa2dZgzAFQ_6_6"></a><a id="Tc_uEk49pd1UkyqqMo0esHmXg_7_0"></a><a id="Tc_i5fYl4qwQUi6b66aUU1uAQ_7_6"></a><a id="Tc_NdveH4haG0WHXw60oeoKFw_8_0"></a><a id="Tc_Aib9sEV7GUiMwX1vt5YiZQ_9_0"></a><a id="Tc_FiqJLr-rEUi0PLdAxRJ3VQ_9_3"></a><a id="Tc_olBVOcb9lUmHHSewnHjjPg_10_0"></a><a id="Tc_vse6FZV0x0ewhhVhZZum9Q_10_3"></a><a id="Tc_6sds29D_50KEe0qfbf94wQ_11_0"></a><a id="Tc_pSAK4imdvECJYGqZ3qjfyw_11_2"></a><a id="Tc_e-PI33JWwUaaSe8BeHiNMA_11_5"></a><a id="Tc_9NBXL_y0hUqsxcsEtfWfXg_11_8"></a><a id="_f976a4b2_2d92_4160_969c_39d02a3ec415"></a><a id="Tc_bfwUUSV4G0aaCDUqGcs40Q_1_2"></a><a id="Tc_QhXEJW_iV0m9vMyI_Vq--w_1_8"></a><a id="Tc_c8Wbsi8AsE644rA772Zx0Q_2_0"></a><a id="Tc_RqdkEcTQUUaUfTfCBpgmEA_2_2"></a><a id="Tc_06T0-dNI0Uq3jL4XI4gmgw_2_5"></a><a id="Tc_MSCs1J3shkiSRltUHaHQjQ_2_8"></a><a id="Tc_imzpxRvIg0GUc69lydaIMQ_3_0"></a><a id="Tc_dXB2Y-UvlkKO6GP2Gh3SxQ_3_2"></a><a id="Tc_-uKPjGPWEk26x5-iz7YxEw_3_5"></a><a id="Tc_tA1v0lLpx02oxCefl3Pflg_3_6"></a><a id="Tc_eL361otuiEqEWRLd7ADP1Q_3_8"></a><a id="Tc_U92CykEMjUSHrAKpQjZlNA_4_0"></a><a id="Tc_Ng11YldjwkKIwC1McOCN1A_4_6"></a><a id="Tc_WS0cuLTk3EWK7jh2nhCLDw_5_0"></a><a id="Tc_1dUttAbmREGb4BH8nvlZww_5_6"></a><a id="Tc_SfZszr5N6EKRSa6Fb5NAyQ_6_0"></a><a id="Tc_gg_-R8MfPkKKXakimgWXTA_6_6"></a><a id="Tc_oGgsVtd4UkqFw_dA8Vfo8w_7_0"></a><a id="Tc_kGWj82iAL0S29BREZ7eyqA_7_6"></a><a id="Tc_zLhvufsLK0GVr8yXXJXTaw_8_0"></a><a id="Tc_M-jRfVgQ4Uup9MW5TtmUAA_8_6"></a><a id="Tc_ByLGEKFpwEu2wB0zW_szEA_9_0"></a><a id="Tc_Sh9sDHeDgU6T2tFOroVQsg_9_6"></a><a id="Tc_kkjaNlNG40yl8LPrLxevCg_10_0"></a><a id="Tc_eWLAG-l4vUmlIQ3Gejgutg_11_0"></a><a id="Tc_PvIH6IJxMk20lzRlumbapw_11_3"></a><a id="Tc_xIRPJ9k-wke1055lHxYCDw_11_6"></a><a id="Tc_cAr2pdKgpUSXvNDlS6kY1A_11_9"></a><a id="Tc_XJ9ABgf4T0yMWqrgcAX7pw_12_0"></a><a id="Tc__s9cmCUuNk6RftQ9RtMJ6A_12_2"></a><a id="Tc_n4pTCxrx8kGn5IF_ONnC8Q_12_5"></a><a id="Tc_-PEh7b0SYUCiMyrlTn3KLw_12_8"></a><ix:continuation id="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont1" continuedAt="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont2"><ix:continuation id="Tb_ZNSVlOFotU-PiDjRmPOAFA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" id="Tb_xoURK7bCsE2Dol7d3diEaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity in convertible preferred stock for the&#160;years ended December&#160;31, 2022 and 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January&#160;1,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_94WSWWTYZ0-oiPrmTAHAog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_JyVg4yUsY0qLATD2rfVyKQ_3_3">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_6VpDzTSR20uMNh9CpJUjBg_3_9">6,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_WsB6XkUK_EudysZ944qZNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_7BbbosxTt0C2pt5sKH0OpQ_4_3">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_hgo_W7bSWkWj9tGhuyqUcw_4_9">8,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kPXiLC6i0kmzr0XFHhfPLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_lO4vkBygXkWsoCs-Xy0fIw_5_3">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_dUbhjqn1TEy2hTaRq9mktw_5_9">10,611</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_3a3-tw6PskK-JRJJsHXixQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_JjZvuU2j7EC9A1elG5XT5g_6_3">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_DL2y0SsQ8EWKG0hSUmZqJA_6_9">1,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_H2sJkceQxk2-u0Rxe759jQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_-ZBM0aCcUECMBQMzvYawlA_7_3">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_P2oEzV6jlkSnrrS7L4Ytug_7_9">12,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_VQjBztCgREimLMoQNXlNZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_3QmiQE-UfkWVEL0rThn0Bg_8_3">15,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_hN-8AGcFuEuZnr2HwF1cJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JR2YlRlb90icpI9xQBK-oQ_8_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_zfD85pbcVUequSUPk1Yxyg_8_9">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_YRX9eNe2yk2VIn3MFun3YA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_q4Q5G3ZJf0-AxSa7m-UdGQ_9_6">84,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_LA-MIFsTK0iEpIrEuH5c4g_9_9">84,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_lounZVZfw0O8AKj7iHFE-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_rXdHKI4PnUWI2s3nGd-avw_10_6">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_2ntMInsZs02xXM_6VSSHsw_10_9">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_dtFerdW6g0GCAK0beQ6IQw_11_3">55,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Oh20LuCzo0qkuRWcDarJzQ_11_6">104,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_eXGjAsoTaUqcHxiQ7U68GA_11_9">160,507</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_cB7cgGM8oEOtGencKby59A_3_3">6,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_MiO6_gnw4Ey-xSJquUkNZg_3_9">6,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_P1JISxESS0eQckNPQFMmnw_4_3">8,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_V5Ni2ublpEawHX_k6YWgIQ_4_9">8,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_d3N3Ynk1GUaFZ-2GWU-sKw_5_3">10,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_HSQ6bdMPhEaSTsgRs9IKBw_5_9">10,611</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_aIegGWhz5kqMLX0rTKdi0Q_6_3">1,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_rPhR-KICVkCyBXPQEgr6iA_6_9">1,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_jm0XoRVS20Cg-r7sr6SBQw_7_3">12,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_fweaYOgo7EiDer_Jj0iMxQ_7_9">12,858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_LjcZWcxWuUSITTdL6RdCow_8_3">15,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_hQUHyPeSPkqLbtVnsycgoA_8_9">15,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_lexe6yWxz0y9Ps4TablZzg_9_3">84,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_qStYvPs2Y0mM6alK2DgOfw_9_9">84,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Ny2Nm138AkKbXDHYSQMThQ_10_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_O5fxRCrtokW-R1I0H5B_ew_10_6">3,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_J567YakE00GMEU11CJYl-w_10_9">23,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_pcl9TQ0R0E2lvMPf10nUdQ_12_3">160,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_EstPg_8LyEeZ2fbdd2aytw_12_6">3,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_9gm77vUXAECmHRK0q8hUAA_12_9">164,006</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December&#160;31, 2022, the Company was authorized to issue up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_E_wEMSOHfUS7ry7_Z6wm7Q">21,910,800</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of preferred stock, with </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquitySharesAvailableForIssuance" scale="0" id="Narr_UWN9f6zbFkavEpjO1QILCQ">4,213</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-5, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquitySharesAvailableForIssuance" scale="0" id="Narr_8-9BnTx_9Ua-WXbECJ_6gw">5,190</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-6, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquitySharesAvailableForIssuance" scale="0" id="Narr_r4LtLr7XjESWN0GtQf427Q">36,707</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquitySharesAvailableForIssuance" scale="0" id="Narr_Fv61R1qekUSWi34BuVarhQ">1,059,365</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2, and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquitySharesAvailableForIssuance" scale="0" id="Narr_w8y2I6FnFUWJ4oVePY0OEA">8,474,924</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 available for issuance. All other authorized shares have been issued. The original issue prices for the Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2 and B-3 preferred stock are </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_tFXpALqdIk2Ye-8djd2Gmg">49.520</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_ehfp0-mppEueIa7O95iroA">15.660</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_W1i96E_jTUmntIhdmYQ1gg">17.40</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_tuka63GdLEiGcYJgvhym1A">16.030</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_LooWtVJmkkassoE-f1Qsxw">17.81</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_sPNMWs83gEOXW1Zb6VQiPg">20.23</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_aegR91XnSE-AiSDHAkdIuA">12.14</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_m_yd-toS1Eu-PGLex8XuyQ">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_-NMSPMnpGE6Iw7mZAIjiLA">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_qNhRy1ro9EedbWIE5KWV1w">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively. All shares of preferred stock had the following rights as of December&#160;31, 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-style:italic;">Conversion</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Each share of preferred stock is convertible into common stock at any time at the option of the holder. The conversion rate is equal to the original issue price for each share of preferred stock plus any declared but unpaid dividends divided by the conversion price. The conversion ratio may be adjusted from time to time based upon the occurrence of certain events or circumstances, such as stock splits, dividends, recapitalizations, certain corporate transactions, and certain dilutive issuances, including the issuance of shares of Series&#160;B-2 preferred stock and the B-3 Warrants (as defined below). Each share of preferred stock will be automatically convertible into shares of the common stock at the then-prevailing conversion ratio (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended in which (a)&#160;the per share price of the common stock is not less than </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="tlsi:AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" scale="0" id="Narr_tKVcdp-UpkW7S5ZsIwVHcw">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (adjusted for any stock dividends, combinations, splits, or recapitalizations) and (b)&#160;the aggregate net cash proceeds are at least </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AutomaticConversionOfPreferredStockThresholdCashProceeds" scale="3" id="Narr_LDKd29WwEk6y_mM21pJWNA">50,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, (ii)&#160;the consummation of a transaction or series of related transactions by merger, consolidation, share exchange or otherwise with a publicly traded &#8220;special purpose acquisition corporation&#8221; or its subsidiary in which the common stock or share capital of such entity or its successor entity remains listed, in which the aggregate proceeds resulting from such transaction or series of related transactions, including any private placement or other financing transaction and proceeds received from the &#8220;special purpose acquisition corporation&#8221; trust account are equal to or in excess of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-6" format="ixt:numdotdecimal" name="tlsi:AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" scale="6" id="Narr_3YSap1DlDE-SYyPipWt1AA">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;million or (iii)&#160;upon the consent or vote of the holders of a majority of the outstanding shares of preferred stock (voting together as a single class on an as converted basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(ii)</i></span><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each holder of shares of preferred stock is entitled to the number of votes on an as-if converted basis to shares of common stock. Certain corporate actions require the approval of a majority of the holders of preferred stock, including but not limited to changes in the authorized shares of preferred stock, authorization of any new class or series of preferred stock, effecting a recapitalization, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_90727695_fc2d_4411_b748_b26ebd2726c9"></a><a id="Tc_s0xToffB60KpvgcauttJoQ_1_9"></a><a id="Tc_oDcTCv13KUu-TjH5eWT9mA_2_0"></a><a id="Tc_TZZsn9Kl2UGNYpEjBKVJ2A_2_9"></a><a id="Tc_CWBCZTcJqUO5m3nH65L_6A_3_0"></a><a id="Tc_obfNl7PpRECdYzh_4nD74w_3_2"></a><a id="Tc_ENssd523u0-D9UyxEjQbdg_3_4"></a><a id="Tc_lIgUqZbWKkek0LQ-bXw6qw_3_6"></a><a id="Tc_ch8d4IgMe0iBISbek381fA_3_9"></a><a id="Tc_I10RRmB49EqePmO-cKs1sw_4_0"></a><a id="Tc_ykL-q6bLu0a_3tQJCbBSgA_4_2"></a><a id="Tc_1mYOM9fxTUevMfrDLRKwow_4_4"></a><a id="Tc_9aBh5cCmj0yO04CKrVfGAg_4_6"></a><a id="Tc_R4702s9JOUS2GH7H0maWFQ_4_9"></a><a id="Tc_BgEnScInIUyYS3XxfTF4cQ_4_10"></a><a id="Tc_9MeKhK6NpEWAGF9CG7HjLw_5_0"></a><a id="Tc_MxcJ2y-Y8kuARCRME4t8Ig_5_2"></a><a id="Tc_b96ivN-OQU6x-Xc3g4ezqw_6_0"></a><a id="Tc_OWVOWHkfvUOYkYTZa9wiWQ_6_2"></a><a id="Tc_CB2yXvD4fUOILTHfPGY7IQ_7_0"></a><a id="Tc_bbs8ScwpLkS84D-h98Ccgw_7_2"></a><a id="Tc_eNgBEvzu1kC8xoaoUI8yYA_8_0"></a><a id="Tc_fPe96S7MOEiMJhrFwYocIA_8_2"></a><a id="Tc_8_Zm5Pv6fUe4jDuPCmvJzw_9_0"></a><a id="Tc_CDEDxr1mVUidQsZmLGFOJQ_9_2"></a><a id="Tc_LoY3V53AD0e1VCmJv4OQuQ_10_0"></a><a id="Tc_yzaH60bzdEavLr6T2WK8Kg_10_2"></a><a id="Tc_6EQzzfRtdUGJeax0lVrbcg_11_0"></a><a id="Tc_Hyvfbj6Bh0K4lVnBz3bhRw_11_2"></a><a id="Tc_II-x1O1r5k-ueAhERyhP8Q_12_0"></a><a id="Tc_BCFxeFquHE6ek2eyfDgQZg_12_2"></a><a id="Tc_HLN1l4Sahk-7CRk6hkCqEg_13_0"></a><a id="Tc_CoE5y9mimUewhNnWM_qUtA_13_2"></a><a id="Tc_5qkKky3m8kWCnP2-JeZ3cg_14_2"></a><a id="Tc_EfyqZi9Hokmdg292Ph6T-A_14_9"></a><ix:continuation id="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont2" continuedAt="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">increasing the authorized size of the Board of Directors to a number greater than <ix:nonFraction unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="tlsi:NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" scale="0" id="Narr_ZnhkevWFS0uKAVvcHm5qow">11</ix:nonFraction>, the payment of certain dividends and capital distributions, the sale, liquidation or dissolution of the Company, and certain incurrence of debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iii)</i></span><i style="font-style:italic;">Anti-dilution Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The conversion price of each series of preferred stock is subject to in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-style:italic;">Dividends</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Dividends are payable on (i)&#160;the Series&#160;B-2 and Series&#160;B-3 preferred stock in preference to all other series of preferred stock and the common stock and (ii)&#160;all such other series of preferred stock in preference to the common stock, in each case, when and if declared by the Board of Directors on a noncumulative, annual basis and are paid to the holders of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock, and all other series of preferred stock, on a pro&#160;rata, pari&#160;passu basis (based on the series or preferred stock participating) preferred stock in proportion of their individual dividend amounts to the total dividend amount of all preferred holders. The per annum preferred dividend rates for each share of Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2, and B-3 preferred stock are </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw" decimals="5" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_OlPwhX01ZkK2-hW06QNquw">3.97000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw" decimals="5" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_a4UR_xg4GUewI4-SQSC3bQ">1.26000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg" decimals="4" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_L4nZRv6eFUmUDI5jPDMwuw">1.4000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA" decimals="5" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_qG294iOWJkmvu3z1dRzm0Q">1.29000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ" decimals="4" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_-drGp0dE3UmtfMX1eNRikg">1.4300</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_AysA1nrY0Uyoznjx7CJDlQ">1.62</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_M41Uw6yq7kyp2uDbb3kvGg">0.980</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_2ZHQMuOYUEmQnkNn1sModg">1.140</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_FNV6_qVGyEaARDKVSeEl8w">1.140</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityDividendPerShare" scale="0" id="Narr_nKclx8ke-UeAb_rh0nDJWA">0.170</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively. To date, the Board of Directors has not declared any dividends on the preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(v)</i></span><i style="font-style:italic;">Liquidation Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of the preferred stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a Liquidation Event), none of which were deemed probable of occurring at December&#160;31, 2022. Preferences are payable in the following order of priority and in the following amounts as of December&#160;31, 2022 (plus all declared but unpaid dividends);</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" id="Tb_pGwR8htWyEOExKw5-VWnmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_fQ83mkThOUeUI1ZorWi84g_4_7">2.030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_7JhT7jqeyEy0fYHp_LMH7g_5_4">706,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_olJ1YeeNIkapoghVe1Wcew_5_7">14.160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_Ch1GLGTQ7EaDmxe-nbGEpA_5_10">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_JSV-Wxz9_UuayER31kasQA_6_4">1,659,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_OJWgbLHaGkS7i0cYwIio5w_6_7">14.160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_9Wbbyl7XmkyFd4pnRjI50w_6_10">23,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_XDe3MA6oM0Suki8NfYdr8w_7_4">6,984,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_dPT6aLhgS06BRBgey24giw_7_7">12.140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_ct6XmtEL1UG2TMxS6b2EMg_7_10">84,774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Mb0G5TfPkU-Mt8VcjOFBCQ_8_4">800,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc__TmUL-LCyUWje5rQnBLxtw_8_7">20.230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_XNnbtOh_SUiQC1a18UsR4A_8_10">16,196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_bBXzMmz9fUKDKxGJ54G_5A_9_4">730,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_XKO_ZT_5g02waeeYxh8Qyw_9_7">17.810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_PWH9tTfY4EmGMiRbgH8eNA_9_10">13,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_csGS_a5nnESjUVkjLW5KEw_10_4">127,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_AfHNT4Rc_U-UZimBiuUyMw_10_7">16.030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_dd33uLzveU6gk69G4qmhow_10_10">2,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_LpZp819XqUO_BIK0UhRBBw_11_4">612,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_eAKOhn_ZJE6GCO20MvVSgA_11_7">17.400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_pqsfsNlm0kOPzJYWQ8eWXg_11_10">10,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_pBe2aPlKskS8r9kqvqRhJA_12_4">576,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_buXzs0OghEa7bY4Boe24kg_12_7">15.660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_CUppAeObIk-3TfSKNo7TmA_12_10">9,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_ijQhycvWokWEz5JsNi1wYA_13_4">131,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw" decimals="3" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Tc_sjpRyoiROka7-IPFbflrLg_13_7">49.520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_kHy3EBDK_kGQxUi06b2ANQ_13_10">6,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liquidation preference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_6jdzqzcCQEalxMDkbM07eA_14_10">175,724</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment in full to all holders of a particular series of preferred stock, then such assets will be distributed ratably to the holders of such series of preferred stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned liquidation preferences, any remaining proceeds from a Liquidation Event will be distributed to all preferred and common stockholders&#8201;&#8212;&#8201;except for stockholders holding Series&#160;A-1 or Series&#160;A-2 Preferred Stock&#8201;&#8212;&#8201;pro&#160;rata on an as-if converted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">March&#160;2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2021, we executed a financing round in which we raised </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_BuCxN-gjN0mEWxPOZcs4KQ">10,907</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> net of issuance costs, through the sale of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tGweR9uVt0-WoeeFukG68A">906,346</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at an original issue price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_kDCsY4_Y5U-X9mHozCI_wQ">12.14</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share. At that time, in accordance with their terms, as amended, all convertible notes, with a value of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="3" id="Narr_AM5w_giScEyYAsNriKQ7xw">49,118</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (including accumulated interest) were converted into </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_Njrd8wp-UkSPr5vy3bnFOA">4,047,069</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont3" continuedAt="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Spring 2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May, June&#160;and July&#160;2021, we raised an additional </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_UE15pSn6EE2Hhyd9QBr5IQ"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_FcuxMZ5_3UC4Nfa4j7lChw"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_YIby7hQNuEedpz6WiwUwmA">20,989</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, net of issuance costs, through the sale of an additional </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_km6YliXPR0W2LfhwoWbgQg"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QOwbPJqGekyc2cpCsYBF_Q"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_GjWo4KfmikiTt_lyAor9cw">1,742,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at a price per share of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_gjRdH4wYNEGMHMPcpCFGZQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_tip5j-ZnWkmtFddJZKQnNg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_hwHQ8rIfHE6ERDDrgM57-g">12.14</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fall 2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In August&#160;and December&#160;2021, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_F5yOMhzbPEO5EdkhDkkw1A"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_sOfxX2etEU6X21moe4MLSw">20,000</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, net of issuance costs, through the sale of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5a96lQlcMk-H4bwsSr1fDw"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SypHUoFQjkW2qSkPXBwqaQ">1,412,487</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;shares of Series&#160;B-1 preferred stock at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_atFl6RSh5Uu5JW3Kl_uwxg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw" decimals="2" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityOriginalIssuePrice" scale="0" id="Narr_LxWzQKm-o0afB3-7MG-63Q">14.16</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Exercises</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In November&#160;2020, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_e-IRiyeUokWhELXaV-4wUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_7_LkezWxyUS2y4lZbSAqBA">19</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the exercise of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_CMmCuzre6E-tcEDvHRTyuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Hc9NtEDA-kG87WJYYSkL5A">59,102</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-6 preferred stock. Between March&#160;and July&#160;2021, we raised an additional </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_0iOOdQCvqky-8LHpNIwfpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_cfI1EnCtHUSJeSNi-fRh7Q"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_NkH9eTFLRkK7c-mjvyXwSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_cLvW8LFYxUOQHrKXM1oYFg">117</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the exercise of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_5P40y196CUq_heFGRG6Rdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1PFv1ZKd-06QUMAqW2nZow"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dqYj144kIECijtd5V_e50g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_73XJODcenkGctaUP7-lELA">289,552</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2022 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May&#160;and June&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_R72vr7foKUq_wQpjgYph4w"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_GdI8UA90Dkm3PPkzW2IHCA">247,185</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-1 preferred stock in a private financing, to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_aQAt3IxfvU6l-oEcuIHn0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_LdoQDBGxfEyCtOkVnUtUoQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_GRTEC4z9hku2SFFVuuuxUA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_2aoh4biHFUicc_NMY2vSwA">14.16</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Narr_KdS9TXnNJUOqQrklIrUlNw"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Narr_h70nJ5n44UCx94-lNxNTrA">3,499</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds. This financing was an extension of the Series&#160;B-1 financing round begun in the fall of 2021.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In early October&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_B67DGCb8NkqnfG74PgxBDA">706,243</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Ec4h4Ih9e0SsOEo33kjoRQ">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Narr_x0BwgMDDrkap5Gl0l0ofiQ">9,755</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds. For each share sold, we also issued a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_0ubM5IiwMkGLoWayP7oi8A">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock (with total warrants issued being for </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_wyBiU6Mq20mrjFCU3RYwBA">2,824,974</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock) with a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_T2VN133i10qd0pM9570SUA">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;per share. The B-2 Preferred Stock Financing included, at our audit committee&#8217;s option, a second tranche for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:MaximumNumberOfSharesAgreedToSell" scale="0" id="Narr_elvEMXvMNUaecw2g1evO1w">518,854</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AggregateProceedsReceivableFromStockOffering" scale="3" id="Narr_U-Ju93beLkqd6KMTxC6Izg">7,347</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares" scale="3" id="Narr_TeOrqn38WUWBD5BBrGsX3A">10,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_yBF0_-DQK061Wq26UjULhw">four</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_2hPoehUnhECWIMazi_m-Jg">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr__swjVpf8Skq_qJFFlHrs0A">2,075,417</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:MaximumNumberOfSharesAgreedToSell" scale="0" id="Narr_vSgwrTRNJUWYMfv_drVJfw">306,053</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:AggregateProceedsReceivableFromStockOffering" scale="3" id="Narr_a0onC-e5tEuPDm6CgRqr1A">4,334</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="INF" format="ixt:numdotdecimal" name="tlsi:MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" scale="0" id="Narr_V3YgfJL-k0aAlQZejm4_RQ">353,121</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares" scale="3" id="Narr_eIZm4YWlCEe7ioENcr5kew">5,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_q0d6Q1qdQ0OurNYMYvFoTQ">eight</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_tbv-t2oZq024ZTTBeMrYwA">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_RqX5qcsK10-1lzN8HDNK9g">2,448,428</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock to immediately convert to common stock and the warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_I2WBsnKGNUycRpRz633v4g">42.89</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_9SacmvxzgEShJO_paIjkEg">13.36</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_OiIqPqVFwUK9OL1CWHh-FA">14.97</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_PE8wxqdL_ESJgVPPrDqayA">13.76</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_HoJozP47uEOr_42ODp8qiA">14.97</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_jAbKNCRj4U-VPrXs3Io1FA">17.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_CEWcRIb6kkyworm1AHccUQ">10.52</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_VFOQTupZKU68tO57lu7OWg">12.14</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;set to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_DOdaY9dBIUaRZ7mNjRUSZg">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_PZ5hNrI8LkihKECnNujkow">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_9Kul8QgFskWzsNdXJHZuXQ">1.155</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_KxcpXZXiN0KWXSzvVN-_cg">1.173</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_kvPrYmqGlEmO9N434fp3Jw">1.162</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_Y3SRrcwupUmSsP15EDMe5Q">1.165</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_1mfipDfGqESgYu9cUxd1_g">1.189</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_weZ9dsiG4EiB1yNYtLnaog">1.190</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_1OEZBcKjskOUjHyh3wn8mw">1.154</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_GWg247DnUUmUgtqFNauGLw">1.167</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_tyxJOMen3EG0sKPrjI679Q">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_C84EueHcgkqlrwtbA5abVw">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g" decimals="3" format="ixt:numdotdecimal" name="tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" scale="-2" id="Narr_WPpwT8daTUCp3lt_bdyAog">99.2</ix:nonFraction>% of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;16), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other non-service provider holders. As such, the Company concluded </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont4" continuedAt="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The warrants to purchase Series&#160;B-3 preferred stock (&#8220;Series&#160;B-3 Warrants&#8221;) represent freestanding financial instruments that should be recognized as a liability as the Company is required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Tranche Liability&#8221;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of the control of the Company, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the balance sheet at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#8217;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions: the fair value of underlying Series&#160;B-2 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_nysdtTEnvUyJymOGjXTL2A" decimals="2" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_557kd3i81Eu9Jn55ZsPL2w">14.97</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, a price for Series&#160;B-2 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_jzrdTKUMPkaJYvHWOVu7LQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_pBFaPM9AzkGK9LK7LHYqwA">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, the fair value of underlying Series&#160;B-3 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_21ZnY62BB0aviR0_y6NS1w" decimals="2" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_I8A7MxTLB0u2fGCieO89NQ">3.24</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, an exercise price for the warrants to purchase Series&#160;B-3 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_RBw78ON9SUGlT5g_SudELQ" decimals="2" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_uuYvcSKDXU67kBMCdmQ4AQ">2.03</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, an expected volatility of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ebJaNhnAhkKomsCxm4SEeQ" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_e6EQiHUcdUGq6axFPee-Ag">50.0</ix:nonFraction>%-</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_06c-BVDZVUSTkxyfqRQpPg" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_DGgSBpbf4kuAakpgLeZM5A">65.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';">, a risk free interest rate of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kVYk9im19EGexCFAmViCqA" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_-1ylWzVcA0qD74ZtEtZI6A">4.0</ix:nonFraction>%-</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pILTs-HrB0uQSMTr-D17nA" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_2gMJLBBvYUm8JX9ZQ2cwsQ">4.7</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';">, an expected term of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lGYh6vgZNkWoq1VwMwVVnA" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_ewqf2EfjwE-BZ8bFSDl65A">0.2</ix:nonFraction>-</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_siP3YoYtZU2LiMLvWdN7xQ" decimals="1" format="ixt:numdotdecimal" name="tlsi:TrancheLiabilityMeasurementInput" scale="0" id="Narr_zDO9mIncFkO_VK44KiC0rQ">0.4</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years for the Series&#160;B-2 Tranche Liability and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_G8V4djaCEkCway9XsOM4DA" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_06w2Iw7zSUO_rGoU9LbXtg">5.8</ix:nonFraction>-</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Xpnlw4k0NkuO1sNJfiAs9Q" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_1Cwe5USv6EyUNda7xN-Ong">6.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years for the Series&#160;B-3 Warrants and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendPaymentMember_Tw6UZ9TXRk2sGpM7oFAZCg" decimals="-3" format="ixt-sec:numwordsen" name="tlsi:TrancheLiabilityMeasurementInput" scale="3" id="Narr_MnVUUplrYk20S8RmQ7SSzw">no</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> dividends. The fair value of the underlying shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock used in these models were derived from estimates of the Company&#8217;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#8217;s forecasted 2023 and 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_MB7pT5iLf0uF_V9jm7PXzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_VKtj3KnbM0eHSi3zRaADtw">10.93</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> per share, which is based upon the enterprise value stated in the merger agreement of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_xbdsgc83CU-hmC04QM8BBA" decimals="-3" format="ixt:numdotdecimal" name="tlsi:EnterpriseValueAllocated" scale="3" id="Narr_nhq-Pt440E6cexoi2gSvdA">220</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;million allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, discounted at </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputInceptionDiscountRateMember_mzUQ236JO0anFu5jzI22tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_KVwBXUzirUK_SlphO5dcvA">30</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> from the expected Business Combination closing date. The Business Combination scenario as of December&#160;31, 2022, assumed the second and third tranches will not be exercised, and thus </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_ycMhMOSauU-qDs_XF5sQ8Q" decimals="-3" format="ixt-sec:numwordsen" name="tlsi:ValueAssignedToTrancheRightsAndObligations" scale="3" id="Narr_HZUIVGzZ3k2RA97V7pIBQA">no</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> value is assigned to the tranche rights and obligations, as the Company would not exercise its right to call the second tranche.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Series&#160;B-3 Warrant Liability and the Series&#160;B-2 Tranche Liability were estimated at $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_TMgwoaCwVkuAPz22E8hFLg">11,966</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_4mN-bA9Uz0yu-SCx5mjf4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_b51wdy4CW0mOYsQ4XOt3zA">6,347</ix:nonFraction>, respectively, upon completion of the financing. The excess of the liabilities&#8217; fair values compared to the proceeds received in the transaction resulted in a charge to loss on equity issuance in the consolidated statements of operations of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" sign="-" scale="3" id="Narr_rleun0P7K0W_aU5W3zJCXA">8,312</ix:nonFraction>. The warrant liability associated with the Series&#160;B-3 Warrants was remeasured to its fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Narr_Hy1ocaBv0E2U_q6sNF9CYg">15,819</ix:nonFraction> at December&#160;31, 2022, and the Series&#160;B-2 Tranche Liability were remeasured to their fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:GainLossOnEquityIssuance" scale="3" id="Narr_j6KYjEmmbk2MIdiY1qW2Ag">4,702</ix:nonFraction> at December&#160;31, 2022, resulting in an additional loss recorded as change in fair value of warrant and tranche liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities" scale="3" id="Narr_aTL2PE9n_0aJs7Z0A-fgvQ">2,208</ix:nonFraction> in the consolidated statements of operations for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, the warrants issued and issuable under the second and third tranches to purchase Series&#160;B-3 preferred stock were amended to provide that, in connection with the Business Combination, any portion of the warrants that remain unexercised at the time the Business Combination is consummated will automatically be net settled for shares of TriSalus Common Stock immediately prior to the closing of the Business Combination and exchanged into shares of Combined Company Common Stock at the Effective Time The warrant amendment did not change the liability classification of these warrants and the warrant liabilities will continue to be measured at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2023 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In January&#160;through March&#160;2023, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_6DPEmwJddE6K2-IbaVKDiQ">2,330,811</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_GWy7uUXZB0aOm-obxy2m_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_qMgCdBEA9kqvRxBjaG6wJQ">4,715</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ePYxzYjjoUCHHIX78Ei6qQ_cont5"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we effectuated </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_tKNgd2GCgESsCQV33cAzXg" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfStockOfferingClosingsEffectuated" scale="0" id="Narr_6pA_fTZCVU6Ors4NGviYEA">two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_0r7I6QWZA0GsYAkditjprg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rhbNbUFDBUSH8HedIJUP5w">207,541</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';">shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lE_mD9hOd0STU9O_pFbkxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Bi2OuP3fXk2Av2bv81QKgg">830,167</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentageOfSharesCommittedSold" scale="-2" id="Narr_zG7MpThyZUmGQ_DG-IwZhw">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_ZQ7FYV30Uk-fDLpM8NPS3Q">2,939</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_G42a6weQT06upXOSAO8LBA" decimals="INF" format="ixt:numdotdecimal" name="tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_veJ7Xvssy0GIGF3YxoLIbw">17,656</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember__XDMheCIA0mYIUNydTkduw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_OLEIyf55aEGWCi6z_noudQ">70,624</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA" decimals="2" format="ixt:numdotdecimal" name="tlsi:PercentageOfSharesCommittedSold" scale="-2" id="Narr_5tALD9ClN0-_jozKYAHCzg">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_-Se46GqhqkOY9d-d6pMyOA">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the foregoing closings of a portion of the second tranche of the B-2 Preferred Stock Financing, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_3I7fEXkOMUaYpBtHqqw1Sg">41.27</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_JdtE9CnEI0K1mEQwUOMBSQ">12.95</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_-eqqZJ3kmE2ex3G4pOWhLA">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_iLAIuLafVEW9wAk_W4IB7Q">13.36</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_mpcpOXqzykmn4aTzXUQXTg">14.16</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_absOkn-FFUedCv9L9eskIQ">16.19</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_yUm2xx8SL06Z0iPU1Cjbdg">10.12</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_4kAKVfKgAkquzma-WqzseQ">11.74</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock </span><span style="-sec-ix-hidden:Hidden_PxxmfclgUkWgfznbDZcazQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">($14.16)</span></span><span style="font-family:'Times New Roman','Times','serif';"> and Series&#160;B-3 preferred stock </span><span style="-sec-ix-hidden:Hidden_qYvtfI9-2EK0FA_smo_g4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">($2.03)</span></span><span style="font-family:'Times New Roman','Times','serif';">, which correlate to approximate (in&#160;each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_J2eDD6cHC0KcdHLOm4CtdA">1.200</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_0CajVw1NTUaJ8K3iX8ktmg">1.209</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">&#160;to&#160;1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_EjfNIVZ6N0eUJ2OjN4xCMg">1.229</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_BQSzJCKlqEaw8OmoO8CISA">1.200</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_odZquKIoJ0G7nyoos6ewkw">1.257</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_md_gW0uubUCmZzhHRh-Gsg">1.250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_d36wnqJRVUiVMVwzrWAcew">1.200</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_6V9F81utgUax0nUZrJaIYg">1.207</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_cQeUEz04N0GozcXgbwDQqg">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_bLUccbwHI0-dlZRZX8E9-g">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_1H7DdlM88EGV0-JwmKVWTQ_1_0"></a><a id="Tc_1RYbdn80A0KFe6uYTzW_ig_2_0"></a><a id="Tc_D0o1U9Hw0ki_vhchTMybSQ_3_0"></a><a id="Tc_oKhSGfuRbU2DmpFjUCZRpw_4_0"></a><a id="Tc_1frKirklGEGFWc5Oqcno7w_5_0"></a><a id="Tc_WyZQznDjVEaFw4qb0H1t5Q_6_0"></a><a id="Tc_nsWyZfX1ZU61LVpI9HKQHw_7_0"></a><a id="Tc_UvzVQ2OTqEiC2vsdqWtCIQ_8_0"></a><a id="Tc_J3UhaTyye0-KBshWWQhSdg_9_0"></a><a id="Tc_3A6wLy6upk6VMwvyFE90uw_10_0"></a><a id="Tc_JgOTDSmRPkq6DIxgiBhIxQ_12_0"></a><a id="Tc_lYRo0AEqmEu2xD44a7avAg_13_0"></a><a id="Tc_pueRpRurykW782lggLfEPw_14_0"></a><a id="Tc_Pnk1XzCikkOWgUU9FaeohQ_15_0"></a><a id="Tc_OLNB8HBgLUmqDknBHtcH2g_16_0"></a><a id="Tc_I_fHO7J7xEqxoEHr8CMLIA_18_0"></a><a id="Tc_PNvo0h0jVkWOILdi8uyKdQ_19_0"></a><a id="Tc_uj_nDeIBB0WgTsWn8UIUzQ_20_0"></a><a id="Narr_OU0leBI4IUCwE60BXRxanw"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="Tb_LpU2IVF0T0SQneIgmvP8rg" continuedAt="Tb_LpU2IVF0T0SQneIgmvP8rg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(13)</b></span><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December&#160;31, 2022 and 2021, the Company&#8217;s authorized shares of common stock were </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9cGMVpoO2EmqBKevMyving">30,898,162</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JSC99mSR7U2mMxaDyFpcww">15,696,266</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively. As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance in connection with the conversion of shares of Preferred Stock, at the applicable conversion rates (see Note&#160;12) and upon the exercise of certain options and warrants:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="Tb_LsTr9mmKLU6sdWGDvWNhpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AbCmIlVGwU2jFoD1_oyB1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_YKulUGzDfkimvryg-DKjfQ_2_2">152,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_D2982Aa3FUev4xmNbgrmLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_Ak25t-HwykSI2kXSRkUpTA_3_2">675,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_CMG6zRmmJk-DrVcCs784UQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_v_gavXeaWEO9rWcR5Bl5Hw_4_2">712,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_78cDcL2q8UmHmCn5D2OBjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_rwd6JgMKx0GYTb0ezmF64A_5_2">148,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JfpRQYxY-UKeBky1qs6kyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_9KKMsWH5BEGqDSTS1OmveQ_6_2">868,487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_L9okU4WLpk-102h2M_xYYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_AUR7gkqkSECQlHKbje-iUg_7_2">953,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesBConvertiblePreferredStockMember_YcYnzFlBjEak37oDh3RW8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc__FDKqT1RR0u3tgQH9HI-fQ_8_2">8,059,581</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_R3C848oe2UKgjk229Eov0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_xvnQlvDoa0Wy4c2rGmO7bQ_9_2">1,936,284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_ubWSfyc1rESSfcBRziTGkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_s54AHTb7gkuuRbRKWXEDCQ_10_2">706,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_ConvertiblePreferredStockMember__NAecSCB_kCj1haUJLi3OQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_IrfQcmDNCkiuV2sDF7m8RQ_11_2">14,212,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrants:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_kmZ2EGx-bE20yy95aA1umQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_iRvx5UANlUSXyxQM7YRY8w_13_2">5,010</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_IUEdiusOq0Ggfdrn4ZnVkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_WFLXO4H3_UydDHO8XbID7w_14_2">6,179</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_FH-Sf7Hf3EiGk-qmzaSrtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_9VHrpzFB9U6SKmhEnrJQlg_15_2">42,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_ZQxUbocD4UC-2DmmXP5A4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_eQNVYFP-bESTeVBXarF78A_16_2">2,824,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_WarrantMember_IqC1qJJSQUWIbrrHEeO5HA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_zvrhqZznRkarOjGnpXJ6Dg_17_2">2,878,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsOutstandingMember_Qeaap63POUSl7kq016l15Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_a9-B4co5pkOniS-oyMmjww_19_2">1,671,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options available for future grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsAvailableForFutureGrantMember_x-OjXsG_GU2kREkY5w2Tfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ugXIO63-bEGI_9XhVLdnpw_20_2">432,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_EmployeeStockOptionMember_3KKxG7YSZUSyqE0uG1rr9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_Mn8fJ1eDvkuiSV4IlRFOWA_21_2">2,103,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_LlvRQyFtlECXEO6aiJfUnw_22_2">19,194,621</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Under the 2009 Equity Incentive Plan&#160;As Amended (the &#8220;Plan&#8221;), the Company&#8217;s board of directors may grant incentive stock options and/or nonstatutory stock options to employees, directors, and consultants of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. As of December&#160;31, 2022 and 2021, there were in total </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr__5flGIwaIk6bV8prWpaltg">1,671,075</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_3Zxu1rKTgkKQFy0dgO-Bgw">1,307,079</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, respectively, stock options </span><span style="-sec-ix-hidden:Hidden_RXte8gIJ0UWW5BmmCYcnHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">outstanding</span><span style="font-family:'Times New Roman','Times','serif';">. The Plan was originally set to expire on July&#160;28, 2019, the </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_lxQdn-wrREW7rwNPp0qXtA"><span style="font-family:'Times New Roman','Times','serif';">ten-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> anniversary of its establishment, however, the </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_2xPeI0mtG0yQbE5YkyQbiw"><span style="font-family:'Times New Roman','Times','serif';">ten-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';"> life automatically renews each time the plan is amended to increase the authorized shares. The most recent amendment was on September&#160;15, 2022, so the revised expiration date of the Plan is September&#160;15, 2032.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Incentive stock options may be granted only to employees. Nonstatutory stock options may be granted to employees and nonemployees. On March&#160;2, 2021, in conjunction with the Series&#160;B financing, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_3_2_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_hYo6l3T-EkW_DjtHSivOsQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_2Mx3ezXjVkSuvmZMJ6yC3Q">1,235,926</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. On September&#160;23, 2021, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_23_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_SEb9zumk50CCxQ_gl3sqTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Usk9AaZXpUW8A3e7vhx06w">1,606,704</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">, and, on December&#160;20, 2021, to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_20_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_C40yv7V3Uk-CTwQZSf-3fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_KGC7LrIbCE6bX-PMrWYtFQ">1,804,452</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. On July&#160;13, 2022, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_7_13_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_mmQ5QRZtFUmMijBSylDvfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_jIRyiv-rQEGP_psgI47P0w">2,101,075</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and, on September&#160;15, 2022, to </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_9_15_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_FJuc69Mu_0KlSo6eQPUexg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_AoTfwKBykU2prnJXhBh_Dg">2,348,260</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';">. At December&#160;31, 2022, options to purchase </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_yGi5H7oYkEq8mpiLkYKMzA">432,413</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock were available for grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan is administered by our chief executive officer and chief financial officer, who act on the recommendation of managers of the Company to select the individuals to whom the awards will be granted and to determine the amount and vesting period for the grants. All grants are subject to approval by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock options are granted with an exercise price equal to the estimated fair value of the stock at the date of grant. The fair value is determined by a third-party valuation performed in accordance with IRS Section&#160;409A. Options generally have a <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_fWVyf3Y7nUKdDom5xeUcrw">ten-year</ix:nonNumeric> contractual term and typically have graded vesting over <span style="-sec-ix-hidden:Hidden_huQWM8PukUiNaHCwSJKzHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>&#160;to <span style="-sec-ix-hidden:Hidden_RgKa1fvyFki-3G_4NLjGcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Tc_IUTbSFq54kKCLKjd7It3Og_1_7"></a><a id="Tc_PGo06eeQ-Ue4Ro5bQV8c0g_2_4"></a><a id="Tc_JgWuAfJ9q0-33lCf1bc4Aw_2_7"></a><a id="Tc_00nDi76Z70CAa-LC1YekOg_3_4"></a><a id="Tc_VsfXu3uOG06qJsokwi9ppw_3_7"></a><a id="Tc_wVOp1pJdhUKG0It2wQfVyw_4_2"></a><a id="Tc_sGaW7bEP7kiVASQltOJCuA_4_4"></a><a id="Tc_jXFjoo-bs0uN9KIoI9afFg_4_7"></a><a id="Tc_DaCqaduVxUuTUUEx6scqpQ_5_2"></a><a id="Tc_Rl4eEaFEB0ysTZvolpPuug_5_4"></a><a id="Tc_PFgBi_oEPU-9kWpQ5LLD9Q_5_7"></a><a id="Tc_6MFY6jK6F0G0w4ELpDe5wQ_6_0"></a><a id="Tc_lmqEUM0720qm0Jouwk5ALw_6_4"></a><a id="Tc_uoHYpOcNMEmKHV6uziCg1Q_7_0"></a><a id="Tc_uw5CbIdliUKQHTOHSIMlpw_7_7"></a><a id="Tc_gKSQlMShv06iLicWnlgOBw_8_0"></a><a id="Tc_YLE8jmIWCEW35VhZFDJhag_8_7"></a><a id="Tc_vwztx6BScU2_b0R_qAzlcQ_9_0"></a><a id="Tc_UTbcid1HUUqlpeTaHuXrTw_9_7"></a><a id="Tc_BKl-rxvKA0CV2gxJMtfO1g_10_0"></a><a id="Tc_DTSVceO2kESHRb7RGrgHAw_11_0"></a><a id="Tc_kEE-q-RPrk2txBnFWYi-iQ_11_7"></a><a id="Tc_fWb-rpxVEkacMU9HyV8HTA_12_0"></a><a id="Tc_0dqQmEUgckW6M2FMyBuUaA_12_7"></a><a id="Tc_HLs3PrQB9kKfPvwTl445RA_13_0"></a><a id="Tc_p2Ld3BRjHEeL-zMLrDynAA_13_7"></a><a id="Tc_ouHLiClGUEW2oD3ARwnOzA_14_0"></a><a id="Tc_lW1UUDIAuEi7ZA36MJiBnA_1_2"></a><a id="Tc_oh1St8qOzUGTLh6WKTIR8A_1_6"></a><a id="Tc_oBUwKeE6DES4dVJoXitBPQ_2_4"></a><a id="Tc_MHmuWjFFzUmHvFXYmYZNUg_3_2"></a><a id="Tc_f2oiiJtoRk2VcxDEcmRIWQ_3_4"></a><a id="Tc_OEU2TB6IEk63WRNw7lvZpA_3_6"></a><a id="Tc_vTn886GGOEqCDQ5kRu3EIg_4_2"></a><a id="Tc_2IlJKsic40u963-BMLDE3A_4_4"></a><a id="Tc_JILOrhR8V0C2VFxdxS3wdA_4_6"></a><a id="Tc_avLbGJHeyUWUK1x7JkV62Q_5_2"></a><a id="Tc_yd3B2Wo2R0yv8KiAs-ik0Q_5_4"></a><a id="Tc_R6dbrBb5Ak6hzwtBX8yu_w_5_6"></a><a id="Tc_Xc-Eajj4DUWNrJ3WeQ2oeA_6_0"></a><a id="Tc_3Hud3DibHEWWH9fEsHVitQ_6_2"></a><a id="Tc_KCxkBtK_oUS3IKvw0DTGNw_6_4"></a><a id="Tc_hmzsgMH7Kk-kkl6JybNFBA_6_6"></a><a id="Tc_-VA9Zb_CtECTmhJIJDQVtQ_13_0"></a><a id="_e916baf1_33ff_49ae_bf01_4ddf354b9b72"></a><a id="Tc_0cnv4cTAvkiNm8CVICkWvg_1_2"></a><a id="Tc_kxU1hQd4r0iSFVifqTWCtw_1_4"></a><a id="Tc_O9-AnhTRUkaYUoml3Bmg3g_2_0"></a><a id="Tc_Qww_H6L010eC7IFeno6tLw_3_0"></a><a id="Tc_mLTEqr7XAkGlDRlxWV9DTw_3_2"></a><a id="Tc_eNewatW-eUaUZWyJVUhPZg_3_3"></a><a id="Tc_Es1dEDemu0qr2aIKyphkzQ_3_4"></a><a id="Tc_EVGSfXekmESblrn-8rwijQ_3_5"></a><a id="Tc_pQvDpCeZx0Ge9W34_spSiQ_4_0"></a><a id="Tc_hWxXlpTarkGF7_IKh8oavg_4_3"></a><a id="Tc_KreprFiC60upRotqNf7iMg_4_5"></a><a id="Tc_uDxGJi8RqEC9bg-Q3gX8fQ_5_0"></a><a id="Tc_lx86xopObEOcyaszY953IA_5_2"></a><a id="Tc_-juDi7BI2EeXaFqOHPo3tw_5_4"></a><a id="Tc_cetwCyQGU0OfAyA7IkKT6Q_6_0"></a><a id="Tc_KIQlzDqk8ECSXTTmc20DXQ_6_3"></a><a id="Tc_n5460m_Bb0ahpLOAq_uPmA_6_5"></a><ix:continuation id="Tb_LpU2IVF0T0SQneIgmvP8rg_cont1" continuedAt="Tb_LpU2IVF0T0SQneIgmvP8rg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize activity for options issued to employees, consultants, and directors:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_TMboqGMP_UahJ4YwCHgZRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_oFp0NhdbokinvRBvAswLaQ_6_2">735,803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_gA1_xwRxMUa1Q-ibXqjObA_6_5">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_EkuHWeii3ECgCDZp8f1zsw_6_7"> 8.2</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_0ZMKpUoaqkqiQ4RUeChpjw_7_2">700,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_w-jzcnX7hUulWfEwVNRx6g_7_5">1.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_3c9A4TgZrUWFiDXLkG5m1A_8_2">71,647</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_z9jKMj_UEE2iQx0-taI45w_8_5">0.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_H7-ThvZJEk-g8LH0K3CdIQ_9_2">57,246</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_bs3Wn5PEhEqxK4FwMZ712g_9_5">2.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_4AdnUrkFN02m_XQUqasUrw_10_2">1,307,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_i1zrO0rsRUSQ3rGPE5sLgw_10_5">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Qj1f3odsb02t4xsBg0AoWQ_10_7"> 8.4</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_90sIih9rwEiBxz3ZeQybkQ_11_2">550,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_y9m79c1MBkWROxaIY18UHg_11_5">2.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_w3XaiYCGRUy7JWsxKgvq-A_12_2">82,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_BdELQdFsIkWq0hou5hi5fA_12_5">0.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_gvXpRB40VkepYjxks1wWlQ_13_2">103,174</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fymqy15ES0qE8DU1DAdsBA_13_5">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_7x16Y_23MUesCxKIU2ZIPQ_14_2">1,671,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_dKhXkqYDhk-6AyW-XPzYDQ_14_5">1.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_iMW4WVxfQk-4zMbpsrBw3w_14_7"> 8.2</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We granted </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OCE06-VX20WwiST2nFqLhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_3v-ErKGunUiIYjRTtnhufw">177,973</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_xHLJVJ8VWkiIevSmCiWZ6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_16rapgIlDk6NLvbTMnNRzA">55,305</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> options to members of the Board of Directors and other non-employees during the&#160;years ended </span><span style="-sec-ix-hidden:Hidden_0XVq7K5E4EaVAxzq8BPz2g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31, 2022</span></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="-sec-ix-hidden:Hidden_PCQ3iCsu6kiybYaKiTQPcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2021</span></span><span style="font-family:'Times New Roman','Times','serif';">, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes certain information about all options outstanding as of December&#160;31, 2022.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_dVMMOLxJlE6_qcp43YwrCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_eUuLZ5RwbUavib4hVV5BDg_7_0">0.41</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_2AWYzrr-FEuZwMZxoi-mmw_7_2">540,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_MV9Q-_fVqEOu7Gqmcpl5ig_7_4"> 8.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_EE8rPxmw4EGXl687P3ZI5w_7_6">380,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_IGWMbaoN7kWD-UKNTcSZQA_8_0">1.22</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_dy_GvLBug0GJtOEEPCJ6gQ_8_2">211,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_yHkvRopeLUOjcb9LYhJXhg_8_4"> 5.20</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_9Wsok7d4_k2ArERgpyU_MQ_8_6">211,134</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_1M3WS6ivPUasTxavRIlblQ_9_0">1.62</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_gsJ76bMspU2KNLapWiuSJQ_9_2">4,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_kb2zOADeM0aAmSHTbQk74A_9_4"> 1.10</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_u-Cp_rSRN0K6pYMba8fEDA_9_6">4,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_fnuTZc8dZEi2PsLNqPamHA_10_0">2.03</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_jEw1XivkbkWjO6whC_DP0g_10_2">7,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_DHAnTGmOxUmJUTsXYTuNuA_10_4"> 4.60</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_gU2jotQRUUyxuNLHCI9n5A_10_6">7,415</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_0kanz8U5FEy6xKdzhQNCLA_11_0">2.43</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_ZTTEsOrtPESh7ow8yBNuAA_11_2">900,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_OakFH2R3XUavfvuTKI4Gbw_11_4"> 9.20</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Fw4-4I3KxUKC4pYPRyvu_w_11_6">203,651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_6qBRe7f74kOiz-3H7_Q9UA_12_0">2.84</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_Eq4ixsuQ-kqdeJpgamwK9g_12_2">1,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_If09cJFfNU2ZODlHdR9n2A_12_4"> 2.80</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_e7nlc_OML0iWKyHraSdBvw_12_6">1,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_PkkKP_WaZUCbc1PbtBZfiQ">3.65</ix:nonFraction>&#8201;&#8211;&#8201;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_1w0f1cr6sEia4_6l5glvkA">18.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_8YJDeE11cE2EQ4ztbjcPYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_Umwp67B7dU-zIC0x8Ay7sA_13_2">5,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_IfMj_NoRGkiXk8s120Z0tg_13_4"> 3.32</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_ihWyFEBunE6w0-BkUQdbXA_13_6">5,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_SERG6Rayc02m2qNwC_vRIA_14_2">1,671,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" scale="0" id="Tc_JBEzwcR49Ei--PgqhBvqWA_14_6">813,943</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The grant date per share fair value of options was determined using the Black-Scholes-Merton option valuation model, and was computed to be approximately </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_GbrCpHSl6UuZJHlHFKysfQ">0.81</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_FMUt5fd8ZkWViuZXKHAZ2Q">0.41</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for grants in the&#160;years ended December&#160;31, 2022 and 2021, respectively, using the following assumptions:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_oF4FBYCTxk-hMlAPVhFDXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_IUbm4Y6vwUK2UPAkYCEO0g_4_2">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_LuYYda_deUe2IvpM0uHe5Q_4_4">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_-vVRuuYOS0yFk8mPXLMGtQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_ndtsJ-MTwk6J3oJIB0MVzA">5.6</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_aM0ySl_E90mqpY8DYct2uw">6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Ewnc-WVz9ku_b5ftkI7wMA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_6y-xyHN570icPa2r_Vg3Tw">5.0</ix:nonNumeric>&#8201;&#8211;&#8201;<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_EbEeXi4j7EGJVYkS9xiwOA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_FIqEZOQbm0SeWSuLkETMaQ">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_zPBezQLsBkCThhxVwXpbKQ_6_2">2.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_PI0SY-TlCEO_9W_cFgu2bw_6_4">1.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Our historical exercise behavior for previous grants does not provide a reasonable estimate for future exercise activity for employees who have been awarded stock options in the past three&#160;years. Therefore, the average expected term was calculated using the simplified method, as defined by GAAP, for estimating the expected term.</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Recognized compensation expense for employees and nonemployees in 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvBwoibMpE-Z98sDm4_9Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_Z5ByKkFD2karA2j1MBI6lg">368</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s45KCdyGNkGuDVWgIQ86KA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_1b7jPFxnp02jOkgGtZ-WPg">109</ix:nonFraction>, respectively, which was predominately included in general and administrative expense in the accompanying consolidated statements of operations. As of December&#160;31, 2022 and 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_3S_35BZeUUiztiB_uAZgtA">433</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_B_8Bpxb6DUe-qqp4Vzb1dA">24</ix:nonFraction>, respectively, of unrecognized compensation expense related to unvested share-based compensation arrangements granted under the equity incentive plan. The December&#160;31, 2022, balance will be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_rtccgP_cTUikQyyEoXvCFA">2.9</ix:nonNumeric>&#160;years.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_LpU2IVF0T0SQneIgmvP8rg_cont2"></ix:continuation><a id="Tc_GUMozyXa90ypLhiGPFLirg_1_2"></a><a id="Tc_2pHpmOS3e0KKlCdwrO-rqw_2_2"></a><a id="Tc_aHvC3SOjeUC2X5pTGzf7IQ_2_4"></a><a id="Tc_R8o_de9_f0SBpQQACgI-aQ_3_0"></a><a id="Tc_ui2t8fr56Ua2bxWS6Vy_nA_4_0"></a><a id="Tc_I6LXdJX1Gk2BrvXgHgwTew_5_0"></a><a id="Tc_rZ2LwmXaFUKagCQA031XiA_5_2"></a><a id="Tc_wPNyDZxGiEOIxFIo9RR9Eg_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:EarningsPerShareTextBlock" id="Tb_2gcsKfOJHUqItixqah4Twg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock, if any, participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the&#160;years ended December&#160;31, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for those periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_2Z0qbXJSI0in3yEH9rzo9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_MMnEXq3f5UuA9b_f9X_bWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_iLQtagMJPESRyh81L2_gfQ_3_2">12,330,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_SXG7MYzIGUCgqGneHO46ZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_EyYW-_--S0Syp1Cv929USg_3_4">11,376,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_sFPUIoXf4E6S5yFU1jhaWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_R-sT-BMfbU-FHPqDCBwBfA_4_2">2,878,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_egZnUbZL7UuFABnCiYNEEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_kU7f9Mt_PkqIlSgr1RYQBw_4_4">46,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantsMember_XSIPBticd0u3pNKbWJTJMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_StjTTam0g0WMH5J6fhM-tQ_5_4">1,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember__tC8H3YIX0S5r6g2u5BcaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-6lk8cCgHES9o9cfFSrbPA_6_2">1,671,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_tO2ji53wmU-1qqLGxMnwug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ky2IqVtm9E67SoKcB9KT-Q_6_4">1,307,079</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_fYraOH7BMkGuWDbHwhMPPA_7_2">16,879,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_i0f1v55THUONwYMRaE4wXQ_7_4">12,731,606</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;12, the triggering of the anti-dilution feature resulting from the B-2 Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" scale="3" id="Narr_d57PWmS_aUCUb_W7r_pgqg">2,829</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common shareholders reflected in our consolidated statement of operations for the&#160;year ended December&#160;31, 2022. This deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="2" format="ixt:numdotdecimal" name="tlsi:DeemedDividendIncreaseInNetLossPerShare" scale="0" id="Narr_bwjXEF-hzUuROn88zcDQ6Q">9.14</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';"> for the&#160;year ended December&#160;31, 2022.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="Tb_0UMS1FQ2yEqEw_MHqwoEnQ" continuedAt="Tb_0UMS1FQ2yEqEw_MHqwoEnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(15)</b></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfOperatingLeases" scale="0" id="Narr_WQ5fbAMMp06CQOWG0u3XlQ">four</ix:nonFraction> property leases in effect as of December&#160;31, 2022, which we account for as operating leases:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for our principal administrative and production facility at West 91st Avenue, Westminster, Colorado, which expires in December&#160;2026. This lease includes </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_CWI5Bga8AE2e_En3lvUg6A" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Narr_1q8T4uL2NEOEiYCFfN9A1Q"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two options</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to extend the lease by </span><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_nogwz9gxqU-ku2Q36qb4nQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_CbJ6vvyF-0avlBZHm7kmwg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> each at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for office space at 2275 Half Day Road, Bannockburn, Illinois, which expires in November&#160;2024. This lease includes an option to extend the lease by </span><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_Wpnc4LkhDkOnH49fJmT_-g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_Dk0SHL5PBk-r4IW0OR9Wfg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for office space at 1000 Chapel View Blvd, Cranston, Rhode Island, which expires in October&#160;2024. This lease includes an option to extend the lease by </span><ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_dgoxY8Ls70O_K7Kv_4YFDw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for laboratory and research space at 1 Hoppin Street, Providence, Rhode Island, which expires on February&#160;1, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfFinanceLeases" scale="0" id="Narr_cAzUhzSEwk-ZRQIFtLT10Q">four</ix:nonFraction> finance leases, <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierEquipmentMember_yN9PhUZ9oUmQbLbfhyWOVg" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfFinanceLeases" scale="0" id="Narr_Mx-4vBphnEaH74LkNNkOlA">three</ix:nonFraction> for copier equipment in our Westminster, Bannockburn and Cranston facilities, and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_XOapO_xAxkSVGyKMkyZktQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfFinanceLeases" scale="0" id="Narr_ldZ5q3wLRECxpMoDthTCuw">one</ix:nonFraction> for laboratory equipment in our research space in Providence.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_1f0b904e_7a2d_4d38_91bf_b8fa42566ee1"></a><a id="Tc_6v3xI7swzkSkLeg8hUaAvg_1_2"></a><a id="Tc_mZciGkb6sUW_Rj2wik1Zsw_1_5"></a><a id="Tc_3w-LVDlya0CvoMmx7JHYdQ_2_2"></a><a id="Tc_c-QmYf0ENkGxLHCNUyJGOg_2_5"></a><a id="Tc_r3Pzy6BkvEufSftspQi4Kw_3_0"></a><a id="Tc_x7wZzED51UCT2PAdFw_uwg_3_2"></a><a id="Tc_vgg0So1xKEGZiN_I-LwiLA_3_5"></a><a id="Tc_vFGyRsWcm0SNq5K4ktunEA_3_7"></a><a id="Tc_r3eI51N_j0Kz-7B8ZD8Ttw_4_0"></a><a id="Tc_g17k1Lxy_EyqSz-317pbdw_4_2"></a><a id="Tc_V0bfSl9vUkOkpMrQUI_WWw_4_5"></a><a id="Tc_o57zhA4QGEq7Nd_lLlyDPw_5_0"></a><a id="Tc_Ldm4QK_jukK7HoI8d_7zow_5_2"></a><a id="Tc_Y2uP-wmz9kSDCzkeJ13E8Q_5_5"></a><a id="_c57256ec_4ce9_4e01_86d5_bea52aa34ef1"></a><a id="Tc_a868U0uOM0KdeO9m2z1K9w_1_0"></a><a id="Tc_qv0486It-0KYCGW0h1qjkw_1_2"></a><a id="Tc_z5OH_emfg0Gu_ojT0w5hNA_2_0"></a><a id="Tc_ZEX3HGQtdk-oXbNZV6YcPg_3_0"></a><a id="Tc_3bGhbbAagU6jhJLX1ZnZFA_4_0"></a><a id="Tc_OY7ki7T2FEaizMjMa80MIg_5_0"></a><a id="Tc___pMmYozPUKWOxaG6eg3pg_6_0"></a><a id="Tc_rqO5NJ3pEkyJJrw87nh12A_6_2"></a><a id="_a06bb55a_9b34_4baa_9302_e77684a0d4b4"></a><a id="Tc_zFOwFgij-0SK3rZ5RlYHTg_1_2"></a><a id="Tc_feUoVHGQ90aHIPZ3RlvlPg_1_5"></a><a id="Tc_rWge76P0PEacIkaBCVu6Gw_2_2"></a><a id="Tc_dpcHzvjYekKokUbf80TZ9w_2_5"></a><a id="Tc_8WsddZONVkGY6_OaRTsqlA_3_0"></a><a id="Tc_oKxU-5ZtNEq9V8-6qbF0sQ_3_2"></a><a id="Tc_0oR5gbtcW02hXDkmNL5Sxg_3_5"></a><a id="Tc__qCkDy_FuES1bSUzU4v_WA_4_0"></a><a id="Tc_QRaxCuaFCkGAOf-ppxpOug_5_0"></a><a id="Tc_nH0ejbEuukSzZWH1jgBxHw_6_0"></a><a id="Tc_58afDPbewUC5g7d0VGPZdA_7_0"></a><a id="Tc_J5cXHGLWxUq-9r7054pgGg_8_0"></a><a id="Tc_mfn4FuWn7UuEBjr2_7xIbQ_8_6"></a><a id="Tc_uD6XcUv8Qkes0eOgP49B9Q_9_0"></a><a id="Tc_2odqQrhJyU2MuE2d77pq0g_10_0"></a><a id="Tc_zY-Ct_rhnk2NchhkAIkvcA_11_0"></a><a id="Tc_8iT2Rdx1uUGlHYi8m79hMQ_11_2"></a><a id="Tc_CwlIZk3nNk2f_nGxgv8wrQ_11_5"></a><ix:continuation id="Tb_0UMS1FQ2yEqEw_MHqwoEnQ_cont1" continuedAt="Tb_0UMS1FQ2yEqEw_MHqwoEnQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" id="Tb_eTc7-9639E-23bNjNSq8kg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of right-of-use assets, short-term lease liabilities and long-term lease liabilities at December&#160;31, 2022, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_rnbR7Iup9Ui5fh0J17p5CA_3_3">1,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_1Xk1ntezNECATkZZcwH61w_3_6">349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_8xv9M9DfwEW-zKfObUwLvA_4_3">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_TBS-MXIQX0C4lZcIaf-RiA_4_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_OEW0_XjVn0Gt6rczhKRl2g_5_3">1,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_N2hIoiLDm0OQT8oO3JxQMA_5_6">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Net of accumulated depreciation, included in fixed assets</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:LeaseCostTableTextBlock" id="Tb_ce5ItRhl1EKRngE9yVFucQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense for the&#160;year ended December&#160;31, 2022, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_LlZ-YIdgiUWw5x_RtlzlWA_1_3">443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_ZIv0kqukxUiXE4brC9Jg9A_3_3">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_iN5x3LNmY0S-YIXaK94PYQ_4_3">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total finance lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FinanceLeaseCost" scale="3" id="Tc_EO7rnH1_q06sFLiR2Uj3HQ_5_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_r2l6-J6KrEe4zTSOngV8IQ_6_3">463</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="tlsi:ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" id="Tb_g4W-sfNt5k6xGbEA9_rY9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maturities of lease liabilities under noncancellable leases as of December&#160;31, 2022, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_UdRoE4lglE-sa_4oXKW8DQ_3_3">429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_B_3smnss20GgBunhZtpcoQ_3_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_95bZm7-h2EG559A-gGY9_Q_4_3">378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_83WqAEkinE-8yknEwNMS-A_4_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_myhA0H7v7EyGqqWlheu0UA_5_3">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_iIJAkE3cm0Kf1RmdK0EpAg_5_6">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_UfnTT-ZvgkeYwtnh83L_6w_6_3">213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_7lyi4bhWcUWeWymhMRBHrg_6_6">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_YL_wA-nk5ES4i0HIqJOMrg_7_3">219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_57aJJ1XAa0S7c-HIrKhDBQ_7_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_NiucNWEFa0ig5NSjy7Amqg_8_3">884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_P7PynhLZVk-c03EjbVOTXg_9_3">2,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_2k982oDUEESqRJ6D7hoRoA_9_6">267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_uOunYqnyek2Vzl-X7_hjVA_10_3">600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_dRfV8eAork-fokvWYj59Tg_10_6">33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_HeaNGDKRf0i6EA1sf0ZLXg_11_3">1,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_fVBdTlaqVUayOrU--10fUQ_11_6">234</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, we recorded $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Narr__TBFbT2ackyaRJGxfk3WmQ">38</ix:nonFraction> in fixed assets for a finance lease for a copier in our Westminster facility, and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Narr_WhkTDaZ8_kazfZx1IQIojQ">6</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Narr_0u-siTKtskSvIZH6MkAcJA">32</ix:nonFraction> in current liabilities and long-term liabilities, respectively, for the related lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, we recorded $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Narr_pG7qK063KkuvS_bvbuXjcQ">310</ix:nonFraction> in fixed assets for a finance lease for analytical equipment in our laboratory facility in Providence, and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ" decimals="-3" format="ixt:numdotdecimal" name="tlsi:FinanceLeaseLiabilitiesCurrent" scale="3" id="Narr_dmbCozwswECPAIx4ayQCQw">178</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Narr_ersjCSmyFkiSK3B10LIAOA">132</ix:nonFraction> in current liabilities and long-term liabilities, respectively, for the related lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the weighted average life of our operating and finance leases is <span style="-sec-ix-hidden:Hidden_IhjA9SxPWke_WdT-YL8OYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span></span> and <ix:nonNumeric contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" format="ixt-sec:durwordsen" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_zXJuPYv9o0ubIFGc_Bf8FA">three&#160;years</ix:nonNumeric>, respectively. The weighted average discount rate for both operating and finance leases is <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_Ue990LviCU-yvAgweibR5w">8.1</ix:nonFraction>%, <span style="-sec-ix-hidden:Hidden_QpMaoZ2rLEe3kuE2nEwMHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span></span> is based on interest rates we paid for our most recent term loan and convertible notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total lease expense for the&#160;years ended December&#160;31, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Narr_7eX19ICooUS2Nk4YbWneXQ">385</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We record rent expense on a straight-line basis&#8201;&#8212;&#8201;the terms of all leases provide for increases in rental payments over time.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ff60d82_dc4d_4990_9c98_8d2ecb47bef7"></a><a id="Tc_cAGfkMtSX0W88lVIlg0DCw_1_0"></a><a id="Tc_6Fn71eGxaU600GzbZRLD1A_1_2"></a><a id="Tc_GxygX3TYb0G53YMZFDYriA_2_0"></a><a id="Tc_mjOBQHoEYU2B4wnVzVZLwA_3_0"></a><a id="Tc_6JbyYOOSIk-lbAZMSkj5Og_4_0"></a><a id="Tc_NYApBMggp0OgQHhboIuxSw_5_0"></a><a id="Tc_waNG0dcm8UCBVg8YKcuXEQ_6_0"></a><a id="Tc_Z2tGZQfc_keGQwxy5TsmTA_7_2"></a><ix:continuation id="Tb_0UMS1FQ2yEqEw_MHqwoEnQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="Tb_zNwh7Qxc50qbC0h9BAXCGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments for each of the five&#160;years ending December&#160;31, 2021, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="Tc_XmvAm8xneUu1AjkJOJ1VOQ_1_3">188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="Tc_FaKmuV_zWECuZPPtnduB1Q_2_3">194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="Tc_U4yO80eVgkih_QuYRqeQPg_3_3">199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="Tc_04-zO3ncaESPThaLeyb5TA_4_3">205</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="Tc_c0xUk5VcYU2tMG45to_qUg_5_3">213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="Tc_WBJuxPvWPUiWPoUJIPFQ_A_6_3">1,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="Tc_xjCgaIDpZUG3vx5Jrr3mtA_7_3">2,101</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_NKezCnRRK0mPlXfGT-7fjA" continuedAt="Tb_NKezCnRRK0mPlXfGT-7fjA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(16)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a salary reduction savings plan under Section&#160;401(k)&#160;of the Internal Revenue Code, which we administer for participating employees&#8217; contributions. All full-time employees are covered under the plan after meeting minimum service requirements. We paid matching contributions of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_rDCLKRWgw0exnCFxpLar4w">431</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_rMhZ2_38aE-yzik1n7Ja6Q">287</ix:nonFraction> to the plan for the&#160;years ended December&#160;31, 2022 and 2021, respectively. Our contributions were based on compensation at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionUptoThreePercentMember_cv3StuhiV0WTIiY4lV9S9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_3Xd39tUS30SghQdB26AXzg">3</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_Fo9HbOq37U21cbLPB6-3eQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_Hmhp9XBMw0aEDzZ6uoA6Dg">3.5</ix:nonFraction>%, and <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenFourAndFivePercentMember_aGOIseMil0e-w33qyFfkww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_sTApfyb50UicBuAx7dOzIA">4</ix:nonFraction>% for an employee&#8217;s contribution of up to 3%, between 3% and 4%, and between 4% and 5%, respectively, with the match-eligible contribution being limited to <ix:nonFraction unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_xcWWTY96Nk-zZTL1_eKYgg">4</ix:nonFraction>% of the employee&#8217;s eligible compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, an individual filed a suit against the Company in the District of Colorado asserting joint inventorship of <ix:nonFraction unitRef="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg" contextRef="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfPatentsSuitFiled" scale="0" id="Narr_60x9CtxanEygRw86cqNSiA">six</ix:nonFraction> patents assigned to the Company. The individual sought to be added as a co-inventor and co-owner of the patents in question. In a series of rulings, the Court struck monetary damages and jury trial demand, limited the individual&#8217;s expert testimony to <ix:nonFraction unitRef="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg" contextRef="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:NumberOfPatentsTestimonyLimited" scale="0" id="Narr_9Snj0S-PP0STtQbUtiOJ_Q">one</ix:nonFraction> patent, and barred rebuttal testimony to defendant&#8217;s expert or testimony related to prior art, severely limiting the scope of this case. Following a notice that we would be seeking sanctions against the plaintiff and his attorney, it was agreed that the plaintiff would dismiss his case with prejudice and no sanctions or attorney fees&#8217; request would be filed. A stipulated Dismissal Order was entered June&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, TriSalus exercised its right to terminate, for cause, an agreement with a distributor, pursuant to which the distributor was acting as exclusive distributor of the TriNav Infusion System in several Western states. We determined that the distributor had failed to perform many aspects of the contract resulting in poor sales. The distributor was put on notice in September&#160;of 2020 that performance must improve, or we would terminate the contract. Despite being allowed a <ix:nonNumeric contextRef="Duration_2_1_2021_To_2_28_2021_Kxpz0qSUe0mhCS0fzXQnrQ" format="ixt-sec:durday" name="tlsi:CurePeriod" id="Narr_b5jzK18j3kWt7ZujnlWCtg">60</ix:nonNumeric>-day cure period, the distributor&#8217;s performance did not improve and in February&#160;2021 we exercised our right to terminate. On March&#160;11, 2021, the distributor filed a lawsuit against us in the Utah state court, asserting a claim for wrongful termination of the contract by us and several other related, common-law claims. The distributor sought monetary damages in an amount of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_3_11_2021_To_3_11_2021__-g4Qp5Pyka4gA7LbeyrTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="3" id="Narr_hy009OBJek2_mpxWPgZ2og">750</ix:nonFraction>, plus attorneys&#8217; fees and other relief. On November&#160;15, 2021, we agreed to settle the case for $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_15_2021_To_11_15_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NTqWL_rATUeGsMWY1n5tKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesPaidValue" scale="3" id="Narr_bM4wCXNLrEOp0rQrzxbecw">425</ix:nonFraction>, which was recorded as expense in general and administrative expense in the accompanying consolidated statements of operations. The settlement was paid in <ix:nonFraction unitRef="Unit_Standard_installment_0xHPpLFYGkuxngV0kCBNoQ" contextRef="Duration_11_15_2021_To_11_15_2021_b3QxwyefQ0edxXCsFdJSjA" decimals="INF" format="ixt-sec:numwordsen" name="tlsi:LossContingencyDamagesPaidValueNumberOfInstallments" scale="0" id="Narr_xpEd-ety6kmltoe0q8_zRA">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_18_2021_To_11_18_2021_srt_StatementScenarioAxis_tlsi_FirstInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Lr-_cbK0CE6ccIYutbIUoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesPaidValue" scale="3" id="Narr_KhybmELHnkqqGYv8GGC42g">200</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_1_3_2022_To_1_3_2022_srt_StatementScenarioAxis_tlsi_SecondInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XU3a0ehnaEO_Yn_QEfUcqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesPaidValue" scale="3" id="Narr_gJHeo8k2H0aBlaGXNitUJg">225</ix:nonFraction>, on November&#160;18, 2021, and January&#160;3, 2022, respectively. The settlement amounted to the contractual fee if we were to terminate the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NKezCnRRK0mPlXfGT-7fjA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_oFir2UAIXUSwjk7g0qW98g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(17)</b></span><b style="font-weight:bold;">Merger Agreement with MedTech Acquisition Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;11, 2022, we entered into a Business Combination Agreement with MedTech Acquisition Corporation, a Delaware corporation (&#8220;MTAC&#8221;), and MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of MTAC (&#8220;Merger Sub&#8221;). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into TriSalus (the &#8220;Business Combination&#8221;), with TriSalus surviving as a wholly owned subsidiary of MTAC (the &#8220;Surviving Corporation&#8221;). Following completion of the combination, MTAC will be renamed &#8220;TriSalus Life Sciences,&#160;Inc.&#8221; The aggregate consideration payable to our stockholders is $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="3" id="Narr_O-cFI2qYcku5v-FAu8KaiQ">220,000</ix:nonFraction>, payable solely in shares of MTAC common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately prior to the effective time of the Business Combination, each outstanding warrant to purchase Series&#160;B-3 preferred stock must be exercised pursuant to the net-exercise provisions of the warrants, and then each issued and outstanding share of TriSalus&#8217; Series&#160;A-<span style="-sec-ix-hidden:Hidden_b4QB_34hYkSQy8m2zvvSVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_mW0ye0ape0K0u7SnjgQyTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_D1tTYpAKD0mwadhIRhVubw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_Wp2d5AfagUeiDJyLPZ20iQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_F187q8J5AkCMoKigjnNSmw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_s43EmyAlY0-5J-sKfRJXGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span>, Series&#160;B, Series&#160;B-<span style="-sec-ix-hidden:Hidden_iGujevr0gUmbUx_6BKltrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>, Series&#160;B-<span style="-sec-ix-hidden:Hidden_IoB8wHCgok2nthhVpcAt4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>, and Series&#160;B-<span style="-sec-ix-hidden:Hidden_7EvRLYEDcEumV76exoXIWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A" contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_v8JMAlK36k2t47JlYo0chg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_cmkkV1wPskqaWzXzrgSP0Q">0.001</ix:nonFraction> (collectively, the &#8220;TriSalus Preferred Stock&#8221;) will be converted into shares of TriSalus Common Stock at the then-applicable conversion rates. In addition, each remaining outstanding warrant to purchase shares of TriSalus Common Stock or TriSalus Preferred Stock (each, a &#8220;TriSalus Warrant&#8221;) that is in-the-money and would be exercised or otherwise exchanged in full in accordance with its terms by virtue of the occurrence of the Business Combination, will automatically be exercised for shares of TriSalus Common Stock. TriSalus Warrants that are out-of-the-money will be canceled for no consideration. Upon closing of the Business Combination, all shares of TriSalus Common Stock, including all shares of preferred stock converted as described above, will convert into shares of MTAC common stock at a conversion ratio equal to the $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q" decimals="-3" format="ixt:numdotdecimal" name="tlsi:BusinessCombinationWarrantsConsideration" scale="3" id="Narr_VT0OWFiWdEu9SUNAwBPLHg">220,000</ix:nonFraction> consideration stipulated in the Business Combination Agreement divided by the total shares of TriSalus Common Stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the effective time, each outstanding option to purchase shares of TriSalus Common Stock under TriSalus&#8217; equity incentive plans (each, a &#8220;TriSalus Option&#8221;), whether or not then vested and exercisable, will be assumed and converted into an option to purchase shares of MTAC common stock under similar terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we have deferred $<ix:nonFraction unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_HDWwXtuDDUqAhelDAH9-9A" decimals="-3" format="ixt:numdotdecimal" name="tlsi:BusinessCombinationAcquisitionExpensesDeferred" scale="3" id="Narr_UJL8n59Z1EaRZLEdILZ0qA">2,719</ix:nonFraction> of eligible expenses related to the registration and issuance of MTAC common stock in conjunction with the Business Combination. The deferral is recorded in other current assets in the accompanying consolidated balance sheet as of December&#160;31, 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_987fe20d_7d22_4a06_84f8_be35e375816e"></a><a id="_Hlk150564225"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;13.</b></span><b style="font-weight:bold;">Other Expenses of Issuance and Distribution.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of the securities being registered. All amounts shown are estimates except for the SEC registration fee.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SEC registration fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">44,671</p></td></tr><tr><td style="vertical-align:bottom;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accountants&#8217; fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">35,000</p></td></tr><tr><td style="vertical-align:bottom;width:87.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">350,000</p></td></tr><tr><td style="vertical-align:bottom;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Miscellaneous fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">160,000</p></td></tr><tr><td style="vertical-align:bottom;width:87.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">589,671</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Discounts, concessions, commissions and similar selling expenses attributable to the sale of shares of Common Stock covered by this prospectus will be borne by the selling securityholders. We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of the shares with the SEC, as estimated in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_12ab44f0_fd27_44e2_a253_4b8cd479bbcc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;14.</b></span><b style="font-weight:bold;">Indemnification of Directors and Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the Registrant. The DGCL provides that Section&#160;145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant&#8217;s Certificate of Incorporation and Bylaws provide for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;102(b)(7)&#160;of the DGCL permits a corporation to provide in its Certificate of Incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (2)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&#160;for unlawful payments of dividends or unlawful stock repurchases redemptions or other distributions or (4)&#160;for any transaction from which the director derived an improper personal benefit. The Registrant&#8217;s Certificate of Incorporation provides for such limitation of liability to the fullest extent permitted by the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Registrant has entered into indemnification agreements with each of its directors and executive officers to provide contractual indemnification in addition to the indemnification provided in our Certificate of Incorporation. Each indemnification agreement provides for indemnification and advancements by the Registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Registrant or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law. We believe that these provisions and agreements are necessary to attract qualified directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Registrant also maintains standard policies of insurance under which coverage is provided (1)&#160;to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, while acting in their capacity as directors and officers of the Registrant and (2)&#160;to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to any indemnification provision contained in the Registrant&#8217;s Certificate of Incorporation and Bylaws or otherwise as a matter of law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b99f68d5_a12d_4891_9556_dacc7f0dec5a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;15.</b></span><b style="font-weight:bold;">Recent Sales of Unregistered Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following list sets forth information regarding all unregistered securities sold by us since inception on September&#160;11, 2020. None of the following transactions involved any underwriters, underwriting discounts or commissions, or any public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;11, 2020, the Sponsor purchased an aggregate of 5,750,000 Founder Shares for an aggregate purchase price of $25,000, or approximately $0.004 per share. In December&#160;2020, MTAC effected a stock dividend, resulting in the Sponsor holding an aggregate of 6,325,000 Founder Shares (up to 825,000 of which are subject to forfeiture by the Sponsor). As a result of the underwriters partially exercising their over-allotment option, the Sponsor forfeited 75,000 Founder Shares, resulting in ownership of 6,250,000 Founder Shares. Sponsor also agreed to forfeit 2,187,500 of its Founder Shares in connection with the consummation of the Business Combination and at the Closing the remaining 4,062,500 shares converted automatically, on a one-for-one basis into a share of our Common Stock. Such securities were issued pursuant to the exemption from registration contained in Section&#160;4(a)(2)&#160;of the Securities Act. Sponsor is an accredited investor for purposes of Rule&#160;501 of Regulation D under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Placement Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the consummation of the initial public offering of MTAC, the Sponsor purchased in a private placement an aggregate of 4,933,333 Private Placement Warrants at a price of $1.50 per warrant and generated gross proceeds of $7,400,000. Each Private Placement Warrant is exercisable for one share of common stock at a price of $11.50 per share. The Private Placement Warrants are non-redeemable and exercisable on a cashless basis so long as they are held by Sponsor or its permitted transferees. The sale of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section&#160;4(a)(2)&#160;of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subscription Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Business Combination and pursuant to the Subscription Agreements, the Preferred Stock PIPE Investors purchased from the Company an aggregate of 4,015,002 shares of Preferred Stock at a purchase price of $10.00 per share, resulting in an aggregate purchase price of $40,150,020. The sale of the PIPE Shares was made pursuant to the exemption from registration contained in Section&#160;4(a)(2)&#160;of the Securities Act and/or Rule&#160;506(c)&#160;promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Standby Equity Purchase Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In October 2023, the Company entered into the purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd. (&#8220;Yorkville&#8221;), whereby it has the right, but not the obligation, to sell to Yorkville up to $30.0 million of shares of Common Stock at the Company&#8217;s request any time during the 24 months following the execution of such purchase agreement, subject to certain conditions. As of the date of this prospectus, no sales have been made under the Yorkville Purchase Agreement. Yorkville represented to the Company, among other things, that it is an institutional &#8220;accredited investor&#8221; as defined in Rule 501(a)(3) of Regulation D under the Securities Act. The securities are being issued and sold by the Company to Yorkville in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7af99c8c_5abb_4504_aee4_f8a730bdde1a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;16.</b></span><b style="font-weight:bold;">Exhibits and Financial Statement Schedules.</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The exhibits listed below are filed as part of this registration statement</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b>&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule/Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibits</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">2.1&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/tm2230343d1_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">2.2**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/tm2311821d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 5, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">2.3**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923060142/tm2315541d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">May 13, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">2.4**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923078462/tm2320024d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">July 6, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3.2**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3.3**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex3-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.2**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Warrant Certificate.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.3**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465920139004/tm2039161d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agreement, dated December 17, 2020, by and between MTAC and Continental Stock Transfer &amp; Trust Company.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December 23, 2020</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">5.1*</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="tlsi-20230630xex5d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Opinion of Cooley LLP.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Registration Rights Agreement, dated August 9, 2023, by and among TriSalus Life Sciences, Inc., members of MedTech Acquisition Sponsor LLC, and certain former stockholders of TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.2**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/tm2317638d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Subscription Agreement for PIPE Financing (Initial).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">June 8, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.3**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923078462/tm2320024d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Subscription Agreement for PIPE Financing (Subsequent).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">July 6, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.4**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/tm2230343d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsor Support Agreement, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, TriSalus Life Sciences, Inc., and MedTech Acquisition Sponsor LLC.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.5**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/tm2230343d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stockholder Support Agreement, by and among MedTech Acquisition Corporation, TriSalus Life Sciences, Inc. and certain stockholders of TriSalus Life Sciences, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.6**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465920139004/tm2039161d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated December 17, 2020, by and among MedTech Acquisition Corporation, its officers and directors and MedTech Acquisition Sponsor LLC.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December 23, 2020</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.7**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/tm2230343d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Lock- up Agreement, by and among certain stockholders of TriSalus Life Sciences, Inc. and MedTech Acquisition Corporation.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.8+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated November 11, 2022, by and between TriSalus Life Sciences, Inc. and Mary Szela.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.9+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated November 12, 2022, by and between TriSalus Life Sciences, Inc. and Steven C. Katz, MD.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.10+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated July 9, 2022, by and between TriSalus Life Sciences, Inc. and Sean Murphy.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.11+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement, dated October 11, 2022, by and between TriSalus Life Sciences, Inc. and Richard Marshak.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b>&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule/Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibits</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.12+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated November 11, 2022, by and between TriSalus Life Sciences, Inc. and Jennifer L. Stevens.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.13+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated November 4, 2022, by and between TriSalus Life Sciences, Inc. and Bryan F. Cox, Ph.D.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.14+&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923109964/tm2324982d7_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated August 28, 2023, by and between TriSalus Life Sciences, Inc. and Jodi Devlin.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">October 19, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.15+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.16+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (Pre-2020).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.17+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Early Exercise Stock Option Grant Notice and Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for grants prior to 2020).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.18+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for grants after 2020).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.19+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Early Exercise Stock Option Grant Notice and Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for grants after 2020).</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.20+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.21+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.22+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2023 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.23+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under 2023 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.24+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.25+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement by and between the Company and its directors and executive officers.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.26+**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex10-26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Policy.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.27&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923078759/tm2314644d10_ex10-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office/Warehouse Lease, dated February 4, 2014 between Colorado Industrial Portfolio LLC and Surefire Medical, Inc., as amended.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">July 6, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.28&#8224;&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated as of July 31, 2020, by and between Dynavax Technologies Corporation and Surefire Medical Inc. d/b/a TriSalus Life Sciences.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.29&#8224;&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000141057823000762/mtac-20221231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Strategic Collaboration Agreement, dated March 2, 2021, by and between Surefire Medical Inc. d/b/a TriSalus Life Sciences and The University of Texas M.D. Anderson Cancer Center.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">April 21, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.30&#8224;&#8224;**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923069459/tm2314644d6_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Distribution and Collaboration Agreement, dated May 7, 2019, between Hangzhou Ruizhen Therapeutics Co., Ltd. and Surefire Medical, Inc. d/b/a TriSalus Life Sciences.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-4/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-269138</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">June 8, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.31**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923106087/tm2327123d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Standby Equity Purchase Agreement, dated October 2, 2023, by and between TriSalus Life Sciences, Inc. and YA II PN, LTD.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">October 2, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">16.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex16-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter from WithumSmith+Brown, PC to the SEC, dated August 16, 2023.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">16.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">21.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form 8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">001-39813</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 16, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">23.1*</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="tlsi-20230630xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of WithumSmith+Brown, PC, independent registered public accounting firm.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">23.2*</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="tlsi-20230630xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">23.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Consent of Cooley LLP (included in Exhibit 5.1).</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">24.1**</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1826667/000110465923097317/tm2324982-1_s1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Power of Attorney</span></a> </p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">24.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">August 31, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Instance Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Taxonomy Extension Schema Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b>&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule/Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibits</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1.0pt solid transparent;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.35%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.87%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.38%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.61%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Taxonomy Extension Labels Linkbase Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Form S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">333-274292</p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">September 1, 2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">107*</p></td><td style="vertical-align:top;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:37.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="tlsi-20230630xexfilingfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Previously filed.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Certain portions of this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(10)(iv) because they are not material and are the type of information that the Registrant treats as private or confidential. The Registrant agrees to furnish supplementally an unredacted copy of the Exhibit, or any section thereof, to the SEC upon request.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c7aebd6f_cfad_464d_acd5_8822991e1b80"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 17.</b></span><b style="font-weight:bold;">Undertakings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 20pt;"><span style="display:inline-block;text-indent:0pt;width:16pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The undersigned registrant hereby undertakes as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:19.5pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c7e48ff6_f3fe_4ecb_991d_23063fa43ff6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirements of the Securities Act of 1933, the Company has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on this 14th day of December, 2023.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">TRISALUS LIFE SCIENCES, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td style="vertical-align:bottom;width:45.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">/s/ Mary Szela </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Mary Szela</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.35pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Mary Szela</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director<br/>(<i style="font-style:italic;">Principal Executive Officer</i>)</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Mary Szela</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Sean Murphy</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Director<br/>(<i style="font-style:italic;">Principal Financial and Accounting Officer</i>)</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Sean Murphy</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board of Directors</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Mats Wahlstr&#246;m</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.35pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Arjun Desai</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Andrew von Eschenbach</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.35pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Kerry Hicks</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">George Kelly Martin</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">David J. Matlin</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.9pt;"><td style="vertical-align:middle;width:31.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.35pt;"><td style="vertical-align:middle;width:31.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">*</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 14, 2023</p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:31.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Anil Singhal</p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4.3pt;"><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*By:</p></td><td style="vertical-align:middle;white-space:nowrap;width:49.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Szela</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:49.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Szela</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attorney-in-Fact</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tlsi-20230630xex5d1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/15/2023 02:03:03 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 5.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tlsi-20230630xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carlos A. Ramirez</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">T: +1 858 550 6157</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cramirez@cooley.com</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">December 14, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TriSalus Life Sciences, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6272 W. 91st Ave.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Westminster, CO 80031</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Re:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TriSalus Life Sciences, Inc. &#8211; Registration Statement on Form S-1</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have acted as counsel to TriSalus Life Sciences, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) (f/k/a MedTech Acquisition Corporation), in connection with the filing by the Company of a Registration Statement on Form S-1 (the &#8220;<font style="font-style:italic;font-weight:bold;">Registration Statement</font>&#8221;) with the Securities and Exchange Commission (the &#8220;<font style="font-style:italic;font-weight:bold;">Commission</font>&#8221;), including a related prospectus included in the Registration Statement (the &#8220;<font style="font-style:italic;font-weight:bold;">Prospectus</font>&#8221;), covering the registration of (a) the sale of shares of common stock, $0.0001 par value per share (&#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221;), of the Company upon the exercise of warrants issued by the Company, and (b) the resale of shares of Common Stock and warrants issued by the Company, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the sale of up to 13,215,112 shares of Common Stock consisting of:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 4,933,333 shares (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Private Warrant Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of Common Stock issuable by the Company upon the exercise by the holders thereof of certain outstanding warrants (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Private Warrants</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) originally issued in a private placement in connection with the initial public offering of the Company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 8,281,779 shares (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Public Warrant Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of Common Stock issuable by the Company upon the exercise by the holders thereof of certain outstanding warrants (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Public Warrants</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) originally issued in the initial public offering of the Company;</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the resale of up to 36,772,040 shares of Common Stock (the &#8220;<font style="font-style:italic;font-weight:bold;">Selling Stockholder Shares</font>&#8221;), consisting of:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 25,237,094 shares of Common Stock that are issuable upon the conversion of 4,015,002 shares of Series A Convertible Preferred Stock originally issued in a private placement pursuant to those certain subscription agreements, dated June 7, 2023 and July 4, 2023 (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Subscription Agreements</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 4,062,500 shares of common stock (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Founder Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) originally issued in a private placement to MedTech Acquisition Sponsor LLC (the</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cooley LLP&#160;&#160;&#160;10265 Science Center Drive&#160;&#160;&#160;San Diego, CA&#160;&#160;&#160;92121-1117</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">t: +1 858 550 6000&#160;&#160;&#160;f: +1 858 550-6420&#160;&#160;&#160;cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4</b></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tlsi-20230630xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TriSalus Life Sciences, Inc.</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 14, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Page Two</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 90pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Sponsor</font>&#8221;) prior to the Company&#8217;s initial public offering, including 3,125,000 Founder Shares subject to vesting and forfeiture (the &#8220;<font style="font-style:italic;font-weight:bold;">Sponsor Vesting Shares</font>&#8221;);</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 1,452,965 shares of Common Stock (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Option Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) issuable upon exercise of outstanding options that were initially granted by TriSalus Operating Life Sciences, Inc. (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Legacy TriSalus</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and assumed by the Company and converted into options to purchase Common Stock pursuant to that Agreement and Plan of Merger, dated as of November 11, 2022, as amended on April 4, 2023, May 13, 2023 and July 5, 2023 (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), by and among the Company, MTAC Merger Sub, Inc. and Legacy TriSalus;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 86,148 shares of Common Stock (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RSU Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) issuable upon the settlement of restricted stock units that were initially granted by Legacy TriSalus and assumed by the Company and converted into restricted stock units with respect to the Common Stock pursuant to the Merger Agreement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 4,933,333 Private Warrant Shares; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">up to 1,000,000 shares (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Conversion Warrant Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the Private Warrant Shares and the Public Warrant Shares, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Warrant Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of Common Stock issuable upon the exercise of certain warrants (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Conversion Warrants</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the Private Warrants and the Public Warrants, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) issued upon the conversion of a promissory note issued by the Company to the Sponsor;</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the resale of 5,933,333 Warrants (the &#8220;<font style="font-style:italic;font-weight:bold;">Resale Warrants</font>&#8221;) consisting of:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4,933,333 Private Warrants; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,000,000 Conversion Warrants.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We understand that the Private Warrants and the Public Warrants have been issued in book entry form pursuant to a Warrant Agreement, dated December 17, 2020, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent (&#8220;<font style="font-style:italic;font-weight:bold;">Warrant Agreement</font>&#8221;) as permitted by the Warrant Agreement and the Conversion Warrants have been issued in book entry form pursuant to that certain Notice of Exercise of Convertible Promissory Note, dated August 10, 2023, by the Sponsor (the &#8220;<font style="font-style:italic;font-weight:bold;">Exercise Notice</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Company&#8217;s certificate of incorporation and bylaws, each as currently in effect, (c) the Subscription Agreements, (d) the Warrant Agreement and the form of Warrants attached as an exhibit thereto, (e) the Exercise Notice and f) such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cooley LLP&#160;&#160;&#160;10265 Science Center Drive&#160;&#160;&#160;San Diego, CA&#160;&#160;&#160;92121-1117</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">t: +1 858 550 6000&#160;&#160;&#160;f: +1 858 550-6420&#160;&#160;&#160;cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tlsi-20230630xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TriSalus Life Sciences, Inc.</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 14, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Page Three</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; and the accuracy, completeness and authenticity of certificates of public officials and the due authorization by all persons other than the Company and the execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness thereof. &#160;As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With respect to the Warrants and the Warrant Shares, we express no opinion to the extent that future issuances of securities of the Company, antidilution adjustments to outstanding securities of the Company and/or other matters cause the Warrants to be exercisable for more shares of Common Stock than the number available for issuance by the Company. Further, we have assumed the exercise price of the Warrants will not be adjusted to an amount below the par value per share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware and, as to the Resale Warrants constituting valid and binding obligations of the Company, the laws of the State of New York. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With regard to our opinion concerning the Resale Warrants constituting valid and binding obligations of the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>Our opinion is subject to, and may be limited by, (a) applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance, debtor and creditor, and similar laws which relate to or affect creditors&#8217; rights generally, and (b) general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>Our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>We express no opinion as to any provision of the Resale Warrants that: (a) provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties; (b) relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights; (c) restricts non-written modifications and waivers; (d) provides for the payment of legal and other professional fees where such payment is contrary to law or public policy; (e) relates to exclusivity, election or accumulation of rights or remedies; (f)&#160;authorizes or validates conclusive or discretionary determinations; or (g) provides that provisions of the Resale Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cooley LLP&#160;&#160;&#160;10265 Science Center Drive&#160;&#160;&#160;San Diego, CA&#160;&#160;&#160;92121-1117</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">t: +1 858 550 6000&#160;&#160;&#160;f: +1 858 550-6420&#160;&#160;&#160;cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4</b></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tlsi-20230630xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TriSalus Life Sciences, Inc.</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 14, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Page Four</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>We express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Resale Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>The Private Warrant Shares and the Public Warrant Shares, when issued and paid for upon exercise of the Private Warrants and the Public Warrants, respectively, in accordance with the terms of such warrants, will be validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The Resale Warrants constitute valid and binding obligations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>The Selling Stockholder Shares, other than the Sponsor Vesting Shares, the Option Shares, the RSU Shares and any Warrant Shares included in the Selling Stockholder Shares, are validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The Option Shares and the RSU Shares included in the Selling Stockholder Shares, when issued, and if applicable paid for, in accordance with the terms of the related stock options or restricted stock units, will be validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The Sponsor Vesting Shares have been validly issued and are nonassessable and, when the applicable conditions to vesting have been satisfied, will be fully paid and no longer subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>Any Private Warrant Shares or Conversion Warrant Shares included in the Selling Stockholder Shares, when issued and paid for in accordance with the terms of the Private Warrants or the Conversion Warrants, respectively, will be validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our opinion is limited to the matters expressly set forth in this letter, and no opinion should be implied or may be inferred beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We hereby consent to the reference to our firm under the caption &#8220;Legal Matters&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cooley LLP&#160;&#160;&#160;10265 Science Center Drive&#160;&#160;&#160;San Diego, CA&#160;&#160;&#160;92121-1117</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">t: +1 858 550 6000&#160;&#160;&#160;f: +1 858 550-6420&#160;&#160;&#160;cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">44</b></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="tlsi-20230630xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TriSalus Life Sciences, Inc.</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 14, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Page Five</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COOLEY LLP</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Carlos A. Ramirez</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carlos A. Ramirez</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Cooley LLP&#160;&#160;&#160;10265 Science Center Drive&#160;&#160;&#160;San Diego, CA&#160;&#160;&#160;92121-1117</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">t: +1 858 550 6000&#160;&#160;&#160;f: +1 858 550-6420&#160;&#160;&#160;cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tlsi-20230630xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/15/2023 02:03:04 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Amendment No. 3 to Form S-1 of our report dated March 22, 2023, (which includes an explanatory paragraph relating to MedTech Acquisition Corporation&#8217;s ability to continue as a going concern), relating to the financial statements of MedTech Acquisition Corporation, which is contained in that Prospectus. We also consent to the reference to our Firm under the caption &#8220;Experts&#8221; in the Prospectus.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ WithumSmith+Brown, PC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New York, New York</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">December 14, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>tlsi-20230630xex23d2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/15/2023 02:03:03 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:31.5pt;"><td style="position:relative;vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><div style="height:0pt;position:relative;width:100%;"><div style="height:28.54pt;left:0%;position:absolute;top:-0.05pt;width:70.86pt;z-index:251658240;"><div style="height:28.34pt;left:0pt;padding-bottom:0.2pt;position:relative;width:70.86pt;"><img src="tlsi-20230630xex23d2001.jpg" alt="Graphic" style="height:28.34pt;width:70.86pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:23.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">KPMG LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suite 800<br>1225 17th Street<br>Denver, CO 80202-5598</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the use of our report dated April&#160;21,&#160;2023, except for Note 2a, as to which the date is December 14, 2023, with respect to the consolidated financial statements of TriSalus Life Sciences, Inc, included herein, and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tlsi-20230630xex23d2002.jpg" alt="Graphic" style="display:inline-block;height:21.26pt;width:98.65pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:38.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denver, Colorado </p></td><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:38.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 14, 2023</p></td><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:50%;" align="center"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:5.5pt;line-height:1.19;margin:0pt;">KPMG LLP, a Delaware limited liability partnership and a member firm of<br>the KPMG global organization of independent member firms affiliated <br>withKPMG International Limited, a private English company limited by guarantee.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>tlsi-20230630xexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/15/2023 02:03:04 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Calculation of Filing Fee Tables</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">S-1/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Form Type)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TriSalus Life Sciences, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Table 1: Newly Registered and Carry Forward Securities</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:9.41%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><br><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:middle;width:10.64%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><br><b style="font-weight:bold;">Class</b><br><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:middle;width:10.76%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee</b><br><b style="font-weight:bold;">Calculation</b><br><b style="font-weight:bold;">or Carry</b><br><b style="font-weight:bold;">Forward</b><br><b style="font-weight:bold;">Rule</b></p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b><br><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proposed</b><br><b style="font-weight:bold;">Maximum</b><br><b style="font-weight:bold;">Offering</b><br><b style="font-weight:bold;">Price Per</b><br><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b><br><b style="font-weight:bold;">Aggregate Offering</b><br><b style="font-weight:bold;">Price</b><sup style="font-size:9.37pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee Rate</b></p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount of</b><br><b style="font-weight:bold;">Registration </b><br><b style="font-weight:bold;">Fee</b></p></td></tr><tr><td colspan="9" style="vertical-align:middle;width:100%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Newly Registered Securities</b></p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:middle;width:9.41%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:middle;width:10.64%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:middle;width:10.76%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">457(g)</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13,215,112<sup style="font-size:9.37pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$11.50<sup style="font-size:9.37pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$151,973,788</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0.00014760</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$22,431.33</p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:middle;width:9.41%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:middle;width:10.64%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Warrants</p></td><td style="vertical-align:middle;width:10.76%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">457(i)</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4,933,333<sup style="font-size:9.37pt;vertical-align:top;">(4)(2)</sup></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8212;<sup style="font-size:9.37pt;vertical-align:top;">(5)</sup></p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:middle;width:9.41%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:middle;width:10.64%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:middle;width:10.76%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">457(c)</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36,772,040<sup style="font-size:9.37pt;vertical-align:top;">(6)(2)</sup></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.0975<sup style="font-size:9.37pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$150,673,434</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0.00014760</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$22,239.40</p></td></tr><tr style="height:13.85pt;"><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:middle;width:45.25%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Offering Amounts</b></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$302,647,222</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$44,670.73</p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:middle;width:45.25%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fees Previously Paid</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$56,985.70</p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:middle;width:45.25%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fee Offsets</b></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$(12,314.97)</p></td></tr><tr><td style="vertical-align:middle;width:5.51%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:middle;width:45.25%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Fees Due</b></p></td><td style="vertical-align:middle;width:11.74%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:14.87%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.69%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.9%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</font></font><font style="display:inline-block;width:6.3pt;"></font>Consists of up to (i) 4,933,333 shares of common stock of the Registrant (&#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;) issuable upon the exercise of private placement warrants at an exercise price of $11.50 per share of Common Stock (the &#8220;<b style="font-weight:bold;">Private Placement Warrants</b>&#8221;) and (ii) 8,281,779 shares of Common Stock issuable upon the exercise of warrants originally issued in the initial public offering of MedTech Acquisition Corporation (&#8220;<b style="font-weight:bold;">MTAC</b>&#8221;) by the holders thereof (the &#8220;<b style="font-weight:bold;">Public Warrants</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font><font style="display:inline-block;width:6.3pt;"></font>Includes an indeterminable number of additional securities that, pursuant to Rule 416 under the Securities Act of 1933, as amended, may be issued to prevent dilution from stock splits, stock dividends or similar transactions that could affect the securities to be offered by the selling securityholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</font></font><font style="display:inline-block;width:6.3pt;"></font>Calculated pursuant to Rule 457(g) under the Securities Act, based on the $11.50 exercise price per share of common stock issuable upon exercise of the Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</font></font><font style="display:inline-block;width:6.3pt;"></font>Represents 4,933,333 Private Placement Warrants registered for resale by the selling securityholders identified in this registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</font></font><font style="display:inline-block;width:6.3pt;"></font>In accordance with Rule 457(i), the entire registration fee for the Private Placement Warrants is allocated to the Common Stock underlying the Private Placement Warrants, and no separate fee is payable for the Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(6)</font></font><font style="display:inline-block;width:6.3pt;"></font>Consists of (i) up to 25,237,094 shares of Common Stock issuable upon the conversion of the 4,015,002 shares of Series A Convertible Preferred Stock originally issued to investors in a private placement concurrently with the closing of the business combination described in the prospectus accompanying this registration statement, (ii) up to 4,062,500 shares of Common Stock originally issued in a private placement to MedTech Acquisition Sponsor LLC (&#8220;<b style="font-weight:bold;">Sponsor</b>&#8221;) in connection with the initial public offering MTAC, (iii) up to 4,933,333 shares of Common Stock issuable upon exercise of the Private Placement Warrants, (iv) up to 1,000,000 shares of Common Stock issuable upon exercise of warrants previously issued by MTAC to Sponsor upon the conversion of certain working capital loans in connection with the closing of the business combination, (v) 1,452,965 shares of Common Stock issuable upon exercise of outstanding options and (vi) 86,148 shares of common stock issuable in connection with the vesting and settlement of outstanding restricted stock units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</font></font><font style="display:inline-block;width:6.3pt;"></font>Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based on the average of the high and low sales price of the Registrant&#8217;s ordinary shares as reported on the Nasdaq Global Market on December 8, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:11.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(8)</font></font><font style="display:inline-block;width:6.3pt;"></font>Previously paid in connection with the initial filing of Registration Statement on Form S-1 (No. 333-274292) filed on August 31, 2023 to which this Amendment No. 3 relates.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tlsi-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/15/2023 2:04:02 AM-->
<!--Modified on: 12/15/2023 2:04:02 AM-->
<xsd:schema xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:attributeFormDefault="unqualified" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:tlsi="http://trisaluslifesci.com/20230630" xmlns:xs="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://trisaluslifesci.com/20230630" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss" id="StatementCondensedConsolidatedStatementsOfOperationsss">
        <link:definition>111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails">
        <link:definition>111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" id="DisclosureIncomeTaxDeferredTaxAssetsDetails">
        <link:definition>111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" id="DisclosureIncomeTaxIncomeTaxProvisionDetails">
        <link:definition>111240902 - Disclosure - INCOME TAX - Income tax provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" id="StatementCondensedConsolidatedBalanceSheetss">
        <link:definition>1200100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" id="StatementCondensedConsolidatedStatementsOfOperationss">
        <link:definition>1200200 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" id="StatementCondensedConsolidatedStatementsOfCashFlowss">
        <link:definition>1200400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" id="DisclosureBusinessCombinationsDetails">
        <link:definition>1240301 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>1240501 - Disclosure - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
        <link:definition>1240701 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>222100100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>222100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>222100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss" id="DisclosureCashCashEquivalentsAndRestrictedCashDetailss">
        <link:definition>222140401 - Disclosure - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventoryDetailss" id="DisclosureInventoryDetailss">
        <link:definition>222140501 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" id="DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails">
        <link:definition>222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" id="DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>222140604 - Disclosure - Long-Lived Assets - Intangible Assets, amortization expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss" id="DisclosureAccruedLiabilitiesDetailss">
        <link:definition>222140701 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" id="DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails">
        <link:definition>222140801 - Disclosure - Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" id="DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails">
        <link:definition>222140802 - Disclosure - Income Taxes - Provision for federal income tax statutory rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
        <link:definition>222140803 - Disclosure - Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails">
        <link:definition>222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss" id="DisclosureLeasesComponentsOfLeaseExpenseDetailss">
        <link:definition>222141502 - Disclosure - Leases - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" id="DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>222141503 - Disclosure - Leases - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2" id="DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2">
        <link:definition>222141503 - Disclosure - Leases - Components of lease expense (Details) Cal 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss" id="DisclosureLeasesFutureMinimumLeasePaymentsDetailss">
        <link:definition>222141504 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>111100090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>111200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit">
        <link:definition>111200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" id="DisclosureDescriptionOfOrganizationAndBusinessOperations">
        <link:definition>111210101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>111210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePublicOffering" id="DisclosurePublicOffering">
        <link:definition>111210301 - Disclosure - PUBLIC OFFERING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacement" id="DisclosurePrivatePlacement">
        <link:definition>111210401 - Disclosure - PRIVATE PLACEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>111210501 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>111210601 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficit" id="DisclosureStockholdersDeficit">
        <link:definition>111210701 - Disclosure - STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilities" id="DisclosureWarrantLiabilities">
        <link:definition>111210801 - Disclosure - WARRANT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTax" id="DisclosureIncomeTax">
        <link:definition>111210901 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>111211001 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>111211101 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>111220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>111230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxTables" id="DisclosureIncomeTaxTables">
        <link:definition>111230903 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>111231003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails">
        <link:definition>111240102 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>111240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails">
        <link:definition>111240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails">
        <link:definition>111240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails" id="DisclosurePublicOfferingDetails">
        <link:definition>111240301 - Disclosure - PUBLIC OFFERING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails" id="DisclosurePrivatePlacementDetails">
        <link:definition>111240401 - Disclosure - PRIVATE PLACEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" id="DisclosureRelatedPartyTransactionsFounderSharesDetails">
        <link:definition>111240501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>111240502 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>111240601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails" id="DisclosureStockholdersDeficitPreferredStockDetails">
        <link:definition>111240701 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails" id="DisclosureStockholdersDeficitCommonStockDetails">
        <link:definition>111240702 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails" id="DisclosureWarrantLiabilitiesDetails">
        <link:definition>111240801 - Disclosure - WARRANT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" id="DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails">
        <link:definition>111240903 - Disclosure - INCOME TAX - Reconciliation of the federal income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>111241001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>111241002 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" id="DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails">
        <link:definition>111241003 - Disclosure - FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" id="DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails">
        <link:definition>111241004 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>111241101 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>1240101 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails" id="DisclosureAccountingPoliciesDetails">
        <link:definition>1240201 - Disclosure - Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails" id="DisclosureFinancialInstrumentsNarrativeDetails">
        <link:definition>1240401 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" id="DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails">
        <link:definition>1240402 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails" id="DisclosureContingentEarnoutLiabilityNarrativeDetails">
        <link:definition>1240801 - Disclosure - Contingent Earnout Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" id="DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails">
        <link:definition>1240802 - Disclosure - Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" id="DisclosureWarrantsScheduleOfWarrantsOutstandingDetails">
        <link:definition>1240901 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails" id="DisclosureWarrantsNarrativeDetails">
        <link:definition>1240902 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails" id="DisclosurePreferredStockNarrativeDetails">
        <link:definition>1241101 - Disclosure - Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" id="DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails">
        <link:definition>1241102 - Disclosure - Preferred Stock - Summary of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" id="DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails">
        <link:definition>1241103 - Disclosure - Preferred Stock - Convertible Preferred Stock Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" id="DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails">
        <link:definition>1241104 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" id="DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails">
        <link:definition>1241105 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails" id="DisclosurePreferredStockFairValueMeasurementsDetails">
        <link:definition>1241106 - Disclosure - Preferred Stock - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails">
        <link:definition>1241201 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>1241301 - Disclosure - Share-Based Compensation - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss" id="DisclosureShareBasedCompensationDetailss">
        <link:definition>1241302 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails" id="DisclosureDynavaxPurchaseDetails">
        <link:definition>1241401 - Disclosure - Dynavax Purchase (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" id="StatementConsolidatedStatementsOfStockholdersDeficit">
        <link:definition>222100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" id="DisclosureSummaryOfSignificantAccountingPoliciesDetailss">
        <link:definition>222140201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails" id="DisclosureFinancialInstrumentsDetails">
        <link:definition>222140301 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" id="DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails">
        <link:definition>222140302 - Disclosure - Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss" id="DisclosureDynavaxPurchaseDetailss">
        <link:definition>222140901 - Disclosure - Dynavax Purchase (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails" id="DisclosureDebtPppLoanDetails">
        <link:definition>222141001 - Disclosure - Debt - PPP Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails" id="DisclosureDebtTermLoanDetails">
        <link:definition>222141002 - Disclosure - Debt - Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails" id="DisclosureConvertibleNotesDetails">
        <link:definition>222141101 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockDetails">
        <link:definition>222141201 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails">
        <link:definition>222141202 - Disclosure - Convertible Preferred Stock, activity in convertible preferred stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails" id="DisclosureConvertiblePreferredStockNarrativeDetails">
        <link:definition>222141203 - Disclosure - Convertible Preferred Stock, narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails" id="DisclosureConvertiblePreferredStockDividendsDetails">
        <link:definition>222141206 - Disclosure - Convertible Preferred Stock, Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" id="DisclosureConvertiblePreferredStockLiquidationPreferencesDetails">
        <link:definition>222141207 - Disclosure - Convertible Preferred Stock, Liquidation Preferences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails" id="DisclosureConvertiblePreferredStockMarch2021FinancingDetails">
        <link:definition>222141208 - Disclosure - Convertible Preferred Stock, March 2021 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails" id="DisclosureConvertiblePreferredStockSpring2021FinancingDetails">
        <link:definition>222141209 - Disclosure - Convertible Preferred Stock, Spring 2021 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails" id="DisclosureConvertiblePreferredStockFall2021FinancingDetails">
        <link:definition>222141210 - Disclosure - Convertible Preferred Stock, Fall 2021 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails" id="DisclosureConvertiblePreferredStockWarrantExercisesDetails">
        <link:definition>222141211 - Disclosure - Convertible Preferred Stock, Warrant Exercises (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails" id="DisclosureConvertiblePreferredStock2022FinancingDetails">
        <link:definition>222141212 - Disclosure - Convertible Preferred Stock - 2022 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails" id="DisclosureConvertiblePreferredStock2023FinancingDetails">
        <link:definition>222141213 - Disclosure - Convertible Preferred Stock - 2023 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>222141301 - Disclosure - Stockholders' Equity - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" id="DisclosureStockholdersEquityStockOptionActivityDetails">
        <link:definition>222141302 - Disclosure - Stockholders' Equity - Stock Option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" id="DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails">
        <link:definition>222141303 - Disclosure - Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" id="DisclosureStockholdersEquityValuationAssumptionsDetails">
        <link:definition>222141304 - Disclosure - Stockholders' Equity - Valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>222141305 - Disclosure - Stockholders' Equity - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>222141401 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>222141505 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss" id="DisclosureCommitmentsAndContingenciesDetailss">
        <link:definition>222141601 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" id="DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails">
        <link:definition>222141701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" id="StatementCondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>1210101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess" id="DisclosureSummaryOfSignificantAccountingPoliciess">
        <link:definition>1210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombination" id="DisclosureBusinessCombination">
        <link:definition>1210301 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>1210401 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" id="DisclosureCashCashEquivalentsAndRestrictedCash">
        <link:definition>1210501 - Disclosure - Cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>1210601 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>1210701 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability" id="DisclosureContingentEarnoutLiability">
        <link:definition>1210801 - Disclosure - Contingent Earnout Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>1210901 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>1211001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>1211101 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>1211201 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>1211301 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchase" id="DisclosureDynavaxPurchase">
        <link:definition>1211401 - Disclosure - Dynavax Purchase</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess" id="DisclosureCommitmentsAndContingenciess">
        <link:definition>1211501 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" id="DisclosureSummaryOfSignificantAccountingPoliciesPoliciess">
        <link:definition>1220202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>1230403 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" id="DisclosureCashCashEquivalentsAndRestrictedCashTables">
        <link:definition>1230503 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>1230603 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>1230703 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables" id="DisclosureContingentEarnoutLiabilityTables">
        <link:definition>1230803 - Disclosure - Contingent Earnout Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>1230903 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockTables" id="DisclosurePreferredStockTables">
        <link:definition>1231103 - Disclosure - Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>1231203 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>1231303 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>1240601 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>1241001 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails" id="DisclosureNetLossPerShareNarrativeDetails">
        <link:definition>1241202 - Disclosure - Net Loss per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>222100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>222100405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss" id="DisclosureNatureOfBusinesss">
        <link:definition>222110101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss" id="DisclosureSummaryOfSignificantAccountingPoliciesss">
        <link:definition>222110201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss" id="DisclosureFinancialInstrumentss">
        <link:definition>222110301 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs" id="DisclosureCashCashEquivalentsAndRestrictedCashs">
        <link:definition>222110401 - Disclosure - Cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventorys" id="DisclosureInventorys">
        <link:definition>222110501 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssets" id="DisclosureLongLivedAssets">
        <link:definition>222110601 - Disclosure - Long-Lived Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess" id="DisclosureAccruedLiabilitiess">
        <link:definition>222110701 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxess" id="DisclosureIncomeTaxess">
        <link:definition>222110801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchases" id="DisclosureDynavaxPurchases">
        <link:definition>222110901 - Disclosure - Dynavax Purchase</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>222111001 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>222111101 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>222111201 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>222111301 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShares" id="DisclosureNetLossPerShares">
        <link:definition>222111401 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>222111501 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss" id="DisclosureCommitmentsAndContingenciesss">
        <link:definition>222111601 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation" id="DisclosureMergerAgreementWithMedtechAcquisitionCorporation">
        <link:definition>222111701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss" id="DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss">
        <link:definition>222120202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless" id="DisclosureFinancialInstrumentsTabless">
        <link:definition>222130303 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless" id="DisclosureCashCashEquivalentsAndRestrictedCashTabless">
        <link:definition>222130403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureInventoryTabless" id="DisclosureInventoryTabless">
        <link:definition>222130503 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables" id="DisclosureLongLivedAssetsTables">
        <link:definition>222130603 - Disclosure - Long-Lived Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless" id="DisclosureAccruedLiabilitiesTabless">
        <link:definition>222130703 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>222130803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>222131003 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables" id="DisclosureConvertiblePreferredStockTables">
        <link:definition>222131203 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>222131301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless" id="DisclosureNetLossPerShareTabless">
        <link:definition>222131403 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>222131503 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss" id="DisclosureNatureOfBusinessDetailss">
        <link:definition>222140101 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails" id="DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails">
        <link:definition>222140602 - Disclosure - Long-Lived Assets - Property and Equipment, narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails" id="DisclosureLongLivedAssetsIntangibleAssetsDetails">
        <link:definition>222140603 - Disclosure - Long-Lived Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>222140805 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails" id="DisclosureConvertiblePreferredStockConversionDetails">
        <link:definition>222141204 - Disclosure - Convertible Preferred Stock, Conversion (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails" id="DisclosureConvertiblePreferredStockVotingRightsDetails">
        <link:definition>222141205 - Disclosure - Convertible Preferred Stock, Voting Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>222141402 - Disclosure - Net Loss per Share - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails" id="DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails">
        <link:definition>222141501 - Disclosure - Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsi-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsi-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsi-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsi-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://trisaluslifesci.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xbrli:periodType="duration" name="UnitsIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_SaleOfStockUnderwritingFees" xbrli:periodType="instant" xbrli:balance="credit" name="SaleOfStockUnderwritingFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_SaleOfStockOtherOfferingCosts" xbrli:periodType="instant" xbrli:balance="credit" name="SaleOfStockOtherOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xbrli:periodType="duration" name="PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_InitialPublicOfferingAbstract" xbrli:periodType="duration" abstract="true" name="InitialPublicOfferingAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_InitialPublicOfferingTextBlock" xbrli:periodType="duration" name="InitialPublicOfferingTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_NumberOfSharesIssuedPerUnit" xbrli:periodType="duration" name="NumberOfSharesIssuedPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_NumberOfWarrantsIssuedPerUnit" xbrli:periodType="instant" name="NumberOfWarrantsIssuedPerUnit" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_EmergingGrowthCompanyPolicyTextBlock" xbrli:periodType="duration" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_PrivatePlacementAbstract" xbrli:periodType="duration" abstract="true" name="PrivatePlacementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_PrivatePlacementTextBlock" xbrli:periodType="duration" name="PrivatePlacementTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xbrli:periodType="instant" name="ClassOfWarrantOrRightPriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_SponsorMember" xbrli:periodType="duration" abstract="true" name="SponsorMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfSharesSubjectToForfeiture" xbrli:periodType="instant" name="NumberOfSharesSubjectToForfeiture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xbrli:periodType="duration" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xbrli:periodType="duration" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xbrli:periodType="duration" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xbrli:periodType="duration" name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_PromissoryNoteWithRelatedPartyMember" xbrli:periodType="duration" abstract="true" name="PromissoryNoteWithRelatedPartyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_RelatedPartyLoansMember" xbrli:periodType="duration" abstract="true" name="RelatedPartyLoansMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xbrli:periodType="duration" xbrli:balance="debit" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_CommonStockNumberOfVotesPerShare" xbrli:periodType="instant" name="CommonStockNumberOfVotesPerShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xbrli:periodType="duration" abstract="true" name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xbrli:periodType="duration" name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xbrli:periodType="duration" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xbrli:periodType="duration" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_MaximumLoansConvertibleIntoWarrants" xbrli:periodType="instant" xbrli:balance="credit" name="MaximumLoansConvertibleIntoWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xbrli:periodType="instant" xbrli:balance="credit" name="MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_RedemptionPeriod" xbrli:periodType="duration" name="RedemptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xbrli:periodType="duration" name="ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_TransactionCosts" xbrli:periodType="instant" xbrli:balance="credit" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xbrli:periodType="instant" name="MaximumNumberOfDemandsForRegistrationOfSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_AdministrativeSupportAgreementMember" xbrli:periodType="duration" abstract="true" name="AdministrativeSupportAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AggregateNumberOfSharesOwned" xbrli:periodType="instant" name="AggregateNumberOfSharesOwned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xbrli:periodType="duration" name="AssetsHeldInTrustAccountPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_TemporaryEquityPolicyPolicyTextBlock" xbrli:periodType="duration" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_PaymentsForInvestmentOfCashInTrustAccount" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentsForInvestmentOfCashInTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DeferredOfferingCostsNoncurrent" xbrli:periodType="instant" xbrli:balance="credit" name="DeferredOfferingCostsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PublicWarrantsMember" xbrli:periodType="duration" abstract="true" name="PublicWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PrivatePlacementWarrantsMember" xbrli:periodType="duration" abstract="true" name="PrivatePlacementWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xbrli:periodType="duration" name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CommonClassaSubjectToRedemptionMember" xbrli:periodType="duration" abstract="true" name="CommonClassaSubjectToRedemptionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WorkingCapitalLoansWarrantMember" xbrli:periodType="duration" abstract="true" name="WorkingCapitalLoansWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xbrli:periodType="duration" name="ConditionForFutureBusinessCombinationUseOfProceedsPercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xbrli:periodType="duration" name="ConditionForFutureBusinessCombinationThresholdPercentageOwnership" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xbrli:periodType="instant" xbrli:balance="debit" name="ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_RedemptionLimitPercentageWithoutPriorConsent" xbrli:periodType="duration" name="RedemptionLimitPercentageWithoutPriorConsent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_RedemptionPeriodUponClosure" xbrli:periodType="duration" name="RedemptionPeriodUponClosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_MaximumAllowedDissolutionExpenses" xbrli:periodType="duration" xbrli:balance="debit" name="MaximumAllowedDissolutionExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xbrli:periodType="duration" name="TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_WarrantExercisePriceAdjustmentMultiple" xbrli:periodType="duration" name="WarrantExercisePriceAdjustmentMultiple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_WarrantRedemptionPriceAdjustmentMultiple" xbrli:periodType="duration" name="WarrantRedemptionPriceAdjustmentMultiple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xbrli:periodType="duration" name="RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xbrli:periodType="duration" name="PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xbrli:periodType="duration" name="PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xbrli:periodType="duration" name="MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_WarrantExercisePeriodConditionTwo" xbrli:periodType="duration" name="WarrantExercisePeriodConditionTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_WarrantExercisePeriodConditionOne" xbrli:periodType="duration" name="WarrantExercisePeriodConditionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_WarrantRedemptionConditionMinimumSharePrice" xbrli:periodType="duration" name="WarrantRedemptionConditionMinimumSharePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_WarrantLiabilitiesPolicyTextBlock" xbrli:periodType="duration" name="WarrantLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_WarrantsAbstract" xbrli:periodType="duration" abstract="true" name="WarrantsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xbrli:periodType="instant" name="NumberOfSharesNoLongerSubjectToForfeiture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_NumberOfTrading" xbrli:periodType="duration" name="NumberOfTrading" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_StockholderEquity" xbrli:periodType="instant" xbrli:balance="credit" name="StockholderEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_WorkingCapital" xbrli:periodType="instant" xbrli:balance="debit" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xbrli:periodType="duration" abstract="true" name="NumeratorForCalculationOfEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xbrli:periodType="duration" abstract="true" name="DenominatorForCalculationOfEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_AccruedExpensesMember" xbrli:periodType="duration" abstract="true" name="AccruedExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ConvertibleStockConversionRatio" xbrli:periodType="duration" name="ConvertibleStockConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xbrli:periodType="instant" name="SharePriceTriggerUsedToMeasureDilutionOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xbrli:periodType="duration" xbrli:balance="debit" name="CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xbrli:periodType="duration" xbrli:balance="debit" name="LegalFeeContingentUponConsummationOfBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xbrli:periodType="duration" xbrli:balance="debit" name="InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_FounderSharesMember" xbrli:periodType="duration" abstract="true" name="FounderSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DueToSponsorForCertainReimbursableExpenses" xbrli:periodType="duration" xbrli:balance="debit" name="DueToSponsorForCertainReimbursableExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TwoThousandTwentyOnePromissoryNoteMember" xbrli:periodType="duration" abstract="true" name="TwoThousandTwentyOnePromissoryNoteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xbrli:periodType="duration" abstract="true" name="TwoThousandTwentyTwoPromissoryNoteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xbrli:periodType="duration" name="DerivativeWarrantLiabilitiesDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_OperatingBankAccounts" xbrli:periodType="duration" xbrli:balance="debit" name="OperatingBankAccounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xbrli:periodType="instant" xbrli:balance="credit" name="ConvertibleNotesPayableRelatedPartyNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_InitialPublicOfferingTable" xbrli:periodType="duration" abstract="true" name="InitialPublicOfferingTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_InitialPublicOfferingLineItems" xbrli:periodType="duration" abstract="true" name="InitialPublicOfferingLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_ExtensionNotesPayableCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="ExtensionNotesPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xbrli:periodType="duration" xbrli:balance="debit" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromTrustAccountInConnectionWithRedemption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xbrli:periodType="duration" xbrli:balance="debit" name="LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xbrli:periodType="duration" abstract="true" name="IssuanceOfPromissoryNote2022ToSponsorMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xbrli:periodType="instant" name="StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xbrli:periodType="instant" xbrli:balance="debit" name="ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xbrli:periodType="duration" name="ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xbrli:periodType="instant" xbrli:balance="debit" name="ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AmountDepositedIntoTrustAccount" xbrli:periodType="instant" xbrli:balance="debit" name="AmountDepositedIntoTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xbrli:periodType="instant" name="PercentOfDepositsIntoTrustAccountDrawnDown" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xbrli:periodType="instant" name="PercentOfDepositsIntoTrustAccountFundedByAcquiree" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_PercentageOfTransactionalFeePaid" xbrli:periodType="duration" name="PercentageOfTransactionalFeePaid" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_PercentageOfAmountDepositedInTrustAccount" xbrli:periodType="duration" name="PercentageOfAmountDepositedInTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_ExtensionDeposit" xbrli:periodType="duration" xbrli:balance="credit" name="ExtensionDeposit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xbrli:periodType="duration" xbrli:balance="credit" name="DeferredUnderwritingFeesUponConsummationOfBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_RaymondJamesAgreementsMember" xbrli:periodType="duration" abstract="true" name="RaymondJamesAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExtensionNoteMember" xbrli:periodType="duration" abstract="true" name="ExtensionNoteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PromissoryNote2022ThreeMember" xbrli:periodType="duration" abstract="true" name="PromissoryNote2022ThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrisalusMember" xbrli:periodType="duration" abstract="true" name="TrisalusMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MergerAgreementMember" xbrli:periodType="duration" abstract="true" name="MergerAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xbrli:periodType="duration" name="StockholderApprovalAfterDeliveringBusinessCombinationDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_MtacClassCommonStockMember" xbrli:periodType="duration" abstract="true" name="MtacClassCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfHoldings" xbrli:periodType="instant" name="NumberOfHoldings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_BusinessCombinationsOfWarrantToPurchase" xbrli:periodType="duration" name="BusinessCombinationsOfWarrantToPurchase" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_PaymentForInvestmentOfCashInTrustAccount" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentForInvestmentOfCashInTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ProceedsFromExtensionNote" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromExtensionNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MedtechAcquisitionCorpMember" xbrli:periodType="duration" abstract="true" name="MedtechAcquisitionCorpMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AccountingPoliciesTable" xbrli:periodType="duration" abstract="true" name="AccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_AccountingPoliciesLineItems" xbrli:periodType="duration" abstract="true" name="AccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xbrli:periodType="instant" xbrli:balance="debit" name="DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_IncreaseDecreaseInValuationAllowance" xbrli:periodType="duration" xbrli:balance="debit" name="IncreaseDecreaseInValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xbrli:periodType="duration" name="PercentageOfChangesInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_IncomeTaxTable" xbrli:periodType="duration" abstract="true" name="IncomeTaxTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_IncomeTaxLineItems" xbrli:periodType="duration" abstract="true" name="IncomeTaxLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_LeaseLiabilityCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="LeaseLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_LeaseLiabilityNoncurrent" xbrli:periodType="instant" xbrli:balance="credit" name="LeaseLiabilityNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xbrli:periodType="instant" xbrli:balance="credit" name="WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_CapitalShareReservedForFutureIssuanceAxis" xbrli:periodType="duration" abstract="true" name="CapitalShareReservedForFutureIssuanceAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xbrli:periodType="duration" abstract="true" name="CapitalSharesReservedForFutureIssuanceDomain" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MeasurementAxis" xbrli:periodType="duration" abstract="true" name="MeasurementAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_FairValueDisclosureItemAmountDomain" xbrli:periodType="duration" abstract="true" name="FairValueDisclosureItemAmountDomain" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xbrli:periodType="instant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xbrli:periodType="duration" name="PreferredStockConversionPriceAutomaticResetDurationSecondReset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_ContingentEarnoutLiabilityMember" xbrli:periodType="duration" abstract="true" name="ContingentEarnoutLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xbrli:periodType="duration" name="PreferredStockConversionPriceAutomaticResetDurationFirstReset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_ScheduleOfReverseRecapitalizationTable" xbrli:periodType="duration" abstract="true" name="ScheduleOfReverseRecapitalizationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_CommercialMilestone250000AnnualSalesMember" xbrli:periodType="duration" abstract="true" name="CommercialMilestone250000AnnualSalesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xbrli:periodType="duration" name="CommonStockSharePricePercentageOfAverageDailyVolume" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xbrli:periodType="duration" abstract="true" name="DerivativeFinancialInstrumentsTrancheLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StandbyEquityPurchaseAgreementTerm" xbrli:periodType="duration" name="StandbyEquityPurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_BlackScholesModelMember" xbrli:periodType="duration" abstract="true" name="BlackScholesModelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_A2009PlanMember" xbrli:periodType="duration" abstract="true" name="A2009PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xbrli:periodType="duration" name="ClassOfWarrantOrRightConversionTermsThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromRefundablePrepaymentsForPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_GainLossOnEquityIssuance" xbrli:periodType="duration" xbrli:balance="credit" name="GainLossOnEquityIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xbrli:periodType="duration" name="ClassOfWarrantOrRightConversionOfConvertibleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xbrli:periodType="instant" name="DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightWarrantsExercised" xbrli:periodType="duration" name="ClassOfWarrantOrRightWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_PurchaseAgreementExchangeCap" xbrli:periodType="instant" name="PurchaseAgreementExchangeCap" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xbrli:periodType="duration" xbrli:balance="debit" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xbrli:periodType="duration" name="PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_SeriesA3ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA3ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesB2TrancheLiabilityMember" xbrli:periodType="duration" abstract="true" name="SeriesB2TrancheLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xbrli:periodType="duration" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ShareBasedCompensationArrangementNumberOfPlans" xbrli:periodType="instant" name="ShareBasedCompensationArrangementNumberOfPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CommercialMilestoneTypeDomain" xbrli:periodType="duration" abstract="true" name="CommercialMilestoneTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentsOfReverseRecapitalizationTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xbrli:periodType="duration" xbrli:balance="credit" name="AssetAcquisitionRoyaltiesSalesThresholdAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PreferredStockConversionPercentageOfOutstandingShares" xbrli:periodType="duration" name="PreferredStockConversionPercentageOfOutstandingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xbrli:periodType="duration" name="CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xbrli:periodType="duration" abstract="true" name="CommercialMilestoneFirstCommercialSaleOfProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodDomain" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodDomain" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MedTechAcquisitionCorporationMember" xbrli:periodType="duration" abstract="true" name="MedTechAcquisitionCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PaymentsForAssetAcquisition" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentsForAssetAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xbrli:periodType="duration" xbrli:balance="debit" name="SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRollForward" xbrli:periodType="duration" abstract="true" name="ClassOfWarrantOrRightRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xbrli:periodType="duration" abstract="true" name="ValuationReverseRecapitalizationApproachEnterpriseValueMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PreferredStockIssuedPricePerShare" xbrli:periodType="instant" name="PreferredStockIssuedPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xbrli:periodType="instant" name="SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationTransactionCostsIncurred" xbrli:periodType="duration" xbrli:balance="debit" name="ReverseRecapitalizationTransactionCostsIncurred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_WarrantsLiabilitiesTextBlock" xbrli:periodType="duration" name="WarrantsLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xbrli:periodType="duration" xbrli:balance="debit" name="AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodAxis" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_CommercialMilestone1000000AnnualSalesMember" xbrli:periodType="duration" abstract="true" name="CommercialMilestone1000000AnnualSalesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PreferredStockConversionPriceFloor" xbrli:periodType="duration" name="PreferredStockConversionPriceFloor" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightConversionDaysNotice" xbrli:periodType="duration" name="ClassOfWarrantOrRightConversionDaysNotice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodThreeMember" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ConvertibleNotesAndWarrantsMember" xbrli:periodType="duration" abstract="true" name="ConvertibleNotesAndWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PurchaseAgreementOwnershipLimitation" xbrli:periodType="instant" name="PurchaseAgreementOwnershipLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_AssetAcquisitionMilestoneAmount" xbrli:periodType="instant" xbrli:balance="credit" name="AssetAcquisitionMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_StandbyEquityPurchaseAgreementMember" xbrli:periodType="duration" abstract="true" name="StandbyEquityPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xbrli:periodType="duration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xbrli:periodType="duration" abstract="true" name="DerivativeFinancialInstrumentsWarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xbrli:periodType="duration" name="DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CommonStockWarrantMember" xbrli:periodType="duration" abstract="true" name="CommonStockWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesAConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xbrli:periodType="duration" xbrli:balance="credit" name="ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xbrli:periodType="instant" name="ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xbrli:periodType="duration" name="AssetAcquisitionRoyaltyPercentageOverThresholdAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_PreferredStockAutomaticConversionPeriod" xbrli:periodType="instant" name="PreferredStockAutomaticConversionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_AssetAcquisitionSalesMilestone" xbrli:periodType="instant" xbrli:balance="credit" name="AssetAcquisitionSalesMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xbrli:periodType="duration" name="SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRedemptionPrice" xbrli:periodType="duration" name="ClassOfWarrantOrRightRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentContingentEarnoutLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PreferredStockPercentageOfSharesCommitted" xbrli:periodType="duration" name="PreferredStockPercentageOfSharesCommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationLineItems" xbrli:periodType="duration" abstract="true" name="ReverseRecapitalizationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_AssetAcquisitionMaximumMilestoneAmount" xbrli:periodType="duration" xbrli:balance="credit" name="AssetAcquisitionMaximumMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_GainLossOnWarrantExpirations" xbrli:periodType="duration" xbrli:balance="debit" name="GainLossOnWarrantExpirations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_SeriesA6ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA6ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xbrli:periodType="instant" name="StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationDisclosureTextBlock" xbrli:periodType="duration" name="ReverseRecapitalizationDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_SeriesB3ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesB3ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NatureOfBusinessLineItems" xbrli:periodType="duration" abstract="true" name="NatureOfBusinessLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_PreferredStockWarrantMember" xbrli:periodType="duration" abstract="true" name="PreferredStockWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xbrli:periodType="duration" xbrli:balance="credit" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xbrli:periodType="duration" name="ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_SeriesA4ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA4ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ProceedsFromReverseRecapitalization" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xbrli:periodType="duration" xbrli:balance="debit" name="ReverseRecapitalizationStockValueIfConvertedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TrancheTwoMember" xbrli:periodType="duration" abstract="true" name="TrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodFourMember" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodFourMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesB1ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesB1ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xbrli:periodType="duration" xbrli:balance="debit" name="AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TrancheDomain" xbrli:periodType="duration" abstract="true" name="TrancheDomain" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodOneMember" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SaleOfStockAuthorizedAmountValue" xbrli:periodType="duration" xbrli:balance="credit" name="SaleOfStockAuthorizedAmountValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_A2023PlanMember" xbrli:periodType="duration" abstract="true" name="A2023PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xbrli:periodType="duration" xbrli:balance="credit" name="ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xbrli:periodType="duration" name="ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xbrli:periodType="instant" name="SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_SeriesA1ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA1ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xbrli:periodType="duration" name="DerivativeInstrumentContingentConsiderationLiabilityShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_PrivateWarrantsMember" xbrli:periodType="duration" abstract="true" name="PrivateWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xbrli:periodType="duration" abstract="true" name="DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xbrli:periodType="duration" name="ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_GuidelinePublicCompanyModelMember" xbrli:periodType="duration" abstract="true" name="GuidelinePublicCompanyModelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MTACWarrantsMember" xbrli:periodType="duration" abstract="true" name="MTACWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrancheAxis" xbrli:periodType="duration" abstract="true" name="TrancheAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationAbstract" xbrli:periodType="duration" abstract="true" name="ReverseRecapitalizationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_NatureOfBusinessTable" xbrli:periodType="duration" abstract="true" name="NatureOfBusinessTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_ProceedsFromReverseRecapitalizationTransaction" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromReverseRecapitalizationTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xbrli:periodType="duration" name="CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_RecapitalizationExchangeRatio" xbrli:periodType="instant" name="RecapitalizationExchangeRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xbrli:periodType="duration" name="ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_SeriesBConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xbrli:periodType="duration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xbrli:periodType="duration" name="DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CommercialMilestoneMember" xbrli:periodType="duration" abstract="true" name="CommercialMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MeasurementInputExerciseSharePriceMember" xbrli:periodType="duration" abstract="true" name="MeasurementInputExerciseSharePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xbrli:periodType="duration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_SeriesA2ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA2ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesA5ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA5ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PaymentsForAssetsAcquisitionMilestone" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentsForAssetsAcquisitionMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AssetAcquisitionNumberOfCommercialMilestones" xbrli:periodType="duration" name="AssetAcquisitionNumberOfCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_MeasurementInputFairValueSharePriceMember" xbrli:periodType="duration" abstract="true" name="MeasurementInputFairValueSharePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_CommercialMilestoneTypeAxis" xbrli:periodType="duration" abstract="true" name="CommercialMilestoneTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xbrli:periodType="instant" name="DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_StockConvertedReverseRecapitalization" xbrli:periodType="instant" name="StockConvertedReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xbrli:periodType="duration" name="DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_DerivativeInstrumentPeriodTwoMember" xbrli:periodType="duration" abstract="true" name="DerivativeInstrumentPeriodTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_CommercialMilestone500000AnnualSalesMember" xbrli:periodType="duration" abstract="true" name="CommercialMilestone500000AnnualSalesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfProductLinesInDevelopment" xbrli:periodType="duration" name="NumberOfProductLinesInDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xbrli:periodType="duration" xbrli:balance="credit" name="GainLossOnMilestonePaymentForAssetAcquistion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" xbrli:periodType="duration" name="IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_TrancheThreeMember" xbrli:periodType="duration" abstract="true" name="TrancheThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xbrli:periodType="duration" name="ClassOfWarrantOrRightConversionStockPriceThreshold" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_TrancheAndWarrantLiabilityMember" xbrli:periodType="duration" abstract="true" name="TrancheAndWarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentsForAssetAcquisitionMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DynavaxTechnologiesMember" xbrli:periodType="duration" abstract="true" name="DynavaxTechnologiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesB2ConvertiblePreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesB2ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xbrli:periodType="duration" name="ClassOfWarrantOrRightNumberOfWarrantsRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_ReverseRecapitalizationTransactionCostsPaid" xbrli:periodType="duration" xbrli:balance="debit" name="ReverseRecapitalizationTransactionCostsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_BinomialTrancheModelMember" xbrli:periodType="duration" abstract="true" name="BinomialTrancheModelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xbrli:periodType="duration" name="AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" />
  <xsd:element id="tlsi_SeriesBTwoTrancheLiabilityCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="SeriesBTwoTrancheLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_SeriesBThreeTrancheLiabilityCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="SeriesBThreeTrancheLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_GainLossOnConversionOfConvertibleNotes" xbrli:periodType="duration" xbrli:balance="credit" name="GainLossOnConversionOfConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xbrli:periodType="duration" xbrli:balance="debit" name="FairValueAdjustmentOfTrancheAndWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xbrli:periodType="duration" xbrli:balance="debit" name="DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xbrli:periodType="duration" xbrli:balance="credit" name="AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xbrli:periodType="duration" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_GainOnPppLoanForgiveness" xbrli:periodType="duration" xbrli:balance="credit" name="GainOnPppLoanForgiveness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MilestonePaymentToDynavaxOperatingActivity" xbrli:periodType="duration" xbrli:balance="debit" name="MilestonePaymentToDynavaxOperatingActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xbrli:periodType="duration" xbrli:balance="credit" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MilestonePaymentToDynavaxInvestingActivity" xbrli:periodType="duration" xbrli:balance="credit" name="MilestonePaymentToDynavaxInvestingActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xbrli:periodType="duration" xbrli:balance="debit" name="ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes" xbrli:periodType="duration" xbrli:balance="credit" name="ValueOfWarrantsIssuedWithConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" xbrli:periodType="duration" xbrli:balance="credit" name="TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" xbrli:periodType="duration" xbrli:balance="credit" name="FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital" xbrli:periodType="duration" xbrli:balance="credit" name="PutOptionLiabilityTransferredToAdditionalPaidInCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" xbrli:periodType="duration" xbrli:balance="credit" name="CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_CashPaidDuringYearForAbstract" xbrli:periodType="duration" abstract="true" name="CashPaidDuringYearForAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xbrli:periodType="duration" name="ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" xbrli:periodType="duration" name="WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_CumulativeIncomeLoss" xbrli:periodType="duration" xbrli:balance="credit" name="CumulativeIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PreferredStockWarrantsMember" xbrli:periodType="duration" abstract="true" name="PreferredStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_CommonStockWarrantsMember" xbrli:periodType="duration" abstract="true" name="CommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AccruedIncentiveCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="AccruedIncentiveCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MedtechAcquisitionCorporationMember" xbrli:periodType="duration" abstract="true" name="MedtechAcquisitionCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PaycheckProtectionProgramMember" xbrli:periodType="duration" abstract="true" name="PaycheckProtectionProgramMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_LongLivedAssetsDisclosureTextBlock" xbrli:periodType="duration" name="LongLivedAssetsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_LongLivedAssetsAbstract" xbrli:periodType="duration" abstract="true" name="LongLivedAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_NumberOfCustomer" xbrli:periodType="instant" name="NumberOfCustomer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_BusinessCombinationWarrantsConsideration" xbrli:periodType="duration" xbrli:balance="credit" name="BusinessCombinationWarrantsConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_BusinessCombinationAcquisitionExpensesDeferred" xbrli:periodType="instant" xbrli:balance="debit" name="BusinessCombinationAcquisitionExpensesDeferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_DeemedDividendIncreaseInNetLossPerShare" xbrli:periodType="duration" name="DeemedDividendIncreaseInNetLossPerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_WarrantLiabilitiesMember" xbrli:periodType="duration" abstract="true" name="WarrantLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrancheLiabilitiesMember" xbrli:periodType="duration" abstract="true" name="TrancheLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xbrli:periodType="duration" abstract="true" name="TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xbrli:periodType="duration" abstract="true" name="TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xbrli:periodType="instant" xbrli:balance="debit" name="FairValueLiabilitiesTransfersBetweenLevelsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xbrli:periodType="instant" name="PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_PutOptionLiabilityMember" xbrli:periodType="duration" abstract="true" name="PutOptionLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesB2TrancheLiabilitiesMember" xbrli:periodType="duration" abstract="true" name="SeriesB2TrancheLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesB3WarrantLiabilitiesMember" xbrli:periodType="duration" abstract="true" name="SeriesB3WarrantLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" xbrli:periodType="duration" name="ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" xbrli:periodType="duration" name="ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_ConvertiblePreferredStockDisclosureTextBlock" xbrli:periodType="duration" name="ConvertiblePreferredStockDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_TemporaryEquitySharesAvailableForIssuance" xbrli:periodType="instant" name="TemporaryEquitySharesAvailableForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_TemporaryEquityOriginalIssuePrice" xbrli:periodType="duration" name="TemporaryEquityOriginalIssuePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" xbrli:periodType="duration" name="AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds" xbrli:periodType="duration" xbrli:balance="debit" name="AutomaticConversionOfPreferredStockThresholdCashProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" xbrli:periodType="duration" xbrli:balance="debit" name="AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_TemporaryEquityDividendPerShare" xbrli:periodType="duration" name="TemporaryEquityDividendPerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" />
  <xsd:element id="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xbrli:periodType="duration" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xbrli:periodType="duration" abstract="true" name="B2PreferredStockFinancingSecondTrancheClosingsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_B2PreferredStockFinancingThirdTrancheMember" xbrli:periodType="duration" abstract="true" name="B2PreferredStockFinancingThirdTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xbrli:periodType="duration" abstract="true" name="MeasurementInputFairValueOfUnderlyingStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_MaximumNumberOfSharesAgreedToSell" xbrli:periodType="instant" name="MaximumNumberOfSharesAgreedToSell" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_AggregateProceedsReceivableFromStockOffering" xbrli:periodType="instant" xbrli:balance="debit" name="AggregateProceedsReceivableFromStockOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xbrli:periodType="instant" xbrli:balance="debit" name="MaximumProceedsReceivableThroughSaleOfAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xbrli:periodType="instant" name="MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_EnterpriseValueAllocated" xbrli:periodType="instant" xbrli:balance="debit" name="EnterpriseValueAllocated" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ValueAssignedToTrancheRightsAndObligations" xbrli:periodType="instant" xbrli:balance="debit" name="ValueAssignedToTrancheRightsAndObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_BusinessCombinationScenarioMember" xbrli:periodType="duration" abstract="true" name="BusinessCombinationScenarioMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TrancheLiabilityMeasurementInput" xbrli:periodType="instant" name="TrancheLiabilityMeasurementInput" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" />
  <xsd:element id="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xbrli:periodType="duration" abstract="true" name="B2PreferredStockFinancingSecondTrancheClosingOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xbrli:periodType="duration" abstract="true" name="B2PreferredStockFinancingSecondTrancheClosingTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfStockOfferingClosingsEffectuated" xbrli:periodType="duration" name="NumberOfStockOfferingClosingsEffectuated" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_PercentageOfSharesCommittedSold" xbrli:periodType="duration" name="PercentageOfSharesCommittedSold" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_Financing2022Member" xbrli:periodType="duration" abstract="true" name="Financing2022Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_Financing2023Member" xbrli:periodType="duration" abstract="true" name="Financing2023Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PercentageOfSharesOutstanding" xbrli:periodType="duration" name="PercentageOfSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_CustomerOneMember" xbrli:periodType="duration" abstract="true" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_TermLoanAndSupplementalTermLoanMember" xbrli:periodType="duration" abstract="true" name="TermLoanAndSupplementalTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsIssuedOn08262015Member" xbrli:periodType="duration" abstract="true" name="WarrantsIssuedOn08262015Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsIssuedOn10272016Member" xbrli:periodType="duration" abstract="true" name="WarrantsIssuedOn10272016Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsIssuedOn06302017Member" xbrli:periodType="duration" abstract="true" name="WarrantsIssuedOn06302017Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsIssuedOn11202018Member" xbrli:periodType="duration" abstract="true" name="WarrantsIssuedOn11202018Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesA5PreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA5PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SeriesA6PreferredStockMember" xbrli:periodType="duration" abstract="true" name="SeriesA6PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xbrli:periodType="instant" name="ClassOfWarrantOrRightNumberOfWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xbrli:periodType="duration" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xbrli:periodType="instant" xbrli:balance="debit" name="DeferredTaxAssetsFixedAssetsAndIntangible" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage" xbrli:periodType="duration" name="NetDeferredTaxAssetsChangeInValuationPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_FirstInstallmentMember" xbrli:periodType="duration" abstract="true" name="FirstInstallmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_SecondInstallmentMember" xbrli:periodType="duration" abstract="true" name="SecondInstallmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_EmployeeContributionUptoThreePercentMember" xbrli:periodType="duration" abstract="true" name="EmployeeContributionUptoThreePercentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xbrli:periodType="duration" abstract="true" name="EmployeeContributionBetweenThreeAndFourPercentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xbrli:periodType="duration" abstract="true" name="EmployeeContributionBetweenFourAndFivePercentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfPatentsSuitFiled" xbrli:periodType="duration" name="NumberOfPatentsSuitFiled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_NumberOfPatentsTestimonyLimited" xbrli:periodType="duration" name="NumberOfPatentsTestimonyLimited" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CurePeriod" xbrli:periodType="duration" name="CurePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element id="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xbrli:periodType="duration" name="LossContingencyDamagesPaidValueNumberOfInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_DynavaxPurchaseAbstract" xbrli:periodType="duration" abstract="true" name="DynavaxPurchaseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_DynavaxPurchaseAgreementMember" xbrli:periodType="duration" abstract="true" name="DynavaxPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_UponFirstCommercialSaleOfProductMember" xbrli:periodType="duration" abstract="true" name="UponFirstCommercialSaleOfProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xbrli:periodType="duration" abstract="true" name="UponFirstOccurrenceOfAnnualNetSalesOf250000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xbrli:periodType="duration" abstract="true" name="UponFirstOccurrenceOfAnnualNetSalesOf500000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xbrli:periodType="duration" abstract="true" name="UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xbrli:periodType="duration" abstract="true" name="AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xbrli:periodType="duration" abstract="true" name="AggregateAnnualNetSalesGreaterThan1000000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_UpfrontPaymentAmount" xbrli:periodType="duration" xbrli:balance="debit" name="UpfrontPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_PaymentOfUpfrontAmount" xbrli:periodType="duration" xbrli:balance="credit" name="PaymentOfUpfrontAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MinimumMilestonePaymentAmount" xbrli:periodType="duration" xbrli:balance="debit" name="MinimumMilestonePaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumMilestonePaymentAmount" xbrli:periodType="duration" xbrli:balance="debit" name="MaximumMilestonePaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumDevelopmentMilestonePayments" xbrli:periodType="duration" xbrli:balance="debit" name="MaximumDevelopmentMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MilestonePaymentsMade" xbrli:periodType="duration" xbrli:balance="credit" name="MilestonePaymentsMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_NumberOfCommercialMilestoneToBeMade" xbrli:periodType="duration" name="NumberOfCommercialMilestoneToBeMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_CommercialMilestonePaymentAmount" xbrli:periodType="duration" xbrli:balance="debit" name="CommercialMilestonePaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AnnualNetSales" xbrli:periodType="duration" xbrli:balance="credit" name="AnnualNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_MaximumCommercialMilestonePayments" xbrli:periodType="duration" xbrli:balance="debit" name="MaximumCommercialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_AnnualRoyaltyRate" xbrli:periodType="duration" name="AnnualRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xbrli:periodType="duration" name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.001Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.001Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.003Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.003Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.004Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.004Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.005Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.005Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.006Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.006Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.007Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.007Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ExercisePriceOf0.09To0.46Member" xbrli:periodType="duration" abstract="true" name="ExercisePriceOf0.09To0.46Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_EquityIncentivePlan2019AsAmendedMember" xbrli:periodType="duration" abstract="true" name="EquityIncentivePlan2019AsAmendedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ConvertibleDebtDisclosureTextBlock" xbrli:periodType="duration" name="ConvertibleDebtDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xbrli:periodType="duration" name="DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_QualifiedFinancingMinimumProceeds" xbrli:periodType="duration" xbrli:balance="debit" name="QualifiedFinancingMinimumProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xbrli:periodType="duration" name="ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xbrli:periodType="duration" name="ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_DebtInstrumentConversionDiscountPercentage" xbrli:periodType="duration" name="DebtInstrumentConversionDiscountPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_EliminationOfOccurrenceOfDiscountPercentage" xbrli:periodType="duration" name="EliminationOfOccurrenceOfDiscountPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" />
  <xsd:element id="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" xbrli:periodType="duration" name="NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_March2021FinancingMember" xbrli:periodType="duration" abstract="true" name="March2021FinancingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_Spring2021FinancingMember" xbrli:periodType="duration" abstract="true" name="Spring2021FinancingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_Fall2021FinancingMember" xbrli:periodType="duration" abstract="true" name="Fall2021FinancingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xbrli:periodType="duration" abstract="true" name="WarrantsToPurchaseSeriesBPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xbrli:periodType="duration" abstract="true" name="WarrantsToPurchaseSeriesB3PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockOptionsOutstandingMember" xbrli:periodType="duration" abstract="true" name="StockOptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_StockOptionsAvailableForFutureGrantMember" xbrli:periodType="duration" abstract="true" name="StockOptionsAvailableForFutureGrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xbrli:periodType="duration" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" xbrli:periodType="duration" name="ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" />
  <xsd:element id="tlsi_FinanceLeaseCostAbstract" xbrli:periodType="duration" abstract="true" name="FinanceLeaseCostAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_FinanceLeaseCost" xbrli:periodType="duration" xbrli:balance="debit" name="FinanceLeaseCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_FinanceLeaseAbstract" xbrli:periodType="duration" abstract="true" name="FinanceLeaseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element id="tlsi_CopierEquipmentMember" xbrli:periodType="duration" abstract="true" name="CopierEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_CopierInWestminsterFacilityMember" xbrli:periodType="duration" abstract="true" name="CopierInWestminsterFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xbrli:periodType="duration" abstract="true" name="AnalyticalEquipmentInLaboratoryFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_PrincipalAdministrativeAndProductionFacilityMember" xbrli:periodType="duration" abstract="true" name="PrincipalAdministrativeAndProductionFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xbrli:periodType="duration" abstract="true" name="LeaseForOfficeSpaceAtHalfDayRoadMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_NumberOfOperatingLeases" xbrli:periodType="duration" name="NumberOfOperatingLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_NumberOfFinanceLeases" xbrli:periodType="duration" name="NumberOfFinanceLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element id="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xbrli:periodType="duration" name="ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element id="tlsi_InitialWarrantLiability" xbrli:periodType="duration" xbrli:balance="credit" name="InitialWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_WarrantIssued" xbrli:periodType="duration" xbrli:balance="credit" name="WarrantIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element id="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xbrli:periodType="duration" abstract="true" name="WarrantToPurchaseSeriesFivePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xbrli:periodType="duration" abstract="true" name="WarrantToPurchaseSeriesSixPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" />
  <xsd:element id="tlsi_FinanceLeaseLiabilitiesCurrent" xbrli:periodType="instant" xbrli:balance="credit" name="FinanceLeaseLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>tlsi-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/15/2023 2:04:02 AM-->
<!--Modified on: 12/15/2023 2:04:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxDeferredTaxAssetsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxIncomeTaxProvisionDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlowss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureBusinessCombinationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventoryDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureInventoryDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_638382026334836366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638382026334836366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638382026334836366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638382026334836366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638382026334836366" xlink:to="tlsi_DeferredOfferingCostsNoncurrent_638382026334836366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638382026334836366" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026334836366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638382026334836366" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026334836366" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026334836366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638382026334836366" xlink:to="us-gaap_LiabilitiesCurrent_638382026334836366" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334836366" xlink:to="us-gaap_NotesPayableCurrent_638382026334846366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNotesPayableCurrent" xlink:label="tlsi_ExtensionNotesPayableCurrent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334836366" xlink:to="tlsi_ExtensionNotesPayableCurrent_638382026334846366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334836366" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638382026334846366" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334836366" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026334846366" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334836366" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638382026334846366" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026334846366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026334846366" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss" xlink:type="extended" xlink:title="111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense_638382026334856369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638382026334856369" xlink:to="us-gaap_InvestmentIncomeInterest_638382026334856369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638382026334856369" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638382026334856369" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss_638382026334856369" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_638382026334856369" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable_638382026334856369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638382026334856369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638382026334856369" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_638382026334866368" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromExtensionNote" xlink:label="tlsi_ProceedsFromExtensionNote_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="tlsi_ProceedsFromExtensionNote_638382026334866368" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributedCapital_638382026334866368" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="tlsi_PaymentForInvestmentOfCashInTrustAccount_638382026334866368" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026334866368" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026334866368" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638382026334866368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss_638382026334866368" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638382026334876365" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeInterest_638382026334876365" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026334876365" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638382026334876365" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_638382026334876365" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026334876365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026334876365" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xlink:type="extended" xlink:title="111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransactionCosts" xlink:label="TransactionCosts" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockUnderwritingFees" xlink:label="tlsi_SaleOfStockUnderwritingFees_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TransactionCosts" xlink:to="tlsi_SaleOfStockUnderwritingFees_638382026334886369" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TransactionCosts" xlink:to="tlsi_DeferredOfferingCostsNoncurrent_638382026334886369" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockOtherOfferingCosts" xlink:label="tlsi_SaleOfStockOtherOfferingCosts_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TransactionCosts" xlink:to="tlsi_SaleOfStockOtherOfferingCosts_638382026334886369" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638382026334886369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026334886369" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026334886369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026334886369" xlink:to="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_638382026334886369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638382026334886369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638382026334886369" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="111240902 - Disclosure - INCOME TAX - Income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638382026334896370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026334896370" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026334896370" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInValuationAllowance" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="tlsi_IncreaseDecreaseInValuationAllowance_638382026334896370" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xlink:type="extended" xlink:title="1200100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638382026334896370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638382026334896370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638382026334896370" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638382026334906368" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638382026334906368" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638382026334906368" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_1" xlink:to="us-gaap_PreferredStockValue_638382026334906368" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_1" xlink:to="us-gaap_CommonStockValue_638382026334906368" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_1" xlink:to="us-gaap_AdditionalPaidInCapital_638382026334906368" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026334906368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_1" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026334906368" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_1" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026334916366" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_1" xlink:to="tlsi_LeaseLiabilityNoncurrent_638382026334916366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_1" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026334916366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_1" xlink:to="us-gaap_LiabilitiesCurrent_638382026334916366" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334916366" xlink:to="us-gaap_AccountsPayableTradeCurrent_638382026334916366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334916366" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026334916366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_638382026334916366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334916366" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_638382026334916366" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334916366" xlink:to="tlsi_LeaseLiabilityCurrent_638382026334926371" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026334916366" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026334926371" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xlink:type="extended" xlink:title="1200200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026334926371" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026334926371" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_638382026334926371" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026334926371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638382026334926371" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026334926371" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638382026334926371" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638382026334936367" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026334936367" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="tlsi_GainLossOnEquityIssuance_638382026334936367" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_InterestExpense_638382026334936367" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_InvestmentIncomeInterest_638382026334936367" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_OperatingIncomeLoss_638382026334936367" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638382026334936367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026334936367" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638382026334936367" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638382026334946367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026334936367" xlink:to="us-gaap_SellingAndMarketingExpense_638382026334946367" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638382026334946367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026334936367" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638382026334946367" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638382026334946367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026334936367" xlink:to="us-gaap_GrossProfit_638382026334946367" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638382026334946367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638382026334946367" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638382026334946367" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026334946367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638382026334946367" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026334946367" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xlink:type="extended" xlink:title="1200400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026334956369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_638382026334956369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026334956369" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="tlsi_ProceedsFromReverseRecapitalization_638382026334956369" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026334956369" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638382026334956369" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638382026334956369" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026334956369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026334956369" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetsAcquisitionMilestone" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="tlsi_PaymentsForAssetsAcquisitionMilestone_638382026334966366" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638382026334966366" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization_638382026334966366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026334966366" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="tlsi_GainLossOnEquityIssuance_638382026334966366" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation_638382026334966366" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026334966366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026334966366" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_638382026334976368" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026334976368" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories_638382026334976368" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026334976368" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026334976368" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026334976368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026334976368" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026334986369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss_638382026334986369" order="12" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xlink:type="extended" xlink:title="1240301 - Disclosure - Business Combinations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalizationTransaction" xlink:label="ProceedsFromReverseRecapitalizationTransaction" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638382026334986369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProceedsFromReverseRecapitalizationTransaction" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638382026334986369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638382026334986369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProceedsFromReverseRecapitalizationTransaction" xlink:to="us-gaap_ProceedsFromContributedCapital_638382026334986369" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="1240501 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026334986369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026334986369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638382026334986369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638382026334986369" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="1240701 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_638382026334996369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638382026334996369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_638382026334996369" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638382026334996369" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="222100100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638382026334996369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638382026334996369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638382026334996369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638382026335006369" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638382026335006369" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638382026335006369" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638382026335006369" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026335006369" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638382026335006369" xlink:to="us-gaap_AccountsReceivableNetCurrent_638382026335006369" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638382026335006369" xlink:to="us-gaap_InventoryNet_638382026335006369" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638382026335006369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638382026335006369" xlink:to="us-gaap_PrepaidExpenseCurrent_638382026335006369" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_638382026335016367" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="tlsi_LeaseLiabilityNoncurrent_638382026335016367" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="us-gaap_LiabilitiesCurrent_638382026335016367" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026335016367" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="tlsi_LeaseLiabilityCurrent_638382026335016367" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBThreeTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="tlsi_SeriesBThreeTrancheLiabilityCurrent_638382026335016367" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBTwoTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="tlsi_SeriesBTwoTrancheLiabilityCurrent_638382026335016367" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026335016367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026335016367" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638382026335016367" xlink:to="us-gaap_AccountsPayableCurrent_638382026335026373" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="222100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_638382026335026373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638382026335026373" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="us-gaap_InvestmentIncomeInterest_638382026335026373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="us-gaap_InterestExpense_638382026335026373" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_638382026335026373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_638382026335026373" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="tlsi_GainLossOnEquityIssuance_638382026335036370" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026335036370" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638382026335036370" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026335026373" xlink:to="us-gaap_OperatingIncomeLoss_638382026335036370" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026335036370" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638382026335036370" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026335036370" xlink:to="us-gaap_SellingAndMarketingExpense_638382026335036370" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026335036370" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638382026335036370" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638382026335036370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638382026335036370" xlink:to="us-gaap_GrossProfit_638382026335036370" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638382026335036370" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026335046371" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638382026335036370" xlink:to="us-gaap_CostOfRevenue_638382026335046371" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638382026335026373" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026335046371" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026335046371" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="222100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026335046371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_NetIncomeLoss_638382026335046371" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainOnPppLoanForgiveness" xlink:label="tlsi_GainOnPppLoanForgiveness_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_GainOnPppLoanForgiveness_638382026335056374" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_638382026335056374" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_GainLossOnEquityIssuance_638382026335056374" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026335056374" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_638382026335056374" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638382026335056374" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_ShareBasedCompensation_638382026335056374" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026335056374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026335056374" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026335066368" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026335066368" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_IncreaseDecreaseInInventories_638382026335066368" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026335066368" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638382026335066368" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026335066368" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026335066368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026335046371" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026335066368" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026335076368" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026335076368" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026335076368" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxInvestingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026335076368" xlink:to="tlsi_MilestonePaymentToDynavaxInvestingActivity_638382026335076368" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026335076368" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638382026335076368" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026335076368" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026335076368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026335076368" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638382026335086369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638382026335086369" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt_638382026335086369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="us-gaap_RepaymentsOfBankDebt_638382026335086369" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638382026335086369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638382026335086369" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_638382026335086369" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026335076368" xlink:to="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_638382026335086369" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss" xlink:type="extended" xlink:title="222140401 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026335096392" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026335096392" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_638382026335096392" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_638382026335096392" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventoryDetailss" xlink:type="extended" xlink:title="222140501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638382026335096392" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638382026335096392" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026335106370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026335106370" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xlink:type="extended" xlink:title="222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638382026335106370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638382026335106370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638382026335106370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638382026335106370" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended" xlink:title="222140604 - Disclosure - Long-Lived Assets - Intangible Assets, amortization expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638382026335106370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638382026335106370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638382026335116373" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638382026335116373" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638382026335116373" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638382026335116373" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638382026335116373" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss" xlink:type="extended" xlink:title="222140701 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638382026335116373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638382026335116373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedIncentiveCurrent" xlink:label="tlsi_AccruedIncentiveCurrent_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="tlsi_AccruedIncentiveCurrent_638382026335126374" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638382026335126374" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_638382026335126374" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" xlink:type="extended" xlink:title="222140801 - Disclosure - Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026335126374" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638382026335136379" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638382026335136379" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026335136379" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026335126374" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026335136379" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" xlink:type="extended" xlink:title="222140802 - Disclosure - Income Taxes - Provision for federal income tax statutory rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026335136379" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026335136379" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026335136379" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026335136379" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026335136379" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026335136379" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638382026335146370" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638382026335146370" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="222140803 - Disclosure - Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638382026335146370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638382026335146370" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638382026335146370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsGross_638382026335146370" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026335146370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026335146370" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_638382026335156371" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638382026335156371" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsInventory_638382026335156371" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsOther_638382026335156371" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638382026335156371" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638382026335146370" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638382026335156371" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638382026335156371" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet_638382026335156371" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638382026335166373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638382026335166373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638382026335166373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638382026335166373" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss" xlink:type="extended" xlink:title="222141502 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseCost" xlink:label="tlsi_FinanceLeaseCost_638382026335166373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="tlsi_FinanceLeaseCost_638382026335166373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638382026335166373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tlsi_FinanceLeaseCost_638382026335166373" xlink:to="us-gaap_FinanceLeaseInterestExpense_638382026335166373" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tlsi_FinanceLeaseCost_638382026335166373" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638382026335176376" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638382026335176376" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="222141503 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638382026335176376" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638382026335176376" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638382026335176376" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638382026335176376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638382026335176376" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638382026335186374" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638382026335186374" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638382026335186374" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638382026335186374" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638382026335186374" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638382026335186374" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638382026335186374" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638382026335196372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638382026335196372" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2" xlink:type="extended" xlink:title="222141503 - Disclosure - Leases - Components of lease expense (Details) Cal 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638382026335196372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_638382026335196372" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638382026335196372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638382026335196372" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638382026335196372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638382026335196372" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638382026335196372" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638382026335196372" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss" xlink:type="extended" xlink:title="222141504 - Disclosure - Leases - Future minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638382026335206377" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638382026335206377" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638382026335206377" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_638382026335206377" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_638382026335206377" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_638382026335206377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_638382026335206377" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>tlsi-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/15/2023 2:04:02 AM-->
<!--Modified on: 12/15/2023 2:04:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperations" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePublicOffering" roleURI="http://trisaluslifesci.com/role/DisclosurePublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePrivatePlacement" roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactions" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantLiabilities" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTax" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurements" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxTables" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePublicOfferingDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePrivatePlacementDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactionsFounderSharesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficitPreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficitCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxDeferredTaxAssetsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxIncomeTaxProvisionDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlowss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccountingPoliciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureBusinessCombinationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiabilityNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantsNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockFairValueMeasurementsDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensationDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchaseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchaseDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebtPppLoanDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebtTermLoanDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertibleNotesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockDividendsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockMarch2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockSpring2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockFall2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockWarrantExercisesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStock2022FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStock2023FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityStockOptionActivityDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityValuationAssumptionsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple" />
  <link:roleRef roleURI="http://trisaluslifesci.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tlsi-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://trisaluslifesci.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:label="CapitalShareReservedForFutureIssuanceAxis" xlink:title="CapitalShareReservedForFutureIssuanceAxis" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:label="CapitalSharesReservedForFutureIssuanceDomain" xlink:title="CapitalSharesReservedForFutureIssuanceDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CapitalShareReservedForFutureIssuanceAxis" xlink:to="CapitalSharesReservedForFutureIssuanceDomain" xlink:title="definition: CapitalShareReservedForFutureIssuanceAxis to CapitalSharesReservedForFutureIssuanceDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:title="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="AdjustmentsForErrorCorrectionDomain" xlink:title="AdjustmentsForErrorCorrectionDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="AdjustmentsForErrorCorrectionDomain" xlink:title="definition: ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis to AdjustmentsForErrorCorrectionDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="RelatedAndNonrelatedPartyStatusAxis" xlink:title="RelatedAndNonrelatedPartyStatusAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="RelatedAndNonrelatedPartyStatusDomain" xlink:title="RelatedAndNonrelatedPartyStatusDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedAndNonrelatedPartyStatusAxis" xlink:to="RelatedAndNonrelatedPartyStatusDomain" xlink:title="definition: RelatedAndNonrelatedPartyStatusAxis to RelatedAndNonrelatedPartyStatusDomain" use="optional" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_MeasurementAxis" xlink:label="MeasurementAxis" xlink:title="MeasurementAxis" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_FairValueDisclosureItemAmountDomain" xlink:label="FairValueDisclosureItemAmountDomain" xlink:title="FairValueDisclosureItemAmountDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementAxis" xlink:to="FairValueDisclosureItemAmountDomain" xlink:title="definition: MeasurementAxis to FairValueDisclosureItemAmountDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="OptionIndexedToIssuersEquityEquityAxis" xlink:title="OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityEquityAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityEquityAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShortTermDebtTypeAxis" xlink:to="ShortTermDebtTypeDomain" xlink:title="definition: ShortTermDebtTypeAxis to ShortTermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodAxis" xlink:label="DerivativeInstrumentPeriodAxis" xlink:title="DerivativeInstrumentPeriodAxis" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodDomain" xlink:label="DerivativeInstrumentPeriodDomain" xlink:title="DerivativeInstrumentPeriodDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentPeriodAxis" xlink:to="DerivativeInstrumentPeriodDomain" xlink:title="definition: DerivativeInstrumentPeriodAxis to DerivativeInstrumentPeriodDomain" use="optional" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_TrancheAxis" xlink:label="TrancheAxis" xlink:title="TrancheAxis" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_TrancheDomain" xlink:label="TrancheDomain" xlink:title="TrancheDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TrancheAxis" xlink:to="TrancheDomain" xlink:title="definition: TrancheAxis to TrancheDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="ValuationTechniqueAxis" xlink:title="ValuationTechniqueAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="ValuationTechniqueDomain" xlink:title="ValuationTechniqueDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ValuationTechniqueAxis" xlink:to="ValuationTechniqueDomain" xlink:title="definition: ValuationTechniqueAxis to ValuationTechniqueDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeAxis" xlink:label="CommercialMilestoneTypeAxis" xlink:title="CommercialMilestoneTypeAxis" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeDomain" xlink:label="CommercialMilestoneTypeDomain" xlink:title="CommercialMilestoneTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CommercialMilestoneTypeAxis" xlink:to="CommercialMilestoneTypeDomain" xlink:title="definition: CommercialMilestoneTypeAxis to CommercialMilestoneTypeDomain" use="optional" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: IncomeStatementAbstract to FairValueAdjustmentOfWarrants" use="optional" priority="0" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="LeaseLiabilityNoncurrent" xlink:title="LeaseLiabilityNoncurrent" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesNoncurrentAbstract to LeaseLiabilityNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:label="WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:title="WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:title="definition: LiabilitiesNoncurrentAbstract to WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="OfficerMember" xlink:title="OfficerMember" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="OfficerMember" xlink:title="definition: RelatedPartyDomain to OfficerMember" use="optional" priority="0" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="definition: RelatedPartyDomain to RelatedPartyMember" use="optional" priority="0" order="2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="LeaseLiabilityCurrent" xlink:title="LeaseLiabilityCurrent" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LeaseLiabilityCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LeaseLiabilityCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" xlink:type="locator" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" use="optional" priority="0" order="2" />
  </link:definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNotesPayableCurrent" xlink:label="tlsi_ExtensionNotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="tlsi_ExtensionNotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="tlsi_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="111200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xlink:type="extended" xlink:title="111200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderEquity" xlink:label="tlsi_StockholderEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_StockholderEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="tlsi_PaymentForInvestmentOfCashInTrustAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromExtensionNote" xlink:label="tlsi_ProceedsFromExtensionNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tlsi_ProceedsFromExtensionNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xlink:type="extended" xlink:title="111210101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NatureOfOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="111210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePublicOffering" xlink:type="extended" xlink:title="111210301 - Disclosure - PUBLIC OFFERING" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTextBlock" xlink:label="tlsi_InitialPublicOfferingTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_InitialPublicOfferingTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePrivatePlacement" xlink:type="extended" xlink:title="111210401 - Disclosure - PRIVATE PLACEMENT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementTextBlock" xlink:label="tlsi_PrivatePlacementTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_PrivatePlacementTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="111210501 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="111210601 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficit" xlink:type="extended" xlink:title="111210701 - Disclosure - STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantLiabilities" xlink:type="extended" xlink:title="111210801 - Disclosure - WARRANT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="111210901 - Disclosure - INCOME TAX" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="111211001 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="111211101 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="111220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_EmergingGrowthCompanyPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityPolicyPolicyTextBlock" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_TemporaryEquityPolicyPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesPolicyTextBlock" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_WarrantLiabilitiesPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="111230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxTables" xlink:type="extended" xlink:title="111230903 - Disclosure - INCOME TAX (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="111231003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xlink:type="extended" xlink:title="111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_PaymentsForInvestmentOfCashInTrustAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransactionCosts" xlink:label="tlsi_TransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_TransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockUnderwritingFees" xlink:label="tlsi_SaleOfStockUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_TransactionCosts" xlink:to="tlsi_SaleOfStockUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_TransactionCosts" xlink:to="tlsi_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockOtherOfferingCosts" xlink:label="tlsi_SaleOfStockOtherOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_TransactionCosts" xlink:to="tlsi_SaleOfStockOtherOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriodUponClosure" xlink:label="tlsi_RedemptionPeriodUponClosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_RedemptionPeriodUponClosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_RedemptionLimitPercentageWithoutPriorConsent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumAllowedDissolutionExpenses" xlink:label="tlsi_MaximumAllowedDissolutionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_MaximumAllowedDissolutionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" xlink:type="extended" xlink:title="111240102 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="tlsi_SponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNoteWithRelatedPartyMember" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_PromissoryNoteWithRelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyOnePromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="tlsi_TwoThousandTwentyOnePromissoryNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_OperatingBankAccounts" xlink:label="tlsi_OperatingBankAccounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_OperatingBankAccounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapital" xlink:label="tlsi_WorkingCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_WorkingCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfTransactionalFeePaid" xlink:label="tlsi_PercentageOfTransactionalFeePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_PercentageOfTransactionalFeePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DueToSponsorForCertainReimbursableExpenses" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_DueToSponsorForCertainReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfAmountDepositedInTrustAccount" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_PercentageOfAmountDepositedInTrustAccount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="111240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesTable" xlink:label="tlsi_AccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesLineItems" xlink:label="tlsi_AccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_AccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_AssetsHeldInTrust" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AmountDepositedIntoTrustAccount" xlink:label="tlsi_AmountDepositedIntoTrustAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_AmountDepositedIntoTrustAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xlink:type="extended" xlink:title="111240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesTable" xlink:label="tlsi_AccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesLineItems" xlink:label="tlsi_AccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_AccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionDeposit" xlink:label="tlsi_ExtensionDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_ExtensionDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" xlink:type="extended" xlink:title="111240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails" xlink:type="extended" xlink:title="111240301 - Disclosure - PUBLIC OFFERING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTable" xlink:label="tlsi_InitialPublicOfferingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_InitialPublicOfferingTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="tlsi_InitialPublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="tlsi_InitialPublicOfferingTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="tlsi_InitialPublicOfferingTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingLineItems" xlink:label="tlsi_InitialPublicOfferingLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="tlsi_InitialPublicOfferingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesIssuedPerUnit" xlink:label="tlsi_NumberOfSharesIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="tlsi_NumberOfSharesIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfWarrantsIssuedPerUnit" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="tlsi_NumberOfWarrantsIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails" xlink:type="extended" xlink:title="111240401 - Disclosure - PRIVATE PLACEMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivatePlacementWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xlink:type="extended" xlink:title="111240501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FounderSharesMember" xlink:label="tlsi_FounderSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_FounderSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="tlsi_SponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockDividendsShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateNumberOfSharesOwned" xlink:label="tlsi_AggregateNumberOfSharesOwned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_AggregateNumberOfSharesOwned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_NumberOfSharesSubjectToForfeiture" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_NumberOfSharesNoLongerSubjectToForfeiture" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="111240502 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNoteWithRelatedPartyMember" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_PromissoryNoteWithRelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyLoansMember" xlink:label="tlsi_RelatedPartyLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_RelatedPartyLoansMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdministrativeSupportAgreementMember" xlink:label="tlsi_AdministrativeSupportAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tlsi_AdministrativeSupportAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapitalLoansWarrantMember" xlink:label="tlsi_WorkingCapitalLoansWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_WorkingCapitalLoansWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="tlsi_SponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedExpensesMember" xlink:label="tlsi_AccruedExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="tlsi_AccruedExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumLoansConvertibleIntoWarrants" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_MaximumLoansConvertibleIntoWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="111240601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tlsi_TrisalusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RaymondJamesAgreementsMember" xlink:label="tlsi_RaymondJamesAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tlsi_RaymondJamesAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MtacClassCommonStockMember" xlink:label="tlsi_MtacClassCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_MtacClassCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationsOfWarrantToPurchase" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_BusinessCombinationsOfWarrantToPurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfHoldings" xlink:label="tlsi_NumberOfHoldings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_NumberOfHoldings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfTrading" xlink:label="tlsi_NumberOfTrading" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_NumberOfTrading" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails" xlink:type="extended" xlink:title="111240701 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails" xlink:type="extended" xlink:title="111240702 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockNumberOfVotesPerShare" xlink:label="tlsi_CommonStockNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tlsi_CommonStockNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleStockConversionRatio" xlink:label="tlsi_ConvertibleStockConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tlsi_ConvertibleStockConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="111240801 - Disclosure - WARRANT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionOne" xlink:label="tlsi_WarrantExercisePeriodConditionOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_WarrantExercisePeriodConditionOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionTwo" xlink:label="tlsi_WarrantExercisePeriodConditionTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_WarrantExercisePeriodConditionTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriod" xlink:label="tlsi_RedemptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_RedemptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_WarrantRedemptionConditionMinimumSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePriceAdjustmentMultiple" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_WarrantExercisePriceAdjustmentMultiple" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_WarrantRedemptionPriceAdjustmentMultiple" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="111240902 - Disclosure - INCOME TAX - Income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInValuationAllowance" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncreaseDecreaseInValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" xlink:type="extended" xlink:title="111240903 - Disclosure - INCOME TAX - Reconciliation of the federal income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="111241001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="111241002 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" xlink:type="extended" xlink:title="111241003 - Disclosure - FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="111241004 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="111241101 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNote2022ThreeMember" xlink:label="tlsi_PromissoryNote2022ThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="tlsi_PromissoryNote2022ThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNoteMember" xlink:label="tlsi_ExtensionNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tlsi_ExtensionNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tlsi_TrisalusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MergerAgreementMember" xlink:label="tlsi_MergerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tlsi_MergerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AssetsHeldInTrust" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xlink:type="extended" xlink:title="1200100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_ContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="tlsi_LeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="tlsi_LeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_EquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xlink:type="extended" xlink:title="1200200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_TrancheAndWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_ContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_GainLossOnEquityIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="1200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xlink:type="extended" xlink:title="1200400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_TrancheAndWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_ContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tlsi_GainLossOnEquityIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tlsi_GainLossOnMilestonePaymentForAssetAcquistion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetsAcquisitionMilestone" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="tlsi_PaymentsForAssetsAcquisitionMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="tlsi_ProceedsFromReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="1240101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessTable" xlink:label="tlsi_NatureOfBusinessTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="tlsi_NatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesAndWarrantsMember" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tlsi_ConvertibleNotesAndWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="tlsi_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMember" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_StandbyEquityPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="tlsi_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessLineItems" xlink:label="tlsi_NatureOfBusinessLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_NatureOfBusinessTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfProductLinesInDevelopment" xlink:label="tlsi_NumberOfProductLinesInDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_NumberOfProductLinesInDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_ProceedsFromReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockAuthorizedAmountValue" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_SaleOfStockAuthorizedAmountValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementTerm" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_StandbyEquityPurchaseAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementOwnershipLimitation" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_PurchaseAgreementOwnershipLimitation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementExchangeCap" xlink:label="tlsi_PurchaseAgreementExchangeCap" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_PurchaseAgreementExchangeCap" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails" xlink:type="extended" xlink:title="1240201 - Disclosure - Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="tlsi_PreferredStockConversionPercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xlink:type="extended" xlink:title="1240301 - Disclosure - Business Combinations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfReverseRecapitalizationTable" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MTACWarrantsMember" xlink:label="tlsi_MTACWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_MTACWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedTechAcquisitionCorporationMember" xlink:label="tlsi_MedTechAcquisitionCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tlsi_MedTechAcquisitionCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodAxis" xlink:label="tlsi_DerivativeInstrumentPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="tlsi_DerivativeInstrumentPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodDomain" xlink:label="tlsi_DerivativeInstrumentPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="tlsi_DerivativeInstrumentPeriodAxis" xlink:to="tlsi_DerivativeInstrumentPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodOneMember" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_DerivativeInstrumentPeriodDomain" xlink:to="tlsi_DerivativeInstrumentPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodTwoMember" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_DerivativeInstrumentPeriodDomain" xlink:to="tlsi_DerivativeInstrumentPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodThreeMember" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_DerivativeInstrumentPeriodDomain" xlink:to="tlsi_DerivativeInstrumentPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodFourMember" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_DerivativeInstrumentPeriodDomain" xlink:to="tlsi_DerivativeInstrumentPeriodFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationLineItems" xlink:label="tlsi_ReverseRecapitalizationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ScheduleOfReverseRecapitalizationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RecapitalizationExchangeRatio" xlink:label="tlsi_RecapitalizationExchangeRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_RecapitalizationExchangeRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockConvertedReverseRecapitalization" xlink:label="tlsi_StockConvertedReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_StockConvertedReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalizationTransaction" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ProceedsFromReverseRecapitalizationTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ProceedsFromReverseRecapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsIncurred" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsPaid" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xlink:type="extended" xlink:title="1240401 - Disclosure - Financial Instruments - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MTACWarrantsMember" xlink:label="tlsi_MTACWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_MTACWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_ContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_TrancheAndWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnWarrantExpirations" xlink:label="tlsi_GainLossOnWarrantExpirations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tlsi_GainLossOnWarrantExpirations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xlink:type="extended" xlink:title="1240402 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails" xlink:type="extended" xlink:title="1240801 - Disclosure - Contingent Earnout Liability - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="tlsi_ContingentEarnoutLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" xlink:type="extended" xlink:title="1240802 - Disclosure - Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="1240901 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails" xlink:type="extended" xlink:title="1240902 - Disclosure - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPrice" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionDaysNotice" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightConversionDaysNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails" xlink:type="extended" xlink:title="1241101 - Disclosure - Preferred Stock - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesAConvertiblePreferredStockMember" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesAConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAxis" xlink:label="tlsi_TrancheAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="tlsi_TrancheAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheDomain" xlink:label="tlsi_TrancheDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="tlsi_TrancheAxis" xlink:to="tlsi_TrancheDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheTwoMember" xlink:label="tlsi_TrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_TrancheDomain" xlink:to="tlsi_TrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheThreeMember" xlink:label="tlsi_TrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_TrancheDomain" xlink:to="tlsi_TrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueSharePriceMember" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tlsi_MeasurementInputFairValueSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ValuationTechniqueAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockIssuedPricePerShare" xlink:label="tlsi_PreferredStockIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockAutomaticConversionPeriod" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockAutomaticConversionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceFloor" xlink:label="tlsi_PreferredStockConversionPriceFloor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockConversionPriceFloor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockConversionPercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_ClassOfWarrantOrRightWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockPercentageOfSharesCommitted" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PreferredStockPercentageOfSharesCommitted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_GainLossOnEquityIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="1241102 - Disclosure - Preferred Stock - Summary of Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" xlink:type="extended" xlink:title="1241103 - Disclosure - Preferred Stock - Convertible Preferred Stock Rollforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="1241104 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" xlink:type="extended" xlink:title="1241105 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRollForward" xlink:label="tlsi_ClassOfWarrantOrRightRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="tlsi_ClassOfWarrantOrRightRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_ClassOfWarrantOrRightRollForward" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_ClassOfWarrantOrRightRollForward" xlink:to="tlsi_ClassOfWarrantOrRightWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_ClassOfWarrantOrRightRollForward" xlink:to="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_ClassOfWarrantOrRightRollForward" xlink:to="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails" xlink:type="extended" xlink:title="1241106 - Disclosure - Preferred Stock - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilityMember" xlink:label="tlsi_SeriesB2TrancheLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2TrancheLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueSharePriceMember" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tlsi_MeasurementInputFairValueSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputExerciseSharePriceMember" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tlsi_MeasurementInputExerciseSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ValuationTechniqueAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GuidelinePublicCompanyModelMember" xlink:label="tlsi_GuidelinePublicCompanyModelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="tlsi_GuidelinePublicCompanyModelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BlackScholesModelMember" xlink:label="tlsi_BlackScholesModelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="tlsi_BlackScholesModelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BinomialTrancheModelMember" xlink:label="tlsi_BinomialTrancheModelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="tlsi_BinomialTrancheModelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="1241201 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantMember" xlink:label="tlsi_PreferredStockWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tlsi_PreferredStockWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantMember" xlink:label="tlsi_CommonStockWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tlsi_CommonStockWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="1241301 - Disclosure - Share-Based Compensation - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2009PlanMember" xlink:label="tlsi_A2009PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tlsi_A2009PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2023PlanMember" xlink:label="tlsi_A2023PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="tlsi_A2023PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss" xlink:type="extended" xlink:title="1241302 - Disclosure - Share-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2009PlanMember" xlink:label="tlsi_A2009PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tlsi_A2009PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2023PlanMember" xlink:label="tlsi_A2023PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="tlsi_A2023PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementNumberOfPlans" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tlsi_ShareBasedCompensationArrangementNumberOfPlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails" xlink:type="extended" xlink:title="1241401 - Disclosure - Dynavax Purchase (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxTechnologiesMember" xlink:label="tlsi_DynavaxTechnologiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tlsi_DynavaxTechnologiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeAxis" xlink:label="tlsi_CommercialMilestoneTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="tlsi_CommercialMilestoneTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeDomain" xlink:label="tlsi_CommercialMilestoneTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="tlsi_CommercialMilestoneTypeAxis" xlink:to="tlsi_CommercialMilestoneTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneMember" xlink:label="tlsi_CommercialMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_CommercialMilestoneTypeDomain" xlink:to="tlsi_CommercialMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_CommercialMilestoneMember" xlink:to="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone250000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_CommercialMilestoneMember" xlink:to="tlsi_CommercialMilestone250000AnnualSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone500000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_CommercialMilestoneMember" xlink:to="tlsi_CommercialMilestone500000AnnualSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone1000000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tlsi_CommercialMilestoneMember" xlink:to="tlsi_CommercialMilestone1000000AnnualSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisition" xlink:label="tlsi_PaymentsForAssetAcquisition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_PaymentsForAssetAcquisition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_PaymentsForAssetAcquisitionMilestoneAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionNumberOfCommercialMilestones" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionNumberOfCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMaximumMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionMaximumMilestoneAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMilestoneAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionMilestoneAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionSalesMilestone" xlink:label="tlsi_AssetAcquisitionSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="222100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" xlink:type="extended" xlink:title="222140201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CustomerOneMember" xlink:label="tlsi_CustomerOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tlsi_CustomerOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCustomer" xlink:label="tlsi_NumberOfCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="tlsi_NumberOfCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="tlsi_MilestonePaymentToDynavaxOperatingActivity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesOutstanding" xlink:label="tlsi_PercentageOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="tlsi_PercentageOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccruedRentCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="222140301 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementAxis" xlink:label="tlsi_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="tlsi_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueDisclosureItemAmountDomain" xlink:label="tlsi_FairValueDisclosureItemAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="tlsi_MeasurementAxis" xlink:to="tlsi_FairValueDisclosureItemAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_FairValueDisclosureItemAmountDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_WarrantLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilitiesMember" xlink:label="tlsi_TrancheLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_TrancheLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_TrancheLiabilitiesMember" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_TrancheLiabilitiesMember" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xlink:type="extended" xlink:title="222140302 - Disclosure - Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_WarrantLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PutOptionLiabilityMember" xlink:label="tlsi_PutOptionLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_PutOptionLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilitiesMember" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_SeriesB2TrancheLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3WarrantLiabilitiesMember" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_SeriesB3WarrantLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xlink:type="extended" xlink:title="222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss" xlink:type="extended" xlink:title="222140901 - Disclosure - Dynavax Purchase (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAgreementMember" xlink:label="tlsi_DynavaxPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tlsi_DynavaxPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstCommercialSaleOfProductMember" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_UponFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UpfrontPaymentAmount" xlink:label="tlsi_UpfrontPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_UpfrontPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentOfUpfrontAmount" xlink:label="tlsi_PaymentOfUpfrontAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_PaymentOfUpfrontAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MinimumMilestonePaymentAmount" xlink:label="tlsi_MinimumMilestonePaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_MinimumMilestonePaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumMilestonePaymentAmount" xlink:label="tlsi_MaximumMilestonePaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_MaximumMilestonePaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumDevelopmentMilestonePayments" xlink:label="tlsi_MaximumDevelopmentMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_MaximumDevelopmentMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentsMade" xlink:label="tlsi_MilestonePaymentsMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_MilestonePaymentsMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCommercialMilestoneToBeMade" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_NumberOfCommercialMilestoneToBeMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestonePaymentAmount" xlink:label="tlsi_CommercialMilestonePaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_CommercialMilestonePaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualNetSales" xlink:label="tlsi_AnnualNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_AnnualNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumCommercialMilestonePayments" xlink:label="tlsi_MaximumCommercialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_MaximumCommercialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualRoyaltyRate" xlink:label="tlsi_AnnualRoyaltyRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tlsi_AnnualRoyaltyRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails" xlink:type="extended" xlink:title="222141001 - Disclosure - Debt - PPP Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaycheckProtectionProgramMember" xlink:label="tlsi_PaycheckProtectionProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tlsi_PaycheckProtectionProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails" xlink:type="extended" xlink:title="222141002 - Disclosure - Debt - Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TermLoanAndSupplementalTermLoanMember" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tlsi_TermLoanAndSupplementalTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn08262015Member" xlink:label="tlsi_WarrantsIssuedOn08262015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_WarrantsIssuedOn08262015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn10272016Member" xlink:label="tlsi_WarrantsIssuedOn10272016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_WarrantsIssuedOn10272016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn06302017Member" xlink:label="tlsi_WarrantsIssuedOn06302017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_WarrantsIssuedOn06302017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn11202018Member" xlink:label="tlsi_WarrantsIssuedOn11202018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tlsi_WarrantsIssuedOn11202018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5PreferredStockMember" xlink:label="tlsi_SeriesA5PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6PreferredStockMember" xlink:label="tlsi_SeriesA6PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails" xlink:type="extended" xlink:title="222141101 - Disclosure - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6PreferredStockMember" xlink:label="tlsi_SeriesA6PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_PutOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_QualifiedFinancingMinimumProceeds" xlink:label="tlsi_QualifiedFinancingMinimumProceeds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_QualifiedFinancingMinimumProceeds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionDiscountPercentage" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_DebtInstrumentConversionDiscountPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialWarrantLiability" xlink:label="tlsi_InitialWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_InitialWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantIssued" xlink:label="tlsi_WarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_WarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EliminationOfOccurrenceOfDiscountPercentage" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_EliminationOfOccurrenceOfDiscountPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="us-gaap_DerivativeNotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeNotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="222141201 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="222141202 - Disclosure - Convertible Preferred Stock, activity in convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails" xlink:type="extended" xlink:title="222141203 - Disclosure - Convertible Preferred Stock, narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquitySharesAvailableForIssuance" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquitySharesAvailableForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails" xlink:type="extended" xlink:title="222141206 - Disclosure - Convertible Preferred Stock, Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityDividendPerShare" xlink:label="tlsi_TemporaryEquityDividendPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityDividendPerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" xlink:type="extended" xlink:title="222141207 - Disclosure - Convertible Preferred Stock, Liquidation Preferences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails" xlink:type="extended" xlink:title="222141208 - Disclosure - Convertible Preferred Stock, March 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_March2021FinancingMember" xlink:label="tlsi_March2021FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_March2021FinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails" xlink:type="extended" xlink:title="222141209 - Disclosure - Convertible Preferred Stock, Spring 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Spring2021FinancingMember" xlink:label="tlsi_Spring2021FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_Spring2021FinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails" xlink:type="extended" xlink:title="222141210 - Disclosure - Convertible Preferred Stock, Fall 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Fall2021FinancingMember" xlink:label="tlsi_Fall2021FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_Fall2021FinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails" xlink:type="extended" xlink:title="222141211 - Disclosure - Convertible Preferred Stock, Warrant Exercises (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails" xlink:type="extended" xlink:title="222141212 - Disclosure - Convertible Preferred Stock - 2022 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2022Member" xlink:label="tlsi_Financing2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_Financing2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingThirdTrancheMember" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_B2PreferredStockFinancingThirdTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tlsi_MeasurementInputFairValueOfUnderlyingStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:label="us-gaap_MeasurementInputInceptionDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputInceptionDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationScenarioMember" xlink:label="tlsi_BusinessCombinationScenarioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_BusinessCombinationScenarioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_WarrantLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilitiesMember" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tlsi_SeriesB2TrancheLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSell" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateProceedsReceivableFromStockOffering" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_AggregateProceedsReceivableFromStockOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilityMeasurementInput" xlink:label="tlsi_TrancheLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TrancheLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EnterpriseValueAllocated" xlink:label="tlsi_EnterpriseValueAllocated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_EnterpriseValueAllocated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValueAssignedToTrancheRightsAndObligations" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_ValueAssignedToTrancheRightsAndObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_GainLossOnEquityIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails" xlink:type="extended" xlink:title="222141213 - Disclosure - Convertible Preferred Stock - 2023 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2023Member" xlink:label="tlsi_Financing2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:to="tlsi_Financing2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfStockOfferingClosingsEffectuated" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_NumberOfStockOfferingClosingsEffectuated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesCommittedSold" xlink:label="tlsi_PercentageOfSharesCommittedSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tlsi_PercentageOfSharesCommittedSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="222141301 - Disclosure - Stockholders' Equity - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:label="tlsi_CapitalShareReservedForFutureIssuanceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tlsi_CapitalShareReservedForFutureIssuanceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:label="tlsi_CapitalSharesReservedForFutureIssuanceDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:to="tlsi_CapitalSharesReservedForFutureIssuanceDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WarrantMember" xlink:to="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsOutstandingMember" xlink:label="tlsi_StockOptionsOutstandingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="tlsi_StockOptionsOutstandingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsAvailableForFutureGrantMember" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="tlsi_StockOptionsAvailableForFutureGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" xlink:type="extended" xlink:title="222141302 - Disclosure - Stockholders' Equity - Stock Option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="222141303 - Disclosure - Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.001Member" xlink:label="tlsi_ExercisePriceOf0.001Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.001Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.003Member" xlink:label="tlsi_ExercisePriceOf0.003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.003Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.004Member" xlink:label="tlsi_ExercisePriceOf0.004Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.004Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.005Member" xlink:label="tlsi_ExercisePriceOf0.005Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.005Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.006Member" xlink:label="tlsi_ExercisePriceOf0.006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.007Member" xlink:label="tlsi_ExercisePriceOf0.007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.09To0.46Member" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="tlsi_ExercisePriceOf0.09To0.46Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" xlink:type="extended" xlink:title="222141304 - Disclosure - Stockholders' Equity - Valuation assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="222141305 - Disclosure - Stockholders' Equity - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EquityIncentivePlan2019AsAmendedMember" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tlsi_EquityIncentivePlan2019AsAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="222141401 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantsMember" xlink:label="tlsi_PreferredStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tlsi_PreferredStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantsMember" xlink:label="tlsi_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tlsi_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="222141505 - Disclosure - Leases - Future minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierEquipmentMember" xlink:label="tlsi_CopierEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tlsi_CopierEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierInWestminsterFacilityMember" xlink:label="tlsi_CopierInWestminsterFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tlsi_CopierEquipmentMember" xlink:to="tlsi_CopierInWestminsterFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrincipalAdministrativeAndProductionFacilityMember" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tlsi_PrincipalAdministrativeAndProductionFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfOperatingLeases" xlink:label="tlsi_NumberOfOperatingLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tlsi_NumberOfOperatingLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfFinanceLeases" xlink:label="tlsi_NumberOfFinanceLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tlsi_NumberOfFinanceLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseLiabilitiesCurrent" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tlsi_FinanceLeaseLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="222141601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FirstInstallmentMember" xlink:label="tlsi_FirstInstallmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_FirstInstallmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SecondInstallmentMember" xlink:label="tlsi_SecondInstallmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_SecondInstallmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionUptoThreePercentMember" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_EmployeeContributionUptoThreePercentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tlsi_EmployeeContributionBetweenFourAndFivePercentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsSuitFiled" xlink:label="tlsi_NumberOfPatentsSuitFiled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tlsi_NumberOfPatentsSuitFiled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsTestimonyLimited" xlink:label="tlsi_NumberOfPatentsTestimonyLimited" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tlsi_NumberOfPatentsTestimonyLimited" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CurePeriod" xlink:label="tlsi_CurePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tlsi_CurePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesPaidValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" xlink:type="extended" xlink:title="222141701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tlsi_TrisalusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorporationMember" xlink:label="tlsi_MedtechAcquisitionCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="tlsi_MedtechAcquisitionCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationWarrantsConsideration" xlink:label="tlsi_BusinessCombinationWarrantsConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tlsi_BusinessCombinationWarrantsConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationAcquisitionExpensesDeferred" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tlsi_BusinessCombinationAcquisitionExpensesDeferred" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>tlsi-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/15/2023 2:04:02 AM-->
<!--Modified on: 12/15/2023 2:04:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MedtechAcquisitionCorpMember" xlink:to="tlsi_MedtechAcquisitionCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MedtechAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the information pertaining to MedTech acquisition corp member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MedtechAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MedtechAcquisitionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corp</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonClassaSubjectToRedemptionMember" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock representing ownership interest in a corporation that is subject to redemption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Stock Subject to Redemption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock subject to possible redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Class B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held-in-trust, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and investments held in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held in Trust Account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity (Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES, CLASS A COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current, Related Party, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNotesPayableCurrent" xlink:label="tlsi_ExtensionNotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExtensionNotesPayableCurrent" xlink:to="tlsi_ExtensionNotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExtensionNotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values as of the balance sheet date of the portions of extension notes payable due within one year or the operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExtensionNotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExtensionNotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory note - related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Current, Related Party, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount for convertible notes payable, payable to related parties, which are due after one year (or one business cycle).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable Related Party Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible promissory note outstanding</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeferredOfferingCostsNoncurrent" xlink:to="tlsi_DeferredOfferingCostsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' DEFICIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 and 0 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 4,015,002 and 0 shares at September 30, 2023, and December 31, 2022, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value $0.0001 per share; 1,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value per share. Authorized 400,000,000 and 30,898,162 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 26,316,681 and 347,926 shares at September 30, 2023, and December 31, 2022, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares subject to redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock subject to possible redemption, price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest earned on marketable securities held in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest earned on marketable securities held in Trust Account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss available to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderEquity" xlink:label="tlsi_StockholderEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockholderEquity" xlink:to="tlsi_StockholderEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockholderEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockholderEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholder Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tlsi_StockholderEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tlsi_StockholderEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase to additional paid-in capital (APIC) for investment pursuant to Business Combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Investment Pursuant to Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment pursuant to business combination agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of shares of Class A common stock to redemption amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of carrying value to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Officers and Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables, accrued expenses and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentForInvestmentOfCashInTrustAccount" xlink:to="tlsi_PaymentForInvestmentOfCashInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payment for investment of cash into trust account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Investment of Cash in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment of cash into Trust Account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash withdrawn from Trust Account for franchise and income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Withdrawn From Trust Account For Franchise And Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash withdrawn from Trust Account to pay franchise and income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash withdrawn of interest income from the Trust Account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash withdrawn from Trust Account for franchise and income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Trust Account in Connection with Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemptions of Class A common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from trust account in connection with redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash withdrawn from Trust Account in connection with redemptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from promissory note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional amount drawn on Promissory Note</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xlink:to="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cash inflow from convertible promissory notes of the related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Related Party Debt, Convertible Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from convertible promissory note - related party</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromExtensionNote" xlink:label="tlsi_ProceedsFromExtensionNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromExtensionNote" xlink:to="tlsi_ProceedsFromExtensionNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromExtensionNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of proceeds from extension note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromExtensionNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Extension Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromExtensionNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from extension note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Contributed Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from MTAC trust account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Contribution by Sponsor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Repurchase of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemptions of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRIVATE PLACEMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingAbstract" xlink:label="tlsi_InitialPublicOfferingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InitialPublicOfferingAbstract" xlink:to="tlsi_InitialPublicOfferingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PUBLIC OFFERING</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTextBlock" xlink:label="tlsi_InitialPublicOfferingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InitialPublicOfferingTextBlock" xlink:to="tlsi_InitialPublicOfferingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on information about initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PUBLIC OFFERING</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementAbstract" xlink:label="tlsi_PrivatePlacementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PrivatePlacementAbstract" xlink:to="tlsi_PrivatePlacementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRIVATE PLACEMENT</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementTextBlock" xlink:label="tlsi_PrivatePlacementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PrivatePlacementTextBlock" xlink:to="tlsi_PrivatePlacementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on information about private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRIVATE PLACEMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' DEFICIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsAbstract" xlink:label="tlsi_WarrantsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsAbstract" xlink:to="tlsi_WarrantsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xlink:to="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of derivative warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Warrant Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IncomeTaxTable" xlink:to="tlsi_IncomeTaxTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about Income Tax .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IncomeTaxLineItems" xlink:to="tlsi_IncomeTaxLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX [Line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_IncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EmergingGrowthCompanyPolicyTextBlock" xlink:to="tlsi_EmergingGrowthCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy on emerging growth company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for assets held in trust.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held In Trust Account, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Investments Held in Trust Account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityPolicyPolicyTextBlock" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquityPolicyPolicyTextBlock" xlink:to="tlsi_TemporaryEquityPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Stock Subject to Possible Redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesPolicyTextBlock" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantLiabilitiesPolicyTextBlock" xlink:to="tlsi_WarrantLiabilitiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Loss) Income per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk and Other Risks and Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant and Tranche Liabilities / Contingent Earnout Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Class A common stock subject to possible redemption reflected in the balance sheets reconciled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net (loss) income per common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of company's net deferred tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant portions of deferred income tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income tax provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income tax expenses (benefits) from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the federal income tax rate to the company's effective tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of federal statutory tax rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Company's assets and liabilities that are measured at fair value on a recurring basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of company's assets that are measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of key inputs into the monte carlo simulation for the private placement warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in the level 3 fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-allotment option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PrivatePlacementWarrantsMember" xlink:to="tlsi_PrivatePlacementWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition For Future Business Combination Number Of Businesses Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination number of businesses minimum</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new units issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of units, net of underwriting discounts (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price, per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of shares sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase Series B-3 preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of private placement warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of private placements warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentsForInvestmentOfCashInTrustAccount" xlink:to="tlsi_PaymentsForInvestmentOfCashInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash outflow for investment of cash in trust account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Investment Of Cash In Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for investment of cash in trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransactionCosts" xlink:label="tlsi_TransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TransactionCosts" xlink:to="tlsi_TransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of transaction costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tlsi_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockUnderwritingFees" xlink:label="tlsi_SaleOfStockUnderwritingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SaleOfStockUnderwritingFees" xlink:to="tlsi_SaleOfStockUnderwritingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of offering fees incurred and paid for underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock Underwriting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting fees</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockOtherOfferingCosts" xlink:label="tlsi_SaleOfStockOtherOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SaleOfStockOtherOfferingCosts" xlink:to="tlsi_SaleOfStockOtherOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of other offering costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Other Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other offering costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:to="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold percentage of the assets held in the trust account funded by proceeds from the offering which must be used for purposes of consummating a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition For Future Business Combination Use Of Proceeds Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination use of proceeds percentage</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold percentage of voting interest to be acquired in a future business combination as specified for the use of proceeds from the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition For Future Business Combination Threshold Percentage Ownership</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination threshold percentage ownership</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition For Future Business Combination Threshold Net Tangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination threshold net tangible assets</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriodUponClosure" xlink:label="tlsi_RedemptionPeriodUponClosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RedemptionPeriodUponClosure" xlink:to="tlsi_RedemptionPeriodUponClosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RedemptionPeriodUponClosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time in which the reporting entity must redeem shares issued pursuant to the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RedemptionPeriodUponClosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Period Upon Closure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RedemptionPeriodUponClosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption period upon closure</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RedemptionLimitPercentageWithoutPriorConsent" xlink:to="tlsi_RedemptionLimitPercentageWithoutPriorConsent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The limit on the percentage of shares which may be redeemed with out prior consent of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Limit Percentage Without Prior Consent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption limit percentage without prior consent</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumAllowedDissolutionExpenses" xlink:label="tlsi_MaximumAllowedDissolutionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumAllowedDissolutionExpenses" xlink:to="tlsi_MaximumAllowedDissolutionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumAllowedDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount permitted to be paid for dissolution expenses if a business combination is not completed within the specified period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumAllowedDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Allowed Dissolution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumAllowedDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum allowed dissolution expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Class A common stock issued upon conversion of each share (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SponsorMember" xlink:to="tlsi_SponsorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for sponsor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNoteWithRelatedPartyMember" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PromissoryNoteWithRelatedPartyMember" xlink:to="tlsi_PromissoryNoteWithRelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for promissory note with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note With Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note - Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyOnePromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TwoThousandTwentyOnePromissoryNoteMember" xlink:to="tlsi_TwoThousandTwentyOnePromissoryNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Two Thousand Twenty One Promissory Note Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Twenty One Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Promissory Note</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:to="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Two Thousand Twenty two Promissory Note Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Twenty Two Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Promissory Note</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_OperatingBankAccounts" xlink:label="tlsi_OperatingBankAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_OperatingBankAccounts" xlink:to="tlsi_OperatingBankAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_OperatingBankAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating bank accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_OperatingBankAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Bank Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_OperatingBankAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating bank accounts</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapital" xlink:label="tlsi_WorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WorkingCapital" xlink:to="tlsi_WorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents the information about the working capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum borrowing capacity of related party promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Borrowing Capacity of Related Party Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity of related party promissory note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unused Borrowing Capacity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowed aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of convertible promissory note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total expenses incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses incurred</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfTransactionalFeePaid" xlink:label="tlsi_PercentageOfTransactionalFeePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfTransactionalFeePaid" xlink:to="tlsi_PercentageOfTransactionalFeePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfTransactionalFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents percentage of transactional fee paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfTransactionalFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Transactional Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfTransactionalFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of transactional fee paid</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DueToSponsorForCertainReimbursableExpenses" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DueToSponsorForCertainReimbursableExpenses" xlink:to="tlsi_DueToSponsorForCertainReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to due to the Sponsor for certain reimbursable expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Sponsor for Certain Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to the Sponsor for certain reimbursable expenses</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfAmountDepositedInTrustAccount" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfAmountDepositedInTrustAccount" xlink:to="tlsi_PercentageOfAmountDepositedInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents percentage of amount deposited in trust account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Amount Deposited In Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of amount deposited in trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesTable" xlink:label="tlsi_AccountingPoliciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AccountingPoliciesTable" xlink:to="tlsi_AccountingPoliciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PublicWarrantsMember" xlink:to="tlsi_PublicWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xlink:to="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to issuance of promissory notes to sponsor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Promissory Note 2022 to Sponsor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Note</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesLineItems" xlink:label="tlsi_AccountingPoliciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AccountingPoliciesLineItems" xlink:to="tlsi_AccountingPoliciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash held in the Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrust" xlink:to="us-gaap_AssetsHeldInTrust_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held-in-trust</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposited in trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xlink:to="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares held through shares redemption for Pro data basis of the funds in the Trust account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders, Number of Public Shares Held, Redeem for Pro Rata Portion of Funds in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of public shares held</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of removal in Trust Accounts to pay stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Redemptions, Removal of Trust Account to Pay Stockholders, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount removed from trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The per share amount of removal in Trust Accounts to pay stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Redemptions, Removal of Trust Account to Pay Stockholders, Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share removal from trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xlink:to="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of non-removal in Trust Accounts to pay stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Redemptions, Amount Not Removed and Held in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining amount held in the trust account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares outstanding</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AmountDepositedIntoTrustAccount" xlink:label="tlsi_AmountDepositedIntoTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AmountDepositedIntoTrustAccount" xlink:to="tlsi_AmountDepositedIntoTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AmountDepositedIntoTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deposits into the Trust Account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AmountDepositedIntoTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Deposited into Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AmountDepositedIntoTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposited into trust account</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of deposits that are drawn down in Trust Account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of Deposits into Trust Account, Drawn Down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of deposits drawn down</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of deposits that are funded by Acquiree.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of Deposits into Trust Account, Funded by Acquiree</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of deposits funded by TriSalus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective federal tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits accrued for interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities attributable to warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs related to IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionDeposit" xlink:label="tlsi_ExtensionDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExtensionDeposit" xlink:to="tlsi_ExtensionDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExtensionDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the amount of extension deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExtensionDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExtensionDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Repurchase of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for repurchase of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds allocated to Public Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net (loss) income per share of common stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xlink:to="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator For Calculation Of Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocation of net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:to="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator For Calculation Of Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTable" xlink:label="tlsi_InitialPublicOfferingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InitialPublicOfferingTable" xlink:to="tlsi_InitialPublicOfferingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InitialPublicOfferingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InitialPublicOfferingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingLineItems" xlink:label="tlsi_InitialPublicOfferingLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InitialPublicOfferingLineItems" xlink:to="tlsi_InitialPublicOfferingLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InitialPublicOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InitialPublicOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_InitialPublicOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PUBLIC OFFERING</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesIssuedPerUnit" xlink:label="tlsi_NumberOfSharesIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfSharesIssuedPerUnit" xlink:to="tlsi_NumberOfSharesIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares in a unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares in a unit</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfWarrantsIssuedPerUnit" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfWarrantsIssuedPerUnit" xlink:to="tlsi_NumberOfWarrantsIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of warrants in a unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant in each unit (as percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, number of securities called by each warrant or right (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FounderSharesMember" xlink:label="tlsi_FounderSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FounderSharesMember" xlink:to="tlsi_FounderSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FounderSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Founder Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FounderSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Founder Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FounderSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Founder Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock with PIPE financing (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumption of preferred stock in connection with the Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Dividends, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share dividend</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateNumberOfSharesOwned" xlink:label="tlsi_AggregateNumberOfSharesOwned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AggregateNumberOfSharesOwned" xlink:to="tlsi_AggregateNumberOfSharesOwned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AggregateNumberOfSharesOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares owned by the founders after the impact of the stock dividend.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AggregateNumberOfSharesOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Number Of Shares Owned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AggregateNumberOfSharesOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of shares owned</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfSharesSubjectToForfeiture" xlink:to="tlsi_NumberOfSharesSubjectToForfeiture_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Subject To Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares subject to forfeiture</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xlink:to="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of the company that were no longer subject to forfeiture.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares No Longer Subject To Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares no longer subject to forfeiture</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after completion of a business combination during which the shares or warrant may not be transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions On Transfer Period Of Time After Business Combination Completion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on transfer period of time after business combination completion</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyLoansMember" xlink:label="tlsi_RelatedPartyLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RelatedPartyLoansMember" xlink:to="tlsi_RelatedPartyLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RelatedPartyLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for related party loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RelatedPartyLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RelatedPartyLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Loans</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdministrativeSupportAgreementMember" xlink:label="tlsi_AdministrativeSupportAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AdministrativeSupportAgreementMember" xlink:to="tlsi_AdministrativeSupportAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Administrative Support Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative Support Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative Services Agreement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapitalLoansWarrantMember" xlink:label="tlsi_WorkingCapitalLoansWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WorkingCapitalLoansWarrantMember" xlink:to="tlsi_WorkingCapitalLoansWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for working capital loans warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital Loans Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital loans warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedExpensesMember" xlink:label="tlsi_AccruedExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AccruedExpensesMember" xlink:to="tlsi_AccruedExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AccruedExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AccruedExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The contractual monthly amount to be paid for support services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party Per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses per month</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumLoansConvertibleIntoWarrants" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumLoansConvertibleIntoWarrants" xlink:to="tlsi_MaximumLoansConvertibleIntoWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount which a potential loan could have repaid through issuance of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">maximum Loans Convertible Into Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan conversion agreement warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrisalusMember" xlink:to="tlsi_TrisalusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrisalusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for TriSalus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrisalusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TriSalus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrisalusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TriSalus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MtacClassCommonStockMember" xlink:label="tlsi_MtacClassCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MtacClassCommonStockMember" xlink:to="tlsi_MtacClassCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MtacClassCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for MTAC class a common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MtacClassCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC Class A Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MtacClassCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC Class A Common Stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RaymondJamesAgreementsMember" xlink:label="tlsi_RaymondJamesAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RaymondJamesAgreementsMember" xlink:to="tlsi_RaymondJamesAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RaymondJamesAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The information pertaining to Raymond James Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RaymondJamesAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raymond James Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RaymondJamesAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raymond James Agreements</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:to="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of demands for registration of securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number Of Demands For Registration Of Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of demands for registration of securities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xlink:to="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of  deferred underwriting fees upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fees Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fees upon consummation of business combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xlink:to="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of legal fee which is contingent upon consummation of business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Fee Contingent Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal fees</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xlink:to="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Advisory Fee Contingent Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Advisory Fee Contingent Upon Consummation Of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment advisory fees</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xlink:to="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of legal fee which is contingent upon consummation of merger with subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Fees Contingent Upon Consummation Of Merger with Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal fees upon merger</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Acquisition Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Liabilities Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationsOfWarrantToPurchase" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BusinessCombinationsOfWarrantToPurchase" xlink:to="tlsi_BusinessCombinationsOfWarrantToPurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of business combination of warrants to purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations Of Warrant To Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations of warrant to purchase</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfHoldings" xlink:label="tlsi_NumberOfHoldings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfHoldings" xlink:to="tlsi_NumberOfHoldings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfHoldings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents of number of holdings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfHoldings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Holdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfHoldings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of holdings</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfTrading" xlink:label="tlsi_NumberOfTrading" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfTrading" xlink:to="tlsi_NumberOfTrading_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfTrading_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of trading.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfTrading_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Trading</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfTrading_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xlink:to="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of stockholder approval after delivering business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholder Approval After Delivering Business Combination Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of stockholder approval after delivering business combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend rate, percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fees received</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockNumberOfVotesPerShare" xlink:label="tlsi_CommonStockNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockNumberOfVotesPerShare" xlink:to="tlsi_CommonStockNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of votes that each common share is entitled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, votes per share</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleStockConversionRatio" xlink:label="tlsi_ConvertibleStockConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConvertibleStockConversionRatio" xlink:to="tlsi_ConvertibleStockConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConvertibleStockConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The ratio to be applied to the stock in a conversion of convertible stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConvertibleStockConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Stock Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConvertibleStockConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio to be applied to the stock in the conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:to="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionOne" xlink:label="tlsi_WarrantExercisePeriodConditionOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantExercisePeriodConditionOne" xlink:to="tlsi_WarrantExercisePeriodConditionOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantExercisePeriodConditionOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after completion of a business combination before a warrant may be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantExercisePeriodConditionOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Period Condition One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantExercisePeriodConditionOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise period condition one</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionTwo" xlink:label="tlsi_WarrantExercisePeriodConditionTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantExercisePeriodConditionTwo" xlink:to="tlsi_WarrantExercisePeriodConditionTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The alternate period of time after completion of an initial public offering before a warrant may be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Period Condition Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise period condition two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public warrants expiration term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public warrants, term</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:to="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Period After Business Combination In Which To File Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum period after business combination in which to file registration statement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:to="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Of Time Within Which Registration Statement Is Expected To Become Effective</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time within which registration statement is expected to become effective</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per public warrant (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriod" xlink:label="tlsi_RedemptionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RedemptionPeriod" xlink:to="tlsi_RedemptionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of period of redemption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption period</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantRedemptionConditionMinimumSharePrice" xlink:to="tlsi_WarrantRedemptionConditionMinimumSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Redemption Condition Minimum Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant redemption condition minimum share price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days for redemption of public warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days for redemption of public warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:to="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold  number of business days before sending notice of redemption to warrant holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Number of Business Days Before Sending Notice of Redemption to Warrant Holders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of business days before sending notice of redemption to warrant holders</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:to="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price Trigger Used To Measure Dilution Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price trigger used to measure dilution of warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Period After Business Combination Used To Measure Dilution of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading period after business combination used to measure dilution of warrant</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePriceAdjustmentMultiple" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantExercisePriceAdjustmentMultiple" xlink:to="tlsi_WarrantExercisePriceAdjustmentMultiple_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price Adjustment Multiple</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price adjustment multiple</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantRedemptionPriceAdjustmentMultiple" xlink:to="tlsi_WarrantRedemptionPriceAdjustmentMultiple_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Redemption Price Adjustment Multiple</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant redemption price adjustment multiple</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total NOLs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:to="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized start up and organization costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Capitalized Start Up And Organization Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organizational costs/start-up expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, net of allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInValuationAllowance" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IncreaseDecreaseInValuationAllowance" xlink:to="tlsi_IncreaseDecreaseInValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryover</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local taxes</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xlink:to="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Changes in fair value of warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Changes In Fair Value Of Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Treasury securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Warrants exercise price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected share price volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and rights outstanding measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Unrealized (Gains) Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer to level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers in or out of Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNote2022ThreeMember" xlink:label="tlsi_PromissoryNote2022ThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PromissoryNote2022ThreeMember" xlink:to="tlsi_PromissoryNote2022ThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PromissoryNote2022ThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Promissory Note 2022 III.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PromissoryNote2022ThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note 2022 Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PromissoryNote2022ThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Promissory Note III</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNoteMember" xlink:label="tlsi_ExtensionNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExtensionNoteMember" xlink:to="tlsi_ExtensionNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExtensionNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for extension note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExtensionNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExtensionNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MergerAgreementMember" xlink:label="tlsi_MergerAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MergerAgreementMember" xlink:to="tlsi_MergerAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MergerAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MergerAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MergerAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount drawn on Second Extension Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Contract [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Tranche Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Tranche Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 tranche liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Series B-3 Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Series B-3 Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ContingentEarnoutLiabilityMember" xlink:to="tlsi_ContingentEarnoutLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Earnout Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Earnout Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent earnout liability</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, current</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LeaseLiabilityCurrent" xlink:to="tlsi_LeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LeaseLiabilityNoncurrent" xlink:to="tlsi_LeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheAndWarrantLiabilityMember" xlink:to="tlsi_TrancheAndWarrantLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche and Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche and Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche and warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated interest</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GainLossOnEquityIssuance" xlink:to="tlsi_GainLossOnEquityIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GainLossOnEquityIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Equity Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GainLossOnEquityIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Equity Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_GainLossOnEquityIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on equity issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_GainLossOnEquityIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on equity issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_GainLossOnEquityIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on equity issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on equity issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on derivatives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income and expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend related to Series B-2 preferred stock down round provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend to preferred stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undeclared dividends on Series A preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undeclared dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrants Assumed In Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrants Assumed In Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumption of warrants to purchase common stock in connection with the Business Combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon closing the Business Combination, net of expenses</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon closing of the Business Combination (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital, Recognition Of Derivative Instrument, Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital, Recognition Of Derivative Instrument, Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent earnout liability recognized upon closing of the Business Combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on disposal of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xlink:to="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Milestone Payment for Asset Acquistion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Milestone Payment for Asset Acquistion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments to Dynavax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetsAcquisitionMilestone" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentsForAssetsAcquisitionMilestone" xlink:to="tlsi_PaymentsForAssetsAcquisitionMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Assets Acquisition Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Assets Acquisition Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments to Dynavax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for intellectual property and licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for intellectual property and licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xlink:to="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Refundable Prepayments for Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Refundable Prepayments for Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refundable prepayments for Series B-2 preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of preferred stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of Series B preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromReverseRecapitalization" xlink:to="tlsi_ProceedsFromReverseRecapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from business combination</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Reverse Recapitalization, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Reverse Recapitalization, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs related to Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to business combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on finance lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from the exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of exercise of stock option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash items:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:to="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Transfer of Warrant to Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Transfer of Warrant to Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of warrant liability to preferred stock upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationAbstract" xlink:label="tlsi_ReverseRecapitalizationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationAbstract" xlink:to="tlsi_ReverseRecapitalizationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationDisclosureTextBlock" xlink:label="tlsi_ReverseRecapitalizationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationDisclosureTextBlock" xlink:to="tlsi_ReverseRecapitalizationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ReverseRecapitalizationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables and Accruals [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Earnout Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Note Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsLiabilitiesTextBlock" xlink:label="tlsi_WarrantsLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsLiabilitiesTextBlock" xlink:to="tlsi_WarrantsLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination and Asset Acquisition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment and Disposal of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Components of Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of components of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrant liabilities that are carried at fair value, the initial fair values recorded as debt discount at the time of issuance and amortized as additional interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Plan Balances</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessTable" xlink:label="tlsi_NatureOfBusinessTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NatureOfBusinessTable" xlink:to="tlsi_NatureOfBusinessTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NatureOfBusinessTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NatureOfBusinessTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NatureOfBusinessTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesAndWarrantsMember" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConvertibleNotesAndWarrantsMember" xlink:to="tlsi_ConvertibleNotesAndWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes and Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes and warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMember" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StandbyEquityPurchaseAgreementMember" xlink:to="tlsi_StandbyEquityPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessLineItems" xlink:label="tlsi_NatureOfBusinessLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NatureOfBusinessLineItems" xlink:to="tlsi_NatureOfBusinessLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfProductLinesInDevelopment" xlink:label="tlsi_NumberOfProductLinesInDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfProductLinesInDevelopment" xlink:to="tlsi_NumberOfProductLinesInDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfProductLinesInDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Product Lines in Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfProductLinesInDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Product Lines in Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfProductLinesInDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of product lines in development</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockAuthorizedAmountValue" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SaleOfStockAuthorizedAmountValue" xlink:to="tlsi_SaleOfStockAuthorizedAmountValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock, Authorized Amount, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock, Authorized Amount, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock, authorized amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementTerm" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StandbyEquityPurchaseAgreementTerm" xlink:to="tlsi_StandbyEquityPurchaseAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement period</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xlink:to="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Percentage Of Average Daily Volume</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Percentage Of Average Daily Volume</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, maximum shares allowed, percentage of average daily volume</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xlink:to="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Average Daily Volume, Number Of Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Average Daily Volume, Number Of Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, number of days used for measurement of average daily trading volume</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xlink:to="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement, Maximum Amount Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby Equity Purchase Agreement, Maximum Amount Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum shares of common stock allowed under Purchase Agreement (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price As Percentage Of Market Price Commencing On Advance Notice Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price As Percentage Of Market Price Commencing On Advance Notice Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, sales price, percentage of market price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price As Percentage Of Market Price With Advance Notice, Option Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price As Percentage Of Market Price With Advance Notice, Option Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, sales price, percentage of market price during three consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xlink:to="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Market Price, Number Of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Share Price, Market Price, Number Of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, number of trading days used for measurement of market price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementOwnershipLimitation" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PurchaseAgreementOwnershipLimitation" xlink:to="tlsi_PurchaseAgreementOwnershipLimitation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Ownership Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Ownership Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, ownership limitation</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementExchangeCap" xlink:label="tlsi_PurchaseAgreementExchangeCap" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PurchaseAgreementExchangeCap" xlink:to="tlsi_PurchaseAgreementExchangeCap_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PurchaseAgreementExchangeCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Exchange Cap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PurchaseAgreementExchangeCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Exchange Cap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PurchaseAgreementExchangeCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement, exchange cap</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Earnout Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Earnout Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent earnout liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful Life (Years)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:to="tlsi_PreferredStockConversionPercentageOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion, Percentage of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion, Percentage of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of then-outstanding preferred stock on an as-converted to common stock basis</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Unvested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares unvested (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative instrument, contingent consideration, liability, earnout period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfReverseRecapitalizationTable" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable" xlink:to="tlsi_ScheduleOfReverseRecapitalizationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reverse Recapitalization [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reverse Recapitalization [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MTACWarrantsMember" xlink:label="tlsi_MTACWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MTACWarrantsMember" xlink:to="tlsi_MTACWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MTACWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MTACWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MTACWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTAC Warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedTechAcquisitionCorporationMember" xlink:label="tlsi_MedTechAcquisitionCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MedTechAcquisitionCorporationMember" xlink:to="tlsi_MedTechAcquisitionCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MedTechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MedTechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MedTechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corporation</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodAxis" xlink:label="tlsi_DerivativeInstrumentPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodAxis" xlink:to="tlsi_DerivativeInstrumentPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodDomain" xlink:label="tlsi_DerivativeInstrumentPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodDomain" xlink:to="tlsi_DerivativeInstrumentPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodOneMember" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodOneMember" xlink:to="tlsi_DerivativeInstrumentPeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodTwoMember" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodTwoMember" xlink:to="tlsi_DerivativeInstrumentPeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodThreeMember" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodThreeMember" xlink:to="tlsi_DerivativeInstrumentPeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Three</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodFourMember" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentPeriodFourMember" xlink:to="tlsi_DerivativeInstrumentPeriodFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Period Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Four</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationLineItems" xlink:label="tlsi_ReverseRecapitalizationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationLineItems" xlink:to="tlsi_ReverseRecapitalizationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ReverseRecapitalizationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RecapitalizationExchangeRatio" xlink:label="tlsi_RecapitalizationExchangeRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_RecapitalizationExchangeRatio" xlink:to="tlsi_RecapitalizationExchangeRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_RecapitalizationExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recapitalization Exchange Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_RecapitalizationExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recapitalization Exchange Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_RecapitalizationExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange ratio</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockConvertedReverseRecapitalization" xlink:label="tlsi_StockConvertedReverseRecapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockConvertedReverseRecapitalization" xlink:to="tlsi_StockConvertedReverseRecapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockConvertedReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Converted, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockConvertedReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Converted, Reverse Recapitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockConvertedReverseRecapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock converted, reverse recapitalization (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalizationTransaction" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromReverseRecapitalizationTransaction" xlink:to="tlsi_ProceedsFromReverseRecapitalizationTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Reverse Recapitalization Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Reverse Recapitalization Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from private placement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsIncurred" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationTransactionCostsIncurred" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization, Transaction Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization, Transaction Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs incurred</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsPaid" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationTransactionCostsPaid" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization, Transaction Costs Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization, Transaction Costs Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs paid from proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Loss on Derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain on Derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options and RSU's outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock, price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds on sale of stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnout shares vesting percentage</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnout shares vesting requirement, weighted average price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnout period, threshold trading days</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnout period, threshold consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PrivateWarrantsMember" xlink:to="tlsi_PrivateWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnWarrantExpirations" xlink:label="tlsi_GainLossOnWarrantExpirations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GainLossOnWarrantExpirations" xlink:to="tlsi_GainLossOnWarrantExpirations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GainLossOnWarrantExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Warrant Expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GainLossOnWarrantExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Warrant Expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_GainLossOnWarrantExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on expired warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Unrealized (Gains) Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances (Settlements)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Transfer In (Out) of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Transfer In (Out) of Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final net exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash (included in Other assets)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Valuation Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for excess or obsolete inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued bonus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments, Gain (Loss) [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments, Gain (Loss) [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="us-gaap_DerivativeInstrumentsGainLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments, Gain (Loss) [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments, Gain (Loss) [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, measurement input</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xlink:to="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Days From Which Warrant Or Rights Become Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Days From Which Warrant Or Rights Become Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise period</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPrice" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRedemptionPrice" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Redemption Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Redemption Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, redemption price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionDaysNotice" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightConversionDaysNotice" xlink:to="tlsi_ClassOfWarrantOrRightConversionDaysNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Days Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Days Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of business days before sending notice of redemption to warrant holders</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xlink:to="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Stock Price Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Stock Price Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant redemption condition, share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Terms, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Conversion Terms, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, conversion terms, threshold trading days</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Conversion Terms, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Conversion Terms, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, conversion terms, threshold consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xlink:to="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Threshold Number of Days for Warrants to be Transferable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Threshold Number of Days for Warrants to be Transferable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, threshold number of days for warrants to be transferable</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xlink:to="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Repurchase Program, Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Repurchase Program, Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant repurchase program, authorized amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Number Of Warrants Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Number Of Warrants Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants repurchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesAConvertiblePreferredStockMember" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesAConvertiblePreferredStockMember" xlink:to="tlsi_SeriesAConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-3 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-3 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-3 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-4 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-4 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-4</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-4 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesBConvertiblePreferredStockMember" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-1 Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-1 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAxis" xlink:label="tlsi_TrancheAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheAxis" xlink:to="tlsi_TrancheAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche [Axis]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheDomain" xlink:label="tlsi_TrancheDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheDomain" xlink:to="tlsi_TrancheDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheTwoMember" xlink:label="tlsi_TrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheTwoMember" xlink:to="tlsi_TrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheThreeMember" xlink:label="tlsi_TrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheThreeMember" xlink:to="tlsi_TrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Three</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueSharePriceMember" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MeasurementInputFairValueSharePriceMember" xlink:to="tlsi_MeasurementInputFairValueSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Fair Value Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Fair Value Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2, B-3 preferred stock fair value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 preferred stock fair value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Approach and Technique [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xlink:to="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation, Reverse Recapitalization Approach, Enterprise Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation, Reverse Recapitalization Approach, Enterprise Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation, Reverse Recapitalization Approach, Enterprise Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock available for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockIssuedPricePerShare" xlink:label="tlsi_PreferredStockIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockIssuedPricePerShare" xlink:to="tlsi_PreferredStockIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original issue price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockAutomaticConversionPeriod" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockAutomaticConversionPeriod" xlink:to="tlsi_PreferredStockAutomaticConversionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Automatic Conversion, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Automatic Conversion, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Automatic conversion, anniversary</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Automatic Reset Duration, First Reset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Automatic Reset Duration, First Reset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price, first automatic reset</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Automatic Reset Duration, Second Reset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Automatic Reset Duration, Second Reset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price, second automatic reset</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceFloor" xlink:label="tlsi_PreferredStockConversionPriceFloor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockConversionPriceFloor" xlink:to="tlsi_PreferredStockConversionPriceFloor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockConversionPriceFloor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Floor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockConversionPriceFloor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Conversion Price, Floor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockConversionPriceFloor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock, floor conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xlink:to="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Trading Days, Volume Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Trading Days, Volume Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days, VWAP</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xlink:to="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Strike Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Strike Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xlink:to="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction, Potential Increased Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction, Potential Increased Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration received, potential increased amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xlink:to="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction, Potential Increased Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction, Potential Increased Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued in transaction, potential increased amount (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange ratios</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:to="tlsi_ClassOfWarrantOrRightWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercises (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockPercentageOfSharesCommitted" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockPercentageOfSharesCommitted" xlink:to="tlsi_PreferredStockPercentageOfSharesCommitted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Percentage of Shares Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Percentage of Shares Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares committed</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xlink:to="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Enterprise Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Recapitalization, Stock Value, If-Converted Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Enterprise value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:to="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Value, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Value, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirements / Conversions</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRollForward" xlink:label="tlsi_ClassOfWarrantOrRightRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightRollForward" xlink:to="tlsi_ClassOfWarrantOrRightRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xlink:to="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Outstanding, Warrants Issued During Period, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Outstanding, Warrants Issued During Period, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances (in shares)</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xlink:to="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirements/Conversion (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilityMember" xlink:label="tlsi_SeriesB2TrancheLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB2TrancheLiabilityMember" xlink:to="tlsi_SeriesB2TrancheLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB2TrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Tranche Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB2TrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Tranche Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB2TrancheLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Tranche Liability</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputExerciseSharePriceMember" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MeasurementInputExerciseSharePriceMember" xlink:to="tlsi_MeasurementInputExerciseSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 preferred stock exercise price per share</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GuidelinePublicCompanyModelMember" xlink:label="tlsi_GuidelinePublicCompanyModelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GuidelinePublicCompanyModelMember" xlink:to="tlsi_GuidelinePublicCompanyModelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GuidelinePublicCompanyModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guideline Public Company Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GuidelinePublicCompanyModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guideline Public Company Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_GuidelinePublicCompanyModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guideline Public Company Model</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BlackScholesModelMember" xlink:label="tlsi_BlackScholesModelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BlackScholesModelMember" xlink:to="tlsi_BlackScholesModelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BlackScholesModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Black-Scholes Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BlackScholesModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Black-Scholes Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BlackScholesModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Black-Scholes Model</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BinomialTrancheModelMember" xlink:label="tlsi_BinomialTrancheModelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BinomialTrancheModelMember" xlink:to="tlsi_BinomialTrancheModelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BinomialTrancheModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Binomial Tranche Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BinomialTrancheModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Binomial Tranche Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BinomialTrancheModelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Binomial Tranche Model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantMember" xlink:label="tlsi_PreferredStockWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockWarrantMember" xlink:to="tlsi_PreferredStockWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantMember" xlink:label="tlsi_CommonStockWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockWarrantMember" xlink:to="tlsi_CommonStockWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" xlink:label="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" xlink:to="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Preferred Stock, Convertible, Down Round Feature, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Preferred Stock, Convertible, Down Round Feature, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in net loss per common share, deemed dividend (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Award Types</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2009PlanMember" xlink:label="tlsi_A2009PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_A2009PlanMember" xlink:to="tlsi_A2009PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_A2009PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2009 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_A2009PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2009 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_A2009PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2009 Plan</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2023PlanMember" xlink:label="tlsi_A2023PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_A2023PlanMember" xlink:to="tlsi_A2023PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_A2023PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_A2023PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_A2023PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of option activity</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Number of Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Number of Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share reserve increase, number of years</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Percentage of Total Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Percentage of Total Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fully diluted common stock determined in preceding year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, weighted average fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date per share fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU weighted average fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense, options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense, RSUs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Granted, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Granted, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options exercise price, percentage of fair value</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementNumberOfPlans" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedCompensationArrangementNumberOfPlans" xlink:to="tlsi_ShareBasedCompensationArrangementNumberOfPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement, Number of Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement, Number of Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of plans</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for Issue (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxTechnologiesMember" xlink:label="tlsi_DynavaxTechnologiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DynavaxTechnologiesMember" xlink:to="tlsi_DynavaxTechnologiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DynavaxTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Technologies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DynavaxTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Technologies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DynavaxTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Technologies</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeAxis" xlink:label="tlsi_CommercialMilestoneTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestoneTypeAxis" xlink:to="tlsi_CommercialMilestoneTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestoneTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestoneTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestoneTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeDomain" xlink:label="tlsi_CommercialMilestoneTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestoneTypeDomain" xlink:to="tlsi_CommercialMilestoneTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestoneTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestoneTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestoneTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneMember" xlink:label="tlsi_CommercialMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestoneMember" xlink:to="tlsi_CommercialMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xlink:to="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, First Commercial Sale of Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, First Commercial Sale of Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, First Commercial Sale of Product</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone250000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestone250000AnnualSalesMember" xlink:to="tlsi_CommercialMilestone250000AnnualSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $250,000 Annual Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $250,000 Annual Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $250,000 Annual Sales</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone500000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestone500000AnnualSalesMember" xlink:to="tlsi_CommercialMilestone500000AnnualSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $500,000 Annual Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $500,000 Annual Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $500,000 Annual Sales</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone1000000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestone1000000AnnualSalesMember" xlink:to="tlsi_CommercialMilestone1000000AnnualSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $1,000,000 Annual Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $1,000,000 Annual Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone, $1,000,000 Annual Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisition" xlink:label="tlsi_PaymentsForAssetAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentsForAssetAcquisition" xlink:to="tlsi_PaymentsForAssetAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentsForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentsForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PaymentsForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for asset acquisition</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xlink:to="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Asset Acquisition, Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Asset Acquisition, Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for milestone</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionNumberOfCommercialMilestones" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionNumberOfCommercialMilestones" xlink:to="tlsi_AssetAcquisitionNumberOfCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Number of Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Number of Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of commercial milestones</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMaximumMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionMaximumMilestoneAmount" xlink:to="tlsi_AssetAcquisitionMaximumMilestoneAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Maximum Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Maximum Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone payments per development milestone</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMilestoneAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionMilestoneAmount" xlink:to="tlsi_AssetAcquisitionMilestoneAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Milestone, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Milestone, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionSalesMilestone" xlink:label="tlsi_AssetAcquisitionSalesMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionSalesMilestone" xlink:to="tlsi_AssetAcquisitionSalesMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalty Percentage, Under Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalty Percentage, Under Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties as a percentage of net sales, under sales threshold</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xlink:to="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalties, Sales Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalties, Sales Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties, sales threshold amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalty Percentage, Over Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Royalty Percentage, Over Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties as a percentage of sales, over threshold amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBTwoTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesBTwoTrancheLiabilityCurrent" xlink:to="tlsi_SeriesBTwoTrancheLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values as of the balance sheet date of the portions of series B-2  tranche liability, due within one year or the operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Two, Tranche Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 tranche liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBThreeTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesBThreeTrancheLiabilityCurrent" xlink:to="tlsi_SeriesBThreeTrancheLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values as of the balance sheet date of the portions of series B-3  warrant liability, due within one year or the operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Three, Tranche Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:to="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values of warrant liability, and other liabilities, classified as noncurrent, due after one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities And Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities and other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GainLossOnConversionOfConvertibleNotes" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) related to conversion of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain Loss On Conversion Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on conversion of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on conversion of convertible notes</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of tranche and warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment Of Tranche And Warrants Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of tranche and warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of tranche and warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deemed dividend related to Series B-2 preferred stock down round provision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Dividend Related To Series B Two, Preferred Stock Down Round Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend related to Series B-2 preferred stock down round provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend to the preferred stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in additional paid-in capital from modification of convertible debt to remove conversion discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Modification of Convertible Debt to Remove Conversion Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of convertible debt to remove conversion discount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Common Stock Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Amortization and Accretion, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainOnPppLoanForgiveness" xlink:label="tlsi_GainOnPppLoanForgiveness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_GainOnPppLoanForgiveness" xlink:to="tlsi_GainOnPppLoanForgiveness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_GainOnPppLoanForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gains on forgiveness of PPP loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_GainOnPppLoanForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain On PPP Loan Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_GainOnPppLoanForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on PPP loan forgiveness</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount amortization and amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:to="tlsi_MilestonePaymentToDynavaxOperatingActivity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment to Dynavax, classified under operating activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment To Dynavax, Operating Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to Dynavax</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxInvestingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MilestonePaymentToDynavaxInvestingActivity" xlink:to="tlsi_MilestonePaymentToDynavaxInvestingActivity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow associated with the milestone payment to Dynavax, classified as investing activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment To Dynavax, Investing Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to Dynavax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Bank Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments on term loan (including $254 balloon payment)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible notes and warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xlink:to="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow from exercise of stock options and warrants for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Stock Options And Warrants For Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from the exercise of stock options and warrants for common stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashPaidDuringYearForAbstract" xlink:label="tlsi_CashPaidDuringYearForAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CashPaidDuringYearForAbstract" xlink:to="tlsi_CashPaidDuringYearForAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Paid During the Year For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid during the year for:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash items:</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValueOfWarrantsIssuedWithConvertibleNotes" xlink:label="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes" xlink:to="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of warrants issued with convertible notes in noncash investing and financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Warrants Issued With Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of warrants issued with convertible notes</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" xlink:label="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" xlink:to="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of warrant liability transferred to preferred stock upon exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer Of Warrant Liability To Preferred Stock Upon Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of warrant liability to preferred stock upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" xlink:label="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" xlink:to="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of fixed asset purchases included in trade payables and accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Asset Purchases Included In Trade Payables And Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed asset purchases included in trade payables and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital" xlink:label="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital" xlink:to="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of put option liability transferred to additional paid-In capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put Option Liability Transferred To Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put option liability transferred to Additional paid-In capital</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" xlink:label="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" xlink:to="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying value of convertible notes and accumulated interest transferred to preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Value Of Convertible Notes And Accumulated Interest Transferred To Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of convertible notes and accumulated interest transferred to preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balloon payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="tlsi_LongLivedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LongLivedAssetsAbstract" xlink:to="tlsi_LongLivedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LongLivedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LongLivedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsDisclosureTextBlock" xlink:label="tlsi_LongLivedAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LongLivedAssetsDisclosureTextBlock" xlink:to="tlsi_LongLivedAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LongLivedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on long-lived assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LongLivedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LongLivedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAbstract" xlink:label="tlsi_DynavaxPurchaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DynavaxPurchaseAbstract" xlink:to="tlsi_DynavaxPurchaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DynavaxPurchaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DynavaxPurchaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleDebtDisclosureTextBlock" xlink:label="tlsi_ConvertibleDebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConvertibleDebtDisclosureTextBlock" xlink:to="tlsi_ConvertibleDebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertiblePreferredStockDisclosureTextBlock" xlink:label="tlsi_ConvertiblePreferredStockDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConvertiblePreferredStockDisclosureTextBlock" xlink:to="tlsi_ConvertiblePreferredStockDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConvertiblePreferredStockDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConvertiblePreferredStockDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConvertiblePreferredStockDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity and Share-Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases of Lessee Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement with MedTech Acquisition Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement with MedTech Acquisition Corporation</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations Of Credit Risk And Other Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable and Customer Concentrations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Cost [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" xlink:label="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" xlink:to="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for warrant and tranche rights and obligation liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant And Tranche Rights And Obligation Liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant and Tranche Rights and Obligation Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of aggregate amortization expense for intangible assets subject to amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" xlink:label="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" xlink:to="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of activity in convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Activity In Convertible Preferred Stock [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity in convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" xlink:label="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" xlink:to="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of aggregate liquidation preference of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Aggregate Liquidation Preference Of Convertible Preferred Stock [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of aggregate liquidation preference of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of common stock shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock reserved for future issuance in connection with the conversion of shares of Preferred Stock and upon the exercise of certain options and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity for options issued to employees, consultants, and directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of information about all options outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental balance sheet information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of right-of-use assets, short-term lease liabilities and long-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expense</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" xlink:label="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" xlink:to="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of of maturities of operating and finance leases liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturities Of Operating And Finance Leases Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of lease liabilities under noncancellable leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CumulativeIncomeLoss" xlink:label="tlsi_CumulativeIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CumulativeIncomeLoss" xlink:to="tlsi_CumulativeIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CumulativeIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent information pertaining to cumulative income loss from issuance of securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CumulativeIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CumulativeIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative net losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Benchmark [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CustomerOneMember" xlink:label="tlsi_CustomerOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CustomerOneMember" xlink:to="tlsi_CustomerOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to customer one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCustomer" xlink:label="tlsi_NumberOfCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfCustomer" xlink:to="tlsi_NumberOfCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising expense</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesOutstanding" xlink:label="tlsi_PercentageOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfSharesOutstanding" xlink:to="tlsi_PercentageOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Rent, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net of accrued rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementAxis" xlink:label="tlsi_MeasurementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MeasurementAxis" xlink:to="tlsi_MeasurementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MeasurementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by measurement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MeasurementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueDisclosureItemAmountDomain" xlink:label="tlsi_FairValueDisclosureItemAmountDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FairValueDisclosureItemAmountDomain" xlink:to="tlsi_FairValueDisclosureItemAmountDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FairValueDisclosureItemAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FairValueDisclosureItemAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosure Item Amount [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantLiabilitiesMember" xlink:to="tlsi_WarrantLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilitiesMember" xlink:label="tlsi_TrancheLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheLiabilitiesMember" xlink:to="tlsi_TrancheLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for tranche liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for tranche rights and obligations associated with the second tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Rights And Obligations Associated With The Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche rights and obligations associated with the second tranche</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for tranche rights and obligations associated with the third tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Rights And Obligations Associated With The Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche rights and obligations associated with the third tranche</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xlink:to="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of liabilities measured on a recurring basis between various levels of fair value hierarchy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Transfers Between Levels, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers between levels</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:to="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the then outstanding shares on an as-converted to common stock basis, offered under the stock offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Then Outstanding Shares On An As-Converted To Common Stock Basis, Offered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of then outstanding shares on an as-converted to common stock basis, offered</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PutOptionLiabilityMember" xlink:label="tlsi_PutOptionLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PutOptionLiabilityMember" xlink:to="tlsi_PutOptionLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PutOptionLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for put option liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PutOptionLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put Option Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PutOptionLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put option liability</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilitiesMember" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB2TrancheLiabilitiesMember" xlink:to="tlsi_SeriesB2TrancheLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series B-2 tranche liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 Tranche Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-2 tranche liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3WarrantLiabilitiesMember" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesB3WarrantLiabilitiesMember" xlink:to="tlsi_SeriesB3WarrantLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series B-3 warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 Warrant Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B-3 warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash (included in Other assets)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:label="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net, Items Net of Reserve Alternative [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryAdjustments" xlink:to="us-gaap_InventoryAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for excess inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computers and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:to="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Capitalized Property Plant and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated life of the patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense related to intellectual property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amortization expense for intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedIncentiveCurrent" xlink:label="tlsi_AccruedIncentiveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AccruedIncentiveCurrent" xlink:to="tlsi_AccruedIncentiveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AccruedIncentiveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable for unused incentive owed to employees based on the entity's incentive benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AccruedIncentiveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Incentive Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AccruedIncentiveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued incentives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Payroll Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Permanent differences tax rate applicable to pretax income (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xlink:to="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fixed assets and intangibles.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Fixed Assets And Intangible</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets and intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred income tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred income tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOLs expiring between 2029 and 2037</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOLs which do not expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in deferred tax assets valuation amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NetDeferredTaxAssetsChangeInValuationPercentage" xlink:label="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage" xlink:to="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying deferred tax assets change in valuation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Assets Change In Valuation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets change in valuation percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAgreementMember" xlink:label="tlsi_DynavaxPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DynavaxPurchaseAgreementMember" xlink:to="tlsi_DynavaxPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DynavaxPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dyvanax purchase agreement to purchase of in-process research and development ("IPR&amp;D").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DynavaxPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DynavaxPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax purchase agreement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstCommercialSaleOfProductMember" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UponFirstCommercialSaleOfProductMember" xlink:to="tlsi_UponFirstCommercialSaleOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to event of first commercial sale of product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon First Commercial Sale of Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon first commercial sale of product</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to event of first occurrence of annual net sales of $250000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon First Occurrence of Annual Net Sales of $250000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon first occurrence of annual net sales of $250000</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to event of first occurrence of annual net sales of $500000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon First Occurrence of Annual Net Sales of $500000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon first occurrence of annual net sales of $500000</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to event of first occurrence of annual net sales of $1000000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon First Occurrence of Annual Net Sales of $1000000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon first occurrence of annual net sales of $1000000</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xlink:to="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to aggregate annual net sales less than or equal to $1,000,000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Annual Net Sales Less Than or Equal to $1,000,000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate annual net sales less than or equal to $1,000,000</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xlink:to="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to aggregate annual net sales greater than $1,000,000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Annual Net Sales Greater Than $1,000,000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate annual net sales greater than $1,000,000</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dynavax purchase agreement</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UpfrontPaymentAmount" xlink:label="tlsi_UpfrontPaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_UpfrontPaymentAmount" xlink:to="tlsi_UpfrontPaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_UpfrontPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_UpfrontPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_UpfrontPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentOfUpfrontAmount" xlink:label="tlsi_PaymentOfUpfrontAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaymentOfUpfrontAmount" xlink:to="tlsi_PaymentOfUpfrontAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaymentOfUpfrontAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of upfront amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaymentOfUpfrontAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Upfront Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PaymentOfUpfrontAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of upfront amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MinimumMilestonePaymentAmount" xlink:label="tlsi_MinimumMilestonePaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MinimumMilestonePaymentAmount" xlink:to="tlsi_MinimumMilestonePaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MinimumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum milestone payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MinimumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Milestone Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MinimumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum milestone payment amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumMilestonePaymentAmount" xlink:label="tlsi_MaximumMilestonePaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumMilestonePaymentAmount" xlink:to="tlsi_MaximumMilestonePaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Milestone Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone payment amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumDevelopmentMilestonePayments" xlink:label="tlsi_MaximumDevelopmentMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumDevelopmentMilestonePayments" xlink:to="tlsi_MaximumDevelopmentMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum development milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Development Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum development milestone payments</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentsMade" xlink:label="tlsi_MilestonePaymentsMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MilestonePaymentsMade" xlink:to="tlsi_MilestonePaymentsMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments made</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCommercialMilestoneToBeMade" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfCommercialMilestoneToBeMade" xlink:to="tlsi_NumberOfCommercialMilestoneToBeMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of commercial milestone to be made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Commercial Milestone to be Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of commercial milestone to be made</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestonePaymentAmount" xlink:label="tlsi_CommercialMilestonePaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommercialMilestonePaymentAmount" xlink:to="tlsi_CommercialMilestonePaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommercialMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial milestone payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommercialMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestone Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommercialMilestonePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial milestone payment amount</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualNetSales" xlink:label="tlsi_AnnualNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AnnualNetSales" xlink:to="tlsi_AnnualNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AnnualNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AnnualNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AnnualNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual net sales</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumCommercialMilestonePayments" xlink:label="tlsi_MaximumCommercialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumCommercialMilestonePayments" xlink:to="tlsi_MaximumCommercialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Commercial Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumCommercialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum commercial milestone payments</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualRoyaltyRate" xlink:label="tlsi_AnnualRoyaltyRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AnnualRoyaltyRate" xlink:to="tlsi_AnnualRoyaltyRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AnnualRoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual royalty rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AnnualRoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Royalty Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AnnualRoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual royalty rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First and second development milestone payments in R&amp;D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaycheckProtectionProgramMember" xlink:label="tlsi_PaycheckProtectionProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PaycheckProtectionProgramMember" xlink:to="tlsi_PaycheckProtectionProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PaycheckProtectionProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Paycheck Protection Program .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PaycheckProtectionProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paycheck Protection Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PaycheckProtectionProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income and expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Decrease, Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan forgiveness</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TermLoanAndSupplementalTermLoanMember" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TermLoanAndSupplementalTermLoanMember" xlink:to="tlsi_TermLoanAndSupplementalTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to term loan and supplemental term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan and Supplemental Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan and supplemental term loan</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn08262015Member" xlink:label="tlsi_WarrantsIssuedOn08262015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsIssuedOn08262015Member" xlink:to="tlsi_WarrantsIssuedOn08262015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsIssuedOn08262015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued on 08262015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsIssuedOn08262015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued on 08262015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsIssuedOn08262015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued on 08262015</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn10272016Member" xlink:label="tlsi_WarrantsIssuedOn10272016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsIssuedOn10272016Member" xlink:to="tlsi_WarrantsIssuedOn10272016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsIssuedOn10272016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued on 10272016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsIssuedOn10272016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued on 10272016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsIssuedOn10272016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued on 10272016</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn06302017Member" xlink:label="tlsi_WarrantsIssuedOn06302017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsIssuedOn06302017Member" xlink:to="tlsi_WarrantsIssuedOn06302017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsIssuedOn06302017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued on 06302017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsIssuedOn06302017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued on 06302017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsIssuedOn06302017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued on 06302017</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn11202018Member" xlink:label="tlsi_WarrantsIssuedOn11202018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsIssuedOn11202018Member" xlink:to="tlsi_WarrantsIssuedOn11202018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsIssuedOn11202018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued on 11202018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsIssuedOn11202018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued on 11202018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsIssuedOn11202018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued on 11202018</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5PreferredStockMember" xlink:label="tlsi_SeriesA5PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA5PreferredStockMember" xlink:to="tlsi_SeriesA5PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA5PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A5 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA5PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA5PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-5 Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6PreferredStockMember" xlink:label="tlsi_SeriesA6PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SeriesA6PreferredStockMember" xlink:to="tlsi_SeriesA6PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SeriesA6PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A6 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SeriesA6PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SeriesA6PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-6 Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quantity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PutOptionMember" xlink:to="us-gaap_PutOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PutOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PutOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Put option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative Financial Instruments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded derivative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xlink:to="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of price per share paid by cash purchasers for the preferred stock issued in the qualified financing under the debt conversion arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion, Threshold Percentage Of Price Per Share Paid By Cash Purchasers Of Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of price per share paid by the cash purchasers</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_QualifiedFinancingMinimumProceeds" xlink:label="tlsi_QualifiedFinancingMinimumProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_QualifiedFinancingMinimumProceeds" xlink:to="tlsi_QualifiedFinancingMinimumProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_QualifiedFinancingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum proceeds from the issuance of capital to be considered as qualified financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_QualifiedFinancingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Qualified Financing, Minimum Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_QualifiedFinancingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum proceeds to be considered as qualified financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xlink:to="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of probability of occurrence of qualified financing under the debt conversion covenant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability Of Occurrence Of Qualified Financing, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of probability of occurrence of qualified financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xlink:to="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of probability of convertible notes converting at maturity under the debt conversion covenant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability Of Convertible Notes Converting At Maturity, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of probability of convertible notes converting at maturity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionDiscountPercentage" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DebtInstrumentConversionDiscountPercentage" xlink:to="tlsi_DebtInstrumentConversionDiscountPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of discount on convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Conversion Discount Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion discount percentage</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialWarrantLiability" xlink:label="tlsi_InitialWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_InitialWarrantLiability" xlink:to="tlsi_InitialWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_InitialWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of initial value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_InitialWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_InitialWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantIssued" xlink:label="tlsi_WarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantIssued" xlink:to="tlsi_WarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of warrant issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EliminationOfOccurrenceOfDiscountPercentage" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EliminationOfOccurrenceOfDiscountPercentage" xlink:to="tlsi_EliminationOfOccurrenceOfDiscountPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage on elimination of occurrence of discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elimination Of Occurrence Of Discount Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of discount modification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="us-gaap_DerivativeNotionalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNotionalAmount" xlink:to="us-gaap_DerivativeNotionalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeNotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Notional Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeNotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquitySharesAvailableForIssuance" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquitySharesAvailableForIssuance" xlink:to="tlsi_TemporaryEquitySharesAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares available for issuance for convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Available for Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, available for issuance</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquityOriginalIssuePrice" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the original issue price for convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Original Issue Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, original issue prices</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold per share price of common stock for automatic conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Automatic Conversion of Preferred Stock, Threshold Share Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold per share price of common stock for automatic conversion of preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold net cash proceeds for automatic conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Automatic Conversion of Preferred Stock, Threshold Cash Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold net cash proceeds for automatic conversion of preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold proceeds received from the "special purpose acquisition corporation" trust account for automatic conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Automatic Conversion of Preferred Stock, Threshold Proceeds From Special Purpose Acquisition Corporation Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold proceeds received from the "special purpose acquisition corporation" trust account for automatic conversion of preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" xlink:label="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" xlink:to="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of board of director above which majority preferred shareholders voting approval will be required.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Board Of Director Above Which Majority Preferred Shareholders Voting Approval Will Be Required</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of board of director above which majority preferred shareholders voting approval will be required</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityDividendPerShare" xlink:label="tlsi_TemporaryEquityDividendPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquityDividendPerShare" xlink:to="tlsi_TemporaryEquityDividendPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquityDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the dividend per share of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquityDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Dividend per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TemporaryEquityDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per annum preferred dividend rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Liquidation Preference</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_March2021FinancingMember" xlink:label="tlsi_March2021FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_March2021FinancingMember" xlink:to="tlsi_March2021FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_March2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to March 2021 Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_March2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2021 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_March2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2021 Financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes value converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion of notes</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Spring2021FinancingMember" xlink:label="tlsi_Spring2021FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_Spring2021FinancingMember" xlink:to="tlsi_Spring2021FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_Spring2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Spring 2021 Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_Spring2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spring 2021 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_Spring2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spring 2021 Financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Fall2021FinancingMember" xlink:label="tlsi_Fall2021FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_Fall2021FinancingMember" xlink:to="tlsi_Fall2021FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_Fall2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Fall 2021 Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_Fall2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fall 2021 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_Fall2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fall 2021 Financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2022Member" xlink:label="tlsi_Financing2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_Financing2022Member" xlink:to="tlsi_Financing2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_Financing2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2022 Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_Financing2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_Financing2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second Tranche, Closings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second tranche, closings</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingThirdTrancheMember" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_B2PreferredStockFinancingThirdTrancheMember" xlink:to="tlsi_B2PreferredStockFinancingThirdTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to B-2 Preferred Stock Financing, Third tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Third tranche</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xlink:to="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using fair value of underlying stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Fair Value Of Underlying Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of underlying stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:label="us-gaap_MeasurementInputInceptionDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:to="us-gaap_MeasurementInputInceptionDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputInceptionDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Inception Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputInceptionDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationScenarioMember" xlink:label="tlsi_BusinessCombinationScenarioMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BusinessCombinationScenarioMember" xlink:to="tlsi_BusinessCombinationScenarioMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BusinessCombinationScenarioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to business combination scenario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BusinessCombinationScenarioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Scenario [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BusinessCombinationScenarioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination scenario</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSell" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumNumberOfSharesAgreedToSell" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSell_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares agreed to be sold by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number Of Shares Agreed To Sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares agreed to sell</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateProceedsReceivableFromStockOffering" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AggregateProceedsReceivableFromStockOffering" xlink:to="tlsi_AggregateProceedsReceivableFromStockOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate proceeds receivable by the company through stock offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Proceeds Receivable From Stock Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate proceeds receivable</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xlink:to="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum proceeds receivable by the company through the sale of additional shares under the stock offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Proceeds Receivable Through The Sale Of Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum proceeds receivable through the sale of additional shares</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares agreed to be sold by the company, through sale of additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number Of Shares Agreed To Sell Through Sale Of Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares agreed to sell through sale of additional shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion prices of the Company's preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilityMeasurementInput" xlink:label="tlsi_TrancheLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_TrancheLiabilityMeasurementInput" xlink:to="tlsi_TrancheLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_TrancheLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure tranche liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_TrancheLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_TrancheLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B 2 Tranche Liability, measurement input</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EnterpriseValueAllocated" xlink:label="tlsi_EnterpriseValueAllocated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EnterpriseValueAllocated" xlink:to="tlsi_EnterpriseValueAllocated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EnterpriseValueAllocated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of enterprise value allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EnterpriseValueAllocated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Enterprise Value Allocated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EnterpriseValueAllocated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Enterprise value allocated</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValueAssignedToTrancheRightsAndObligations" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ValueAssignedToTrancheRightsAndObligations" xlink:to="tlsi_ValueAssignedToTrancheRightsAndObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to value assigned to the tranche rights and obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Assigned To The Tranche Rights And Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value assigned to the tranche rights and obligations</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closing one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second Tranche, Closing One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second tranche, closing one</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closing two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second Tranche, Closing Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B-2 Preferred Stock Financing, Second tranche, closing two</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2023Member" xlink:label="tlsi_Financing2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_Financing2023Member" xlink:to="tlsi_Financing2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_Financing2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2023 Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_Financing2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_Financing2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Financing</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfStockOfferingClosingsEffectuated" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfStockOfferingClosingsEffectuated" xlink:to="tlsi_NumberOfStockOfferingClosingsEffectuated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of closings of stock offerings effectuated during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Stock Offering Closings Effectuated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of closings effectuated</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesCommittedSold" xlink:label="tlsi_PercentageOfSharesCommittedSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PercentageOfSharesCommittedSold" xlink:to="tlsi_PercentageOfSharesCommittedSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PercentageOfSharesCommittedSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares committed by the company sold during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PercentageOfSharesCommittedSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Shares Committed Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PercentageOfSharesCommittedSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares committed sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:label="tlsi_CapitalShareReservedForFutureIssuanceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:to="tlsi_CapitalShareReservedForFutureIssuanceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CapitalShareReservedForFutureIssuanceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The table relating to information on capital stock reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CapitalShareReservedForFutureIssuanceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Share Reserved for Future Issuance [Axis]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:label="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:to="tlsi_CapitalSharesReservedForFutureIssuanceDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CapitalSharesReservedForFutureIssuanceDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The table relating to information on capital stock reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CapitalSharesReservedForFutureIssuanceDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Shares Reserved for Future Issuance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xlink:to="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants to purchase Series A5 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant to Purchase Series A Five Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase Series A5 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xlink:to="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants to purchase Series A6 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant to Purchase Series A Six Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase Series A6 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xlink:to="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants to purchase Series B Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase Series B preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xlink:to="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants to purchase Series B-3 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Series B-3 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase Series B3 preferred stock</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsOutstandingMember" xlink:label="tlsi_StockOptionsOutstandingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockOptionsOutstandingMember" xlink:to="tlsi_StockOptionsOutstandingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockOptionsOutstandingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to stock options outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockOptionsOutstandingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Outstanding [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockOptionsOutstandingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsAvailableForFutureGrantMember" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_StockOptionsAvailableForFutureGrantMember" xlink:to="tlsi_StockOptionsAvailableForFutureGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to stock options available for future grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Available for Future Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options available for future grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of Board of Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding at the ending (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.001Member" xlink:label="tlsi_ExercisePriceOf0.001Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.001Member" xlink:to="tlsi_ExercisePriceOf0.001Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.001Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.001.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.001Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.001 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.001Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.01</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.003Member" xlink:label="tlsi_ExercisePriceOf0.003Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.003Member" xlink:to="tlsi_ExercisePriceOf0.003Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.003Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.003.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.003Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.003 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.003Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.03</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.004Member" xlink:label="tlsi_ExercisePriceOf0.004Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.004Member" xlink:to="tlsi_ExercisePriceOf0.004Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.004.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.004 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.004Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.04</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.005Member" xlink:label="tlsi_ExercisePriceOf0.005Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.005Member" xlink:to="tlsi_ExercisePriceOf0.005Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.005.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.005 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.05</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.006Member" xlink:label="tlsi_ExercisePriceOf0.006Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.006Member" xlink:to="tlsi_ExercisePriceOf0.006Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.006Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.006.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.006Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.006 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.006Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.06</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.007Member" xlink:label="tlsi_ExercisePriceOf0.007Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.007Member" xlink:to="tlsi_ExercisePriceOf0.007Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.007.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">0.07</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.09To0.46Member" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ExercisePriceOf0.09To0.46Member" xlink:to="tlsi_ExercisePriceOf0.09To0.46Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to exercise price of $0.09 to $0.46.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of $0.09 to $0.46 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$0.09-$0.46</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise prices of options outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lower range of Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upper range of Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xlink:to="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangements, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EquityIncentivePlan2019AsAmendedMember" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EquityIncentivePlan2019AsAmendedMember" xlink:to="tlsi_EquityIncentivePlan2019AsAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2019 Equity Incentive Plan as Amended (the Plan).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2019 As Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expiration term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period of recognition</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantsMember" xlink:label="tlsi_PreferredStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PreferredStockWarrantsMember" xlink:to="tlsi_PreferredStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for preferred stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantsMember" xlink:label="tlsi_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CommonStockWarrantsMember" xlink:to="tlsi_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendIncreaseInNetLossPerShare" xlink:label="tlsi_DeemedDividendIncreaseInNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_DeemedDividendIncreaseInNetLossPerShare" xlink:to="tlsi_DeemedDividendIncreaseInNetLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_DeemedDividendIncreaseInNetLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of per share increase in net loss from deemed dividend.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_DeemedDividendIncreaseInNetLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Dividend, Increase In Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_DeemedDividendIncreaseInNetLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in net loss per share from deemed dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Operating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseAbstract" xlink:label="tlsi_FinanceLeaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FinanceLeaseAbstract" xlink:to="tlsi_FinanceLeaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FinanceLeaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FinanceLeaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FinanceLeaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseCostAbstract" xlink:label="tlsi_FinanceLeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FinanceLeaseCostAbstract" xlink:to="tlsi_FinanceLeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FinanceLeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseCost" xlink:label="tlsi_FinanceLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FinanceLeaseCost" xlink:to="tlsi_FinanceLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lease cost on finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total finance lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierEquipmentMember" xlink:label="tlsi_CopierEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CopierEquipmentMember" xlink:to="tlsi_CopierEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CopierEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for copier equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CopierEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Copier Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CopierEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Copier</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierInWestminsterFacilityMember" xlink:label="tlsi_CopierInWestminsterFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CopierInWestminsterFacilityMember" xlink:to="tlsi_CopierInWestminsterFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CopierInWestminsterFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for copier in westminster facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CopierInWestminsterFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Copier In Westminster Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CopierInWestminsterFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Copier in westminster facility</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xlink:to="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for analytical equipment in laboratory facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Analytical Equipment In Laboratory Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Analytical equipment in laboratory facility</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrincipalAdministrativeAndProductionFacilityMember" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_PrincipalAdministrativeAndProductionFacilityMember" xlink:to="tlsi_PrincipalAdministrativeAndProductionFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for principal administrative and production facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Administrative And Production Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal administrative and production facility</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xlink:to="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for lease for office space at Half Day Road.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease For Office Space At Half Day Road [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease for office space at 2275 Half Day Road</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfOperatingLeases" xlink:label="tlsi_NumberOfOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfOperatingLeases" xlink:to="tlsi_NumberOfOperatingLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to extend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfFinanceLeases" xlink:label="tlsi_NumberOfFinanceLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfFinanceLeases" xlink:to="tlsi_NumberOfFinanceLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Finance Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfFinanceLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of finance leases</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseLiabilitiesCurrent" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FinanceLeaseLiabilitiesCurrent" xlink:to="tlsi_FinanceLeaseLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average life of operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average life of finance lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate of operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate of finance lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FirstInstallmentMember" xlink:label="tlsi_FirstInstallmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_FirstInstallmentMember" xlink:to="tlsi_FirstInstallmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_FirstInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for first installment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_FirstInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_FirstInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First installment</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SecondInstallmentMember" xlink:label="tlsi_SecondInstallmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_SecondInstallmentMember" xlink:to="tlsi_SecondInstallmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_SecondInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for second installment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_SecondInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_SecondInstallmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second installment</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionUptoThreePercentMember" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EmployeeContributionUptoThreePercentMember" xlink:to="tlsi_EmployeeContributionUptoThreePercentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for employees contribution upto three percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Contribution Upto Three Percent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee's contribution of up to 3%</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xlink:to="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for employees contribution between three and four percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Contribution Between Three And Four Percent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee's contribution between 3% and 4%</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xlink:to="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for employees contribution between four and five percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Contribution Between Four And Five Percent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee's contribution between 4% and 5%</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of matching contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of matching contribution</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsSuitFiled" xlink:label="tlsi_NumberOfPatentsSuitFiled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfPatentsSuitFiled" xlink:to="tlsi_NumberOfPatentsSuitFiled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfPatentsSuitFiled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents for which suit was filed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfPatentsSuitFiled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Patents, Suit Filed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfPatentsSuitFiled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents for which suit filed</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsTestimonyLimited" xlink:label="tlsi_NumberOfPatentsTestimonyLimited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_NumberOfPatentsTestimonyLimited" xlink:to="tlsi_NumberOfPatentsTestimonyLimited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_NumberOfPatentsTestimonyLimited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents for which testimony is limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_NumberOfPatentsTestimonyLimited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Patents, Testimony Limited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_NumberOfPatentsTestimonyLimited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents for which testimony is limited</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CurePeriod" xlink:label="tlsi_CurePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_CurePeriod" xlink:to="tlsi_CurePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_CurePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_CurePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_CurePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Damages sought value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Paid, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Damages settled value</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xlink:to="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of installments in which agreed damages is paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Damages Paid Value, Number Of Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorporationMember" xlink:label="tlsi_MedtechAcquisitionCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_MedtechAcquisitionCorporationMember" xlink:to="tlsi_MedtechAcquisitionCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_MedtechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to MedTech Acquisition Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_MedtechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_MedtechAcquisitionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MedTech Acquisition Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement with MedTech Acquisition Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate consideration payable</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationWarrantsConsideration" xlink:label="tlsi_BusinessCombinationWarrantsConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BusinessCombinationWarrantsConsideration" xlink:to="tlsi_BusinessCombinationWarrantsConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BusinessCombinationWarrantsConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of  consideration for the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BusinessCombinationWarrantsConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Warrants Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BusinessCombinationWarrantsConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants consideration</label>
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationAcquisitionExpensesDeferred" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsi_BusinessCombinationAcquisitionExpensesDeferred" xlink:to="tlsi_BusinessCombinationAcquisitionExpensesDeferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of business acquisition cost deferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Acquisition Expenses, Deferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred expenses</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>tlsi-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/15/2023 2:04:02 AM-->
<!--Modified on: 12/15/2023 2:04:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperations" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePublicOffering" roleURI="http://trisaluslifesci.com/role/DisclosurePublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePrivatePlacement" roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactions" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantLiabilities" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTax" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurements" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxTables" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePublicOfferingDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePrivatePlacementDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactionsFounderSharesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficitPreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersDeficitCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxDeferredTaxAssetsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxIncomeTaxProvisionDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlowss" roleURI="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNatureOfBusiness" roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciess" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureBusinessCombination" roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstruments" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCash" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventory" roleURI="http://trisaluslifesci.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilities" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiability" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrants" roleURI="http://trisaluslifesci.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxes" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStock" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShare" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensation" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchase" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciess" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashTables" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventoryTables" roleURI="http://trisaluslifesci.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesTables" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiabilityTables" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantsTables" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockTables" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareTables" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensationTables" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccountingPoliciesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureBusinessCombinationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventoryDetails" roleURI="http://trisaluslifesci.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiabilityNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" roleURI="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureWarrantsNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosurePreferredStockFairValueMeasurementsDetails" roleURI="http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureShareBasedCompensationDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchaseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfStockholdersDeficit" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNatureOfBusinesss" roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesss" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentss" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashs" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventorys" roleURI="http://trisaluslifesci.com/role/DisclosureInventorys" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssets" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiess" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxess" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxess" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchases" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebt" roleURI="http://trisaluslifesci.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertibleNotes" roleURI="http://trisaluslifesci.com/role/DisclosureConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStock" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquity" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShares" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShares" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeases" roleURI="http://trisaluslifesci.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciesss" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureMergerAgreementWithMedtechAcquisitionCorporation" roleURI="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsTabless" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashTabless" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventoryTabless" roleURI="http://trisaluslifesci.com/role/DisclosureInventoryTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsTables" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesTabless" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesTables" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebtTables" roleURI="http://trisaluslifesci.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockTables" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityTables" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareTabless" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesTables" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNatureOfBusinessDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCashCashEquivalentsAndRestrictedCashDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureInventoryDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureInventoryDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsIntangibleAssetsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureAccruedLiabilitiesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDynavaxPurchaseDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebtPppLoanDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureDebtTermLoanDetails" roleURI="http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertibleNotesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockNarrativeDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockConversionDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockVotingRightsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockDividendsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockMarch2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockSpring2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockFall2021FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStockWarrantExercisesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStock2022FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureConvertiblePreferredStock2023FinancingDetails" roleURI="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityStockOptionActivityDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityValuationAssumptionsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureCommitmentsAndContingenciesDetailss" roleURI="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tlsi-20230630.xsd#DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" roleURI="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="111100090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638382026338846427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638382026338846427" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638382026338846427" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638382026338846427" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638382026338846427" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638382026338846427" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638382026338846427" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638382026338846427" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription_638382026338846427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentDescription_638382026338846427" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638382026338856427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338856427" xlink:to="dei_LegalEntityAxis_638382026338856427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026338856427" xlink:to="dei_EntityDomain_638382026338856427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026338856427" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026338856427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338856427" xlink:to="us-gaap_StatementClassOfStockAxis_638382026338856427" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026338856427" xlink:to="us-gaap_ClassOfStockDomain_638382026338856427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338856427" xlink:to="us-gaap_CommonClassAMember_638382026338856427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_638382026338856427" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_638382026338856427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338856427" xlink:to="us-gaap_CommonClassBMember_638382026338856427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026338856427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338856427" xlink:to="us-gaap_StatementLineItems_638382026338856427" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338856427" xlink:to="us-gaap_AssetsAbstract_638382026338866509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026338866509" xlink:to="us-gaap_AssetsCurrentAbstract_638382026338866509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026338866509" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026338866509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026338866509" xlink:to="us-gaap_PrepaidExpenseCurrent_638382026338866509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026338866509" xlink:to="us-gaap_AssetsCurrent_638382026338866509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026338866509" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_638382026338866509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026338866509" xlink:to="us-gaap_Assets_638382026338866509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338856427" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" xlink:to="us-gaap_LiabilitiesAbstract_638382026338866509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026338866509" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638382026338876425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026338876425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_638382026338876425" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638382026338876425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638382026338876425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNotesPayableCurrent" xlink:label="tlsi_ExtensionNotesPayableCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="tlsi_ExtensionNotesPayableCurrent_638382026338876425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="us-gaap_NotesPayableCurrent_638382026338876425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableCurrent_638382026338876425" xlink:to="us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_638382026338876425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026338876425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026338866509" xlink:to="us-gaap_LiabilitiesCurrent_638382026338876425" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026338866509" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026338886426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026338866509" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026338886426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026338866509" xlink:to="tlsi_DeferredOfferingCostsNoncurrent_638382026338886426" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026338866509" xlink:to="us-gaap_Liabilities_638382026338886426" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026338886426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" xlink:to="us-gaap_StockholdersEquityAbstract_638382026338886426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638382026338886426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026338886426" xlink:to="us-gaap_PreferredStockValue_638382026338886426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638382026338896434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026338886426" xlink:to="us-gaap_CommonStockValue_638382026338896434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638382026338896434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026338886426" xlink:to="us-gaap_AdditionalPaidInCapital_638382026338896434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026338896434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026338886426" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026338896434" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026338896434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026338886426" xlink:to="us-gaap_StockholdersEquity_638382026338896434" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638382026338896434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026338866509" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638382026338896434" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="111200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638382026338906429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338906429" xlink:to="dei_LegalEntityAxis_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026338906429" xlink:to="dei_EntityDomain_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026338906429" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338906429" xlink:to="us-gaap_StatementClassOfStockAxis_638382026338906429" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026338906429" xlink:to="us-gaap_ClassOfStockDomain_638382026338906429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338906429" xlink:to="us-gaap_CommonClassAMember_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_638382026338906429" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338906429" xlink:to="us-gaap_CommonClassBMember_638382026338906429" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338906429" xlink:to="us-gaap_StatementLineItems_638382026338906429" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026338906429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026338906429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026338906429" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638382026338916430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_PreferredStockSharesAuthorized_638382026338916430" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_PreferredStockSharesIssued_638382026338916430" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_PreferredStockSharesOutstanding_638382026338916430" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026338916430" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_CommonStockSharesAuthorized_638382026338916430" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_CommonStockSharesIssued_638382026338916430" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026338916430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338906429" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026338916430" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638382026338966430" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338966430" xlink:to="dei_LegalEntityAxis_638382026338966430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026338966430" xlink:to="dei_EntityDomain_638382026338966430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026338966430" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026338966430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338966430" xlink:to="us-gaap_StatementClassOfStockAxis_638382026338966430" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026338966430" xlink:to="us-gaap_ClassOfStockDomain_638382026338966430" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338966430" xlink:to="us-gaap_CommonClassAMember_638382026338966430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026338966430" xlink:to="us-gaap_CommonClassBMember_638382026338966430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338966430" xlink:to="us-gaap_StatementLineItems_638382026338966430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638382026338966430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026338966430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_OperatingIncomeLoss_638382026338966430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638382026338976432" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638382026338976432" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638382026338976432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638382026338976432" xlink:to="us-gaap_InvestmentIncomeInterest_638382026338976432" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638382026338976432" xlink:to="us-gaap_NonoperatingIncomeExpense_638382026338976432" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026338976432" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026338976432" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_NetIncomeLoss_638382026338976432" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026338976432" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026338976432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026338976432" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_EarningsPerShareBasic_638382026338986884" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338966430" xlink:to="us-gaap_EarningsPerShareDiluted_638382026338986884" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" xlink:type="extended" xlink:title="111200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638382026338986884" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338986884" xlink:to="dei_LegalEntityAxis_638382026338986884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026338986884" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026338986884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026338986884" xlink:to="dei_EntityDomain_638382026338986884" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338986884" xlink:to="us-gaap_StatementClassOfStockAxis_638382026338986884" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026338986884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026338986884" xlink:to="us-gaap_CommonClassBMember_638382026338986884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026338986884" xlink:to="us-gaap_ClassOfStockDomain_638382026338996434" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338986884" xlink:to="us-gaap_StatementEquityComponentsAxis_638382026338996434" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026338996434" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638382026338996434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026338996434" xlink:to="us-gaap_RetainedEarningsMember_638382026338996434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026338996434" xlink:to="us-gaap_CommonStockMember_638382026338996434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026338996434" xlink:to="us-gaap_EquityComponentDomain_638382026338996434" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026338986884" xlink:to="us-gaap_StatementLineItems_638382026338996434" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026338996434" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderEquity" xlink:label="tlsi_StockholderEquity_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="tlsi_StockholderEquity_638382026338996434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="us-gaap_SharesIssued_638382026338996434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_638382026338996434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination_638382026338996434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339006430" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="us-gaap_NetIncomeLoss_638382026339006430" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderEquity" xlink:label="tlsi_StockholderEquity_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="tlsi_StockholderEquity_638382026339006430" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026338996434" xlink:to="us-gaap_SharesIssued_638382026339006430" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638382026339006430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339006430" xlink:to="dei_LegalEntityAxis_638382026339006430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339006430" xlink:to="dei_EntityDomain_638382026339006430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339006430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339006430" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339006430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339006430" xlink:to="us-gaap_StatementLineItems_638382026339016464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_ProfitLoss_638382026339016464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638382026339016464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_InvestmentIncomeInterest_638382026339016464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026339016464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638382026339016464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_638382026339016464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026339016464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339016464" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026339016464" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339016464" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026339026444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentForInvestmentOfCashInTrustAccount_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" xlink:to="tlsi_PaymentForInvestmentOfCashInTrustAccount_638382026339026444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026339026444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339026444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026339026444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_ProceedsFromNotesPayable_638382026339026444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638382026339026444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638382026339026444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote" xlink:label="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote_638382026339036430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromExtensionNote" xlink:label="tlsi_ProceedsFromExtensionNote_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="tlsi_ProceedsFromExtensionNote_638382026339036430" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_ProceedsFromContributedCapital_638382026339036430" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_638382026339036430" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026339026444" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026339036430" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026339036430" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339036430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339036430" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339046428" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339016464" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638382026339046428" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638382026339046428" xlink:to="us-gaap_IncomeTaxesPaidNet_638382026339046428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" xlink:type="extended" xlink:title="111210101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339046428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339046428" xlink:to="dei_LegalEntityAxis_638382026339046428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339046428" xlink:to="dei_EntityDomain_638382026339046428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339046428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339046428" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339046428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339046428" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638382026339056435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339056435" xlink:to="us-gaap_NatureOfOperations_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="111210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339056435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339056435" xlink:to="dei_LegalEntityAxis_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339056435" xlink:to="dei_EntityDomain_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339056435" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339056435" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339056435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339056435" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePublicOffering" xlink:type="extended" xlink:title="111210301 - Disclosure - PUBLIC OFFERING" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingAbstract" xlink:label="InitialPublicOfferingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339056435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InitialPublicOfferingAbstract" xlink:to="us-gaap_StatementTable_638382026339056435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339056435" xlink:to="dei_LegalEntityAxis_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339066430" xlink:to="dei_EntityDomain_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339066430" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339056435" xlink:to="us-gaap_StatementLineItems_638382026339066430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTextBlock" xlink:label="tlsi_InitialPublicOfferingTextBlock_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339066430" xlink:to="tlsi_InitialPublicOfferingTextBlock_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePrivatePlacement" xlink:type="extended" xlink:title="111210401 - Disclosure - PRIVATE PLACEMENT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementAbstract" xlink:label="PrivatePlacementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339066430" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339066430" xlink:to="dei_LegalEntityAxis_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339066430" xlink:to="dei_EntityDomain_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339066430" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339066430" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638382026339066430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementTextBlock" xlink:label="tlsi_PrivatePlacementTextBlock_638382026339066430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339066430" xlink:to="tlsi_PrivatePlacementTextBlock_638382026339066430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="111210501 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339076425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339076425" xlink:to="dei_LegalEntityAxis_638382026339076425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339076425" xlink:to="dei_EntityDomain_638382026339076425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339076425" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339076425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339076425" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638382026339076425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339076425" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638382026339076425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="111210601 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638382026339076425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339076425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339076425" xlink:to="dei_LegalEntityAxis_638382026339076425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339076425" xlink:to="dei_EntityDomain_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339086428" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339076425" xlink:to="us-gaap_OtherCommitmentsLineItems_638382026339086428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339086428" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficit" xlink:type="extended" xlink:title="111210701 - Disclosure - STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638382026339086428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339086428" xlink:to="dei_LegalEntityAxis_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339086428" xlink:to="dei_EntityDomain_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339086428" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339086428" xlink:to="us-gaap_ClassOfStockLineItems_638382026339086428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638382026339086428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339086428" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638382026339086428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantLiabilities" xlink:type="extended" xlink:title="111210801 - Disclosure - WARRANT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsAbstract" xlink:label="WarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339096422" xlink:to="dei_LegalEntityAxis_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339096422" xlink:to="dei_EntityDomain_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339096422" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339096422" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026339096422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock" xlink:label="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339096422" xlink:to="tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="111210901 - Disclosure - INCOME TAX" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_IncomeTaxTable_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339096422" xlink:to="dei_LegalEntityAxis_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339096422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339096422" xlink:to="dei_EntityDomain_638382026339096422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339096422" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339096422" xlink:to="tlsi_IncomeTaxLineItems_638382026339106427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339106427" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="111211001 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339106427" xlink:to="dei_LegalEntityAxis_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339106427" xlink:to="dei_EntityDomain_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339106427" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339106427" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339106427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638382026339106427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339106427" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638382026339106427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="111211101 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339116425" xlink:to="dei_LegalEntityAxis_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339116425" xlink:to="dei_EntityDomain_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339116425" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339116425" xlink:to="us-gaap_SubsequentEventLineItems_638382026339116425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638382026339116425" xlink:to="us-gaap_SubsequentEventsTextBlock_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="111220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339116425" xlink:to="dei_LegalEntityAxis_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339116425" xlink:to="dei_EntityDomain_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339116425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339116425" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339116425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339116425" xlink:to="us-gaap_StatementLineItems_638382026339126427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026339126427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638382026339126427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmergingGrowthCompanyPolicyTextBlock" xlink:label="tlsi_EmergingGrowthCompanyPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="tlsi_EmergingGrowthCompanyPolicyTextBlock_638382026339126427" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_UseOfEstimates_638382026339126427" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026339126427" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock_638382026339126427" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityPolicyPolicyTextBlock" xlink:label="tlsi_TemporaryEquityPolicyPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="tlsi_TemporaryEquityPolicyPolicyTextBlock_638382026339126427" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638382026339126427" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesPolicyTextBlock" xlink:label="tlsi_WarrantLiabilitiesPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="tlsi_WarrantLiabilitiesPolicyTextBlock_638382026339126427" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638382026339126427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638382026339126427" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638382026339136425" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638382026339136425" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638382026339136425" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_DerivativesPolicyTextBlock_638382026339136425" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339126427" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026339136425" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="111230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638382026339136425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339136425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339136425" xlink:to="dei_LegalEntityAxis_638382026339136425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339136425" xlink:to="dei_EntityDomain_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339146425" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339136425" xlink:to="us-gaap_StatementLineItems_638382026339146425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339146425" xlink:to="us-gaap_TemporaryEquityTableTextBlock_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339146425" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638382026339146425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxTables" xlink:type="extended" xlink:title="111230903 - Disclosure - INCOME TAX (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_IncomeTaxTable_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339146425" xlink:to="dei_LegalEntityAxis_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339146425" xlink:to="dei_EntityDomain_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339146425" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339146425" xlink:to="tlsi_IncomeTaxLineItems_638382026339146425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638382026339146425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339146425" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638382026339146425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339146425" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638382026339156434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339146425" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638382026339156434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="111231003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339156434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339156434" xlink:to="dei_LegalEntityAxis_638382026339156434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339156434" xlink:to="dei_EntityDomain_638382026339156434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339156434" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339156434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339156434" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339156434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339156434" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638382026339156434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339156434" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026339156434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026339156434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339156434" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026339156434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" xlink:type="extended" xlink:title="111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" xlink:to="dei_LegalEntityAxis_638382026339166428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339166428" xlink:to="dei_EntityDomain_638382026339166428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339166428" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339166428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026339166428" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026339166428" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339166428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339166428" xlink:to="us-gaap_IPOMember_638382026339166428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339166428" xlink:to="us-gaap_PrivatePlacementMember_638382026339166428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638382026339166428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339166428" xlink:to="us-gaap_OverAllotmentOptionMember_638382026339166428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339176430" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339176430" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339176430" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339176430" xlink:to="us-gaap_WarrantMember_638382026339176430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026339176430" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339176430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" xlink:to="us-gaap_SubsequentEventTypeAxis_638382026339176430" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638382026339176430" xlink:to="us-gaap_SubsequentEventTypeDomain_638382026339176430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638382026339176430" xlink:to="us-gaap_SubsequentEventMember_638382026339176430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339166428" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_638382026339176430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_638382026339176430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_638382026339176430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="us-gaap_SharesIssuedPricePerShare_638382026339186431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638382026339186431" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339186431" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339186431" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339186431" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="tlsi_PaymentsForInvestmentOfCashInTrustAccount_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_PaymentsForInvestmentOfCashInTrustAccount_638382026339186431" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransactionCosts" xlink:label="tlsi_TransactionCosts_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_TransactionCosts_638382026339186431" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockUnderwritingFees" xlink:label="tlsi_SaleOfStockUnderwritingFees_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TransactionCosts_638382026339186431" xlink:to="tlsi_SaleOfStockUnderwritingFees_638382026339186431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredOfferingCostsNoncurrent" xlink:label="tlsi_DeferredOfferingCostsNoncurrent_638382026339186431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TransactionCosts_638382026339186431" xlink:to="tlsi_DeferredOfferingCostsNoncurrent_638382026339186431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockOtherOfferingCosts" xlink:label="tlsi_SaleOfStockOtherOfferingCosts_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TransactionCosts_638382026339186431" xlink:to="tlsi_SaleOfStockOtherOfferingCosts_638382026339196442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage" xlink:label="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage_638382026339196442" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership_638382026339196442" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets" xlink:label="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets_638382026339196442" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriodUponClosure" xlink:label="tlsi_RedemptionPeriodUponClosure_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_RedemptionPeriodUponClosure_638382026339196442" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionLimitPercentageWithoutPriorConsent" xlink:label="tlsi_RedemptionLimitPercentageWithoutPriorConsent_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_RedemptionLimitPercentageWithoutPriorConsent_638382026339196442" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_638382026339196442" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumAllowedDissolutionExpenses" xlink:label="tlsi_MaximumAllowedDissolutionExpenses_638382026339196442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="tlsi_MaximumAllowedDissolutionExpenses_638382026339196442" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339176430" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638382026339206436" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails" xlink:type="extended" xlink:title="111240102 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" xlink:to="dei_LegalEntityAxis_638382026339206436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339206436" xlink:to="dei_EntityDomain_638382026339206436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339206436" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339206436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339206436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339206436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339206436" xlink:to="us-gaap_RelatedPartyDomain_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638382026339216434" xlink:to="us-gaap_RelatedPartyMember_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638382026339216434" xlink:to="tlsi_SponsorMember_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" xlink:to="us-gaap_RelatedPartyTransactionAxis_638382026339216434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638382026339216434" xlink:to="us-gaap_RelatedPartyTransactionDomain_638382026339216434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNoteWithRelatedPartyMember" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339216434" xlink:to="tlsi_PromissoryNoteWithRelatedPartyMember_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" xlink:to="us-gaap_ShortTermDebtTypeAxis_638382026339216434" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638382026339216434" xlink:to="us-gaap_ShortTermDebtTypeDomain_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyOnePromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyOnePromissoryNoteMember_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638382026339216434" xlink:to="tlsi_TwoThousandTwentyOnePromissoryNoteMember_638382026339216434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638382026339216434" xlink:to="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_638382026339216434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339206436" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_OperatingBankAccounts" xlink:label="tlsi_OperatingBankAccounts_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_OperatingBankAccounts_638382026339226435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026339226435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapital" xlink:label="tlsi_WorkingCapital_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_WorkingCapital_638382026339226435" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_638382026339226435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_NotesPayable_638382026339226435" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638382026339226435" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_SharePrice_638382026339226435" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_DebtInstrumentFaceAmount_638382026339226435" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638382026339226435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638382026339226435" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent" xlink:label="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026339236432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent_638382026339236432" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfTransactionalFeePaid" xlink:label="tlsi_PercentageOfTransactionalFeePaid_638382026339236432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_PercentageOfTransactionalFeePaid_638382026339236432" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638382026339236432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="us-gaap_DebtInstrumentFaceAmount_638382026339236432" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DueToSponsorForCertainReimbursableExpenses" xlink:label="tlsi_DueToSponsorForCertainReimbursableExpenses_638382026339236432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_DueToSponsorForCertainReimbursableExpenses_638382026339236432" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfAmountDepositedInTrustAccount" xlink:label="tlsi_PercentageOfAmountDepositedInTrustAccount_638382026339236432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339216434" xlink:to="tlsi_PercentageOfAmountDepositedInTrustAccount_638382026339236432" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="111240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesTable" xlink:label="tlsi_AccountingPoliciesTable_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="tlsi_AccountingPoliciesTable_638382026339246439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="dei_LegalEntityAxis_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339246439" xlink:to="dei_EntityDomain_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339246439" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339246439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339246439" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339246439" xlink:to="tlsi_PublicWarrantsMember_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339246439" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339246439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339246439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339246439" xlink:to="us-gaap_ClassOfStockDomain_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339246439" xlink:to="us-gaap_CommonClassAMember_638382026339246439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_638382026339246439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339246439" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_638382026339246439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026339256432" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026339256432" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339256432" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339256432" xlink:to="us-gaap_IPOMember_638382026339256432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="us-gaap_RelatedPartyTransactionAxis_638382026339256432" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638382026339256432" xlink:to="us-gaap_RelatedPartyTransactionDomain_638382026339256432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IssuanceOfPromissoryNote2022ToSponsorMember" xlink:label="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339256432" xlink:to="tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_638382026339256432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesLineItems" xlink:label="tlsi_AccountingPoliciesLineItems_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339246439" xlink:to="tlsi_AccountingPoliciesLineItems_638382026339256432" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_Cash_638382026339256432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638382026339256432" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339256432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339256432" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_638382026339266436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_AssetsHeldInTrust_638382026339266436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount" xlink:label="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount_638382026339266436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount_638382026339266436" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare" xlink:label="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare_638382026339266436" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount" xlink:label="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount_638382026339266436" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_SharesOutstanding_638382026339266436" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AmountDepositedIntoTrustAccount" xlink:label="tlsi_AmountDepositedIntoTrustAccount_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_AmountDepositedIntoTrustAccount_638382026339266436" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountDrawnDown" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_638382026339266436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountDrawnDown_638382026339266436" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree" xlink:label="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree_638382026339276434" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026339276434" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638382026339276434" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026339276434" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026339276434" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_UnrecognizedTaxBenefits_638382026339276434" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638382026339276434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638382026339276434" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026339286431" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638382026339286431" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339256432" xlink:to="us-gaap_DeferredOfferingCosts_638382026339286431" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails" xlink:type="extended" xlink:title="111240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesTable" xlink:label="tlsi_AccountingPoliciesTable_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="tlsi_AccountingPoliciesTable_638382026339286431" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339286431" xlink:to="dei_LegalEntityAxis_638382026339286431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339286431" xlink:to="dei_EntityDomain_638382026339286431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339286431" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339296431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339286431" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339296431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339296431" xlink:to="us-gaap_ClassOfStockDomain_638382026339296431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339296431" xlink:to="us-gaap_CommonClassAMember_638382026339296431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_638382026339296431" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_638382026339296431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccountingPoliciesLineItems" xlink:label="tlsi_AccountingPoliciesLineItems_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesTable_638382026339286431" xlink:to="tlsi_AccountingPoliciesLineItems_638382026339296431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026339296431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339296431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638382026339296431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionDeposit" xlink:label="tlsi_ExtensionDeposit_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="tlsi_ExtensionDeposit_638382026339296431" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6383820263392964311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6383820263392964311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_638382026339296431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_AccountingPoliciesLineItems_638382026339296431" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_638382026339296431" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails" xlink:type="extended" xlink:title="111240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339306440" xlink:to="dei_LegalEntityAxis_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339306440" xlink:to="dei_EntityDomain_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339306440" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339306440" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339306440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339306440" xlink:to="us-gaap_ClassOfStockDomain_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339306440" xlink:to="us-gaap_CommonClassAMember_638382026339306440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339306440" xlink:to="us-gaap_CommonClassBMember_638382026339306440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339306440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026339306440" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339306440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026339306440" xlink:to="us-gaap_EarningsPerShareAbstract_638382026339316456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumeratorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638382026339316456" xlink:to="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_638382026339316456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NumeratorForCalculationOfEarningsPerShareAbstract_638382026339316456" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026339316456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DenominatorForCalculationOfEarningsPerShareAbstract" xlink:label="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638382026339316456" xlink:to="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026339316456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026339316456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" xlink:to="us-gaap_EarningsPerShareBasic_638382026339316456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638382026339316456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DenominatorForCalculationOfEarningsPerShareAbstract_638382026339316456" xlink:to="us-gaap_EarningsPerShareDiluted_638382026339316456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails" xlink:type="extended" xlink:title="111240301 - Disclosure - PUBLIC OFFERING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingAbstract" xlink:label="InitialPublicOfferingAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingTable" xlink:label="tlsi_InitialPublicOfferingTable_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InitialPublicOfferingAbstract" xlink:to="tlsi_InitialPublicOfferingTable_638382026339326441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingTable_638382026339326441" xlink:to="dei_LegalEntityAxis_638382026339326441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339326441" xlink:to="dei_EntityDomain_638382026339326441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339326441" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339326441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingTable_638382026339326441" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026339326441" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026339326441" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339326441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339326441" xlink:to="us-gaap_IPOMember_638382026339326441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339326441" xlink:to="us-gaap_OverAllotmentOptionMember_638382026339326441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingTable_638382026339326441" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339326441" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339326441" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339326441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339326441" xlink:to="tlsi_PublicWarrantsMember_638382026339326441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339326441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingTable_638382026339326441" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339326441" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339326441" xlink:to="us-gaap_ClassOfStockDomain_638382026339336441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339336441" xlink:to="us-gaap_CommonClassAMember_638382026339336441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialPublicOfferingLineItems" xlink:label="tlsi_InitialPublicOfferingLineItems_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingTable_638382026339326441" xlink:to="tlsi_InitialPublicOfferingLineItems_638382026339336441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="tlsi_UnitsIssuedDuringPeriodSharesNewIssues_638382026339336441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="us-gaap_SharesIssuedPricePerShare_638382026339336441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesIssuedPerUnit" xlink:label="tlsi_NumberOfSharesIssuedPerUnit_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="tlsi_NumberOfSharesIssuedPerUnit_638382026339336441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfWarrantsIssuedPerUnit" xlink:label="tlsi_NumberOfWarrantsIssuedPerUnit_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="tlsi_NumberOfWarrantsIssuedPerUnit_638382026339336441" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026339336441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026339336441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_InitialPublicOfferingLineItems_638382026339336441" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026339336441" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails" xlink:type="extended" xlink:title="111240401 - Disclosure - PRIVATE PLACEMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementAbstract" xlink:label="PrivatePlacementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" xlink:to="dei_LegalEntityAxis_638382026339346435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339346435" xlink:to="dei_EntityDomain_638382026339346435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339346435" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339346435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026339346435" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026339346435" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339346435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339346435" xlink:to="us-gaap_PrivatePlacementMember_638382026339346435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339346435" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339346435" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339346435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339346435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339346435" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339346435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638382026339346435" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339356435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339356435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339356435" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026339356435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638382026339356435" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026339356435" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xlink:type="extended" xlink:title="111240501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339356435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="dei_LegalEntityAxis_638382026339356435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339356435" xlink:to="dei_EntityDomain_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339366433" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="us-gaap_RelatedPartyTransactionAxis_638382026339366433" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638382026339366433" xlink:to="us-gaap_RelatedPartyTransactionDomain_638382026339366433" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FounderSharesMember" xlink:label="tlsi_FounderSharesMember_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339366433" xlink:to="tlsi_FounderSharesMember_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339366433" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339366433" xlink:to="us-gaap_RelatedPartyDomain_638382026339366433" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638382026339366433" xlink:to="us-gaap_RelatedPartyMember_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638382026339366433" xlink:to="tlsi_SponsorMember_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339366433" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339366433" xlink:to="us-gaap_ClassOfStockDomain_638382026339366433" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026339366433" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339366433" xlink:to="us-gaap_CommonClassBMember_638382026339366433" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026339376437" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026339376437" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339376437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026339376437" xlink:to="us-gaap_OverAllotmentOptionMember_638382026339376437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339356435" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026339376437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026339376437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="us-gaap_CommonStockDividendsShares_638382026339376437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateNumberOfSharesOwned" xlink:label="tlsi_AggregateNumberOfSharesOwned_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_AggregateNumberOfSharesOwned_638382026339376437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesSubjectToForfeiture_638382026339376437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_NumberOfSharesSubjectToForfeiture_638382026339376437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfSharesNoLongerSubjectToForfeiture" xlink:label="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_NumberOfSharesNoLongerSubjectToForfeiture_638382026339386434" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_638382026339386434" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_638382026339386434" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_638382026339386434" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_638382026339386434" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_638382026339386434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339376437" xlink:to="tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_638382026339386434" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="111240502 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="dei_LegalEntityAxis_638382026339396434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339396434" xlink:to="dei_EntityDomain_638382026339396434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339396434" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339396434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_RelatedPartyTransactionAxis_638382026339396434" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638382026339396434" xlink:to="us-gaap_RelatedPartyTransactionDomain_638382026339396434" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNoteWithRelatedPartyMember" xlink:label="tlsi_PromissoryNoteWithRelatedPartyMember_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339396434" xlink:to="tlsi_PromissoryNoteWithRelatedPartyMember_638382026339396434" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyLoansMember" xlink:label="tlsi_RelatedPartyLoansMember_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339396434" xlink:to="tlsi_RelatedPartyLoansMember_638382026339396434" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdministrativeSupportAgreementMember" xlink:label="tlsi_AdministrativeSupportAgreementMember_638382026339396434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638382026339396434" xlink:to="tlsi_AdministrativeSupportAgreementMember_638382026339396434" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339436436" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339436436" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339436436" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WorkingCapitalLoansWarrantMember" xlink:label="tlsi_WorkingCapitalLoansWarrantMember_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339436436" xlink:to="tlsi_WorkingCapitalLoansWarrantMember_638382026339436436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339436436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339436436" xlink:to="us-gaap_RelatedPartyDomain_638382026339436436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638382026339436436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638382026339436436" xlink:to="us-gaap_RelatedPartyMember_638382026339436436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SponsorMember" xlink:label="tlsi_SponsorMember_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638382026339436436" xlink:to="tlsi_SponsorMember_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_ShortTermDebtTypeAxis_638382026339446436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638382026339446436" xlink:to="us-gaap_ShortTermDebtTypeDomain_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638382026339446436" xlink:to="tlsi_TwoThousandTwentyTwoPromissoryNoteMember_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="srt_RangeAxis_638382026339446436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026339446436" xlink:to="srt_RangeMember_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026339446436" xlink:to="srt_MaximumMember_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_BalanceSheetLocationAxis_638382026339446436" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638382026339446436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638382026339446436" xlink:to="us-gaap_BalanceSheetLocationDomain_638382026339446436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedExpensesMember" xlink:label="tlsi_AccruedExpensesMember_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638382026339446436" xlink:to="tlsi_AccruedExpensesMember_638382026339456437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638382026339396434" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_638382026339456437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_638382026339456437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638382026339456437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumLoansConvertibleIntoWarrants" xlink:label="tlsi_MaximumLoansConvertibleIntoWarrants_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="tlsi_MaximumLoansConvertibleIntoWarrants_638382026339456437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights_638382026339456437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638382026339456437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638382026339456437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="us-gaap_NotesPayable_638382026339466442" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638382026339456437" xlink:to="us-gaap_DebtInstrumentFaceAmount_638382026339466442" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="111240601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638382026339466442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="dei_LegalEntityAxis_638382026339466442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339466442" xlink:to="dei_EntityDomain_638382026339466442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339466442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339466442" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339466442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="us-gaap_BusinessAcquisitionAxis_638382026339476438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638382026339476438" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638382026339476438" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638382026339476438" xlink:to="tlsi_TrisalusMember_638382026339476438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="srt_RangeAxis_638382026339476438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026339476438" xlink:to="srt_RangeMember_638382026339476438" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026339476438" xlink:to="srt_MaximumMember_638382026339476438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026339476438" xlink:to="srt_MinimumMember_638382026339476438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339476438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339476438" xlink:to="us-gaap_ClassOfStockDomain_638382026339476438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MtacClassCommonStockMember" xlink:label="tlsi_MtacClassCommonStockMember_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339476438" xlink:to="tlsi_MtacClassCommonStockMember_638382026339476438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339476438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339476438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638382026339476438" xlink:to="us-gaap_RelatedPartyDomain_638382026339486438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RaymondJamesAgreementsMember" xlink:label="tlsi_RaymondJamesAgreementsMember_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638382026339486438" xlink:to="tlsi_RaymondJamesAgreementsMember_638382026339486438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638382026339466442" xlink:to="us-gaap_OtherCommitmentsLineItems_638382026339486438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities_638382026339486438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination" xlink:label="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination_638382026339486438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_LegalFeeContingentUponConsummationOfBusinessCombination_638382026339486438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination" xlink:label="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination_638382026339486438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries" xlink:label="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries_638382026339486438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638382026339486438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638382026339486438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638382026339496435" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026339496435" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_BusinessAcquisitionSharePrice_638382026339496435" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationsOfWarrantToPurchase" xlink:label="tlsi_BusinessCombinationsOfWarrantToPurchase_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_BusinessCombinationsOfWarrantToPurchase_638382026339496435" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfHoldings" xlink:label="tlsi_NumberOfHoldings_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_NumberOfHoldings_638382026339496435" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfTrading" xlink:label="tlsi_NumberOfTrading_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_NumberOfTrading_638382026339496435" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays" xlink:label="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays_638382026339496435" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638382026339496435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_PreferredStockSharesAuthorized_638382026339496435" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339506446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339506446" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638382026339506446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_SharesIssuedPricePerShare_638382026339506446" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339506446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638382026339506446" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638382026339506446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638382026339506446" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived_638382026339506446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638382026339486438" xlink:to="us-gaap_ProceedsFromFeesReceived_638382026339506446" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails" xlink:type="extended" xlink:title="111240701 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638382026339516439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339516439" xlink:to="dei_LegalEntityAxis_638382026339516439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339516439" xlink:to="dei_EntityDomain_638382026339516439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339516439" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339516439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339516439" xlink:to="us-gaap_ClassOfStockLineItems_638382026339516439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339516439" xlink:to="us-gaap_PreferredStockSharesAuthorized_638382026339516439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339516439" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339516439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339516439" xlink:to="us-gaap_PreferredStockSharesIssued_638382026339516439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638382026339516439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339516439" xlink:to="us-gaap_PreferredStockSharesOutstanding_638382026339516439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails" xlink:type="extended" xlink:title="111240702 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638382026339526437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339526437" xlink:to="dei_LegalEntityAxis_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339526437" xlink:to="dei_EntityDomain_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339526437" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339526437" xlink:to="us-gaap_StatementClassOfStockAxis_638382026339526437" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026339526437" xlink:to="us-gaap_ClassOfStockDomain_638382026339526437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339526437" xlink:to="us-gaap_CommonClassAMember_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonClassaSubjectToRedemptionMember" xlink:label="tlsi_CommonClassaSubjectToRedemptionMember_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_638382026339526437" xlink:to="tlsi_CommonClassaSubjectToRedemptionMember_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026339526437" xlink:to="us-gaap_CommonClassBMember_638382026339526437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026339526437" xlink:to="us-gaap_ClassOfStockLineItems_638382026339526437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638382026339526437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_CommonStockSharesAuthorized_638382026339526437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026339536437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockNumberOfVotesPerShare" xlink:label="tlsi_CommonStockNumberOfVotesPerShare_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="tlsi_CommonStockNumberOfVotesPerShare_638382026339536437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_CommonStockSharesIssued_638382026339536437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026339536437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026339536437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638382026339536437" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleStockConversionRatio" xlink:label="tlsi_ConvertibleStockConversionRatio_638382026339536437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026339526437" xlink:to="tlsi_ConvertibleStockConversionRatio_638382026339536437" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="111240801 - Disclosure - WARRANT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsAbstract" xlink:label="WarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" xlink:to="dei_LegalEntityAxis_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339546439" xlink:to="dei_EntityDomain_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339546439" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339546439" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339546439" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339546439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339546439" xlink:to="us-gaap_WarrantMember_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026339546439" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026339546439" xlink:to="tlsi_PublicWarrantsMember_638382026339546439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" xlink:to="srt_StatementScenarioAxis_638382026339546439" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638382026339546439" xlink:to="srt_ScenarioUnspecifiedDomain_638382026339546439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_638382026339546439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026339546439" xlink:to="tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_638382026339546439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026339546439" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638382026339556435" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionOne" xlink:label="tlsi_WarrantExercisePeriodConditionOne_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_WarrantExercisePeriodConditionOne_638382026339556435" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePeriodConditionTwo" xlink:label="tlsi_WarrantExercisePeriodConditionTwo_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_WarrantExercisePeriodConditionTwo_638382026339556435" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638382026339556435" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_638382026339556435" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_638382026339556435" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_638382026339556435" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RedemptionPeriod" xlink:label="tlsi_RedemptionPeriod_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_RedemptionPeriod_638382026339556435" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionConditionMinimumSharePrice" xlink:label="tlsi_WarrantRedemptionConditionMinimumSharePrice_638382026339556435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_WarrantRedemptionConditionMinimumSharePrice_638382026339556435" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_638382026339566435" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_638382026339566435" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_638382026339566435" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants_638382026339566435" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_638382026339566435" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_638382026339566435" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantExercisePriceAdjustmentMultiple" xlink:label="tlsi_WarrantExercisePriceAdjustmentMultiple_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_WarrantExercisePriceAdjustmentMultiple_638382026339566435" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="tlsi_WarrantRedemptionPriceAdjustmentMultiple_638382026339566435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_WarrantRedemptionPriceAdjustmentMultiple_638382026339566435" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026339576438" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_638382026339576438" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026339556435" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026339576438" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_IncomeTaxTable_638382026339576438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339576438" xlink:to="dei_LegalEntityAxis_638382026339576438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339576438" xlink:to="dei_EntityDomain_638382026339576438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339576438" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339576438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems_638382026339576438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339576438" xlink:to="tlsi_IncomeTaxLineItems_638382026339576438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339576438" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" xlink:to="tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_638382026339586439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" xlink:to="us-gaap_DeferredTaxAssetsGross_638382026339586439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638382026339586439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638382026339586439" xlink:to="us-gaap_DeferredTaxAssetsNet_638382026339586439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="111240902 - Disclosure - INCOME TAX - Income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_IncomeTaxTable_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339586439" xlink:to="dei_LegalEntityAxis_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339586439" xlink:to="dei_EntityDomain_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339586439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339586439" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339586439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339586439" xlink:to="tlsi_IncomeTaxLineItems_638382026339596437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339596437" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638382026339596437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026339596437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339596437" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026339596437" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026339596437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInValuationAllowance" xlink:label="tlsi_IncreaseDecreaseInValuationAllowance_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339596437" xlink:to="tlsi_IncreaseDecreaseInValuationAllowance_638382026339596437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339596437" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026339596437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638382026339596437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339596437" xlink:to="us-gaap_OperatingLossCarryforwards_638382026339596437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails" xlink:type="extended" xlink:title="111240903 - Disclosure - INCOME TAX - Reconciliation of the federal income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxTable" xlink:label="tlsi_IncomeTaxTable_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_IncomeTaxTable_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339606441" xlink:to="dei_LegalEntityAxis_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339606441" xlink:to="dei_EntityDomain_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339606441" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeTaxLineItems" xlink:label="tlsi_IncomeTaxLineItems_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxTable_638382026339606441" xlink:to="tlsi_IncomeTaxLineItems_638382026339606441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_IncomeTaxLineItems_638382026339606441" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026339606441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026339606441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities" xlink:label="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" xlink:to="tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities_638382026339606441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026339606441" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026339606441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638382026339606441" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026339606441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="111241001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" xlink:to="dei_LegalEntityAxis_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339616447" xlink:to="dei_EntityDomain_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339616447" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638382026339616447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638382026339616447" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638382026339616447" xlink:to="us-gaap_MoneyMarketFundsMember_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" xlink:to="us-gaap_FinancialInstrumentAxis_638382026339616447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638382026339616447" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638382026339616447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638382026339616447" xlink:to="us-gaap_USTreasurySecuritiesMember_638382026339616447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339616447" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" xlink:to="us-gaap_Cash_638382026339626444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_638382026339626444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes" xlink:label="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" xlink:to="tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes_638382026339626444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339626444" xlink:to="tlsi_ProceedsFromTrustAccountInConnectionWithRedemption_638382026339626444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="111241002 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" xlink:to="dei_LegalEntityAxis_638382026339626444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339626444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339626444" xlink:to="dei_EntityDomain_638382026339626444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339626444" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339636439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339636439" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339636439" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339636439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339636439" xlink:to="us-gaap_FairValueInputsLevel1Member_638382026339636439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339636439" xlink:to="us-gaap_FairValueInputsLevel3Member_638382026339636439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638382026339636439" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638382026339636439" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638382026339636439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638382026339636439" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638382026339636439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339636439" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339636439" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339636439" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339636439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339636439" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339636439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339636439" xlink:to="tlsi_PublicWarrantsMember_638382026339646441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339626444" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339646441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339646441" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638382026339646441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638382026339646441" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_638382026339646441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339646441" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638382026339646441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638382026339646441" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_638382026339646441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails" xlink:type="extended" xlink:title="111241003 - Disclosure - FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339646441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" xlink:to="dei_LegalEntityAxis_638382026339646441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339646441" xlink:to="dei_EntityDomain_638382026339656438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339656438" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339656438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026339656438" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026339656438" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026339656438" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638382026339656438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputSharePriceMember_638382026339656438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638382026339656438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638382026339656438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026339656438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026339656438" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638382026339656438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339656438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339656438" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339656438" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339666437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339666437" xlink:to="us-gaap_FairValueInputsLevel3Member_638382026339666437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026339646441" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339666437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026339666437" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638382026339666437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="111241004 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" xlink:to="dei_LegalEntityAxis_638382026339666437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339666437" xlink:to="dei_EntityDomain_638382026339666437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339666437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339666437" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339666437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339676444" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026339676444" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339676444" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026339676444" xlink:to="us-gaap_FairValueInputsLevel3Member_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026339676444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026339676444" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026339676444" xlink:to="us-gaap_WarrantMember_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivatePlacementWarrantsMember" xlink:label="tlsi_PrivatePlacementWarrantsMember_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026339676444" xlink:to="tlsi_PrivatePlacementWarrantsMember_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026339676444" xlink:to="tlsi_PublicWarrantsMember_638382026339676444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026339666437" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339676444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026339676444" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026339676444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026339676444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638382026339686437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638382026339686437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_638382026339686437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_638382026339686437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026339676444" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026339686437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="111241101 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638382026339686437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026339686437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="dei_LegalEntityAxis_638382026339686437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026339686437" xlink:to="dei_EntityDomain_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorpMember" xlink:label="tlsi_MedtechAcquisitionCorpMember_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026339696437" xlink:to="tlsi_MedtechAcquisitionCorpMember_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="us-gaap_SubsequentEventTypeAxis_638382026339696437" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638382026339696437" xlink:to="us-gaap_SubsequentEventTypeDomain_638382026339696437" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638382026339696437" xlink:to="us-gaap_SubsequentEventMember_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="us-gaap_ShortTermDebtTypeAxis_638382026339696437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638382026339696437" xlink:to="us-gaap_ShortTermDebtTypeDomain_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638382026339696437" xlink:to="us-gaap_ConvertibleNotesPayableMember_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PromissoryNote2022ThreeMember" xlink:label="tlsi_PromissoryNote2022ThreeMember_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638382026339696437" xlink:to="tlsi_PromissoryNote2022ThreeMember_638382026339696437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="us-gaap_LongtermDebtTypeAxis_638382026339696437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638382026339696437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638382026339696437" xlink:to="us-gaap_LongtermDebtTypeDomain_638382026339696437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExtensionNoteMember" xlink:label="tlsi_ExtensionNoteMember_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638382026339696437" xlink:to="tlsi_ExtensionNoteMember_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="srt_CounterpartyNameAxis_638382026339706443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638382026339706443" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638382026339706443" xlink:to="tlsi_TrisalusMember_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="us-gaap_TypeOfArrangementAxis_638382026339706443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638382026339706443" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MergerAgreementMember" xlink:label="tlsi_MergerAgreementMember_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026339706443" xlink:to="tlsi_MergerAgreementMember_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638382026339686437" xlink:to="us-gaap_SubsequentEventLineItems_638382026339706443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638382026339706443" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638382026339706443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638382026339706443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638382026339706443" xlink:to="us-gaap_LongTermDebt_638382026339706443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638382026339706443" xlink:to="us-gaap_AssetsHeldInTrust_638382026339716445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss" xlink:type="extended" xlink:title="1200100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638382026339716445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339716445" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026339716445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026339716445" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026339716445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339716445" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026339716445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339716445" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026339716445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339716445" xlink:to="tlsi_ContingentEarnoutLiabilityMember_638382026339716445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026339716445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339716445" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026339716445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339716445" xlink:to="us-gaap_StatementLineItems_638382026339726440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339726440" xlink:to="us-gaap_AssetsAbstract_638382026339726440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_AssetsCurrentAbstract_638382026339726440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026339726440" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026339726440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026339726440" xlink:to="us-gaap_AccountsReceivableNetCurrent_638382026339726440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026339726440" xlink:to="us-gaap_InventoryNet_638382026339726440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026339726440" xlink:to="us-gaap_PrepaidExpenseCurrent_638382026339726440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026339726440" xlink:to="us-gaap_AssetsCurrent_638382026339726440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638382026339726440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638382026339726440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638382026339726440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638382026339736437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_OtherAssetsNoncurrent_638382026339736437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026339726440" xlink:to="us-gaap_Assets_638382026339736437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339726440" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" xlink:to="us-gaap_LiabilitiesAbstract_638382026339736437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026339736437" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="us-gaap_AccountsPayableTradeCurrent_638382026339736437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026339736437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_638382026339736437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_638382026339736437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="tlsi_LeaseLiabilityCurrent_638382026339746438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026339746438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026339736437" xlink:to="us-gaap_LiabilitiesCurrent_638382026339746438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026339736437" xlink:to="tlsi_LeaseLiabilityNoncurrent_638382026339746438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026339736437" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026339746438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638382026339736437" xlink:to="us-gaap_Liabilities_638382026339746438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026339746438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026339746438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" xlink:to="us-gaap_EquityAbstract_638382026339756437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_638382026339756437" xlink:to="us-gaap_PreferredStockValue_638382026339756437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_638382026339756437" xlink:to="us-gaap_CommonStockValue_638382026339756437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_638382026339756437" xlink:to="us-gaap_AdditionalPaidInCapital_638382026339756437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_638382026339756437" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026339756437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_638382026339756437" xlink:to="us-gaap_StockholdersEquity_638382026339756437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638382026339756437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026339736437" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638382026339756437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="1200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638382026339766437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockLiquidationPreference_638382026339766437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638382026339766437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638382026339766437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638382026339766437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026339766437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026339766437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638382026339776443" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638382026339776443" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026339776443" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss" xlink:type="extended" xlink:title="1200200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638382026339776443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339776443" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026339776443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026339776443" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026339776443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339776443" xlink:to="tlsi_TrancheAndWarrantLiabilityMember_638382026339776443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339776443" xlink:to="tlsi_ContingentEarnoutLiabilityMember_638382026339776443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339776443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339776443" xlink:to="us-gaap_StatementLineItems_638382026339776443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026339786445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638382026339786445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_GrossProfit_638382026339786445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_OperatingExpensesAbstract_638382026339786445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026339786445" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638382026339786445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026339786445" xlink:to="us-gaap_SellingAndMarketingExpense_638382026339786445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026339786445" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638382026339786445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_OperatingIncomeLoss_638382026339786445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_InvestmentIncomeInterest_638382026339786445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_InterestExpense_638382026339786445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026339786445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="tlsi_GainLossOnEquityIssuance_638382026339786445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026339796439" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638382026339796439" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026339796439" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026339796439" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_NetIncomeLoss_638382026339796439" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026339796439" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026339796439" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026339796439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026339796439" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638382026339806441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_EarningsPerShareBasic_638382026339806441" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638382026339806441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_EarningsPerShareDiluted_638382026339806441" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026339806441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026339806441" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026339806441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339776443" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026339806441" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="1200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339806441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638382026339806441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339806441" xlink:to="us-gaap_StatementEquityComponentsAxis_638382026339816445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026339816445" xlink:to="us-gaap_PreferredStockMember_638382026339816445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026339816445" xlink:to="us-gaap_CommonStockMember_638382026339816445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026339816445" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638382026339816445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026339816445" xlink:to="us-gaap_RetainedEarningsMember_638382026339816445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026339816445" xlink:to="us-gaap_EquityComponentDomain_638382026339816445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339806441" xlink:to="us-gaap_StatementLineItems_638382026339816445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339816445" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_PreferredStockSharesOutstanding_638382026339816445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockholdersEquity_638382026339816445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026339816445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026339816445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026339816445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638382026339826439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638382026339826439" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1_638382026339826439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638382026339826439" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638382026339826439" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization_638382026339826439" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="tlsi_StockIssuedDuringPeriodValueReverseRecapitalization_638382026339826439" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:label="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization_638382026339826439" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_638382026339826439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability_638382026339826439" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026339836438" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026339836438" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_NetIncomeLoss_638382026339836438" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_PreferredStockSharesOutstanding_638382026339836438" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_StockholdersEquity_638382026339836438" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026339836438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638382026339816445" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026339836438" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss" xlink:type="extended" xlink:title="1200400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339846442" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026339846442" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339846442" xlink:to="tlsi_TrancheAndWarrantLiabilityMember_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026339846442" xlink:to="tlsi_ContingentEarnoutLiabilityMember_638382026339846442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026339846442" xlink:to="us-gaap_StatementLineItems_638382026339846442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_NetIncomeLoss_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_DepreciationAndAmortization_638382026339846442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026339846442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026339846442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="tlsi_GainLossOnEquityIssuance_638382026339856442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_ShareBasedCompensation_638382026339856442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026339856442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnMilestonePaymentForAssetAcquistion" xlink:label="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="tlsi_GainLossOnMilestonePaymentForAssetAcquistion_638382026339856442" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026339856442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" xlink:to="us-gaap_IncreaseDecreaseInInventories_638382026339856442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026339856442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026339856442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026339856442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026339856442" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026339866439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026339846442" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026339866439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026339866439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetsAcquisitionMilestone" xlink:label="tlsi_PaymentsForAssetsAcquisitionMilestone_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="tlsi_PaymentsForAssetsAcquisitionMilestone_638382026339866439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638382026339866439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026339866439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026339876442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock" xlink:label="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock_638382026339876442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026339876442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="tlsi_ProceedsFromReverseRecapitalization_638382026339876442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026339876442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638382026339876442" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638382026339876442" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026339876442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638382026339866439" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026339876442" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026339886447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026339886447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339886447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026339886447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383820263398864471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383820263398864471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638382026339886447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026339846442" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638382026339886447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_638382026339886447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638382026339886447" xlink:to="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_638382026339886447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="1210101 - Disclosure - Nature of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638382026339896440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638382026339896440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess" xlink:type="extended" xlink:title="1210201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638382026339896440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638382026339896440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureBusinessCombination" xlink:type="extended" xlink:title="1210301 - Disclosure - Business Combination" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationAbstract" xlink:label="ReverseRecapitalizationAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationDisclosureTextBlock" xlink:label="tlsi_ReverseRecapitalizationDisclosureTextBlock_638382026339906439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationAbstract" xlink:to="tlsi_ReverseRecapitalizationDisclosureTextBlock_638382026339906439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="1210401 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638382026339906439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638382026339906439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash" xlink:type="extended" xlink:title="1210501 - Disclosure - Cash, cash equivalents and restricted cash" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_638382026339916446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_638382026339916446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventory" xlink:type="extended" xlink:title="1210601 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638382026339916446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638382026339916446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilities" xlink:type="extended" xlink:title="1210701 - Disclosure - Accrued Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638382026339926441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638382026339926441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability" xlink:type="extended" xlink:title="1210801 - Disclosure - Contingent Earnout Liability" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638382026339926441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638382026339926441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="1210901 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsLiabilitiesTextBlock" xlink:label="tlsi_WarrantsLiabilitiesTextBlock_638382026339936445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="tlsi_WarrantsLiabilitiesTextBlock_638382026339936445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="1211001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638382026339936445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638382026339936445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStock" xlink:type="extended" xlink:title="1211101 - Disclosure - Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_638382026339946443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock_638382026339946443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="1211201 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638382026339946443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638382026339946443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="1211301 - Disclosure - Share-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638382026339956442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638382026339956442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchase" xlink:type="extended" xlink:title="1211401 - Disclosure - Dynavax Purchase" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock_638382026339956442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock_638382026339956442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess" xlink:type="extended" xlink:title="1211501 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026339966443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026339966443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" xlink:type="extended" xlink:title="1220202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026339966443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026339966443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026339966443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026339966443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638382026339966443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638382026339966443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638382026339976445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638382026339976445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638382026339976445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638382026339976445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_638382026339976445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638382026339976445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638382026339976445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638382026340046443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638382026340046443" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638382026340046443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638382026340046443" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638382026340046443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638382026340046443" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638382026340056439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638382026340056439" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026340056439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026340056439" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="1230403 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026340056439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026340056439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables" xlink:type="extended" xlink:title="1230503 - Disclosure - Cash, cash equivalents and restricted cash (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638382026340066449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638382026340066449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638382026340066449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638382026340066449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="1230603 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638382026340066449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638382026340066449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="extended" xlink:title="1230703 - Disclosure - Accrued Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638382026340076452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638382026340076452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables" xlink:type="extended" xlink:title="1230803 - Disclosure - Contingent Earnout Liability (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026340076452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026340076452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="1230903 - Disclosure - Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026340086444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026340086444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockTables" xlink:type="extended" xlink:title="1231103 - Disclosure - Preferred Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_638382026340086444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock_638382026340086444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026340086444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026340086444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026340096451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638382026340096451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="1231203 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638382026340096451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638382026340096451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="1231303 - Disclosure - Share-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="1240101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessTable" xlink:label="tlsi_NatureOfBusinessTable_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tlsi_NatureOfBusinessTable_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessTable_638382026340106455" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340106455" xlink:to="us-gaap_ClassOfStockDomain_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340106455" xlink:to="us-gaap_PreferredStockMember_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340106455" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340106455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessTable_638382026340106455" xlink:to="us-gaap_StatementEquityComponentsAxis_638382026340106455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026340106455" xlink:to="us-gaap_EquityComponentDomain_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleNotesAndWarrantsMember" xlink:label="tlsi_ConvertibleNotesAndWarrantsMember_638382026340106455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638382026340106455" xlink:to="tlsi_ConvertibleNotesAndWarrantsMember_638382026340106455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessTable_638382026340106455" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026340116449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026340116449" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340116449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMember" xlink:label="tlsi_StandbyEquityPurchaseAgreementMember_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340116449" xlink:to="tlsi_StandbyEquityPurchaseAgreementMember_638382026340116449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessTable_638382026340106455" xlink:to="us-gaap_SubsequentEventTypeAxis_638382026340116449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638382026340116449" xlink:to="us-gaap_SubsequentEventTypeDomain_638382026340116449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638382026340116449" xlink:to="us-gaap_SubsequentEventMember_638382026340116449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NatureOfBusinessLineItems" xlink:label="tlsi_NatureOfBusinessLineItems_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessTable_638382026340106455" xlink:to="tlsi_NatureOfBusinessLineItems_638382026340116449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfProductLinesInDevelopment" xlink:label="tlsi_NumberOfProductLinesInDevelopment_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_NumberOfProductLinesInDevelopment_638382026340116449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638382026340116449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_ProceedsFromReverseRecapitalization_638382026340116449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026340116449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026340116449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026340126447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026340126447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638382026340126447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340126447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockAuthorizedAmountValue" xlink:label="tlsi_SaleOfStockAuthorizedAmountValue_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_SaleOfStockAuthorizedAmountValue_638382026340126447" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026340126447" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementTerm" xlink:label="tlsi_StandbyEquityPurchaseAgreementTerm_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_StandbyEquityPurchaseAgreementTerm_638382026340126447" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePricePercentageOfAverageDailyVolume" xlink:label="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_CommonStockSharePricePercentageOfAverageDailyVolume_638382026340126447" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays" xlink:label="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_638382026340126447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays_638382026340126447" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized" xlink:label="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized_638382026340136459" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate_638382026340136459" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo" xlink:label="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo_638382026340136459" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays" xlink:label="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays_638382026340136459" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementOwnershipLimitation" xlink:label="tlsi_PurchaseAgreementOwnershipLimitation_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_PurchaseAgreementOwnershipLimitation_638382026340136459" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PurchaseAgreementExchangeCap" xlink:label="tlsi_PurchaseAgreementExchangeCap_638382026340136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_NatureOfBusinessLineItems_638382026340116449" xlink:to="tlsi_PurchaseAgreementExchangeCap_638382026340136459" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails" xlink:type="extended" xlink:title="1240201 - Disclosure - Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" xlink:to="srt_RangeAxis_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340146444" xlink:to="srt_RangeMember_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340146444" xlink:to="srt_MinimumMember_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340146444" xlink:to="srt_MaximumMember_638382026340146444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026340146444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638382026340146444" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638382026340146444" xlink:to="us-gaap_FairValueInputsLevel1Member_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340146444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340146444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340146444" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340146444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340146444" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340156444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638382026340146444" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_638382026340156444" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638382026340156444" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="tlsi_PreferredStockConversionPercentageOfOutstandingShares_638382026340156444" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340156444" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_638382026340156444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="us-gaap_NumberOfOperatingSegments_638382026340156444" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638382026340156444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638382026340156444" xlink:to="us-gaap_NumberOfReportableSegments_638382026340156444" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails" xlink:type="extended" xlink:title="1240301 - Disclosure - Business Combinations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationAbstract" xlink:label="ReverseRecapitalizationAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfReverseRecapitalizationTable" xlink:label="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationAbstract" xlink:to="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340166453" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MTACWarrantsMember" xlink:label="tlsi_MTACWarrantsMember_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340166453" xlink:to="tlsi_MTACWarrantsMember_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340166453" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340166453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="srt_CounterpartyNameAxis_638382026340166453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638382026340166453" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedTechAcquisitionCorporationMember" xlink:label="tlsi_MedTechAcquisitionCorporationMember_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638382026340166453" xlink:to="tlsi_MedTechAcquisitionCorporationMember_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodAxis" xlink:label="tlsi_DerivativeInstrumentPeriodAxis_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodAxis_638382026340166453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodDomain" xlink:label="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DerivativeInstrumentPeriodAxis_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodOneMember" xlink:label="tlsi_DerivativeInstrumentPeriodOneMember_638382026340166453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodOneMember_638382026340166453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodTwoMember" xlink:label="tlsi_DerivativeInstrumentPeriodTwoMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodTwoMember_638382026340176449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodThreeMember" xlink:label="tlsi_DerivativeInstrumentPeriodThreeMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodThreeMember_638382026340176449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentPeriodFourMember" xlink:label="tlsi_DerivativeInstrumentPeriodFourMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_DerivativeInstrumentPeriodDomain_638382026340166453" xlink:to="tlsi_DerivativeInstrumentPeriodFourMember_638382026340176449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="srt_RangeAxis_638382026340176449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340176449" xlink:to="srt_RangeMember_638382026340176449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340176449" xlink:to="srt_MinimumMember_638382026340176449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340176449" xlink:to="srt_MaximumMember_638382026340176449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026340176449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026340176449" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026340176449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340176449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340176449" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340176449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationLineItems" xlink:label="tlsi_ReverseRecapitalizationLineItems_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ScheduleOfReverseRecapitalizationTable_638382026340166453" xlink:to="tlsi_ReverseRecapitalizationLineItems_638382026340186445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_RecapitalizationExchangeRatio" xlink:label="tlsi_RecapitalizationExchangeRatio_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_RecapitalizationExchangeRatio_638382026340186445" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockConvertedReverseRecapitalization" xlink:label="tlsi_StockConvertedReverseRecapitalization_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_StockConvertedReverseRecapitalization_638382026340186445" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalizationTransaction" xlink:label="tlsi_ProceedsFromReverseRecapitalizationTransaction_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_ProceedsFromReverseRecapitalizationTransaction_638382026340186445" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_ProceedsFromContributedCapital_638382026340186445" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638382026340186445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsOfReverseRecapitalizationTransactionCosts" xlink:label="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_PaymentsOfReverseRecapitalizationTransactionCosts_638382026340186445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromReverseRecapitalization" xlink:label="tlsi_ProceedsFromReverseRecapitalization_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_ProceedsFromReverseRecapitalization_638382026340186445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsIncurred" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsIncurred_638382026340186445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsIncurred_638382026340186445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationTransactionCostsPaid" xlink:label="tlsi_ReverseRecapitalizationTransactionCostsPaid_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_ReverseRecapitalizationTransactionCostsPaid_638382026340196452" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340196452" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_DerivativeLossOnDerivative_638382026340196452" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_DerivativeGainOnDerivative_638382026340196452" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026340196452" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340196452" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340196452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340196452" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638382026340206446" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_SaleOfStockPricePerShare_638382026340206446" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638382026340206446" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340206446" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod_638382026340206446" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage_638382026340206446" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_638382026340206446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger_638382026340206446" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_638382026340216448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays_638382026340216448" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_638382026340216448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ReverseRecapitalizationLineItems_638382026340186445" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays_638382026340216448" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails" xlink:type="extended" xlink:title="1240401 - Disclosure - Financial Instruments - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340216448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340216448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340216448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340216448" xlink:to="us-gaap_ClassOfStockDomain_638382026340216448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340216448" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340226452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340226452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340226452" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340226452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340226452" xlink:to="tlsi_PublicWarrantsMember_638382026340226452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340226452" xlink:to="tlsi_PrivateWarrantsMember_638382026340226452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MTACWarrantsMember" xlink:label="tlsi_MTACWarrantsMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340226452" xlink:to="tlsi_MTACWarrantsMember_638382026340226452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026340226452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026340226452" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026340226452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340226452" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340226452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340226452" xlink:to="tlsi_ContingentEarnoutLiabilityMember_638382026340226452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026340226452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340226452" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026340226452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340226452" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340236446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAndWarrantLiabilityMember" xlink:label="tlsi_TrancheAndWarrantLiabilityMember_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340226452" xlink:to="tlsi_TrancheAndWarrantLiabilityMember_638382026340236446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340216448" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340236446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340236446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340236446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_SharePrice_638382026340236446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_DerivativeLiabilities_638382026340236446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_638382026340236446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_638382026340236446" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026340246449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026340246449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026340246449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnWarrantExpirations" xlink:label="tlsi_GainLossOnWarrantExpirations_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340236446" xlink:to="tlsi_GainLossOnWarrantExpirations_638382026340246449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xlink:type="extended" xlink:title="1240402 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026340246449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638382026340246449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026340246449" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638382026340246449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638382026340246449" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember" xlink:label="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" xlink:to="tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_638382026340256450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" xlink:to="tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_638382026340256450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" xlink:to="tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_638382026340256450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026340256450" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340256450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026340246449" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026340256450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_638382026340256450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_638382026340256450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638382026340256450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638382026340256450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6383820263402564501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6383820263402564501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638382026340266449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_638382026340266449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340256450" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638382026340266449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="1240501 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340266449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent_638382026340266449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340266449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340266449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="1240601 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638382026340276461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026340276461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet_638382026340276461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryValuationReserves_638382026340276461" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="1240701 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638382026340276461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638382026340276461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent_638382026340276461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedVacationCurrent_638382026340286446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent_638382026340286446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026340286446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails" xlink:type="extended" xlink:title="1240801 - Disclosure - Contingent Earnout Liability - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_638382026340286446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_638382026340286446" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026340286446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026340286446" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026340286446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ContingentEarnoutLiabilityMember" xlink:label="tlsi_ContingentEarnoutLiabilityMember_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026340286446" xlink:to="tlsi_ContingentEarnoutLiabilityMember_638382026340286446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_638382026340286446" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026340286446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026340286446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026340286446" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026340286446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340286446" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340296448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_638382026340286446" xlink:to="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares" xlink:label="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" xlink:to="tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares_638382026340296448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340296448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638382026340296448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossLineItems_638382026340296448" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638382026340296448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails" xlink:type="extended" xlink:title="1240802 - Disclosure - Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340296448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026340296448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340296448" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026340296448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026340296448" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026340306455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340306455" xlink:to="us-gaap_MeasurementInputSharePriceMember_638382026340306455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340306455" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638382026340306455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340306455" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026340306455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340306455" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638382026340306455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340306455" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340306455" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026340296448" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340306455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638382026340306455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026340306455" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638382026340306455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="1240901 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340316447" xlink:to="tlsi_PublicWarrantsMember_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340316447" xlink:to="tlsi_PrivateWarrantsMember_638382026340316447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340316447" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340316447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026340316447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails" xlink:type="extended" xlink:title="1240902 - Disclosure - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340326450" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PublicWarrantsMember" xlink:label="tlsi_PublicWarrantsMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340326450" xlink:to="tlsi_PublicWarrantsMember_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrivateWarrantsMember" xlink:label="tlsi_PrivateWarrantsMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340326450" xlink:to="tlsi_PrivateWarrantsMember_638382026340326450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340326450" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340326450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_SubsequentEventTypeAxis_638382026340326450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638382026340326450" xlink:to="us-gaap_SubsequentEventTypeDomain_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638382026340326450" xlink:to="us-gaap_SubsequentEventMember_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="srt_RangeAxis_638382026340326450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340326450" xlink:to="srt_RangeMember_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340326450" xlink:to="srt_MinimumMember_638382026340326450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340326450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340326450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340326450" xlink:to="us-gaap_ClassOfStockDomain_638382026340336448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340336448" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340336448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340316447" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340336448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340336448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable" xlink:label="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable_638382026340336448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638382026340336448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRedemptionPrice" xlink:label="tlsi_ClassOfWarrantOrRightRedemptionPrice_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightRedemptionPrice_638382026340336448" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionDaysNotice" xlink:label="tlsi_ClassOfWarrantOrRightConversionDaysNotice_638382026340336448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightConversionDaysNotice_638382026340336448" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold" xlink:label="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold_638382026340346447" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays_638382026340346447" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays" xlink:label="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays_638382026340346447" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable" xlink:label="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable_638382026340346447" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638382026340346447" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026340346447" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026340346447" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount" xlink:label="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_638382026340346447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount_638382026340346447" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_638382026340356451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased_638382026340356451" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_638382026340356451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340336448" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_638382026340356451" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="1241001 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026340356451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026340356451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails" xlink:type="extended" xlink:title="1241101 - Disclosure - Preferred Stock - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340366447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340366447" xlink:to="us-gaap_ClassOfStockDomain_638382026340366447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesAConvertiblePreferredStockMember" xlink:label="tlsi_SeriesAConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesAConvertiblePreferredStockMember_638382026340366447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340366447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340366447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340366447" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340366447" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340366447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340366447" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340376450" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340376450" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340376450" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340376450" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340366447" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340376450" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026340376450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026340376450" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340376450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026340376450" xlink:to="us-gaap_PrivatePlacementMember_638382026340376450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="srt_RangeAxis_638382026340376450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340376450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340376450" xlink:to="srt_RangeMember_638382026340376450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340376450" xlink:to="srt_MaximumMember_638382026340386511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheAxis" xlink:label="tlsi_TrancheAxis_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="tlsi_TrancheAxis_638382026340386511" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheDomain" xlink:label="tlsi_TrancheDomain_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TrancheAxis_638382026340386511" xlink:to="tlsi_TrancheDomain_638382026340386511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheTwoMember" xlink:label="tlsi_TrancheTwoMember_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TrancheDomain_638382026340386511" xlink:to="tlsi_TrancheTwoMember_638382026340386511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheThreeMember" xlink:label="tlsi_TrancheThreeMember_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TrancheDomain_638382026340386511" xlink:to="tlsi_TrancheThreeMember_638382026340386511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340386511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340386511" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340386511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340386511" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340386511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340386511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340386511" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340386511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026340396451" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026340396451" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026340396451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueSharePriceMember" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340396451" xlink:to="tlsi_MeasurementInputFairValueSharePriceMember_638382026340396451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340396451" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638382026340396451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_ValuationTechniqueAxis_638382026340396451" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis_638382026340396451" xlink:to="us-gaap_ValuationTechniqueDomain_638382026340396451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember" xlink:label="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_638382026340396451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_638382026340396451" xlink:to="tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_638382026340396451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340366447" xlink:to="us-gaap_TemporaryEquityLineItems_638382026340406449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638382026340406449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638382026340406449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockSharesAuthorized_638382026340406449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_638382026340406449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockIssuedPricePerShare" xlink:label="tlsi_PreferredStockIssuedPricePerShare_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockIssuedPricePerShare_638382026340406449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638382026340406449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638382026340406449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638382026340416451" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockAutomaticConversionPeriod" xlink:label="tlsi_PreferredStockAutomaticConversionPeriod_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockAutomaticConversionPeriod_638382026340416451" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset_638382026340416451" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset" xlink:label="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset_638382026340416451" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPriceFloor" xlink:label="tlsi_PreferredStockConversionPriceFloor_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockConversionPriceFloor_638382026340416451" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice" xlink:label="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_638382026340416451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice_638382026340416451" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockLiquidationPreference_638382026340426453" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638382026340426453" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_SaleOfStockPricePerShare_638382026340426453" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638382026340426453" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026340426453" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340426453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340426453" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights" xlink:label="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_638382026340436453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights_638382026340436453" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_638382026340436453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount_638382026340436453" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount" xlink:label="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_638382026340436453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount_638382026340436453" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_638382026340436453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_638382026340436453" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_638382026340436453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_638382026340436453" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockConversionPercentageOfOutstandingShares" xlink:label="tlsi_PreferredStockConversionPercentageOfOutstandingShares_638382026340446450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockConversionPercentageOfOutstandingShares_638382026340446450" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_638382026340446450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_ClassOfWarrantOrRightWarrantsExercised_638382026340446450" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026340446450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026340446450" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock" xlink:label="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_638382026340446450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock_638382026340446450" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockPercentageOfSharesCommitted" xlink:label="tlsi_PreferredStockPercentageOfSharesCommitted_638382026340446450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_PreferredStockPercentageOfSharesCommitted_638382026340446450" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638382026340456450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638382026340456450" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ReverseRecapitalizationStockValueIfConvertedAmount" xlink:label="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_638382026340456450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_ReverseRecapitalizationStockValueIfConvertedAmount_638382026340456450" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638382026340456450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638382026340456450" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026340456450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340406449" xlink:to="tlsi_GainLossOnEquityIssuance_638382026340456450" order="32" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="1241102 - Disclosure - Preferred Stock - Summary of Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026340466448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340466448" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340466448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340466448" xlink:to="us-gaap_ClassOfStockDomain_638382026340466448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340466448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340466448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340466448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340466448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340476454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340476454" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340476454" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340476454" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340476454" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340476454" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340466448" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340476454" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340466448" xlink:to="us-gaap_TemporaryEquityLineItems_638382026340476454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340476454" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026340476454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340476454" xlink:to="us-gaap_TemporaryEquitySharesIssued_638382026340476454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026340476454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340476454" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026340476454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340476454" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638382026340486453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340476454" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340486453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails" xlink:type="extended" xlink:title="1241103 - Disclosure - Preferred Stock - Convertible Preferred Stock Rollforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026340486453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340486453" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340486453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340486453" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026340486453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026340486453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340486453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026340486453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026340496450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340496450" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340496450" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340496450" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026340496450" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340486453" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340496450" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026340486453" xlink:to="us-gaap_TemporaryEquityLineItems_638382026340496450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026340496450" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340496450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638382026340496450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:label="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_638382026340496450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" xlink:to="tlsi_TemporaryEquityValueConversionOfConvertibleSecurities_638382026340496450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638382026340496450" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340506449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="1241104 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026340506449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340506449" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340506449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340506449" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340506449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340506449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340506449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340506449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340506449" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340506449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340506449" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026340516448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340516448" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026340516448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340516448" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340516448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails" xlink:type="extended" xlink:title="1241105 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638382026340516448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340516448" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340516448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340516448" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026340516448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340516448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026340516448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026340526454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340516448" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340526454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638382026340516448" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638382026340526454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightRollForward" xlink:label="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638382026340526454" xlink:to="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638382026340526454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tlsi_ClassOfWarrantOrRightWarrantsExercised_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" xlink:to="tlsi_ClassOfWarrantOrRightWarrantsExercised_638382026340526454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues" xlink:label="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" xlink:to="tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues_638382026340526454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities" xlink:label="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_638382026340526454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" xlink:to="tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities_638382026340526454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6383820263405264541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_ClassOfWarrantOrRightRollForward_638382026340526454" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6383820263405264541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails" xlink:type="extended" xlink:title="1241106 - Disclosure - Preferred Stock - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="us-gaap_StatementClassOfStockAxis_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026340536451" xlink:to="us-gaap_ClassOfStockDomain_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340536451" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340536451" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026340536451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilityMember" xlink:label="tlsi_SeriesB2TrancheLiabilityMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026340536451" xlink:to="tlsi_SeriesB2TrancheLiabilityMember_638382026340536451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="srt_RangeAxis_638382026340536451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340536451" xlink:to="srt_RangeMember_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340536451" xlink:to="srt_MinimumMember_638382026340536451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340536451" xlink:to="srt_MaximumMember_638382026340536451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026340536451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026340536451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026340536451" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026340546451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueSharePriceMember" xlink:label="tlsi_MeasurementInputFairValueSharePriceMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="tlsi_MeasurementInputFairValueSharePriceMember_638382026340546451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputExerciseSharePriceMember" xlink:label="tlsi_MeasurementInputExerciseSharePriceMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="tlsi_MeasurementInputExerciseSharePriceMember_638382026340546451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638382026340546451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638382026340546451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026340546451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638382026340546451" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026340546451" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638382026340546451" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026340546451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026340546451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026340546451" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026340546451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember" xlink:label="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026340546451" xlink:to="tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_638382026340556450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="us-gaap_ValuationTechniqueAxis_638382026340556450" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis_638382026340556450" xlink:to="us-gaap_ValuationTechniqueDomain_638382026340556450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GuidelinePublicCompanyModelMember" xlink:label="tlsi_GuidelinePublicCompanyModelMember_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_638382026340556450" xlink:to="tlsi_GuidelinePublicCompanyModelMember_638382026340556450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BlackScholesModelMember" xlink:label="tlsi_BlackScholesModelMember_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_638382026340556450" xlink:to="tlsi_BlackScholesModelMember_638382026340556450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BinomialTrancheModelMember" xlink:label="tlsi_BinomialTrancheModelMember_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_638382026340556450" xlink:to="tlsi_BinomialTrancheModelMember_638382026340556450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638382026340536451" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638382026340556450" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638382026340556450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638382026340556450" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638382026340556450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="1241201 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026340566454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026340566454" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026340566454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026340566454" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" xlink:to="us-gaap_PreferredStockMember_638382026340566454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantMember" xlink:label="tlsi_PreferredStockWarrantMember_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" xlink:to="tlsi_PreferredStockWarrantMember_638382026340566454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantMember" xlink:label="tlsi_CommonStockWarrantMember_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" xlink:to="tlsi_CommonStockWarrantMember_638382026340566454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638382026340566454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638382026340566454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638382026340626455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026340566454" xlink:to="us-gaap_EmployeeStockOptionMember_638382026340626455" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026340626455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026340566454" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026340626455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026340626455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026340626455" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026340626455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails" xlink:type="extended" xlink:title="1241202 - Disclosure - Net Loss per Share - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026340636451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_638382026340636451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare" xlink:label="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_638382026340636451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare_638382026340636451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="1241301 - Disclosure - Share-Based Compensation - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340636451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340636451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340636451" xlink:to="us-gaap_AwardTypeAxis_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638382026340646544" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638382026340646544" xlink:to="us-gaap_EmployeeStockOptionMember_638382026340646544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340636451" xlink:to="us-gaap_PlanNameAxis_638382026340646544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638382026340646544" xlink:to="us-gaap_PlanNameDomain_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2009PlanMember" xlink:label="tlsi_A2009PlanMember_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638382026340646544" xlink:to="tlsi_A2009PlanMember_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2023PlanMember" xlink:label="tlsi_A2023PlanMember_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638382026340646544" xlink:to="tlsi_A2023PlanMember_638382026340646544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340636451" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340646544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_638382026340646544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears_638382026340646544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock_638382026340656451" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638382026340656451" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026340656451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638382026340656451" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026340656451" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638382026340656451" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638382026340656451" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_638382026340656451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340646544" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent_638382026340656451" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss" xlink:type="extended" xlink:title="1241302 - Disclosure - Share-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340666453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340666453" xlink:to="us-gaap_PlanNameAxis_638382026340666453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638382026340666453" xlink:to="us-gaap_PlanNameDomain_638382026340666453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2009PlanMember" xlink:label="tlsi_A2009PlanMember_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638382026340666453" xlink:to="tlsi_A2009PlanMember_638382026340666453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_A2023PlanMember" xlink:label="tlsi_A2023PlanMember_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638382026340666453" xlink:to="tlsi_A2023PlanMember_638382026340666453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026340666453" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementNumberOfPlans" xlink:label="tlsi_ShareBasedCompensationArrangementNumberOfPlans_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" xlink:to="tlsi_ShareBasedCompensationArrangementNumberOfPlans_638382026340666453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026340666453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" xlink:to="tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_638382026340666453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638382026340666453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026340666453" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638382026340666453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails" xlink:type="extended" xlink:title="1241401 - Disclosure - Dynavax Purchase (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638382026340676460" xlink:to="srt_RangeAxis_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026340676460" xlink:to="srt_RangeMember_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340676460" xlink:to="srt_MinimumMember_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026340676460" xlink:to="srt_MaximumMember_638382026340676460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638382026340676460" xlink:to="us-gaap_AssetAcquisitionAxis_638382026340676460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638382026340676460" xlink:to="us-gaap_AssetAcquisitionDomain_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxTechnologiesMember" xlink:label="tlsi_DynavaxTechnologiesMember_638382026340676460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638382026340676460" xlink:to="tlsi_DynavaxTechnologiesMember_638382026340676460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeAxis" xlink:label="tlsi_CommercialMilestoneTypeAxis_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638382026340676460" xlink:to="tlsi_CommercialMilestoneTypeAxis_638382026340686456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneTypeDomain" xlink:label="tlsi_CommercialMilestoneTypeDomain_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneTypeAxis_638382026340686456" xlink:to="tlsi_CommercialMilestoneTypeDomain_638382026340686456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneMember" xlink:label="tlsi_CommercialMilestoneMember_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneTypeDomain_638382026340686456" xlink:to="tlsi_CommercialMilestoneMember_638382026340686456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember" xlink:label="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneMember_638382026340686456" xlink:to="tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_638382026340686456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone250000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone250000AnnualSalesMember_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneMember_638382026340686456" xlink:to="tlsi_CommercialMilestone250000AnnualSalesMember_638382026340686456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone500000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone500000AnnualSalesMember_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneMember_638382026340686456" xlink:to="tlsi_CommercialMilestone500000AnnualSalesMember_638382026340686456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestone1000000AnnualSalesMember" xlink:label="tlsi_CommercialMilestone1000000AnnualSalesMember_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CommercialMilestoneMember_638382026340686456" xlink:to="tlsi_CommercialMilestone1000000AnnualSalesMember_638382026340686456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638382026340676460" xlink:to="us-gaap_AssetAcquisitionLineItems_638382026340686456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638382026340686456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisition" xlink:label="tlsi_PaymentsForAssetAcquisition_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_PaymentsForAssetAcquisition_638382026340686456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentsForAssetAcquisitionMilestoneAmount" xlink:label="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_638382026340686456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_PaymentsForAssetAcquisitionMilestoneAmount_638382026340686456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionNumberOfCommercialMilestones" xlink:label="tlsi_AssetAcquisitionNumberOfCommercialMilestones_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionNumberOfCommercialMilestones_638382026340696458" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMaximumMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMaximumMilestoneAmount_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionMaximumMilestoneAmount_638382026340696458" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionMilestoneAmount" xlink:label="tlsi_AssetAcquisitionMilestoneAmount_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionMilestoneAmount_638382026340696458" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionSalesMilestone" xlink:label="tlsi_AssetAcquisitionSalesMilestone_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionSalesMilestone_638382026340696458" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount_638382026340696458" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount_638382026340696458" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount" xlink:label="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_638382026340696458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638382026340686456" xlink:to="tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount_638382026340696458" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="222100100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638382026340706454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_AssetsCurrentAbstract_638382026340706454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026340706454" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026340706454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026340706454" xlink:to="us-gaap_AccountsReceivableNetCurrent_638382026340706454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026340706454" xlink:to="us-gaap_InventoryNet_638382026340706454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026340706454" xlink:to="us-gaap_PrepaidExpenseCurrent_638382026340706454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638382026340706454" xlink:to="us-gaap_AssetsCurrent_638382026340706454" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638382026340706454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638382026340706454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638382026340706454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638382026340706454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_OtherAssetsNoncurrent_638382026340716452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638382026340706454" xlink:to="us-gaap_Assets_638382026340716452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="us-gaap_AccountsPayableCurrent_638382026340716452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026340716452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBTwoTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBTwoTrancheLiabilityCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="tlsi_SeriesBTwoTrancheLiabilityCurrent_638382026340716452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBThreeTrancheLiabilityCurrent" xlink:label="tlsi_SeriesBThreeTrancheLiabilityCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="tlsi_SeriesBThreeTrancheLiabilityCurrent_638382026340716452" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityCurrent" xlink:label="tlsi_LeaseLiabilityCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="tlsi_LeaseLiabilityCurrent_638382026340716452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638382026340716452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="us-gaap_OtherLiabilitiesCurrent_638382026340716452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638382026340716452" xlink:to="us-gaap_LiabilitiesCurrent_638382026340726462" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseLiabilityNoncurrent" xlink:label="tlsi_LeaseLiabilityNoncurrent_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="tlsi_LeaseLiabilityNoncurrent_638382026340726462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent" xlink:label="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent_638382026340726462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="us-gaap_Liabilities_638382026340726462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026340726462" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="us-gaap_StockholdersEquityAbstract_638382026340726462" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026340726462" xlink:to="us-gaap_CommonStockValue_638382026340726462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638382026340726462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026340726462" xlink:to="us-gaap_AdditionalPaidInCapital_638382026340726462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026340736455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026340726462" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026340736455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026340736455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638382026340726462" xlink:to="us-gaap_StockholdersEquity_638382026340736455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638382026340736455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638382026340716452" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638382026340736455" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="222100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638382026340746459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638382026340746459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638382026340746459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638382026340746459" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="222100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638382026340746459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue_638382026340746459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit_638382026340746459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638382026340746459" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026340746459" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638382026340746459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638382026340746459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026340746459" xlink:to="us-gaap_SellingAndMarketingExpense_638382026340746459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026340746459" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638382026340756452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638382026340746459" xlink:to="us-gaap_OperatingIncomeLoss_638382026340756452" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_638382026340756452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_638382026340756452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_638382026340756452" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="tlsi_GainLossOnEquityIssuance_638382026340756452" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026340756452" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638382026340756452" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638382026340756452" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026340756452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026340756452" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638382026340766462" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026340766462" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638382026340766462" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638382026340766462" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638382026340766462" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638382026340766462" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026340766462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638382026340766462" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="222100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638382026340776458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026340776458" xlink:to="us-gaap_StatementEquityComponentsAxis_638382026340776458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026340776458" xlink:to="us-gaap_CommonStockMember_638382026340776458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026340776458" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638382026340776458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026340776458" xlink:to="us-gaap_RetainedEarningsMember_638382026340776458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026340776458" xlink:to="us-gaap_EquityComponentDomain_638382026340776458" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638382026340776458" xlink:to="us-gaap_StatementLineItems_638382026340776458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_StockholdersEquity_638382026340776458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_CommonStockSharesIssued_638382026340776458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638382026340776458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638382026340776458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026340786456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_638382026340786456" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_638382026340786456" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_638382026340786456" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026340786456" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_NetIncomeLoss_638382026340786456" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_StockholdersEquity_638382026340786456" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638382026340786456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638382026340776458" xlink:to="us-gaap_CommonStockSharesIssued_638382026340786456" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="222100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_NetIncomeLoss_638382026340796456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_638382026340796456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainOnPppLoanForgiveness" xlink:label="tlsi_GainOnPppLoanForgiveness_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="tlsi_GainOnPppLoanForgiveness_638382026340796456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_638382026340796456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="tlsi_GainLossOnEquityIssuance_638382026340796456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026340796456" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638382026340796456" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638382026340796456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_ShareBasedCompensation_638382026340796456" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026340806532" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026340806532" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638382026340806532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="us-gaap_IncreaseDecreaseInInventories_638382026340806532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638382026340806532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638382026340806532" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638382026340806532" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638382026340806532" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638382026340806532" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026340806532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638382026340796456" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638382026340806532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638382026340816455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxInvestingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxInvestingActivity_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" xlink:to="tlsi_MilestonePaymentToDynavaxInvestingActivity_638382026340816455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638382026340816455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638382026340816455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026340816455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026340816455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026340816455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638382026340826453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_RepaymentsOfBankDebt_638382026340826453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638382026340826453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock" xlink:label="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock_638382026340826453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638382026340816455" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638382026340826453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638382026340826453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340826453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340826453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026340836459" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638382026340836459" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CashPaidDuringYearForAbstract" xlink:label="tlsi_CashPaidDuringYearForAbstract_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638382026340836459" xlink:to="tlsi_CashPaidDuringYearForAbstract_638382026340836459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CashPaidDuringYearForAbstract_638382026340836459" xlink:to="us-gaap_InterestPaidNet_638382026340836459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CashPaidDuringYearForAbstract_638382026340836459" xlink:to="us-gaap_IncomeTaxesPaid_638382026340836459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValueOfWarrantsIssuedWithConvertibleNotes" xlink:label="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_638382026340836459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" xlink:to="tlsi_ValueOfWarrantsIssuedWithConvertibleNotes_638382026340836459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants" xlink:label="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_638382026340846454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" xlink:to="tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants_638382026340846454" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses" xlink:label="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_638382026340846454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" xlink:to="tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses_638382026340846454" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital" xlink:label="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_638382026340846454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" xlink:to="tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital_638382026340846454" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock" xlink:label="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_638382026340846454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638382026340836459" xlink:to="tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock_638382026340846454" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="222100405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638382026340856455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638382026340856455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638382026340856455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638382026340856455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss" xlink:type="extended" xlink:title="222110101 - Disclosure - Nature of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638382026340866454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638382026340866454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss" xlink:type="extended" xlink:title="222110201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638382026340866454" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638382026340866454" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss" xlink:type="extended" xlink:title="222110301 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_638382026340876457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_638382026340876457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs" xlink:type="extended" xlink:title="222110401 - Disclosure - Cash, cash equivalents and restricted cash" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_638382026340876457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_638382026340876457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventorys" xlink:type="extended" xlink:title="222110501 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638382026340886466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638382026340886466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssets" xlink:type="extended" xlink:title="222110601 - Disclosure - Long-Lived Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsDisclosureTextBlock" xlink:label="tlsi_LongLivedAssetsDisclosureTextBlock_638382026340886466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="tlsi_LongLivedAssetsDisclosureTextBlock_638382026340886466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess" xlink:type="extended" xlink:title="222110701 - Disclosure - Accrued Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638382026340896456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638382026340896456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxess" xlink:type="extended" xlink:title="222110801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638382026340906457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638382026340906457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchases" xlink:type="extended" xlink:title="222110901 - Disclosure - Dynavax Purchase" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAbstract" xlink:label="DynavaxPurchaseAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638382026340906457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DynavaxPurchaseAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638382026340906457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebt" xlink:type="extended" xlink:title="222111001 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638382026340916458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638382026340916458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertibleNotes" xlink:type="extended" xlink:title="222111101 - Disclosure - Convertible Notes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertibleDebtDisclosureTextBlock" xlink:label="tlsi_ConvertibleDebtDisclosureTextBlock_638382026340916458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="tlsi_ConvertibleDebtDisclosureTextBlock_638382026340916458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="222111201 - Disclosure - Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConvertiblePreferredStockDisclosureTextBlock" xlink:label="tlsi_ConvertiblePreferredStockDisclosureTextBlock_638382026340926457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_ConvertiblePreferredStockDisclosureTextBlock_638382026340926457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="222111301 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638382026340936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638382026340936471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShares" xlink:type="extended" xlink:title="222111401 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638382026340936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638382026340936471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeases" xlink:type="extended" xlink:title="222111501 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_638382026340946457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_638382026340946457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss" xlink:type="extended" xlink:title="222111601 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026340946457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638382026340946457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation" xlink:type="extended" xlink:title="222111701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638382026340956459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638382026340956459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss" xlink:type="extended" xlink:title="222120202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638382026340966458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638382026340966458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_638382026340966458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638382026340966458" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638382026340966458" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638382026340966458" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638382026340966458" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638382026340966458" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638382026340966458" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638382026340966458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638382026340966458" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638382026340976469" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638382026340976469" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638382026340976469" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_638382026340976469" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638382026340976469" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock" xlink:label="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock_638382026340976469" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026340976469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638382026340976469" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless" xlink:type="extended" xlink:title="222130303 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026340986456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638382026340986456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless" xlink:type="extended" xlink:title="222130403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638382026340996457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638382026340996457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventoryTabless" xlink:type="extended" xlink:title="222130503 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638382026340996457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638382026340996457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables" xlink:type="extended" xlink:title="222130603 - Disclosure - Long-Lived Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638382026341006465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638382026341006465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_638382026341006465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_638382026341006465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless" xlink:type="extended" xlink:title="222130703 - Disclosure - Accrued Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638382026341016461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638382026341016461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="222130803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638382026341016461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638382026341016461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638382026341016461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638382026341016461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638382026341016461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638382026341016461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638382026341016461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638382026341016461" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="222131003 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026341026462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638382026341026462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables" xlink:type="extended" xlink:title="222131203 - Disclosure - Convertible Preferred Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_638382026341036469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock_638382026341036469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock" xlink:label="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_638382026341036469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock_638382026341036469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock" xlink:label="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_638382026341036469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock_638382026341036469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="222131301 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638382026341046465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638382026341046465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638382026341046465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638382026341046465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638382026341046465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638382026341046465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638382026341046465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638382026341046465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless" xlink:type="extended" xlink:title="222131403 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638382026341046465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638382026341046465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="222131503 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_638382026341056457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_638382026341056457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638382026341056457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638382026341056457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock" xlink:label="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_638382026341056457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_638382026341056457" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_638382026341056457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_638382026341056457" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss" xlink:type="extended" xlink:title="222140101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638382026341066458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638382026341066458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638382026341066458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CumulativeIncomeLoss" xlink:label="tlsi_CumulativeIncomeLoss_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tlsi_CumulativeIncomeLoss_638382026341066458" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638382026341066458" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_638382026341066458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_638382026341066458" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638382026341076463" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss" xlink:type="extended" xlink:title="222140201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638382026341076463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638382026341076463" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638382026341076463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638382026341076463" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638382026341076463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638382026341076463" xlink:to="us-gaap_AccountsReceivableMember_638382026341076463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638382026341076463" xlink:to="us-gaap_SalesRevenueNetMember_638382026341076463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638382026341076463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638382026341076463" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638382026341076463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638382026341076463" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638382026341086462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638382026341086462" xlink:to="us-gaap_CustomerConcentrationRiskMember_638382026341086462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638382026341076463" xlink:to="srt_MajorCustomersAxis_638382026341086462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638382026341086462" xlink:to="srt_NameOfMajorCustomerDomain_638382026341086462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CustomerOneMember" xlink:label="tlsi_CustomerOneMember_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638382026341086462" xlink:to="tlsi_CustomerOneMember_638382026341086462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638382026341076463" xlink:to="us-gaap_ConcentrationRiskLineItems_638382026341086462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCustomer" xlink:label="tlsi_NumberOfCustomer_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="tlsi_NumberOfCustomer_638382026341086462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638382026341086462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_ConcentrationRiskPercentage1_638382026341086462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentToDynavaxOperatingActivity" xlink:label="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="tlsi_MilestonePaymentToDynavaxOperatingActivity_638382026341096463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_AdvertisingExpense_638382026341096463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesOutstanding" xlink:label="tlsi_PercentageOfSharesOutstanding_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="tlsi_PercentageOfSharesOutstanding_638382026341096463" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssets_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssets_638382026341096463" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_AccruedRentCurrent_638382026341096463" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_LiabilitiesCurrent_638382026341096463" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638382026341096463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638382026341086462" xlink:to="us-gaap_LiabilitiesNoncurrent_638382026341096463" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="222140301 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementAxis" xlink:label="tlsi_MeasurementAxis_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" xlink:to="tlsi_MeasurementAxis_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueDisclosureItemAmountDomain" xlink:label="tlsi_FairValueDisclosureItemAmountDomain_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_MeasurementAxis_638382026341106501" xlink:to="tlsi_FairValueDisclosureItemAmountDomain_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FairValueDisclosureItemAmountDomain_638382026341106501" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638382026341106501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638382026341106501" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341106501" xlink:to="tlsi_WarrantLiabilitiesMember_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilitiesMember" xlink:label="tlsi_TrancheLiabilitiesMember_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341106501" xlink:to="tlsi_TrancheLiabilitiesMember_638382026341106501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_638382026341106501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TrancheLiabilitiesMember_638382026341106501" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_638382026341106501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember" xlink:label="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_TrancheLiabilitiesMember_638382026341106501" xlink:to="tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_638382026341116461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341116461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341116461" xlink:to="us-gaap_ClassOfStockDomain_638382026341116461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341116461" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341116461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638382026341106501" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026341116461" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026341116461" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638382026341116461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount" xlink:label="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026341116461" xlink:to="tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount_638382026341116461" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_638382026341116461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638382026341116461" xlink:to="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_638382026341116461" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails" xlink:type="extended" xlink:title="222140302 - Disclosure - Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026341126460" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638382026341126460" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" xlink:to="tlsi_WarrantLiabilitiesMember_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PutOptionLiabilityMember" xlink:label="tlsi_PutOptionLiabilityMember_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" xlink:to="tlsi_PutOptionLiabilityMember_638382026341126460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilitiesMember" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" xlink:to="tlsi_SeriesB2TrancheLiabilitiesMember_638382026341126460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3WarrantLiabilitiesMember" xlink:label="tlsi_SeriesB3WarrantLiabilitiesMember_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341126460" xlink:to="tlsi_SeriesB3WarrantLiabilitiesMember_638382026341126460" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638382026341126460" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026341126460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638382026341126460" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026341126460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026341126460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638382026341136459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_638382026341136459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638382026341136459" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638382026341136459" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638382026341136459" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638382026341136459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638382026341126460" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638382026341136459" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss" xlink:type="extended" xlink:title="222140401 - Disclosure - Cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638382026341146472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_638382026341146472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638382026341146472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_638382026341146472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureInventoryDetailss" xlink:type="extended" xlink:title="222140501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:label="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_638382026341146472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_638382026341146472" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638382026341146472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_638382026341146472" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638382026341146472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_638382026341146472" xlink:to="us-gaap_InventoryNet_638382026341146472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments_638382026341146472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryAdjustments_638382026341146472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails" xlink:type="extended" xlink:title="222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638382026341156460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638382026341156460" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341156460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341156460" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" xlink:to="us-gaap_MachineryAndEquipmentMember_638382026341156460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" xlink:to="us-gaap_ComputerEquipmentMember_638382026341156460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" xlink:to="us-gaap_FurnitureAndFixturesMember_638382026341156460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" xlink:to="us-gaap_LeaseholdImprovementsMember_638382026341156460" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341156460" xlink:to="us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_638382026341156460" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026341156460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638382026341156460" xlink:to="srt_RangeAxis_638382026341156460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026341156460" xlink:to="srt_RangeMember_638382026341166459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341166459" xlink:to="srt_MinimumMember_638382026341166459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341166459" xlink:to="srt_MaximumMember_638382026341166459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638382026341156460" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638382026341166459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638382026341166459" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638382026341166459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638382026341166459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638382026341166459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638382026341166459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638382026341166459" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638382026341166459" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="222140602 - Disclosure - Long-Lived Assets - Property and Equipment, narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638382026341176463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_Depreciation_638382026341176463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026341176463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638382026341176463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="222140603 - Disclosure - Long-Lived Assets - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638382026341186462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638382026341186462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638382026341186462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638382026341186462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended" xlink:title="222140604 - Disclosure - Long-Lived Assets - Intangible Assets, amortization expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LongLivedAssetsAbstract" xlink:label="LongLivedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638382026341186462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638382026341186462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638382026341196463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638382026341196463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638382026341196463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638382026341196463" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638382026341196463" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638382026341186462" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638382026341196463" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss" xlink:type="extended" xlink:title="222140701 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638382026341196463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AccruedIncentiveCurrent" xlink:label="tlsi_AccruedIncentiveCurrent_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="tlsi_AccruedIncentiveCurrent_638382026341196463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638382026341196463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedVacationCurrent_638382026341196463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_638382026341206462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_638382026341206462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638382026341206462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638382026341206462" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails" xlink:type="extended" xlink:title="222140801 - Disclosure - Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341256463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341256463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341256463" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638382026341266462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341256463" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638382026341266462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341256463" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638382026341266462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341266462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341266462" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638382026341266462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_638382026341266462" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638382026341266462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638382026341266462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails" xlink:type="extended" xlink:title="222140802 - Disclosure - Income Taxes - Provision for federal income tax statutory rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026341266462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638382026341266462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638382026341276464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638382026341276464" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638382026341276464" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638382026341276464" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638382026341276464" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="222140803 - Disclosure - Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026341276464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeferredTaxAssetsFixedAssetsAndIntangible" xlink:label="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_638382026341276464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="tlsi_DeferredTaxAssetsFixedAssetsAndIntangible_638382026341276464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638382026341286465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsInventory_638382026341286465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsOther_638382026341286465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638382026341286465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638382026341286465" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638382026341276464" xlink:to="us-gaap_DeferredTaxAssetsGross_638382026341286465" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638382026341286465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638382026341286465" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638382026341286465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638382026341286465" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638382026341286465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638382026341286465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638382026341286465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_638382026341286465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638382026341296468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638382026341296468" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638382026341296468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638382026341296468" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638382026341296468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638382026341296468" xlink:to="us-gaap_DomesticCountryMember_638382026341296468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638382026341296468" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638382026341296468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638382026341296468" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638382026341296468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638382026341296468" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638382026341296468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638382026341296468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638382026341296468" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638382026341296468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026341306468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638382026341296468" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638382026341306468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="222140805 - Disclosure - Income Taxes - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638382026341306468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638382026341306468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638382026341306468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638382026341306468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NetDeferredTaxAssetsChangeInValuationPercentage" xlink:label="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_638382026341306468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="tlsi_NetDeferredTaxAssetsChangeInValuationPercentage_638382026341306468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss" xlink:type="extended" xlink:title="222140901 - Disclosure - Dynavax Purchase (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAbstract" xlink:label="DynavaxPurchaseAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DynavaxPurchaseAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638382026341316464" xlink:to="us-gaap_TypeOfArrangementAxis_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638382026341316464" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DynavaxPurchaseAgreementMember" xlink:label="tlsi_DynavaxPurchaseAgreementMember_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638382026341316464" xlink:to="tlsi_DynavaxPurchaseAgreementMember_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638382026341316464" xlink:to="srt_StatementScenarioAxis_638382026341316464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638382026341316464" xlink:to="srt_ScenarioUnspecifiedDomain_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstCommercialSaleOfProductMember" xlink:label="tlsi_UponFirstCommercialSaleOfProductMember_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_UponFirstCommercialSaleOfProductMember_638382026341316464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_638382026341316464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_638382026341316464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_638382026341326467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member" xlink:label="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_638382026341326467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_638382026341326467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateAnnualNetSalesGreaterThan1000000Member" xlink:label="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341316464" xlink:to="tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_638382026341326467" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638382026341316464" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_UpfrontPaymentAmount" xlink:label="tlsi_UpfrontPaymentAmount_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_UpfrontPaymentAmount_638382026341326467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaymentOfUpfrontAmount" xlink:label="tlsi_PaymentOfUpfrontAmount_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_PaymentOfUpfrontAmount_638382026341326467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MinimumMilestonePaymentAmount" xlink:label="tlsi_MinimumMilestonePaymentAmount_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_MinimumMilestonePaymentAmount_638382026341326467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumMilestonePaymentAmount" xlink:label="tlsi_MaximumMilestonePaymentAmount_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_MaximumMilestonePaymentAmount_638382026341326467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumDevelopmentMilestonePayments" xlink:label="tlsi_MaximumDevelopmentMilestonePayments_638382026341326467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_MaximumDevelopmentMilestonePayments_638382026341326467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MilestonePaymentsMade" xlink:label="tlsi_MilestonePaymentsMade_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_MilestonePaymentsMade_638382026341336469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfCommercialMilestoneToBeMade" xlink:label="tlsi_NumberOfCommercialMilestoneToBeMade_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_NumberOfCommercialMilestoneToBeMade_638382026341336469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommercialMilestonePaymentAmount" xlink:label="tlsi_CommercialMilestonePaymentAmount_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_CommercialMilestonePaymentAmount_638382026341336469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualNetSales" xlink:label="tlsi_AnnualNetSales_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_AnnualNetSales_638382026341336469" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumCommercialMilestonePayments" xlink:label="tlsi_MaximumCommercialMilestonePayments_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_MaximumCommercialMilestonePayments_638382026341336469" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnnualRoyaltyRate" xlink:label="tlsi_AnnualRoyaltyRate_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="tlsi_AnnualRoyaltyRate_638382026341336469" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638382026341336469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638382026341326467" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638382026341336469" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails" xlink:type="extended" xlink:title="222141001 - Disclosure - Debt - PPP Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341346470" xlink:to="us-gaap_DebtInstrumentAxis_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638382026341346470" xlink:to="us-gaap_DebtInstrumentNameDomain_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PaycheckProtectionProgramMember" xlink:label="tlsi_PaycheckProtectionProgramMember_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638382026341346470" xlink:to="tlsi_PaycheckProtectionProgramMember_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341346470" xlink:to="us-gaap_IncomeStatementLocationAxis_638382026341346470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638382026341346470" xlink:to="us-gaap_IncomeStatementLocationDomain_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638382026341346470" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341346470" xlink:to="us-gaap_DebtInstrumentLineItems_638382026341346470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638382026341346470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341346470" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638382026341346470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341346470" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_638382026341356466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails" xlink:type="extended" xlink:title="222141002 - Disclosure - Debt - Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341356466" xlink:to="us-gaap_DebtInstrumentAxis_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638382026341356466" xlink:to="us-gaap_DebtInstrumentNameDomain_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TermLoanAndSupplementalTermLoanMember" xlink:label="tlsi_TermLoanAndSupplementalTermLoanMember_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638382026341356466" xlink:to="tlsi_TermLoanAndSupplementalTermLoanMember_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341356466" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638382026341356466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638382026341356466" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn08262015Member" xlink:label="tlsi_WarrantsIssuedOn08262015Member_638382026341356466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" xlink:to="tlsi_WarrantsIssuedOn08262015Member_638382026341356466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn10272016Member" xlink:label="tlsi_WarrantsIssuedOn10272016Member_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" xlink:to="tlsi_WarrantsIssuedOn10272016Member_638382026341366466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn06302017Member" xlink:label="tlsi_WarrantsIssuedOn06302017Member_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" xlink:to="tlsi_WarrantsIssuedOn06302017Member_638382026341366466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsIssuedOn11202018Member" xlink:label="tlsi_WarrantsIssuedOn11202018Member_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638382026341356466" xlink:to="tlsi_WarrantsIssuedOn11202018Member_638382026341366466" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341356466" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341366466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341366466" xlink:to="us-gaap_ClassOfStockDomain_638382026341366466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5PreferredStockMember" xlink:label="tlsi_SeriesA5PreferredStockMember_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341366466" xlink:to="tlsi_SeriesA5PreferredStockMember_638382026341366466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6PreferredStockMember" xlink:label="tlsi_SeriesA6PreferredStockMember_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341366466" xlink:to="tlsi_SeriesA6PreferredStockMember_638382026341366466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341356466" xlink:to="us-gaap_DebtInstrumentLineItems_638382026341366466" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341366466" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638382026341366466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638382026341366466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341366466" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638382026341366466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341366466" xlink:to="tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued_638382026341376462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341366466" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341376462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341366466" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638382026341376462" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails" xlink:type="extended" xlink:title="222141101 - Disclosure - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentTable_638382026341376462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_LongtermDebtTypeAxis_638382026341376462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638382026341376462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638382026341376462" xlink:to="us-gaap_LongtermDebtTypeDomain_638382026341376462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638382026341376462" xlink:to="us-gaap_ConvertibleDebtMember_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341386463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341386463" xlink:to="us-gaap_ClassOfStockDomain_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6PreferredStockMember" xlink:label="tlsi_SeriesA6PreferredStockMember_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341386463" xlink:to="tlsi_SeriesA6PreferredStockMember_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341386463" xlink:to="us-gaap_SeriesBPreferredStockMember_638382026341386463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_StatementEquityComponentsAxis_638382026341386463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638382026341386463" xlink:to="us-gaap_EquityComponentDomain_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638382026341386463" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638382026341386463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638382026341386463" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember_638382026341386463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638382026341386463" xlink:to="us-gaap_PutOptionMember_638382026341386463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638382026341396463" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638382026341396463" xlink:to="us-gaap_DerivativeContractTypeDomain_638382026341396463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638382026341396463" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_638382026341396463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638382026341376462" xlink:to="us-gaap_DebtInstrumentLineItems_638382026341396463" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638382026341396463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638382026341396463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638382026341396463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued" xlink:label="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued_638382026341396463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_QualifiedFinancingMinimumProceeds" xlink:label="tlsi_QualifiedFinancingMinimumProceeds_638382026341396463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_QualifiedFinancingMinimumProceeds_638382026341396463" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage" xlink:label="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage_638382026341406466" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage" xlink:label="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage_638382026341406466" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_ConvertibleNotesPayable_638382026341406466" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638382026341406466" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DebtInstrumentConversionDiscountPercentage" xlink:label="tlsi_DebtInstrumentConversionDiscountPercentage_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_DebtInstrumentConversionDiscountPercentage_638382026341406466" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341406466" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341406466" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_InitialWarrantLiability" xlink:label="tlsi_InitialWarrantLiability_638382026341406466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_InitialWarrantLiability_638382026341406466" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantIssued" xlink:label="tlsi_WarrantIssued_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_WarrantIssued_638382026341416470" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EliminationOfOccurrenceOfDiscountPercentage" xlink:label="tlsi_EliminationOfOccurrenceOfDiscountPercentage_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_EliminationOfOccurrenceOfDiscountPercentage_638382026341416470" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount" xlink:label="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount_638382026341416470" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="us-gaap_DerivativeNotionalAmount_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_DerivativeNotionalAmount_638382026341416470" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_InterestExpense_638382026341416470" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638382026341416470" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnConversionOfConvertibleNotes" xlink:label="tlsi_GainLossOnConversionOfConvertibleNotes_638382026341416470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="tlsi_GainLossOnConversionOfConvertibleNotes_638382026341416470" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638382026341426469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638382026341396463" xlink:to="us-gaap_InterestExpenseDebt_638382026341426469" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="222141201 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341426469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341426469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341426469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341426469" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341426469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341426469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341426469" xlink:to="us-gaap_ClassOfStockDomain_638382026341426469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341436470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341436470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341436470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341436470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341436470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341436470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341436470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341436470" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341436470" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341426469" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341436470" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341426469" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341436470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026341436470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341436470" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026341436470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341436470" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638382026341446474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341436470" xlink:to="us-gaap_TemporaryEquitySharesIssued_638382026341446474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341436470" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026341446474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341436470" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341446474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="222141202 - Disclosure - Convertible Preferred Stock, activity in convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341446474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341446474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341446474" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341446474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341446474" xlink:to="us-gaap_ClassOfStockDomain_638382026341456468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341456468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341456468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341456468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341456468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341456468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341456468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341456468" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341456468" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341456468" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341446474" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341456468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341456468" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341456468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638382026341456468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341456468" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_638382026341456468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341456468" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638382026341466470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails" xlink:type="extended" xlink:title="222141203 - Disclosure - Convertible Preferred Stock, narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341466470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341466470" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341466470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341466470" xlink:to="us-gaap_ClassOfStockDomain_638382026341466470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341466470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341466470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341466470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341476467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341476467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341476467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341476467" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341476467" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341476467" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341476467" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341466470" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341476467" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341466470" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341476467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341476467" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638382026341476467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquitySharesAvailableForIssuance" xlink:label="tlsi_TemporaryEquitySharesAvailableForIssuance_638382026341476467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341476467" xlink:to="tlsi_TemporaryEquitySharesAvailableForIssuance_638382026341476467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_638382026341486469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341476467" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_638382026341486469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails" xlink:type="extended" xlink:title="222141204 - Disclosure - Convertible Preferred Stock, Conversion (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_638382026341486469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock_638382026341486469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_638382026341486469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds_638382026341486469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount" xlink:label="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_638382026341486469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount_638382026341486469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails" xlink:type="extended" xlink:title="222141205 - Disclosure - Convertible Preferred Stock, Voting Rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired" xlink:label="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_638382026341496473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired_638382026341496473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails" xlink:type="extended" xlink:title="222141206 - Disclosure - Convertible Preferred Stock, Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341506466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341506466" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341506466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341506466" xlink:to="us-gaap_ClassOfStockDomain_638382026341506466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341506466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341506466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341506466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341506466" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341506466" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341506466" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341506466" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341506466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341506466" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341516474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341506466" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341516474" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341506466" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341516474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityDividendPerShare" xlink:label="tlsi_TemporaryEquityDividendPerShare_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341516474" xlink:to="tlsi_TemporaryEquityDividendPerShare_638382026341516474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails" xlink:type="extended" xlink:title="222141207 - Disclosure - Convertible Preferred Stock, Liquidation Preferences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341516474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341516474" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341516474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341516474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341516474" xlink:to="us-gaap_ClassOfStockDomain_638382026341516474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341526472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341526472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341526472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341526472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341526472" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341526472" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341526472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341526472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341526472" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341516474" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341526472" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341516474" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341526472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638382026341526472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341526472" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638382026341526472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341526472" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_638382026341536466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341526472" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_638382026341536466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails" xlink:type="extended" xlink:title="222141208 - Disclosure - Convertible Preferred Stock, March 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341536466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341536466" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341536466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341536466" xlink:to="us-gaap_ClassOfStockDomain_638382026341536466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341536466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341536466" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341536466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341536466" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026341546475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026341546475" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341546475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_March2021FinancingMember" xlink:label="tlsi_March2021FinancingMember_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341546475" xlink:to="tlsi_March2021FinancingMember_638382026341546475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341536466" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341546475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341546475" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341546475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341546475" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341546475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341546475" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_638382026341546475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341546475" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_638382026341546475" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638382026341546475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341546475" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638382026341546475" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails" xlink:type="extended" xlink:title="222141209 - Disclosure - Convertible Preferred Stock, Spring 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341556467" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341556467" xlink:to="us-gaap_ClassOfStockDomain_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341556467" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341556467" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026341556467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026341556467" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Spring2021FinancingMember" xlink:label="tlsi_Spring2021FinancingMember_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341556467" xlink:to="tlsi_Spring2021FinancingMember_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341556467" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341556467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341556467" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341556467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341556467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341556467" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341556467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341556467" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_638382026341566466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails" xlink:type="extended" xlink:title="222141210 - Disclosure - Convertible Preferred Stock, Fall 2021 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341566466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341566466" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341566466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341566466" xlink:to="us-gaap_ClassOfStockDomain_638382026341566466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341566466" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341566466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341566466" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026341566466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341566466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026341566466" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341566466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Fall2021FinancingMember" xlink:label="tlsi_Fall2021FinancingMember_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341566466" xlink:to="tlsi_Fall2021FinancingMember_638382026341576474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341566466" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341576474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341576474" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638382026341576474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341576474" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341576474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityOriginalIssuePrice" xlink:label="tlsi_TemporaryEquityOriginalIssuePrice_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341576474" xlink:to="tlsi_TemporaryEquityOriginalIssuePrice_638382026341576474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails" xlink:type="extended" xlink:title="222141211 - Disclosure - Convertible Preferred Stock, Warrant Exercises (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341576474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341576474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341576474" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341576474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341576474" xlink:to="us-gaap_ClassOfStockDomain_638382026341586467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341586467" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341586467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341586467" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341586467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341576474" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341586467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341586467" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026341586467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341586467" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341586467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails" xlink:type="extended" xlink:title="222141212 - Disclosure - Convertible Preferred Stock - 2022 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341596465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341596465" xlink:to="us-gaap_ClassOfStockDomain_638382026341596465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341596465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341596465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341596465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341596465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341596465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341596465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341596465" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341596465" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341596465" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341596465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341596465" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341596465" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026341606465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026341606465" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341606465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2022Member" xlink:label="tlsi_Financing2022Member_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341606465" xlink:to="tlsi_Financing2022Member_638382026341606465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341606465" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341606465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingThirdTrancheMember" xlink:label="tlsi_B2PreferredStockFinancingThirdTrancheMember_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341606465" xlink:to="tlsi_B2PreferredStockFinancingThirdTrancheMember_638382026341606465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="us-gaap_MeasurementInputTypeAxis_638382026341606465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638382026341606465" xlink:to="us-gaap_MeasurementInputTypeDomain_638382026341606465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MeasurementInputFairValueOfUnderlyingStockMember" xlink:label="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="tlsi_MeasurementInputFairValueOfUnderlyingStockMember_638382026341606465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638382026341606465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputSharePriceMember_638382026341606465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638382026341616468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638382026341616468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638382026341616468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638382026341616468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember_638382026341616468" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:label="us-gaap_MeasurementInputInceptionDiscountRateMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638382026341606465" xlink:to="us-gaap_MeasurementInputInceptionDiscountRateMember_638382026341616468" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="srt_RangeAxis_638382026341616468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026341616468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026341616468" xlink:to="srt_RangeMember_638382026341616468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341616468" xlink:to="srt_MinimumMember_638382026341626470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341616468" xlink:to="srt_MaximumMember_638382026341626470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="srt_StatementScenarioAxis_638382026341626470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638382026341626470" xlink:to="srt_ScenarioUnspecifiedDomain_638382026341626470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationScenarioMember" xlink:label="tlsi_BusinessCombinationScenarioMember_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341626470" xlink:to="tlsi_BusinessCombinationScenarioMember_638382026341626470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638382026341626470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341626470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638382026341626470" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341626470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantLiabilitiesMember" xlink:label="tlsi_WarrantLiabilitiesMember_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341626470" xlink:to="tlsi_WarrantLiabilitiesMember_638382026341636466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2TrancheLiabilitiesMember" xlink:label="tlsi_SeriesB2TrancheLiabilitiesMember_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638382026341626470" xlink:to="tlsi_SeriesB2TrancheLiabilitiesMember_638382026341636466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341586467" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341636466" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341636466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_SharesIssuedPricePerShare_638382026341636466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638382026341636466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026341636466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638382026341636466" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341646469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638382026341646469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSell" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSell_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSell_638382026341646469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AggregateProceedsReceivableFromStockOffering" xlink:label="tlsi_AggregateProceedsReceivableFromStockOffering_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_AggregateProceedsReceivableFromStockOffering_638382026341646469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares_638382026341646469" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares" xlink:label="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_638382026341646469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares_638382026341646469" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_638382026341656467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_638382026341656467" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_638382026341656467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_638382026341656467" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered" xlink:label="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_638382026341656467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered_638382026341656467" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrancheLiabilityMeasurementInput" xlink:label="tlsi_TrancheLiabilityMeasurementInput_638382026341656467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_TrancheLiabilityMeasurementInput_638382026341656467" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638382026341656467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638382026341656467" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EnterpriseValueAllocated" xlink:label="tlsi_EnterpriseValueAllocated_638382026341666466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_EnterpriseValueAllocated_638382026341666466" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ValueAssignedToTrancheRightsAndObligations" xlink:label="tlsi_ValueAssignedToTrancheRightsAndObligations_638382026341666466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_ValueAssignedToTrancheRightsAndObligations_638382026341666466" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638382026341666466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638382026341666466" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_GainLossOnEquityIssuance" xlink:label="tlsi_GainLossOnEquityIssuance_638382026341666466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_GainLossOnEquityIssuance_638382026341666466" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities" xlink:label="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026341666466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341636466" xlink:to="tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities_638382026341666466" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails" xlink:type="extended" xlink:title="222141213 - Disclosure - Convertible Preferred Stock - 2023 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638382026341676471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" xlink:to="us-gaap_SubsequentEventTypeAxis_638382026341676471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638382026341676471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638382026341676471" xlink:to="us-gaap_SubsequentEventTypeDomain_638382026341676471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638382026341676471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638382026341676471" xlink:to="us-gaap_SubsequentEventMember_638382026341676471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026341676471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" xlink:to="us-gaap_StatementClassOfStockAxis_638382026341676471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026341676471" xlink:to="us-gaap_ClassOfStockDomain_638382026341686468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341686468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341686468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341686468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341686468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341686468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341686468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341686468" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341686468" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341686468" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341686468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026341686468" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026341686468" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638382026341696468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638382026341696468" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341696468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638382026341696468" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341696468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341696468" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_638382026341696468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember" xlink:label="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341696468" xlink:to="tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_638382026341696468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_Financing2023Member" xlink:label="tlsi_Financing2023Member_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_638382026341696468" xlink:to="tlsi_Financing2023Member_638382026341696468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638382026341676471" xlink:to="us-gaap_TemporaryEquityLineItems_638382026341696468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638382026341696468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638382026341696468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="us-gaap_ProceedsFromWarrantExercises_638382026341696468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfStockOfferingClosingsEffectuated" xlink:label="tlsi_NumberOfStockOfferingClosingsEffectuated_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="tlsi_NumberOfStockOfferingClosingsEffectuated_638382026341706467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638382026341706467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PercentageOfSharesCommittedSold" xlink:label="tlsi_PercentageOfSharesCommittedSold_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="tlsi_PercentageOfSharesCommittedSold_638382026341706467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638382026341706467" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_638382026341706467" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_638382026341706467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638382026341696468" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_638382026341706467" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="222141301 - Disclosure - Stockholders' Equity - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638382026341716468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalShareReservedForFutureIssuanceAxis" xlink:label="tlsi_CapitalShareReservedForFutureIssuanceAxis_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026341716468" xlink:to="tlsi_CapitalShareReservedForFutureIssuanceAxis_638382026341716468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CapitalSharesReservedForFutureIssuanceDomain" xlink:label="tlsi_CapitalSharesReservedForFutureIssuanceDomain_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CapitalShareReservedForFutureIssuanceAxis_638382026341716468" xlink:to="tlsi_CapitalSharesReservedForFutureIssuanceDomain_638382026341716468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain_638382026341716468" xlink:to="us-gaap_ConvertiblePreferredStockMember_638382026341716468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026341716468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026341716468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026341716468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026341716468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341716468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026341716468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026341726476" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026341726476" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026341726476" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638382026341716468" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026341726476" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain_638382026341716468" xlink:to="us-gaap_WarrantMember_638382026341726476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesFivePreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026341726476" xlink:to="tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_638382026341726476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantToPurchaseSeriesSixPreferredStockMember" xlink:label="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026341726476" xlink:to="tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_638382026341726476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesBPreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026341726476" xlink:to="tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_638382026341726476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember" xlink:label="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638382026341726476" xlink:to="tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_638382026341726476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CapitalSharesReservedForFutureIssuanceDomain_638382026341716468" xlink:to="us-gaap_EmployeeStockOptionMember_638382026341726476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsOutstandingMember" xlink:label="tlsi_StockOptionsOutstandingMember_638382026341726476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOptionMember_638382026341726476" xlink:to="tlsi_StockOptionsOutstandingMember_638382026341726476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_StockOptionsAvailableForFutureGrantMember" xlink:label="tlsi_StockOptionsAvailableForFutureGrantMember_638382026341736466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOptionMember_638382026341726476" xlink:to="tlsi_StockOptionsAvailableForFutureGrantMember_638382026341736466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638382026341736466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638382026341716468" xlink:to="us-gaap_ClassOfStockLineItems_638382026341736466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638382026341736466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638382026341736466" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638382026341736466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" xlink:type="extended" xlink:title="222141302 - Disclosure - Stockholders' Equity - Stock Option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341736466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341736466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638382026341736466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341736466" xlink:to="us-gaap_GranteeStatusAxis_638382026341736466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638382026341736466" xlink:to="us-gaap_GranteeStatusDomain_638382026341746468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638382026341746468" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638382026341746468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638382026341746468" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638382026341746468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341736466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341746468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638382026341746468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638382026341746468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638382026341746468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638382026341746468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383820263417464681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383820263417464681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638382026341756476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638382026341756476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638382026341756476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638382026341756476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638382026341756476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638382026341756476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638382026341756476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638382026341756476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6383820263417564761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6383820263417564761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638382026341756476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638382026341746468" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638382026341756476" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="222141303 - Disclosure - Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341766469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341766469" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638382026341766469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638382026341766469" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.001Member" xlink:label="tlsi_ExercisePriceOf0.001Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.001Member_638382026341766469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.003Member" xlink:label="tlsi_ExercisePriceOf0.003Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.003Member_638382026341766469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.004Member" xlink:label="tlsi_ExercisePriceOf0.004Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.004Member_638382026341766469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.005Member" xlink:label="tlsi_ExercisePriceOf0.005Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.005Member_638382026341766469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.006Member" xlink:label="tlsi_ExercisePriceOf0.006Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.006Member_638382026341766469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.007Member" xlink:label="tlsi_ExercisePriceOf0.007Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.007Member_638382026341766469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ExercisePriceOf0.09To0.46Member" xlink:label="tlsi_ExercisePriceOf0.09To0.46Member_638382026341766469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638382026341766469" xlink:to="tlsi_ExercisePriceOf0.09To0.46Member_638382026341766469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341766469" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638382026341776470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638382026341776470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638382026341776470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638382026341776470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638382026341776470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice" xlink:label="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_638382026341776470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341776470" xlink:to="tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice_638382026341776470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" xlink:type="extended" xlink:title="222141304 - Disclosure - Stockholders' Equity - Valuation assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341786472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341786472" xlink:to="srt_RangeAxis_638382026341786472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026341786472" xlink:to="srt_RangeMember_638382026341786472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341786472" xlink:to="srt_MinimumMember_638382026341786472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341786472" xlink:to="srt_MaximumMember_638382026341786472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341786472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638382026341786472" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341786472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026341836481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341786472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638382026341836481" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638382026341836481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638382026341786472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638382026341836481" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638382026341836481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638382026341836481" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638382026341836481" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638382026341836481" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638382026341846471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638382026341836481" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638382026341846471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="222141305 - Disclosure - Stockholders' Equity - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" xlink:to="us-gaap_PlanNameAxis_638382026341846471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638382026341846471" xlink:to="us-gaap_PlanNameDomain_638382026341846471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EquityIncentivePlan2019AsAmendedMember" xlink:label="tlsi_EquityIncentivePlan2019AsAmendedMember_638382026341846471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638382026341846471" xlink:to="tlsi_EquityIncentivePlan2019AsAmendedMember_638382026341846471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" xlink:to="srt_RangeAxis_638382026341856474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026341856474" xlink:to="srt_RangeMember_638382026341856474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341856474" xlink:to="srt_MinimumMember_638382026341856474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341856474" xlink:to="srt_MaximumMember_638382026341856474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" xlink:to="us-gaap_IncomeStatementLocationAxis_638382026341856474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638382026341856474" xlink:to="us-gaap_IncomeStatementLocationDomain_638382026341856474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638382026341856474" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638382026341856474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638382026341846471" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_CommonStockSharesAuthorized_638382026341856474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638382026341856474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638382026341856474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638382026341856474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638382026341866474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638382026341866474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638382026341866474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638382026341866474" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638382026341866474" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638382026341866474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638382026341866474" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638382026341866474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638382026341856474" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638382026341866474" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="222141401 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026341876471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026341876471" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026341876471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638382026341876471" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" xlink:to="us-gaap_PreferredStockMember_638382026341876471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PreferredStockWarrantsMember" xlink:label="tlsi_PreferredStockWarrantsMember_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" xlink:to="tlsi_PreferredStockWarrantsMember_638382026341876471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CommonStockWarrantsMember" xlink:label="tlsi_CommonStockWarrantsMember_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" xlink:to="tlsi_CommonStockWarrantsMember_638382026341876471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638382026341876471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638382026341876471" xlink:to="us-gaap_EmployeeStockOptionMember_638382026341876471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026341886470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638382026341876471" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026341886470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026341886470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638382026341886470" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638382026341886470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="extended" xlink:title="222141402 - Disclosure - Net Loss per Share - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision" xlink:label="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026341886470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision_638382026341886470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_DeemedDividendIncreaseInNetLossPerShare" xlink:label="tlsi_DeemedDividendIncreaseInNetLossPerShare_638382026341896470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="tlsi_DeemedDividendIncreaseInNetLossPerShare_638382026341896470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails" xlink:type="extended" xlink:title="222141501 - Disclosure - Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_638382026341896470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_638382026341896470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638382026341896470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_638382026341896470" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638382026341896470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638382026341896470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_638382026341896470" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638382026341896470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_638382026341896470" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638382026341906470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseAbstract" xlink:label="tlsi_FinanceLeaseAbstract_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="tlsi_FinanceLeaseAbstract_638382026341906470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseAbstract_638382026341906470" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638382026341906470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseAbstract_638382026341906470" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638382026341906470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseAbstract_638382026341906470" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638382026341906470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss" xlink:type="extended" xlink:title="222141502 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638382026341906470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseCostAbstract" xlink:label="tlsi_FinanceLeaseCostAbstract_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="tlsi_FinanceLeaseCostAbstract_638382026341906470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638382026341906470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseCostAbstract_638382026341906470" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638382026341906470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseCostAbstract_638382026341906470" xlink:to="us-gaap_FinanceLeaseInterestExpense_638382026341916478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseCost" xlink:label="tlsi_FinanceLeaseCost_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_FinanceLeaseCostAbstract_638382026341906470" xlink:to="tlsi_FinanceLeaseCost_638382026341916478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCost_638382026341916478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="222141503 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638382026341916478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638382026341916478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638382026341916478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638382026341916478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638382026341916478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638382026341926473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638382026341926473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638382026341926473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638382026341926473" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638382026341916478" xlink:to="us-gaap_OperatingLeaseLiability_638382026341926473" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638382026341926473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638382026341926473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638382026341926473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638382026341926473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638382026341926473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638382026341926473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638382026341936471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638382026341936471" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638382026341926473" xlink:to="us-gaap_FinanceLeaseLiability_638382026341936471" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss" xlink:type="extended" xlink:title="222141504 - Disclosure - Leases - Future minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638382026341936471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638382026341936471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638382026341936471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638382026341936471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_638382026341946470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_638382026341946470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_638382026341946470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_638382026341946470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="222141505 - Disclosure - Leases - Future minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638382026341946470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638382026341946470" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341946470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638382026341946470" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierEquipmentMember" xlink:label="tlsi_CopierEquipmentMember_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" xlink:to="tlsi_CopierEquipmentMember_638382026341956485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CopierInWestminsterFacilityMember" xlink:label="tlsi_CopierInWestminsterFacilityMember_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tlsi_CopierEquipmentMember_638382026341956485" xlink:to="tlsi_CopierInWestminsterFacilityMember_638382026341956485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_AnalyticalEquipmentInLaboratoryFacilityMember" xlink:label="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" xlink:to="tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_638382026341956485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_PrincipalAdministrativeAndProductionFacilityMember" xlink:label="tlsi_PrincipalAdministrativeAndProductionFacilityMember_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" xlink:to="tlsi_PrincipalAdministrativeAndProductionFacilityMember_638382026341956485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember" xlink:label="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638382026341946470" xlink:to="tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_638382026341956485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638382026341946470" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfOperatingLeases" xlink:label="tlsi_NumberOfOperatingLeases_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="tlsi_NumberOfOperatingLeases_638382026341956485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_638382026341956485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638382026341956485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfFinanceLeases" xlink:label="tlsi_NumberOfFinanceLeases_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="tlsi_NumberOfFinanceLeases_638382026341956485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638382026341956485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638382026341956485" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638382026341966472" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FinanceLeaseLiabilitiesCurrent" xlink:label="tlsi_FinanceLeaseLiabilitiesCurrent_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="tlsi_FinanceLeaseLiabilitiesCurrent_638382026341966472" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638382026341966472" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638382026341966472" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638382026341966472" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638382026341966472" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638382026341966472" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638382026341966472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638382026341956485" xlink:to="us-gaap_LeaseCost_638382026341966472" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss" xlink:type="extended" xlink:title="222141601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638382026341976472" xlink:to="us-gaap_IncomeStatementLocationAxis_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638382026341976472" xlink:to="us-gaap_IncomeStatementLocationDomain_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638382026341976472" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638382026341976472" xlink:to="srt_StatementScenarioAxis_638382026341976472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638382026341976472" xlink:to="srt_ScenarioUnspecifiedDomain_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_FirstInstallmentMember" xlink:label="tlsi_FirstInstallmentMember_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341976472" xlink:to="tlsi_FirstInstallmentMember_638382026341976472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SecondInstallmentMember" xlink:label="tlsi_SecondInstallmentMember_638382026341976472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341976472" xlink:to="tlsi_SecondInstallmentMember_638382026341976472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionUptoThreePercentMember" xlink:label="tlsi_EmployeeContributionUptoThreePercentMember_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341976472" xlink:to="tlsi_EmployeeContributionUptoThreePercentMember_638382026341986476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenThreeAndFourPercentMember" xlink:label="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341976472" xlink:to="tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_638382026341986476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_EmployeeContributionBetweenFourAndFivePercentMember" xlink:label="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638382026341976472" xlink:to="tlsi_EmployeeContributionBetweenFourAndFivePercentMember_638382026341986476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638382026341976472" xlink:to="srt_RangeAxis_638382026341986476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638382026341986476" xlink:to="srt_RangeMember_638382026341986476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638382026341986476" xlink:to="srt_MaximumMember_638382026341986476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638382026341976472" xlink:to="us-gaap_LossContingenciesLineItems_638382026341986476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638382026341986476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638382026341986476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsSuitFiled" xlink:label="tlsi_NumberOfPatentsSuitFiled_638382026341986476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="tlsi_NumberOfPatentsSuitFiled_638382026341986476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_NumberOfPatentsTestimonyLimited" xlink:label="tlsi_NumberOfPatentsTestimonyLimited_638382026341996473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="tlsi_NumberOfPatentsTestimonyLimited_638382026341996473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_CurePeriod" xlink:label="tlsi_CurePeriod_638382026341996473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="tlsi_CurePeriod_638382026341996473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_638382026341996473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_638382026341996473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue_638382026341996473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="us-gaap_LossContingencyDamagesPaidValue_638382026341996473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_LossContingencyDamagesPaidValueNumberOfInstallments" xlink:label="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_638382026341996473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638382026341986476" xlink:to="tlsi_LossContingencyDamagesPaidValueNumberOfInstallments_638382026341996473" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails" xlink:type="extended" xlink:title="222141701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" xlink:to="us-gaap_BusinessAcquisitionAxis_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638382026342006472" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_TrisalusMember" xlink:label="tlsi_TrisalusMember_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638382026342006472" xlink:to="tlsi_TrisalusMember_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" xlink:to="dei_LegalEntityAxis_638382026342006472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638382026342006472" xlink:to="dei_EntityDomain_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_MedtechAcquisitionCorporationMember" xlink:label="tlsi_MedtechAcquisitionCorporationMember_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638382026342006472" xlink:to="tlsi_MedtechAcquisitionCorporationMember_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" xlink:to="us-gaap_StatementClassOfStockAxis_638382026342006472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638382026342006472" xlink:to="us-gaap_ClassOfStockDomain_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA1ConvertiblePreferredStockMember_638382026342006472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026342006472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA2ConvertiblePreferredStockMember_638382026342006472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA3ConvertiblePreferredStockMember_638382026342016470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA4ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA4ConvertiblePreferredStockMember_638382026342016470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA5ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA5ConvertiblePreferredStockMember_638382026342016470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesA6ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesA6ConvertiblePreferredStockMember_638382026342016470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesBConvertiblePreferredStockMember" xlink:label="tlsi_SeriesBConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesBConvertiblePreferredStockMember_638382026342016470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB1ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesB1ConvertiblePreferredStockMember_638382026342016470" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB2ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesB2ConvertiblePreferredStockMember_638382026342016470" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_SeriesB3ConvertiblePreferredStockMember" xlink:label="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638382026342006472" xlink:to="tlsi_SeriesB3ConvertiblePreferredStockMember_638382026342016470" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638382026342006472" xlink:to="us-gaap_BusinessAcquisitionLineItems_638382026342016470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_638382026342016470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638382026342016470" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_638382026342016470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026342026473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638382026342016470" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638382026342026473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationWarrantsConsideration" xlink:label="tlsi_BusinessCombinationWarrantsConsideration_638382026342026473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638382026342016470" xlink:to="tlsi_BusinessCombinationWarrantsConsideration_638382026342026473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tlsi-20230630.xsd#tlsi_BusinessCombinationAcquisitionExpensesDeferred" xlink:label="tlsi_BusinessCombinationAcquisitionExpensesDeferred_638382026342026473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638382026342016470" xlink:to="tlsi_BusinessCombinationAcquisitionExpensesDeferred_638382026342026473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tlsi-20230630xex5d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xex5d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L (@# 2(  A$! Q$!_\0
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MMJ=3^QW\0]3TO]F_XAE6:8^&H[J]L=W.W-NTNP>V]&;ZN:P_V / NF>*-?\
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MX<B@GU&VMK**9-.BW9GFEF=2JA>2S*B*,<\\4SXG?\I!-,_["FE_^B(:]/\
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M_A5X*\0W\E]JG@_0-2O9.7N;S3()9&^K,I)KHK&PMM,M(K6SMXK2UB&V."!
MB(/0*.!4]%)12=TC6>(K58J%2;:6R;;2]#AOC9\2H/A)\,];\2R;'N+:+9:0
MOTEN'^6-<=QN()Q_"&/:OG#]@;X:SW1UWXEZP))KR^D>SLI9>K@MNGE]\MA<
M_P"RX[UZY^TM\+]/^+%GHNF:M?ZC:65K))<B*QE1!)(0%#-N1L[1N QC[S>M
M>G>!/">G^!?!VCZ!I49BL+"V2&(,06;C)9B ,LQ)8G Y)K@<75Q5Y;17XL^]
@IXF&5\,.%%/VN*E:3[0A?W5UU>_DVC>HHHKT3\[/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tlsi-20230630xex23d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xex23d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y (X# 2(  A$! Q$!_\0
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M:]##UZLJ<W*3=O-_R3.6K3@IQ2BOZE$]._X9N^$G_1+?!?\ X3UI_P#&Z/\
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M7*NQ0$X&6QR17=#A>4;1Q&(C&3V6[_-?@<TLX3NZ5)R2Z_U<_;^OB;_@J_\
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(#4HTD[V/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tlsi-20230630xex23d2002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xex23d2002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  K ,8# 2(  A$! Q$!_\0
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M '(>#KJ?XE_#C1[OQ=X4&CWE_;)+>Z!J:I<?9Y>Z-D8;!&0<>G0UUZJ$4*H
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tlsi-20230630xs1a002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !) 2 # 2(  A$! Q$!_\0
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M%G5O^O2;_P! -<-^S<?^+.Z#_N/_ .AFNX\59/AG5N?^72;_ - -<+^S>?\
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M$URPUV.S)\!.C5=;%)P7+*R>C;Y7T_-GWD!E17F/Q2_9Q\#?%N3[3K>DA=3
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M?6?^O^;_ -&&@Z,+3]HI(_=& @Q@K@J>01TQVI9,;>>E5]*_Y!MK_P!<D_\
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>P2 1\ >&/^3]8/\ L*'^8K]78_NT#Q%Z3C)/4__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tlsi-20230630xs1a003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (, OT# 2(  A$! Q$!_\0
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M6BBN,[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)-  I< C!I5P<XI%6$QGK0./_P!=. HP/2@!.N>OYT!<]:7&**  J!28/O\
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M4]N?RKVK5_AGX7UJXU"XO]#M;J?446.Z9P<S*O3//4>HYJ+1_A9X2T,Q?8-
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MFEV<EU>745G:QKN>:9PJ*/4DUP9\?^(/%0"^$/#D@MVX.J:^KVL _P!I(_\
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M.@_L]-,N5MIHO]+A3[N\LA((]5Q5QO@G96EZ\^E:_KNAB>"."[CT^:-5N0@
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M.IIU9&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"G;>:3/%/4<\TA"XX]\4JT8S]*=C;]/K0,4\@]JKW5U#96\D\\BPPQJ7=Y"
MJJ.Y-3,05/85YA>(WQ>U^?3D=D\':9+LNY(VQ_:%P#S"#_SS7^+U/%0V5%7>
MHP&^^-%W\K3V/@6)NH)2752#Z]5AX^K?2O3[*UAL[>.""&.""-0J11*%5 .
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M&L]NCR$9)(YS73_#_P  6OA;3XP$!E/+,1R37;(,+_*NB,4C*4GT/.Q\%="
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M$_\ T ;K\U_QH_M[Q1_T ;K\U_QKT'%&* //O[>\3_\ 0!NOS7_&C^WO$_\
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M>>AKV_RRL1&=WRD9/4\5XU\ /#FJ^'OASK]GJ>G7-A=3:E?R10W$11W5R=C
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M2R@7?)-*V%4>OO\ 3K0(X?3/@1X>M-3U34KR?4=>O-3LS87<FK79F\R'.=N
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M7 SMMU'"CJ:#BEQN;VJ1K<<QVC-<UXZ\9V/@;PW>:O?.J10(6 ;JS=@*Z-R
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M8I<L AVG+9!;VKOM ^$/B*+5=.N-8\26CPZ9$R6ZZ-IJV;S.5VB2<Y8.5'(
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M=JNJ<+6'XX&?!NO?]>$__H!JV1!7E9EW0M537=%L-1C1HX[RWCN%1OO*'4,
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M.?<TO%+BD)J@$_&G+BDP3ZT] 0><TF,5?\\4OY44N/K4E"=?2G!?I0HX]*4
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MV"C%]3O <#M2YX]ZX/\ X5WK_;XBZX/^V4/_ ,33O^%>>(/^BAZ[_P!^8/\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \Z\4?\ (=N/HO\
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MF YKQ3Y$<..E*HQ24Y>E26+1110 4444 %%%% !1110 4444 %%%% !1110
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ME5CZ<,"1SS4MFRINUT?060#UQ7-?$#P):_$;PY+HUW=36D,DB2>;;A2X*L&
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ME!)P,9YKPJM-TI<LE8^!QN%GAJKA)6)\_2C&*:'#'%.SS6>YP![TH-)WHQ3
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M9S@,XQSZ9S7DOCKX46WBR\9A/;2V1.Y':0!H_P :3P+^SL+3Q!92Q>(+.TM
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MALK?_GDF.GW11]CM@<"!,_[HH^L+L4L/W9RRG<#1P:ZE[6  XA0\_P!VFB"
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MA:Y;'B]"8#!Q2;_K^=,!(I00:+#)%;CH:7<*C&#W_*@'M2 DW#'_ ->K5O\
MZL?6J.?S]*N6AS"/K42V-(EBBBBLC0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0UY5\7-$\0
MZKXD\$W'A^UMY9[+4)999;U&>WA4V\BAI-OS#)( ([D5ZJ>E>3?M&0747PQU
MO6+#5M5TB_TVW>:&32[UK?<V0/G"_>'H#[T <YH'P;\6>!Y[&7P_JNBSRC23
MI]RVHPS##M,\C/&$[ N0 >PK3TOX1ZUX%GT:[\)ZCI[7UOIW]G7D>KQ.8;@;
MS()%\OE6#LW'0@^U.\-B]\._%S3-"36=6U#3)/#DMZ\>IWKW),WG1 /EO0$@
M?C7F/COQ;K%KXP\?M%?^,$NK35[>RTJXLKTII-J[Q1;4G4L %W,2V5Q@]10!
MZY>_!6#Q-:V$OB+7]2O=6B0^=/;R1HC,SE\*K1L0@)(49X %0Z/\ -"3Q-KF
MJZW;6^L"\N(9+59&DS&L<84!U!".<C/3%<)/XK\6^'_BI$]]=:E>?:==-E&D
M-TK:6;3R QC$88LLP.YB2N0,&NMTWXAW?Q36_P!'N-,U#PW&D#3K>Z;J,\4V
M5Y"AO(3&>X!_"@#G_%7[._B#6M.U;3K77[*+3]3U&^NY[:19E3;,BK$3L(+/
M&5S@G:<].*N_\*&UD>*M&U.+5-+LUM;>"*ZEM8IA+=>7;^5LD4DHPXR&P&'K
M6;X)\2ZYX:^'GA.]M-3O=;\0>*+XV(F\1W\MS;6Y5Y/FV9!'" 84@DUS#?&7
MQ#X@\2V5X^HSZ=;&>PBN+6QF9X"1=2QRE!R2KA.G)QQ0!V5U^SIJ$_ARTTY-
M7L%DAT%M),@A?:7-TLV_'IA2,'G-6+GX"ZYJOC\:WJ.N6LMC').(UVS&=898
M?+\L G8NT\@@9.3DUD_$WXL3IXZT>71;Z^?2IK- ]MF>S!D-VB;]I"L< D<C
M!!Q65X3^/_B/3?A[K%Y- NIW.E7/V55O"[W5Q)+<LL<OW@!$!A0.I*]10!TO
MB/X=>++;X<RZ5=&SU._A%K;:6V@V;))$T;<33.YSM )R!P!G'6KFM? "ZU B
M&RU"UM+&/0[:PCB='=EN()_.1CC@QEL@CKBNB\)^.-;\4> O$-SK&G#1]8T\
M3Q'RL)DJA*N$$CE#TX9LUY#\-/'6KV%]X:O'NO%DSOHEQJ>I1>(KSS8+U50$
M?906/S;O3! /(YH [/4OV>=6\30W$NJ:S917U_<W5W>+912")'E@$*",'D@;
M03NZ\UUGP]^'NNZ'?>(KS7+S2I;K5+6"V5=,ADC1/*0H&(;G)!'3I7!Z1^T-
MXMFT)KF]\.V5E<WJ6CZ=-< Q08GD"*9%\YG*C(.\;0>G%7/$_P </&.A:A#I
M%MHVE:OK%O;SW=]+ITAEM_+CD"8!,J&(\\[RVWN*8&AH?P=\0SZ9H.B>(M2T
MEM#T0.T/]F1S+/-(5959V?@ ;LX7J0*P-*_9EO\ 3O#>J:5]KT2%Y;9+."[M
M[><RNBRA]TI=C@D*/E0 9YK5U'XY^([;7+HII^DQ:5;WMI9/"[N]XQN$4J5V
MMM.TGD8.0..E<WX6^-'C2Q\*VT4DFCW^HK#J.JW-UJ)F4/!%<M&(H\/]_)X[
M*H'%(#JM4^!VM)XCN]=TG4],6^DOKFXCAO8)##Y4T B8-M.=XP2".*@MOV?-
M2B\-WVF_VO8^=/HB:4)5A<!667S-V/[N.,5V'PW\?:SXY\2:X'MK"TT6Q\E(
MU4.;AVDC63);.W SC@5YWI?B;Q5I'Q=TZWOKS5KDW^L3VQ7[2DFFM:B/*K%&
M&RLB=6R!CN: )YOV:M8O+F82ZW8K;">[GA*PR%_WT2J V>.&7MU'O7I&C>"=
M8U#PMJVF>*+C3'EOT\G=HULT2QH$VY+-\SMWR>G2N]C(;'3GUJ;R5!SWH \9
MG^%WC+Q!X=/AS6_$MDFCPV$EE&=,BD26Z)3:C3AN, #E5ZFN5@_9DU*30UM6
MN-!L+I)H3YEC;SD21QH5!=I&+;B3G ^45](>2N<XH\E>3CDT ?/OAOX!Z[X8
M\1:-J=MJ.E1C3D#3-:0RK)>E4*['0DH><8<88=*]MT&ZNKS3K*:_@%I>R1*\
MT')V.1RO/H:UO*7TYIOD@<CKZF@"0=*6D7ITQ2T %%%% !1110 AZ&N;U3F\
M;/M72,< US.JDB]?VQ6]'XC*IL0@9QZ4 [335/3TI3QS78SACH/I0<4S=G%.
MS4FH\<TH/7TI@..V*7O2'8>.>:<&J,/VI>:!>I)VS29/I2!\CI3L&E82?<%/
MYT[K3<&@'!I#W%QGVI<8I<^U(U T]0!YYI<<4S&33@?;FI:N:(0QJW4?G3@H
M88QGZ4OU-*,#OBIL%[:"; .*4QX&!0#EL@\TO/\ >H2"_D(#AL9Y]N*D1-O/
M6H\8.<T\'/<T6)=V.SD^E*1Q2#!I00*!W%Q2;3[TN1V_E1D'_P#53%< "!WI
M.AI3]/QI,>M P[]*4'V-( 1T%'XTAW%SS[UH69S"/K6:>.16A8KB$'K6<]BX
M%FBD Q2UB;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "5G:QH%CXAT^XL-2MH[ZQN%V2V\Z[D
M=?0BM*DQ0!RWB'X7>%?%MU;W6LZ%9ZC<V\9ABEGCRR)U*@^G'2K8\":"MIJ-
MJ-)M/L^HC%Y&8P5N/D"?/Z_*H'T K?HH YC3OAKX8T?5X]4LM#LK;48XA MS
M'$ ZH%"@ _0 >N!70/;"2-D<[T.00QR"*FQ2T <W>?#OPY?^'TT.XT:SETB,
M[DLFB'EH<DY ['))X]:CB^&?A>&2&2/0;!)(!$(F6  H(R6CQ_NDDCW-=110
M!@:OX%T/Q!>17>IZ7:W]U&H1)KB/>R@,& !/^T ?J*IGX8>%3;O =!L# \+6
M[QF 8:-F+LI]BQ)^IKJB,T8H Q-&\%:)X=T9M)TS3+:QTU]VZUAC"HV[[V1W
MS4;> O#[V^F0-I%H8=,_X\D\H8M^,?)Z<<5T%% '(VGPF\'Z?IU_8VWAO3H;
M2^&+F%;<;90#D ^V>U17/P@\&7&G65E+X9TR2SLF+6\+6XVQ$G+8^O?-=G28
MXQ0!Y]I7P;\.:?XSU'Q-+917FIW4JRQ23Q+_ *+M0*!'^ K0NOA!X,O((HIO
M#.FRQQ3O=(C0 A96Y9A[GOZUUXB4$''(]Z?0!FZ?X>T[2I[N:SM(;:6[<23O
M$FTRL!@$_AQ6;%\._#L&MW&LQZ-9IJMRI2:[6("1U(P03[CBNDHH JV.FV^F
MV\5O;1+##$H5$3HH P *M444 %%%% !1110 4444 %%%% !1110 C=/:N9U4
M@WTF.F!72M]TU"L:M@E02>.E5"?([F<X\RL<IGYNO%29S]!74B-,_=7\J?Y2
M$?='Y5O[>_0Q]AHKLY,L.QQ3@QQUQ74_9X\_<'Y4ODI_='Y4.MY%*BD<L6^G
MYT"0],UU!C0?P+^5*(TQ]U?RI>V\BG31S /O3PWM72&-/[H_*F^4G]T?E2]M
MY"]GV.=!]J?OS6_Y:_W1^5'EI_='Y4>V\A>RON8&ZE##V_.M\1H3]T?E3O+3
M^Z/RI^V\@]DCGMP_R:4. >N*WS$A_A'Y4>2G]T4O:^0>R1@F0?WAFC=[BM[R
M4_NC\J/)3^Z*/:E>S,'=QZTH8D5NF-0/NC\J0*O90/PJ?:KL-0,4'G@4H!Q6
MT44#H*0 '&5'Y5/M%V#D?<Q\L#THY]*VB .P_*DX]!^5'M5V'R/N8W(Z"E7(
M[&M@@'L*./0?E1[1=A<C[F1N/I1FM; /4#\J H7H!1[5=@Y'W,KJ.M*%_P!J
MM554C.T?E2[%_NC\J?M Y'W,D':>#FEK5\M<]!1L7T%'./D,KW-7K(8AS4^Q
M?2E QTI.7,AQC86BD!S2UF6%%%%, HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tlsi-20230630xs1a004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '6 X,# 2(  A$! Q$!_\0
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M-U/&1VKG]9\6WVD:%I.NZ3?^,KK51=Q^?J]V98K&?+8($<F!M/;"T ?<$SA
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M>,17$UF$9)E'3<K*1GWJWX ^!>G^$+C5-1U"_N?$6NZFGE76HW^-S1X(V!0
M .3T'>O3Z* /#(/V:;OP[]IM/"GCK6?#FBW#EVTZ$12(F>NTLA(_.O0?A_\
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MM0DD,C]V"NIP?I7KU% 'CG_"F[#P/X5\5ZA'-=ZWX@U&SD%Q?W3;I9/E.%4
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MB@#B/ 7PSM_ EWKMQ#=RW+ZK=F[<2]$)["NRCC*MG/']:EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :YP*Y#X
MC0:]?>%KNV\/)"VHSH8]\K[0H/4BNO<9J(Q$]?O'J:RJ0YX\I<)<DE+L?#NI
M_LX_&"(-_9L]EALY2:X5E.>O!4US,7[(_P 4;C54O[[0M&BOE)VWVG:AY+<]
M0R$%6'MBOT+V@+@G)^E1;0[8QD9K@PN6T,+K!;'TD^(L;*#A=*_96/.O@+X%
MU3P!X$AT?4Y(S)'(S+'$VY4!Y(!^I)_EQ7::9X;BTVWO8D=B+J1Y'/NW6M6&
M/9G@#)[5+7I.*;NSYOGEKYF#!X7AA\.MI =OL[1-$3WP16=KG@)[^6UN;#5;
MK2[VWC$2RPD%64= RD$5U]%"BE:PU4E%\R9Q.E?#9([ZZO\ 5]0GUF^N(#;&
M2?"JD1ZJBJ!C/Y\5D77P=DU'2)-$N]?O9M"*E$M!A2J_P@L!D@5Z;11RHT5>
MHFVF<O#X'MH=:T_4C*[2V5LUK&IZ%&QG/O\ **Q1\+9;*ZNAI>NW>G:?=R&6
M:TB"L-Q.6*E@<9YS]:]"HIV1*K3CLSA-.^%\>@^'H-*T?4KG3EMI&DBD3#'D
MY(;(.0:O>&/ QT34+G4[R^DU+5;A0DES(H7"CHH XQ76T4E%('5FTTWN4VLV
M+$[_ ,Q15RBKN97"BBBD(**** "BBB@ HHHH **** "BBF2.5' S0 ^BH5D#
M]#C'6I#@CK0 M+3%(-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"!5>HH H_V?)_S]S?G1_9TG_/W+^=7J* */]G/_P _4W_?5']G/_S]2_\
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MU_1IVD6/Q#;2,@RX6[0[1ZGGBG0ZSI-Q;2W$6NV\D$7^LE6Z4JF?4YP*^3-
MTIHOA!J^GF"[DUE[>1/L/]CA)@=__/4*';CWJ#Q-H4^I:*+C0=%OX=,AT^VB
MU".*S:,2S!TR?+'WB #DU0'V%I]Q9ZI&9++54NT!P6MY@X!]R":NC3F//VF7
M_OHUXE\'(/\ BN];OM'L+BP\.26L,8C> P))< ?,RIVXP,U[Q']T5(%3^S7[
M7,H_X$:/[-?_ )^IO^^C5ZB@"C_9\G_/W-^=']GR?\_<WYU>HH H_P!G2?\
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M=])\'7?@^\D\)W%OYMSXD3F. GH< =!WKVNV\367B'18K_2+R*[MY<%9XFW
M_A6E/;I=@I)$DD9&"' .1^->6>)_@C]DN+G5O ^I2>%-6)+M!"-UG<-_MQ?=
MYZ9QFA)7U-':2LCU"PNG^V+&R$97)8=#6S7AOACXQ7?AJ^BT_P"(6COX<N
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MC(]:+H!U%-R/6C(]:+H!U%-R/6C(]:+H!U%-R/6C(]:+H!U%-R/6C(]:+KN
MZBFY'K1D>M%T ZBFY'K1D>M%T ZBFY'K1N']ZBZ =2'I29']ZD)]Z+KN !_4
M4GF'.,4TOQD@4W>01P #WI7 FWT57>4*Q'-%%WV*Y66J***HD**** "BBB@
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MC//S MG]:]+T+PEJFE73RWGBK4=9C9"@@N88$5??*(#6T$NQ_P O+?\ ?/\
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MO\:/^%WZU_SZVGY-_C7GN:,T?ZV9W_T$R_#_ "%_8V _Y]+\?\ST(?'#6O\
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M6R".)1WQFLJW@$8C)^9BW)K94 "N>>]CI@M+CJ***S-"/RESTH\A.>.M244
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M(;3XMZ5)XQU/P[<A[2YM)%CCE<?+,2"<#TZ=ZGF^+_A: VI;4PRW#%$:.!V
M(.#NP/E7/<UY_J_P:\0^(M*U[497M-/\4ZA<QSP*C[X[?;D ;L\D@FJOB']G
M^^^V6;6$4%];2VJ6UVDESY2QL""7QU;..@(H$>EZG\6O#VGW5Q:K<M+=Q*S*
MGDLL<A49*K(1M)QV!S42_&#0+3PWI&L:K,VFIJ<>^"$QF1CUR/ESZ5Y5?_ W
MQ?J&KQRRRVCV]O(3%-YX"M'M"@"/J",=23FNKO/A+JUSHGA"S62U>72H)$N
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M&G36QLKRY,CVL<JQ$KY87.[!Q@]AC- 'KW_";:(=%L]6^W*=/NV"Q3!3@D]
M?3\:QM5^+GAO3=.EN8]1BG=96A"8(RZ_>%8FG?##4U^"L/A.=H5U2"+;'(K
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M!W0VJ?[P]Z#@@<?E7DFC?'E=5N=:F-I8IINF&3.V\!N'V\9\O&1FJZ?'^Y2
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MM[K1;JWDMX3-$JS1R&8 XPP5CM/UQ3(/@ ([>(MKTJWBW/VAIK>%43IC 0
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M'0C1')SUI]9,=U):8#9DC]NHJ]!=I./E89].]0U898HIA? '.*<,FD M%%%
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M6^(D,OB/Q-KFMZ9+J!$EKING7[VZ6L!^X"%.-Q')/OCM70CX#V/_ $,OBO\
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MP7S+<?05S9Z&ND\%_P"MN/H*B?PLA['C?Q6'_%;WY]EKE4Z=JZOXK''C:_\
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MT_%+0 4444 %5920QQ5JDP/2@#S2S^%UQI/B/4=<M?$>H->79+-'/% ZCCA
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M*>N:J"5_[QH\U_[QHY6!:$*#&!BI:H>8YZ,:/-?^\:.5@7Z*H>;)_>-'G/\
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M2O\ \+@\%?\ 0T:7_P"!*?XT?\+@\%?]#/IG_@2O^-6?^%:>%"?^1=TS_P
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M\T_2+33[>.2:VN%/^DD_>P<\9[5PVM?&'Q7XC\.WY>%[;3[I"T<RQ/ UN5<
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MKP.]4M1UK3M'"/?W]M9!SM5KF98]Q]!DT3:UIUM<00SZC9I-/_JHWG4,_P!
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M(I, ["<@ ].?2N)OK&YCN=4N/^$=E>'4K'[/;0J@;R6Z?,,?(">>U5;KP7J
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M,/=/]X6\?584)Z*,\XZD"O0_[1G=@ /*7&3N[_\ UZXVI7-W+2R-<P10J4C
M7=SBO(?CCXALO"MGI^IZA.+:SBD.YSSN/]T#N:V?&'Q5L_"M[!I\,4VL^(K@
M;;72;0!G<GHS\_(GJQXKSW7_ (6ZOXB^S^*O&T\6HZQ!.'@TR%BUG8KGHJGA
MG]6P>>AK6GI.S,G&ZNR"PTO7?C/%#/JZW'A[P;NRFFAMMU?^\K#A4_V1FO:M
M$TRTTBQM[&PMH[2TA3$<,0PH'TK-T@[X4)ZX[=:WK904!Q@].*WDM3!3;T1?
M"_(AJQP9(A[U#%S",]:F3_CYA'O7+(T6YJKTI:04M<YTA1110!7NAB/CUK&O
M]%L]4FMI;JUCN)+63S86D&3&_P#>7WK8NS\@^M>7?&?4;BPM]%C^U75CI$UV
M%U"YM&9)$3'&&3!'/H:I =-?^ M!U-;\W.D07#7V/M9*<R$=,\]L]JYF[^!/
MA2]U^POY-.1K6SA,,-C@^6,G);KDFO&_&WCB>.^CAT34=<NC:"(V]Q<S3PEU
M+=50'$ON7!JRFKZZEC?WM]JNLQV4^L-#>3B:8?9X!G 3!^09QRN* /;[CX=^
M#M2UQII='LYM3B5<Y4Y4#[IQTXJ6[^$_A6^A>.XT*UDC,WVAE*D9?^]UXKY\
MU?4M2O\ QSIVGZ5K6O/HUP]O#]L_>Q3/&6;(W<'\2:M7&OZU;6T=IJFKZS;:
M1;RW207*22B:69<>4CN#N8?4X- 'T%=?#CPQ?ZA:7L^BVLEU;*JPRE2-BCH,
M#K^-0#X7^%8YKN4:':E[D?OQM)##.<8Z 5\\SWGBW5YC<7FL:]:W)N+.#RX)
MI8T".%#_ "J0,D'KVJQJ_BS5=,T:32I[S6IY+>[N$MYGO)H054#:&D5@[G)X
M!R#0![[??"CPEJ-LD%QH%F\,;%D0@C!/7I3;CX2^#KJ)8I?#]D54@_=(Y'3G
M-+\*-3O=7^'F@W6I/)+>26RB5Y00Q;'\6><UUVP>N1Z$TUJ!AZ'X+T/PY<"?
M2]+@L9%C\G?&O)7T^E;HY_\ U8HQTYZ>]*H&,=!32 3'M1^%+WQ2L *8#<>U
M.8<]*;^5+G/I0 F/:E'Y4GY4O:@!<\^U(]!/2D//7% NIX5^TY/K=SX:DL(-
M)OYM$6/S[FZLMIRP/"')!Q[BJ6KZ7#/XC^%.L/%>17+A$,,Q^6,!/[HZ5] 2
M1),A1T1T/!5@"#^%,>S@D*%H8V*<+E1\OT]/PI6&>1_&KQ-X;>"#3W2SO=:O
MU>WMYYP3' .C,Q'3'TKRB_MKOPUXF9'NK?47@6VBLH9K=I#=+ZHV1CFOJ&'P
M?HD,;1_V9:RHSF0B>)9/F/4_,#5X:58[H3]BMLPC$1$*YC'^SQQ^%*P'S?X0
MVR>-M#BBC,/B1=3FDO1\PD$..C'IBOIO))(QFJZ:=:PW+W"VT*W#\-,(P';Z
MMUJ8?+TQ30!C';]:,>U'Y4?E3 .G:EVD=:3\J7.?2@!,>U&/:G8'M2$#/:@
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M/K104&/>ND\&#+W/T%<WS72>"_\ 67/T%1/8S>J/'/BM_P CK?CV6N43[O\
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M>M=)N+36Y(R"<>E+CVH[XQ0,3&2.,#M@8H SG(8^N3_*G#K0._% " $=.#W
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M9'.FTJE;W?*_]?,A8Z,XZ4]3V(6T;Q"/R4=5P=F. :?Y7# H",8P>./2N/\
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MCCN8H[:6)MI&2CH[$@#^]T/:O2X?@5X/CNVG^P2%]S,JM-\J;A@E1CC-3?\
M"E_"L6F?8_L<TT?G+<;Y)<R%E^[\V.@]* //8?COXA;Q-<Z9;6VGZMF"66W%
MK;RKM*''WRQ$G_ :=J'QYUNRTFT@,5C-K%U,8LI8S;8L+N(>'=OSVZ^]=Q9_
M WP9;3>='I\OF%65<R_ZL-UV\<59;X,>%GTC^SC:2L-_F&<R_OPW3._'I[4
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M"U/_ "Q(_P"!'_&BX6$"H,X_G1M7/;\Z<;&T&/W7'KN/^--:SM N?)Q]7/\
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M#Z9-<OJOQ:^(L&M>/;J>:SFT>P,(2!9'C>,,5VA2![\FO5M9_9)\':OK5UJ
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M%(6 ZFC<* %HI-PHW#UH 6BDW#UI"X'4T .HI-PHR* %HHHH **** "BBB@
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M*!'B?AWXZ>,?%?B:YGT[PDD_@R&[>R>^6Y G5UZML(^[^-0P?M'ZG+H-E?\
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M<5?VH ]A@&7&1UJUM%5K=2K 9SZDU:H 3 HP/2EHH 3 ]*,"EHH 3:,TM%%
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MK1503<[LY*XQM]L4EG^RM'=^"M<L=>UV;4_$>JSK=2:NJ*I251\A50  !]*
M..^&GC.X^"_C7Q3H=W?:SKV@6MI#>1VY_P!)N$=^H7ID9-;GP"_:?N?B#XCU
M31M9LM0ED>^>.RDAT_9%%$.BRMNX:NV^#GP1O/A_K.IZ[K^N-XA\07JK$UV4
M"*L:]%55 'Z5WO@CX=:%X&.IMH]J]N=1N6NKG=*S[I#U/)X_"G<#I820V,8'
M;FIZ8L8':GT@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.SU6X@VV]TZYRJ-WZ5L_!SX,:AX ^'VH^']8U1;^6^,FY8"1! K#&V('&%_
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M5G&U#^7->GQ2K* RG<I[T")J*** "BBB@ HHHH **** "BBB@ HHHH ****
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MEBUM%\P"M\O4=J** )!:P11&(1+Y9X*!>"*:ND681(Q:Q*L;!E 484^HHHH
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MN*,1JJJH4#L.U%%,":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tlsi-20230630xs1a005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $I G@# 2(  A$! Q$!_\0
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MYHQ379^Z_LQT^4N;I;Y%'Q/^TUXO\)W6FZ#J/AG0-,\6S027UU!J&L"&TMX
M2(U$I^]*^#QGTKV#X1_%"U^+_P .;3Q':6[61E\R.:V9P_E2H<,H8=1W!]#7
M)?%O]GR7QYXQM/%>B:Y!HFMQVALIOMFG1WL$T1)(.Q^ RY.#7>?#7P"?A_X*
MM-";4YM6EC#&6]GC1&D=NIVJ  .P'/U-8U'2=-<J][YG=A88Z&*FJTFZ=M/A
MUVL]+.^]]+?@?"O@>S\.ZO'KDWB#1?B+K=Z-5N42?PVSM;J@<X4G^\.?PQ7T
M9J_QA\1^#_%>C_#WP;X23691H$5[;MJU\T,L2@'(F..2 ,'N6-,\._LU>/\
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MQ+)I">%9OBCJ$O@-7R-*^R*)3'G/EF3/3]/:MO4_!G]I_';P1H^FV,MOX?\
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MPC^R)JGAC5?#5R?&-K/;Z!<M+;6\>CI&9%.<^8X;<S\]3FK4J$H^]O;S\_\
M@&4Z68TJEJ-VN:[?NZKW=]O[VWW;' ^ OCI?_"3X;:A<I:Q:C<ZAXFNK5+G4
M[ETM;8 GF1@"0/0"OHWX'?$W4_B=X>N+[5-.T^SDAF,:3Z5J*7=O./[RD'<O
MT89KA$_9=U/3O"-QI.F^-7M)Y-5EU++V"26TP<Y\J:%B0X'K^E=;\"?@4GP<
MCUF:34TU'4-5G$TYMK5;6WCQT6.)20!4UI49QDX[W\QY?2S"A5IPJ7]FEK\-
MD[?-O7T]3UNBBBO//JPHHHH **** "BBB@ HHHH **** /$?&O[7?@'P#XJU
M'P[JIU4:C82".;R+$R)DJ&X;//!%8G_#=/PR]=;_ /!<?_BJ^1?VG^?V@/&W
M_7XG_HI*\N (S7TE/+Z,H1D[W:1^1XKBC,*.(J4H<MHR:6CV3]3]#/\ ANGX
M8_WM:_\ !<?_ (JD_P"&ZOAEZZW_ ."X_P#Q5?GH>,FE#9J_[.H>?WG+_K9F
M/]W[G_F?H5_PW3\,O76O_!<?_BJ7_ANGX9>NM_\ @M/_ ,57YZCK2X]\4?V=
M0\_O'_K9F/\ =^Y_YGZ$?\-U?#+UUO\ \%Q_^*H_X;K^&/\ >UK_ ,%Q_P#B
MJ_/?;2;:?]G4/,7^M>9?W?N?^9^A/_#=7PQ/\6M?^"X__%4?\-T_#+UUO_P6
MG_XJOSUSCWI<CZTO[.H>?WA_K9F*_E^Y_P"9^A/_  W3\,?[VM?^"X__ !5'
M_#=7PQ_O:U_X+C_\57YZ]\TJCFG_ &=0\P_ULS+^[]S_ ,S]"?\ ANKX8_WM
M:_\ !<?_ (JC_ANKX8_WM:_\%Q_^*K\]<BD(P/:DLMH>8?ZV9C_=^Y_YGZ%_
M\-U?#+UUO_P6M_\ %4?\-U?#(_Q:U_X+C_\ %5^>O44=?K3_ +-H>?WA_K9F
M/]W[G_F?H4/VZ_AC_>UK_P %Q_\ BJ#^W7\,?[VM?^"X_P#Q5?GML I=HH_L
MZAY_>'^M>9?W?N_X)^A'_#=7PQ_O:U_X+C_\51_PW5\,?[VM?^"X_P#Q5?GK
MQG XH!&<8I?V=0\_O#_6S,O[OW/_ #/ON3_@H%\*XM;@TLG7/M$T#W"G^SCC
M:I /\77YA5__ (;J^&7KK?\ X+3_ /%5^9EX!_PL[2A_U#+G_P!#CKJE%1'+
MZ+;W_JQT5>*<P@H-<NJOL^[7?R/T)/[=/PQ'5M:_\%Q_^*H'[=7PQ_O:U_X+
MC_\ %5^>M*#QFK_LZAYG/_K9F/\ =^Y_YGZ$_P##=?PQ/?6L_P#8./\ \51_
MPW3\,O[VM?\ @N/_ ,57Y[#!/O2XH_LZAY_>/_6S,O[OW/\ S/T(_P"&ZOAD
M/XM:_P#!<?\ XJC_ (;J^&1[ZW_X+3_\57Y[#FD(P:/[.H>?WB_UKS+^[]S_
M ,S]"O\ ANKX8_WM:_\ !<?_ (JC_ANOX8^NM?\ @N/_ ,57YZ]#SS1G%']G
M4//[P_ULS+^[]S_S/T*_X;J^&/\ >UK_ ,%Q_P#BJ#^W5\,?[VM?^"X__%5^
M>HQVI,_-3_LVAY_>'^MF9?W?N?\ F?H5_P -U_#'UUK_ ,%Q_P#BJ7_ANKX8
M]CK7_@N/_P 57Y[ \XI<8I?V=0\QKBO,?[OW/_,_0C_ANOX8_P![6O\ P7'_
M .*H_P"&ZOAB?XM:_P#!:?\ XJOSUHSBC^SJ'G]XO];,Q_N_<_\ ,_0K_ANK
MX8_WM:_\%Q_^*H_X;J^&/][6O_!<?_BJ_/8')I<4?V=0\Q_ZUYC_ '?N?^9^
MA'_#=7PQ_O:U_P""X_\ Q5'_  W5\,1_%K7_ (+C_P#%5^>I.#29QUI_V;0\
MQ?ZV9C_=^Y_YGZ%_\-U_#'^]K7_@N/\ \51_PW5\,?[VM_\ @M;_ .*K\]<Y
MHS2_LVAY_>'^MF8_W?N?^9^A0_;J^&)[ZW_X+3_\51_PW5\,O76__!:?_BJ_
M/4G!H.#Z_E1_9U#S^\/];,Q_N_<_\S]"O^&ZOAB.^M?^"X__ !5'_#=?PQ_O
M:U_X+C_\57Y[8^:@@YI_V=0\_O#_ %LS+^[]S_S/T(_X;K^&/][6O_!<?_BJ
M7_ANOX8_WM:_\%Q_^*K\]J"<4O[.H>?WA_K9F/\ =^Y_YGZ$_P##=?PQ_O:U
M_P""X_\ Q5'_  W7\,?[VM?^"X__ !5?GIGB@'(I_P!G4//[P_ULS'^[]S_S
M/T+_ .&ZOAC_ 'M:_P#!<?\ XJC_ (;J^&/][6__  6G_P"*K\].AQ3@H(H_
MLZAY_>+_ %LS+^[]S_S/T)_X;K^&)_BUO_P7-_\ %4?\-U?#'UUL_P#<./\
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M5-*:/[-H>?WA_K9F7]W[G_F?H3_PW5\,O76__!<?_BJ/^&Z?AEZZW_X+3_\
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MHH_LZAYA_K9F7]W[G_F?H5_PW7\,?[VM?^"X_P#Q5'_#=?PQ_O:U_P""X_\
MQ5?GOMIIP.U']G4//[P_ULS+^[]W_!/T*_X;J^&(_BUK_P %S?\ Q5'_  W5
M\,?[VM?^"X__ !5?GO@$=*:0,T?V=0\_O'_K9F7]W[G_ )GZ(6?[;_PUO[RW
MM8CK)EGE6)-VGD#<Q &3N]317P#X7_Y&?1_^OV#_ -&+17+6P5*FTE<]K+^(
M,9BHR=2VG9?\$[[]J$[?C]XW.,_Z8G_HI*K>)_@9KOAO0M>U<7-KJ-MHFJ#3
M+Q;<,&3*1MYX!_Y9@RHI[@G)X-6/VHAN^/WC8=/],3_T4E7M2_:"=]?.IZ?I
M!B636[C4;BTNY%DBN;6:VA@DM9 !R"(B<].5/45Z474]G#D[?HCY"LL,\7B?
MK#L^=V^^5WYVT*VH_ <:-?1Z?J7C'2-/U&YU&XTRSAN+:XV7$L+(IS(%(C5F
MD4 MTSS6;:?!75I+:*YO[ZRT>TCCO9M1FNPY&GK:SB!]X4$NS.P"JO4FNCU_
MXR^$_%>JV^I:MX8U>XGL=7N]4M+:'4(HX'$SQNL<QV%B%,:@[<9!JA%\<8=2
MTY]/UW2IKVSU&+4(]6^RSK$\AN;I;E)("00K1N@X;((]*E.O9:>NWX&DX9:I
MRLU:VGQ;Z?%^.W3SL8FG_"DZWXMTK2-+\2:3?V&H6SW@U<%XXK6%,^8;B-L/
M$5(Q@]<@@X-7-,^$%M/8>(9=4\7V.AW?A]RFJ64^GW,KV_[[R5(9!A]S$$8[
M$5+:_%/0_"EAJ4'A+PT+*ZN;%-/%_JQBNY)HC(9)WG0KL9FPB* ,*JGJ32>)
MOB]!XEM_%$TNDO#JOB/2[*TOKB-T6(W4$RNTZH!PKJBC;V.3TJ_WK=ME\K_U
M;\C"*P4(MNSEJ[>];9V2>C^)+?I+?0JQ?"":.QCU._U^PTW0CIUMJ$FI2PRN
M%\]Y%AA6)1N>1O*8X& !UJVGP#UV^MM8NM+OK+5[:STV+5K26UW?\3&W=F7]
MT& (==CYC;G*D#M3E^*VD:GX?MO#NMZ->S:(NEV5I(]E=(ES'<VS2E)XRRE2
MI65E*-]<YI]U\:_LFG26'A[3[C1H+**Q@T>5K@22V_V>X:=I)3@;WD9SD*
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M&R/S&A8=0X&/;G-)K/P<;3X+R.T\3:;J6LV5BFHW.D)!-%,L+()"5=AL<JK
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M/[&/AGXC>,]6\2WNO:S:W6I2B62*V,7EJ0H7Y=R$]!ZUSX_X)^>$!_S,NO\
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MSP?G_D9=?_.#_P"-T'_@GYX/_P"AFU_\X/\ XW5_VA0[O[C#_5;,OY5]Y\*
M4=\5]UC_ ()]>#_^ADU_\X/_ (W1_P .^_!__0RZ_P#G!_\ &Z/[0H=W]P?Z
MK9G_ "K_ ,"1\*"DP2:^[/\ AWWX/'_,RZ_^<'_QNC_AWWX/_P"AFU_\X/\
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MK$RD80D!U8CH>AS7T_J/@CP]J]M=V][H>FWEO=S"XN(KBSCD6:0  .X*X9@
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MC=[T!8^O_P#A;G@X_P#,PV/_ 'W_ /6I?^%M^#O^AAL?^_G_ -:OCXR*#@N
M?<T%N1SU]Z L?8/_  MOP=_T,-C_ -_/_K4?\+;\'?\ 0PV/_?S_ .M7Q]SW
M)S]:7GUH"Q]?_P#"W/!W_0Q67_??_P!:K%A\3/"VJ7<5K:ZY9S7$IVI&LG+'
MT%?'!R:56((8$A@<@@\@^M 6/NP,#17C'P<^,:ZPD.B:W,%U 86WN7Z3C^Z3
M_>_G7LRG(H)'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0SQF6U=!C+*0,^XKXQTC]BGQ-ISZ=,VI:4YM;>PE%L)G\I;Y+N-KF8?
M)_%;Q(H/4MD'CFOLRYN!;6<DS L(T+D#J<#/]*^/?^%\>*OAUX8\)_$'7M6N
M=2T;Q;H^I/\ 87PT5MJ.]IK*./ RH*?NL9_ASUS7K8!XA*2H-:V^;U=OP9UT
M/:6?)_6Y:7]C[Q')<>.HI[W3+A=3L-6M[+4)YW:2>2[F$L9GC$8QL(&6+.=P
M!7;TJQ??LS>.=;\=Z'K5Q%X6LK2QEL)A;63M&L4<5N898<+$&DY)(<N/E.T
M'FK&D?'?Q?X*U+P]X)UCR-?NRD.FZIK/FR&Z@U":U>X(?$8B78?E$>2Q4;N*
MS?"O[0GB;1-#\.3SROKVK:GX9T%8AJ5T(K5KR\NYXC-+M3*@!!N(/.  !7I7
MQNK33[>CZ_.QT7K>15T7]D7QEI_@K7]()\.&)Y=-FL--ED,\;/:S^8VZ<PB1
M8V0E C;R QRQ[W=3_98\::[XXU;5[Y?#)M;Q-4A,44LD4;Q74(6.,I%$C *0
M S;V9N#QC%,B_:8\8>#_  CKMW=1Z7KNNCQ#K"?8I+J618K6T1&9(/*CRT8)
M(\Q]H7(W9-6(?CKXSUOQ)?27,\=GI#^)_#]G96]A<;988KJ%)6CD)0[U*OEN
MA+<# &:=\;=RTZZ_<G8?[^[>G]614_X9+\;R>";&TFO-)DFL=;?4(=(>X'EO
M"UKY!$EP+?YY WS*6B.%R,YYK1T3]E/Q9X=\>>#]4T^ZT:VATR/3TO+QIY+A
MG6W4JZ"*6-LM@[4D5TP.H)J[)^U[K<.D76LR^&]-.EWVFZIJ&BI%?L]P/L+8
M=;M O[O?U!4G!X->D?"7XP:SXQO?%MCXBTBSTV]T**TNP--N'N$DAN(#,@RR
MJ=Z@$' P3TK"I5QM.#E-*VO;O;:_1_CN9RE62;:T/7LX'- .1Q7R-K7[5GBW
M7/ 6K7=CI6F:3)JWAV_US0;JWO6GFMHK=PK_ &E-N%DVG<N,KN&TUZ+=_$7Q
M+\._AA\.;$+;:YXM\0R0V2W6KWS"W61HFE:264(&/RK@ *#D@=J\V6!K0LI6
MNW:U^V[^1SNA);GNM%?,NO\ [5>NZ7%+/;:#HES#HND0:OKA36?,5UDE:/99
M.JXE(V,<G R0O6HY_P!ICQQ>^()++2?"VAR6UQ?ZEI]E+>:C-&^ZTB$S22J(
MS@%,C:#G=Z"FL!7:O9?>O7\M05">Y].;A2@@U\@VW[3WBJ#7]3\31VEG=^&O
M[%T34KC2+J]*2VJW+.D@M@%_>,20?F('R@=36S!^T#XNTL2Z?I&G6NMWEQJ>
MOL)=:OG00PV3(0J[$Z%6("]N.>M4\NKKM]Z[7_ ;H36A]2DXI-X]:^8IOVL]
M5NO$WA>TT_0].FT_6$T^.;_29FFM)[N$R()"$\M<<?+DLR\\5Q_AO]I?Q7HF
MAZ%XC\3-_:LS:'JM\UK97 BMYVCNTBB\Q=GRD%B-P. HSR30LNQ#6J_'U_R#
MZO4ZGV?2$@5\TS_M,^+[.Z_X1^3PYH<_BM-<M-(<V^I2-8,+F!I4=9-F[*[<
M,N/<=15WX:_&?7?&?CWP5/=H+6UU^SU2QN],BE,D$%U92X\Z(D X8;ASZCTK
M-X*M&+D]O7RO^2)=&:5V?15%(.@I:X# \ \2_P#)[/@G_L3]5_\ 2BUKJ?B5
M^SSX9^)?B0:[=7>N:'JYM?L%Q>>'M6FT][RUR6\B;RS\Z9)([C)P1FN6\2_\
MGL>"O^Q/U7_THM:L?'KX1>//B#X[\!ZKX8\;3:!INCZF+F[M4M;=Q&!%(IF4
MNI,C'<J[&^7!SU% '/>/OV;O@UX*M[S6O$FLW_A7PI<I:VEYI#^(IK+2+I88
MQ%#%)"&'F?*H&W)W=\\UV7B?XG?!:'P>D.H^+O"VF:-XELI((;F&_A@%W !L
M;8ZGD*"!_LUB?';1M4TGXC?#'QL?#NI>,]$\.O=QWUCI5J+FZAEFA"17:09&
M_80P.W+*)"0.*\ITSX7^,_B!\6]*UW0/#$_P9TB[L=8+RR:3;W;R>;-;8>XA
MD^6&:;8S;>2 @SR2*!GK+? KX2_$+6]!^R:A_:$NF:38H;#3M88PZA80G-H;
MJ-3B>,,A*L>IW<D$BO6+3P!I5KX[O?%Z))_;5Y8QZ=-(9#L,*.SJ G0'+'FO
M$_@'\#YO@S\9M5T^PM;^;PS:^%;*QM]6NT4"YN!=7$LHRH !S)G:H 4$ <"O
MI*@1EKX<TX:^VM_8;<:JUO\ 93>A!YIAW!O+W?W=P!QZUG:1X!TO0_%VO>)+
M19DU+6X[>.\9IF*,(0XCVKT7_6-G'7-=+10!XX/V8M"MO&6H^(M/\2^,-(DU
M&_\ [2N]-T_Q!-#8S384$M /E(8(H(Z'%5?#/[(_@CPUK=OJ'G:[JD5G<3W>
MGZ;JNLSW%C832LS/)!;D[%;+O@X.W/&*]MHH \6^'G[)W@OX<ZSI6HVL^O:N
MVC;_ .R;76]9GO+;32V0Q@A8[$;#, V"0"<$5V,_P@\/W&L^+=3:&X^T^)[.
M*QU$BX8*\48=4"C^ XD;D5W%% 'C^G?LJ_#W3O ^L>%?[(>ZT_52IN9[J8RW
M7RQI&FV8_,FQ8U"XZ8KM_ /P[TOX<:;=6.D?:##=7<E].]U.TKO-)C>Q8^NT
M?K74T4 (>E?'/Q/_ .2A:]_U\_T%?8QZ5\<_$\?\7!U[_KY_H*!HY@G%%+BD
M Q04!KUK5M5TJSNX--N)5NFDM[58M/73(T6%V"GS/.ZGZ=\UY*1D4YG=G#L[
MLPQABQ)&.G- CU.3P/HVNZE?7MM9W<5O#=W$4\)N,*2O(8%4+*.<;54FBZ^&
M&E1-JD,4=\\\3?N6DD*(J^6&X;9@D$\A]O'3FO,(KRY@??%<SQ-DG<DC*<GJ
M<@TOVZZVR+]JN-DHPZ^:V''OSS^- ';^-_ VF>'M#%S:27!N(WB1G?>4F#+D
MD$H /;:6&*CT>QMM=\.:);QV$-NRZGLFG7+/*H0LQ8GM@=!Q7%27,\T<<<D\
MLL<?"(\A94^@)P/PI$FEB&$EDC'HK$4 =YIU]9ZWI]](NF6T+_VM WGJ,NZ,
M^ N.BK@=!U[U5\?^'K/3Y3>V]C=:8TFH2P&VNVR) #GS$&!A>V.1TYKBT=T7
M:K,JY!PI(Y'2GSW,]TRM/-+.RC ,LC.0/09/% 6/5]>U;28=<?2IG2]E>6W2
M"S&F1Q+:MA26\T<MQGCOFIW$DWC.TBF6_:T2ZE^6[T2*")  <;6 ^?'8'K7C
MYDD9]Y=R_P#?+$M^=32:E>R@"2]NI .0'G<X_,T!8]5B2SU5-'N8\:Q&Z7._
M47L8H"A"']TR)W'4$_A5:VL[G^T;?3AI<#^$FL1(]Q]E781LRTIFQD.&]_;%
M>717$T2%4ED12<X5R!^E.%U<"V^SB>;[/G/D^8VS/KMSB@5CN/"FE?8-/O[G
M2I;+7=2_<A$@A,[11L^'RKKC.."1G'K2:Q#80Z3XNMK73K>)[6ZC(N5RS8+#
MY!GA0#GI7#03S6K[X)98'QC=$Y4X],BFAG"LH9@K=0"<'Z^M SL?"GB"^M/"
M^N)&T!%I"C0&2UB<H6?!.64D\>M;J^$=,OI)=/M8+PR>;;&Y9ID_>EQN.W*?
M(![?D:\Q5F4,%9E5N& ) /U]:>MQ.K;EFE5L@[@[ Y'3G/:@+'HWB_PE8>'O
M"=[+:1.JS^1(/-+.4.\@A69%;!]P*\TJ:>[N;G/G7,\VXY/F2LV?S-18H!"4
M4M(3CK0,%8HRLI*LIR"#@@]C7UQ\);K7[SP?;/K\>V?_ )8N_P#K'C[%QV->
M>?!OX-\0:]KT&3P]K9OV]'<?R%>[A1@8H)'4444""BBB@ HHHH **** "BBB
M@ HHHH ***0T +1110 4444 %%%% #,;DQC/UK@O#OP6\/Z/X0MO#-_:PZ[H
M]CJ$E_I]OJ,"N+0F5I(U7U\LLP4GG&!VKN3=PQ$JS@$=12?;X!_RT'ZU<9RB
MK1=BE)K8Y:_^$?@[5/$Q\0W?AG2[C6RZ2&_DMP9=ZC"MN]0.,]<<4DWP?\&7
M&F2:=+X7TJ2QDLHM.:W:V4H;:-B\<6/[JLQ8#L3D5U7V^#_GH/RH^W0?\]!^
MM5[6II[ST\PYI=SB9O@3X N-.M]/D\':*UC;S23Q6YM%V([J%=@/]H 9]<#-
M6X_@]X,AU!;Y/#&EK=J+;$PMQN_T?_CWY]8^-I[8KJ_M\'_/04?;[?\ YZ"G
M[:J_M/[Q\\NYR:_!KP1'=:S<IX4TA9]9C:'4)!:*#=(QRROQR&/)'<]:W-*\
M*:3HE]>7MAIUM9W=XD4=Q-#&%:58UVQACW"KP/05H?;X!_RT'ZTG]H6__/4?
MK4.I.6CDQ.3>[.4MO@WX)LFUIK?PII$#:S&T6H&.T5?M*-RRO@<@GDCH3S6I
MXC\!>'_%WA]=$UG1K+4])0)ML[F$/&NW[N!VQV(K8^WP?\]!1]OM_P#GJ*?M
M)MI\SNO,.:6]SD[OX.>"+]]':X\):-*='54T_-FF+90<A4&. #SCIGGK5Y/A
MQX:CN5N5T*P6X6>>Y600C(EG7;,^?5UX8]Q6]]O@_P">@_(T?;X/^>@_*CVD
MW]IAS2?4XX_!'P&U]I]XWA#1FNM/6)+24VBEH5BSY84^BYX':M"/X9^&(Y_.
M70-.67=<MO$ SFXQYY_[:8&[UQ70_;H/^>@H^W0#_EH/R--U:CWD_O!RD]V<
M</@EX%74[/4!X2T@7MFD*6\XM5#Q"+_5;3VV@  ]0..E36'P>\%Z6TQM?"VD
MP"99TD"VRX=9B#,I'3#D#(Z'%=7]O@_YZ#]:/MT'_/04>UJ;<S^\?/+N<MI/
MPB\&Z#8V=GIWAC2[*VL[L7UO%#;*HCN ,"4?[0!QGTJII/P@T71/&MMXALHD
MM%L[.:UM-/@C5((6FE\R>48Y+N0,GZ^M=I]O@_YZ"C[?!_ST%'M:FOO/4.>7
M<G P*6J_V^#_ )Z"@7T'_/05D0>$>)?^3V/!/_8GZK_Z46M>^[!Z5\_^))D/
M[:G@F0'*_P#"'ZKS_P!O%M7O7VZ#_GH* )MB^@H"@'( !J'[=!_ST%'VZ#_G
MH/UH GVC.<<^M+5?[=!_ST%'VZ#_ )Z#]: +%%5_MT'_ #T%'VZ#_GH/UH L
M457^W0?\]!1]N@_YZ#]: +%%5_MT'_/04&_@'_+0?E0!8HJO]O@_YZ#\C1]N
M@_YZ#]: )V&17$ZK\&O"FM:C<7UYIK2W4[;Y'^T2#)^@-=?]N@_YZ#]:/M\'
M_/04 <-_PH;P5_T"F_\  F3_ .*H_P"%#^"_^@4W_@3)_P#%5W/V^#_GH/UH
M^WP?\]!^M '#?\*&\%?] IO_  )D_P#BJ/\ A0W@H_\ ,);_ ,"9/_BJ[G[?
M;G_EJ*/MT'_/04 <-_PH?P7_ - EO_ F3_XJC_A0_@K_ *!+?^!,G_Q5=S]O
M@_YZ"C[?!_ST% '"_P#"AO!7_0);_P "9/\ XJC_ (4-X*_Z!+?^!,G_ ,57
M=?;H/^>@_6C[?!_ST% '#?\ "A_!?_0);_P)D_\ BJ/^%#>"O^@4W_@3)_\
M%5W/V^#_ )Z"C[= ?^6@H X;_A0_@O\ Z!+?^!,G_P 51_PH;P5_T"6_\"9/
M_BJ[DWT _P"6@H^WP'_EH/UH X7_ (4-X*'_ #"6_P# F3_XJE_X4/X+_P"@
M2W_@3)_\57<_;H/^>@_6C[=!_P ]!0!PW_"AO!1_YA+?^!,G_P 52?\ "AO!
M7_0);_P)D_\ BJ[K[?!_ST'ZT?;X/^>@_6@#A?\ A0W@K_H$M_X$R?\ Q5+_
M ,*&\%?] EO_  )D_P#BJ[G[?!_ST'ZT?;[?_GH* .&_X4-X*_Z!+?\ @3)_
M\51_PH?P7_T"F_\  F3_ .*KN?M\'_/0?K1]O@_YZ#]: .&_X4-X*_Z!+?\
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MV'C!(KOO$_Q_AU;X3ZSKGPYGT3Q#XJL=*CU&;1[G4E!TY9(A)NN57+#8#]T
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MMV!_*DVM_=/Y4(!O2ESQ2A6_NG\C04;^Z?RHN TBD[4\JQ_A/Y&@1L?X3^5
M#2,4J]*4HQ_A/Y4GEM_=/Y4P/$_$7_)XG@G_ +$[5O\ THMZT/C!^S_%\6?%
MOA'6V\3:[HIT.]%R]OIVIS0)*@1U_=JA 27+C]YUV@CO5#Q$/^,Q?!(P<_\
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MZMVA9U@5=H3+'Y2?XB/H*^A!X?TW_H%67_@(G_Q-(= TT?\ ,*LO_ 1/_B:
M/F?PMKUIIVD2I+*JR6M[#?)'O ,RKD,H]\'-:>E?$JSM;>2VNK>:6*9KC?(1
M'*RB1PPPK\'&,$&OH4Z!II_YA5E^%HG_ ,31_P (_II_YA5E_P" B?\ Q-.P
M'A=O\9;5)Y3-I[7,3RA<2,FXVY #1G& "2H/' ]:Y;3_ !=;_P!K:Q/J G\C
M5$:.1[211-$"05VYXX  Q7T[_P (_IP_YA5E_P" B?\ Q-']@:;_ - FR_\
M 1/_ (FBP'SV_P 1M+/D3+#J1N+.*2"WCENUDCE1P/FE)YW>PX[46OQ,M(YM
M1\V"Y>&\E5OEF7?$GE;#MR<!NX[5]!_\(_IW_0*LO_ 1/_B:7_A']._Z!5E_
MX")_\318#YSO?B#9MIUM86D=T(;66W*2SS+YDJ1DD[\'J<\#D"F:O?V^NV1L
M]*\RZNM4U)KI+8D-+&,8 ;'&22?P%?1__"/Z:/\ F%67_@(G_P 34EOH]G:R
M"2#3[:"4='BMU5A^(&:+ <=\,_AE!X+M1=702?695^>0<K"#_ O]37<@TX*P
M[''TI-A_NM^5.P!T%!^F:-C=P?RI=K'^%ORI,! ,&@C-&U\_=/Y4H5O[I_*F
M F,4@'6G;'_NG\J-C>A_*E8!HH/6EV,.BG\J-C'^$_E3 !P*3I3MK_W3^5!5
MO[I_*I :30#BEV-Z,?PH\MO[I_*J 3WI<\4;6_NFC8^.A'X46 0G/M2YQ1L8
M'D'\J<4/H?RH 9UH YIP1O[I_*C8V>A_*@!",TA'-/*L/X3^1I"C<?*?R-2
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M\9_X:;TC_H#ZA_WU'_C1_P -.:1_T!M0_P"^H_\ &@=CV>D(S7C/_#3>C_\
M0'U#_OJ/_&C_ (:;TC_H#:A_WU'_ (T"/9@,48S7C1_:;T@?\P;4/^^H_P#&
MD_X::T@_\P;4/^^H_P#&@#V8C- &*\9_X:;T<?\ ,'U ?\"C_P :0?M/:,W3
M2+XCV>/_ !H'8]G Q01FO&?^&F](/_,&U#_OJ/\ QI?^&FM(_P"@/J'_ 'U'
M_C0(]EVT;:\9_P"&F](_Z ^H?]]1_P"-'_#3FCC_ )@]^?\ @<?^- ['LP&*
M",UXS_PTWI'_ $!M0'_ H_\ &E'[36D'_F#ZA_WU'_C0%CV:BO&/^&F](_Z
MU_\ ]]1_XT?\--Z1_P! ?4/^^H_\: L>S$9HVUXR/VF](_Z VH?]]1_XTO\
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MMY\3?#VAQ:+9R:+JLUK:-/%<R/<6\L]MYX\S$?E+@<;-^\CYL 5ZLOP@\&)
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MP:79PV,N?,M8[=%B?(P<H!@Y [BK.GZ39:3#Y-C:06<62WEV\:QKGUP !V%
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M^/[\Z1IVG6%U/9P06I@F50O[PEB20V-P&#CK7V#]AM_^>$?_ 'P/\*/L-O\
M\\(O^^!0%SY4U7X@6>IVT*_;-<1(XX5^PYB^S$H!_P "P<9IM[\3VU@W<>H"
MZFMQ>+>685E#1X/W'Z!EQ]<&OJW[%;_\\(_^^!1]BM_^>$?_ 'P*!'R7>>+M
M#UNXAN-3L[\36LTCP"UD3$L;/O"/G[I![C-1V_Q $^IW,M_I]J+>Z\U9GM(%
M6YVN,8\P_>QZ'TKZX^Q6_P#SPC_[X%'V*W_YX1_]\"@#Y4@\;:##O86^I07,
M5LEG:7D8B:2.( Y/S<!F)ZC.!TKF/#VLPZ'JYNFCDEC\N1 !C=\P(!/Y\U]I
M?8K?_GA'_P!\"C[#;_\ /"/_ +X% 'R)IGC>&QL[&VDBN9([>REM619,*S.V
M=P]/YUN:E\3]*FTZXM;:QND\U) ,K&H4LFWD@DMC^\>37T_]BM_^>$?_ 'P*
M/L5O_P \(_\ O@4 ?"RL .OZ4NX5]T?8;?\ YX1_]\#_  H^Q6__ #PC_P"^
M!0.Y\+[AV-&X5]T?8K?_ )X1_P#? H^Q6_\ SPC_ .^!0%SX7++ZU[%\'/@X
MVMO%K>MPE=/!#V]J_!F/]YA_=]N]?0WV*W_YX1_]\"I0H48' H 2.-8E"J J
M@8 '  I]%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_GH/RK'V/_=-!5@,D$"D!L?VA;_\]!^1I?[0M_\ GH/R-8G2G'O3 V?M]O\
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MQ_9F>\GN-+-R[WXU&'9=;!%(%P WRG</RKD[BY:\N)KA\;Y7:1BO3).3_.@
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M8<CC:2#R:YGQ5=2Z#X_%Q8%;625(6*F) Z[@-PD0C:'/< =Z[#_AGFYWH_\
MPDPWIPK?97ROT._BFG]G69F+'Q)&6)R2;-B2?^^J!F9K#V^IZYK4NJQ27@L+
MN&WLXH76!8MY&2=J_-CK@UHO\/-."W5U);SM=(YN$N/,9E;$F,$!1&!C^'.Z
MG?\ #.L^2?\ A)$)/)/V1O\ XNG?\,\W97;_ ,).-H.=OV9\9^F^@1Y;XK14
M\4:NBJ$5;J0!5   S65MKV4_LYRDD_\ "11DGKFS;_XJD_X9SE_Z&*/_ , V
M_P#BJ"KGCG6CH.PKV,?LYRC_ )F./_P#;_XJM;PS\![/1]5CO-1U!=5BB^9;
M<0>6I;L6R3D>U 7,'X4_"8W_ )&MZW"1:CY[>S<8,OH[?[/H.]>Y+T  P!P!
MZ4B^G2G4R1&Z4$FD.:.N: %!R:-U'2D !H 3BE S0 #1TJ@#=1P324 XI,!]
M(:6D(S1<!,YI<"DQBEQS18!"<T@&:<12"@ /!HQ2XSUI,X.* $IP^[28-+R!
M0 @&:4#BD6E)Q0 ;:0J*4'-!- !T-)G!I>]-/!H0#U.77ZBBD0#<OU%%2.Y-
M>*S74A"DC/I4.QO[I_*MU/O5)3N(P-K?W3^5($;^ZWY5T%% '/E&_NG\J C?
MW3^5=!12 Y\JQ_A/Y4@C;NI_*NAHIW Y_:_3:?RH*-C[I_*N@HI <^$;^ZWY
M4;6_NM^5=!13 Y_:W]T_E0$(_A/Y5T%% '/[6S]T_E05;KM/Y5T%%%P,#:W]
MT_E3?+;^Z?RKH:*0'/[6_NM^5+M;^ZWY5OTUNM.X'SUX@L[AOVO/!<ZV\K0)
MX0U5&E$9V*QGM\ MC )]*]G$;#^%ORK7_P"7D_[G]:L+THN!S^QO[I_*@(P_
MA/Y5T-%%P.>",#]T_E2[&S]T_E7044@.?VM_=/Y4;6_NG\JZ"BF!S^QNZM^5
M)L./NG\JZ&BBX'/!&'\)_*EVM_=/Y5T%%%P.?"M_=/Y4;6_NM^5;[=*%Z4 8
M.UO[K?E2;&S]T_E6^W2A>E(# VM_=;\J0HQ/W3^5=#13 Y[RV_NG\J7RV_NM
M^5=!33UHN!@A&'\)_*D",,_*?RKH:*0'/E&/\+?E0%;NI_*N@I!WIW P-C?W
M6_*D\MNZM^5;XZTZBX&!M;^ZWY4FUO[I_*MX=:=0!S^UO[I_*C:_]T_E7044
M <_Y9_NM^5*$;^ZWY5OTT]:+@8.UO[K?E04?^ZWY5T%%(#G]K_W3^5 4C^%O
MRKH*:W6@# V-_=/Y4H5A_"WY5T%%.X'/>6W96_*CRV_NG\JZ&BBX& 4;^ZWY
M4@0C^$_E6\O6G4@.>\MO[I_*G;3_ '3^5;]%,#G]K?W6_*DV,3G:?RKH:*0'
M/['_ +C?E2[6_NG\JWZ2G<# *M_=/Y4"-O[K?E704P]:0&'L;^XWY4;6_NM^
M5;JTZ@#GPC8/RG\J C8QM;\JWFI1]VF!@!"/X6_*C8Q/W6_*MY:0]: ,)D;^
=Z?RI/+;^Z?RK?6G47 P%1@X^5NOI16\>E%(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tlsi-20230630xs1a006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  Z@# 2(  A$! Q$!_\0
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M+_PQ]\%O^B:>'O\ P$%>Q44 >.?\,??!?_HF?AW_ ,!11_PQ]\%_^B9^'O\
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M+S[+/;O%)/"@RSQ!A\XQZ4 :7_#'WP4_Z)IX=_\  04H_8_^"AZ?#3P[_P"
M@KB=#_;\^$?B+Q+;^'[*_P!6?59I%B$#:9*"I8X!;C@9[GBM?6?VVOA!H/C1
MO"]YXK07Z3BUDG6%VMHIB<!&E V@Y.*!V-__ (8^^"W_ $33P]_X"#_&C_AC
M_P""W_1,_#W_ (""NO\ '_Q)T+X9^%CXAUR[,&E>9%$)HU+Y:1MJ=/4D5U%C
M<K<P1SH<Q2()%/L1D4"/*#^Q]\%>_P ,_#P_[=!2#]C[X*=OAIX=_P# 05ZV
MNH6SQB19XF0MM#!P03Z9SUIWVJ(,RET!098;AE1ZGTH \C_X8^^"O?X:>'?_
M  $% _8^^"W;X9^'?_ 05U_Q#^*OASX;:/8:IKEZ(+*]O(K&"6,;P\LAP@X]
MZZ>WOX'E\I9HS*5W"+>-V/7'6@#RD_L?_!7O\,_#O_@(*#^Q]\%#_P TT\._
M^ @KV(8-&* /'A^Q]\%>WPT\._\ @&*0_L??!7//PT\._P#@(*]CI,4 >._\
M,?\ P6[?#/P[_P" @H/['WP7_P"B9^'?_ 05[%BEH \<_P"&/O@M_P!$T\._
M^ @H'['WP6Q_R3/P[_X""O8L4M 'CH_8]^"H_P"::>'?_ ,4G_#'WP5!_P"2
M:>'?_ 05['28H \<_P"&/O@I_P!$T\._^ @I?^&/O@MV^&?AW_P$%>Q8I: /
M'1^Q]\%L?\DT\._^ @I/^&/O@M_T3/P]_P" @KV.B@#QW_ACWX+#_FFGA[_P
M#'^-'_#'WP6_Z)IX=_\  05[%10!XY_PQ_\ !7O\-/#O_@(*/^&/?@M_T33P
M]_X""O8L4M 'CG_#'WP6_P"B9^'O_ 04?\,??!;_ *)GX=_\!!7L=% 'CG_#
M'WP5/_--/#O_ (""E_X8^^"W_1-/#O\ X""O8<4M 'CA_8^^"P_YIIX=_P#
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M-MK%Y/8P7!U 1GY7PZ'8V.,BNI^(/[*7AGXA?$[P1XUOI9DOO#"A4@C4+'=
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MAEB<=G1@&7UYKKC)25T>A&2DE);,Z^D)Q3?-3^\/SILDJGY<C/H:HH?O7U%
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MC-;G4=)N&3S2[AZBN4N?'V@0^%-3\30ZG!>Z-812SSW-FWG +&I9\8ZD#M7
M1_M&6JZ#=:U>^%-;L=,73VU.UNCY4L=S$,<!HW(1R"#M?!H'8]I+J.I%+N'K
M7E7A7XUKK?B32M#UCPWJGAB^U>V:[TYKUHI8;E5&64/&QPP'.UL''-:WC?XN
MZ%X#\3>&-!U W,NJ>(;Q+.TAMH2X0MGYY&Z(N1C)ZGI0%COMZCN*4,#WKR6+
M]H#19O&BZ+_9FI+8M?MI2:X47[(UXJY:+KNXZ;L8SQFMGX=_&#0?B9K7B;3M
M$^U.^@726MS// 8XY'9=V8\\L.V>GI0%CT#</44;QG&1FL0^)=.C\2)H37*C
M5)+5KQ;<]3$K*I;_ +Z91^-<;XF^.7AWPE\6?#W@+4A<0:IKD#S6MT4S;Y4C
M]VS?PL<\9ZT"/3=P]13J\V\(_&71/%<A:/\ T"+SYK??>3(A,D<OE$!<Y.6Z
M'IVKI]:^('ASPXLAU37+#3Q'*L#_ &FX5,2,,A3GN00<4#.BHJ*"XCN(U>-U
MD1@"K*<AAZ@U+0(**** /,?VFN/V??B%_P!@2[_]%FBE_::_Y-]^(7_8$N__
M $6:* ,G]C[_ )-B^&?_ &!(/Y5['7C?['__ ";!\-!_U!(/Y5[&.E "TUAD
M$4>8,]13J ,R/1[2.[^T+:0K-NSYHC&[/KG%?.O_  4.^7]G.7/_ $'=)_\
M2V*OIVOF/_@HCS^SG)_V'=)_]+8J /IL=:6FAN:7- "T4F1ZTFX4 .HI P-+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBPFC$L=PC?(R^N?2N5N?C5X*M_"\WB(^(+631XKEK,W4.Z0-,IP44 $D@^E
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MA^E?FMXOT/4W\4:J4T^Z8&ZDP1 ^#\Y]J_2._E^SVTLQ7<(T9\#O@9KXKO\
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MNS'L#0(\.\ ?LR>+TTM[;Q9/837<NE7]M)=VLG_+U)=B>&4#M]U2?3D58G^
MOCFS70?$=[HVB>+_ !-/'J']M6-Y.$A$]P JS1,PP0JJ%(Z[>!7N/A#XNZ-X
MP?=;;[: 336WFW++'^]CD\LJ!G)R1P:ZC5/%VBZ*KMJ&JV5DJ2+$QN)U3#L,
MA3D]2.<4#.?^#_@F\^'WPW\.^'KVZ6[O-.M5AEF3.PGDD+GG:,X&?2NYJ**=
M)%5D8,K<@CN*EH$%%%% 'F/[3?\ R;[\0O\ L"77_HLT4O[37_)OWQ!_[ EW
M_P"BS10!D_L??\FQ?#/_ + D'\J[OXA?$GP[\+?#DFN^)]172]*C=4:X:-Y
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MR*SJ2E&+<%=]C&M*<*<I4U>26B[L^?E_X*??"!FVKI_C L>,#09,G]:M7?\
MP4I^%MA&CW>A^.+5'X5I_#<R!OH3C-.LOV*+NSO;>?\ X2>%A%(KX^RGG!!_
MO>U:/[9EM]F\(^&8B?N7#+D=#A*\UXNM3I2J5*=K>>Y\]+,<;0PE7$8JBHN-
MK*][F-!_P4V^$EU*L5OIGC.>5C@)%X?E9C] #3[S_@I=\*=/D$=YH_C:U<C(
M2?P[,AQ]#BO(?@&H_P"%L:!Z>=_0UW'[82 ?$:#_ *]4_F:Y%FK=!UN39VW/
M-I\15)Y?+&^S5T[6N=+9_P#!2_X3W\OEVND>-KF3&=D/AZ9V_(&H+K_@I_\
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M;C2=/@>:>>!@R1QHN6^[Z '@5Y[!^TEH1TF[U&[T37M-LXM/;4K>6[L2J7D
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M,9'&#SUKW>PMX["TB@CR(XD5%#-DX P.3R>E?EX?B[^T$#C_ (6])_X*X?\
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MN5 U%(ON$_-Z=*])_P""@UG-+^T!,4A=A]@AY5"1U:N&_9-L;A/V@O!I>%U
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MVK_@C\2OASK7PUU/Q?\ %W4_'6F7'BNU6'3;R+:D),@((/L.*_42T_X]HO\
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M'O"TWC_0=<M/A[\49998'?3O$'C&Z-U:6<;IRT9,AV[UP-V,GBOL07 XX/-
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MAZ'W63?\B^C_ (4%%%%>D>R%%%% !1110 4444 %%%% !1110 4444 %%%%
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M57DQA<]LULZ/\?\ P3KWC!/#-EJZS:O([QQ1B-@DK+]X*^,-COB@#T:BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B?X3/CKP+
MKV@*4#ZC:/;@R,57+#N1R!]*ZZLO7=7M-"TZ[U"_G2VLK6)IIIG. B 9)- '
MR0%T[PU?^%?#?C;X4>&/$-Y9RQV-EJ^D:W:R3JZ8P?+G$<F1P2 6-?85LP6&
M,*A08&%/;VK\[+[X4^']7\1Z9XOU/Q7;Q>'?$6K9T"ZETMP\6Z;>YD<\*[$!
M5;N*_0#5&O[?P]/_ &.()M16#%L+IB(V<#C<1SCZ4 +K'C+1O#U_I]EJ>I6M
MC=ZA(8K2&>4*\[XSM0=S6+8_&;P5J?C:X\'VGB;3+CQ1;@F728YP;A,=<KVK
MY]^(GPJ\3^(_B)\)/&.M^'+-_%UIJKIJ=UH\TLT$%L$^7&_  SU.!S7/?#_X
M;^)]&_:0UB\\.:3XF\/17DMW+K-YK1BFL)BX_<R6[ 9)SSC/UH G_P""D4F[
M3OA+QC_BKK0_^/K7V7:'-K#_ +@_E7YI?MA_#SXH^$]1^&5WXT^(\7BW2I?%
M=J(+&/3EMS$?,&#N!YXK]+;3_CUA_P!P?RH FHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y_U3?0U^8/B7_D8=2_
MZ^9/_0S7Z>W)_=M_NFOS$\1HY\0:D=I_X^9/_0S7RV=_\N_F?G/&2;IT;=W^
MA]B_L:_\DUO?^OYO_05KWRO OV-OE^&UZ",'[<W'_ 5KWVO7R[_=8>A]=DZM
ME]'_  H****](]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \Q_::_P"3?OB%_P!@.[_]%FBC]IK_ )-^^(7_ & [O_T6:* ,O]CX?\8P
M_#3_ + D'\C7K<EG'*C)(HD1@596&01Z$5Y)^Q]_R;#\-/\ L"0?RKV*@#RU
M?V9_AQ;?$?2_'5EX8L]-\3:<\CPWEBGDY+KM8LJ\-D$\XKU$=*6B@ KYC_X*
M(#_C'24_]1W2/_2V&OIO-?,G_!1#G]G27_L.Z3_Z6Q4 >\WO@/2-0.K>?%(W
M]J&,W6)&&_9]W'/'X8I+KP!H]Y_:/FPNW]H1)#<?O&&Y5^Z!SQ^%='ZTM &!
M<>"M+N9+QY(F+7EJ+*8AV&Z(9 '7@\]::G@72(YDE6%PZ61L ?,;_4_W>OZ]
M:Z&B@#G[7P/I5F]F\43@VELUI#^\8[8V&".O/UZTVP\!Z/IK:6UO Z'38G@M
MLR,=JL,,#SSU[UT5% '-V?@'1K!--2&!T73I'EM\R,=K-G<3SSU/6EMO &C6
MB6BQP/BUN&NHLRL<2-U/7GKTKHZ* .;'@#1A$L8@?:M]_:(_>M_K\YW=>F>W
M2EN? .CW<-U%) [)=70O)1YK#,@Q@]>.@XKHZ* .<NO .CWJWXEA=A?3QW$_
M[QOF=,;>_ XZ"G7W@72M175!/$[?VD$6YQ(PW!1QCGC\*Z&B@#G)O 6D7!O3
M)$Y-Y;I:S'S&&Z-?NCKQ]:?)X'TF5I&:%R9+06+?O&_U7IU_6N@HH YY/ ^D
MI/!,L+AX;0V*'S&XB...OL.>M-M/ 6D60T_RH7'V&"2W@S(QVH_W@>>?QKHZ
M* .>M? NDV1TXQ0NIL ZP$R,=H;[W?G\:CM/A]HUBFG+% X&GS//!F5CM=\A
MB>>>IZUTM% '-IX!T=(H8Q"^V*[-\H\UO];USU_3I3?^%?Z-L*_9WP;P7Q_>
MM_KA_%U_3I7344 <W<> -&NHKQ)(7*W=REW-^]8;I%(VGKQT' I;OP'I%ZVH
MM-"['4&1[C$C#<5Z=^/PKHZ0]* /G[]JWPGIL'PRU6Y6)C+>/#',2YY"_=[\
M?A7Q!)HUK--*S(2TL?DO\QY7TK[W_:S_ .247/\ UV3^=?"V!OS7Q.:R:Q.C
MZ(_'N+7_ +=%?W5^9]C?"WPMI_\ PSZU_P"4WVA=-FM0V]L>7CIC/Z]:^+Y-
M&M?M.\(040Q+\QX4]17W-\+/^3:I/^O6;^5?$TI/FOQ_$:SQTFH4;/[)7$?^
M[X3_  _Y'TY^Q=X6T\Z5JL_E-YMFPCA.\_*K*<CKS^-?GC\:-(M;'XK^)X88
MRL<6HSE 6)QESFOTD_8K_P"0#XC_ .NJ?R-?G/\ '/\ Y*]XM_[",W_H9K]=
MX#UIROV_4^ORUO\ LN@>L?\ !/;0K.Y^/]B7C)^SVTTL?S'AL=?>OU(T7PU9
M:#!/'9*T:33O<."Q;+MU/-?F/_P3O_Y+]!_UY3?^@U^IO:M^)%;'?)'T>$UI
M'G/B?X874LVHZGX<URZTK7+HJ=]RYGM\#JIB/&#WQ65X(^#MUX;\)>*;"^U.
M&;4O$32R3M:P>5;PNZ;<1Q]AW/K7K)C!&,TGE#UKY4[3YFC_ &4]5LM E\.V
MWB2 >']1M[6/5$:US<.\*A<Q/_"&P.O2N>^&/@?QA%\6?#5F^DWMGX9\-W%T
MR2WUHL9VO]W$H/[S/L![U]<F $8)S^%'D#(Y/% $@I:** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N'^,UKI-]\,_$]OKMTUCI$MA*
MEU<H,M%&5Y8#OBNXK@OCAIECK'PH\6V6IZ@-*T^;3I5N+TQE_)3;RVT=?I0!
M\\:#\'_B7\0O!GA;PEK&N^&)/AS9/;W4&HZ?!*M_=Q1D-$"K?*A.!DBOKN&V
M5(8T!(5  /PKXH\*?#OX >!/!'P^\1WO@W5UM]3EB@MM9F^U(JR@@))*GF'R
MPYY&1WK[9M @@0)]S:-OT[4 .^SCKDY]:!  >I-.+X.*!)STH ^,?^"DB[=,
M^$@S_P S=:?^AK7V7:<6L/\ N#^5?&W_  4D.=,^$A_ZFZT_]#6OLJU_X]HO
M]P?RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ6LIB^&VB>;L;;B#OCB@#HE_:L^$>?F^(OAT?6^3_&A_VK/A$!\OQ&\.$_\
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M\-=%+;3MQ!WQQ7A7[)O[$'A2#1O&H^(OPSLENF\0SMIOV^,,?L>!LVX/W>M
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M*-M+'H4J:I1Y4>@ Y%+2 8%+7F&P4444 %%%% !1110 4444 %%%% !1110
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M'_XFOG^U_98$?[8=]XW;POH1\#2Z$EDD/V>+ N >3Y6/UQ0!H?\ #R7X!_\
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M4^*O@NRU:XM(](U9GEANM-,PD,4L3E'VGJRY'#8KXRE>ZFU6Z^(?P[U+Q/\
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M[>*,NTA10NYCDG QD^]34""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^?OKTKWOX9?#OQ!\-_!WB/0M7NK;QSX)MH#/H4%T/,NGB"[E@D!X8 @!3]*
M/8;OQ?I.GMIR76IVENVHMLM!+*%\\XR F>IQ7RQI_P"V%K'@;X]ZSX$\>6D%
MUIUWJHL]'O=. $D((&%F09(7G[_>N#A\8V?[3]YX4TCXEZ3%H^DW%S,/#^I>
M')VV6=ZHP+>Y!^:*9,97L<5[0_AS4_@E\*O$GB_Q#H6B^*O&NGPB(:O%;YEO
M($($;S\$Y4<MM]* L>L?$CX@WFA:3=V/A>WL]=\9M );+19KI(&D!./,;=_
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M2WJWI7#>%?"FH?%WQQKGC+1IF\$_'/2FMS>6[3^;IM]:%<)M(^_!(H)4]0:
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M\%- \#:_K/C=M$M(/''B"..75[N!VE7S%C"LL1/W4)!. !G- &3\/_AUX/\
MV;AJ=]J/C">6_P!?EA@?4?$NH()9_*5EBB#'&X@,>>IKSJQ^/WBWQ/-XA^'G
MBK2K'P5XGUE[B#PKJ6K0>;8:E &VX* _?"Y.TGYL@UYAXS\5:S^T5X@TJWU3
MPE::5X[TB2]^P>&?$'[NQ\3:4[M$_E2/_JY@%!]1P>AKZ*_9M^&NM>'OAG8Z
M7XZTN,SZ=?R3Z/97TZ7L^G6^?W49E'!91D @],4#,OX<_LP^$?@;J-AXHO\
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M^60K,#V&:H_!+]G#4_$&N76N^,KW0/%WA'4M)BM!<V\;"3745P\,]W%]U9$
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M,+P!4BJ%Z4 Q:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA>/Q#I\GB&%/,DTU;A3,JXZE<T =#I>BV.BZ;:Z?8VZ6ME:QK%!#&,+&BC
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M_$%W-::=J<%U=0QI-)#&3O5&^Z2.V:DN_%FF:=K-CI%UJ$,&IWP8VUJ[8DF
MZ[1[4 ;N:6L0^)],775T4ZA"-6:+SQ9EOWACS]['I6F'+'&><T 6**0=*6@
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M( H:",L,L.."37K_ .UO^S;KWQKT[P@_ANZ@L]2L6:PU"25]H>PF0).@/<\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \Q_:;_Y-]^(7_8$NO_19HH_::_Y-]^(7_8$N_P#T6:*
M,O\ 8^/_ !C#\-/^P)!_(U[%7R]^RM\>?AQH/[.?P]T[4O'7A^PO[;1X8IK:
MXU&))(V .592<@UZP/VDOA5C_DHOAC_P:0__ !5 'I#=/>N*^(?PL\,_%C0Q
MI'BO1XM6L5D$J+(65D<=&5E((/T-9G_#27PK_P"BB^&/_!I#_P#%4#]I'X5Y
M_P"2B^&?_!I#_P#%4 3>'O@EX+\+7GA^YTGP_;V,^@P2V^GM%N'D+)CS,9/)
M..2:\D_:(_8[3X_>,$U6;5[73;>2W2TN ; /<>6K G8X(!SCC<#C/%>J_P##
M2/PJ_P"BB^&/_!I#_P#%4?\ #2/PK_Z*+X8_\&D/_P 50!S5_P#LC?"S6?$L
MNNZAX4BN]2E:)YGEFEV3-&H5"Z!@K$!1U%=)JWP#\!Z[IOB*PO\ PW:W-GX@
M:-]1A8';,R#"'@\8 &,4O_#2/PJ'_-1?#'_@TA_^*H_X:1^%7_11?#/_ (-(
M?_BJ )])^"G@S1K+Q!;6V@6RQ:Z=VHAE+&X_=^7R3S]P8XI;SX*^#M2^'%MX
M%N]"AN?"UM L$-A(6*QHO*[6SN!'8YJO_P -(_"K_HHOAC_P:0__ !5'_#2/
MPJ_Z*+X8_P#!K#_\50!A7O[*7PLO_"FG^')?!]JVE6$KSV\:O(K([_?;>&W'
M=WR>:V;GX > KQ+Y7\-6JI>:2NB3QQ[E5K)3D0X!Z9Y]:D/[2/PJ_P"BB^&/
M_!I#_P#%4?\ #2/PJ _Y*+X9_P#!I#_\50!D:Q^RW\,]=U*:_N_"D#W<T$$#
M2K)(IVP@"(C#<,H  /7%6-$_9J^'?A[R6T_PU# 84NHT(=R56X4+.!D_Q@<U
M?_X:1^%1_P":B^&?_!I#_P#%4?\ #2'PK_Z*+X9_\&D/_P 50!GW'[-7PZO;
M."UG\,6Y@@TM=&1<M\MHKAUBZ]-P!]:OS? 7P-<B82^'X)/.OH]2<,6P;A%"
MJYYZ@ "E_P"&D?A5G_DHOAC_ ,&D/_Q5)_PTC\*_^BB^&/\ P:0__%4 9&G?
MLM?#/2KJYGMO"MNKW%O/:2!GD93#*<R1@%L!2<G J6Q_9A^&MAI-[ID?A6V:
MQO;&+3IXI&=P]O&2T:9+9^4DD$<UI#]I+X59_P"2B^&/_!I#_P#%4O\ PTC\
M*N?^+B^&?_!K#_\ %4 5M!_9W^'_ (6L-,L=+\-VUK;Z;=F^M]I<L)RI7>6)
M)8X..378>"/!&C> -)?3-"L4T^R:9[@Q(3@N[%F//J2:Y?\ X:1^%?\ T47P
MS_X-(?\ XJE_X:1^%7_11?#'_@TA_P#BJ /2:*\V_P"&DOA7_P!%%\,?^#2'
M_P"*H_X:2^%7_11?#'_@TA_^*H ])HKS;_AI'X5_]%%\,_\ @TA_^*I1^TE\
M*S_S47PQ_P"#6'_XJ@#TBBO-C^TE\*Q_S47PQ_X-(?\ XJC_ (:2^%?_ $47
MPQ_X-(?_ (J@#TFBO-O^&DOA7_T47PQ_X-(?_BJ/^&DOA6?^:B^&/_!I#_\
M%4 >DT5YM_PTE\*_^BB^&?\ P:0__%4?\-)?"O\ Z*+X8_\ !I#_ /%4 >DT
M5YM_PTE\*_\ HHOAC_P:0_\ Q5'_  TE\*_^BB^&/_!I#_\ %4 >DT5YM_PT
ME\*_^BB^&?\ P:0__%4?\-)?"O\ Z*+X8_\ !I#_ /%4 >DT5YM_PTE\*_\
MHHOAC_P:0_\ Q5'_  TE\*_^BB^&/_!I#_\ %4 >DT5YM_PTE\*O^BB^&/\
MP:0__%4?\-)?"K_HHOAC_P &D/\ \50!Z317FW_#27PJ_P"BB^&/_!I#_P#%
M4']I+X5?]%%\,?\ @TA_^*H ])HKS7_AI+X5_P#11?#'_@TA_P#BJ7_AI'X5
M_P#11?#'_@TA_P#BJ /2:*\V_P"&DOA7_P!%%\,?^#2'_P"*I?\ AI'X5_\
M11?#'_@TA_\ BJ /2**\V_X:2^%?_11?#'_@TA_^*H_X:2^%?_11?#'_ (-(
M?_BJ /2:*\V_X:2^%>/^2B^&/_!I#_\ %4?\-)?"K_HHOAC_ ,&D/_Q5 'I-
M%>;?\-(_"O\ Z*+X8_\ !I#_ /%4?\-)?"K_ **+X8_\&D/_ ,50!Z317FW_
M  TE\*_^BB^&/_!I#_\ %4']I+X5Y_Y*+X8_\&D/_P 50!Z317FW_#27PK_Z
M*+X9_P#!I#_\50/VDOA7G_DHOAG_ ,&D/_Q5 'I-%>;?\-(_"O\ Z*+X8_\
M!I#_ /%4?\-)?"K_ **+X8_\&D/_ ,50!Z317FW_  TE\*O^BB^&/_!I#_\
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M_AI+X5_]%%\,_P#@TA_^*H ])HKS;_AI+X5_]%%\,_\ @TA_^*H_X:2^%?\
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5/<Q0P0ZE$SR.R$!5 ;DDGI10!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tlsi-20230630xs1a007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &$ J<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO\:^C:1ONGOQ0!\UWG[)^I-:RI%\1M3!53M L(OOXX/WJQOAUXV\8_ K7O\
MA&/'MS-K&D74^;#5I=I=(R0B*4C& /E9LD\9KZD5-R\C:0.<<US'C_P+8^/=
M#FT^\B#LZ%59L\<$>H]: -VQOX=1M8KJWD6:*10P=6!XQFK2,#)CJ"-VZOF+
MPEXLUC]GSQ&/#^O&6]\-W$PCM;A4SY.Y@JKM4= J$Y)KZ/T?4+?68(+RUG%Q
M;S()48=@>0/_ *U &Q124M !2'FEI"<4  &*6FEO0T;NE #J*3-&: %HHI*
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M*Y%>;+/\1;$9^PV-VH[RWF#^@JM??$3Q7I-M-/?:!9B*%&=S#.[G &3@8]*
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M*** "BBDH 6BDR*6@ HHI,T +13=XSC(S2@YH 6BBB@ HHHH **** "BBB@
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M\^4/_?H4?\*9\.?\^4/_ 'Z% &+_ ,)OXS_Y\O#O_@W%)_PG'C//_'EX=_\
M!N*W/^%->'/^?*'_ +]"D_X4SX<_Y\H?^_0H Q/^$X\9_P#/EX=_\&XH_P"$
MX\9_\^7A[_P;BMO_ (4UX<_Y\H?^_0H_X4UX<_Y\H?\ OT* ,3_A./&?_/EX
M>_\ !N*7_A-_&7_/EX>_\&XK:_X4UX<_Y\H?^_0H_P"%,^&_^?*'_OT* ,7_
M (3?QE_SY^'?_!N*/^$W\9?\^?AW_P &XK:_X4SX;_Y\H?\ OT*/^%,^&_\
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M7>6H*QX)W'^]ZUQ/P=4O\,O##%FR=/0;0>#UY-=Q;IY<87TH EHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $JM/Q(#DC&1STJU5288D*\ON['H*
M /)?VA_CYHG[/7@:;7-726X3A$@B3?N).WIN!QDBN%_8Z_:O\._M%>&)&T_3
MSH^J6Y"36JQE8\X9OEW,21@55_X*(Z%I][^S;J]S<V$%W<6UQ;K#)*FYD#2<
MX/;H*\1_X) Z/82_"W7M1DL(?[16Y@5+O9^\VF-]PW>] 'Z$("S,IRP')STS
M[5<A.8U.2?<U5(^Z"Y7'7'>K4>-@P,"@!]%%% !1110!&4P:0J3W-2 Y[4M
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M?6N)^#A"?"_PMD\_V?'7:HXV]<#WH$244FX>M (/0YH 6BBB@ HHHH ****
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MXEMVGTG4K34X$;:TEG,LJ@^A*D^HJY-&LJE#@YX&>HKXJ^(_A+QY\"_!DO\
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MH7<@)6&!=S-^[D' _$4 ?-7_  1ZR?@WXB^[@ZA!G_P&%?H(0"P(/X5\(_\
M!*;P/XA\#?"WQ!:>(M$OM%GDOHFC2\CV%E$ &1[9K[I$B*=O4GG H L[A01F
MH68 EB?E'.:&G+*"@+ ^E $H.>*-PJ&*3<VT\-C.*>K!C\IS@X.* ):*** "
MBBB@ HHHH **** "F2ML0D4^FR#*$8S0!7+=54#<.F[G->._&#3$3Q5HM]=_
MVA>:.BS?:=/MY<H[$*$^0_*<'GFO92OS@[3GUJK=:=%>?\?,"38/'R@_SH \
M\TWPW?>+A";V)M%T2+_4:;: V\G7G>HRI^89X[&O1-.TRVTV-(;2"*VB ^Y$
M@4?D!5GR\,K!>G:EBC*NQYYZY_I0!+M%&,4M% !1110 5'."5&WKFI*CF4,F
M"2!ZB@"G?70T^VEN9,".*,R/CT R:XVS\<^$?$T;7MQ)9+);7'DJUUL+*ZX(
M(/..M=9K,#W&D7D$2^;NMW51U+'& *^1'^"GB?5_%.L+>:=JMMIC>;- +4M%
MN?=\O3@\4TKC1]&ZWX]\%W>LQ:!JMUIMU/- +I8KG8ZLA.W< V>*M2S^"KBP
MA>X&BR6<$@CB+11E$<#@#(X('I7RAXG^#?BF.>60^']=OKEM+.GV\\!^:+D[
M26)SQ[5O>*OA!XBT73M!DAT?7]8LVTB"*6QTZ0B:.]VG=(^2!C'![Y-79&EE
M8^A_%M_X,\-:')J6LVVD"RBB,Z^;!%B1,9 &1@\5'H<G@3Q9H<=U%IFD26&T
M3B.6UA8*I ^8C!&,&OEOQ%\*?'MM978U?1];\1V=[IHALK2PW;K20C*B;><$
MJ,J=O?I3HO GQ \'Z3J<%MX9U^]BU/0TLHX[4'_1Y"0<G)&",8XYI<J[BLCZ
MV9_"UG<P6,D>DPRW 5(HO*0%U/W548Y'H*MZ1+X>T>\EL-.CTZQN!^\DAM(T
MC.&/WF"@=3WKY;\,> ?%NA^,--F\0:'X@U;S;.W2WN+1B([.7K^]WG/RC(.W
MO7-:9\%?B'_PL'6+V:+7A*[&1+@2R"!HS(2B 9Z@=>U)Q0FE8^U]/UW3]:2;
M^S[R&[*$JP@?.T@X/ZUIVO0X^[Z=Z\M^ G@&7P/X1EANXKQ+^6YE>073DO@D
M'//;/2O4K1'529,;S_=&!CM4D%BBBB@ HHHH **** "H)QDA>F><U/44P) P
M* ,W5-/BU>TEMKF*.6VD4K(CJ"<D8XSQWKS'2/V=?#^A7RW46I:X\,<;0PV;
M7V8HD88(";,#UXKUWR6).>I]*BN\K$^1_"22![4#1X#!\#_A=X9\17+RZ[+%
MJ,BO;B*>^CW*' ! &S(/3%=9X7_9]\+>'8I);6XU2[$J&,-/<K)A2,''R#%?
M)_C#4#+\4_B.6UJ" IK"&.*XD8NH\I3A/3_&NTM_BOK4=EX<LCXDL/#]E!:%
MX/[59C)J!5R5\ME/S;C\G/>K+L>Y77[-O@B#4['59/M5L]FH1 )46.0[MP+#
MR_F.>],UO]F;P9XGN;N]N7U*1+VX^UE8[A/+1_5 4.T"O /'WQ>\1>-&MXM7
MUBU\(R^8B1:9>;H;BY!;[Z;"01D[>>]=5X9^)?C"RUGP]X"$3S7EP8[^&782
M39(X21B2V3RW7I4B=T>\^%_A!H?A*_L[RQ%P\UK;_9(WG=6+)G.20HR?>O0X
M<X.1CFJD0: *DC D#:&'3Z?6KD.<<_K2(W)**** "BBB@ HHHH **** "BBB
M@ JI,K--AB0A^Z5XQZYJW4,BMN^7G/K0!X#^T=X$U_Q4VEMIUC:WL$7F E+=
MGN$SMQL8=.1S[5YU9_LX>*Y)K9]8>WU2X3.'*R2(,_[P]/Y5]@>63T !'0F@
MPL2%)X]5X--.P[GQOKO[/OC336U9-!%NME<LA,$J2$M@8Y"@ XYJG\/OV<?%
M-C%I\.L1+<6*9WV\J.P0Y.,*PP.>:^U1&ZDD 9;KD4-$V]> 1@]*?,5S'RKJ
M'P)UJ>S\>Z5:Z=I]E'<WEK+I=U:VIC?:BDMEPN3R1TKD=:_9]^($GPVT:.06
MM[KET@?5V,<KLTXD(5ER-P 3'WLFOM@1$=!@^]!1MP^7Y>^.M',',?'W@W]F
M_P 2PVMI:ZG(A-GI]P@G._S//P3%M8KG&[&>YJMX@_9K\8ZK\(+:WN[TW/B)
M[BWEN@CRG<1NW<$9].M?9/D[0>"1[]:<(BH Z@#\2:.87,>0_ GX:MX1^'=K
MI6L0F60E)#!,-PC8 @85AQ7>6?@#0+34SJ,.DVD=]R3,MO&&)/?(7/;UKH!"
M<[L<MR<]C3O+;.3C'7CKFI$W<BPS#<H QP=PX-%2A,#[K<\T4")Z*3</6D#@
MD@'I0 ZD/0TM(>AH JNW<\KV]Z\G\??&*3P'\0-+L+V,'39H+B1F4 '**"!D
MGU->M;2@/&1V'I7D?Q/^!MQ\0/$UGJ2W\-O';AQLD5C]['I]* .4US]K'2Y/
M"U]J&B6,TNH)*B1P2%'+ANK*,]!WK3^'/[1UGK_@QM1UJ$VNI6<L=M?* J;)
M7R0,9..,5'??LU-<WUK<0WMI$T*E2JQ,$.3Z 5@>)_V5=:OM0F72M>L+'2+R
MZCN[NWEAD,CNA&W:PZ#&>*O0NZ.QMOVG/"^H^)+K0K-G>\ABE?>75D!1<XQU
M[U5?]H;18M,MHM3@75+RX42FUM@N8X^C,P;C ZFN:O\ ]E#4+GQ5%J$.M6$%
MDD4D9187$K;L8RPZU9N_V8-4T^^MK_0=8LH;K[.UI<?;H7F5D?(?:.QQT/8T
M:!H;-Y^T=X'\.7-E:V%N&CNXO/+611%10<;B..@Y^E=#\1/BLGA?X=:=XOTT
MI/:7<L6)&&Y1$P8D]NRUR&B_LM)HUP\D=];REM.FL1YR,X!<8##(XQ76:U\'
M9]<^%FA^$&NHHQIGDH\KJVR4("#@=<'/>C0-#A_^&L-(N-=TJ*QO;;4+.;2Q
M?7:PX+1MOPP.>F!73>/OV@]/\/\ A>/4-,0S7EQIIU*WB.&!C(..._(K.\1?
MLPV>L-9>0T-H+?2_[-/E(49FR3ORHY'/?FN4'[)/B&\5DU'Q'82PP::VF6:Q
MQ2KLCZKN]2.>:-!:'IGPB^.EE\2[:SLY+=]/UA[!+R6.;:-R':"R@9P"S<5Z
MG%'M92I./7/6O%?@]\"=4\":[#JFN:G9ZA-;6*Z;;"PB:(")65EWY^\>#D]Z
M]L7>LG;;GI4B+5+112$%%%% !1110 4444 %%%% "8HI:3.* %HI-P]: 0:
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M!UI QG5RS# 'RC/K4\))!S411B,,,YY'M4T*[4 /44")**** "BBB@ HHHH
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MO.?^$,\8?]!^Q_\  9O\:/\ A#/&'_0?L?\ P&;_ !H ]&S1FO.?^$,\8?\
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M S?XTA\&>,#_ ,Q^R_\  9O\: /1LT9KSG_A#/&'_0?L?_ 9O\:/^$,\8?\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AYI:** "BBB@ HHHH
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MV(D=#3/[-WY.#Q6X,,.F*1=JY% &#_9I/8T?8,=5)K=)CP3V%5Y+JV!.6Z4
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M%% !1110 4444 %%%% !1110 444F: %HI,TM !1110 4444 %%%% !1110
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MR?EX]*1)5^*61XGT'N/,B_\ 1M>I"O+OB>I/B/02OW3)%_Z-KU$=* %HHHH
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M$>16/[,/@NSU2>]2Q$C'F.-F<",G.X@[N<YK3B_9_P#"B6\:+9@HN<KEN?\
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MNLUP8T>X_P!W^M<E\"SCX8Z3_OS_ /HYZ /0**:7 HWB@!U%)N'J*0L .HH
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M71$NXQ=)&=R*^< ]*X'PUH&A^"]!T^STZ*-XH6!^4\NVT \9/'%=S!JL2Q*
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M!#W7I3+VY2SMVESF0]%]*H:K+%:@3^85N!T0=_ZU7L)/M[K+,=LIYV-P!^=
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M_B3/[O3KD,W7,;_X5]7"VC'2-10+=0?N@>XI<K"Y\H#2/$Q;$>GSY/7=&_\
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M$1 *A*A@3P.IS4@<[?Q2Q7+RH&^SR?*Z =>YKQKQMX=TN#Q,D=@X-]<L#Y*
M84L2<G'(YKW_ %N\CT^U6,!6N9FVK&>V>AQ7S7\4?!.N_#3QC8>+[RY9M.O9
M4BXD)\O):3I@8P!ZTFA%S2_@SJ^LZC;117D2333; /-''Z5WT'[*.LQN)O[2
MC#X&Y4E&#^E7O".J64GBOP_JUC?"6WE:(30F121QEF 'KD<U]+V:I)$DJ$$,
M P/UI**87L?,:?LIZG$QF745.1RA<8_E3K?]E/4X)&/]H+*CC[KR#"GVXKZ@
M$9(Z '/0=#2^6=V<X%5R(.9GS%'^R[JELCH-068'^^X^7Z<5/:_LSZM &62^
MCG!^Z7D&1^E?2WE]QP?:@1X&, ?2CD0U-H^:$_9HU@ J]Y$Y/W29 <?I3?\
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M".F:])E@$R%7 (/K7#>(_!WE.+BU4D_Q(H_PH'<I-)]F8,DBR+Z(<FK<5P&
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M] _ZZ1?^C:]2%>6_%/CQ1H _Z:1?^C17J0I@+1110!F:Z?\ B43_ $_K7)_
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MSTQ0!)13=XH+@#/6@!U%1&;! VD@]_2G"0&@!]%)N'K2;QZT .HI@?)]J4N
M: '44TL*1I HSUH ?140G##(!Q2^<",@9H DHJ(SX_A)I1.K-@<T 244T.#F
MD,@ ]: 'T5&9@,<&D\\<Y&,4 2T5%YXVYP<9_/WI?.''!Y_2@"2BH6N-I7"$
MY.,TX2Y.,'ZT 244T.,XI&E"J3U]J 'T5%YPS@ FG+(&SV- #Z*3</6FF0 C
MOF@!]%1>>-I.T_3UIRR;B>"/K0 ^BDW#UIK2 >] #Z*A%QE@-I]_:GK*&&:
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M[ADG&<T6$,C7@Y'R@;0.V*FA "TP. #D%0/6G*X'0'%,"6BH_-X)P:03 @D
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MX)\>>,_"7]DW&HPIX<N+UVF=;103 RJ/+R#D':1\U>Z^,O TFJ_#.;PU9O\
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MNO$$\ZR12Z5!I^Q$V@-&V2W7H?2MSXM^!KGQYX$U/3+.86^I/"PM9]N?+<X
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M%.!VH'\ ]<T45)(K #CM0$!<+VHHI@&T#</0TWJ&;N#BBBI >0%D '0BAN)
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&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tlsi-20230630xs1a008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlsi-20230630xs1a008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (R Z4# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8 [_ )AM/!&X5C^&]-^,/PCMI]&T_2+7Q1IIE9X;AI=Q!/?E@P!ZX/3UKZ6
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M %!X&2<G)KWHC/O2C%>-2RFE3E'WI.,7=1;T3/<JYS7JPDN2*E)6E)+WFO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBFNVU2>N!0 ZBO'9/C[)'(Z_V,IVDC/V@^O\ NTW_ (: D_Z J_\
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M^!!_^)H_X: D_P"@*O\ X$'_ .)H]A4[!]4K?RGLE%>-_P##0$G_ $!5_P#
M@_\ Q-'_  T!)_T!5_\  @__ !-'L*G8/JE;^4]DHKQO_AH"3_H"K_X$'_XF
MC_AH"3_H"K_X$'_XFCV%3L'U2M_*>R45XW_PT!)_T!5_\"#_ /$T?\- 2?\
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MO_AH"3_H"K_X$'_XFC_AH"3_ * J_P#@0?\ XFCV%3L'U2M_*>R45XW_ ,-
M2?\ 0%7_ ,"#_P#$T?\ #0$G_0%7_P "#_\ $T>PJ=@^J5OY3V2BO&_^&@)/
M^@*O_@0?_B:/^&@)/^@*O_@0?_B:/85.P?5*W\I[)17C?_#0$G_0%7_P(/\
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M_.C\Z #'UHQ]:/SH_.@ Q]:,?6C\Z/SH ,?6C'UH_.C\Z #'UHQ]:/SH_.@
MQ]:,?6C\Z/SH ,?6C'UH_.C\Z #'UHQ]:/SH_.@ Q]:,?6C\Z/SH ,?6C'UH
M_.C\Z #'UHQ]:/SH_.@ Q]:,?6C\Z/SH ,?6C'UH_.C\Z #'UHQ]:/SH_.@
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M1^='YT &/K1CZT?G1^= !CZT8^M'YT?G0 8^M&/K1^='YT &/K1CZT?G1^=
M!CZT8^M'YT?G0 8^M&/K1^='YT &/K1CZT?G1^= !CZT8^M'YT?G0 8^M&/K
M1^='YT &/K1CZT?G1^= !CZT8^M'YT?G0 8^M&/K1^='YT &/K1^='YT?G2
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M^Q<HJG_;%C_S^V__ '\'^-']L6/_ #^V_P#W\'^-%@L^Q<HJG_;%C_S^V_\
MW\'^-']L6/\ S^V__?P?XT686?8N4R7[C?2JW]L6/_/[;_\ ?P?XT+J-I<[E
MCN8I" 2=K@\=Z LSY0G_ -?)_OM_,U'G_.:]_/PY\$NQ8K$222?]+/\ C1_P
MK;P3_=B_\"S_ (UZ*Q$5T9[ZQM.VS/ ,_P"<T9_SFO?_ /A6W@G^[%_X%G_&
MC_A6W@G^[%_X%G_&G]9CV8_KM/LSP#/^<T9_SFO?_P#A6W@G^[%_X%G_ !H_
MX5MX)_NQ?^!9_P :/K,>S%]=I]F> 9_SFC/^<U[_ /\ "MO!/]V+_P "S_C1
M_P *V\$_W8O_  +/^-'UF/9A]=I]F> 9_P YHS_G->__ /"MO!/]V+_P+/\
MC1_PK;P3_=B_\"S_ (T?68]F/Z[3[,\ S_G-&?\ .:]__P"%;>"?[L7_ (%G
M_&C_ (5MX)_NQ?\ @6?\:/K,>S#Z[3[,\ S_ )S1G_.:]_\ ^%;>"?[L7_@6
M?\:/^%;>"?[L?_@6?\:/K,>S#Z[3[,\ S_G-&?\ .:]__P"%;>"?[L7_ (%G
M_&C_ (5MX)_NQ?\ @6?\:/K,>S%]=I]F> 9_SFC/^<U[]_PK?P0/X8__  +/
M^-.'PR\&&(RB)#&#M+_:FP#Z9S1]9CV8?7:?9GS_ )_SFC/^<U[]_P *W\$>
MD?\ X%G_ !I?^%;^"?[L?_@6?\:/K,>S#Z[3[,\ S_G-&?\ .:]__P"%;>"?
M[L7_ (%G_&C_ (5MX)_NQ?\ @6?\:/K,>S']=I]F> 9_SFC/^<U[_P#\*V\$
M_P!V+_P+/^-'_"MO!/\ =C_\"S_C1]9CV8?7:?9G@&?\YHS_ )S7O_\ PK;P
M3_=B_P# L_XT?\*V\$_W8O\ P+/^-'UF/9B^NT^S/ ,_YS1G_.:]_P#^%;>"
M?[L7_@6?\:/^%;>"?[L7_@6?\:/K,>S#Z[3[,\ S_G-&?\YKW_\ X5MX)_NQ
M?^!9_P :/^%;>"?[L7_@6?\ &CZS'LQ_7:?9G@&?\YHS_G->_P#_  K;P3_=
MB_\  L_XT?\ "MO!/]V/_P "S_C1]9CV8?7:?9G@&?\ .:,_YS7O_P#PK;P3
M_=B_\"S_ (T?\*V\$_W8_P#P+/\ C1]9CV8?7:?9G@&?\YHS_G->_P#_  K;
MP3_=B_\  L_XT?\ "MO!/]V+_P "S_C1]9CV8OKM/LSP#/\ G-'%>_\ _"MO
M!/\ =B_\"S_C2'X;^"?[L?\ X%G_ !H^LQ[,/KM/LSP>.]N8D")=31H.BI(0
M!^ -,>:21=KRNPSNPS$C/K]:]]?X9>#(@I>)4##*DW3#(]1S3?\ A6_@C^['
M_P"!9_QJ?;P["6-I;I,\#>9Y2#)([D# +,21],U)+?7,[1M+<S2-']PO(25^
MG/%>\?\ "MO!/]V/_P "S_C2_P#"MO!/]V/_ ,"S_C1]8AV']<I_RL\!)+$E
MB2QY))ZTF?\ .:]__P"%;>"?[L?_ (%G_&C_ (5MX)_NQ_\ @6?\:?UB/9C^
MNT^S/ ,_YS1G_.:]_P#^%;>"?[L7_@6?\:/^%;>"?[L7_@6?\:?UF/9B^NT^
MS/ ,_P"<T9_SFO?_ /A6W@G^[%_X%G_&C_A6W@G^[%_X%G_&CZS'LP^NT^S/
M ,_YS1G_ #FO?_\ A6W@G^[%_P"!9_QH_P"%;>"?[L7_ (%G_&CZS'LQ_7:?
M9G@&?\YHS_G->_\ _"MO!/\ =B_\"S_C1_PK;P3_ '8__ L_XT?68]F'UVGV
M9X!G_.:,_P"<U[__ ,*V\$_W8O\ P+/^-'_"MO!/]V+_ ,"S_C1]9CV8OKM/
MLSP#/^<T9_SFO?\ _A6W@G^[%_X%G_&C_A6W@G^[%_X%G_&CZS'LP^NT^S/
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M9S<D=)1116)PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"'I7D_B\#_A([WC^(?R%>L'I7E'B_P#Y&2^_WA_(5I3W.O#?$S&P/2C ]*6B
MMSTA,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:*
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M(;R*ST#2W\I9]4+1[WD0DX6-,$%FZ]1P:+H.>/<]\P/048'H*\2_9X^*6O\
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M/VFKZX^%/C"ZT;3[_P &>-?#E[96][I>KQ1R2P)-,@#C&5=64D CH:ZOQ?\
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MTYI]/OFN9/-D<(IW(5;[I_.NCM_V<O$6DGX?:CINK>&[;6_#NI7-_=I;Z/\
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M+>Z@\0:=I,1EG32;F.5CR!MR&P#SWKH=+\5:7JFF_;([ZV5$ACFN$:=,VP=
MX$G/RG![XHL@]G':Y\A:_P#"CQWH?PT^&6K^&/#]Y)XH'AV;PKJ]D5VR013*
M0LCYZ"-N?H:^HO"7PLT/PMX>\*Z:MLLLGAVQ-C:3ABNT-&$E. <'=SU'?BMJ
M]\8Z!ISV*7>N:9:M?8^R+->1H;C/3R\M\WX5Y_XL^,NM^%O&.IZ*W@^.ZMK+
M3)-8-ZNKHA>V1@I/EF/(?<0-N>G.:+)%*,8ZG2^'/@[X.\(WT%[H^B16-U!L
M\N1)9"1LB:)>K'.$9EY]?6O%OVGOA3XD\3?$#PWJ/AS2YK^UUJTD\.:Y) !^
MXM'D1_,?_9 #C\:]&\ ?'NW\>^+]-T"+19K26[T4ZM),]PKK X<*T! '+#.=
MW ]J]5I[E6C-:'Q;H?P1\71^#OBS%?Z!=&YT[0IO"_AF(*"UU:^;+*'C'^UN
MC7_@-=+#X UK2/BEIMXWA"]F@O?AZFD_;K>T1DM[Y4Y65L@JV!MSR>0.E?5U
M%'*3[-'R)X%^#6K^'8/V<[B#PG)I]_I$T[:Y-';*DEN&1A^^8<\G'7-?70&
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MH>S/S]'@;5VTKXQII&A:E-8ZGX5M4LF@\,MI,5W*LHW"*V4') [M\QY-=O\
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M_O\ 5+10%WW9%_8NB?\ /M<_]_JO)I>EKHLD0MY_LYF#,ID^;=C@YJM5U/\
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M0'.^[/H+^Q-$_P"?:Y_[_4?V)HG_ #[7/_?ZI%.1FEH*N^[(O[$T3_GVN?\
MO]1_8FB?\^US_P!_JEHH"[[LB_L31/\ GVN?^_U']B:)_P ^US_W^J6B@+ON
MR+^Q-$_Y]KG_ +_4?V)HG_/M<_\ ?ZI:* N^[(O[$T3_ )]KG_O]1_8FB?\
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M[VTSEC#NR,2'IZ\5]K#Y>A(^AH QT)'T-'*+V1\K_#WX.QW_ .T1I6I:_P"
MS8:5I?@O3UL8+PM=P:?>)+D1+.WWY(U/4\CM7EFH^&G\/:9\,+;Q1X3O=2@/
MQ#UJ\DT9[/?-=0L&=66(XW@CY@/X@,5]][1C':L37?!6C>)=7T+5-2LENK_0
M[AKO3YF=@8)2NTL #@_*2.<T6!T^Q\2Z]\+=3UOX3_$W6M$\!:C8^'M0\7Z7
MJNB>'Y--*74=I"RB[E2V(W1AQGY ,D#&,5U'Q+^'7B;QIJWQVN/"_AS4+73]
M9T?PZ^GVK6K6AO;>(%IK5 0,.$^4IQ@_+WK[-QWR<^N:",]>?K1RC]FCXJF\
M,GQQXF\4ZYX!^'^K>$O#L/@*]T>\MKG1SI[7]XZ_N84AP#(R8^\ <^O-=!\/
M?A-<>$_B-^SMJ&G^%)-*^S^&[V'7KJ"S\LI,ULNU;E@,[BY;&[G-?6IY.223
M[F@#%'*/V:"EHHJS4*V_"?\ Q]WG_7I+_(5B5M^$_P#C[O/^O27^0J7L9U?@
M9@2Q+- T;C*.I5AZ@C!KR+PQX1^(GA?P]I?@FQDTNTT3372&'Q/'=$W1LTDW
M",6IC($NS]V6+E?XNO%>N3F1;=S$JO*%.Q7;:"<< G!QSWQ7S_X>_:+U:S\%
M>&3K%MH\OB*_L+C4IVN]3^R0-"D[Q(J'RCF5BI 7  VY)YIL)-)JYNV7PR\4
M1#3?#LT.G)X?TS7)]<BU=;IFN;C<\LB1&'9\C[I=KR;B"J\#G N^%_A1JFBV
M'AB&1K+=I?@^YT&3RG.!<RM$<K\H^0[&R>#ST.:GT+XQZIXSNUG\,^%)-3T:
MV%F;YY[H072M<(LA2*(KAS&CJS[F7/1<FN8\ _&CQ'::'HC^(M*2[M-3FU6"
MTU-;T&>62V-Q*H>(( J,D)52&)^4$CFEH1>*+FF?!36K3PQK6GS-I[SWTV@N
MI$A*E+*.%90WR_WHV*C'.1TS6IJ?@'Q/I'Q%O/&>DV]AJLQU.>>/3KF[-N7A
MFM8(2XDV,$D5H>A!!5B,C-58?CUJEGI\=UK/A(637^CQ:MI=M:ZBL\D_F2Q0
MK#*2BK&Y>:/D%@ 3SD4NL_%36;/7;'1-7M(M!U2RU:P:^%A<_:;>XLIDG)VN
MR*W!A8$%0?E!!P:- ]WH96A_"+Q=X+FN+W38M'U>]UG3+JQOX+JX:&"QDFNI
M;C=%\C&2,&8JRX4ML![X$VD_!WQ+H5AI/DG3[BYT_4="N_*^T-&DB6EMY,PW
M;#M/)*C'.,<9K0?X^W6BZ-;:UK_AU;'2-3TR;4]+:TO?/GE5%5Q%,A10CNC*
MPP6 R03D5)+\;-<T+7[G2?$?A*'3I;2.QN;J:SU,7,<4%S<-!OR8U.8V4;AC
MN<$@4M M PI/AQ\0;'3_  CHJ:9H6N>'=&66YGL9]9EM1=7AN))(C(! ^^.-
M65@G&7ZY"BID^#6O/XFOH;A(KK0[_7AK\ETVLSJL+DHY06JJ \BNGRR;@,8)
M'&#Z%I_C>[\1^%_$VIZ98*C:?<7EI8M<2[4NS!E3+D*=JF0.!P?N9[UYWX0^
M+7BBP\!6DTND)X@N]*T2#6-=O+G4]KL)E:4)#^Z =_+5FP0JJ,+D]:>@6B:_
M@7X?>+-&U#P18ZC:Z2FD>$TNH$OXKII+B]62)D1Q'L CSD%P6.6Y!Q7L (KA
M?!/Q(NO'7B76[:ST=8M!TTPHNJ2W/SW#RVT-P@6';P-DW))X(& >W'Z!\5O$
M6E7^K3:OI:7OAM/%\^AKJ?VP"> /*D<.(0F#&C,%)+;OFS@@4%IJ)[72=*\9
MT[]H=KCQ%<:7)HUM=S&SO[NWMM(U#[9<@VPR8I55 BNXZ!';!X-1Z3\<_P#A
M(-/TR]N%LX(?[4M8))-$U07"!9(Y'9)D>)9$*[#N0JN>"K=11<.='M=%<'\/
M/'FO^,TL;^[\+KIN@ZG9_;K"^CO1-(J$@HEQ'M78[H0XVEAU!.:[L4RT[ZBU
MMP_\B=<_]?:?RK$K;A_Y$ZY_Z^T_E2?0SJ;+U/*?C5X,O_'WP^NM'TVVLKRZ
M>XMIA;:C(8X)ECF21D=@K8#!2.AZUYX?@]XH4:[J.BZ+X;\$7-U:1VRZ/H=V
M7BNV6X20R22M"%20(K(CB,E=^<\"O0OC1XGUSPAX(_M'P_';27XOK2$BZ?8F
MR2=$;^%N2&QTXSGM7*^&_B=XFL_$.J0ZII,-UH3>+[C08K_[</.ARP$:K#LP
MT:'Y2Q8,<YQ0[!+EOJ9_A_X2>*XO%$NIW\=K##+K4&K8FU>6^G55L9;9HVD=
M 78,Z'/"X)QC',1^$/B^P\,:SX:M8=)NK/Q'I=G87NH2W;(]@T4/DR%4V'SE
MV_,@RN&)SUS3]3_:%O[EM:TZQT_2EU0:;J-U9?9]4^TM ]LI.+C;&44D?, K
M-@C:?4=Q>^/]1\._""R\4WVG+>ZD;&VFGM[=V:,-($W.S*A8(N[>Q"$@ X!Q
M1H2E'H<KI_PL\3:>(O#.VPD\-Q>(QX@_MJ2Y9KMU$HE$)AV?ZS< OF;L;>V>
M*VO"OPSU30H_ARDIM%'AY;_[8(7.&,Z.%*?*,\L,YQWZUSY^-VLW.L>%+M(-
M&/AZ<ZHVISZ?J8NXY8[>W\T/"PCW<#)V-L;<-I '-7;[XZ:SH&BKJ.K^$4A6
M^TPZKI<%IJ(E>90T8,,N441R;9D;C<O49XI: N5$WCCP!XHU&]\966E6VF7&
ME>+K>""XO;NY,<MALC,3?NMA\Y=IW* 5PV<]<U6M_A;XFLK76O"T*:3)X;U/
M4;C4'UJY=GO(A+'M*K#MQYRL!MEWX [9JQXA^.&K>$UU>SUCPQ%:ZQ8R6C'R
M;QYK..VN&=!<32K%N18VC8/A#SMP<'(Z_P />/'UKP!)XD>UM6:.*:0Q66H1
M3P2^7GE)^%VM@'+;2,_,!BGH.T6SAH/A]XRU#PYI.CZC8^'K&+18;"UMY[:5
MI);E8)XG=PQ0>4A2+(B^;+$9/%06/PR\8?;-%TVYMM#.A:-?:I<)<2W,DDEX
MEREP(P\00; IGPPW'(Y!%5Q\=KOQ/8:A:VIL;/4;*XTJ4W.CWQO(&AN+I8WC
MWM&OS  @[000<@UTDOBS5X_@9K^NK=2R:M;+J1AF7:''EW,R1@=N%50,^E&@
MERO8Y#3O@_XQFBM+:46^D:59SZ:8M,FU=]05?(N5D=H)7C#Q1A%*K"2W)'3'
M-VV^$WBV?0-'\,7,6F0Z9X>BOOL>II>,\U^\L,T46^/8/*_UQ:0Y;)7CK5OQ
M'\4O$5FT6E:EIT7AW5Q=Z5<(]E>?:DFM)KM(I%9BB[7&=K  CY@0:O6_QVFC
MLK'7=1T..U\):H+IM.OH;SS+AEACDD!EA* *)%B<KACCC=UX- 2@;?A?P#?Z
M)XA\+7LAMA;:7X73195B8Y\X&$DJ,#Y/W;<\=1QS7*:_\-?%MU-JFD65MI$N
MBWWB6W\0G4[B[99T598G>$Q;#EQY6%?=C!QQ5G4OCQJ/A:.*/Q'X8CM-1U*R
MCO-(M+*_\_[2SRQ1""5BBB-PTT1)&Y<$X)QSL?#;Q'XIU;QYX[L/$5M%8M8?
M8!:V5O<_:($WPN79)"BL0S 9RN00:6@_=>ARO@7X*:MHFIZ3IVK11WVB:-/=
MS0WLVKSRF<3>:!LM<!8FVRL')+ \X'.0_P -_ [7]-TF*/4=1MK[4+?6-.$$
MXD8;-*LI<PIRO^MVLQ(Z%L<UCZ)\5/$?AJ_N]7\43R2V0DUN4V%K<B96%O+%
M%!&F8TV8)('7.[<3VKN'^+^J:!J\>E^*/#]MI=TSVDC2V>H>? EO/*8?,+%%
M.Z.3:K+C!#9!HT$N4YB3X/>+M2^' \"7,>@V>G:=8S6UGJR.\EQ=.9-\9V[0
M8 >DF"Q;/%=G\,O!NK:1K6LZYK=FME?WL,%JJ-J\VI2F.,L?FE<*N,L=JA<@
M9R3G A^'GQG_ .%@7NG6L>BR6,]Q]L>XCEF!:WBB,?E.0!SYHEC('8,?2O3*
MJR+BD]4%(>U+2&F:&SXA_P"/'1O^O7_V:O+OBCX=U3Q!:626FCZ-XGTU6<7V
MA:UM2.Y4CY725D?8Z'GI@@D9'%>H^(/^/'1O^O7_ -FKS?QGXSU'1M;TG0]#
MTF#5]9U&.:X$=U>?988X(MN]F<(YSET4 #J>< 5"V,(VY-3SWPO\(_$_AI="
MN+./3K%+76;J]31DO9)8-,MI[1H-D3LO[S:S>84PJG<5&!6$/@KX\U6T1-4-
MD\PT*^T>66?6))TDDE"%98XO+"0Q,4QY:C*@\DXP9M)_:0N]%\-Z?;ZA:VMW
MKD5C+J-_'J6I+;2%?M$J)!" C"67$9 ^ZORCGFNOA^.IO/'-EHD&E006MU]E
M,?\ :-X;2\G2:,/YL,3ILD5,[64/OR&P..307N-%;QI\*=>U3QA'XBTK^SY6
ML+?2S:V-S*42>6UFD=HV(4[%*R#:V#A@.*SG^'GC\7U]JRPV$$NH:X=1N--T
M[5FMI/*-JL*_Z4(BP967+;0-X/7L5T_XZ:L/!KZCI'AU]=@TK21JFIS:AJB1
M3A6:79&F(\2/MB8G.P 8ZFM!_COJ:W=U<CPM'_PCUEJMGI5U?'40)M]PL)5X
MX=GS!3,H;+#VS3T'[A1\$?!37=.@N(=7ELH2^AZCI"W%K</.ZM<79F$@+@-C
M:Q!R<Y'.<UJ^"/!/BZW\:^&M3UNPT;3[+0M FT1?[/NVF>X8F#;(%,:[$(B)
MVDD@GO71^/\ Q[JWAC7M'T31M#AUG4-1ANI@;F]^S0PB!59MS!&)SNP,#KBN
M'L/VD[G^S+/4-3\+?8H-6TG^U-(B@U 32W'[V.'RI1L"QDO,F""PQG.#Q1H/
MW5H:.K?"75[ZZ\2RJUB5U+Q9INMQ[Y#S;VX@WJWR_?\ W3X'(Y'(S6+XO^ N
MN>*M;UB7[;9VMI?3:O()-[,X%S;P)%N7'/S1-N&>A[YKIKKXN:YIFH3>'K[P
MS;#Q<T]M%:6EOJ6ZTG6<28D,QC#($\F7<-A/RC&<UPTGQ5\7P3:Y;7$+P:['
M+K7V:T^W*;2%;>T@D7+>42X&]F0X')PP]%H)\MSO%\*^*_%&J:-J&N:7H.EG
M3]3L[@06<YN)&CA20,3*47/S.NR/'R@$YR:R[CX9^)[II?#CQV">''U]M=.M
M"[8W1!D\WRO)V?ZS=\OF;L;>V>*Q=*^,]SX*TS[)K,K7FMLNEVRMJNJ*+4S3
MVS3/(91""JA5);Y22< "N@TCXX:AXLALK+P_X?M;_6Y3=&='U+9:1QP% TD<
M_EDR!S(@3Y1U.<8-.Z"\&C/'@#Q^O@*/PU;VWAVR.DZ<;*QOTD\R6[.]3E=T
M9%L&13NX?YR#VJAI_P */&=MJ>MZJ]O:&:\U31M4AM[O6Y;N3_1&?S(I)W3)
M)5LA@-O; ZUU/A7XD:AI7P*T;Q;K4,M_=>6CWV]U#HIN"CL2!@[%.>.NVLT?
MM"6^M1ZG:66EW*W$-[>VJNEPJL;:""23[8IVD!6,9501U_*C0&HZ7(9_@EJU
MYX5\.:0US:6S6>N:EJ%U-#(<B*Y2Y563Y?F<><A(..AYXK%C^!OBC4O!>IZ1
M>QVT%[#X=ET.PNI]:GO!*S!!N"E0L$1\M25PQ!/' Y@;XL>-KAK[[);QS6T-
M]X>2QB^UJ)YDNH]TD<K>6 -_.YAG&.!S7L?@'Q=>^*8=7AU/38=+U32KYK&Y
MAMK@W$1;8CJR.54D%7'4 @YI:,$HMV/-KWX1^);_ ,0:DUQ;Q3:9KEU:7UYN
MUV=(K5XXXU>,P(H\_!B!1]R]>0,<^F?#KPQ<>$] N+.Z$/GRZC>7C& Y!$L[
MNI)P/FVLH/TKJ**JUC112U05MZ1_R+^M?[L?_H58E;>D?\B_K7^['_Z%2EL*
M>WW'">/-,U;5_#-W;:))9+J#%2L6HQ"2WG4,"\,@(.%=<KNP<9S@UXXGP+UB
M]A\0M9Z%HW@NRU&&VB&@6%\T]M++'<I*UP^$"(VU2@"KSGFO6/B;XWE^'WA8
MZM!IIU:<W=O:1V@F$.]IIEC'S$$#!;/X5Q5A\:M?&MM::KX2M+*SM=<CT"]N
MK?5?.*7$@4QO$AB7?'AUW%BI!/ .*!2Y;ZDGBCX4ZSK%SXJEMY+-?[5\1:7J
ML)DD(/DVQBWAOE^]\C8'/;D5S=M\)_'=YK.G7&IM9W'V.74$DN&U60QS)<1R
MJDD5L(Q' %W*"O+'D[O6]/\ M"FYOM2TJ:SM(9#87]S VDZHMQ<0&W4DB7]W
MY:.P&1M9\'@BKC?'35()[YT\,)/H6E7]CIMYJ$NI 3LUQ'"P=(A'AMIF&[++
MGMZ4M"?=9N:-X U71/$_@F[BCLWT_2_#\FBWL:RE?+8B(AHUVX=<Q$$?+US[
M5QUK\$O%6C:5XNATV_T]9=@LO#B,W^HLC<&XEC=F0A'9CL5@&VA4/:K]G\8_
M$6C^&Y;K6[/0X[Q]<OK"*6ZU7R($BA9L XBWNW 4!$)/4D5#;?M!->V-MK5A
MHEY>R7NGV4D6EM>(D8DFNWM^"4X(9<ECU7' -/05XCO"WPH\3P>*+[4]3AMX
MK>[U33M1V3ZO+?SJD,<B/&\CH-[?,"",+R1QCFC_ ,,^ZV?#GB33Y-4MW*2P
MP^'D$KH(;**X^TB*5P,J6<[,KG"HAYZ5LZM\>M1T*TO8=0\/VEEJECJZZ5=S
M27TC:;;;H!,DLEPL1958$*,H/FZD#FM;QWXZUJ;X$ZGXFT2*WLM7;3VGCVWJ
M2QPG."Z2HK*^.JG'/&<4M!VB7_AAX/U'0KS7=7U>U6SU'57AW1G5)=1EV1J0
MIDF< $_,<!5&!U)[<##\(?%^CC3KJWCAN[FPEU*W$%IK<MB98+FX\Y)?,6,X
M(/RM&0<CD&NBMOBQJVDVGG7&BQW.@Z5=6^DZCJ;ZD7N3<$1B21$\L"1%:102
M2I/)"\8J*#X]7=NHU#5?#8TWP]+>7UA!?_;@[M+;"7EH]N%5S$0ISG)Z=,F@
M>ZT4]%^%7B?P,9X-"L= U"VU33+6PNO[1GE:.R:)I"V$<,UQ$?-8["RG(]#Q
M8C^#VLQ:'I=FKV*R6WB^?7I"LA56@<R8QA?OX9>/UXI^D_M"+KGAN34K;18X
M)X-,2\O(=0OTMX[.=[AH1!+(1@8V.Q(!.!P"346F_'V^UI;*TTS0+35-6N=6
MDTD?9M186A*VQG\X2O$&*;1@_)G(XS1H"Y"#5_@AK&J>#_"^C+<6%M)IF@7.
MFS,2S1^<XC*X '*$QG=T.#T-3W_PY\5>,O$I\2:O;:9HUXK:? MA;7AN%\F"
MY\Z20R;%Y/1$QP.IYI%^*'B;Q%XF\$SVVDII?A;4]9EM5NEO0\US&D<H_>1;
M!L5GC)7#$_*,XS5?XK^+/%FD^.[V'3[L66C67AF>_7R;C#O.9DC5V0QG.W.
M-V.<]L%Z![MC.UOX3>)-2\(6?A[5?L>G:+X>AOI(-5L9WN+B\\R*5$S $!4X
ME)<;B6(XZUS5MJ!\?7^O:CJ[:59Z)9>#%TTWVE/-/'',94:+.Z-"K_)N$0!*
M8P3DBO4)/C+J(F>_A\/1R^%UU8Z(M_\ ;<7+7 81[_)V8$7FG9G=NZG&*SH_
MVC8'<(V@S1N=)%\,W"X-WYFPV><??[[O;I2T8GR]SJ?@EH>I:5X"M+[78O+\
M1ZRQU75!@@B>15^7!Z;45%QVP:[ZN.^)'CJ3P)I=G.L>F^;<3B$OJE_]E@B^
M4DY8*SN>,!44DY[#-<1:?'K5O$%EITF@^%8+Z:XTJXU6<W.I>1%"L,QB= WE
MEF+$$K\H]\56QIS*.A[117@WBSXXZYXC\"ZUJ?@[1B+2STRVNKG49KP13VSS
MQB4".+81)L0@L2R]<#)KW:(EHD).25!_2@I2OL/I#2TE,H]'^'?_ "!I?^NQ
M_D**/AU_R!I?^NQ_D**YI;GCU?C9U5%%%29!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% "'I7E'B__ )&2^_WA_(5ZN>E>4>+_ /D9+[_>
M'\A6E/<Z\-\3,>BBBMST@HHHH **** "BBB@ HHHH **** "MOPG_P ?=Y_U
MZ2_R%8E;?A/_ (^[S_KTE_D*E[&=7X&81("9)P!SDUYKI'PB\-OHVF/H.N:M
M:V\5O-!;7VFZB"TEI+(9##OVD-&&)*G[R]C7HUPQ6VD(X(0D?E7R[H?B+Q;K
MGP\U;5W\4ZU97&D^"+35;>*S9(D>\(N&9Y%V?,#Y:@ITQVIL4FE:Z/8/^%;^
M$+WQ#=V=IJ=U%<1I9R:CHUIJ)V3K#@6[W$?+'A0,Y&\*-V:TA\)?#JZ7HUAL
MN?L^E37<]L//.0]RDJ2[CWXGDQZ9'I7EUOJLG@_Q7K6OS:M<V-I?>*]+CU.>
MYE_T=8)-/4D-D81-[*N<X& ,UEZM\2-4UNPFU"U\6^3IXU;6%M[>34SI+W4,
M31B(PW+1E#Y8+$1O@.&SR!2N2I+L>O7WPT\*>)(?[-E9[@Z9IJ:*8XKHB2WB
M)BECSCE9 88V5NO&>]2VGPET6*Z-[?3W^L:F]W!>2W^H7 >:5H5=8D8JH'EJ
M)'^4 9+$G)->06?Q#U;4M8B34M<U+1/#=[J&FQWFI2A+2>!'TKS5C>11B+S9
M@-S9X/R@C(K6\(ZGK_C76M,TUO%FN)H.-::VO[2189]0@AFA2VD:7;DXWR88
M8W@ G.>2X<R?0[*]^!NDIH-W9Q/<ZP(]-GT[3;+6[QWM;.*0#,:; '4?*HW9
M9E"@ \5P]]\/-6TO1O&FL^(;FRM;K7-*MO#\2ZYK[7"1C>^)6G\M>=T@V1JN
M25Y.YLUT]SXQUH?LZZ#KTVHSVVH7%K8G4-42,>;!$\JK/<8Q@,J%FSC Y..*
MX[5Q_P )1K=OI]MXAU/7?#&G>+]&^P:C]M\\M(R.TT?G ?O%0B,@\[2Y&>P3
M!\O1'LEA9Z#\.O!VC^&;[58+2!+7^SXGO)A')<LL9\QAD\L?G<^G)K&?X.>&
M]6TZW%G?:E!IMQID&G3QV%]MBU&S1?W2RG!W#:Q&Y2I(;&<&L7XTZ*M_XCTJ
M\-Q>*T.A:X5ABE(B)^RCJN.<YQ[X%<18_%"X\,^"9])?7'L]66'PY'I5GC]]
MY,MO;"0QKC)0GS=QZ#G.*?DQMI:-'NWA?2-$TEM9O-'EC:.^N_-NC'*&C26*
M)("@ X7:L2@KV(-<FOPW\'HS:_)K-U-HEWJ7]MFVEU -ITEV[#9,!CGYMNT!
MMN<'!->>#QK?3^(+FP\1>*+WPQH ?6WM[VVD6W-Q<17>R. OM.[9%\PCZOGO
MBMS3]2O=#_95\+W-A-)#=QV6FJ)#%A\-<Q*V4(."5)R,<9]J NI=#J;#X$>'
M]-_L^,:AK4D&F07-G902:@0EK!,NV2--H! Z$,?F&T?-Q5RP^$>AO>1ZI>7^
MH:_?&6WF6^OKE)&=80_EH2BJ&0>:Y/4G/)-<##=>(99])OIO$NM7!U3Q7J6C
M267FA8([0"Y$:H@7AE\M"'SG\*X_P/XIAT[X<:%9WGC74=!M;'PBEUIGD78C
M:ZO1)*LJ$E3YK1LL2>3_ +?(.>%=$IQ['O?A+X7:1X,O;>XL[G4ITM+9K.QM
M[R[,L-E S!C'$N.!\JC+9(  !Q78@@CBO*?'OB[5])^$GAR]U&6XT?6M0;3X
M+QK>X2S$,L@4RJ\SAA F<J7P2,X'-3_ 'Q9>>*/#^OI>ZF-4;3]:N+2";[2U
MP1!MC9!YK*K2#YFPY49'J.:JYHI*]D>H5MP_\B=<_P#7VG\JQ*VX?^1-NO\
MK[7^5)]!3V7J<3XO\*V7C30)])U!YX[:5HY/,MI/+D1T<.C*V#@AE!Z5G_\
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M7'FR2F-2J'@ +@'&  *\1\/_ ! \5W_B1?M&M+:ZD=0U&&[T9M3,K16\2R[
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M])?Y"L2MOPG_ ,?=Y_UZ2_R%2]C.K\#.?GFCMK=YI7$<4:EW=C@* ,DGVQ7
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M$&]<$-G )P5QWKM-:^$FDZSI]Y;BXO+22XUE==6XB9&:&Z4*%*JZLI4!!\K
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M:B]X[KD$@]1Q144=U%--+$DJ/-&1YB*P)3/(R.V>U2TS8*VM)_Y%[6O]V/\
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MBB@ HHHH **** "BBB@ HHHH **** "MN'_D3KG_ *^T_E6)6U#_ ,B;=?\
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M!7*]-PKUJ#1["TAGA@L+6"&=BTT<4"(LI/4L ,,3W)J2ST^UT^(16EM#:Q
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MBH"_E>7"R##*L@(., YQ7G'P\.EI<Z9+X]&C0^$);769='COF!L5S=*0(3(
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ME_E4OH9SZ>IB#I2T@Z4M4:!1110 4444 %%%% !1110 4444 %%%% !1110
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M*C.3CDGUJ7PIXYB\0>)+2WU#PS)H>IWVG&_L9YWAFDGM@5W*73E&'F(2A/\
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MF<9179_V#HG_ #RN_P#OX*/[!T3_ )Y7?_?P4<P>V79G&5M:3_R+VM?[L?\
MZ%6S_8.B?\\KO_OX*NV>DZ7'IM]'''<")POF!G&3@\8I.1$ZJ:M8\?\ &W@Z
MU\<:*+"XGGLY(KB*[MKNV(\VWGC<-'(N00<$=",$$@UQ\WP+MKF2YOI]>OKK
M79K]-2_M*YM[>4)*L1A*B!D,?EE#C9CW!SS7T%_86B'_ )97?_?P4O\ 8.B?
M\\KO_OX*.9#=2+W1X!?? G2=3TM;2[U&_F8VDEI)./*1I/,GCG9MJJ%7YHE
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MUZZM+'^S;)[R.)/L]OE25_=J-['8@+MR0H]Z]F_L+1/^>5W_ -_!1_86B?\
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MN_\ OX*/[!T3_GE=_P#?P4^8?MEV9QE%=G_8.B?\\KO_ +^"C^P=$_YY7?\
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M#"NT*@R(^S]\>>"/+^[TYZT"U':G^T'X7TUI9%34+W3;:&UGOM5MH ;>Q2X
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M%XC>]MYM+2R%U=7D171(?[0WS[R4>[))9%:1B,*K' !; H#4ZY/BI:Z)\(]
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MCC0!51%"JH P  . *91YG^T1\1M<^%_P^36/#UM;7FJ/J-I9I!=(71Q+*$(
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MWK]XMU>WB6X@#*B!(HPH)X51U)R22?0 &DT=;11106%%%% BYJ'^HLO^N?\
M6J=7-0_U%E_US_K5.DB8[!7B'[1FJOHUWI=TL<=P(M$UN0V]P&,4A6"(@. 1
MD?C7M]96N>']&UQ%.KV%I>*(Y+=3=(" DH"NG/9@ ".^!3&SP>3XH?$"[U2X
M.GZKH]EIZ^+XO"T%M+I9E98Y((F\YG\P$LA<X7 !Q@US/C3XB>)M5TOQ!;27
MMG;Z]INB>(;<:[:VABF/V6: *R('Q&65L'&<$ @CI7O/A2Y\'^*[7[9INC(E
MFTRZT+J>R\J)K@,T0E#GCS5\K![@!?45-=:9X%B\0VFDS6&EG5=;MKV2*'R
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M !1110 4444 %<GK'_(2F_#^0KK*Y/6/^0E-^'\A51W-:>Y3HHHJSH"BBB@
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M'\A765R>L?\ (2F_#^0JH[FM/<IT4459T!1110 4444 %%%% !1110 4444
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M[YHH\._\>3?[YHK-[G)+=FK1112)"BBB@ HHHH **** "BBB@ HHHH ****
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M_P#GF/\ OH?XUY?I?B&QUQ)WT[48;]()FMY6MIQ((Y%^\C8/##N#R*O>:_\
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MXOTW2[O[+=WQMY_.@MPKAP#),Q6)0<8)8J1UX[XXHL'LGW/6/['N_P#GF/\
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M'*P]D^YZ%_8]W_SS'_?0_P :#I%W_P \L_\  A_C7GOFO_?;_OHT&5_[[?\
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MT?X=_P#(&E_Z['^0HH^'7_(&E_Z['^0HKFEN>/5^-G54445)D%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (>E>4>+_P#D9+[_ 'A_(5ZN
M>E>4>+_^1DOO]X?R%:4]SKPWQF/1116YZ04444 %%%% !1110 4444 %%%%
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MW[>#@8(JOH_PD\5>&/$#^*-.O]'N/$&I&]&IP7:RK:QBXD1U,)4%CY?E*"&
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M.O-9\6^ ],2ZU*VTRXO[@:@-.N)(/,C6V<JDCH00I8#N.>AHN4I:7/2 I).
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M3\-C6=2L=5U/5M(AM[E96E$DTP-I=L&&0 P(+G^%@34'C_7M;\-^);B"PO\
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MIY\=H+]PKDJEN4WB5G VA2O()//;-5H_C#X1GTB?4TUG-M!*ENZFVG$_F/\
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M^RCT_P .7.@VLMM-,YG9Q$J2L#&/+7$7*#=@GJ:Z?Q'\)]3U'P]J,5I<6XU
M^(DUZW07$MNDNU441O*@WH2%;YE!Q\O7FC45Y]CHM4^*?@N?PW#J-YJL5QIT
M]QY$<1MYGE>9/F,?D!/,WKC<5*Y &3Q5+3_CQX2U'7]5L(]23[)8:7#JSZH2
M?L[Q2.R@*<<D$#CKDX R"!S.E_"KQ+H&HZ=XGTZ#23XABNKJ6?3KK4KF:*2.
M:%(LFZ=6<RJ(U^8(%()7 ZU5U_X+^*=<N[ZYDO=($]WIEB&-KYMK&MY;7;W
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MAH)X'*E6VNO9E)4@Y!!KDM(^$/@J]TR-=#GO8((&NK1KK3-4E624/*6N(9)
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ML8G4KMQ(D;'Y"=I(!S75VWP;\.PW$5Q<MJ.JW4)M_)N-3OY)Y(DA??%&K'^
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M5ZN>E>4>+_\ D9+[_>'\A6E/<Z\-\3,>BBBMST@HHHH **** "BBB@ HHHH
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M_/5LTGQM\7WFAZCXW-]XCUCPY)9:-%-X<BTYWC6ZF*R>:^%4B9E8(I4_=7G
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M"LH;"C)QBN2O?VFX+1HK"33K'3]=A6[^W6NI:@T<4;P3>44BD2-C(7894D*
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MB",XY(Q5LOA/XN;1KBTN=-MVT^VCM$LM%N?$,L[I)#)N\RUO @DM@H&(T8L
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MM'YEO"50J$);&1Q\M='9?&'7([?4?M'A^UECT;1[2_O[U]36&.26: NJ)O4
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M&^'?_(&E_P"NQ_D**/AW_P @:7_KL?Y"BN:6YXU3XV=51114F84444 %%%%
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M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: 9Z/\
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MD=B#D#'&:Z3XC?";7=<\77>NZ252..^TV\@MK>Z6VFF$$<Z.%=D98W'FJ5+
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MH1H2P/S*5 QGU!&:\F^(OP5UOQ%J@N]*>"TAMM.TJ*.""<0--):7)E:+.TA
M5/RL00#C(Q79?"[P=J/AV'Q%>:E%)#?:Q>"X9+N_%[*0L0C#2NBJFXXY"#H!
MDDTM24Y-V:-2T\<>"]9:\M[?6=&NO['4RSIYD9%HJG!?GA0",;AP#QFJQ^)G
MAN^ATZ^TBYL]=CO+Y-.-Q:R(?)<JSC>2,@?+G!]0:\C/P2\8W&E-I5M;0:7I
MEM;XCL+S4DO;9Y%N(YEAMG\OS8+=]C!E=C]X#'&:Z^?X?>)/$GBVX\2W>GVF
MBR3WEDW]GB[69A'!'.#([JH4L3,  .BJ,GM1J+FD^AO:]\8/"^B^"K?4]7N]
M,BFO-/:_ATEKR&4W"@9VHWW7!/ ;H36SXE^(NB>#;7P^VJRBT36KJ&RMD.
MTBY&<X^4#@X]>E>/Z7\&_%_AWP7J.AQZ5I6MS:QX;L])DENKT)%8RP1NC#!0
MF2,E]XVX^8'/K7JGC7PSJ>I:7X3_ +/MX;JYTC4[*\EAEF$6](P5?:Q!&><C
MUQ[T:C3D;(\1>'%M(G^WZ:+6^:;8=R!+@QAC+[,5"-NZX"G/2L2/XO\ P\A.
M(_%OA]"K)#\MU&.2/D'';'0]!7FT7PE\9R0Z#H\MAIL>G:+)K!6^%_N:Z%U%
M.L)$>W*8,P# GMQD5NZI\'M0N-.U&"WMM.1YO \?AV'D +<*6)_AX3D<_I1J
M%WV/1+CQQX:M?$<.@3:UI\6M2D&.Q>91*Q;)7 _O$9('4]JET'Q%X>\076H1
M:-?Z??SP.!>+9LCE&R0!)M[_ "L.>>#7EK?#+Q,;*^\.FPLFL=0U>TU1]>^U
MKYD(C$)9/*V[F=3"51@<88'C!!] ^%OA&;P7X373[J*WBNWO;RZE-N00WFW$
MDBDG R=K+GZ8IZC3;>IU$ME!/+%++!%)+$<QN\:LR'_9)&1^%.GMHKJ(Q3Q)
M-$>L<J!E/U!XJ6B@T&A%7& !@8' X'I3J**8!6UI/_(OZU_NQ_\ H58M;6D_
M\B_K7^['_P"A5,MC.IM]QB^M%'<T51J%%%% @HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#T;X=_\ (&E_Z['^0HH^'?\ R!I?^NQ_D**Y
MI;GC5/C9U5%%%29A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "'I7E'B__ )&2^_WA_(5ZN>E>4>+_ /D9+[_>'\A6E/<Z\-\9CT445N>D
M%%%% !1110 4444 %%%% !1110 5M^$_^/N\_P"O27^0K$K;\)_\?=Y_UZ2_
MR%2]C.K\#,,=!2T@Z"EJC0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MMN'_ )$ZY_Z^T_E6)6W#_P B=<_]?:?RJ7T,JFR]3#'2EI!TI:HU.&^(_CA?
M!FJ>&MWVMTNI+PM%;L@200VDDVV3<"<?)QM(YQG(XKS[QQ\</$B^ -2GLO#Q
MT#5[KP^FM:9/)?13E8FECC;>-F%D7S5(7Y@<]>,5ZMXO\":9XTGTV746G5M/
M-P8?)DVC]] \#YXY^1VQ[XK+UKX0Z%KUA!:7+W?E0:/_ &(OES '[/OB?GC[
MV84Y^M2[F;3;9S+?$_4?!J:O#JAM[MX=8&FQS:IJ45K# !:Q.0TNS+L6+8VH
M22W0#ISNL?'S4=0T\:O8V<EIX>E\*7NL,T$\9NXIH9_*/EED*G!! R,'<"1Q
MBO1M<^%.FZCK?]N0ZKJ&CZHM[+??;+22/*M)"L4B@2(RA2J+SC((R#61_P ,
M^>'O[#BTDZEJ[62:?>:6P:Y5GEMKF3S'1F*Y)5_F5NOJ31J3RSV)6^,DBS2W
M2:%+-X:MM4CT:?5?M2B59V9$+B';EHU>15+;@<Y(&!3O"WQ@NO$.JZ'%<>&I
M=-T[6KF\M+.[>]21VDM_,+%HP/E1A$Y4YSQR!FK9^#FD'5WN!J&I+I;Z@FK2
MZ()4^QR7:;<2D;=_WD5RH;:6 .*NI\,]-L]/T:"TENHWT:2[GLI/.P1).DJN
M6(';SFQZ8'7%&H[2&?&/Q%J/A3X<ZKJND[SJ%N;?RECV[GW7$:E1NXY#$9/3
M-8VK?&2Z\/\ ]K6VK:#;Z7JFGSVR.EQJ\2V?DS[]DIN&48 ,;*5"EL@8!SFN
M@U#P%'XC^'<?A77-2O;LO;0PW.H13E+B5T96\P.1G=N4'.*Q[GX+6-Y+]NG\
M0:S/X@%[%?+K<KPM<(T:/&B!3'Y>P+(XQLZL3G/-'H#YGJCA==^-^HZ_8V&H
MZ'/_ &= ^EZ[YT4;).AN+0PJCHY4;E!=B.!D-R*[*;XS-9R/>S:(X\,0ZJFB
MRZN;M?,%P66,N(-N3$)&"$[L]2%P*DM/@/H%M;20R7^JW@<7XWW-RKO_ *9Y
M9N#NVC))C!&>F2!Q@"V?@YI+:N;AM0U)]+;4%U9M#>5#9F[&,2XV[_O -LW;
M2PSBC45IF,OQW>+2K+6KGPY+#H.IPW4NF7:7B/)/Y,<D@$D>T>7YBQ.5.6[9
MQFM[P7\1[WQ+K::9J7A]]#GGTJ+6+8&\2X+0NP4J^T#8X)&1DC!Z\5DV/P:\
M.>=)I9UK4+ZSTZ&>*UT>2ZC9-,6Y1U8H%4/RK.$+D[03BNRL/"&GZ=KEMJT3
M2_:K?3$TI S_ "^2K*PR,?>RHYHU&E*^IO44@(/2EJC4**** "D/:EI#VH V
MO$'_ !Y:-_UZ_P#LU8U;/B#_ (\M&_Z]?_9JQJF.QG3^$****HT"DQ2T4 %%
M%% !1110 GX44M% "4M%% !1110 4444 %;>D?\ (OZU_NQ_^A5B5MZ1_P B
M_K7^['_Z%4RV,Y[?-&'W/UI:3N?K2U1H%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %(:6D- ,]'^'?_(&E_Z['^0HH^'?_(&E_P"NQ_D*
M*YI;GCU?C9U5%%%29!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBN:6YXU3XV=51114F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664979344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRISALUS LIFE SCIENCES,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001826667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT NO. 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667605328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 9,414,000<span></span>
</td>
<td class="nump">$ 30,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,772,000<span></span>
</td>
<td class="nump">2,181,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,214,000<span></span>
</td>
<td class="nump">35,131,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,995,000<span></span>
</td>
<td class="nump">37,837,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to stockholders</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,357,000<span></span>
</td>
<td class="nump">6,373,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,319,000<span></span>
</td>
<td class="nump">6,934,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">164,006,000<span></span>
</td>
<td class="nump">160,507,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">10,028,000<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(176,330,000)<span></span>
</td>
<td class="num">(129,604,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">21,995,000<span></span>
</td>
<td class="nump">37,837,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">153,563<span></span>
</td>
<td class="nump">200,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">206,329<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">359,892<span></span>
</td>
<td class="nump">525,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and investments held in Trust Account</a></td>
<td class="nump">19,827,884<span></span>
</td>
<td class="nump">250,007,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,187,776<span></span>
</td>
<td class="nump">250,533,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,442,941<span></span>
</td>
<td class="nump">$ 1,057,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to stockholders</a></td>
<td class="nump">$ 48,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">srt:OfficerMember<span></span>
</td>
<td class="text">srt:OfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">$ 27,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ExtensionNotesPayableCurrent', window );">Extension Note</a></td>
<td class="nump">39,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note - related party</a></td>
<td class="nump">$ 944,000<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration', window );">Notes Payable, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 3,842,998<span></span>
</td>
<td class="nump">$ 1,601,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liabilities</a></td>
<td class="nump">1,061,334<span></span>
</td>
<td class="nump">6,898,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent', window );">Convertible Promissory Note - related party</a></td>
<td class="nump">1,341,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,654,332<span></span>
</td>
<td class="nump">17,250,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(13,267,211)<span></span>
</td>
<td class="num">(16,717,728)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(13,266,586)<span></span>
</td>
<td class="num">(16,717,103)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">20,187,776<span></span>
</td>
<td class="nump">250,533,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">19,800,030<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for convertible notes payable, payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ExtensionNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of extension notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ExtensionNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for notes payable classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667639712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">30,898,162<span></span>
</td>
<td class="nump">15,696,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Number of shares subject to redemption</a></td>
<td class="nump">1,953,422<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Common stock subject to possible redemption, price per share</a></td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667873776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 12,483,000<span></span>
</td>
<td class="nump">$ 8,753,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,439,000)<span></span>
</td>
<td class="num">(24,032,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(47,178,000)<span></span>
</td>
<td class="num">(28,842,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (47,187,000)<span></span>
</td>
<td class="num">$ (28,845,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 2,746,125<span></span>
</td>
<td class="nump">$ 3,040,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,746,125)<span></span>
</td>
<td class="num">(3,040,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">5,837,332<span></span>
</td>
<td class="nump">7,744,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">3,018,726<span></span>
</td>
<td class="nump">63,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">8,856,058<span></span>
</td>
<td class="nump">7,807,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="nump">6,109,933<span></span>
</td>
<td class="nump">4,767,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(570,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="nump">$ 5,539,079<span></span>
</td>
<td class="nump">$ 4,767,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">23,358,326<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">23,358,326<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667626240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)<br></strong></div></th>
<th class="th">
<div>MedTech Acquisition Corp </div>
<div>Class B Common Stock </div>
<div>Common stock</div>
</th>
<th class="th">
<div>MedTech Acquisition Corp </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th">
<div>MedTech Acquisition Corp </div>
<div>Accumulated Deficit</div>
</th>
<th class="th"><div>MedTech Acquisition Corp</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockholderEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,485,011)<span></span>
</td>
<td class="num">$ (21,484,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,767,283<span></span>
</td>
<td class="nump">4,767,283<span></span>
</td>
<td class="num">$ (28,845,000)<span></span>
</td>
<td class="num">$ (28,845,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockholderEquity', window );">Balance at the ending at Dec. 31, 2021</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,717,728)<span></span>
</td>
<td class="num">(16,717,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination', window );">Investment pursuant to business combination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of shares of Class A common stock to redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (82,741)<span></span>
</td>
<td class="num">(2,088,562)<span></span>
</td>
<td class="num">(2,171,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,539,079<span></span>
</td>
<td class="nump">5,539,079<span></span>
</td>
<td class="num">$ (47,187,000)<span></span>
</td>
<td class="num">$ (47,187,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockholderEquity', window );">Balance at the ending at Dec. 31, 2022</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,267,211)<span></span>
</td>
<td class="num">$ (13,266,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for investment pursuant to Business Combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockholderEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockholderEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667708688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="num">$ (187,000)<span></span>
</td>
<td class="num">$ (75,000)<span></span>
</td>
<td class="num">$ (180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (Decrease) in Operating Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,041,000<span></span>
</td>
<td class="num">(1,306,000)<span></span>
</td>
<td class="num">(2,592,000)<span></span>
</td>
<td class="num">$ (1,840,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(2,772,000)<span></span>
</td>
<td class="nump">1,108,000<span></span>
</td>
<td class="nump">5,246,000<span></span>
</td>
<td class="nump">3,175,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,196,000)<span></span>
</td>
<td class="num">(24,003,000)<span></span>
</td>
<td class="num">(32,313,000)<span></span>
</td>
<td class="num">(22,697,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,421,000)<span></span>
</td>
<td class="num">(1,514,000)<span></span>
</td>
<td class="num">(1,786,000)<span></span>
</td>
<td class="num">(2,258,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">54,586,000<span></span>
</td>
<td class="nump">7,554,000<span></span>
</td>
<td class="nump">13,462,000<span></span>
</td>
<td class="nump">50,768,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">11,969,000<span></span>
</td>
<td class="num">(17,963,000)<span></span>
</td>
<td class="num">(20,637,000)<span></span>
</td>
<td class="nump">25,813,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">9,664,000<span></span>
</td>
<td class="nump">30,301,000<span></span>
</td>
<td class="nump">30,301,000<span></span>
</td>
<td class="nump">4,488,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">21,633,000<span></span>
</td>
<td class="nump">12,338,000<span></span>
</td>
<td class="nump">9,664,000<span></span>
</td>
<td class="nump">30,301,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,539,079<span></span>
</td>
<td class="nump">4,767,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,837,332)<span></span>
</td>
<td class="num">(7,744,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,018,726)<span></span>
</td>
<td class="num">(63,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (Decrease) in Operating Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,671<span></span>
</td>
<td class="nump">348,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,325<span></span>
</td>
<td class="nump">954,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,736,994)<span></span>
</td>
<td class="num">(1,738,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentForInvestmentOfCashInTrustAccount', window );">Investment of cash into Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes', window );">Cash withdrawn from Trust Account to pay franchise and income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from Trust Account in connection with redemptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,371,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,198,137<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote', window );">Proceeds from convertible promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromExtensionNote', window );">Proceeds from extension note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Redemptions of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232,371,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230,508,464)<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,321)<span></span>
</td>
<td class="num">(1,134,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">$ 153,563<span></span>
</td>
<td class="nump">$ 200,884<span></span>
</td>
<td class="nump">200,884<span></span>
</td>
<td class="nump">1,334,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,563<span></span>
</td>
<td class="nump">$ 200,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawn from Trust Account for franchise and income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentForInvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment for investment of cash into trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentForInvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromExtensionNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from extension note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromExtensionNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash inflow from convertible promissory notes of the related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawn from Trust Account for franchise and income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671990992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Nature of Business</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023 (the "Closing Date"), TriSalus Life Sciences,&#160;Inc., a Delaware corporation (the &#8220;Company,&#8221; &#8220;TriSalus,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), formerly known as MedTech Acquisition Corporation (&#8220;MTAC&#8221;), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023 (as amended, the &#8220;Merger Agreement&#8221;), by and between MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (&#8220;Merger Sub&#8221;) and TriSalus Operating Life Sciences,&#160;Inc. (formerly known as TriSalus Life Sciences,&#160;Inc.), a Delaware corporation (&#8220;Legacy TriSalus&#8221;), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and TriSalus Life Sciences,&#160;Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as &#8220;the Closing.&#8221; In connection with the consummation of the Merger, on August&#160;10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc., the surviving company ("New TriSalus&#8221;). As further described in Note&#160;3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of the Business</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing </span><span style="font-family:'Times New Roman','Times','serif';">two</span><span style="font-family:'Times New Roman','Times','serif';"> product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June&#160;1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC&#8221;) code with CMS and met with CMS on June&#160;26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January&#160;1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September&#160;30, 2023, we have issued for cash </span><span style="font-family:'Times New Roman','Times','serif';">$164,364</span><span style="font-family:'Times New Roman','Times','serif';"> of preferred stock (of which </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> was raised at the closing of the Business Combination, including issuance of Series&#160;A convertible preferred stock), which, along with </span><span style="font-family:'Times New Roman','Times','serif';">$551</span><span style="font-family:'Times New Roman','Times','serif';"> from common stock and </span><span style="font-family:'Times New Roman','Times','serif';">$44,692</span><span style="font-family:'Times New Roman','Times','serif';"> from convertible notes and warrants, has funded our accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';">. During the nine&#160;months ended September&#160;30, 2023, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$9,189</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$9,630</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$94</span><span style="font-family:'Times New Roman','Times','serif';"> from the exercise of stock options, and </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> from the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had cash and cash equivalents of </span><span style="font-family:'Times New Roman','Times','serif';">$21,383</span><span style="font-family:'Times New Roman','Times','serif';">. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12&#160;months.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In accordance with ASC Topic 205-40,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i><span style="font-family:'Times New Roman','Times','serif';">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management&#8217;s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management&#8217;s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On October&#160;2, 2023, we entered into a Standby Equity Purchase Agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN,&#160;Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to </span><span style="font-family:'Times New Roman','Times','serif';">$30,000</span><span style="font-family:'Times New Roman','Times','serif';"> of common stock, par value </span><span style="font-family:'Times New Roman','Times','serif';">$0.0001</span><span style="font-family:'Times New Roman','Times','serif';"> per share of the Company (the &#8220;Common Stock&#8221;), at the Company&#8217;s request any time during the commitment period commencing on October&#160;2, 2023 (the &#8220;Effective Date&#8221;), and terminating on the first day of the&#160;month following the </span><span style="font-family:'Times New Roman','Times','serif';">24</span><span style="font-family:'Times New Roman','Times','serif';">-</span><span style="font-family:'Times New Roman','Times','serif';">month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an &#8220;Advance&#8221;) is subject to a maximum limit equal to the greater of: (i)&#160;an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';">100%</span><span style="font-family:'Times New Roman','Times','serif';"> of the average of the daily volume traded of the Company&#8217;s Common Stock on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) for the </span><span style="font-family:'Times New Roman','Times','serif';">10</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days immediately preceding an Advance notice, or (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">1,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">96%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on 4:00&#160;p.m. New York City time on the applicable Advance notice date (the &#8220;Option 1 Pricing Period&#8221;), and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">97%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price for any </span><span style="-sec-ix-hidden:Hidden_3ei8mRKxXUqQjdtfqOZDNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days commencing on the Advance notice date (the &#8220;Option 2 Pricing Period,&#8221; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#8220;Pricing Period&#8221;). &#8220;Market Price&#8221; is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (&#8220;VWAP&#8221;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than </span><span style="font-family:'Times New Roman','Times','serif';">4.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than </span><span style="font-family:'Times New Roman','Times','serif';">19.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus Life Sciences,&#160;Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), a Delaware corporation, was incorporated in 2009 as Surefire Medical,&#160;Inc. The Company began doing business as TriSalus Life Sciences (&#8220;TriSalus&#8221;) in 2018, and changed its name to TriSalus Life Sciences, Inc, in August&#160;2021. We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;&#8221;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav infusion System, introduced in 2020, the Surefire Medical infusion System and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023; we are actively seeking an extension of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded operations to date principally with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009 through December&#160;31, 2022, we have issued for cash <span style="-sec-ix-hidden:Hidden_ZCuk_ZdpA0SUrfc6xIvFJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$108,664</span></span> of preferred stock, $458 of common stock and $57,466 of convertible notes and warrants, which has funded the cumulative net losses of $186,358. During the&#160;year ended December&#160;31, 2022, we raised $13,499 in cash through the issuance of Series&#160;B-1 and Series&#160;B-2 preferred stock and $94 from the exercise of stock options. In March&#160;2021, all of the then outstanding principle amount of convertible notes, with accumulated interest, converted to shares of Series&#160;B preferred stock in accordance with the terms contained in the note agreements; the note conversion did not raise any cash. See notes 10 and 11 for further discussion of the convertible debt, warrants and the 2022 financing rounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had cash, cash equivalents and restricted cash of $9,664. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $186,358 as of December&#160;31, 2022. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC Topic 205-40,&#160;<i style="font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MedTech Acquisition Corporation (the &#8220;Company&#8221;) was incorporated in Delaware on September 11, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. The Company has one wholly-owned subsidiary that was created on November 9, 2022, MTAC Merger Sub, Inc, a Delaware corporation (&#8220;Merger Sub&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had not commenced any operations. All activity from inception through December 31, 2022, relates to the Company&#8217;s formation, the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination, including the terminated Memic Business Combination and the Merger Agreement with TriSalus (as defined and more fully described in Note 6). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statements for the Company&#8217;s Initial Public Offering were declared effective on December 17, 2020. On December 22, 2020, the Company consummated the Initial Public Offering of 25,000,000 units (the &#8220;Units&#8221; and, with respect to the Class A common stock included in the Units sold, the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250,000,000 which is described in Note&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 4,933,333 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $1.50 per Private Placement Warrant in a private placement to MedTech Acquisition Sponsor LLC (the &#8220;Sponsor&#8221;), generating gross proceeds of $7,400,000, which is described in Note&#160;4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on December 22, 2020, an amount of $250,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $14,161,525, consisting of $5,000,000 in cash underwriting fees, $8,750,000 of deferred underwriting fees and $411,525 of other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held in trust and net of taxes payable). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide the holders of the outstanding Public Shares (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will only proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 following any related redemptions and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (b) to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination by June 22, 2023 (or such earlier date as determined by the board of directors of the Company (the &#8220;Board&#8221;)) and (c) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company&#8217;s obligation to allow redemptions in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders&#8217; rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will have until June 22, 2023 (or such earlier date as determined by the Board) to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_8o7rIpLqL0adL1dGev6vwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining stockholders and the Board, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders. At the meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;Extension Amendment&#8221;) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of&#8201; (i)&#160;$10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company had $153,563 in its operating bank account and working capital deficit of $2,114,252, which excludes $27,854 of income taxes payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company issued an unsecured promissory note to the Sponsor in the principal amount of $544,000 (the &#8220;2021 Promissory Note&#8221;). The 2021 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#8217;s initial Business Combination. As of December 31, 2022 and 2021, there was $544,000 outstanding under the 2021 Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2022, the Company issued an unsecured promissory note in the principal amount of up to $400,000 to the Sponsor (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#8217;s initial Business Combination. As of December 31, 2022 and 2021, there was $400,000 and $0 outstanding under the 2022 Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 24, 2022, the Company issued the Convertible Promissory Note (as defined in Note 5) in the principal amount of up to $1,500,000 to the Sponsor. As of December 31, 2022 and 2021, there were amounts of $1,341,000 and $0 outstanding under the Convertible Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued a promissory note in the aggregate principal amount of up to $468,821 to the Sponsor (the &#8220;Extension Note&#8221;), pursuant to which the Sponsor agreed to loan to the Company up to $468,821 (the &#8220;Extension Funds&#8221;) to deposit into the Company&#8217;s trust account (the &#8220;Trust Account&#8221;) for the shares of Class A common stock of the Company (the &#8220;Public Shares&#8221;) that were not redeemed in connection with the extension of the Company&#8217;s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the Board (the &#8220;Extension&#8221;). The Extension Note, as described in Note 5, does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there were the amounts of $39,068 and $0 outstanding under Extension Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will deposit $0.04 per share into the Trust Account for each month (commencing on December 23, 2022 and ending on the 22nd day of each subsequent month) (the &#8220;Extension Deposit&#8221;), or portion thereof, that is needed by the Company to complete an initial business combination until June 22, 2023 or such earlier date as determined by the Board (the &#8220;Extension&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, TriSalus has agreed to pay, as a transactional expense and not as a loan, for 50% of the costs incurred by the Company in connection with the preparation and filing of applicable proxy materials and the holding of the Meeting (as defined below) (TriSalus&#8217; portion of such fees, the &#8220;TriSalus Extension Fees&#8221;), in addition to 50% of the amounts deposited into the Trust Account in connection with the Extension, with the remainder to be funded by the Sponsor and/or its designee in the form of a loan to the Company; provided that TriSalus&#8217; obligation to pay the TriSalus Extension Fees and its portion of the deposits for the Extension will terminate immediately at the earliest to occur of (i) the closing date of the TriSalus Business Combination and (ii) the valid termination of the Merger Agreement. Upon such termination, the Company will have no obligation to repay the TriSalus Extension Fees or any portion of the Extension Funds paid by TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the &#8220;Working Capital Note&#8221;) to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its amendment and restated certificate of incorporation, as amended from time to time. As of December 31, 2022 and 2021, there was no outstanding amount under the Working Capital Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) Topic 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; the Company has until June 22, 2023, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management plans to consummate a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 22, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inflation Reduction Act of 2022</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, a vote by the stockholders to extend the period of time to complete the Company&#8217;s initial Business Combination (the &#8220;extension vote&#8221;) or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any &#8220;PIPE&#8221; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company&#8217;s ability to complete a Business Combination.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667749280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;)<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which were formed on November 9, 2022. All significant intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $153,563 and $200,884 of cash as of December 31, 2022 and 2021, respectively, and no cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Investments Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its U.S. Treasury and equivalent securities as held to maturity in accordance with FASB Accounting Standard Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities.&#8221; Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, substantially all of the assets held in the Trust Account were held in a demand deposit account held by Continental Stock Transfer &amp; Trust Company. At December 31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest primarily in U.S. Treasury securities. The money market funds are presented at fair value within the accompanying consolidated balance sheets, and fair value of the investments in the Trust Account is equal to the amortized cost basis of the money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Shares of Class A common stock subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; equity. The Company&#8217;s Class A common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the special meeting in lieu of the 2022 annual meeting of stockholders held by the Company on December 12, 2022, stockholders holding 23,046,578 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $232.37 million (approximately $10.08 per Public Share) was removed from the Trust Account to pay such holders and approximately $19.70 million remains in the Trust Account. Following redemptions, the Company has 1,953,422 Public Shares outstanding. $78,137 was deposited into the Trust Account of which 50% was be drawn down under the Extension Note and 50% was funded by TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, at December 31, 2022 and 2021, 1,953,422 and 25,000,000 shares of Class A common stock subject to possible redemption are presented at $10.14 and $10.00 redemption value, respectively, as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares of common stock to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2022 and 2021, the Class A common stock subject to possible redemption reflected in the consolidated balance sheets is reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock subject to possible redemption, January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 250,000,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Redemptions of Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232,371,273)</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,093,167</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Extension Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,136</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,800,030</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A common stock issued were initially charged to temporary equity and then accreted to common stock subject to redemption upon the completion of the Initial Public Offering. A total of $14,161,525 in offering costs was incurred. Of these offering costs, $13,638,664 was related to the Initial Public Offering and charged to Class A Common Stock subject to possible redemption. Offering costs allocable to Public Warrants (as defined below) and Private Placement Warrants were $514,106 and $8,755, respectively, and expensed at the date of Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the Public Warrants and Private Placement Warrants (together with the Public Warrants, the &#8220;Warrants&#8221;) in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model. The Public Warrants for periods where no observable traded price was available were also valued using a Monte Carlo simulation Model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in interim periods under ASC 740-270-30-5. As of December 31, 2022 and 2021, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it. The Company&#8217;s effective tax rate was 9.34% and 0% for the years ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate of 21% for the years ended December 31, 2022 and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has been subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Income per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per share of common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. The Company has two classes of common stock, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock, which assumes a business combination as to be the most likely outcome. Accretion associated with the redeemable shares of Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,266,666 shares of Class A common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income per common stock is the same as basic net income per common stock for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basic and diluted net income per share of common stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allocation of net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,369,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,169,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,813,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 953,457</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,358,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net income per share of common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the Warrant Liabilities (See Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU Topic 2020-06, &#8220;Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8221; (&#8220;ASU 2020-06&#8221;), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665984144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingTextBlock', window );">PUBLIC OFFERING</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 3. PUBLIC OFFERING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Initial Public Offering, the Company sold 25,000,000 Units, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and <span style="-sec-ix-hidden:Hidden_MkCiTlqYpkyh8SfuJUz1DA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50&#160;per share, subject to adjustment (see Note 8).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664968720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 4. PRIVATE PLACEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 4,933,333 Private Placement Warrants at a price of&#8201;$1.50 per Private Placement Warrant ($7,400,000) from the Company in a private placement. Each Private Placement Warrant will be exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7). The proceeds from the sale of the Private Placement Warrants were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667557616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5. RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 11, 2020, the Sponsor purchased 5,750,000 shares (the &#8220;Founder Shares&#8221;) of the Company&#8217;s Class B common stock for an aggregate price of $25,000. In December 2020, the Company effected a stock dividend for 0.1 shares for each share of Class B common stock outstanding,resulting in 6,325,000 Founder Shares outstanding. As a result of the partial over-allotment exercised by the underwriters, 75,000 shares of Class B common stock were forfeited, and no shares remain subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of (A)&#160;one year&#160;after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the reported closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of common stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement, commencing on December 22, 2020, to pay the Sponsor an amount not to exceed $10,000 per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022, the Company incurred $120,000, in fees for these services. For the year ended December 31, 2021, the Company incurred $120,000, in fees for these services. There were $240,000 and $120,000 included in accrued expenses for these services in the accompanying consolidated balance sheets at December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Note&#8201;&#8212;&#8201;Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company issued the 2021 Promissory Note to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $544,000. The 2021 Promissory Note is non-interest bearing. No amount shall be due under the 2021 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there was $544,000 outstanding under the 2021 Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2022, the Company issued the 2022 Promissory Note I in the principal amount of up to $400,000 to the Sponsor. The 2022 Promissory Note is non-interest bearing. No amount shall be due under 2022 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there were amounts of $400,000 and $0 outstanding under the 2022 Promissory Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued the Extension Note, a promissory note in the aggregate principal amount of up to $468,821 to the Sponsor, pursuant to which the Sponsor agreed to loan to the Company the Extension Funds to deposit into the Trust Account for the Public Shares that were not redeemed in connection with the Extension. The Extension Note does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there was $39,068 and $0 outstanding under Extension Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued the 2022 Promissory Note I, an unsecured promissory note in the principal amount of up to $1,000,000 to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the Combination Period. As of December 31, 2022 and 2021, there was no outstanding under Working Capital Note, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants as described in Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On May 24, 2022, the Company issued a promissory note in the principal amount of up to $1,500,000 to the Sponsor for working capital requirements and payment of certain expenses in connection the Company&#8217;s initial Business Combination (&#8220;Convertible Promissory Note&#8221;). The Convertible Promissory Note is non-interest bearing and payable on the earlier of (i) the date of the initial Business Combination or (ii) the winding up of the Company. At any time prior to payment in full of the principal balance of the Convertible Promissory Note, the Sponsor may elect to convert all or any portion of the unpaid principal balance into that number of warrants, each exercisable for one share of Class A common stock of the Company (the &#8220;Conversion Warrants&#8221;), equal to (x) the portion of the principal amount of this Note being converted, divided by (y) $1.50, rounded up to the nearest whole number of warrants. The Conversion Warrants and their underlying securities are entitled to certain demand and piggyback registration rights as set forth in the Convertible Promissory Note. The Company determined that the fair value of the Convertible Promissory Note was par value. As of December 31, 2022 and 2021, the Company had $1,341,000 and $0, respectively, borrowings under the Working Capital Loans.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667654064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(15)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commitments and Contingencies</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registrations and will indemnify the parties thereto against certain liabilities related to such registrations. The Company&#8217;s registration obligations under the Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto on the date that such party no longer holds any Registrable Securities (as defined in the Amended and Restated Registration Rights Agreement). The Amended and Restated Registration Rights Agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(16)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a salary reduction savings plan under Section&#160;401(k)&#160;of the Internal Revenue Code, which we administer for participating employees&#8217; contributions. All full-time employees are covered under the plan after meeting minimum service requirements. We paid matching contributions of $431 and $287 to the plan for the&#160;years ended December&#160;31, 2022 and 2021, respectively. Our contributions were based on compensation at the rate of 3%, 3.5%, and 4% for an employee&#8217;s contribution of up to 3%, between 3% and 4%, and between 4% and 5%, respectively, with the match-eligible contribution being limited to 4% of the employee&#8217;s eligible compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, an individual filed a suit against the Company in the District of Colorado asserting joint inventorship of six patents assigned to the Company. The individual sought to be added as a co-inventor and co-owner of the patents in question. In a series of rulings, the Court struck monetary damages and jury trial demand, limited the individual&#8217;s expert testimony to one patent, and barred rebuttal testimony to defendant&#8217;s expert or testimony related to prior art, severely limiting the scope of this case. Following a notice that we would be seeking sanctions against the plaintiff and his attorney, it was agreed that the plaintiff would dismiss his case with prejudice and no sanctions or attorney fees&#8217; request would be filed. A stipulated Dismissal Order was entered June&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, TriSalus exercised its right to terminate, for cause, an agreement with a distributor, pursuant to which the distributor was acting as exclusive distributor of the TriNav Infusion System in several Western states. We determined that the distributor had failed to perform many aspects of the contract resulting in poor sales. The distributor was put on notice in September&#160;of 2020 that performance must improve, or we would terminate the contract. Despite being allowed a 60-day cure period, the distributor&#8217;s performance did not improve and in February&#160;2021 we exercised our right to terminate. On March&#160;11, 2021, the distributor filed a lawsuit against us in the Utah state court, asserting a claim for wrongful termination of the contract by us and several other related, common-law claims. The distributor sought monetary damages in an amount of $750, plus attorneys&#8217; fees and other relief. On November&#160;15, 2021, we agreed to settle the case for $425, which was recorded as expense in general and administrative expense in the accompanying consolidated statements of operations. The settlement was paid in two installments of $200 and $225, on November&#160;18, 2021, and January&#160;3, 2022, respectively. The settlement amounted to the contractual fee if we were to terminate the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;6. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a registration rights agreement entered into on December 17, 2020, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will have registration rights to require the Company to register a sale of any of the securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering. These holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have &#8220;piggy-back&#8221; registration rights to include their securities in other registration statements filed by the Company, subject to certain limitations. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raymond James Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;) was originally engaged by the Company to act as sole manager for the Initial Public Offering and would be entitled to a deferred underwriting fee of $8,750,000 upon the consummation of a Business Combination. In connection with the entry into the Merger Agreement with TriSalus, on November 11, 2022, the Company and Raymond James amended that certain Underwriting Agreement, dated December 17, 2020, pursuant to which, Raymond James agreed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to waive the foregoing deferred underwriting fee in its entirety if the proposed Business Combination between the Company and TriSalus is consummated. Raymond James was separately engaged by the Company to act as its investment banking advisor in connection with a Business Combination, and will receive customary fees for its services in that role if the Business Combination with TriSalus is consummated. The Company also engaged Raymond James to act as sole placement agent for an institutional debt financing that resulted in the Company&#8217;s entry into the non-binding term sheet with Magnetar Capital LLC (&#8220;Magnetar&#8221;). In consideration for its services as the Company&#8217;s investment banking advisor and its services as placement agent, Raymond James will be entitled to receive an aggregate fee ranging between $3 million to $4.5 million from the Company at the closing of the Business Combination with TriSalus plus expense reimbursements, depending on the amount raised in the institutional debt financing with Magnetar and/or other institutional investors, excluding any incremental fee consideration for exercise of the greenshoe. If the Company is unable to consummate the Business Combination with TriSalus or is unable to obtain private financing in connection with the Business Combination with TriSalus, then Raymond James will not receive any compensation for its investment banking advisory or placement agent services, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Professional Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company incurred legal fees of $508,525 and investment advisory fees of $400,000, which were contingent upon the consummation of the Memic Business Combination. On March 12, 2022, the Memic Business Combination was terminated, as such, the incurred contingent legal and investment advisory fees are no longer due. These fees were not recorded on the Company&#8217;s consolidated balance sheets, therefore no reversal was required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The company incurred legal fees of $479,262, which are contingent on the consummation of the Merger with TriSalus. These fees were not recorded on the Company&#8217;s consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 12, 2021, the Company entered into the Business Combination Agreement (the &#8220;Memic Business Combination Agreement&#8221;) with Memic Innovative Surgery Ltd., a private company organized under the laws of the State of Israel (&#8220;Memic&#8221;), and Maestro Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Memic (&#8220;Merger Sub&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of Business Combination Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2022, the Company, Memic and Merger Sub entered into a Termination of Business Combination Agreement (the &#8220;Termination Agreement&#8221;), pursuant to which the parties agreed to mutually terminate the Business Combination Agreement. The termination of the Business Combination Agreement was effective as of March 9, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the termination of the Business Combination Agreement, the Business Combination Agreement, along with any Transaction Agreement (as defined in the Business Combination Agreement) entered into in connection therewith, are void and there is no liability under either of the Business Combination Agreement or any Transaction Agreement on the part of any party thereto (including, without limitation, under the SPAC Sponsor Letter Agreement by and among Memic, the Sponsor, and the other parties signatory thereto dated August 12, 2021). Pursuant to the Termination Agreement, subject to certain exceptions, the Company, Memic and Merger Sub have also agreed, on behalf of themselves and their respective related parties, to a release of claims relating to the business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company (herein referred to as &#8220;MTAC&#8221; in this Note 6), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (&#8220;Merger Sub&#8221;), and TriSalus Life Sciences, Inc., a Delaware corporation (&#8220;TriSalus&#8221;), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the &#8220;Merger&#8221;), with TriSalus surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of MTAC (the transactions contemplated by the Merger Agreement and the related ancillary agreements, the &#8220;TriSalus Business Combination&#8221;). The TriSalus Business Combination is subject to certain closing conditions. Upon consummation of the TriSalus Business Combination, MTAC will be renamed &#8220;TriSalus Life Sciences, Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aggregate consideration payable to the stockholders of TriSalus at the closing of the TriSalus Business Combination (the &#8220;Closing&#8221;) is $220,000,000, payable solely in shares of MTAC common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), valued at $10.00 per share (the &#8220;Closing Merger Consideration&#8221;). Immediately prior to the Closing, the shares of Class A Common Stock of MTAC and the warrants to purchase shares of Class A Common Stock of MTAC issued to the public that comprise each issued and outstanding Unit will be automatically separated, if not already separated prior to such time, and the holder thereof shall be deemed to hold one share of Class A Common Stock of MTAC and <span style="-sec-ix-hidden:Hidden_tErA0HV8TUSeW-q1gHsPXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third of one warrant to purchase Class A Common Stock; provided that any fractional warrants issuable to a holder upon the separation of the Units will be rounded down to the nearest whole number of warrants. Following the separation of the Units but prior to the Closing, the Class B Common Stock of MTAC will automatically convert into Class A Common Stock, and pursuant to the proposed amended and restated certificate of incorporation of MTAC to be effective immediately prior to the effective time of the Merger, if approved by MTAC&#8217;s stockholders, Class A Common Stock and Class B Common Stock will be reclassified into a single class of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately prior to the Closing, each share of TriSalus&#8217; issued and outstanding preferred stock will automatically convert into shares of TriSalus common stock (the &#8220;Preferred Conversion&#8221;), and all in-the-money TriSalus warrants that would be exercised or otherwise exchanged in full in accordance with their terms by virtue of the occurrence of the TriSalus Business Combination will be exercised for shares of TriSalus common stock, such that the holders thereof will receive Closing Merger Consideration as holders of TriSalus common stock. TriSalus warrants that are out-of-the-money will be cancelled for no consideration immediately prior to the Closing. At the time of the TriSalus Business Combination, the outstanding options for shares of TriSalus common stock under TriSalus&#8217; equity plan will be assumed by MTAC and converted into options to purchase Common Stock (the &#8220;Assumed Equity&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Representations, Warranties and Covenants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations, warranties and covenants by the parties thereto, including, among other things, covenants with respect to the conduct of MTAC and TriSalus during the period between execution of the Merger Agreement and the Closing, including the parties&#8217; agreement not to solicit or enter into any inquiry, proposal or offer, or any indication of interest in making an offer or proposal for an alternative competing transactions. The representations, warranties and covenants made under the Merger Agreement will not survive the Closing; provided, however, that any covenants that are to be performed at or after the Closing shall survive until such covenant has been performed or satisfied pursuant to their terms. Each of MTAC and TriSalus have agreed to use their commercially reasonable efforts to cause the TriSalus Business Combination to be consummated as soon as practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be terminated prior to the Closing under certain circumstances, including, among others, (i) by written consent of TriSalus and MTAC, (ii) by written notice from either MTAC or TriSalus, if (A) the Closing has not occurred on or before December 22, 2022, as such date may be extended to match the extension of the last date for MTAC to consummate a Business Combination under its certificate of incorporation (currently June 22, 2023) obtained by MTAC stockholder approval (the &#8220;Outside Date&#8221;), unless the terminating party&#8217;s failure to comply in any material respect with its obligations under the Merger Agreement shall have contributed to the failure of the Closing to have occurred on or prior to the Outside Date, (B) the consummation of the TriSalus Business Combination is permanently enjoined, (C) MTAC does not obtain stockholder approval of the TriSalus Business Combination at the special meeting at which such approval shall be voted upon, or (D) by March 31, 2023, MTAC shall not have obtained commitments for private financing of at least $40,000,000 in support of the TriSalus Business Combination, (iii) by written notice from either MTAC or TriSalus, in the event that the other party breaches any of its representations, warranties, covenants or other agreements under the Merger Agreement that would result in the failure of the conditions to MTAC&#8217;s or TriSalus&#8217; obligation to consummate the TriSalus Business Combination and such breach has not been cured by the breaching party within 30 days after receiving notice of such breach, (iv) by TriSalus at any time prior to the approval of the TriSalus Business Combination by MTAC&#8217;s public stockholders, if the board of directors of MTAC has made a change in recommendation to its stockholders regarding the TriSalus Business Combination, and (v) by written notice to TriSalus from MTAC, if TriSalus does not obtain stockholder approval within 25 days after delivering an information statement regarding the TriSalus Business Combination to its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For additional information, refer to MTAC&#8217;s Current Report on Form 8-K, as filed with the SEC on November 14, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667616480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;7. STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock &#8212; </span>The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December 31, 2022 and 2021, there were no shares of preferred stock issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;A Common Stock &#8212; </span>The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At December 31, 2022 and 2021, there were 1,953,422 and 25,000,000 shares of Class&#160;A common stock subject to possible redemption which are presented as temporary equity, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;B Common Stock &#8212; </span>The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At December 31, 2022 and 2021, there were 6,250,000 shares of Class B common stock issued and outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company&#8217;s stockholders except as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with a Business Combination, the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of the Initial Public Offering, plus the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any shares of Class A common stock or equity-linked securities exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in a Business Combination and any private placement-equivalent warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans; provided that such conversion of Founder Shares will never occur on a less than one for one basis. The Company cannot determine at this time whether a majority of the holders of Class B common stock at the time of any future issuance would agree to waive such adjustment to the conversion ratio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667593168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock', window );">WARRANT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 8. WARRANT LIABILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were 8,333,333 Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a)&#160;30 days&#160;after the completion of a Business Combination and (b)&#160;12 months&#160;from the closing of the Initial Public Offering. The Public Warrants will expire five years&#160;after the completion of a Business Combination or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any shares of Class&#160;A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class&#160;A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class&#160;A common stock upon exercise of a warrant unless Class&#160;A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement registering the issuance of the shares of Class A common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60<span style="font-size:8pt;">th</span>&#160;business day after the closing of a Business Combination or within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per Public Warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the reported closing price of the Class A common stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading day period ending </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> business days before the Company sends the notice of redemption to the warrant holders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of Class&#160;A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of Class&#160;A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if&#8201; (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company&#8217;s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company&#8217;s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022 and 2021, there were 4,933,333 Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until 30 days&#160;after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of derivative warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683895094080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncomeTaxLineItems', window );"><strong>INCOME TAX</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(10)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Income Taxes</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full calendar&#160;year and use that rate to provide for income taxes on a current&#160;year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the annual effective tax rate, including use of the actual effective rate for the&#160;year-to-date. The impact of the discrete items is recorded in the quarter in which they occur.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We utilize the balance sheet method of accounting for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings, forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Based on our full valuation allowance against the net deferred tax assets, our effective federal tax rate for the calendar&#160;year is </span><span style="font-family:'Times New Roman','Times','serif';">zero</span><span style="font-family:'Times New Roman','Times','serif';">, and we recorded an immaterial income tax expense in the nine&#160;months ended September&#160;30, 2023 and 2022.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,002</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,306</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,708</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,630</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,630)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of our deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As we do not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, we do not believe it is more likely than not that we will realize the benefits of the net deferred tax assets and, accordingly, have established a valuation allowance equal to 100% of net deferred tax assets. The change in the valuation allowance for the&#160;years ended December&#160;31, 2022 and 2021 was $8,728 and $5,779, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had net operating losses (&#8220;NOLs&#8221;) as follows (the NOLs which do not expire are subject to an annual utilization limitation of 80% of taxable income):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Federal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">State</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs expiring between 2029 and 2037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,380</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs which do not expire</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,398</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total NOLs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,778</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Internal Revenue Code contains provisions that may further limit the net operating loss carryovers available to be used in any one&#160;year if certain events occur, including significant changes in ownership interests. Utilization of net operating loss and tax credit carryforwards are subject to a substantial annual limitation due to the ownership change limitations set forth in Section&#160;382 of the Code and similar state provisions. We prepared an Internal Revenue Code 382 analysis to determine the annual limitations on our consolidated net operating loss carryforwards. All of our tax attributes are subject to an annual limitation. Such annual limitations could result in the expiration of the net operating loss and tax credit carryforwards before utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, we did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12&#160;months. Our accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our federal and state returns for all&#160;years remain open to examination by tax authorities.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncomeTaxLineItems', window );"><strong>INCOME TAX</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;9. INCOME TAX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s net deferred tax assets for the year ended December 31, 2022 and 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,819</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Organizational costs/start-up expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,160,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606,383</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,160,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 647,202</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,160,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (647,202)</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets, net of allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The income tax provision for the years ended December 31, 2022 and 2021 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (513,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (625,111)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 513,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 625,111</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, the Company had a U.S. federal net operating loss carryover of approximately $0 and $194,000 available to offset future taxable income, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended December 31, 2022 and 2021, the change in the valuation allowance was $513,464 and $625,111,respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate at December 31, 2022 and 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664963872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, contingent earnout liability, and warrants to purchase preferred and common stock. The carrying values of these financial instruments (other than warrants and tranche liabilities, which are held at fair value) approximate fair value at September&#160;30, 2023, and December&#160;31, 2022. In general, asset and liability fair values are determined using the following categories:</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;1&#8201;&#8212;&#8201;Inputs utilize quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;2&#8201;&#8212;&#8201;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;3&#8201;&#8212;&#8201;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#8217;s own assumptions about the assumptions that a market participant would use.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrant, tranche and earnout liabilities are measured at fair value on a recurring basis.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments After Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The carrying amount of our outstanding MTAC warrants liabilities was </span><span style="font-family:'Times New Roman','Times','serif';">$5,421</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. The carrying amount of outstanding earnout liability was </span><span style="font-family:'Times New Roman','Times','serif';">$9,023</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. These carrying values of the warrant liabilities represent the remeasurement to fair value each reporting period based on Level 1 inputs for the publicly traded MTAC Warrants and Level 2 inputs for the private placement MTAC Warrants. The carrying amounts of the contingent earnout liability represent the remeasurement to fair value each reporting period based on unobservable, or Level 3, inputs, using assumptions made by us, including the market price of our common stock and the observed volatility of a peer group of companies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we assumed warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">14,266,605</span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock for </span><span style="font-family:'Times New Roman','Times','serif';">$11.50</span><span style="font-family:'Times New Roman','Times','serif';"> (see Note&#160;9). Of these, </span><span style="font-family:'Times New Roman','Times','serif';">8,333,272</span><span style="font-family:'Times New Roman','Times','serif';"> are traded publicly and </span><span style="font-family:'Times New Roman','Times','serif';">5,933,333</span><span style="font-family:'Times New Roman','Times','serif';"> are privately held. At the Closing Date, we determined the fair value of all the warrants to be </span><span style="font-family:'Times New Roman','Times','serif';">$2,568</span><span style="font-family:'Times New Roman','Times','serif';"> based on the closing price of </span><span style="font-family:'Times New Roman','Times','serif';">$0.18</span><span style="font-family:'Times New Roman','Times','serif';"> for the publicly traded warrants (Level 1).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we determined the fair value of the earnout liability to be </span><span style="font-family:'Times New Roman','Times','serif';">$28,927</span><span style="font-family:'Times New Roman','Times','serif';"> based on a Monte Carlo simulation of future trading prices for our common stock. See Note&#160;8 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,904)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments Prior to the Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrants and tranche liabilities are measured at fair value on a recurring basis. The carrying amount of outstanding warrant liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$16,188</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. The carrying amount of outstanding tranche liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$4,702</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. These carrying values represent the remeasurement to fair value each reporting period based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to a status quo scenario and the potential closing of the Business Combination (see Note&#160;3) scenario, the value of the Series&#160;B-3 Warrants (as defined below) upon closing of the Business Combination, the fair value of the Company, the fair value of the underlying preferred stock, the Company&#8217;s volatility, discount rate, and expected term of the related instrument.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See Note&#160;9 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$4,654</span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$584</span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$10,047</span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$3,425</span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to the exercise of the warrants to purchase Series&#160;B-3 preferred stock in February, March, June&#160;and July&#160;2023, the associated liabilities were remeasured to fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2023, warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">2,239,309</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock were exercised for </span><span style="font-family:'Times New Roman','Times','serif';">$4,530</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were remeasured to fair value, net-exercised, converted to shares of common stock of Legacy TriSalus, and then exchanged for shares of TriSalus common stock at the Exchange Ratio. Out-of-the-money warrants expired, resulting in a gain on expiration of </span><span style="font-family:'Times New Roman','Times','serif';">$18</span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$4,800</span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';">14,701</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.2pt;text-indent:-16.2pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;10. FAIR VALUE MEASUREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, assets held in the Trust Account were comprised of $19,827,884 in cash. During the year ended December 31, 2022, the Company withdrew $905,000 of interest income from the Trust Account to pay for taxes and $232,371,273 in connection with redemptions of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, assets held in the Trust Account were comprised of $250,007,295 in money market funds. During the year ended December 31, 2021, the Company withdrew $60,000 of interest income from the Trust Account to pay for taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2022 and 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. The gross holding loss and fair value of the Trust Account at December 31, 2022 and 2021, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,827,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">250,007,295</p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 666,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,333,333</p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"> 394,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,565,333</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrants in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model, which is considered to be a Level 3 fair value measurement. The Monte Carlo Simulation model&#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. Significant increases (decreases) in the expected volatility in isolation would result in a significantly higher (lower) fair value measurement. The expected volatility as of the Initial Public Offering date and subsequent was derived from observable Public Warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified target. A Monte Carlo simulation methodology was used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The key inputs into the Monte Carlo Simulation for the Private Placement Warrants as of December 31, 2022 and 2021, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents the changes in the Level 3 fair value of warrant liabilities during the years ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gXPw_HPigEaLTrob0MTpMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,170,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,170,666)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 394,667</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 394,667</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,476,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,166,666</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 14,642,666</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2rj7F36mjUqkt3ooiJGgKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,910,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,833,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,744,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transfer to level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,333,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,333,333)</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the year ended December 31, 2021 was $4,333,333, when the Public Warrants were separately listed and traded. There were no transfers in or out of Level 3 from other levels in the fair value hierarchy during the year ended December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671785312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 11. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than the below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2022, $78,136 was drawn on the Extension Note, as described in Note 5 and deposited into the Trust Account. In addition, TriSalus deposited $78,136 in the Trust Account pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023, the Company drew an additional $159,000 on the Convertible Promissory Note as described in Note 5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023 and February 8, 2023, the Company drew an additional $215,222 and $200,000 on the 2022 Promissory Note III as described in Note 5, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2023, the Company and the Sponsor engaged Ceros Financial Services, Inc. to render certain advisory and placement services to the Company. Pursuant to such engagement, the Sponsor (and not the Company) would be solely responsible for any and all fees and expenses payable to Ceros Financial Services, Inc., if any, that would arise or accrue prior to, or in connection with, the closing of an initial Business Combination.<br/><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667443904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$8,617</span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(o)</span></span><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes pursuant to ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#8217;s income tax liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(j)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Concentrations of Credit Risk and Other Risks and Uncertainties</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(g)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Warrant and Tranche Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">99.2</span><span style="font-family:'Times New Roman','Times','serif';">% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(h)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Contingent Earnout Liability</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#8220;Sponsor Support Agreement&#8221;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#8221;), Legacy TriSalus and MTAC&#8217;s directors and officers (the Sponsor and MTAC&#8217;s directors and officers, collectively, the &#8220;Sponsor Holders&#8221;). Pursuant to the Sponsor Support Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#8220;Sponsor Earnout Shares&#8221;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date (the &#8220;Earnout Period&#8221;). The Sponsor Earnout Shares are classified as a liability in the Company&#8217;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;)<i style="font-style:italic;">.</i></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which were formed on November 9, 2022. All significant intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $153,563 and $200,884 of cash as of December 31, 2022 and 2021, respectively, and no cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock', window );">Cash and Investments Held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Investments Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its U.S. Treasury and equivalent securities as held to maturity in accordance with FASB Accounting Standard Codification (&#8220;ASC&#8221;) Topic 320, &#8220;Investments &#8212; Debt and Equity Securities.&#8221; Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2022, substantially all of the assets held in the Trust Account were held in a demand deposit account held by Continental Stock Transfer &amp; Trust Company. At December 31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest primarily in U.S. Treasury securities. The money market funds are presented at fair value within the accompanying consolidated balance sheets, and fair value of the investments in the Trust Account is equal to the amortized cost basis of the money market funds.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityPolicyPolicyTextBlock', window );">Class A Common Stock Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Shares of Class A common stock subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; equity. The Company&#8217;s Class A common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the special meeting in lieu of the 2022 annual meeting of stockholders held by the Company on December 12, 2022, stockholders holding 23,046,578 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $232.37 million (approximately $10.08 per Public Share) was removed from the Trust Account to pay such holders and approximately $19.70 million remains in the Trust Account. Following redemptions, the Company has 1,953,422 Public Shares outstanding. $78,137 was deposited into the Trust Account of which 50% was be drawn down under the Extension Note and 50% was funded by TriSalus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, at December 31, 2022 and 2021, 1,953,422 and 25,000,000 shares of Class A common stock subject to possible redemption are presented at $10.14 and $10.00 redemption value, respectively, as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares of common stock to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2022 and 2021, the Class A common stock subject to possible redemption reflected in the consolidated balance sheets is reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock subject to possible redemption, January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 250,000,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Redemptions of Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232,371,273)</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,093,167</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Extension Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,136</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,800,030</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A common stock issued were initially charged to temporary equity and then accreted to common stock subject to redemption upon the completion of the Initial Public Offering. A total of $14,161,525 in offering costs was incurred. Of these offering costs, $13,638,664 was related to the Initial Public Offering and charged to Class A Common Stock subject to possible redemption. Offering costs allocable to Public Warrants (as defined below) and Private Placement Warrants were $514,106 and $8,755, respectively, and expensed at the date of Initial Public Offering.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the Public Warrants and Private Placement Warrants (together with the Public Warrants, the &#8220;Warrants&#8221;) in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model. The Public Warrants for periods where no observable traded price was available were also valued using a Monte Carlo simulation Model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in interim periods under ASC 740-270-30-5. As of December 31, 2022 and 2021, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it. The Company&#8217;s effective tax rate was 9.34% and 0% for the years ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate of 21% for the years ended December 31, 2022 and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has been subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Income per Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per share of common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. The Company has two classes of common stock, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock, which assumes a business combination as to be the most likely outcome. Accretion associated with the redeemable shares of Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,266,666 shares of Class A common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income per common stock is the same as basic net income per common stock for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basic and diluted net income per share of common stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allocation of net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,369,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,169,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,813,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 953,457</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,358,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net income per share of common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations and cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the Warrant Liabilities (See Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU Topic 2020-06, &#8220;Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8221; (&#8220;ASU 2020-06&#8221;), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assets held in trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy on emerging growth company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672063088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Class A common stock subject to possible redemption reflected in the balance sheets reconciled</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements / </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Class A common stock subject to possible redemption reflected in the balance sheets reconciled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class A common stock subject to possible redemption, January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 250,000,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Redemptions of Class A common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232,371,273)</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,093,167</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Extension Deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,136</p></td></tr><tr><td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption, December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,800,030</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net (loss) income per common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basic and diluted net income per share of common stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allocation of net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,369,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,169,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,813,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 953,457</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,358,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,250,000</p></td></tr><tr><td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic and diluted net income per share of common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.15</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666402304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncomeTaxLineItems', window );"><strong>INCOME TAX</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of company's net deferred tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,002</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,306</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,708</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,630</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,630)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the federal income tax rate to the company's effective tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncomeTaxLineItems', window );"><strong>INCOME TAX</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of company's net deferred tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,819</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Organizational costs/start-up expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,160,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606,383</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,160,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 647,202</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,160,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (647,202)</p></td></tr><tr><td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets, net of allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (513,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (625,111)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 513,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 625,111</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the federal income tax rate to the company's effective tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671968768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of key inputs into the monte carlo simulation for the private placement warrants</a></td>
<td class="text"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in the level 3 fair value of warrant liabilities</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,904)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$4,800</span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';">14,701</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;(Out)&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains)&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Put option liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,702</p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>This amount includes settlements of $3,397, reduced by issuances of $10.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of company's assets that are measured at fair value on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and investments held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,827,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">250,007,295</p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 666,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,333,333</p></td></tr><tr><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant Liabilities &#8211; Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"> 394,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,565,333</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of key inputs into the monte carlo simulation for the private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in the level 3 fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gXPw_HPigEaLTrob0MTpMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,170,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,170,666)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 394,667</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 394,667</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Placement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Public</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,476,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,166,666</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 14,642,666</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2rj7F36mjUqkt3ooiJGgKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,910,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,833,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,744,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transfer to level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,333,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,333,333)</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,565,333</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664369984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition for future business combination number of businesses minimum | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 14,161,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">$ 8,750,000<span></span>
</td>
<td class="nump">$ 8,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="nump">$ 411,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage', window );">Condition for future business combination use of proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership', window );">Condition for future business combination threshold percentage ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets', window );">Condition for future business combination threshold net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RedemptionPeriodUponClosure', window );">Redemption period upon closure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RedemptionLimitPercentageWithoutPriorConsent', window );">Redemption limit percentage without prior consent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumAllowedDissolutionExpenses', window );">Maximum allowed dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of units, net of underwriting discounts (in shares) | shares</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsForInvestmentOfCashInTrustAccount', window );">Payments for investment of cash in trust account</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Private Placement | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Sale of private placement warrants (in shares) | shares</a></td>
<td class="nump">4,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of private placements warrants</a></td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of units, net of underwriting discounts (in shares) | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold percentage of voting interest to be acquired in a future business combination as specified for the use of proceeds from the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold percentage of the assets held in the trust account funded by proceeds from the offering which must be used for purposes of consummating a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumAllowedDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount permitted to be paid for dissolution expenses if a business combination is not completed within the specified period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumAllowedDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsForInvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for investment of cash in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsForInvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RedemptionLimitPercentageWithoutPriorConsent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The limit on the percentage of shares which may be redeemed with out prior consent of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RedemptionLimitPercentageWithoutPriorConsent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RedemptionPeriodUponClosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time in which the reporting entity must redeem shares issued pursuant to the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RedemptionPeriodUponClosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661679760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,414,000<span></span>
</td>
<td class="nump">$ 21,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,301,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_OperatingBankAccounts', window );">Operating bank accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,114,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent', window );">Convertible promissory note outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfTransactionalFeePaid', window );">Percentage of transactional fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfAmountDepositedInTrustAccount', window );">Percentage of amount deposited in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DueToSponsorForCertainReimbursableExpenses', window );">Due to the Sponsor for certain reimbursable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Sponsor | Promissory Note - Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Sponsor | Promissory Note - Related Party | 2021 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DueToSponsorForCertainReimbursableExpenses', window );">Due to the Sponsor for certain reimbursable expenses</a></td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Sponsor | Promissory Note - Related Party | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for convertible notes payable, payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DueToSponsorForCertainReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to due to the Sponsor for certain reimbursable expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DueToSponsorForCertainReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_OperatingBankAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating bank accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_OperatingBankAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfAmountDepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of amount deposited in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfAmountDepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfTransactionalFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of transactional fee paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfTransactionalFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the information about the working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyOnePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyOnePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683659850992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 242,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities attributable to warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,097,831<span></span>
</td>
<td class="nump">13,381,126<span></span>
</td>
<td class="nump">16,879,990<span></span>
</td>
<td class="nump">12,731,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,563<span></span>
</td>
<td class="nump">$ 200,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,171,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount', window );">Number of public shares held</a></td>
<td class="nump">23,046,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount', window );">Amount removed from trust account</a></td>
<td class="nump">$ 232,370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare', window );">Per share removal from trust account</a></td>
<td class="nump">$ 10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount', window );">Remaining amount held in the trust account</a></td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AmountDepositedIntoTrustAccount', window );">Deposited into trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree', window );">Percent of deposits funded by TriSalus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.34%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits accrued for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,161,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Extension Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentOfDepositsIntoTrustAccountDrawnDown', window );">Percent of deposits drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs related to IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,638,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities attributable to warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,266,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,093,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Redemption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Number of shares subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953,422<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AmountDepositedIntoTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deposits into the Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AmountDepositedIntoTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentOfDepositsIntoTrustAccountDrawnDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of deposits that are drawn down in Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentOfDepositsIntoTrustAccountDrawnDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of deposits that are funded by Acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-removal in Trust Accounts to pay stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of removal in Trust Accounts to pay stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of removal in Trust Accounts to pay stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares held through shares redemption for Pro data basis of the funds in the Trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_IssuanceOfPromissoryNote2022ToSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_IssuanceOfPromissoryNote2022ToSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669594496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">$ 160,507,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="nump">164,006,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Redemptions of Class A common stock</a></td>
<td class="num">(232,371,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">2,171,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccountingPoliciesLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Redemptions of Class A common stock</a></td>
<td class="num">(232,371,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="num">(2,093,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ExtensionDeposit', window );">Extension Deposit</a></td>
<td class="nump">78,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="nump">$ 19,800,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ExtensionDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of extension deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ExtensionDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawn from Trust Account for franchise and income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664588960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumeratorForCalculationOfEarningsPerShareAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="num">$ (1,744,000)<span></span>
</td>
<td class="num">$ (8,093,000)<span></span>
</td>
<td class="num">$ (26,968,000)<span></span>
</td>
<td class="num">$ (24,645,000)<span></span>
</td>
<td class="num">$ (50,016,000)<span></span>
</td>
<td class="num">$ (28,845,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DenominatorForCalculationOfEarningsPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">13,173,422<span></span>
</td>
<td class="nump">311,823<span></span>
</td>
<td class="nump">4,749,849<span></span>
</td>
<td class="nump">299,936<span></span>
</td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">13,173,422<span></span>
</td>
<td class="nump">311,823<span></span>
</td>
<td class="nump">4,749,849<span></span>
</td>
<td class="nump">299,936<span></span>
</td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (25.95)<span></span>
</td>
<td class="num">$ (5.68)<span></span>
</td>
<td class="num">$ (82.17)<span></span>
</td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (25.95)<span></span>
</td>
<td class="num">$ (5.68)<span></span>
</td>
<td class="num">$ (82.17)<span></span>
</td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumeratorForCalculationOfEarningsPerShareAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,369,839<span></span>
</td>
<td class="nump">$ 3,813,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DenominatorForCalculationOfEarningsPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,358,326<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,358,326<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumeratorForCalculationOfEarningsPerShareAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,169,240<span></span>
</td>
<td class="nump">$ 953,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DenominatorForCalculationOfEarningsPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DenominatorForCalculationOfEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DenominatorForCalculationOfEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumeratorForCalculationOfEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumeratorForCalculationOfEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667517664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PUBLIC OFFERING (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfWarrantsIssuedPerUnit', window );">Warrant in each unit (as percent)</a></td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issuable per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Public Warrants | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfSharesIssuedPerUnit', window );">Number of shares in a unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units sold</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Initial Public Offering | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialPublicOfferingLineItems', window );"><strong>PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units sold</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_InitialPublicOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_InitialPublicOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667433040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRIVATE PLACEMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Private Placement | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Sale of private placement warrants (in shares)</a></td>
<td class="nump">4,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of private placements warrants</a></td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issuable per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661135200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Founder Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 11, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,151,000<span></span>
</td>
<td class="nump">$ 551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Founder Shares | Sponsor | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock with PIPE financing (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Share dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AggregateNumberOfSharesOwned', window );">Aggregate number of shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Founder Shares | Sponsor | Class B Common Stock | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfSharesSubjectToForfeiture', window );">Shares subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfSharesNoLongerSubjectToForfeiture', window );">Shares no longer subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AggregateNumberOfSharesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders after the impact of the stock dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AggregateNumberOfSharesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfSharesNoLongerSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of the company that were no longer subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfSharesNoLongerSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660406288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,068<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Working capital loans warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,341,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Working capital loans warrant | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Promissory Note - Related Party | Sponsor | 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Borrowed aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Related Party Loans | Sponsor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Related Party Loans | Working capital loans warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumLoansConvertibleIntoWarrants', window );">Loan conversion agreement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Administrative Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Administrative Services Agreement | Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=tlsi_TwoThousandTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WorkingCapitalLoansWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_WorkingCapitalLoansWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tlsi_AdministrativeSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tlsi_AdministrativeSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=tlsi_AccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=tlsi_AccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664680080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>D </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities', window );">Maximum number of demands for registration of securities | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LegalFeeContingentUponConsummationOfBusinessCombination', window );">Legal fees</a></td>
<td class="nump">$ 508,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination', window );">Investment advisory fees</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries', window );">Legal fees upon merger</a></td>
<td class="nump">479,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business combination related costs</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfTrading', window );">Number of trading | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays', window );">Period of stockholder approval after delivering business combination</a></td>
<td class="text">25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Raymond James Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination', window );">Deferred underwriting fees upon consummation of business combination</a></td>
<td class="nump">$ 8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | MTAC Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_BusinessCombinationsOfWarrantToPurchase', window );">Business combinations of warrant to purchase</a></td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfHoldings', window );">Number of holdings | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Maximum | Raymond James Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Aggregate fees received</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Minimum | Raymond James Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Aggregate fees received</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | TriSalus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration payable</a></td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_BusinessCombinationsOfWarrantToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of business combination of warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_BusinessCombinationsOfWarrantToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of  deferred underwriting fees upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Advisory Fee Contingent Upon Consummation Of Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LegalFeeContingentUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of legal fee which is contingent upon consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LegalFeeContingentUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of legal fee which is contingent upon consummation of merger with subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of demands for registration of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfHoldings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of number of holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfHoldings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfTrading">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of trading.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfTrading</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of stockholder approval after delivering business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_RaymondJamesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tlsi_RaymondJamesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_MtacClassCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_MtacClassCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664433728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661358000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">30,898,162<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,696,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommonStockNumberOfVotesPerShare', window );">Common stock, votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class A common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Number of shares subject to redemption</a></td>
<td class="nump">1,953,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommonStockNumberOfVotesPerShare', window );">Common stock, votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of Class A common stock issued upon conversion of each share (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConvertibleStockConversionRatio', window );">Ratio to be applied to the stock in the conversion</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConvertibleStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio to be applied to the stock in a conversion of convertible stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConvertibleStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669453456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">2,871,084<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement', window );">Maximum period after business combination in which to file registration statement</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective', window );">Period of time within which registration statement is expected to become effective</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding | $</a></td>
<td class="nump">$ 4,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,933,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantExercisePeriodConditionOne', window );">Warrant exercise period condition one</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantExercisePeriodConditionTwo', window );">Warrant exercise period condition two</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrants | $ / shares</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantExercisePriceAdjustmentMultiple', window );">Warrant exercise price adjustment multiple</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">8,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp | Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of period of redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold  number of business days before sending notice of redemption to warrant holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantExercisePeriodConditionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantExercisePeriodConditionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantExercisePeriodConditionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The alternate period of time after completion of an initial public offering before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantExercisePeriodConditionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantExercisePriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantExercisePriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantRedemptionPriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantRedemptionPriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661534368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX - Deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 30,421,000<span></span>
</td>
<td class="nump">$ 27,002,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">38,459,000<span></span>
</td>
<td class="nump">29,708,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="num">(38,358,000)<span></span>
</td>
<td class="num">(29,630,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts', window );">Organizational costs/start-up expenses</a></td>
<td class="nump">1,160,666<span></span>
</td>
<td class="nump">606,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">1,160,666<span></span>
</td>
<td class="nump">647,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,160,666)<span></span>
</td>
<td class="num">(647,202)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized start up and organization costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660414688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Income tax provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and Local</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570,854<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(513,464)<span></span>
</td>
<td class="num">(625,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and Local</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncreaseDecreaseInValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,464<span></span>
</td>
<td class="nump">625,111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 194,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_IncreaseDecreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_IncreaseDecreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667837664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Reconciliation of the federal income tax (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective income tax rate reconciliation, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">MedTech Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective income tax rate reconciliation, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.10%)<span></span>
</td>
<td class="num">(34.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.34%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Changes in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669572304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - MedTech Acquisition Corp - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash held in the Trust Account</a></td>
<td class="nump">$ 153,563<span></span>
</td>
<td class="nump">$ 200,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Assets held in Trust Account</a></td>
<td class="nump">19,827,884<span></span>
</td>
<td class="nump">250,007,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes', window );">Cash withdrawn of interest income from the Trust Account</a></td>
<td class="nump">905,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Proceeds from trust account in connection with redemption</a></td>
<td class="nump">232,371,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">U S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash held in the Trust Account</a></td>
<td class="nump">19,827,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes', window );">Cash withdrawn of interest income from the Trust Account</a></td>
<td class="nump">905,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Proceeds from trust account in connection with redemption</a></td>
<td class="nump">$ 232,371,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Assets held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,007,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawn from Trust Account for franchise and income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawn from Trust Account for franchise and income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669586000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details) - MedTech Acquisition Corp - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and investments held in Trust Account</a></td>
<td class="nump">$ 19,827,884<span></span>
</td>
<td class="nump">$ 250,007,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liabilities</a></td>
<td class="nump">1,061,334<span></span>
</td>
<td class="nump">6,898,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and investments held in Trust Account</a></td>
<td class="nump">19,827,884<span></span>
</td>
<td class="nump">250,007,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 1 | Recurring | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liabilities</a></td>
<td class="nump">666,667<span></span>
</td>
<td class="nump">4,333,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 3 | Recurring | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liabilities</a></td>
<td class="nump">$ 394,667<span></span>
</td>
<td class="nump">$ 2,565,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667613824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details) - MedTech Acquisition Corp - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">10.03<span></span>
</td>
<td class="nump">9.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.0640<span></span>
</td>
<td class="nump">0.0960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input | Y</a></td>
<td class="nump">5.25<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.0391<span></span>
</td>
<td class="nump">0.0127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Estimated dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.0000<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683895100768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details) - MedTech Acquisition Corp - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</a></td>
<td class="text">Change in fair value of warrant liabilities<span></span>
</td>
<td class="text">Change in fair value of warrant liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers in or out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,333,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 3 | Warrants Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">2,565,333<span></span>
</td>
<td class="nump">14,642,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(2,170,666)<span></span>
</td>
<td class="num">(7,744,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer to level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,333,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">394,667<span></span>
</td>
<td class="nump">2,565,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 3 | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">2,565,333<span></span>
</td>
<td class="nump">5,476,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(2,170,666)<span></span>
</td>
<td class="num">(2,910,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">394,667<span></span>
</td>
<td class="nump">2,565,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Level 3 | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,166,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,833,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer to level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,333,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667361744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - MedTech Acquisition Corp - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 08, 2023</div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Additional amount drawn on Promissory Note</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">TriSalus | Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Deposited in trust account</a></td>
<td class="nump">78,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Extension Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn on Second Extension Note</a></td>
<td class="nump">$ 78,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Subsequent Events | Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn on Second Extension Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember', window );">Subsequent Events | 2022 Promissory Note III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn on Second Extension Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 215,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tlsi_TrisalusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tlsi_TrisalusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tlsi_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tlsi_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tlsi_ExtensionNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tlsi_ExtensionNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=tlsi_PromissoryNote2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=tlsi_PromissoryNote2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667328112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,052<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,041<span></span>
</td>
<td class="nump">17,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">33,554<span></span>
</td>
<td class="nump">21,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">4,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,305<span></span>
</td>
<td class="nump">32,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,067<span></span>
</td>
<td class="nump">34,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 and 0 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 4,015,002 and 0 shares at September 30, 2023, and December 31, 2022, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share. Authorized 400,000,000 and 30,898,162 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 26,316,681 and 347,926 shares at September 30, 2023, and December 31, 2022, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">221,351<span></span>
</td>
<td class="nump">10,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(212,867)<span></span>
</td>
<td class="num">(186,358)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">8,487<span></span>
</td>
<td class="num">(176,330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">33,554<span></span>
</td>
<td class="nump">21,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember', window );">Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember', window );">Series B-3 Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669534000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,898,162<span></span>
</td>
<td class="nump">15,696,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667820896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,193<span></span>
</td>
<td class="nump">$ 3,923<span></span>
</td>
<td class="nump">$ 12,790<span></span>
</td>
<td class="nump">$ 9,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,604<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">10,767<span></span>
</td>
<td class="nump">7,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,367<span></span>
</td>
<td class="nump">4,808<span></span>
</td>
<td class="nump">21,871<span></span>
</td>
<td class="nump">15,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">4,689<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">11,430<span></span>
</td>
<td class="nump">8,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">17,498<span></span>
</td>
<td class="nump">8,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,477)<span></span>
</td>
<td class="num">(8,111)<span></span>
</td>
<td class="num">(40,032)<span></span>
</td>
<td class="num">(24,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(8,093)<span></span>
</td>
<td class="num">(23,521)<span></span>
</td>
<td class="num">(24,642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(8,093)<span></span>
</td>
<td class="num">(23,529)<span></span>
</td>
<td class="num">(24,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount', window );">Deemed dividend related to Series B-2 preferred stock down round provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,981)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Undeclared dividends on Series A preferred stock</a></td>
<td class="num">(458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,744)<span></span>
</td>
<td class="num">$ (8,093)<span></span>
</td>
<td class="num">$ (26,968)<span></span>
</td>
<td class="num">$ (24,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (25.95)<span></span>
</td>
<td class="num">$ (5.68)<span></span>
</td>
<td class="num">$ (82.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (25.95)<span></span>
</td>
<td class="num">$ (5.68)<span></span>
</td>
<td class="num">$ (82.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">13,173,422<span></span>
</td>
<td class="nump">311,823<span></span>
</td>
<td class="nump">4,749,849<span></span>
</td>
<td class="nump">299,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">13,173,422<span></span>
</td>
<td class="nump">311,823<span></span>
</td>
<td class="nump">4,749,849<span></span>
</td>
<td class="nump">299,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember', window );">Tranche and warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivatives</a></td>
<td class="num">$ (2,812)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivatives</a></td>
<td class="nump">$ 19,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660683008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,364,000<span></span>
</td>
<td class="num">$ (107,497,000)<span></span>
</td>
<td class="num">$ (106,133,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,845,000)<span></span>
</td>
<td class="num">(28,845,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,873,000)<span></span>
</td>
<td class="num">(7,873,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,861,000<span></span>
</td>
<td class="num">(144,215,000)<span></span>
</td>
<td class="num">(137,354,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,645,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,062,000<span></span>
</td>
<td class="num">(160,987,000)<span></span>
</td>
<td class="num">(153,925,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,187,000)<span></span>
</td>
<td class="num">(47,187,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">$ (176,330,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,861,000<span></span>
</td>
<td class="num">(144,215,000)<span></span>
</td>
<td class="num">$ (137,354,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,679,000)<span></span>
</td>
<td class="num">(8,679,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,936,000<span></span>
</td>
<td class="num">(152,894,000)<span></span>
</td>
<td class="num">(145,958,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,093,000)<span></span>
</td>
<td class="num">(8,093,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,062,000<span></span>
</td>
<td class="num">(160,987,000)<span></span>
</td>
<td class="num">(153,925,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">$ (176,330,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959,000<span></span>
</td>
<td class="num">(959,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,268,000)<span></span>
</td>
<td class="num">(8,268,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,110,000<span></span>
</td>
<td class="num">(195,585,000)<span></span>
</td>
<td class="num">(184,475,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">$ (176,330,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Assumption of preferred stock in connection with the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,529,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,015,002<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2023</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">221,351,000<span></span>
</td>
<td class="num">(212,867,000)<span></span>
</td>
<td class="nump">$ 8,487,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,110,000<span></span>
</td>
<td class="num">(195,585,000)<span></span>
</td>
<td class="num">$ (184,475,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, beginning of period (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,592<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022,000<span></span>
</td>
<td class="num">(2,022,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,974,000)<span></span>
</td>
<td class="num">(13,974,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,217,000<span></span>
</td>
<td class="num">(211,581,000)<span></span>
</td>
<td class="num">(198,364,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,646<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">204,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,236,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization', window );">Assumption of warrants to purchase common stock in connection with the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,568,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,568,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock upon closing the Business Combination, net of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock upon closing of the Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,316,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability', window );">Contingent earnout liability recognized upon closing of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,927,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,927,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock with PIPE financing (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Assumption of preferred stock in connection with the Business Combination</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,151,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,286,000)<span></span>
</td>
<td class="num">$ (1,286,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,015,002<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2023</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 221,351,000<span></span>
</td>
<td class="num">$ (212,867,000)<span></span>
</td>
<td class="nump">$ 8,487,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances, end of period (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Recognition Of Derivative Instrument, Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Assumed In Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665130432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (23,529)<span></span>
</td>
<td class="num">$ (24,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance</a></td>
<td class="nump">4,171<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnMilestonePaymentForAssetAcquistion', window );">Milestone payments to Dynavax</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,477)<span></span>
</td>
<td class="num">(936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(158)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="num">(1,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">ROU assets</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="num">(2,772)<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,196)<span></span>
</td>
<td class="num">(24,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsForAssetsAcquisitionMilestone', window );">Milestone payments to Dynavax</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for intellectual property and licenses</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
<td class="nump">9,189<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock', window );">Refundable prepayments for Series B-2 preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants</a></td>
<td class="nump">9,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromReverseRecapitalization', window );">Proceeds from Business Combination</a></td>
<td class="nump">36,854<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsOfReverseRecapitalizationTransactionCosts', window );">Offering costs related to Business Combination</a></td>
<td class="num">(1,116)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liabilities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from the exercise of stock options</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">54,586<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">11,969<span></span>
</td>
<td class="num">(17,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">9,664<span></span>
</td>
<td class="nump">30,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">21,633<span></span>
</td>
<td class="nump">12,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock', window );">Transfer of warrant liability to preferred stock upon exercise of warrants</a></td>
<td class="nump">25,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember', window );">Tranche and warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(660)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">$ (19,904)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Transfer of Warrant to Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnMilestonePaymentForAssetAcquistion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Milestone Payment for Asset Acquistion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnMilestonePaymentForAssetAcquistion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsForAssetsAcquisitionMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Assets Acquisition Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsForAssetsAcquisitionMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsOfReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Reverse Recapitalization, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsOfReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Refundable Prepayments for Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672208480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Nature of Business</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023 (the "Closing Date"), TriSalus Life Sciences,&#160;Inc., a Delaware corporation (the &#8220;Company,&#8221; &#8220;TriSalus,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), formerly known as MedTech Acquisition Corporation (&#8220;MTAC&#8221;), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023 (as amended, the &#8220;Merger Agreement&#8221;), by and between MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (&#8220;Merger Sub&#8221;) and TriSalus Operating Life Sciences,&#160;Inc. (formerly known as TriSalus Life Sciences,&#160;Inc.), a Delaware corporation (&#8220;Legacy TriSalus&#8221;), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and TriSalus Life Sciences,&#160;Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as &#8220;the Closing.&#8221; In connection with the consummation of the Merger, on August&#160;10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc., the surviving company ("New TriSalus&#8221;). As further described in Note&#160;3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of the Business</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing </span><span style="font-family:'Times New Roman','Times','serif';">two</span><span style="font-family:'Times New Roman','Times','serif';"> product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June&#160;1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC&#8221;) code with CMS and met with CMS on June&#160;26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January&#160;1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September&#160;30, 2023, we have issued for cash </span><span style="font-family:'Times New Roman','Times','serif';">$164,364</span><span style="font-family:'Times New Roman','Times','serif';"> of preferred stock (of which </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> was raised at the closing of the Business Combination, including issuance of Series&#160;A convertible preferred stock), which, along with </span><span style="font-family:'Times New Roman','Times','serif';">$551</span><span style="font-family:'Times New Roman','Times','serif';"> from common stock and </span><span style="font-family:'Times New Roman','Times','serif';">$44,692</span><span style="font-family:'Times New Roman','Times','serif';"> from convertible notes and warrants, has funded our accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';">. During the nine&#160;months ended September&#160;30, 2023, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$9,189</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$9,630</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$94</span><span style="font-family:'Times New Roman','Times','serif';"> from the exercise of stock options, and </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> from the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had cash and cash equivalents of </span><span style="font-family:'Times New Roman','Times','serif';">$21,383</span><span style="font-family:'Times New Roman','Times','serif';">. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12&#160;months.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In accordance with ASC Topic 205-40,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i><span style="font-family:'Times New Roman','Times','serif';">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management&#8217;s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management&#8217;s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On October&#160;2, 2023, we entered into a Standby Equity Purchase Agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN,&#160;Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to </span><span style="font-family:'Times New Roman','Times','serif';">$30,000</span><span style="font-family:'Times New Roman','Times','serif';"> of common stock, par value </span><span style="font-family:'Times New Roman','Times','serif';">$0.0001</span><span style="font-family:'Times New Roman','Times','serif';"> per share of the Company (the &#8220;Common Stock&#8221;), at the Company&#8217;s request any time during the commitment period commencing on October&#160;2, 2023 (the &#8220;Effective Date&#8221;), and terminating on the first day of the&#160;month following the </span><span style="font-family:'Times New Roman','Times','serif';">24</span><span style="font-family:'Times New Roman','Times','serif';">-</span><span style="font-family:'Times New Roman','Times','serif';">month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an &#8220;Advance&#8221;) is subject to a maximum limit equal to the greater of: (i)&#160;an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';">100%</span><span style="font-family:'Times New Roman','Times','serif';"> of the average of the daily volume traded of the Company&#8217;s Common Stock on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) for the </span><span style="font-family:'Times New Roman','Times','serif';">10</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days immediately preceding an Advance notice, or (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">1,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">96%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on 4:00&#160;p.m. New York City time on the applicable Advance notice date (the &#8220;Option 1 Pricing Period&#8221;), and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">97%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price for any </span><span style="-sec-ix-hidden:Hidden_3ei8mRKxXUqQjdtfqOZDNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days commencing on the Advance notice date (the &#8220;Option 2 Pricing Period,&#8221; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#8220;Pricing Period&#8221;). &#8220;Market Price&#8221; is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (&#8220;VWAP&#8221;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than </span><span style="font-family:'Times New Roman','Times','serif';">4.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than </span><span style="font-family:'Times New Roman','Times','serif';">19.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus Life Sciences,&#160;Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), a Delaware corporation, was incorporated in 2009 as Surefire Medical,&#160;Inc. The Company began doing business as TriSalus Life Sciences (&#8220;TriSalus&#8221;) in 2018, and changed its name to TriSalus Life Sciences, Inc, in August&#160;2021. We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;&#8221;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav infusion System, introduced in 2020, the Surefire Medical infusion System and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023; we are actively seeking an extension of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded operations to date principally with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009 through December&#160;31, 2022, we have issued for cash <span style="-sec-ix-hidden:Hidden_ZCuk_ZdpA0SUrfc6xIvFJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$108,664</span></span> of preferred stock, $458 of common stock and $57,466 of convertible notes and warrants, which has funded the cumulative net losses of $186,358. During the&#160;year ended December&#160;31, 2022, we raised $13,499 in cash through the issuance of Series&#160;B-1 and Series&#160;B-2 preferred stock and $94 from the exercise of stock options. In March&#160;2021, all of the then outstanding principle amount of convertible notes, with accumulated interest, converted to shares of Series&#160;B preferred stock in accordance with the terms contained in the note agreements; the note conversion did not raise any cash. See notes 10 and 11 for further discussion of the convertible debt, warrants and the 2022 financing rounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had cash, cash equivalents and restricted cash of $9,664. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $186,358 as of December&#160;31, 2022. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC Topic 205-40,&#160;<i style="font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665821664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$8,617</span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(b)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accounts Receivable</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(c)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Inventory</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#8212; including direct labor and manufacturing overhead&#160;&#8212; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(d)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Property and Equipment</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(e)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Impairment and Disposal of Long-Lived Assets</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows</span><span style="font-family:'Times New Roman','Times','serif';"> expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(f)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i><span style="font-family:'Times New Roman','Times','serif';">. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#8220;ROU&#8221;) representing the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(g)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Warrant and Tranche Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">99.2</span><span style="font-family:'Times New Roman','Times','serif';">% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(h)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Contingent Earnout Liability</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#8220;Sponsor Support Agreement&#8221;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#8221;), Legacy TriSalus and MTAC&#8217;s directors and officers (the Sponsor and MTAC&#8217;s directors and officers, collectively, the &#8220;Sponsor Holders&#8221;). Pursuant to the Sponsor Support Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#8220;Sponsor Earnout Shares&#8221;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date (the &#8220;Earnout Period&#8221;). The Sponsor Earnout Shares are classified as a liability in the Company&#8217;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(j)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Concentrations of Credit Risk and Other Risks and Uncertainties</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(k)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Share-Based Compensation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(l)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have determined, in accordance with ASC Topic 280, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i><span style="font-family:'Times New Roman','Times','serif';">, that we operate under </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> operating segment, and therefore </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(m)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i><span style="font-family:'Times New Roman','Times','serif';">, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#160;&#8212; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#160;&#8212; We recognize revenue at the point</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(c)</span></span><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Accounts Receivable and Customer Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, one distributor customer constituted 19% of our accounts receivable balance. As of December&#160;31, 2021, one distributor customer constituted 34% of our accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had one distributor customer which constituted 20% and 25% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(e)</span></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,&#160;<i style="font-style:italic;">Leases</i>. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(f)</span></span><span style="font-style:italic;font-weight:bold;">Inventory</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#8201;&#8212;&#8201;including direct labor and manufacturing overhead&#8201;&#8212;&#8201;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(h)</span></span><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(i)</span></span><span style="font-style:italic;font-weight:bold;">Impairment and Disposal of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(j)</span></span><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(k)</span></span><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined, in accordance with ASC Topic 280,&#160;<i style="font-style:italic;">Segment Reporting</i>, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(l)</span></span><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;<i style="font-style:italic;">Revenue Recognition</i>, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price&#8201;&#8212;&#8201;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#8201;&#8212;&#8201;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#8201;&#8212;&#8201;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(m)</span></span><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;D costs are expensed as incurred and included milestone payments of $1,000 to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(n)</span></span><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $2,201 and $1,400, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(o)</span></span><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes pursuant to ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#8217;s income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(p)</span></span><span style="font-style:italic;font-weight:bold;">Warrant and Tranche Rights and Obligation Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665731616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(3)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Business Combination</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023, we consummated the previously announced merger pursuant to the Merger Agreement by and among MTAC, Merger Sub,&#160;Inc., and TriSalus Life Sciences,&#160;Inc. Upon the closing of the transactions contemplated by the Merger Agreement, Merger Sub merged with and into Legacy TriSalus (the &#8220;Business Combination&#8221;) with Legacy TriSalus surviving the merger as a wholly-owned subsidiary of MTAC, renamed &#8220;TriSalus Operating Life Sciences,&#160;Inc.&#8221; In addition, in connection with the consummation of the Business Combination, MTAC was renamed &#8220;TriSalus Life Sciences,&#160;Inc.&#8221;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to the effective time of the Merger, each in-the-money warrant of Legacy TriSalus that was unexercised and unexpired was automatically net exercised into the respective series of preferred stock of Legacy TriSalus. Each share of preferred stock of Legacy TriSalus (&#8220;Legacy TriSalus Preferred Stock&#8221;) that was issued and outstanding was then automatically converted into shares of common stock of Legacy TriSalus (&#8220;Legacy TriSalus Common Stock&#8221;) in accordance with the Amended and Restated Certificate of Incorporation of Legacy TriSalus at the then current conversion price, such that each converted share of Legacy TriSalus Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy TriSalus Preferred Stock thereafter ceased to have any rights with respect to such securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, by virtue of the Business Combination and without any action on the part of MTAC, Merger Sub, Legacy TriSalus or the holders of any of the following securities:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each share of Legacy TriSalus Common Stock (including shares of Legacy TriSalus Common Stock resulting from the conversion of shares of TriSalus Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time were exchanged at an exchange ratio of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.02471853</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;Exchange Ratio&#8221;) for an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21,999,886</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of our Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each option to purchase shares of Legacy TriSalus Common Stock, whether vested or unvested, converted into an option to purchase shares of our Common Stock (&#8220;TriSalus Assumed Option&#8221;), with each TriSalus Assumed Option subject to the same terms and conditions as were applicable to the original Legacy TriSalus option and with the resulting exercise price and number of shares of TriSalus Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each Legacy TriSalus restricted stock unit (&#8220;RSU&#8221;) award converted into a restricted stock unit award to receive shares of our Common Stock (&#8220;TriSalus Assumed RSU Award&#8221;), with each TriSalus Assumed RSU Award subject to the same terms and conditions as were applicable to the original Legacy TriSalus restricted stock unit award, and with the number of shares of TriSalus Common Stock to which the TriSalus Assumed RSU Award relates being based on the Exchange Ratio and other terms contained in the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, MTAC was treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, the Legacy TriSalus stockholders have a majority of the voting power of TriSalus, Legacy TriSalus comprises all of our ongoing operations, Legacy TriSalus has appointed a majority of our governing body, and Legacy TriSalus&#8217; senior management comprises all of our senior management. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy TriSalus with the business combination being treated as the equivalent of Legacy TriSalus issuing stock for the net assets of MTAC, accompanied by a recapitalization. Operations prior to the Business Combination are those of Legacy TriSalus. Reported shares and earnings per share available to holders of the Company&#8217;s common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination (1.0 share of Legacy TriSalus for approximately </span><span style="font-family:'Times New Roman','Times','serif';">0.02471853</span><span style="font-family:'Times New Roman','Times','serif';"> shares of TriSalus).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Proceeds from this transaction totaled </span><span style="font-family:'Times New Roman','Times','serif';">$42,854</span><span style="font-family:'Times New Roman','Times','serif';">. These proceeds were comprised of </span><span style="font-family:'Times New Roman','Times','serif';">$2,704</span><span style="font-family:'Times New Roman','Times','serif';"> from the MTAC trust account, and </span><span style="font-family:'Times New Roman','Times','serif';">$40,150</span><span style="font-family:'Times New Roman','Times','serif';"> received from the assumption of a concurrent private investment in public equity financing (&#8220;PIPE Financing&#8221;). Pursuant to the terms of the Merger Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">$6,000</span><span style="font-family:'Times New Roman','Times','serif';"> of the proceeds were used to pay expenses incurred by MTAC related to the merger, resulting in net cash proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';">. The Company incurred </span><span style="font-family:'Times New Roman','Times','serif';">$6,069</span><span style="font-family:'Times New Roman','Times','serif';"> in transaction costs relating to the merger with MTAC, of which </span><span style="font-family:'Times New Roman','Times','serif';">$1,742</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as a reduction of equity and the balance of </span><span style="font-family:'Times New Roman','Times','serif';">$4,327</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded in general and administrative expense.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy TriSalus exchanged their interests for shares of common stock of TriSalus. In addition, MTAC had previously issued public warrants and private placement warrants (collectively, the &#8220;MTAC Warrants&#8221;) as part of its initial public offering in November&#160;2020. None of the terms of the MTAC Warrants were modified as a result of the Business Combination. On the Closing Date, the Company recorded a liability related to the MTAC Warrants of </span><span style="font-family:'Times New Roman','Times','serif';">$2,568</span><span style="font-family:'Times New Roman','Times','serif';">. During the period from August&#160;10, 2023, to September&#160;30, 2023, the fair value of the MTAC Warrants increased to </span><span style="font-family:'Times New Roman','Times','serif';">$5,421</span><span style="font-family:'Times New Roman','Times','serif';">, resulting in a loss on the change in fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$2,853</span><span style="font-family:'Times New Roman','Times','serif';"> and a gain of </span><span style="font-family:'Times New Roman','Times','serif';">$660</span><span style="font-family:'Times New Roman','Times','serif';"> in the Condensed Consolidated Statements of Operations for the three and nine&#160;months ended September&#160;30, 2023, respectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately following the Business Combination, there were </span><span style="font-family:'Times New Roman','Times','serif';">26,316,681</span><span style="font-family:'Times New Roman','Times','serif';"> shares of our Common Stock outstanding, options and RSUs to purchase an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">2,816,224</span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock and warrants outstanding to purchase </span><span style="font-family:'Times New Roman','Times','serif';">14,266,605</span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">PIPE Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On the Closing Date, certain investors agreed to purchase an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">4,015,002</span><span style="font-family:'Times New Roman','Times','serif';"> newly-issued shares of Series&#160;A Convertible Preferred Stock at a purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> per share for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$40,150</span><span style="font-family:'Times New Roman','Times','serif';">, pursuant to separate subscription agreements dated June&#160;7, 2023, and July&#160;4, 2023 (collectively, the &#8220;Subscription Agreements&#8221;). See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sponsor Earnout</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement. Pursuant to the Sponsor Support Agreement, the </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> Sponsor Earnout Shares became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="font-family:'Times New Roman','Times','serif';">5</span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date. Pursuant to the Sponsor Support Agreement, (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">25%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_V-mQW-qQIUa1vQtlrdyyEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$15.00</span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';">20</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days, (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">25%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_2n4YMje6bU2yQX9mVj9haw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$20.00</span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';">20</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days, (iii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">25%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor</span><span style="font-family:'Times New Roman','Times','serif';"> Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_tM-2Y2RyQUOzCJbuqMIVTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$25.00</span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';">20</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days; and (iv)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">25%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the </span><span style="-sec-ix-hidden:Hidden_i6irmobClEimgYt4sNAgmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;year</span></span><span style="font-family:'Times New Roman','Times','serif';"> period following the Closing, the volume weighted average price of our Common Stock equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';">$30.00</span><span style="font-family:'Times New Roman','Times','serif';"> for any </span><span style="font-family:'Times New Roman','Times','serif';">20</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days within a period of </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days. Additionally, the Sponsor Earnout Shares will vest if there is a change in control of our company on or before the </span><span style="font-family:'Times New Roman','Times','serif';">5</span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date that results in the holders of our Common Stock receiving a price per share equal to or in excess of the applicable earnout targets. Any such shares held by the Sponsor Holders that remain unvested after the </span><span style="font-family:'Times New Roman','Times','serif';">5</span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing will be forfeited.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757922304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, contingent earnout liability, and warrants to purchase preferred and common stock. The carrying values of these financial instruments (other than warrants and tranche liabilities, which are held at fair value) approximate fair value at September&#160;30, 2023, and December&#160;31, 2022. In general, asset and liability fair values are determined using the following categories:</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;1&#8201;&#8212;&#8201;Inputs utilize quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;2&#8201;&#8212;&#8201;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Level&#160;3&#8201;&#8212;&#8201;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#8217;s own assumptions about the assumptions that a market participant would use.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrant, tranche and earnout liabilities are measured at fair value on a recurring basis.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments After Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The carrying amount of our outstanding MTAC warrants liabilities was </span><span style="font-family:'Times New Roman','Times','serif';">$5,421</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. The carrying amount of outstanding earnout liability was </span><span style="font-family:'Times New Roman','Times','serif';">$9,023</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023. These carrying values of the warrant liabilities represent the remeasurement to fair value each reporting period based on Level 1 inputs for the publicly traded MTAC Warrants and Level 2 inputs for the private placement MTAC Warrants. The carrying amounts of the contingent earnout liability represent the remeasurement to fair value each reporting period based on unobservable, or Level 3, inputs, using assumptions made by us, including the market price of our common stock and the observed volatility of a peer group of companies.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we assumed warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">14,266,605</span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock for </span><span style="font-family:'Times New Roman','Times','serif';">$11.50</span><span style="font-family:'Times New Roman','Times','serif';"> (see Note&#160;9). Of these, </span><span style="font-family:'Times New Roman','Times','serif';">8,333,272</span><span style="font-family:'Times New Roman','Times','serif';"> are traded publicly and </span><span style="font-family:'Times New Roman','Times','serif';">5,933,333</span><span style="font-family:'Times New Roman','Times','serif';"> are privately held. At the Closing Date, we determined the fair value of all the warrants to be </span><span style="font-family:'Times New Roman','Times','serif';">$2,568</span><span style="font-family:'Times New Roman','Times','serif';"> based on the closing price of </span><span style="font-family:'Times New Roman','Times','serif';">$0.18</span><span style="font-family:'Times New Roman','Times','serif';"> for the publicly traded warrants (Level 1).</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we determined the fair value of the earnout liability to be </span><span style="font-family:'Times New Roman','Times','serif';">$28,927</span><span style="font-family:'Times New Roman','Times','serif';"> based on a Monte Carlo simulation of future trading prices for our common stock. See Note&#160;8 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,904)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments Prior to the Business Combination</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our warrants and tranche liabilities are measured at fair value on a recurring basis. The carrying amount of outstanding warrant liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$16,188</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. The carrying amount of outstanding tranche liabilities was zero and </span><span style="font-family:'Times New Roman','Times','serif';">$4,702</span><span style="font-family:'Times New Roman','Times','serif';"> at September&#160;30, 2023, and December&#160;31, 2022, respectively. These carrying values represent the remeasurement to fair value each reporting period based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to a status quo scenario and the potential closing of the Business Combination (see Note&#160;3) scenario, the value of the Series&#160;B-3 Warrants (as defined below) upon closing of the Business Combination, the fair value of the Company, the fair value of the underlying preferred stock, the Company&#8217;s volatility, discount rate, and expected term of the related instrument.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">See Note&#160;9 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$4,654</span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$584</span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$10,047</span><span style="font-family:'Times New Roman','Times','serif';"> and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a </span><span style="font-family:'Times New Roman','Times','serif';">$3,425</span><span style="font-family:'Times New Roman','Times','serif';"> loss on equity issuance.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Immediately prior to the exercise of the warrants to purchase Series&#160;B-3 preferred stock in February, March, June&#160;and July&#160;2023, the associated liabilities were remeasured to fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2023, warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">2,239,309</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock were exercised for </span><span style="font-family:'Times New Roman','Times','serif';">$4,530</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were remeasured to fair value, net-exercised, converted to shares of common stock of Legacy TriSalus, and then exchanged for shares of TriSalus common stock at the Exchange Ratio. Out-of-the-money warrants expired, resulting in a gain on expiration of </span><span style="font-family:'Times New Roman','Times','serif';">$18</span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$4,800</span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';">14,701</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.2pt;text-indent:-16.2pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671538000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,414</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,664</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Restricted cash is </span><span style="font-family:'Times New Roman','Times','serif';">$250</span><span style="font-family:'Times New Roman','Times','serif';"> held by our bank to support our corporate credit card program.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash is $250 held by our bank to support our corporate credit card program.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664530320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The components of inventory are summarized as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 718</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Finished goods amounts include a reserve for excess or obsolete inventory of </span><span style="font-family:'Times New Roman','Times','serif';">nil</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$43</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023, and December&#160;31, 2022.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of inventory at December&#160;31 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,292</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The finished goods amounts in the table above include a reserve for excess inventory of $43 and $97 as of December&#160;31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665914880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accrued Liabilities</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accrued Liabilities consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,896</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,910</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,969</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665947568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Earnout Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Contingent Earnout Liability</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(8)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Contingent Earnout Liability</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;2 and Note&#160;3, in connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement with the Sponsor Holders and Legacy TriSalus, pursuant to which, </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares of our Common Stock held by the Sponsor immediately after the Closing Date became unvested and subject to potential forfeiture if certain triggering events are not achieved during the Earnout Period. The earnout shares are classified as a liability and were initially measured at fair value at the Closing Date and will subsequently be remeasured at the end of each reporting period with the change in fair value of the earnout liability recorded in the Condensed Consolidated Statements of Operations.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The estimated fair value of the total contingent earnout liability at the closing on August&#160;10, 2023, was </span><span style="font-family:'Times New Roman','Times','serif';">$28,927</span><span style="font-family:'Times New Roman','Times','serif';"> based on a Monte Carlo simulation valuation model. The liability was remeasured to its fair value of </span><span style="font-family:'Times New Roman','Times','serif';">$9,023</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. This remeasurement resulted in the recording of </span><span style="font-family:'Times New Roman','Times','serif';">$19,904</span><span style="font-family:'Times New Roman','Times','serif';"> for the three and nine&#160;months ended September&#160;30, 2023, classified as change in fair value of contingent earnout liability in the Condensed Consolidated Statements of Operations. Assumptions used in the valuation are described below:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected share price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The estimated fair value of the liability was determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes. The inputs and assumptions utilized in the calculation require management to apply judgment and make estimates including:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(a)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected volatility, which is based on the historical equity volatility of publicly traded peer companies for a term equal to the expected term of the earnout period;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(b)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected term, which we based on the earnout period per the agreement;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(c)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time periods commensurate with the expected term of the earnout period; and</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:16.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(d)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expected dividend yield, which we estimate to be </span><span style="font-family:'Times New Roman','Times','serif';">zero</span><span style="font-family:'Times New Roman','Times','serif';"> based on the fact that we have never paid or declared dividends.</span></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665993344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantsLiabilitiesTextBlock', window );">Warrants</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(9)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Warrants</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,333,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Series B-3 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Public and Private Placement Warrant Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with consummation of the Business Combination, the Company assumed the warrant liabilities associated with </span><span style="font-family:'Times New Roman','Times','serif';">8,333,272</span><span style="font-family:'Times New Roman','Times','serif';"> MTAC Public Warrants. Each Public Warrant is exercisable to purchase one share of common stock at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$11.50</span><span style="font-family:'Times New Roman','Times','serif';"> per share, subject to adjustment. As of September&#160;30, 2023, there were </span><span style="font-family:'Times New Roman','Times','serif';">8,333,272</span><span style="font-family:'Times New Roman','Times','serif';"> Public Warrants outstanding.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Public Warrants will become exercisable </span><span style="font-family:'Times New Roman','Times','serif';">30&#160;days</span><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination. The Public Warrants expire </span><span style="font-family:'Times New Roman','Times','serif';">5&#160;years</span><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination or earlier upon redemption or liquidation.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;31, 2023, the Company filed an amended registration statement on Form&#160;S-1 a(as may be amended from time to time) with the SEC registering the issuance of the shares of common stock issuable upon exercise of the warrants and will use its best efforts to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed, as specified in the warrant agreement.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">a.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">in whole and not in part;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">b.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">at a price of $</span><span style="font-family:'Times New Roman','Times','serif';">0.01</span><span style="font-family:'Times New Roman','Times','serif';"> per Public Warrant;</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">c.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> days&#8217; prior written notice of redemption to each warrant holder; and</span></p></td></tr></table><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">d.</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">if, and only if, the reported closing price of the Common Stock equals or exceeds $</span><span style="font-family:'Times New Roman','Times','serif';">18.00</span><span style="font-family:'Times New Roman','Times','serif';"> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any </span><span style="font-family:'Times New Roman','Times','serif';">20</span><span style="font-family:'Times New Roman','Times','serif';"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';">30</span><span style="font-family:'Times New Roman','Times','serif';"> trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.</span></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis.&#8221; The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. Accordingly, the warrants may expire worthless.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition to the Public Warrants, the Company assumed the warrant liabilities associated with </span><span style="font-family:'Times New Roman','Times','serif';">5,933,333</span><span style="font-family:'Times New Roman','Times','serif';"> MTAC Private Placement Warrants. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until </span><span style="font-family:'Times New Roman','Times','serif';">30&#160;days</span><span style="font-family:'Times New Roman','Times','serif';"> after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. As of September&#160;30, 2023, there were </span><span style="font-family:'Times New Roman','Times','serif';">5,933,333</span><span style="font-family:'Times New Roman','Times','serif';"> Private Placement Warrants outstanding.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the Public and Private placement Warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. As a result, the Private and Public Warrants do not meet the criteria for equity classification.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the close of the Business Combination, the fair values of the Public Warrants and Private Placement Warrants were </span><span style="font-family:'Times New Roman','Times','serif';">$1,500</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$1,068</span><span style="font-family:'Times New Roman','Times','serif';">, respectively. As of September&#160;30, 2023, the fair values of the Public Warrants and Private Placement Warrants were </span><span style="font-family:'Times New Roman','Times','serif';">$3,166</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$2,255</span><span style="font-family:'Times New Roman','Times','serif';">, respectively. The fair value of the Public Warrants has been measured based on the quoted price of such warrants on the Nasdaq Global Market. The transfer of Private Placement Warrants to anyone outside of a small group of individuals who are permitted transferees would result in the Private Placement Warrants having substantially the same terms as the Public Warrants. Therefore, we determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Series&#160;B-3 Warrants</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-3 Warrants were issued in conjunction with shares of Series&#160;B-2 preferred stock in October&#160;2022, March&#160;2023 and May&#160;2023. Each warrant allowed the holder to purchase one share of Series&#160;B-3 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$0.05</span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;B-3 Warrants expired at the earlier of October&#160;5, 2028, or the closing date of a change of control transaction. All in-the-money warrants that were outstanding at a change of control transaction would automatically net exercise.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2023, Series&#160;B-3 Warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">2,239,309</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock were exercised for </span><span style="font-family:'Times New Roman','Times','serif';">$4,530</span><span style="font-family:'Times New Roman','Times','serif';">. At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were net-exercised and converted to shares of common stock of Legacy TriSalus, then exchanged for shares of TriSalus common stock. Out-of-the-money warrants for other classes of preferred stock expired. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event: Warrant Repurchase Program</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In August&#160;2023, our Board approved a warrant repurchase program, authorizing the repurchase of some or all of the Public Warrants (the &#8220;Warrant Repurchase Program&#8221;). The Board authorized an aggregate expenditure of up to </span><span style="font-family:'Times New Roman','Times','serif';">$4,000</span><span style="font-family:'Times New Roman','Times','serif';"> for such repurchases. The repurchases may be made from time to time in open market or privately negotiated transactions. We may adopt one or more purchase plans pursuant to Rule&#160;10b5-1 under the Exchange Act, in order to implement the Warrant Repurchase Program. The Warrant Repurchase Program does not obligate us to purchase any Public Warrants and may be terminated, increased or decreased by the Board in its discretion at any time. We adopted a purchase plan in October&#160;2023. Through October&#160;31, 2023, we had repurchased </span><span style="font-family:'Times New Roman','Times','serif';">28,502</span><span style="font-family:'Times New Roman','Times','serif';"> Public Warrants for </span><span style="font-family:'Times New Roman','Times','serif';">$10</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantsLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantsLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665850624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(10)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Income Taxes</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full calendar&#160;year and use that rate to provide for income taxes on a current&#160;year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the annual effective tax rate, including use of the actual effective rate for the&#160;year-to-date. The impact of the discrete items is recorded in the quarter in which they occur.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We utilize the balance sheet method of accounting for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings, forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Based on our full valuation allowance against the net deferred tax assets, our effective federal tax rate for the calendar&#160;year is </span><span style="font-family:'Times New Roman','Times','serif';">zero</span><span style="font-family:'Times New Roman','Times','serif';">, and we recorded an immaterial income tax expense in the nine&#160;months ended September&#160;30, 2023 and 2022.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,002</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,306</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,708</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,630</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,630)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of our deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As we do not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, we do not believe it is more likely than not that we will realize the benefits of the net deferred tax assets and, accordingly, have established a valuation allowance equal to 100% of net deferred tax assets. The change in the valuation allowance for the&#160;years ended December&#160;31, 2022 and 2021 was $8,728 and $5,779, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had net operating losses (&#8220;NOLs&#8221;) as follows (the NOLs which do not expire are subject to an annual utilization limitation of 80% of taxable income):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Federal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">State</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs expiring between 2029 and 2037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,380</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs which do not expire</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,398</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total NOLs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,778</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Internal Revenue Code contains provisions that may further limit the net operating loss carryovers available to be used in any one&#160;year if certain events occur, including significant changes in ownership interests. Utilization of net operating loss and tax credit carryforwards are subject to a substantial annual limitation due to the ownership change limitations set forth in Section&#160;382 of the Code and similar state provisions. We prepared an Internal Revenue Code 382 analysis to determine the annual limitations on our consolidated net operating loss carryforwards. All of our tax attributes are subject to an annual limitation. Such annual limitations could result in the expiration of the net operating loss and tax credit carryforwards before utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, we did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12&#160;months. Our accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our federal and state returns for all&#160;years remain open to examination by tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683774961664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(11)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Series&#160;A Convertible Preferred Stock</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the Closing Date, we issued </span><span style="font-family:'Times New Roman','Times','serif';">4,015,002</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A Convertible Preferred Stock for </span><span style="font-family:'Times New Roman','Times','serif';">$40,150</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, the Company is authorized to issue up to </span><span style="font-family:'Times New Roman','Times','serif';">10,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of preferred stock with </span><span style="font-family:'Times New Roman','Times','serif';">5,984,998</span><span style="font-family:'Times New Roman','Times','serif';"> shares available for issuance. The original issue price of the Series&#160;A Convertible Preferred Stock was </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';">. The Series&#160;A Convertible Preferred Stock accrues cumulative dividends at the rate of </span><span style="font-family:'Times New Roman','Times','serif';">8.00%</span><span style="font-family:'Times New Roman','Times','serif';"> per annum on the original issue price. As of September&#160;30, 2023, total undeclared cumulative dividends were </span><span style="font-family:'Times New Roman','Times','serif';">$458</span><span style="font-family:'Times New Roman','Times','serif';">. We have not recorded the undeclared dividends in our condensed consolidated financial statements.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">All shares of Series&#160;A Convertible Preferred Stock had the following rights:</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion</i></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">(a)</i></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Optional Conversion</i></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;A Convertible Preferred Stock are convertible at any time at the option of the holder thereof into the number of shares of our Common Stock determined by the quotient of (i)&#160;the sum of </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> (as adjusted for any stock dividend, stock split, reverse stock split, combination or similar event affecting the Series&#160;A Convertible Preferred Stock) (the &#8220;Liquidation Preference&#8221;) and, if we have not elected to otherwise pay the accrued Annual Dividends (as defined below) in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price (as defined in our Certificate of Designations, Preferences, and Rights of Series&#160;A Convertible Preferred Stock (the "Certificate of Designations")) of such shares in effect at the time of conversion.</span></p><table style="border:0;border-collapse:collapse;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">(b)</i></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">Automatic </i><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conversion</i></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-family:'Times New Roman','Times','serif';">On the </span><span style="font-family:'Times New Roman','Times','serif';">four-year</span><span style="font-family:'Times New Roman','Times','serif';"> anniversary of the Closing, all then outstanding shares of Series&#160;A Convertible Preferred Stock shall automatically convert into the number of shares of our Common Stock equal to the quotient of (i)&#160;the sum of the Liquidation Preference and if we had not elected to otherwise pay the accrued Annual Dividends in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price of such shares in effect at the time of conversion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(ii)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Voting Rights</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Holders of the Series&#160;A Convertible Preferred Stock are entitled to vote with the holders of our Common Stock on all matters submitted to a vote of our stockholders, except as otherwise provided in the Certificate of Designations or as required by applicable law, voting together with the holders of our Common Stock as a single class. Each holder is entitled to a number of votes in respect of the shares of Series&#160;A Convertible Preferred Stock owned as of the record date by it, or if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, equal to the quotient of (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> divided by (ii)&#160;the Minimum Price (as defined in Nasdaq Listing Rule&#160;5635(d)) of our Common Stock as determined at Closing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As long as any shares of Series&#160;A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the Holders of a majority of the then-outstanding shares of the Series&#160;A Convertible Preferred Stock, (i)&#160;amend, alter, repeal or otherwise modify any provision of our certificate of incorporation or the Certificate of Designations in a manner that would alter or change the terms or the powers, preferences, rights or privileges of the Series&#160;A Convertible Preferred Stock as to affect them adversely; (ii)&#160;authorize, create, increase the authorized amount of, or issue any class or series of capital stock senior to the Series&#160;A Convertible Preferred Stock; (iii)&#160;increase the authorized number of shares of Series&#160;A Convertible Preferred Stock or enter into any agreement with respect to the foregoing.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iii)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dividends</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Holders of the Series&#160;A Convertible Preferred Stock are entitled to participate equally in any dividends declared to holders of Common Stock. In addition, each holder of the Series&#160;A Convertible Preferred Stock is entitled to receive cumulative annual dividends that accrue and accumulate on a daily basis at a rate per annum (calculated on the basis of an actual 365- or 366-day&#160;year, as applicable) equal to </span><span style="font-family:'Times New Roman','Times','serif';">8.00%</span><span style="font-family:'Times New Roman','Times','serif';"> of the original issue price of </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> per share (the "Annual Dividends&#8221;). The Annual Dividends will be either paid in cash, paid by issuing fully paid and nonassessable shares of Common Stock, or a combination thereof when, as and if authorized and declared by our Board. Upon conversion or a change of control, any unpaid Annual Dividends will be paid to the holders, either in the form of common stock upon a conversion, or in cash upon a change of control. So long as any shares of Series&#160;A Convertible Preferred Stock remain outstanding, unless all Annual Dividends on all outstanding shares of Series&#160;A Convertible Preferred Stock have been declared and paid in cash, we will be prohibited from declaring any dividends on, or making any distributions relating to, other classes of our capital stock ranking junior to the Series&#160;A Convertible Preferred Stock, subject to certain exceptions.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Anti-dilution Provisions</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The initial Conversion Price of </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> is subject to customary adjustments in the case of certain distributions to holders of our Common Stock payable in shares of our Common Stock, subdivisions, splits or combinations of the shares of our Common Stock and distributions to all holders of shares of our Common Stock of any convertible securities or options or any other assets for which there is no corresponding distribution in respect of the Series&#160;A Convertible Preferred Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Conversion Price will automatically reset upon each of February&#160;10, 2025, and July&#160;10, 2027, the </span><span style="font-family:'Times New Roman','Times','serif';">eighteen-month</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">forty-seven-month</span><span style="font-family:'Times New Roman','Times','serif';"> anniversaries of the Closing Date, to be equal to the lowest of:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initial Conversion Price, subject to adjustments for stock dividends and distributions or other distributions made to common stockholders for which there is no corresponding distribution for Preferred Stock,</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the then-current Conversion Price, and</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the higher of 1) the&#160;Floor Price (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.10</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share) or 2) the trailing </span><span style="-sec-ix-hidden:Hidden_5hLzbZ6A6U-WazkWaQSF7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-Trading Day VWAP of the Common Stock determined as of the date of such reset.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Liquidation Preferences</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The terms of the Series&#160;A Convertible Preferred Stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a &#8220;Liquidation Event&#8221;), none of which were deemed probable as of September&#160;30, 2023. The Liquidation Preferences of </span><span style="font-family:'Times New Roman','Times','serif';">$10.00</span><span style="font-family:'Times New Roman','Times','serif';"> per share, plus all unpaid dividends, are payable prior to payment to any class of capital stock that is junior to the Series&#160;A Convertible Preferred Stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment of the full Liquidation Preferences to all holders of Series&#160;A Convertible Preferred Stock, then such assets will be distributed ratably to the holders of Series&#160;A Convertible Preferred Stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned Liquidation Preferences, any remaining proceeds from a Liquidation Event will be distributed to all classes of capital stock that are junior to the Series&#160;A Convertible Preferred Stock pro&#160;rata on an as-if converted basis.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Legacy TriSalus Preferred Stock</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Since inception, we have issued various series of preferred stock as described below. As described in Note&#160;3, all of the Legacy TriSalus Preferred Stock was converted to Legacy TriSalus Common Stock immediately prior to the Merger and, upon consummation of the Merger, were exchanged for shares of our Common Stock. In accordance with the terms of the Legacy TriSalus Preferred Stock, upon an acquisition of the Company, the proceeds would be used to first pay the liquidation preferences on the preferred stock prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our Board and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#8201;&#8212;&#8201;and thereby redeem the convertible preferred stock&#8201;&#8212;&#8201;was deemed to be outside of our control. As a result, the Legacy TriSalus Preferred Stock has been classified as temporary equity in the accompanying Condensed Consolidated Balance Sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments were not currently redeemable and we believed it was not probable that the instruments would become redeemable.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements / </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $17.81 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $20.23 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.41 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $2.03 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,871,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercises</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,771,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (649,109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;A-5 and A-6 warrants were retired at the Closing Date as they were out-of-the money. The Series&#160;B and B-3 warrants were net-converted to shares of Legacy TriSalus Common Stock, then exchanged for shares of our Common Stock at the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The rights associated with the Legacy TriSalus Preferred Stock are described in our December&#160;31, 2022, financial statements included in MTAC&#8217;s definitive proxy statement filed with the SEC on July&#160;18, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">October&#160;2022 Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In early October&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';">706,243</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$9,755</span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds (the &#8220;B-2 Preferred Stock Financing&#8221;). For each share sold, we also issued a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock (with total warrants issued being for </span><span style="font-family:'Times New Roman','Times','serif';">2,824,974</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock) with a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> per share. The B-2 Preferred Stock Financing included, at our audit committee&#8217;s option, a second tranche for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';">518,854</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$7,347</span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to </span><span style="font-family:'Times New Roman','Times','serif';">$10,000</span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';">2,075,417</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';">306,053</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$4,334</span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">353,121</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for approximately </span><span style="font-family:'Times New Roman','Times','serif';">$5,000</span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">eight</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';">2,448,428</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock to immediately convert to common stock and any warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$1.06</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.33</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.37</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.34</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.37</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.42</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$0.26</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$0.30</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;set to </span><span style="font-family:'Times New Roman','Times','serif';">$0.35</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">$0.05</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';">1.155</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.173</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.162</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.165</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.189</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.190</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.154</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.167</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">99.2%</span><span style="font-family:'Times New Roman','Times','serif';"> of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;11), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other holders who do not provide services. As such, the Company concluded the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The warrants to purchase Series&#160;B-3 preferred stock (&#8220;Series&#160;B-3 Warrants&#8221;) represent freestanding financial instruments that should be recognized as a liability as we are required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Tranche Liability&#8221;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of our control, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the accompanying Condensed Consolidated Balance Sheets at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">2023 Financing</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In January&#160;through September&#160;2023, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">4,771,642</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$9,630</span><span style="font-family:'Times New Roman','Times','serif';">. In addition, </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';"> of warrant liabilities was transferred to Series&#160;B-3 preferred stock. Also, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">11,123</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock exercised their purchase rights, for proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$4</span><span style="font-family:'Times New Roman','Times','serif';">, plus the transfer of warrant liabilities of </span><span style="font-family:'Times New Roman','Times','serif';">$106</span><span style="font-family:'Times New Roman','Times','serif';"> to Series&#160;B preferred stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we effectuated closings (&#8220;Second Tranche Closings&#8221;) of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">207,541</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">830,167</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing </span><span style="font-family:'Times New Roman','Times','serif';">40%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$2,932</span><span style="font-family:'Times New Roman','Times','serif';">, net of execution costs, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">17,656</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">70,624</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$250</span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock&#160;were adjusted. The conversion prices were further adjusted as a result of the June&#160;2023 exercise of a portion of the second tranche of the B-2 Preferred Stock Financing described below, which represent the conversion prices in effect on the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2023, we effectuated closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">257,779</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">1,031,116</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">49.7%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">approximately </span><span style="font-family:'Times New Roman','Times','serif';">$3,650</span><span style="font-family:'Times New Roman','Times','serif';">, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">165,967</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">663,868</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$2,350</span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the closings of a portion of the second tranche of the B-2&#160;Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$38.84</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$12.14</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$13.36</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$12.55</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$13.36</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$14.97</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$9.71</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$10.93</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> and Series&#160;B-3 preferred stock </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';">, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';">1.275</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.290</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.303</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.277</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.333</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.351</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.250</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.296</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';">&#160;to 1 for Series&#160;B-3 preferred stock. These conversion prices remained in effect at the Closing Date. Any portion of the Series&#160;B-3 Warrants that remained unexercised at the time the Business Combination is consummated were automatically net settled for shares of Legacy TriSalus Common Stock immediately prior to the closing of the Business Combination (see Note&#160;3) and exchanged into shares of our Common Stock at the Closing Date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#8217;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. The fair value of the Series&#160;B-3 Warrants as of August&#160;10, 2023, was determined solely using the scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. </span><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 preferred stock fair value per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.97</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 preferred stock exercise price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.16</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 preferred stock fair value per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.24</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrants exercise price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.03</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50.0%<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span>65.0%</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.0%<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span>4.7%</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 Tranche Liability expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.2<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span>0.4 years</p></td></tr><tr><td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrants expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8<span style="font-family:'Arial','Helvetica','sans-serif';">&#8201;&#8211;&#8201;</span>6.0 years</p></td></tr><tr><td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the underlying shares of Series&#160;B-2 preferred stock and the Series&#160;B-3 Warrants used in these models were derived from estimates of the Company&#8217;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#8217;s forecasted 2023 and</span><span style="font-family:'Times New Roman','Times','serif';"> 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of </span><span style="font-family:'Times New Roman','Times','serif';">$9.31</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$10.93</span><span style="font-family:'Times New Roman','Times','serif';"> per share, as of August&#160;10, 2023, and December&#160;31, 2022, respectively, which is based upon the enterprise value stated in the Merger Agreement of </span><span style="font-family:'Times New Roman','Times','serif';">$220,000</span><span style="font-family:'Times New Roman','Times','serif';"> allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, and for the December&#160;31, 2022 valuation, discounted at </span><span style="font-family:'Times New Roman','Times','serif';">30%</span><span style="font-family:'Times New Roman','Times','serif';"> from the expected Business Combination Closing Date. The Business Combination scenario as of August&#160;10, 2023, and December&#160;31, 2022, assumed there would be no additional exercises of the second and third tranches, and thus no value was assigned to the outstanding tranche rights and obligations, as the Company would not exercise its right to call the remaining second tranche.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrant Liabilities at issuance resulting from the completion of the Second Tranche Closings was estimated at </span><span style="font-family:'Times New Roman','Times','serif';">$14,701</span><span style="font-family:'Times New Roman','Times','serif';">. The excess of the warrant liability&#8217;s fair value compared to the proceeds received in the Second Tranche Closings resulted in a charge to loss on equity issuance in the Condensed Consolidated statements of operations of </span><span style="font-family:'Times New Roman','Times','serif';">$4,171</span><span style="font-family:'Times New Roman','Times','serif';"> for the nine&#160;months ended September&#160;30, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671997680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(12)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Loss per Share</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the nine-month periods ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,015,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,624,155</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,632,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,710,860</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,097,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,381,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;9, the triggering of the anti-dilution feature resulting from the closing of the second tranche of the Initial Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$2,981</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common stockholders reflected in our unaudited Condensed Consolidated Statements of Operations for the nine&#160;months ended September&#160;30, 2023. The deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$0.72</span><span style="font-family:'Times New Roman','Times','serif';"> for the nine&#160;months ended September&#160;30, 2023.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock, if any, participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the&#160;years ended December&#160;31, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for those periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,330,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,376,970</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,079</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,879,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,731,606</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;12, the triggering of the anti-dilution feature resulting from the B-2 Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$2,829</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common shareholders reflected in our consolidated statement of operations for the&#160;year ended December&#160;31, 2022. This deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$9.14</span><span style="font-family:'Times New Roman','Times','serif';"> for the&#160;year ended December&#160;31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666072016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(13)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Share-Based Compensation</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We currently maintain the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which our Board of Directors and stockholders approved in connection with the Business Combination for purposes of granting equity-based incentive awards to our employees and consultants, including our executive officers and directors. Prior to the Business Combination, TriSalus granted equity incentive awards under the 2009 Amended and Restated Equity Incentive Plan (the &#8220;2009 Plan&#8221;). The 2009 Plan will not be used following the Business Combination. However, any awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan and the applicable award agreement. Historically, we have used options as an incentive for long-term compensation to our executive officers because options allow our executive officers to realize value from this form of equity compensation only if the value of the underlying equity securities increase relative to the option&#8217;s exercise price, which exercise price is set at the fair market value of the underlying equity securities on the grant date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Under the 2023 Plan, the Company&#8217;s Board may grant equity-based incentive awards to employees, consultants and other service providers of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. Initially, </span><span style="font-family:'Times New Roman','Times','serif';">5,585,008</span><span style="font-family:'Times New Roman','Times','serif';"> shares were authorized under the 2023 Plan. In addition, the share reserve will automatically increase on January&#160;1 of each&#160;year for a period of </span><span style="-sec-ix-hidden:Hidden_MGlu3JgwP0qQ1n5yi83_7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10&#160;years</span></span><span style="font-family:'Times New Roman','Times','serif';">, commencing on January&#160;1, 2024, and ending on January&#160;1, 2033, in an amount equal to (1)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">five</span><span style="font-family:'Times New Roman','Times','serif';">&#160;percent of the total number of shares of the fully diluted Common Stock determined on December&#160;31 of the preceding&#160;year, or (2)&#160;a lesser number of shares of Common Stock determined by our Board prior to January&#160;1 of a given&#160;year. During the nine&#160;months ended September&#160;30, 2023, we granted </span><span style="font-family:'Times New Roman','Times','serif';">1,179,480</span><span style="font-family:'Times New Roman','Times','serif';"> options with a weighted average fair value of $</span><span style="font-family:'Times New Roman','Times','serif';">2.66</span><span style="font-family:'Times New Roman','Times','serif';">, and </span><span style="font-family:'Times New Roman','Times','serif';">184,018</span><span style="font-family:'Times New Roman','Times','serif';"> restricted stock units with a weighted average fair value of $</span><span style="font-family:'Times New Roman','Times','serif';">2.43</span><span style="font-family:'Times New Roman','Times','serif';">. As of September&#160;30, 2023, the balances under the </span><span style="font-family:'Times New Roman','Times','serif';">two</span><span style="font-family:'Times New Roman','Times','serif';"> plans are below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available for Issue</b></p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2009 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,915,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,915,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,585,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,684,508</p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,816,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,684,508</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had unrecognized compensation expense of $</span><span style="font-family:'Times New Roman','Times','serif';">250</span><span style="font-family:'Times New Roman','Times','serif';"> and $</span><span style="font-family:'Times New Roman','Times','serif';">337</span><span style="font-family:'Times New Roman','Times','serif';">, respectively, for options and RSUs granted under the 2009 Plan, and $</span><span style="font-family:'Times New Roman','Times','serif';">3,002</span><span style="font-family:'Times New Roman','Times','serif';"> for options granted under the 2023 Plan.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our Board, or a duly authorized committee thereof, administers the 2023 Plan. Our Board may also delegate to one or more of our officers the authority to, among other things, (1)&#160;designate employees (other than officers) to receive specified stock awards and (2)&#160;determine the number of shares subject to such stock awards. Under the 2023 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value and exercise price, and the provisions of each stock award, including the exercise period and the vesting schedule applicable to a stock award, subject to the limitations of the 2023 Plan.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Stock options are granted with an exercise price no less than </span><span style="font-family:'Times New Roman','Times','serif';">100</span><span style="font-family:'Times New Roman','Times','serif';">% of the estimated fair value of a share of Common Stock at the date of grant.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757975008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dynavax Purchase<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Dynavax Purchase</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(14)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dynavax Purchase</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#8220;Dynavax&#8221;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#8220;IPR&amp;D&#8221;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#8220;TLR9&#8221;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells (&#8220;MDSCs&#8221;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of </span><span style="font-family:'Times New Roman','Times','serif';">$9,000</span><span style="font-family:'Times New Roman','Times','serif';"> that was split into two payments (</span><span style="font-family:'Times New Roman','Times','serif';">$5,000</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$4,000</span><span style="font-family:'Times New Roman','Times','serif';">, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The milestone payments range from </span><span style="font-family:'Times New Roman','Times','serif';">$1,000</span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="font-family:'Times New Roman','Times','serif';">$10,000</span><span style="font-family:'Times New Roman','Times','serif';">, triggered by development achievements for each of up to </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> indications. The development milestone payments cannot exceed </span><span style="font-family:'Times New Roman','Times','serif';">$170,000</span><span style="font-family:'Times New Roman','Times','serif';">. We have made milestone payments of </span><span style="font-family:'Times New Roman','Times','serif';">$1,000</span><span style="font-family:'Times New Roman','Times','serif';"> in September&#160;2021, after initiating our clinical study of uveal melanoma liver metastases, June&#160;2022, after initiating our clinical study for primary liver tumors, and August&#160;2023, after initiating our clinical study for pancreatic cancer.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, we will have to pay up to </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> commercial milestones, </span><span style="font-family:'Times New Roman','Times','serif';">$10,000</span><span style="font-family:'Times New Roman','Times','serif';"> upon first commercial sale of the product; </span><span style="font-family:'Times New Roman','Times','serif';">$20,000</span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$250,000</span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales; </span><span style="font-family:'Times New Roman','Times','serif';">$20,000</span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$500,000</span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales; and </span><span style="font-family:'Times New Roman','Times','serif';">$30,000</span><span style="font-family:'Times New Roman','Times','serif';"> upon the first occurrence of </span><span style="font-family:'Times New Roman','Times','serif';">$1,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> in annual net sales. In aggregate, the commercial milestones shall not exceed </span><span style="font-family:'Times New Roman','Times','serif';">$80,000</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We will also pay annual royalties at the rate of </span><span style="font-family:'Times New Roman','Times','serif';">10%</span><span style="font-family:'Times New Roman','Times','serif';"> for aggregate annual net sales less than or equal to </span><span style="font-family:'Times New Roman','Times','serif';">$1,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">12%</span><span style="font-family:'Times New Roman','Times','serif';"> for aggregate annual net sales above that amount.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We record the milestone payments in R&amp;D expense when they are incurred. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665899520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(15)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commitments and Contingencies</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registrations and will indemnify the parties thereto against certain liabilities related to such registrations. The Company&#8217;s registration obligations under the Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto on the date that such party no longer holds any Registrable Securities (as defined in the Amended and Restated Registration Rights Agreement). The Amended and Restated Registration Rights Agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(16)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a salary reduction savings plan under Section&#160;401(k)&#160;of the Internal Revenue Code, which we administer for participating employees&#8217; contributions. All full-time employees are covered under the plan after meeting minimum service requirements. We paid matching contributions of $431 and $287 to the plan for the&#160;years ended December&#160;31, 2022 and 2021, respectively. Our contributions were based on compensation at the rate of 3%, 3.5%, and 4% for an employee&#8217;s contribution of up to 3%, between 3% and 4%, and between 4% and 5%, respectively, with the match-eligible contribution being limited to 4% of the employee&#8217;s eligible compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, an individual filed a suit against the Company in the District of Colorado asserting joint inventorship of six patents assigned to the Company. The individual sought to be added as a co-inventor and co-owner of the patents in question. In a series of rulings, the Court struck monetary damages and jury trial demand, limited the individual&#8217;s expert testimony to one patent, and barred rebuttal testimony to defendant&#8217;s expert or testimony related to prior art, severely limiting the scope of this case. Following a notice that we would be seeking sanctions against the plaintiff and his attorney, it was agreed that the plaintiff would dismiss his case with prejudice and no sanctions or attorney fees&#8217; request would be filed. A stipulated Dismissal Order was entered June&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, TriSalus exercised its right to terminate, for cause, an agreement with a distributor, pursuant to which the distributor was acting as exclusive distributor of the TriNav Infusion System in several Western states. We determined that the distributor had failed to perform many aspects of the contract resulting in poor sales. The distributor was put on notice in September&#160;of 2020 that performance must improve, or we would terminate the contract. Despite being allowed a 60-day cure period, the distributor&#8217;s performance did not improve and in February&#160;2021 we exercised our right to terminate. On March&#160;11, 2021, the distributor filed a lawsuit against us in the Utah state court, asserting a claim for wrongful termination of the contract by us and several other related, common-law claims. The distributor sought monetary damages in an amount of $750, plus attorneys&#8217; fees and other relief. On November&#160;15, 2021, we agreed to settle the case for $425, which was recorded as expense in general and administrative expense in the accompanying consolidated statements of operations. The settlement was paid in two installments of $200 and $225, on November&#160;18, 2021, and January&#160;3, 2022, respectively. The settlement amounted to the contractual fee if we were to terminate the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683659796096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$8,617</span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(b)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accounts Receivable</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(c)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Inventory</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#8212; including direct labor and manufacturing overhead&#160;&#8212; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(f)</span></span><span style="font-style:italic;font-weight:bold;">Inventory</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#8201;&#8212;&#8201;including direct labor and manufacturing overhead&#8201;&#8212;&#8201;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(d)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Property and Equipment</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(h)</span></span><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment and Disposal of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(e)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Impairment and Disposal of Long-Lived Assets</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows</span><span style="font-family:'Times New Roman','Times','serif';"> expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(i)</span></span><span style="font-style:italic;font-weight:bold;">Impairment and Disposal of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(f)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i><span style="font-family:'Times New Roman','Times','serif';">. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#8220;ROU&#8221;) representing the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(e)</span></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,&#160;<i style="font-style:italic;">Leases</i>. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant and Tranche Liabilities / Contingent Earnout Liability</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(g)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Warrant and Tranche Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">99.2</span><span style="font-family:'Times New Roman','Times','serif';">% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(h)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Contingent Earnout Liability</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#8220;Sponsor Support Agreement&#8221;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#8221;), Legacy TriSalus and MTAC&#8217;s directors and officers (the Sponsor and MTAC&#8217;s directors and officers, collectively, the &#8220;Sponsor Holders&#8221;). Pursuant to the Sponsor Support Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#8220;Sponsor Earnout Shares&#8221;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date (the &#8220;Earnout Period&#8221;). The Sponsor Earnout Shares are classified as a liability in the Company&#8217;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(j)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Concentrations of Credit Risk and Other Risks and Uncertainties</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(k)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Share-Based Compensation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(j)</span></span><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(l)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have determined, in accordance with ASC Topic 280, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i><span style="font-family:'Times New Roman','Times','serif';">, that we operate under </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> operating segment, and therefore </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(k)</span></span><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined, in accordance with ASC Topic 280,&#160;<i style="font-style:italic;">Segment Reporting</i>, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(m)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i><span style="font-family:'Times New Roman','Times','serif';">, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#160;&#8212; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#160;&#8212; We recognize revenue at the point</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(l)</span></span><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;<i style="font-style:italic;">Revenue Recognition</i>, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price&#8201;&#8212;&#8201;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#8201;&#8212;&#8201;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#8201;&#8212;&#8201;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666002272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,904)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$4,800</span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';">14,701</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;(Out)&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains)&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Put option liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,702</p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>This amount includes settlements of $3,397, reduced by issuances of $10.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672622960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,414</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,664</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,414</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,664</p></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671538000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Components of Inventory</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The components of inventory are summarized as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 718</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,292</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665804720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accrued Liabilities consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,896</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,910</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,969</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757964192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Earnout Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665965120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,333,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Series B-3 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $17.81 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $20.23 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.41 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $2.03 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,871,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercises</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,771,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (649,109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial&#160;Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">08&#8209;26&#8209;2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">10&#8209;27&#8209;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">06&#8209;30&#8209;2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">11&#8209;20&#8209;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665995952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements / </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,333,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Series B-3 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $17.81 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $20.23 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.41 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $2.03 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,871,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercises</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,771,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (649,109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial&#160;Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">08&#8209;26&#8209;2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">10&#8209;27&#8209;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">06&#8209;30&#8209;2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">11&#8209;20&#8209;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665955248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,015,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,624,155</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,632,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,710,860</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,097,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,381,126</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,330,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,376,970</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,079</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,879,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,731,606</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665982704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Share-Based Compensation Plan Balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available for Issue</b></p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2009 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,915,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,915,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,585,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,684,508</p></td></tr><tr><td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,816,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,684,508</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683659928288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">168 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfProductLinesInDevelopment', window );">Number of product lines in development | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,151<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromReverseRecapitalization', window );">Proceeds from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,854<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,867<span></span>
</td>
<td class="nump">212,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,358<span></span>
</td>
<td class="nump">$ 136,342<span></span>
</td>
<td class="nump">$ 186,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,189<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">13,499<span></span>
</td>
<td class="nump">51,900<span></span>
</td>
<td class="nump">113,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StandbyEquityPurchaseAgreementTerm', window );">Purchase agreement period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays', window );">Purchase agreement, number of trading days used for measurement of market price</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PurchaseAgreementOwnershipLimitation', window );">Purchase agreement, ownership limitation</a></td>
<td class="nump">4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PurchaseAgreementExchangeCap', window );">Purchase agreement, exchange cap</a></td>
<td class="nump">19.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockAuthorizedAmountValue', window );">Sale of stock, authorized amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommonStockSharePricePercentageOfAverageDailyVolume', window );">Purchase agreement, maximum shares allowed, percentage of average daily volume</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays', window );">Purchase agreement, number of days used for measurement of average daily trading volume</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized', window );">Maximum shares of common stock allowed under Purchase Agreement (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate', window );">Purchase agreement, sales price, percentage of market price</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo', window );">Purchase agreement, sales price, percentage of market price during three consecutive trading days</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tlsi_ConvertibleNotesAndWarrantsMember', window );">Convertible notes and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Share Price, Average Daily Volume, Number Of Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Share Price, Market Price, Number Of Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommonStockSharePricePercentageOfAverageDailyVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Share Price, Percentage Of Average Daily Volume</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommonStockSharePricePercentageOfAverageDailyVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of Business [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfProductLinesInDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Product Lines in Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfProductLinesInDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PurchaseAgreementExchangeCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Exchange Cap</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PurchaseAgreementExchangeCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PurchaseAgreementOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Ownership Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PurchaseAgreementOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SaleOfStockAuthorizedAmountValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SaleOfStockAuthorizedAmountValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price As Percentage Of Market Price Commencing On Advance Notice Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price As Percentage Of Market Price With Advance Notice, Option Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standby Equity Purchase Agreement, Maximum Amount Of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StandbyEquityPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standby Equity Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StandbyEquityPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tlsi_ConvertibleNotesAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tlsi_ConvertibleNotesAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671411184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPercentageOfOutstandingShares', window );">Percentage of then-outstanding preferred stock on an as-converted to common stock basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod', window );">Derivative instrument, contingent consideration, liability, earnout period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember', window );">Derivative Instrument, Contingent Earnout Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares', window );">Shares unvested (in shares) | shares</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Investments in money market funds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Unvested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockConversionPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion, Percentage of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockConversionPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660900976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_RecapitalizationExchangeRatio', window );">Exchange ratio | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02471853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockConvertedReverseRecapitalization', window );">Stock converted, reverse recapitalization (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,999,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromReverseRecapitalizationTransaction', window );">Proceeds from transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from MTAC trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsOfReverseRecapitalizationTransactionCosts', window );">Expenses related to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromReverseRecapitalization', window );">Proceeds from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,854<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationTransactionCostsIncurred', window );">Transaction costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationTransactionCostsPaid', window );">Transaction costs paid from proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">MTAC warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,224<span></span>
</td>
<td class="nump">7,500,732<span></span>
</td>
<td class="nump">7,500,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod', window );">Derivative instrument, contingent consideration, liability, earnout period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">MTAC warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays', window );">Earnout period, threshold trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays', window );">Earnout period, threshold consecutive trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage', window );">Earnout shares vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger', window );">Earnout shares vesting requirement, weighted average price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage', window );">Earnout shares vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger', window );">Earnout shares vesting requirement, weighted average price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodThreeMember', window );">Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage', window );">Earnout shares vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger', window );">Earnout shares vesting requirement, weighted average price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodFourMember', window );">Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage', window );">Earnout shares vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger', window );">Earnout shares vesting requirement, weighted average price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tlsi_MedTechAcquisitionCorporationMember', window );">MedTech Acquisition Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsOfReverseRecapitalizationTransactionCosts', window );">Expenses related to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember', window );">MTAC Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">MTAC warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationLineItems', window );"><strong>Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares', window );">Shares unvested (in shares) | shares</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Unvested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsOfReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Reverse Recapitalization, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsOfReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromReverseRecapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reverse Recapitalization Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromReverseRecapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_RecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_RecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationTransactionCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Transaction Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationTransactionCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationTransactionCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Transaction Costs Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationTransactionCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockConvertedReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Converted, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockConvertedReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentPeriodAxis=tlsi_DerivativeInstrumentPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tlsi_MedTechAcquisitionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tlsi_MedTechAcquisitionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660657552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 28,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Outstanding warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on equity issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,904)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(19,904)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember', window );">Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember', window );">Series B-3 Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,047<span></span>
</td>
<td class="nump">$ 4,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnWarrantExpirations', window );">Gain on expired warrants</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember', window );">Tranche and warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on equity issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,425<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price (in dollars per share)</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember', window );">MTAC Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnWarrantExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Warrant Expirations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnWarrantExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_TrancheAndWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_MTACWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660735568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="num">(19,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="nump">28,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net Transfer In (Out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="num">(369)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net Transfer In (Out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember', window );">Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">4,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="num">(3,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="num">(1,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net Transfer In (Out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember', window );">Series B-3 Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">15,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="num">(311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="num">(15,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net Transfer In (Out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="nump">25,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Final net exercise</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">$ 14,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660301856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in Other assets)</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 21,633<span></span>
</td>
<td class="nump">$ 9,664<span></span>
</td>
<td class="nump">$ 12,338<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
<td class="nump">$ 4,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671916992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for excess or obsolete inventory</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667430208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 3,404<span></span>
</td>
<td class="nump">$ 2,905<span></span>
</td>
<td class="nump">$ 2,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
<td class="nump">$ 4,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671310784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Earnout Liability - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 28,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Estimated dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember', window );">Contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares', window );">Shares unvested (in shares) | shares</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Unvested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=tlsi_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667300240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>Y </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>Y </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input | $</a></td>
<td class="nump">5.12<span></span>
</td>
<td class="nump">11.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected share price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input | Y</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Estimated dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672016736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Schedule of Warrants Outstanding (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">8,333,272<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">5,933,333<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember', window );">Series B-3 Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,819,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660086432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable', window );">Class of warrant or right, threshold number of days for warrants to be transferable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount', window );">Warrant repurchase program, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRedemptionPrice', window );">Class of warrant or right, redemption price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold', window );">Warrant redemption condition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays', window );">Class of warrant or right, conversion terms, threshold trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays', window );">Class of warrant or right, conversion terms, threshold consecutive trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionDaysNotice', window );">Threshold number of business days before sending notice of redemption to warrant holders | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember', window );">Public Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased', window );">Warrants repurchased (in shares) | shares</a></td>
<td class="nump">28,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants | $</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember', window );">Series B-3 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightConversionDaysNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Conversion Days Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightConversionDaysNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Conversion Stock Price Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Conversion Terms, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Conversion Terms, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Days From Which Warrant Or Rights Become Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Repurchase Program, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Number of Days for Warrants to be Transferable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672539200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective federal tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656174688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,984,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,984,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Undeclared dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockAutomaticConversionPeriod', window );">Automatic conversion, anniversary</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset', window );">Conversion price, first automatic reset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset', window );">Conversion price, second automatic reset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">47 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPriceFloor', window );">Series A Convertible Preferred Stock, floor conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice', window );">Number of trading days, VWAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock | $</a></td>
<td class="nump">$ 40,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPercentageOfOutstandingShares', window );">Percentage of then-outstanding preferred stock on an as-converted to common stock basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock', window );">Transfer of warrant liability to preferred stock upon exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ReverseRecapitalizationStockValueIfConvertedAmount', window );">Enterprise value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,171<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,771,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock', window );">Transfer of warrant liability to preferred stock upon exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheAxis=tlsi_TrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockPercentageOfSharesCommitted', window );">Percentage of shares committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.7<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Fair value of warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights', window );">Strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock | $</a></td>
<td class="nump">$ 40,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockIssuedPricePerShare', window );">Original issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,967<span></span>
</td>
<td class="nump">17,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PreferredStockConversionPercentageOfOutstandingShares', window );">Percentage of then-outstanding preferred stock on an as-converted to common stock basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,779<span></span>
</td>
<td class="nump">207,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,650<span></span>
</td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount', window );">Consideration received, potential increased amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount', window );">Number of shares issued in transaction, potential increased amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Private Placement | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Private Placement | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds on sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Private Placement | Maximum | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount', window );">Consideration received, potential increased amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Private Placement | Maximum | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount', window );">Consideration received, potential increased amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount', window );">Number of shares issued in transaction, potential increased amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,868<span></span>
</td>
<td class="nump">70,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Series B-2, B-3 preferred stock fair value per share | Valuation, Reverse Recapitalization Approach, Enterprise Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input | $ / shares</a></td>
<td class="nump">9.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,771,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,116<span></span>
</td>
<td class="nump">830,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights', window );">Strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights', window );">Strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Private Placement | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Private Placement | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,448,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B | Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Strike Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Transfer of Warrant to Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockAutomaticConversionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Automatic Conversion, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockAutomaticConversionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockConversionPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion, Percentage of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockConversionPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion Price, Automatic Reset Duration, First Reset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion Price, Automatic Reset Duration, Second Reset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockConversionPriceFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Conversion Price, Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockConversionPriceFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Issued Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Number of Trading Days, Volume Weighted Average Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PreferredStockPercentageOfSharesCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Percentage of Shares Committed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PreferredStockPercentageOfSharesCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ReverseRecapitalizationStockValueIfConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ReverseRecapitalizationStockValueIfConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Potential Increased Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Issued in Transaction, Potential Increased Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TrancheAxis=tlsi_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TrancheAxis=tlsi_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TrancheAxis=tlsi_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TrancheAxis=tlsi_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660187152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock - Summary of Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,910,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">$ 203,974<span></span>
</td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 55,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">$ 6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">$ 8,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">$ 10,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,545,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,545,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
<td class="nump">$ 15,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,021,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,021,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">84,637<span></span>
</td>
<td class="nump">$ 84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">23,500<span></span>
</td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,474,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,474,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">$ 39,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656095312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock - Convertible Preferred Stock Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 55,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="nump">39,968<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">104,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(203,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,006<span></span>
</td>
<td class="nump">164,006<span></span>
</td>
<td class="nump">160,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(6,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(8,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(10,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(1,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(12,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(15,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(84,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">23,499<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">(23,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="nump">39,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Retirements / Conversions</a></td>
<td class="num">$ (39,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660414224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">14,266,605<span></span>
</td>
<td class="nump">2,871,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,974<span></span>
</td>
<td class="nump">2,824,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671248688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,871,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities', window );">Retirements/Conversion (in shares)</a></td>
<td class="num">(4,213)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities', window );">Retirements/Conversion (in shares)</a></td>
<td class="num">(5,190)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">36,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightWarrantsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(11,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities', window );">Retirements/Conversion (in shares)</a></td>
<td class="num">(25,584)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,824,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightWarrantsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(4,771,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues', window );">Issuances (in shares)</a></td>
<td class="nump">2,595,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities', window );">Retirements/Conversion (in shares)</a></td>
<td class="num">(649,109)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Warrants Issued During Period, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656688576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock - Fair Value Measurements (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>Y</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Series B-3 Warrants exercise price per share | Series B-3 Warrant liabilities | Black-Scholes Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected share price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input | Y</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Expected share price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Expected share price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Series B-3 preferred stock fair value per share | Guideline Public Company Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 | Series B-2 preferred stock exercise price per share | Guideline Public Company Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 | Series B-3 preferred stock fair value per share | Guideline Public Company Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember', window );">Series B-2 Tranche Liability | Minimum | Expected term (years) | Binomial Tranche Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember', window );">Series B-2 Tranche Liability | Minimum | Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember', window );">Series B-2 Tranche Liability | Maximum | Expected term (years) | Binomial Tranche Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember', window );">Series B-2 Tranche Liability | Maximum | Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=tlsi_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=tlsi_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=tlsi_GuidelinePublicCompanyModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=tlsi_GuidelinePublicCompanyModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputExerciseSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputExerciseSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2TrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=tlsi_BinomialTrancheModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=tlsi_BinomialTrancheModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671289840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">21,097,831<span></span>
</td>
<td class="nump">13,381,126<span></span>
</td>
<td class="nump">16,879,990<span></span>
</td>
<td class="nump">12,731,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="nump">11,624,155<span></span>
</td>
<td class="nump">12,330,395<span></span>
</td>
<td class="nump">11,376,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantMember', window );">Preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">14,266,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">184,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,632,206<span></span>
</td>
<td class="nump">1,710,860<span></span>
</td>
<td class="nump">1,671,076<span></span>
</td>
<td class="nump">1,307,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666402160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount', window );">Deemed dividend to preferred stockholders</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,981<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare', window );">Increase in net loss per common share, deemed dividend (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Preferred Stock, Convertible, Down Round Feature, Per Basic Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664926736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares)</a></td>
<td class="nump">7,500,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears', window );">Share reserve increase, number of years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,179,480<span></span>
</td>
<td class="nump">550,049<span></span>
</td>
<td class="nump">700,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, weighted average fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_A2009PlanMember', window );">2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares)</a></td>
<td class="nump">1,915,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, options | $</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, RSUs | $</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_A2023PlanMember', window );">2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares)</a></td>
<td class="nump">5,585,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,585,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock', window );">Percentage of fully diluted common stock determined in preceding year</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, options | $</a></td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">184,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU weighted average fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent', window );">Stock options exercise price, percentage of fair value</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Number of Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Percentage of Total Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Granted, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tlsi_A2009PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tlsi_A2009PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tlsi_A2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tlsi_A2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672153152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 08, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementNumberOfPlans', window );">Number of plans | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,732<span></span>
</td>
<td class="nump">2,816,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for Issue (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,684,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_A2009PlanMember', window );">2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,915,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,915,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_A2023PlanMember', window );">2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">5,585,008<span></span>
</td>
<td class="nump">5,585,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for Issue (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,684,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedCompensationArrangementNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedCompensationArrangementNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tlsi_A2009PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tlsi_A2009PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tlsi_A2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tlsi_A2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656695712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dynavax Purchase (Details) - Dynavax Technologies<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsForAssetAcquisition', window );">Payment for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionNumberOfCommercialMilestones', window );">Number of commercial milestones | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMaximumMilestoneAmount', window );">Maximum aggregate milestone payments per development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount', window );">Royalties as a percentage of net sales, under sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount', window );">Royalties, sales threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount', window );">Royalties as a percentage of sales, over threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember', window );">Commercial Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMaximumMilestoneAmount', window );">Maximum aggregate milestone payments per development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember', window );">Commercial Milestone, First Commercial Sale of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMilestoneAmount', window );">Milestone amount</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember', window );">Commercial Milestone, $250,000 Annual Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMilestoneAmount', window );">Milestone amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionSalesMilestone', window );">Sales milestone</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember', window );">Commercial Milestone, $500,000 Annual Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMilestoneAmount', window );">Milestone amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionSalesMilestone', window );">Sales milestone</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember', window );">Commercial Milestone, $1,000,000 Annual Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionMilestoneAmount', window );">Milestone amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AssetAcquisitionSalesMilestone', window );">Sales milestone</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsForAssetAcquisitionMilestoneAmount', window );">Payments for milestone</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentsForAssetAcquisitionMilestoneAmount', window );">Payments for milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionMaximumMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionMaximumMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Milestone, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionNumberOfCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Number of Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionNumberOfCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Royalties, Sales Threshold Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Royalty Percentage, Over Threshold Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Royalty Percentage, Under Threshold Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AssetAcquisitionSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AssetAcquisitionSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentsForAssetAcquisitionMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisition, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentsForAssetAcquisitionMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=tlsi_DynavaxTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone250000AnnualSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone250000AnnualSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone500000AnnualSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone500000AnnualSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone1000000AnnualSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestoneTypeAxis=tlsi_CommercialMilestone1000000AnnualSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660904592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,414<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">2,181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,214<span></span>
</td>
<td class="nump">35,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,995<span></span>
</td>
<td class="nump">37,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">4,947<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">6,377<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SeriesBTwoTrancheLiabilityCurrent', window );">Series B-2 tranche liabilities</a></td>
<td class="nump">4,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_SeriesBThreeTrancheLiabilityCurrent', window );">Series B-3 warrant liabilities</a></td>
<td class="nump">15,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to stockholders</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,357<span></span>
</td>
<td class="nump">6,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent', window );">Warrant liabilities and other long-term liabilities</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,319<span></span>
</td>
<td class="nump">6,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">164,006<span></span>
</td>
<td class="nump">160,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">10,028<span></span>
</td>
<td class="nump">6,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(186,358)<span></span>
</td>
<td class="num">(136,342)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(176,330)<span></span>
</td>
<td class="num">(129,604)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 21,995<span></span>
</td>
<td class="nump">$ 37,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SeriesBThreeTrancheLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of series B-3  warrant liability, due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SeriesBThreeTrancheLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_SeriesBTwoTrancheLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of series B-2  tranche liability, due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_SeriesBTwoTrancheLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values of warrant liability, and other liabilities, classified as noncurrent, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661649296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,898,162<span></span>
</td>
<td class="nump">15,696,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,316,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671166944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,398<span></span>
</td>
<td class="nump">$ 8,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">10,140<span></span>
</td>
<td class="nump">7,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,358<span></span>
</td>
<td class="nump">14,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">12,738<span></span>
</td>
<td class="nump">8,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,483<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,439)<span></span>
</td>
<td class="num">(24,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnConversionOfConvertibleNotes', window );">Loss on conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance</a></td>
<td class="num">(8,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities', window );">Change in fair value of tranche and warrant liabilities</a></td>
<td class="num">(2,186)<span></span>
</td>
<td class="num">(379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="num">(420)<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(47,178)<span></span>
</td>
<td class="num">(28,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">(47,187)<span></span>
</td>
<td class="num">(28,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision', window );">Deemed dividend related to Series B-2 preferred stock down round provision</a></td>
<td class="num">(2,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (50,016)<span></span>
</td>
<td class="num">$ (28,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (161.55)<span></span>
</td>
<td class="num">$ (131.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">309,609<span></span>
</td>
<td class="nump">219,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividend related to Series B-2 preferred stock down round provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of tranche and warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656035568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)<br></strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,364,000<span></span>
</td>
<td class="num">$ (107,497,000)<span></span>
</td>
<td class="num">$ (106,133,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">193,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">71,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount', window );">Modification of convertible debt to remove conversion discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,845,000)<span></span>
</td>
<td class="num">(28,845,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">33,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,873,000)<span></span>
</td>
<td class="num">(7,873,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,861,000<span></span>
</td>
<td class="num">(144,215,000)<span></span>
</td>
<td class="num">(137,354,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,645,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,062,000<span></span>
</td>
<td class="num">(160,987,000)<span></span>
</td>
<td class="num">(153,925,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,738,000<span></span>
</td>
<td class="num">(136,342,000)<span></span>
</td>
<td class="num">$ (129,604,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">264,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">82,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount', window );">Modification of convertible debt to remove conversion discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829,000<span></span>
</td>
<td class="num">(2,829,000)<span></span>
</td>
<td class="nump">2,829,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,187,000)<span></span>
</td>
<td class="num">(47,187,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">$ (176,330,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,861,000<span></span>
</td>
<td class="num">(144,215,000)<span></span>
</td>
<td class="num">$ (137,354,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">9,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,679,000)<span></span>
</td>
<td class="num">(8,679,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,936,000<span></span>
</td>
<td class="num">(152,894,000)<span></span>
</td>
<td class="num">(145,958,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">12,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,093,000)<span></span>
</td>
<td class="num">(8,093,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,062,000<span></span>
</td>
<td class="num">(160,987,000)<span></span>
</td>
<td class="num">(153,925,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">(176,330,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">95,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,268,000)<span></span>
</td>
<td class="num">(8,268,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,110,000<span></span>
</td>
<td class="num">(195,585,000)<span></span>
</td>
<td class="num">(184,475,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,028,000<span></span>
</td>
<td class="num">(186,358,000)<span></span>
</td>
<td class="num">$ (176,330,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">347,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,529,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2023</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">221,351,000<span></span>
</td>
<td class="num">(212,867,000)<span></span>
</td>
<td class="nump">$ 8,487,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,110,000<span></span>
</td>
<td class="num">(195,585,000)<span></span>
</td>
<td class="num">$ (184,475,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,974,000)<span></span>
</td>
<td class="num">(13,974,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,217,000<span></span>
</td>
<td class="num">(211,581,000)<span></span>
</td>
<td class="num">(198,364,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">50,646<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,286,000)<span></span>
</td>
<td class="num">(1,286,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2023</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 221,351,000<span></span>
</td>
<td class="num">$ (212,867,000)<span></span>
</td>
<td class="nump">$ 8,487,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,316,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid-in capital from modification of convertible debt to remove conversion discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividend related to Series B-2 preferred stock down round provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683669515488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,187)<span></span>
</td>
<td class="num">$ (28,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainOnPppLoanForgiveness', window );">Gain on PPP loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnConversionOfConvertibleNotes', window );">Loss on conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities', window );">Change in fair value of tranche and warrant liabilities</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Discount amortization and amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on disposal of fixed assets</a></td>
<td class="nump">310<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MilestonePaymentToDynavaxOperatingActivity', window );">Milestone payment to Dynavax</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(1,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,313)<span></span>
</td>
<td class="num">(22,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(655)<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MilestonePaymentToDynavaxInvestingActivity', window );">Milestone payment to Dynavax</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for intellectual property and licenses</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,786)<span></span>
</td>
<td class="num">(2,258)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="nump">13,499<span></span>
</td>
<td class="nump">51,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liabilities</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayments on term loan (including $254 balloon payment)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock', window );">Cash proceeds from the exercise of stock options and warrants for common stock</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13,462<span></span>
</td>
<td class="nump">50,768<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(20,637)<span></span>
</td>
<td class="nump">25,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">30,301<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">9,664<span></span>
</td>
<td class="nump">30,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CashPaidDuringYearForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ValueOfWarrantsIssuedWithConvertibleNotes', window );">Value of warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants', window );">Transfer of warrant liability to preferred stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses', window );">Fixed asset purchases included in trade payables and accrued expenses</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital', window );">Put option liability transferred to Additional paid-In capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock', window );">Carrying value of convertible notes and accumulated interest transferred to preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value of convertible notes and accumulated interest transferred to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of tranche and warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of fixed asset purchases included in trade payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainOnPppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gains on forgiveness of PPP loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainOnPppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MilestonePaymentToDynavaxInvestingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the milestone payment to Dynavax, classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MilestonePaymentToDynavaxInvestingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MilestonePaymentToDynavaxOperatingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment to Dynavax, classified under operating activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MilestonePaymentToDynavaxOperatingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options and warrants for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of put option liability transferred to additional paid-In capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of warrant liability transferred to preferred stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ValueOfWarrantsIssuedWithConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of warrants issued with convertible notes in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ValueOfWarrantsIssuedWithConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661574976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757921248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Nature of Business</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August&#160;10, 2023 (the "Closing Date"), TriSalus Life Sciences,&#160;Inc., a Delaware corporation (the &#8220;Company,&#8221; &#8220;TriSalus,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), formerly known as MedTech Acquisition Corporation (&#8220;MTAC&#8221;), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023 (as amended, the &#8220;Merger Agreement&#8221;), by and between MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (&#8220;Merger Sub&#8221;) and TriSalus Operating Life Sciences,&#160;Inc. (formerly known as TriSalus Life Sciences,&#160;Inc.), a Delaware corporation (&#8220;Legacy TriSalus&#8221;), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and TriSalus Life Sciences,&#160;Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as &#8220;the Closing.&#8221; In connection with the consummation of the Merger, on August&#160;10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc., the surviving company ("New TriSalus&#8221;). As further described in Note&#160;3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of the Business</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing </span><span style="font-family:'Times New Roman','Times','serif';">two</span><span style="font-family:'Times New Roman','Times','serif';"> product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June&#160;1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC&#8221;) code with CMS and met with CMS on June&#160;26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January&#160;1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September&#160;30, 2023, we have issued for cash </span><span style="font-family:'Times New Roman','Times','serif';">$164,364</span><span style="font-family:'Times New Roman','Times','serif';"> of preferred stock (of which </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> was raised at the closing of the Business Combination, including issuance of Series&#160;A convertible preferred stock), which, along with </span><span style="font-family:'Times New Roman','Times','serif';">$551</span><span style="font-family:'Times New Roman','Times','serif';"> from common stock and </span><span style="font-family:'Times New Roman','Times','serif';">$44,692</span><span style="font-family:'Times New Roman','Times','serif';"> from convertible notes and warrants, has funded our accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';">. During the nine&#160;months ended September&#160;30, 2023, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$9,189</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$9,630</span><span style="font-family:'Times New Roman','Times','serif';"> in cash through the issuance of Series&#160;B-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$94</span><span style="font-family:'Times New Roman','Times','serif';"> from the exercise of stock options, and </span><span style="font-family:'Times New Roman','Times','serif';">$36,854</span><span style="font-family:'Times New Roman','Times','serif';"> from the Business Combination.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of September&#160;30, 2023, we had cash and cash equivalents of </span><span style="font-family:'Times New Roman','Times','serif';">$21,383</span><span style="font-family:'Times New Roman','Times','serif';">. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of </span><span style="font-family:'Times New Roman','Times','serif';">$212,867</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12&#160;months.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In accordance with ASC Topic 205-40,&#160;</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i><span style="font-family:'Times New Roman','Times','serif';">, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management&#8217;s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management&#8217;s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Subsequent Event</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">On October&#160;2, 2023, we entered into a Standby Equity Purchase Agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN,&#160;Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to </span><span style="font-family:'Times New Roman','Times','serif';">$30,000</span><span style="font-family:'Times New Roman','Times','serif';"> of common stock, par value </span><span style="font-family:'Times New Roman','Times','serif';">$0.0001</span><span style="font-family:'Times New Roman','Times','serif';"> per share of the Company (the &#8220;Common Stock&#8221;), at the Company&#8217;s request any time during the commitment period commencing on October&#160;2, 2023 (the &#8220;Effective Date&#8221;), and terminating on the first day of the&#160;month following the </span><span style="font-family:'Times New Roman','Times','serif';">24</span><span style="font-family:'Times New Roman','Times','serif';">-</span><span style="font-family:'Times New Roman','Times','serif';">month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an &#8220;Advance&#8221;) is subject to a maximum limit equal to the greater of: (i)&#160;an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';">100%</span><span style="font-family:'Times New Roman','Times','serif';"> of the average of the daily volume traded of the Company&#8217;s Common Stock on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) for the </span><span style="font-family:'Times New Roman','Times','serif';">10</span><span style="font-family:'Times New Roman','Times','serif';"> trading&#160;days immediately preceding an Advance notice, or (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">1,000,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">96%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on 4:00&#160;p.m. New York City time on the applicable Advance notice date (the &#8220;Option 1 Pricing Period&#8221;), and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">97%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Market Price for any </span><span style="-sec-ix-hidden:Hidden_3ei8mRKxXUqQjdtfqOZDNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-family:'Times New Roman','Times','serif';"> consecutive trading&#160;days commencing on the Advance notice date (the &#8220;Option 2 Pricing Period,&#8221; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#8220;Pricing Period&#8221;). &#8220;Market Price&#8221; is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (&#8220;VWAP&#8221;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than </span><span style="font-family:'Times New Roman','Times','serif';">4.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than </span><span style="font-family:'Times New Roman','Times','serif';">19.99%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriSalus Life Sciences,&#160;Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;), a Delaware corporation, was incorporated in 2009 as Surefire Medical,&#160;Inc. The Company began doing business as TriSalus Life Sciences (&#8220;TriSalus&#8221;) in 2018, and changed its name to TriSalus Life Sciences, Inc, in August&#160;2021. We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines&#8201;&#8212;&#8201;Pressure Enabled Drug Delivery (&#8220;PEDD&#8482;&#8221;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve&#8482; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TriNav&#8482; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav infusion System, introduced in 2020, the Surefire Medical infusion System and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#8220;TPT&#8221;) approval from the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023; we are actively seeking an extension of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded operations to date principally with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009 through December&#160;31, 2022, we have issued for cash <span style="-sec-ix-hidden:Hidden_ZCuk_ZdpA0SUrfc6xIvFJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$108,664</span></span> of preferred stock, $458 of common stock and $57,466 of convertible notes and warrants, which has funded the cumulative net losses of $186,358. During the&#160;year ended December&#160;31, 2022, we raised $13,499 in cash through the issuance of Series&#160;B-1 and Series&#160;B-2 preferred stock and $94 from the exercise of stock options. In March&#160;2021, all of the then outstanding principle amount of convertible notes, with accumulated interest, converted to shares of Series&#160;B preferred stock in accordance with the terms contained in the note agreements; the note conversion did not raise any cash. See notes 10 and 11 for further discussion of the convertible debt, warrants and the 2022 financing rounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had cash, cash equivalents and restricted cash of $9,664. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $186,358 as of December&#160;31, 2022. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#8201;&#8212;&#8201;including the development of a candidate pharmaceutical&#8201;&#8212;&#8201;that, in the short term, will not be fully offset by increased revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC Topic 205-40,&#160;<i style="font-style:italic;">Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757901744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$8,617</span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(b)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accounts Receivable</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(c)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Inventory</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#8212; including direct labor and manufacturing overhead&#160;&#8212; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(d)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Property and Equipment</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(e)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Impairment and Disposal of Long-Lived Assets</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows</span><span style="font-family:'Times New Roman','Times','serif';"> expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(f)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i><span style="font-family:'Times New Roman','Times','serif';">. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#8220;ROU&#8221;) representing the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(g)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Warrant and Tranche Liabilities</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Times New Roman','Times','serif';">, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">99.2</span><span style="font-family:'Times New Roman','Times','serif';">% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(h)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Contingent Earnout Liability</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#8220;Sponsor Support Agreement&#8221;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#8221;), Legacy TriSalus and MTAC&#8217;s directors and officers (the Sponsor and MTAC&#8217;s directors and officers, collectively, the &#8220;Sponsor Holders&#8221;). Pursuant to the Sponsor Support Agreement, </span><span style="font-family:'Times New Roman','Times','serif';">3,125,000</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#8220;Sponsor Earnout Shares&#8221;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the </span><span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span><span style="font-family:'Times New Roman','Times','serif';">th anniversary of the Closing Date (the &#8220;Earnout Period&#8221;). The Sponsor Earnout Shares are classified as a liability in the Company&#8217;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(j)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Concentrations of Credit Risk and Other Risks and Uncertainties</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(k)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Share-Based Compensation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(l)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have determined, in accordance with ASC Topic 280, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i><span style="font-family:'Times New Roman','Times','serif';">, that we operate under </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> operating segment, and therefore </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(m)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i><span style="font-family:'Times New Roman','Times','serif';">, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#160;&#8212; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#160;&#8212; We recognize revenue at the point</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(2)</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(c)</span></span><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Accounts Receivable and Customer Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, one distributor customer constituted 19% of our accounts receivable balance. As of December&#160;31, 2021, one distributor customer constituted 34% of our accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had one distributor customer which constituted 20% and 25% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(e)</span></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,&#160;<i style="font-style:italic;">Leases</i>. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(f)</span></span><span style="font-style:italic;font-weight:bold;">Inventory</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#8201;&#8212;&#8201;including direct labor and manufacturing overhead&#8201;&#8212;&#8201;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(h)</span></span><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(i)</span></span><span style="font-style:italic;font-weight:bold;">Impairment and Disposal of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(j)</span></span><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(k)</span></span><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined, in accordance with ASC Topic 280,&#160;<i style="font-style:italic;">Segment Reporting</i>, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(l)</span></span><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;<i style="font-style:italic;">Revenue Recognition</i>, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price&#8201;&#8212;&#8201;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#8201;&#8212;&#8201;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#8201;&#8212;&#8201;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(m)</span></span><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;D costs are expensed as incurred and included milestone payments of $1,000 to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(n)</span></span><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $2,201 and $1,400, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(o)</span></span><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes pursuant to ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#8217;s income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(p)</span></span><span style="font-style:italic;font-weight:bold;">Warrant and Tranche Rights and Obligation Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666079088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(3)</b></span><b style="font-weight:bold;">Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial instruments consist of cash, accounts receivable, trade accounts payable, tranche and warrant liabilities to purchase preferred stock, long-term debt and convertible notes. The carrying values of these financial instruments (other than tranche liabilities and warrant liabilities, which are held at fair value) approximate fair value for the&#160;years ended December&#160;31, 2022 and 2021. In general, asset and liability fair values are determined using the following categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;1&#8201;&#8212;&#8201;Inputs utilize quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;2&#8201;&#8212;&#8201;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Level&#160;3&#8201;&#8212;&#8201;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#8217;s own assumptions about the assumptions that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our financial instruments, including tranche liabilities and warrant liabilities, are measured at fair value on a recurring basis, including immediately prior to exercise. The carrying amount of outstanding warrant liabilities was $16,188 and $391 at </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">December&#160;31, 2022 and 2021, respectively, and the carrying amount of outstanding tranche liabilities was $4,702 and $0 at December&#160;31, 2022 and 2021, respectively. These carrying values approximate fair value based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the fair value of the underlying preferred stock, volatility, discount rate, and expected term. The put option liability was retired in March&#160;2021 in conjunction with the conversion of all convertible notes to Series&#160;B preferred stock; see note 11 for further discussion. There were no transfers between levels for the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock (see Note&#160;12). This also included rights and obligations exercisable for additional Series&#160;B-2 preferred stock and Series&#160;B-3 warrants through a second and third tranche. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of $11,966 (remeasured to $15,819 at December&#160;31, 2022), the tranche rights and obligations associated with the second tranche had a fair value of $3,109 (remeasured to $2,250 at December&#160;31, 2022), and the tranche rights and obligations associated with the third tranche had a fair value of $3,238 (remeasured to $2,452 at December&#160;31, 2022), all of which have been classified as liabilities. The fair value is determined based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to both a status quo scenario and the potential closing of the Business Combination (see Note&#160;16), the value of the Series&#160;B-3 warrants upon closing of the Business Combination, the fair value of the Company and resulting fair value of the underlying preferred stock, volatility, and expected term; see note 12 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities for the&#160;years ended December&#160;31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;(Out)&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains)&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Put option liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,702</p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>This amount includes settlements of $3,397, reduced by issuances of $10.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683774961664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,414</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,664</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Restricted cash is </span><span style="font-family:'Times New Roman','Times','serif';">$250</span><span style="font-family:'Times New Roman','Times','serif';"> held by our bank to support our corporate credit card program.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(4)</b></span><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash is $250 held by our bank to support our corporate credit card program.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757945072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(6)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The components of inventory are summarized as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 718</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Finished goods amounts include a reserve for excess or obsolete inventory of </span><span style="font-family:'Times New Roman','Times','serif';">nil</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$43</span><span style="font-family:'Times New Roman','Times','serif';"> as of September&#160;30, 2023, and December&#160;31, 2022.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(5)</b></span><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of inventory at December&#160;31 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,292</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The finished goods amounts in the table above include a reserve for excess inventory of $43 and $97 as of December&#160;31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665976656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Lived Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LongLivedAssetsAbstract', window );"><strong>Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LongLivedAssetsDisclosureTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(6)</b></span><b style="font-weight:bold;">Long-Lived Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December&#160;31 consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#8201;&#8211;&#8201;7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,031</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 783</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other property</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,946</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,149)</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,797</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for property and equipment for the&#160;years ended December&#160;31, 2022 and 2021, was $276 and $361, respectively. The Company did not recognize any impairment losses for the&#160;years ended December&#160;31, 2022 and 2021, other than a loss on disposal of $310 in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Intangible assets consist entirely of patent costs that provide the Company with rights, titles, and interests in the development of certain processes, discoveries, and inventions with the right to commercialize that are probable of future economic benefits. Patent costs associated with pharmaceutical intellectual property are expensed as incurred as future economic benefits are not deemed to be probable. Intangible assets are recorded at cost and are amortized over the estimated life of the patents, based on the approval and expiration dates applicable to each patent&#8201;&#8212;&#8201;typically 20&#160;years&#8201;&#8212;&#8201;on a straight-line basis. Amortization expense related to intellectual property for 2022 and 2021 was $122 and $103, respectively. We did not record any impairment losses in 2022 or 2021. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal&#160;years is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 477</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 802</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LongLivedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LongLivedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665910192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(7)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accrued Liabilities</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accrued Liabilities consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,896</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(7)</b></span><b style="font-weight:bold;">Accrued Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,910</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,969</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661518832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(10)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Income Taxes</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full calendar&#160;year and use that rate to provide for income taxes on a current&#160;year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the annual effective tax rate, including use of the actual effective rate for the&#160;year-to-date. The impact of the discrete items is recorded in the quarter in which they occur.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We utilize the balance sheet method of accounting for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings, forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Based on our full valuation allowance against the net deferred tax assets, our effective federal tax rate for the calendar&#160;year is </span><span style="font-family:'Times New Roman','Times','serif';">zero</span><span style="font-family:'Times New Roman','Times','serif';">, and we recorded an immaterial income tax expense in the nine&#160;months ended September&#160;30, 2023 and 2022.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(8)</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,002</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,306</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,708</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,630</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,630)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of our deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As we do not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, we do not believe it is more likely than not that we will realize the benefits of the net deferred tax assets and, accordingly, have established a valuation allowance equal to 100% of net deferred tax assets. The change in the valuation allowance for the&#160;years ended December&#160;31, 2022 and 2021 was $8,728 and $5,779, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had net operating losses (&#8220;NOLs&#8221;) as follows (the NOLs which do not expire are subject to an annual utilization limitation of 80% of taxable income):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Federal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">State</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs expiring between 2029 and 2037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,380</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs which do not expire</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,398</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total NOLs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,778</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Internal Revenue Code contains provisions that may further limit the net operating loss carryovers available to be used in any one&#160;year if certain events occur, including significant changes in ownership interests. Utilization of net operating loss and tax credit carryforwards are subject to a substantial annual limitation due to the ownership change limitations set forth in Section&#160;382 of the Code and similar state provisions. We prepared an Internal Revenue Code 382 analysis to determine the annual limitations on our consolidated net operating loss carryforwards. All of our tax attributes are subject to an annual limitation. Such annual limitations could result in the expiration of the net operating loss and tax credit carryforwards before utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, we did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12&#160;months. Our accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our federal and state returns for all&#160;years remain open to examination by tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757924368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dynavax Purchase<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DynavaxPurchaseAbstract', window );"><strong>Dynavax Purchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Dynavax Purchase</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(9)</b></span><b style="font-weight:bold;">Dynavax Purchase</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#8220;Dynavax&#8221;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#8220;IPR&amp;D&#8221;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#8220;TLR9&#8221;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(&#8220;MDSCs&#8221;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of $9,000 that was split into two payments ($5,000 and $4,000, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The milestone payments range from $1,000 to $10,000, triggered by development achievements for each of up to four indications. The development milestone payments cannot exceed $170,000. We made a milestone payment of $1,000 in September&#160;2021 after initiating our clinical study of uveal melanoma liver metastases. We made an additional $1,000 milestone payment in June&#160;2022 after initiating our clinical study for primary liver tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we will have to pay up to four commercial milestones, $10,000 upon first commercial sale of the product; $20,000 upon the first occurrence of $250,000 in annual net sales; $20,000 upon the first occurrence of $500,000 in annual net sales; and $30,000 upon the first occurrence of $1,000,000 in annual net sales. In aggregate, the commercial milestones shall not exceed $80,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will also pay annual royalties at the rate of 10% for aggregate annual net sales less than or equal to $1,000,000 and 12% for aggregate annual net sales above that amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recorded the first and second development milestone payments of $1,000 in R&amp;D in 2022 and 2021. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DynavaxPurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DynavaxPurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683775199040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(10)</b></span><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, we applied for, and received, a loan of $828 under the Small Business Administration (&#8220;SBA&#8221;) Paycheck Protection Program (&#8220;PPP&#8221;) program. Under the terms of the program, the loan was used to fund retention of employees and facility expenses. The program provides for forgiveness of the loan after a period of time if the loan was used for approved expenditures. On April&#160;19, 2021, we received notice that the SBA had forgiven the loan. We recorded the forgiveness as a $828 gain included in other income and expense, net, in 2021 in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Term Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The term loan and supplemental term loan matured on November&#160;30, 2021, and were paid in full, with a final payment of $1,348.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the term loan, we issued the following warrants. All the warrants expire 10&#160;years after the issuance date. The warrant liabilities are carried at fair value; the initial fair values listed below were recorded as debt discount at the time of issuance and amortized as additional interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial&#160;Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">08&#8209;26&#8209;2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">10&#8209;27&#8209;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">06&#8209;30&#8209;2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">11&#8209;20&#8209;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666036368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConvertibleDebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(11)</b></span><b style="font-weight:bold;">Convertible Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;and September&#160;2018, we issued convertible notes for aggregate cash proceeds of $5,000, which had an original maturity date of December&#160;31, 2019. The maturity date for the convertible notes was revised in 2019 to be December&#160;31, 2020, and in 2020 to be December&#160;31, 2021. The extension of maturity dates in each case were determined to be modifications to the debt instruments. Between May&#160;and September&#160;2019, we issued additional convertible notes for aggregate cash proceeds of $15,000, with a maturity date of December&#160;31, 2020, which was also modified to December&#160;31, 2021. Between March&#160;and October&#160;2020, we issued convertible notes for aggregate cash proceeds of $9,102, with a maturity date of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The convertible notes accrued interest at 8% and could only be prepaid upon the favorable vote of the majority holders. When and if we complete a &#8220;qualified financing&#8221; on or prior to the maturity date, the unpaid principal and accrued interest on the convertible notes are automatically convertible into the same class of preferred stock offered in the qualified financing at the lesser of $0.50 per share or 85% of the price per share paid by cash purchasers for the preferred stock issued in the qualified financing. (This discount on the price per share paid by cash purchasers was subsequently modified in 2021, see below.) A &#8220;qualified financing&#8221; is a preferred stock financing transaction for the purpose of raising capital with gross proceeds of at least $5,000, excluding all proceeds from convertible notes that convert into preferred stock in connection with the financing. This conversion upon a qualified financing feature essentially provides the holder with a fixed return that is settled in a variable number of shares. As such, it qualified to be accounted for as an embedded derivative, a put option liability, at fair value. The put option liability was initially recorded as a debt discount and subsequently remeasured at its fair value each period end. We estimated the fair value of the put option liability based upon the 90% probability of a qualified financing occurring multiplied by the value to be received by the holder (Level&#160;3 inputs). (We estimated a 10% probability that the convertible notes would convert at maturity.) The put option liabilities associated with the 2018, 2019 and 2020 convertible notes were initially measured at $794, $2,382 and $1,446, respectively. The fair value of the put liabilities did not change at December&#160;31, 2019, 2020 or 2021, as management&#8217;s estimate of the probability of a qualified financing did not change. Through December&#160;31, 2021, additional put option liability was recorded for the conversion feature applied to the accumulating accrued interest balance of $303, which was recorded as additional put option liability and debt discount. The discounts on the debt as a result of recording the initial put liabilities was amortized to interest expense over the term of the loans using the effective interest method.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Between March&#160;2020 and December&#160;2020, we also issued convertible notes for aggregate cash proceeds of </span><span style="font-family:'Times New Roman','Times','serif';">$15,545</span><span style="font-family:'Times New Roman','Times','serif';">. An additional convertible note for </span><span style="font-family:'Times New Roman','Times','serif';">$45</span><span style="font-family:'Times New Roman','Times','serif';"> was issued in January&#160;2021. These notes differed from the other notes issued during 2018 through 2020 in that they did not contain the conversion discount of </span><span style="font-family:'Times New Roman','Times','serif';">15%</span><span style="font-family:'Times New Roman','Times','serif';">. Instead, they were accompanied by warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">385,361</span><span style="font-family:'Times New Roman','Times','serif';"> Series&#160;A-6 preferred shares at </span><span style="font-family:'Times New Roman','Times','serif';">$0.01</span><span style="font-family:'Times New Roman','Times','serif';"> per share initially, which upon issuance of the Series&#160;B Preferred Stock in 2021, were automatically converted into warrants to purchase Series&#160;B Preferred Stock. The warrants expire on the fifth anniversary of the issue date. All other terms of the notes were the same. Since the warrants are for preferred stock that were initially redeemable, they were recorded as a liability in the accompanying balance sheet at December&#160;31, 2020. The initial value of the warrant liability of </span><span style="font-family:'Times New Roman','Times','serif';">$3,887</span><span style="font-family:'Times New Roman','Times','serif';"> (</span><span style="font-family:'Times New Roman','Times','serif';">$3,877</span><span style="font-family:'Times New Roman','Times','serif';"> for the warrants issued in 2020; </span><span style="font-family:'Times New Roman','Times','serif';">$10</span><span style="font-family:'Times New Roman','Times','serif';"> for the warrant issued in 2021) was determined using the Black-Scholes method and resulted in an additional debt discount that was being amortized to interest expense using the effective interest method.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The convertible notes also included a provision whereby upon a change in control prior to the conversion or repayment in full of the principal amount of the convertible notes, the Company would be obligated, at each holder&#8217;s option, to either (A)&#160;pay such holder in cash an amount equal to (is) the outstanding principal and interest accrued to that date, plus (ii)&#160;a premium equal to 100% of the unpaid principal and accrued interest, or (B)&#160;convert the outstanding principal and interest accrued to date into Series&#160;A-6 preferred stock at a conversion price of $0.50 per share. This change in control prepayment and conversion provision qualifies as an embedded derivative and has been included in the fair value of the embedded derivative noted above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, the convertible notes also included a provision whereby the unpaid principal and accrued interest would convert at maturity, at the option of the holders of at least 2/3 of the outstanding principal amount of the outstanding convertible notes, into shares of the Company&#8217;s Series&#160;A-6 preferred stock at a conversion price of $0.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest expense related to convertible notes was $1,773 for the&#160;year ended December&#160;31, 2021, which included the 8% stated interest and amortization of the debt discounts associated with the embedded put liabilities and attached warrants.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2021, the Company&#8217;s board and note holders (many of whom are also stockholders) agreed to eliminate the </span><span style="font-family:'Times New Roman','Times','serif';">15%</span><span style="font-family:'Times New Roman','Times','serif';"> discount in the next qualified round of financing attached to the 2018, 2019 and 2020 issuances of convertible notes. We determined the elimination of the </span><span style="font-family:'Times New Roman','Times','serif';">15%</span><span style="font-family:'Times New Roman','Times','serif';"> discount was a modification of the convertible notes with related parties and, as a result, we recorded the impact of removing the put option liability associated with the convertible notes of </span><span style="font-family:'Times New Roman','Times','serif';">$5,210</span><span style="font-family:'Times New Roman','Times','serif';"> to Additional Paid-in Capital in the </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">accompanying consolidated balance sheet for the&#160;year ended December&#160;31, 2021. Also in March&#160;2021, the issuance of Series&#160;B preferred stock was determined to be a qualified financing event. Accordingly, all of the convertible notes, with a notional amount of </span><span style="font-family:'Times New Roman','Times','serif';">$44,692</span><span style="font-family:'Times New Roman','Times','serif';">, were converted, with accumulated interest of </span><span style="font-family:'Times New Roman','Times','serif';">$4,426</span><span style="font-family:'Times New Roman','Times','serif';">, into </span><span style="font-family:'Times New Roman','Times','serif';">4,047,069</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at a conversion price of </span><span style="font-family:'Times New Roman','Times','serif';">$0.30</span><span style="font-family:'Times New Roman','Times','serif';"> per share. Upon the conversion of the convertible notes to Series&#160;B preferred stock, we also recognized the remaining unamortized debt discounts associated with the conversion features and warrants in the aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">$3,416</span><span style="font-family:'Times New Roman','Times','serif';"> as a loss on conversion of convertible notes in the accompanying consolidated statements of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConvertibleDebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConvertibleDebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757984176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConvertiblePreferredStockDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(12)</b></span><b style="font-weight:bold;">Convertible Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have issued various series of preferred stock as more fully described below. Prior to March&#160;2021, the preferred stock was redeemable at any time after February&#160;21, 2022, upon the affirmative vote of two thirds of the then outstanding shares of preferred stock. In March&#160;2021, the redemption feature was eliminated, however, the in-substance redemption feature described below is still in place. Upon an acquisition of the Company, the proceeds will be used to first pay the liquidation preferences on the preferred stock, as defined below, prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our board of directors and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#8201;&#8212;&#8201;and thereby redeem the convertible preferred stock&#8201;&#8212;&#8201;is deemed to be outside of our control. As a result, our convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments are currently not redeemable and we believe it is not probable that the instruments will become redeemable at this point in time. Adjustments to increase the carrying values of the respective liquidation preferences will be made if and when it becomes probable that an event would occur obligating us to pay such amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity in convertible preferred stock for the&#160;years ended December&#160;31, 2022 and 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January&#160;1,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December&#160;31, 2022, the Company was authorized to issue up to </span><span style="font-family:'Times New Roman','Times','serif';">21,910,800</span><span style="font-family:'Times New Roman','Times','serif';"> shares of preferred stock, with </span><span style="font-family:'Times New Roman','Times','serif';">4,213</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-5, </span><span style="font-family:'Times New Roman','Times','serif';">5,190</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-6, </span><span style="font-family:'Times New Roman','Times','serif';">36,707</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B, </span><span style="font-family:'Times New Roman','Times','serif';">1,059,365</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2, and </span><span style="font-family:'Times New Roman','Times','serif';">8,474,924</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 available for issuance. All other authorized shares have been issued. The original issue prices for the Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2 and B-3 preferred stock are </span><span style="font-family:'Times New Roman','Times','serif';">$49.520</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$15.660</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$17.40</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$16.030</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$17.81</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$20.23</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$12.14</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';">, respectively. All shares of preferred stock had the following rights as of December&#160;31, 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-style:italic;">Conversion</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Each share of preferred stock is convertible into common stock at any time at the option of the holder. The conversion rate is equal to the original issue price for each share of preferred stock plus any declared but unpaid dividends divided by the conversion price. The conversion ratio may be adjusted from time to time based upon the occurrence of certain events or circumstances, such as stock splits, dividends, recapitalizations, certain corporate transactions, and certain dilutive issuances, including the issuance of shares of Series&#160;B-2 preferred stock and the B-3 Warrants (as defined below). Each share of preferred stock will be automatically convertible into shares of the common stock at the then-prevailing conversion ratio (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended in which (a)&#160;the per share price of the common stock is not less than </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> (adjusted for any stock dividends, combinations, splits, or recapitalizations) and (b)&#160;the aggregate net cash proceeds are at least </span><span style="font-family:'Times New Roman','Times','serif';">$50,000</span><span style="font-family:'Times New Roman','Times','serif';">, (ii)&#160;the consummation of a transaction or series of related transactions by merger, consolidation, share exchange or otherwise with a publicly traded &#8220;special purpose acquisition corporation&#8221; or its subsidiary in which the common stock or share capital of such entity or its successor entity remains listed, in which the aggregate proceeds resulting from such transaction or series of related transactions, including any private placement or other financing transaction and proceeds received from the &#8220;special purpose acquisition corporation&#8221; trust account are equal to or in excess of </span><span style="font-family:'Times New Roman','Times','serif';">$30</span><span style="font-family:'Times New Roman','Times','serif';">&#160;million or (iii)&#160;upon the consent or vote of the holders of a majority of the outstanding shares of preferred stock (voting together as a single class on an as converted basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(ii)</i></span><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each holder of shares of preferred stock is entitled to the number of votes on an as-if converted basis to shares of common stock. Certain corporate actions require the approval of a majority of the holders of preferred stock, including but not limited to changes in the authorized shares of preferred stock, authorization of any new class or series of preferred stock, effecting a recapitalization, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">increasing the authorized size of the Board of Directors to a number greater than 11, the payment of certain dividends and capital distributions, the sale, liquidation or dissolution of the Company, and certain incurrence of debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iii)</i></span><i style="font-style:italic;">Anti-dilution Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The conversion price of each series of preferred stock is subject to in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(iv)</i></span><i style="font-style:italic;">Dividends</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Dividends are payable on (i)&#160;the Series&#160;B-2 and Series&#160;B-3 preferred stock in preference to all other series of preferred stock and the common stock and (ii)&#160;all such other series of preferred stock in preference to the common stock, in each case, when and if declared by the Board of Directors on a noncumulative, annual basis and are paid to the holders of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock, and all other series of preferred stock, on a pro&#160;rata, pari&#160;passu basis (based on the series or preferred stock participating) preferred stock in proportion of their individual dividend amounts to the total dividend amount of all preferred holders. The per annum preferred dividend rates for each share of Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2, and B-3 preferred stock are </span><span style="font-family:'Times New Roman','Times','serif';">$3.97000</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.26000</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.4000</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.29000</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.4300</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.62</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$0.980</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.140</span><span style="font-family:'Times New Roman','Times','serif';">, </span><span style="font-family:'Times New Roman','Times','serif';">$1.140</span><span style="font-family:'Times New Roman','Times','serif';">, and </span><span style="font-family:'Times New Roman','Times','serif';">$0.170</span><span style="font-family:'Times New Roman','Times','serif';">, respectively. To date, the Board of Directors has not declared any dividends on the preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(v)</i></span><i style="font-style:italic;">Liquidation Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of the preferred stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a Liquidation Event), none of which were deemed probable of occurring at December&#160;31, 2022. Preferences are payable in the following order of priority and in the following amounts as of December&#160;31, 2022 (plus all declared but unpaid dividends);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,659,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,500</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,984,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,774</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,196</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 730,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,047</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 612,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,661</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 576,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,020</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49.520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,526</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liquidation preference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,724</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment in full to all holders of a particular series of preferred stock, then such assets will be distributed ratably to the holders of such series of preferred stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned liquidation preferences, any remaining proceeds from a Liquidation Event will be distributed to all preferred and common stockholders&#8201;&#8212;&#8201;except for stockholders holding Series&#160;A-1 or Series&#160;A-2 Preferred Stock&#8201;&#8212;&#8201;pro&#160;rata on an as-if converted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">March&#160;2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2021, we executed a financing round in which we raised </span><span style="font-family:'Times New Roman','Times','serif';">$10,907</span><span style="font-family:'Times New Roman','Times','serif';"> net of issuance costs, through the sale of </span><span style="font-family:'Times New Roman','Times','serif';">906,346</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at an original issue price of </span><span style="font-family:'Times New Roman','Times','serif';">$12.14</span><span style="font-family:'Times New Roman','Times','serif';"> per share. At that time, in accordance with their terms, as amended, all convertible notes, with a value of </span><span style="font-family:'Times New Roman','Times','serif';">$49,118</span><span style="font-family:'Times New Roman','Times','serif';"> (including accumulated interest) were converted into </span><span style="font-family:'Times New Roman','Times','serif';">4,047,069</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Spring 2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May, June&#160;and July&#160;2021, we raised an additional </span><span style="font-family:'Times New Roman','Times','serif';">$20,989</span><span style="font-family:'Times New Roman','Times','serif';">, net of issuance costs, through the sale of an additional </span><span style="font-family:'Times New Roman','Times','serif';">1,742,003</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock at a price per share of </span><span style="font-family:'Times New Roman','Times','serif';">$12.14</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fall 2021 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In August&#160;and December&#160;2021, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$20,000</span><span style="font-family:'Times New Roman','Times','serif';">, net of issuance costs, through the sale of </span><span style="font-family:'Times New Roman','Times','serif';">1,412,487</span><span style="font-family:'Times New Roman','Times','serif';">&#160;shares of Series&#160;B-1 preferred stock at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Exercises</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In November&#160;2020, we raised </span><span style="font-family:'Times New Roman','Times','serif';">$19</span><span style="font-family:'Times New Roman','Times','serif';"> through the exercise of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">59,102</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;A-6 preferred stock. Between March&#160;and July&#160;2021, we raised an additional </span><span style="font-family:'Times New Roman','Times','serif';">$117</span><span style="font-family:'Times New Roman','Times','serif';"> through the exercise of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">289,552</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2022 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In May&#160;and June&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';">247,185</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-1 preferred stock in a private financing, to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$3,499</span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds. This financing was an extension of the Series&#160;B-1 financing round begun in the fall of 2021.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In early October&#160;2022, we sold </span><span style="font-family:'Times New Roman','Times','serif';">706,243</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> per share, raising approximately </span><span style="font-family:'Times New Roman','Times','serif';">$9,755</span><span style="font-family:'Times New Roman','Times','serif';"> in net proceeds. For each share sold, we also issued a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock (with total warrants issued being for </span><span style="font-family:'Times New Roman','Times','serif';">2,824,974</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock) with a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';">&#160;per share. The B-2 Preferred Stock Financing included, at our audit committee&#8217;s option, a second tranche for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';">518,854</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$7,347</span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to </span><span style="font-family:'Times New Roman','Times','serif';">$10,000</span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">four</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';">&#160;per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';">2,075,417</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to </span><span style="font-family:'Times New Roman','Times','serif';">306,053</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for </span><span style="font-family:'Times New Roman','Times','serif';">$4,334</span><span style="font-family:'Times New Roman','Times','serif';"> (which could be increased up to an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">353,121</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-2 preferred stock for approximately </span><span style="font-family:'Times New Roman','Times','serif';">$5,000</span><span style="font-family:'Times New Roman','Times','serif';"> through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';">eight</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock at a strike price of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> per share, for a total of </span><span style="font-family:'Times New Roman','Times','serif';">2,448,428</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock to immediately convert to common stock and the warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$42.89</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$13.36</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$14.97</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$13.76</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$14.97</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$17.00</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$10.52</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$12.14</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;set to </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';">1.155</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.173</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.162</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.165</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.189</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.190</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.154</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.167</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately 99.2% of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;16), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other non-service provider holders. As such, the Company concluded </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The warrants to purchase Series&#160;B-3 preferred stock (&#8220;Series&#160;B-3 Warrants&#8221;) represent freestanding financial instruments that should be recognized as a liability as the Company is required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Tranche Liability&#8221;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of the control of the Company, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the balance sheet at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#8217;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions: the fair value of underlying Series&#160;B-2 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$14.97</span><span style="font-family:'Times New Roman','Times','serif';"> per share, a price for Series&#160;B-2 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> per share, the fair value of underlying Series&#160;B-3 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$3.24</span><span style="font-family:'Times New Roman','Times','serif';"> per share, an exercise price for the warrants to purchase Series&#160;B-3 preferred stock of </span><span style="font-family:'Times New Roman','Times','serif';">$2.03</span><span style="font-family:'Times New Roman','Times','serif';"> per share, an expected volatility of </span><span style="font-family:'Times New Roman','Times','serif';">50.0%-</span><span style="font-family:'Times New Roman','Times','serif';">65.0%</span><span style="font-family:'Times New Roman','Times','serif';">, a risk free interest rate of </span><span style="font-family:'Times New Roman','Times','serif';">4.0%-</span><span style="font-family:'Times New Roman','Times','serif';">4.7%</span><span style="font-family:'Times New Roman','Times','serif';">, an expected term of </span><span style="font-family:'Times New Roman','Times','serif';">0.2-</span><span style="font-family:'Times New Roman','Times','serif';">0.4</span><span style="font-family:'Times New Roman','Times','serif';">&#160;years for the Series&#160;B-2 Tranche Liability and </span><span style="font-family:'Times New Roman','Times','serif';">5.8-</span><span style="font-family:'Times New Roman','Times','serif';">6.0</span><span style="font-family:'Times New Roman','Times','serif';">&#160;years for the Series&#160;B-3 Warrants and </span><span style="font-family:'Times New Roman','Times','serif';">no</span><span style="font-family:'Times New Roman','Times','serif';"> dividends. The fair value of the underlying shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock used in these models were derived from estimates of the Company&#8217;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#8217;s forecasted 2023 and 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of </span><span style="font-family:'Times New Roman','Times','serif';">$10.93</span><span style="font-family:'Times New Roman','Times','serif';"> per share, which is based upon the enterprise value stated in the merger agreement of </span><span style="font-family:'Times New Roman','Times','serif';">$220</span><span style="font-family:'Times New Roman','Times','serif';">&#160;million allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, discounted at </span><span style="font-family:'Times New Roman','Times','serif';">30%</span><span style="font-family:'Times New Roman','Times','serif';"> from the expected Business Combination closing date. The Business Combination scenario as of December&#160;31, 2022, assumed the second and third tranches will not be exercised, and thus </span><span style="font-family:'Times New Roman','Times','serif';">no</span><span style="font-family:'Times New Roman','Times','serif';"> value is assigned to the tranche rights and obligations, as the Company would not exercise its right to call the second tranche.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Series&#160;B-3 Warrant Liability and the Series&#160;B-2 Tranche Liability were estimated at $11,966 and $6,347, respectively, upon completion of the financing. The excess of the liabilities&#8217; fair values compared to the proceeds received in the transaction resulted in a charge to loss on equity issuance in the consolidated statements of operations of $8,312. The warrant liability associated with the Series&#160;B-3 Warrants was remeasured to its fair value of $15,819 at December&#160;31, 2022, and the Series&#160;B-2 Tranche Liability were remeasured to their fair value of $4,702 at December&#160;31, 2022, resulting in an additional loss recorded as change in fair value of warrant and tranche liabilities of $2,208 in the consolidated statements of operations for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, the warrants issued and issuable under the second and third tranches to purchase Series&#160;B-3 preferred stock were amended to provide that, in connection with the Business Combination, any portion of the warrants that remain unexercised at the time the Business Combination is consummated will automatically be net settled for shares of TriSalus Common Stock immediately prior to the closing of the Business Combination and exchanged into shares of Combined Company Common Stock at the Effective Time The warrant amendment did not change the liability classification of these warrants and the warrant liabilities will continue to be measured at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2023 Financing</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In January&#160;through March&#160;2023, holders of warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">2,330,811</span><span style="font-family:'Times New Roman','Times','serif';"> shares Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately </span><span style="font-family:'Times New Roman','Times','serif';">$4,715</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In March&#160;2023, we effectuated </span><span style="font-family:'Times New Roman','Times','serif';">two</span><span style="font-family:'Times New Roman','Times','serif';"> closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">207,541 </span><span style="font-family:'Times New Roman','Times','serif';">shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">830,167</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">40%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$2,939</span><span style="font-family:'Times New Roman','Times','serif';">, and (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';">17,656</span><span style="font-family:'Times New Roman','Times','serif';">&#160;shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';">70,624</span><span style="font-family:'Times New Roman','Times','serif';"> shares of Series&#160;B-3 preferred stock, representing approximately </span><span style="font-family:'Times New Roman','Times','serif';">3%</span><span style="font-family:'Times New Roman','Times','serif';"> of the shares committed in the second tranche, were sold for an aggregate purchase price of </span><span style="font-family:'Times New Roman','Times','serif';">$250</span><span style="font-family:'Times New Roman','Times','serif';">. As a result of the foregoing closings of a portion of the second tranche of the B-2 Preferred Stock Financing, in accordance with the anti-dilution rights in the Company&#8217;s certificate of incorporation, the conversion prices of the Company&#8217;s preferred stock (i)&#160;were adjusted to </span><span style="font-family:'Times New Roman','Times','serif';">$41.27</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$12.95</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$13.36</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$14.16</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$16.19</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">$10.12</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B preferred stock, and </span><span style="font-family:'Times New Roman','Times','serif';">$11.74</span><span style="font-family:'Times New Roman','Times','serif';"> for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock </span><span style="-sec-ix-hidden:Hidden_PxxmfclgUkWgfznbDZcazQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">($14.16)</span></span><span style="font-family:'Times New Roman','Times','serif';"> and Series&#160;B-3 preferred stock </span><span style="-sec-ix-hidden:Hidden_qYvtfI9-2EK0FA_smo_g4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">($2.03)</span></span><span style="font-family:'Times New Roman','Times','serif';">, which correlate to approximate (in&#160;each case rounded to three decimals) exchange ratios of </span><span style="font-family:'Times New Roman','Times','serif';">1.200</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.209</span><span style="font-family:'Times New Roman','Times','serif';">&#160;to&#160;1 for Series&#160;A-2 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.229</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-3 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.200</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-4 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.257</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-5 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.250</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;A-6 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.200</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1.207</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-1 preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-2 preferred stock and </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to 1 for Series&#160;B-3 preferred stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666050832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(13)</b></span><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As of December&#160;31, 2022 and 2021, the Company&#8217;s authorized shares of common stock were </span><span style="font-family:'Times New Roman','Times','serif';">30,898,162</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">15,696,266</span><span style="font-family:'Times New Roman','Times','serif';">, respectively. As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance in connection with the conversion of shares of Preferred Stock, at the applicable conversion rates (see Note&#160;12) and upon the exercise of certain options and warrants:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152,188</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675,638</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,198</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,834</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868,487</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 953,163</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,059,581</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,936,284</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706,243</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,212,616</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrants:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,010</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,179</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,354</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,517</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,075</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options available for future grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 432,413</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,103,488</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,194,621</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Under the 2009 Equity Incentive Plan&#160;As Amended (the &#8220;Plan&#8221;), the Company&#8217;s board of directors may grant incentive stock options and/or nonstatutory stock options to employees, directors, and consultants of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. As of December&#160;31, 2022 and 2021, there were in total </span><span style="font-family:'Times New Roman','Times','serif';">1,671,075</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">1,307,079</span><span style="font-family:'Times New Roman','Times','serif';">, respectively, stock options </span><span style="-sec-ix-hidden:Hidden_RXte8gIJ0UWW5BmmCYcnHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">outstanding</span><span style="font-family:'Times New Roman','Times','serif';">. The Plan was originally set to expire on July&#160;28, 2019, the </span><span style="font-family:'Times New Roman','Times','serif';">ten-year</span><span style="font-family:'Times New Roman','Times','serif';"> anniversary of its establishment, however, the </span><span style="font-family:'Times New Roman','Times','serif';">ten-year</span><span style="font-family:'Times New Roman','Times','serif';"> life automatically renews each time the plan is amended to increase the authorized shares. The most recent amendment was on September&#160;15, 2022, so the revised expiration date of the Plan is September&#160;15, 2032.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Incentive stock options may be granted only to employees. Nonstatutory stock options may be granted to employees and nonemployees. On March&#160;2, 2021, in conjunction with the Series&#160;B financing, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';">1,235,926</span><span style="font-family:'Times New Roman','Times','serif';">. On September&#160;23, 2021, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';">1,606,704</span><span style="font-family:'Times New Roman','Times','serif';">, and, on December&#160;20, 2021, to </span><span style="font-family:'Times New Roman','Times','serif';">1,804,452</span><span style="font-family:'Times New Roman','Times','serif';">. On July&#160;13, 2022, our board of directors authorized an increase in the number of shares under the Plan to </span><span style="font-family:'Times New Roman','Times','serif';">2,101,075</span><span style="font-family:'Times New Roman','Times','serif';"> and, on September&#160;15, 2022, to </span><span style="font-family:'Times New Roman','Times','serif';">2,348,260</span><span style="font-family:'Times New Roman','Times','serif';">. At December&#160;31, 2022, options to purchase </span><span style="font-family:'Times New Roman','Times','serif';">432,413</span><span style="font-family:'Times New Roman','Times','serif';"> shares of common stock were available for grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan is administered by our chief executive officer and chief financial officer, who act on the recommendation of managers of the Company to select the individuals to whom the awards will be granted and to determine the amount and vesting period for the grants. All grants are subject to approval by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock options are granted with an exercise price equal to the estimated fair value of the stock at the date of grant. The fair value is determined by a third-party valuation performed in accordance with IRS Section&#160;409A. Options generally have a ten-year contractual term and typically have graded vesting over <span style="-sec-ix-hidden:Hidden_huQWM8PukUiNaHCwSJKzHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>&#160;to <span style="-sec-ix-hidden:Hidden_RgKa1fvyFki-3G_4NLjGcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four&#160;years</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize activity for options issued to employees, consultants, and directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 735,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (57,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.4</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (103,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We granted </span><span style="font-family:'Times New Roman','Times','serif';">177,973</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">55,305</span><span style="font-family:'Times New Roman','Times','serif';"> options to members of the Board of Directors and other non-employees during the&#160;years ended </span><span style="-sec-ix-hidden:Hidden_0XVq7K5E4EaVAxzq8BPz2g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31, 2022</span></span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="-sec-ix-hidden:Hidden_PCQ3iCsu6kiybYaKiTQPcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2021</span></span><span style="font-family:'Times New Roman','Times','serif';">, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes certain information about all options outstanding as of December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$0.41 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,641</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$1.22 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,134</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$1.62 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,100</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.03 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,415</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.43 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,651</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.84 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,413</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$3.65&#8201;&#8211;&#8201;$18.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813,943</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The grant date per share fair value of options was determined using the Black-Scholes-Merton option valuation model, and was computed to be approximately </span><span style="font-family:'Times New Roman','Times','serif';">$0.81</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">$0.41</span><span style="font-family:'Times New Roman','Times','serif';"> for grants in the&#160;years ended December&#160;31, 2022 and 2021, respectively, using the following assumptions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.6&#8201;&#8211;&#8201;6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.0&#8201;&#8211;&#8201;6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Our historical exercise behavior for previous grants does not provide a reasonable estimate for future exercise activity for employees who have been awarded stock options in the past three&#160;years. Therefore, the average expected term was calculated using the simplified method, as defined by GAAP, for estimating the expected term.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Recognized compensation expense for employees and nonemployees in 2022 and 2021 was $368 and $109, respectively, which was predominately included in general and administrative expense in the accompanying consolidated statements of operations. As of December&#160;31, 2022 and 2021, there was $433 and $24, respectively, of unrecognized compensation expense related to unvested share-based compensation arrangements granted under the equity incentive plan. The December&#160;31, 2022, balance will be recognized over a weighted average period of 2.9&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666012688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(12)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Loss per Share</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the nine-month periods ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,015,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,624,155</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,632,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,710,860</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,097,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,381,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;9, the triggering of the anti-dilution feature resulting from the closing of the second tranche of the Initial Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$2,981</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common stockholders reflected in our unaudited Condensed Consolidated Statements of Operations for the nine&#160;months ended September&#160;30, 2023. The deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$0.72</span><span style="font-family:'Times New Roman','Times','serif';"> for the nine&#160;months ended September&#160;30, 2023.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(14)</b></span><b style="font-weight:bold;">Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#8220;two-class method&#8221;). Our preferred stock, if any, participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the&#160;years ended December&#160;31, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for those periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,330,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,376,970</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,079</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,879,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,731,606</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note&#160;12, the triggering of the anti-dilution feature resulting from the B-2 Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of </span><span style="font-family:'Times New Roman','Times','serif';">$2,829</span><span style="font-family:'Times New Roman','Times','serif';"> was recorded as an increase in the net loss attributable to common shareholders reflected in our consolidated statement of operations for the&#160;year ended December&#160;31, 2022. This deemed dividend increased the net loss per common share by </span><span style="font-family:'Times New Roman','Times','serif';">$9.14</span><span style="font-family:'Times New Roman','Times','serif';"> for the&#160;year ended December&#160;31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683860164384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(15)</b></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have four property leases in effect as of December&#160;31, 2022, which we account for as operating leases:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for our principal administrative and production facility at West 91st Avenue, Westminster, Colorado, which expires in December&#160;2026. This lease includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two options</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to extend the lease by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five&#160;years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> each at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for office space at 2275 Half Day Road, Bannockburn, Illinois, which expires in November&#160;2024. This lease includes an option to extend the lease by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three&#160;years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for office space at 1000 Chapel View Blvd, Cranston, Rhode Island, which expires in October&#160;2024. This lease includes an option to extend the lease by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two&#160;years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> at the end of the current term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A lease for laboratory and research space at 1 Hoppin Street, Providence, Rhode Island, which expires on February&#160;1, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have four finance leases, three for copier equipment in our Westminster, Bannockburn and Cranston facilities, and one for laboratory equipment in our research space in Providence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of right-of-use assets, short-term lease liabilities and long-term lease liabilities at December&#160;31, 2022, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Net of accumulated depreciation, included in fixed assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense for the&#160;year ended December&#160;31, 2022, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 443</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total finance lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 463</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maturities of lease liabilities under noncancellable leases as of December&#160;31, 2022, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, we recorded $38 in fixed assets for a finance lease for a copier in our Westminster facility, and $6 and $32 in current liabilities and long-term liabilities, respectively, for the related lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, we recorded $310 in fixed assets for a finance lease for analytical equipment in our laboratory facility in Providence, and $178 and $132 in current liabilities and long-term liabilities, respectively, for the related lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the weighted average life of our operating and finance leases is <span style="-sec-ix-hidden:Hidden_IhjA9SxPWke_WdT-YL8OYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span></span> and three&#160;years, respectively. The weighted average discount rate for both operating and finance leases is 8.1%, <span style="-sec-ix-hidden:Hidden_QpMaoZ2rLEe3kuE2nEwMHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span></span> is based on interest rates we paid for our most recent term loan and convertible notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total lease expense for the&#160;years ended December&#160;31, 2021, was $385.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We record rent expense on a straight-line basis&#8201;&#8212;&#8201;the terms of all leases provide for increases in rental payments over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments for each of the five&#160;years ending December&#160;31, 2021, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 188</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,102</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,101</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757983376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(15)</b></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commitments and Contingencies</b></p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registrations and will indemnify the parties thereto against certain liabilities related to such registrations. The Company&#8217;s registration obligations under the Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto on the date that such party no longer holds any Registrable Securities (as defined in the Amended and Restated Registration Rights Agreement). The Amended and Restated Registration Rights Agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(16)</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a salary reduction savings plan under Section&#160;401(k)&#160;of the Internal Revenue Code, which we administer for participating employees&#8217; contributions. All full-time employees are covered under the plan after meeting minimum service requirements. We paid matching contributions of $431 and $287 to the plan for the&#160;years ended December&#160;31, 2022 and 2021, respectively. Our contributions were based on compensation at the rate of 3%, 3.5%, and 4% for an employee&#8217;s contribution of up to 3%, between 3% and 4%, and between 4% and 5%, respectively, with the match-eligible contribution being limited to 4% of the employee&#8217;s eligible compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, an individual filed a suit against the Company in the District of Colorado asserting joint inventorship of six patents assigned to the Company. The individual sought to be added as a co-inventor and co-owner of the patents in question. In a series of rulings, the Court struck monetary damages and jury trial demand, limited the individual&#8217;s expert testimony to one patent, and barred rebuttal testimony to defendant&#8217;s expert or testimony related to prior art, severely limiting the scope of this case. Following a notice that we would be seeking sanctions against the plaintiff and his attorney, it was agreed that the plaintiff would dismiss his case with prejudice and no sanctions or attorney fees&#8217; request would be filed. A stipulated Dismissal Order was entered June&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, TriSalus exercised its right to terminate, for cause, an agreement with a distributor, pursuant to which the distributor was acting as exclusive distributor of the TriNav Infusion System in several Western states. We determined that the distributor had failed to perform many aspects of the contract resulting in poor sales. The distributor was put on notice in September&#160;of 2020 that performance must improve, or we would terminate the contract. Despite being allowed a 60-day cure period, the distributor&#8217;s performance did not improve and in February&#160;2021 we exercised our right to terminate. On March&#160;11, 2021, the distributor filed a lawsuit against us in the Utah state court, asserting a claim for wrongful termination of the contract by us and several other related, common-law claims. The distributor sought monetary damages in an amount of $750, plus attorneys&#8217; fees and other relief. On November&#160;15, 2021, we agreed to settle the case for $425, which was recorded as expense in general and administrative expense in the accompanying consolidated statements of operations. The settlement was paid in two installments of $200 and $225, on November&#160;18, 2021, and January&#160;3, 2022, respectively. The settlement amounted to the contractual fee if we were to terminate the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757937280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger Agreement with MedTech Acquisition Corporation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger Agreement with MedTech Acquisition Corporation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(17)</b></span><b style="font-weight:bold;">Merger Agreement with MedTech Acquisition Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;11, 2022, we entered into a Business Combination Agreement with MedTech Acquisition Corporation, a Delaware corporation (&#8220;MTAC&#8221;), and MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of MTAC (&#8220;Merger Sub&#8221;). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into TriSalus (the &#8220;Business Combination&#8221;), with TriSalus surviving as a wholly owned subsidiary of MTAC (the &#8220;Surviving Corporation&#8221;). Following completion of the combination, MTAC will be renamed &#8220;TriSalus Life Sciences,&#160;Inc.&#8221; The aggregate consideration payable to our stockholders is $220,000, payable solely in shares of MTAC common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately prior to the effective time of the Business Combination, each outstanding warrant to purchase Series&#160;B-3 preferred stock must be exercised pursuant to the net-exercise provisions of the warrants, and then each issued and outstanding share of TriSalus&#8217; Series&#160;A-<span style="-sec-ix-hidden:Hidden_b4QB_34hYkSQy8m2zvvSVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_mW0ye0ape0K0u7SnjgQyTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_D1tTYpAKD0mwadhIRhVubw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_Wp2d5AfagUeiDJyLPZ20iQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_F187q8J5AkCMoKigjnNSmw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>, Series&#160;A-<span style="-sec-ix-hidden:Hidden_s43EmyAlY0-5J-sKfRJXGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span>, Series&#160;B, Series&#160;B-<span style="-sec-ix-hidden:Hidden_iGujevr0gUmbUx_6BKltrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>, Series&#160;B-<span style="-sec-ix-hidden:Hidden_IoB8wHCgok2nthhVpcAt4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>, and Series&#160;B-<span style="-sec-ix-hidden:Hidden_7EvRLYEDcEumV76exoXIWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> preferred stock, par value $0.001 (collectively, the &#8220;TriSalus Preferred Stock&#8221;) will be converted into shares of TriSalus Common Stock at the then-applicable conversion rates. In addition, each remaining outstanding warrant to purchase shares of TriSalus Common Stock or TriSalus Preferred Stock (each, a &#8220;TriSalus Warrant&#8221;) that is in-the-money and would be exercised or otherwise exchanged in full in accordance with its terms by virtue of the occurrence of the Business Combination, will automatically be exercised for shares of TriSalus Common Stock. TriSalus Warrants that are out-of-the-money will be canceled for no consideration. Upon closing of the Business Combination, all shares of TriSalus Common Stock, including all shares of preferred stock converted as described above, will convert into shares of MTAC common stock at a conversion ratio equal to the $220,000 consideration stipulated in the Business Combination Agreement divided by the total shares of TriSalus Common Stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the effective time, each outstanding option to purchase shares of TriSalus Common Stock under TriSalus&#8217; equity incentive plans (each, a &#8220;TriSalus Option&#8221;), whether or not then vested and exercisable, will be assumed and converted into an option to purchase shares of MTAC common stock under similar terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we have deferred $2,719 of eligible expenses related to the registration and issuance of MTAC common stock in conjunction with the Business Combination. The deferral is recorded in other current assets in the accompanying consolidated balance sheet as of December&#160;31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683659731376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Basis of Presentation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#8217;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#8221;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(a)</span></span><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#8217;s equity structure including the consolidated statements of stockholders&#8217; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#8217;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#8220;Exchange Ratio&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(a)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had </span><span style="font-family:'Times New Roman','Times','serif';">$8,617</span><span style="font-family:'Times New Roman','Times','serif';"> invested in a money market fund, which is is a Level 1 instrument.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(b)</span></span><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(c)</span></span><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable and Customer Concentrations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(d)</span></span><span style="font-style:italic;font-weight:bold;">Accounts Receivable and Customer Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#8217;s expectations of realization based on historical write-off experience, as well </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, one distributor customer constituted 19% of our accounts receivable balance. As of December&#160;31, 2021, one distributor customer constituted 34% of our accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had one distributor customer which constituted 20% and 25% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(f)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Leases</i><span style="font-family:'Times New Roman','Times','serif';">. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#8220;ROU&#8221;) representing the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(e)</span></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,&#160;<i style="font-style:italic;">Leases</i>. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(c)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Inventory</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#8212; including direct labor and manufacturing overhead&#160;&#8212; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(f)</span></span><span style="font-style:italic;font-weight:bold;">Inventory</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#8201;&#8212;&#8201;including direct labor and manufacturing overhead&#8201;&#8212;&#8201;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(i)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Use of Estimates</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(g)</span></span><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(d)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Property and Equipment</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span><span style="font-family:'Times New Roman','Times','serif';"> to </span><span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span><span style="font-family:'Times New Roman','Times','serif';">&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(h)</span></span><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment and Disposal of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(e)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Impairment and Disposal of Long-Lived Assets</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows</span><span style="font-family:'Times New Roman','Times','serif';"> expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(i)</span></span><span style="font-style:italic;font-weight:bold;">Impairment and Disposal of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(k)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Share-Based Compensation</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i><span style="font-family:'Times New Roman','Times','serif';">, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(j)</span></span><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#8220;Black-Scholes&#8221;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#8217;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;<i style="font-style:italic;">Compensation&#8201;&#8212;&#8201;Stock Compensation</i>, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(l)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have determined, in accordance with ASC Topic 280, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Segment Reporting</i><span style="font-family:'Times New Roman','Times','serif';">, that we operate under </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> operating segment, and therefore </span><span style="font-family:'Times New Roman','Times','serif';">one</span><span style="font-family:'Times New Roman','Times','serif';"> reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(k)</span></span><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have determined, in accordance with ASC Topic 280,&#160;<i style="font-style:italic;">Segment Reporting</i>, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">(m)</i></span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue Recognition</i><span style="font-family:'Times New Roman','Times','serif';">, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</span></p><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8201;&#8212;&#8201;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#160;&#8212; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#160;&#8212; We recognize revenue at the point</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(l)</span></span><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;<i style="font-style:italic;">Revenue Recognition</i>, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the contract&#8201;&#8212;&#8201;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identify the performance obligation&#8201;&#8212;&#8201;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determine the transaction price&#8201;&#8212;&#8201;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocate the transaction price&#8201;&#8212;&#8201;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognize revenue&#8201;&#8212;&#8201;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(m)</span></span><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;D costs are expensed as incurred and included milestone payments of $1,000 to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(n)</span></span><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $2,201 and $1,400, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(o)</span></span><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes pursuant to ASC Topic 740,&#160;<i style="font-style:italic;">Income Taxes</i>, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#8217;s income tax liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock', window );">Warrant and Tranche Rights and Obligation Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(p)</span></span><span style="font-style:italic;font-weight:bold;">Warrant and Tranche Rights and Obligation Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Financial Instruments&#160;&#8212; Credit Losses: Measurement of Credit Losses on Financial Instruments</i><span style="font-family:'Times New Roman','Times','serif';">. Current GAAP requires an &#8220;incurred loss&#8221; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. </span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">(q)</span></span><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02,&#160;<i style="font-style:italic;">Leases (&#8220;ASC&#160;Topic 842&#8221;)</i>, which supersedes FASB ASC Topic 840,&#160;<i style="font-style:italic;">Leases</i>, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU 2020-06,&#160;<i style="font-style:italic;">Debt&#8201;&#8212;&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;&#8212;&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU &#8220;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#8221; In addition, the ASU &#8220;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#8221; and &#8220;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#8221; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the FASB issued ASU 2021-07,&#160;<i style="font-style:italic;">Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards</i>, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant and tranche rights and obligation liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757918448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in the level 3 fair value of warrant liabilities</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent earnout liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,904)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Out)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">in</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Value</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">at</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">30,</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3 Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,508)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border:0;border-collapse:collapse;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">This amount includes settlements of </span><span style="font-family:'Times New Roman','Times','serif';">$25,409</span><span style="font-family:'Times New Roman','Times','serif';">, and final net exercise of </span><span style="font-family:'Times New Roman','Times','serif';">$4,800</span><span style="font-family:'Times New Roman','Times','serif';">, transferred to convertible preferred stock, offset by issuances of $</span><span style="font-family:'Times New Roman','Times','serif';">14,701</span></p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net&#160;Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;at</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;(Out)&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains)&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)&#160;&#160;</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Put option liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Transfer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In (Out) of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Gains) Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Settlements)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-2 tranche liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,702</p></td></tr><tr><td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B-3 warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,819</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>This amount includes settlements of $3,397, reduced by issuances of $10.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665944432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,414</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,664</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr><tr><td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash (included in Other assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757918448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of components of inventory</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The components of inventory are summarized as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 718</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 646</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,292</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664539984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Lived Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LongLivedAssetsAbstract', window );"><strong>Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December&#160;31 consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#8201;&#8211;&#8201;7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,031</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 783</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other property</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,946</p></td></tr><tr><td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,149)</p></td></tr><tr><td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,797</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Summary of aggregate amortization expense for intangible assets subject to amortization</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 477</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 802</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660596624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Accrued Liabilities consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,896</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,910</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,969</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665948128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expenses (benefits) from continuing operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Federal:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of computation of federal statutory tax rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State and local taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant portions of deferred income tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">NOL carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,002</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,306</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,708</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,630</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,630)</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred income tax assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of net operating loss carryforwards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Federal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">State</b></p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs expiring between 2029 and 2037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,380</p></td></tr><tr><td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">NOLs which do not expire</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,398</p></td></tr><tr><td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total NOLs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,778</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757950080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant liabilities that are carried at fair value, the initial fair values recorded as debt discount at the time of issuance and amortized as additional interest expense</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,333,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,933,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Series B-3 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr><tr><td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,819,000</p></td></tr></table><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $17.81 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $20.23 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.41 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td></tr><tr><td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $2.03 exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,871,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercises</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,771,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (649,109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quantity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial&#160;Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">08&#8209;26&#8209;2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">10&#8209;27&#8209;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">06&#8209;30&#8209;2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">11&#8209;20&#8209;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757662944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Class A common stock subject to possible redemption reflected in the balance sheets reconciled</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 10,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retirements / </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> September 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A-6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,006</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock', window );">Summary of activity in convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity in convertible preferred stock for the&#160;years ended December&#160;31, 2022 and 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January&#160;1,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,065</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,976</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,611</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,993</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,858</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,476</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,528</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,499</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock', window );">Summary of aggregate liquidation preference of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,659,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,500</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,984,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,774</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,196</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 730,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;4 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,047</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 612,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,661</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 576,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,020</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;1 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49.520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,526</p></td></tr><tr><td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liquidation preference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,724</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of activity in convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of aggregate liquidation preference of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666060992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of common stock reserved for future issuance in connection with the conversion of shares of Preferred Stock and upon the exercise of certain options and warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152,188</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675,638</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,198</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148,834</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868,487</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series A&#8209;6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 953,163</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,059,581</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,936,284</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706,243</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,212,616</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrants:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;5 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,010</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series A&#8209;6 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,179</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,354</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to purchase Series B&#8209;3 preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,824,974</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,517</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock options:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,075</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options available for future grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 432,413</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,103,488</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,194,621</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of activity for options issued to employees, consultants, and directors</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 735,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (57,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.4</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (103,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of information about all options outstanding and exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$0.41 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,641</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$1.22 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,134</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$1.62 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,100</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.03 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,415</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.43 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,651</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$2.84 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,413</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">$3.65&#8201;&#8211;&#8201;$18.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589</p></td></tr><tr><td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813,943</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation assumptions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.6&#8201;&#8211;&#8201;6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.0&#8201;&#8211;&#8201;6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Our historical exercise behavior for previous grants does not provide a reasonable estimate for future exercise activity for employees who have been awarded stock options in the past three&#160;years. Therefore, the average expected term was calculated using the simplified method, as defined by GAAP, for estimating the expected term.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665965120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding</a></td>
<td class="text"><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,015,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,624,155</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,266,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,632,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,710,860</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,097,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,381,126</p></td></tr></table><span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,330,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,376,970</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,878,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,671,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,307,079</p></td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,879,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,731,606</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665840032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of components of right-of-use assets, short-term lease liabilities and long-term lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of right-of-use assets, short-term lease liabilities and long-term lease liabilities at December&#160;31, 2022, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Net of accumulated depreciation, included in fixed assets</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense for the&#160;year ended December&#160;31, 2022, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 443</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total finance lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 463</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock', window );">Schedule of maturities of lease liabilities under noncancellable leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maturities of lease liabilities under noncancellable leases as of December&#160;31, 2022, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments for each of the five&#160;years ending December&#160;31, 2021, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 188</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,102</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,101</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of of maturities of operating and finance leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661520816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">168 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="nump">$ 9,189<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 13,499<span></span>
</td>
<td class="nump">$ 51,900<span></span>
</td>
<td class="nump">$ 113,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">57,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CumulativeIncomeLoss', window );">Cumulative net losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of exercise of stock option</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 212,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,358<span></span>
</td>
<td class="nump">$ 136,342<span></span>
</td>
<td class="nump">$ 186,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CumulativeIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent information pertaining to cumulative income loss from issuance of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CumulativeIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660182752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MilestonePaymentToDynavaxOperatingActivity', window );">Milestone payment to Dynavax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,201<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssets', window );">Increase in assets</a></td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Net of accrued rent</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">$ 32,357<span></span>
</td>
<td class="nump">$ 6,373<span></span>
</td>
<td class="nump">$ 9,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Long-term liabilities</a></td>
<td class="nump">$ 1,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfCustomer', window );">Number of customer | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfCustomer', window );">Number of customer | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MilestonePaymentToDynavaxOperatingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment to Dynavax, classified under operating activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MilestonePaymentToDynavaxOperatingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tlsi_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tlsi_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661550576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount', window );">Transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered', window );">Percentage of then outstanding shares on an as-converted to common stock basis, offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">15,819<span></span>
</td>
<td class="nump">$ 11,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember', window );">Tranche rights and obligations associated with the second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember', window );">Tranche rights and obligations associated with the third tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">$ 3,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MeasurementAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying amount | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">16,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MeasurementAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying amount | Tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">$ 4,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis between various levels of fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the then outstanding shares on an as-converted to common stock basis, offered under the stock offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MeasurementAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MeasurementAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_TrancheLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671123696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 3,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_PutOptionLiabilityMember', window );">Put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,210)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember', window );">Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="num">(1,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="nump">6,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">4,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB3WarrantLiabilitiesMember', window );">Series B-3 warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, liabilities measured on recurring basis, unobservable input reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in Unrealized (Gains) Losses</a></td>
<td class="nump">3,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Issuances (Settlements)</a></td>
<td class="nump">11,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 15,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_PutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_PutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB3WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB3WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664431104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash (included in Other assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 21,633<span></span>
</td>
<td class="nump">$ 9,664<span></span>
</td>
<td class="nump">$ 12,338<span></span>
</td>
<td class="nump">$ 30,301<span></span>
</td>
<td class="nump">$ 4,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660339584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Components of inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 1,629<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Reserve for excess inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660077376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Lived Assets - Property and Equipment, tabular (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,656<span></span>
</td>
<td class="nump">$ 3,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,795<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757707440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Lived Assets - Property and Equipment, narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LongLivedAssetsAbstract', window );"><strong>Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense for property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671538000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Lived Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LongLivedAssetsAbstract', window );"><strong>Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life of the patents</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intellectual property</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660558992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Lived Assets - Intangible Assets, amortization expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Aggregate amortization expense for intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Aggregate amortization expense</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672595984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 3,404<span></span>
</td>
<td class="nump">$ 2,905<span></span>
</td>
<td class="nump">$ 2,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AccruedIncentiveCurrent', window );">Accrued incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
<td class="nump">$ 4,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AccruedIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused incentive owed to employees based on the entity's incentive benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AccruedIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672443776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672040272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for federal income tax statutory rate (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Permanent differences tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683672046368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant portions of deferred income tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 30,421<span></span>
</td>
<td class="nump">$ 27,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeferredTaxAssetsFixedAssetsAndIntangible', window );">Fixed assets and intangibles</a></td>
<td class="nump">2,371<span></span>
</td>
<td class="nump">2,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">38,459<span></span>
</td>
<td class="nump">29,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax assets and liabilities</a></td>
<td class="nump">38,358<span></span>
</td>
<td class="nump">29,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Less: valuation allowance</a></td>
<td class="num">$ (38,358)<span></span>
</td>
<td class="num">$ (29,630)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeferredTaxAssetsFixedAssetsAndIntangible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fixed assets and intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeferredTaxAssetsFixedAssetsAndIntangible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656682224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net operating loss carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="nump">$ 30,421<span></span>
</td>
<td class="nump">$ 27,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">NOLs expiring between 2029 and 2037</a></td>
<td class="nump">43,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs which do not expire</a></td>
<td class="nump">82,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="nump">125,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">NOLs expiring between 2029 and 2037</a></td>
<td class="nump">67,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs which do not expire</a></td>
<td class="nump">18,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Total NOLs</a></td>
<td class="nump">$ 85,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757662944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in deferred tax assets valuation amount</a></td>
<td class="nump">$ 8,728<span></span>
</td>
<td class="nump">$ 5,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NetDeferredTaxAssetsChangeInValuationPercentage', window );">Deferred tax assets change in valuation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NetDeferredTaxAssetsChangeInValuationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying deferred tax assets change in valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NetDeferredTaxAssetsChangeInValuationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660461088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dynavax Purchase (Details) - Dynavax purchase agreement<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_UpfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PaymentOfUpfrontAmount', window );">Payment of upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MinimumMilestonePaymentAmount', window );">Minimum milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumMilestonePaymentAmount', window );">Maximum milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumDevelopmentMilestonePayments', window );">Maximum development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MilestonePaymentsMade', window );">Milestone payments made</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfCommercialMilestoneToBeMade', window );">Number of commercial milestone to be made | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumCommercialMilestonePayments', window );">Maximum commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">First and second development milestone payments in R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Upon first commercial sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommercialMilestonePaymentAmount', window );">Commercial milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Upon first occurrence of annual net sales of $250000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommercialMilestonePaymentAmount', window );">Commercial milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualNetSales', window );">Annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Upon first occurrence of annual net sales of $500000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommercialMilestonePaymentAmount', window );">Commercial milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualNetSales', window );">Annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Upon first occurrence of annual net sales of $1000000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CommercialMilestonePaymentAmount', window );">Commercial milestone payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualNetSales', window );">Annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Aggregate annual net sales less than or equal to $1,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualNetSales', window );">Annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualRoyaltyRate', window );">Annual royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember', window );">Aggregate annual net sales greater than $1,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Dynavax purchase agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AnnualRoyaltyRate', window );">Annual royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AnnualRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AnnualRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CommercialMilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CommercialMilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumMilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumMilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MilestonePaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MilestonePaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MinimumMilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum milestone payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MinimumMilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfCommercialMilestoneToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commercial milestone to be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfCommercialMilestoneToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PaymentOfUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of upfront amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PaymentOfUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_UpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_UpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tlsi_DynavaxPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_UponFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_UponFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_AggregateAnnualNetSalesGreaterThan1000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_AggregateAnnualNetSalesGreaterThan1000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757595008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - PPP Loan (Details) - PPP - Other income and expense, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 19, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Loan received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tlsi_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tlsi_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656008800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Term Loan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn08262015Member', window );">Warrants issued on 08262015 | Series A-5 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Quantity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Initial Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn10272016Member', window );">Warrants issued on 10272016 | Series A-5 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Quantity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Initial Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn06302017Member', window );">Warrants issued on 06302017 | Series A-6 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Quantity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Initial Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn11202018Member', window );">Warrants issued on 11202018 | Series A-6 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Quantity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Initial Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tlsi_TermLoanAndSupplementalTermLoanMember', window );">Term loan and supplemental term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Final payment</a></td>
<td class="nump">$ 1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn08262015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn08262015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn10272016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn10272016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn06302017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn06302017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn11202018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tlsi_WarrantsIssuedOn11202018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tlsi_TermLoanAndSupplementalTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tlsi_TermLoanAndSupplementalTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683657589328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">168 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_InitialWarrantLiability', window );">Initial value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_WarrantIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">$ 3,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount', window );">Modification of convertible debt to remove conversion discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,210<span></span>
</td>
<td class="nump">5,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 44,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Accumulated interest</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnConversionOfConvertibleNotes', window );">Loss on conversion of convertible notes</a></td>
<td class="nump">$ 3,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember', window );">Put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,382<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount', window );">Modification of convertible debt to remove conversion discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember', window );">Series A-6 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember', window );">Series A-6 Preferred Stock | Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of shares</a></td>
<td class="nump">4,047,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 9,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued', window );">Threshold percentage of price per share paid by the cash purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_QualifiedFinancingMinimumProceeds', window );">Minimum proceeds to be considered as qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage', window );">Percentage of probability of occurrence of qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage', window );">Percentage of probability of convertible notes converting at maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DebtInstrumentConversionDiscountPercentage', window );">Conversion discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_EliminationOfOccurrenceOfDiscountPercentage', window );">Percentage of discount modification</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Series A-6 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,361<span></span>
</td>
<td class="nump">385,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,361<span></span>
</td>
<td class="nump">385,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid-in capital from modification of convertible debt to remove conversion discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DebtInstrumentConversionDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DebtInstrumentConversionDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of price per share paid by cash purchasers for the preferred stock issued in the qualified financing under the debt conversion arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_EliminationOfOccurrenceOfDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage on elimination of occurrence of discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_EliminationOfOccurrenceOfDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_InitialWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of initial value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_InitialWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of probability of convertible notes converting at maturity under the debt conversion covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of probability of occurrence of qualified financing under the debt conversion covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_QualifiedFinancingMinimumProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum proceeds from the issuance of capital to be considered as qualified financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_QualifiedFinancingMinimumProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683658363856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,910,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">$ 203,974<span></span>
</td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 55,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">$ 6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">$ 8,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">$ 10,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,545,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,545,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,476<span></span>
</td>
<td class="nump">$ 15,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,021,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,021,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">84,637<span></span>
</td>
<td class="nump">$ 84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">23,500<span></span>
</td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,474,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,474,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">$ 39,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656310832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, activity in convertible preferred stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">$ 164,006<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 160,507<span></span>
</td>
<td class="nump">$ 55,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="nump">39,968<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">104,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,006<span></span>
</td>
<td class="nump">164,006<span></span>
</td>
<td class="nump">160,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">12,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
<td class="nump">84,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance</a></td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,499<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661271792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">21,910,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">5,331,943<span></span>
</td>
<td class="nump">5,331,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 49.520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">23,307,464<span></span>
</td>
<td class="nump">23,307,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 15.660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">24,792,020<span></span>
</td>
<td class="nump">24,792,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 17.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">5,169,690<span></span>
</td>
<td class="nump">5,169,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 16.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">734,533<span></span>
</td>
<td class="nump">734,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquitySharesAvailableForIssuance', window );">Convertible preferred stock, available for issuance</a></td>
<td class="nump">4,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 17.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">805,848<span></span>
</td>
<td class="nump">805,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquitySharesAvailableForIssuance', window );">Convertible preferred stock, available for issuance</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 20.230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">7,021,678<span></span>
</td>
<td class="nump">7,021,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquitySharesAvailableForIssuance', window );">Convertible preferred stock, available for issuance</a></td>
<td class="nump">36,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 12.140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">1,659,672<span></span>
</td>
<td class="nump">1,659,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 14.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">1,765,609<span></span>
</td>
<td class="nump">1,765,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquitySharesAvailableForIssuance', window );">Convertible preferred stock, available for issuance</a></td>
<td class="nump">1,059,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 14.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">8,474,924<span></span>
</td>
<td class="nump">8,474,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquitySharesAvailableForIssuance', window );">Convertible preferred stock, available for issuance</a></td>
<td class="nump">8,474,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 2.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquitySharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares available for issuance for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquitySharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665968016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Conversion (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock', window );">Threshold per share price of common stock for automatic conversion of preferred stock | $ / shares</a></td>
<td class="nump">$ 14.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds', window );">Threshold net cash proceeds for automatic conversion of preferred stock</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount', window );">Threshold proceeds received from the "special purpose acquisition corporation" trust account for automatic conversion of preferred stock</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold net cash proceeds for automatic conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold proceeds received from the "special purpose acquisition corporation" trust account for automatic conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold per share price of common stock for automatic conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757933744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Voting Rights (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Vote</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired', window );">Number of board of director above which majority preferred shareholders voting approval will be required</a></td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of board of director above which majority preferred shareholders voting approval will be required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660274416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Dividends (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">$ 3.97000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.26000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.4000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.29000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.4300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">0.980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">1.140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityDividendPerShare', window );">Per annum preferred dividend rates</a></td>
<td class="nump">$ 0.170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the dividend per share of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683653813920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Liquidation Preferences (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 175,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 2.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">706,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 14.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,659,672<span></span>
</td>
<td class="nump">1,412,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 14.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">6,984,971<span></span>
</td>
<td class="nump">6,984,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 12.140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 84,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">800,657<span></span>
</td>
<td class="nump">800,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 20.230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 16,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">730,320<span></span>
</td>
<td class="nump">730,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 17.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">127,787<span></span>
</td>
<td class="nump">127,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 16.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 2,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">612,822<span></span>
</td>
<td class="nump">612,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 17.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 10,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">576,126<span></span>
</td>
<td class="nump">576,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 15.660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 9,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">131,797<span></span>
</td>
<td class="nump">131,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 49.520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 6,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683665005328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, March 2021 Financing (Details) - Series B preferred stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">March 2021 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds, net of issuance costs</a></td>
<td class="nump">$ 10,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">906,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Convertible notes value converted</a></td>
<td class="nump">$ 49,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of notes</a></td>
<td class="nump">4,047,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_March2021FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_March2021FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664949664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Spring 2021 Financing (Details) - Series B preferred stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Spring 2021 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds, net of issuance costs</a></td>
<td class="nump">$ 20,989<span></span>
</td>
<td class="nump">$ 20,989<span></span>
</td>
<td class="nump">$ 20,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">1,742,003<span></span>
</td>
<td class="nump">1,742,003<span></span>
</td>
<td class="nump">1,742,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_Spring2021FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_Spring2021FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664369728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Fall 2021 Financing (Details) - Series B-1 preferred stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Fall 2021 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds, net of issuance costs</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">1,412,487<span></span>
</td>
<td class="nump">1,412,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityOriginalIssuePrice', window );">Convertible preferred stock, original issue prices</a></td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_Fall2021FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_Fall2021FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666572272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Warrant Exercises (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares)</a></td>
<td class="nump">289,552<span></span>
</td>
<td class="nump">289,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683647687568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - 2022 Financing (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,171)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities', window );">Change in fair value of tranche and warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities | $</a></td>
<td class="nump">$ 11,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember', window );">Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities | $</a></td>
<td class="nump">6,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=tlsi_BusinessCombinationScenarioMember', window );">Business Combination scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_EnterpriseValueAllocated', window );">Enterprise value allocated | $</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ValueAssignedToTrancheRightsAndObligations', window );">Value assigned to the tranche rights and obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price | Business Combination scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected share price volatility | Minimum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected share price volatility | Maximum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term | Minimum | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term | Minimum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term | Maximum | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term | Maximum | Series B-2 tranche liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendPaymentMember', window );">Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input | $</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember', window );">Discount rate | Business Combination scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_Financing2022Member', window );">2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_GainLossOnEquityIssuance', window );">Loss on equity issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities', window );">Change in fair value of tranche and warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 42.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 13.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,552<span></span>
</td>
<td class="nump">289,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock | Fair value of underlying stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,185<span></span>
</td>
<td class="nump">247,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered', window );">Percentage of then outstanding shares on an as-converted to common stock basis, offered</a></td>
<td class="nump">99.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock | Fair value of underlying stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold | shares</a></td>
<td class="nump">706,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price of shares sold</a></td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds | $</a></td>
<td class="nump">$ 9,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock | B-2 Preferred Stock Financing, Second tranche, closings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumNumberOfSharesAgreedToSell', window );">Maximum number of shares agreed to sell | shares</a></td>
<td class="nump">518,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AggregateProceedsReceivableFromStockOffering', window );">Aggregate proceeds receivable | $</a></td>
<td class="nump">$ 7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares', window );">Maximum proceeds receivable through the sale of additional shares | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock | B-2 Preferred Stock Financing, Third tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="nump">2,448,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumNumberOfSharesAgreedToSell', window );">Maximum number of shares agreed to sell | shares</a></td>
<td class="nump">306,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_AggregateProceedsReceivableFromStockOffering', window );">Aggregate proceeds receivable | $</a></td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares', window );">Maximum proceeds receivable through the sale of additional shares | $</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares', window );">Maximum number of shares agreed to sell through sale of additional shares | shares</a></td>
<td class="nump">353,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | Fair value of underlying stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | Series B-3 Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TrancheLiabilityMeasurementInput', window );">Series B 2 Tranche Liability, measurement input</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="nump">2,824,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | B-2 Preferred Stock Financing, Second tranche, closings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="nump">2,075,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_AggregateProceedsReceivableFromStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds receivable by the company through stock offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_AggregateProceedsReceivableFromStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_EnterpriseValueAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of enterprise value allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_EnterpriseValueAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of tranche and warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_GainLossOnEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_GainLossOnEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumNumberOfSharesAgreedToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares agreed to be sold by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumNumberOfSharesAgreedToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares agreed to be sold by the company, through sale of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum proceeds receivable by the company through the sale of additional shares under the stock offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the then outstanding shares on an as-converted to common stock basis, offered under the stock offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TrancheLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TrancheLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ValueAssignedToTrancheRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to value assigned to the tranche rights and obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ValueAssignedToTrancheRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tlsi_SeriesB2TrancheLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_BusinessCombinationScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_BusinessCombinationScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_Financing2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_Financing2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueOfUnderlyingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tlsi_MeasurementInputFairValueOfUnderlyingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683654677856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - 2023 Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.275<span></span>
</td>
<td class="nump">1.155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.290<span></span>
</td>
<td class="nump">1.173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.303<span></span>
</td>
<td class="nump">1.162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.277<span></span>
</td>
<td class="nump">1.165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.333<span></span>
</td>
<td class="nump">1.189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.351<span></span>
</td>
<td class="nump">1.190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,552<span></span>
</td>
<td class="nump">289,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.250<span></span>
</td>
<td class="nump">1.154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.296<span></span>
</td>
<td class="nump">1.167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="nump">2,239,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants | $</a></td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | B-2 Preferred Stock Financing, Second tranche, closings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock | B-2 Preferred Stock Financing, Second tranche, closing one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | B-2 Preferred Stock Financing, Second tranche, closings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfStockOfferingClosingsEffectuated', window );">Number of closings effectuated | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | B-2 Preferred Stock Financing, Second tranche, closing one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfSharesCommittedSold', window );">Percentage of shares committed sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | B-2 Preferred Stock Financing, Second tranche, closing two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_PercentageOfSharesCommittedSold', window );">Percentage of shares committed sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Series B preferred stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-1 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-2 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-3 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-4 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-5 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A-6 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-1 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-2 preferred stock | B-2 Preferred Stock Financing, Second tranche, closing one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-2 preferred stock | B-2 Preferred Stock Financing, Second tranche, closing two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-2 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-3 preferred stock | B-2 Preferred Stock Financing, Second tranche, closing two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B-3 preferred stock | 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Series B-3 preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,330,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,330,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion prices of the Company's preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfStockOfferingClosingsEffectuated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of closings of stock offerings effectuated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfStockOfferingClosingsEffectuated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_PercentageOfSharesCommittedSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares committed by the company sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_PercentageOfSharesCommittedSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tlsi_Financing2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tlsi_Financing2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R165.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683656757568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">19,194,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_ConvertiblePreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">14,212,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">152,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">675,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">712,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">148,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">868,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">953,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">8,059,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,936,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">706,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">2,878,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesFivePreferredStockMember', window );">Warrants to purchase Series A5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">5,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesSixPreferredStockMember', window );">Warrants to purchase Series A6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">6,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesBPreferredStockMember', window );">Warrants to purchase Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">42,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember', window );">Warrants to purchase Series B3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">2,824,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">2,103,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsOutstandingMember', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,671,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsAvailableForFutureGrantMember', window );">Stock options available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">432,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesFivePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesFivePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesSixPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantToPurchaseSeriesSixPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsAvailableForFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CapitalShareReservedForFutureIssuanceAxis=tlsi_StockOptionsAvailableForFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R166.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683659306080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the beginning</a></td>
<td class="nump">1,671,076<span></span>
</td>
<td class="nump">1,307,080<span></span>
</td>
<td class="nump">735,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,179,480<span></span>
</td>
<td class="nump">550,049<span></span>
</td>
<td class="nump">700,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,879)<span></span>
</td>
<td class="num">(71,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103,174)<span></span>
</td>
<td class="num">(57,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,671,076<span></span>
</td>
<td class="nump">1,307,080<span></span>
</td>
<td class="nump">735,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the beginning (in dollars per share)</a></td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.43<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.81<span></span>
</td>
<td class="nump">0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeiture (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the ending (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Members of Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,973<span></span>
</td>
<td class="nump">55,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Other non employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">2,237,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R167.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660825952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of Exercise price | $ / shares</a></td>
<td class="nump">$ 3.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of Exercise price | $ / shares</a></td>
<td class="nump">$ 18.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">1,671,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">813,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.001Member', window );">0.01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">540,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">380,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.003Member', window );">0.03</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">211,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">211,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.004Member', window );">0.04</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 1.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.005Member', window );">0.05</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">7,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">7,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.006Member', window );">0.06</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">900,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">203,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.007Member', window );">0.07</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.09To0.46Member', window );">$0.09-$0.46</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">5,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice', window );">Options Exercisable</a></td>
<td class="nump">5,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.001Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.001Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.09To0.46Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=tlsi_ExercisePriceOf0.09To0.46Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R168.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683670949920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Valuation assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Exercise prices of options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date per share fair value of options</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.76%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R169.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660861216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 10, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Summary of option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">30,898,162<span></span>
</td>
<td class="nump">15,696,266<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the beginning</a></td>
<td class="nump">1,671,076<span></span>
</td>
<td class="nump">1,307,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,732<span></span>
</td>
<td class="nump">2,816,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,684,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Summary of option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized compensation expense</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_EquityIncentivePlan2019AsAmendedMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Summary of option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options issued</a></td>
<td class="nump">1,671,075<span></span>
</td>
<td class="nump">52,878,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the beginning</a></td>
<td class="nump">1,307,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options and RSU's outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,260<span></span>
</td>
<td class="nump">2,101,075<span></span>
</td>
<td class="nump">1,804,452<span></span>
</td>
<td class="nump">1,606,704<span></span>
</td>
<td class="nump">1,235,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for grant</a></td>
<td class="nump">432,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_EquityIncentivePlan2019AsAmendedMember', window );">2019 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Summary of option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tlsi_EquityIncentivePlan2019AsAmendedMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Summary of option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tlsi_EquityIncentivePlan2019AsAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tlsi_EquityIncentivePlan2019AsAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R170.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683660500800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">21,097,831<span></span>
</td>
<td class="nump">13,381,126<span></span>
</td>
<td class="nump">16,879,990<span></span>
</td>
<td class="nump">12,731,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,015,002<span></span>
</td>
<td class="nump">11,624,155<span></span>
</td>
<td class="nump">12,330,395<span></span>
</td>
<td class="nump">11,376,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantsMember', window );">Preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878,519<span></span>
</td>
<td class="nump">46,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,632,206<span></span>
</td>
<td class="nump">1,710,860<span></span>
</td>
<td class="nump">1,671,076<span></span>
</td>
<td class="nump">1,307,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tlsi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R171.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683666124000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision', window );">Deemed dividend to the preferred stockholders | $</a></td>
<td class="nump">$ 2,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_DeemedDividendIncreaseInNetLossPerShare', window );">Increase in net loss per share from deemed dividend | $ / shares</a></td>
<td class="nump">$ 9.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeemedDividendIncreaseInNetLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of per share increase in net loss from deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeemedDividendIncreaseInNetLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividend related to Series B-2 preferred stock down round provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R172.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683664999232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">$ 1,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FinanceLeaseAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FinanceLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FinanceLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R173.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683667842368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FinanceLeaseCostAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FinanceLeaseCost', window );">Total finance lease expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R174.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683671007088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Components of lease expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R175.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683757673504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future minimum lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 2,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R176.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683647613360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Future minimum lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfOperatingLeases', window );">Number of operating leases</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfFinanceLeases', window );">Number of finance leases</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average life of operating lease</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average life of finance lease</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of operating lease</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of finance lease</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierEquipmentMember', window );">Copier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfFinanceLeases', window );">Number of finance leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierInWestminsterFacilityMember', window );">Copier in westminster facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_AnalyticalEquipmentInLaboratoryFacilityMember', window );">Analytical equipment in laboratory facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfFinanceLeases', window );">Number of finance leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_FinanceLeaseLiabilitiesCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_PrincipalAdministrativeAndProductionFacilityMember', window );">Principal administrative and production facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">two options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember', window );">Lease for office space at 2275 Half Day Road</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_FinanceLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_FinanceLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierInWestminsterFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_CopierInWestminsterFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_AnalyticalEquipmentInLaboratoryFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_AnalyticalEquipmentInLaboratoryFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_PrincipalAdministrativeAndProductionFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_PrincipalAdministrativeAndProductionFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R177.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683661320080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Mar. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Amount of matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfPatentsSuitFiled', window );">Number of patents for which suit filed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_NumberOfPatentsTestimonyLimited', window );">Number of patents for which testimony is limited | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_CurePeriod', window );">Cure period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_LossContingencyDamagesPaidValueNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionUptoThreePercentMember', window );">Employee's contribution of up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenThreeAndFourPercentMember', window );">Employee's contribution between 3% and 4%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenFourAndFivePercentMember', window );">Employee's contribution between 4% and 5%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages settled value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense | First installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages settled value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense | Second installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages settled value</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_CurePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cure period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_CurePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_LossContingencyDamagesPaidValueNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of installments in which agreed damages is paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_LossContingencyDamagesPaidValueNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfPatentsSuitFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents for which suit was filed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfPatentsSuitFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_NumberOfPatentsTestimonyLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents for which testimony is limited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_NumberOfPatentsTestimonyLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionUptoThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_EmployeeContributionUptoThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenThreeAndFourPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenThreeAndFourPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenFourAndFivePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_EmployeeContributionBetweenFourAndFivePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_FirstInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_FirstInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tlsi_SecondInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tlsi_SecondInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R178.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140683647640112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger Agreement with MedTech Acquisition Corporation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember', window );">Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember', window );">Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember', window );">Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember', window );">Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember', window );">Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember', window );">Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Aggregate consideration payable</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_BusinessCombinationWarrantsConsideration', window );">Warrants consideration</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsi_BusinessCombinationAcquisitionExpensesDeferred', window );">Deferred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-4 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-5 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series A-6 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series B-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series B-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember', window );">TriSalus | MedTech Acquisition Corporation | Series B-3 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger Agreement with MedTech Acquisition Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_BusinessCombinationAcquisitionExpensesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of business acquisition cost deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_BusinessCombinationAcquisitionExpensesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsi_BusinessCombinationWarrantsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  consideration for the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsi_BusinessCombinationWarrantsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA4ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA5ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesA6ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tlsi_SeriesB3ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tlsi_TrisalusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>tlsi-20230630xs1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tlsi="http://trisaluslifesci.com/20230630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tlsi-20230630.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_25lDX06in0-qNkGhQyvfQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Rp9zrLRlm0CYZN74Ck2XNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_m13ANPolnkC_TrigPHT8kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_0Joxy8nL_k6rabaYjK9iOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_nHo1vJsJrkKTnWl_TCasMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_G8V4djaCEkCway9XsOM4DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Xpnlw4k0NkuO1sNJfiAs9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_MB7pT5iLf0uF_V9jm7PXzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputInceptionDiscountRateMember_mzUQ236JO0anFu5jzI22tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_Wce1nzVCUkqX390MzkZu9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Qppm2hRKWU60ummLMBfT1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_iVlKykJbaEi1jw6dwN8Bmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WdW_HNNUdE21vIAEvcd5UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_a8ra3C8AWUOIDlIdA4ccMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_Rf1rpKHlWkavH2VB0BmDhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_n9CPBSe_t0CIf2MEce1Hbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_X-8bVslRMUid_3Y3ZJ4oPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_cJo1v1yvJ0KPv470OFqLQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_YRX9eNe2yk2VIn3MFun3YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_lounZVZfw0O8AKj7iHFE-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_hN-8AGcFuEuZnr2HwF1cJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_v8JMAlK36k2t47JlYo0chg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w_J4gh8nE0iBqb1LS2a64w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_kucXttDDKkm2baEp3zUfTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e_Hw10IjjUGLlhJfGUN8KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_4OU6RNLQI0m02PWitPh6_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_pkty5j8Sy0Go5dYfRJilQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_d8SWm3qiNEy8rA1CdxgJzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kfYB5YdzlU25J8QBvIS-0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_rHR-FeR1skyizmwP_cj_wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_2BqQnWUrKUS-sNcB_hxrKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dVErUypF_kmGT88HG0br_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mxqu6HErZkefO1cAxk8GhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_iTZWPgkZoEq7CXYI1m6Ohg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_SwY35kQgfk2dbaaXKgOEjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_yR9f-JPIGUujVs37FEydrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_az5NgdPmYEyG5PMwrX8MQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_n2Hy7mytPUCwfCaVDdp1yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0AcI-Ohrv0KOD6jjNcyFJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_p1P46KnXQEWJ8sMTS1L0LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_j-5jcvWtPkWU5cOve1Ihkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UBHriL6i-U6Bz3QKMBjg8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_lAPd1qaSFUOkNSYqELJ4Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_GkzygEWdwkGIA2Hdptj-cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AtUfw1J3o0mUu0fWLK3F2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_SpKOv8seVEehXwRiUfpyGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Ud_kLyd8f0OBg8UKavOv8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_FovQYveUg0eH1LzMQqa8QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_L9vZuhgzoEacaBLEGmOqKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_B4SIjbwX80epv50y8th_fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_j2yRaHhWpkeOdK0kZMluwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bssbHLSzMUK2YenLYRNChw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_w6jktUReSU6j4r6UpAQFPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_cea7kamFTU22C8ALOM0GOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Zc1cKHOFuE287fqlH5Vrlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_gjy8I8__kk2j4tbbvWuraA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_TPmSEZHn3kuue57QJjzxuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_no3I2F75LU6zm401jb81jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_Odw8LxLv6U6EdXprDOfRGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_u1kddxNyJUmK6bKY3LELxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Z9YkJw2n8E-yk3Qt_1NPmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_AQay36hQlke0WUBpyZbKSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_VQjBztCgREimLMoQNXlNZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_H2sJkceQxk2-u0Rxe759jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_3a3-tw6PskK-JRJJsHXixQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kPXiLC6i0kmzr0XFHhfPLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_WsB6XkUK_EudysZ944qZNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_94WSWWTYZ0-oiPrmTAHAog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9ph7-9habkWVkrJfwFcs6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_V6c578Z9dUakm48y3fS_Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_tlsi_ConvertibleNotesAndWarrantsMember_w8EJUYCkGEaDC6o1zmBY8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tlsi:ConvertibleNotesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mOezHh-BNkaD4qPijc7hSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-MRJe6VGPUipa0NC3BILAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4B_cIF7e5UODEBv68U8L3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Adumul5f_Emd_SmbobiJGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-11</startDate>
            <endDate>2020-09-11</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wLjUOHJXF0auOVXVpPAl0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YYKvXH4qESsBarliMaTVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PI-ObqYFzUCIPTC8H9DIcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J5RUj6hZ_kW5XH1lPZrp9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_b5EJjukOmUCZShWroteuUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gAe7cbk-Ik2xnUHTe-lZNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VwGAxYqj30auZ7FoL0bSaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_daSSC4kDIUWJG6OwMuYQ7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NSmQJB__l0yYnVCxzz6oDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gBMde9-vjEq-B-QzZmmW9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gexd2UdIVEm-wcSYwLDc0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZZNP8UD0GUO6uzjHEM33Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_Bf2tptIPOU6oGPVXVUCTjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_c6idVF-ySEuT1HSIivSjLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iOL4HjdfO0Km7gzdEnTioA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_OYgjx4XmSkGPAAF-Re-xWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jSD5X1FfwUGwejMu7znIQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vK2xj6_BxUyXDij_MHIdJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jrQIVcWI-069v0ykyuASTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_polfWIhfYU6ib1Sd0a3R4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0kAqZczoU06tzJG4_2vBug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_GRTEC4z9hku2SFFVuuuxUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_aQAt3IxfvU6l-oEcuIHn0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tc_V7gDSeUmpSxYMDtGWdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_8YJDeE11cE2EQ4ztbjcPYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.09To0.46Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.005Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.001Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember__BRrOWeWS02G7DSzlPGD0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wfMDLkDNqEO3xSkwvmaxgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OCE06-VX20WwiST2nFqLhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-JQHw6enTUqU0PtNBY6i1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_xHLJVJ8VWkiIevSmCiWZ6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_8_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_eJO2ISwMrkCXvzy18ph9pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-08</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_FJuc69Mu_0KlSo6eQPUexg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_mmQ5QRZtFUmMijBSylDvfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-13</instant>
        </period>
    </context>
    <context id="As_Of_12_20_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_C40yv7V3Uk-CTwQZSf-3fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="As_Of_9_23_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_SEb9zumk50CCxQ_gl3sqTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-23</instant>
        </period>
    </context>
    <context id="As_Of_3_2_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_hYo6l3T-EkW_DjtHSivOsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_-vVRuuYOS0yFk8mPXLMGtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Ewnc-WVz9ku_b5ftkI7wMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_EbEeXi4j7EGJVYkS9xiwOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_5m-lXEUUKkGjcNnQvX8_4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_9Uda4Ka9V0W5_fLKlUaijw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:EquityIncentivePlan2019AsAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vVJ6K-dKOUaqNkzDlxnlNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_y-7dsjtGUkKm-ryLp0va2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FcaQ3gGcXUGxDiS7u2MNxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_8Jq5kxQISkum-Rv6Ika4FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_cg1NyxPfCkWCdJlnSrnvrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TJoHaLkdN0KmClA53sXJgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gIaBMU-_LU6xAQZ8ZjYntA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_gSf4GXYVD0WuBgBuDWBn0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">tlsi:AccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_ffngkVT0QkSB0YxjNIwPKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Mnxv0wTYjEKdigU5lNSyow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Bd5mwUEb0keN4-RoxS7_YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">tlsi:AccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_R6XCzzcbnUOZXAK4sUOmgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Ss29-0arFEmgdC-qVRGyZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_COg4MMgPikKQtsRGe2ldbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_TpLPz4TCh0OaDlbyebwvQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Yy4qomYWEumToz2Q3IF5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_grIe4j2NjUW8eovYdmDsAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ANvX6KP4G0CXL1ffGVduvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_Yzsv-OD0SkGrA-t5QrzSQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ekxf6NMJqU2o-owseUO9jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_8jVm0JgFSkq10jUH1ZLKNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4rbUCoNCLkiKBrrFNhgp2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dnZOErz2JUevW3yh4sbChw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_5abH1QNeh0GMJn5kZVJQ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_GWy7uUXZB0aOm-obxy2m_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_NkH9eTFLRkK7c-mjvyXwSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_0iOOdQCvqky-8LHpNIwfpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_e-IRiyeUokWhELXaV-4wUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_1_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_LqmQyedzNEqB45yzduiYgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_V-j5MOfUwUGyMV160Ndygg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_PDIZOYv6rka-K3_56EQVNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_6hORdNW_yE623vRVLJelFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_10_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f8UN7L2qYEiwdyhrpna6mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_JxTqOZ5zzEWxBqVPHktsLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_9_30_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_2DKAccvY4ESMxGwfCcxgEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_9_2023_To_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_EQp5eTc6Nk61dCNahJBvFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_jVhbJpAu0kG_D4Un6eb0-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_rmbLcmOtAU-0t0vs9Lj3pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dQMI2sHi4EGNCkXWwNvsLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3grY9SX1cEWH0kR90lBaDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_tfAYqXS-rkCNMjlKTM0Vmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-z57Xm8kCEOcnn9iDm5FJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NYFdJrTKuU2AdqrUK_6Juw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kHWGZ6RfI0-CW2KwDqzmJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUa9pt6UYU2qKZU1q7KGtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BHFAAUN4h0mbBW1Dpe_8vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wivqVnmy-EKDR9DGDZZYDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_1lqC9l63wEiuJzSe6Hi-cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_3_11_2021_To_3_11_2021__-g4Qp5Pyka4gA7LbeyrTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_srt_StatementScenarioAxis_tlsi_SecondInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XU3a0ehnaEO_Yn_QEfUcqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:SecondInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2021_To_11_18_2021_srt_StatementScenarioAxis_tlsi_FirstInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Lr-_cbK0CE6ccIYutbIUoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:FirstInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-18</endDate>
        </period>
    </context>
    <context id="Duration_11_15_2021_To_11_15_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NTqWL_rATUeGsMWY1n5tKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="As_Of_2_8_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_I5SxmOgITEqkvbLNanEY2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:PromissoryNote2022ThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-08</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aZgwMCP6sEuHAa1-q5dwCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-13</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8QPxAWLYn0eSa29pAZk5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:PromissoryNote2022ThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_LongtermDebtTypeAxis_tlsi_ExtensionNoteMember_tiwUkSJfkE-HqTQAgDXx9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tlsi:ExtensionNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_jb_q390JZkiH38PyUwE9zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_rS227lpA-0ato7P2m7Pn8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_wbUeBXlixU2vDzFtryoUTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_J6vJujbvTU-jEUmIjkq0yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_OKx8PR3Il0avdary9MaUKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_UfT8ljsnjEiwXR-Eomw_NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheRightsAndObligationsAssociatedWithSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_4mN-bA9Uz0yu-SCx5mjf4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_UO7Dm79BGEGf58YUPTUeig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_om9EAvh6fk-yKmSCpi6WYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:MeasurementAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_nogwz9gxqU-ku2Q36qb4nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:PrincipalAdministrativeAndProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_Wpnc4LkhDkOnH49fJmT_-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:LeaseForOfficeSpaceAtHalfDayRoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_CWI5Bga8AE2e_En3lvUg6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:PrincipalAdministrativeAndProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w0DdgmyjNEGACAuQcuscQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_4rgr5dtwgkOc8kEvgOYxOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:CopierInWestminsterFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_oBhuknZam0qxfv5h_KKCBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_UH_cOo5McUeHvPGUA75elg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_0h9HVSfBy0CDyP55pbIu_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_-mgXyb38JkOXu9Btsyc7MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_prO-azAGCkKvlOGQ87zRuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_0GubflhbPUawUpS7hbiulg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_wRJ1i4W4p0yQRHB5YvbGBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB3WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_7kh5ioPPCU2NcXnDWvOSDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_5m4IloO620mxYhPYECQr_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_4e0nEOiYy0GXKQ8LC542oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_HJefUCEOC0ila6lDpRZnrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_t0-7UkxO_EO65rt0UdRyZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_z7ZUYrej5U-HRCyTPGR3Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9FstVZm760uM_Oiv3BV2pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_mON5gWTp7EKirtCszFVuWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lDZmpqyvbUGnBpoWYEe-5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_NpeQJRDSdU60CDOOsBwD5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WJzJV0pqcEuaZ1x08vBwUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_ZC3gPhsLq0C-Ql-nVHkpag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_7fyqcBdnXkWyRm6NSBBkYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:PutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dOs7dd0euEGpMogpANdTlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XjvP2qF1UUWER7JjNd59jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_4G4-51YVe0-W2QwDgj40EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB3WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_5bX39y7wV06kY0hYQDIn6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9tvbOtUSfE2CdGMRe7SRBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:PutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_peL04lSM_U-U4I3kzipk2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_YldtoLvAcESUUN65IvBRSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_zWZM6-KBpkui8gyBIKU0hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_DAgjRnDA-kiGIHGiIR6buA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_T7Li9gpr_0G4t4E0kCavKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Wub9s-eMQkCXY7--e9OtAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LjBcrN9xrU2acLCoC3csdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_UBk3dK2cpk-EifzkXC7RPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:ValuationReverseRecapitalizationApproachEnterpriseValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yQXpaQmMKkOs4sGjRq4fiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_U3Mfr4KP40avhKdtSM8eCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_tK0vLXJF0k6IM1QbPso1tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lJ2gu3Wxtka5YhLPEJVNXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_79RwHeAEqk6ErcJTlraR9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_bjN6UWcFCUm13QmQZ585Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BinomialTrancheModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_gJ1cZLTqKkOyAt34WAIZFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BinomialTrancheModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_xf9JNaLZckaWeYpqmrjafw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:ValuationReverseRecapitalizationApproachEnterpriseValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_o6rFJS2RUEmPlThbUoOgeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_ljGYthGmzESwFy_58hlCQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputExerciseSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_HEqBbWgIskKT23W1Znx3WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputExerciseSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:GuidelinePublicCompanyModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_ValuationTechniqueAxis_tlsi_BlackScholesModelMember_Bc0NkOT9wEihH_2yOvMkbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">tlsi:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_jRIu7P7O9kCs7H6PMq9I4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_bGF1dz-8s06ozP-Wejxjuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2TrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_D-d-uo6wjU6j8DmtuRLnlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_YfJXZ7psnU-0gET12ACfMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_yQOpRc5_AUSFptkZf40mhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1gIIWYB_SU-WziuVHJK-DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember__2jiobm5aUuVXVU4BFopyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_djynE7y46UuGJtBrPjxTbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_MdOc8gt9DkG_ANRSNF1Feg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_vLPoVC9kzEqm61EhV_wbdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_7-Ei6pQlX0-G_ZB2qY5krg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_kVRrUl0H3EKb1JhB7W02Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:MTACWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_u3QAPFO_gkSJ1bhVwH2ETQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_p0n0zYd2Y0m3WvEBclIL9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_TN5C51PNT0GEkx_dOCvSqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_0y-vFKCdP0GBKfV2QNnuaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_VNbM6PPC7Ui-DQUvI1KgNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:TrancheAndWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionUptoThreePercentMember_cv3StuhiV0WTIiY4lV9S9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionUptoThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_Fo9HbOq37U21cbLPB6-3eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionBetweenThreeAndFourPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenFourAndFivePercentMember_aGOIseMil0e-w33qyFfkww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:EmployeeContributionBetweenFourAndFivePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_oBl1u_pQM06egIcZ8MCY8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_8Tcmoc6fkkCSZMerDheLAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_MiWZm6fBjEKUajPVpCkIUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_HS9G4zEpn0eaK4XwwKWnBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-28</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_30_2021_us-gaap_DebtInstrumentAxis_tlsi_TermLoanAndSupplementalTermLoanMember_K5TX_Dl3_UOXwI1TQxgdow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:TermLoanAndSupplementalTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_Jzm_A_jvhUqwLkEpaKybUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:RelatedPartyLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_IJINUXuw9ECauZXpwrbGYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="Duration_4_19_2021_To_4_19_2021_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_SAPDdK4uLkukkpYiynrn7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tlsi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_JJrctF3Ss0aVYnhFS_75uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_Z3lUDqKSpU2d131KWzDy6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_QnfyiZ486EqFzaXxwbOqWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_o2D8Am3EA0qP-aO4LNlnsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_n7C8O3tfnEa9PI51Rt_RTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_c8vgoPz11Emp9qsaEJDkKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_unAxPM_nUkazhDm3agcBLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ciY8mEnJHkKZYJWWeE3zcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_spU-CoGWskCTi4k7rsFi5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o17RMY4e1kCnffIskGGRgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_chTyyFWls023GE6-jbCH2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_WarrantMember_IqC1qJJSQUWIbrrHEeO5HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_EmployeeStockOptionMember_3KKxG7YSZUSyqE0uG1rr9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_ConvertiblePreferredStockMember__NAecSCB_kCj1haUJLi3OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_IUEdiusOq0Ggfdrn4ZnVkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantToPurchaseSeriesSixPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_kmZ2EGx-bE20yy95aA1umQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantToPurchaseSeriesFivePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_FH-Sf7Hf3EiGk-qmzaSrtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantsToPurchaseSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_ZQxUbocD4UC-2DmmXP5A4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:WarrantsToPurchaseSeriesB3PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsOutstandingMember_Qeaap63POUSl7kq016l15Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:StockOptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsAvailableForFutureGrantMember_x-OjXsG_GU2kREkY5w2Tfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:StockOptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesBConvertiblePreferredStockMember_YcYnzFlBjEak37oDh3RW8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_ubWSfyc1rESSfcBRziTGkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_R3C848oe2UKgjk229Eov0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_L9okU4WLpk-102h2M_xYYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JfpRQYxY-UKeBky1qs6kyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_78cDcL2q8UmHmCn5D2OBjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_CMG6zRmmJk-DrVcCs784UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_D2982Aa3FUev4xmNbgrmLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AbCmIlVGwU2jFoD1_oyB1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:CapitalShareReservedForFutureIssuanceAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ly_yjlxk9kaGKN3_pao1QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_-wdfKUjnDUyvvNS1vvWscg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_TqnHEEX_6U2SUQQnKIvWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_RdkVFV-BmUiRk_p7buc6iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember__XDMheCIA0mYIUNydTkduw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lE_mD9hOd0STU9O_pFbkxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dqYj144kIECijtd5V_e50g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_5P40y196CUq_heFGRG6Rdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_CMmCuzre6E-tcEDvHRTyuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OXuKzykTU0aBwch15YAXNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_g1Y_0bPfVUeHvgx_nTS4NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_Q_kjqMAvdUaQjRHDJ3DK2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_JNDGtibE0E6YxR5fvB4Kuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ilNvF-LtlEuM40NvOR74NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DMJEIP8fGUaGXbZBbwD0BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_pSuIgL5MgkW3Hup01vec-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_P_hbBZGvG0SAPWdr9iTosQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1sI5wKqJ1kuQbBSeQbH8aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tt5jNBG_Ik2_dw16N9eu5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_ApO8mJ0Y8k2llY2j78FSwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_CounterpartyNameAxis_tlsi_TrisalusMember_us-gaap_TypeOfArrangementAxis_tlsi_MergerAgreementMember_ZN8XEh8o7U6Eq1INZQlX_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_LyZj3LV5jUiUFferyoGtMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_M4z_mBalEE6paS3q3L0Vjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Hdz3D5qVJE2TxNezwlDqVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantMember_nusetr3QVEyFrcC8HvKhQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_MMnEXq3f5UuA9b_f9X_bWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember__tC8H3YIX0S5r6g2u5BcaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_sFPUIoXf4E6S5yFU1jhaWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_bEObA7CvVkWwdUC6J69fXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RlRaDCvakUCj5EZrtYDWeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantMember_OZsWLbb_CUea_sEX2DVygw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_SXG7MYzIGUCgqGneHO46ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_tO2ji53wmU-1qqLGxMnwug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_egZnUbZL7UuFABnCiYNEEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantsMember_XSIPBticd0u3pNKbWJTJMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tlsi:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvBwoibMpE-Z98sDm4_9Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s45KCdyGNkGuDVWgIQ86KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_ycMhMOSauU-qDs_XF5sQ8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lGYh6vgZNkWoq1VwMwVVnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_siP3YoYtZU2LiMLvWdN7xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kVYk9im19EGexCFAmViCqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ebJaNhnAhkKomsCxm4SEeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pILTs-HrB0uQSMTr-D17nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_06c-BVDZVUSTkxyfqRQpPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tlsi:SeriesB2TrancheLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_RBw78ON9SUGlT5g_SudELQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_21ZnY62BB0aviR0_y6NS1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_jzrdTKUMPkaJYvHWOVu7LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_nysdtTEnvUyJymOGjXTL2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tlsi:MeasurementInputFairValueOfUnderlyingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendPaymentMember_Tw6UZ9TXRk2sGpM7oFAZCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UK6sekRvOEe_2GBgz560wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_3b9pYLI57U2CBSFmckSYmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_zcWk9JPUm0aHGEFVscgstQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_PWoqiQtqAEGjuMjXT5sw3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_G42a6weQT06upXOSAO8LBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_0r7I6QWZA0GsYAkditjprg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Fall2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Fall2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Spring2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:March2021FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA4ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RT4r_FWuwky0MaFoh-QwIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CzvQjMCE50yLWqH7Ft3yaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_26RYOBDJd0m4B-qQpNBrnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_12_2022_To_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_71ivAMN5WEaesHqSjeTrwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.09To0.46Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.005Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">tlsi:ExercisePriceOf0.001Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jdMJ3tTPVki2UbZF3EKNtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_uj5I6WUTUkaK0xF0RTcbcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tlsi:A2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_wobYTtCwpU6MS4kEO9U9KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_6MR-PsP6QE615ZeUhGehHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_aUCSUO5VHk6A6DggrcFYYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_II1Zn2a3G0K5tjXGFPo3uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_GF-K_2uVu02v02J0fL-JeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_gKTiACbSCUajmar_Jm_ALg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_OZVZQrBqCEGgs_ptg5yGoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:IssuanceOfPromissoryNote2022ToSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_srt_CounterpartyNameAxis_tlsi_MedTechAcquisitionCorporationMember_Nh62w64sX0GFn1hFJJgndg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tlsi:MedTechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_wJYhKnteSUeKXfPhHtBzkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_BhA3ZSO6j0m1LCmgkuwIQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RCz63iBnwEquUzALofbf-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3-ZqQhxZkGHRMDML9MFaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_rezUy1wqukqJitR5qGefCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_LAf8O94CsUeODp-5oXER8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_tKNgd2GCgESsCQV33cAzXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_xbC97N33okWvF9zYFtzwMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_y3jzsSpPn06F9ea0zBxkMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:MtacClassCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierEquipmentMember_yN9PhUZ9oUmQbLbfhyWOVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:CopierEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_XOapO_xAxkSVGyKMkyZktQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:AnalyticalEquipmentInLaboratoryFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LVK9Ysk-RU6dEwdwJdOHYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_TmWc_b8zrkOoESGM-nlcbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pP0da2xH7UW_LfRCdr8p5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xh7u3lp9k0iiIeQaqMuClw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tlsi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_A5ZRtG0Mp0KDhqGdsKvyPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_lt1UpQkALESaPZXbSwBQZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_XlqBY_bMDkKgTAzVoxZklQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="As_Of_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_Vt3SPP67yUGmnpcjM2X0Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="Duration_11_15_2021_To_11_15_2021_b3QxwyefQ0edxXCsFdJSjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_XOPnCg0EYEC20KqnpImsyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tlsi:AnalyticalEquipmentInLaboratoryFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:Financing2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_xbdsgc83CU-hmC04QM8BBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:BusinessCombinationScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_HwXyrgNF9kSQ67jpRCw_4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyOnePromissoryNoteMember_rhZTQ658W0at8bOMTC8FaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">tlsi:TwoThousandTwentyOnePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="Duration_10_8_2023_To_10_8_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_b2HZiZvawEOx8-1-aQfYAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-08</startDate>
            <endDate>2023-10-08</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_Pqp-qsKfKUquIRMTUTshbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:DerivativeInstrumentContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_QW7EfoeCZUGUfloNheRNUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">tlsi:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_S0Lcn3b7qUysLIF0lPwnmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_cmpIjKVmEEiX0-ssByWUEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_wfMBzSQGZkKbDc2aHYdY9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_cjlWfxkjMkGCwnUKknuA_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_QkCtTzY3sU-AQnJ_aipXPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_Kkt3ckHCjEGBa9C6I-e57g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_bzhbnoR9okG4s-q-sw9axQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_k5WzB7ynsUKBqdgC_-pE5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsi:DerivativeInstrumentPeriodAxis">tlsi:DerivativeInstrumentPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="As_Of_10_8_2023_-N_ZHqE3nU2aqMlyR4MjcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2023-10-08</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_1J2ClcRDUUC7d2IrxMQFMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:RaymondJamesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wbWlcEUxYUS1rDanZQ4z-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jGJ8x1reCEyfHu4lILMFaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_Kxpz0qSUe0mhCS0fzXQnrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2009-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-10-02</endDate>
        </period>
    </context>
    <context id="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-10-02</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember__otGtNiDqUS3D-2IJAK-XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:TrancheAxis">tlsi:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_dsiZTjMLTEKnTS_3xuMRbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_qmSmw3DpY0WjaiDXUJYiOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_qO_tJd7jHECOCsFdPPXStg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:RelatedPartyLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn11202018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn10272016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn08262015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA5PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:WarrantsIssuedOn06302017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesA6PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesB3ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA6ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:SeriesA5ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_RHMSaTNJIEmzTCVVY75WyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tlsi:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7GgzZHKQ-Em17ealfdPxcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_vkr2IKtEfkK2saNonouWWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:MtacClassCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_HDWwXtuDDUqAhelDAH9-9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tlsi:TrisalusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3VDT5dIz0yqR_H8-7yMPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestoneFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone500000AnnualSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone250000AnnualSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestone1000000AnnualSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_1pk8tgoJY0SRZ1kWItulfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tlsi:CommercialMilestoneTypeAxis">tlsi:CommercialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tlsi:DynavaxTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_xsabo2n52UilLgijgS19aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:AggregateAnnualNetSalesGreaterThan1000000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf500000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf250000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:UponFirstOccurrenceOfAnnualNetSalesOf1000000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tlsi:AggregateAnnualNetSalesLessThanOrEqualTo1000000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tlsi:DynavaxPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tlsi:SeriesB2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tlsi:B2PreferredStockFinancingSecondTrancheClosingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_wGOWYsCQ5ku3FPlY92CUbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tlsi:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tlsi:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tlsi:MedtechAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ">
        <measure>tlsi:customer</measure>
    </unit>
    <unit id="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg">
        <measure>tlsi:patent</measure>
    </unit>
    <unit id="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">
        <measure>tlsi:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q">
        <measure>tlsi:segment</measure>
    </unit>
    <unit id="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA">
        <measure>tlsi:Milestone</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">
        <measure>tlsi:D</measure>
    </unit>
    <unit id="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg">
        <measure>tlsi:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">
        <measure>tlsi:item</measure>
    </unit>
    <unit id="Unit_Standard_installment_0xHPpLFYGkuxngV0kCBNoQ">
        <measure>tlsi:installment</measure>
    </unit>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      id="Hidden_hEWHjdpaqEmDJ8rJJtuMSg">http://fasb.org/srt/2023#OfficerMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      id="Hidden_0uAmhLx37kmMeu6JYwSpdQ">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      id="Hidden_wC5tKaPCI02xKBFgae0GHg">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      id="Hidden_srz1yOgJk0yT6Oi9nTltqw">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Hidden_IHOqsN5VBE2fYTqDamTD_g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Hidden_4Rb3HZ7YJUO-talCZjeiIQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Hidden_OJYM0hi69UmtMbvo15SFqA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Hidden_b6ImW9IeQUasGJKmmhoIyA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Hidden_pk70F63lqki1D9grphKNIQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Hidden_5SPZGeCxe0S-tXPBv0ErJA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Hidden_E2BSRmatsEOoepPdjWNoDQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Hidden_-TYIfX8tYUq6QGwvbRq2KQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Hidden_PGeoap2kbES85OLJxH3XvQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Hidden_Wpt77xBz9kWEzY7OiYMTMg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Hidden_jz_e7WblyE-1Bl5cl61WeA">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="INF"
      id="Hidden_GmdJagC4QEqR94i1L7BnQg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5331943</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Hidden_fMqDHJuZfkKsjkdzOr-5PA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5331943</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="INF"
      id="Hidden_PdbO3qeysEm9BeCQ1HyZjA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5331943</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Hidden_lZ1wbBR_AEqRNTeQ2eNi_A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5331943</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="INF"
      id="Hidden_d9HmYbhmUEql5W0hyfnOjw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23307464</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Hidden_yVozK5movEyUEipRcm_skg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23307464</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="INF"
      id="Hidden_NNRfWnBCw0eJNjdjreMURQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23307464</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Hidden_84VBOMPLm0-dL0j-3ECVwQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23307464</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="INF"
      id="Hidden_udhlawH-MUKOYrDpM2aydg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">24792020</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Hidden_dsSoj5LstEuFvQsmenN0xw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">24792020</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="INF"
      id="Hidden_3cOPFsYw70aXK0x_YY5ibg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">24792020</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Hidden_ePMPpDq6v0CK7s_8g3honA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">24792020</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="INF"
      id="Hidden_bLf7M8D1zE2rC3pxfJMSLA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5169690</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Hidden_voFa5pe7DUypjGRp8OQjew"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5169690</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="INF"
      id="Hidden_9V6TE6x1wEauvuI-rrDxyQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5169690</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Hidden_PmLSRxbUwE2QryRQulmbxg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5169690</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="INF"
      id="Hidden_4sUcCQK9wEyjFzRHLObDBw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">29545455</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Hidden_7KYGLEay5EibqsGMIE89vA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">29545455</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="INF"
      id="Hidden_MZUlS2GiW0G7nLTHy5Zcxw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">32391000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Hidden_M6HJZyLV9U26_Ok0b0Uy2Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">32391000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q"
      decimals="INF"
      id="Hidden_XJ_7vamH80anLN9UOIzRgA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Hidden_RC5nkNkWiUaAYNYHOZbyPw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:TemporaryEquitySharesIssued>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tc_ICBlboi8H0Ov3ke1Ktbj1w_2_1">0001826667</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tc__ZoB-TK--UGkBJrMb2YdXw_3_1">true</dei:AmendmentFlag>
    <dei:AmendmentDescription
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Hidden_Pz3-aZKVPEagACyzY8ZLrg">AMENDMENT NO. 3</dei:AmendmentDescription>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Hidden_xWgaFrhPg0G0LJX8EzlMuw">S-1/A</dei:DocumentType>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      id="Hidden_6NASHxsNhUWqUIlF6AmGRw">http://fasb.org/srt/2023#OfficerMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      id="Hidden_iNvGd1yKm0-3yMIN_CTOsw">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Hidden_mJe2zsZH4kOfjy-NS1oSag"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3842998</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      id="Hidden__l_n-zwG9EeRbMmLFtmXMw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      id="Hidden_2f0FE7DwkUujpx4HM72l_w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg"
      xsi:nil="true"/>
    <tlsi:RedemptionPeriodUponClosure
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Hidden_8o7rIpLqL0adL1dGev6vwQ">P10D</tlsi:RedemptionPeriodUponClosure>
    <tlsi:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="4"
      id="Hidden_MkCiTlqYpkyh8SfuJUz1DA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0033</tlsi:NumberOfWarrantsIssuedPerUnit>
    <tlsi:BusinessCombinationsOfWarrantToPurchase
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_vkr2IKtEfkK2saNonouWWA"
      decimals="4"
      id="Hidden_tErA0HV8TUSeW-q1gHsPXg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0033</tlsi:BusinessCombinationsOfWarrantToPurchase>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Hidden_gXPw_HPigEaLTrob0MTpMA">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      id="Hidden_2rj7F36mjUqkt3ooiJGgKw">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden__lATSp_YGkqaGlHAuRVnnA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg"
      decimals="INF"
      id="Hidden_Ik-aY2A_jE63wIuR7UyzxQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_HWG6UscIlEaGvR5SEqX7hg"
      decimals="-3"
      id="Hidden_E4ll_gLBaEKReg0u9L57fA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw"
      decimals="-3"
      id="Hidden_KK59tWCaEUuJB54qaw6hYw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw"
      decimals="INF"
      id="Hidden_6PBZ3tLP70iHvRVOg6SEvw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eDCmMiD-S0i65hll1NDjsw"
      decimals="-3"
      id="Hidden_mStXdH1f4ki5O4OxCGWhIA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA"
      decimals="-3"
      id="Hidden_9ja8HteS90a0p7WpZcVgWw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A"
      decimals="INF"
      id="Hidden_Ev_u3OXaCUWJcSjZ4HGqRg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EB7JuijCSEaef5uRzur8-A"
      decimals="-3"
      id="Hidden_NzkeQmyzwEqzGAZViRfbSw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw"
      decimals="-3"
      id="Hidden_rORiQd8xoUiQi4Bgch3EXg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw"
      decimals="-3"
      id="Hidden_P_r4of4hd0KZsZrm_28PQQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA"
      decimals="-3"
      id="Hidden_O8EyWJtM2kqmmJRUvl-qlA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ"
      decimals="-3"
      id="Hidden_bjBXccsdxkSy45ztWFjM-Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w"
      decimals="-3"
      id="Hidden_wkeHRludRkq2fuu18Uz84Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:StockholdersEquity>
    <tlsi:CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays
      contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww"
      id="Hidden_3ei8mRKxXUqQjdtfqOZDNA">P3D</tlsi:CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_COg4MMgPikKQtsRGe2ldbw"
      id="Hidden_TGerLk0gnEGuJJZj4XcYiQ">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_TpLPz4TCh0OaDlbyebwvQw"
      id="Hidden_n3iyYUo2ik-Sz0AnGN46Zg">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_10_8_2023_-N_ZHqE3nU2aqMlyR4MjcQ"
      id="Hidden_Lb4zgAF5e0CJPYvsKdE9Yw">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Hidden_V-mQW-qQIUa1vQtlrdyyEg">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Hidden_2n4YMje6bU2yQX9mVj9haw">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Hidden_tM-2Y2RyQUOzCJbuqMIVTw">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Hidden_i6irmobClEimgYt4sNAgmg">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice
      contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw"
      id="Hidden_5hLzbZ6A6U-WazkWaQSF7A">P10D</tlsi:PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Hidden_MGlu3JgwP0qQ1n5yi83_7Q">P10Y</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden_6Tz5Z9c8bUyOeKGuhhUwgw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">142000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden_gI9YjpVWsES8mrCJx_zz-A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">32357000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden_G_sKOz3pS0e7k4l56q5hag"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">34319000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Hidden_aaQdiWrtqEOASK7EYWjkdA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Hidden_xTDCpcpvCUOG0LVU4dkrTA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">264977</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden_F9yMPOv05EiBNsMwQ9IylA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10028000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Hidden_M1dWk5e9m0KG5yLnLGB_PA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-176330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw"
      decimals="-3"
      id="Hidden_X5CnAy8BbkqdT58gfX2FcQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Hidden_NaQHkAWSzk2neGw_XEl-TQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-129604000</us-gaap:StockholdersEquity>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw"
      decimals="-3"
      id="Hidden_ZCuk_ZdpA0SUrfc6xIvFJg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">113796000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      id="Hidden_b16GYIIPRE-ojj7RlH_rdQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA"
      decimals="2"
      id="Hidden_PxxmfclgUkWgfznbDZcazQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.35</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg"
      decimals="2"
      id="Hidden_qYvtfI9-2EK0FA_smo_g4g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.05</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember__BRrOWeWS02G7DSzlPGD0Q"
      decimals="INF"
      id="Hidden_RXte8gIJ0UWW5BmmCYcnHg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">52878539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_5m-lXEUUKkGjcNnQvX8_4Q"
      id="Hidden_huQWM8PukUiNaHCwSJKzHA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_9Uda4Ka9V0W5_fLKlUaijw"
      id="Hidden_RgKa1fvyFki-3G_4NLjGcA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wfMDLkDNqEO3xSkwvmaxgA"
      decimals="INF"
      id="Hidden_0XVq7K5E4EaVAxzq8BPz2g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-JQHw6enTUqU0PtNBY6i1A"
      decimals="INF"
      id="Hidden_PCQ3iCsu6kiybYaKiTQPcQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2237414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Hidden_IhjA9SxPWke_WdT-YL8OYQ">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="3"
      id="Hidden_QpMaoZ2rLEe3kuE2nEwMHQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.081</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_2BqQnWUrKUS-sNcB_hxrKQ"
      decimals="INF"
      id="Hidden_b4QB_34hYkSQy8m2zvvSVA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_rHR-FeR1skyizmwP_cj_wA"
      decimals="INF"
      id="Hidden_mW0ye0ape0K0u7SnjgQyTg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kfYB5YdzlU25J8QBvIS-0A"
      decimals="INF"
      id="Hidden_D1tTYpAKD0mwadhIRhVubw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_d8SWm3qiNEy8rA1CdxgJzw"
      decimals="INF"
      id="Hidden_Wp2d5AfagUeiDJyLPZ20iQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_pkty5j8Sy0Go5dYfRJilQQ"
      decimals="INF"
      id="Hidden_F187q8J5AkCMoKigjnNSmw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_4OU6RNLQI0m02PWitPh6_A"
      decimals="INF"
      id="Hidden_s43EmyAlY0-5J-sKfRJXGg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e_Hw10IjjUGLlhJfGUN8KA"
      decimals="INF"
      id="Hidden_iGujevr0gUmbUx_6BKltrg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_kucXttDDKkm2baEp3zUfTw"
      decimals="INF"
      id="Hidden_IoB8wHCgok2nthhVpcAt4w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w_J4gh8nE0iBqb1LS2a64w"
      decimals="INF"
      id="Hidden_7EvRLYEDcEumV76exoXIWA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Narr_NQf-KsZ-9kinBavKdve4jQ">TRISALUS LIFE SCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tc_zH-nGDeMp0SfOA19lCcsnA_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tc_u6eOerWhPkSmi1EMT-Ltfw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tc_6qWV2U1M4kewShRnQSiZ_A_3_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Narr_hLHZpn-AQUC6RoGqLYusRA">false</dei:EntityExTransitionPeriod>
    <tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_9_30_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_qO_tJd7jHECOCsFdPPXStg"
      decimals="2"
      id="Narr_6D4waJPNBUmtZOPrxadgiA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.50</tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_x0dUB3ew-0yUGkZevDm5Eg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">153563</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_rZo0p5aG_0yhCRPY07BJEw_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200884</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_sxjyX8MHvUOUnE4u35DXSQ_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">206329</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_cIxroCf06kmBeL4RmPuHiQ_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">325000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_swoR3bwu_kaZdXxIPZmI8g_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">359892</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_LGoYiGhaGkKtK2dXXYa4Yg_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">525884</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_89uUqth8UUSYaMc6zEBSmg_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19827884</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_XKxLJB6H8EKeVF0umFksog_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250007295</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_-cJJZq1Q20mUibKmU5OQ7w_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20187776</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_NOxhBxpHq0KSTa3rQ6oHiQ_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250533179</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_QBoqo2l0qUikTt0vdhllfw_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1442941</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_JsWm48ij0EicXa-tH7Q6yw_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1057616</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_BejHiuQgCU69i7rHrcjkeg_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">48135</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_PqzxRfK6-U-Nc7BNCPrsjQ_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">27854</us-gaap:AccruedIncomeTaxesCurrent>
    <tlsi:ExtensionNotesPayableCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_SuSYIrSaD0Sn36YJWCSvqw_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39068</tlsi:ExtensionNotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_zEWg2RfbcEmQx3Wfmn1PVw_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">944000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_cBS-D1_tDkiHDiu2_aRjoQ_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_4ThZ1Eq4zU2FXKlTiy2UKA_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1601616</us-gaap:LiabilitiesCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_wCj6nAF7oEW7IXdE-SizHg_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1061334</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_1pA6jIKIlEaLIDz0X7UGXQ_19_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6898666</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_FXmmh-oYxUC3_nN730y0IA_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1341000</tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent>
    <tlsi:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_lMZz1d8NPEuDxTfAX9JWOw_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8750000</tlsi:DeferredOfferingCostsNoncurrent>
    <tlsi:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_DUzfIbbKj0yo5glcqTcW5w_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8750000</tlsi:DeferredOfferingCostsNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_KypFHsXMS0ayMg6apUcw9w_22_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13654332</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_rdak905SxE--g21BpnToYQ_22_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">17250282</us-gaap:Liabilities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="INF"
      id="Narr_Y_yhmdr71E--bX7qX83Nog"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1953422</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="INF"
      id="Narr_h_vlZdstsEG9iuG-9-BaGQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="2"
      id="Narr_6KKYnwqYHUKzw91JDi8wbA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.14</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="2"
      id="Narr_ZUGASeT5C0mBew4874_1HA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="0"
      id="Tc_vli6dic-PkGlhmL-zOliVQ_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19800030</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="0"
      id="Tc_Ny9vWmOp_E226wGcsC3npw_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_GWxX8VER5U2UjbRjYBT9HQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_M82xDr6GLE2-nYsEGBPRgg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_zL2ndLzyMEWsYbI5bXQv5g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_EXlIZxwq50Ko8RnDx2VHNg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_obvS9J01YEG7bd87grKN8A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_xE5Vw63KSU2qLoEOnmBWGg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Narr_fA3JhCbA-0icWvDz_u-5Bg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_4jQV-f3t902kv0rCHr4KJg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Narr_LGlOR82muUiO_whfVA_VJg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_TA6UlvTiUUW0egly3GAjmw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Narr_VHfe_ZajkkK_AzrqAD684g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_HwsEIJ9Lr0-hOBcvxYY10g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_LuwY8nUJPEqjwlEwgv9drw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_8rqva54S2Uqhmh9j9Hhv6g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_B9CyYkjJpUiuBXt_JxhFPA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_bcJoZEAtrEmI_rp0R2Hhww"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_R2G78H41gEqG85uKOjPCxg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_lAPmT4AoJ0yA3XPN9H_IFw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="0"
      id="Tc_Duavmn9x20O4awbQx4vPkg_28_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="0"
      id="Tc_mLohlHD1e0-vSs0hdMqJJQ_28_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_RLQP9LcEGk6C-omcVMf_4w_30_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13267211</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_zBCEB2CSC0KMWuPsQ1jjEQ_30_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-16717728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_ToaEEhHFpkaRc25W0upe7w_31_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13266586</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_RztVn65v7EO5xRJeiuwNXQ_31_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-16717103</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="0"
      id="Tc_nH7ngSD-G06ysf2JLL3D7w_32_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20187776</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="0"
      id="Tc_kN9udw-gS0Osqb8p7CzCBQ_32_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250533179</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_8Sca9tTpJUm9j1iPeGzIUg_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2746125</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_kp9wUOysn0660TnYeUAPqQ_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3040714</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_BIzYqst5lEKrb2Azi9oOdg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2746125</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_HBg7awgH10aVdpV4TfWlSw_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-3040714</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_1XZwOds3I0qF9Zd1U5fVZg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-5837332</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_rUBhijw9VkGNM6ybBa78kA_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-7744000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_-aJ_ZYLKuk-MnfSOkhBiyQ_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3018726</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_7G2jQmF4FUCjA_qibn2LhA_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">63997</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_KbSmuGcqw0myc87Exc_U3w_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8856058</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_1AlPwgz740KWs451LBsdww_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7807997</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_tOFALvz-70CU3bVNd4YYcw_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6109933</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_l7RN4GmhvUWqj8SFT4OgSA_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4767283</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_AWIUcZJ_Gk6ddKftBEGPpg_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">570854</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_QY-yEJRpMU2MItxWXLnDYw_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5539079</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_5wVomSSuC0-_hlvQzLA6Dw_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4767283</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="0"
      id="Tc_6p0-Q8tbEk6axrpvD3d37w_13_3"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23358326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="0"
      id="Tc_6p0-Q8tbEk6axrpvD3d37w_13_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23358326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="0"
      id="Tc_EevRoZWFA0eUZwTfB0a71g_13_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="0"
      id="Tc_EevRoZWFA0eUZwTfB0a71g_13_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="2"
      id="Tc_jXeNqKWEAUaga38gOQbp-w_14_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="2"
      id="Tc_jXeNqKWEAUaga38gOQbp-w_14_3_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="2"
      id="Tc_LdTQR3rDGkO3kKBzfFNT7A_14_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="2"
      id="Tc_LdTQR3rDGkO3kKBzfFNT7A_14_6_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Tc_ZHkShQ6y50CNavdSOhiPhA_15_3"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Tc_ZHkShQ6y50CNavdSOhiPhA_15_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="0"
      id="Tc_NhKo7w3E0kukoZNrXGIeXw_15_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="0"
      id="Tc_NhKo7w3E0kukoZNrXGIeXw_15_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="2"
      id="Tc_8eXDDkV0z0Cvh63bEG1QQw_16_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="2"
      id="Tc_8eXDDkV0z0Cvh63bEG1QQw_16_3_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="2"
      id="Tc_Jf8EdWMAtU-wFr5oCSj6GQ_16_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="2"
      id="Tc_Jf8EdWMAtU-wFr5oCSj6GQ_16_6_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ"
      decimals="INF"
      id="Tc_UVmivPCUcU646KXwQvHugg_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:SharesIssued>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ"
      decimals="0"
      id="Tc_fjc6sBsxVUuRinMVa84oXg_4_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_26RYOBDJd0m4B-qQpNBrnA"
      decimals="0"
      id="Tc_5KhIQyYNWUKitCp_Ha6mzw_4_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-21485011</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA"
      decimals="0"
      id="Tc_PTSD97EW-kmWUsNiYEIWUQ_4_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-21484386</tlsi:StockholderEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BHFAAUN4h0mbBW1Dpe_8vg"
      decimals="0"
      id="Tc_DC2hL3q76EmslnZfpAnWAw_5_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4767283</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_-Cf_sHKilUutkvVRDEtxWg_5_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4767283</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw"
      decimals="INF"
      id="Tc_Y4S9j9PgvkCzsuA3Mp4bEw_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:SharesIssued>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7v6BWg9Tx0u2WI7pkqvAkw"
      decimals="0"
      id="Tc_cm6eTwXffEC_BxSRRTYkmw_6_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CzvQjMCE50yLWqH7Ft3yaQ"
      decimals="0"
      id="Tc_lcmku5nfDEKoe9QNLuKByw_6_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-16717728</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_Fq44kBmYakOu8P8ysYRtPg_6_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-16717103</tlsi:StockholderEquity>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w"
      decimals="0"
      id="Tc_qxDOI4mGGUehnfM6ThjBDg_7_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-82741</tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_0kn2P8_tFUCzzwMr1rn7ng_7_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-82741</tlsi:AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zGTyV1GIyUOe2wmpYmJA2w"
      decimals="0"
      id="Tc_FpNEsDV90Eya9mYeXvnd9g_8_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">82741</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg"
      decimals="0"
      id="Tc_0HidGjrgAku46BRFLOzb0A_8_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2088562</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_8CL0XzXZFUWJHcRu8zhOKA_8_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2171303</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wRtVDy0a1EGG9HKqOs9SQg"
      decimals="0"
      id="Tc_vZVbYpoGnkab9ap7y1kEtQ_9_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5539079</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_JfasDfUOp0GnFN-OjWKRSw_9_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5539079</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw"
      decimals="INF"
      id="Tc_2ZSF7k8TikO6wIrXF_lgVw_10_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:SharesIssued>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_taVduv-el0CRgIQ66lMaVw"
      decimals="0"
      id="Tc_rnQdDMrEhEWqxbyU-200bg_10_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RT4r_FWuwky0MaFoh-QwIA"
      decimals="0"
      id="Tc_pZO2Fe0YRkaj1Kl4Or8-Cg_10_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13267211</tlsi:StockholderEquity>
    <tlsi:StockholderEquity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_9hywFJuoW0WMebTTVJa8QQ_10_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13266586</tlsi:StockholderEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_lHC6G8xyGUqZKbt9qZGJTA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5539079</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_pxsJ3aAZIUuP0dq2t3DgAg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4767283</us-gaap:ProfitLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_ZYZ6bw3JnkCjjSIqb6K9xg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-5837332</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_nvT4SVQGBkOT0IV34mLHcw_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-7744000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_ydvSDK9qeECb1Excp9BnOQ_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3018726</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_x98wRKqwcUOhdBGlgu4rIA_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">63997</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_QXM-L2tT4UmAtLllT2ucQA_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-118671</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_vxd-azam3UKOAMpCr0Olzw_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-348200</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_FnBe3GJDXEqVuPR3g2p89g_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">385325</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_EiYgyKHD2ECs9EQahIskqg_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">954400</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_P3gD8QS_G0u8IkD7CmDkCg_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">48135</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_wNOAyT7hfkudp1MFrsakYg_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">27854</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_DiDFs-OGDEq-cDJ8HaIxfg_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2736994</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_fy4eDsZGz0OPsIbRFl5J8g_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1738114</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <tlsi:PaymentForInvestmentOfCashInTrustAccount
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_5W2oSlB0dk-dgMhihi-uEg_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78136</tlsi:PaymentForInvestmentOfCashInTrustAccount>
    <tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_VJCn8DLqz0eG1Y36Ocd7FA_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">905000</tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes>
    <tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_0CZMZmcSpEeVfFXBRz2Y6Q_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">60000</tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes>
    <tlsi:ProceedsFromTrustAccountInConnectionWithRedemption
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_tKDMbdCCEkqQMVREFPngNA_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">232371273</tlsi:ProceedsFromTrustAccountInConnectionWithRedemption>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_gy09Cko74EugKnZMdYI4uQ_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">233198137</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_-ltDpmoRX0e-SKUbbmHk5g_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">60000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_eaKCCi1NcECELM-o0G3X2w_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39068</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_iBZuyObXCUOOKtdqpR9jsg_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_KMXR1iAhfkKz1hE0vPO9LA_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:ProceedsFromRelatedPartyDebt>
    <tlsi:ProceedsFromRelatedPartyDebtConvertiblePromissoryNote
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_3tb3RjCjPk2RLhPyNo3BJg_22_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1341000</tlsi:ProceedsFromRelatedPartyDebtConvertiblePromissoryNote>
    <tlsi:ProceedsFromExtensionNote
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_d0-sASJ8802KYJWW7Z8LCw_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">82741</tlsi:ProceedsFromExtensionNote>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_o26nXyuaEU2LV_0PfMzk6A_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">232371273</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_xrEdOItMME-sQR-Qm33TXw_25_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-230508464</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_eso-ZJz33EeaZ7HAqWEZlw_25_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_ECWZtPsoC0OMZEYg7pEkag_26_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_bej3I4eUp0mlsjJkL5CYKA_26_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1134114</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_mLH_NcBkvEO8mKYtJ2M_pQ_27_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_hEC687OshUmc06xIuyZSEA"
      decimals="0"
      id="Tc_tNkY8WYFgEq0MN1_qFsuHA_27_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1334998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_JdJSegtKt0OfPBsVhPiwbg_28_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">153563</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_ExjP7_5ncUWOgvcCsiyPbA_28_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_ioAylDLZQkSSpm3kkKH2yQ_30_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">543000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_tbJXgmlLxEWNGzAkbA81hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;MedTech Acquisition Corporation (the &#x201c;Company&#x201d;) was incorporated in Delaware on September 11, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#x201c;Business Combination&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. The Company has one wholly-owned subsidiary that was created on November 9, 2022, MTAC Merger Sub, Inc, a Delaware corporation (&#x201c;Merger Sub&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had not commenced any operations. All activity from inception through December 31, 2022, relates to the Company&#x2019;s formation, the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination, including the terminated Memic Business Combination and the Merger Agreement with TriSalus (as defined and more fully described in Note 6). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, held in the Trust Account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The registration statements for the Company&#x2019;s Initial Public Offering were declared effective on December 17, 2020. On December 22, 2020, the Company consummated the Initial Public Offering of 25,000,000 units (the &#x201c;Units&#x201d; and, with respect to the Class A common stock included in the Units sold, the &#x201c;Public Shares&#x201d;), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250,000,000 which is described in Note&#160;3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 4,933,333 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a price of $1.50 per Private Placement Warrant in a private placement to MedTech Acquisition Sponsor LLC (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $7,400,000, which is described in Note&#160;4.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the closing of the Initial Public Offering on December 22, 2020, an amount of $250,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transaction costs amounted to $14,161,525, consisting of $5,000,000 in cash underwriting fees, $8,750,000 of deferred underwriting fees and $411,525 of other offering costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held in trust and net of taxes payable). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will provide the holders of the outstanding Public Shares (the &#x201c;Public Stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will only proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 following any related redemptions and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#x201c;Certificate of Incorporation&#x201d;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (b) to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination by June 22, 2023 (or such earlier date as determined by the board of directors of the Company (the &#x201c;Board&#x201d;)) and (c) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company&#x2019;s obligation to allow redemptions in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders&#x2019; rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will have until June 22, 2023 (or such earlier date as determined by the Board) to complete a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than &lt;span style="-sec-ix-hidden:Hidden_8o7rIpLqL0adL1dGev6vwQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#x2019; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining stockholders and the Board, dissolve and liquidate, subject in each case to the Company&#x2019;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders. At the meeting, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation (the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&#x201c;Extension Amendment&#x201d;) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of&#x2009; (i)&#160;$10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account nor will it apply to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#x2019;s independent registered public accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company had $153,563 in its operating bank account and working capital deficit of $2,114,252, which excludes $27,854 of income taxes payable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2021, the Company issued an unsecured promissory note to the Sponsor in the principal amount of $544,000 (the &#x201c;2021 Promissory Note&#x201d;). The 2021 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#x2019;s initial Business Combination. As of December 31, 2022 and 2021, there was $544,000 outstanding under the 2021 Promissory Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 28, 2022, the Company issued an unsecured promissory note in the principal amount of up to $400,000 to the Sponsor (the &#x201c;2022 Promissory Note&#x201d;). The 2022 Promissory Note, as described in Note 5, does not bear interest and matures upon closing of the Company&#x2019;s initial Business Combination. As of December 31, 2022 and 2021, there was $400,000 and $0 outstanding under the 2022 Promissory Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 24, 2022, the Company issued the Convertible Promissory Note (as defined in Note 5) in the principal amount of up to $1,500,000 to the Sponsor. As of December 31, 2022 and 2021, there were amounts of $1,341,000 and $0 outstanding under the Convertible Promissory Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 16, 2022, the Company issued a promissory note in the aggregate principal amount of up to $468,821 to the Sponsor (the &#x201c;Extension Note&#x201d;), pursuant to which the Sponsor agreed to loan to the Company up to $468,821 (the &#x201c;Extension Funds&#x201d;) to deposit into the Company&#x2019;s trust account (the &#x201c;Trust Account&#x201d;) for the shares of Class A common stock of the Company (the &#x201c;Public Shares&#x201d;) that were not redeemed in connection with the extension of the Company&#x2019;s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the Board (the &#x201c;Extension&#x201d;). The Extension Note, as described in Note 5, does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there were the amounts of $39,068 and $0 outstanding under Extension Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will deposit $0.04 per share into the Trust Account for each month (commencing on December 23, 2022 and ending on the 22nd day of each subsequent month) (the &#x201c;Extension Deposit&#x201d;), or portion thereof, that is needed by the Company to complete an initial business combination until June 22, 2023 or such earlier date as determined by the Board (the &#x201c;Extension&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Merger Agreement, TriSalus has agreed to pay, as a transactional expense and not as a loan, for 50% of the costs incurred by the Company in connection with the preparation and filing of applicable proxy materials and the holding of the Meeting (as defined below) (TriSalus&#x2019; portion of such fees, the &#x201c;TriSalus Extension Fees&#x201d;), in addition to 50% of the amounts deposited into the Trust Account in connection with the Extension, with the remainder to be funded by the Sponsor and/or its designee in the form of a loan to the Company; provided that TriSalus&#x2019; obligation to pay the TriSalus Extension Fees and its portion of the deposits for the Extension will terminate immediately at the earliest to occur of (i) the closing date of the TriSalus Business Combination and (ii) the valid termination of the Merger Agreement. Upon such termination, the Company will have no obligation to repay the TriSalus Extension Fees or any portion of the Extension Funds paid by TriSalus.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the &#x201c;Working Capital Note&#x201d;) to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its amendment and restated certificate of incorporation, as amended from time to time. As of December 31, 2022 and 2021, there was no outstanding amount under the Working Capital Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) Topic 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern,&#x201d; the Company has until June 22, 2023, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management plans to consummate a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 22, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#x2019;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inflation Reduction Act of 2022&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, a vote by the stockholders to extend the period of time to complete the Company&#x2019;s initial Business Combination (the &#x201c;extension vote&#x201d;) or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any &#x201c;PIPE&#x201d; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company&#x2019;s ability to complete a Business Combination.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <tlsi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="INF"
      id="Narr_ZSpz9DQ9SEyIIyuO_UVYbg"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">1</tlsi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <tlsi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"
      decimals="INF"
      id="Narr_2VFn_JVHvU-rJLaSV0e3cg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</tlsi:UnitsIssuedDuringPeriodSharesNewIssues>
    <tlsi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw"
      decimals="INF"
      id="Narr_fQkWhGeKpkawZsBIgwJtxg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3000000</tlsi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA"
      decimals="2"
      id="Narr_y4BghahNREqlPO7aNF5CiQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"
      decimals="0"
      id="Narr_un297zLIK0-bPaZpcYP7_Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"
      decimals="INF"
      id="Narr_frWlGOdE-EuzekMjxOqN-Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4933333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"
      decimals="2"
      id="Narr_7WTwyYo-fUCzoe7WAcw8zg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.50</tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw"
      decimals="0"
      id="Narr_n_c6ldt--EaVq7XO9CKXXA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <tlsi:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"
      decimals="0"
      id="Narr_CEENtxdYt0m-XNxrYC3xFA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</tlsi:PaymentsForInvestmentOfCashInTrustAccount>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tc_V7gDSeUmpSxYMDtGWdw"
      decimals="2"
      id="Narr_9Uci8XBbk0y4HxPuzqPOqg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <tlsi:TransactionCosts
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="0"
      id="Narr_zMqKSFVvp0ajCaPS9bSVBA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14161525</tlsi:TransactionCosts>
    <tlsi:SaleOfStockUnderwritingFees
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="0"
      id="Narr_G6Nsf9T6-0qKD3PfxKmpLw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:SaleOfStockUnderwritingFees>
    <tlsi:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="0"
      id="Narr_0tlwTHS4FEuOw29tQlTbmw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8750000</tlsi:DeferredOfferingCostsNoncurrent>
    <tlsi:SaleOfStockOtherOfferingCosts
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="0"
      id="Narr_AOsZfKkEM0m3T1ZN7S0meA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">411525</tlsi:SaleOfStockOtherOfferingCosts>
    <tlsi:ConditionForFutureBusinessCombinationUseOfProceedsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_WKw0aArYzkSDhuKcP5FAyg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">80</tlsi:ConditionForFutureBusinessCombinationUseOfProceedsPercentage>
    <tlsi:ConditionForFutureBusinessCombinationThresholdPercentageOwnership
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_bEkcAS5SaE-CJCEPld-tXA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">50</tlsi:ConditionForFutureBusinessCombinationThresholdPercentageOwnership>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="2"
      id="Narr_lF-epmnUWU6-1BmHVSjyKA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <tlsi:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_eFUhwp8y2EuS_P91AOB3cA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000001</tlsi:ConditionForFutureBusinessCombinationThresholdNetTangibleAssets>
    <tlsi:RedemptionLimitPercentageWithoutPriorConsent
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_HEK3tRu7fUu_Y6YWyEx9rw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">15</tlsi:RedemptionLimitPercentageWithoutPriorConsent>
    <tlsi:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="2"
      id="Narr_0Tqtk9Tjf06OxGuJdIeAsw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</tlsi:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <tlsi:MaximumAllowedDissolutionExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_NGSahLccYk2e7wTAN0_TBw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">100000</tlsi:MaximumAllowedDissolutionExpenses>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="2"
      id="Narr_Gp05lJBb1UuZbEf6kSCSng"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="2"
      id="Narr_SPLXJ8CHPkCERab1sNxaxw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <tlsi:OperatingBankAccounts
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_72gQ8HtKTkGIad-j9kkmuQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">153563</tlsi:OperatingBankAccounts>
    <tlsi:WorkingCapital
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_40ODIDpWgkqYI4GKYzTsLA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2114252</tlsi:WorkingCapital>
    <tlsi:DueToSponsorForCertainReimbursableExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_HwXyrgNF9kSQ67jpRCw_4w"
      decimals="0"
      id="Narr_dDBVyidioEOt4PD9xZ2pOQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">27854</tlsi:DueToSponsorForCertainReimbursableExpenses>
    <tlsi:DueToSponsorForCertainReimbursableExpenses
      contextRef="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyOnePromissoryNoteMember_rhZTQ658W0at8bOMTC8FaA"
      decimals="0"
      id="Narr_WG01BWZn-E-ClwDNgVqfgw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</tlsi:DueToSponsorForCertainReimbursableExpenses>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_tfAYqXS-rkCNMjlKTM0Vmw"
      decimals="0"
      id="Narr_aP6FhkbZFEGe3_OggOW7uw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g"
      decimals="0"
      id="Narr_-nqPaUNo5Ee7PeXVTcABRA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw"
      decimals="0"
      id="Narr_qyTnFqapeUqJwL2Aqj9rvw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA"
      decimals="0"
      id="Narr_5JazsVAuJ0mtYVoCGdH2xA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw"
      decimals="0"
      id="Narr_tfJF3hmSsESDs-veTRNR0Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_IJINUXuw9ECauZXpwrbGYA"
      decimals="0"
      id="Narr_f3RQbcTgzUK-VRW39hEUWA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1500000</us-gaap:DebtInstrumentFaceAmount>
    <tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_z25sOGIM20ifmLNdRoZCYw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1341000</tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent>
    <tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_io7-LZGwqkeYmvKK6-eVYQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:ConvertibleNotesPayableRelatedPartyNoncurrent>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg"
      decimals="0"
      id="Narr_D-v5Fy2i6UmeaDptTrynvA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">468821</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_JzShSkRCDE6y8zNk2FL0wg"
      decimals="0"
      id="Narr_bNYEeuHv-0ybY657xj-OFw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">468821</tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A"
      decimals="0"
      id="Narr_P2ijqYguiEq-WixRVlnIpg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39068</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q"
      decimals="0"
      id="Narr_l3ErAACBpU2OU_rUwLBMbw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="2"
      id="Narr_qng7JWcC0EiNZ2Np7W3ZDQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.04</us-gaap:SharePrice>
    <tlsi:PercentageOfTransactionalFeePaid
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="2"
      id="Narr_cZf3UFfCYkGWe3wUe3TL2w"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.50</tlsi:PercentageOfTransactionalFeePaid>
    <tlsi:PercentageOfAmountDepositedInTrustAccount
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="2"
      id="Narr_7aTDH6wyQUymAVSKGvE-3A"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.50</tlsi:PercentageOfAmountDepositedInTrustAccount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_MiWZm6fBjEKUajPVpCkIUQ"
      decimals="0"
      id="Narr_31AZFI-zVE66HGQ-MhOu8Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_A1kFE1uOcE6ixb7a2UYb6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which were formed on November 9, 2022. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $153,563 and $200,884 of cash as of December 31, 2022 and 2021, respectively, and no cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Investments Held in Trust Account&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its U.S. Treasury and equivalent securities as held to maturity in accordance with FASB Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 320, &#x201c;Investments &#x2014; Debt and Equity Securities.&#x201d; Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2022, substantially all of the assets held in the Trust Account were held in a demand deposit account held by Continental Stock Transfer &amp;amp; Trust Company. At December 31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest primarily in U.S. Treasury securities. The money market funds are presented at fair value within the accompanying consolidated balance sheets, and fair value of the investments in the Trust Account is equal to the amortized cost basis of the money market funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class A Common Stock Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Shares of Class A common stock subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; equity. The Company&#x2019;s Class A common stock features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the special meeting in lieu of the 2022 annual meeting of stockholders held by the Company on December 12, 2022, stockholders holding 23,046,578 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $232.37 million (approximately $10.08 per Public Share) was removed from the Trust Account to pay such holders and approximately $19.70 million remains in the Trust Account. Following redemptions, the Company has 1,953,422 Public Shares outstanding. $78,137 was deposited into the Trust Account of which 50% was be drawn down under the Extension Note and 50% was funded by TriSalus.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, at December 31, 2022 and 2021, 1,953,422 and 25,000,000 shares of Class A common stock subject to possible redemption are presented at $10.14 and $10.00 redemption value, respectively, as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares of common stock to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At December 31, 2022 and 2021, the Class A common stock subject to possible redemption reflected in the consolidated balance sheets is reconciled in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class A common stock subject to possible redemption, January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 250,000,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Redemptions of Class A common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (232,371,273)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,093,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Extension Deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,800,030&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A common stock issued were initially charged to temporary equity and then accreted to common stock subject to redemption upon the completion of the Initial Public Offering. A total of $14,161,525 in offering costs was incurred. Of these offering costs, $13,638,664 was related to the Initial Public Offering and charged to Class A Common Stock subject to possible redemption. Offering costs allocable to Public Warrants (as defined below) and Private Placement Warrants were $514,106 and $8,755, respectively, and expensed at the date of Initial Public Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the Public Warrants and Private Placement Warrants (together with the Public Warrants, the &#x201c;Warrants&#x201d;) in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model. The Public Warrants for periods where no observable traded price was available were also valued using a Monte Carlo simulation Model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in interim periods under ASC 740-270-30-5. As of December 31, 2022 and 2021, the Company&#x2019;s deferred tax asset had a full valuation allowance recorded against it. The Company&#x2019;s effective tax rate was 9.34% and 0% for the years ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate of 21% for the years ended December 31, 2022 and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has been subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Income per Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income per share of common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. The Company has two classes of common stock, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock, which assumes a business combination as to be the most likely outcome. Accretion associated with the redeemable shares of Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,266,666 shares of Class A common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income per common stock is the same as basic net income per common stock for the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Basic and diluted net income per share of common stock&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Allocation of net income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,369,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,169,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,813,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 953,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,358,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic and diluted net income per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the Warrant Liabilities (See Note 10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the FASB issued ASU Topic 2020-06, &#x201c;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x201d; (&#x201c;ASU 2020-06&#x201d;), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_hL2crN-aKkO0XWsicblMZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_rUCWDfahIkWeafAJx3ueUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, which were formed on November 9, 2022. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <tlsi:EmergingGrowthCompanyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_vqi_aGZwb0-KdKeKigf7sQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</tlsi:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_OWKkorqfkk-zfGt3fo9JhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_D5EPrqmacEyGQHDxKL6mXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $153,563 and $200,884 of cash as of December 31, 2022 and 2021, respectively, and no cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_TlFjrrnkTEaLoPmwEn6Axw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">153563</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_GKjnvH-XKka1GMqCAO9Nbw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200884</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_3m-48D6GA0OElvse4Fke4A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_gIq_PVAv2EWnR-KiGl0cjA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:CashEquivalentsAtCarryingValue>
    <tlsi:AssetsHeldInTrustAccountPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_8-zSUlW0f0qdgp0s-gNpNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Investments Held in Trust Account&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its U.S. Treasury and equivalent securities as held to maturity in accordance with FASB Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 320, &#x201c;Investments &#x2014; Debt and Equity Securities.&#x201d; Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying consolidated balance sheets and adjusted for the amortization or accretion of premiums or discounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2022, substantially all of the assets held in the Trust Account were held in a demand deposit account held by Continental Stock Transfer &amp;amp; Trust Company. At December 31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest primarily in U.S. Treasury securities. The money market funds are presented at fair value within the accompanying consolidated balance sheets, and fair value of the investments in the Trust Account is equal to the amortized cost basis of the money market funds.&lt;/p&gt;</tlsi:AssetsHeldInTrustAccountPolicyPolicyTextBlock>
    <tlsi:TemporaryEquityPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_Rsnn70bGCEuGCYmlY1RNIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class A Common Stock Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Shares of Class A common stock subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; equity. The Company&#x2019;s Class A common stock features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the special meeting in lieu of the 2022 annual meeting of stockholders held by the Company on December 12, 2022, stockholders holding 23,046,578 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $232.37 million (approximately $10.08 per Public Share) was removed from the Trust Account to pay such holders and approximately $19.70 million remains in the Trust Account. Following redemptions, the Company has 1,953,422 Public Shares outstanding. $78,137 was deposited into the Trust Account of which 50% was be drawn down under the Extension Note and 50% was funded by TriSalus.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, at December 31, 2022 and 2021, 1,953,422 and 25,000,000 shares of Class A common stock subject to possible redemption are presented at $10.14 and $10.00 redemption value, respectively, as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares of common stock to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At December 31, 2022 and 2021, the Class A common stock subject to possible redemption reflected in the consolidated balance sheets is reconciled in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class A common stock subject to possible redemption, January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 250,000,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Redemptions of Class A common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (232,371,273)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,093,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Extension Deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,800,030&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tlsi:TemporaryEquityPolicyPolicyTextBlock>
    <tlsi:StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount
      contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg"
      decimals="INF"
      id="Narr_ipnKcXGqUUa74E7-2e55nA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23046578</tlsi:StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount>
    <tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount
      contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg"
      decimals="-4"
      id="Narr_dgK9dzpLuUCQQhoH4grwBA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">232370000</tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount>
    <tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare
      contextRef="Duration_12_12_2022_To_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_71ivAMN5WEaesHqSjeTrwQ"
      decimals="2"
      id="Narr_J7AYLByhdE6_kZ_xw-NOgg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.08</tlsi:ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare>
    <tlsi:ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount
      contextRef="As_Of_12_12_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_CJn-H2HKw0GoJAcmNbC4Gg"
      decimals="-4"
      id="Narr_UgCouH0Y1UKS8PaB3wanTg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19700000</tlsi:ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_vBfNBoX3EEGfvb8pEDrtLg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1953422</us-gaap:SharesOutstanding>
    <tlsi:AmountDepositedIntoTrustAccount
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_fC2oE0sEqUyHfsza6_t_bw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78137</tlsi:AmountDepositedIntoTrustAccount>
    <tlsi:PercentOfDepositsIntoTrustAccountDrawnDown
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_IssuanceOfPromissoryNote2022ToSponsorMember_OZVZQrBqCEGgs_ptg5yGoA"
      decimals="2"
      id="Narr_PETSa-zoHUq_DjqiU5wvZA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.50</tlsi:PercentOfDepositsIntoTrustAccountDrawnDown>
    <tlsi:PercentOfDepositsIntoTrustAccountFundedByAcquiree
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="2"
      id="Narr_dvN2CO4jRkeh0f3MY0ZUkw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.50</tlsi:PercentOfDepositsIntoTrustAccountFundedByAcquiree>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="INF"
      id="Narr_qykoVvaASUS7WM_Wwc7VNg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1953422</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="INF"
      id="Narr_LcniZ9J3sU--Rpq2BaoKdg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="2"
      id="Narr_cJmLkb7uqEmrqPzaz3uu-Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.14</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="2"
      id="Narr_2TPHBwl9GkWtrC__8V8Osg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_UyF2zaZ3mkmr4qlKvGJhwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class A common stock subject to possible redemption, January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 250,000,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Redemptions of Class A common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (232,371,273)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,093,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Extension Deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A common stock subject to possible redemption, December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,800,030&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_AQay36hQlke0WUBpyZbKSQ"
      decimals="0"
      id="Tc_gde5vugi1E2Ycuq_mpxC-g_1_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="0"
      id="Tc_2Na5uq1SqUyKwtQcg62MfQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:ProceedsFromTrustAccountInConnectionWithRedemption
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A"
      decimals="0"
      id="Tc_VPCstSdQyEu2Zh-n-L6_0A_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">232371273</tlsi:ProceedsFromTrustAccountInConnectionWithRedemption>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A"
      decimals="0"
      id="Tc_a9p-eu7RvECHxRNclWHgdg_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2093167</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <tlsi:ExtensionDeposit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A"
      decimals="0"
      id="Tc_enBFIb25nUmEvgHLPG9WIw_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78136</tlsi:ExtensionDeposit>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="0"
      id="Tc_iIUopaUey0OU5V-L-_Laqw_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19800030</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_5TJK_TT7rE-U1F2GH8ychQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Offering costs consisted of legal, accounting and other expenses incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the Class A common stock issued were initially charged to temporary equity and then accreted to common stock subject to redemption upon the completion of the Initial Public Offering. A total of $14,161,525 in offering costs was incurred. Of these offering costs, $13,638,664 was related to the Initial Public Offering and charged to Class A Common Stock subject to possible redemption. Offering costs allocable to Public Warrants (as defined below) and Private Placement Warrants were $514,106 and $8,755, respectively, and expensed at the date of Initial Public Offering.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_wj8TWr2dNUeQkUxSYBA6_g"
      decimals="0"
      id="Narr_HITddlXY6k6ICDRsA6ienw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14161525</us-gaap:DeferredOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"
      decimals="0"
      id="Narr_F6KCm3FBHUyT8Te0cuEOxg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13638664</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_oBl1u_pQM06egIcZ8MCY8g"
      decimals="0"
      id="Narr_maDLA_dZSE6a8RNBIWHORw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">514106</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_8Tcmoc6fkkCSZMerDheLAw"
      decimals="0"
      id="Narr_UGVoJLE-KEm6wbXiISA0RQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8755</us-gaap:DeferredOfferingCosts>
    <tlsi:WarrantLiabilitiesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_tKjFtV4OAEGk2X6OJl4giA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the Public Warrants and Private Placement Warrants (together with the Public Warrants, the &#x201c;Warrants&#x201d;) in accordance with the guidance contained in ASC 815-40 under which the Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model. The Public Warrants for periods where no observable traded price was available were also valued using a Monte Carlo simulation Model. For periods subsequent to the detachment of the Public Warrants from the Units, the Public Warrant quoted market price was used as the fair value as of each relevant date.&lt;/p&gt;</tlsi:WarrantLiabilitiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_I5-vYhQLQkq0bUkhat7XiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740-270-25-2 requires that an annual effective tax rate be determined and such annual effective rate applied to year to date income in interim periods under ASC 740-270-30-5. As of December 31, 2022 and 2021, the Company&#x2019;s deferred tax asset had a full valuation allowance recorded against it. The Company&#x2019;s effective tax rate was 9.34% and 0% for the years ended December 31, 2022 and 2021, respectively. The effective tax rate differs from the statutory tax rate of 21% for the years ended December 31, 2022 and 2021, due to changes in fair value in warrant liability and the valuation allowance on the deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has been subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="4"
      id="Narr_huAN_J8lLUeRDOF2mXqgbw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0934</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="2"
      id="Narr_FKqcLFBoAkm9Am-RT1IbSg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="INF"
      id="Narr_wis7oCuiI0imwC_WGWu_eg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="INF"
      id="Narr_QtgN_hr_-ku3vt6sW6HZsA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_wGBQNtMBlkC7pynxqB8wmg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_b9SX4xD9ykSB93AAUXFL2w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_x-ms3kcaQE6gT8iA5zixOA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_7Yk8mYP6QUuEa--2cWRcXg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_FENWmKOtDUyFoPvG_jIvaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Income per Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with accounting and disclosure requirements of ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income per share of common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. The Company has two classes of common stock, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock, which assumes a business combination as to be the most likely outcome. Accretion associated with the redeemable shares of Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,266,666 shares of Class A common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any other dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income per common stock is the same as basic net income per common stock for the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Basic and diluted net income per share of common stock&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Allocation of net income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,369,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,169,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,813,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 953,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,358,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic and diluted net income per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="INF"
      id="Narr_Qjv8IDhFrkSSuhS9bsrtzw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">13266666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_JfQilB6MkEeOa0QeyfI2nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Basic and diluted net income per share of common stock&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Allocation of net income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,369,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,169,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,813,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 953,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,358,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic and diluted net income per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="0"
      id="Tc_VRBcQ9UhY0OO4dMps49dwQ_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4369839</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Tc_PC5cgcdg7kS9E665gW1quw_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1169240</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="0"
      id="Tc_CQyd8hqkwEipYjzUmCQTEA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3813826</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="0"
      id="Tc_OXK97vxb6kehl0sFuoXEPA_6_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">953457</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="0"
      id="Tc_ZokKaf3S7EOH0ZXCHVqL6A_8_3"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23358326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="0"
      id="Tc_ZokKaf3S7EOH0ZXCHVqL6A_8_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">23358326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Tc_85DCpX2o6kGnegiKXAc4Ig_8_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Tc_85DCpX2o6kGnegiKXAc4Ig_8_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="0"
      id="Tc_TMsPqP6ADki4ZOVvzk-8DQ_8_9"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="0"
      id="Tc_TMsPqP6ADki4ZOVvzk-8DQ_8_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="0"
      id="Tc_P74xhmyjoU6KZ2gjpzsorQ_8_12"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="0"
      id="Tc_P74xhmyjoU6KZ2gjpzsorQ_8_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="2"
      id="Tc_AOpnt1PcRESUFY1awVUK5w_9_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ"
      decimals="2"
      id="Tc_AOpnt1PcRESUFY1awVUK5w_9_3_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="2"
      id="Tc_SSc7jurvKku5iYhHgTZYzQ_9_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="2"
      id="Tc_SSc7jurvKku5iYhHgTZYzQ_9_6_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="2"
      id="Tc_BYO9mvwN0U6AjRRy5kDaUA_9_9"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Uiz-soyY_UqTappZ9BZRPA"
      decimals="2"
      id="Tc_BYO9mvwN0U6AjRRy5kDaUA_9_9_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="2"
      id="Tc_J339RXykX0-X5pbdlwK3YQ_9_12"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YUvmn3C08EOPJoG9KEzCog"
      decimals="2"
      id="Tc_J339RXykX0-X5pbdlwK3YQ_9_12_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_IPWQnC45l0SMZ8dwqyOILA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations and cash flows.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_jQCpxA1Ws0uWRIfm3x_iqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the Warrant Liabilities (See Note 10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_J1YNnz2YO0SmOfl5RUDd0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the FASB issued ASU Topic 2020-06, &#x201c;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x201d; (&#x201c;ASU 2020-06&#x201d;), to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <tlsi:InitialPublicOfferingTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_nPShHRVDbkeF7Kr2a2Chgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 3. PUBLIC OFFERING&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Initial Public Offering, the Company sold 25,000,000 Units, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and &lt;span style="-sec-ix-hidden:Hidden_MkCiTlqYpkyh8SfuJUz1DA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-third of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50&#160;per share, subject to adjustment (see Note 8).&lt;/p&gt;</tlsi:InitialPublicOfferingTextBlock>
    <tlsi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_v7jjL2Bn1EygYrYo77bqwg"
      decimals="INF"
      id="Narr_w96krJG7p0ykqTkmiz1CwQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</tlsi:UnitsIssuedDuringPeriodSharesNewIssues>
    <tlsi:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Ccp0adKOG0y_risRELDRLw"
      decimals="INF"
      id="Narr_m5mgNlw8BUK70ilHui2npg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3000000</tlsi:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_kTqUXygPxUOh-V6ZQwbDuA"
      decimals="2"
      id="Narr_3k3AIYP7vk2PnNOkZ__ojA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SharesIssuedPricePerShare>
    <tlsi:NumberOfSharesIssuedPerUnit
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_xbC97N33okWvF9zYFtzwMA"
      decimals="INF"
      id="Narr_SYs39qv0xEituO1oS71kyw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1</tlsi:NumberOfSharesIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OXuKzykTU0aBwch15YAXNQ"
      decimals="INF"
      id="Narr_SLxoG7aubk63EH3yJwFYoQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ilNvF-LtlEuM40NvOR74NA"
      decimals="2"
      id="Narr_8ANmTNIXB0y5-A2v5HrRpw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tlsi:PrivatePlacementTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_KehyZ8-uKESa9cyV09ZDbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 4. PRIVATE PLACEMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 4,933,333 Private Placement Warrants at a price of&#x2009;$1.50 per Private Placement Warrant ($7,400,000) from the Company in a private placement. Each Private Placement Warrant will be exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7). The proceeds from the sale of the Private Placement Warrants were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.&lt;/p&gt;</tlsi:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"
      decimals="INF"
      id="Narr_B-_jPg6zL0W-NM-N9X59kA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4933333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"
      decimals="2"
      id="Narr_QjkNF1FfDU6MRB2Ec-Wndw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.50</tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4Gwp9_I7_U2QMCJUdTQsPw"
      decimals="INF"
      id="Narr_47ObvDojhUa37P35BxZ0fA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AsGdM6nURE6-4fixMBGiNw"
      decimals="INF"
      id="Narr_P1eNNREBkU20Ar7pmgecbQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DMJEIP8fGUaGXbZBbwD0BQ"
      decimals="2"
      id="Narr_p1hrJM7Wgk6tGQ8Vq_C2Yg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_msfYcro5okO9tOYpUZy_1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Founder Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 11, 2020, the Sponsor purchased 5,750,000 shares (the &#x201c;Founder Shares&#x201d;) of the Company&#x2019;s Class B common stock for an aggregate price of $25,000. In December 2020, the Company effected a stock dividend for 0.1 shares for each share of Class B common stock outstanding,resulting in 6,325,000 Founder Shares outstanding. As a result of the partial over-allotment exercised by the underwriters, 75,000 shares of Class B common stock were forfeited, and no shares remain subject to forfeiture.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of (A)&#160;one year&#160;after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the reported closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#x2019;s stockholders having the right to exchange their shares of common stock for cash, securities or other property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Administrative Services Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into an agreement, commencing on December 22, 2020, to pay the Sponsor an amount not to exceed $10,000 per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#x2019;s liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022, the Company incurred $120,000, in fees for these services. For the year ended December 31, 2021, the Company incurred $120,000, in fees for these services. There were $240,000 and $120,000 included in accrued expenses for these services in the accompanying consolidated balance sheets at December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Promissory Note&#x2009;&#x2014;&#x2009;Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2021, the Company issued the 2021 Promissory Note to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $544,000. The 2021 Promissory Note is non-interest bearing. No amount shall be due under the 2021 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there was $544,000 outstanding under the 2021 Promissory Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 28, 2022, the Company issued the 2022 Promissory Note I in the principal amount of up to $400,000 to the Sponsor. The 2022 Promissory Note is non-interest bearing. No amount shall be due under 2022 Promissory Note if the Business Combination is not consummated on or before June 22, 2023 (or such earlier date as determined by the Board). As of December 31, 2022 and 2021, there were amounts of $400,000 and $0 outstanding under the 2022 Promissory Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 16, 2022, the Company issued the Extension Note, a promissory note in the aggregate principal amount of up to $468,821 to the Sponsor, pursuant to which the Sponsor agreed to loan to the Company the Extension Funds to deposit into the Trust Account for the Public Shares that were not redeemed in connection with the Extension. The Extension Note does not bear interest and is repayable in full upon the date of the consummation of an initial business combination. As of December 31, 2022 and 2021, there was $39,068 and $0 outstanding under Extension Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 16, 2022, the Company issued the 2022 Promissory Note I, an unsecured promissory note in the principal amount of up to $1,000,000 to the Sponsor for working capital purposes, which may be drawn down from time to time upon request by the Company. The Working Capital Note does not bear interest and the principal amount will not be payable if the Company fails to complete its initial business combination within the Combination Period. As of December 31, 2022 and 2021, there was no outstanding under Working Capital Note, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Related Party Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants as described in Note 8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On May 24, 2022, the Company issued a promissory note in the principal amount of up to $1,500,000 to the Sponsor for working capital requirements and payment of certain expenses in connection the Company&#x2019;s initial Business Combination (&#x201c;Convertible Promissory Note&#x201d;). The Convertible Promissory Note is non-interest bearing and payable on the earlier of (i) the date of the initial Business Combination or (ii) the winding up of the Company. At any time prior to payment in full of the principal balance of the Convertible Promissory Note, the Sponsor may elect to convert all or any portion of the unpaid principal balance into that number of warrants, each exercisable for one share of Class A common stock of the Company (the &#x201c;Conversion Warrants&#x201d;), equal to (x) the portion of the principal amount of this Note being converted, divided by (y) $1.50, rounded up to the nearest whole number of warrants. The Conversion Warrants and their underlying securities are entitled to certain demand and piggyback registration rights as set forth in the Convertible Promissory Note. The Company determined that the fair value of the Convertible Promissory Note was par value. As of December 31, 2022 and 2021, the Company had $1,341,000 and $0, respectively, borrowings under the Working Capital Loans.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw"
      decimals="INF"
      id="Narr_kCOToJAFfkqBH6HAMm3T7Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw"
      decimals="0"
      id="Narr_h5smdKF280qqRRNp-1YLXw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockDividendsShares
      contextRef="Duration_12_1_2020_To_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_chTyyFWls023GE6-jbCH2A"
      decimals="1"
      id="Narr_9Mu6A9Ehoki1s4x7c01EkQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0.1</us-gaap:CommonStockDividendsShares>
    <tlsi:AggregateNumberOfSharesOwned
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_wGOWYsCQ5ku3FPlY92CUbw"
      decimals="INF"
      id="Narr_McfyxwIs3E-m3SRg3e9hYg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6325000</tlsi:AggregateNumberOfSharesOwned>
    <tlsi:NumberOfSharesSubjectToForfeiture
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w"
      decimals="INF"
      id="Narr_4q4SxLFX5kO9vyn0-n25lg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">75000</tlsi:NumberOfSharesSubjectToForfeiture>
    <tlsi:NumberOfSharesNoLongerSubjectToForfeiture
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fgz49Le9xkm3-63RQi0Z6w"
      decimals="INF"
      id="Narr_4n7neVYvT02kligFNwdt9A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</tlsi:NumberOfSharesNoLongerSubjectToForfeiture>
    <tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"
      id="Narr_64W6-wCy0USCjiOvENB1Hg">P1Y</tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"
      decimals="2"
      id="Narr_H0vzIFfK_0q2DGsjJ8IzPg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.00</tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
    <tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"
      decimals="INF"
      id="Narr_fPXRfFAHwk2Oc5330aDpIw"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"
      decimals="INF"
      id="Narr_DOzRdJHUEk2k-jSEnM9QBA"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <tlsi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ziGTxYzMVUuVL3QmeQ4MIg"
      id="Narr_hn6FJGBxGEqJa5yKEjt6mA">P150D</tlsi:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <tlsi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="Duration_12_22_2020_To_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_aUCSUO5VHk6A6DggrcFYYw"
      decimals="0"
      id="Narr_vtRINIsYKUGC9XeYzQtiLA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</tlsi:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Mnxv0wTYjEKdigU5lNSyow"
      decimals="0"
      id="Narr_WJMNAiUMpky5vPOVmjm_LQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Ss29-0arFEmgdC-qVRGyZg"
      decimals="0"
      id="Narr_7ntPLtlD0kuD7zYZEY1e9w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_gSf4GXYVD0WuBgBuDWBn0w"
      decimals="0"
      id="Narr_ZmeiVV5ls0SPMsJvmgqkSQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">240000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BalanceSheetLocationAxis_tlsi_AccruedExpensesMember_us-gaap_RelatedPartyTransactionAxis_tlsi_AdministrativeSupportAgreementMember_Bd5mwUEb0keN4-RoxS7_YA"
      decimals="0"
      id="Narr_cmy-bodhLEKPcV_ZzF_9Yg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="As_Of_12_30_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_Vt3SPP67yUGmnpcjM2X0Eg"
      decimals="0"
      id="Narr_g3SgDUQO_02RlddM3i13DA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_GJ6jDUJ4J0KcEIvxBmoE3g"
      decimals="0"
      id="Narr_vZdUHoDFX0qFuJtpne0MMQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">544000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_1_28_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_d_chocOxdE6LE4DUMR7TCw"
      decimals="0"
      id="Narr_cwRZJGWkvUqC1fLYroVK9A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_my47yYv2l0e91gqVW4b2mA"
      decimals="0"
      id="Narr_S473jYSQc02m_lmoUr_ZLA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_PromissoryNoteWithRelatedPartyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_2TMsG971pkWXYUhKNJLzEw"
      decimals="0"
      id="Narr_rGzouwhmu0aG-_cT9NC0ow"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_XlqBY_bMDkKgTAzVoxZklQ"
      decimals="0"
      id="Narr_rFVDa6Zr00G3Ke-osMtlgQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">468821</tlsi:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W6d1ntUm0UKD87NruBIZ5A"
      decimals="0"
      id="Narr_YONUEau-vEGjLZLEvVptjg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39068</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QSGB8w1tOEGE34tU1YsF7Q"
      decimals="0"
      id="Narr_c7UtyyJb6UmUBjc4QyYp7g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_12_16_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_TwoThousandTwentyTwoPromissoryNoteMember_HS9G4zEpn0eaK4XwwKWnBQ"
      decimals="0"
      id="Narr_G9wTsM4-6UKdvDfkY1da9g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3grY9SX1cEWH0kR90lBaDQ"
      decimals="0"
      id="Narr_8ZnaKBIrE0-AtiXRvHdThA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_dQMI2sHi4EGNCkXWwNvsLA"
      decimals="0"
      id="Narr_pUWDu6qODUmnFHbWtjePfw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:NotesPayable>
    <tlsi:MaximumLoansConvertibleIntoWarrants
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ"
      decimals="0"
      id="Narr_-VatKJgPjEmUNQn2P2oqYg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1500000</tlsi:MaximumLoansConvertibleIntoWarrants>
    <tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_xWxBmnOfOkKQONP5GeELRQ"
      decimals="2"
      id="Narr_XfL8uPIat0KgIufUb_Q-nQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.50</tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_24_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_tlsi_RelatedPartyLoansMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_Jzm_A_jvhUqwLkEpaKybUA"
      decimals="0"
      id="Narr_JtDcJZii9kyLJnkWe7i8Fw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1500000</us-gaap:DebtInstrumentFaceAmount>
    <tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="2"
      id="Narr_G8PrpEED9k22iXWcwxeAqg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.50</tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_ffngkVT0QkSB0YxjNIwPKw"
      decimals="0"
      id="Narr_awXpii3I00OMK6KkE30M9g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1341000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_R6XCzzcbnUOZXAK4sUOmgw"
      decimals="0"
      id="Narr_wLflIDP7gEaCZPLbXtN2PA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_EzGzZBZgcU-WdFfJbS3hZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;6. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Registration Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to a registration rights agreement entered into on December 17, 2020, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will have registration rights to require the Company to register a sale of any of the securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering. These holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have &#x201c;piggy-back&#x201d; registration rights to include their securities in other registration statements filed by the Company, subject to certain limitations. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#x2019;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Raymond James Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Raymond James &amp;amp; Associates, Inc. (&#x201c;Raymond James&#x201d;) was originally engaged by the Company to act as sole manager for the Initial Public Offering and would be entitled to a deferred underwriting fee of $8,750,000 upon the consummation of a Business Combination. In connection with the entry into the Merger Agreement with TriSalus, on November 11, 2022, the Company and Raymond James amended that certain Underwriting Agreement, dated December 17, 2020, pursuant to which, Raymond James agreed &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;to waive the foregoing deferred underwriting fee in its entirety if the proposed Business Combination between the Company and TriSalus is consummated. Raymond James was separately engaged by the Company to act as its investment banking advisor in connection with a Business Combination, and will receive customary fees for its services in that role if the Business Combination with TriSalus is consummated. The Company also engaged Raymond James to act as sole placement agent for an institutional debt financing that resulted in the Company&#x2019;s entry into the non-binding term sheet with Magnetar Capital LLC (&#x201c;Magnetar&#x201d;). In consideration for its services as the Company&#x2019;s investment banking advisor and its services as placement agent, Raymond James will be entitled to receive an aggregate fee ranging between $3 million to $4.5 million from the Company at the closing of the Business Combination with TriSalus plus expense reimbursements, depending on the amount raised in the institutional debt financing with Magnetar and/or other institutional investors, excluding any incremental fee consideration for exercise of the greenshoe. If the Company is unable to consummate the Business Combination with TriSalus or is unable to obtain private financing in connection with the Business Combination with TriSalus, then Raymond James will not receive any compensation for its investment banking advisory or placement agent services, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent Professional Fees&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred legal fees of $508,525 and investment advisory fees of $400,000, which were contingent upon the consummation of the Memic Business Combination. On March 12, 2022, the Memic Business Combination was terminated, as such, the incurred contingent legal and investment advisory fees are no longer due. These fees were not recorded on the Company&#x2019;s consolidated balance sheets, therefore no reversal was required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The company incurred legal fees of $479,262, which are contingent on the consummation of the Merger with TriSalus. These fees were not recorded on the Company&#x2019;s consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 12, 2021, the Company entered into the Business Combination Agreement (the &#x201c;Memic Business Combination Agreement&#x201d;) with Memic Innovative Surgery Ltd., a private company organized under the laws of the State of Israel (&#x201c;Memic&#x201d;), and Maestro Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Memic (&#x201c;Merger Sub&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Termination of Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 10, 2022, the Company, Memic and Merger Sub entered into a Termination of Business Combination Agreement (the &#x201c;Termination Agreement&#x201d;), pursuant to which the parties agreed to mutually terminate the Business Combination Agreement. The termination of the Business Combination Agreement was effective as of March 9, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the termination of the Business Combination Agreement, the Business Combination Agreement, along with any Transaction Agreement (as defined in the Business Combination Agreement) entered into in connection therewith, are void and there is no liability under either of the Business Combination Agreement or any Transaction Agreement on the part of any party thereto (including, without limitation, under the SPAC Sponsor Letter Agreement by and among Memic, the Sponsor, and the other parties signatory thereto dated August 12, 2021). Pursuant to the Termination Agreement, subject to certain exceptions, the Company, Memic and Merger Sub have also agreed, on behalf of themselves and their respective related parties, to a release of claims relating to the business combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 11, 2022, the Company (herein referred to as &#x201c;MTAC&#x201d; in this Note 6), entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (&#x201c;Merger Sub&#x201d;), and TriSalus Life Sciences, Inc., a Delaware corporation (&#x201c;TriSalus&#x201d;), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the &#x201c;Merger&#x201d;), with TriSalus surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of MTAC (the transactions contemplated by the Merger Agreement and the related ancillary agreements, the &#x201c;TriSalus Business Combination&#x201d;). The TriSalus Business Combination is subject to certain closing conditions. Upon consummation of the TriSalus Business Combination, MTAC will be renamed &#x201c;TriSalus Life Sciences, Inc.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Merger Consideration&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate consideration payable to the stockholders of TriSalus at the closing of the TriSalus Business Combination (the &#x201c;Closing&#x201d;) is $220,000,000, payable solely in shares of MTAC common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;), valued at $10.00 per share (the &#x201c;Closing Merger Consideration&#x201d;). Immediately prior to the Closing, the shares of Class A Common Stock of MTAC and the warrants to purchase shares of Class A Common Stock of MTAC issued to the public that comprise each issued and outstanding Unit will be automatically separated, if not already separated prior to such time, and the holder thereof shall be deemed to hold one share of Class A Common Stock of MTAC and &lt;span style="-sec-ix-hidden:Hidden_tErA0HV8TUSeW-q1gHsPXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-third of one warrant to purchase Class A Common Stock; provided that any fractional warrants issuable to a holder upon the separation of the Units will be rounded down to the nearest whole number of warrants. Following the separation of the Units but prior to the Closing, the Class B Common Stock of MTAC will automatically convert into Class A Common Stock, and pursuant to the proposed amended and restated certificate of incorporation of MTAC to be effective immediately prior to the effective time of the Merger, if approved by MTAC&#x2019;s stockholders, Class A Common Stock and Class B Common Stock will be reclassified into a single class of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Immediately prior to the Closing, each share of TriSalus&#x2019; issued and outstanding preferred stock will automatically convert into shares of TriSalus common stock (the &#x201c;Preferred Conversion&#x201d;), and all in-the-money TriSalus warrants that would be exercised or otherwise exchanged in full in accordance with their terms by virtue of the occurrence of the TriSalus Business Combination will be exercised for shares of TriSalus common stock, such that the holders thereof will receive Closing Merger Consideration as holders of TriSalus common stock. TriSalus warrants that are out-of-the-money will be cancelled for no consideration immediately prior to the Closing. At the time of the TriSalus Business Combination, the outstanding options for shares of TriSalus common stock under TriSalus&#x2019; equity plan will be assumed by MTAC and converted into options to purchase Common Stock (the &#x201c;Assumed Equity&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Representations, Warranties and Covenants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Merger Agreement contains customary representations, warranties and covenants by the parties thereto, including, among other things, covenants with respect to the conduct of MTAC and TriSalus during the period between execution of the Merger Agreement and the Closing, including the parties&#x2019; agreement not to solicit or enter into any inquiry, proposal or offer, or any indication of interest in making an offer or proposal for an alternative competing transactions. The representations, warranties and covenants made under the Merger Agreement will not survive the Closing; provided, however, that any covenants that are to be performed at or after the Closing shall survive until such covenant has been performed or satisfied pursuant to their terms. Each of MTAC and TriSalus have agreed to use their commercially reasonable efforts to cause the TriSalus Business Combination to be consummated as soon as practicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Termination&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Merger Agreement may be terminated prior to the Closing under certain circumstances, including, among others, (i) by written consent of TriSalus and MTAC, (ii) by written notice from either MTAC or TriSalus, if (A) the Closing has not occurred on or before December 22, 2022, as such date may be extended to match the extension of the last date for MTAC to consummate a Business Combination under its certificate of incorporation (currently June 22, 2023) obtained by MTAC stockholder approval (the &#x201c;Outside Date&#x201d;), unless the terminating party&#x2019;s failure to comply in any material respect with its obligations under the Merger Agreement shall have contributed to the failure of the Closing to have occurred on or prior to the Outside Date, (B) the consummation of the TriSalus Business Combination is permanently enjoined, (C) MTAC does not obtain stockholder approval of the TriSalus Business Combination at the special meeting at which such approval shall be voted upon, or (D) by March 31, 2023, MTAC shall not have obtained commitments for private financing of at least $40,000,000 in support of the TriSalus Business Combination, (iii) by written notice from either MTAC or TriSalus, in the event that the other party breaches any of its representations, warranties, covenants or other agreements under the Merger Agreement that would result in the failure of the conditions to MTAC&#x2019;s or TriSalus&#x2019; obligation to consummate the TriSalus Business Combination and such breach has not been cured by the breaching party within 30 days after receiving notice of such breach, (iv) by TriSalus at any time prior to the approval of the TriSalus Business Combination by MTAC&#x2019;s public stockholders, if the board of directors of MTAC has made a change in recommendation to its stockholders regarding the TriSalus Business Combination, and (v) by written notice to TriSalus from MTAC, if TriSalus does not obtain stockholder approval within 25 days after delivering an information statement regarding the TriSalus Business Combination to its stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For additional information, refer to MTAC&#x2019;s Current Report on Form 8-K, as filed with the SEC on November 14, 2022.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tlsi:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_w-SHwMHuNkGZ_jYL3cG67Q"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">3</tlsi:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <tlsi:DeferredUnderwritingFeesUponConsummationOfBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_1J2ClcRDUUC7d2IrxMQFMg"
      decimals="0"
      id="Narr_5Zzgt7mwpUOB9PUmvLwtRg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8750000</tlsi:DeferredUnderwritingFeesUponConsummationOfBusinessCombination>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_V-j5MOfUwUGyMV160Ndygg"
      decimals="-6"
      id="Narr_8KwwO3NyLkeKa2tepMmstw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_RaymondJamesAgreementsMember_PDIZOYv6rka-K3_56EQVNg"
      decimals="-5"
      id="Narr_I7DetgjDAEKeQU5HtI_jOA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4500000</us-gaap:ProceedsFromFeesReceived>
    <tlsi:LegalFeeContingentUponConsummationOfBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_fcaQv_yfY0KVxq2dMDpwOA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">508525</tlsi:LegalFeeContingentUponConsummationOfBusinessCombination>
    <tlsi:InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_SYSer_RvL0y5fKrDqvyvHw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">400000</tlsi:InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination>
    <tlsi:LegalFeesContingentUponConsummationOfMergerWithSubsidiaries
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr__DwEtU8ZKEyq501VB4pGPg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">479262</tlsi:LegalFeesContingentUponConsummationOfMergerWithSubsidiaries>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_P_hbBZGvG0SAPWdr9iTosQ"
      decimals="0"
      id="Narr_xKlMPZGV1EmB4y3q9aDhWw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">220000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA"
      decimals="INF"
      id="Narr_Q4gCJc9vTUOLucx6xlIHaw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_VnMl30ctkEiaJbqB8ToVUA"
      decimals="2"
      id="Narr_DX59ujkaWUm3aTRfGkbDeA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:BusinessAcquisitionSharePrice>
    <tlsi:NumberOfHoldings
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_MtacClassCommonStockMember_y3jzsSpPn06F9ea0zBxkMQ"
      decimals="INF"
      id="Narr_bmBwCZwCbkOLhdy56NjGHQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1</tlsi:NumberOfHoldings>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_frFkjPXujEqyCGSDsM9GUA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">40000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <tlsi:NumberOfTrading
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="INF"
      id="Narr_ilLhr9dZxkKZgCx1jRE36g"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:NumberOfTrading>
    <tlsi:StockholderApprovalAfterDeliveringBusinessCombinationDays
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Narr_KjJhK5JMokiBHqHXUZpI8g">P25D</tlsi:StockholderApprovalAfterDeliveringBusinessCombinationDays>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb__T7BkZ_nwU6DIMtzu4G0kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;7. STOCKHOLDERS&#x2019; DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock &#x2014; &lt;/span&gt;The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. At December 31, 2022 and 2021, there were no shares of preferred stock issued or outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class&#160;A Common Stock &#x2014; &lt;/span&gt;The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At December 31, 2022 and 2021, there were 1,953,422 and 25,000,000 shares of Class&#160;A common stock subject to possible redemption which are presented as temporary equity, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class&#160;B Common Stock &#x2014; &lt;/span&gt;The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At December 31, 2022 and 2021, there were 6,250,000 shares of Class B common stock issued and outstanding. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company&#x2019;s stockholders except as otherwise required by law.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with a Business Combination, the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of the Initial Public Offering, plus the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any shares of Class A common stock or equity-linked securities exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in a Business Combination and any private placement-equivalent warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans; provided that such conversion of Founder Shares will never occur on a less than one for one basis. The Company cannot determine at this time whether a majority of the holders of Class B common stock at the time of any future issuance would agree to waive such adjustment to the conversion ratio.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_FMBPSG5p-ky3kPb2AH1oag"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_xahw9v-N40O2yNMSba-qHQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_hWBWxXa7g0WZoMnWgbyKUA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_2ws_r22n0UGa3Do6ioERPQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="INF"
      id="Narr_ngFY_8HcEEuQEEAl2NbNZA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="INF"
      id="Narr_dDze9KqAakGyGsIcEnsfqQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Narr_2Sz9jWvS3U-AyYL13SEDCg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_a5AI8q9AA0GPAcw7lEiROA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_--E25hDsVUmrofcH1Ze5Bg"
      decimals="INF"
      id="Narr_RQx3d5NvI0SslmQE-yJwLw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_FcZD3e1cbku0c8J3PltdvA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <tlsi:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA"
      decimals="INF"
      id="Narr_lhqKJQSjDk-C5KalHbqqUg"
      unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg">1</tlsi:CommonStockNumberOfVotesPerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w"
      decimals="INF"
      id="Narr_JegcenqVz0epmh1lF4opTw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1953422</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_Deu4Gj4CBkyArvxkivc2lQ"
      decimals="INF"
      id="Narr_RWoqMkojzECnu7FaRAov4A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_Gd7htElxmkC0xtUxILbzJg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_HMnMMJ_9nEShBegxBMPR8w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_ou5F3YoozUa6bOXGHPWXWA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_RkaSsxSYdEGeAQcZN5ljOw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <tlsi:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_dK8-qchhFEW_i6LjGTi0IA"
      unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg">1</tlsi:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_Wqjm8UOPiUmX6E5OzjzL7g"
      decimals="INF"
      id="Narr_HZ2N4zgF00WQ9mQbsREwBA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_llOi4aDM4ES6cVKQlTLiIw"
      decimals="INF"
      id="Narr_-Zt243UdGE2YmQpbMX8_0A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="INF"
      id="Narr_5b9JOHIeIkeRFSwQZRH0hQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1</us-gaap:ConversionOfStockSharesIssued1>
    <tlsi:ConvertibleStockConversionRatio
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_T2Q69OwdhU2xXCJCq-3vnA"
      decimals="0"
      id="Narr_3olLDo0H-0-L1uxxpZgrog"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">20</tlsi:ConvertibleStockConversionRatio>
    <tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_uwuC6cNrN0-N87vr11Lb5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8. WARRANT LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were 8,333,333 Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a)&#160;30 days&#160;after the completion of a Business Combination and (b)&#160;12 months&#160;from the closing of the Initial Public Offering. The Public Warrants will expire five years&#160;after the completion of a Business Combination or earlier upon redemption or liquidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will not be obligated to deliver any shares of Class&#160;A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class&#160;A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class&#160;A common stock upon exercise of a warrant unless Class&#160;A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement registering the issuance of the shares of Class A common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60&lt;span style="font-size:8pt;"&gt;th&lt;/span&gt;&#160;business day after the closing of a Business Combination or within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; pursuant to the exemption provided by Section 3(a)(9) of the Securities Act; provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;in whole and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per Public Warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;upon not less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2019; prior written notice of redemption to each warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;if, and only if, the reported closing price of the Class A common stock equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$18.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; trading days within a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;trading day period ending &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; business days before the Company sends the notice of redemption to the warrant holders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. The exercise price and number of shares of Class&#160;A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of Class&#160;A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, if&#x2009; (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company&#x2019;s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company&#x2019;s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2022 and 2021, there were 4,933,333 Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until 30 days&#160;after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/p&gt;</tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_-wdfKUjnDUyvvNS1vvWscg"
      decimals="INF"
      id="Narr_cfEphI6eHEa2NdKnRUCYaw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag"
      decimals="INF"
      id="Narr_h6I6CvWv4U2qbZkhLMGIsQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:WarrantExercisePeriodConditionOne
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      id="Narr_VE19MU405EWLboJ7lubg9A">P30D</tlsi:WarrantExercisePeriodConditionOne>
    <tlsi:WarrantExercisePeriodConditionTwo
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      id="Narr_Lldfh3NWY0-I1s5B3r0pkw">P12M</tlsi:WarrantExercisePeriodConditionTwo>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag"
      id="Narr_fS97UZyQiUCR4iNqdVRInQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tlsi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA"
      id="Narr_RIJrIzsJU06F0ZEHr2_weg">P15D</tlsi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
    <tlsi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA"
      id="Narr_88hSwZcZkUmqohTqr3rrqA">P60D</tlsi:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
    <tlsi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="2"
      id="Narr_75nzNJm3aEiGypsOe-yOKg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.01</tlsi:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <tlsi:RedemptionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      id="Narr_qGZmUebVfUK2bsO6iWL8JQ">P30D</tlsi:RedemptionPeriod>
    <tlsi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="2"
      id="Narr_DuFpLshRl0akvYgc6Aoqng"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">18.00</tlsi:WarrantRedemptionConditionMinimumSharePrice>
    <tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="INF"
      id="Narr_ysi6mlX9hUuzVqRNkjCqvA"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="INF"
      id="Narr_t39xScKWcEW3sUKlHbVyjA"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <tlsi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="INF"
      id="Narr_-vIfGFeuPUCjNxd8me8a8Q"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">3</tlsi:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders>
    <tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag"
      decimals="2"
      id="Narr_DQaCYcHKaUSPYIAKVr8CXA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.20</tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <tlsi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      decimals="0"
      id="Narr_ULWw-fF5JE6wjqq5Bi9big"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">60</tlsi:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <tlsi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      decimals="INF"
      id="Narr_fhQpjpRMnkGQLqbcBJ-60Q"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
    <tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_jinWmGY5EUCnCiFmCbTZag"
      decimals="2"
      id="Narr_cLu5o_Bm8k247KHpyhJS6w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.20</tlsi:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <tlsi:WarrantExercisePriceAdjustmentMultiple
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      decimals="0"
      id="Narr_0XnWv8HQSUWHkGX-Gz4ufA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">115</tlsi:WarrantExercisePriceAdjustmentMultiple>
    <tlsi:WarrantRedemptionConditionMinimumSharePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_StatementScenarioAxis_tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_FFvo6Nvw8kG4_jk5HosEaQ"
      decimals="2"
      id="Narr_vaJR6TJwC02WjgetjAb0Tw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">18.00</tlsi:WarrantRedemptionConditionMinimumSharePrice>
    <tlsi:WarrantRedemptionPriceAdjustmentMultiple
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_xxvwPhxUxUmVT3U4n8TgfA"
      decimals="0"
      id="Narr_4GEjc4jFmEOnbJcxDKX5_A"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">180</tlsi:WarrantRedemptionPriceAdjustmentMultiple>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_X-8bVslRMUid_3Y3ZJ4oPQ"
      decimals="0"
      id="Narr_JG8DMUz3ikakXJ40BihrLA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4933333</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_n9CPBSe_t0CIf2MEce1Hbg"
      decimals="0"
      id="Narr_2IpKA3q3bE2Ewc3T7Dpffw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4933333</us-gaap:WarrantsAndRightsOutstanding>
    <tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_6MR-PsP6QE615ZeUhGehHg"
      id="Narr_1GXTq_kRU0mqT7fhf4bvNg">P30D</tlsi:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_US-yiEmGJEq00ozTsVHY6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;9. INCOME TAX&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s net deferred tax assets for the year ended December 31, 2022 and 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Organizational costs/start-up expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,160,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 606,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,160,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 647,202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,160,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (647,202)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets, net of allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The income tax provision for the years ended December 31, 2022 and 2021 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (513,464)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (625,111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 513,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 625,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, the Company had a U.S. federal net operating loss carryover of approximately $0 and $194,000 available to offset future taxable income, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended December 31, 2022 and 2021, the change in the valuation allowance was $513,464 and $625,111,respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate at December 31, 2022 and 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_GT0l1CfR5EOigCcmJUWAYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Organizational costs/start-up expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,160,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 606,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,160,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 647,202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,160,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (647,202)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets, net of allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_peeH7xmihk6B18-CtGtP2A_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_lvGIbIoQ8EaOlPf9wnyqAA_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">40819</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_YJ5rkIQsdkK_C1RCbGpkXg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1160666</tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts>
    <tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_KsqxRuudZEKd7Cfhv1K3Kg_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">606383</tlsi:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_pXMxGG1aRkaSp8YG8bwspA_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1160666</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_M4xlxDqit06WZMoc8se4TQ_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">647202</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_kChYhdCvQUCXN-Mjd8ibOw_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1160666</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_NL_uROErXk-zmjY4AqCHWg_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">647202</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Tc_96yGiroYtUmj0N5jQeQRQA_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Tc_a1-2V8fAY0SPG6TYevBAsg_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_12FACrNjaECTzzXJy6hr8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (513,464)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (625,111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 513,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 625,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_3K8yOxe_502xbh-n7n3wJQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">570854</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_t9az2f9ryk--UgmB7ioLEQ_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_1jDXPz7QsEG4bJvgDqQFhw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-513464</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_CCkgw80cr0eWQlFusRV2RQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-625111</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <tlsi:IncreaseDecreaseInValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_bOrElSfKMUOR8SC67XuxxA_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">513464</tlsi:IncreaseDecreaseInValuationAllowance>
    <tlsi:IncreaseDecreaseInValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Tc_qXsfyR_iF0q5aQNn3EauiQ_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625111</tlsi:IncreaseDecreaseInValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Tc_W0Us2RffDkOCw-FdZrscjw_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">570854</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ"
      decimals="0"
      id="Narr_zg_BX-o7LkyJGWcjZbc2TA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ieV1Q6zxNEiMzCa5pQSnrg"
      decimals="0"
      id="Narr_vZ-VGcSYeEWQWAjwyJfcSw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">194000</us-gaap:OperatingLossCarryforwards>
    <tlsi:IncreaseDecreaseInValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_oeKyLPEtj02gaBAlOLSaVA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">513464</tlsi:IncreaseDecreaseInValuationAllowance>
    <tlsi:IncreaseDecreaseInValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="0"
      id="Narr_gkqX43r-QUixRgC5i4q6aQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">625111</tlsi:IncreaseDecreaseInValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_XBwKOntoGUWbD2V--XUeww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="INF"
      id="Tc_oSE9qMdtAUC3chfiOqo1Kg_3_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="INF"
      id="Tc_S_pq0ndPSUShpiCPQfST4Q_3_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="3"
      id="Tc_AM_3NCi78USfe0PgWVJDDA_4_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="3"
      id="Tc_455F2n8XzkKs9aPywsjv_g_4_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="3"
      id="Tc_iXTrJEQZ4UiYtB-4tLIuew_5_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.201</tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities>
    <tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="3"
      id="Tc_loMMSttceEGTWu8vp1C5aA_5_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.341</tlsi:PercentageOfChangesInFairValueOfWarrantLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="3"
      id="Tc__ICtDchwoEGhm2USNVoTpw_6_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.084</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="3"
      id="Tc_HrSstvoks02YmJqlccDmDg_6_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.131</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="3"
      id="Tc_J5WQ0pyWp0qY_vB7Xz221w_7_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.093</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_ojhyNtu6JEW7hCweX16OOw"
      decimals="3"
      id="Tc_4iRrn2r660ye-yX5v1ZHww_7_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_JsXbDQWh40mGzfLbeYjRcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;10. FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2022, assets held in the Trust Account were comprised of $19,827,884 in cash. During the year ended December 31, 2022, the Company withdrew $905,000 of interest income from the Trust Account to pay for taxes and $232,371,273 in connection with redemptions of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2021, assets held in the Trust Account were comprised of $250,007,295 in money market funds. During the year ended December 31, 2021, the Company withdrew $60,000 of interest income from the Trust Account to pay for taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2022 and 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. The gross holding loss and fair value of the Trust Account at December 31, 2022 and 2021, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and investments held in Trust Account&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,827,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;250,007,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant Liabilities &#x2013; Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 666,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,333,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant Liabilities &#x2013; Private Placement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"&gt; 394,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,565,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrants in the statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Private Placement Warrants were initially and subsequently valued using a Monte Carlo Simulation Model, which is considered to be a Level 3 fair value measurement. The Monte Carlo Simulation model&#x2019;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. Significant increases (decreases) in the expected volatility in isolation would result in a significantly higher (lower) fair value measurement. The expected volatility as of the Initial Public Offering date and subsequent was derived from observable Public Warrant pricing on comparable &#x2018;blank-check&#x2019; companies without an identified target. A Monte Carlo simulation methodology was used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The key inputs into the Monte Carlo Simulation for the Private Placement Warrants as of December 31, 2022 and 2021, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table presents the changes in the Level 3 fair value of warrant liabilities during the years ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gXPw_HPigEaLTrob0MTpMA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,170,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,170,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 394,667&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 394,667&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,476,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,166,666&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,642,666&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_2rj7F36mjUqkt3ooiJGgKw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,910,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,833,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,744,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Transfer to level 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,333,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,333,333)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the year ended December 31, 2021 was $4,333,333, when the Public Warrants were separately listed and traded. There were no transfers in or out of Level 3 from other levels in the fair value hierarchy during the year ended December 31, 2022.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_pSuIgL5MgkW3Hup01vec-g"
      decimals="0"
      id="Narr_zwfTeJsakUWoviYqvGQ02w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19827884</us-gaap:Cash>
    <tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w"
      decimals="0"
      id="Narr_-RksQlhqL0WxvVDEh4N2oQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">905000</tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes>
    <tlsi:ProceedsFromTrustAccountInConnectionWithRedemption
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_GNwAlWZdm0GlEbvd6iWV3w"
      decimals="0"
      id="Narr_SlJceyRenkeiVDwR8KrLLg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">232371273</tlsi:ProceedsFromTrustAccountInConnectionWithRedemption>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_ApO8mJ0Y8k2llY2j78FSwA"
      decimals="0"
      id="Narr_dORJ69w63karfVGJ7S511w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250007295</us-gaap:AssetsHeldInTrustNoncurrent>
    <tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_7GgzZHKQ-Em17ealfdPxcw"
      decimals="0"
      id="Narr_9yONw7Gp40e4RKYCY6HKTw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">60000</tlsi:CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_8dBzeY_VHE2Trnp4nwoh_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and investments held in Trust Account&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,827,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;250,007,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant Liabilities &#x2013; Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 666,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,333,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant Liabilities &#x2013; Private Placement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"&gt; 394,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,565,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1sI5wKqJ1kuQbBSeQbH8aw"
      decimals="0"
      id="Tc_sA_vpdA8F027sM8zeDkPzg_4_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19827884</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tt5jNBG_Ik2_dw16N9eu5g"
      decimals="0"
      id="Tc_ecC882wxwkq4SbUJqaNUOA_4_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250007295</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vK2xj6_BxUyXDij_MHIdJg"
      decimals="0"
      id="Tc_b0Ni2ckJcUeNhymocwQlvg_6_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">666667</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_polfWIhfYU6ib1Sd0a3R4Q"
      decimals="0"
      id="Tc_lZos9YI0REqo9bx8JFWpVA_6_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4333333</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jrQIVcWI-069v0ykyuASTw"
      decimals="0"
      id="Tc_sApU8x_VOUqgqlUbnGMV0g_7_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">394667</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0kAqZczoU06tzJG4_2vBug"
      decimals="0"
      id="Tc_6Q4PoD_YlUK7L0Iz2d6IFA_7_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2565333</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_ZjyY6cp84EOYjHwjgT6_kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A"
      decimals="2"
      id="Tc_CJLtKJK7qUergetVoiFMww_3_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_Rf1rpKHlWkavH2VB0BmDhA"
      decimals="2"
      id="Tc_GOQoKJ42AUSJpomhkk1WiA_3_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_25lDX06in0-qNkGhQyvfQg"
      decimals="2"
      id="Tc_CVmnXCqPe0WwKBsclQr0mQ_4_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_Wce1nzVCUkqX390MzkZu9A"
      decimals="2"
      id="Tc_oPCOuwDbT0-NUnsTebo4zg_4_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_m13ANPolnkC_TrigPHT8kQ"
      decimals="4"
      id="Tc_eiHlzpxlUU6iQ_KNAOHBYg_5_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0640</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_iVlKykJbaEi1jw6dwN8Bmg"
      decimals="4"
      id="Tc_3p5u4IThx0aY2MzRIMZD8w_5_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0960</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_0Joxy8nL_k6rabaYjK9iOA"
      decimals="2"
      id="Tc_ZiVE65t9GEKkhgEcflNkWQ_6_3"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">5.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WdW_HNNUdE21vIAEvcd5UQ"
      decimals="2"
      id="Tc_bIxVqNT2ek2sr79MzLJTsA_6_6"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">5.16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Rp9zrLRlm0CYZN74Ck2XNw"
      decimals="4"
      id="Tc_f6eV9l5TGkaNm7FUn6DFlA_7_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0391</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Qppm2hRKWU60ummLMBfT1w"
      decimals="4"
      id="Tc_rijD24maKUaumkvvSdW6Vw_7_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0127</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_nHo1vJsJrkKTnWl_TCasMA"
      decimals="4"
      id="Tc_XoTWNkJEvEe9yRgVRHblQQ_8_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_a8ra3C8AWUOIDlIdA4ccMw"
      decimals="4"
      id="Tc_LE9Pgy7c5kqtmIKfH9QCew_8_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_IogKnMMNX0uzLtWgLHXI7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gXPw_HPigEaLTrob0MTpMA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,170,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,170,666)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 394,667&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 394,667&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Placement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,476,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,166,666&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,642,666&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_2rj7F36mjUqkt3ooiJGgKw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,910,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,833,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,744,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Transfer to level 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,333,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,333,333)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value as of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,565,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg"
      decimals="0"
      id="Tc_sRNj3c2rZkSn5DefVsyP_g_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2565333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ"
      decimals="0"
      id="Tc_2we1WgDOqkGRwMYrsb_nNg_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2565333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_XjvP2qF1UUWER7JjNd59jw"
      decimals="0"
      id="Tc_Cngb9ZfmFEqlAxZh-81y8Q_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2170666</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dOs7dd0euEGpMogpANdTlQ"
      decimals="0"
      id="Tc_x3piW-1bYEuUbhe-o5Sc2A_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2170666</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_0GubflhbPUawUpS7hbiulg"
      decimals="0"
      id="Tc_DbvdrStsu0muN6sBmCM3xw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">394667</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_prO-azAGCkKvlOGQ87zRuw"
      decimals="0"
      id="Tc_PFrHTld_V0Wyxs_kADDu3g_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">394667</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WJzJV0pqcEuaZ1x08vBwUw"
      decimals="0"
      id="Tc_IPATj5Dq_0ySkViG9l9mBw_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5476000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_NpeQJRDSdU60CDOOsBwD5g"
      decimals="0"
      id="Tc_RgvC6NUU6ESdA8qJwRQaIQ_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9166666</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lDZmpqyvbUGnBpoWYEe-5A"
      decimals="0"
      id="Tc__u5bWo-h50q4pZsQo6Z2Zg_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14642666</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_5bX39y7wV06kY0hYQDIn6w"
      decimals="0"
      id="Tc_Vox7ocTi4kiXMMqAB-xZaw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2910667</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA"
      decimals="0"
      id="Tc_w5xrwltERku_gc-cgbBHXg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4833333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ"
      decimals="0"
      id="Tc_SPw4q8hKZEW-qpYCbkrU_w_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-7744000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_4t8TNDhImEWsIlhj8eOhMA"
      decimals="0"
      id="Tc_g1QviIZdyUq-s39_rRPuUA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4333333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_hJ70YpWjS0GaNPJnHzs4RQ"
      decimals="0"
      id="Tc_BPDF3nkep0mf5mCBLIOrPQ_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4333333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qX2h1Uy910iFOPDEZ8lBSg"
      decimals="0"
      id="Tc_R8iRIidU7kCfycGaLQx7Kw_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2565333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9FstVZm760uM_Oiv3BV2pg"
      decimals="0"
      id="Tc_Yd_WuJRcKE-Yf4LO1fo9Iw_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_GwQ3pG2wEUS91ZqmVlDHbQ"
      decimals="0"
      id="Tc_w9LGdZuMdEOeqY17iDJ5tA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2565333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9tvbOtUSfE2CdGMRe7SRBA"
      decimals="0"
      id="Narr_kzavE-a5JU--5EFqqfcZMA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4333333</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      decimals="0"
      id="Narr_qcjD5SB6REq8Hgvnh5UI1Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg"
      id="Tb_EyxPqvVoE0CnzZzBAPRssw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 11. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than the below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to December 31, 2022, $78,136 was drawn on the Extension Note, as described in Note 5 and deposited into the Trust Account. In addition, TriSalus deposited $78,136 in the Trust Account pursuant to the Merger Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 13, 2023, the Company drew an additional $159,000 on the Convertible Promissory Note as described in Note 5.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 13, 2023 and February 8, 2023, the Company drew an additional $215,222 and $200,000 on the 2022 Promissory Note III as described in Note 5, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2023, the Company and the Sponsor engaged Ceros Financial Services, Inc. to render certain advisory and placement services to the Company. Pursuant to such engagement, the Sponsor (and not the Company) would be solely responsible for any and all fees and expenses payable to Ceros Financial Services, Inc., if any, that would arise or accrue prior to, or in connection with, the closing of an initial Business Combination.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_LongtermDebtTypeAxis_tlsi_ExtensionNoteMember_tiwUkSJfkE-HqTQAgDXx9w"
      decimals="0"
      id="Narr_jGSGW8oskEeJG7Tl5Ucqfw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78136</us-gaap:LongTermDebt>
    <us-gaap:AssetsHeldInTrust
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_CounterpartyNameAxis_tlsi_TrisalusMember_us-gaap_TypeOfArrangementAxis_tlsi_MergerAgreementMember_ZN8XEh8o7U6Eq1INZQlX_w"
      decimals="0"
      id="Narr_gZRoIkUh3EeFAOJBgYkNIg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78136</us-gaap:AssetsHeldInTrust>
    <us-gaap:LongTermDebt
      contextRef="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aZgwMCP6sEuHAa1-q5dwCg"
      decimals="0"
      id="Narr_ZuuGw60rZkyS8_8SXN4PWg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">159000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_1_13_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8QPxAWLYn0eSa29pAZk5ig"
      decimals="0"
      id="Narr_7Pd7-IjNDUeW8GF2moYDDQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">215222</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_2_8_2023_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ShortTermDebtTypeAxis_tlsi_PromissoryNote2022ThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_I5SxmOgITEqkvbLNanEY2g"
      decimals="0"
      id="Narr_v-aG3LDiyk6QBoee0li4fw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200000</us-gaap:LongTermDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_LdkZGq5LRk2UG4KiMC9o_w_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21383000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_8QWkNHA0vkWJ01DhrRCgOA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9414000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_pL5FiF7EJUmVNDCdbl_whA_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3052000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_LDSBiRVXy0KzJh18QVr1ng_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1557000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_fUA6eAFtZEqhGFkEheModg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1629000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_crH9iFSqHUi5qfTPHjG03w_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1471000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_atDmrYjdTEuzYkIKkE3PlQ_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2977000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_7azYVc8GsEKj0U0eu-AAfg_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4772000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_lT-Hcz4i-0Sd9pQW-o4pBg_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29041000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_aBXeyt9LQ0GmSuYWMjegcg_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">17214000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_BIsDZtrFXUqoVqO3TGfp3Q_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Xj1HXC6bvkqTX1I8q6KmYg_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2231000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_7jW9rB2rskSh0RWSjky3gg_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1252000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_OmUHwaL7lkiQHGy7hytIew_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1381000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_DOTZbWCePECMxdd0kTQtiw_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">997000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_fvmbP5aiCkKhnxxXi-cOTQ_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_XNeQMwn0Hku0y05l-7t_fA_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">367000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_8ovwzcZG0UmS3Mma44oQWQ_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">367000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_y2MiQnehNkmgwWZ1DztC3A_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">33554000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_SFeaGi4CrEmbvFdUiLjERA_14_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21995000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_0z-dESqgiEKW7TSG-RHqGQ_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1899000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_TsZyU6DrZkiPDbzPnRU_OQ_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4947000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_VbsSSh3ZUUuPmdp3CLdHHA_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6600000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Yvw9mi0cTEmFhlyxOxxLHA_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6377000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ"
      decimals="-3"
      id="Tc_ybt2RdAR3EKaXcU1V11gMA_19_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_7-Ei6pQlX0-G_ZB2qY5krg"
      decimals="-3"
      id="Tc_pXANtf26hE2BQJdtlmZ53A_20_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</us-gaap:DerivativeLiabilitiesCurrent>
    <tlsi:LeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_npyyCPmr9EydP6ngejISNA_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">379000</tlsi:LeaseLiabilityCurrent>
    <tlsi:LeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_6AY_NHiewU6Kuf17LpqWNg_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">370000</tlsi:LeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_3UeXXR_5HE-uifZlrf7qQw_22_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">427000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_O52VQmzLSkqw0u9kFlHLpw_22_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">142000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_0ckZaTIfpkOnWZdEv_RnMA_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9305000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_K1KgOKQ5rkCBC-dn2_pHkA_23_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">32357000</us-gaap:LiabilitiesCurrent>
    <tlsi:LeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_tBhkeYbnZ0K9rLlFTfyrIg_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1318000</tlsi:LeaseLiabilityNoncurrent>
    <tlsi:LeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_DkQnESWpY0GNvLLw2tbN8w_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1593000</tlsi:LeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw"
      decimals="-3"
      id="Tc_iQIJIdexski4TllYsG6NWw_25_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9023000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ"
      decimals="-3"
      id="Tc_Mv0sKiTaQE-_9a7LRSTmqA_26_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5421000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_djynE7y46UuGJtBrPjxTbg"
      decimals="-3"
      id="Tc_Z5BKY1njJkGUgKb_KX9IPQ_26_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">369000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_nvdkejMI10Kkh-8ikQ6XoQ_27_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25067000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_hE__nxZZg0CUDEa-CKOdVQ_27_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">34319000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Vl95CsaHzkeodosTc0tw-A_29_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_qXNTsmBJckSI6GoAVaCTmw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_iRG2NtnTH0i9Zqbl0q76QQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_9XTbgl3mUEmogKtzyP47Sw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_9_1X5zXjg0uOJOCqiorANg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_FoxGdjXrtk6lSjYm44Mprw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_oUsG1eehwk6NnrNnc53HtA_31_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_7Gy582q5nUKr1ZWZGCZ9Hw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_as7upiRgd0e27KdEHqYJDQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_4FurbMzBWkK3NDaVMyTWsg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_bqnx8EfHME-hRjrBq0m9sw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">30898162</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_H-1oDNV3uUmZx1gQ5pS2PQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">26316681</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_-ll8B2FRMkqlpVWNZ5vezA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">26316681</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_mSUfA0jMFkmQcIE77N4iVw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_o5dIWReGykGjaAIK2-O_6w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_krk23REpVkCXpYF6jNmbPA_32_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_57b5Nv9zAE2dSxOUeUS_iA_33_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">221351000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_z73BU1TppUCxocPEi7XyGg_33_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10028000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_-JKyo8ysqUSfflYiWXBJVg_34_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-212867000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_qw9aZ_7j7UWVIwkkyDAt_g_34_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-186358000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_veskGXe2ZU6iwXuUuERXUA_35_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Cqf7dZod0E-sU4exBmsgTw_35_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-176330000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_LQGjSQphg0GmS1gxOUz6Bg_36_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">33554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_bdzcoXSzhEueFv_c8dykJQ_36_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21995000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_NYdo0uAZH0CcLQhUN6sYSg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_c1PdJH7v-0iO-pflJAzPUg_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_uV2Tgdz130ew6Tmaxu19LQ_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_6O71_rBQ2EGpCeDYrJ3tjQ_5_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_Kt-nk8muV0mGq6obgqXGAg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">589000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_mAyxdMjP6ky398jmYT7B9w_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">701000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_C86YI1BB-U6lzNGBCYuNUA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2023000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_kFZm2fq36kS0Cao-DZevcg_6_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1442000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_OKkiGqJ5ykSTZ6S6zHMrPA_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4604000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_2RbBNvBmaEqUocG8a04FYw_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3222000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_voVcMvmf0kiOsv657Brisw_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10767000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_urOIF4KCm0-tC57jpIi3SA_7_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7730000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_7TtjEML_PEax6jyXxGSJJQ_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9367000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_Zc9fuG01ZkupqNYx_Q3NFw_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4808000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_tYGDlqLs0kC0NRp_ZRmGZA_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21871000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_56bp4Yxo90OhYboeLPRtGg_9_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_l7lDGeG8TkiLsAmJOlPU0g_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4689000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_8tZY4lzlNkitjNxE5vPMhg_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3030000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_TQtloQ-Tl0qrS-wglZk69w_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11430000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_xG_d9vwk4U2xaqETz2ASaA_10_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8881000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_0yHQCFbgGUynQCITxbu2TQ_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9025000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_apjWn9P4rEi96AmZ75D4Fw_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3495000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_2hXFFDY-0km9YALSUtZylg_11_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">17498000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_MWU35pnbeEa6-ZAYmrKuaQ_11_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8425000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_ADCyzjjMCUOwBNgQDmr7BQ_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-18477000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_DK5Wd7e0Gk-U23LTDQetTw_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8111000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_15LqtN10cEuN3s1RcMAUfA_12_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-40032000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_Ccksevz2REeszHgCVTFuAA_12_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24667000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_wHPjlJ0ml0OeKCNF6_-JQg_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">116000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_WhBcseAWpEGiHjLcQ30WPA_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">49000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc__PL5Jd-Fi0WvwvC90BxOIw_13_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">187000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_5B9eqfGCwEeFA_cOz9-IvA_13_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">75000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_JJgAvkWbkEmVGfSacjo3gQ_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_lfPx-Hq37kStq_uCMOpv4g_14_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_XLjB4pBwNEGpnY22z2ApCA_14_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_ktL0BhEwWkuRRjhFWVYzpQ_14_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:InterestExpense>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_wKYejvcOH0y_LVNc5JwIaQ_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:GainLossOnEquityIssuance>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_wyXGuu-cbEiVPFvazraOLg_15_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:GainLossOnEquityIssuance>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_mYZLM8kmVkq8mTfCpX82KA_15_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4171000</tlsi:GainLossOnEquityIssuance>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_NUQ8WKnJ8EqLfH0d6ZsKSQ_15_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:GainLossOnEquityIssuance>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_u3QAPFO_gkSJ1bhVwH2ETQ"
      decimals="-3"
      id="Tc_OkKDNAJf3UGLLAmoK1FLag_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2812000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_0y-vFKCdP0GBKfV2QNnuaw"
      decimals="-3"
      id="Tc_bKOrYOd25EWS_Rd0ITu7dA_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA"
      decimals="-3"
      id="Tc_L4irDd9BxUmfXsQRfT-kPw_16_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">660000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg"
      decimals="-3"
      id="Tc_6n6dane990u68QIyNJeL2w_16_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A"
      decimals="-3"
      id="Tc_MnsxK1ekK0Oa1gT6eVi82A_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19904000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_VNbM6PPC7Ui-DQUvI1KgNg"
      decimals="-3"
      id="Tc_GwJbS1TwRk68XSacM-NhSA_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA"
      decimals="-3"
      id="Tc_q4ROv0TWiky4XkC8LhztlQ_17_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19904000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA"
      decimals="-3"
      id="Tc_HLmyF__iWUaMbnQZU053WA_17_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_Y4sxXoHiC0We7SrQcqCEsA_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_5GyNfqrRqUSxPY8gstPjkA_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-31000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_kc26FXlIRkGyZaIDC8jFGQ_18_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-56000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_H45rN8Yao0CMLsosfcieFA_18_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-71000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_VgNDvlXc30aWcclT5vvr9w_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_QFRnNktx0U6AfL34RBlI_g_19_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8093000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_rGLvlNwtnUOXoZp4gNrwxQ_19_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-23521000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_7HyGEp6vKkOMsAO5uglACg_19_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_sNfHZclCnUWhqw1ZrryzOQ_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_EKbxvVltn0yai1mN3Opf8w_20_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_D3PiMPqVEEW1tiWwiAFVkw_20_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_HM_wMONvCkqZMcMu5grTNQ_20_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_uPXyiLQp0EGZ0V6wwf838w_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_BVONEZHOr0yKopAItLj83A_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_u7HB-dtYnEWYRsVBFuc99A_21_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-23529000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_IjgOh4QavkGIeZaHlFcm1g_21_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24645000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_ndTIGJhRRESqwwkxmnUyww_22_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_xkRysL0h_UCOoztdla_f0A_22_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_AsF-jXgo8EeRrVCYjHZ6cw_22_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2981000</us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_EwF8q2bbD0i-Ahsvuf5B0g_22_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_AWRZVV0_LEar5DbQqxAl4w_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">458000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_7oTKwxX00UGVMJxiOhk8iw_23_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_HxdICK2fP0-mgQOcHvzU9A_23_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">458000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_nd-6lERLFkud5RTARpY-BQ_23_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_sg4eXuniakeXQ2oqLDcg8g_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1744000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_Ur6hmw2hoUm1395ke03GAw_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8093000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_0fHV6Ur0TkqIbtYoVTTTuA_24_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-26968000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_OCyRxeHpwEyPKPqEF5rd6w_24_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24645000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="2"
      id="Tc_hUlS3ava60qRTX0wWnwOGA_25_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="2"
      id="Tc_hUlS3ava60qRTX0wWnwOGA_25_3_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="2"
      id="Tc_UROfL39YFkyQnBp1LfLZ-A_25_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-25.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="2"
      id="Tc_UROfL39YFkyQnBp1LfLZ-A_25_6_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-25.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Tc_K9F_iEyit0KFTqEerrmhug_25_9"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-5.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Tc_K9F_iEyit0KFTqEerrmhug_25_9_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-5.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="2"
      id="Tc_Q3pNx1zcCEa7g8B4FLjMPQ_25_12"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-82.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="2"
      id="Tc_Q3pNx1zcCEa7g8B4FLjMPQ_25_12_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-82.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="INF"
      id="Tc_NhLfPD4WdEeBHrrRXMoARg_26_3"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">13173422</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="INF"
      id="Tc_NhLfPD4WdEeBHrrRXMoARg_26_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">13173422</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="INF"
      id="Tc_bJHKb_JplUar2RCHLnUJPg_26_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">311823</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="INF"
      id="Tc_bJHKb_JplUar2RCHLnUJPg_26_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">311823</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Tc_x343sDrPikaQmNA5x7K0VA_26_9"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4749849</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Tc_x343sDrPikaQmNA5x7K0VA_26_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4749849</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="INF"
      id="Tc__i2-ma8H70iHJqa8BVaiHg_26_12"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">299936</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="INF"
      id="Tc__i2-ma8H70iHJqa8BVaiHg_26_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">299936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw"
      decimals="INF"
      id="Tc_0g2ys7O-IEytJb4va4p1eA_4_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA"
      decimals="-3"
      id="Tc_QyASKvv4vkmnDNTTOcajIQ_4_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw"
      decimals="-3"
      id="Tc_vvWax9PUtkqFhvN55bVT4A_4_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-186358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_gg3RatWsykGUZBoSJAJYCA_4_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-176330000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mOezHh-BNkaD4qPijc7hSw"
      decimals="INF"
      id="Tc_AlazJ7rNsUGDgZ24IJvrdg_5_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">95842</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q"
      decimals="-3"
      id="Tc_BJVr7cf_tECca4yQBfgN2Q_5_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA"
      decimals="-3"
      id="Tc_HvjhXEbDA06xCELNGusyrA_5_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q"
      decimals="-3"
      id="Tc_BiHrQw8cdEeAu51zRaGKDw_6_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">73000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA"
      decimals="-3"
      id="Tc_R5gK4wxIPkKQfPU2U4XDIg_6_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">73000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vV6Jpy-8JEmG8gmNefia9Q"
      decimals="-3"
      id="Tc_WJBriMIX2U-D4L35WyIPOQ_7_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">959000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg"
      decimals="-3"
      id="Tc_YkPZujt2V0mpgH4D5O6wQw_7_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-959000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovYgzBLlhke7QEaYS6Yyzg"
      decimals="-3"
      id="Tc_jj_GrxwkxEiDpwUkXkRxmg_8_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8268000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_ug5fEHymMUuubVfVi8MasA"
      decimals="-3"
      id="Tc_ujSY0-XPvU6tJsqUxk-rEQ_8_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8268000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wkszM0B4WEue0QIPYuu_EA"
      decimals="INF"
      id="Tc_qf6D7ow8SUuGTSvcbjDVXQ_9_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">443768</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VwGAxYqj30auZ7FoL0bSaA"
      decimals="-3"
      id="Tc_VTcXzgB6sES47zHBGoY3kg_9_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gAe7cbk-Ik2xnUHTe-lZNQ"
      decimals="-3"
      id="Tc_5OBxTygttECoLhun9Kpqaw_9_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-195585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_daSSC4kDIUWJG6OwMuYQ7Q"
      decimals="-3"
      id="Tc_bgefJwkGcUihmi9h1NCgAw_9_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-184475000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9ph7-9habkWVkrJfwFcs6Q"
      decimals="INF"
      id="Tc_ahDgu_LmxEeHT7k1EOGBCA_10_7"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4592</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA"
      decimals="-3"
      id="Tc_fWQ6JH0XakmvgGcIDO9Icg_10_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA"
      decimals="-3"
      id="Tc_aav9S7fTfkeqVS0Pr4aAUw_10_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA"
      decimals="-3"
      id="Tc_m8WkX74WWEKO6BFyDXvRFA_11_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">69000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA"
      decimals="-3"
      id="Tc_a9ExlCw2uEiXe3ubCDtX-g_11_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">69000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-MmocAIJgkaePuZBj3hDYA"
      decimals="-3"
      id="Tc_8stM-BRKcUyvfPr-xSnZxg_12_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2022000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw"
      decimals="-3"
      id="Tc_nvGdMsWZA06P2XXC0TD6Eg_12_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2022000</us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fqano7mjTkG_a704CmLjrw"
      decimals="-3"
      id="Tc_oTs26iKcCEC2dQ4-0YPwBg_13_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_l4YLJMg2DUS0OPL6wykkaA"
      decimals="-3"
      id="Tc_wyXEpwf44UWf5V0dceK7AQ_13_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-13974000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ba3s9Cn0NU6DCv50490lPw"
      decimals="INF"
      id="Tc_-1mj77RXX0Cdn_8IV724mw_14_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">448360</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J5RUj6hZ_kW5XH1lPZrp9w"
      decimals="-3"
      id="Tc__sDopmZeW0GYlIH5D-NEhA_14_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PI-ObqYFzUCIPTC8H9DIcw"
      decimals="-3"
      id="Tc_Yq9WzNzReE2Dch_2_aceuA_14_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-211581000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_b5EJjukOmUCZShWroteuUg"
      decimals="-3"
      id="Tc_zsf-TF9GPUqPAlwxAG394w_14_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-198364000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g"
      decimals="INF"
      id="Tc_hzkwkxTfEkGwkOiLDlrBXw_15_7"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">50646</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_UqK-XDhrt0G2Zd-LfPwGOw_15_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_fKvvQcf0Xkib_mfYMAzENg_15_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_wLQ8QsBgs0K9IVSCBvpkQA_16_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_nNPjapI6Xk6dx0kijRxuwg_16_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g"
      decimals="INF"
      id="Tc_S-Bb9NHkyUOCUJ63T-66kw_18_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">21500867</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g"
      decimals="-3"
      id="Tc_MxIpFFa2vUORuXMcCd43Pg_18_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_qYcoibvE90eFCRSmQnVpVw_18_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">204234000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_eIykxy4XG0CiMseMChDLhA_18_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">204236000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_xuON8vw5sk6EZtCwkvBE-g_19_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2568000</tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_Bjz_Gs4J4UmFJ1-_bO0Kjg_19_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2568000</tlsi:AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization>
    <tlsi:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMVO05h4F0iEO9QiUTOO2g"
      decimals="INF"
      id="Tc_3tVSlOSG9UW8wRs3WnP0Pw_20_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4316808</tlsi:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <tlsi:StockIssuedDuringPeriodValueReverseRecapitalization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_p8uDGcWBPU2n7J73kpVBRQ_20_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">957000</tlsi:StockIssuedDuringPeriodValueReverseRecapitalization>
    <tlsi:StockIssuedDuringPeriodValueReverseRecapitalization
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_tQ4H6CjsCk-lj4rsF6r-eg_20_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">957000</tlsi:StockIssuedDuringPeriodValueReverseRecapitalization>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_BEc363TbnEqn52LEWui7_A_21_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">28927000</tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_7AtFAtqK60K2xp8yyBUkJw_21_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">28927000</tlsi:AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw"
      decimals="INF"
      id="Tc_CWW4_4SQH0K6yYYYCCx_LQ_22_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_dxU9ioZp3Eq2Z5qrLk-fAw"
      decimals="-3"
      id="Tc_gJeXgNuX7UKpRUhT3vui7g_22_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Iu03cAURe0mIUL-L-6uxvg"
      decimals="-3"
      id="Tc_mJUviHATNEq-RieF2y_P2g_22_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">34150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_xq7vc9wzbECyfVN2v03NOA_22_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">34151000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-z57Xm8kCEOcnn9iDm5FJg"
      decimals="-3"
      id="Tc_0QbkkUATUEaEbEHNWJtI4Q_23_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw"
      decimals="-3"
      id="Tc_npOayvHb30aGCptC-vN0og_23_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1286000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw"
      decimals="INF"
      id="Tc_uKVlo85zoUaE_7mU7f67JQ_24_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pHNBc-KaS068YHkN7SZrMw"
      decimals="-3"
      id="Tc_F5ewbBZZ00q3kuRqzIXOkQ_24_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw"
      decimals="INF"
      id="Tc_k2rjXmd_kU2rWVSfc3DeHA_24_7"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">26316681</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iqa3fDYblk2FxFB8NC0Kyw"
      decimals="-3"
      id="Tc_QllQXzH4eU6UuX6jKeAJiQ_24_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YYKvXH4qESsBarliMaTVQ"
      decimals="-3"
      id="Tc_MjuAKVKu3EOzVczLuG3-cQ_24_13"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">221351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wLjUOHJXF0auOVXVpPAl0w"
      decimals="-3"
      id="Tc_6ij5am30HEyRwH0EV00Qkw_24_16"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-212867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_YN7S-Ccdg0O29xXuyl3ObA_24_19"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8487000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw"
      decimals="INF"
      id="Tc_5heNRyPxXUKfrORV-N70sQ_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">264978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__r5QsPVw_E2MBHoUSyIrLw"
      decimals="-3"
      id="Tc_2N01Opu_TUyP3qMlmQfP8g_4_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ"
      decimals="-3"
      id="Tc_YRpoZtwp30S36lbi5W7pVQ_4_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-136342000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_YKF6MorbPUqcKbwFWkljIw_4_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-129604000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Adumul5f_Emd_SmbobiJGw"
      decimals="INF"
      id="Tc_hEvmOjS0aUafWgfNPd7fLQ_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">33747</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg"
      decimals="-3"
      id="Tc_RmNxqB61OEWSKxgJbYoabg_5_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag"
      decimals="-3"
      id="Tc_mdkklA23-EqEedgjhH4DQw_5_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg"
      decimals="-3"
      id="Tc_Q6l8AR1owEKrxBRA76nnSA_6_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag"
      decimals="-3"
      id="Tc_tBDSm4OP8065-wlsOIzUcg_6_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wUa9pt6UYU2qKZU1q7KGtQ"
      decimals="-3"
      id="Tc_8Nl5vDDTtUq8v9AcBJEBXA_7_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-7873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_4fOaewqGlEiaNb8iN0EYag"
      decimals="-3"
      id="Tc_rxcKRScqXEy-Tm5ovX6qrg_7_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-7873000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mN0Y7XfrYkuY5BPn8WXxhA"
      decimals="INF"
      id="Tc_jOfXygYvckq4krlTC_kgrA_8_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">298725</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iOL4HjdfO0Km7gzdEnTioA"
      decimals="-3"
      id="Tc_GeB4rpe3iUmP_gsYRTAjiw_8_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_c6idVF-ySEuT1HSIivSjLg"
      decimals="-3"
      id="Tc_AIozaA52a0a-vouKFCrGtA_8_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-144215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_OYgjx4XmSkGPAAF-Re-xWA"
      decimals="-3"
      id="Tc_S5j5wMJX_kCvkZWtaKfWKQ_8_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-137354000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4B_cIF7e5UODEBv68U8L3w"
      decimals="INF"
      id="Tc_1ieEXeMYdk6_M44ZcNxKsg_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">9393</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg"
      decimals="-3"
      id="Tc_XGfT7SuWC0K2vunWvhlwaQ_9_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ"
      decimals="-3"
      id="Tc_gjLa5sctAEGcKg3V2xl_9g_9_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qINbI3aISUG6Rt2dpgPnlg"
      decimals="-3"
      id="Tc_gk-yNDzvGU-7UzmIuSJxYQ_10_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">70000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ"
      decimals="-3"
      id="Tc_pyRShoCksk-vRKkXJPc4OA_10_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">70000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kHWGZ6RfI0-CW2KwDqzmJw"
      decimals="-3"
      id="Tc_WDjzPTF34kqwDWtt2UMBOA_11_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8679000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_fq7omxWBoEK-MABx69oyEQ"
      decimals="-3"
      id="Tc_e9uWmTUju0as1XknjpLz7A_11_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8679000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_huvicFdgTUCwEqeS-VoGLQ"
      decimals="INF"
      id="Tc_EzQ4QU6GpUaN6nfI0aY70Q_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">308118</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZZNP8UD0GUO6uzjHEM33Eg"
      decimals="-3"
      id="Tc_7TT7Ii-05Ui-gAqlLiGgzA_12_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gexd2UdIVEm-wcSYwLDc0A"
      decimals="-3"
      id="Tc_jrba9F2pAEm533XwwCpQZQ_12_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-152894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_Bf2tptIPOU6oGPVXVUCTjg"
      decimals="-3"
      id="Tc_KyPk0MM3c02gjeGaQK63Mg_12_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-145958000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-MRJe6VGPUipa0NC3BILAg"
      decimals="INF"
      id="Tc_sH_PKqjJnEKBN8eDY9XJvA_13_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">12128</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg"
      decimals="-3"
      id="Tc_XcEMQGqMP0qTV8U3rTyZ7w_13_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_79AXRlla9ku3E3HOU9XNfw_13_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zx0K7c4MZEGpVaICw62Bkg"
      decimals="-3"
      id="Tc_BbeNPNpubEW-YJXwMor7HQ_14_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_sBUqImn0rUqi8b3a_doYAQ_14_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NYFdJrTKuU2AdqrUK_6Juw"
      decimals="-3"
      id="Tc_fuNfo-K0dU6Y4P-hZgqq3Q_15_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_yowqojqd60mPIfJj903FvA"
      decimals="-3"
      id="Tc_0WxyFYVNEE2Obyn54JERgA_15_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8093000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UOTJTOg7r0GFmn8grW7d6w"
      decimals="INF"
      id="Tc_ZZzVkIfCCkOAJYBjh9QhUw_16_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">320245</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gBMde9-vjEq-B-QzZmmW9A"
      decimals="-3"
      id="Tc_RrKjao-_P0u-W9Iu_AaT0Q_16_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NSmQJB__l0yYnVCxzz6oDg"
      decimals="-3"
      id="Tc_Gysu31sr9EyjVq-EnO2r-Q_16_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-160987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ"
      decimals="-3"
      id="Tc_sPDGSvgCNEavcGTVOfj7QQ_16_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-153925000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_7kZ5WYU65EWW3hPc2cla6Q_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-23529000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_5xks-Ly1fEOmeCzoL3PzSg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24645000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_IGI9NhomDkiKW0qp3ZNNVw_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_J21awQJd5UWC_XZI1C5H1A_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">452000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_IPZd-4S0yEO8prRFDmW7TA"
      decimals="-3"
      id="Tc_2KmDtD-1pEqtX_JrbLReVg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">660000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_VBJJ4CPlQEia9BUdUW2zWg"
      decimals="-3"
      id="Tc_yRrvLF_SI0q3MSmFuX49VQ_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_vzbARdsdukqCex56t3INQA"
      decimals="-3"
      id="Tc_9l00ipe5JUSvyCYYGEbr3w_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19904000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_YPi_EiO7OkmMbVIuOf6QvA"
      decimals="-3"
      id="Tc_H3eZn64Z8UeE79GkwIYopw_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_ing-_qS4yUSmxFNUQBEcuw_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4171000</tlsi:GainLossOnEquityIssuance>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_7gUfV4jdPECIt8_cnGr-Fw_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:GainLossOnEquityIssuance>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_1cHhsMby902oD9YFwgLpRQ_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">402000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_gekngVpMI06SdOwMaUK6mg_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">251000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_GEW1ULfDakKeNsa34PRZdw_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-60000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_J6B_MQef2k2NnDVxFgJENg_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-50000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <tlsi:GainLossOnMilestonePaymentForAssetAcquistion
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_DIudcViUx0ON2fYnNNDoWw_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1000000</tlsi:GainLossOnMilestonePaymentForAssetAcquistion>
    <tlsi:GainLossOnMilestonePaymentForAssetAcquistion
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_4mk2P_smJU2dXJN-WGzBMA_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1000000</tlsi:GainLossOnMilestonePaymentForAssetAcquistion>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_DvY5AuB9K0y8WSVjrvhkSg_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1477000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_u5rCU2pZXE6EEY04xiQM4Q_14_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">936000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_nk8zxaDSz02MfLj4rVWYzA_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">158000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_ZUu7BJIruUmmtU9mvvOmbw_15_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-6000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_Ojqtpw5asEOMrUh4Pidemw_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1041000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_X-0Tld64HUe907bRaSa9zQ_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1306000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_VRhFwMc5ukW3m629atYW5g_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">130000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_XkYN_p925EerXZDnyxhnuw_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">38000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_6gfVQvU43kKhBAPfs-2SnA_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2772000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_mO3PN4n5HEiqyufC1pMDoQ_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1108000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_yOTWg-D5ZkOHg4cl4pkQmQ_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-41196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_nCnf7tciakmsmtx_ZWBrcQ_19_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24003000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_nS-VGbGgO06d7stVWHM-Pg_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">216000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_-DaV4AvX9EWSHU_SKsqJlA_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">451000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <tlsi:PaymentsForAssetsAcquisitionMilestone
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_VypP8Q65GUiLYqNjh9udug_22_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:PaymentsForAssetsAcquisitionMilestone>
    <tlsi:PaymentsForAssetsAcquisitionMilestone
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_FMjL4qOdxEGgfECGnl1R6w_22_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:PaymentsForAssetsAcquisitionMilestone>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_nB_O-YUlH0Wy7v8xq0mxQw_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">205000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_rAeNqEHJgESHj1Nom2EjZg_23_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">63000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_aNDMrOT9LEifu4yxar9rAg_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1421000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_FS2Yvj8a5k2eCVkpZMWAjg_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1514000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc__rsAWKVcQEub5YTdvnHkPQ_26_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9189000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_W9utDHz5dUO8iPk6iWr4oA_26_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_vZwQMztmuE-ezWlSYvwVOQ_27_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock>
    <tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_nb-XQmxU0EiHlcYaBx0lvg_27_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3986000</tlsi:ProceedsFromRefundablePrepaymentsForPreferredStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_-jOdeltSJ0i5BDqwfyWDhg_28_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9630000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_c9knsxDv90qdylpeAq3TEA_28_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:ProceedsFromReverseRecapitalization
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_NV81dUHSJEq1JtFcKEcKTw_29_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">36854000</tlsi:ProceedsFromReverseRecapitalization>
    <tlsi:ProceedsFromReverseRecapitalization
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_fc32muH-MUGFguYi021o9A_29_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:ProceedsFromReverseRecapitalization>
    <tlsi:PaymentsOfReverseRecapitalizationTransactionCosts
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_STUnXBQm9UW7ARVMvF-3wQ_30_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1116000</tlsi:PaymentsOfReverseRecapitalizationTransactionCosts>
    <tlsi:PaymentsOfReverseRecapitalizationTransactionCosts
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_CHBFR-rQGE2B-csIt2QZQA_30_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:PaymentsOfReverseRecapitalizationTransactionCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_HRrry_Ab8kidZSRBa7NYmA_31_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_aiNOIRmEIEe5rgae2j7bVQ_31_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_2qnLZZcekEmOJSp3tZKp9g_32_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_YWV4H9sVFkChLiF7i4rUQw_32_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">73000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_UqIp49goVUOMX8j-7QdhYQ_33_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">54586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_-MICMvks70qINal5KNlSiA_33_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7554000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_aXvK_7JdT0aHpw2L2GHh5Q_34_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11969000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_EMdk31hJckO-2u2fRyXz3Q_34_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-17963000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_LwfGSpkWi0-jRl2vvJMT5Q_35_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_YKxu5lmcokyR_uojDGhjEQ_35_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_1yv1ShDeVEiPkU-mY3E8oQ_36_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ"
      decimals="-3"
      id="Tc_TGyqBWxlo0WtVQMQGsNkfg_36_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_Lebo3-n--ECzyY6rSANqNg_39_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25409000</tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock>
    <tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_ig74gCtI-UmkUr_9N-lhng_39_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_j4VhpNJppU21ITvEiKTi8w">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Nature of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On August&#160;10, 2023 (the "Closing Date"), TriSalus Life Sciences,&#160;Inc., a Delaware corporation (the &#x201c;Company,&#x201d; &#x201c;TriSalus,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d;), formerly known as MedTech Acquisition Corporation (&#x201c;MTAC&#x201d;), consummated the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of November&#160;11, 2022, as amended by that certain First Amendment to Agreement and Plan of Merger, dated as of April&#160;4, 2023, the Second Amendment to Agreement and Plan of Merger, dated as of May&#160;13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July&#160;5, 2023 (as amended, the &#x201c;Merger Agreement&#x201d;), by and between MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (&#x201c;Merger Sub&#x201d;) and TriSalus Operating Life Sciences,&#160;Inc. (formerly known as TriSalus Life Sciences,&#160;Inc.), a Delaware corporation (&#x201c;Legacy TriSalus&#x201d;), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub ceasing (the &#x201c;Merger&#x201d; and, together with the other transactions contemplated by the Merger Agreement, the &#x201c;Business Combination&#x201d;) and TriSalus Life Sciences,&#160;Inc. becoming the surviving company. The closing of the Business Combination is herein referred to as &#x201c;the Closing.&#x201d; In connection with the consummation of the Merger, on August&#160;10, 2023, Legacy TriSalus changed its name from TriSalus Life Sciences,&#160;Inc. to TriSalus Operating Life Sciences,&#160;Inc., and MTAC changed its name from MedTech Acquisition Corporation to TriSalus Life Sciences,&#160;Inc., the surviving company ("New TriSalus&#x201d;). As further described in Note&#160;3, Legacy TriSalus was deemed to be the accounting acquirer and predecessor company in the Business Combination. Thus, the prior periods presented in these consolidated financial statements are of Legacy TriSalus.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Description of the Business&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; product lines&#x2009;&#x2014;&#x2009;Pressure Enabled Drug Delivery (&#x201c;PEDD&#x2122;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. The combination of our PEDD technology with SD-101, is focused on solving the two main barriers in the tumor micro environment that inhibits the success of immunotherapy. The first barrier (mechanical) is comprised of high intratumoral pressure within tumors that limits drug uptake and the second barrier (biological) is the reversal of intratumoral immunosuppression. Our PEDD with SmartValve&#x2122; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;TriNav&#x2122; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020, and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#x201c;TPT&#x201d;) approval from the Centers for Medicare&#160;&amp;amp; Medicaid Services (&#x201c;CMS&#x201d;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023. On June&#160;1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications ("APC&#x201d;) code with CMS and met with CMS on June&#160;26, 2023, to review the application. If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January&#160;1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement rates, or at all. SD-101 has a dual mechanism of action in solid tumors which includes the alteration of the tumor microenvironment by reducing immunosuppressive myeloid derived suppressor cells while simultaneously activating immune response and recruiting T cells to the tumor, allowing checkpoint inhibitors to work more effectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs. In July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We have funded operations to date principally with proceeds from the sale of preferred stock, from the issuance of debt and convertible debt, and the closing of the Business Combination. Since inception of the Company in 2009 through September&#160;30, 2023, we have issued for cash &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$164,364&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of preferred stock (of which &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$36,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was raised at the closing of the Business Combination, including issuance of Series&#160;A convertible preferred stock), which, along with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$551&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from common stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$44,692&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from convertible notes and warrants, has funded our accumulated deficit of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$212,867&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. During the nine&#160;months ended September&#160;30, 2023, we raised &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,189&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in cash through the issuance of Series&#160;B-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,630&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in cash through the issuance of Series&#160;B-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$94&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from the exercise of stock options, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$36,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from the Business Combination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As of September&#160;30, 2023, we had cash and cash equivalents of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$21,383&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has an accumulated deficit of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$212,867&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; as of September&#160;30, 2023. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed in combination with the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#x2009;&#x2014;&#x2009;including the development of a candidate pharmaceutical&#x2009;&#x2014;&#x2009;that, in the short term, will not be fully offset by increased revenues. Without additional financing and based on our sales, operations and research and development plans, our management estimates that our existing cash and cash equivalents will be insufficient to fund our projected liquidity requirements for the next 12&#160;months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In accordance with ASC Topic 205-40,&#160;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events have raised substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management&#x2019;s plans to address the conditions and events have considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and management&#x2019;s plans do not alleviate the existence of substantial doubt. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, the process to obtain continuing CMS approval and application for a new ACS code for our PEDD product for reimbursement, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in sufficient amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will succeed in addressing such risks.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Subsequent Event&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On October&#160;2, 2023, we entered into a Standby Equity Purchase Agreement (the &#x201c;Yorkville Purchase Agreement&#x201d;) with YA II PN,&#160;Ltd. (&#x201c;Yorkville&#x201d;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Pursuant to the Yorkville Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$30,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of common stock, par value &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.0001&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share of the Company (the &#x201c;Common Stock&#x201d;), at the Company&#x2019;s request any time during the commitment period commencing on October&#160;2, 2023 (the &#x201c;Effective Date&#x201d;), and terminating on the first day of the&#160;month following the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;24&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Yorkville Purchase Agreement (an &#x201c;Advance&#x201d;) is subject to a maximum limit equal to the greater of: (i)&#160;an amount equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;100%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the average of the daily volume traded of the Company&#x2019;s Common Stock on the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) for the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;10&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading&#160;days immediately preceding an Advance notice, or (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Common Stock. The shares will be issued and sold to Yorkville at a per-share price equal to, at the election of the Company as specified in the relevant Advance notice: (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;96%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Market Price (as defined below) for any period commencing on the receipt of the Advance notice by Yorkville and ending on 4:00&#160;p.m. New York City time on the applicable Advance notice date (the &#x201c;Option 1 Pricing Period&#x201d;), and (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;97%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Market Price for any &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_3ei8mRKxXUqQjdtfqOZDNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; consecutive trading&#160;days commencing on the Advance notice date (the &#x201c;Option 2 Pricing Period,&#x201d; and each of the Option 1 Pricing Period and the Option 2 Pricing Period, a &#x201c;Pricing Period&#x201d;). &#x201c;Market Price&#x201d; is defined as, for any Option 1 Pricing Period, the daily volume-weighted average price (&#x201c;VWAP&#x201d;) of the Common Stock on Nasdaq, and for any Option 2 Pricing Period, the lowest VWAP of the Common Stock on the Nasdaq during the Option 2 Pricing Period. The Advances are subject to certain limitations, including that Yorkville cannot purchase any shares that would result in it beneficially owning more than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4.99%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Company&#x2019;s outstanding Common Stock at the time of an Advance or acquiring since the Effective Date under the Yorkville Purchase Agreement more than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;19.99%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Company&#x2019;s outstanding Common Stock, as of the date of the Yorkville Purchase Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <tlsi:NumberOfProductLinesInDevelopment
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Narr_ECSJi_RjbEa_wiTwHZfPkQ"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">2</tlsi:NumberOfProductLinesInDevelopment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_V6c578Z9dUakm48y3fS_Gw"
      decimals="-3"
      id="Narr_CPa8fMW0AESOwBk5qBEs9Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164364000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tlsi:ProceedsFromReverseRecapitalization
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_e5Qt_y1YokWjMwpgtZpC8g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">36854000</tlsi:ProceedsFromReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_t4I2eBPw_UKJp3mdZf18_g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">551000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_tlsi_ConvertibleNotesAndWarrantsMember_w8EJUYCkGEaDC6o1zmBY8g"
      decimals="-3"
      id="Narr_i73WgkjP3E-p-QMTZgBh8w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">44692000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Narr_wV08Ar1aqkGrPBlvjfF8Bw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-212867000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_Uof0l7IEhE6opTkV-B3e2Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9189000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_YxlNQctQ7ECaOjMEuLfZUA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9630000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_jva_HcfXLkaAW8p8tB4zfg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</us-gaap:ProceedsFromStockOptionsExercised>
    <tlsi:ProceedsFromReverseRecapitalization
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_gng7WCNysky0seR7jtVpIg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">36854000</tlsi:ProceedsFromReverseRecapitalization>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Narr_nyr-eGrJTU-uKVZjV3x7Aw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21383000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Narr_1yTSJLFT4EyM94jgOQJ2Tg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-212867000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <tlsi:SaleOfStockAuthorizedAmountValue
      contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ"
      decimals="-3"
      id="Narr_1E902mz29Uul1wOt2YfVQA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30000000</tlsi:SaleOfStockAuthorizedAmountValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA"
      decimals="INF"
      id="Narr_uCtjCcPEF0qcbGQrVC4sKg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <tlsi:StandbyEquityPurchaseAgreementTerm
      contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QknB2GXEmkiH_WR7kr-kww"
      id="Narr_eVZIxCb6IE26B_oaHg6B_g">P24M</tlsi:StandbyEquityPurchaseAgreementTerm>
    <tlsi:CommonStockSharePricePercentageOfAverageDailyVolume
      contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ"
      decimals="0"
      id="Narr_8gybkS02bk-5ghHbnamApw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">100</tlsi:CommonStockSharePricePercentageOfAverageDailyVolume>
    <tlsi:CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays
      contextRef="Duration_10_2_2023_To_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_j4Lx9_HqhkiLNYJxvI5HGQ"
      id="Narr_CJraqTrRaEqB_UStq9y2hA">P10D</tlsi:CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays>
    <tlsi:StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg"
      decimals="INF"
      id="Narr_K30qIuiLuEueAnASULaepQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1000000</tlsi:StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized>
    <tlsi:SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg"
      decimals="0"
      id="Narr_dRUKmXLD20aWGYFgIVRFjw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">96</tlsi:SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate>
    <tlsi:SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_StandbyEquityPurchaseAgreementMember_5pnkmU0ig0umNntsmE1iVg"
      decimals="0"
      id="Narr_iXkuetSPfUWXnZZY8ywd1Q"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">97</tlsi:SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo>
    <tlsi:PurchaseAgreementOwnershipLimitation
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA"
      decimals="2"
      id="Narr_t-a4m3PhD0iq0mmQYXgVrA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4.99</tlsi:PurchaseAgreementOwnershipLimitation>
    <tlsi:PurchaseAgreementExchangeCap
      contextRef="As_Of_10_2_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Yd_-1bZNcU-eJpPWC0mIcA"
      decimals="2"
      id="Narr_uAseic8j7kW0-4Dmmd0Hdw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">19.99</tlsi:PurchaseAgreementExchangeCap>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_59cnX9xJg0uDnepKCWrbsQ">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#x2019;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#x201d;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$8,617&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; invested in a money market fund, which is is a Level 1 instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#x2019;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Inventory&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#x2014; including direct labor and manufacturing overhead&#160;&#x2014; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(d)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(e)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Impairment and Disposal of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(f)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We account for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Leases&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#x201c;ROU&#x201d;) representing the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(g)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Warrant and Tranche Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;99.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(h)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Contingent Earnout Liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#x201c;Sponsor Support Agreement&#x201d;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#x201d;), Legacy TriSalus and MTAC&#x2019;s directors and officers (the Sponsor and MTAC&#x2019;s directors and officers, collectively, the &#x201c;Sponsor Holders&#x201d;). Pursuant to the Sponsor Support Agreement, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3,125,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#x201c;Sponsor Earnout Shares&#x201d;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;th anniversary of the Closing Date (the &#x201c;Earnout Period&#x201d;). The Sponsor Earnout Shares are classified as a liability in the Company&#x2019;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#x2019;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(j)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(k)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Share-Based Compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#x201c;Black-Scholes&#x201d;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#x2019;s stock, as well as &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(l)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We have determined, in accordance with ASC Topic 280, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, that we operate under &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; operating segment, and therefore &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(m)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the contract&#x2009;&#x2014;&#x2009;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the performance obligation&#x2009;&#x2014;&#x2009;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Determine the transaction price&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(d)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Allocate the transaction price&#160;&#x2014; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(e)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Recognize revenue&#160;&#x2014; We recognize revenue at the point&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;in&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In June&#160;2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Financial Instruments&#160;&#x2014; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. Current GAAP requires an &#x201c;incurred loss&#x201d; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_xMSvDUguNk2YqSjNxW4iTA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the&#160;year ended December&#160;31, 2022, included in MTAC&#x2019;s Proxy Statement/Prospectus filed with the SEC on July&#160;18, 2023. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal&#160;year financial statements prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP&#x201d;) have been condensed or omitted. The Condensed Consolidated Balance Sheets as of December&#160;31, 2022, was derived from the audited financial statements. We do not have any activity that would be reported on a Statement of Comprehensive Income.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_BaZrq7FWvUWZeYY__QXN7A">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We consider all highly liquid investments with original maturities of three&#160;months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money market funds. At September&#160;30, 2023, we had &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$8,617&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; invested in a money market fund, which is is a Level 1 instrument.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_1lqC9l63wEiuJzSe6Hi-cw"
      decimals="-3"
      id="Narr_Ki22CHU8F0akYx238BfOMg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8617000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_G0H1gCuA5Uu2xr5BL9skcA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We periodically review our allowance for doubtful accounts and establish reserves based on management&#x2019;s expectations of realization based on historical write-off experience, as well as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_Ndbth8LlWE6zH7AXd6GnvQ">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Inventory&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw material, and finished goods&#160;&#x2014; including direct labor and manufacturing overhead&#160;&#x2014; and is recorded on the first-in-first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its cost exceeds its net realizable value.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_MZa7oSBS1ESXf8hJKb0yUg">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(d)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_TGerLk0gnEGuJJZj4XcYiQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_n3iyYUo2ik-Sz0AnGN46Zg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_Nxd_qGDkY0OvImNXarzy4Q">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(e)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Impairment and Disposal of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_UVdN6vX7fEKu6jT-jH23SQ">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(f)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We account for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Leases&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. We determine if an arrangement is or contains a lease at contract inception, and, if it does, the lease is recorded on the Condensed Consolidated Balance Sheets with right-of-use assets (&#x201c;ROU&#x201d;) representing the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities representing our obligation to make lease payments. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease ROU assets also include the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. As the implicit rate in our leases is typically unknown, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating our incremental borrowing rates, we consider our credit risk, the term of the lease, and total lease payments and adjusts for the impacts of collateral as necessary. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We have elected to not separate lease and non-lease components for any leases within our existing classes of assets and, as a result, account for any lease and non-lease components as a single lease component. We have also elected not to apply the recognition requirement for leases with a term of 12&#160;months or less. We recognize an ROU asset and a lease liability at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Finance lease ROU assets are presented with property and equipment, net in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_tVWCaXUlJkyICbEIetyWkg">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(g)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Warrant and Tranche Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the Condensed Consolidated Balance Sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value is recognized in the Condensed Consolidated Statements of Operations. Historically, we have determined that the warrants issued to investors and lenders which are exercisable for shares of our Series&#160;B-3 convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock. See Note&#160;9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We determined that both the public and private placement warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. In addition, the private placement warrants include a feature that can require an adjustment of the exercise price in certain circumstances after a change of control. As a result, the Private and Public Warrants do not meet the criteria for equity classification. See Note&#160;9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Series&#160;B-2 Preferred Stock Financing (as described in Note&#160;11) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;99.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;% of our then-outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations were exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC 480. See Note&#160;11 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(h)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Contingent Earnout Liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with the execution of the Merger Agreement, MTAC entered into a sponsor support agreement (the &#x201c;Sponsor Support Agreement&#x201d;) with MedTech Acquisition Sponsor LLC (the "Sponsor&#x201d;), Legacy TriSalus and MTAC&#x2019;s directors and officers (the Sponsor and MTAC&#x2019;s directors and officers, collectively, the &#x201c;Sponsor Holders&#x201d;). Pursuant to the Sponsor Support Agreement, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3,125,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Common Stock in the Company held by the Sponsor Holders immediately after the Closing Date (such shares, the &#x201c;Sponsor Earnout Shares&#x201d;) became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Lb4zgAF5e0CJPYvsKdE9Yw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;th anniversary of the Closing Date (the &#x201c;Earnout Period&#x201d;). The Sponsor Earnout Shares are classified as a liability in the Company&#x2019;s Condensed Consolidated Balance Sheets because they do not qualify as being indexed to the Company&#x2019;s own stock. The earnout liability was initially measured at fair value at the Closing Date and is subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the Condensed Consolidated Statements of Operations. See Notes&#160;3 and 8 for further detail.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <tlsi:PreferredStockConversionPercentageOfOutstandingShares
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Narr_kBEv0EaKmkCD6eOj6IBXHA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">99.2</tlsi:PreferredStockConversionPercentageOfOutstandingShares>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares
      contextRef="Duration_10_8_2023_To_10_8_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_b2HZiZvawEOx8-1-aQfYAw"
      decimals="-3"
      id="Narr_HksUTk6pLEqfeJCCxdT_9w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3125000</tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_bvAgD8z-fEy-4u7l7BJfoA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of earnout, warrant and tranche liabilities, and the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_fp0bbi-bREq_oXqN314lvA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(j)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our cash and cash equivalents are deposited primarily with two financial institutions and one investment institution. At times, the deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_q4lkPhsAeUOd1Iy_21TwcA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(k)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Share-Based Compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We account for all employee and non-employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#x201c;Black-Scholes&#x201d;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#x2019;s stock, as well as &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards. The fair value of options granted to non-employees is periodically reevaluated and adjusted to current fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_riVPdDWkTEOlmNhwhPV2Qg">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(l)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We have determined, in accordance with ASC Topic 280, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, that we operate under &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; operating segment, and therefore &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;one&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Narr_jAbKSGgmb0GUlqxnH_dsTg"
      unitRef="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Narr_YqJQeXajGke6jpt2DqdcLA"
      unitRef="Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_632XL7DfGk2_5-DOKxrA6g">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(m)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals, clinics and physicians. Under ASC Topic 606, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the contract&#x2009;&#x2014;&#x2009;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the performance obligation&#x2009;&#x2014;&#x2009;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Determine the transaction price&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(d)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Allocate the transaction price&#160;&#x2014; We do not have multiple performance obligations to complete when we fulfill a purchase order, therefore, the transaction price is fully allocated to the units being sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(e)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Recognize revenue&#160;&#x2014; We recognize revenue at the point&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;in&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;time when the units for a purchase order have been shipped and control of the units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In a small number of cases, the purchase order specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the units have been delivered and control has transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_7KHkQ8jMskeTWBGt8WsCew">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In June&#160;2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Financial Instruments&#160;&#x2014; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. Current GAAP requires an &#x201c;incurred loss&#x201d; methodology for recognizing credit losses that delays recognition until it is probable a loss has been incurred. ASU 2016-13 replaces the current incurred loss methodology for credit losses and removes the thresholds that companies apply to measure credit losses on financial statements measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The determination of the allowance for credit losses under the new standard would typically be based on evaluation of a number of factors, including, but not limited to, general economic conditions, payment status, historical collection patterns and loss experience, financial strength of the borrower, and nature, extent and value of the underlying collateral. For smaller reporting companies, ASU 2016-13 is effective for fiscal&#160;years and for interim periods within those fiscal&#160;years beginning after December&#160;15, 2022. It requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We adopted ASU 2016-13 on January&#160;1, 2023. The effect of the adoption had an immaterial impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <tlsi:ReverseRecapitalizationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_1zI7Frd_JUGVx4M0lMwkUg">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Business Combination&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On August&#160;10, 2023, we consummated the previously announced merger pursuant to the Merger Agreement by and among MTAC, Merger Sub,&#160;Inc., and TriSalus Life Sciences,&#160;Inc. Upon the closing of the transactions contemplated by the Merger Agreement, Merger Sub merged with and into Legacy TriSalus (the &#x201c;Business Combination&#x201d;) with Legacy TriSalus surviving the merger as a wholly-owned subsidiary of MTAC, renamed &#x201c;TriSalus Operating Life Sciences,&#160;Inc.&#x201d; In addition, in connection with the consummation of the Business Combination, MTAC was renamed &#x201c;TriSalus Life Sciences,&#160;Inc.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Immediately prior to the effective time of the Merger, each in-the-money warrant of Legacy TriSalus that was unexercised and unexpired was automatically net exercised into the respective series of preferred stock of Legacy TriSalus. Each share of preferred stock of Legacy TriSalus (&#x201c;Legacy TriSalus Preferred Stock&#x201d;) that was issued and outstanding was then automatically converted into shares of common stock of Legacy TriSalus (&#x201c;Legacy TriSalus Common Stock&#x201d;) in accordance with the Amended and Restated Certificate of Incorporation of Legacy TriSalus at the then current conversion price, such that each converted share of Legacy TriSalus Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy TriSalus Preferred Stock thereafter ceased to have any rights with respect to such securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the Closing Date, by virtue of the Business Combination and without any action on the part of MTAC, Merger Sub, Legacy TriSalus or the holders of any of the following securities:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;each share of Legacy TriSalus Common Stock (including shares of Legacy TriSalus Common Stock resulting from the conversion of shares of TriSalus Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time were exchanged at an exchange ratio of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.02471853&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; (the &#x201c;Exchange Ratio&#x201d;) for an aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;21,999,886&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of our Common Stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;each option to purchase shares of Legacy TriSalus Common Stock, whether vested or unvested, converted into an option to purchase shares of our Common Stock (&#x201c;TriSalus Assumed Option&#x201d;), with each TriSalus Assumed Option subject to the same terms and conditions as were applicable to the original Legacy TriSalus option and with the resulting exercise price and number of shares of TriSalus Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;each Legacy TriSalus restricted stock unit (&#x201c;RSU&#x201d;) award converted into a restricted stock unit award to receive shares of our Common Stock (&#x201c;TriSalus Assumed RSU Award&#x201d;), with each TriSalus Assumed RSU Award subject to the same terms and conditions as were applicable to the original Legacy TriSalus restricted stock unit award, and with the number of shares of TriSalus Common Stock to which the TriSalus Assumed RSU Award relates being based on the Exchange Ratio and other terms contained in the Merger Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, MTAC was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, the Legacy TriSalus stockholders have a majority of the voting power of TriSalus, Legacy TriSalus comprises all of our ongoing operations, Legacy TriSalus has appointed a majority of our governing body, and Legacy TriSalus&#x2019; senior management comprises all of our senior management. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy TriSalus with the business combination being treated as the equivalent of Legacy TriSalus issuing stock for the net assets of MTAC, accompanied by a recapitalization. Operations prior to the Business Combination are those of Legacy TriSalus. Reported shares and earnings per share available to holders of the Company&#x2019;s common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination (1.0 share of Legacy TriSalus for approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;0.02471853&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of TriSalus).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Proceeds from this transaction totaled &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$42,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. These proceeds were comprised of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,704&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from the MTAC trust account, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$40,150&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; received from the assumption of a concurrent private investment in public equity financing (&#x201c;PIPE Financing&#x201d;). Pursuant to the terms of the Merger Agreement, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$6,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the proceeds were used to pay expenses incurred by MTAC related to the merger, resulting in net cash proceeds of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$36,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Company incurred &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$6,069&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in transaction costs relating to the merger with MTAC, of which &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,742&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was recorded as a reduction of equity and the balance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,327&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was recorded in general and administrative expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy TriSalus exchanged their interests for shares of common stock of TriSalus. In addition, MTAC had previously issued public warrants and private placement warrants (collectively, the &#x201c;MTAC Warrants&#x201d;) as part of its initial public offering in November&#160;2020. None of the terms of the MTAC Warrants were modified as a result of the Business Combination. On the Closing Date, the Company recorded a liability related to the MTAC Warrants of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,568&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. During the period from August&#160;10, 2023, to September&#160;30, 2023, the fair value of the MTAC Warrants increased to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,421&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, resulting in a loss on the change in fair value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,853&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and a gain of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$660&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in the Condensed Consolidated Statements of Operations for the three and nine&#160;months ended September&#160;30, 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Immediately following the Business Combination, there were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;26,316,681&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of our Common Stock outstanding, options and RSUs to purchase an aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,816,224&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of common stock and warrants outstanding to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;14,266,605&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;PIPE Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On the Closing Date, certain investors agreed to purchase an aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,015,002&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; newly-issued shares of Series&#160;A Convertible Preferred Stock at a purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$40,150&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, pursuant to separate subscription agreements dated June&#160;7, 2023, and July&#160;4, 2023 (collectively, the &#x201c;Subscription Agreements&#x201d;). See Note&#160;11 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Sponsor Earnout&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement. Pursuant to the Sponsor Support Agreement, the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3,125,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Sponsor Earnout Shares became unvested and subject to potential forfeiture if certain triggering events are not achieved prior to the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;th anniversary of the Closing Date. Pursuant to the Sponsor Support Agreement, (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_V-mQW-qQIUa1vQtlrdyyEg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; period following the Closing, the volume weighted average price of our Common Stock equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$15.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading&#160;days within a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; consecutive trading&#160;days, (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_2n4YMje6bU2yQX9mVj9haw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; period following the Closing, the volume weighted average price of our Common Stock equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading&#160;days within a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; consecutive trading&#160;days, (iii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares of our Common Stock held by the Sponsor&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Holders will only vest if, during the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_tM-2Y2RyQUOzCJbuqMIVTw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; period following the Closing, the volume weighted average price of our Common Stock equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$25.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading&#160;days within a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; consecutive trading&#160;days; and (iv)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares of our Common Stock held by the Sponsor Holders will only vest if, during the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_i6irmobClEimgYt4sNAgmg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; period following the Closing, the volume weighted average price of our Common Stock equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$30.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading&#160;days within a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; consecutive trading&#160;days. Additionally, the Sponsor Earnout Shares will vest if there is a change in control of our company on or before the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;th anniversary of the Closing Date that results in the holders of our Common Stock receiving a price per share equal to or in excess of the applicable earnout targets. Any such shares held by the Sponsor Holders that remain unvested after the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;th anniversary of the Closing will be forfeited.&lt;/span&gt;&lt;/p&gt;</tlsi:ReverseRecapitalizationDisclosureTextBlock>
    <tlsi:RecapitalizationExchangeRatio
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="8"
      id="Narr_A6wDVXETWUOzvyHdNRa6Xg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0.02471853</tlsi:RecapitalizationExchangeRatio>
    <tlsi:StockConvertedReverseRecapitalization
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="INF"
      id="Narr_xgPZlcKNNEifIvSIDyqeKA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">21999886</tlsi:StockConvertedReverseRecapitalization>
    <tlsi:RecapitalizationExchangeRatio
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="8"
      id="Narr_hA3TFnIhHkGb-q3UsZe6jg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0.02471853</tlsi:RecapitalizationExchangeRatio>
    <tlsi:ProceedsFromReverseRecapitalizationTransaction
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_uMM8lGATYUOSjx0A9wKMug"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">42854000</tlsi:ProceedsFromReverseRecapitalizationTransaction>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_9hikV5KHZ0eycA3Ln-d4tQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2704000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_rm2tdjipAE-56WcAcQ0Sow"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">40150000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <tlsi:PaymentsOfReverseRecapitalizationTransactionCosts
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_CounterpartyNameAxis_tlsi_MedTechAcquisitionCorporationMember_Nh62w64sX0GFn1hFJJgndg"
      decimals="-3"
      id="Narr_mpQ2Wb6MvUu3R5p00dMkkg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6000000</tlsi:PaymentsOfReverseRecapitalizationTransactionCosts>
    <tlsi:ProceedsFromReverseRecapitalization
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_AOqWd4z6YUuJNdp3Nv9xKw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">36854000</tlsi:ProceedsFromReverseRecapitalization>
    <tlsi:ReverseRecapitalizationTransactionCostsIncurred
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_uni4iFyaVUuCCJ3s7QnORg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6069000</tlsi:ReverseRecapitalizationTransactionCostsIncurred>
    <tlsi:PaymentsOfReverseRecapitalizationTransactionCosts
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_Zz8g5cHQJk-9XLuuKVKAUg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1742000</tlsi:PaymentsOfReverseRecapitalizationTransactionCosts>
    <tlsi:ReverseRecapitalizationTransactionCostsPaid
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_MLjGfj5ZYEaY9CbLah_j9Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4327000</tlsi:ReverseRecapitalizationTransactionCostsPaid>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow"
      decimals="-3"
      id="Narr_UMIz0OMwo0Ow-mU2_7en1Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2568000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ"
      decimals="-3"
      id="Narr_vXafRp9NMki44aH7Q7shoA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5421000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_YldtoLvAcESUUN65IvBRSQ"
      decimals="-3"
      id="Narr_ZomDKz3UqUW7KsjnU2UvJQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2853000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_kVRrUl0H3EKb1JhB7W02Wg"
      decimals="-3"
      id="Narr_gKuirC-YN0GGp7xGQcm4Iw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">660000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="INF"
      id="Narr_fxSuvEZEWUmk1LryBKdO9A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">26316681</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="INF"
      id="Narr_JYladCbATEW8vaNJdEZi3A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2816224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="INF"
      id="Narr_98MiLwy3qUirRTBedHnwkg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">14266605</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="INF"
      id="Narr_1GddLHy4N0u5cwyGHakZ2w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="2"
      id="Narr_M296iw47A0WExRQ7IhA_0A"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_8_10_2023_To_8_10_2023_uJV1T1iyOUq0exP5ccXIEQ"
      decimals="-3"
      id="Narr_pCqecvAnAk2rWQIchf8CeQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">40150000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares
      contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_Pqp-qsKfKUquIRMTUTshbQ"
      decimals="INF"
      id="Narr_o89m4IQqOU6re3UWQLG7ew"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3125000</tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Narr_dMux_ykGJkazLZYlk6-R1A">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage
      contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_wfMBzSQGZkKbDc2aHYdY9Q"
      decimals="0"
      id="Narr_nE9y9M1byU-ZAOn7DjLKjw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">25</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger
      contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodOneMember_bzhbnoR9okG4s-q-sw9axQ"
      decimals="2"
      id="Narr_v6dctT0Uzk2mZeqyH8HtxQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">15.00</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw"
      decimals="INF"
      id="Narr_ygQGq2NShkS-a3XGLJDM1Q"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw"
      decimals="INF"
      id="Narr_nQt2q-CCe02SPKCkqVKPDw"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage
      contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_S0Lcn3b7qUysLIF0lPwnmw"
      decimals="0"
      id="Narr_CYve8Kwa6Ey_Dr2M9n5IiA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">25</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger
      contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodTwoMember_QkCtTzY3sU-AQnJ_aipXPw"
      decimals="2"
      id="Narr_hAsXeEHMBEumaWGR5WGFPw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.00</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw"
      decimals="INF"
      id="Narr_BqZiu-iSRUW2vbGPTFsEFg"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw"
      decimals="INF"
      id="Narr_MH2ElKgGokKPIk-XW8qF8w"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage
      contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_cmpIjKVmEEiX0-ssByWUEg"
      decimals="0"
      id="Narr_SqyA-W2HrU2pxv_7SD2JTw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">25</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger
      contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodThreeMember_Kkt3ckHCjEGBa9C6I-e57g"
      decimals="2"
      id="Narr_jtiz-40zUEWHIqBWX058qg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">25.00</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw"
      decimals="INF"
      id="Narr_fizJLc6AmUuWzuDoZKq2MQ"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw"
      decimals="INF"
      id="Narr_VlBCV1uCzEmIEKwzG_B8CQ"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage
      contextRef="Duration_8_10_2023_To_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_cjlWfxkjMkGCwnUKknuA_w"
      decimals="0"
      id="Narr_dGOz9H1YPUKS7aMaS91qdQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">25</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger
      contextRef="As_Of_8_10_2023_tlsi_DerivativeInstrumentPeriodAxis_tlsi_DerivativeInstrumentPeriodFourMember_k5WzB7ynsUKBqdgC_-pE5w"
      decimals="2"
      id="Narr_3crwZ29r3US7EZMmLkaVGQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">30.00</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MinimumMember_dw0mH-UT6US-M9Y33-Oytw"
      decimals="INF"
      id="Narr_QvSnf06tCEOUX36oqktGRQ"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="Duration_8_10_2023_To_8_10_2023_srt_RangeAxis_srt_MaximumMember_4upq-UiuFUmCk8mTOZlzMw"
      decimals="INF"
      id="Narr_i8KIfIxan06dvziwLOpcIw"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Narr_J5rcS5YJaEiU2fQ7_KQGRw">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Narr_MnteuQH7vkyxh8KcrFfz7w">P5Y</tlsi:DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_cp3cQ4BmE0yDwyd_EGVWUQ">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, contingent earnout liability, and warrants to purchase preferred and common stock. The carrying values of these financial instruments (other than warrants and tranche liabilities, which are held at fair value) approximate fair value at September&#160;30, 2023, and December&#160;31, 2022. In general, asset and liability fair values are determined using the following categories:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Inputs utilize quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#x2019;s own assumptions about the assumptions that a market participant would use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our warrant, tranche and earnout liabilities are measured at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Financial Instruments After Business Combination&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The carrying amount of our outstanding MTAC warrants liabilities was &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,421&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; at September&#160;30, 2023. The carrying amount of outstanding earnout liability was &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,023&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; at September&#160;30, 2023. These carrying values of the warrant liabilities represent the remeasurement to fair value each reporting period based on Level 1 inputs for the publicly traded MTAC Warrants and Level 2 inputs for the private placement MTAC Warrants. The carrying amounts of the contingent earnout liability represent the remeasurement to fair value each reporting period based on unobservable, or Level 3, inputs, using assumptions made by us, including the market price of our common stock and the observed volatility of a peer group of companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the Closing Date, we assumed warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;14,266,605&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of common stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$11.50&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (see Note&#160;9). Of these, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8,333,272&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; are traded publicly and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,933,333&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; are privately held. At the Closing Date, we determined the fair value of all the warrants to be &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,568&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; based on the closing price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.18&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the publicly traded warrants (Level 1).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the Closing Date, we determined the fair value of the earnout liability to be &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$28,927&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; based on a Monte Carlo simulation of future trading prices for our common stock. See Note&#160;8 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Out)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent earnout liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,904)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Financial Instruments Prior to the Business Combination&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our warrants and tranche liabilities are measured at fair value on a recurring basis. The carrying amount of outstanding warrant liabilities was zero and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$16,188&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; at September&#160;30, 2023, and December&#160;31, 2022, respectively. The carrying amount of outstanding tranche liabilities was zero and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,702&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; at September&#160;30, 2023, and December&#160;31, 2022, respectively. These carrying values represent the remeasurement to fair value each reporting period based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to a status quo scenario and the potential closing of the Business Combination (see Note&#160;3) scenario, the value of the Series&#160;B-3 Warrants (as defined below) upon closing of the Business Combination, the fair value of the Company, the fair value of the underlying preferred stock, the Company&#x2019;s volatility, discount rate, and expected term of the related instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;See Note&#160;9 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In March&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,654&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$584&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; loss on equity issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In June&#160;2023, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings (see Note&#160;9). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,047&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and were classified as a liability. The issuance of the Series&#160;B-2 preferred stock and accompanying warrants to purchase Series&#160;B-3 preferred stock as part of the Second Tranche Closings resulted in a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,425&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; loss on equity issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Immediately prior to the exercise of the warrants to purchase Series&#160;B-3 preferred stock in February, March, June&#160;and July&#160;2023, the associated liabilities were remeasured to fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In July&#160;2023, warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,239,309&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock were exercised for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,530&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were remeasured to fair value, net-exercised, converted to shares of common stock of Legacy TriSalus, and then exchanged for shares of TriSalus common stock at the Exchange Ratio. Out-of-the-money warrants expired, resulting in a gain on expiration of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$18&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Out)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In (Out) of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains) Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2 tranche liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,200)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3 Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&#160;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;This amount includes settlements of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$25,409&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and final net exercise of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,800&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, transferred to convertible preferred stock, offset by issuances of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;14,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.2pt;text-indent:-16.2pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EpRi081NpEe5pgVd-nZFFQ"
      decimals="-3"
      id="Narr_eQs6v3ICbkSDNRLasIsTmg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5421000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw"
      decimals="-3"
      id="Narr_FlTPQCmPcUu1fXuinF9wmQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9023000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="INF"
      id="Narr_ZH4caqhdqU2kcQ3RThO0nA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">14266605</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="2"
      id="Narr_WSz9xgGh-0awui3E-6uptw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="INF"
      id="Narr_ANxEjcLOfEenO7ZZICFoNQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333272</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg"
      decimals="INF"
      id="Narr_Y-tAHk4ARkmzr2jGYRuL-A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5933333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_MTACWarrantsMember_OUOVdSNfGkaUCa4_ZlQcow"
      decimals="-3"
      id="Narr_5vrM1Cc2RUyHU2I3EC7eHg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2568000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:SharePrice
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="2"
      id="Narr_5SoPOebGtkWCpPA3MCyxhg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.18</us-gaap:SharePrice>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="-3"
      id="Narr_gOsR8R5VA0CEVTan0luU7w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">28927000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Group_Vs0kxX3OOkatbgPr-wFJKw">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following tables summarize the changes in fair value of our outstanding earnout liability in the nine&#160;months ended September&#160;30, 2023. The warrant and earnout liability were not present in the nine&#160;months ended September&#160;30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Out)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent earnout liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,904)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine&#160;months ended September&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(Out)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;in&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;at&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In (Out) of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains) Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2 tranche liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,200)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3 Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,508)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&#160;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;This amount includes settlements of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$25,409&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and final net exercise of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,800&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, transferred to convertible preferred stock, offset by issuances of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;14,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_5m4IloO620mxYhPYECQr_w"
      decimals="-3"
      id="Tc_pUZJu8XJmk6X9yXFEcHsqg_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ"
      decimals="-3"
      id="Tc_eOt051wPskmDB3kX_poX_w_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19904000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ"
      decimals="-3"
      id="Tc_ECzU_yUNLU6h28ATqiBLYA_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">28927000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ"
      decimals="-3"
      id="Tc_2Qjc3Em0HUiw2EgmUWJRcA_4_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_oBhuknZam0qxfv5h_KKCBw"
      decimals="-3"
      id="Tc_1WK_FxJCqU2xyBnL6k1gCA_4_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9023000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_gCF57fEhRE2zmytqtvYPow"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16188000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_MvVVUtFQS0yvN6r5JBszPQ"
      decimals="-3"
      id="Narr_qeP2RaQrQUiKA4KpIZg-Gg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_vLPoVC9kzEqm61EhV_wbdA"
      decimals="-3"
      id="Narr_SOhWRLiEJUWFqG-5sWWVdQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4654000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_TN5C51PNT0GEkx_dOCvSqA"
      decimals="-3"
      id="Narr_GjN_aqIXXUqQpKkAbuEdWA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-584000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_MdOc8gt9DkG_ANRSNF1Feg"
      decimals="-3"
      id="Narr_UIjZ9bkZI06eD2mIDhoN0g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10047000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_TrancheAndWarrantLiabilityMember_p0n0zYd2Y0m3WvEBclIL9g"
      decimals="-3"
      id="Narr_SV27rHXY5kePlKNbpS9kPg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-3425000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_TqnHEEX_6U2SUQQnKIvWrQ"
      decimals="INF"
      id="Narr_ogJjAvwloE-OFezTr9HegA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2239309</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw"
      decimals="-3"
      id="Narr_DU9c7TXJSUCF55hor5hngA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4530000</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:GainLossOnWarrantExpirations
      contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_XOPnCg0EYEC20KqnpImsyw"
      decimals="-3"
      id="Narr_9oFZq1mtOkSzl4eHdRoIZA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-18000</tlsi:GainLossOnWarrantExpirations>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_mON5gWTp7EKirtCszFVuWg"
      decimals="-3"
      id="Tc_GFIUPOZprk6epKTEkPb6LQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng"
      decimals="-3"
      id="Tc_8xzA2Nmrikm-8gPA9PrOOA_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng"
      decimals="-3"
      id="Tc_yVjX3BrpxEW1Z8xmHcY4TA_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_admRb57LKkSr6UrDyHRbng"
      decimals="-3"
      id="Tc_0ayHzAzlW0egVtowWx9NZg_4_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_z7ZUYrej5U-HRCyTPGR3Zw"
      decimals="-3"
      id="Tc_D5bQGTtiEE2lvNUXzoOHnw_4_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">372000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_4e0nEOiYy0GXKQ8LC542oA"
      decimals="-3"
      id="Tc_QmaBYK_LvUOsPdy3Y9Tviw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g"
      decimals="-3"
      id="Tc_pxeYBTO7f0aBT9uraAaBmw_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g"
      decimals="-3"
      id="Tc_cnKDtD6J60i4GAvTpNayLw_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_EAwcs-25dkSrsIW_1yyj8g"
      decimals="-3"
      id="Tc_a7TC__6jwkmVx4f4gW1fzw_4_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember_UH_cOo5McUeHvPGUA75elg"
      decimals="-3"
      id="Tc_jGnYh4h2HEayy1fvNGccVw_4_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_HJefUCEOC0ila6lDpRZnrw"
      decimals="-3"
      id="Tc_3zlAlG_PeEOPC0g7tKbFRw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw"
      decimals="-3"
      id="Tc_viPRfzEgW0ab9KIK7BRwsA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3200000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw"
      decimals="-3"
      id="Tc_VCaWchvyh0OzdQp7TwWz6w_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1502000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_dRrLa--2mUy-eKHMO4IPbw"
      decimals="-3"
      id="Tc_veF3qI-YYkef7HGo3crR5g_5_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember_0h9HVSfBy0CDyP55pbIu_A"
      decimals="-3"
      id="Tc_slf0IxkoHEKb8OsnXXV27g_5_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_t0-7UkxO_EO65rt0UdRyZw"
      decimals="-3"
      id="Tc_H0iz9xpRg0yPHzlsS27bwA_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Tc_7A57i6gqGUCYV0lqB-N5qg_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">311000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Tc_-tlUUi3u80O5DWvbcj-T9g_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-15508000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Tc_-dzxAJsM-UyQ97yR0-cg8Q_6_12"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_-mgXyb38JkOXu9Btsyc7MA"
      decimals="-3"
      id="Tc_KHF_FwtQE0m0_nsOJAmzXA_6_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Narr_Y33p3hr0LUGpNiKzOz0Cmw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Narr_qnksrUX6fUSfE2qKtXblJw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_D3ABWyHxxEGIE8ACFCRECA"
      decimals="-3"
      id="Narr_jxoBMk-yDkSgnV-RcqX-Jw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14701000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_hApBuAD9mE2j4fFF-nVVmA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash (included in Other assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Restricted cash is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; held by our bank to support our corporate credit card program.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_0weMS52kpU-do90Tp2to7A">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash (included in Other assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_5ZDbBaNi9kSOxXutGUjlHA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash (included in Other assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_BNEBo75kWUCLa5s0kqC84g_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21383000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_FKUXn3kljkuoJZvzvTNa8A_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9414000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_073p7SiLAUOf0CtMnysi9w_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_A2VHY6w8PkCDkGcCxrFrWg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_B6q_KeJP70ir3ASH63rOjg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_SOXlMnP4S0i49NFVtlAMyQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_-ZGfr1VHCk6ORmjLj7zpkg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_VpygLjGHL0OdGlO7oCPNLQ">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(6)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Finished goods amounts include a reserve for excess or obsolete inventory of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;nil&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$43&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; as of September&#160;30, 2023, and December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_iPLiUv-SiEiZdzlxV-3wBA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_JEL7IcDzxEiJm6FeEIE5Dw_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">289000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_KiL0X8-yxkO0VF48YPEvaA_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">753000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_-UdhjSt-2Uu5HN6FbRmVkQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1340000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_FvZwqIsNKEuLL76w6PbV0g_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">718000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_G_5-n7ugUEy-phYumLw0Zw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1629000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_9g0BJ1s9X0WbEKGAPrQmMA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1471000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Narr_OauPt8mvwUWMudca1qguQg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_-Ru3VoFU002zWQRa_OCGzw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">43000</us-gaap:InventoryValuationReserves>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_YGfi3A7zDEC2JzjYJWQOFw">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(7)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Accrued Liabilities consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_6Dt_vbDw_0WWXnVlCp5LyA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Accrued Liabilities consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_vej69PDPGEuRb3z87sm3bQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3404000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_QdWd2qkmbkuXmefrCyuv9g_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2905000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_LKYUs83nEECscFllijtFpA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2706000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_rDcvZEeo7U6dpIYr9GGgdQ_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2896000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_doQVThRuQ06zdLyGaAcZ4w_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">475000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_1n-yiwELc0--PsLkXW-TsQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">329000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_O8gEYfLbe0utu65tVjJFDw_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_S-fof5oqDUSZbQZTpkyLgA_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">247000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="-3"
      id="Tc_h-W9I7dJYEWPHBFhExrIgg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6600000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_V8TzkTlguEKYM2ehjzB6AA_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6377000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_2gmCQV_mjkOxe3Y4DArR4Q">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(8)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Contingent Earnout Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As described in Note&#160;2 and Note&#160;3, in connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement with the Sponsor Holders and Legacy TriSalus, pursuant to which, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3,125,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares of our Common Stock held by the Sponsor immediately after the Closing Date became unvested and subject to potential forfeiture if certain triggering events are not achieved during the Earnout Period. The earnout shares are classified as a liability and were initially measured at fair value at the Closing Date and will subsequently be remeasured at the end of each reporting period with the change in fair value of the earnout liability recorded in the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The estimated fair value of the total contingent earnout liability at the closing on August&#160;10, 2023, was &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$28,927&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; based on a Monte Carlo simulation valuation model. The liability was remeasured to its fair value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,023&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; as of September&#160;30, 2023. This remeasurement resulted in the recording of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$19,904&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the three and nine&#160;months ended September&#160;30, 2023, classified as change in fair value of contingent earnout liability in the Condensed Consolidated Statements of Operations. Assumptions used in the valuation are described below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;August 10,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected share price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The estimated fair value of the liability was determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes. The inputs and assumptions utilized in the calculation require management to apply judgment and make estimates including:&lt;/span&gt;&lt;/p&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:16.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;expected volatility, which is based on the historical equity volatility of publicly traded peer companies for a term equal to the expected term of the earnout period;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:16.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;expected term, which we based on the earnout period per the agreement;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:16.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time periods commensurate with the expected term of the earnout period; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:16.2pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;(d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;expected dividend yield, which we estimate to be &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;zero&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; based on the fact that we have never paid or declared dividends.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares
      contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_QW7EfoeCZUGUfloNheRNUg"
      decimals="INF"
      id="Narr_miGCW357f0KB9LGQQW_N-A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3125000</tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="-3"
      id="Narr_xX8qBpS53UOLcOzeN-gu8w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">28927000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_G012VaeCnUacjmURPt78Jw"
      decimals="-3"
      id="Narr_LerLiJRoXEC3rcs3ysRR4A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9023000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_p5wTMoj_ukORhFyNw0RR7A"
      decimals="-3"
      id="Narr_falOt-3VWEuRwf-PW2SoZQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19904000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_zWZM6-KBpkui8gyBIKU0hQ"
      decimals="2"
      id="Tc_8Q0Om5D-S06_l2NA4sssgQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5.12</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yQXpaQmMKkOs4sGjRq4fiA"
      decimals="2"
      id="Tc_4EgLNzPxekWBpt1NNm0XAQ_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11.34</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_T7Li9gpr_0G4t4E0kCavKg"
      decimals="1"
      id="Tc_x9DqjiuzJUGefgVOqqgCEw_4_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">65.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_tK0vLXJF0k6IM1QbPso1tQ"
      decimals="1"
      id="Tc_grbvlIghEUuqdBHGe0ZwaA_4_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">65.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_DAgjRnDA-kiGIHGiIR6buA"
      decimals="1"
      id="Tc_O0GLEgGMC0-HB0YLnEFETQ_5_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_U3Mfr4KP40avhKdtSM8eCg"
      decimals="1"
      id="Tc_I2xRrJDCBkCbbu7ApxW37Q_5_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Wub9s-eMQkCXY7--e9OtAg"
      decimals="INF"
      id="Tc_eUtYEq9F40qyl4AmpnEm-w_6_3"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">4.9</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lJ2gu3Wxtka5YhLPEJVNXw"
      decimals="INF"
      id="Tc_fO6_zj1HBEiO1YOgdNhxYg_6_6"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LjBcrN9xrU2acLCoC3csdQ"
      decimals="2"
      id="Tc_eSY3NsBHn0yJROr991ME8A_7_3"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_79RwHeAEqk6ErcJTlraR9A"
      decimals="2"
      id="Tc_fGNqhLtYa0Czki9-VEmcpw_7_6"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="0"
      id="Narr_SCl9YgPpEUOC4yNBJt6Thw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <tlsi:WarrantsLiabilitiesTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_wKnyi7HHv0imwZKhgjTIeA">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(9)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,333,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Private Placement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,933,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Series B-3 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,266,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Public and Private Placement Warrant Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with consummation of the Business Combination, the Company assumed the warrant liabilities associated with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8,333,272&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; MTAC Public Warrants. Each Public Warrant is exercisable to purchase one share of common stock at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$11.50&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, subject to adjustment. As of September&#160;30, 2023, there were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8,333,272&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Public Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Public Warrants will become exercisable &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&#160;days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; after the completion of the Business Combination. The Public Warrants expire &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; after the completion of the Business Combination or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On August&#160;31, 2023, the Company filed an amended registration statement on Form&#160;S-1 a(as may be amended from time to time) with the SEC registering the issuance of the shares of common stock issuable upon exercise of the warrants and will use its best efforts to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed, as specified in the warrant agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Once the warrants become exercisable, the Company may redeem for cash the outstanding Public Warrants:&lt;/span&gt;&lt;/p&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;a.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;in whole and not in part;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;b.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;at a price of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per Public Warrant;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;c.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;upon not less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; days&#x2019; prior written notice of redemption to each warrant holder; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;d.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;if, and only if, the reported closing price of the Common Stock equals or exceeds $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;18.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading days within a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis.&#x201d; The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. Accordingly, the warrants may expire worthless.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In addition to the Public Warrants, the Company assumed the warrant liabilities associated with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,933,333&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; MTAC Private Placement Warrants. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or saleable until &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30&#160;days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. As of September&#160;30, 2023, there were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,933,333&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Private Placement Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We determined that both the Public and Private placement Warrants do not meet the criteria to be equity classified and should be recorded as liabilities. Our analysis concluded liability classification under ASC 815, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, as these warrants include a provision that could allow cash settlement upon an event outside the control of the Company, and such event may not result in a change in control of the Company. As a result, the Private and Public Warrants do not meet the criteria for equity classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the close of the Business Combination, the fair values of the Public Warrants and Private Placement Warrants were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,500&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,068&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively. As of September&#160;30, 2023, the fair values of the Public Warrants and Private Placement Warrants were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,166&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,255&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively. The fair value of the Public Warrants has been measured based on the quoted price of such warrants on the Nasdaq Global Market. The transfer of Private Placement Warrants to anyone outside of a small group of individuals who are permitted transferees would result in the Private Placement Warrants having substantially the same terms as the Public Warrants. Therefore, we determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Series&#160;B-3 Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Series&#160;B-3 Warrants were issued in conjunction with shares of Series&#160;B-2 preferred stock in October&#160;2022, March&#160;2023 and May&#160;2023. Each warrant allowed the holder to purchase one share of Series&#160;B-3 preferred stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.05&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Series&#160;B-3 Warrants expired at the earlier of October&#160;5, 2028, or the closing date of a change of control transaction. All in-the-money warrants that were outstanding at a change of control transaction would automatically net exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In July&#160;2023, Series&#160;B-3 Warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,239,309&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock were exercised for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,530&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. At the Closing Date of the Business Combination, all in-the-money outstanding warrants and Series&#160;B-3 Warrants were net-exercised and converted to shares of common stock of Legacy TriSalus, then exchanged for shares of TriSalus common stock. Out-of-the-money warrants for other classes of preferred stock expired. The Series&#160;B-2 tranche liabilities also expired at the Closing Date of the Business Combination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Subsequent Event: Warrant Repurchase Program&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In August&#160;2023, our Board approved a warrant repurchase program, authorizing the repurchase of some or all of the Public Warrants (the &#x201c;Warrant Repurchase Program&#x201d;). The Board authorized an aggregate expenditure of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for such repurchases. The repurchases may be made from time to time in open market or privately negotiated transactions. We may adopt one or more purchase plans pursuant to Rule&#160;10b5-1 under the Exchange Act, in order to implement the Warrant Repurchase Program. The Warrant Repurchase Program does not obligate us to purchase any Public Warrants and may be terminated, increased or decreased by the Board in its discretion at any time. We adopted a purchase plan in October&#160;2023. Through October&#160;31, 2023, we had repurchased &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;28,502&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Public Warrants for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;</tlsi:WarrantsLiabilitiesTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Group_DqtoymI-ok6sSmCYeH7lqg">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Warrants outstanding at September&#160;30, 2023, and December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,333,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Private Placement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,933,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Series B-3 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,266,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,819,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-5 preferred stock, $17.81 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-6 preferred stock, $20.23 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B preferred stock, $0.41 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-3 preferred stock, $2.03 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,871,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Retirements /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercises&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Conversions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,584)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,771,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,595,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (649,109)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg"
      decimals="INF"
      id="Tc_Cmf-IP0xbUCF-S1EcyvcFA_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333272</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg"
      decimals="INF"
      id="Tc_b4vraasYukyXcoFhgsFKzg_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5933333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w"
      decimals="INF"
      id="Tc_tTMI_mJSY0aVudzs6Thybg_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">15819000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Tc_Pdpul-ppJUuXfqqiA_DVeg_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">14266605</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_H5weziMWh0KlLJy0QfMc3w"
      decimals="INF"
      id="Tc_AGFj7b-2JEy_-IGW6Ot-fA_6_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">15819000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="INF"
      id="Narr_2hz7BfEs002wZUeVU-SOfQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333272</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="2"
      id="Narr_EvwSPWi9MUebZrI-klp4iA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="INF"
      id="Narr_u0xVG9dfrUWhHudbdqX_Sg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8333272</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"
      id="Narr_nIhXR2EzYEm5qs0DgA3pJg">P30D</tlsi:ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg"
      id="Narr_KUzUl0D8FEmuIBsJrug-PQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tlsi:ClassOfWarrantOrRightRedemptionPrice
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"
      decimals="2"
      id="Narr_fjlxRs2DukyuK97XwRe1LQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.01</tlsi:ClassOfWarrantOrRightRedemptionPrice>
    <tlsi:ClassOfWarrantOrRightConversionDaysNotice
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_RHMSaTNJIEmzTCVVY75WyQ"
      decimals="INF"
      id="Narr_y7O_mUZhXES9YXw_8gL88g"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:ClassOfWarrantOrRightConversionDaysNotice>
    <tlsi:ClassOfWarrantOrRightConversionStockPriceThreshold
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"
      decimals="2"
      id="Narr_SLooJbiyz0O0LugBoEQd1A"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">18.00</tlsi:ClassOfWarrantOrRightConversionStockPriceThreshold>
    <tlsi:ClassOfWarrantOrRightConversionTermsThresholdTradingDays
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"
      decimals="INF"
      id="Narr_XnaytNiPE0yq9UgkspPwig"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">20</tlsi:ClassOfWarrantOrRightConversionTermsThresholdTradingDays>
    <tlsi:ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HgXMotz1n026ccRMl_4tpA"
      decimals="INF"
      id="Narr_qvd1_UO9rkyeCv4felMmTA"
      unitRef="Unit_Standard_D_vOySgBMXhEmYKcgOftbvSQ">30</tlsi:ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg"
      decimals="INF"
      id="Narr_iUzVz3nSvkmMuRD6Ys8Lpw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5933333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Narr_oU_dWTYlQ0avTZlHVX4LCQ">P30D</tlsi:ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg"
      decimals="INF"
      id="Narr_H0pCYSs4fUGdmBhg28UZZw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5933333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_x3m1rLvIEU-Ha7oy75c6-w"
      decimals="-3"
      id="Narr_cfcG06OqrUSv8b0oq8McUA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1500000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_8_10_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember_hEg-kSIgZkCC7TArweK3fg"
      decimals="-3"
      id="Narr_M4CDa-1olEetC4CFUHmfXw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1068000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_HaO1OtQPY0KqMYiebKM_Dg"
      decimals="-3"
      id="Narr_3YTcyIdAXEmZMQhnuP67qg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3166000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PrivateWarrantsMember__UCgLSpvJ0SNeIsm09_yJg"
      decimals="-3"
      id="Narr_9Sxtip3EUUSeR9cOHurQEw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2255000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_JNDGtibE0E6YxR5fvB4Kuw"
      decimals="2"
      id="Narr_L29IaNRPEEaFk_pUcinoUw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_Q_kjqMAvdUaQjRHDJ3DK2Q"
      decimals="2"
      id="Narr_O7qLLwpn50KNCyPlXZZ4cQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_g1Y_0bPfVUeHvgx_nTS4NQ"
      decimals="2"
      id="Narr_KBUamnW95km4gaZc0ISLKg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_RdkVFV-BmUiRk_p7buc6iw"
      decimals="INF"
      id="Narr_HZjxrj-TO0iMR_dqkGIpqQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2239309</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2023_To_7_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mhgd7pufWUCV0MhkIfsUHw"
      decimals="-3"
      id="Narr_f39JFztaOUONTwOxzh44ug"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4530000</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount
      contextRef="Duration_8_1_2023_To_8_31_2023_qmSmw3DpY0WjaiDXUJYiOg"
      decimals="-3"
      id="Narr_5PhUmXRYQUWFcjKF7E8HYQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000000</tlsi:ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount>
    <tlsi:ClassOfWarrantOrRightNumberOfWarrantsRepurchased
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q"
      decimals="INF"
      id="Narr_v3VnbqZCh0KB71vKG5tyCw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">28502</tlsi:ClassOfWarrantOrRightNumberOfWarrantsRepurchased>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_PublicWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mOMhDyQ9AE-Hq0U11XQw4Q"
      decimals="-3"
      id="Narr_Jt7KcwaRSU6o4u7J2aFATA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_QglO07lewkm1gVw93BiuPw">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(10)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full calendar&#160;year and use that rate to provide for income taxes on a current&#160;year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the annual effective tax rate, including use of the actual effective rate for the&#160;year-to-date. The impact of the discrete items is recorded in the quarter in which they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We utilize the balance sheet method of accounting for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings, forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Based on our full valuation allowance against the net deferred tax assets, our effective federal tax rate for the calendar&#160;year is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;zero&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and we recorded an immaterial income tax expense in the nine&#160;months ended September&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Narr_NCEJx4laAkKgmB6Kzf-yow"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:PreferredStockTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_qpFZA5LJL0O_uDqNOzuSWA">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(11)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Series&#160;A Convertible Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;At the Closing Date, we issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,015,002&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;A Convertible Preferred Stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$40,150&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As of September&#160;30, 2023, the Company is authorized to issue up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;10,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of preferred stock with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,984,998&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares available for issuance. The original issue price of the Series&#160;A Convertible Preferred Stock was &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Series&#160;A Convertible Preferred Stock accrues cumulative dividends at the rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8.00%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per annum on the original issue price. As of September&#160;30, 2023, total undeclared cumulative dividends were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$458&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. We have not recorded the undeclared dividends in our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;All shares of Series&#160;A Convertible Preferred Stock had the following rights:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Conversion&lt;/i&gt;&lt;/p&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;(a)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Optional Conversion&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Series&#160;A Convertible Preferred Stock are convertible at any time at the option of the holder thereof into the number of shares of our Common Stock determined by the quotient of (i)&#160;the sum of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (as adjusted for any stock dividend, stock split, reverse stock split, combination or similar event affecting the Series&#160;A Convertible Preferred Stock) (the &#x201c;Liquidation Preference&#x201d;) and, if we have not elected to otherwise pay the accrued Annual Dividends (as defined below) in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price (as defined in our Certificate of Designations, Preferences, and Rights of Series&#160;A Convertible Preferred Stock (the "Certificate of Designations")) of such shares in effect at the time of conversion.&lt;/span&gt;&lt;/p&gt;&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;(b)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Automatic &lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Conversion&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;On the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; anniversary of the Closing, all then outstanding shares of Series&#160;A Convertible Preferred Stock shall automatically convert into the number of shares of our Common Stock equal to the quotient of (i)&#160;the sum of the Liquidation Preference and if we had not elected to otherwise pay the accrued Annual Dividends in cash to the holder, the accrued Annual Dividends on such shares as of the date of conversion, divided by (ii)&#160;the Conversion Price of such shares in effect at the time of conversion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Voting Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Holders of the Series&#160;A Convertible Preferred Stock are entitled to vote with the holders of our Common Stock on all matters submitted to a vote of our stockholders, except as otherwise provided in the Certificate of Designations or as required by applicable law, voting together with the holders of our Common Stock as a single class. Each holder is entitled to a number of votes in respect of the shares of Series&#160;A Convertible Preferred Stock owned as of the record date by it, or if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, equal to the quotient of (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; divided by (ii)&#160;the Minimum Price (as defined in Nasdaq Listing Rule&#160;5635(d)) of our Common Stock as determined at Closing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As long as any shares of Series&#160;A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the Holders of a majority of the then-outstanding shares of the Series&#160;A Convertible Preferred Stock, (i)&#160;amend, alter, repeal or otherwise modify any provision of our certificate of incorporation or the Certificate of Designations in a manner that would alter or change the terms or the powers, preferences, rights or privileges of the Series&#160;A Convertible Preferred Stock as to affect them adversely; (ii)&#160;authorize, create, increase the authorized amount of, or issue any class or series of capital stock senior to the Series&#160;A Convertible Preferred Stock; (iii)&#160;increase the authorized number of shares of Series&#160;A Convertible Preferred Stock or enter into any agreement with respect to the foregoing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Holders of the Series&#160;A Convertible Preferred Stock are entitled to participate equally in any dividends declared to holders of Common Stock. In addition, each holder of the Series&#160;A Convertible Preferred Stock is entitled to receive cumulative annual dividends that accrue and accumulate on a daily basis at a rate per annum (calculated on the basis of an actual 365- or 366-day&#160;year, as applicable) equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8.00%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the original issue price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share (the "Annual Dividends&#x201d;). The Annual Dividends will be either paid in cash, paid by issuing fully paid and nonassessable shares of Common Stock, or a combination thereof when, as and if authorized and declared by our Board. Upon conversion or a change of control, any unpaid Annual Dividends will be paid to the holders, either in the form of common stock upon a conversion, or in cash upon a change of control. So long as any shares of Series&#160;A Convertible Preferred Stock remain outstanding, unless all Annual Dividends on all outstanding shares of Series&#160;A Convertible Preferred Stock have been declared and paid in cash, we will be prohibited from declaring any dividends on, or making any distributions relating to, other classes of our capital stock ranking junior to the Series&#160;A Convertible Preferred Stock, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(iv)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Anti-dilution Provisions&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The initial Conversion Price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; is subject to customary adjustments in the case of certain distributions to holders of our Common Stock payable in shares of our Common Stock, subdivisions, splits or combinations of the shares of our Common Stock and distributions to all holders of shares of our Common Stock of any convertible securities or options or any other assets for which there is no corresponding distribution in respect of the Series&#160;A Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Conversion Price will automatically reset upon each of February&#160;10, 2025, and July&#160;10, 2027, the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;eighteen-month&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;forty-seven-month&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; anniversaries of the Closing Date, to be equal to the lowest of:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Initial Conversion Price, subject to adjustments for stock dividends and distributions or other distributions made to common stockholders for which there is no corresponding distribution for Preferred Stock,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the then-current Conversion Price, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the higher of 1) the&#160;Floor Price (&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.10&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share) or 2) the trailing &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_5hLzbZ6A6U-WazkWaQSF7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-Trading Day VWAP of the Common Stock determined as of the date of such reset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(iv)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Liquidation Preferences&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The terms of the Series&#160;A Convertible Preferred Stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a &#x201c;Liquidation Event&#x201d;), none of which were deemed probable as of September&#160;30, 2023. The Liquidation Preferences of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, plus all unpaid dividends, are payable prior to payment to any class of capital stock that is junior to the Series&#160;A Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment of the full Liquidation Preferences to all holders of Series&#160;A Convertible Preferred Stock, then such assets will be distributed ratably to the holders of Series&#160;A Convertible Preferred Stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned Liquidation Preferences, any remaining proceeds from a Liquidation Event will be distributed to all classes of capital stock that are junior to the Series&#160;A Convertible Preferred Stock pro&#160;rata on an as-if converted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Legacy TriSalus Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Since inception, we have issued various series of preferred stock as described below. As described in Note&#160;3, all of the Legacy TriSalus Preferred Stock was converted to Legacy TriSalus Common Stock immediately prior to the Merger and, upon consummation of the Merger, were exchanged for shares of our Common Stock. In accordance with the terms of the Legacy TriSalus Preferred Stock, upon an acquisition of the Company, the proceeds would be used to first pay the liquidation preferences on the preferred stock prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our Board and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#x2009;&#x2014;&#x2009;and thereby redeem the convertible preferred stock&#x2009;&#x2014;&#x2009;was deemed to be outside of our control. As a result, the Legacy TriSalus Preferred Stock has been classified as temporary equity in the accompanying Condensed Consolidated Balance Sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments were not currently redeemable and we believed it was not probable that the instruments would become redeemable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;August 10,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Retirements / &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,065)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,611)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,993)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (203,974)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Warrants to purchase convertible preferred stock at September&#160;30, 2023, and December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-5 preferred stock, $17.81 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-6 preferred stock, $20.23 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B preferred stock, $0.41 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-3 preferred stock, $2.03 exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,871,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following table summarizes activity in warrants to purchase preferred stock in the nine&#160;months ended September&#160;30, 2023. There was no activity in the nine&#160;months ended September&#160;30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Retirements /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercises&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Conversions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,584)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,771,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,595,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (649,109)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Series&#160;A-5 and A-6 warrants were retired at the Closing Date as they were out-of-the money. The Series&#160;B and B-3 warrants were net-converted to shares of Legacy TriSalus Common Stock, then exchanged for shares of our Common Stock at the Closing Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The rights associated with the Legacy TriSalus Preferred Stock are described in our December&#160;31, 2022, financial statements included in MTAC&#x2019;s definitive proxy statement filed with the SEC on July&#160;18, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;October&#160;2022 Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In early October&#160;2022, we sold &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;706,243&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, raising approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,755&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in net proceeds (the &#x201c;B-2 Preferred Stock Financing&#x201d;). For each share sold, we also issued a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock (with total warrants issued being for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,824,974&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock) with a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share. The B-2 Preferred Stock Financing included, at our audit committee&#x2019;s option, a second tranche for the sale of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;518,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$7,347&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (which could be increased up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock at a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, for a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,075,417&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;306,053&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,334&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (which could be increased up to an aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;353,121&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;eight&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock at a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, for a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,448,428&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock to immediately convert to common stock and any warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#x2019;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#x2019;s preferred stock (i)&#160;were adjusted to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.06&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.33&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.37&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.34&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.37&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.42&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.26&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B preferred stock, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-1 preferred stock and (ii)&#160;set to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.35&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.05&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.155&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.173&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.162&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.165&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.189&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.190&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.154&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.167&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-3 preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;99.2%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;11), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other holders who do not provide services. As such, the Company concluded the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The warrants to purchase Series&#160;B-3 preferred stock (&#x201c;Series&#160;B-3 Warrants&#x201d;) represent freestanding financial instruments that should be recognized as a liability as we are required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#x201c;Series&#160;B-2 Tranche Liability&#x201d;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of our control, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the accompanying Condensed Consolidated Balance Sheets at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-style:italic;"&gt;2023 Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In January&#160;through September&#160;2023, holders of warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,771,642&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,630&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. In addition, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$25,409&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of warrant liabilities was transferred to Series&#160;B-3 preferred stock. Also, holders of warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;11,123&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock exercised their purchase rights, for proceeds of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, plus the transfer of warrant liabilities of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$106&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to Series&#160;B preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In March&#160;2023, we effectuated closings (&#x201c;Second Tranche Closings&#x201d;) of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;207,541&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;830,167&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, representing &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;40%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,932&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, net of execution costs, and (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;17,656&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;70,624&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. As a result of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#x2019;s certificate of incorporation, the conversion prices of the Company&#x2019;s preferred stock&#160;were adjusted. The conversion prices were further adjusted as a result of the June&#160;2023 exercise of a portion of the second tranche of the B-2 Preferred Stock Financing described below, which represent the conversion prices in effect on the Closing Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In May&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In June&#160;2023, we effectuated closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;257,779&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,031,116&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;49.7%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares committed in the second tranche, were sold for an aggregate purchase price of &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,650&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;165,967&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;663,868&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,350&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. As a result of the closings of a portion of the second tranche of the B-2&#160;Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company&#x2019;s certificate of incorporation, the conversion prices of the Company&#x2019;s preferred stock (i)&#160;were adjusted to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$38.84&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$13.36&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.55&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$13.36&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.97&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9.71&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B preferred stock, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.93&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and Series&#160;B-3 preferred stock &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, which correlate to approximate (in each case rounded to three decimals) exchange ratios of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.275&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.290&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.303&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.277&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.333&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.351&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.296&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;to 1 for Series&#160;B-3 preferred stock. These conversion prices remained in effect at the Closing Date. Any portion of the Series&#160;B-3 Warrants that remained unexercised at the time the Business Combination is consummated were automatically net settled for shares of Legacy TriSalus Common Stock immediately prior to the closing of the Business Combination (see Note&#160;3) and exchanged into shares of our Common Stock at the Closing Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#x2019;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. The fair value of the Series&#160;B-3 Warrants as of August&#160;10, 2023, was determined solely using the scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2 preferred stock fair value per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2 preferred stock exercise price per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3 preferred stock fair value per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3 Warrants exercise price per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.03&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;50.0%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2009;&#x2013;&#x2009;&lt;/span&gt;65.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.0%&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2009;&#x2013;&#x2009;&lt;/span&gt;4.7%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2 Tranche Liability expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.2&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2009;&#x2013;&#x2009;&lt;/span&gt;0.4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3 Warrants expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.8&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2009;&#x2013;&#x2009;&lt;/span&gt;6.0 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the underlying shares of Series&#160;B-2 preferred stock and the Series&#160;B-3 Warrants used in these models were derived from estimates of the Company&#x2019;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#x2019;s forecasted 2023 and&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9.31&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.93&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, as of August&#160;10, 2023, and December&#160;31, 2022, respectively, which is based upon the enterprise value stated in the Merger Agreement of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$220,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, and for the December&#160;31, 2022 valuation, discounted at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from the expected Business Combination Closing Date. The Business Combination scenario as of August&#160;10, 2023, and December&#160;31, 2022, assumed there would be no additional exercises of the second and third tranches, and thus no value was assigned to the outstanding tranche rights and obligations, as the Company would not exercise its right to call the remaining second tranche.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the Series&#160;B-3 Warrant Liabilities at issuance resulting from the completion of the Second Tranche Closings was estimated at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14,701&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The excess of the warrant liability&#x2019;s fair value compared to the proceeds received in the Second Tranche Closings resulted in a charge to loss on equity issuance in the Condensed Consolidated statements of operations of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,171&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the nine&#160;months ended September&#160;30, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw"
      decimals="INF"
      id="Narr_e6tFgRkHrUOpriQ2o9HSDw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_8_10_2023_To_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_xDVMDir2Tk-szFT8dTjUAw"
      decimals="-3"
      id="Narr_kHIDvh-kBUmFmFGP44w14w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">40150000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg"
      decimals="INF"
      id="Narr_Qh5vZeweaE2HPzcq2HTx2g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_PrJ46V1dvkCVSrf-h1yfzQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5984998</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <tlsi:PreferredStockIssuedPricePerShare
      contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg"
      decimals="2"
      id="Narr_JWg1ZyR3dUuigPtA7eIsIg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</tlsi:PreferredStockIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_jVhbJpAu0kG_D4Un6eb0-g"
      decimals="4"
      id="Narr_PaF1tV7tDE6ZbEzC_QKpkQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0800</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr__quI-UF7vU6wObiC6Q4MHA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">458000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <tlsi:PreferredStockIssuedPricePerShare
      contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ"
      decimals="2"
      id="Narr_xMLGjeEhUESFVGKM4yCZIQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</tlsi:PreferredStockIssuedPricePerShare>
    <tlsi:PreferredStockAutomaticConversionPeriod
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      id="Narr_kcAdTVOQyk2eyHa6L5t6gA">P4Y</tlsi:PreferredStockAutomaticConversionPeriod>
    <tlsi:PreferredStockIssuedPricePerShare
      contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ"
      decimals="2"
      id="Narr_YiWEsUVkN0ShZ4djHcxbKQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</tlsi:PreferredStockIssuedPricePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_8_9_2023_To_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_EQp5eTc6Nk61dCNahJBvFw"
      decimals="4"
      id="Narr_CA6ii2NXMkK5y1Yu-gVdMw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0800</us-gaap:PreferredStockDividendRatePercentage>
    <tlsi:PreferredStockIssuedPricePerShare
      contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ"
      decimals="2"
      id="Narr_61egRqKzn02PURDx4OjGXQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</tlsi:PreferredStockIssuedPricePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_8_9_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_dTVXPZqRcEaQkOFoSW1kSQ"
      decimals="2"
      id="Narr_0R1eIjV3EUubTlQwrMBxsw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:PreferredStockLiquidationPreference>
    <tlsi:PreferredStockConversionPriceAutomaticResetDurationFirstReset
      contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw"
      id="Narr_X7tk81K90EGUxCSBJcFU_g">P18M</tlsi:PreferredStockConversionPriceAutomaticResetDurationFirstReset>
    <tlsi:PreferredStockConversionPriceAutomaticResetDurationSecondReset
      contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw"
      id="Narr_QO9VFTYmaEKePjw3vUb8Ww">P47M</tlsi:PreferredStockConversionPriceAutomaticResetDurationSecondReset>
    <tlsi:PreferredStockConversionPriceFloor
      contextRef="Duration_8_9_2023_To_8_9_2023_8hNX1CS39EGKsj5g_fQ9zw"
      decimals="2"
      id="Narr_QT_Iq30TmESmqQs1Vj8pNA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.10</tlsi:PreferredStockConversionPriceFloor>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesAConvertiblePreferredStockMember_ohs0tz3ipkSG2mM1Qdmkeg"
      decimals="2"
      id="Narr_lRkAnltKA0qFpwejhqPINA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_GnsCzGj9q0KbYbHqKAGjPg">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Convertible preferred stock at September&#160;30, 2023, August&#160;10, 2023, and December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;August 10,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 131,797 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-2 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 576,126 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-3 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 612,822 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-4 preferred stock, $0.001 par value per share. Issued, and outstanding 0 and 127,787 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-5 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023;authorized 734,533, issued and outstanding 730,320 and December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series A-6 preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 805,848, issued and outstanding 800,657 at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B preferred stock, $0.001 par value per share. Issued and outstanding 0 shares at September 30, 2023; authorized 7,021,678, issued and outstanding 6,984,971 at December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-1 preferred stock, $0.001 par value per share. Issued, and outstanding 0 shares at September 30, 2023, authorized, issued and outstanding 1,659,672 at and December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-2 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 706,243 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Series B-3 preferred stock, $0.001 par value per share. Issued and outstanding 0 and 0 shares at September 30, 2023, and December 31, 2022, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following table summarizes activity in convertible preferred stock in the nine&#160;months ended September&#160;30, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Retirements / &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,065)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,611)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,993)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (203,974)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A-6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Narr_9JGnGHK1pUOEmLMcNYKx3A"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Narr_W6cvkYPAG0SDf2gMFU7AMg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">131797</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_p1P46KnXQEWJ8sMTS1L0LQ"
      decimals="-3"
      id="Tc_3uj0SOH0UkSdWSFSen25RQ_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="-3"
      id="Tc_NbGfjJ_8K0aN3UKfyA7MWQ_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Narr_uu1krdvpSkqg3Pm6Ueojpg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Narr_alC7IAKjiUuc49ZXKbpaFA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">576126</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0AcI-Ohrv0KOD6jjNcyFJA"
      decimals="-3"
      id="Tc_SktNu7WJwEqysocidL3sXw_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="-3"
      id="Tc_v81-JLetYkaTUXHSI4huBA_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Narr_fhVHbioT6U23prrETSQarQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Narr_ndJRQOjJUkiCvrPRf0PlGg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">612822</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_n2Hy7mytPUCwfCaVDdp1yw"
      decimals="-3"
      id="Tc__5r0GhgNeEO2JFMTBnb2nw_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="-3"
      id="Tc_8Cwd1uMdmUy4cboKJGnOlQ_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Narr_8EJFKbCNTk-7AcBridUGDA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Narr_wC69y0K4iEqsT8Wa87kZuQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">127787</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_az5NgdPmYEyG5PMwrX8MQw"
      decimals="-3"
      id="Tc_65MIoEa1cEGA1CPlrqNVig_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="-3"
      id="Tc_rBpiRuSBnUOEAuLueOLDnA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_tx-URdNDSUCUnyIkcHUMHA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_A485uUOxFkmARK8JorceQg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">734533</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_HrJWNJEO-EexFVI5j6R05w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">730320</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_yR9f-JPIGUujVs37FEydrQ"
      decimals="-3"
      id="Tc_RO0w8LH6J0aDBDSQOxWifw_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="-3"
      id="Tc_UlCv7rFGK0-nTrrydvbaMQ_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_C8RIvdj1uU63xtOB39ZHbg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_TA61s2LxgE2BHJjJ-Kkkiw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">805848</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_MKuITITD4kqQsY5Gvkr58Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">800657</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_SwY35kQgfk2dbaaXKgOEjw"
      decimals="-3"
      id="Tc_B3QRtZJAA0OZ3rNUmOfK6A_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="-3"
      id="Tc_PDEB-E38dUSzMnVRo4ZmVA_8_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_nsSkDDroeE65kxzTlq_Zjw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_njAkuEk8k0W0WfXMt9LkTw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7021678</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_lX74RLaaNkaWnfNupq-hvg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6984971</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dVErUypF_kmGT88HG0br_Q"
      decimals="-3"
      id="Tc_sDdQRIYQIEKAc246Tqge_Q_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84637000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="-3"
      id="Tc_d9jtOFxZwEiO8vhnhtypww_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Narr_VdVYUAXaKkG8srtvzc-JZA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Narr_8MpDuY2CN0iN-QH7KYNEcA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1659672</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_iTZWPgkZoEq7CXYI1m6Ohg"
      decimals="-3"
      id="Tc_tDrk0xyxbkSnxJCupUZqbA_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="-3"
      id="Tc_R5Ton_qfpUWp2F4roCJHVw_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23499000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr_KeU9QqTrS0e9njYFB29tDA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr_k-gKCB0hgk-3b5Q7sQ7RIQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Narr_hCRH8jlnj0eZcHYow9nEaA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mxqu6HErZkefO1cAxk8GhA"
      decimals="-3"
      id="Tc_P_GJp6JGDUqlSMT7TJtyug_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw"
      decimals="-3"
      id="Tc_tjgLXpDcWkO1PFkQ-ztzig_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">203974000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_SkCjl3PfT0-0tXqUGrGO9Q_13_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AtUfw1J3o0mUu0fWLK3F2g"
      decimals="-3"
      id="Tc_4KrPnnXQekC4mW0C7LLBSQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_PWoqiQtqAEGjuMjXT5sw3Q"
      decimals="-3"
      id="Tc_i-grYBMrvEGEIzSTj11cvQ_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_GkzygEWdwkGIA2Hdptj-cA"
      decimals="-3"
      id="Tc_xY22yT66nUe8PunA1Km0LQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_zcWk9JPUm0aHGEFVscgstQ"
      decimals="-3"
      id="Tc_Yt_LgW4qika6jmp7VDI-3A_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_lAPd1qaSFUOkNSYqELJ4Zg"
      decimals="-3"
      id="Tc_TGLrkNRFSEKwhGsLBOYSzw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_3b9pYLI57U2CBSFmckSYmw"
      decimals="-3"
      id="Tc_m4t0f4hkSEuyO52FKYGr8g_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UBHriL6i-U6Bz3QKMBjg8g"
      decimals="-3"
      id="Tc_yepHyhzwO06uF6Jp5fSu-Q_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_UK6sekRvOEe_2GBgz560wQ"
      decimals="-3"
      id="Tc_NcCfzexFyEuBzi8Aqs0mDw_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ"
      decimals="-3"
      id="Tc_fiLbapa0rkm1Wsy4sSa9Gw_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w"
      decimals="-3"
      id="Tc_-ea-KX8KWUiHPiNyinS0jw_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A"
      decimals="-3"
      id="Tc_fiUN8jXknE6iFLl2C9MozQ_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A"
      decimals="-3"
      id="Tc_9t2yf5DWS0u2gNUKIOb_og_8_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A"
      decimals="-3"
      id="Tc_ztbn6lVO5ECMI2XBAMp_Cw_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"
      decimals="-3"
      id="Tc_W290GjzTPk6sV2S78vFFtw_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">109000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"
      decimals="-3"
      id="Tc_MnJ03puxPUubSPMhIpL14A_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84637000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_j-5jcvWtPkWU5cOve1Ihkg"
      decimals="-3"
      id="Tc_fRBYfweRDkuGwFDyut85WA_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23499000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg"
      decimals="-3"
      id="Tc_Nx4QF2i8n024GoRDelaHcQ_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_W0TVntawhkmRekTwcYD-Cg"
      decimals="-3"
      id="Tc_RnW1ANi3jEeYrSPOZBRgkw_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23500000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"
      decimals="-3"
      id="Tc_svxyRopoWUOrTxX2YHjehw_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39858000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"
      decimals="-3"
      id="Tc_Bz2gXeB5hU6T-EBixS3n6g_12_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39858000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_yj1a0pkL10-SzH4LrUcE6w_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_uZGQsYcfnE6EAOK7oWXIRA_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">39968000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tlsi:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Tc_DxzzRJPu2kuhOx5nEhEpnQ_13_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">203974000</tlsi:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Z9YkJw2n8E-yk3Qt_1NPmQ"
      decimals="-3"
      id="Tc_vOUZFhbgNkSxeyOCXCyu5w_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_w6jktUReSU6j4r6UpAQFPg"
      decimals="-3"
      id="Tc_V3tPP-MYzEazcJjNDri6zw_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_u1kddxNyJUmK6bKY3LELxg"
      decimals="-3"
      id="Tc_YH0S8aA09kG8wQzBtGg_pw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bssbHLSzMUK2YenLYRNChw"
      decimals="-3"
      id="Tc_7XkkYHZryEW-GOwhLvRIVA_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_Odw8LxLv6U6EdXprDOfRGA"
      decimals="-3"
      id="Tc_RYhTbR9z0ESn_K1dAfe4hQ_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_j2yRaHhWpkeOdK0kZMluwg"
      decimals="-3"
      id="Tc_Vac0QpJRWEC9Z1cqIU4LFg_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_no3I2F75LU6zm401jb81jQ"
      decimals="-3"
      id="Tc_JgKiFtFXnUm7DJQMpnNxkg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_B4SIjbwX80epv50y8th_fQ"
      decimals="-3"
      id="Tc_yDQE2htO70aJdfAinX23HQ_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_TPmSEZHn3kuue57QJjzxuQ"
      decimals="-3"
      id="Tc_9NpRPnU5Iku5ToLtPKVPsg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_L9vZuhgzoEacaBLEGmOqKA"
      decimals="-3"
      id="Tc_j53OvK_EukGOsrVn2BY2Vw_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_gjy8I8__kk2j4tbbvWuraA"
      decimals="-3"
      id="Tc_jV6ufyDVNE6FE7AuvAyzYA_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_FovQYveUg0eH1LzMQqa8QQ"
      decimals="-3"
      id="Tc_KvKmOz3VnUqGrNgD09VlXg_8_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_cea7kamFTU22C8ALOM0GOQ"
      decimals="-3"
      id="Tc_O2Xeipimc02SYWgixqSFIQ_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_SpKOv8seVEehXwRiUfpyGQ"
      decimals="-3"
      id="Tc_8O1OfyNAQ0OdcDKA3q_9_w_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Zc1cKHOFuE287fqlH5Vrlw"
      decimals="-3"
      id="Tc_dAb14nOJmk-C69aQ5klX8g_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_cJo1v1yvJ0KPv470OFqLQg"
      decimals="-3"
      id="Tc_LWwuQYmga0C5kjJvt5Sdkw_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Ud_kLyd8f0OBg8UKavOv8w"
      decimals="-3"
      id="Tc_jndfN-5mrEmmTlHQ715fdA_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23499000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_eC-cr6C3UUGyTI_rFnutzw_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">160507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="-3"
      id="Tc_6Fn8rgK_QkOeGFaU4zLevw_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2022_4vQjORCOnkantgzUgRvHVQ"
      decimals="-3"
      id="Tc_AfpA9sBfb02V1M4NdFyU8w_11_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ"
      decimals="2"
      id="Narr_E0LxqvMzOk2zspV-PNr1NQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ"
      decimals="INF"
      id="Tc_TWZQrttP30i8mhrs6XTBqg_3_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4213</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A"
      decimals="2"
      id="Narr_YE__CuwfiUGBUMHLSDjtfA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A"
      decimals="INF"
      id="Tc_OJZ3govFBUOnlo8cUeGTJQ_4_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5190</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A"
      decimals="2"
      id="Narr_FKBnwMlYQUS1Agaleoy3Kw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A"
      decimals="INF"
      id="Tc_Cxsyi2g5yEaeIqyi3-QfoQ_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">36707</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg"
      decimals="2"
      id="Narr_T6kb4kX_x0S9ZgRG1dJLcA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg"
      decimals="INF"
      id="Tc_yjQgM9WUDUKvCOvjttQ77Q_6_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2824974</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Tc_yBhgCZo2jEK2TrrxlFuE0w_7_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2871084</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ"
      decimals="INF"
      id="Tc_gOhsWZRlH0KRDlxD3f1Msw_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4213</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w"
      decimals="INF"
      id="Tc_XkZ5aUI9J0GQ9SbeABUdFg_3_8"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4213</tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_9NZawEVP0EWdrrCIb1t-2A"
      decimals="INF"
      id="Tc_vmALJGT1cU68IHIbOt1eEA_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5190</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_D_olx3S4BEiEfoo5MOyG0A"
      decimals="INF"
      id="Tc_2NzHHHkyiESXMO2_DJSbEA_4_8"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5190</tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_ui5kHMi1c0CHYAGFYShA3A"
      decimals="INF"
      id="Tc_6geRXd70wk2F983Ymo0oQQ_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">36707</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightWarrantsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"
      decimals="INF"
      id="Tc_fPBQUzeM_UOQ6OluHCTJAw_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">11123</tlsi:ClassOfWarrantOrRightWarrantsExercised>
    <tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"
      decimals="INF"
      id="Tc_yUHSzdhEmUmM0xHN7bgCvg_5_8"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">25584</tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ksaHUGOHUEO6a5WwL761xg"
      decimals="INF"
      id="Tc_2dFlqhAJZESHp00KQ_b-dQ_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2824974</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightWarrantsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"
      decimals="INF"
      id="Tc_WFsWRxkyxUit59vhYonG1w_6_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4771642</tlsi:ClassOfWarrantOrRightWarrantsExercised>
    <tlsi:ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"
      decimals="INF"
      id="Tc_BUcs-UazBkCm_4EUNpQADQ_6_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2595777</tlsi:ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues>
    <tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FMxQzdGbG0642s4hIigrtg"
      decimals="INF"
      id="Tc_mWNzBw7FUU6rdR0o3s1OOA_6_8"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">649109</tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities>
    <tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg"
      decimals="INF"
      id="Narr_PfH040V_YU2t8ZDx5Bm3Eg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vVJ6K-dKOUaqNkzDlxnlNQ"
      decimals="2"
      id="Narr_61d28YQSqUadGbHDoG-i9g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:SaleOfStockPricePerShare>
    <tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JR3aZuScq0S29i0bTuSRgg"
      decimals="-3"
      id="Narr_AoCPjPyTkEGQN4Z3lFXj6w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9755000</tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q"
      decimals="INF"
      id="Narr_WTDsxf3WwEGrIUfkK99-sg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_ly_yjlxk9kaGKN3_pao1QA"
      decimals="INF"
      id="Narr_edL1npK5WUmaKwB0MLl2Ig"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2824974</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights
      contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_dsiZTjMLTEKnTS_3xuMRbA"
      decimals="2"
      id="Narr_Nr4ITjTOTEyOmk-vPuifOg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ"
      decimals="INF"
      id="Narr_bJ0vellW1E6kWX7Xb3ygbw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">518854</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_70BMZ9dYg0GNPeXjKt6cZQ"
      decimals="-3"
      id="Narr_h5LGBug5xEulPhmhI2l-qA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7347000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_wobYTtCwpU6MS4kEO9U9KA"
      decimals="-3"
      id="Narr_i5f_apwHTkS88ID1LVT4qA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A"
      decimals="INF"
      id="Narr_ho0gRHtjKk2phGSmW1ua5Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights
      contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_gHBfPQU5H0ynhO4bnF5M_A"
      decimals="2"
      id="Narr_XaMxELzO2kiMkUIiiHUafA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_TJoHaLkdN0KmClA53sXJgw"
      decimals="INF"
      id="Narr__JvzdV40XkyN93mZdIMOIw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2075417</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow"
      decimals="INF"
      id="Narr_tv_b59peZUeE5WTNhEZ6vA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">306053</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-3ZVJj9XfEmFCXu0AM4vow"
      decimals="-3"
      id="Narr_VO7dkNeSY0uNJU4Qvn8qyQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4334000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg"
      decimals="INF"
      id="Narr_0qmxiEC8YEGF3lQbR6AIeQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">353121</tlsi:SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount>
    <tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_RangeAxis_srt_MaximumMember_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CxIenPHJ3EmT7KQ4209Gpg"
      decimals="-3"
      id="Narr_6qNjjnK56UOqboNQKzN5YA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA"
      decimals="INF"
      id="Narr_pML8Hm70h0-23rXFaRAVuw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights
      contextRef="As_Of_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_vKcGRjyGEEKB_3S8VYBcPA"
      decimals="2"
      id="Narr_d7kJnMP1xESkKhn9qdaCWA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</tlsi:ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_10_1_2022_To_10_31_2022_tlsi_TrancheAxis_tlsi_TrancheThreeMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gIaBMU-_LU6xAQZ8ZjYntA"
      decimals="INF"
      id="Narr_35IAOr7nXkCj3AFJU5hr-g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2448428</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg"
      decimals="2"
      id="Narr_ZmJzDgf-D0-BbNQlElviCw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.06</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw"
      decimals="2"
      id="Narr_HcsVgL-vQUKHWWQJbEt1dw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.33</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg"
      decimals="2"
      id="Narr_EX9XrSEePEuRJZaejLu5OA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.37</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw"
      decimals="2"
      id="Narr_uqATAjW8CkODtxCkaygPAw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.34</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA"
      decimals="2"
      id="Narr_f9wvkHkvWU2wkE7cszAh1g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.37</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA"
      decimals="2"
      id="Narr_gdi9OYMZZUODgW24EUrltw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.42</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg"
      decimals="2"
      id="Narr_A4zdAZkQj0uQaTHp7FSzMw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.26</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ"
      decimals="2"
      id="Narr_1K2F4BdhjUCHcuueoK4-Pg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.30</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g"
      decimals="2"
      id="Narr_t-Q-zDFDiEiOafiKMY4XRg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.35</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q"
      decimals="2"
      id="Narr_UAbun1yjv06m2kEmsHBFXQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.05</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_0Ds0zLQ0KUy1-I8Czg62sg"
      decimals="3"
      id="Narr_ACacmRC9sEGDzLC7ckSwpg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.155</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_SJ5O7wrFKEiwJ9SkZcHqxw"
      decimals="3"
      id="Narr_-H1ZkjNyHEqWJ-mKlS07cw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.173</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_4YG4p4jr5U-A_GBcwy8HAg"
      decimals="3"
      id="Narr_5aq-VkRCIk-eD3JmBQrOuw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.162</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_M-uab8DWLE2yYDVxRrK-nw"
      decimals="3"
      id="Narr_qBz5tY8hIEKc6izKdbjBzw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.165</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_hGK29xBB_kKl3Z7CIZh1aA"
      decimals="3"
      id="Narr_xA-qm3JiuUattMeHy-myog"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.189</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_xCtKbGXvs0SWjhYVPU_2oA"
      decimals="3"
      id="Narr_Td7QR_vLG0afeMouNEXz1g"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.190</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_vaB-NjzkOUq9oIslZoO9bg"
      decimals="3"
      id="Narr_J1J1OwGNv0GBPhLZ6qyLlg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.154</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_9V5Hs17OIE63gv0MDW1_IQ"
      decimals="3"
      id="Narr_55t39TGWKUyQotf--AkhEw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.167</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g"
      decimals="0"
      id="Narr_dMpxh7pZPEaF5bIdEWpKCA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_mOCz97IXekW70ZoRc3Se2Q"
      decimals="0"
      id="Narr_sg2e0oI40EWinGEE7it-Jw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <tlsi:PreferredStockConversionPercentageOfOutstandingShares
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_gKTiACbSCUajmar_Jm_ALg"
      decimals="1"
      id="Narr_Qspke79Uk0S3h7e2383uSg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">99.2</tlsi:PreferredStockConversionPercentageOfOutstandingShares>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_5abH1QNeh0GMJn5kZVJQ3g"
      decimals="-3"
      id="Narr_Ot5SKhIv9UC_2FrjsvmibQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4771642000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_mk3BivT8k0SRnXR4ccWB5g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9630000</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_ywY09sKJbEOIABjnWcFUbQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25409000</tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock>
    <tlsi:ClassOfWarrantOrRightWarrantsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA"
      decimals="INF"
      id="Narr_8y_aWkQGIEa2_sDu8FGV1Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">11123</tlsi:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_p2J2fFJ7YkKotm_ZngsAzA"
      decimals="-3"
      id="Narr_PtZTKga030yglatR7g-hYw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesBConvertiblePreferredStockMember_9qrCV62lUEWWcK_q240cBg"
      decimals="-3"
      id="Narr_909IjRxLLEmGeKWgpKY8dw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">106000</tlsi:ClassOfWarrantOrRightTransferOfWarrantToPreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw"
      decimals="INF"
      id="Narr_b4UEWJ203EyKkVLRGkEwkg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">207541</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_8Jq5kxQISkum-Rv6Ika4FA"
      decimals="INF"
      id="Narr_YyMVlzQB_E-Fm7IkmXZEyw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">830167</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tlsi:PreferredStockPercentageOfSharesCommitted
      contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_GF-K_2uVu02v02J0fL-JeQ"
      decimals="0"
      id="Narr_346lrS0RTUGeXOUE3FLjHA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">40</tlsi:PreferredStockPercentageOfSharesCommitted>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_dS1RRmBHqEqBRTJAgXf2Tw"
      decimals="-3"
      id="Narr_Zwx8xuxh_0Ot6JUVRz4wfQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2932000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA"
      decimals="INF"
      id="Narr_dPMQ0sCBVEiQTmdjstB91Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">17656</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_cg1NyxPfCkWCdJlnSrnvrg"
      decimals="INF"
      id="Narr_MeN7KA3HtkqxeMj9WWpYDA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">70624</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_aBezDxbn60evGoJNCG3KaA"
      decimals="-3"
      id="Narr_Gua6mOkHGkCw5XshKgtrUg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA"
      decimals="INF"
      id="Narr_vaE354unmEaZ9mHmUw_irA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">257779</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_y-7dsjtGUkKm-ryLp0va2g"
      decimals="INF"
      id="Narr_KxzEtmzToU6o8tf0u9fXOg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1031116</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tlsi:PreferredStockPercentageOfSharesCommitted
      contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_II1Zn2a3G0K5tjXGFPo3uw"
      decimals="1"
      id="Narr_thuaqYVbJEGBrYsbB2gMyw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">49.7</tlsi:PreferredStockPercentageOfSharesCommitted>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_mLZh9KyF-k2JuaDa3f4QjA"
      decimals="-3"
      id="Narr_q_ETKKHzzU-TI2ZI1890WQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3650000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ"
      decimals="INF"
      id="Narr_oyvSYvbvAEiXM7lUC0qRfQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">165967</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_FcaQ3gGcXUGxDiS7u2MNxQ"
      decimals="INF"
      id="Narr_SLJIjfJv8E29NKzTjzWHTQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">663868</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_f0CTKB5zVUy1T2yU7K99tQ"
      decimals="-3"
      id="Narr_c9wkNC3VQkuURuapANuzIg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2350000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg"
      decimals="2"
      id="Narr_qQ8jM6oBMUipeavnAdQEeg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">38.84</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw"
      decimals="2"
      id="Narr_G3NMckn90EGFWV-Qm-qizw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ"
      decimals="2"
      id="Narr_veWaagNasESe9O6X9KFOfw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">13.36</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA"
      decimals="2"
      id="Narr_9OcYTcIJi0OwFGqMTdELqA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.55</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g"
      decimals="2"
      id="Narr_-5V5eGUeL0aYjDdi6zL2Tg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">13.36</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew"
      decimals="2"
      id="Narr_XjOb6fy2YECOzlYjgyhjgQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.97</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ"
      decimals="2"
      id="Narr_CxWoxhjRY0ePHhttDrSRiw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.71</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A"
      decimals="2"
      id="Narr_aP4JwDelqEuFSfVdFwEtoA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.93</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg"
      decimals="2"
      id="Narr_RP2Wt6GS9EmJAp_UvElmyw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig"
      decimals="2"
      id="Narr_FYTFxS6HVEyPP9JvTVVsKg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_daUZtWwSSkyWZfVCbrMmTg"
      decimals="3"
      id="Narr_TmJsZRrm8EWxo2qvVrQ75A"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.275</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_bsit5b7lgUCCkE9eQMqzmw"
      decimals="3"
      id="Narr_CM29zq2kH0eRFSUVI5K1Vg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.290</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_qwKFwHNGp0qZ5t_-e9c8mQ"
      decimals="3"
      id="Narr_4F3OyeT3hEi2SovYkCRCpA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.303</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_jZEsWCAkX0u2mjb8WSubaA"
      decimals="3"
      id="Narr_k8YbsRYkBUqnb49D5U44OQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.277</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_IKXZEg7A0UScOA-9pj3w-g"
      decimals="3"
      id="Narr_ZTU8piC3EkWVuiYli7dBtg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.333</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_JugXN0Y7fUi75TrkmPW4ew"
      decimals="3"
      id="Narr_k8IRP2fWGkq1rinsGKiikw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.351</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_9eppB6rgPkaDlgmJvOYLiQ"
      decimals="3"
      id="Narr_xfEgKr5pE0mMtgN0lT0_Pw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.250</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_Tm30HixuVEaoSktFTApJ_A"
      decimals="3"
      id="Narr_ndRbrvIFdEKyNkizrLhIQA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.296</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_wpwCrWn530qYXrH8hlNgAg"
      decimals="0"
      id="Narr_8Uyxbu0bK0m1Kns4e1p7Zw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_w9lWYrkSeUqpEkNYur08ig"
      decimals="0"
      id="Narr_Ne-ISMP7_EiWi9aTno9_fw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Group_Q8TBgG2ARUOAI-LluY2qDQ">&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates:&lt;/span&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_ljGYthGmzESwFy_58hlCQQ"
      decimals="2"
      id="Tc_ath2thKzpkmfXFlmA7n3mA_3_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.97</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputExerciseSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_HEqBbWgIskKT23W1Znx3WA"
      decimals="2"
      id="Tc_fLSl2Nw6OUOcIlxtMbLhOg_4_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_GuidelinePublicCompanyModelMember_o6rFJS2RUEmPlThbUoOgeA"
      decimals="2"
      id="Tc_V_rF3WVvn0GU3dqNnExs1g_5_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">3.24</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_ValuationTechniqueAxis_tlsi_BlackScholesModelMember_Bc0NkOT9wEihH_2yOvMkbw"
      decimals="2"
      id="Tc_WiyLTzbqzkuRGQ3pulocPA_6_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_YfJXZ7psnU-0gET12ACfMw"
      decimals="3"
      id="Narr_P5bLVMnSDkmE0361szcl3g"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.500</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1gIIWYB_SU-WziuVHJK-DA"
      decimals="3"
      id="Narr_9nTvzqRkTE6CsdRe88If0w"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.650</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_D-d-uo6wjU6j8DmtuRLnlQ"
      decimals="3"
      id="Narr_AaWVB7XZ60es5p4JW3YKpw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.040</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_yQOpRc5_AUSFptkZf40mhw"
      decimals="3"
      id="Narr_ntUYKftaG0aVsm-lwqRrUQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.047</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_bjN6UWcFCUm13QmQZ585Iw"
      decimals="2"
      id="Narr_pEmSfZkCTkqwKAB1eL-gyw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_us-gaap_ValuationTechniqueAxis_tlsi_BinomialTrancheModelMember_gJ1cZLTqKkOyAt34WAIZFg"
      decimals="2"
      id="Narr_BlVjsn_GiUeiTe6NC_NgrA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_jRIu7P7O9kCs7H6PMq9I4A"
      decimals="2"
      id="Narr_eW2W0fp7RUGFWsn49xnTDw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">5.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2TrancheLiabilityMember_bGF1dz-8s06ozP-Wejxjuw"
      decimals="2"
      id="Narr_l8hIJ1xbFkGL9Pfiqq1DrA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">6.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_10_2023_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_UBk3dK2cpk-EifzkXC7RPA"
      decimals="2"
      id="Narr_OVLjfOGEGkCZwsivHrqN7w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.31</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueSharePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_ValuationTechniqueAxis_tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember_xf9JNaLZckaWeYpqmrjafw"
      decimals="2"
      id="Narr_DyNcmHSPy0i2fRpsP0GUcg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.93</us-gaap:DerivativeLiabilityMeasurementInput>
    <tlsi:ReverseRecapitalizationStockValueIfConvertedAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_EACFwOGaWk2HdYPIH3eg5A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">220000000</tlsi:ReverseRecapitalizationStockValueIfConvertedAmount>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember__2jiobm5aUuVXVU4BFopyA"
      decimals="0"
      id="Narr_WNYz1xJ6l0m-YIiofFoEig"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">30</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_6_1_2023_To_6_1_2023_tlsi_TrancheAxis_tlsi_TrancheTwoMember_LqmQyedzNEqB45yzduiYgw"
      decimals="-3"
      id="Narr_cShqI7bPDUClzvqINZt4nQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14701000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_m1sIOlZ7wkilsdZwBq8t8Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-4171000</tlsi:GainLossOnEquityIssuance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_K8HrkewmgUeCN0A2TMVPCA">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(12)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Net Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#x201c;two-class method&#x201d;). Our preferred stock participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the nine-month periods ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,015,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,624,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,266,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,632,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,710,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,097,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,381,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As described in Note&#160;9, the triggering of the anti-dilution feature resulting from the closing of the second tranche of the Initial Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,981&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was recorded as an increase in the net loss attributable to common stockholders reflected in our unaudited Condensed Consolidated Statements of Operations for the nine&#160;months ended September&#160;30, 2023. The deemed dividend increased the net loss per common share by &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.72&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the nine&#160;months ended September&#160;30, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb__mplDanh3UaJWPoSasAOcA">&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,015,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,624,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,266,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,632,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,710,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,097,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,381,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_M4z_mBalEE6paS3q3L0Vjg"
      decimals="INF"
      id="Tc_8mNLeXVCSkKOt1yeuZyvtw_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4015002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_bEObA7CvVkWwdUC6J69fXw"
      decimals="INF"
      id="Tc_lJUCCvVLqkCEH_xOm1ROxw_3_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">11624155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantMember_OZsWLbb_CUea_sEX2DVygw"
      decimals="INF"
      id="Tc_FFZwv3ak7Eu1LWmz5QKdWw_4_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">46111</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantMember_nusetr3QVEyFrcC8HvKhQg"
      decimals="INF"
      id="Tc_Ml6DJDEkzkiTSNy0jkkWhA_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">14266605</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_LyZj3LV5jUiUFferyoGtMw"
      decimals="INF"
      id="Tc_s-DMPR2Sb0uIMjoSTV0URA_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">184018</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Hdz3D5qVJE2TxNezwlDqVg"
      decimals="INF"
      id="Tc_S3lXxAUbyU6Z-PRgHBIf8g_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2632206</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RlRaDCvakUCj5EZrtYDWeA"
      decimals="INF"
      id="Tc_5rBsdUzLeUeJ-XhcfK7CdA_7_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1710860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Tc_asvotkr09E-kTTsTiBJhVw_8_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">21097831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_KgFgKJQJakCJWwiRSE0bDg"
      decimals="INF"
      id="Tc_Y6TgxjckLUyLjWtsyypTHw_8_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">13381126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="-3"
      id="Narr_T49qL1FH9kemF9p8GEXyPA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2981000</us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <tlsi:IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Narr_HigrmBU_TUSxMaZL2NzkTA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.72</tlsi:IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_bkW4gfdUjk6OhcACWzo_NQ">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(13)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We currently maintain the 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;), which our Board of Directors and stockholders approved in connection with the Business Combination for purposes of granting equity-based incentive awards to our employees and consultants, including our executive officers and directors. Prior to the Business Combination, TriSalus granted equity incentive awards under the 2009 Amended and Restated Equity Incentive Plan (the &#x201c;2009 Plan&#x201d;). The 2009 Plan will not be used following the Business Combination. However, any awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan and the applicable award agreement. Historically, we have used options as an incentive for long-term compensation to our executive officers because options allow our executive officers to realize value from this form of equity compensation only if the value of the underlying equity securities increase relative to the option&#x2019;s exercise price, which exercise price is set at the fair market value of the underlying equity securities on the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Under the 2023 Plan, the Company&#x2019;s Board may grant equity-based incentive awards to employees, consultants and other service providers of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. Initially, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,585,008&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares were authorized under the 2023 Plan. In addition, the share reserve will automatically increase on January&#160;1 of each&#160;year for a period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_MGlu3JgwP0qQ1n5yi83_7Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&#160;years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, commencing on January&#160;1, 2024, and ending on January&#160;1, 2033, in an amount equal to (1)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;five&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;percent of the total number of shares of the fully diluted Common Stock determined on December&#160;31 of the preceding&#160;year, or (2)&#160;a lesser number of shares of Common Stock determined by our Board prior to January&#160;1 of a given&#160;year. During the nine&#160;months ended September&#160;30, 2023, we granted &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,179,480&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; options with a weighted average fair value of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2.66&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;184,018&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; restricted stock units with a weighted average fair value of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2.43&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. As of September&#160;30, 2023, the balances under the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; plans are below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Available for Issue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2009 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,915,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,915,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,585,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 900,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,684,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,816,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,684,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As of September&#160;30, 2023, we had unrecognized compensation expense of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;337&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively, for options and RSUs granted under the 2009 Plan, and $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3,002&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for options granted under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Our Board, or a duly authorized committee thereof, administers the 2023 Plan. Our Board may also delegate to one or more of our officers the authority to, among other things, (1)&#160;designate employees (other than officers) to receive specified stock awards and (2)&#160;determine the number of shares subject to such stock awards. Under the 2023 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value and exercise price, and the provisions of each stock award, including the exercise period and the vesting schedule applicable to a stock award, subject to the limitations of the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Stock options are granted with an exercise price no less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;100&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;% of the estimated fair value of a share of Common Stock at the date of grant.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_10_8_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_eJO2ISwMrkCXvzy18ph9pg"
      decimals="INF"
      id="Narr_ZhASKkQSIEiPaCIqGmXyOg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5585008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_uj5I6WUTUkaK0xF0RTcbcQ"
      decimals="0"
      id="Narr_MHkYA866MkiqMbPFHU7E2g"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">5</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="INF"
      id="Narr_6AxkZysWl0WQQRPt7qOOyg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1179480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      decimals="2"
      id="Narr_UDJ6wP5OC06029JulO2sTA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ"
      decimals="INF"
      id="Narr_FFuLUN7Gq0ufn38n2YzhHw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">184018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_5jUO4FU0nkSuG4c_fslnDQ"
      decimals="2"
      id="Narr_-DRiWtJty0yYzbpgH8XDag"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <tlsi:ShareBasedCompensationArrangementNumberOfPlans
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Narr_edSSpImG_kysBzP0o_O9kg"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">2</tlsi:ShareBasedCompensationArrangementNumberOfPlans>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_jr7TAwLfLEu81W9rZS1FsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Available for Issue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2009 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,915,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,915,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,585,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 900,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,684,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,816,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,684,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA"
      decimals="INF"
      id="Tc_x5NCLdc8GkSNmCEpyvQItw_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1915724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA"
      decimals="INF"
      id="Tc_3WAHgaLYBUuP3TF5piT1gw_3_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1915724</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg"
      decimals="INF"
      id="Tc_MMlHZQjkpUm8FUn61oD22g_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5585008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg"
      decimals="INF"
      id="Tc_Bdi6rV_P806gqGFtCGKuag_4_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">900500</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg"
      decimals="INF"
      id="Tc_m1YrA3Tx-0uD4IqhyE5gOA_4_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4684508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Tc_CdbTFNpLSECYkChIoFrBcA_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7500732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Tc_OCoCPvAa40iH4B6Q5snJLQ_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2816224</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ"
      decimals="INF"
      id="Tc_7c9dOCO5c0S32-R8n5ZKuQ_5_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4684508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA"
      decimals="-3"
      id="Narr_78jR3Opgy0-_dTAcTV-mtA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA"
      decimals="-3"
      id="Narr_zNMTOZzMMkWavAix_LUtMw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">337000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2023PlanMember_wDnVAbxoz0-j11biXV9-sg"
      decimals="-3"
      id="Narr_ESYuKRZNCE-vSGLqtPWhqA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3002000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jdMJ3tTPVki2UbZF3EKNtw"
      decimals="0"
      id="Narr_Ac_BmWJCdEWbsDNmTjw7Mw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">100</tlsi:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb_xteGQAPQbESvIxATJtuYAQ">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(14)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Dynavax Purchase&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#x201c;Dynavax&#x201d;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#x201c;TLR9&#x201d;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells (&#x201c;MDSCs&#x201d;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; that was split into two payments (&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The milestone payments range from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, triggered by development achievements for each of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; indications. The development milestone payments cannot exceed &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$170,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. We have made milestone payments of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in September&#160;2021, after initiating our clinical study of uveal melanoma liver metastases, June&#160;2022, after initiating our clinical study for primary liver tumors, and August&#160;2023, after initiating our clinical study for pancreatic cancer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In addition, we will have to pay up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; commercial milestones, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; upon first commercial sale of the product; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; upon the first occurrence of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$250,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in annual net sales; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; upon the first occurrence of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$500,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in annual net sales; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$30,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; upon the first occurrence of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in annual net sales. In aggregate, the commercial milestones shall not exceed &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$80,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We will also pay annual royalties at the rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;10%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for aggregate annual net sales less than or equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;12%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for aggregate annual net sales above that amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We record the milestone payments in R&amp;amp;D expense when they are incurred. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw"
      decimals="-3"
      id="Narr_3g57X8u49UuMBakeMnaArw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <tlsi:PaymentsForAssetAcquisition
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_rezUy1wqukqJitR5qGefCQ"
      decimals="-3"
      id="Narr_BjTmksDj_UaYrvEstc8khQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:PaymentsForAssetAcquisition>
    <tlsi:PaymentsForAssetAcquisition
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3-ZqQhxZkGHRMDML9MFaQ"
      decimals="-3"
      id="Narr_CFBFE4mRR0KqvG0N0JlorQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000000</tlsi:PaymentsForAssetAcquisition>
    <tlsi:PaymentsForAssetAcquisitionMilestoneAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_BhA3ZSO6j0m1LCmgkuwIQw"
      decimals="-3"
      id="Narr_Fqla51dZkUWu1gRiAfWcXQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:PaymentsForAssetAcquisitionMilestoneAmount>
    <tlsi:PaymentsForAssetAcquisitionMilestoneAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RCz63iBnwEquUzALofbf-g"
      decimals="-3"
      id="Narr_pPn93N07KkKPHUgwrGXfXw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:PaymentsForAssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionNumberOfCommercialMilestones
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="INF"
      id="Narr_MVWRaeTLpUyY2TNbWDQ3MA"
      unitRef="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA">4</tlsi:AssetAcquisitionNumberOfCommercialMilestones>
    <tlsi:AssetAcquisitionMaximumMilestoneAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="-3"
      id="Narr_XEZOOV2dsUGxe2Mlx0yLZA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">170000000</tlsi:AssetAcquisitionMaximumMilestoneAmount>
    <tlsi:PaymentsForAssetAcquisitionMilestoneAmount
      contextRef="Duration_9_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_wJYhKnteSUeKXfPhHtBzkw"
      decimals="-3"
      id="Narr_acrcWRl6oEaWlA-8mIQjrg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:PaymentsForAssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionNumberOfCommercialMilestones
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="INF"
      id="Narr_btYxmdejC0SfqOfKRkcdHw"
      unitRef="Unit_Standard_Milestone_HLXR30YIo0C9r_Or_FefuA">4</tlsi:AssetAcquisitionNumberOfCommercialMilestones>
    <tlsi:AssetAcquisitionMilestoneAmount
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_Z3VDT5dIz0yqR_H8-7yMPQ"
      decimals="-3"
      id="Narr_uuKLMFpudUqAfu1LC6XYvw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:AssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionMilestoneAmount
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw"
      decimals="-3"
      id="Narr_JhRVbMIFKUuq5WAqJbGlew"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</tlsi:AssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionSalesMilestone
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone250000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_RSR6eKZiRE6GAulcbLMCQw"
      decimals="-3"
      id="Narr_FofJDZWDukuTxNVWQCOSng"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</tlsi:AssetAcquisitionSalesMilestone>
    <tlsi:AssetAcquisitionMilestoneAmount
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw"
      decimals="-3"
      id="Narr_pqtHWmgTOEiqc8h5Z1Rs7w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</tlsi:AssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionSalesMilestone
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone500000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_XEUFlNSOGUGfP50DnD1CZw"
      decimals="-3"
      id="Narr_iopQGOyLnkegfgGiZ843Rw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">500000000</tlsi:AssetAcquisitionSalesMilestone>
    <tlsi:AssetAcquisitionMilestoneAmount
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw"
      decimals="-3"
      id="Narr_Z3ld7uM-zkGmrbWIOJ5xOw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30000000</tlsi:AssetAcquisitionMilestoneAmount>
    <tlsi:AssetAcquisitionSalesMilestone
      contextRef="As_Of_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestone1000000AnnualSalesMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_sxrJ8y4dF0q_1RZqnJUXCw"
      decimals="-3"
      id="Narr_pbaJ7OCFW0qbRMiW1K7aPQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000000</tlsi:AssetAcquisitionSalesMilestone>
    <tlsi:AssetAcquisitionMaximumMilestoneAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_tlsi_CommercialMilestoneTypeAxis_tlsi_CommercialMilestoneMember_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_1pk8tgoJY0SRZ1kWItulfQ"
      decimals="-3"
      id="Narr_WMEuGGoKrkOSccHFdZdpDA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">80000000</tlsi:AssetAcquisitionMaximumMilestoneAmount>
    <tlsi:AssetAcquisitionRoyaltyPercentageUnderThresholdAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="0"
      id="Narr_uOZ5LPv1I0q98YC-H88XuA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">10</tlsi:AssetAcquisitionRoyaltyPercentageUnderThresholdAmount>
    <tlsi:AssetAcquisitionRoyaltiesSalesThresholdAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="-3"
      id="Narr_QvLnnJgmX0mwCfST0wPgrg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000000</tlsi:AssetAcquisitionRoyaltiesSalesThresholdAmount>
    <tlsi:AssetAcquisitionRoyaltyPercentageOverThresholdAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_9wvTUgNb0kaBMDJA37HDiw"
      decimals="0"
      id="Narr_GsWZQDoBakOAXQf1Zj87jw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">12</tlsi:AssetAcquisitionRoyaltyPercentageOverThresholdAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg"
      id="Tb__qkc_NeWUU-xhlDkEjC0gw">&lt;table style="border:0;border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;(15)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Pursuant to the Amended and Restated Registration Rights Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand registration rights to the parties thereto, will pay certain expenses related to such registrations and will indemnify the parties thereto against certain liabilities related to such registrations. The Company&#x2019;s registration obligations under the Amended and Restated Registration Rights Agreement will terminate with respect to any party thereto on the date that such party no longer holds any Registrable Securities (as defined in the Amended and Restated Registration Rights Agreement). The Amended and Restated Registration Rights Agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#x2019;s securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_urCvNJslvUyDMpEMNkdOaw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9414000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_1Llet6lZ60q268ZxD-eBiw_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_3XBoI_DpJ0OOKKT8PqeMLg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1557000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_gENhdteOdEysYDZAQ_KAlg_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1357000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_pvBrETptsEWWeRf6TCzP_w_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1471000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_W9mbx40nXkK_-uau81BapA_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1292000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_3Rby1iyEQk-DxNpRTVCBhA_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4772000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_PgG1aixt_k-HCV8iVZKzUg_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2181000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_t2OIlqdQuUKyI4MBaZiKlQ_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">17214000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_uK51CD50AUqhHrpdsYvOVg_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">35131000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_zxl7L7SY2kCSsjDIKyZ4IQ_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2231000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_ZTi9IMFT1E-7r1zV7PBbaA_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1797000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Ibv0dSdhhEm6Q-liv78Dxg_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1381000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_i92E0ltb7kazpSx7PmWpEg_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_2wGHzY9N5EuDcaztHq2Xdg_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">794000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_J_PaA4nXzUiG-QWZQv88pw_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">367000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_fai5h8egREuPzmYNK4aGfA_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">115000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_zNAfde_RYUS6yzQgO7tiyQ_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21995000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_wJFkoK007EepOARbE2kcaQ_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">37837000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_A3Dgy0GQjUmVIxTrTFMQqA_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4947000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_5gjyN8F0WEiV7EqO-Tj2Tg_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_x3tQ2JXNFkWOXWZUaSm9sA_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6377000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_4OuYfcQWOUyTnEdYTYfjaw_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4969000</us-gaap:AccruedLiabilitiesCurrent>
    <tlsi:SeriesBTwoTrancheLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_hp5b1C76CEq56FyLep_46Q_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</tlsi:SeriesBTwoTrancheLiabilityCurrent>
    <tlsi:SeriesBThreeTrancheLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_XneBmU0e7kqMNxRtb4cKVQ_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</tlsi:SeriesBThreeTrancheLiabilityCurrent>
    <tlsi:LeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_yR9qSomfNki6D8BqgFb1XQ_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">370000</tlsi:LeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_rzJ-UVohukGxhFpuyLXn2Q_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">104000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_hSt-fittCkSZaMa6kH7ZOg_22_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6373000</us-gaap:LiabilitiesCurrent>
    <tlsi:LeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_lS5Zcb6XkkGWGLxKHNEDDw_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1593000</tlsi:LeaseLiabilityNoncurrent>
    <tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_4wrxzfLKh023giAbamQ-MQ_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">369000</tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent>
    <tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_wbFUGgQNnUKU3hngyOZDYw_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">561000</tlsi:WarrantLiabilitiesAndOtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_r1__ITgUK0SCp0dUO0ZYWA_25_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6934000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_7judIPKu_UGmF2fXe9Nkog_27_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_b1toPWYXXk2teN0W4wrzpw_27_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">160507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Narr_nVK8GYrlM0yEF8UBOzzNzA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_c-79td-73UuNirGDcnGyzw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_rNXHCiGBV0WLmyqRWKxtJw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">30898162</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Narr_Ck8dwXQ5EkWMQs6PFffjLg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">15696266</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_BMHQsXPUxUuUx3oq6VESFQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Narr_x9y9ruezOE-7jjaVogaWQg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">264977</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_fMf3Gn0zDEOz9Ur9q8IiUg_30_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6738000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_RK8rlUtP7UKX2n7ebnRi6Q_31_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-186358000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_rDCeTlRu8UKYNnHbRVgA-w_31_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-136342000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_I-yWvv7SL0SBAH4bydzfbw_32_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-129604000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc__dReN1pwJEilUanOIpPBqA_33_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21995000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_Mc4K6e-WB0OE7cXHyjvdYw_33_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">37837000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_4Z42LLBNb0ugLqOlidfsmQ_2_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_nDXC6Fut40qfHJR917wu6A_2_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_d9xKad2AEECEd9Bc2yiF4Q_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2258000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_pCEi-X95yUCNKv4UZCA01g_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1193000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_2f1KgrGd70WPgx_4HuGGVA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10140000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_UqqOX5k-_E-8VswpC-7DMg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7208000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_KCVjRRAO_0KNAFVSuyPFIg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">21358000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_BRR9MsH6TkGGmXx1P2yWvg_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">14224000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_AjiTttCUMUGGPJo3LyjHtA_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12738000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_ybEUIBfqGUKYFTIwef0Ydw_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8263000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_ugmp6_FuLU6XLUjODKiRgA_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12483000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_UIcJ92XjME2oQyaZSFYC_Q_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8753000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_1DQF9vv4bU6kmSIXIQlx0w_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-36439000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_Cn1cl59nk0CJEG41jMn5mw_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-24032000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_0GQ0EBDt4UqFOMom1puKRQ_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">180000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_YmeCTCIwxkSy3wrAVTtm9Q_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_buIKeogy0kWan0UsHmZlSg_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1761000</us-gaap:InterestExpense>
    <tlsi:GainLossOnConversionOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_avhBdanTkEW1yAD9MLeEPw_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-3416000</tlsi:GainLossOnConversionOfConvertibleNotes>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_ejjrVpPBvEau_X_QQHGBoA_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8312000</tlsi:GainLossOnEquityIssuance>
    <tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_4O5OP6tCVUeASVxtIS9myA_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2186000</tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities>
    <tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_IE3jSuFznE-xINVnesCyVQ_14_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">379000</tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_pcyI7rzmsEG6QYIx1Kqu0g_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-420000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_yPxl8bMr006wOw2pOVZWAw_15_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">746000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_TwjwT2iKXEa2PprJMFXBVA_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_HvppRhA8wE6cIrg-Erzdzw_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28842000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_QDKVDDwAeUOw7ynOhF1Auw_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_Wq0h4fdTz0aMjyuMLxLtmg_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_GI7BC1zu_k2Rnqg1mY66Fw_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_gHg2IUzJMU2O5E-Dwmad5w_18_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28845000</us-gaap:NetIncomeLoss>
    <tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_8aj14JpklEmwvt0kcnanyA_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2829000</tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_K63TVQ-UlkG27atxldSnAw_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-50016000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_0RH843Qz3EWsrIREpSilRQ_20_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28845000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_sWNVEB2ThkWz0dGFHUk7LQ_21_3"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-161.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_sWNVEB2ThkWz0dGFHUk7LQ_21_3_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-161.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_gkzgEWWeXkq0V8oMT-W90g_21_6"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-131.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_gkzgEWWeXkq0V8oMT-W90g_21_6_2"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">-131.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="0"
      id="Tc_tOGJ8_X-2UyNcMkjkT2giw_22_3"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">309609</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="0"
      id="Tc_tOGJ8_X-2UyNcMkjkT2giw_22_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">309609</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="0"
      id="Tc_2XTDSbm_PU25YpMTN0iANw_22_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">219100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="0"
      id="Tc_2XTDSbm_PU25YpMTN0iANw_22_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">219100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o17RMY4e1kCnffIskGGRgQ"
      decimals="INF"
      id="Tc_IeHg80drNEO0CVx3JvNanw_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">193303</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg"
      decimals="-3"
      id="Tc_6Ur9zgF7wkywVIZmS7rNew_4_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1364000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jSD5X1FfwUGwejMu7znIQQ"
      decimals="-3"
      id="Tc_ssjHJ0kYpUevpM0V8BH9dw_4_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-107497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"
      decimals="-3"
      id="Tc_fJMthFnmeESuzQbRTQrjZw_4_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-106133000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg"
      decimals="INF"
      id="Tc_9B32Czhin0mLbluUiXSsVA_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">71647</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA"
      decimals="-3"
      id="Tc_XFwwq2LKSECRAsl31exRpw_5_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">54000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_34TTIeNgGUGADADP9-JNQw_5_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">54000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA"
      decimals="-3"
      id="Tc_doEYtaLPyEKLGlKTLlKsHw_6_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5210000</tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_SDd1AioS8UKLrxTJfMsVJQ_6_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5210000</tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount>
    <tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vRZJGV8ezkCT50Gbc7Pdqg"
      decimals="INF"
      id="Tc_2Oi27CmYPUGqDbWBOe5N1Q_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">28</tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pRr_ged_FEu5PQ7lsXgviA"
      decimals="-3"
      id="Tc__b4ahBBnjk6GZIvVVZO0Tw_8_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">109000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_XogeVbmpHkGV3640uyaLGg_8_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">109000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wivqVnmy-EKDR9DGDZZYDA"
      decimals="-3"
      id="Tc_A7xOiSbRPUiNV2Pkpf3Deg_9_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28845000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_agUxxESaV0-x7R5aD8ryMw_9_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28845000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z--E1Dje3EGMmFmAfi11Aw"
      decimals="INF"
      id="Tc_5lCUujh8hUeMPjTMAPTLsw_10_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">264978</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fS3Y5f4L70ikePJxH7InVQ"
      decimals="-3"
      id="Tc_CXoyK3e1fEWaITWBNqelFQ_10_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-136342000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w"
      decimals="INF"
      id="Tc_cjgB_WHiP06Re9bbPCXT2Q_11_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">82879</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw"
      decimals="-3"
      id="Tc_OoBUwaRz60auKxrHan4I4w_11_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_OOLx5MyL0EKnhAEjRkAusQ_11_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o1JktP4wyk256u3LQJ1Z1w"
      decimals="INF"
      id="Tc_sflc5RWxxE6kAwtiqOMPsQ_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">69</tlsi:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw"
      decimals="-3"
      id="Tc_li_s-HW3ukKcW5jCwANMwg_13_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_VDF8TgdVu0-eenxyJII0JA_13_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ULTptJ3-00a9dPptf-rNtw"
      decimals="-3"
      id="Tc_szBfYpzHhE26J-NQKQb7fw_14_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2829000</tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision>
    <tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg"
      decimals="-3"
      id="Tc_Edb23gLgq0uzthg_Ksv8HQ_14_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2829000</tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dgl3tzNLKkWOG99CQuMtTg"
      decimals="-3"
      id="Tc_ymiq2nENbkqdWcBi9iBgkg_15_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_smApB81hY0eNKxbpsSNetg_15_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47187000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xT4ryKVxzk6eis3s1J4rrw"
      decimals="INF"
      id="Tc_nqORHBWXJke2vjq6eAY8XQ_16_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">347926</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D3YqveUjGUS1h-OvVXIpuA"
      decimals="-3"
      id="Tc_0E7ZYfrmKU6ZNsH3IlzcHg_16_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BdT9UNPKwU-scGW0UlRWxw"
      decimals="-3"
      id="Tc_bLWhGpELNUCV7q_sr0defw_16_11"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-186358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_51_5DbmTSk28W1Upq7pdNQ_16_14"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-176330000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_8vMTfkYTdUq1B_hC38Uk3A_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-47187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_UTTT-9MrXU-PmwZoCuzRXg_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-28845000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_1tFMBPkbxU6SU9rIoy1Dtg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">398000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_J_ZhIT_gbUy6HR1pHW0khQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">464000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <tlsi:GainOnPppLoanForgiveness
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_iL59EN5LN0eZRaiV3PyJXA_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">828000</tlsi:GainOnPppLoanForgiveness>
    <tlsi:GainLossOnConversionOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_WaucMeYDdkCTzFWrQQu9Ug_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-3416000</tlsi:GainLossOnConversionOfConvertibleNotes>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_cdy7bFbQukmR2Q5PBBdXWA_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8312000</tlsi:GainLossOnEquityIssuance>
    <tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_G4hu6WtmG0easaGE3sexxg_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2186000</tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities>
    <tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_hrgmRf2K_E2rf_qtzlW87A_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">379000</tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_MmkK-1qzs0-acMHT19YbJA_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1743000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_TSA0TTA0gE6TOR8cqrudPA_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">368000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_gT_HSRTMQ0Wov2IUFXT4jQ_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">109000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_qK1TsBsMI0aef2e4xH0Q9Q_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-310000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_qxaHx1YZWEW9sPD_H7fQ8Q_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <tlsi:MilestonePaymentToDynavaxOperatingActivity
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_6ZVvjUNAVkiHm5Oq8JlkUw_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxOperatingActivity>
    <tlsi:MilestonePaymentToDynavaxOperatingActivity
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_T6kgIBPJ3UyRlIuvNOlpTA_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxOperatingActivity>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_LhDfY1XGa063h1kdOS4PGw_15_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_xLCPe5PvuEKrOF0hxOKNgw_15_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">741000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_FVQYSWH_0UCNxdpcDCl3-w_16_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">179000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_v7T6bbzpmUCKneSPAgQv4Q_16_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">725000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_HT0TnITIZ0KHrwmCDmnWng_17_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2592000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_LdSzCtMYr0eVisV1KzsIVA_17_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1840000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <tlsi:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_nrZZ9E-HEkC_f4qOLDzmlA_18_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-112000</tlsi:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_boCyw9dKRUmtuOxDeknyMQ_19_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-87000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_PAkqhVBaOU--kjmABOxEUQ_20_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5246000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_WEnrORr0cEu1UdP3YfP5yQ_20_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3175000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_29StP5pKAEGGwRDcjx5q5A_21_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-32313000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_qkslZztK1k20EDbgGiXaeQ_21_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-22697000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_aYHstM1C8UGyyofhOXnCag_23_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">655000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_torMeXDUbUiV4-e6AiPX9A_23_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1097000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <tlsi:MilestonePaymentToDynavaxInvestingActivity
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_DbbUhpOXrEKcW0IlRtSC4A_24_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxInvestingActivity>
    <tlsi:MilestonePaymentToDynavaxInvestingActivity
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_jK4_gMmLkkatsnprrsL1ug_24_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxInvestingActivity>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_RisUrdjvA0OYtGLj_ATf0A_25_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">131000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_mmXrXFivrUaYFnRneE4Zew_25_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">161000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_P23-KkOXKEiIuooBKMyBYg_26_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1786000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_g1TLA3hbZUGoopGz-wmMBQ_26_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-2258000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_tiHFD8d49UOmS-TqcQ4WVw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_v6jV-QRGEkyn3LrqNz7yyg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">242000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_iHuk5c3U_kyeNlB5nOBdnQ_28_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13499000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_lTLt-69ieEKt0CtR4B0ziA_28_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">51900000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_tEIfWxa200m7v5lBkjwBWA_29_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">117000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_SAsymQ3xcUS8uXLuxDbszA_30_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">131000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Narr_pMD_G96oKk-fD1ixkfk_yQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">254000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_OBBWJ5WDfk279mzC0X5_ng"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">254000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_LoQX3lapqkmwfmkMI5eHoA_31_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1348000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_zvzUfWfbJUSOWIUyPshl1Q_32_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">45000</us-gaap:ProceedsFromConvertibleDebt>
    <tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_4oYHVAeSdUC0jFVZZx1LDg_33_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock>
    <tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_lUXMim4n_kuCN7lZeq3SSw_33_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">54000</tlsi:ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_x6igB39_l0O5ZPa2B4xlMQ_34_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13462000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_rtvuepKELEya6-OxETeW_w_34_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">50768000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_UyIfTZu5IUamwmf9bIl1AQ_35_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-20637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_DvUx7JatDESqhw9SqGCOgQ_35_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">25813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_nEUeIeLY6ESN38egotVNxg_36_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"
      decimals="-3"
      id="Tc__Vkr9Bp1_0OmnGGMyBU-cQ_36_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_l09nIsWme0-8pygg09wmMQ_37_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_zwvWHrRSREC-Jl1PESz-dw_37_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_5CGJk_vQyEueeDt0PKImRg_40_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">18000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_ysGGRzNTUk2wAza93H0IOw_41_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_I4uWRWTxv0iccoqgwJrXKQ_41_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:IncomeTaxesPaid>
    <tlsi:ValueOfWarrantsIssuedWithConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_Xz0wqht4qEGXow56ig2fOw_43_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</tlsi:ValueOfWarrantsIssuedWithConvertibleNotes>
    <tlsi:TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_NZf_rgAS_0aDtDSi04npyQ_44_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3397000</tlsi:TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants>
    <tlsi:FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_mwevurUV2EGnrxwknsHbVw_45_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12000</tlsi:FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses>
    <tlsi:PutOptionLiabilityTransferredToAdditionalPaidInCapital
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_52e0V0eWRUO2DfBBBUZ19w_46_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5210000</tlsi:PutOptionLiabilityTransferredToAdditionalPaidInCapital>
    <tlsi:CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_zEgABnR8v0-qpHeWNh1pJA_47_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">49118000</tlsi:CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_qURQqBhA90--5ocY13LH9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Nature of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;TriSalus Life Sciences,&#160;Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d;), a Delaware corporation, was incorporated in 2009 as Surefire Medical,&#160;Inc. The Company began doing business as TriSalus Life Sciences (&#x201c;TriSalus&#x201d;) in 2018, and changed its name to TriSalus Life Sciences, Inc, in August&#160;2021. We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We are developing and marketing two product lines&#x2009;&#x2014;&#x2009;Pressure Enabled Drug Delivery (&#x201c;PEDD&#x2122;&#x201d;) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve&#x2122; is the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;TriNav&#x2122; is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav infusion System, introduced in 2020, the Surefire Medical infusion System and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (&#x201c;TPT&#x201d;) approval from the Centers for Medicare&#160;&amp;amp; Medicaid Services (&#x201c;CMS&#x201d;), which allows hospitals to cover the cost of using TriNav. The approval is scheduled to expire at the end of 2023; we are actively seeking an extension of the approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We believe the full potential of our technology can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July&#160;2020, we acquired our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We have funded operations to date principally with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009 through December&#160;31, 2022, we have issued for cash &lt;span style="-sec-ix-hidden:Hidden_ZCuk_ZdpA0SUrfc6xIvFJg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$108,664&lt;/span&gt;&lt;/span&gt; of preferred stock, $458 of common stock and $57,466 of convertible notes and warrants, which has funded the cumulative net losses of $186,358. During the&#160;year ended December&#160;31, 2022, we raised $13,499 in cash through the issuance of Series&#160;B-1 and Series&#160;B-2 preferred stock and $94 from the exercise of stock options. In March&#160;2021, all of the then outstanding principle amount of convertible notes, with accumulated interest, converted to shares of Series&#160;B preferred stock in accordance with the terms contained in the note agreements; the note conversion did not raise any cash. See notes 10 and 11 for further discussion of the convertible debt, warrants and the 2022 financing rounds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, we had cash, cash equivalents and restricted cash of $9,664. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and has accumulated deficit of $186,358 as of December&#160;31, 2022. We are currently undergoing a strategic transformation from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices will be marketed alongside the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating infrastructure, resulting in an increase in operating expenses&#x2009;&#x2014;&#x2009;including the development of a candidate pharmaceutical&#x2009;&#x2014;&#x2009;that, in the short term, will not be fully offset by increased revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC Topic 205-40,&#160;&lt;i style="font-style:italic;"&gt;Presentation of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period. In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about our ability to continue as a going concern within one&#160;year after the date that these consolidated financial statements were issued. Management considered our current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one&#160;year from the date of issuance of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations as they become due in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures, and reducing other operating costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We are subject to various risks and uncertainties frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain, and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw"
      decimals="-3"
      id="Narr_P6Qe-rVn2k2Jk6Q17yn6mg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">458000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw"
      decimals="-3"
      id="Narr_zRL2Bt5Snk-kHTcFjCsiHQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">57466000</us-gaap:ProceedsFromConvertibleDebt>
    <tlsi:CumulativeIncomeLoss
      contextRef="Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw"
      decimals="-3"
      id="Narr_ZjYOa42QsEGg-M08Yt1wjA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">186358000</tlsi:CumulativeIncomeLoss>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_kT04EDtU2UOEU-d8V1Jn-g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13499000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_oD15EJjtsECCCg512y0sdg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">94000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_OnijvPUTI0ycBMVsY-9j3Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9664000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_xzrSqpooEEyLVKbDAihRqg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-186358000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_5M9lEVI-qkKq-87DJ2-H2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#x2019;s equity structure including the consolidated statements of stockholders&#x2019; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#x2019;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#x201c;Exchange Ratio&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Customer Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#x2019;s expectations of realization based on historical write-off experience, as well &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, one distributor customer constituted 19% of our accounts receivable balance. As of December&#160;31, 2021, one distributor customer constituted 34% of our accounts receivable balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We had one distributor customer which constituted 20% and 25% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(e)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(f)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#x2009;&#x2014;&#x2009;including direct labor and manufacturing overhead&#x2009;&#x2014;&#x2009;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(g)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(h)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(i)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment and Disposal of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(j)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#x201c;Black-Scholes&#x201d;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#x2019;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(k)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We have determined, in accordance with ASC Topic 280,&#160;&lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt;, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(l)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;&lt;i style="font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the contract&#x2009;&#x2014;&#x2009;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the performance obligation&#x2009;&#x2014;&#x2009;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Determine the transaction price&#x2009;&#x2014;&#x2009;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Allocate the transaction price&#x2009;&#x2014;&#x2009;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Recognize revenue&#x2009;&#x2014;&#x2009;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(m)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;amp;D costs are expensed as incurred and included milestone payments of $1,000 to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(n)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $2,201 and $1,400, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(o)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for income taxes pursuant to ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#x2019;s income tax liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(p)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant and Tranche Rights and Obligation Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(q)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases (&#x201c;ASC&#160;Topic 842&#x201d;)&lt;/i&gt;, which supersedes FASB ASC Topic 840,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU 2019-12,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the FASB issued ASU 2020-06,&#160;&lt;i style="font-style:italic;"&gt;Debt&#x2009;&#x2014;&#x2009;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2009;&#x2014;&#x2009;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, the ASU &#x201c;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#x201d; In addition, the ASU &#x201c;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#x201d; and &#x201c;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#x201d; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2021, the FASB issued ASU 2021-07,&#160;&lt;i style="font-style:italic;"&gt;Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards&lt;/i&gt;, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_ZcVqojG4HkCmda8yMq7W2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S.&#160;Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as of December&#160;31, 2022 and 2021, respectively: TriSalus Medical LLC and TriSalus Therapeutics&#160;LLC. Unless otherwise specified, references to the Company are references to TriSalus Life Sciences&#160;Inc. and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The presentation of change in fair value of warrants for 2021 on the consolidated statement of operations has been reclassified to conform to current&#160;year presentation.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In connection with the Business Combination with MTAC that was consummated on August 10, 2023 (see Note 17), the Company retroactively applied the recapitalization of the Company&#x2019;s equity structure including the consolidated statements of stockholders&#x2019; deficit from January 1, 2021 to December 31, 2022 and the weighted average common shares outstanding, basic and diluted for the years ended December 31, 2022 and 2021. The retroactive application reflects the equivalent number of shares of New TriSalus common stock, $0.0001 par value per share, issued to the Company&#x2019;s stockholders in connection with the Business Combination at the applicable exchange ratio of 0.02471853 (the &#x201c;Exchange Ratio&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_YKLw0Y9530-3CGjRzdVo8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We consider all highly liquid investments with original maturities of three&#160;months or less at the time of purchase to be cash equivalents. We invest excess cash primarily in money market funds.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <tlsi:ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_gBTlOfqGDkiR08b5JEzFfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(c)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cash is deposited primarily with one financial institution. At times, the deposits in this institution may exceed the amount of insurance provided on such deposits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant risk on these balances.&lt;/p&gt;</tlsi:ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_LOF6JpGiRUe1ry9wu3NutQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Customer Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts periodically and establish reserves based on management&#x2019;s expectations of realization based on historical write-off experience, as well &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;as current general economic conditions and expectations regarding collection. Account balances are charged against the allowance after all reasonable means of collection have been exhausted and the potential for recovery is considered remote.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, one distributor customer constituted 19% of our accounts receivable balance. As of December&#160;31, 2021, one distributor customer constituted 34% of our accounts receivable balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We had one distributor customer which constituted 20% and 25% of our revenue for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The arrangement with this distributor terminated on December&#160;31, 2022.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <tlsi:NumberOfCustomer
      contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_TmWc_b8zrkOoESGM-nlcbw"
      decimals="INF"
      id="Narr_LhoZaWIfR0WzLJVJ1eLLPw"
      unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ">1</tlsi:NumberOfCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_unAxPM_nUkazhDm3agcBLw"
      decimals="2"
      id="Narr_YodGdtDTzUy120h5Iw4tbw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.19</us-gaap:ConcentrationRiskPercentage1>
    <tlsi:NumberOfCustomer
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xh7u3lp9k0iiIeQaqMuClw"
      decimals="INF"
      id="Narr_wG4TvuzFiUSQaHus9Y8_Dw"
      unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ">1</tlsi:NumberOfCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_spU-CoGWskCTi4k7rsFi5g"
      decimals="2"
      id="Narr_QMPof6c0QEaw9YTVGf7jVA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.34</us-gaap:ConcentrationRiskPercentage1>
    <tlsi:NumberOfCustomer
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pP0da2xH7UW_LfRCdr8p5w"
      decimals="INF"
      id="Narr_d6cvFnRXQ0-YoYc5hDe1OQ"
      unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ">1</tlsi:NumberOfCustomer>
    <tlsi:NumberOfCustomer
      contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LVK9Ysk-RU6dEwdwJdOHYQ"
      decimals="INF"
      id="Narr_D5_LR0rJc0SXI9CE1NlGiQ"
      unitRef="Unit_Standard_customer_mDGqPtBwsEKvf1JrXpKMwQ">1</tlsi:NumberOfCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_c8vgoPz11Emp9qsaEJDkKA"
      decimals="2"
      id="Narr_luSZR93hX0OX4-_la0XI6Q"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tlsi_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ciY8mEnJHkKZYJWWeE3zcw"
      decimals="2"
      id="Narr_YwAk9_rk8UyxiRYOdzWHJw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_RupvBSuCeUyLMfpI16pI_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(e)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;. We determine if an arrangement is or contains a lease at contract inception, and, if it does, we recognize a right-of-use (ROU) asset and a lease liability at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For operating and finance leases, the lease liability is initially measured at the present value of the unpaid lease payments at the lease commencement date. The lease liability is subsequently measured at amortized cost using the effective-interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_AaRvAGpxPkSUrYAPEsZzxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(f)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is carried at the lower of cost or net realizable value. The balance includes the cost of raw materials, and finished goods&#x2009;&#x2014;&#x2009;including direct labor and manufacturing overhead&#x2009;&#x2014;&#x2009;and is recorded on the first-in first-out method. Write-downs for excess and obsolete inventory are charged to cost of goods sold in the period when conditions giving rise to the write-downs are first recognized. Valuation reserves are recorded when, in our best judgment, we determine the carrying value of the affected inventory may be impaired or its net realizable value exceeds its cost.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_N3LwdqLHWUyvnRk0rPHiAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(g)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the valuation of warrant liabilities and tranche liabilities, and the valuation allowance on deferred tax assets.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_VFt6rIB28ECdru7lfR3rDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(h)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from two to seven&#160;years. Leasehold improvements are amortized on a straight-line basis over the lesser of estimated useful lives or the lease term.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_4xtsiBc_R0GeIR-9T-o_Gg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(i)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment and Disposal of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We review long-lived assets and intangible assets (principally patents) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is generally measured by a comparison of the carrying amount of the asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the estimated fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_L-GyQrEU006Um48SEtDkrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(j)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for all employee share-based compensation awards by recording expense based on the estimated fair value of the awards at the time of grant using the Black-Scholes-Merton option valuation model (&#x201c;Black-Scholes&#x201d;). The determination of fair value using an option-pricing model is affected by the estimated fair value of the Company&#x2019;s stock, as well as assumptions regarding a number of variables including, but not limited to, the fair value of underlying stock at the grant date, expected volatility of the underlying stock over the term of the awards, projected employee stock option exercise behaviors, and risk-free interest rates. We have elected to not include an estimated forfeiture rate in our share-based compensation expense recognition, in accordance with ASC Topic 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;, and we account for forfeitures in the period in which they occur. The estimated fair value of options granted is recognized as compensation expense on a straight-line basis over the expected life for each separately vesting portion of the awards.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_V8aQp4AtlEewFj2v0-8l3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(k)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We have determined, in accordance with ASC Topic 280,&#160;&lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt;, that we operate under one operating segment, and therefore one reportable segment, TriSalus. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of assessing performance and allocation resources. All of our long-lived assets, and all of our customers, are located in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_jDnVZqXllkq35st_PTF4Pw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(l)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospital, clinics and physicians. Under ASC Topic 606,&#160;&lt;i style="font-style:italic;"&gt;Revenue Recognition&lt;/i&gt;, we evaluate five steps to determine the appropriate timing and amount to recognize revenue. The five steps are:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the contract&#x2009;&#x2014;&#x2009;We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to us for delivery of a quantity of our products, which incorporate enforceable rights and obligations constituting the contract with the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Identify the performance obligation&#x2009;&#x2014;&#x2009;Our performance obligation is to deliver the ordered products in accordance with the terms of the purchase order, which constitutes a single performance obligation. We do not have any on-going service obligation after delivery.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Determine the transaction price&#x2009;&#x2014;&#x2009;We maintain a single sales price for each of our products, which is generally fixed. We do not have a history of any significant refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after delivery of the product. We do not offer discounts, except to distributors as discussed below. We have certain arrangements with distributors under which the distributors purchase our products and then resell them in geographic markets where we do not have a sales presence. Those arrangements provide for a discount on the invoice; when the distributor resells our&#160;units at our normal sales price, the discount serves to compensate the distributor for their efforts. We record these sales net of the discounts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Allocate the transaction price&#x2009;&#x2014;&#x2009;We do not have multiple performance obligations to complete when we fulfill a purchase order, as such, the transaction price is allocated fully to the&#160;units being sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Recognize revenue&#x2009;&#x2014;&#x2009;We recognize revenue at the point-in-time when the&#160;units for a purchase order have been shipped and control of the&#160;units has transferred to the customer, as evidenced by the delivery terms on the shipping documents. Typically, we ship Ex Works, so we recognize revenue when the shipment leaves our premises. In certain cases, the purchase order &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;specifies alternate shipping terms, usually DAP (delivery at place). In those cases, we defer revenue recognition until we are assured the&#160;units have been delivered and control has transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_SK9MXE0yqECeIvfPQaCHTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(m)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs include our engineering, regulatory, pre-clinical and clinical activities. R&amp;amp;D costs are expensed as incurred and included milestone payments of $1,000 to Dynavax for SD-101 in each of the&#160;years ended December&#160;31, 2022 and 2021, respectively. See Note&#160;9 for further discussion of Dynavax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We are required to estimate our expenses resulting from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&amp;amp;D activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result in payment flows that do not match the periods over which goods or services are provided. We reflect R&amp;amp;D expenses in our consolidated financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <tlsi:MilestonePaymentToDynavaxOperatingActivity
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_7q0ECVOhiUCg5q21Gd-9yg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxOperatingActivity>
    <tlsi:MilestonePaymentToDynavaxOperatingActivity
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_YEwvW3VS4UGubYtgoOuL8w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentToDynavaxOperatingActivity>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_42iqh7WF3kS-vFJfqvuJAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(n)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising expense, which is included in sales and marketing costs, is expensed as incurred, and expense for the&#160;years ended December&#160;31, 2022 and 2021, was $2,201 and $1,400, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_pCs8C58etke2iQci41L5gw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2201000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_598Jn1GCCEqy6QLY8i13Ng"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1400000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_sEBXygPRJUGWlmZlKb2fcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(o)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for income taxes pursuant to ASC Topic 740,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, which requires the use of the asset-and-liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the effect of income tax positions when it is more likely than not, based on technical merits, that the position will be sustained upon examination. Through 2022, management determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company&#x2019;s income tax liabilities.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <tlsi:WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_LIRNO4NOaUeTMcQ3b_mvYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(p)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant and Tranche Rights and Obligation Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently redeemable are required to be reported as liabilities in the financial statements. We present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting period, and any change in value are recognized in the consolidated statements of operations. We have determined that the warrants issued to investors and lenders, which are exercisable for shares of our convertible preferred stock, should be classified as liabilities due to contingent redemption features of the underlying convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The B-2 Preferred Stock Financing (as described in Note&#160;12) included second and third tranche rights and obligations to investors who participated in the initial B-2 Preferred Stock Financing round. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). The second and third tranche rights and obligations are exercisable into shares of our convertible preferred stock at a specified future date. The second and third tranche rights and obligations are considered freestanding financial instruments, and are classified as liabilities under ASC&#160;480. See Note&#160;12 for further discussion.&lt;/p&gt;</tlsi:WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock>
    <tlsi:PercentageOfSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Narr_kY4yQks4k0eF2V1ntIOakA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.992</tlsi:PercentageOfSharesOutstanding>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_KxN24Ol8JUKwVQ5Yh-PSDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(q)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases (&#x201c;ASC&#160;Topic 842&#x201d;)&lt;/i&gt;, which supersedes FASB ASC Topic 840,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, and makes other conforming amendments to U.S. GAAP. ASU 2016-02 requires, among other changes to the lease accounting guidance, lessees to recognize most leases on the balance sheet via a right of use asset and lease liability, and additional qualitative and quantitative disclosures. ASU 2016-02 was effective for us, as a private company, for fiscal&#160;years beginning after December&#160;15, 2021, permits early adoption, and mandates a modified retrospective transition method. We adopted this guidance as of January&#160;1, 2022. The adoption resulted in an increase in assets of $1,512 (net of $320 of accrued rent and unamortized tenant improvement allowances), current liabilities of $236, and long-term liabilities of $1,596.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU 2019-12,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The ASU removes certain exceptions to the general principles in ASC Topic&#160;740 and clarifies the existing guidance to improve consistent application. ASU 2019-12 was effective for us, as a private company, beginning on January&#160;1, 2022, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) for adopting the guidance depends on the specific facts and circumstances addressed in the guidance. We adopted this guidance with no material impact on our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the FASB issued ASU 2020-06,&#160;&lt;i style="font-style:italic;"&gt;Debt&#x2009;&#x2014;&#x2009;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2009;&#x2014;&#x2009;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, the ASU &#x201c;simplifies accounting for convertible instruments by removing major separation models required under current GAAP, including the concept of beneficial conversion features.&#x201d; In addition, the ASU &#x201c;removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it&#x201d; and &#x201c;simplifies the diluted earnings per share (EPS) calculation in certain areas.&#x201d; ASU 2020-06 is effective for private and emerging growth companies for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years, with early adoption permitted in&#160;years beginning after December&#160;15, 2020. ASU 2020-06 permits adoption on a retrospective basis to financial instruments outstanding as of the beginning of the first comparative reporting period presented. We elected to adopt ASU 2020-06 on January&#160;1, 2022, on a retrospective basis. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2021, the FASB issued ASU 2021-07,&#160;&lt;i style="font-style:italic;"&gt;Determining the Current Price of an Underlying Share for Equity-Classified Share-Based Awards&lt;/i&gt;, which allows nonpublic entities to use, as a practical expedient, the application of a reasonable valuation method to determine the current price input of equity-classified share-based payment awards issued in exchange for goods or services. The ASU notes that a valuation performed in accordance with specified U.S. Treasury regulations related to internal Revenue Code Section&#160;409A is an example of a reasonable valuation method. The guidance is effective for fiscal&#160;years beginning on or after December&#160;15, 2021. We adopted this guidance on January&#160;1, 2022. The adoption did not have a material impact on our consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInOperatingAssets
      contextRef="Duration_1_1_2022_To_1_1_2022_4rgr5dtwgkOc8kEvgOYxOA"
      decimals="-3"
      id="Narr_agh1SAvB2EeLLfyk5n2acg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1512000</us-gaap:IncreaseDecreaseInOperatingAssets>
    <us-gaap:AccruedRentCurrent
      contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg"
      decimals="-3"
      id="Narr_ll422Rub6kCK9xMm49diWQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">320000</us-gaap:AccruedRentCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg"
      decimals="-3"
      id="Narr_xG5uWF1I4UmNWXxQiyRndw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">236000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_1_1_2022_zmJIrNqrmkOz0RtboUL_bg"
      decimals="-3"
      id="Narr_VDGCrvyhKUyiXINC9wTILQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1596000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_HwYbNpHRsUW21V8MoEiiiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(3)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our financial instruments consist of cash, accounts receivable, trade accounts payable, tranche and warrant liabilities to purchase preferred stock, long-term debt and convertible notes. The carrying values of these financial instruments (other than tranche liabilities and warrant liabilities, which are held at fair value) approximate fair value for the&#160;years ended December&#160;31, 2022 and 2021. In general, asset and liability fair values are determined using the following categories:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;Level&#160;1&#x2009;&#x2014;&#x2009;Inputs utilize quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;Level&#160;2&#x2009;&#x2014;&#x2009;Inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"&gt;Level&#160;3&#x2009;&#x2014;&#x2009;Inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company&#x2019;s own assumptions about the assumptions that a market participant would use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Our financial instruments, including tranche liabilities and warrant liabilities, are measured at fair value on a recurring basis, including immediately prior to exercise. The carrying amount of outstanding warrant liabilities was $16,188 and $391 at &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;December&#160;31, 2022 and 2021, respectively, and the carrying amount of outstanding tranche liabilities was $4,702 and $0 at December&#160;31, 2022 and 2021, respectively. These carrying values approximate fair value based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the fair value of the underlying preferred stock, volatility, discount rate, and expected term. The put option liability was retired in March&#160;2021 in conjunction with the conversion of all convertible notes to Series&#160;B preferred stock; see note 11 for further discussion. There were no transfers between levels for the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2022, we sold shares of Series&#160;B-2 preferred stock with accompanying warrants to purchase Series&#160;B-3 preferred stock (see Note&#160;12). This also included rights and obligations exercisable for additional Series&#160;B-2 preferred stock and Series&#160;B-3 warrants through a second and third tranche. We offered the Series&#160;B-2 preferred stock to all of our preferred stockholders at the time of the initial B-2 Preferred Stock Financing round (representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis). At issuance, the warrants issued to purchase Series&#160;B-3 preferred stock had a fair value of $11,966 (remeasured to $15,819 at December&#160;31, 2022), the tranche rights and obligations associated with the second tranche had a fair value of $3,109 (remeasured to $2,250 at December&#160;31, 2022), and the tranche rights and obligations associated with the third tranche had a fair value of $3,238 (remeasured to $2,452 at December&#160;31, 2022), all of which have been classified as liabilities. The fair value is determined based on unobservable inputs, or Level&#160;3 inputs, using assumptions made by us, including the probabilities assigned to both a status quo scenario and the potential closing of the Business Combination (see Note&#160;16), the value of the Series&#160;B-3 warrants upon closing of the Business Combination, the fair value of the Company and resulting fair value of the underlying preferred stock, volatility, and expected term; see note 12 for further discussion. These assumptions require significant judgment on the part of management and actual outcomes may materially differ from those estimated by management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities for the&#160;years ended December&#160;31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;(Out)&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&#160;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,387)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&#160;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Put option liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,210)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In (Out) of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains) Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B-2 tranche liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B-3 warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;This amount includes settlements of $3,397, reduced by issuances of $10.&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_jb_q390JZkiH38PyUwE9zQ"
      decimals="-3"
      id="Narr_L4p9jRWjskiZPQWGnf8znw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16188000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_UO7Dm79BGEGf58YUPTUeig"
      decimals="-3"
      id="Narr_t2IW0NAOOEmk2n5ytfi6GA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">391000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_rS227lpA-0ato7P2m7Pn8A"
      decimals="-3"
      id="Narr_ED0vcNKvXk6lnKv5KzBYhw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_tlsi_MeasurementAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheLiabilitiesMember_om9EAvh6fk-yKmSCpi6WYQ"
      decimals="-3"
      id="Narr_EFtYhff3A0yztiTOS9_sng"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:LiabilitiesFairValueDisclosure>
    <tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Narr_o7gN0kEnC0eM_ijN-F5YtA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount>
    <tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_5dYdjmbrN0ie5eTatgjxXA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount>
    <tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g"
      decimals="3"
      id="Narr_cx8MMogFnEKKb7h8GmCQKQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.992</tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g"
      decimals="-3"
      id="Narr_LiJykRWkS0KhUlbL1p6Hgw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11966000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA"
      decimals="-3"
      id="Narr_4kwyEyFqtUy8Xv94Fsromg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_UfT8ljsnjEiwXR-Eomw_NA"
      decimals="-3"
      id="Narr_bbcDXJOHkU-fyaPzD6jW2Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3109000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember_J6vJujbvTU-jEUmIjkq0yw"
      decimals="-3"
      id="Narr_KMbEzXSpJkKQYNYrj5fJhA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2250000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_OKx8PR3Il0avdary9MaUKw"
      decimals="-3"
      id="Narr_kGCteG7BWkOl0MbYQIqw9A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3238000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember_wbUeBXlixU2vDzFtryoUTA"
      decimals="-3"
      id="Narr_GJ2qWw-xIk6IY0kMCHX0HA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2452000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_wYA1YoehDESgNRFA4k4OAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;(Out)&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains)&#160;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,387)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&#160;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Put option liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,210)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Transfer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In (Out) of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Gains) Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Settlements)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B-2 tranche liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:49.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B-3 warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;This amount includes settlements of $3,397, reduced by issuances of $10.&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_ZC3gPhsLq0C-Ql-nVHkpag"
      decimals="-3"
      id="Tc_nJ8st4Kmsk2EvfNdE59qDA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3399000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og"
      decimals="-3"
      id="Tc_utH6VCbZnEiAJ7s0IDoLWQ_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">379000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og"
      decimals="-3"
      id="Tc_bRsOS82oLEmj-Fgl5g4krg_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-3387000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg"
      decimals="-3"
      id="Tc_Idxqiz-cXk-lCU4pWK4Mtw_4_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_7fyqcBdnXkWyRm6NSBBkYw"
      decimals="-3"
      id="Tc_OSF-_1GkDUu0cK4sc2OE1A_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5140000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg"
      decimals="-3"
      id="Tc_4q2LYqyz5kKYkeygJdd8PA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">70000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_PutOptionLiabilityMember_jLuBgiWJlUitn9lSweFGAg"
      decimals="-3"
      id="Tc_KiwzJHMNgEe4jaMSjRfqTA_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-5210000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg"
      decimals="-3"
      id="Tc_Ft2PGgabo0GDRMXqRrnMOQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_4G4-51YVe0-W2QwDgj40EQ"
      decimals="-3"
      id="Tc_uIclSO9I5UeplyGQ8lsiIA_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-22000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA"
      decimals="-3"
      id="Tc_J3dY44gNN0iTa4AVy9Cxvw_4_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg"
      decimals="-3"
      id="Tc_W2yRU-GJI0WiCkdD71pfog_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-1645000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_m21VJB-kiECaKbUmyLznhg"
      decimals="-3"
      id="Tc_Pti5enyhaUS_Rf80lDf9PQ_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6347000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_7kh5ioPPCU2NcXnDWvOSDA"
      decimals="-3"
      id="Tc_CIaJVvdLiUi5mTv-ZJqRKw_5_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ"
      decimals="-3"
      id="Tc_RsMQOyoDf0i4gHSH-MvQUg_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3853000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_IQ4LKpMhxk-GaXZnz8l_tQ"
      decimals="-3"
      id="Tc_iYwODIF4S06WXFmarcESXg_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11966000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB3WarrantLiabilitiesMember_wRJ1i4W4p0yQRHB5YvbGBA"
      decimals="-3"
      id="Tc_lu4WlyGZ7EaTPVQE9Kko_w_6_15"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og"
      decimals="-3"
      id="Narr_oFmPs4VxM0e8VeGkN_-aLw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3397000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_dWYCUISW5kidsOoBn8X9og"
      decimals="-3"
      id="Narr_6zY3enybYEKw7JbJBP8SWA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_D1_hUWwPrUyoXXZX6bqOEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(4)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash, as presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash (included in Other assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash is $250 held by our bank to support our corporate credit card program.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_cTkYeIQK9U2eLP7lYausFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash (included in Other assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b16GYIIPRE-ojj7RlH_rdQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_iqABfrutGUClrk7CGHzTbg_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9414000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_XSmtlMhcgkyP4fwUyLkIEQ_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_-yc8rnX710-8WbeqLtcKbA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_0TKNXlY5FEqaFHedv0d4-A_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_YEOQ--_eWEO_fFnh9z8qAQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_GnMLcpg1S0S3J3gxI6S7vw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_q25N343E8UqJElJvMS_LOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(5)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of inventory at December&#160;31 are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The finished goods amounts in the table above include a reserve for excess inventory of $43 and $97 as of December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_DVN1ri3XEEWPOuo-CEDdDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_a4G4K0cWt0y05Rs8AUsrHg_2_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">753000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_jK6AeLHRuUutQ4ryOUDI3A_2_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">646000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_KYbrSUPiOkKAq8w8_0pyWw_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">718000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_L6xmd99xHEeP4LoN6voOig_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">646000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Hob8Ww0HXEaZ8vUtt2_Qjg_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1471000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_ZCatLj5jmUyX9a-InevPYg_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1292000</us-gaap:InventoryNet>
    <us-gaap:InventoryAdjustments
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_nhnRstolYkOHsYz1OJrk6w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">43000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Narr_i7r4SD1oekqQTrSSLR5KYA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">97000</us-gaap:InventoryAdjustments>
    <tlsi:LongLivedAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_b49v-0hztUKWibZGE4S3aQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(6)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December&#160;31 consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#x2009;&#x2013;&#x2009;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other property&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,149)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for property and equipment for the&#160;years ended December&#160;31, 2022 and 2021, was $276 and $361, respectively. The Company did not recognize any impairment losses for the&#160;years ended December&#160;31, 2022 and 2021, other than a loss on disposal of $310 in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets consist entirely of patent costs that provide the Company with rights, titles, and interests in the development of certain processes, discoveries, and inventions with the right to commercialize that are probable of future economic benefits. Patent costs associated with pharmaceutical intellectual property are expensed as incurred as future economic benefits are not deemed to be probable. Intangible assets are recorded at cost and are amortized over the estimated life of the patents, based on the approval and expiration dates applicable to each patent&#x2009;&#x2014;&#x2009;typically 20&#160;years&#x2009;&#x2014;&#x2009;on a straight-line basis. Amortization expense related to intellectual property for 2022 and 2021 was $122 and $103, respectively. We did not record any impairment losses in 2022 or 2021. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal&#160;years is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 802&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tlsi:LongLivedAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_DuTWEFJ4zEi3gvu1mtC7Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December&#160;31 consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#x2009;&#x2013;&#x2009;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other property&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,149)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Yy4qomYWEumToz2Q3IF5A"
      id="Narr_mfLrmWqpsEmge1l1mlDkDw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_grIe4j2NjUW8eovYdmDsAQ"
      id="Narr_BEDSUlekYk6ZIMpc8YqFvA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ANvX6KP4G0CXL1ffGVduvA"
      decimals="-3"
      id="Tc_yc9Sw1MRKkmuM0PH2-0MGg_3_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_ekxf6NMJqU2o-owseUO9jQ"
      decimals="-3"
      id="Tc_GTXAjH8WQEuZVmtVVFXzpQ_3_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ"
      id="Tc_4qS60Fjc40SpRE97x8bKHw_4_2">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0DoBUIRW9kKp3p9CqLuaPQ"
      decimals="-3"
      id="Tc_y2nMUnXi5EKoqZLQFCJeLw_4_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">602000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dnZOErz2JUevW3yh4sbChw"
      decimals="-3"
      id="Tc_5YAkrqmWxUGnFCzSv3kK2Q_4_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">672000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA"
      id="Tc_PO4OmUsPV02ctk_x69f1VQ_5_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zn_JCeO9VkmcrIwk6UUxbA"
      decimals="-3"
      id="Tc_aIEwKzaODU-PJLXDxbDDog_5_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4rbUCoNCLkiKBrrFNhgp2Q"
      decimals="-3"
      id="Tc_gSnHjyXsg06LYVoE_RqhUg_5_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">448000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw"
      id="Tc_hWMM4IECIUmbRVsnBjds6A_6_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ZwnOyD4Jc06y2-deanyTnw"
      decimals="-3"
      id="Tc_6cN2wGoPTUCpfDrHEofAcw_6_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_8jVm0JgFSkq10jUH1ZLKNA"
      decimals="-3"
      id="Tc_D7NDC5Dk50-RcqZjYMHcHw_6_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">783000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ"
      id="Tc_jCy5V8O5CkSGoJvxlTGCNw_7_2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_GW8J6O1NFEm8pBLOoc1ycQ"
      decimals="-3"
      id="Tc_CmC0W4nFB0uGvNvLWdW_UA_7_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_Yzsv-OD0SkGrA-t5QrzSQQ"
      decimals="-3"
      id="Tc_Dd9eRvizi0OCmHX2Yb8YPg_7_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_Hrb_ptmzik69uktLnL6llw_8_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_OX35ToCYDki0pdlRGH5kFg_8_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3946000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_IKXhHBsRsUqgLFS_hA_h6w_9_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2425000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_xrFE_QeL8Ue649H2STeLYA_9_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2149000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_yE77C_4Ky0iwd5727rkFwg_10_5"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2231000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_fNuPt1zg-EWIoh2lKAph9A_10_8"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1797000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_Id83Xzt5U0Crt1IzTLoRlQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">276000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_QvLbjMH7cUWLDzkiLI0bvA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">361000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_zjU8THEr4EWBUIPXE3BE6w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-310000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Narr_sB7vGY0qnEy2K3AKcAbp_Q">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_uyXebUyZW0ijIpgkuI-sAw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">122000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_VnKnhp8wEU2S-sBenxdEjA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">103000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_BPpX71UPxEeRuJCPOZzaMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 802&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_-xza3WJvE0G3Oh-PxwWtwQ_1_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_n7Z7lX0HIEGJkjOaIEyd1g_2_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_nDELfuQUSUqjv7zopACtcA_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_lvZI9fVcgEW_SNeQmCBYUw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_7xyDCEspFk-muwAG153WEw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">65000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_AI91zDdW8E2w7YvjjJ2pDg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">477000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_VHsnO8gBMkWOfBsoP-pHDQ_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_wT5eyRvvvk-a_YaCf81GNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(7)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued liabilities consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued incentives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,969&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb__zOCNAI7iUaLM9lCNPgl7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued incentives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,969&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_4n1LF1xfEUKV2tjXfTNYCg_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2905000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_LcfK8H7XTUyr_GyUpOlwKw_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2910000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <tlsi:AccruedIncentiveCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_0xLjB7BNvUy5rMYwfTX-xA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2896000</tlsi:AccruedIncentiveCurrent>
    <tlsi:AccruedIncentiveCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_rgGuFmhS7k6NsUWXkl_y6Q_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1562000</tlsi:AccruedIncentiveCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_6WS6yllQwEykI7xQv83EQw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">329000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_JGodAjXit0i_HRmJCmIN9g_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">271000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_NpONSPiHSkqqTZCTB48PtQ_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">247000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_FpcMEMr1Lkyla7V4CnYRcw_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">226000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_26Bxxa1vo0CNiolLLwBCkw_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6377000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_xADfxCfDA0mAJ5GoAgCjrA_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4969000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_Xgg-ffIrNUGh-g-GnYuuEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(8)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and local taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (78)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred income tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,630)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred income tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing the realizability of our deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As we do not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, we do not believe it is more likely than not that we will realize the benefits of the net deferred tax assets and, accordingly, have established a valuation allowance equal to 100% of net deferred tax assets. The change in the valuation allowance for the&#160;years ended December&#160;31, 2022 and 2021 was $8,728 and $5,779, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, we had net operating losses (&#x201c;NOLs&#x201d;) as follows (the NOLs which do not expire are subject to an annual utilization limitation of 80% of taxable income):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Federal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;State&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOLs expiring between 2029 and 2037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOLs which do not expire&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total NOLs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Internal Revenue Code contains provisions that may further limit the net operating loss carryovers available to be used in any one&#160;year if certain events occur, including significant changes in ownership interests. Utilization of net operating loss and tax credit carryforwards are subject to a substantial annual limitation due to the ownership change limitations set forth in Section&#160;382 of the Code and similar state provisions. We prepared an Internal Revenue Code 382 analysis to determine the annual limitations on our consolidated net operating loss carryforwards. All of our tax attributes are subject to an annual limitation. Such annual limitations could result in the expiration of the net operating loss and tax credit carryforwards before utilization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022 and 2021, we did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12&#160;months. Our accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Our federal and state returns for all&#160;years remain open to examination by tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_P1xZBIpWLkyIJ0tW1Y2H7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The income tax expenses (benefits) from continuing operations for the&#160;years ended December&#160;31, 2022 and 2021, are summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_uYo08aIeLkKXnu717tiG4g_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_-ZIiVlBbWUW6L7nN85S0pg_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_aEfVoPX7tkGOgU36rQEdkQ_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_iK1_vMrzyEKuDaZ_Uh5gYA_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_1WbI4JEdtkKagK-vcQb5xQ_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_rZ2PD1RwJ0CBXmAHI9lLOQ_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_LL8p4K9F9UOB0Vml9sOmGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The provision for income taxes differs from income taxes computed at the federal statutory tax rates for the&#160;years ended December&#160;31, 2022 and 2021, due to the following items:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State and local taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Tc_7om0mlzf10WGndjNPiIQeA_2_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="3"
      id="Tc_IIKVp4XtU0Wjc4uerZwS2g_2_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Tc_YV4UmjcJVkGZuH3UhqnaCw_3_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="3"
      id="Tc_FqXz-3kBOU-Pa7KDwCWuNg_3_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Tc_gKjhaG8W0U2PwMlT7dPPTw_4_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.190</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="3"
      id="Tc_V01UOPS8K0Cb2uwd-NjP_A_4_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.200</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Tc_AunLTJZKZEqaNJc5mNGlkA_5_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="3"
      id="Tc_R95tCUobdUOXflltUGAr4w_5_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="3"
      id="Tc_onNaxV7YrEyEaL-zm8NxDQ_6_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.050</tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="3"
      id="Tc_8rTAK0gNkky95kiZlgDFsw_6_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">-0.034</tlsi:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_CTjj49HBuEOossp9-O4Y6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The income tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities at December&#160;31, 2022 and 2021, are presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (78)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred income tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,630)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred income tax assets and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_YMazCPvSZUeJc5Xbhx-sPg_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30421000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_rnWLZEvpRECP1He_4NLhHA_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">27002000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tlsi:DeferredTaxAssetsFixedAssetsAndIntangible
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_xL2KH3QxD0upCSRL2uN7EA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2371000</tlsi:DeferredTaxAssetsFixedAssetsAndIntangible>
    <tlsi:DeferredTaxAssetsFixedAssetsAndIntangible
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_mIVA9KbFw0Sk6C9lOJ-zNw_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2306000</tlsi:DeferredTaxAssetsFixedAssetsAndIntangible>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_UBpBCyELY02nCutxgGJNGQ_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">815000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_UDB5XV_4f0GifZ3ZoHCFFA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">108000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_DB8vDxeP4k6mjd72V4OsNg_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">76000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_YFBv8Aj7oEmKKT88SSVNmQ_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">229000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_TCp0ci7fpU6ax9vpG9tVqw_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">87000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_ObUUkgzzskOftyK203iZTA_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4613000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_vPI2AfRYKEeOuUH8BD5zVw_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">76000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_P5sgFNAMrkWscCPM9wyD-Q_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">63000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_b9Lk3PbfsUSc2QMatvDZ7g_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">38459000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_yJYgX_gD3ky7SStjPoUShw_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29708000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_oyAVpxYJdU2EC00YlGk1iw_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">101000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_a1N3ugHsoUCIcUEWuXt2IA_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">78000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_fgozKmc_aUOH2TQtrYg9PQ_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">38358000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_8lh2f_zggUWDSkDMK-BcCg_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29630000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_4msNSaAeWkihsYdybwRkLQ_14_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">38358000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_yHfCvaj8BEaOczyEbx0mKw_14_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">29630000</us-gaap:DeferredTaxAssetsNet>
    <tlsi:NetDeferredTaxAssetsChangeInValuationPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_kUvNiK8vdEutX1IexakhUg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</tlsi:NetDeferredTaxAssetsChangeInValuationPercentage>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_Sv9ixvU_nU6parPNu5nMNQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8728000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_7kkIwCZFwUqHQjjN3MW3cQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5779000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_VXF4wdnBck2G8tNrFM9Xqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Federal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;State&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOLs expiring between 2029 and 2037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOLs which do not expire&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total NOLs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA"
      decimals="-3"
      id="Tc_gxk35Kw4kkSVYBrpuOQqcA_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">43912000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ"
      decimals="-3"
      id="Tc_B1l_XnvDok-pUm0lg6rw1Q_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">67380000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA"
      decimals="-3"
      id="Tc_2XuvOyWu4ECfA7zDN7OarQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">82009000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ"
      decimals="-3"
      id="Tc_cZT7APlOh0KQqWkUzGmPxw_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">18398000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA"
      decimals="-3"
      id="Tc_Gt9Wblhww0q2halzq5m2QQ_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">125921000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_AqaJlkZd5Umdzudx0rgZoQ"
      decimals="-3"
      id="Tc_s7wqASYZD0q3_z08zCWukQ_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">85778000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Narr_7rKX0x8pqEmHPvYAjvtrEg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_1y7KbGaJZEmypCCh5fMUdg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_IJQ9NRGb70m4kY_3HymqOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(9)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Dynavax Purchase&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July&#160;2020, we purchased all of the intellectual property and trial drug substance for SD-101 from Dynavax Technologies (&#x201c;Dynavax&#x201d;). We did not acquire any equity in Dynavax, nor any production facilities or personnel; this was a purchase of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). SD-101, an investigational agent in development, is a toll-like receptor 9 (&#x201c;TLR9&#x201d;) agonist which is believed to bind to the TLR9 receptors found on suppressive immune cells including myeloid-derived suppressor cells &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;(&#x201c;MDSCs&#x201d;) and antigen-presenting immune cells. Toll-like receptors play a key role in the innate immune system and create a bridge to adaptive immunity. It is believed that activating TLR9 primes immune cells to promote anti-tumor T cell function. We believe that SD-101, when delivered using our PEDD devices, can improve therapeutic distribution to solid tumors and improve outcomes for liver metastases and pancreatic cancer. We initiated a clinical study to evaluate SD-101 for the treatment of uveal melanoma liver metastases in September&#160;2021, and initiated an additional study, for primary liver tumors, in March&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments under the Dynavax purchase agreement consist of: (a)&#160;one upfront payment of $9,000 that was split into two payments ($5,000 and $4,000, paid in July&#160;and December&#160;2020, respectively), (b)&#160;milestone payments upon the achievement of certain development and commercial milestones, and (c)&#160;royalty payments based on aggregate annual net sales after SD-101 receives FDA approval to be sold.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The milestone payments range from $1,000 to $10,000, triggered by development achievements for each of up to four indications. The development milestone payments cannot exceed $170,000. We made a milestone payment of $1,000 in September&#160;2021 after initiating our clinical study of uveal melanoma liver metastases. We made an additional $1,000 milestone payment in June&#160;2022 after initiating our clinical study for primary liver tumors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, we will have to pay up to four commercial milestones, $10,000 upon first commercial sale of the product; $20,000 upon the first occurrence of $250,000 in annual net sales; $20,000 upon the first occurrence of $500,000 in annual net sales; and $30,000 upon the first occurrence of $1,000,000 in annual net sales. In aggregate, the commercial milestones shall not exceed $80,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We will also pay annual royalties at the rate of 10% for aggregate annual net sales less than or equal to $1,000,000 and 12% for aggregate annual net sales above that amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We recorded the first and second development milestone payments of $1,000 in R&amp;amp;D in 2022 and 2021. We have reflected these milestone payments in the Consolidated Statements of Cash Flows as investing activities to reflect the contractual investment in the IPR&amp;amp;D. The milestone payments and royalty payments are contingent upon future events and therefore will also be recorded as expense when it is probable that a milestone has been achieved or when royalties are due.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <tlsi:UpfrontPaymentAmount
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg"
      decimals="-3"
      id="Narr_0zFWB9LdF0iudnGtrY68DQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000000</tlsi:UpfrontPaymentAmount>
    <tlsi:PaymentOfUpfrontAmount
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg"
      decimals="-3"
      id="Narr_eRtqwonc2U-KhihNPCyI6w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:PaymentOfUpfrontAmount>
    <tlsi:PaymentOfUpfrontAmount
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_LAf8O94CsUeODp-5oXER8g"
      decimals="-3"
      id="Narr_UKBdTd0va0eooUhrNgctgA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000000</tlsi:PaymentOfUpfrontAmount>
    <tlsi:MinimumMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="-3"
      id="Narr_fBDy9Qjx4kKRH6wSVfFDKA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MinimumMilestonePaymentAmount>
    <tlsi:MaximumMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="-3"
      id="Narr_hxwzdZfkHUq6wdCQkqZkDg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:MaximumMilestonePaymentAmount>
    <tlsi:MaximumDevelopmentMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="-3"
      id="Narr_9QYZxVX-akaOpBJJkUxLtA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">170000000</tlsi:MaximumDevelopmentMilestonePayments>
    <tlsi:MilestonePaymentsMade
      contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_lt1UpQkALESaPZXbSwBQZw"
      decimals="-3"
      id="Narr_g5BPp0qdske3SdYmA9_MPw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentsMade>
    <tlsi:MilestonePaymentsMade
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_A5ZRtG0Mp0KDhqGdsKvyPA"
      decimals="-3"
      id="Narr__JVqsdgnlkOhoB0k7ifGpQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</tlsi:MilestonePaymentsMade>
    <tlsi:NumberOfCommercialMilestoneToBeMade
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="INF"
      id="Narr_gJrH1D37PUy7S3mKZFoTFA"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">4</tlsi:NumberOfCommercialMilestoneToBeMade>
    <tlsi:CommercialMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstCommercialSaleOfProductMember_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember__otGtNiDqUS3D-2IJAK-XQ"
      decimals="-3"
      id="Narr_fDBLP4jcW06-9Ovpd1tjjA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:CommercialMilestonePaymentAmount>
    <tlsi:CommercialMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg"
      decimals="-3"
      id="Narr_64PGZiDl_kSHjBlvuXHnjw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</tlsi:CommercialMilestonePaymentAmount>
    <tlsi:AnnualNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_RxJsMEfIdkOMro6MmKRwSg"
      decimals="-3"
      id="Narr_6-06xzL22kizmJw8oR-b3w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000000</tlsi:AnnualNetSales>
    <tlsi:CommercialMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg"
      decimals="-3"
      id="Narr_tnDacvbXgESKI-yWWj3C-g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</tlsi:CommercialMilestonePaymentAmount>
    <tlsi:AnnualNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_yY62IPiA90-RSqxuyhgneg"
      decimals="-3"
      id="Narr_HDsbXnuXJUa0foRIECTYhQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">500000000</tlsi:AnnualNetSales>
    <tlsi:CommercialMilestonePaymentAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g"
      decimals="-3"
      id="Narr_Sk6JOzHmLEuCBSOuUfevJg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30000000</tlsi:CommercialMilestonePaymentAmount>
    <tlsi:AnnualNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_jXEMCRVb0ESVKW7KPjob0g"
      decimals="-3"
      id="Narr_OO5_mYBMNk6mOnTdUXJWOQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000000</tlsi:AnnualNetSales>
    <tlsi:MaximumCommercialMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="-3"
      id="Narr_IFtBwR_3a02gKb061dlLpw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">80000000</tlsi:MaximumCommercialMilestonePayments>
    <tlsi:AnnualRoyaltyRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg"
      decimals="2"
      id="Narr_bX2bi_7Ei0q6oVktQXCPPA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.10</tlsi:AnnualRoyaltyRate>
    <tlsi:AnnualNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_G4yAKYjPhkCwo9LRznUvYg"
      decimals="-3"
      id="Narr_9KyyLmOD6ESoW5cjufAMrA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000000</tlsi:AnnualNetSales>
    <tlsi:AnnualRoyaltyRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_AggregateAnnualNetSalesGreaterThan1000000Member_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_xsabo2n52UilLgijgS19aQ"
      decimals="2"
      id="Narr_26oqyzG9PkCdwgqwgI8VsQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.12</tlsi:AnnualRoyaltyRate>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_rmbLcmOtAU-0t0vs9Lj3pw"
      decimals="-3"
      id="Narr_UclupzQKtU6MyipMnYlBzw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_Y53dpOcAWEecXKHyjc2Khg"
      decimals="-3"
      id="Narr__pu4bQurm0mLeTWUbUkERA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_IzZKdkHvJEq2iWKex8nKZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(10)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;PPP Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2020, we applied for, and received, a loan of $828 under the Small Business Administration (&#x201c;SBA&#x201d;) Paycheck Protection Program (&#x201c;PPP&#x201d;) program. Under the terms of the program, the loan was used to fund retention of employees and facility expenses. The program provides for forgiveness of the loan after a period of time if the loan was used for approved expenditures. On April&#160;19, 2021, we received notice that the SBA had forgiven the loan. We recorded the forgiveness as a $828 gain included in other income and expense, net, in 2021 in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The term loan and supplemental term loan matured on November&#160;30, 2021, and were paid in full, with a final payment of $1,348.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In conjunction with the term loan, we issued the following warrants. All the warrants expire 10&#160;years after the issuance date. The warrant liabilities are carried at fair value; the initial fair values listed below were recorded as debt discount at the time of issuance and amortized as additional interest expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&#160;Class&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quantity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;08&#x2011;26&#x2011;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;10&#x2011;27&#x2011;2016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;06&#x2011;30&#x2011;2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;11&#x2011;20&#x2011;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 741&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w"
      decimals="-3"
      id="Narr_hzKXHUKa1EWlKM-duz1VfQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">828000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="Duration_4_19_2021_To_4_19_2021_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_SAPDdK4uLkukkpYiynrn7A"
      decimals="-3"
      id="Narr_QsLjTMiTbE6tAFGox36fYQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">828000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_DebtInstrumentAxis_tlsi_TermLoanAndSupplementalTermLoanMember_K5TX_Dl3_UOXwI1TQxgdow"
      decimals="-3"
      id="Narr_2DV5MSfEakm3-vu1Tgoo_w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1348000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Narr_eY8Sd4knlkW8tUGMvbUTVw">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_34UTSUtsg0qsC0cvxA-1tg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&#160;Class&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quantity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial&#160;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;08&#x2011;26&#x2011;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;10&#x2011;27&#x2011;2016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;06&#x2011;30&#x2011;2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;11&#x2011;20&#x2011;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 741&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg"
      decimals="INF"
      id="Tc_zPCEk--olkefHZeUAg3cZw_2_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">3370</tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg"
      decimals="2"
      id="Tc_0A6iQrfUlEuhE2ZPWLv3cg_2_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg"
      decimals="-3"
      id="Tc_MKhrncsMp0ec9EDRsNdhWw_2_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">54000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ"
      decimals="INF"
      id="Tc_TQ-443VvV0GcyCXku93EcA_3_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">842</tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ"
      decimals="2"
      id="Tc_IdZTEB5j-kuF4rLwyASIuw_3_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn10272016Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_kEByBIuEx0KX9axLLfM-CQ"
      decimals="-3"
      id="Tc_dX-47yEjw0uHKLP0Kdc-Og_3_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA"
      decimals="INF"
      id="Tc_JoqVjqfS1EOTM7s7PUEQ2A_4_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4449</tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA"
      decimals="2"
      id="Tc_goHW2Hnbx0C30peL4nuaoA_4_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn06302017Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember__zfDD9u5K0O46GqUXQUfYA"
      decimals="-3"
      id="Tc_G3lu_0fqb0mVBxAtiKUDeQ_4_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">102000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg"
      decimals="INF"
      id="Tc_DHKwLApHMUurVJDB5dZGZg_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">741</tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg"
      decimals="2"
      id="Tc_EQtqcxcQzUOmx6v9_O3hnA_5_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn11202018Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_hCAC0i1PG0q6zi5CDeyZqg"
      decimals="-3"
      id="Tc_kE8H6WHcGUSrlU2Hp8WSLg_5_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <tlsi:ConvertibleDebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_xgQQefXGJk2SW3KOvp0daw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(11)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Convertible Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;and September&#160;2018, we issued convertible notes for aggregate cash proceeds of $5,000, which had an original maturity date of December&#160;31, 2019. The maturity date for the convertible notes was revised in 2019 to be December&#160;31, 2020, and in 2020 to be December&#160;31, 2021. The extension of maturity dates in each case were determined to be modifications to the debt instruments. Between May&#160;and September&#160;2019, we issued additional convertible notes for aggregate cash proceeds of $15,000, with a maturity date of December&#160;31, 2020, which was also modified to December&#160;31, 2021. Between March&#160;and October&#160;2020, we issued convertible notes for aggregate cash proceeds of $9,102, with a maturity date of December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The convertible notes accrued interest at 8% and could only be prepaid upon the favorable vote of the majority holders. When and if we complete a &#x201c;qualified financing&#x201d; on or prior to the maturity date, the unpaid principal and accrued interest on the convertible notes are automatically convertible into the same class of preferred stock offered in the qualified financing at the lesser of $0.50 per share or 85% of the price per share paid by cash purchasers for the preferred stock issued in the qualified financing. (This discount on the price per share paid by cash purchasers was subsequently modified in 2021, see below.) A &#x201c;qualified financing&#x201d; is a preferred stock financing transaction for the purpose of raising capital with gross proceeds of at least $5,000, excluding all proceeds from convertible notes that convert into preferred stock in connection with the financing. This conversion upon a qualified financing feature essentially provides the holder with a fixed return that is settled in a variable number of shares. As such, it qualified to be accounted for as an embedded derivative, a put option liability, at fair value. The put option liability was initially recorded as a debt discount and subsequently remeasured at its fair value each period end. We estimated the fair value of the put option liability based upon the 90% probability of a qualified financing occurring multiplied by the value to be received by the holder (Level&#160;3 inputs). (We estimated a 10% probability that the convertible notes would convert at maturity.) The put option liabilities associated with the 2018, 2019 and 2020 convertible notes were initially measured at $794, $2,382 and $1,446, respectively. The fair value of the put liabilities did not change at December&#160;31, 2019, 2020 or 2021, as management&#x2019;s estimate of the probability of a qualified financing did not change. Through December&#160;31, 2021, additional put option liability was recorded for the conversion feature applied to the accumulating accrued interest balance of $303, which was recorded as additional put option liability and debt discount. The discounts on the debt as a result of recording the initial put liabilities was amortized to interest expense over the term of the loans using the effective interest method.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Between March&#160;2020 and December&#160;2020, we also issued convertible notes for aggregate cash proceeds of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$15,545&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. An additional convertible note for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$45&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was issued in January&#160;2021. These notes differed from the other notes issued during 2018 through 2020 in that they did not contain the conversion discount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. Instead, they were accompanied by warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;385,361&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; Series&#160;A-6 preferred shares at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share initially, which upon issuance of the Series&#160;B Preferred Stock in 2021, were automatically converted into warrants to purchase Series&#160;B Preferred Stock. The warrants expire on the fifth anniversary of the issue date. All other terms of the notes were the same. Since the warrants are for preferred stock that were initially redeemable, they were recorded as a liability in the accompanying balance sheet at December&#160;31, 2020. The initial value of the warrant liability of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,887&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,877&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the warrants issued in 2020; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the warrant issued in 2021) was determined using the Black-Scholes method and resulted in an additional debt discount that was being amortized to interest expense using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The convertible notes also included a provision whereby upon a change in control prior to the conversion or repayment in full of the principal amount of the convertible notes, the Company would be obligated, at each holder&#x2019;s option, to either (A)&#160;pay such holder in cash an amount equal to (is) the outstanding principal and interest accrued to that date, plus (ii)&#160;a premium equal to 100% of the unpaid principal and accrued interest, or (B)&#160;convert the outstanding principal and interest accrued to date into Series&#160;A-6 preferred stock at a conversion price of $0.50 per share. This change in control prepayment and conversion provision qualifies as an embedded derivative and has been included in the fair value of the embedded derivative noted above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Finally, the convertible notes also included a provision whereby the unpaid principal and accrued interest would convert at maturity, at the option of the holders of at least 2/3 of the outstanding principal amount of the outstanding convertible notes, into shares of the Company&#x2019;s Series&#160;A-6 preferred stock at a conversion price of $0.25 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Interest expense related to convertible notes was $1,773 for the&#160;year ended December&#160;31, 2021, which included the 8% stated interest and amortization of the debt discounts associated with the embedded put liabilities and attached warrants.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In March&#160;2021, the Company&#x2019;s board and note holders (many of whom are also stockholders) agreed to eliminate the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; discount in the next qualified round of financing attached to the 2018, 2019 and 2020 issuances of convertible notes. We determined the elimination of the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; discount was a modification of the convertible notes with related parties and, as a result, we recorded the impact of removing the put option liability associated with the convertible notes of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,210&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to Additional Paid-in Capital in the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;accompanying consolidated balance sheet for the&#160;year ended December&#160;31, 2021. Also in March&#160;2021, the issuance of Series&#160;B preferred stock was determined to be a qualified financing event. Accordingly, all of the convertible notes, with a notional amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$44,692&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, were converted, with accumulated interest of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,426&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, into &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,047,069&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock at a conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share. Upon the conversion of the convertible notes to Series&#160;B preferred stock, we also recognized the remaining unamortized debt discounts associated with the conversion features and warrants in the aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,416&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; as a loss on conversion of convertible notes in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</tlsi:ConvertibleDebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_8_1_2018_To_9_30_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_2DKAccvY4ESMxGwfCcxgEA"
      decimals="-3"
      id="Narr_SNiat9stw0GOjSwfNylSEA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_5_1_2019_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_JxTqOZ5zzEWxBqVPHktsLg"
      decimals="-3"
      id="Narr_w0VUQ7-ZX0CwSmHiTaYxYw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_3_1_2020_To_10_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f8UN7L2qYEiwdyhrpna6mA"
      decimals="-3"
      id="Narr_4LjeKJ-1akmEZPWpvhKn_g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9102000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg"
      decimals="INF"
      id="Narr_0CJ_pzz0lUmi7opab-kWyA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_3rJ2FO5LJUSoqyUTUmjEHg"
      decimals="2"
      id="Narr_6vSyDrzYAEa8bCqilq9-Ow"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <tlsi:DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA"
      decimals="2"
      id="Narr_bc6YMkZmE0aV_nRVA1Cnmg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.85</tlsi:DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued>
    <tlsi:QualifiedFinancingMinimumProceeds
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA"
      decimals="-3"
      id="Narr_ZayNdoz1k0CL98W0hA5W3A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:QualifiedFinancingMinimumProceeds>
    <tlsi:ProbabilityOfOccurrenceOfQualifiedFinancingPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA"
      decimals="2"
      id="Narr_nkRhgx3Lak2jdnzLEOnpfw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.90</tlsi:ProbabilityOfOccurrenceOfQualifiedFinancingPercentage>
    <tlsi:ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jDMn_chTsUipaUG6KSbVaA"
      decimals="2"
      id="Narr_DiXwgC4GKU2npdG0i3SmmA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.10</tlsi:ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_12_31_2018_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_n7C8O3tfnEa9PI51Rt_RTw"
      decimals="-3"
      id="Narr_icl_n570D0KOuoo8jjRjRw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">794000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_o2D8Am3EA0qP-aO4LNlnsw"
      decimals="-3"
      id="Narr_UinwBJ5o00aQO_p2LpqWBQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2382000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_PutOptionMember_QnfyiZ486EqFzaXxwbOqWA"
      decimals="-3"
      id="Narr_2uY-VCH4cECTwj3v0q4-Lw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1446000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA"
      decimals="-3"
      id="Narr_BuAFRsYgiEC4M_zSIjK6HA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">303000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_3_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_6hORdNW_yE623vRVLJelFw"
      decimals="-3"
      id="Narr_eZvYQ2pHp0GC-o2HmLOOLw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15545000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg"
      decimals="-3"
      id="Narr_ZjHNGsQBQUieTKH9UPxzvQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">45000</us-gaap:ProceedsFromConvertibleDebt>
    <tlsi:DebtInstrumentConversionDiscountPercentage
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_jGJ8x1reCEyfHu4lILMFaw"
      decimals="2"
      id="Narr_XxEQ0KJTjESQq2Tkcm4UUw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.15</tlsi:DebtInstrumentConversionDiscountPercentage>
    <tlsi:DebtInstrumentConversionDiscountPercentage
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pg8Y_UprR0OnU_7ys9KuHg"
      decimals="2"
      id="Narr_2ZmyeQ9Y-UOQNLg0_a_OkA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.15</tlsi:DebtInstrumentConversionDiscountPercentage>
    <tlsi:DebtInstrumentConversionDiscountPercentage
      contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wbWlcEUxYUS1rDanZQ4z-A"
      decimals="2"
      id="Narr_RK3kZgmGeEW4br6ZVWUEgw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.15</tlsi:DebtInstrumentConversionDiscountPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w"
      decimals="INF"
      id="Narr_MJ9W3dmsEk6qy7Ek7cQ_vw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">385361</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ"
      decimals="INF"
      id="Narr_CMzjeV9K-U-hWP2yd39gXQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">385361</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA"
      decimals="INF"
      id="Narr_SefCuqd2PUqLPsySyGLVJg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">385361</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_SwFCrTlCYkiqCliIR5UN0w"
      decimals="2"
      id="Narr_R-OjogEUQ0GdNG1HDmSuFA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_lcM0xmixKUitv2wCoSzmgQ"
      decimals="2"
      id="Narr_I5T1IqKa3EWip4j9AegEGw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_fboQzfXOnECH-QCUkdPggA"
      decimals="2"
      id="Narr_vRL2IfFpO0u7cVCe4hneZQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tlsi:InitialWarrantLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_lR88djeyOkSoAka2w4PVuw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3887000</tlsi:InitialWarrantLiability>
    <tlsi:WarrantIssued
      contextRef="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg"
      decimals="-3"
      id="Narr_KGImDPbHuU-0LUk-LA3adA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3877000</tlsi:WarrantIssued>
    <tlsi:WarrantIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_4KUuVLQHnkeMmyfp8bxGzQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000</tlsi:WarrantIssued>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_JJrctF3Ss0aVYnhFS_75uQ"
      decimals="2"
      id="Narr_3kEwp6Igr0SqUkmRvnq1rg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6PreferredStockMember_Z3lUDqKSpU2d131KWzDy6g"
      decimals="2"
      id="Narr_I5phJSu5MEmFiWJ2HKrVmA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_w0DdgmyjNEGACAuQcuscQQ"
      decimals="-3"
      id="Narr_x2Srf1ogh0CGdNJkvdLojA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1773000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_CH96jPdXdE-FSCsP_tdWlA"
      decimals="INF"
      id="Narr_MG6ESS3k-kOnez8ZgJ4H2w"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <tlsi:EliminationOfOccurrenceOfDiscountPercentage
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A"
      decimals="2"
      id="Narr_DfDtblZ9xk-H-dmxgruapg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.15</tlsi:EliminationOfOccurrenceOfDiscountPercentage>
    <tlsi:EliminationOfOccurrenceOfDiscountPercentage
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_HzB1wA_ogUKEmSx8HTJF5A"
      decimals="2"
      id="Narr_T0M44rwwp02amFKtLpDivg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.15</tlsi:EliminationOfOccurrenceOfDiscountPercentage>
    <tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_jIkLa_6ke0SuqPB-AO6YHg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5210000</tlsi:AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="As_Of_3_31_2021_peL04lSM_U-U4I3kzipk2A"
      decimals="-3"
      id="Narr_5H0BrmDqUk2-KjoYljakeA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">44692000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:InterestExpense
      contextRef="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg"
      decimals="-3"
      id="Narr_fp6tHzX5H0OUcmOSUg1swA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4426000</us-gaap:InterestExpense>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw"
      decimals="INF"
      id="Narr_KsvlqYy--EiWOn8_HmhiTQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4047069</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_P-xG5DhTZU2N7p7Ve0A9Fw"
      decimals="2"
      id="Narr_1dgD9UgSsUOUT0C3-2EgTQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <tlsi:GainLossOnConversionOfConvertibleNotes
      contextRef="Duration_3_1_2021_To_3_31_2021_egjLtGrNvU6KVbD1lTziTg"
      decimals="-3"
      id="Narr_6LTPlEjQR0G553HBryGErQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3416000</tlsi:GainLossOnConversionOfConvertibleNotes>
    <tlsi:ConvertiblePreferredStockDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_ePYxzYjjoUCHHIX78Ei6qQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(12)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, we have issued various series of preferred stock as more fully described below. Prior to March&#160;2021, the preferred stock was redeemable at any time after February&#160;21, 2022, upon the affirmative vote of two thirds of the then outstanding shares of preferred stock. In March&#160;2021, the redemption feature was eliminated, however, the in-substance redemption feature described below is still in place. Upon an acquisition of the Company, the proceeds will be used to first pay the liquidation preferences on the preferred stock, as defined below, prior to payment to common stockholders. We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our board of directors and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms of an acquisition&#x2009;&#x2014;&#x2009;and thereby redeem the convertible preferred stock&#x2009;&#x2014;&#x2009;is deemed to be outside of our control. As a result, our convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments are currently not redeemable and we believe it is not probable that the instruments will become redeemable at this point in time. Adjustments to increase the carrying values of the respective liquidation preferences will be made if and when it becomes probable that an event would occur obligating us to pay such amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity in convertible preferred stock for the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As of December&#160;31, 2022, the Company was authorized to issue up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;21,910,800&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of preferred stock, with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,213&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;A-5, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5,190&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;A-6, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;36,707&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,059,365&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;8,474,924&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 available for issuance. All other authorized shares have been issued. The original issue prices for the Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2 and B-3 preferred stock are &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$49.520&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$15.660&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$17.40&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$16.030&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$17.81&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20.23&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively. All shares of preferred stock had the following rights as of December&#160;31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Conversion&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Each share of preferred stock is convertible into common stock at any time at the option of the holder. The conversion rate is equal to the original issue price for each share of preferred stock plus any declared but unpaid dividends divided by the conversion price. The conversion ratio may be adjusted from time to time based upon the occurrence of certain events or circumstances, such as stock splits, dividends, recapitalizations, certain corporate transactions, and certain dilutive issuances, including the issuance of shares of Series&#160;B-2 preferred stock and the B-3 Warrants (as defined below). Each share of preferred stock will be automatically convertible into shares of the common stock at the then-prevailing conversion ratio (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended in which (a)&#160;the per share price of the common stock is not less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (adjusted for any stock dividends, combinations, splits, or recapitalizations) and (b)&#160;the aggregate net cash proceeds are at least &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$50,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, (ii)&#160;the consummation of a transaction or series of related transactions by merger, consolidation, share exchange or otherwise with a publicly traded &#x201c;special purpose acquisition corporation&#x201d; or its subsidiary in which the common stock or share capital of such entity or its successor entity remains listed, in which the aggregate proceeds resulting from such transaction or series of related transactions, including any private placement or other financing transaction and proceeds received from the &#x201c;special purpose acquisition corporation&#x201d; trust account are equal to or in excess of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;million or (iii)&#160;upon the consent or vote of the holders of a majority of the outstanding shares of preferred stock (voting together as a single class on an as converted basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Each holder of shares of preferred stock is entitled to the number of votes on an as-if converted basis to shares of common stock. Certain corporate actions require the approval of a majority of the holders of preferred stock, including but not limited to changes in the authorized shares of preferred stock, authorization of any new class or series of preferred stock, effecting a recapitalization, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;increasing the authorized size of the Board of Directors to a number greater than 11, the payment of certain dividends and capital distributions, the sale, liquidation or dissolution of the Company, and certain incurrence of debt.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Anti-dilution Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The conversion price of each series of preferred stock is subject to in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments, including adjustment if common stock is issued for less than the Original Issue Price of each series of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(iv)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Dividends are payable on (i)&#160;the Series&#160;B-2 and Series&#160;B-3 preferred stock in preference to all other series of preferred stock and the common stock and (ii)&#160;all such other series of preferred stock in preference to the common stock, in each case, when and if declared by the Board of Directors on a noncumulative, annual basis and are paid to the holders of Series&#160;B-2 preferred stock and Series&#160;B-3 preferred stock, and all other series of preferred stock, on a pro&#160;rata, pari&#160;passu basis (based on the series or preferred stock participating) preferred stock in proportion of their individual dividend amounts to the total dividend amount of all preferred holders. The per annum preferred dividend rates for each share of Series&#160;A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2, and B-3 preferred stock are &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3.97000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.26000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.4000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.29000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.4300&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.62&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.980&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.140&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$1.140&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.170&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively. To date, the Board of Directors has not declared any dividends on the preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;(v)&lt;/i&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Liquidation Preferences&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of the preferred stock provide for liquidation preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a Liquidation Event), none of which were deemed probable of occurring at December&#160;31, 2022. Preferences are payable in the following order of priority and in the following amounts as of December&#160;31, 2022 (plus all declared but unpaid dividends);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,659,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,984,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 730,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 612,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 576,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49.520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total liquidation preference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the assets of the Company or the consideration received in such Liquidation Event are insufficient to make payment in full to all holders of a particular series of preferred stock, then such assets will be distributed ratably to the holders of such series of preferred stock in proportion to the full amounts to which they would otherwise have been entitled. After payment of the aforementioned liquidation preferences, any remaining proceeds from a Liquidation Event will be distributed to all preferred and common stockholders&#x2009;&#x2014;&#x2009;except for stockholders holding Series&#160;A-1 or Series&#160;A-2 Preferred Stock&#x2009;&#x2014;&#x2009;pro&#160;rata on an as-if converted basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;March&#160;2021 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In March&#160;2021, we executed a financing round in which we raised &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,907&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; net of issuance costs, through the sale of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;906,346&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock at an original issue price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share. At that time, in accordance with their terms, as amended, all convertible notes, with a value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$49,118&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (including accumulated interest) were converted into &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4,047,069&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Spring 2021 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In May, June&#160;and July&#160;2021, we raised an additional &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20,989&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, net of issuance costs, through the sale of an additional &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,742,003&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock at a price per share of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fall 2021 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In August&#160;and December&#160;2021, we raised &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$20,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, net of issuance costs, through the sale of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,412,487&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;shares of Series&#160;B-1 preferred stock at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Exercises&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In November&#160;2020, we raised &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$19&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the exercise of warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;59,102&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;A-6 preferred stock. Between March&#160;and July&#160;2021, we raised an additional &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$117&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the exercise of warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;289,552&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2022 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In May&#160;and June&#160;2022, we sold &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;247,185&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-1 preferred stock in a private financing, to existing stockholders, at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, raising approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3,499&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in net proceeds. This financing was an extension of the Series&#160;B-1 financing round begun in the fall of 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In early October&#160;2022, we sold &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;706,243&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, raising approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9,755&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; in net proceeds. For each share sold, we also issued a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock (with total warrants issued being for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,824,974&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock) with a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;per share. The B-2 Preferred Stock Financing included, at our audit committee&#x2019;s option, a second tranche for the sale of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;518,854&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$7,347&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (which could be increased up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the sale of additional shares), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;four&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock at a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;per share, for a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,075,417&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;306,053&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,334&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; (which could be increased up to an aggregate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;353,121&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-2 preferred stock for approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$5,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through the sale of additional shares of Series&#160;B-2 preferred stock), with each such share of Series&#160;B-2 preferred stock accompanied by a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;eight&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock at a strike price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, for a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,448,428&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock. Investors can elect to not participate in the second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock to immediately convert to common stock and the warrants to purchase Series&#160;B-3 preferred stock to convert to warrants to purchase common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As a result of the issuance of the Series&#160;B-2 preferred stock, accompanying warrants to purchase Series&#160;B-3 preferred stock, and the second and third tranche rights and obligations, the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the Company&#x2019;s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion prices of the Company&#x2019;s preferred stock (i)&#160;were adjusted to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$42.89&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$13.36&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.97&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$13.76&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.97&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$17.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.52&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B preferred stock, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-1 preferred stock and (ii)&#160;set to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-3 preferred stock, which correlate to approximate (in each case rounded to three decimals) exchange ratios of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.155&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.173&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.162&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.165&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.189&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.190&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.154&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.167&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-3 preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;We offered the Series&#160;B-2 preferred stock to all of our existing preferred stockholders (representing approximately 99.2% of our then-outstanding shares on an as-converted to common stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note&#160;16), including expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members, executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other non-service provider holders. As such, the Company concluded &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the B-2 Preferred Stock Financing was not compensatory and is not within the scope of ASC Topic 718,&#160;&lt;i style="font-style:italic;"&gt;Compensation&#x2009;&#x2014;&#x2009;Stock Compensation&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The warrants to purchase Series&#160;B-3 preferred stock (&#x201c;Series&#160;B-3 Warrants&#x201d;) represent freestanding financial instruments that should be recognized as a liability as the Company is required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series&#160;B-2 preferred stock (&#x201c;Series&#160;B-2 Tranche Liability&#x201d;) represents a freestanding financial instrument that should be classified as a liability under ASC 480 as, (i)&#160;the decision to exercise the tranche is outside of the control of the Company, as holders of Series&#160;B-2 preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing determines whether to call the second tranche), and (ii)&#160;the Company is required to deliver puttable shares upon execution of the tranches rights and obligations, which may be ultimately settled in cash. Both the Series&#160;B-3 Warrants and the Series&#160;B-2 Tranche Liability are classified as liabilities and are presented on the balance sheet at their estimated fair values at each reporting date and immediately prior to settlement with the resulting change in fair value recognized in earnings.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The fair value of the Series&#160;B-3 Warrants as of December&#160;31, 2022, was determined using a probability-weighted expected outcome model whereby the following two scenarios were probability-weighted based on the Company&#x2019;s expectation of each occurring: (1)&#160;a status quo scenario whereby the Company would continue as a private company and (2)&#160;a scenario where the Business Combination would close. Under the status quo scenario, the Series&#160;B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes model. The fair value of the Series&#160;B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions: the fair value of underlying Series&#160;B-2 preferred stock of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.97&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, a price for Series&#160;B-2 preferred stock of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, the fair value of underlying Series&#160;B-3 preferred stock of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$3.24&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, an exercise price for the warrants to purchase Series&#160;B-3 preferred stock of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2.03&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, an expected volatility of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;50.0%-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;65.0%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, a risk free interest rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4.0%-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;4.7%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, an expected term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;0.2-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;0.4&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;years for the Series&#160;B-2 Tranche Liability and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;5.8-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;6.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;years for the Series&#160;B-3 Warrants and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;no&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; dividends. The fair value of the underlying shares of Series&#160;B-2 preferred stock and warrants to purchase Series&#160;B-3 preferred stock used in these models were derived from estimates of the Company&#x2019;s equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied by the Company&#x2019;s forecasted 2023 and 2024 revenue. The valuation of Series&#160;B-3 Warrants under the Business Combination scenario incorporates an estimate of the fair value of the underlying Series&#160;B-3 preferred stock upon the close of the Business Combination of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.93&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; per share, which is based upon the enterprise value stated in the merger agreement of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$220&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;million allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis, discounted at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; from the expected Business Combination closing date. The Business Combination scenario as of December&#160;31, 2022, assumed the second and third tranches will not be exercised, and thus &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;no&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; value is assigned to the tranche rights and obligations, as the Company would not exercise its right to call the second tranche.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the Series&#160;B-3 Warrant Liability and the Series&#160;B-2 Tranche Liability were estimated at $11,966 and $6,347, respectively, upon completion of the financing. The excess of the liabilities&#x2019; fair values compared to the proceeds received in the transaction resulted in a charge to loss on equity issuance in the consolidated statements of operations of $8,312. The warrant liability associated with the Series&#160;B-3 Warrants was remeasured to its fair value of $15,819 at December&#160;31, 2022, and the Series&#160;B-2 Tranche Liability were remeasured to their fair value of $4,702 at December&#160;31, 2022, resulting in an additional loss recorded as change in fair value of warrant and tranche liabilities of $2,208 in the consolidated statements of operations for the&#160;year ended December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2022, the warrants issued and issuable under the second and third tranches to purchase Series&#160;B-3 preferred stock were amended to provide that, in connection with the Business Combination, any portion of the warrants that remain unexercised at the time the Business Combination is consummated will automatically be net settled for shares of TriSalus Common Stock immediately prior to the closing of the Business Combination and exchanged into shares of Combined Company Common Stock at the Effective Time The warrant amendment did not change the liability classification of these warrants and the warrant liabilities will continue to be measured at fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In January&#160;through March&#160;2023, holders of warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,330,811&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares Series&#160;B-3 preferred stock exercised their purchase rights, for proceeds of approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$4,715&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2023, we amended the Series&#160;B-2 preferred stock agreement and warrant agreement to purchase Series&#160;B-3 preferred stock to extend the expiration date for the second tranche from February&#160;28, 2023, to May&#160;31, 2023.&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;In March&#160;2023, we effectuated &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; closings of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;207,541 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;830,167&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;40%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares committed in the second tranche, were sold for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,939&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and (ii)&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;17,656&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;shares of Series&#160;B-2 preferred stock and accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;70,624&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of Series&#160;B-3 preferred stock, representing approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the shares committed in the second tranche, were sold for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. As a result of the foregoing closings of a portion of the second tranche of the B-2 Preferred Stock Financing, in accordance with the anti-dilution rights in the Company&#x2019;s certificate of incorporation, the conversion prices of the Company&#x2019;s preferred stock (i)&#160;were adjusted to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$41.27&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$12.95&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$13.36&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$14.16&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$16.19&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$10.12&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B preferred stock, and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$11.74&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for Series&#160;B-1 preferred stock and (ii)&#160;remained the same for Series&#160;B-2 preferred stock &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_PxxmfclgUkWgfznbDZcazQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;($14.16)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and Series&#160;B-3 preferred stock &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_qYvtfI9-2EK0FA_smo_g4g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;($2.03)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, which correlate to approximate (in&#160;each case rounded to three decimals) exchange ratios of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.200&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.209&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;&#160;to&#160;1 for Series&#160;A-2 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.229&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-3 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.200&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-4 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.257&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-5 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;A-6 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.200&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1.207&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-1 preferred stock, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-2 preferred stock and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; to 1 for Series&#160;B-3 preferred stock.&lt;/span&gt;&lt;/p&gt;</tlsi:ConvertiblePreferredStockDisclosureTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_ZNSVlOFotU-PiDjRmPOAFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Convertible preferred stock, net of issuance costs, at December&#160;31, 2022 and 2021, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 131,797 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 576,126 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 612,822 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 127,787 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 preferred stock, $0.001 par value per share. Authorized 734,533 shares; issued and outstanding 730,320 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 preferred stock, $0.001 par value per share. Authorized 805,848 shares; issued and outstanding 800,657 shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B preferred stock, $0.001 par value per share. Authorized 7,021,678 shares; issued and outstanding 6,984,971 and 6,984,971 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1 preferred stock, $0.001 par value per share. Authorized 1,659,672 shares; issued and outstanding 1,659,672 and 1,412,487 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2 preferred stock, $0.001 par value per share. Authorized 1,765,609 shares; issued and outstanding 706,243 and 0 shares at December 31, 2022 and 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;3 preferred stock, $0.001 par value per share. Authorized 8,474,924 shares; issued and outstanding 0 at shares at December 31, 2022 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="INF"
      id="Narr_Ox5JoLyNRUex-6P4P9cCTA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Narr_QHjN0JdJckmHuA2DbFLEuQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="INF"
      id="Narr_HxeFLiP48kGKY7H5KEYWcg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">131797</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Narr_laz41fKv4UyF1aXbKwmmtQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">131797</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="-3"
      id="Tc_nI4mMcg87U-Mv_vA6qFPOQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="-3"
      id="Tc_H1EDHADeu0WV20kewvK9Sg_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="INF"
      id="Narr_1zycMJTvj0i3fwcsot--yQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Narr_PXqYwKW9tUqpKiyHf2ETbA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="INF"
      id="Narr_XbfwEg1qvUCMcuu6SsNAEA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">576126</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Narr_ZtFNrrCoN0aH34e5OpF_xw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">576126</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="-3"
      id="Tc_Kcy88n1-bEOoPvj0kqh5Bg_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="-3"
      id="Tc_ZzLYbA9SMUCAAoEBP9Fm5Q_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="INF"
      id="Narr_oV4PKcrOMkq4RnbAh0A_sQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Narr_kHIToVUDr0-ujAwZq0XBpg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="INF"
      id="Narr_05ZT2eJ0BkKDQqxiVmUk7g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">612822</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Narr_nYOBJ0X1dE2g9ZosLy8fLg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">612822</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="-3"
      id="Tc_8U3-2Vj5gkKLdqHngnscqg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="-3"
      id="Tc_bjtnVIJQrk2I7uNw6Uttkg_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="INF"
      id="Narr_c-aZjRABuEKY4kO9mZQu-w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Narr_f5DOSnRE_k2vWKnUucnkeg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="INF"
      id="Narr_bb6M-nkh50GtQjCOvKAWqA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">127787</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Narr_1lW0KcHUgUO1lkUU7arZ1A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">127787</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="-3"
      id="Tc_l1ATchiFBkyckne1elHT0A_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="-3"
      id="Tc_UdFKCeP_Vkmxl_Cnn0DuxQ_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="INF"
      id="Narr_iT-WIrLSK02zsjMMTZw35Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_AHxpXJ9ikUaH1klmVzlaQQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="INF"
      id="Narr_t9fTedoXu0-dcLHJ-vBEnw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">734533</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_1db3fwFQHkqe_fHIo_NDDw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">734533</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="INF"
      id="Narr_WMFfd8KVVE2gUvV-C97nUQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">730320</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_C4DIRbwa40CSAuk5vuys8g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">730320</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="-3"
      id="Tc_zGEUSsEHAkyFAfwSkqHRfQ_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="-3"
      id="Tc_dwynKVfbKEWEGMqm9vTojA_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="INF"
      id="Narr_WEf3711DaE6pzBbKZW3crw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_hDY9LeOdFUSqCWSjUP8q9w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="INF"
      id="Narr_gh7eM3GFQUW1IFhM08Okng"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">805848</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_AVR3iuQRck2QDwyeXOvDUg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">805848</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="INF"
      id="Narr_wjH5EbOl-UCPAv4nNR9Wfg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">800657</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_XPBWstTTnE-QZijcSEZc8Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">800657</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="-3"
      id="Tc_xGEgerm-CEuLy37cn_eWIQ_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="-3"
      id="Tc_Ae8oD3Izo0mVAgJdp4RE4w_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="INF"
      id="Narr_FvRCkzRJPUmwAAusJtLdQg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_q3t8qCo8Gk2zRHm-rdAxhA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="INF"
      id="Narr_i657U6JLIk6x33Kpn1SoeA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7021678</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_bTQHaAz75USoQiQv2j4shA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7021678</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_3Sux7uI2gkCN6KKTYvZZvg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6984971</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="INF"
      id="Narr_DVdjV39RPE6l53fcaCkx4w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6984971</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="-3"
      id="Tc_g-dbb-Y34UGqV1rZoiy1Pg_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="-3"
      id="Tc_DmrgXnvWvk-XpEBzda9Ttg_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="INF"
      id="Narr_s7hv50y0vUGcguzop5cS8g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Narr_LmS72rySrU-NaX2kPIg2rw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="INF"
      id="Narr_twQnf1KIzkS28EDEVLcidw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1659672</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Narr_NNho6G4hIkC-xav9z6MUtA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1659672</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Narr_2LchdvFvrUiTfp0RkP0ETg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1659672</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="INF"
      id="Narr_SXsj0oij5E-sIrlquQgAbA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1412487</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="-3"
      id="Tc_xLB886tS9UOsTBwhbvYQYw_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23499000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="-3"
      id="Tc_Ugj15VXfkEm9hecbAXjKow_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w"
      decimals="INF"
      id="Narr_UgEGEnUtK0Kq3bQafHiucQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr__5utx0Kxx0WbsnxwkB5Ihg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w"
      decimals="INF"
      id="Narr__pbUIQ4f706tC1dUbGMpEg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1765609</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr_44MzKmr_3k6AdmJ8Dk_i_g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1765609</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr_7qBInBUlmEGRwMLaJY_qQg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zgyCOb5HWkSMRy--FXWw1w"
      decimals="INF"
      id="Narr_58r3zl_Ou0ueNK6GWjHXzQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q"
      decimals="INF"
      id="Narr_kgV4oHA5EkeB_G9fctQr7A"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Narr_2tMiln59s0q9ufQU4uIMpg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q"
      decimals="INF"
      id="Narr_W0pP7nL-kUKoqmXG9OndpA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8474924</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Narr_u7I-ISpK8EideEDRBuZCHg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8474924</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_yQ66s7FKiEGPnhEoHhUE8Q"
      decimals="INF"
      id="Narr_R-tGGS1uC0yuUg_GBvanbg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Narr_Na_4x6j8CEWXiB29Gu-D9g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_h0bUSXb1UUWjxamhyvVFuQ_13_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_iJbV8WHBUUSiHtm7r90eaQ_13_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">160507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <tlsi:ScheduleOfActivityInConvertiblePreferredStockTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_xoURK7bCsE2Dol7d3diEaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity in convertible preferred stock for the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January&#160;1,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,611&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tlsi:ScheduleOfActivityInConvertiblePreferredStockTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_94WSWWTYZ0-oiPrmTAHAog"
      decimals="-3"
      id="Tc_JyVg4yUsY0qLATD2rfVyKQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="-3"
      id="Tc_6VpDzTSR20uMNh9CpJUjBg_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_WsB6XkUK_EudysZ944qZNA"
      decimals="-3"
      id="Tc_7BbbosxTt0C2pt5sKH0OpQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="-3"
      id="Tc_hgo_W7bSWkWj9tGhuyqUcw_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_kPXiLC6i0kmzr0XFHhfPLw"
      decimals="-3"
      id="Tc_lO4vkBygXkWsoCs-Xy0fIw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="-3"
      id="Tc_dUbhjqn1TEy2hTaRq9mktw_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_3a3-tw6PskK-JRJJsHXixQ"
      decimals="-3"
      id="Tc_JjZvuU2j7EC9A1elG5XT5g_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="-3"
      id="Tc_DL2y0SsQ8EWKG0hSUmZqJA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_H2sJkceQxk2-u0Rxe759jQ"
      decimals="-3"
      id="Tc_-ZBM0aCcUECMBQMzvYawlA_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="-3"
      id="Tc_P2oEzV6jlkSnrrS7L4Ytug_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_VQjBztCgREimLMoQNXlNZQ"
      decimals="-3"
      id="Tc_3QmiQE-UfkWVEL0rThn0Bg_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15472000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_hN-8AGcFuEuZnr2HwF1cJA"
      decimals="-3"
      id="Tc_JR2YlRlb90icpI9xQBK-oQ_8_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="-3"
      id="Tc_zfD85pbcVUequSUPk1Yxyg_8_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_YRX9eNe2yk2VIn3MFun3YA"
      decimals="-3"
      id="Tc_q4Q5G3ZJf0-AxSa7m-UdGQ_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="-3"
      id="Tc_LA-MIFsTK0iEpIrEuH5c4g_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_lounZVZfw0O8AKj7iHFE-w"
      decimals="-3"
      id="Tc_rXdHKI4PnUWI2s3nGd-avw_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="-3"
      id="Tc_2ntMInsZs02xXM_6VSSHsw_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"
      decimals="-3"
      id="Tc_dtFerdW6g0GCAK0beQ6IQw_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">55975000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Tc_Oh20LuCzo0qkuRWcDarJzQ_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">104532000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_eXGjAsoTaUqcHxiQ7U68GA_11_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">160507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_JywN7xiu8EmYdUxkdRtdOw"
      decimals="-3"
      id="Tc_cB7cgGM8oEOtGencKby59A_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="-3"
      id="Tc_MiO6_gnw4Ey-xSJquUkNZg_3_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6065000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_0j3_5GSgI0aLqKTXWaDOZw"
      decimals="-3"
      id="Tc_P1JISxESS0eQckNPQFMmnw_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="-3"
      id="Tc_V5Ni2ublpEawHX_k6YWgIQ_4_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">8976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_HloPFR5AKEuTO3qlFpp3VA"
      decimals="-3"
      id="Tc_d3N3Ynk1GUaFZ-2GWU-sKw_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="-3"
      id="Tc_HSQ6bdMPhEaSTsgRs9IKBw_5_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10611000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_nk2m38VXXEWrtLbj34vNUg"
      decimals="-3"
      id="Tc_aIegGWhz5kqMLX0rTKdi0Q_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="-3"
      id="Tc_rPhR-KICVkCyBXPQEgr6iA_6_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1993000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_XrpeXgnfbEeasY8BLXs87A"
      decimals="-3"
      id="Tc_jm0XoRVS20Cg-r7sr6SBQw_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="-3"
      id="Tc_fweaYOgo7EiDer_Jj0iMxQ_7_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">12858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_mq7c31mtW0uyV4HmpdIiFA"
      decimals="-3"
      id="Tc_LjcZWcxWuUSITTdL6RdCow_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="-3"
      id="Tc_hQUHyPeSPkqLbtVnsycgoA_8_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15476000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_g00bFFaTyE2z35Xpl-QTlQ"
      decimals="-3"
      id="Tc_lexe6yWxz0y9Ps4TablZzg_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="-3"
      id="Tc_qStYvPs2Y0mM6alK2DgOfw_9_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84528000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_UCVYEb_NqUOIBFWv12O2DQ"
      decimals="-3"
      id="Tc_Ny2Nm138AkKbXDHYSQMThQ_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg"
      decimals="-3"
      id="Tc_O5fxRCrtokW-R1I0H5B_ew_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="-3"
      id="Tc_J567YakE00GMEU11CJYl-w_10_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23499000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Tc_pcl9TQ0R0E2lvMPf10nUdQ_12_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">160507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_EstPg_8LyEeZ2fbdd2aytw_12_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_9gm77vUXAECmHRK0q8hUAA_12_9"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164006000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_E_wEMSOHfUS7ry7_Z6wm7Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">21910800</us-gaap:TemporaryEquitySharesAuthorized>
    <tlsi:TemporaryEquitySharesAvailableForIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Narr_UWN9f6zbFkavEpjO1QILCQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4213</tlsi:TemporaryEquitySharesAvailableForIssuance>
    <tlsi:TemporaryEquitySharesAvailableForIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Narr_8-9BnTx_9Ua-WXbECJ_6gw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5190</tlsi:TemporaryEquitySharesAvailableForIssuance>
    <tlsi:TemporaryEquitySharesAvailableForIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Narr_r4LtLr7XjESWN0GtQf427Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">36707</tlsi:TemporaryEquitySharesAvailableForIssuance>
    <tlsi:TemporaryEquitySharesAvailableForIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Narr_Fv61R1qekUSWi34BuVarhQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1059365</tlsi:TemporaryEquitySharesAvailableForIssuance>
    <tlsi:TemporaryEquitySharesAvailableForIssuance
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_eQgfhSl4EE2JUVD7Jb0Thg"
      decimals="INF"
      id="Narr_w8y2I6FnFUWJ4oVePY0OEA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8474924</tlsi:TemporaryEquitySharesAvailableForIssuance>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw"
      decimals="3"
      id="Narr_tFXpALqdIk2Ye-8djd2Gmg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">49.520</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw"
      decimals="3"
      id="Narr_ehfp0-mppEueIa7O95iroA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">15.660</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg"
      decimals="3"
      id="Narr_W1i96E_jTUmntIhdmYQ1gg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.40</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA"
      decimals="3"
      id="Narr_tuka63GdLEiGcYJgvhym1A"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">16.030</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ"
      decimals="3"
      id="Narr_LooWtVJmkkassoE-f1Qsxw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.81</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA"
      decimals="2"
      id="Narr_sPNMWs83gEOXW1Zb6VQiPg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.23</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ"
      decimals="2"
      id="Narr_aegR91XnSE-AiSDHAkdIuA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg"
      decimals="2"
      id="Narr_m_yd-toS1Eu-PGLex8XuyQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw"
      decimals="2"
      id="Narr_-NMSPMnpGE6Iw7mZAIjiLA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w"
      decimals="2"
      id="Narr_qNhRy1ro9EedbWIE5KWV1w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_tKVcdp-UpkW7S5ZsIwVHcw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock>
    <tlsi:AutomaticConversionOfPreferredStockThresholdCashProceeds
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_LDKd29WwEk6y_mM21pJWNA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">50000000</tlsi:AutomaticConversionOfPreferredStockThresholdCashProceeds>
    <tlsi:AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-6"
      id="Narr_3YSap1DlDE-SYyPipWt1AA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">30000000</tlsi:AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount>
    <tlsi:NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Narr_ZnhkevWFS0uKAVvcHm5qow"
      unitRef="Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg">11</tlsi:NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw"
      decimals="5"
      id="Narr_OlPwhX01ZkK2-hW06QNquw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">3.97000</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw"
      decimals="5"
      id="Narr_a4UR_xg4GUewI4-SQSC3bQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.26000</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg"
      decimals="4"
      id="Narr_L4nZRv6eFUmUDI5jPDMwuw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.4000</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA"
      decimals="5"
      id="Narr_qG294iOWJkmvu3z1dRzm0Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.29000</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ"
      decimals="4"
      id="Narr_-drGp0dE3UmtfMX1eNRikg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.4300</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA"
      decimals="2"
      id="Narr_AysA1nrY0Uyoznjx7CJDlQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.62</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ"
      decimals="3"
      id="Narr_M41Uw6yq7kyp2uDbb3kvGg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.980</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg"
      decimals="3"
      id="Narr_2ZHQMuOYUEmQnkNn1sModg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.140</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw"
      decimals="3"
      id="Narr_FNV6_qVGyEaARDKVSeEl8w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.140</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:TemporaryEquityDividendPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w"
      decimals="3"
      id="Narr_nKclx8ke-UeAb_rh0nDJWA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.170</tlsi:TemporaryEquityDividendPerShare>
    <tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_pGwR8htWyEOExKw5-VWnmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;1 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,659,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,984,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;6 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20.230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;5 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 730,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;4 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 612,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 576,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;1 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49.520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total liquidation preference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_KT4EuRJxv0-_-7IZfcHS1w"
      decimals="3"
      id="Tc_fQ83mkThOUeUI1ZorWi84g_4_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.030</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="INF"
      id="Tc_7JhT7jqeyEy0fYHp_LMH7g_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_bRI_haE7l06NBOuUYsrkiw"
      decimals="3"
      id="Tc_olJ1YeeNIkapoghVe1Wcew_5_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.160</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_lvtA-hGAl0GvUhlAjtGCEA"
      decimals="-3"
      id="Tc_Ch1GLGTQ7EaDmxe-nbGEpA_5_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="INF"
      id="Tc_JSV-Wxz9_UuayER31kasQA_6_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1659672</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg"
      decimals="3"
      id="Tc_OJWgbLHaGkS7i0cYwIio5w_6_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.160</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_BHJIEt4PjEqmmOgMs0uPVQ"
      decimals="-3"
      id="Tc_9Wbbyl7XmkyFd4pnRjI50w_6_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">23500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="INF"
      id="Tc_XDe3MA6oM0Suki8NfYdr8w_7_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6984971</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ"
      decimals="3"
      id="Tc_dPT6aLhgS06BRBgey24giw_7_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.140</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_7byU2kORFECCviSlAssdng"
      decimals="-3"
      id="Tc_ct6XmtEL1UG2TMxS6b2EMg_7_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">84774000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="INF"
      id="Tc_Mb0G5TfPkU-Mt8VcjOFBCQ_8_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">800657</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_A6-6LSUcfkquL6StDzEkGA"
      decimals="3"
      id="Tc__TmUL-LCyUWje5rQnBLxtw_8_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">20.230</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_bxGsA4mFBUGpXU1K7480PA"
      decimals="-3"
      id="Tc_XNnbtOh_SUiQC1a18UsR4A_8_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16196000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="INF"
      id="Tc_bBXzMmz9fUKDKxGJ54G_5A_9_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">730320</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_HanrtWlO5UeJpfysxYLOdQ"
      decimals="3"
      id="Tc_XKO_ZT_5g02waeeYxh8Qyw_9_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.810</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA"
      decimals="-3"
      id="Tc_PWH9tTfY4EmGMiRbgH8eNA_9_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">13000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="INF"
      id="Tc_csGS_a5nnESjUVkjLW5KEw_10_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">127787</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_osZIL2aNv0-pmA84D35otA"
      decimals="3"
      id="Tc_AfHNT4Rc_U-UZimBiuUyMw_10_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">16.030</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_ouyV6fJKREuX3kT0ikbwaQ"
      decimals="-3"
      id="Tc_dd33uLzveU6gk69G4qmhow_10_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2047000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="INF"
      id="Tc_LpZp819XqUO_BIK0UhRBBw_11_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">612822</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_TE2k1m1aCkKnrxT9i2lhyg"
      decimals="3"
      id="Tc_eAKOhn_ZJE6GCO20MvVSgA_11_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.400</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_9plwTZuRdkep_boGEeGSaQ"
      decimals="-3"
      id="Tc_pqsfsNlm0kOPzJYWQ8eWXg_11_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10661000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="INF"
      id="Tc_pBe2aPlKskS8r9kqvqRhJA_12_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">576126</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_hYvHcdewaUWI_56P5X1THw"
      decimals="3"
      id="Tc_buXzs0OghEa7bY4Boe24kg_12_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">15.660</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_Vb3SqLrd50SOEmQzSS3FGg"
      decimals="-3"
      id="Tc_CUppAeObIk-3TfSKNo7TmA_12_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9020000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="INF"
      id="Tc_ijQhycvWokWEz5JsNi1wYA_13_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">131797</us-gaap:TemporaryEquitySharesOutstanding>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw"
      decimals="3"
      id="Tc_sjpRyoiROka7-IPFbflrLg_13_7"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">49.520</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ"
      decimals="-3"
      id="Tc_kHy3EBDK_kGQxUi06b2ANQ_13_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6526000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_6jdzqzcCQEalxMDkbM07eA_14_10"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">175724000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"
      decimals="-3"
      id="Narr_BuCxN-gjN0mEWxPOZcs4KQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10907000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"
      decimals="INF"
      id="Narr_tGweR9uVt0-WoeeFukG68A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">906346</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"
      decimals="2"
      id="Narr_kDCsY4_Y5U-X9mHozCI_wQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"
      decimals="-3"
      id="Narr_AM5w_giScEyYAsNriKQ7xw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">49118000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog"
      decimals="INF"
      id="Narr_Njrd8wp-UkSPr5vy3bnFOA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4047069</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg"
      decimals="-3"
      id="Narr_UE15pSn6EE2Hhyd9QBr5IQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20989000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw"
      decimals="-3"
      id="Narr_FcuxMZ5_3UC4Nfa4j7lChw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20989000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g"
      decimals="-3"
      id="Narr_YIby7hQNuEedpz6WiwUwmA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20989000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg"
      decimals="INF"
      id="Narr_km6YliXPR0W2LfhwoWbgQg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1742003</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw"
      decimals="INF"
      id="Narr_QOwbPJqGekyc2cpCsYBF_Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1742003</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g"
      decimals="INF"
      id="Narr_GjWo4KfmikiTt_lyAor9cw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1742003</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_cAKtbCCo9kOUGISadpQHWg"
      decimals="2"
      id="Narr_gjRdH4wYNEGMHMPcpCFGZQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_796ibRSLz0mqE214iGU6Sw"
      decimals="2"
      id="Narr_tip5j-ZnWkmtFddJZKQnNg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g"
      decimals="2"
      id="Narr_hwHQ8rIfHE6ERDDrgM57-g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ"
      decimals="-3"
      id="Narr_F5yOMhzbPEO5EdkhDkkw1A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw"
      decimals="-3"
      id="Narr_sOfxX2etEU6X21moe4MLSw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ"
      decimals="INF"
      id="Narr_5a96lQlcMk-H4bwsSr1fDw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1412487</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw"
      decimals="INF"
      id="Narr_SypHUoFQjkW2qSkPXBwqaQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1412487</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_qC2KN4Veq0S3Ae4s36AvjQ"
      decimals="2"
      id="Narr_atFl6RSh5Uu5JW3Kl_uwxg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:TemporaryEquityOriginalIssuePrice>
    <tlsi:TemporaryEquityOriginalIssuePrice
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw"
      decimals="2"
      id="Narr_LxWzQKm-o0afB3-7MG-63Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:TemporaryEquityOriginalIssuePrice>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_e-IRiyeUokWhELXaV-4wUQ"
      decimals="-3"
      id="Narr_7_LkezWxyUS2y4lZbSAqBA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">19000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_30_2020_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_CMmCuzre6E-tcEDvHRTyuQ"
      decimals="INF"
      id="Narr_Hc9NtEDA-kG87WJYYSkL5A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">59102</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_0iOOdQCvqky-8LHpNIwfpA"
      decimals="-3"
      id="Narr_cfI1EnCtHUSJeSNi-fRh7Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">117000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_NkH9eTFLRkK7c-mjvyXwSQ"
      decimals="-3"
      id="Narr_cLvW8LFYxUOQHrKXM1oYFg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">117000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_5P40y196CUq_heFGRG6Rdw"
      decimals="INF"
      id="Narr_1PFv1ZKd-06QUMAqW2nZow"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">289552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_dqYj144kIECijtd5V_e50g"
      decimals="INF"
      id="Narr_73XJODcenkGctaUP7-lELA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">289552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A"
      decimals="INF"
      id="Narr_R72vr7foKUq_wQpjgYph4w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">247185</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA"
      decimals="INF"
      id="Narr_GdI8UA90Dkm3PPkzW2IHCA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">247185</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_aQAt3IxfvU6l-oEcuIHn0A"
      decimals="2"
      id="Narr_LdoQDBGxfEyCtOkVnUtUoQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_GRTEC4z9hku2SFFVuuuxUA"
      decimals="2"
      id="Narr_2aoh4biHFUicc_NMY2vSwA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_0oGet9etA0C788Cszxj_3A"
      decimals="-3"
      id="Narr_KdS9TXnNJUOqQrklIrUlNw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_Zj0m3Tt8L0KG7ARQMSrQEA"
      decimals="-3"
      id="Narr_h70nJ5n44UCx94-lNxNTrA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">3499000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA"
      decimals="INF"
      id="Narr_B67DGCb8NkqnfG74PgxBDA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ"
      decimals="2"
      id="Narr_Ec4h4Ih9e0SsOEo33kjoRQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wCjNznA1G0a58tvKH8LtwA"
      decimals="-3"
      id="Narr_x0BwgMDDrkap5Gl0l0ofiQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9755000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"
      decimals="INF"
      id="Narr_0ubM5IiwMkGLoWayP7oi8A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"
      decimals="INF"
      id="Narr_wyBiU6Mq20mrjFCU3RYwBA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2824974</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"
      decimals="2"
      id="Narr_T2VN133i10qd0pM9570SUA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tlsi:MaximumNumberOfSharesAgreedToSell
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ"
      decimals="INF"
      id="Narr_elvEMXvMNUaecw2g1evO1w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">518854</tlsi:MaximumNumberOfSharesAgreedToSell>
    <tlsi:AggregateProceedsReceivableFromStockOffering
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ"
      decimals="-3"
      id="Narr_U-Ju93beLkqd6KMTxC6Izg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7347000</tlsi:AggregateProceedsReceivableFromStockOffering>
    <tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_hBfRgHUJgkacpUA8tacaCQ"
      decimals="-3"
      id="Narr_TeOrqn38WUWBD5BBrGsX3A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">10000000</tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q"
      decimals="INF"
      id="Narr_yBF0_-DQK061Wq26UjULhw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q"
      decimals="2"
      id="Narr_2hPoehUnhECWIMazi_m-Jg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_eClFOtQFS0qYr_Hp188v9Q"
      decimals="INF"
      id="Narr__swjVpf8Skq_qJFFlHrs0A"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2075417</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:MaximumNumberOfSharesAgreedToSell
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="INF"
      id="Narr_vSgwrTRNJUWYMfv_drVJfw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">306053</tlsi:MaximumNumberOfSharesAgreedToSell>
    <tlsi:AggregateProceedsReceivableFromStockOffering
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="-3"
      id="Narr_a0onC-e5tEuPDm6CgRqr1A"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4334000</tlsi:AggregateProceedsReceivableFromStockOffering>
    <tlsi:MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="INF"
      id="Narr_V3YgfJL-k0aAlQZejm4_RQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">353121</tlsi:MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares>
    <tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="-3"
      id="Narr_eIZm4YWlCEe7ioENcr5kew"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">5000000</tlsi:MaximumProceedsReceivableThroughSaleOfAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="INF"
      id="Narr_q0d6Q1qdQ0OurNYMYvFoTQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="2"
      id="Narr_tbv-t2oZq024ZTTBeMrYwA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingThirdTrancheMember_GFo-WkZWHk6sEYVGm6qebw"
      decimals="INF"
      id="Narr_RqX5qcsK10-1lzN8HDNK9g"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2448428</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ"
      decimals="2"
      id="Narr_I2WBsnKGNUycRpRz633v4g"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">42.89</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg"
      decimals="2"
      id="Narr_9SacmvxzgEShJO_paIjkEg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">13.36</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg"
      decimals="2"
      id="Narr_OiIqPqVFwUK9OL1CWHh-FA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.97</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ"
      decimals="2"
      id="Narr_PE8wxqdL_ESJgVPPrDqayA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">13.76</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg"
      decimals="2"
      id="Narr_HoJozP47uEOr_42ODp8qiA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.97</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A"
      decimals="2"
      id="Narr_jAbKNCRj4U-VPrXs3Io1FA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">17.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ"
      decimals="2"
      id="Narr_CEWcRIb6kkyworm1AHccUQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.52</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg"
      decimals="2"
      id="Narr_VFOQTupZKU68tO57lu7OWg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.14</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ"
      decimals="2"
      id="Narr_DOdaY9dBIUaRZ7mNjRUSZg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"
      decimals="2"
      id="Narr_PZ5hNrI8LkihKECnNujkow"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_KPadxGpcAUOCztsjDYmWaQ"
      decimals="3"
      id="Narr_9Kul8QgFskWzsNdXJHZuXQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.155</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_z3awZgBKkk--vMnQOHdBhg"
      decimals="3"
      id="Narr_KxcpXZXiN0KWXSzvVN-_cg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.173</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_yyLJsSwab0KjR-ohVbLzRg"
      decimals="3"
      id="Narr_kvPrYmqGlEmO9N434fp3Jw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.162</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_BeXuKIbs4Ua-62xKus4PBQ"
      decimals="3"
      id="Narr_Y3SRrcwupUmSsP15EDMe5Q"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.165</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_wtvzPYwKzkeK9wvFxS98Qg"
      decimals="3"
      id="Narr_1mfipDfGqESgYu9cUxd1_g"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.189</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_HoK8bPxfQUSRRlRkjhm-5A"
      decimals="3"
      id="Narr_weZ9dsiG4EiB1yNYtLnaog"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.190</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_4Arh9seAbkq4tRTUidSMiQ"
      decimals="3"
      id="Narr_1OEZBcKjskOUjHyh3wn8mw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.154</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_2VayZlkkeUS634vzN5Npxg"
      decimals="3"
      id="Narr_GWg247DnUUmUgtqFNauGLw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.167</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_WPytJLVlr0yGoIbBA8UQBQ"
      decimals="0"
      id="Narr_tyxJOMen3EG0sKPrjI679Q"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_6mLDrru3MkqpvhYtDxfNyg"
      decimals="0"
      id="Narr_C84EueHcgkqlrwtbA5abVw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered
      contextRef="As_Of_10_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_zMZEH7jnyk6gyXt3ES_t9g"
      decimals="3"
      id="Narr_WPpwT8daTUCp3lt_bdyAog"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.992</tlsi:PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_nysdtTEnvUyJymOGjXTL2A"
      decimals="2"
      id="Narr_557kd3i81Eu9Jn55ZsPL2w"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.97</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_jzrdTKUMPkaJYvHWOVu7LQ"
      decimals="2"
      id="Narr_pBFaPM9AzkGK9LK7LHYqwA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_tlsi_MeasurementInputFairValueOfUnderlyingStockMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_21ZnY62BB0aviR0_y6NS1w"
      decimals="2"
      id="Narr_I8A7MxTLB0u2fGCieO89NQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">3.24</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_RBw78ON9SUGlT5g_SudELQ"
      decimals="2"
      id="Narr_uuYvcSKDXU67kBMCdmQ4AQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ebJaNhnAhkKomsCxm4SEeQ"
      decimals="1"
      id="Narr_e6EQiHUcdUGq6axFPee-Ag"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">50.0</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_06c-BVDZVUSTkxyfqRQpPg"
      decimals="1"
      id="Narr_DGgSBpbf4kuAakpgLeZM5A"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">65.0</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kVYk9im19EGexCFAmViCqA"
      decimals="1"
      id="Narr_-1ylWzVcA0qD74ZtEtZI6A"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4.0</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pILTs-HrB0uQSMTr-D17nA"
      decimals="1"
      id="Narr_2gMJLBBvYUm8JX9ZQ2cwsQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4.7</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lGYh6vgZNkWoq1VwMwVVnA"
      decimals="1"
      id="Narr_ewqf2EfjwE-BZ8bFSDl65A"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">0.2</tlsi:TrancheLiabilityMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_siP3YoYtZU2LiMLvWdN7xQ"
      decimals="1"
      id="Narr_zDO9mIncFkO_VK44KiC0rQ"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">0.4</tlsi:TrancheLiabilityMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_G8V4djaCEkCway9XsOM4DA"
      decimals="1"
      id="Narr_06w2Iw7zSUO_rGoU9LbXtg"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">5.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Xpnlw4k0NkuO1sNJfiAs9Q"
      decimals="1"
      id="Narr_1Cwe5USv6EyUNda7xN-Ong"
      unitRef="Unit_Standard_Y_IGkC1Z1m5ECiCXgdJzy7fg">6.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <tlsi:TrancheLiabilityMeasurementInput
      contextRef="As_Of_10_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendPaymentMember_Tw6UZ9TXRk2sGpM7oFAZCg"
      decimals="-3"
      id="Narr_MnVUUplrYk20S8RmQ7SSzw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:TrancheLiabilityMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_MB7pT5iLf0uF_V9jm7PXzQ"
      decimals="2"
      id="Narr_VKtj3KnbM0eHSi3zRaADtw"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.93</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <tlsi:EnterpriseValueAllocated
      contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_xbdsgc83CU-hmC04QM8BBA"
      decimals="-3"
      id="Narr_nhq-Pt440E6cexoi2gSvdA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">220000</tlsi:EnterpriseValueAllocated>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputInceptionDiscountRateMember_mzUQ236JO0anFu5jzI22tQ"
      decimals="0"
      id="Narr_KVwBXUzirUK_SlphO5dcvA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">30</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <tlsi:ValueAssignedToTrancheRightsAndObligations
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_tlsi_BusinessCombinationScenarioMember_ycMhMOSauU-qDs_XF5sQ8Q"
      decimals="-3"
      id="Narr_HZUIVGzZ3k2RA97V7pIBQA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">0</tlsi:ValueAssignedToTrancheRightsAndObligations>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_sM0d9jF6TUGovhsMazgl2g"
      decimals="-3"
      id="Narr_TMgwoaCwVkuAPz22E8hFLg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">11966000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_4mN-bA9Uz0yu-SCx5mjf4Q"
      decimals="-3"
      id="Narr_b51wdy4CW0mOYsQ4XOt3zA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6347000</us-gaap:LiabilitiesFairValueDisclosure>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_rleun0P7K0W_aU5W3zJCXA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">-8312000</tlsi:GainLossOnEquityIssuance>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_BJflibPFp0y8c90t8quEMA"
      decimals="-3"
      id="Narr_Hy1ocaBv0E2U_q6sNF9CYg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">15819000</us-gaap:LiabilitiesFairValueDisclosure>
    <tlsi:GainLossOnEquityIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw"
      decimals="-3"
      id="Narr_j6KYjEmmbk2MIdiY1qW2Ag"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4702000</tlsi:GainLossOnEquityIssuance>
    <tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2022Member_5oAERHt59UChzEC3ux8WVw"
      decimals="-3"
      id="Narr_aTL2PE9n_0aJs7Z0A-fgvQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2208000</tlsi:FairValueAdjustmentOfTrancheAndWarrantsLiabilities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg"
      decimals="INF"
      id="Narr_6DPEmwJddE6K2-IbaVKDiQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2330811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_GWy7uUXZB0aOm-obxy2m_g"
      decimals="-3"
      id="Narr_qMgCdBEA9kqvRxBjaG6wJQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4715000</us-gaap:ProceedsFromWarrantExercises>
    <tlsi:NumberOfStockOfferingClosingsEffectuated
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_tKNgd2GCgESsCQV33cAzXg"
      decimals="INF"
      id="Narr_6pA_fTZCVU6Ors4NGviYEA"
      unitRef="Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg">2</tlsi:NumberOfStockOfferingClosingsEffectuated>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_0r7I6QWZA0GsYAkditjprg"
      decimals="INF"
      id="Narr_rhbNbUFDBUSH8HedIJUP5w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">207541</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_lE_mD9hOd0STU9O_pFbkxQ"
      decimals="INF"
      id="Narr_Bi2OuP3fXk2Av2bv81QKgg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">830167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:PercentageOfSharesCommittedSold
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw"
      decimals="2"
      id="Narr_zG7MpThyZUmGQ_DG-IwZhw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.40</tlsi:PercentageOfSharesCommittedSold>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember_OFz719Q4w0aJE7FJuMnZbw"
      decimals="-3"
      id="Narr_ZQ7FYV30Uk-fDLpM8NPS3Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2939000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_G42a6weQT06upXOSAO8LBA"
      decimals="INF"
      id="Narr_veJ7Xvssy0GIGF3YxoLIbw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">17656</tlsi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember__XDMheCIA0mYIUNydTkduw"
      decimals="INF"
      id="Narr_OLEIyf55aEGWCi6z_noudQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">70624</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tlsi:PercentageOfSharesCommittedSold
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA"
      decimals="2"
      id="Narr_5tALD9ClN0-_jozKYAHCzg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.03</tlsi:PercentageOfSharesCommittedSold>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember_Ve4iz2r3YkmCf0NWnnpFNA"
      decimals="-3"
      id="Narr_-Se46GqhqkOY9d-d6pMyOA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">250000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ"
      decimals="2"
      id="Narr_3I7fEXkOMUaYpBtHqqw1Sg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">41.27</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw"
      decimals="2"
      id="Narr_JdtE9CnEI0K1mEQwUOMBSQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">12.95</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ"
      decimals="2"
      id="Narr_-eqqZJ3kmE2ex3G4pOWhLA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA"
      decimals="2"
      id="Narr_iLAIuLafVEW9wAk_W4IB7Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">13.36</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw"
      decimals="2"
      id="Narr_mpcpOXqzykmn4aTzXUQXTg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">14.16</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA"
      decimals="2"
      id="Narr_absOkn-FFUedCv9L9eskIQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">16.19</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g"
      decimals="2"
      id="Narr_yUm2xx8SL06Z0iPU1Cjbdg"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">10.12</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw"
      decimals="2"
      id="Narr_4kAKVfKgAkquzma-WqzseQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">11.74</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_b3S20qPVhEmizoOi2TUiLQ"
      decimals="3"
      id="Narr_J2eDD6cHC0KcdHLOm4CtdA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.200</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_2dUE9CJmekq0riH_BDNyNw"
      decimals="3"
      id="Narr_0CajVw1NTUaJ8K3iX8ktmg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.209</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_mcAKfImwYUq1Ua5VCAedKQ"
      decimals="3"
      id="Narr_EjfNIVZ6N0eUJ2OjN4xCMg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.229</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_Hj-g6VMMGU6_zW_db2kjeA"
      decimals="3"
      id="Narr_BQSzJCKlqEaw8OmoO8CISA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.200</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_JK2QfaFi-0y93MvZb_9Xdw"
      decimals="3"
      id="Narr_odZquKIoJ0G7nyoos6ewkw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.257</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_xs-QgR4CUU-dDWJUN936IA"
      decimals="3"
      id="Narr_md_gW0uubUCmZzhHRh-Gsg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.250</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_-hDlIPKguky1I2DKuwHH5g"
      decimals="3"
      id="Narr_d36wnqJRVUiVMVwzrWAcew"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.200</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_9H8R5Lsxr0G58NCM1AXiDw"
      decimals="3"
      id="Narr_6V9F81utgUax0nUZrJaIYg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1.207</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member__OnlFTnxB0yanTxHXiDlLA"
      decimals="0"
      id="Narr_cQeUEz04N0GozcXgbwDQqg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB3ConvertiblePreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Financing2023Member_1VQOkPJvSUiCSAIUG0Ydgg"
      decimals="0"
      id="Narr_bLUccbwHI0-dlZRZX8E9-g"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_LpU2IVF0T0SQneIgmvP8rg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(13)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As of December&#160;31, 2022 and 2021, the Company&#x2019;s authorized shares of common stock were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;30,898,162&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;15,696,266&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively. As of December&#160;31, 2022, the Company had reserved the following shares of common stock for future issuance in connection with the conversion of shares of Preferred Stock, at the applicable conversion rates (see Note&#160;12) and upon the exercise of certain options and warrants:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 152,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 953,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,059,581&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,936,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,212,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series A&#x2011;5 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series A&#x2011;6 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series B preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series B&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,878,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock options available for future grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 432,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,103,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,194,621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Under the 2009 Equity Incentive Plan&#160;As Amended (the &#x201c;Plan&#x201d;), the Company&#x2019;s board of directors may grant incentive stock options and/or nonstatutory stock options to employees, directors, and consultants of the Company and its affiliates within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended. As of December&#160;31, 2022 and 2021, there were in total &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,671,075&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,307,079&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively, stock options &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_RXte8gIJ0UWW5BmmCYcnHg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;outstanding&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. The Plan was originally set to expire on July&#160;28, 2019, the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;ten-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; anniversary of its establishment, however, the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;ten-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; life automatically renews each time the plan is amended to increase the authorized shares. The most recent amendment was on September&#160;15, 2022, so the revised expiration date of the Plan is September&#160;15, 2032.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;Incentive stock options may be granted only to employees. Nonstatutory stock options may be granted to employees and nonemployees. On March&#160;2, 2021, in conjunction with the Series&#160;B financing, our board of directors authorized an increase in the number of shares under the Plan to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,235,926&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. On September&#160;23, 2021, our board of directors authorized an increase in the number of shares under the Plan to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,606,704&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, and, on December&#160;20, 2021, to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;1,804,452&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. On July&#160;13, 2022, our board of directors authorized an increase in the number of shares under the Plan to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,101,075&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and, on September&#160;15, 2022, to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;2,348,260&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;. At December&#160;31, 2022, options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;432,413&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; shares of common stock were available for grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The plan is administered by our chief executive officer and chief financial officer, who act on the recommendation of managers of the Company to select the individuals to whom the awards will be granted and to determine the amount and vesting period for the grants. All grants are subject to approval by the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options are granted with an exercise price equal to the estimated fair value of the stock at the date of grant. The fair value is determined by a third-party valuation performed in accordance with IRS Section&#160;409A. Options generally have a ten-year contractual term and typically have graded vesting over &lt;span style="-sec-ix-hidden:Hidden_huQWM8PukUiNaHCwSJKzHA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&#160;to &lt;span style="-sec-ix-hidden:Hidden_RgKa1fvyFki-3G_4NLjGcA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&#160;years&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables summarize activity for options issued to employees, consultants, and directors:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 735,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeiture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (57,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,307,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,879)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeiture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (103,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;We granted &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;177,973&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;55,305&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; options to members of the Board of Directors and other non-employees during the&#160;years ended &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_0XVq7K5E4EaVAxzq8BPz2g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_PCQ3iCsu6kiybYaKiTQPcQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes certain information about all options outstanding as of December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$0.41 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.22 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,134&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.62 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.03 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.43 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.84 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.65&#x2009;&#x2013;&#x2009;$18.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The grant date per share fair value of options was determined using the Black-Scholes-Merton option valuation model, and was computed to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.81&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$0.41&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for grants in the&#160;years ended December&#160;31, 2022 and 2021, respectively, using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation assumptions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.6&#x2009;&#x2013;&#x2009;6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.0&#x2009;&#x2013;&#x2009;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;(1)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Our historical exercise behavior for previous grants does not provide a reasonable estimate for future exercise activity for employees who have been awarded stock options in the past three&#160;years. Therefore, the average expected term was calculated using the simplified method, as defined by GAAP, for estimating the expected term.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Recognized compensation expense for employees and nonemployees in 2022 and 2021 was $368 and $109, respectively, which was predominately included in general and administrative expense in the accompanying consolidated statements of operations. As of December&#160;31, 2022 and 2021, there was $433 and $24, respectively, of unrecognized compensation expense related to unvested share-based compensation arrangements granted under the equity incentive plan. The December&#160;31, 2022, balance will be recognized over a weighted average period of 2.9&#160;years.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Narr_9cGMVpoO2EmqBKevMyving"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">30898162</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Narr_JSC99mSR7U2mMxaDyFpcww"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">15696266</us-gaap:CommonStockSharesAuthorized>
    <tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_LsTr9mmKLU6sdWGDvWNhpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 152,188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 675,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series A&#x2011;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 953,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,059,581&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&#x2011;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,936,284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,212,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series A&#x2011;5 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series A&#x2011;6 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series B preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants to purchase Series B&#x2011;3 preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,824,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,878,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock options available for future grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 432,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,103,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,194,621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_AbCmIlVGwU2jFoD1_oyB1Q"
      decimals="INF"
      id="Tc_YKulUGzDfkimvryg-DKjfQ_2_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">152188</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA2ConvertiblePreferredStockMember_D2982Aa3FUev4xmNbgrmLQ"
      decimals="INF"
      id="Tc_Ak25t-HwykSI2kXSRkUpTA_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">675638</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA3ConvertiblePreferredStockMember_CMG6zRmmJk-DrVcCs784UQ"
      decimals="INF"
      id="Tc_v_gavXeaWEO9rWcR5Bl5Hw_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">712198</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA4ConvertiblePreferredStockMember_78cDcL2q8UmHmCn5D2OBjw"
      decimals="INF"
      id="Tc_rwd6JgMKx0GYTb0ezmF64A_5_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">148834</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JfpRQYxY-UKeBky1qs6kyw"
      decimals="INF"
      id="Tc_9KKMsWH5BEGqDSTS1OmveQ_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">868487</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_L9okU4WLpk-102h2M_xYYg"
      decimals="INF"
      id="Tc_AUR7gkqkSECQlHKbje-iUg_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">953163</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesBConvertiblePreferredStockMember_YcYnzFlBjEak37oDh3RW8A"
      decimals="INF"
      id="Tc__FDKqT1RR0u3tgQH9HI-fQ_8_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">8059581</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_R3C848oe2UKgjk229Eov0Q"
      decimals="INF"
      id="Tc_xvnQlvDoa0Wy4c2rGmO7bQ_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1936284</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_SeriesB2ConvertiblePreferredStockMember_ubWSfyc1rESSfcBRziTGkQ"
      decimals="INF"
      id="Tc_s54AHTb7gkuuRbRKWXEDCQ_10_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">706243</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_ConvertiblePreferredStockMember__NAecSCB_kCj1haUJLi3OQ"
      decimals="INF"
      id="Tc_IrfQcmDNCkiuV2sDF7m8RQ_11_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">14212616</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesFivePreferredStockMember_kmZ2EGx-bE20yy95aA1umQ"
      decimals="INF"
      id="Tc_iRvx5UANlUSXyxQM7YRY8w_13_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5010</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantToPurchaseSeriesSixPreferredStockMember_IUEdiusOq0Ggfdrn4ZnVkg"
      decimals="INF"
      id="Tc_WFLXO4H3_UydDHO8XbID7w_14_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">6179</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesBPreferredStockMember_FH-Sf7Hf3EiGk-qmzaSrtg"
      decimals="INF"
      id="Tc_9VHrpzFB9U6SKmhEnrJQlg_15_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">42354</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember_ZQxUbocD4UC-2DmmXP5A4Q"
      decimals="INF"
      id="Tc_eQNVYFP-bESTeVBXarF78A_16_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2824974</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_WarrantMember_IqC1qJJSQUWIbrrHEeO5HA"
      decimals="INF"
      id="Tc_zvrhqZznRkarOjGnpXJ6Dg_17_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2878517</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsOutstandingMember_Qeaap63POUSl7kq016l15Q"
      decimals="INF"
      id="Tc_a9-B4co5pkOniS-oyMmjww_19_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1671075</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_tlsi_StockOptionsAvailableForFutureGrantMember_x-OjXsG_GU2kREkY5w2Tfg"
      decimals="INF"
      id="Tc_ugXIO63-bEGI_9XhVLdnpw_20_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">432413</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_tlsi_CapitalShareReservedForFutureIssuanceAxis_us-gaap_EmployeeStockOptionMember_3KKxG7YSZUSyqE0uG1rr9A"
      decimals="INF"
      id="Tc_Mn8fJ1eDvkuiSV4IlRFOWA_21_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2103488</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Tc_LlvRQyFtlECXEO6aiJfUnw_22_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">19194621</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw"
      decimals="INF"
      id="Narr__5flGIwaIk6bV8prWpaltg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1671075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g"
      decimals="INF"
      id="Narr_3Zxu1rKTgkKQFy0dgO-Bgw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1307079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw"
      id="Narr_lxQdn-wrREW7rwNPp0qXtA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw"
      id="Narr_2xPeI0mtG0yQbE5YkyQbiw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_3_2_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_hYo6l3T-EkW_DjtHSivOsQ"
      decimals="INF"
      id="Narr_2Mx3ezXjVkSuvmZMJ6yC3Q"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1235926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_23_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_SEb9zumk50CCxQ_gl3sqTg"
      decimals="INF"
      id="Narr_Usk9AaZXpUW8A3e7vhx06w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1606704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_20_2021_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_C40yv7V3Uk-CTwQZSf-3fA"
      decimals="INF"
      id="Narr_KGC7LrIbCE6bX-PMrWYtFQ"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1804452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_7_13_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_mmQ5QRZtFUmMijBSylDvfg"
      decimals="INF"
      id="Narr_jIRyiv-rQEGP_psgI47P0w"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2101075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_15_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_FJuc69Mu_0KlSo6eQPUexg"
      decimals="INF"
      id="Narr_AoTfwKBykU2prnJXhBh_Dg"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2348260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_qwl9PUILX0684LIABqmm6g"
      decimals="INF"
      id="Narr_yGi5H7oYkEq8mpiLkYKMzA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">432413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tlsi_EquityIncentivePlan2019AsAmendedMember_L1TfK-mExEeVbXbajllmfw"
      id="Narr_fWVyf3Y7nUKdDom5xeUcrw">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_TMboqGMP_UahJ4YwCHgZRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 735,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeiture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (57,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,307,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,879)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeiture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (103,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"
      decimals="INF"
      id="Tc_oFp0NhdbokinvRBvAswLaQ_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">735803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_WLhlPe3JIkmhKH3V1ot8Tw"
      decimals="2"
      id="Tc_gA1_xwRxMUa1Q-ibXqjObA_6_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_8dYoWiOxfUKpjgth_myDRg"
      id="Tc_EkuHWeii3ECgCDZp8f1zsw_6_7">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="INF"
      id="Tc_0ZMKpUoaqkqiQ4RUeChpjw_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">700170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_w-jzcnX7hUulWfEwVNRx6g_7_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="INF"
      id="Tc_3c9A4TgZrUWFiDXLkG5m1A_8_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">71647</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_z9jKMj_UEE2iQx0-taI45w_8_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="INF"
      id="Tc_H7-ThvZJEk-g8LH0K3CdIQ_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">57246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_bs3Wn5PEhEqxK4FwMZ712g_9_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="INF"
      id="Tc_4AdnUrkFN02m_XQUqasUrw_10_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1307080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="2"
      id="Tc_i1zrO0rsRUSQ3rGPE5sLgw_10_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      id="Tc_Qj1f3odsb02t4xsBg0AoWQ_10_7">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Tc_90sIih9rwEiBxz3ZeQybkQ_11_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">550049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_y9m79c1MBkWROxaIY18UHg_11_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Tc_w3XaiYCGRUy7JWsxKgvq-A_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">82879</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_BdELQdFsIkWq0hou5hi5fA_12_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Tc_gvXpRB40VkepYjxks1wWlQ_13_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">103174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_fymqy15ES0qE8DU1DAdsBA_13_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Tc_7x16Y_23MUesCxKIU2ZIPQ_14_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1671076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="2"
      id="Tc_dKhXkqYDhk-6AyW-XPzYDQ_14_5"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tc_iMW4WVxfQk-4zMbpsrBw3w_14_7">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OCE06-VX20WwiST2nFqLhA"
      decimals="INF"
      id="Narr_3v-ErKGunUiIYjRTtnhufw"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">177973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_xHLJVJ8VWkiIevSmCiWZ6w"
      decimals="INF"
      id="Narr_16rapgIlDk6NLvbTMnNRzA"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">55305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_dVMMOLxJlE6_qcp43YwrCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$0.41 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.22 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,134&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.62 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.03 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,415&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.43 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.84 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.65&#x2009;&#x2013;&#x2009;$18.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw"
      decimals="2"
      id="Tc_eUuLZ5RwbUavib4hVV5BDg_7_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_8HDiw0FvJEirwR38ZxQjBw"
      decimals="INF"
      id="Tc_2AWYzrr-FEuZwMZxoi-mmw_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">540863</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A"
      id="Tc_MV9Q-_fVqEOu7Gqmcpl5ig_7_4">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.001Member_Lfl2mAwxnUOWaXSqqL3W1A"
      decimals="INF"
      id="Tc_EE8rPxmw4EGXl687P3ZI5w_7_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">380641</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g"
      decimals="2"
      id="Tc_IGWMbaoN7kWD-UKNTcSZQA_8_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member__5XEgw4KDkKXFSazBuTp-g"
      decimals="INF"
      id="Tc_dy_GvLBug0GJtOEEPCJ6gQ_8_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">211405</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg"
      id="Tc_yHkvRopeLUOjcb9LYhJXhg_8_4">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.003Member_DiLFk1RnIEGAUTjjo9W5eg"
      decimals="INF"
      id="Tc_9Wsok7d4_k2ArERgpyU_MQ_8_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">211134</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg"
      decimals="2"
      id="Tc_1M3WS6ivPUasTxavRIlblQ_9_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">1.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_0FBMEWG8hEKLnrgfaiU0xg"
      decimals="INF"
      id="Tc_gsJ76bMspU2KNLapWiuSJQ_9_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q"
      id="Tc_kb2zOADeM0aAmSHTbQk74A_9_4">P1Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.004Member_SfzTjEwaQE-6siHhad3Z1Q"
      decimals="INF"
      id="Tc_u-Cp_rSRN0K6pYMba8fEDA_9_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">4100</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q"
      decimals="2"
      id="Tc_fnuTZc8dZEi2PsLNqPamHA_10_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.03</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_zgti8GJwoUixt-tfZ1tq_Q"
      decimals="INF"
      id="Tc_jEw1XivkbkWjO6whC_DP0g_10_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7415</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ"
      id="Tc_DHAnTGmOxUmJUTsXYTuNuA_10_4">P4Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.005Member_LeOCg8_ttUa3tkjuR8kGaQ"
      decimals="INF"
      id="Tc_gU2jotQRUUyxuNLHCI9n5A_10_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">7415</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg"
      decimals="2"
      id="Tc_0kanz8U5FEy6xKdzhQNCLA_11_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_BzgXVYAp0U2XLFtU3CNSwg"
      decimals="INF"
      id="Tc_ZTTEsOrtPESh7ow8yBNuAA_11_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">900291</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ"
      id="Tc_OakFH2R3XUavfvuTKI4Gbw_11_4">P9Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.006Member_eNr_9XT4qUCqP58qhwNKkQ"
      decimals="INF"
      id="Tc_Fw4-4I3KxUKC4pYPRyvu_w_11_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">203651</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w"
      decimals="2"
      id="Tc_6qBRe7f74kOiz-3H7_Q9UA_12_0"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">2.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_DYK1lDy1Lk-8q1F3yA4_2w"
      decimals="INF"
      id="Tc_Eq4ixsuQ-kqdeJpgamwK9g_12_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1413</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g"
      id="Tc_If09cJFfNU2ZODlHdR9n2A_12_4">P2Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.007Member_iyD2RbP4_ki20tXfgBco0g"
      decimals="INF"
      id="Tc_e7nlc_OML0iWKyHraSdBvw_12_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1413</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_PkkKP_WaZUCbc1PbtBZfiQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">3.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_1w0f1cr6sEia4_6l5glvkA"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">18.61</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_8YJDeE11cE2EQ4ztbjcPYg"
      decimals="INF"
      id="Tc_Umwp67B7dU-zIC0x8Ay7sA_13_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5589</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ"
      id="Tc_IfMj_NoRGkiXk8s120Z0tg_13_4">P3Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_tlsi_ExercisePriceOf0.09To0.46Member_pkrgoLDbeEeSiZrP-WJJKQ"
      decimals="INF"
      id="Tc_ihWyFEBunE6w0-BkUQdbXA_13_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">5589</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="INF"
      id="Tc_SERG6Rayc02m2qNwC_vRIA_14_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1671076</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Tc_JBEzwcR49Ei--PgqhBvqWA_14_6"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">813943</tlsi:ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_GbrCpHSl6UuZJHlHFKysfQ"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Narr_FMUt5fd8ZkWViuZXKHAZ2Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_oF4FBYCTxk-hMlAPVhFDXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation assumptions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.6&#x2009;&#x2013;&#x2009;6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.0&#x2009;&#x2013;&#x2009;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;(1)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Our historical exercise behavior for previous grants does not provide a reasonable estimate for future exercise activity for employees who have been awarded stock options in the past three&#160;years. Therefore, the average expected term was calculated using the simplified method, as defined by GAAP, for estimating the expected term.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Tc_IUbm4Y6vwUK2UPAkYCEO0g_4_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="2"
      id="Tc_LuYYda_deUe2IvpM0uHe5Q_4_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_-vVRuuYOS0yFk8mPXLMGtQ"
      id="Narr_ndtsJ-MTwk6J3oJIB0MVzA">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw"
      id="Narr_aM0ySl_E90mqpY8DYct2uw">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Ewnc-WVz9ku_b5ftkI7wMA"
      id="Narr_6y-xyHN570icPa2r_Vg3Tw">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_EbEeXi4j7EGJVYkS9xiwOA"
      id="Narr_FIqEZOQbm0SeWSuLkETMaQ">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="4"
      id="Tc_zPBezQLsBkCThhxVwXpbKQ_6_2"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="4"
      id="Tc_PI0SY-TlCEO_9W_cFgu2bw_6_4"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvBwoibMpE-Z98sDm4_9Mw"
      decimals="-3"
      id="Narr_Z5ByKkFD2karA2j1MBI6lg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_s45KCdyGNkGuDVWgIQ86KA"
      decimals="-3"
      id="Narr_1b7jPFxnp02jOkgGtZ-WPg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Narr_3S_35BZeUUiztiB_uAZgtA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">433000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA"
      decimals="-3"
      id="Narr_B_8Bpxb6DUe-qqp4Vzb1dA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">24000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Narr_rtccgP_cTUikQyyEoXvCFA">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_2gcsKfOJHUqItixqah4Twg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(14)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Net Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and participating securities (the &#x201c;two-class method&#x201d;). Our preferred stock, if any, participates in any dividends declared by us and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. Because we have reported net losses for the&#160;years ended December&#160;31, 2022 and 2021, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,330,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,376,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,878,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,307,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,879,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,731,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;As described in Note&#160;12, the triggering of the anti-dilution feature resulting from the B-2 Preferred Stock Financing decreased the conversion prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$2,829&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; was recorded as an increase in the net loss attributable to common shareholders reflected in our consolidated statement of operations for the&#160;year ended December&#160;31, 2022. This deemed dividend increased the net loss per common share by &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;$9.14&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; for the&#160;year ended December&#160;31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_2Z0qbXJSI0in3yEH9rzo9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,330,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,376,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,878,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,671,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,307,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,879,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,731,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_MMnEXq3f5UuA9b_f9X_bWQ"
      decimals="INF"
      id="Tc_iLQtagMJPESRyh81L2_gfQ_3_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">12330395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_SXG7MYzIGUCgqGneHO46ZA"
      decimals="INF"
      id="Tc_EyYW-_--S0Syp1Cv929USg_3_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">11376970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_sFPUIoXf4E6S5yFU1jhaWw"
      decimals="INF"
      id="Tc_R-sT-BMfbU-FHPqDCBwBfA_4_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">2878519</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_egZnUbZL7UuFABnCiYNEEw"
      decimals="INF"
      id="Tc_kU7f9Mt_PkqIlSgr1RYQBw_4_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">46111</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_CommonStockWarrantsMember_XSIPBticd0u3pNKbWJTJMA"
      decimals="INF"
      id="Tc_StjTTam0g0WMH5J6fhM-tQ_5_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember__tC8H3YIX0S5r6g2u5BcaA"
      decimals="INF"
      id="Tc_-6lk8cCgHES9o9cfFSrbPA_6_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1671076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_tO2ji53wmU-1qqLGxMnwug"
      decimals="INF"
      id="Tc_ky2IqVtm9E67SoKcB9KT-Q_6_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">1307079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Tc_fYraOH7BMkGuWDbHwhMPPA_7_2"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">16879990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="INF"
      id="Tc_i0f1v55THUONwYMRaE4wXQ_7_4"
      unitRef="Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA">12731606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_d57PWmS_aUCUb_W7r_pgqg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2829000</tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision>
    <tlsi:DeemedDividendIncreaseInNetLossPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="2"
      id="Narr_bwjXEF-hzUuROn88zcDQ6Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">9.14</tlsi:DeemedDividendIncreaseInNetLossPerShare>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_0UMS1FQ2yEqEw_MHqwoEnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(15)&lt;/b&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We have four property leases in effect as of December&#160;31, 2022, which we account for as operating leases:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A lease for our principal administrative and production facility at West 91st Avenue, Westminster, Colorado, which expires in December&#160;2026. This lease includes &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two options&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to extend the lease by &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; each at the end of the current term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A lease for office space at 2275 Half Day Road, Bannockburn, Illinois, which expires in November&#160;2024. This lease includes an option to extend the lease by &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; at the end of the current term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A lease for office space at 1000 Chapel View Blvd, Cranston, Rhode Island, which expires in October&#160;2024. This lease includes an option to extend the lease by &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; at the end of the current term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A lease for laboratory and research space at 1 Hoppin Street, Providence, Rhode Island, which expires on February&#160;1, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We also have four finance leases, three for copier equipment in our Westminster, Bannockburn and Cranston facilities, and one for laboratory equipment in our research space in Providence.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of right-of-use assets, short-term lease liabilities and long-term lease liabilities at December&#160;31, 2022, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;Net of accumulated depreciation, included in fixed assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease expense for the&#160;year ended December&#160;31, 2022, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total finance lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Maturities of lease liabilities under noncancellable leases as of December&#160;31, 2022, are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2022, we recorded $38 in fixed assets for a finance lease for a copier in our Westminster facility, and $6 and $32 in current liabilities and long-term liabilities, respectively, for the related lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2022, we recorded $310 in fixed assets for a finance lease for analytical equipment in our laboratory facility in Providence, and $178 and $132 in current liabilities and long-term liabilities, respectively, for the related lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the weighted average life of our operating and finance leases is &lt;span style="-sec-ix-hidden:Hidden_IhjA9SxPWke_WdT-YL8OYQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eight&lt;/span&gt;&lt;/span&gt; and three&#160;years, respectively. The weighted average discount rate for both operating and finance leases is 8.1%, &lt;span style="-sec-ix-hidden:Hidden_QpMaoZ2rLEe3kuE2nEwMHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;which&lt;/span&gt;&lt;/span&gt; is based on interest rates we paid for our most recent term loan and convertible notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Total lease expense for the&#160;years ended December&#160;31, 2021, was $385.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;We record rent expense on a straight-line basis&#x2009;&#x2014;&#x2009;the terms of all leases provide for increases in rental payments over time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum lease payments for each of the five&#160;years ending December&#160;31, 2021, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <tlsi:NumberOfOperatingLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Narr_WQ5fbAMMp06CQOWG0u3XlQ"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4</tlsi:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_CWI5Bga8AE2e_En3lvUg6A"
      id="Narr_1q8T4uL2NEOEiYCFfN9A1Q">two options</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_PrincipalAdministrativeAndProductionFacilityMember_nogwz9gxqU-ku2Q36qb4nQ"
      id="Narr_CbJ6vvyF-0avlBZHm7kmwg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember_Wpnc4LkhDkOnH49fJmT_-g"
      id="Narr_Dk0SHL5PBk-r4IW0OR9Wfg">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Narr_dgoxY8Ls70O_K7Kv_4YFDw">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <tlsi:NumberOfFinanceLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="INF"
      id="Narr_cAzUhzSEwk-ZRQIFtLT10Q"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">4</tlsi:NumberOfFinanceLeases>
    <tlsi:NumberOfFinanceLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierEquipmentMember_yN9PhUZ9oUmQbLbfhyWOVg"
      decimals="INF"
      id="Narr_Mx-4vBphnEaH74LkNNkOlA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">3</tlsi:NumberOfFinanceLeases>
    <tlsi:NumberOfFinanceLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_XOapO_xAxkSVGyKMkyZktQ"
      decimals="INF"
      id="Narr_ldZ5q3wLRECxpMoDthTCuw"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">1</tlsi:NumberOfFinanceLeases>
    <tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_eTc7-9639E-23bNjNSq8kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of right-of-use assets, short-term lease liabilities and long-term lease liabilities at December&#160;31, 2022, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;Net of accumulated depreciation, included in fixed assets&lt;/p&gt;</tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_rnbR7Iup9Ui5fh0J17p5CA_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1381000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_1Xk1ntezNECATkZZcwH61w_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">349000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_8xv9M9DfwEW-zKfObUwLvA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_TBS-MXIQX0C4lZcIaf-RiA_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">70000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_OEW0_XjVn0Gt6rczhKRl2g_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1429000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_N2hIoiLDm0OQT8oO3JxQMA_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">164000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_ce5ItRhl1EKRngE9yVFucQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease expense for the&#160;year ended December&#160;31, 2022, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total finance lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_LlZ-YIdgiUWw5x_RtlzlWA_1_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">443000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_ZIv0kqukxUiXE4brC9Jg9A_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">16000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_iN5x3LNmY0S-YIXaK94PYQ_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">4000</us-gaap:FinanceLeaseInterestExpense>
    <tlsi:FinanceLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_EO7rnH1_q06sFLiR2Uj3HQ_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">20000</tlsi:FinanceLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Tc_r2l6-J6KrEe4zTSOngV8IQ_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">463000</us-gaap:LeaseCost>
    <tlsi:ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_g4W-sfNt5k6xGbEA9_rY9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Maturities of lease liabilities under noncancellable leases as of December&#160;31, 2022, are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tlsi:ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_UdRoE4lglE-sa_4oXKW8DQ_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">429000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_B_3smnss20GgBunhZtpcoQ_3_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">87000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_95bZm7-h2EG559A-gGY9_Q_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_83WqAEkinE-8yknEwNMS-A_4_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">87000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_myhA0H7v7EyGqqWlheu0UA_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">205000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_iIJAkE3cm0Kf1RmdK0EpAg_5_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">77000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_UfnTT-ZvgkeYwtnh83L_6w_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">213000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_7lyi4bhWcUWeWymhMRBHrg_6_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_YL_wA-nk5ES4i0HIqJOMrg_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_57aJJ1XAa0S7c-HIrKhDBQ_7_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">7000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_NiucNWEFa0ig5NSjy7Amqg_8_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">884000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_P7PynhLZVk-c03EjbVOTXg_9_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2328000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_2k982oDUEESqRJ6D7hoRoA_9_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">267000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_uOunYqnyek2Vzl-X7_hjVA_10_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">600000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_dRfV8eAork-fokvWYj59Tg_10_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">33000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_HeaNGDKRf0i6EA1sf0ZLXg_11_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1728000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_fVBdTlaqVUayOrU--10fUQ_11_6"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">234000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg"
      decimals="-3"
      id="Narr__TBFbT2ackyaRJGxfk3WmQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">38000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg"
      decimals="-3"
      id="Narr_WhkTDaZ8_kazfZx1IQIojQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">6000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_10_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_CopierInWestminsterFacilityMember_rvrDACtXPUCkLEHBjCFSjg"
      decimals="-3"
      id="Narr_0u-siTKtskSvIZH6MkAcJA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">32000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ"
      decimals="-3"
      id="Narr_pG7qK063KkuvS_bvbuXjcQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">310000</us-gaap:FinanceLeaseRightOfUseAsset>
    <tlsi:FinanceLeaseLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ"
      decimals="-3"
      id="Narr_dmbCozwswECPAIx4ayQCQw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">178000</tlsi:FinanceLeaseLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tlsi_AnalyticalEquipmentInLaboratoryFacilityMember_9uOQCAn2C0Kap_L8RqvYlQ"
      decimals="-3"
      id="Narr_ersjCSmyFkiSK3B10LIAOA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">132000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      id="Narr_zXJuPYv9o0ubIFGc_Bf8FA">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="3"
      id="Narr_Ue990LviCU-yvAgweibR5w"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_7eX19ICooUS2Nk4YbWneXQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">385000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_zNwh7Qxc50qbC0h9BAXCGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum lease payments for each of the five&#160;years ending December&#160;31, 2021, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_XmvAm8xneUu1AjkJOJ1VOQ_1_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">188000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_FaKmuV_zWECuZPPtnduB1Q_2_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">194000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_U4yO80eVgkih_QuYRqeQPg_3_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">199000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_04-zO3ncaESPThaLeyb5TA_4_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">205000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_c0xUk5VcYU2tMG45to_qUg_5_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">213000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_WBJuxPvWPUiWPoUJIPFQ_A_6_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">1102000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA"
      decimals="-3"
      id="Tc_xjCgaIDpZUG3vx5Jrr3mtA_7_3"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2101000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_NKezCnRRK0mPlXfGT-7fjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(16)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;401(k)&#160;Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains a salary reduction savings plan under Section&#160;401(k)&#160;of the Internal Revenue Code, which we administer for participating employees&#x2019; contributions. All full-time employees are covered under the plan after meeting minimum service requirements. We paid matching contributions of $431 and $287 to the plan for the&#160;years ended December&#160;31, 2022 and 2021, respectively. Our contributions were based on compensation at the rate of 3%, 3.5%, and 4% for an employee&#x2019;s contribution of up to 3%, between 3% and 4%, and between 4% and 5%, respectively, with the match-eligible contribution being limited to 4% of the employee&#x2019;s eligible compensation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Legal Matters&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, we may have certain contingent liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management, there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2017, an individual filed a suit against the Company in the District of Colorado asserting joint inventorship of six patents assigned to the Company. The individual sought to be added as a co-inventor and co-owner of the patents in question. In a series of rulings, the Court struck monetary damages and jury trial demand, limited the individual&#x2019;s expert testimony to one patent, and barred rebuttal testimony to defendant&#x2019;s expert or testimony related to prior art, severely limiting the scope of this case. Following a notice that we would be seeking sanctions against the plaintiff and his attorney, it was agreed that the plaintiff would dismiss his case with prejudice and no sanctions or attorney fees&#x2019; request would be filed. A stipulated Dismissal Order was entered June&#160;23, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2021, TriSalus exercised its right to terminate, for cause, an agreement with a distributor, pursuant to which the distributor was acting as exclusive distributor of the TriNav Infusion System in several Western states. We determined that the distributor had failed to perform many aspects of the contract resulting in poor sales. The distributor was put on notice in September&#160;of 2020 that performance must improve, or we would terminate the contract. Despite being allowed a 60-day cure period, the distributor&#x2019;s performance did not improve and in February&#160;2021 we exercised our right to terminate. On March&#160;11, 2021, the distributor filed a lawsuit against us in the Utah state court, asserting a claim for wrongful termination of the contract by us and several other related, common-law claims. The distributor sought monetary damages in an amount of $750, plus attorneys&#x2019; fees and other relief. On November&#160;15, 2021, we agreed to settle the case for $425, which was recorded as expense in general and administrative expense in the accompanying consolidated statements of operations. The settlement was paid in two installments of $200 and $225, on November&#160;18, 2021, and January&#160;3, 2022, respectively. The settlement amounted to the contractual fee if we were to terminate the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      decimals="-3"
      id="Narr_rDCLKRWgw0exnCFxpLar4w"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">431000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg"
      decimals="-3"
      id="Narr_rMhZ2_38aE-yzik1n7Ja6Q"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">287000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionUptoThreePercentMember_cv3StuhiV0WTIiY4lV9S9Q"
      decimals="2"
      id="Narr_3Xd39tUS30SghQdB26AXzg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenThreeAndFourPercentMember_Fo9HbOq37U21cbLPB6-3eQ"
      decimals="3"
      id="Narr_Hmhp9XBMw0aEDzZ6uoA6Dg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.035</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tlsi_EmployeeContributionBetweenFourAndFivePercentMember_aGOIseMil0e-w33qyFfkww"
      decimals="2"
      id="Narr_sTApfyb50UicBuAx7dOzIA"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Ig2puwCBh0W4qZfZ1e44zw"
      decimals="2"
      id="Narr_xcWWTY96Nk-zZTL1_eKYgg"
      unitRef="Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <tlsi:NumberOfPatentsSuitFiled
      contextRef="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ"
      decimals="INF"
      id="Narr_60x9CtxanEygRw86cqNSiA"
      unitRef="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg">6</tlsi:NumberOfPatentsSuitFiled>
    <tlsi:NumberOfPatentsTestimonyLimited
      contextRef="Duration_10_1_2017_To_10_31_2017_Cb__FeGVDUCSRviprrtjXQ"
      decimals="INF"
      id="Narr_9Snj0S-PP0STtQbUtiOJ_Q"
      unitRef="Unit_Standard_patent_asOWdL9DIEKiKNH1NPZjrg">1</tlsi:NumberOfPatentsTestimonyLimited>
    <tlsi:CurePeriod
      contextRef="Duration_2_1_2021_To_2_28_2021_Kxpz0qSUe0mhCS0fzXQnrQ"
      id="Narr_b5jzK18j3kWt7ZujnlWCtg">P60D</tlsi:CurePeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="Duration_3_11_2021_To_3_11_2021__-g4Qp5Pyka4gA7LbeyrTg"
      decimals="-3"
      id="Narr_hy009OBJek2_mpxWPgZ2og"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">750000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="Duration_11_15_2021_To_11_15_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NTqWL_rATUeGsMWY1n5tKg"
      decimals="-3"
      id="Narr_bM4wCXNLrEOp0rQrzxbecw"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">425000</us-gaap:LossContingencyDamagesPaidValue>
    <tlsi:LossContingencyDamagesPaidValueNumberOfInstallments
      contextRef="Duration_11_15_2021_To_11_15_2021_b3QxwyefQ0edxXCsFdJSjA"
      decimals="INF"
      id="Narr_xpEd-ety6kmltoe0q8_zRA"
      unitRef="Unit_Standard_installment_0xHPpLFYGkuxngV0kCBNoQ">2</tlsi:LossContingencyDamagesPaidValueNumberOfInstallments>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="Duration_11_18_2021_To_11_18_2021_srt_StatementScenarioAxis_tlsi_FirstInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Lr-_cbK0CE6ccIYutbIUoQ"
      decimals="-3"
      id="Narr_KhybmELHnkqqGYv8GGC42g"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">200000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="Duration_1_3_2022_To_1_3_2022_srt_StatementScenarioAxis_tlsi_SecondInstallmentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XU3a0ehnaEO_Yn_QEfUcqw"
      decimals="-3"
      id="Narr_gJHeo8k2H0aBlaGXNitUJg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">225000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q"
      id="Tb_oFir2UAIXUSwjk7g0qW98g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(17)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Merger Agreement with MedTech Acquisition Corporation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;11, 2022, we entered into a Business Combination Agreement with MedTech Acquisition Corporation, a Delaware corporation (&#x201c;MTAC&#x201d;), and MTAC Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of MTAC (&#x201c;Merger Sub&#x201d;). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into TriSalus (the &#x201c;Business Combination&#x201d;), with TriSalus surviving as a wholly owned subsidiary of MTAC (the &#x201c;Surviving Corporation&#x201d;). Following completion of the combination, MTAC will be renamed &#x201c;TriSalus Life Sciences,&#160;Inc.&#x201d; The aggregate consideration payable to our stockholders is $220,000, payable solely in shares of MTAC common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Immediately prior to the effective time of the Business Combination, each outstanding warrant to purchase Series&#160;B-3 preferred stock must be exercised pursuant to the net-exercise provisions of the warrants, and then each issued and outstanding share of TriSalus&#x2019; Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_b4QB_34hYkSQy8m2zvvSVA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;, Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_mW0ye0ape0K0u7SnjgQyTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;, Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_D1tTYpAKD0mwadhIRhVubw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt;, Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_Wp2d5AfagUeiDJyLPZ20iQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4&lt;/span&gt;&lt;/span&gt;, Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_F187q8J5AkCMoKigjnNSmw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt;, Series&#160;A-&lt;span style="-sec-ix-hidden:Hidden_s43EmyAlY0-5J-sKfRJXGg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6&lt;/span&gt;&lt;/span&gt;, Series&#160;B, Series&#160;B-&lt;span style="-sec-ix-hidden:Hidden_iGujevr0gUmbUx_6BKltrg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;, Series&#160;B-&lt;span style="-sec-ix-hidden:Hidden_IoB8wHCgok2nthhVpcAt4w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;, and Series&#160;B-&lt;span style="-sec-ix-hidden:Hidden_7EvRLYEDcEumV76exoXIWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt; preferred stock, par value $0.001 (collectively, the &#x201c;TriSalus Preferred Stock&#x201d;) will be converted into shares of TriSalus Common Stock at the then-applicable conversion rates. In addition, each remaining outstanding warrant to purchase shares of TriSalus Common Stock or TriSalus Preferred Stock (each, a &#x201c;TriSalus Warrant&#x201d;) that is in-the-money and would be exercised or otherwise exchanged in full in accordance with its terms by virtue of the occurrence of the Business Combination, will automatically be exercised for shares of TriSalus Common Stock. TriSalus Warrants that are out-of-the-money will be canceled for no consideration. Upon closing of the Business Combination, all shares of TriSalus Common Stock, including all shares of preferred stock converted as described above, will convert into shares of MTAC common stock at a conversion ratio equal to the $220,000 consideration stipulated in the Business Combination Agreement divided by the total shares of TriSalus Common Stock outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the effective time, each outstanding option to purchase shares of TriSalus Common Stock under TriSalus&#x2019; equity incentive plans (each, a &#x201c;TriSalus Option&#x201d;), whether or not then vested and exercisable, will be assumed and converted into an option to purchase shares of MTAC common stock under similar terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, we have deferred $2,719 of eligible expenses related to the registration and issuance of MTAC common stock in conjunction with the Business Combination. The deferral is recorded in other current assets in the accompanying consolidated balance sheet as of December&#160;31, 2022.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q"
      decimals="-3"
      id="Narr_O-cFI2qYcku5v-FAu8KaiQ"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">220000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_v8JMAlK36k2t47JlYo0chg"
      decimals="INF"
      id="Narr_cmkkV1wPskqaWzXzrgSP0Q"
      unitRef="Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <tlsi:BusinessCombinationWarrantsConsideration
      contextRef="Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q"
      decimals="-3"
      id="Narr_VT0OWFiWdEu9SUNAwBPLHg"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">220000000</tlsi:BusinessCombinationWarrantsConsideration>
    <tlsi:BusinessCombinationAcquisitionExpensesDeferred
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_HDWwXtuDDUqAhelDAH9-9A"
      decimals="-3"
      id="Narr_UJL8n59Z1EaRZLEdILZ0qA"
      unitRef="Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg">2719000</tlsi:BusinessCombinationAcquisitionExpensesDeferred>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>200
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #TK(Y7M0?>+?8"  !D"0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*V6VW+:,!"&7T7CSO0JQ0<2#BDPP[%EFE &D_9:L1?01+9<201X^ZYL,'3&
M$5ST JS3_OIV+>^JLQ/R36T --DG/%5=9Z-U]NBZ*MI 0E5-9)#BS$K(A&KL
MRK6K,@DTSHT2[@:>UW 3RE*GU\G'YK+7$5O-60IS2=0V2:@\#("+7=?QG=/
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MU*LU,8_)HJ07'2VRO(R^"HU%.6]N\!H$TBS ^940^M0Q&Y07J]Y?4$L#!!0
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MIK1<F0+<:KF5EMSECY.00.(XSMGXL>F[+H<=[,"F8,LOLO.+6/VZ*=B:QDO
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M+,B">7]21[I3;:0!A^SPP9-?V>D#21,:1O%LYHGX/S@EMM98 _9!2.:GSHK
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MR?SXTB78(3PR4,]WC,G71G0<E1T_SGX 4$L#!!0    ( /2LCE=JD)RG^ 4
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M/R !,(F\S)7$ ! ^Y+:DH1IC8X-#6O0A/->F4,C81!>J!$:B;S%ZLB9[DM"
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MOC#OBJ1YQ#RQJ3'1;*'G2-[=H^GQ#)AF6!'"TM>5T(&MC.(@/@1CZ/FYPX:
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M!NB=(J @OT;:>_0L?7KF+D/D-A6^\Z2TQIG24I1%X.B\Y4 )S@<VB5/I06<
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MAPZ)AVR27"F[H87ICW? M7 Z0D-L]QQU 1J,Q3; _\=$,%/=P6(]10R4,Z!
M 2C8 AV21T95HY%.E'X"VA88EI#]@^ 8L&'9"P$L90B(#H ,+7">O)B=+M+3
MLP7!_6(^G:87%^1LTU1%4ORCSCB*=-DI&@Q_S-#WMEOVIHI']HVK>F1;CYKK
MZ)!_UP7QSVW3@81>,IOU<87^& 9EEEB?DA*W*,I=PR%QV"1VV0#L#:Y-.E7P
M-I*L>']Y\]9MB]Q]XXSQ%46"XA*X3,3E34@!W-9;L(R+^31U05]\+E+O\]>
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M(32/XIH-:H1EZ&^1%D.R]3L3:# U&W),\$BM.C7K+V%/;$7&CGQ3>O$+O.H
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M;91#4)$3$-83/&2Z8C6I9568C5+.>P0YHM73QB/ #83EK"F*,])]?)H,GQG
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M4><GJSY'3J=ZY-2<W722\QX%&=XVX^O4-KDJ< CIZSM=\A]#ZMR(^Q$Y^O2
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M0.WH1GS\01,7CF_MR*3WQRI7<'VNEL$&>.R%*Q_XPO>UWZK@ S(;^5E3C0%
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M5HG+''\,R+$ WD\M[KCF@0]8_]48_ =02P,$%     @ ]*R.5YVKJ=7_"@
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M&@5/,X S9Q\^77S^^(Y=G?_[U;$!?+AZG#C8-Q8VW@$[8Q]E89::O2M2D?;
M7^R'C^(]"(Z!D8:;N.;F3;P7XZ4H!VP8!BP.XV$?0?O!WXH$P","C_>0,VR$
M.R1\PQ\2KH4=]<.B][[4)4_$ZP-P3RW4C3@X^_67:!R>]C'V1,@Z;(X:-D?[
ML-_#YG[8PR@\8A^*1*X$N^*W0K-SP\Q2,%&D3,Z9X,F29841*ENQ$O[+-&!K
M 2[P33!9@0\+;1C\9>#2 B$(>#X7%!^8X;=,X1-Q6\*22)F1 ,-X6>99PJ]S
MP2 4$M"\RG.6\!QVYHIM!/SC0$2E <N2&XL&H$LE;[+4PF66<D.48U0"GU5*
M%(;@7QCY(D4H"#29AFT!1+ TTXD2L)H9L=(#]F$.8$KD&5'3L)+PHI &:5WQ
M5#BF-Y9Q?)]K670A'/, 5_&\1P8!DIM7:58LB*OZ_<1TWR=&:ZGX? S8%:QD
M*[ D4T-WN6' IA*)5.#/L!N]\;WB"O2'M^ME!NJ$Q0V3"4AJP/X4K#)9GOTM
MZ-UKGO,B$<QFL)4P2TEFP)-$5H5!RK?$CDJ"P"U [JE;LOMP%#:0IB!NPB.,
M]BDJR9(-[(*B$H%Z,6LA[/H\*X" #.2A#7 ,^<K8'5"(5HU(CM;"K:/:@'Z3
M :(%2,^B(1O!3*<;DRRX-3_ D_,UZKT@/%HC5_@*Z!0$8=%M&OEZG+E]R182
MP U6B$_62Y 3"MB@^%=H8WGV3>0;M-N"H161 6N462D5Y4^0(@=[W[T+)")X
M[DS0DH;/ETI6"](A6XA"@*T0MCFXCZD4Z82LTJJ(N 23M2P"=;4^"(P8L3(
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M*H;@3Y<(9%P5]C,I Z*TN-#'ELTZ8;1_UP7#A;EYMEY>0TY=&)69I;)AH/7
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M*.&\N&^$%>$Z7&A3OZ;U())/D3-;LP*G$>6 1;/!:/;Q0WJ2_'Z Y_&.YW%
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MM+LJ8?A6<%($4:46>:(UX0^Q J.1]]&?357A2&)0/E@C0!(^6*@6;W_=:+A
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M?]541,QH=35:$Y_\K8NK>2F^GDTSS\7AM:$+#5_EP#.(VUIL2I1@C>%L,LA
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MECR)!4+("I\^F?5U0PD#1F@!CJS,(ER-IV@C)-I+Y'01L9.#J7U:'@(P+&W
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M&8>J'X1 8VIYF_.2.S#&"21%YC2&;FL73H@EI\Q%0YGI)2!V%6B+D@>(J<T
M+N7-2^H)TFF&OBX3%!]%GPH+(SVYI0&".Q2_[P'GP/7?"BU9TSTQCV[PMJ<N
M:11=DGBS"R/?IN1]FP,@"$BD., %P5Q8!CA>N48RO$ZRW 9QV)L"^\KOQ%C^
M2P590TS1E3U-OF/=T_!<C^:.3X0L4%4,[6I*'-,KN-W[1(Z=&IZDZ)3QW&TM
MXB&5Q93NF,SG;NU.J#2ET;/)X2P^/.*@_;/I>!R?G)!]Q&4$CVIN(.&HLKOL
MT,&[XI_)<,F-1>\[#U&_8-(-W+ O%;KKQ:G?2PG?M3CHNX$:DH;QD&OB8^3R
M_%)1=)@=4EZINF=4P"E1[A$)2"&3'E<H.?9[@C:P?.I2>[VHC'4P<AQEAJ$0
M^=7?E\DPH'@'^2XYWN LJ9'QP/S2CE;[NZ"46608?O3:QN-\39]8D<F++RC_
M340>6KAB_IDU1MU5:X/3UO(N/[H=B#<I_]L=C4'P4503BE!ZK0MD3BLA8;9*
M&88/9+?.0%"2(0F:"*D(5%S3TV0&'9%P?))A)!FHM 2K*BNA-?PJI#=R6)J?
M$Y [:U)]N,+&EK"97#;.7D3??2Y);U@-HI'?_RM9;U[*Y#9CN@?:R7>#MEM4
M:.P(KD8,*A##R^,.VE0%=Z8*(PYAKI8-9#^< I@9=B6XS^5[MYQ1PP[ MXDG
MA(0X-T&5NG<;@ZS6%;9-[JEL(]?%69CN>.D4B@NC('ZVA1.]//<[%48)S_WN
M, ?,UP8"*),!_C43!FG206:E3.A5C_2PW3"9H/ *0 ].'$/]"31BH*@FTRLD
M++_6BE0IYJF6D5ZZC-1[H,3KG=3H)?3 O"_!TF1\V;3H_AS&$>4)DNY/-]LK
MPPK V74-9X+OR1BP!3<>?)+7W:X,\ZYAJV1#/)N4_&RW[DU(!23X8+E@[9<C
MUJXP57)?T7<$-UJ)1VM+JJDLCFEX+32"5@_F&N9,<"D%<41B>+0!*9,,D-"9
MHZ_ICIGM2P\TO11@L6HV.(!=SYIBM=$4V&SQ]AC<MS*-MZ%6;"IC2&W)>:?T
M?ZI*5FS(%4"1JC$PB-I9--XCK09%00*VN=6EES^""2(B/H-AXEN?SN+QP5%\
M>'QBBF;DEAD[FJQXH'W"GR$PM99O)4D<N0?5-F$['O@#F;=GT9&HZ>/[K3*>
ML,KCV70V'<V.HW66YZ2DM7Z>C$?C$VH^Y$.^1XG(G+KH]:(+Q0TRLD2\KK9>
M!6]]:X73T?'8K@]SPLENV\C;$G/UV)UOB"[T<Y(6-XE/P?8X@',-T>W5KXRB
M9\<G\01VSEWU3.TR%3QT]X*-.T@A.!S_DT8 +:=5<E-$*>9L^Q[W6AJO4@D'
M[M<,P1/BL)VI81C1_&(&Q\@!APPBMROZC@H(VD4$3Q L'>T$SWQRP&8;'O_8
M?YJX<\<XZ[*GN'W5AQI^:;FRV[G"-EUHM*VSP<+5OK:A#TLF-"?L$XOQ=&M)
MZDVJBM0QJVAY@LBA/10]I=&R5JJ[]@,3[3.3.BRIIM?8I=<;V.>_P[UD5Q@X
M(-TVR779AH'\8<9F$,T5JQ$]A%AYMI#R 5GMG925R8WZA)X9BL#6?0>0&HU6
MK!!B$:8R#3L-"SI"62HE^Z(!O"L6%:?JH=VBS <CILW1N#K_;4H"A9_)K<C7
M#VBC0MI(ELAJ:EN)":!MDBS=1W<RM[\SKBI.$<78+5-LO_'DW55"RA,NH^1.
MNZRA(4M0JBN*!;5C-37GED52AO0+4@/'LY?W_OL$<.-.E[YGP)?&EC%= (]S
M )SY-FGK9H5TP-]]%P [-F-G6A_@]TKK[1ASZOUV9ML>LPOR-9X=3^+I\6RO
MA9#VOW\50=-X?#J+)T?'GA3Z2<SO]K,D_(Z^#TZG=M9GT>0T/D%DSL9#YJ)K
M03$9[AAAV QP&+W%#_N=RGS$$GP,.)8)DOTLM0SDEH'SR]4RR>-VSAXKZS8:
M8XM%:NEY,\!I)7Z,K)V+%LDL8K8D.LN6D:,VH"(?\G+AC]84;*,F";UM-R1.
M+7QF&Y2V#B)AZ"BMW_DJR,D02^!7UBZ1TX).B*U;M!2B8"I("^H X+XV:E(L
MO.'\]L1#K\ <MB MO2*S]E):EXN,UK)F1.]5$9S0RJXNCP4,;ZZE%YF072'"
ML:=>^AX[D](BE*\O;3WV,\$M//=L<@"<81(?3@\1&V6+(#QD(3(DK!0^%<,D
ML_AH=A(?'1V( ? 0\N-D#H>27G?*,,_90@N23-9N1+#KI>/-\>T)G$YK>A=<
MV!8+=@2=W[-#Q-'XB#7?D_CX\+ O"N$(+(PQ;CN%(3[HR@DGPX45IFN.Y[WI
M98:#LSR:&3X:ID ;3TO%;@_,=TA=,Z&@E4\)MG6Z5-PNB=P*M41YKN#@8O%
MQJ@"@MZJLF4A0<;%'?51:ED 4GREM/$%H[MM2V&^<QW)+>;K9YO4F08<,8)D
MVZN@BDTFK;\-[G_EZBJDBQ#Y*(R[A-BW5Q",(C1-2:>T ^-.0[>#DS%1G5?*
M@H5,QK>WO98#?7E^'0P,<Q72;TFCMB<RT&:)=&>681)N")L7F,Y</:=+N4V6
M)_H1$#H4SW_-C&U)U)1ZU<K$)RNU3X_1R);!E%(LGEBT9_"U MPV.>)>*?!E
MI=K]:.")?M+UZ>=FI4BN=^CBW@8Y$2/4V,SHH1<*?F!-MM>D*T@@"=VPLO-V
M)$G;@#V @3ETYJ,5XF9G]'L=%:K>;W?0*4T'#NV))(\*%@X%DGHH_L_)U$::
MK[K@>4TZ>OWH.*#-^._A\KMUN536W=LW0] =P7SI2J/O<<'+E6=\RYW;/QB+
M=\@%'!_5,0<CBK7UF*_1*374;REP*/FFN1<!#F!HT:/M*>;W$VAY1>Q8K+@-
MV@X,^3."K@"!CK._]DK&S2Q=8I#HJ_69]O4D\\#I;4PV?/?OTQ <-Q,'M>NE
M("R*<P,3>H,.X#ZI\A+K Z4D![Y.52YKM6B7DCE-=>M*40Y\5,Y12+.>4R4I
M=\Q VDO\?!KG[AF 0G>@>.NMZ/9BE#ELK+!8^?VD.A ;MR]6-LG5"9\!<5<B
M)Y,PHH.]$06]Q:DY*42(*%?71AX,Z5!35\,W':[ANZ_'Z_#PQRI/CP!F(%CH
M]WIU;8*\+J\V:\)-UR?]X5DG_>6+,#W2[XE 0J_36KJ3I8@0VC9SMMC?U!M?
M!2FM<U7?4#O6P51&6,M&H0?2*0W_MVM*((C&JP)4_UKB3>'K<K!1*];"F[6D
MUI]<+3#G#>>U&_0XMR"I+[9@O*\9MW3)T^ASRX!EI??US17M"I54BNJX8$X?
MYJEM+I>U8#9ECBS- KH_Q>K>P_VI?Z X>6'"6JZ4 .>LD,7-@XZ!MJ==9P ]
M;%\-4O+[2U ?QN^%/.DE3V%]OJ-5 ^!LO'](D:A[TK[Z @!=E$A)Q54#>.D[
M#R<?Q<>+/MN^$&</:I!!G8YF!_\DJ,;_?.3[04*;T2_6#U;AR^%Q46KH0.%T
M^PR6;4T>O[[I0MG;_A-;$;1\)]8IL:W//,N#;J]Y=U50^&#=BE,P_ (J@-\&
M;3F#+&!LH9C&A'RD)I 66@W7 7#ED[3\XQBG8V*VF0HK3IZ*0:XFK:7;1&?>
M8);V6,I+]GM-NP;3O<VE*16*#E0!BRI8ZG(RFG J;7O)&BS$[26,UM?/2,KA
MAMH4MTYN22-H8&63K!2<G2W?L<HLO5[ PT3<LHQBOO.8'47'H(!/RDL+W,EW
M.$/LI\+;TM3,-/[N#>6AHXP=CWWK^4ZHIO #4$X8:'$&FF[=XL*A%2O1GXK!
MX9Q]:K+K#42V,TD7JOOR6T?M8E,QO7+N)IK<))4R573DGC \%4MJ*!9H&YNZ
MSJ-^YKBIM(L96CAE2D4W74%2F";Q0G-86%CV'83M@>2I[ Z5EL+6R>](V!TZ
M Y@X.PF+X<WDF+KM")3SRDWE-"BA&K\U50IUMC8^1!?I2[&4T@O^%^JVT5X+
M>WB2(B=<FHI'^7L#["3-O#>*D1\U<Z;<E4JIZP[7--+K.U!?2&YTO^3P&],;
M3Q>S@,@6-[#[U<&]G<)(PIO3R:U)4U[;]D.W,.6-RJ_]_.S''V=H>P5WPCN0
MQQSHD&[NVDQ,AQLZ? 21OHL]PNR[#S#EA!M]M)HC]JKNW[7YQ -@]8 ,W-A!
MSC41F&V4M;UY0ZLBUVGXTR.GX6,C0QBLL=LA(T84^E&$ &4.(&VPUDD& X :
MB8&G&?![!*9P@R7!J?,R-=?!*IC1[P9K5!2_56"05WU3LOSH)DS$7J=NV[T5
MNXYNR3^C,@CZX77PP\@<BFEY)6XP0D?J\J9\2^0A8&$5&"D7<U-:O_!?FF;$
M-R?-ZMK(9\ .0C/RHKI]4:7>?)(MH29\NP$7_M E5X8BW*$GVDX:9IVXE"L=
M9%F2QU-ZOQO[0]Z*UZ$HR^7LVV+J5;L/5;L[^Y;WS^$[V;8FE.#Y[6;P!!%4
MIR\V\Q\V_Z0*K;NX7V.W)4.SE3SXQ9^@W34>HU(F+#"9Q=.CH_CHZ.C>$Y.\
M[N42:_O1F_DH\P=.(@U?W<K18SH@M"6\&@-\TRS]N+ =FYR&$+LR4_0*SI67
M=VB]MS;YK7/9R O/)" [LI07)FRU$@T-(14A>VH3-=D^V&<6%0UZ-^/0@)#1
M:)>YQB?8RGZ)@M<QM@B]^R+(H85WL\(T"8KI-2.;VEPZ4OSL%60=<>_AB3??
M^]^W@J+_H*G^IFLM=M)&_ R.WA09&[$5MMO^_/H^3/:+I+\;$1^!<5>8H?[W
MG\49YR8(97F[=YDQ!_'LZ#0^F9WZV3+Q!+Z;@A7FOIO%)\!B3J9'WG>4^'EX
M#.>(#2&+_\Z>NJ?:T0RZ[U=UA#2+9X<G\<S;QU$LN59>[I5-O>H^]!>IZEDT
M'DU.!S\>;ODXI-*ZKE?3X<Y2CWV'T_!TC]9AGPZ<UZ&W^]8=)TB<'>&)+'[Y
M2>M-4^)FI=<>28Z4U'=3,:.I3D)/2>][HD05B\T[_'3<?M?36['=3+;;._O&
MI_-22!5S8(2R0$[)2YU<AA!Y84''^$:0+<@_A&\:0*<HI]8';P@+:K13#'XJ
MK]%FGP_3[<RK:C?ESD$LBJU3DP(Q6'<U=:VXIL,MK]ZBTO=OD\7\X/<Y#<_Z
M:*+\RS"RD.^4OK61W1\[,"J]EX31G_G0CK2<>/6I'I!>IVO7"<S7M'ORE*E1
MEM]]T/A*'U;YYPH1Q<E;2X6(K?5V/7M)13'Z4E^RSJY[T\08DT*"V*E)H!*3
M@F-WG(+HY30HCJY@=522FU:=[*''Z&*22;#&E';2M0\:[E,I.K7V]-O462O-
MA [->U<*^]ZKP"W+R0+4],,%85 9I8KV?=AN$-%>P><$]'G;;(]>1)#5]J6(
M60&6LL0IL3Z4EB)#MV4\V9FB96;:>.,+-*5JM.2J8/0MVII="8H21J77"ZGS
MO%4)_&%;,FKJ+*2,Q?C^T9GW@GI(T'O6CP]\HPN %TR6[<DLLW 6XZ)#I-EF
M$ZANG!X=G[XT;R2-?0KI3FVZBX>;W75HV&OM,\@T;>/D96OU:;"Z+"F%<.@7
MOP_%[?(_FU!+#EWWR6VK?S]$^-DZ ZM@> ,X<7>HV_WV>3H@\PLT</*7=-XA
M9F8!9OH.W?:B!E*J^8UW16GN68H>$FJBPIY5L)]*ZZ)BWQ5&9X2F4ERRW)"[
M$<N@O(XYKK^\C2GI,!KK8DW\XE!T_#K@_-8I89-+/NN@*XC<ZK2B5X<0EOR=
M4V6@1JTQZ!@3=VZZUU_?8Q9K*LJCGA>U6L*%^M/E,+GV7#GBPEK$?;R&P.#0
M#YZQ!X._F,?4T(WA+2G]_Q#]E7)O*^E;RGLIJ^,&!"'O-Y)V=0$2)?&C'YA!
M+<2UG9H.=WEZY&LQAF=[M/;Q9-@>U+9;7+:F>;?-T)S781^+[]RWV[V&XXF]
MNKOI(K8%N4D9H0Q8+6W.VY%=6XS;ITJ-_([FKN%L^,J,->8C"8<S;[330><O
M#I,8[=G''.G)WG<VW99XC/]JL"!?%V,\O!\3K_:R//4"E'%1H'!.&Q/=\%;)
MO53VO]+.]/>R)V$9ICT,Y)1^U77P9@F*QF98!8W-0K5?F^9"!BP]_,VEID-*
M\$:RWFQ>[Q5$A ;*Y$SO!]4_2&I9*W@3V[S'&VWPYJ?*LGO:!CQ(,^&7)D79
ME?<2.:E^I(3C/-]VD"%4P:LDPLHT+F=UZ;@FHX7J5"B+A(2-=-8%]EJ5)H?#
ME*S0O85=8O:?>=L"OX26%'7W)HCV"QN&8KT4>K#]!-F"C#'%G'HRTIGY.[QQ
M-FA9M'+;3;QOFU595KY1V8G0D%HA[Y^H,5_34OV64#9VB^M&0(/7(4L@G[?*
MK-)U[+T#=<,>5Y U8!L>$B8\9#%XL8^&![^L^P%ON&"A]IQLK9] $7KU S:&
M5.<JS\G\+T!N8$33?HON9:S=>'$VW7D.(]WCKW[8 &H^)-A74H/DO8*AX]'Q
MX0Z7^)L/P(AQ2LRBJ\LU_;E2^/(;? !^ORI!990/N,!-67TC\%[]#U!+ P04
M    " #TK(Y7FPZTINT'   ]*0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6S-6FU3XS80_BN:E.G C$ML^2T^7F:2W%U+IW ,<.WTHW $<<^V4DDY
MCO[ZKF3'<?P6!\*U'\"6+*WV6>^N'FU\^L3X%S&G5*)O29R*L\%<RL6[X5"$
M<YH0<<P6-(4G#XPG1$*3/P[%@E,RTY.2>(A-TQLF)$H'YZ>Z[YJ?G[*EC*.4
M7G,DEDE"^/.$QNSI;& -5ATWT>-<JH[A^>F"/-);*C\OKCFTAH6469305$0L
M19P^G W&UKNII\;K ;]']$F4[I%"<L_8%]6XF)T-3*40C6DHE00"EZ]T2N-8
M"0(U_LYE#HHEU<3R_4KZ1XT=L-P30:<L_B.:R?G98#1 ,_I EK&\84^_T!R/
MJ^2%+!;Z/WK*QYH#%"Z%9$D^&31(HC2[DF^Y'?I,P/D$W'>"G4^P-=!,,PWK
M/9'D_)2S)\35:)"F;K1M]&Q $Z7J+=Y*#D\CF"?/;S]?7HYO_D2?/J+;BY^O
M+CY>3,=7=V@\G7[Z?'5W<?4SNO[TV\7TXL,M.KPC]S$51Z=#"0NKZ<,P7V22
M+8);%@G0)4OE7* /Z8S.&N9/N^=;N$/ $! 7L/$*]@1W2KREBV-DFP;")K:;
M%.J>_IZ&,-W2TW&'.G;Q%FPMSVE3!X)SMHPI8@]H&A,AT!B%+$G S\$#PB\0
M9/=_@>,CR="""1'!BX 8FM%D(?-P4G%!9RA*D9Q3\.R8I"%%VC$$/ ]9&D9Q
MH_$GW;I-6?J5<JF7A$3Q0#DLG*M%) )+2IK<4UZ8TT#CY2-X+K**#I+.$-@L
M'Y?;S4"10$2@!Q9#+A'OT(\_C+!IG[S9=5/5DI(;JMU2'E%13%( 6AMX-7K\
MDU4UCH$.S&/3A'["T5<2+\%\L(28$TZ/T8402SK++ /)54BXB=)'9.H>"Q3Q
M S\;+-K,W&)5F+&@.CO&SX6R!_K.PB>E'L\P/;?6+A#A?2)R?<^PL+='1%4\
M(R/PO4JKP&+O$XMG86,$[_[ML(!3>I95;19HG+WZ&O8-?[1/7ZNA,8+ KK0*
M+.Y+L#1 Z5+_A"SEG/'H'YCIVX[AVK9*/HV2?)AD8[,9<#M$\ AW5&T6(+WO
M 1*54(Y,UQ@YHU:4(Q-<RO65I!U NH93"K&\F8.<?&^(OF%BR_#\=I">$8P<
MR -6(\R^:<4Q/-LO-UU<O-G)_M+^EO K<+>B!5NX =@#*QF[>2^LX)IFN>D$
MP1KCBS:"EFSCFYZ!'?L-LTU;NX#SHKV@!<[6]_8*(':PD5-6C^^8)#&PPW96
MUK7GPP4BPBGU6)YCP)&OZ+D#^IA1,@53*LZ?G_' _41V[HKDLV*:74KD1#0%
M-HF2C+Q31=Y;S:0L<_SF'+#M.LD),[S'ZJ,;*B-.X>0*1'I8'EAABO5X4ZZC
M!@N4D6AU]!4-!BBSR'9Z5G^9AWK(4<.8$HEKYD=588?Z\5'M>8E!M9"3FJ3L
M>8>HM?=M,H.Z)/6X0]#:.I7]MRY)/^\05=O6VD7IYZVB)M6M8FVVH&1MO:NT
M"RDY0IZ-"S%K(5G:[A#2GO%?D#1[IJG#K%W7:I>\5<U)!VJ5P!N5.@[S3-;D
M_?]ALNB?'M8O<ITF5CVU%(%?FB)J9[I^Z:!V?.H9_/632K]0KQT*>@9VG6CW
M#.,J>6T)VII=:O2O"%,3/';-H3:#-H_AW4+ A.CV2SV;(HL@::I>O;BB8Z"4
M2E6%BG*?!&V%%$;S02'?MJV]5W*V%&1P%C^KMZZ?!"<[4O%QC5+7:7F]#M-N
MA(ZPW S"7-T=674?=>M%EA[J=M5-<E5W9,Q]5*W74'JHVET6R97=L3C2RPUJ
M)9(^RG94/7)5=ZQ]C&M5C%RCDVW%C-T4[ZQEY*KO6-$8UTH3VU1?52AV4WV/
M%8IQ0ZEAF]*EBH.J$Q:M/B!:3H65#:FR ;TV]96J!EN@E<H+JFAH.. 73L^8
M:(%68;;Y#EJ!]N(T"3KZGFMX0+NW14E>DZ@>Z'<&M(U%OS:=0G9V?/ H[&R#
M9"K]=PJ=-MU?1]LK+*;CIS*G^*G,Z20OEW1V1\,Y&H=_+R,1Z9^_IHPOFG[8
MZI2D?A]_)Q8DI&<#@"0H_TH'YS_^ "J?-'&J/0G; .T6H-W_\>^#G;KM:L9N
MH'T)X@N,8*!?2;HD_!FMSE\'"+LZY^B\<QTO2\QU'(:<:MN!R4/"^;,*JRPV
M07[)MEG?7A1L/R(6.;*D\&]4=%#MFT*N:/6:ZIQ#;&/#]BT#^_91Q2#5ZVL-
MA TSL W+\]&';S+_*N0]!;-$]4.U/S(LV]N/37$Y.P6&HAFF;7;$J%?$J-<[
M1N^)B$*=8V=1O%1QIXY5AS$H> 0A" "R#%]&TA1YG2ON&GG=ZC>5??.T(73*
M"$D<+F.R>N7-$%NPH4/(.S.03CB<)>FWD"[R[4E+*#8[1!*V3*4X>ON/ =JN
M'QG7</^DL!?KSTTV7:CFQV67:HS9E=MFUTFM/=EFR<PT*LRZ@G??UZME0CF1
MC+_]NQB#VX6%9Y70KT/5,6P/HM7>*(! ^@B N9FE/ML86?"'RR0D<(%HPE'B
M/4U9$J7?!U/]K3[I3\H460,J11[IBI^5>5N)&MON",YN:QS 4=W-&A-VB[V@
M/NB57G6 S&,KZ&RZ+<VF7#HL?:$&;O6H/]P3L#1$>_:Q6M%;?!LXUI_$#=?#
MLP\++PE_C&!3B^D#3#6/?6 4//M8+VM(MM#?N]TS*5FB;^>4S"A7 ^#Y V-R
MU5 +%%],GO\+4$L#!!0    ( /2LCE<^T^@R$P8  %D7   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;,U8V6[;.!3]%<)=Q@946XLMVUD,)$Z#*="T
M09/IS#S2$FT3E425I.*D7S^7I#;'BNPF+3 O$DGQ'IY+WDT\V3#^3:P)D>@^
MCA)QVEE+F1X-!B)8DQB+/DM) E^6C,=80I>O!B+E!(=:*(X&KFW[@QC3I#,[
MT6/7?';",AG1A%QS)+(XQOSAG$1L<]IQ.L7 %[I:2S4PF)VD>$5NB/PKO>;0
M&Y0H(8U)(BA+$"?+T\Z9<W3N: $]XRLE&U%K(Z7*@K%OJO,A/.W8BA&)2" 5
M!(;7'9F3*%)(P.-[#MHIUU2"]7:!?JF5!V466) YB_ZFH5R?=B8=%)(ESB+Y
MA6W^)+E"(X47L$CH)]KD<^T."C(A69P+ X.8)N:-[_.-.$3 S05<S=LLI%E>
M8(EG)YQM$%>S 4TUM*I:&LC11)W*C>3PE8*<G'WX-/]\]1[=GOV#NK=X$1'1
M.QE( %:?!T$.<FY W"= '!==L42N!7J?A"3<!A@ HY*66] Z=UL1+TC01YYC
M(==VW18\KU33TWC>7C6;M#.RPV99Y1='(L4!.>V X0O"[TAG]O:5X]O'+<R&
M);-A&_KL!OPLS"*"V!(%+$YQ\O"'0 GX(]@6X9R$2.+[)M;MN+=K@F@"B$3)
M([)<@A\(M8HD<<HXN" **8QRD@1$(+G&$JW 0Q"G F08$G25T"4-<"(1""@G
M,O* 7'*K+8&%(+ "3D(44;R@$944@ $63I/$"\++$]63H %=S G2VYI(@%NH
M,'&$WKZ:N+9W_.RW7D/AP]+5)N8,?Q[^T^>/*,"</T 4W& >BO++:^39UA#6
MJ0;<L67;+KJD][!J;4]H(G&RHLK%*IZ6-W;J/=M'9T' ,QQ5DR;.J&P[]@1]
M2.Y@LQB<7S$Z]BL,=XH^PPGQ2GR\I8_C'J,Y3JG$$?T!#+^\Q7%Z?('(/01Z
M4>,VM'S'VQ&]D2SX]D[%P5";*\A@'5YS^29.OH=N&:S79C7%7&]B#4?32IVI
M-0:5MTZQ9ER[1WG-28IIN*M.U[&=7M4;3WK[23TVY1I);S2ID_0]&WTD @C=
MX2@S.X(CL&4,SE6M:@1K-(QH#WVJ^_OA1%Z7Y[(STA*:1F5H&AT<FFJ<4L[N
MJ,K*34&I'?%Q4"H.J;L@"5E2*7IHR5D,EI5(FF0T62&H/S@VL0>\3P>?!X*Y
M0$2EFKVAQ50;VM*Q0E!G\HP(\'2 N20A$(Q^'G*>P6%#:#W@+"O[?^R.;?VV
M>3<22_)RSI6C>L_G6 <Q+EEMP+36]EI,VB]-VC_8I#D!,PO I8R[YIEM:<ZS
M;J9@?SHAJL]5BC89527,8DZ3/[334?Y0NI.V[VI9< N3GX7QB:TOBD:F$B9D
MUSIK >>:Z=Q0D/IYMPFS4EOC+\H-*50-+_";RE]N2H9Z6UVG;Z,WQ4N;I8EV
M+ !UC+(N?'/[51*<KR&1JD#2&&R[SK0/$;7KVNI5R)B<J%;IVOU:(K@F4-HG
MRJ;KQ5!WI"&\_K#WI$N]J5HMACDN#7/<:@E7)+PEP1JR__<,K$'K-&<\;;*I
M5J1GEJN3DN?D!87TY#<PFY;,IK^ID&['?6FJ*-Y;+K?5:7266J>QBMU?M(+F
M>?($_XV8$%LU;&O>&=K6Q(%"DJ]P0G]H#P-O#)B08@ AALMW6;I;8I5%J@5'
M:OE^K0*T?<N;[)2!+=KL8I18P[$%FX*^MA1:5=%7P-1JKAR@U[2KEC88L*!=
MS.?56HY=_8C;O[S:V@/YJTSW,L\@_T(&,;_X!QAPO3KZ!<71: PV.1H>6ASI
MDQXYGC7T&V)XUW='EN- 'J@RSD>=<5Y*]-""[$G2^P3;D]]CJ7P'=IW(Z __
MDKN&=LBFMUE\[>K)^7\58WOX_)9(WSK85!8]I7,ITU QZ3JIC%T%@A+-?ZQ*
M:5M+F6=E2DM,N;8G?1:0'KBZ]&GZXU1E%;C-&RB.AJ9QF$%.^D.8ZWA]!UZM
M5C?M>PI>5V^-E=6@=ML9$[[2=[JJ),X2:2X^R]'RWOC,W)96T\VE\Q7F*PI_
MEA%9@JC='\/O*S?WN*8C6:KO3A=,2A;KYII@V%XU ;XO&9-%1RU0WJ;/_@-0
M2P,$%     @ ]*R.5_4.*I9S!P  12,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&ULY5K_4]LV%/]7=%FWD3LO\7?'%+@#2K?>P<8![7Y6;(7HL"U/
MDJ'LK]^38CMR,";9Z-K;?J".9+WO[WWTI/K@@?$[L21$HL]Y5HC#T5+*<G\Z
M%<F2Y%A,6$D*>+-@/,<2AOQV*DI.<*J)\FSJVG8XS3$M1D<'>NZ2'QVP2F:T
M()<<B2K/,7\\(1E[.!PYHV;BBMXNI9J8'AV4^)9<$_FQO.0PFK9<4IJ30E!6
M($X6AZ-C9__4L16!7O&)D@=A_$;*E#EC=VKP(3T<V4HCDI%$*A88'O?DE&29
MX@1Z_%$S';4R%:'YN^'^7AL/QLRQ(*<L^YVF<GDXFHU02A:XRN05>_B%U 8%
MBE_",J'_10_U6GN$DDI(EM?$H$%.B]43?ZX=L0V!6Q.XVQ)X-8&G#5UIILUZ
MAR4^.N#L 7&U&KBI']HWFAJLH84*X[7D\)8"G3QZ?_SA"GTZ/O]XAB[.CJ\_
M7IU=G/UZ<XWV;O \(V)\,)4@1:V=)C7'DQ5']QF.,;I@A5P*=%:D).VA/QVF
M=]P!!E,PK[71;6P\<0<Y7I-R@CS;0J[M>GT*#9._(PF0.YK<'5#':UWN:7[>
M;B[O\_2*D=_/2%7XOBAQ0@Y'4,*"\'LR.OKA.R>TW_99^4K,.C;[K<W^$/>C
M:X"?M,H(8@MT1QX1+<I*"GA(AN22H!PB3E""><:0H'F585WD %/Z=<GI/88%
M908* HA(]( YQX44?5X;5N4&^"TPY>@>9Y562$FX)IP2@4Y^<M$-, 9UT3G%
M<YI1^0C"!$"#)!P*D*2H$K2X11B=T(+E%&<MQ05+239!)TPNP2+XK2Q,&"\9
M!^U3+6C!,H!.Q4#0VX(N: )F("P 1TMELVB-ABB41*.<5G7ED108B?V^\ Y:
M_3?#&[3A#;8.;[+$Q2U1EFLK,G)/,N1MN+P.'\IJ'X/O^R(Y+/6FXTZI :O>
MC^B?1$LWE.DJP"H.?U)(7*2*FF!>P+A5Z+'1OP"A.CT!D(@")$B54I)\3GB+
M*1.D5&EL HX][!X(!V9,(NU^6+8]?W>"?OANYMK>VV_F^5XY\Y-V)I;H5'M9
M6;2Y[E=H1%1UB 68TR4ZKQ.C60HP6UL-4-M,?BR@-\D@FFD[]0%*!<H-@MK.
M%&COMTJ.55R;N:X3S]=IUJY0CFT'>S]#QR/&Z)P)8:S9@S9&9AIQX&4SNZFY
M2@%T"B&$1%*1?1K\9N4;_<MQWQHS>TYLQ;8_-J;<F16[T2!5;"FAKUD!9OK*
M&M",\D0YP:+B+?PU3FB1?.MJT1*4]_>_>AK_-]/:>;6T=M'O&T!MYK(7.\8(
M\MC,X:<I^W3&B]Q_+;3_KQ1X360;3($P'@8W6+!=5A@-6!_ZK E\*[+=C@@+
MSJRFD#W'"FQW1[%/[>R*=0)KYL0=N8[3E1J V-D8?HP'1:KW-TLJ$,Y9I1N!
M)*M2!=SKD*B OW$#R[=C9&G 7- ".LT"LHY\)CRA0H/X&]^:V38LD74J*H"&
MGCIAQ3WADL*&H!J.^@6<)I,["^@6( K-H<=I,T[Q0H[RK=/77 XW8E^[9K>K
MY6;V^9H>K/%^IE^VUCO<S%*'PK0W2[M;THUB>C\8+&'+B\V\]J)NEEO>+'H^
MJ=4>< F]#M.'EUX!@>7XMC&.S,%>8+F.O=O&\:T^_]/IYFR=;CLU#>Z6.-W=
M<K;>+'IV),<*_< 4&EJ>/]QLK[8<8ZOH.;X.ZVS- L\8.XX5A^$@R<9^ _4W
M<$X/VW-Z. C4%R2](<D2'2=_5%107;*GC)=]9^]!3KO>/;T2LX[146MT]%KW
M;=%KVOQ*S#HVSUJ;9]M?R+"\Q,7CCT+=,A'H+>02D 1SLC[2P=@\'!8((TZ2
MBG-UTIMC07MO9P95V-5;P_9\:>CN(%\OJ#;/%=!IF-.H>*Q]^O)1]A2+I6[D
M*'1F0JZZO"7)U 2@?B4D5&6B&T(3()W8FKF1-9OYQJ0;V)9M1Y8;!R9,__/S
M= /<FZ<*QWD+N_P\HTFS9(UWIK9A&%IA:(*I;WF>I_Z&>=?WNY?M_>X3,29\
M>K&_(<:U@C!08@9J)VYK)_YV[JH'5=FUAH;M^E=J9W"R>:ZKYZPYRX#7$M+9
M(2>!_>SX6AUDGM+8$]M,DW@RF[7#3TS%J=.,A!/H2[^'9:%ZW!">MZ^"B1L8
M V>]5U]1<??3@A."U)W^.CTGT-=\CYR)&\'C';VG*8%B?Z2JPIM%H)^2M'H,
M9*ICK__WSOXJ%^_#8G?-RQ>,^-+@WJ#+2ZCWA*ZMX'9FA8'M7F! V?NUF[$^
M3G<JH',K9\#58 NX7K4^0QC1;%M#UW(B&P Q''=,,)F9:U[4U+Q=>0JU/=WM
MQIIO+9[K.-;QVREN)@H%EA^%L/6:<['EZ%W/;.<=<(COZLF70A<[*BS1.G1[
MOC5;;9G&7&1%OJ\$C]<G1-B.5C7N/!_V=OL=]\Y]R:3MP[>I\:%"3OBM_GY#
M(-WVK+Y9:&?;;T2.]9<1T_7RU0<F%YC?PG$47+  4GL2!2/$5]]LK :2E?JS
MASF3DN7ZYY+@E'"U -XO&)/-0 EHOYPY^@M02P,$%     @ ]*R.5SW&7%\"
M!P  IBP  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULO9I;;^(X&(;_
MBL6.5AUIMA '>IAMD5HRL]N+%E2F.]+>F<04:Y(X8SNEE?;'K^V$',"XS<BT
M%X4<_'[V@P_?F_AB3=D/OL)8@.<D3OEE;R5$]KG?Y^$*)X@?TPRG\LJ2L@0)
M><@>^SQC&$6Z4!+WX6!PTD\027OC"WUNQL87-!<Q2?&, 9XG"6(OUSBFZ\N>
MU]N<N">/*Z%.],<7&7K$<RP>LAF31_U*)2()3CFA*6!X>=F[\CX'_E 5T'?\
M0_":-[X#U90%I3_4P4UTV1NH&N$8AT))(/GQA"<XCI62K,?/4K17Q50%F]\W
MZE]UXV5C%HCC"8V_DTBL+GMG/1#A)<IC<4_7?^.R02.E%]*8Z_]@7=X[Z($P
MYX(F96%9@X2DQ2=Z+D$T"@SW%8!E ;A5P#_;4\ O"_A;!2#<4V!8%M"H^T53
M-(< "32^8'0-F+I;JJDO&J8N+9M/4O6[SP635XDL)\;!E_GD_F;V[69Z!Z9?
MP?3^KZN[FW^O]/'570"N'^8W=U_F<S"=?;G7I^?@*, "D9A_O.@+604EU _+
M<),B'-P3SH/@EJ9BQ<&7-,)16Z OZUXU &X:< VMB@$.CP&$GP <P %XF ?@
MZ,-'\ 'T 5\AAGGY8:KJ&X1]3PO#2I@(G#34#;+!VV6]C:R%@U_]D+[6]=W]
MD(;*7Q=!AN8@:A+ZS#,4XLN>G&4X9D^X-_[]-^]D\*<)L$NQP)%8"^ZP@CNT
MJ8]GC(08T"58(\90*L!_]CYP;97KBK$0.]-B:AY_&GO'HXO^4Y..HX M.J.*
MSLA*YQ9'WW"X E?ASYQPHN?S"669"8Q5J2L8EV*!([$6P9.*X,E[#-X3EW!=
MB@6.Q%IP3RNXI];N.:%I5'1*F2:!92YRAL$BY_(VSD%(DP5)D;Z>YLD",S7.
M-Y?E^B$779+DB1SR:NXW8;>&[XJ]$#MI#O:MH>XH7(OE6<7RS#X1YBQ<R30+
M9&I&_ 0RB2M/R>L3HE6V*Z-";-1D--B"Y"A>"])Y!>G<"NF;7"(X*O+:D')A
M!'*^VX:A=^*-X-;,/K'&ZCH.'8FUL'B#.M<<6,$\R)R/K9D<C.DC6&)S3RDU
MFB-@--!_6V#LP;J2<:761M-(PSTKF@ O,6,XDJ.IS0ADZ 4M8FQ$Y>V@.CL=
MF5!Y.[W->&/PAAO;#81U Z&U@5.QTE.K;*9JV=YQ4<HT:S#T#,/"'J[SK^](
MK0VGSMT]:_;:88G*N<Y#,T9#C".N)N 0IT):="-,I^E\J=;J;CL=Z!!INE?G
MZ9X]47\[2+&2\5<TCAH( 5VGF/$5,::N]M"=80X-T]PVS$-D]5Z=UGOVO/Y7
M8*98 ('21R*G+(!D K5GE#OU :7::&?)V$Z=7(5M ZVS?,^:YX[O<8233!.3
MG8Y0.=MG*D>(*9=HC9R<IO2O5,\;@ B]&)]IN*I'&UR=P7OV%+X!+B:)3#<;
M8W9-Q(KF0F6DLI>&-.7R@I&ETSS=,R3JVZ;<5<0VM3I7]^S)^G01D\=R@%(@
MDPN,$Y#E\FRX>3A&ED#2(N(%1%0>IE2H<9W%6,C1:Q[K1XC+2^4/8'H$>&VO
M5F?0A=JYQ1&Y"MCF7*?[GCW?OT7/VB&B.*9KF<)%A',:YYH6?LZP[)'F2=!E
M:C_Q#(["D#8'KJ*VG];6'@#:/<"^AT720=Y((TE0#&9%%YV6N:()G3U(5W1.
MU0)7:FW M9. WGL\2X)6O]*9L$NUP)5:FW!M9:#=RLQ1K)-P]>"#?](ICSYJ
M&#<Y!80T3P4'1R0M)]N/LHOO?T!2QFRN)]#L>^VUZ\SR$,X'ULX'VIW/+S]0
M*G5M#X$F]MB=21W"VL#:VL#7WD&4EF_): +D$I.C-,2 E)-FN:Y3VZ0YW$&V
MZ6([Y%QZG<"56IM<[6.@W<?,T$N"U5A4-H:D3Y@+=:P&;8CX2IX"@N5< !3J
M06MDMVLQ]K)S^EK"E5J;76U9H-T36);K&2-/2.:)LUB&UT!-Y[X7;\S,8]BI
MNW&J%KA2:W.O'0\\?9=5W*GG<:H6N%)K$Z[=$;2[H\TJGI5=-JNZ;/F2M\/:
M?;:S=@_/??6W/36X=$:!*[4VP-KV0+OMZ?Q2O-2SOLB>V(-V1G0(L^/79L>W
MFYWVFLWW]3A>=3GCEHS!SM)S.C0M//;*=-YO<0@;X]<VQK>_$+$L/-,GS/Y0
M9KM<QO6#(2,YIQ[&J5K@2JV-M_8P/GR7[4(NO<C$J5K@2JU-N+$?R^YL#N(2
M_=U7,+XQ";57KC/*0U@?O[8^_BO6YU=-HK_K>'9,HCUV9U).K4Z_L;$SP>Q1
M;Y!5CV-EIRGV>%9GJTVX5WKK:;^^O=C!>XO8(TDYB/%2%AT<GTHHK-@46QP(
MFNEMH@LJ!$WTUQ5&LK>J&^3U):5B<Z "5%N3Q_\#4$L#!!0    ( /2LCE?
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M<&G]12?+\O4]SXG6R:+\.%-RHM)BA?SW+TD^V*N^% DVK[T:_@]02P,$%
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M.MJJM#?M1Y,\P&MB9[:!3KH_?K83 EQ#3L?6_E!BQ^_KC]][]G-Z&RZ>Y!)
MH><L9;+O+)7*+UQ7QDO(B#SC.3#]9LY%1I1NBH4K<P$DL499ZOJ>UW8S0ID3
M]6S?G8AZ?*52RN!.(+G*,B)^7$+*-WT'.]N.>[I8*M/A1KV<+& *ZC&_$[KE
M5BH)S8!)RAD2,.\[ WQQB=O&P([XF\)&[CTCLY09YT^F,4[ZCF>(((58&0FB
M?]8PA#0U2IKC>RGJ5',:P_WGK?JU7;Q>S(Q(&/+T"TW4LN]T')3 G*Q2=<\W
MGZ%<4,OHQ3R5]C_:E&,]!\4KJ7A6&FN"C++BESR7CM@S\/TC!GYIX%ON8B)+
M.2**1#W!-TB8T5K-/-BE6FL-1YF)RE0)_99J.Q5-'R>3P?U7='N-IN-/-^/K
M\7!P\X &P^'MX\W#^.83NKO]:SP<7TW11S1,B91H@&*>9=JC&BY^TO&<?=,N
M1HJCG$M)9RGH<"60Y:J,G(D )(@RI):@?9@2%@.RS%*_CSF+::H'O!N!(C25
M[WNNTDLS@&Y<+N.R6(9_9!G81Q/.U%*B*Y9 <BC@:I]4CO&WCKGT&Q5'$)^A
M '] ON?[Z'$Z0N_>OF_0#2J'!U8W^&6'UWFAT#ZOUS8[^$+F)(:^H[>H!+$&
M)_KC#6Y[?S:0GU?DYTWJT9"S-0AE ZSEYR!TF(LD^(!FL*",4;;8QK>.OM!O
M67US7*PCC=;R0L_S>NZZ!JU5H;5.1P.6_ =7(=X^X#K7Q]I1KG;%U6[DFD#R
M /$2#>+O*RJIW1!#+O(ZB$:E$T,;5ISA*R9E^ KDG8J\T^CA^^JDD8C/:T^H
M.N3.BXA_] ,_"+$?!O4A[U9 W4:@01P+L('6.#$1XH=)OC5)5V".R+V3T?;5
MP75?P/DXQ(%WA Q[N[/>.RD=T3^G'.VUIW0CP(FY@/>*&7[%/"[%?S.\OX/W
M7_E\+2<XR)R65_P=R9U=V<*-M>74C5:J_I^=AG<%"3=7I-^PU\H9#OF\;H#;
MX1&Z74W"S47IZEF5M]<1Z.U#5>W\+VM/V,%!^\CDN\*#FRO/+U;$4OV@5'<[
M.HV"?R>2NW?WS$ L[ U;ZKQ8,55<0ZO>ZA8_*.ZNN^'%)\"$")WD$J4PUZ;>
M6:BG%\6MNF@HGMN;[(PK?2^VCTO])0+"#-#OYYRK;<-,4'W;1#\!4$L#!!0
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M=TV3W(#]_A3'V>M./D#]V<CL?U!+ P04    " #TK(Y7 ;14M;($  ![(P
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M@WY_R;EZ7#&/4]3/VTS_ U!+ P04    " #TK(Y7(*1UO&D#   Z$@  &0
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M'Y06@-+"BM;V&>^8SS2Y.6<X.=?X3+5&:=3NU52'DWU"HZ0HX=I=[S([?%W
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MZ]6"*,]=E3>*Y\4YH357BF?%94*PCN2F@'Z_X5P=;DP%]>FW^;]02P,$%
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MA!8\BG0='Q3WG]$;ERD:A/+MS%+:9V9I^27^=8%/#N!C@FYYK#82>?&*K9H
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ML:*^IP^JJ4>EA5@T4Y_6U'LGF?JMZ8#N :/DWT)(G0O+BE12934[@S_9?_K
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MTKKP)2]6M7C51-!"=TGW5,B>2P]CV18#4P;R^992\3Q1 9I&._@?4$L#!!0
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M%H(>\O 'Y#JNB_Y&-A(1X2#0?RU8\]_'PAU8MAK7:G#=:G#='/SJ#/CB!7A
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M;H"%($P#?7_%M5'%B>F@?"<T^1]02P,$%     @ ]*R.5[U:!LC=!@  +B,
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M%HL;FEW<'9WQFHVHCC7]$.&&SMQUS.P6I8NQ0Q3[XFZM7YW\BOB1Y )0?%!
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MB#R^)G*\T&+7O ?Q(+06V^;CAA<09 . []="Z.<+,T#[LL[M_P%02P,$%
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MNSJ8H9Q)@<H&$9'"Z[E, 77*K4Y54J1P$)F%@[RJ]N.6H_7G>BM"=Y(+J%X
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MVZH;#<3?;]MV^.W+I<!_;+M/1Q]7_P=02P,$%     @ ]*R.5]507B&@!P
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MI=?D/T"6+!9YS %__FH27-7'L0YRI<L'BN'B"(=31G@B93T_+5L_+9T1_LA
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MP9-8<\YLFRZ5/1=P7\5Q&\1O=+R9T)/4=_ =F0*0G:5O[]]"U6F0@O?/)'I
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MWEX=C.)1YX'8@0G;FUZ[)"KC "_)O=@]6?-7H^AU'^#BQ2$8?_[E^C:&8N_
M6P$M 2NFVF'@OK!$ "Y*F$^T#]$<@,0@(QR@*I'K[>EVFYOPU89^I."&HR<N
M:7IO3^FK%RU]WT)@UZ?:?FN%^RUIP&4_#3%7\CX7;W17:SXVPJ<+\ ("9G1U
M]>=#V(AVFQK@3.;? Q5X[)"HF@]AC13,9P"XV+(R-MI-/X]-)3V;DZLOX3/Q
MVWG#:>CG%AWM^X;3%WU_Z,&SYH_X^L_#7_/9_XV(A#?MH?;P;84LGA? ]3NP
M.*>9I!P1RSTOP\U8.8N155M]T<'O9_2'U7;.I,NJDTL)NWN'Y!\^_\[[:_Z
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M=SMWNWTYOW'&2UU-DM/I*)E/YZ=# -T\_$*G,'Q&P^<W@'/JD7]*\YT>F&\
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M&255WEKBV1M5NR3+/&M'9H%3,A@#=<D?D[R#DF&$-^NZ;%=K#)7[9OV@8SZ
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M_9Y<U$")CQ&:NEL;$$059X(Z:/<\\G7>.&*KY>!QYVSASZV"T&^'ZRPT[L'
M3->L(X=6@H#7>7T?.;HFX .$6W4HG11Y^&(4.GB3)H5.-@#3A=U,FT3H@R$
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MT1'VL\N7_C3Z4&/MIXH:0$)+;?B!,3H\.0T-M5';;6BW]6_+2Z^C/F"8X/$
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ME+H/@!B<$N_I;\H-_8E==[K&%^ Y_LRY^X +;#$)AN"]^']02P,$%     @
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MF: TZ804FZ5)T^U3L\G @BMG3B<:*9$D\VJR*I,K/ MGUR3?Y\KB9) \H*G
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M,-$N+IWC5#+-*2JL> ,<1Q/"MX=?'*@O*B[;X/C 6Q8*<,69OC5;K^A/RYS
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MNK_20!5K*5?D'!N@CS?6F^Z"(>@^XSFB%9P<(DO$FJ&PJX26*F.BS/KL'3Q
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MHXT:V(%*6N4 2Z?.QM:='FPM/00N7\_D;@)%5!Q"08B"+5$HR=UT*. %-GO
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M<VAE971S+W-H965T-3,N>&ULO5;;CMLV$/V5@1($+6!8$N7U96,;V$N#Y"'
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M[>@T#<,M_>^@\0FTOM;:'0+_@/8/:ODW4$L#!!0    ( /2LCE<3)NY;]P(
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M+ED6P/>E09;7$SZ@>3M?_0U02P,$%     @ ]*R.5W02!=&:"P  X2   !D
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M>%]8X2UQLN0:8SR\H$CFD$)CHOV 1T<7G'U:81'Q',$U9T]X^^_Q;I,$FD
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M$']IWV^VT\%TQA;J6I&THQJS(?4$,(\JN;'IWB3RC8W--M0>T;K7XWQ28+]
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M @S%0AL%L=TA0^]<1S\A,\%4UL'276C.L*."N2GBN.#]9VTVB3[VG;QK4?#
MY$4V&;[8Y]:'AF65F[UBG_#L-)NBP&NI]299Z4VRTF&&E;OFZ=JB=[EU$*8X
M^O%6'9H*HZ'_";&5.-#>X?E7M9#Y1GQT^@YA%HLAZO2B]=.=1KNZF=830TD\
M'-OY/O_2\EB@<0**4G:-F1"X ]$Q^SOGFY!.VV&\W87LMUH:X0^: EL04[RE
M[/RRI9$/JH7"K;,+)U<$H'1G&B%D4:I<6^D*NC9 !4$*M 'KMNNKN#XC="ZM
MTW\TEYV=.90.Z(K$QGN( PGF!QI,G?UA15.3_V.T7](P;9TN=1<+!S\'@FQ%
M5T.ACM2!Y !T +GTF8)=':]&FRU2L]89:'K]E42F>7#;2W1'GX?QFA(9':^*
M?,WAN; A=HR=2/9<G9)46=@J,+5AV8KNJ+8F-9A/C]2*,\M_J%%GCX:SZ?$H
MU81DJ[<)M^B. S?;5'0R=6KJL^(-[U(]XO5XX$=045@8@<HM"U^Q3>L^DU!#
ML*\J28:+28ZL0 KF3L62P2'_-0^INXB>Q"'H6J'0'J_C=^O >Y"]V79L-P9C
MSUX[J6=")T,YL%BVH]M/ 4B_2UET_%P(\/UT^/#3"3/="#2W[XOF2>>S,]_,
MT,=U(@NTO_$+=#O:?K^_BI^MM]/CQW^D213R:!;4'$N'@^?3HW@9V#P$6_%'
M;/0QR '\<ZD 2D<3\'YN47VE!]J@_;\:+O\'4$L#!!0    ( /2LCE?2W,(@
M,@H  &8>   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;+U96V_;.!;^
M*X2G+5+ =6PY%Z>7 &FRQ1:8F19-9^=AL0^T1-O<2J)*4G'<7[_?.:1D.5:2
MMC/8A\02I7-X+M^Y\.CUVM@O;J64%[=%7KHW@Y7WU<O#0Y>N5"'=R%2JQ).%
ML87TN+7+0U=9)3,F*O+#9#P^.2RD+@?GKWGMHSU_;6J?ZU)]M,+512'MYJW*
MS?K-8#)H%C[IY<K3PN'YZTHNU;7R?U0?+>X.6RZ9+E3IM"F%58LW@XO)R\LC
M>I]?^)=6:]>Y%J3)W)@O=/,^>S,8DT J5ZDG#A(_-^I2Y3DQ@AA?(\]!NR41
M=J\;[N]8=^@RETY=FOQ/G?G5F\%L(#*UD'7N/YGU/U74YYCXI29W_%^LP[O3
MZ4"DM?.FB,20H-!E^)6WT0X=@MGX'H(D$B3?2S"-!%-6-$C&:EU)+\]?6[,6
MEMX&-[I@VS UM-$E>?':6SS5H//G[\O4%$I\EK?*O3[TX$CKAVFD?ANHDWNH
MS\1OIO0K)_Y19BKKH;]\F'Z2/,#@$*JT^B2-/F^3!SE>JVHDIN.A2,;)M$^@
MA\FO5 KR"9,G#X@S;<T[97[31\TKKK1+<^-JJ\2_+^;.6R#X/WTF#QR/^CE2
M5+]TE4S5FP'"UBE[HP;GSWZ9G(Q?]:G[-S';4?ZH5?[H(>Z/8NMAZH/)^+GH
MLA 77OB5$JK,A%D()=.5T*575A>BPG^3#<5:(3B^*&%J1+=R7N!/(]@543#Q
M8J$X<P@/GUAZHFXK+*E,> ,:(:LJUZF<YTH@23+1HLYSD<H<.TLK-@K_)(2H
M';BLI ]L0%U9<Z.S0*>#Y)XEIWR%:+96E9[I7WCS(B,JI"#ML"U(E,@ $:NP
MJKTJW$B\7X#,JERS-*TJJ2Q+XTG60F8J*KT)BM/[TIERER(J#[I:YCTV&)*X
M>9WI<LE:->^G?O=]5K2Q2E>/D?B,%5T 2[ZAWM5&0$VK4F,1Y]B-W_A:2PO_
MT>UZI>%.+&Z$26&ID?A3B=KK7']3_.Y<YK),E0BUK5!^91@&,DU-77J2?,_L
MY"2D= 6[9W$I["/)V!#-(J/B$=6!C)P4Q(:Z<%2JR"]^K5187^@2 FC8PWEH
MC$KFPPYDQ.!&$L<Y%=?);9#?:S!:PGJ!#6.$:J!K(5G* #_PR>6:_%XR'^=(
M*WH%/H4A KM-:]^.9G%?QD(*WD A/5FO8"<RL"?S%X2Q7']1^89P6PI"$0/8
MD<TJ8[FRPHH2>+]_%Y0H/(\0#*+1\Y4U]9)]*):J5, *<UL@?#QE/3!@5 87
ML9: ;% 1TC7^8#)6)-@ K#OB* HPPH&\D3IG?C*D!4!==6 ,K%&P :,E;F$9
MBK!4.L_P8Y# %?\-W00>D\<@AC<6P9]WO(W4PLT2-F50KN1-R @;$5-FUFLD
MZ3@8'?J)(+QV42."SDB\;4!'N8HSS(W,ZV T*&S6#'>Y1"?F@H8E@-_K=.*P
M#=*%@O,A>)O@FH#=S6 0YYNR1@35UVH;G4"&+BAO6-)_&U&<*4NGFO"%89%Y
M0OU65+\%JB\B8P[$-268F5,Q'?55IT<JP.Q. > <LR>.$P=SX&VAO7LN%M84
M% %("#7! .UN *+;R5N-P*CW4=Y8\QMY<4M)(C2WC&])',@O[J5X]LLL&4]?
M_?0O[T2[B'?!63_.\C)6D^;^"5]-DE<]*U<-:+I,NJ_VW3_TWC5EP+\N\UE[
M-?UY&;M,/AL/Q&X-<-:YGK;7G[MI>+]JA +@ I1VGN"RJBF!Q)331!H5A!J9
M8]/&W(^C+:NYA6"V##-"+U?.GX?;%F;7K82<$9+):"R>-C_LS5"R3!H2!Q1(
M\"P9'6^=AXJQY-CORU,'D[,1^K6#9$P_#<T'KCZTR\%X--FN?U244 D*W6I[
M<,PLIJ.CY[TJD?>?WKEJ_-E-"YP)0WE5!:H:3J<[^W#)6W(_HQU;W>EEJ1=(
M_) HED&W5P [6]Q3Y<'VL83";79)&)K3"?KO3"57^Z7AQ]G__N%7U EK-\#O
M6MK,=2-H/#S"/MN%Y'0X'B?BG;[E_-C:!%TYL*)1G+?DR7!Z.NG>C4_$19I:
M-)C;EV:3+=XFXQFR/]HFAFVS>GJRY9&<18"UY*=[>+F4E?:Q0_GT3!;5JZMM
MW6A>/AJ>3*9[I-?>I%]>A-Z0(A\T ?5-&>R1Z:3)00^@IDU7L^'1\39#)6?#
M4ZB\X\4.N/9=^=&J2NIL7QV<G#JQ=G"*,OJH4'>AW!%R>CSK"GDR'8M?T<6\
M[,T#[:Z!L"-&('TN?N]V,=\OR$/UK5EYO&^F3NFQOOG_V36'<Q-:Q'!.B_(V
MC7,?%^Z4*ZHGR%5U%0\MW]%PH\+8QB[AN.RZ!R]#F; W7<Y5(%=9C083#+D-
M;JU%_&BXF-4Y)+7J!K53YGOB=WPZ;#IO/.H5==B>JRH<^JA_%S0O\6I)B-"[
MYX9N3WWAR)&983-SHR[+3;>MO[M/YPAPO^',352SQVS]K@[GR\9>01VYH*-N
M8[;65\0B"!@ &OI5*)<;4FS840@50\.\C^(2%(RU"+)P?(X=<K/E/6<)DG3(
M9VI+IZA\,PQF5&AQYKG&X1N*] :^^DJC M32R7C\E':Y9X> ^+1M)DB8/GX_
MUC^)-=KS)[/A:3+CM2?'P]/3LR&=OZIP+,HW# \(ML>%;;R2&8M\UP'B@+)+
M,GZ%RNCX<O+J>><P( Y(2GH8,1&=A:RLX:!PB)@3R,@X<%,<PH391M ZUP6*
M5(.(6;#?+@B?__5.X>[OOC6;)_%0$AM#UHW5(:LT(Q$0G$7S3T\[.?EH.CR;
M))V%D]/A=#:^WT)M\4[03&S+X03UXVP6"Q<3;UE.DN/AV4XG,B-_;\L40>P]
MC09+$']"S)3HKB]-QFG+TXFZ.X?AH*$)VJ*VG/C9'VV8["(B=$>4$EQG!A%&
MA[4+LRU*.J94\9R]$*FRM*D@02@$:<#5';EUV\\0&9QCS!I)W:UT%<:<B$%$
MSQ\=W,0HNR-@DSM3!![4V.WF[N*1;A#;."_#4A&:'3AV3B5;:6+P;E]S I%-
M$>MI(BNNXR>:Z2QIT@W;G@1S(,IA%9ZA=9S -:6BCL:&"42_^XBEQ.J&QFT0
MK!WB=>>;7<'B?(72KLDUC2K[PGS72$@4H9(3)6<N[ZV>UW2LNS>>MYN.Q'5-
M,\9]85)3YUDS$XJYCZ-@IQK\J$OC\+B34.[-=)W#")45-(\[A;(N:08$+'Z+
M*;NM&CQ)-= _!BZKOXK'8%G0!)8VO)\!%Z0(G [<4;O6&F4\#I34K4=PQYG2
M2'R _3OSW0H>3#<B>%[2V4&UD<$2HBV2.7>-5N4RCO0?4(HF=-39&SZ*0O[]
MX5(0HCGH,X)]Z-30*<2A$O5]H4Q911].R7LE;:UN93/0%/,P') U6BW+;="H
M[Q/+8>=37J'LDK]P,G)*'[[JM:OM1]0+_G9XN'T]?(']3=HE9;I<+4 Z'IT>
M#W#@Y:^:X<:;BC\,SHWWIN#+E9+0E%[ \X4QOKFA#=I/R^?_ U!+ P04
M" #TK(Y7P-Y>;&(<  "Q<@  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6SM/6F3VS:6?X75XTRUJMBR2-UQXJINQ]E):KSCBIWDP]9^H$BHA9@B%1XM
M]_[Z?0< @B0HJ7UD]L-6S<0M"@3>?>$!^NZ8%Q_*G1"5]W&?9N7W5[NJ.GS[
M_'D9[\0^*L?Y063PS38O]E$%'XO[Y^6A$%%"+^W3Y^%DLGB^CV1V]?([>O:V
M>/E=7E>IS,3;PBOK_3XJ'N]$FA^_OPJN](-?Y/VNP@?/7WYWB.[%.U']>GA;
MP*?G9I9$[D56RCSS"K']_NHV^/9NAN-IP&]2'$OK;P\QV>3Y!_SP4_+]U00!
M$JF(*YPA@G\>Q"N1IC@1@/&GFO/*+(DOVG_KV7\DW &7352*5WGZNTRJW?=7
MJRLO$=NH3JM?\N,_A,)GCO/%>5K2?[TCCPU@<%R75;Y7+P,$>YGQO]%'10?K
MA=5DX(50O1 2W+P00?E#5$4OORORHU?@:)@-_R!4Z6T 3F;(E'=5 =]*>*]Z
M^1:(((I")-Z[*H\_?/>\@DGQJ^>QFN".)P@')EA[;_*LVI7>ZRP12?O]YP",
M@2C4$-V%)R=\)PYC;SKQO7 23D_,-S483FF^Z<!\K_^L9?7H_=?MIJP*$(+_
M=N'(4\S<4Z!B?%L>HEA\?P627XKB05R]_/O?@L7DQ0D 9P; V:G9+V'!Z0FN
M@V#D=6;QWHE"BM*[]5[EV8,H*KE)16_0;>55.^&]2O-29O<>2)#PO:/P9%G6
M,&CF3X*Y/YF$7KF+ '$OWUXV+Q@+[]ELX@?SB3?V;M6+ATKL-Z(PS/5Y\7Q_
MB+)'6-.+ZFJ7%_)_8)XJ9R"\^H!_!Q, @_YO@7(PJY:TZE%6.V_NKU<S?[U>
MZ8'10R33"*%$J'#2*(O%V'L/:\-B]S*+4K76H9"QP)D1KHL0/4:E]RR8C">(
MY_M+WXKBN*AA5%SOZS1"L^0E\D$F(DL 7N9) ;Q 4%8P]S?> <@695F]]\"2
M50.0GZ1T7L'@&G0T3B.$Q+GV410"&#=? 3:_"V\7P;=97H'UC?,B0;; TM8D
MS9LR\_*Z\.(<OLQ*G#_/RCR5":"1>%L -8LE0%!6\ ",.G@2[S9-GRI8NXAA
MV.8IN!.4V0+-;OFM=RU'ZDWR%]?1R/O7 0T_+&H]OYQ'0(G8^A[8@E):@4?2
M+,II?BTONSQ-@.3P9R'@D<Q ;/$Y, U9 8\:7)%4(/=[>)M72T0E"C#OL/SF
MD5[[L\XK"73"X8@;/BN1_ULM<-<@>U'R!_@(I'!>$'RL"9HOOOI<'E)9^<!&
M)(-H/XSS_0;8PZB NY9[4)?"@Z&P>+3=HOL$.E^J$B/O&H?^_6^K,)R\^*<$
MZYOPY#Q0@/+1E\&+$4 ,(,HMFAPC:^2PV0+D2,RC!(@/$5.%-2?Q;D$7@+$_
M&/E#8H S9@IBJ#%"D8RC<N<I/C!__-/3 )AE'>^,[2@U=Q.ECK$1)5]1F3AV
M+16++%%[2];$!DPIR2LDW5;&:LH?1"GOF0&E;U$)/@!]/(J3+M<0HO[5B26N
M1B,21@M-@$L0H[5DDY2WL!U[UYN1=UM#/ +3Q#:>_\J42M;%S:.(R%!)_!*"
M/$T^Y6$ (]!Y>("$J, 69 G*UA.-  R'62(-"WQXU*KZ1+43?R+[U1LG- [_
M=(LRL4A+</(9 OQ_0UH_23!PMM]RLA)*6/]!T)=/<J5H<('ZLDJ9=@\YX$ N
MO:&'FXL8W(- @#!4.*2L-WM9*0Y$/(]ZC0R?FLKWQ,<8/"61K>%3D3.9)$OU
M"45":PGO%B!$LF#"1@>PJ3$%&VET]'%MLIWYO< 5+D,'S;J'V@*S@)\MP5.^
MCH GRL% G&23*;(D'5$EI@'O#L@U1?\GZE=^1&/52!-[?Q8J0!*=!D926Y!V
MEA9[ (('BKU))20E8-T[0DGCB24PL(H^"'(ZZ+F.!3(MH\!!::'-+AR/ 44L
M*YSVI.8J!^F2^#<RDWM0:J=Q_L^H3*(_0=-+%N8:B#-?3.?7"=M,%ZLLSPTZ
MHNP<16)I#G,@,]$M/XT#J N6@:28G*T>&!B?Q B^9N.PW4K,3C&0TZ*.SRT5
MC$ U_H" L3+F&"WPC=L"7ZJO/E$ZVE.4$:45&JM"' 1P!1C:*-0^3^3VD8A
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M+>9KH$?(;6Y/D5Y883Z9V!]GZW6#XR<Y@@%KLYPL_' V_8K69NBS0>>3?,$
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MF^IDT)LO%+[K#CH57K =#6G6UE3#/%6S E\^@2&]"P8Z[( X P6-N<+[!)\
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MTI\[$8$-Q@'P_3:'E$U]P 7,KU2^_%]02P,$%     @ ]*R.5^-#NVO'!@
MJAD  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL[5E9;]LX$/XKA%L4
M+:#8.GSF G*TV +;-FAVMP^+?:"EL454(E62BIM_OS.DI-AQ[*9H'XK=O"02
MQ?DX\\TI^7BE]&>3 UCVM2RD.>GEUE:'@X%)<RBYZ:L*)#Y9*%URB[=Z.3"5
M!IXYH;(8Q&$X'I1<R-[IL5N[TJ?'JK:%D'"EF:G+DNO;<RC4ZJ07]=J%CV*9
M6UH8G!Y7? G78/^LKC3>#3J43)0@C5"2:5B<],ZBPXLA[7<;_A*P,FO7C"R9
M*_69;MYF)[V0%(("4DL('/_=P 44!0&A&E\:S%YW) FN7[?H;YSM:,N<&[A0
MQ2>1V?RD-^VQ#!:\+NQ'M?H-&GM&A)>JPKB_;.7W)F&/I;6QJFR$48-22/^?
M?VUX6!.8[A*(&X'XL0))(Y X0[UFSJQ+;OGIL58KIFDWHM&%X\9)HS5"DA>O
MK<:G N7LZ7L,E-^5,:P"S:YSKN%X8!&7G@[2!N/<8\0[,&;LG9(V-^RUS"![
M0/YBOWP4[P$8H$&=57%KU7F\%_$:JCY+PH#%89P\I-!^\4M(43QRXO$>=9*.
MY,3A)3OP7G,MA5P:=M62S/X^FQNK,8C_>8AO#S=\&(X2^]!4/(63'F:N 7T#
MO=,7SZ)Q>/20K3\);,/R86?Y<!_Z(\-K/\;+*'[%MH'8.3<B91(?%/2 6ZO%
MO+9\7@"SBJ6J++%.8 :EGW-59*"]L''"PM"&JK:0L?DMR\2-R-!%S.;P?9 H
M3#(K5R\@.^ WH+'\,5F7<SQ-+3HI.M<PK*3&<ND.PR+LA%$MH;(^NZPU+?M;
MPU8Y:$+&O$=L!AA%3C<A$1(">K)2=9$Q7A0JY=;I6'%M12HJ;@G*0(J85N#!
MG%5:54I3]>1%0P.J=X>(Y<^"QB)SGQ-E46#+PITG-91@8R!\NMR!L,D,DK(;
M\R7!O'@VC>/PR*[405IP=% )-E>96XZ.7O79AUJCE;  K=$&YZ<U2(01V#AD
M8QI(Y#@#1-+>X-KK0+Q8HA[=0SIBQT)/XQ9D=[[;[#Z[VJ5\C@8['F"QP/9%
MK&2BJ-VVN;(Y-2(,93K<K>-9T):,NY#--J,#0;S;=L<-/J\=$VU$@W%1T\6+
M5#[0]\7-'%)>&Z?_K;=$4B9(5[UJ=*N:%V+)75-&G":]) :Z;L[LLT]PEVVM
MA46;S>M1P/@"0Y MT3^H1<M]!TX<>N9NULGTCE85;?,^7'&MN;1H6<ZM\^AZ
MWC5,WJ5>P.!K"I5MJ#-UFJ.5<B<G/NTP&/ ,T2K49^<-54BQ(TH#Y=L&_UW.
MHW?AH*2VU_D-J/LQ[%T67.UH&YBSB%I1T)'7E:@M H7QR<<QG[EI(FOW=J^.
M,BT3Z*P_<EK&$%FYH%(6T$@,F=L[ZM<3$UV]7A<9?*G%#2]0J$GL5YZ,.8 D
MFHN:K%QH53I%?5QX#[=Y@<^W:L4#Y;.-3.>N^^G&Y89SF"BQR5ETO:N2C3-:
M!QVZTA(F1]_]?]-;[:KS&GF,7=VK1L,@C$9!&,8LBH)Q/ RBT6AK4Q>]A!?%
M1VPX#J(H8A?K/'>;HF$0C\?!.!QU^S\"#A<BM1UB+07MG-+QTV[;AR9C*/UK
MG>8X#F_Z,@[&21S$X9A%P20*@^DXO+,Q"L+9))@F$8N2()E&012/NZ=G5%I-
MBNT3=< 0>8]AQ&:![P9:+)?@4K#I#^2I ^\J/'L!W-::TL?@,.X:91<MZ+@U
M.72ZPMS 4B3Q]:9=?8O&8L"NT7KMK'DC).YS!0!2?.4Q5--="$H,,O=>4B%K
MU(JJJA!IV_8Q]C?BK@E%2AUL-C="U0:30QA3(^"]]M,G)GAC2H!7&4#IJJ#O
M0&U5NR?63A=HT?,XF$TC=#>%:ZHT90^G*D?EW5E!_'[WW(+GT:N4]P[5ZEKR
M.A.T<(&<XGN:OS*J$!FWCD3\AR]PUJGUH6KJ\F9)8Z6?Y'?5,E]>[I/06I)M
MVK%5K;!)/P_[D_C[CGQH*/[6R#E\S,CY-$[^[\;)@(D%C9#!TUSY-%?^BG/E
M+7JXK867D#:EL/F6T4Z2T=,D^<M-DAO.NO_0.8\<MS4K1G&08*=+9B.:*)/)
M.)A-PMT391Q,)]-@%,WVSY3MA!@%P^'XVW,BCK(3' <G-"<FX02O9IWJT1B/
MG 6S64BZ3M"Z<?B-.1'W_>B@>'X0_W?FOVD\^RGS'^F]<_Y+UV<]T\YZI(':
M'O6HRNPJ,I3WPOS0C#?K1\/'G?70-\K!VN?P$O32_4I  UHMK?\RWJUV/T2<
MN>_O@[OM_E>,=UPO!=I=P )%<?0<]9CVOPSX&ZLJ]W$=VZU5I;O,@2/#M &?
M+Q0&='-#!W0_SYS^"U!+ P04    " #TK(Y7.X4J!#('   F$@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,"YX;6RM6&MOX[82_2N$VULD@-:69#MQ-@\@
MV6W1+5 TV.S>?J8EVN9=251)RE[WU_?,4)+EO+H7[8?$$D7.G'F=&>EJ9^P7
MMU'*BZ]E4;GKT<;[^NUDXK*-*J4;FUI5>+(RMI0>MW8]<;55,N=#93%)X_AL
M4DI=C6ZN>.W>WER9QA>Z4O=6N*8LI=W?J<+LKD?)J%OXJ-<;3PN3FZM:KM6#
M\I_K>XN[22\EUZ6JG#:5L&IU/;I-WM[-:#]O^*]6.S>X%F3)TI@O=/,AOQ[%
M!$@5*O,D0>)GJ]ZIHB!!@/%'*W/4JZ2#P^M.^D]L.VQ92J?>F>)WG?O-]6@Q
M$KE:R:;P'\WN9]7:,R=YF2D<_Q>[L#>=CT36.&_*]C 0E+H*O_)KZX?!@47\
MPH&T/9 R[J"(4;Z77MY<6;,3EG9#&EVPJ7P:X'1%07GP%D\USOF;AXVTZLT=
M[,K%.U,BUDZ2NZXF'M)ISR1K)=T%2>D+DB[$KZ;R&R=^K'*5'Y^? %4/+>V@
MW:6O"GQ0]5A,XTBD<3I]1=ZT-W7*\J;_@JE!TNQY250H;UTM,W4]0B4X9;=J
M=//#=\E9?/D*SEF/<_::]/\+Y^N23I+IJ7A)G/A=(<&L594O]H+JU^-/^(UB
MAXL?_VBTWXL/588=J!QQ7\A*G-#S'[Y;I&E\R=MHE>^3R]-([#8ZVPC36'%G
MI,V%68GWVJ("C75"5KE 0F=?-J;(%2W4M35;X(+>S%156ZD[[3>,XZYQL,@Y
MPKW458 -(A)U8VOCE"/Y:RN!KUH+Q8#?+-E2W<.6.P!QPAN&I<JZ,'NE AHH
M=2A?"' 1'2F:G"3QQJ\J:UB 6:UTIEK\>6?-6-Q;#2B0^Q+42'RR^D$6C0L@
M 2M@?(JN0<W8UO?QA;@%[:&(6.-'Y;RDL]\2$)P=!F0L/G4B>?-.%X6HC!=+
M)1IRT\H4H&6R^24CQN)GLU-;92.@V7=X.WL>X68E5E$R@>:7_X.K.@=Y94N.
MU_%FLI!6D J%SN2R:%TBY-HJ!3=X -#(&HNG1;%'BBFQD=L6OZD)(T)#T1FX
ME9*D,-7Z#:E%F =IWR7"T_@N528A]2"4?//29HA!$RSTGTIL$6*HM*:$*=J1
M\I(L;8-]I-U4*#8=O!#.M2YA3Q;[0R(+!YU6>XU<A6%0!FA6%9)QM%X-4"G<
MR?FE(YPVT]A7PUVJ*\?C50&$#MU>>I:PDMJB^NT7+'T[(!.(@M- Y$C/L?@\
M2(66%R*^)=)!ZO0@ S.4<M\>_]NZ[6LV&A8LIXZ! HP88&"RC-A$,[.T-K2J
M>:NF(XA>H0'7,<FT=%<J67'9K\1#2T&S-.UD?$"BVTH6*,2MJAH2FK.3DHO%
M6<29%ZIUC*WP3LC2>31?S*,X7@A'_ M]RL*FQF^0R7\^JIS6721 R#S7@3SH
M&1\6;8\)Y0L9!M-(*(=#9@#T+[)J,%B)A)-/(O)[)2W7@A2U ETQ(2<QKSM!
M[BR!/6/C!^>YY<XB=AM,>^[Q=$J$244G2].$*,)'B-9)<BI6%$!HI%AV?O3&
M8T/5E$O8C;76+^W354/6Y+IH?.A3)30^4+/ C$5%#&+*"<5[E2D6,4VZL^C!
MF6*49%<D8.])>@J;"W 9=CZG\R4-R_V@>]4=PQ]Y5HHUS*M8V5B\1TFT](DD
M0C*%(2CP-T88WZ)MYQCFKXX]DR@YOXAFB[BG'&Y]$GMHF*0& .+%;!RJM"_/
M[T4Z/CL3(4#)8A;%R8*2Q*.^Z10W6608I?RW2YQ-Q5C<NE &3W&3A4N)-,W4
ML%_YG1$U5E$&R-0E3?EC[D?Q]/(?_S[%T3^Z/932;XU'BPQY>KN5NN V0FG_
MP;EFV&V2Z"*91^?I;'#%O)1>'LIP4+L7<1S-XUC,HC-X>8Z53YS%Y[0:G4]3
MD4:+Y"Q*(>>PIX?XHB^YAQ$'('/-NF(KCMJ$^DK776CF,4?Z>S&=GB/JB'2M
M^&V&F(;L[#L6S0L/GU_MSU$G"Q:F1Z>?.]13TV]=57!]29$WJ-<!GQ&5:.^5
MHH-6F17TY*@I]&YNER](XSX@"V=0A(5:@YJY0:.0H*4TEEU %7EHO)N>1]&3
MO(F(@8BAN!40J:_1*(B%<N7TNB*1AZGOI-N&.'<B3T,SSQ2Q%KE6KW1?16T;
M(I\1J?14$2K^,;,,AA[7@("',EYID<$5&_G4NH'",!<!IZZUXHGUT'Y=-, 3
MT/I]':CNR Y(7/8$%#T>O9X. ]P"'DT5W<S&[=9QZG0-9Z!K.%#3[H.4T(DZ
M*5OP%NVA[PU(JB,\0"N/93Z:*@N-I).^P_ HRP*[]\5A#\P;6+%Z/!I5AGM&
M2(\$A?^?3BJ!+'D,/R9.V;;HQRVEG:XH-OU+ROBYE\/)X-V]5';-7R@<R@E-
M-;S&]ZO]1Y#;\.Y_V!Z^H/PJ[5K#T$*M<#0>G\]'PH:O$N'&FYJ_!"R-QPS!
MEQLED9.T <]7QOCNAA3TGX9N_@)02P,$%     @ ]*R.5X2]Z;3R!@  MA
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M#5'5K"3'88,%*59>%Z4BCV4AFSBX!%H<B=OX-#R5C*GE2S:+X]-XG"?A:1R
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M*,N ]U,IS>I@%51_)L-_4$L#!!0    ( /2LCE<C7ICKR (  .<'   9
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M)@9E$W!]*:79!O8#S=T>_P902P,$%     @ ]*R.5\6P.'$  P  S@@  !D
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M$^S]Z5J^7##EOFA7ZR9)@/*MTJ+<@XT%)>7U2![V<3@"]*,3 +P'X'\%)'M
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MB%V<Z3[.67J2<(%U#_K))TB3M'^"K]_I[@>^_AM\UVCE1OB*@#M-SC9<:(Y
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MKV*9\XSEBHL<2;88.C?^U3@T\E;@,V=;U?A'QI*9$,^F\S ?.M@HQ%*6:,-
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MA/U=P5./22, \PL!U]"R8Q:H'H^COP%02P,$%     @ ]*R.5P)<[?UQ"
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M3]RO,U5S]\)>=7FS5][6*E=JIE4%0&,K_[79W#,EDU7ZM9%DK["U/<^!K[C
M5VS'UU-  -<9M#:$K+6V]LB1FNE10<?83L=/,P-^&H3M=;1VI%ZAL>:9F18D
MC.TDG--%@*H/[H_0A5VP[>;E5"UTI6::63 V[O\$=(%=OI&>.U4+7:F9'50\
M"V#[L\ /T06N8[S?'U4?8>?VJEH;\QROM''QD('M#QFGXD7]#?=EX/M5IYP^
M0;A2,YTJGB"P_25W&[JHO]P&NNA[HZH_3@'>E9KI3P'PV [P)^%%G>=KFZE3
MF'>E9OZR7L!\8(?YI_$BJ'-[U1%[':U_)/=J+SC,1<],M8#QP [CI3G2F&<=
MP'&_YU776GLEK7-]#@ /"@ /[ "N3]TP%,,\H=^H6$:R>034D;LWJCVXV:MJ
M;<QS4'=0.G%BI^Y\:6WT(Z@/4 #@ZEYCKZ*U(4Y?4W=+)[5V5&S2$V\2+7D2
MJ^,QH_QN?JKN57J6K')_YE_-CV?C"IGC4;WW1 #A2,3H&B2]ET/P2QQ/OQTO
M%-^GY\$67"F^2S]N*5E1H0O ]VO.U<.%KB _@SC]#U!+ P04    " #TK(Y7
MNO,4CP #   A"P  &0   'AL+W=O<FMS:&5E=',O<VAE970W."YX;6RM5EU/
MVS 4_2M6AB:0&/G."FLC04.U/4Q#%+:':0]NXC863IS9;LO^_:Z=$/H1JB#U
M);;C>\Z]OB?7N<,U%T\R)T2AYX*5<F3E2E57MBW3G!187O"*E+ SYZ+ "I9B
M8<M*$)P94,%LSW$BN\"TM.*A>7<GXB%?*D9+<B>07!8%%O]N"./KD>5:+R_N
MZ2)7^H4=#RN\(%.B'JL[ 2N[9<EH04I)>8D$F8^L:_=J$FI[8_"3DK7<F"-]
MDAGG3WKQ+1M9C@Z(,)(JS8!A6)$Q84P301A_&TZK=:F!F_,7]HDY.YQEAB49
M<_:+9BH?60,+962.ETS=\_57TIS'!)AR)LT3K1M;QT+I4BI>-&"(H*!E/>+G
M)@\; #=X ^ U *\OP&\ ?E] T ""OH"P 81] 5$#B$SNZV293"=8X7@H^!H)
M;0UL>F+D,FA(,"WUAS55 G8IX%0\QC(_1RD\$?F[I"O,2*DDPF4&GXU4@J:*
M9/7^:4(4IDR>H4_H<9J@TY,S=()HB1YROI2 D$-;04B:V$X;]S>U>^\-]U-2
M72#?.4>>X_D=\/%A>$)2@+L&[G7 D_[>N^"W_;V['?!)?[BS#;=!Q59*KY72
M,WS^ 2F-<&9RNZ'F[^L92 E%_*=+H9HUZ&;5%]N5K'!*1A;<7)*(%;'BCQ_<
MR/G2I=<QR9)CDMT>DVQR)+(MG?U69_\0^ZO.NU7;)6Y-%1HJ_9-9Q9[K#Z#4
M5INJ[5M=!FZP;90<C.J]:NQ[]!W?<;==3H[D<BO-09OFX&":[W>O/UJF;)G!
M$JZ\'RHG F$IB9)G77FON:/-O(?.3M9[V"0'8WQOTH])-CD2V98V8:M->%";
M!ZXP,[+T_'?)G*]++1SHAL:\S* U@CV82<YHAK7A5,%0& H^KR_1"?1=G645
M=I15Y.^6U;[5913MEM6^D>OY_F#;ZG;?JJM>]JV"8/!*5>?:WN@6=//X'8L%
M+25B9 XPY^(SX$7=D-4+Q2O30,RX@G;$3'/H88G0!K _YUR]+'1/TG;%\7]0
M2P,$%     @ ]*R.5U;EGO2P @  20@  !D   !X;"]W;W)K<VAE971S+W-H
M965T-SDN>&ULK59=3]LP%/TK5H8FD!CY3H&ED8 (C8=)B([M8=J#F]RV%HZ=
MV6X#_WZV$Z*V"1V3]M+8R3DGYYY<VTT;+I[D"D"AYXHR.7562M67KBN+%518
MGO$:F'ZRX*+"2D_%TI6U %Q:4D7=P/,2M\*$.5EJ[]V++.5K10F#>X'DNJJP
M>+D&RINIXSNO-Q[(<J7,#3=+:[R$&:C'^E[HF=NKE*0")@EG2,!BZESYEWEB
M\!;PG4 CM\;(5#+G_,E,[LJIXQE#0*%01@'KRP9N@%(CI&W\[C2=_I6&N#U^
M5;^UM>M:YEC"#:<_2*E64^?<024L\)JJ!]Y\@:Z>V.@5G$K[BYH6&\4.*M92
M\:HC:P<58>T5/W<Y;!'\Z U"T!&"]Q+"CA"^EQ!UA,@FTY9B<\BQPEDJ>(.$
M06LU,[!A6K8NGS#SV6=*Z*=$\U1VQS; %!<OZ#@'A0F5)^@3>ISEZ/CH!!TA
MPM"W%5]+S$J9NDJ_T?#<HE._;M6#-]1G4)^AT#M%@1>$(_2;P_0<"DWW+3T8
MH>?OI_N[=%?'U&<5]%D%5B_\:U8YD07E<BT _;R:2R5T^_X:BZ<5C,8%S9*^
ME#4N8.KH-2M!;,#)/G[P$^_S6%C_4RS_3V([089]D.$A]>P!-[J'%0B"Z6A7
MM?38TLW&M<F"\XO4W6RG,<1,XG 7DP\Q293TF!WO4>\].NC]EC"BEUN)EIR/
M+XF6GVR]U \C;\_]$#3QS_?<#S%ONH][]_%!]WT+GR(&:LQ]/'2?!/O9CX"B
MB;]G/QZ$[P<7P;C_I/>?'.Z<MA>1/N\0/!<@)=(C/I><@@*]6W7EC566#/SL
M?Y0A(MKOJ(/V_G79N%O[MCEDOV*Q)$PB"@LM[YU-M!71'ESM1/':;N5SKO3!
M8(<K?=:#, #]?,&Y>IV8TZ'_]Y#] 5!+ P04    " #TK(Y7-NK.!LD"   Y
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6RM5EUOFS 4_2L6JZ9.
MVLHW-%V"U 9-F[1)4=-N#],>''*36#68V29I__UL0UD"-(JJOB0VG'/N/<<8
M,]XQ_B V !(]YK00$VLC97EEVR+;0([%!2NA4'=6C.=8JBE?VZ+D@)>&E%/;
M<YS(SC$IK&1LKLUX,F:5I*2 &4>BRG/,GVZ LMW$<JWG"[=DO9'Z@IV,2[R&
M.<C[<L;5S&Y5EB2'0A!6( ZKB77M7J6QQAO 3P([L3=&VLF"L0<]^;:<6(YN
M""AD4BM@];>%*5"JA50;?QM-JRVIB?OC9_4OQKORLL "IHS^(DNYF5B7%EK"
M"E=4WK+=5VC\A%HO8U287[2KL6%HH:P2DN4-6760DZ+^QX]-#GL$-WB!X#4$
M[U2"WQ#\4PE!0PA,,K45DT.*)4[&G.T0UVBEI@<F3,-6]DFAEWTNN;I+%$\F
MUUG&*UBB[P0O""62@$#G*4A,J/B /J'[>8K.SSZ@,T0*=+=AE<#%4HQMJ6IK
M!3MKZMS4=;P7ZLRAO$"^\Q%YCN</T*?'Z2EDBNX:NC= 3T^GNX=T6P76IN:U
MJ7E&SW]!;X:?\(*JJ%08R$2(J4"_KQ="<O4D_QG*IU8,AA7U[KX2)<Y@8JGM
M*X!OP4K>OW,CY_-06F\IEKZ1V$&2?IND?TR]??[H_^=O*+Q:)#0B^DVV3?S
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M5 M0FIB^NII(E9<3X6OKY1UVCB2TU BJF5#-@FHV5',J[8T2>VB?'E3SH5J
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MN=Y]D/S7LFG*Y>[+>9X]Y-5V0/OSQ[)L7K_9?C;]2UE]VS&N_P=02P,$%
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M\WF:RN>-_)= JI^*F?X'4$L#!!0    ( /2LCE=[JDEIM00  *\@   9
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MU2SKR?"Z_HD*R>-(UI/"(HLOY,-!T-7#!Y+F@]("*%I;DF:_@(QO(Q^";CN
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MH-YO&)/'&UU _3\*\_\ 4$L#!!0    ( /2LCE>JR.'3\@(  (8)   9
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MOVC?C/4""RTK+FC>!LL9Y&G1_))O+8BC !=?"7#; /<T(+P2X+4!WDLS^&V
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MJ#4$I3$HC9>TW5'XTC &U[Z/;39^VC+U.>%^G*1DY]JC'HVS47D:J]G::Q^
MH081E$:A- :E<12M^0#4;I(]1.=RJ*$$I5$HC4%I'$5K"EV[5+;9IJJZMVD2
M/6J?ZS>MNWMS29TU@_I,4!JW]YTFVY!V:[O)-OM-[6GWS!E:YYI.;J-H76;=
M]E__H.X2E$:A- :E<12MJ7IM1-F7Z%P+]9J@- JE,2B-HVA-H6MKRC9[4R?E
MVJN]U.*TY5JHRP2E,2B-'VV0YLJ!VF9RS#93GD7-;R7.O@GB#%O$,)?450PH
MC4%I_'B+--6HK2&GNS6D1S[-/FGD,].[)D0HC4)I#$KC*%I3]=HQ<M".D0-U
MC* T"J4Q*(VC:$VA:\?(.>(8G3#RE8AC(Y^YI,Z:0<T=*(T?;9"F&+6YXYC-
MG5-&OL%>T4.K30RH'P.E,2B-'V^1IAJUT^*8%^X<&/GL;-P[;>R#&B]0&H72
M&)3&4;2F[K7QXHS08Q]T31"41J$T!J5Q%*TI=&WJ.$<6$9TR]EWL91>W+=U"
M+1DHC4%I_&B#-,6HO1;'O.KGE+&O;5%*Z^ ']4V@- :E\1.:I*E';8DXQRR1
M*/LIL54'Z*H<*(U":0Q*XRA:<T] [:NX%GA<<Z%K=* T"J4Q*(VC:$VA:\O&
M-5LVT^TO_=F2<V-&+4%O?S]ZDT[-Q746#NJZ0&F\I+U-I^VYU*W=%-?X$K]=
MEM&J -0V@=(HE,:@-(ZB-17=V6 %WV&%W6*%W6.%W62%W67U([99N;4EXYHM
MF0ZY%+J>!DJC4!J#TGA).[R&H5"NO[.?-Y3Q(M]YG1 O>W$K]J569ZO=W;?Y
MGN8WY^_L:UKLT:XQQ9;Q!Q$O_"@A@9QKI/7A0M<I+G9A%P>I6N6[AI]4FJHP
M_[B48B;C[ 9]?:Y4NCW("JCVPD_^!U!+ P04    " #TK(Y7\3T='L<%  #"
M&   &0   'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6RM66USVC@0_BL:KG/7
MSH1@27[!.<), KEI;W)MIJ37S\*(X*MM.9(<FG]_DB$V6+)H,_T2;-A=/8^T
MJV>E3+:,?Q,;2B7XGF>%N!QLI"PO1B.1;&A.Q#DK::%^63.>$ZE>^<-(E)R2
M5>V49R/D>>$H)VDQF$[J[^[X=,(JF:4%O>- 5'E.^/,US=CV<@ '+U]\3A\V
M4G\QFDY*\D 75'XI[[AZ&S515FE."Y&R G"ZOAQ<P8L9]K1#;?%O2K?BX!EH
M*DO&ONF7#ZO+@:<1T8PF4H<@ZN.)SFB6Z4@*Q^,^Z* 94SL>/K]$_ZLFK\@L
MB: SEGU-5W)S.1@/P(JN297)SVS[GNX)!3I>PC)1_P7;O:TW $DE),OWS@I!
MGA:[3_)]/Q$'#M#O<4![!_2C#GCO@&NB.V0UK3F19#KA; NXME;1]$,]-[6W
M8I,6>AD7DJM?4^4GI[-/'Q>?;C_,K^YOYN#ZZO;JX^P&+-[?W-POP!!\6<S!
MVS?OP!N0%N!^PRI!BI68C*0:6?N/DOTHU[M14,\H<YJ< PS/ /(0LKC/?MP=
M'KN/%-^&-&I(HSH>[B-=<4X+"8@05%KI[/Q]N[\NK0M1DH1>#E3M",J?Z&#Z
M^V\P]/ZTD?M%P8ZHXH8J=D6?SHC8 +5H(-$/]+%*GTBFN%M9[T(%=2A=_T_3
MV(?^9/1TR,8TPA[V8&-U!--O8/I.F%=)PBJ%2NT,"540EQFU =P%"0_&AD$0
M=0!:C/"!T1&^H,$7./%]*)[4I#'^? 8**FW0 G-4/X(=:!8C%",[M+"!%CJA
MW7%:DG0%Z'>UM0MJ7=C0&->/(M0!9QHA..Y9UZ@!%SG!W3-),K6/G:JWR)R8
M"!FI9UKA .(>B.,&XOC$_"E-Y/*YKA)=(*52*=F[SF-SEA#NKK-I!*.X)P7C
M!F?LQ%DK[)"MAY6@CIF,+=D_[N)SCO3*'0EZK>1X)XI)DN(A536^Y]$[V?M
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M^Y[C)['C_IKQ)Q$!2/2<Q*D8&)&4V85IBC""A(@6RR!5=Q:,)T2J+E^:(N-
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MZ=0>Z=1;(FS,F1,6A\""YBA34S[-"F+@"?-1Z[MP3[.+<*NG 8^?,TJ Q4O
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M.$'3R?E@L^N^8QB>3L-1,VS/L5'CV,@;FJOX?U!0T(.4#%0.32C*LX@G+,C
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M"3T ?E_FL-3U%SU!\][EY=]02P,$%     @ ]*R.5Z?P+9>0 @  3P8  !H
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M]O7-#?X\OYP GFPQ;[F5<QOPFL-Y(& +]VC*5&_$1$B9ME@9U]B%]NS#N&3
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M'NDF?;U6+?$H@H735:"*0?4!\(AFY*<K#0802._$%5ZN]09> _9,3T#^KV!
M">^$O_!M50."/","C  ;@0%PP\P%2('@&\$$@6PU<Z'LV*ES2^-Y&)!(;5$%
M /)5/F+[80H@.*RT*LO,)D3<^=/(@&0&=@%LJ!:P+(X 3FB7H/9 C\!CW-\:
MC:H;B:\8&T2I9"6_-+5MQJ88\Q\0R@!NFW4)NOPS\456;@NVLJ)*<*)R 7I=
M-ZQE&#DQ(4$MN9TQ^/"V-RLL": EQ(@( ZU 70/<M6&UAF]N(P!P>@*1=@"V
M\U]H;OX)^&7&]I+1T1>XR,C)* GX3VVV0FDAK9;!%FJ(&S03 VA+S@Q1S6N
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M)N!0]"%\<B8.=D<4\[K(<9PX1CT! =:)V:;C4]8ZFI_,1S68.QE1P&F^(3J
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M@M!OA^LL-.[!P$S7K".'5H* UWE]'SFZ)N #A%MU*)T4>?AB%#IXDR:%3C8
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M\+W]Y.(O]]U[I8'T;V??>C.QE?YL_R_HS#\U_<,.H6T^MZL;9FHG?RL-2;Y
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M+?WOH/$)M+[6VAT"_X#V#VKY-U!+ P04    " #TK(Y7NVSZ_!8%  #O#
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M?ACY$^?G/<==$/>A?AZ'3N)U.!N&8HU4/TKF,[]T-)YA"57=D+\CROL3\2O
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M+D'!6 L@\\?GT"&W6]YQEB!)AWRF-G2**C9#;T:%%F=>Y#A\0Y'>P%=?:52
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M&"C6/B32W!!L*M+2V$H^=([UN\;24K7$=_21*(=BZ!G[:E&H5A?1^3BZXO7
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MV*%O>6F4M\>9-^&QW@X-N]"2?V=6.3M(VE](INLHB=.WZ^[C=W@.SS+=4HY
MK 1FO657[TC93+5ESE1=OF#LH(@;+G/6-A!]C-N&/RG-4=*3<H=:RL__*M*D
M4&4N-$3S]P)<0!FV08LS534E) 9H_?UW5VD:?_C:\M*Y<0.E4&>RWM*3Y /#
M1--PM,0\5_Z @:D1W6IKT@R6P>8&<@%/.S#,JSWA DA5WD+?@+S,> GF#M?
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M%,B4#W4%3P6\5[]^6Q8/O*K%.N?L/1"$5Q7?L ]UF7UZ];R&"7#8\TP#>Z.
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MM'IJRBWN>@#4(T]A.\$QS7%BC9.OCD?&_GVC8V8@\8E'O0#FE[2@C;-"L^7
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M% !P6QGOBEJH@F?L1MR+HB&AB08+I&6$E2'5N.@@9NY"-S920S$M+FO('6)
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M##+W7E(A:]2*JJH0:=OV,?8WXJX)14H=;#8W0M4&DT,84R/@O?;3)R9X8TJ
M5QE Z:J@[T!M5;LGUDX7:-'S.)A-(W0WA6NJ-&4/IRI'Y=U90?Q^]]R"Y]&K
ME/<.U>I:\CH3M'"!G.)[FK\RJA 9MXY$_(<O<-:I]:%JZO)F26.EG^1WU3)?
M7NZ3T%J2;=JQ5:VP23\/^Y/X^XY\:"C^UL@Y?,S(^31._N_&R8")!8V0P=-<
M^317_HISY2UZN*V%EY VI;#YEM%.DM'3)/G+39(;SKK_T#F/'+<U*T9QD&"G
M2V8CFBB3R3B83<+=$V4<3"?38!3-]L^4[808!</A^-MS(HZR$QP')S0G)N$$
MKV:=ZM$8CYP%LUE(ND[0NG'XC3D1]_WHH'A^$/]WYK]I//LI\Q_IO7/^2]=G
M/=/.>J2!VA[UJ,KL*C*4]\+\T(PWZT?#QYWUT#?*P=KG\!+TTOU*0 -:+:W_
M,MZM=C]$G+GO[X.[[?Y7C'=<+P7:7< "17'T'/68]K\,^!NK*O=Q'=NM5:6[
MS($CP[0!GR\4!G1S0P=T/\^<_@M02P,$%     @ ]*R.5WR33*X@!@  +A(
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M7F25WCA7Q/BE&C"V#,E'E>< %8(+<F:?/&JUXC&3$3O.#A#?L84NH'*1,I*
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M%LI:E;EFRBB4-5P \XE2MN[@!LTGHOE?4$L#!!0    ( /2LCE>"QE=LM@D
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M\/* B$DK8G((_;\3<=C-T>CL(_PK7_!%PZ]FB_F*3$=U]GJP0R $M)B"U-Z
M@*O2D5/GR#A?25T9_S-?/8*Y025VPB(D'0Y'']Z=Q_'P\NYA<1T>1Y<?:;-.
M@5<:8<MRU8-;G?3?Q&&+76:4>@:ST\3=E2LG4TG-#<RZ FM]M:"-QS[<E]:5
M@M208I_A#S3W.L1(OU*0\WL5"J82(O=@Y5*HTL$1(];.]P&_" \ K9TK[59N
MI=Z <"3\A_HZ;I:M:2<++W(_$9+9\>?$Y(7"((]P&"%Y(=:K@(/"%5+CUR(G
MW[6/EN<O<HVP3"3J!%V5J-H5/!"@V%#<-L(S--T@*=8Y*\2S6"GDD)N2+B=O
MDD>22-\=2 ?OR4=O.!SVVHW.**0 2 TNHP)PK7*BG!-@0.C#;4XD)?FCO865
MQC9)Q?4:P\T#GBZS1N^^C/0 !54SW9S.4SXY4%1RMBZ0HK1)1M</+-%*HG%U
M/"9'N$;+IR:P@)SN"XX9/J%-I*/UXE6):?3'S5<R-UO)MZMK:-7^7'4::$57
MG*1S):'Q8I=>B C;-EGA#(S.+AN.BV,800QCF, )G-;/"[\G+GNTFR(DK"O]
M)0-M&5Q765@&_27=+?8[,DC=P7,&$SI%[+!0@B0?L4<^VZ\KZTOQZGQD2(0M
M4$ZU\554MNA\'9 ZG%PLO;9J!04LKS=0 6[1^K:WZ</2OBNN6I:3N52"Z@IM
M[AK@-'0]UX=%L*5+L6JMXVYKS02)3IM2>1_WSD8_\6Y4<B.YQO&)9CQ'[BVU
M.29:5PN=(.E\I]MQ'0B*XWZ>=$:(TI^EK@:NT%?>*O9^.*45*:'XZ%FDWIJ&
M*($) 4]*(DRU2\%$[WB=T43"[4/HYZJ3:#J@,@VL5T(%<M4T*_9'I+_OFAUT
M!JC057E,=(1>:E_-4NUJ.XDNJ@'L97LUQMX)NY%47@K79#KLGYU$8*O1L'KQ
MI@CCV,IX&N["8T;3-%K>0-_7QOCFA1VT\_G\+U!+ P04    " #TK(Y7JM/%
M\U0?   J?0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL[3W[;]M&
MTO_*PM<K;$"2)>6=M $<)[W+(;T$=G+YX</W T6NI*TIKKI+6M;]]3>/?5&B
MJ"1M<0?40-%8$O<U[YF=&?ZPT>;&+J6LQ=VJK.R/)\NZ7C\_/[?Y4JXR.])K
M6<$O<VU660T?S>+<KHW,"AJT*L^GX_'C\U6FJI.7/]!W'\S+'W13EZJ2'XRP
MS6J5F>TK6>K-CR>3$__%E5HL:_SB_.4/ZVPAKV7]:?W!P*?S,$NA5K*R2E?"
MR/F/)Q>3YY?3,0Z@)_ZEY,8F?PL\RDSK&_SPMOCQ9(P[DJ7,:YPB@W]NY:4L
M2YP)]O&KF_0DK(D#T[_][#_1X>$PL\S*2UU^5D6]_/'DZ8DHY#QKROI*;_XN
MW8$>X7RY+BW]7VSXV<</3T3>V%JOW&#8P4I5_&]VYP"1#'@Z/C!@Z@9,OW3
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MALB1@)5R^UQ\-.HZ*X$]?Y:%0F9X]^Z2'@X_P%%,MI9-K7*+OX[$IPH.#NO
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MZ0RH:T8;RIE%(MG@8'FG++DIV?X1B/R,O,78)3Y[;#](GIH\@Y+=#]@4S*.
MSQQ6+$4HB=!7605V%(K::.S=H;,1>=K(:!^&<<!?-4AE=#\V()#E4,_G"6L,
MT*O92)#L:+DZF]@YV@*P48&_G),'K:+MWUK8R$5F"O;#2A><'7D,1S<!T0OR
MW2P0FXL,69X!'X"4S6NG9. @5E>$A)7,^'!Q\M3CN%MF#2E,;WBNP; &F06;
M1Y@C/8$!ND74>S4&#QNY@L=@DX<<>Q1EA4+S8]8 ]%P<%A[!24A4P2R39W\E
MOP,QW4'/[N2'5IE\X2H/'G[9*I_9D#@X)UL.Z<S3\5_9AGX45@#BE54CO](
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MH*PWGW;-O$I>#07I#XSA58KD]OKX2?W]:-?>_*V?O]JMT+(OF#GC&$K&)B;
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M8@NP%=[MENI&4FNJK$*U,$AR0V2^9),#[#Q5VT'D/#\=1XAFJ+@L&K[2O2I
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M[FR"@&F'I<1<(T;QDC*J*5%M">JV>@/J5X)!QZ)\C;3%=M&WZ-_$6J\YTW1
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MDOO;LOU"BZV]<%H*K45F'S<$IT0:!GB_$D*7"V.@NK*<_P-02P,$%     @
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M(CD,X8KDW'0\QV5 56!0/V"P>OLFGD471P@F(\'D&/KJ?J@-4"5TFBI/V^_
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M3C.*G!Y:XR!8U?EVM%:6FIN?UO0W@=HIT'ZIE'T2W 'C_\GJ'U!+ P04
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MO^8>Q>$AYM:COO^XH',I*$ ]N+N2)NX?JKH?M+WM=>S"W4*"K7EUE_O*U8/
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MNQ$MR,*>@3PPIS'L],(;;%V7F]9L5F(\RA$T6!M7=S1LF6>T-DUM ><H7]
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M@TD0<DUT$TAO.J32Z5_+V2:CE7BNC 4,^T<2^1?#8= 0TF6;L2-83?!!)?C
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M <(8Z/=+SM7SC6F@.IJ;_ M02P,$%     @ ]*R.5_H]D8:#!   C!L  !H
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M4RF<&K%A06QX7I:;.%E#V^9U>$S>'YY(*_3*1=*S\J^41N.*98UN*R%'JVJ
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M4'NF"L-)STREA3VVOR>XI;&@6Y:N4)+M.'NB9>'=)8-J>E T H5FOL;7FCX
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M8I$8YG29JB>^_@%5/,;!B*?2/,FZLG4L$BVEXED%1@\REI=ONJETV $@3S/
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M@Z9-VJ2H:;>+:1<.^9)8-9C93M*^_6Q#61+<*)5Z S:<<_R=8QLSW#+^(%8
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MYJJL!ZX#U/LY8W+7T1,T?Q22/U!+ P04    " #TK(Y7";=M<9L#  #K#
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q-#4N>&ULK9=K;],P%(;_BA40 HDM
MMS9I2QL)6B$F#9C6 9_=Y+2UYL3!=B_CUV,G69HE;IC0OK2YG//F>4]L'V=Z
M8/Q>; $D.J8T$S-K*V4^L6T1;R'%XI+ED*D[:\93+-4IW]@BYX"3(BFEMN<X
M@9UBDEG1M+AVPZ,IVTE*,KCA2.S2%/.'3T#986:YUN.%6[+92GW!CJ8YWL 2
MY(_\AJLSNU9)2 J9("Q#'-8SZZ,[F;L#G5!$_"1P$(UCI*VL&+O7)U?)S'(T
M$5"(I9; ZF\/<Z!4*RF.WY6H53]3)S:/']4_%^:5F146,&?T%TGD=F:-+)3
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MN\F&=@NIBO*Y;AY4FJH@_[B1SE+&V0YZ^TJI]'4A"U!.^;3X'U!+ P04
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M@::;.#E-HVVVJ":CFH)J*JIIJ*:CFH%J)JI9J&:CFK/3NONHT"$]5//[[$"
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MLU2(AZ4"[==%-1_5 E0+42VBM&:IJ/MU1]W]NE^GTWQ=?4)(=R<$M69]] ;
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MT01J.*!9#A0M@Z(Q*!I'H:DJRUPH&E",,]!P0(MU6K33A@.:[%BR<A2K>F=
MF0#1 :4Z9L-A1G95B>IU,XD?D#CI.@XH+;.EY2A:52<9XM !Y3K'+8<9U5FC
MGCO*I),H3;J;$I260=$X"DT54N8T=$!.X^Y*S&S. NN5+4<$AH8SMK0<1:MJ
M)],9>B*=>>^^A/;D*U$<=NS?==M,N=@[HH&V)X9F/W:D'$6J3@$9_5!S]/-B
M7RSOI0M-?*!H&12-0=$X"DT5^>!^R11I8"CVELG8>R9C;YJ,O6OR6Z1,5*9,
M=$!YSS #8V9VGA&QG8&!LC)+5HYB5564>1(=4/YSPL! XR6JE^*0F*9QTKU.
M%DK+;&DYBE;5289"=$ !D,' 0,,AJI?<'-$(FOM T3@*3152YCYT0.[S"@,#
MS7IH3Z%,O\#0L*>/-B)!I%TZ@J)5GQ0@TY[X1-KSW@U,K,<U04B[OSQ>M\V4
M9WR$49IV)H%YM%PG01^IK_\JBB)5IX ,DF)SD+0W,%:W[S6#N6Z=4+0,BL:@
M:!R%IHHL0Z88^B2M&!HB0=$R*!J#HG$4FJJRC*/B <5"PPR,F=EY1H1V!@;*
MRBQ9.8I555$F2O& 8B*S@3$C.ZND%_:0)*:QKQTVH<F1+2U'T:HZR5 H'E!.
M=-S F%&=-=(+>!(_#K0GA4!9&12-H]!4'0\>ES4@]G'W+V8V9WU[KKGJU1?[
ML"R=53MK?8N4)Y8I3VQ7-61W!U@SF+,FT+HA*!J#HG$4FBJRC(AB:-U0#(V&
MH&@9%(U!T3@*3559YD?Q_ZUNR,SL/",LZX:@K,R2E:-8U8<2RB0I>;.Z(3.R
MJTJ)G@A-HB1*@^[3#*"TS):6HVA5G63<D[Q)W9 9U5DCO6ZH>XT"E)"=)N0H
M0E47F= D_],R(#.;LUYZ/8ZF%S26.4W(482J7C)K2?[@I3^)7EX3IOI5T.9A
M<#T-@J(Q*!I'H>TFU+B:"E%G>9U?7:SR1_%+7C[.EI4W%P\-O'^>- -?SAZG
M^S=UL6J.\B/OMJCK8K%].17YO2@W#9KO'XJB?GDS;O"?B_+'EN/JOU!+ P04
M    " #TK(Y7%B!IP5H&  #\.@  &@   'AL+W=O<FMS:&5E=',O<VAE970Q
M-3,N>&ULM5O1;J,X%/T5*SM:S4B= C:0I)M&FM9>[3R,5$UW=I]IXC:H!++@
MM#-_OT HCHEC3'/3AR:0<X_QN>:2$]NSURQ_+E:<"_1SG:3%]6@EQ.;*<8K%
MBJ^CXC+;\+3\Y#'+UY$H#_,GI]CD/%K60>O$P:X;.NLH3D?S67WN+I_/LJU(
MXI3?Y:C8KM=1_NN&)]GK]<@;O9WX'C^M1'7"F<\VT1._Y^+'YBXOCYR691FO
M>5K$68IR_G@]^N)=,;\.J!'_Q/RUV'N/JJX\9-ES=?!U>3URJROB"5^(BB(J
M7U[X+4^2BJF\CO\:TE';9A6X__Z-_<^Z\V5G'J*"WV;)O_%2K*Y'DQ%:\L=H
MFXCOV>M?O.E04/$MLJ2H_Z/7!NN.T&);B&S=!)=7L([3W6OTLQ%B+Z#DT0?@
M)@!W _PC :0)(-V \$B WP3XMBT$34#==6?7]UHX&HEH/LNS5Y17Z)*M>E.K
M7T>7>L5I-5#N15Y^&I=Q8GZ;I2\\%_%#PM%=F2.>YWR)[D6V>+[893$6OU"<
MHL4><-,"BPJ(/E(NHC@I/J'/Z,<]11\_?$(?JJ"_5]FVB-)E,7-$>;%5D\ZB
MN;";W87A(Q<V1=^R5*P*Q-(E7VKBJ3G>PP8"IU2IE0J_276#C8SW?'.)B'N!
ML(N)YH)N[<.QKC_F<,H79;AW-)S9AWL&,4@[;DC-1X:/&UVN=V2^GJPJAE?%
M)EKPZU$YM J>O_#1_/??O-#]0Z<S)!F%)&- 9$I&_#8COHE=R4CG!KU #_PI
M3M,X?2JK:A*E"ZY+THX_J/FK!\S+W O]\H$S<U[VY=?!W, =JS!J!V.'L""8
MCH,6I6@1M%H$1BV^%L6VZJ6V[NQ"P[T6R70:3CJ]U*#\Z;331QL0.P1YKA\0
MK.]BV'8Q?'^Z>;KLR;61?.@-&1[V4#-PJ!V,Z6#*P%'T&K=ZC8UZW?,\Y@7Z
M\MGKRJ63Q\@U5!Y(,@I)QH#(E(1,VH1,()\@$\B,0))12#(&1*9D9-IF9'KF
M)\CTX-8-W3#H5%8;$+4!L1Z0(H+GRF_$[CDKJYE]Z$@%9:,-6X^L?2A5USVG
MX=E58&Q3@<UD@V6$9*.@; R*34T+EFG!D'6X88/*"R0;!65C4&QJ7J3!\HQN
M : :-PWLW\>3Z;C[==X*1:U0K ^E2B&=C7>"M;&HR$;VP4,6DHTV;'VZ]J!4
M7:5+\LPVJ:W(Q*HB&\D&RPC)1D'9&!2;FA;I[+P0M"*#>CE0-@K*QJ#8U+Q(
M!^F9+21 11YK?@L(/:];DJU@U [&>F&J'-*_>48S<G)5!G5TH&RT8>M5M@^F
M*BM]F&<V8FU=]JWJLI%LL)"0;!24C4&QJ3__2V.(7<BZC$&-("@;!65C4&QJ
M7J2QQ&9C>7I=;AI0;N3IE'3*LA6*6J%8'TJ50IHY;#0EI]9D,_O@(0MJ[AJV
M/EU[4*JNTHQALQEK*W)@4Y'-9(-E!)WO F5C4&QJ6J0QQ#YH108U@J!L%)2-
M0;&I>9'&$IN-)4!%ULR:X4G0G:6S@U$[&.N%J7)(0X?/.E=G9A\\;$$-'M;,
MUNF4[8.IRDI+ABUG]4*KN@PZK0?*1D'9&!2;FA9I#3'HW!X&M8*@;!24C4&Q
MJ7F1QA*?>X8/'\ZY>8%_\*.R'8S:P=@1V)$5%$0:.F*>Z3,N$S''#EZS!&K?
M0-D8.9SO\X](*ST9.<&3]3_RS.R#Q0>=_2,:ZZ89M+TP55EI\8C9XC6/O!N;
M!YZ9:K",H'X.E(U!L:E)V5L-";L<$G8]).R"2-@5D><PB$0:1'+N19%$,_7F
M![AK1.Q@U [&S+UZKVK2OI$3ED^:8P>/7=!I0% V1@[MH)HL55YI!\E9[:"9
M?7 "0.T@.?1YVO'=!U.5E7:06-G!&[M%GF:RP4*"VD%0-@;%IJ9%VD$":@<)
MJ!T$9:.@; R*3<V+M(/DW':P:6!_^3X^7 )_JX.YY5_WZ7CH\S0P9N[5>[=9
M2-?HG^ :S;%#QRXH&_4/?9YFNX(&I29!E4TZ0O^LCM#,/EA84$?8L/7<!4P'
MTRCK[.WF6_/\J=Y&6:!%MDW%;H-6>[;=JOFEWJ#8.7_C7=UZFO/4NV*[C9B2
M?K<O]%N4ES=]@1+^6#;E7H[+:\UW6RUW!R+;U'L)'S(ALG7]=L6C)<\K0/GY
M8Y:)MX.J@7;#Z_Q_4$L#!!0    ( /2LCE?SEE_RVP4  *TN   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$U-"YX;6R]FFMOJS88Q[\*8M.T2><$?.'6)9&:
M=M/VXDC5J;:]IHG3H'+)C).>LT\_;L4Q4,<)IF_: /;?SQ_\.+_@9_Z:T9=\
M1P@SOB5QFB_,'6/[&\O*USN2A/DLVY.TN++-:!*RXI ^6_F>DG!3=4IB"]JV
M:R5AE)K+>77N@2[GV8'%44H>J)$?DB2DWU<DSEX7)C#?3GR-GG>L/&$MY_OP
MF3P2]M?^@19'5JNRB1*2YE&6&I1L%^8MN+G#0=FA:O%W1%[SD\]&:>4IRU[*
M@S\W"],N(R(Q6;-2(BS^'<D=B>-2J8CCWT;4;,<L.YY^?E/_O3)?F'D*<W*7
MQ?]$&[9;F+YI;,@V/,3L:_;Z!VD,.:7>.HOSZJ_Q6K=UH6FL#SG+DJ9S$4$2
MI?7_\%MS(TXZ />=#K#I +L=\#L=4-,!54;KR"I;]R$+EW.:O1JT;%VHE1^J
M>U/U+MQ$:?D8'QDMKD9%/[:\R](CH2QZBHGQ4-Q!0BG9&(\L6[]\,M*0TK"\
MS<;/]X2%49S_8GPV?C0L(]^%E.1SBQ4AE$+6NAEN50\'WQD.0.-+EK)=;OR6
M;LA&%+"*V%L#\,W "DH5[\EZ9B#PR8 VA ,!W:EW!Y)P4'L_4:6'+K^?0W>K
M%L/#8F4*W^3[<$T69I&C.:%'8BY_^@&X]J]#3C6)";YQZQO+U 7?^]9W7L^C
M\,!V&8W^ZS[P^A[4PFXE7*XZQR4$ ;!]VYY;QU-_T@BN].>T_ARIOT="(Y(;
MMY]!U]Z0):G6I8]5DYA@VVUMNSJGLZO3MR8QP;?7^O:FFLY>;SH["($ H\YL
M/M].B-QO(_>OC[R(^CE*P]B(\OQ07H_6PZMX/08XC0X',P=V/$A#N?(1!:W1
M0"TCH4I&2K4NG9F:Q 3;P.;?V+;.G&S4-%G7I29Z/Z$5,%5>-LK"]PQ"MH==
MW)G5*BW%^"&/'WY =C:#".D)G)GK=HU(@[GV87$4 E+BX!F*5#)4+G;Q/)T"
MA@"G(8"UYJ@FM&F\3P%*@),2D*/2F!QU^IF'O:!@\RX+JK04X^?( Z1DH2M'
MZT'\TQ3U9KVE9@K( 9QR@!QSV@S%2ADJ%;MXEFI2$ZUS3 *^U@S5A#J-]RG
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MH'5M='W LGU57OR4,98EU<<="3>$E@V*Z]LL8V\'Y0!MA?KR?U!+ P04
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M."2&)<VX>9#;+U#&<VGY(LEU_B3;TM9S2)1I(],2C!ZD3!1O^ESJL - GGI
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M:@Z=.ED:2=XJ2YMD84MD>^+U*_'Z;>9MOTT1VR0+6R+;$_&J$O&J<0?.E(P
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ME"PM#B.@(?!\@#J_8DR^-_( ]8[;[']02P,$%     @ ]*R.5YGFR%@>*
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MWMES*FV7!49BZ:=JN<V@#]^FS^>\7IE;QL%3C[U0+4.U'-4$JDE44ZBF4:U
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M!4IK)UY=IAC$'WEQ^I3U+P>3<+1WG:W[ -OXCIP<;VAS M4$JDE44ZBF4:U
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M+2B<HP4%5,M0+4<U@6H2U12J:50K4*U$-8-J%M4<JGE4"Y363KRZH' >+RA
M2T+&^TM"#MPE)+XO)R<<6F% -8%J$M44JFE4*U"M1#6#:A;5'*IY5 N4UDZX
MNNAP'B\Z''.^[?S(\VUH30'5<E03J"913:&:1K4"U4I4,ZAF4<VAFD>U0&GM
M_*IK"N?11<'U6;G144=B:$L!U3)4RU%-H)I$-85J&M4*5"M1S:":136':A[5
M J6U N^B;BE<G)$GX2[(]<N7J):A6HYJ M4DJBE4TZA6H%J):@;5+*HY5/.H
M%BBMG7AU:^$BWEKXQV2YG,S7JV2]2.[NEYOYZJI*=L=]'PX\L^&OTWFRNIEL
M=N5OR1^[5P>C$7UN ZIEJ):CFD UB6H*U32J%:A6HII!-8MJ#M4\JH6=-FJ<
M&AM>],[J&^BV,R^M,R_>=#CBM-Q.Z)Z6ZYZ5BP]T<BZAO054$Z@F44VAFD:U
M M5*5#.H9@]_9/K#7F<5'#JJ1[5 :>U@JAL)%_'G)KQ\ONVH57!Q_>1C+K2A
M@&HYJ@E4DZBF4$VC6H%J):H95+.HYE#-HUJ@M'8"U@V%S4OR!-P 33Q2RU M
M1S6!:A+5%*II5"M0K40U@VH6U1RJ>50+E-9.O+KY<!%O/C"KX':#M(Z]NTO@
MXCMR<KRAM094$Z@F44VAFD:U M5*5#.H9E'-H9I'M4!I[7BK:PT7T47$1YUK
M&QUWK@WM**!:CFH"U22J*533J%:@6HEJ!M4LJCE4\Z@6**T=7W5'X2+>47BZ
M$GK4,1BY=/D2U3)4RU%-H)I$-85J&M4*5"M1S:":136':A[5 J6UXZXN+%R<
MHZ??T"<QH%J&:CFJ"523J*903:-:@6HEJAE4LZCF4,VC6J"T=N+5%8>+>,7A
M7[;^#2U#H%J&:CFJ"523J*903:-:@6HEJAE4LZCF=EISC5EZ?C$<=I[2[H_\
MOD#M72O.>F=U@V'[^BM/N#T1W3-NPT'GE-LK8YV:.RR7LYQ@.<ERBN4TRQ4L
M5[*<83G[PL<G[=S%W['#>I8+&-=)JEXCJ>+5@Y?.K1VUUNT5_-0#+);+6"YG
M.<%RDN44RVF6*UBN9#G#<I;E',MYE@L8UPG$M!&(*7GV[8G#(A M,[!<SG*"
MY23+*9;3+%>P7,ERAN4LRSF6\RP7,*X3@?U&!,8;$,QJN*=16C>%.WO;G:Q?
MOK(WIT<>6G)@.<%RDN44RVF6*UBN9#G#<I;E',MYE@L8UXF\02/R!E]_PFYP
M[ F[Z%BG!QK)Y2PG6$ZRG&(YS7(%RY4L9UC.LIQC.<]R >,Z@39L!-I1SW+X
M\&WON&,U]-D-+)>Q7,YR@N4DRRF6TRQ7L%S)<H;E+,LYEO,L%S"NDX"C1@*B
MSW)XXK (1)L2+)>SG& YR7**Y33+%2Q7LIQA.<MRCN4\RP6,ZT3@N!&!\>+$
M4;/:\<%9[:A;7'UEK-,##2U#L)Q@.<ERBN4TRQ4L5[*<83G[PL<GO1CMK4-!
M"P\L%S"N$U7GC:B*/Z7AY?EJ\D<B)M-E\GDRNZ^V5R+NY]?5<O9E.O\4F]"B
MK0B6RU@N9SG!<I+E%,MIEBM8KF0YPW*6Y1S+>98+&->)R(M&1%ZP$UJT_<!R
M&<OE+"=83K*<8CG-<@7+E2QG6,ZRG&,YSW(!X]H1V&OT*GKQ7L7346*2)C\O
M)_.KFRHQT\G'Z6RZ_O)-<EM-5O?+ZK::KY/I_.Y^?3 6=T/TTN81^X&'%;ZR
M+R<''LKE+"=83K*<8CG-<@7+E2QG6,ZRG&,YSW(!XSJ!UZAG](ZK9QR<%A]1
MT(CS)Q\#HES&<CG+"9:3+*=83K-<P7(ERQF6LRSG6,ZS7,"X3B2FC4AD"QH]
MMJ"!<AG+Y2PG6$ZRG&(YS7(%RY4L9UC.LIQC.<]R >,Z$=@H:/3B!0UW?_NQ
M6FZOA3S>^R19+6;7T3NAO"*>GH*/7.M.#(-Q[[Q3O\Z._<:<W4'!<I+E%,MI
MEBM8KF0YPW*6Y1S+>98+&-=)KD;/8O,ZEEQAVR?K!-?AO(HZI^?5(]?JH@W>
M]D9[<774]^7L[@F6DRRG6$ZS7,%R)<L9EK,LYUC.LUS N$Y:-4H4O7B)PE7K
MY&ZYN*JJZ]7F\.HOAY.*K4[T]A\BT1]<7.P%U3'?EK,[)UA.LIQB.<UR!<N5
M+&=8SK*<8SG/<@'C.CG5J#KTXL]W@ K[NU%:!S_IV]Y>OS6^-Z>? F.K#2@G
M6$ZRG&(YS7(%RY4L9UC.LIQC.<]R >,ZD=>H-O2^OMK0.[;:$!_K]$!CJPTH
M)UA.LIQB.<UR!<N5+&=8SK*<8SG/<@'C.H'6*$#TCBQ I,<=J[']!I3+6"YG
M.<%RDN44RVF6*UBN9#G#<I;E',MYE@L8UTG 1K^AQ_8;>FR_ >4RELM93K"<
M9#G%<IKE"I8K6<ZPG&4YQW*>Y0+&M2,P;?0;TJ]_;L2.:*ZHZ'4GM/%A3LXR
ME,M93K"<9#G%<IKE"I8K6<ZPG#WBD^/8(3W+!8SK!%2CCY#&^PBA6EY5\_7D
M4[6[Q#!/%O?KU7HROW[HXS^NZEC,D\GFG]6W5X^'=)O#N/4BN5K<WFY^Y[&]
M\'&RFJZ^V2";P[SJ\!*0W:YL.QC/[]?9VXN+O1L(Q_?Y]+1C6PDH)UA.LIQB
M.<UR!<N5+&=8SK*<8SG/<@'C.L&8-H(QNN@W<OKNS]V_)#[<R9-;E,M8+F<Y
MP7*2Y13+:98K6*YD.<-REN4<RWF6"QC7B<A&:R'MH^?W4K:R@'(9R^4L)UA.
MLIQB.<UR!<N5+&=8SK*<8SG/<@'C.A'8J#]L7A]SE/@U]R_9#=&]?TFWHW#Y
MRKZ<'G@DE[.<8#G)<HKE-,L5+%>RG&$YRW*.Y3S+!8SK!%ZC09$>^1B*0]/B
M(^Y?$N=//P9DGTN!<CG+"9:3+*=83K-<P7(ERQF6LRSG6,ZS7,"X3B0VRAHI
M^UR*E'TN!<IE+)>SG& YR7**Y33+%2Q7LIQA.<MRCN4\RP6,ZT1@H[R1QLL;
M?^+^)3NQ>>U^?#9*!_V]62_;Y4"YG.4$RTF64RRG6:Y@N9+E#,M9EG,LYUDN
M8%PGWQI=CC3>Y3CZ+B<[YY7;C5R^,M[IH<;6,U!.L)QD.<5RFN4*EBM9SK"<
M93G'<I[E L9U0JU1STBCJY^/NQG*SF@V;B_&P^%>GK%="Y3+64ZPG&0YQ7*:
MY0J6*UG.L)QE.<=RGN4"QK7SK-_H6O3C70OHIBF[45X]A(OOS<F1AW(YRPF6
MDRRG6$ZS7,%R)<L9EK,LYUC.LUS N$[D-=H;_7A[XYAZV8Z(ULOBPYR>96SA
M N4$RTF64RRG6:Y@N9+E#,M9EG,LYUDN8%PGR])&EGU%X6+[U<ZUU7JAR3?)
M3]758GZ=K!^7X'V37,T6J\UOO!"(;!,#Y3*6RUE.L)QD.<5RFN4*EBM9SK"<
M93G'<I[E L9ULK/1Q.BS38P^V\1 N8SE<I83+"=93K&<9KF"Y4J6,RQG6<ZQ
MG&>Y@'&="&PT,3:O8X>/=O+[]/;^-IEWEZ),/BVKQ_L5K*K9++XH93=&<ZX\
M[)V?#_?NF!S?F=,3C^1REA,L)UE.L9QFN8+E2I8S+&=9SK&<9[F <9W$:U0Q
M^O$JQH^?-LGV:;*NZJNXR^JJFGZ>; \#7[J@V]]_SL2X/]B[@W)\[-,#CBU6
MH)Q@.<ERBN4TRQ4L5[*<83G+<H[E/,L%C.L$7*-8T8\_!>/ID.Y0O*UOEHO[
M3S</UW=7D]G#XKS)]?5T/5W,)[.G8[\70W"T%X*]L\W_]E*0[5:@7,YR@N4D
MRRF6TRQ7L%S)<H;E+,LYEO,L%S"NDX*-;D4_WJWXFNLB/]],E\^710XG(;E2
M^Y+E,I;+64ZPG&0YQ7*:Y0J6*UG.L)QE.<=RGN4"QG4"LU'6Z)^S%T/8)V^@
M7,9R.<L)EI,LIUA.LUS!<B7+&9:S+.=8SK-<P+A.!#:J'?UXM>-R-ED]+'_^
M;;+<'/RMD\4R64X_W:R_:5X?J:[NEYL)\^;@\FHRFVTR\N.7I)I<W>QME?QU
M.M]-J?_VR@64B[T+*.=[DVJV*X)R.<L)EI,LIUA.LUS!<B7+&9:S+.=8SK-<
MP+AV0 X:79%!O"ORC\>$6VTO"]_=+Z]N)JLJ>9YI]_=FVD<'X&#_D03I8' ^
M2/=B,+Z')\<@RN4L)UA.LIQB.<UR!<N5+&=8SK*<8SG/<@'C.C'8Z(\,7NN/
M5,NKZ:IZ+,PU#AA7#XEWO9C-)LM5<K<Y8'S(O+\=SKS'09J-N?3MV=Z-7.+[
M<GK@L243E!,L)UE.L9QFN8+E2I8S+&=9SK&<9[F <9W 2QN!%R^9(*L$=V,T
MC_'Z9Z.SX7[BL=40E,M93K"<9#G%<IKE"I8K6<ZPG&4YQW*>Y0+&=1*O40T9
M1%=>_\E5@CNTN4!FT._O+8..CWUZP+'%#Y03+"=93K&<9KF"Y4J6,RQG6<ZQ
MG&>Y@'&=@&L4/S:O_SVK!'<#-T-P>&"18'S_3@]!DLM93K"<9#G%<IKE"I8K
M6<ZPG&4YQW*>Y0+&=4*PT049Q+L@Q\YKGP(Q%H:QF>]P?^8[[/?2O1O*Q'?W
M]$QDZR,H)UA.LIQB.<UR!<N5+&=8SK*<8SG/<@'C.IG8J(\,XO61ER_G'LXV
M]K$<*)>Q7,YR@N4DRRF6TRQ7L%S)<H;E+,LYEO,L%S"NDX"-ZLC@<:TUM1)Z
MP)9!4"YCN9SE!,M)EE,LIUFN8+F2Y0S+699S+.=9+F!<)P(;99!!_,D=_[:5
MT+O]:DZ5]R^?L%41E,M93K"<9#G%<IKE"I8K6<ZPG&4YQW*>Y0+&=0*R4149
MQ*LB_[J5T.22\4N6RU@N9SG!<I+E%,MIEBM8KF0Y\\2U^@%I_Z)_=M$^.+#L
MP([E/,L%C&O'X+!1"!G&"R''W$E_N-_MV+OP$1_FY)A"N9SE!,M)EE,LIUFN
M8+F2Y0S+V2,^.8X=TK-<P+A.0#6J&L-X52-R2/9'(B;39?)Y,KM_N*A[/[^N
MEK,OT_FGR.6.^' G'YZA7,9R.<L)EI,LIUA.LUS!<B7+&9:S+.=8SK-<P+A.
M1*:-B$S1RQU#]D$@*)>Q7,YR@N4DRRF6TRQ7L%S)<H;E+,LYEO,L%S"N$X&-
MML<PWO9X.DI,TN3GQ[O^)68Z^3B=3==?ODENJ\GJ?EG=5O-U,IW?W:\/Q^+C
M$+VTN<KO;;IW]2*^*Z?G'5O^0#G!<I+E%,MIEBM8KF0YPW*6Y1S+>98+&-?)
MNT;Y8_/Z3\^*&[_Y?)6C:M_QX/G.!H>3,#KXZ0>())>Q7,YR@N4DRRF6TRQ7
ML%S)<H;E+,LYEO,L%S"N$YB-HLAPR,Z1R47AERR7L5S.<H+E),LIEM,L5[!<
MR7*&Y2S+.9;S+!<PKA.!C5[(\+A>R%?-D4?[<^1#][R*[\KI><>V0%!.L)QD
M.<5RFN4*EBM9SK"<93G'<I[E L9U\J[1 AD>^0"10W/D]"Q-ZR>&',XZMA6"
M<AG+Y2PG6$ZRG&(YS7(%RY4L9UC.LIQC.<]R >,ZD=AHA0S91X0,V4>$H%S&
M<CG+"9:3+*=83K-<P7(ERQF6LRSG6,ZS7,"X3@0V>A_#_T\?$3+<7P&_?VF9
M+7N@7,YR@N4DRRF6TRQ7L%S)<H;E+,LYEO,L%S"N'9"C1B-D]&]Z1,CHP"-"
MSM/!Q7@O!N-[>'(,HES.<H+E),LIEM,L5[!<R7*&Y2S+.9;S+!<PKA.#C=[)
MZ'_C$2&CXQX1$M^7TP./;9&@G& YR7**Y33+%2Q7LIQA.<MRCN4\RP6,ZP1>
MV@B\^"-"'L\-KJ:+^6/D/4R2MS>0OES<WDWF7_YC==3M!'>CO)IX;&D$Y7*6
M$RPG64ZQG&:Y@N5*EC,L9UG.L9QGN8!QG<1KE$9&\=+(,?<^V!'1>Q_$ASD]
MR]A"",H)EI,LIUA.LUS!<B7+&9:S+.=8SK-<P+A.EC4*(9O7?WJQRX=OT^[E
MWGKMRS?)3]758GZ=K!\7!7Z37,T6J\UOO!"(T?TX^9(PRF4LE[.<8#G)<HKE
M-,L5+%>RG&$YRW*.Y3S+!8SK9&>C&S)BNR$CMAN"<AG+Y2PG6$ZRG&(YS7(%
MRY4L9UC.LIQC.<]R >,Z$=CHAHSBW9!_VZJ8W7Y%5\7$]_WT@&3+)"@G6$ZR
MG&(YS7(%RY4L9UC.LIQC.<]R >,Z =DHDXSB99)_W:J8\?ZJF+/Q<- ;[\4@
M6R!!N9SE!,M)EE,LIUFN8+F2Y0S+699S+.=9+F!<)P8;!9)1_+$BT*J8\^.N
M$;-U$93+64ZPG&0YQ7*:Y0J6*UG.L)QE.<=RGN4"QCT&WKO5356ML\EZ\O[[
MVVKYJ;JL9K/-9'9Q/U]OGW?>^&JR.9[;YN%W/Z9OWNU]_4/ONZQWX.MY[SMQ
MZ.NR]YTZ]'7=^ZYX^/J[>G?>?W\W^539R?+3=+Y*9M4OFUT[>SL>OGF<6C_]
M8KVXVT3WF^3C8KU>W#Z\O*DFU]5R^PV;W_]EL5@__6([P&^+Y:\//_[[_P=0
M2P,$%     @ ]*R.5XYPK"GA%0  -I0! !H   !X;"]W;W)K<VAE971S+W-H
M965T,38T+GAM;+W=;5,;QX*&X;\RQ:9VDRH?T.A=7L=5L:??.UG7\6;S619C
M4 4DCB3LG*K\^)5@3*M'0S/"M_TE :RY6@P\T#UZZ'GU>;GZ<WU9EIOLK^NK
MQ?KGD\O-YN;EV=EZ=EE>3]>GRYMRL?V7C\O5]72S?7=U<;:^6973\[N#KJ_.
MNIW.\.QZ.E^<O'YU][%WJ]>OEK>;J_FB?+?*UK?7U]/5O]^45\O//Y_D)U\^
M\,_YQ>5F]X&SUZ]NIA?E^W+S^\V[U?:]LP?E?'Y=+M;SY2);E1]_/ODE?^GS
MO+,[XNXA_S<O/Z_WWLYVG\N'Y?+/W3OF_.>3SNXIE5?E;+,SIMO_?2K?EE=7
M.VK[1/Y5J2</@^X.W'_[BR[O/OOM9_-ANB[?+J_^F)]O+G\^&9]DY^7'Z>W5
MYI_+S[JL/J/!SILMK]9W_\T^5X_MG&2SV_5F>5T=O'T&U_/%_?^G?U5G8N^
M[N21 [K5 =W: ?W!(P?TJ@-Z;4?H5P?TVQXPJ X8M#U@6!TPK'\.CYVE477
MJ#Y"]Y$#QM4!X[8'3*H#)FT/V'XG5E^Y3NV0O/_8(0]?[(.O=O[8(5^^W/G=
MU_OL_AOK[KNRF&ZFKU^MEI^SU>[Q6V_WQMVW]MWQVV_&^6(7P_>;U?9?Y]OC
M-J_?+A>?RM5F_N&JS-YM U"N5N5Y]GZSG/V9_2/K=KJ]3,X7T\5LOKC(?BS*
MS71^M?XI^R$[R]:7TU6YSN:+[/?%?+-^L?W@]NW_O5S>KJ>+\_6KL\WV^>U&
M.9M5S^7-_7/I/O)<\NS7Y6)SN<[$XKP\;SA>I8_O/76\3A\_>>IX^\3S[R:
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M],BD=N^^7^EZS\.DMM5&TFGLZ+"Q=_YB;_W%WON+O?D7>_<O]O9?[/V_V!N
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M3:;3 QX=6K0*A6H"U22J*533J&90S:*:0S5/:7&X0Q5JB.Y5-40K4*A6H)I
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MU='TA^) 5@\OSK4_4[$)E5\16RM19S)5ZTL41\7%@^2[_'CVGDO)X_QVRVC
M1#9 _;_F7!X?,@/5@?WR/U!+ P04    " #TK(Y7'XT2"[\#  "($0  &@
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M WB7 'X#\,\!_@7 N &,*V=J*94/$54T7 B^(T)'(YMN5&96:)3/"OW<GY7
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M07M"0WN@Z164FFZ/(A:?)A;V] '!?VQX5O"#2XII#>LPC/[O\[E[^>NLWP>
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MZST"]!Y=[Q&@=W>].T#O[GIW@-[=]>X O;OKW0%Z=]>[ _3NKG<'Z-WC9A.
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MI-[GE_>N;W__]^7KBR'C:^JY?3_C].E?4$L#!!0    ( /2LCE?(?KH'2@,
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MCS]]+KNZZ5_F1\=-W<U/4$L! A0#%     @ ]*R.5P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #T
MK(Y71%QW<.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #TK(Y7F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /2LCE>U!]XM
M]@(  &0)   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #TK(Y7KOI,R  (  !<+   &
M@($Z"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ]*R.
M5Z"O"PDM!   BA0  !@              ("!<!,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( /2LCE=JD)RG^ 4   $>   8
M      " @=,7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #TK(Y7?5UME_H$   W'0  &               @($!'@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ]*R.5^^0C6EO"0  BD   !@
M             ("!,2,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( /2LCE<?A]$&8"P  "JI   8              " @=8L  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #TK(Y7?=WV1]P;  "-
M6   &               @(%L60  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ ]*R.5PJL&"JJ @  Q04  !@              ("!?G4
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /2LCE>?W>+6
MEP,  ,H(   9              " @5YX  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ ]*R.5\Y9>GC_"@  MR   !D
M ("!+'P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #T
MK(Y7<$#.K\<6  "]2@  &0              @(%BAP  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /2LCE<VIO*XS00  '8,   9
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M970Q-RYX;6Q02P$"% ,4    " #TK(Y7;ETV'UDH  !^E   &0
M    @('YSP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M /2LCE>;#K2F[0<  #TI   9              " @8GX  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ ]*R.5S[3Z#(3!@  61<  !D
M             ("!K0 ! 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #TK(Y7]0XJEG,'  !%(P  &0              @('W!@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /2LCE<]QEQ? @<
M *8L   9              " @:$. 0!X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ ]*R.5\!EE1 B"0   FL  !D              ("!
MVA4! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #TK(Y7
M,?#XV[()  ".7P  &0              @($S'P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( /2LCE=:$3(*EP,  .<,   9
M      " @1PI 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ ]*R.5PY3HEQC!@  0C(  !D              ("!ZBP! 'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #TK(Y7 ;14M;($  ![(P
M&0              @(&$,P$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( /2LCE<@I'6\:0,  #H2   9              " @6TX 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ]*R.5R: 953J
M!0  "2<  !D              ("!#3P! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #TK(Y75-!PE 4*  #SB@  &0
M@($N0@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /2L
MCE=*S%@&J@8  #$N   9              " @6I, 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ ]*R.5S+G8:U0 P  61   !D
M         ("!2U,! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #TK(Y7LX0UWH$%   ,)P  &0              @('25@$ >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /2LCE<"(Y#9JP<  ! Z
M   9              " @8I< 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ ]*R.5[J*NBDO P  P0L  !D              ("!;&0!
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #TK(Y7 =!_
M[RX$  !C&P  &0              @('29P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( /2LCE=#8]BHV0,  "$2   9
M  " @3=L 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M]*R.5S:GN^F= P  = \  !D              ("!1W ! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #TK(Y77VNX8H #  #(#@  &0
M            @($;= $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( /2LCE? 'KXUR0,  +43   9              " @=)W 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ]*R.5\\@IIK;!
M(QD  !D              ("!TGL! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #TK(Y7NOK^DR<$   ?&@  &0              @('D
M@ $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /2LCE>]
M6@;(W08  "XC   9              " @4*% 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ ]*R.5^V5>?>P P  'Q(  !D
M     ("!5HP! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2LCE=.7^XI[R   &R#   9              "
M@3/% 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ]*R.
M5VZ_C?]D#   ?"8  !D              ("!6>8! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #TK(Y7Y%G .0,*  "'(P  &0
M        @('T\@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( /2LCE>C?TM&-P,  !@+   9              " @2[] 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ]*R.5Z- R#<P P  30D
M !D              ("!G  " 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #TK(Y7$R;N6_<"   8"0  &0              @($#! (
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /2LCE>5('O*
M/P8  $</   9              " @3$' @!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ ]*R.5W02!=&:"P  X2   !D
M ("!IPT" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #T
MK(Y7TMS"(#(*  !F'@  &0              @(%X&0( >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /2LCE? WEYL8AP  +%R   9
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M970V,BYX;6Q02P$"% ,4    " #TK(Y7DEKR^GH>   #>0  &0
M    @('87P( >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M /2LCE=Y*7.6S@0  ,D4   9              " @8E^ @!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ ]*R.5[!>\60J P  I0P  !D
M             ("!CH," 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #TK(Y7(UZ8Z\@"  #G!P  &0              @('OA@( >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( /2LCE?%L#AQ  ,
M ,X(   9              " @>Z) @!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ ]*R.5PL?10&Q @  L 4  !D              ("!
M)8T" 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #TK(Y7
MJ9A_^)8$  !(#@  &0              @($-D ( >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( /2LCE<"7.W]<0@  -8J   9
M      " @=J4 @!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ ]*R.5R ?,:^W P  :@D  !D              ("!@IT" 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #TK(Y7&L"FM'("  "J!0
M&0              @(%PH0( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( /2LCE>W#2;L)0H  (YM   9              " @1FD @!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ ]*R.5V!$DK;*
M!   B1H  !D              ("!=:X" 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    " #TK(Y72.S;"+8+  #'B   &0
M@(%VLP( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( /2L
MCE=!)XT'VPH  /B,   9              " @6._ @!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ ]*R.5S7(/7\G!@  CR@  !D
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M=#@Q+GAM;%!+ 0(4 Q0    ( /2LCE<8\AEO_@,  'H4   9
M  " @4C> @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @
M]*R.5]6YO!8X P  \Q   !D              ("!?>(" 'AL+W=O<FMS:&5E
M=',O<VAE970X,RYX;6Q02P$"% ,4    " #TK(Y7=)3'(IX+  #*EP  &0
M            @('LY0( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4
M Q0    ( /2LCE<-WCO&& (  (X$   9              " @<'Q @!X;"]W
M;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ ]*R.5_](4J7T)@
M[?," !D              ("!$/0" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX
M;6Q02P$"% ,4    " #TK(Y74BN:+ ,+   J@0  &0              @($[
M&P, >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( /2LCE>5
M(,-CIP<  *Q,   9              " @74F P!X;"]W;W)K<VAE971S+W-H
M965T.#@N>&UL4$L! A0#%     @ ]*R.5T(C[)IH!   #B$  !D
M     ("!4RX# 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2LCE>#&^6X# 8  %$M   9              "
M@5M& P!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ ]*R.
M5[%B=IV% P  L1,  !D              ("!GDP# 'AL+W=O<FMS:&5E=',O
M<VAE970Y-2YX;6Q02P$"% ,4    " #TK(Y7B"A\_+(&   7/P  &0
M        @(%:4 , >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0
M   ( /2LCE?Q/1T>QP4  ,(8   9              " @4-7 P!X;"]W;W)K
M<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ ]*R.5UO\793Z @  =@H
M !D              ("!05T# 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q0
M2P$"% ,4    " #TK(Y7"N&5F\P%  #C%0  &0              @(%R8 ,
M>&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( /2LCE>8SW0/
MA D  .Q)   :              " @75F P!X;"]W;W)K<VAE971S+W-H965T
M,3 P+GAM;%!+ 0(4 Q0    ( /2LCE>.P(SIP@@  (,I   :
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M,3 U+GAM;%!+ 0(4 Q0    ( /2LCE?DK3*[)0,  !X+   :
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M,3$P+GAM;%!+ 0(4 Q0    ( /2LCE?P>4+%RP8  (<0   :
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M,3$U+GAM;%!+ 0(4 Q0    ( /2LCE?C0[MKQP8  *H9   :
M  " @;H3! !X;"]W;W)K<VAE971S+W-H965T,3$V+GAM;%!+ 0(4 Q0    (
M /2LCE=\DTRN( 8  "X2   :              " @;D:! !X;"]W;W)K<VAE
M971S+W-H965T,3$W+GAM;%!+ 0(4 Q0    ( /2LCE>"QE=LM@D  ,@:   :
M              " @1$A! !X;"]W;W)K<VAE971S+W-H965T,3$X+GAM;%!+
M 0(4 Q0    ( /2LCE=X]\/_H@0  *L+   :              " @?\J! !X
M;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;%!+ 0(4 Q0    ( /2LCE>JT\7S
M5!\  "I]   :              " @=DO! !X;"]W;W)K<VAE971S+W-H965T
M,3(P+GAM;%!+ 0(4 Q0    ( /2LCE<UEHN TP0  +X4   :
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M,3(U+GAM;%!+ 0(4 Q0    ( /2LCE<]K^'N&04  /X/   :
M  " @5IA! !X;"]W;W)K<VAE971S+W-H965T,3(V+GAM;%!+ 0(4 Q0    (
M /2LCE<U00Y-R@0  + .   :              " @:MF! !X;"]W;W)K<VAE
M971S+W-H965T,3(W+GAM;%!+ 0(4 Q0    ( /2LCE>.#URUU@<  ((M   :
M              " @:UK! !X;"]W;W)K<VAE971S+W-H965T,3(X+GAM;%!+
M 0(4 Q0    ( /2LCE<M8UQ]9P8  $ 2   :              " @;MS! !X
M;"]W;W)K<VAE971S+W-H965T,3(Y+GAM;%!+ 0(4 Q0    ( /2LCE<Z\F@R
MK ,  +T)   :              " @5IZ! !X;"]W;W)K<VAE971S+W-H965T
M,3,P+GAM;%!+ 0(4 Q0    ( /2LCE>P7M+C^P,  !(-   :
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M,3,U+GAM;%!+ 0(4 Q0    ( /2LCE>9N:L,5@,  '@-   :
M  " @4R5! !X;"]W;W)K<VAE971S+W-H965T,3,V+GAM;%!+ 0(4 Q0    (
M /2LCE? (IY&H (  #8(   :              " @=J8! !X;"]W;W)K<VAE
M971S+W-H965T,3,W+GAM;%!+ 0(4 Q0    ( /2LCE>F=]#4>P4  !\M   :
M              " @;*;! !X;"]W;W)K<VAE971S+W-H965T,3,X+GAM;%!+
M 0(4 Q0    ( /2LCE?.,G3+VP(  "X)   :              " @66A! !X
M;"]W;W)K<VAE971S+W-H965T,3,Y+GAM;%!+ 0(4 Q0    ( /2LCE>&'++8
MC (  *\&   :              " @7BD! !X;"]W;W)K<VAE971S+W-H965T
M,30P+GAM;%!+ 0(4 Q0    ( /2LCE=6:.DVKP(  )8)   :
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M,30U+GAM;%!+ 0(4 Q0    ( /2LCE=RJ>08&P,  'D-   :
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M,34P+GAM;%!+ 0(4 Q0    ( /2LCE>W^22S/1    T' 0 :
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M,34U+GAM;%!+ 0(4 Q0    ( /2LCE?1)?:&3P(  /P$   :
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M,38P+GAM;%!+ 0(4 Q0    ( /2LCE>T\63J.0,   (-   :
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M,38U+GAM;%!+ 0(4 Q0    ( /2LCE=/_=OK(P4  /$>   :
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M,3<P+GAM;%!+ 0(4 Q0    ( /2LCE?1U0Y.D@(  +$%   :
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M,3<U+GAM;%!+ 0(4 Q0    ( /2LCE=#E/6Z\04  %8K   :
M  " @?*"!0!X;"]W;W)K<VAE971S+W-H965T,3<V+GAM;%!+ 0(4 Q0    (
M /2LCE<?<U=L4@<  "E4   :              " @1N)!0!X;"]W;W)K<VAE
M971S+W-H965T,3<W+GAM;%!+ 0(4 Q0    ( /2LCE>[)E-KFP<   5:   :
M              " @:60!0!X;"]W;W)K<VAE971S+W-H965T,3<X+GAM;%!+
M 0(4 Q0    ( /2LCE>VB7>>@P,  &\9   -              "  7B8!0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ ]*R.5Y>*NQS     $P(   L
M         ( !)IP% %]R96QS+RYR96QS4$L! A0#%     @ ]*R.5RH;'@%=
M"P  L7,   \              ( !#YT% 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( /2LCE?N$,CLHP0  "UH   :              "  9FH!0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /2LCE?(?KH'2@,
M ,]B   3              "  72M!0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    "Z +H G#,  .^P!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>710</ContextCount>
  <ElementCount>654</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>208</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>111100090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>111200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>111200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>111210101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>111210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>111210301 - Disclosure - PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePublicOffering</Role>
      <ShortName>PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111210401 - Disclosure - PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePrivatePlacement</Role>
      <ShortName>PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111210501 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>111210601 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>111210701 - Disclosure - STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>111210801 - Disclosure - WARRANT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrantLiabilities</Role>
      <ShortName>WARRANT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>111210901 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTax</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>111211001 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>111211101 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>111220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>111230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>111230903 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureIncomeTax</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>111231003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>111240102 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>111240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>111240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>111240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>111240301 - Disclosure - PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails</Role>
      <ShortName>PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosurePublicOffering</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>111240401 - Disclosure - PRIVATE PLACEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails</Role>
      <ShortName>PRIVATE PLACEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosurePrivatePlacement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>111240501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Founder Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>111240502 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>111240601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>111240701 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' DEFICIT - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>111240702 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' DEFICIT - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>111240801 - Disclosure - WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails</Role>
      <ShortName>WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureWarrantLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAX - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>111240902 - Disclosure - INCOME TAX - Income tax provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails</Role>
      <ShortName>INCOME TAX - Income tax provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>111240903 - Disclosure - INCOME TAX - Reconciliation of the federal income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails</Role>
      <ShortName>INCOME TAX - Reconciliation of the federal income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>111241001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>111241002 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>111241003 - Disclosure - FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>111241004 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>111241101 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1200100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1200200 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1200400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1210101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1210301 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureBusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1210401 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1210501 - Disclosure - Cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1210601 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1210701 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1210801 - Disclosure - Contingent Earnout Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability</Role>
      <ShortName>Contingent Earnout Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1210901 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1211001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1211101 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1211201 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1211301 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1211401 - Disclosure - Dynavax Purchase</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDynavaxPurchase</Role>
      <ShortName>Dynavax Purchase</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1211501 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1220202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1230403 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1230503 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1230603 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureInventory</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1230703 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1230803 - Disclosure - Contingent Earnout Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables</Role>
      <ShortName>Contingent Earnout Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1230903 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureWarrants</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1231103 - Disclosure - Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockTables</Role>
      <ShortName>Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosurePreferredStock</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1231203 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1231303 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1240101 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1240201 - Disclosure - Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails</Role>
      <ShortName>Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1240301 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureBusinessCombination</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1240401 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1240402 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1240501 - Disclosure - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1240601 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureInventoryTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1240701 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1240801 - Disclosure - Contingent Earnout Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails</Role>
      <ShortName>Contingent Earnout Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1240802 - Disclosure - Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails</Role>
      <ShortName>Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1240901 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Warrants - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1240902 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1241001 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1241101 - Disclosure - Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails</Role>
      <ShortName>Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1241102 - Disclosure - Preferred Stock - Summary of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails</Role>
      <ShortName>Preferred Stock - Summary of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1241103 - Disclosure - Preferred Stock - Convertible Preferred Stock Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails</Role>
      <ShortName>Preferred Stock - Convertible Preferred Stock Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1241104 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails</Role>
      <ShortName>Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1241105 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails</Role>
      <ShortName>Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1241106 - Disclosure - Preferred Stock - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails</Role>
      <ShortName>Preferred Stock - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1241201 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1241202 - Disclosure - Net Loss per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1241301 - Disclosure - Share-Based Compensation - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1241302 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1241401 - Disclosure - Dynavax Purchase (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails</Role>
      <ShortName>Dynavax Purchase (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureDynavaxPurchase</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>222100100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>222100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>222100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>222100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>222100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>222100405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>222110101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>222110201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>222110301 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>222110401 - Disclosure - Cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs</Role>
      <ShortName>Cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>222110501 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventorys</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>222110601 - Disclosure - Long-Lived Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssets</Role>
      <ShortName>Long-Lived Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>222110701 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>222110801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxess</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>222110901 - Disclosure - Dynavax Purchase</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDynavaxPurchases</Role>
      <ShortName>Dynavax Purchase</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>222111001 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>222111101 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>222111201 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>222111301 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>222111401 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShares</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>222111501 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>222111601 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>222111701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation</Role>
      <ShortName>Merger Agreement with MedTech Acquisition Corporation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>222120202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>222130303 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>222130403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>222130503 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventoryTabless</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureInventory</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>222130603 - Disclosure - Long-Lived Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables</Role>
      <ShortName>Long-Lived Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureLongLivedAssets</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>222130703 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>222130803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>222131003 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureDebt</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>222131203 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>222131301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>222131403 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>130</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>222131503 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureLeases</ParentRole>
      <Position>131</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>222140101 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>132</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>222140201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess</ParentRole>
      <Position>133</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>222140301 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>134</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>222140302 - Disclosure - Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>222140401 - Disclosure - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables</ParentRole>
      <Position>136</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>222140501 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureInventoryDetailss</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureInventoryTables</ParentRole>
      <Position>137</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails</Role>
      <ShortName>Long-Lived Assets - Property and Equipment, tabular (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>222140602 - Disclosure - Long-Lived Assets - Property and Equipment, narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Long-Lived Assets - Property and Equipment, narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>222140603 - Disclosure - Long-Lived Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails</Role>
      <ShortName>Long-Lived Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>222140604 - Disclosure - Long-Lived Assets - Intangible Assets, amortization expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Long-Lived Assets - Intangible Assets, amortization expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>222140701 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>142</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>222140801 - Disclosure - Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>222140802 - Disclosure - Income Taxes - Provision for federal income tax statutory rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Provision for federal income tax statutory rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>222140803 - Disclosure - Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net operating loss carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>222140805 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>222140901 - Disclosure - Dynavax Purchase (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss</Role>
      <ShortName>Dynavax Purchase (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureDynavaxPurchase</ParentRole>
      <Position>148</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>222141001 - Disclosure - Debt - PPP Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails</Role>
      <ShortName>Debt - PPP Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>222141002 - Disclosure - Debt - Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails</Role>
      <ShortName>Debt - Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>222141101 - Disclosure - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureConvertibleNotes</ParentRole>
      <Position>151</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>222141201 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables</ParentRole>
      <Position>152</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>222141202 - Disclosure - Convertible Preferred Stock, activity in convertible preferred stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock, activity in convertible preferred stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>153</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>222141203 - Disclosure - Convertible Preferred Stock, narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock, narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>154</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>222141204 - Disclosure - Convertible Preferred Stock, Conversion (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails</Role>
      <ShortName>Convertible Preferred Stock, Conversion (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>155</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>222141205 - Disclosure - Convertible Preferred Stock, Voting Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails</Role>
      <ShortName>Convertible Preferred Stock, Voting Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>156</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>222141206 - Disclosure - Convertible Preferred Stock, Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails</Role>
      <ShortName>Convertible Preferred Stock, Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>157</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>222141207 - Disclosure - Convertible Preferred Stock, Liquidation Preferences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails</Role>
      <ShortName>Convertible Preferred Stock, Liquidation Preferences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>222141208 - Disclosure - Convertible Preferred Stock, March 2021 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails</Role>
      <ShortName>Convertible Preferred Stock, March 2021 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>159</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>222141209 - Disclosure - Convertible Preferred Stock, Spring 2021 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails</Role>
      <ShortName>Convertible Preferred Stock, Spring 2021 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>160</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>222141210 - Disclosure - Convertible Preferred Stock, Fall 2021 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails</Role>
      <ShortName>Convertible Preferred Stock, Fall 2021 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>161</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>222141211 - Disclosure - Convertible Preferred Stock, Warrant Exercises (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails</Role>
      <ShortName>Convertible Preferred Stock, Warrant Exercises (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>162</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>222141212 - Disclosure - Convertible Preferred Stock - 2022 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails</Role>
      <ShortName>Convertible Preferred Stock - 2022 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>163</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>222141213 - Disclosure - Convertible Preferred Stock - 2023 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails</Role>
      <ShortName>Convertible Preferred Stock - 2023 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>164</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R165.htm</HtmlFileName>
      <LongName>222141301 - Disclosure - Stockholders' Equity - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>165</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R166.htm</HtmlFileName>
      <LongName>222141302 - Disclosure - Stockholders' Equity - Stock Option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>166</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R167.htm</HtmlFileName>
      <LongName>222141303 - Disclosure - Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>167</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R168.htm</HtmlFileName>
      <LongName>222141304 - Disclosure - Stockholders' Equity - Valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>168</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R169.htm</HtmlFileName>
      <LongName>222141305 - Disclosure - Stockholders' Equity - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>169</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R170.htm</HtmlFileName>
      <LongName>222141401 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>170</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R171.htm</HtmlFileName>
      <LongName>222141402 - Disclosure - Net Loss per Share - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss per Share - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>171</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R172.htm</HtmlFileName>
      <LongName>222141501 - Disclosure - Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails</Role>
      <ShortName>Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>172</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R173.htm</HtmlFileName>
      <LongName>222141502 - Disclosure - Leases - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss</Role>
      <ShortName>Leases - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>173</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R174.htm</HtmlFileName>
      <LongName>222141503 - Disclosure - Leases - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>174</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R175.htm</HtmlFileName>
      <LongName>222141504 - Disclosure - Leases - Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss</Role>
      <ShortName>Leases - Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>175</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R176.htm</HtmlFileName>
      <LongName>222141505 - Disclosure - Leases - Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>176</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R177.htm</HtmlFileName>
      <LongName>222141601 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess</ParentRole>
      <Position>177</Position>
    </Report>
    <Report instance="tlsi-20230630xs1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R178.htm</HtmlFileName>
      <LongName>222141701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails</Role>
      <ShortName>Merger Agreement with MedTech Acquisition Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation</ParentRole>
      <Position>178</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tlsi-20230630.xsd</File>
    <File>tlsi-20230630_cal.xml</File>
    <File>tlsi-20230630_def.xml</File>
    <File>tlsi-20230630_lab.xml</File>
    <File>tlsi-20230630_pre.xml</File>
    <File doctype="S-1/A" isDefinitelyFs="true" isUsgaap="true" original="tlsi-20230630xs1a.htm">tlsi-20230630xs1a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tlsi-20230630xs1a002.jpg</File>
    <File>tlsi-20230630xs1a003.jpg</File>
    <File>tlsi-20230630xs1a004.jpg</File>
    <File>tlsi-20230630xs1a005.jpg</File>
    <File>tlsi-20230630xs1a006.jpg</File>
    <File>tlsi-20230630xs1a007.jpg</File>
    <File>tlsi-20230630xs1a008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1823">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>206
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tlsi-20230630xs1a.htm": {
   "nsprefix": "tlsi",
   "nsuri": "http://trisaluslifesci.com/20230630",
   "dts": {
    "schema": {
     "local": [
      "tlsi-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tlsi-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tlsi-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tlsi-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tlsi-20230630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tlsi-20230630xs1a.htm"
     ]
    }
   },
   "keyStandard": 404,
   "keyCustom": 250,
   "axisStandard": 38,
   "axisCustom": 5,
   "memberStandard": 51,
   "memberCustom": 127,
   "hidden": {
    "total": 104,
    "http://trisaluslifesci.com/20230630": 11,
    "http://fasb.org/us-gaap/2023": 89,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 710,
   "entityCount": 1,
   "segmentCount": 208,
   "elementCount": 1058,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1823,
    "http://xbrl.sec.gov/dei/2023": 9
   },
   "report": {
    "R1": {
     "role": "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation",
     "longName": "111100090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "111200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "111200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_soMQTCFo6U-Anr-gMiwB1w",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "111200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
     "longName": "111200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ",
      "name": "tlsi:StockholderEquity",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QsbSVFsD0U2NoayKUqETPQ",
      "name": "tlsi:StockholderEquity",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "111200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
     "longName": "111210101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS",
     "shortName": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "111210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://trisaluslifesci.com/role/DisclosurePublicOffering",
     "longName": "111210301 - Disclosure - PUBLIC OFFERING",
     "shortName": "PUBLIC OFFERING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
     "longName": "111210401 - Disclosure - PRIVATE PLACEMENT",
     "shortName": "PRIVATE PLACEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:PrivatePlacementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:PrivatePlacementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
     "longName": "111210501 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "111210601 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R13": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
     "longName": "111210701 - Disclosure - STOCKHOLDERS' DEFICIT",
     "shortName": "STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
     "longName": "111210801 - Disclosure - WARRANT LIABILITIES",
     "shortName": "WARRANT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTax",
     "longName": "111210901 - Disclosure - INCOME TAX",
     "shortName": "INCOME TAX",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R16": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
     "longName": "111211001 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R17": {
     "role": "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
     "longName": "111211101 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "111220202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R19": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "111230203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R20": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
     "longName": "111230903 - Disclosure - INCOME TAX (Tables)",
     "shortName": "INCOME TAX (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R21": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "111231003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R22": {
     "role": "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
     "longName": "111240101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)",
     "shortName": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
     "longName": "111240102 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)",
     "shortName": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "tlsi:OperatingBankAccounts",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "111240201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
     "longName": "111240202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption reflected in the balance sheets reconciled (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_tlsi_CommonClassaSubjectToRedemptionMember_E8GwD-ywWEa5KN045EFI7A",
      "name": "tlsi:ProceedsFromTrustAccountInConnectionWithRedemption",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
     "longName": "111240203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net (loss) income per common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_LC4zDj_rmUKwOgLS2IE4hQ",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
     "longName": "111240301 - Disclosure - PUBLIC OFFERING (Details)",
     "shortName": "PUBLIC OFFERING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OXuKzykTU0aBwch15YAXNQ",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "tlsi:InitialPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
     "longName": "111240401 - Disclosure - PRIVATE PLACEMENT (Details)",
     "shortName": "PRIVATE PLACEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_22_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DMJEIP8fGUaGXbZBbwD0BQ",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "tlsi:PrivatePlacementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
     "longName": "111240501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS - Founder Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_11_2020_To_9_11_2020_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_RelatedPartyTransactionAxis_tlsi_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_tlsi_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_xH5np0PZYUiFvwBNJOtmiw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "111240502 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:ClassOfWarrantOrRightPriceOfWarrantsOrRights",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WorkingCapitalLoansWarrantMember_ffngkVT0QkSB0YxjNIwPKw",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "111240601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "tlsi:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
     "longName": "111240701 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock (Details)",
     "shortName": "STOCKHOLDERS' DEFICIT - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
     "longName": "111240702 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock (Details)",
     "shortName": "STOCKHOLDERS' DEFICIT - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_03PylbqtqEWFiWUnat-FuA",
      "name": "tlsi:CommonStockNumberOfVotesPerShare",
      "unitRef": "Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
     "longName": "111240801 - Disclosure - WARRANT LIABILITIES (Details)",
     "shortName": "WARRANT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_r7-stsYyy0WW4GixkLS0XA",
      "name": "tlsi:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "tlsi:DerivativeWarrantLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
     "longName": "111240901 - Disclosure - INCOME TAX - Deferred tax assets (Details)",
     "shortName": "INCOME TAX - Deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
     "longName": "111240902 - Disclosure - INCOME TAX - Income tax provision (Details)",
     "shortName": "INCOME TAX - Income tax provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
     "longName": "111240903 - Disclosure - INCOME TAX - Reconciliation of the federal income tax (Details)",
     "shortName": "INCOME TAX - Reconciliation of the federal income tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
     "longName": "111241001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_pSuIgL5MgkW3Hup01vec-g",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "111241002 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and liabilities that are measured at fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_KT_rb9ebG0ejToOOgG17eQ",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1sI5wKqJ1kuQbBSeQbH8aw",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
     "longName": "111241003 - Disclosure - FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Monte Carlo Simulation for the Private Placement Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_rKGB_Qqh-0GAiouVXfNZ4A",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
     "longName": "111241004 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Changes in the level 3 fair value of warrant liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
     "longName": "111241101 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_BAS6I-e4UkiVcVIi1rKwxg",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorpMember_srt_CounterpartyNameAxis_tlsi_TrisalusMember_us-gaap_TypeOfArrangementAxis_tlsi_MergerAgreementMember_ZN8XEh8o7U6Eq1INZQlX_w",
      "name": "us-gaap:AssetsHeldInTrust",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
     "longName": "1200100 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
     "longName": "1200105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Cover",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
     "longName": "1200200 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "1200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wyW1MAFCXkusEm-81wMfRg",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
     "longName": "1200400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://trisaluslifesci.com/role/DisclosureNatureOfBusiness",
     "longName": "1210101 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess",
     "longName": "1210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://trisaluslifesci.com/role/DisclosureBusinessCombination",
     "longName": "1210301 - Disclosure - Business Combination",
     "shortName": "Business Combination",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstruments",
     "longName": "1210401 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash",
     "longName": "1210501 - Disclosure - Cash, cash equivalents and restricted cash",
     "shortName": "Cash, cash equivalents and restricted cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventory",
     "longName": "1210601 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilities",
     "longName": "1210701 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability",
     "longName": "1210801 - Disclosure - Contingent Earnout Liability",
     "shortName": "Contingent Earnout Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrants",
     "longName": "1210901 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:WarrantsLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:WarrantsLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxes",
     "longName": "1211001 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStock",
     "longName": "1211101 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShare",
     "longName": "1211201 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://trisaluslifesci.com/role/DisclosureShareBasedCompensation",
     "longName": "1211301 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://trisaluslifesci.com/role/DisclosureDynavaxPurchase",
     "longName": "1211401 - Disclosure - Dynavax Purchase",
     "shortName": "Dynavax Purchase",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess",
     "longName": "1211501 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
     "longName": "1220202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:TradeAndOtherAccountsReceivablePolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables",
     "longName": "1230403 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables",
     "longName": "1230503 - Disclosure - Cash, cash equivalents and restricted cash (Tables)",
     "shortName": "Cash, cash equivalents and restricted cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventoryTables",
     "longName": "1230603 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables",
     "longName": "1230703 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables",
     "longName": "1230803 - Disclosure - Contingent Earnout Liability (Tables)",
     "shortName": "Contingent Earnout Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrantsTables",
     "longName": "1230903 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsi:WarrantsLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockTables",
     "longName": "1231103 - Disclosure - Preferred Stock (Tables)",
     "shortName": "Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables",
     "longName": "1231203 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables",
     "longName": "1231303 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
     "longName": "1240101 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:NumberOfProductLinesInDevelopment",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:NumberOfProductLinesInDevelopment",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
     "longName": "1240201 - Disclosure - Accounting Policies (Details)",
     "shortName": "Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:PreferredStockConversionPercentageOfOutstandingShares",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_v81NDwU8XEK_g5x5FRGW-Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
     "longName": "1240301 - Disclosure - Business Combinations (Details)",
     "shortName": "Business Combinations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "tlsi:RecapitalizationExchangeRatio",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "8",
      "ancestors": [
       "span",
       "p",
       "tlsi:ReverseRecapitalizationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "tlsi:RecapitalizationExchangeRatio",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "8",
      "ancestors": [
       "span",
       "p",
       "tlsi:ReverseRecapitalizationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
     "longName": "1240401 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
     "longName": "1240402 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)",
     "shortName": "Financial Instruments - Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_5m4IloO620mxYhPYECQr_w",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_FairValueByLiabilityClassAxis_tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember_3OZ5fJDv4UW-UlCp7HrCzQ",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "1240501 - Disclosure - Cash, cash equivalents and restricted cash (Details)",
     "shortName": "Cash, cash equivalents and restricted cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventoryDetails",
     "longName": "1240601 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails",
     "longName": "1240701 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
     "longName": "1240801 - Disclosure - Contingent Earnout Liability - Narrative (Details)",
     "shortName": "Contingent Earnout Liability - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_10_2023_To_8_10_2023_us-gaap_DerivativeInstrumentRiskAxis_tlsi_ContingentEarnoutLiabilityMember_QW7EfoeCZUGUfloNheRNUg",
      "name": "tlsi:DerivativeInstrumentContingentConsiderationLiabilityShares",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
     "longName": "1240802 - Disclosure - Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)",
     "shortName": "Contingent Earnout Liability - Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_zWZM6-KBpkui8gyBIKU0hQ",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails",
     "longName": "1240901 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)",
     "shortName": "Warrants - Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "tlsi:WarrantsLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
     "longName": "1240902 - Disclosure - Warrants - Narrative (Details)",
     "shortName": "Warrants - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "tlsi:WarrantsLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails",
     "longName": "1241001 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
     "longName": "1241101 - Disclosure - Preferred Stock - Narrative (Details)",
     "shortName": "Preferred Stock - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "tlsi:PreferredStockAutomaticConversionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
     "longName": "1241102 - Disclosure - Preferred Stock - Summary of Convertible Preferred Stock (Details)",
     "shortName": "Preferred Stock - Summary of Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
     "longName": "1241103 - Disclosure - Preferred Stock - Convertible Preferred Stock Rollforward (Details)",
     "shortName": "Preferred Stock - Convertible Preferred Stock Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:TemporaryEquityValueConversionOfConvertibleSecurities",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
     "longName": "1241104 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)",
     "shortName": "Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_T3caAFynjU-f_j3WYu2JZQ",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
     "longName": "1241105 - Disclosure - Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)",
     "shortName": "Preferred Stock - Summary of Warrants to Purchase Convertible Preferred Stock Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_JAeM_XnmoEWw3hENIORI2w",
      "name": "tlsi:ClassOfWarrantOrRightConversionOfConvertibleSecurities",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
     "longName": "1241106 - Disclosure - Preferred Stock - Fair Value Measurements (Details)",
     "shortName": "Preferred Stock - Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_ValuationTechniqueAxis_tlsi_BlackScholesModelMember_Bc0NkOT9wEihH_2yOvMkbw",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
     "longName": "1241201 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities (Details)",
     "shortName": "Net Loss per Share - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantMember_OZsWLbb_CUea_sEX2DVygw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails",
     "longName": "1241202 - Disclosure - Net Loss per Share - Narrative (Details)",
     "shortName": "Net Loss per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_2_laeFYpM0-Kc5a36QO8Cw",
      "name": "us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "tlsi:IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
     "longName": "1241301 - Disclosure - Share-Based Compensation - (Details)",
     "shortName": "Share-Based Compensation - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_PlanNameAxis_tlsi_A2009PlanMember_3-O2-R9W5UieWhQkR_2mUA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
     "longName": "1241302 - Disclosure - Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "tlsi:ShareBasedCompensationArrangementNumberOfPlans",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "tlsi:ShareBasedCompensationArrangementNumberOfPlans",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails",
     "longName": "1241401 - Disclosure - Dynavax Purchase (Details)",
     "shortName": "Dynavax Purchase (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2020_To_12_31_2020_us-gaap_AssetAcquisitionAxis_tlsi_DynavaxTechnologiesMember_pb_ga-xGTU6mDVDRhkWdAw",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets",
     "longName": "222100100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_iz031UMFE0yxtFyZJCc0yA",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "222100105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Cover",
     "order": "98",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R99": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "222100200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "99",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit",
     "longName": "222100300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "100",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vPzmWFWcdk2_GhsoPaZMcg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o17RMY4e1kCnffIskGGRgQ",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "222100400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "101",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "222100405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "102",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss",
     "longName": "222110101 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "103",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R104": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss",
     "longName": "222110201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "104",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R105": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss",
     "longName": "222110301 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "105",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs",
     "longName": "222110401 - Disclosure - Cash, cash equivalents and restricted cash",
     "shortName": "Cash, cash equivalents and restricted cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "106",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R107": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventorys",
     "longName": "222110501 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "107",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R108": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssets",
     "longName": "222110601 - Disclosure - Long-Lived Assets",
     "shortName": "Long-Lived Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "108",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:LongLivedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:LongLivedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess",
     "longName": "222110701 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "109",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R110": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxess",
     "longName": "222110801 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "110",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R111": {
     "role": "http://trisaluslifesci.com/role/DisclosureDynavaxPurchases",
     "longName": "222110901 - Disclosure - Dynavax Purchase",
     "shortName": "Dynavax Purchase",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "111",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://trisaluslifesci.com/role/DisclosureDebt",
     "longName": "222111001 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "112",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertibleNotes",
     "longName": "222111101 - Disclosure - Convertible Notes",
     "shortName": "Convertible Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "113",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock",
     "longName": "222111201 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "114",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ConvertiblePreferredStockDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ConvertiblePreferredStockDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquity",
     "longName": "222111301 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "115",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShares",
     "longName": "222111401 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "116",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R117": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeases",
     "longName": "222111501 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "117",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss",
     "longName": "222111601 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "118",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R119": {
     "role": "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation",
     "longName": "222111701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation",
     "shortName": "Merger Agreement with MedTech Acquisition Corporation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "119",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss",
     "longName": "222120202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "120",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R121": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless",
     "longName": "222130303 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "121",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R122": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless",
     "longName": "222130403 - Disclosure - Cash, cash equivalents and restricted cash (Tables)",
     "shortName": "Cash, cash equivalents and restricted cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "122",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R123": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventoryTabless",
     "longName": "222130503 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "123",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R124": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables",
     "longName": "222130603 - Disclosure - Long-Lived Assets (Tables)",
     "shortName": "Long-Lived Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "124",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R125": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless",
     "longName": "222130703 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "125",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R126": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables",
     "longName": "222130803 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "126",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R127": {
     "role": "http://trisaluslifesci.com/role/DisclosureDebtTables",
     "longName": "222131003 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "127",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsi:WarrantsLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R128": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables",
     "longName": "222131203 - Disclosure - Convertible Preferred Stock (Tables)",
     "shortName": "Convertible Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "128",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ScheduleOfActivityInConvertiblePreferredStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R129": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables",
     "longName": "222131301 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "129",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R130": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless",
     "longName": "222131403 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "130",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R131": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesTables",
     "longName": "222131503 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "131",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R132": {
     "role": "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss",
     "longName": "222140101 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "132",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2009_To_12_31_2022_e5kzHqbLI0qcSm72FiJTKw",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R133": {
     "role": "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss",
     "longName": "222140201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "133",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:MilestonePaymentToDynavaxOperatingActivity",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R134": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
     "longName": "222140301 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "134",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "tlsi:FairValueLiabilitiesTransfersBetweenLevelsAmount",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R135": {
     "role": "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
     "longName": "222140302 - Disclosure - Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)",
     "shortName": "Financial Instruments - Changes in fair value of outstanding warrant and tranche liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "135",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_IS8HJG5-ukqzi4UD_dzixg",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_tlsi_WarrantLiabilitiesMember_ZC3gPhsLq0C-Ql-nVHkpag",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R136": {
     "role": "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss",
     "longName": "222140401 - Disclosure - Cash, cash equivalents and restricted cash (Details)",
     "shortName": "Cash, cash equivalents and restricted cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "136",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R137": {
     "role": "http://trisaluslifesci.com/role/DisclosureInventoryDetailss",
     "longName": "222140501 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "137",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:InventoryAdjustments",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R138": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
     "longName": "222140601 - Disclosure - Long-Lived Assets - Property and Equipment, tabular (Details)",
     "shortName": "Long-Lived Assets - Property and Equipment, tabular (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "138",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R139": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails",
     "longName": "222140602 - Disclosure - Long-Lived Assets - Property and Equipment, narrative (Details)",
     "shortName": "Long-Lived Assets - Property and Equipment, narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "139",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R140": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails",
     "longName": "222140603 - Disclosure - Long-Lived Assets - Intangible Assets (Details)",
     "shortName": "Long-Lived Assets - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "140",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R141": {
     "role": "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails",
     "longName": "222140604 - Disclosure - Long-Lived Assets - Intangible Assets, amortization expense (Details)",
     "shortName": "Long-Lived Assets - Intangible Assets, amortization expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "141",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "tlsi:LongLivedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R142": {
     "role": "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss",
     "longName": "222140701 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "142",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:AccruedIncentiveCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R143": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails",
     "longName": "222140801 - Disclosure - Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)",
     "shortName": "Income Taxes - Summary of income tax expenses (benefits) from continuing operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "143",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R144": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails",
     "longName": "222140802 - Disclosure - Income Taxes - Provision for federal income tax statutory rate (Details)",
     "shortName": "Income Taxes - Provision for federal income tax statutory rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "144",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R145": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "longName": "222140803 - Disclosure - Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Significant portions of deferred income tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "145",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "tlsi:DeferredTaxAssetsFixedAssetsAndIntangible",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R146": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
     "longName": "222140804 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)",
     "shortName": "Income Taxes - Net operating loss carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "146",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_bQoYjbQsiU6hs5DHhOa_QA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R147": {
     "role": "http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "222140805 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "147",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R148": {
     "role": "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss",
     "longName": "222140901 - Disclosure - Dynavax Purchase (Details)",
     "shortName": "Dynavax Purchase (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "148",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg",
      "name": "tlsi:UpfrontPaymentAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2020_To_7_31_2020_us-gaap_TypeOfArrangementAxis_tlsi_DynavaxPurchaseAgreementMember_vxT4b01YQEuMcOqGr3MrRg",
      "name": "tlsi:UpfrontPaymentAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R149": {
     "role": "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
     "longName": "222141001 - Disclosure - Debt - PPP Loan (Details)",
     "shortName": "Debt - PPP Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "149",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_tlsi_PaycheckProtectionProgramMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_Nzr23illXk2Gq1IugYkV9w",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R150": {
     "role": "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
     "longName": "222141002 - Disclosure - Debt - Term Loan (Details)",
     "shortName": "Debt - Term Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "150",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tlsi_WarrantsIssuedOn08262015Member_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5PreferredStockMember_GsTI8VUvtUCuflrS-YoxLg",
      "name": "tlsi:ClassOfWarrantOrRightNumberOfWarrantsIssued",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R151": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
     "longName": "222141101 - Disclosure - Convertible Notes (Details)",
     "shortName": "Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "151",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2021_To_12_31_2021_77S1LKUyIEKMP7_hfZUBOg",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:InitialWarrantLiability",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "tlsi:ConvertibleDebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R152": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
     "longName": "222141201 - Disclosure - Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "152",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R153": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
     "longName": "222141202 - Disclosure - Convertible Preferred Stock, activity in convertible preferred stock (Details)",
     "shortName": "Convertible Preferred Stock, activity in convertible preferred stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "153",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA6ConvertiblePreferredStockMember_hN-8AGcFuEuZnr2HwF1cJA",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfActivityInConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R154": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
     "longName": "222141203 - Disclosure - Convertible Preferred Stock, narrative (Details)",
     "shortName": "Convertible Preferred Stock, narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "154",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA5ConvertiblePreferredStockMember_EUAGU6yQXUKGAacSDP2WmA",
      "name": "tlsi:TemporaryEquitySharesAvailableForIssuance",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R155": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails",
     "longName": "222141204 - Disclosure - Convertible Preferred Stock, Conversion (Details)",
     "shortName": "Convertible Preferred Stock, Conversion (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "155",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R156": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails",
     "longName": "222141205 - Disclosure - Convertible Preferred Stock, Voting Rights (Details)",
     "shortName": "Convertible Preferred Stock, Voting Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "156",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired",
      "unitRef": "Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired",
      "unitRef": "Unit_Standard_Vote_vwYvNz400Eu_rYz6SG9ZOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R157": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
     "longName": "222141206 - Disclosure - Convertible Preferred Stock, Dividends (Details)",
     "shortName": "Convertible Preferred Stock, Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "157",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw",
      "name": "tlsi:TemporaryEquityDividendPerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_wkSrXgJQWkuZDNB4HE4GQw",
      "name": "tlsi:TemporaryEquityDividendPerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R158": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
     "longName": "222141207 - Disclosure - Convertible Preferred Stock, Liquidation Preferences (Details)",
     "shortName": "Convertible Preferred Stock, Liquidation Preferences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "158",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R159": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
     "longName": "222141208 - Disclosure - Convertible Preferred Stock, March 2021 Financing (Details)",
     "shortName": "Convertible Preferred Stock, March 2021 Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "159",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ",
      "name": "tlsi:TemporaryEquityOriginalIssuePrice",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_March2021FinancingMember_AzqiiqBFFUmRaReHnddxog",
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R160": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
     "longName": "222141209 - Disclosure - Convertible Preferred Stock, Spring 2021 Financing (Details)",
     "shortName": "Convertible Preferred Stock, Spring 2021 Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "160",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_4NeCidOy6EWunKluvpo5tQ",
      "name": "tlsi:TemporaryEquityOriginalIssuePrice",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_7_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Spring2021FinancingMember_65Jt8hk0gkGlKwXC5Zsg2g",
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
       "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R161": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
     "longName": "222141210 - Disclosure - Convertible Preferred Stock, Fall 2021 Financing (Details)",
     "shortName": "Convertible Preferred Stock, Fall 2021 Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "161",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_e45mTB1800-Zfiip3WJ1Cg",
      "name": "tlsi:TemporaryEquityOriginalIssuePrice",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_tlsi_SeriesB1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_Fall2021FinancingMember_yOaEsJ2vEE-E66KLaUlpEw",
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R162": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
     "longName": "222141211 - Disclosure - Convertible Preferred Stock, Warrant Exercises (Details)",
     "shortName": "Convertible Preferred Stock, Warrant Exercises (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "162",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R163": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
     "longName": "222141212 - Disclosure - Convertible Preferred Stock - 2022 Financing (Details)",
     "shortName": "Convertible Preferred Stock - 2022 Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "163",
     "firstAnchor": {
      "contextRef": "As_Of_8_10_2023_RCNVpsayQE-AWWse79BYGw",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2022_us-gaap_FairValueByLiabilityClassAxis_tlsi_SeriesB2TrancheLiabilitiesMember_4mN-bA9Uz0yu-SCx5mjf4Q",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R164": {
     "role": "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
     "longName": "222141213 - Disclosure - Convertible Preferred Stock - 2023 Financing (Details)",
     "shortName": "Convertible Preferred Stock - 2023 Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "164",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2023_To_3_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember_tKNgd2GCgESsCQV33cAzXg",
      "name": "tlsi:NumberOfStockOfferingClosingsEffectuated",
      "unitRef": "Unit_Standard_item_dBTKuO2_m0aeDiqqn9l7bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R165": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails",
     "longName": "222141301 - Disclosure - Stockholders' Equity - Common Stock (Details)",
     "shortName": "Stockholders' Equity - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "165",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R166": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails",
     "longName": "222141302 - Disclosure - Stockholders' Equity - Stock Option activity (Details)",
     "shortName": "Stockholders' Equity - Stock Option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "166",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R167": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails",
     "longName": "222141303 - Disclosure - Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)",
     "shortName": "Stockholders' Equity - Exercise price of options outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "167",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R168": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails",
     "longName": "222141304 - Disclosure - Stockholders' Equity - Valuation assumptions (Details)",
     "shortName": "Stockholders' Equity - Valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "168",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R169": {
     "role": "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "222141305 - Disclosure - Stockholders' Equity - Additional information (Details)",
     "shortName": "Stockholders' Equity - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "169",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R170": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
     "longName": "222141401 - Disclosure - Net Loss per Share (Details)",
     "shortName": "Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "170",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_eX3vBd7yY0S2t4gwYMvFAg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tlsi_PreferredStockWarrantsMember_sFPUIoXf4E6S5yFU1jhaWw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_XKdyuyCbtUu-g67nQAWScA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R171": {
     "role": "http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "222141402 - Disclosure - Net Loss per Share - Additional information (Details)",
     "shortName": "Net Loss per Share - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "171",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:DeemedDividendIncreaseInNetLossPerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R172": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails",
     "longName": "222141501 - Disclosure - Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)",
     "shortName": "Leases - Components of right-of-use assets, short-term lease liabilities and long-term leases liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "172",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_ki8GQ1Ix2UyUJ2c9h-ctMQ",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    },
    "R173": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss",
     "longName": "222141502 - Disclosure - Leases - Components of lease expense (Details)",
     "shortName": "Leases - Components of lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "173",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R174": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
     "longName": "222141503 - Disclosure - Leases - Components of lease expense (Details)",
     "shortName": "Leases - Components of lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "174",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tlsi:ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R175": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss",
     "longName": "222141504 - Disclosure - Leases - Future minimum lease payments (Details)",
     "shortName": "Leases - Future minimum lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "175",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_b0rOxjEgg0SR4tq4it4hIA",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R176": {
     "role": "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "222141505 - Disclosure - Leases - Future minimum lease payments (Details)",
     "shortName": "Leases - Future minimum lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "176",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:NumberOfOperatingLeases",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "tlsi:NumberOfOperatingLeases",
      "unitRef": "Unit_Standard_pure_hJKg_hFykEmh6cy7vcOrxA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R177": {
     "role": "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
     "longName": "222141601 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "177",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3BV5ENjfSkuZ5m8OyMgz2Q",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true,
      "unique": true
     }
    },
    "R178": {
     "role": "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
     "longName": "222141701 - Disclosure - Merger Agreement with MedTech Acquisition Corporation (Details)",
     "shortName": "Merger Agreement with MedTech Acquisition Corporation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "178",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_tlsi_SeriesA1ConvertiblePreferredStockMember_Ct_vxh6gpUu_J0aZWTWVJQ",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_NSQRls7k5EKO3oxN-jTN-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_11_2022_To_11_11_2022_dei_LegalEntityAxis_tlsi_MedtechAcquisitionCorporationMember_us-gaap_BusinessAcquisitionAxis_tlsi_TrisalusMember_jXVB0MfZKEuKVs8-7HgE1Q",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "unitRef": "Unit_Standard_USD_QkbGJm6O90ePxpF6I3kHFg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20230630xs1a.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of information about all options outstanding and exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r486",
      "r491",
      "r618",
      "r684",
      "r913",
      "r914",
      "r915"
     ]
    },
    "tlsi_SeriesA4ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA4ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-4 Convertible Preferred Stock",
        "label": "Series A-4 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-4",
        "verboseLabel": "Series A-4 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ReverseRecapitalizationStockValueIfConvertedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationStockValueIfConvertedAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enterprise Value",
        "label": "Reverse Recapitalization, Stock Value, If-Converted Amount",
        "terseLabel": "Enterprise value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r618",
      "r686",
      "r907",
      "r908",
      "r913",
      "r914",
      "r915"
     ]
    },
    "tlsi_AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalRecognitionOfDerivativeInstrumentContingentConsiderationLiability",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Recognition Of Derivative Instrument, Contingent Consideration Liability",
        "label": "Adjustments To Additional Paid In Capital, Recognition Of Derivative Instrument, Contingent Consideration Liability",
        "negatedTerseLabel": "Contingent earnout liability recognized upon closing of the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r932",
      "r933",
      "r934",
      "r935",
      "r1064",
      "r1068"
     ]
    },
    "tlsi_TrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche [Domain]",
        "label": "Tranche [Domain]",
        "terseLabel": "Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesB1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Convertible Preferred Stock",
        "label": "Series B-1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-1",
        "verboseLabel": "Series B-1 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of warrant or right, number of securities called by each warrant or right (in shares)",
        "verboseLabel": "Number of shares issuable per warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodFourMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period Four",
        "label": "Derivative Instrument, Period Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Two",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProceedsFromReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Reverse Recapitalization",
        "label": "Proceeds From Reverse Recapitalization",
        "terseLabel": "Proceeds from Business Combination",
        "verboseLabel": "Proceeds from business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightConversionTermsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Conversion Terms, Threshold Consecutive Trading Days",
        "label": "Class of Warrant or Right, Conversion Terms, Threshold Consecutive Trading Days",
        "terseLabel": "Class of warrant or right, conversion terms, threshold consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r123",
      "r124",
      "r343",
      "r883"
     ]
    },
    "tlsi_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "terseLabel": "Issuance of common stock upon closing the Business Combination, net of expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r912",
      "r998",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, ending balance",
        "periodStartLabel": "Convertible preferred stock, beginning balance",
        "terseLabel": "Convertible preferred stock",
        "verboseLabel": "Class A common stock subject to possible redemption, 1,144,794 shares at $10.52 and $10.14 per share redemption value as of June 30, 2023 and December 31, 2022, respectively",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r541",
      "r737"
     ]
    },
    "tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceGrantedPercent",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Granted, Percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Exercise Price, Granted, Percent",
        "terseLabel": "Stock options exercise price, percentage of fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r276",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r630",
      "r993"
     ]
    },
    "tlsi_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby Equity Purchase Agreement",
        "label": "Standby Equity Purchase Agreement [Member]",
        "terseLabel": "Standby Equity Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeFinancialInstrumentsWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeFinancialInstrumentsWarrantLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Financial Instruments, Warrant Liability",
        "label": "Derivative Financial Instruments, Warrant Liability [Member]",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdConsecutiveTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Consecutive Trading Days",
        "terseLabel": "Earnout period, threshold consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockWarrantMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightTransferOfWarrantToPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightTransferOfWarrantToPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Transfer of Warrant to Preferred Stock",
        "label": "Class of Warrant or Right, Transfer of Warrant to Preferred Stock",
        "terseLabel": "Transfer of warrant liability to preferred stock upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightStrikePriceOfWarrantsOrRights",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Strike Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Strike Price of Warrants or Rights",
        "terseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred stock, dividend rate, percentage",
        "verboseLabel": "Preferred stock dividend rate",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r859",
      "r861",
      "r862",
      "r876"
     ]
    },
    "tlsi_AssetAcquisitionRoyaltyPercentageOverThresholdAmount": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionRoyaltyPercentageOverThresholdAmount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Royalty Percentage, Over Threshold Amount",
        "label": "Asset Acquisition, Royalty Percentage, Over Threshold Amount",
        "terseLabel": "Royalties as a percentage of sales, over threshold amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PreferredStockAutomaticConversionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockAutomaticConversionPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Automatic Conversion, Period",
        "label": "Preferred Stock, Automatic Conversion, Period",
        "terseLabel": "Automatic conversion, anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Basic net (loss) income per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r303",
      "r307",
      "r311",
      "r312",
      "r313",
      "r317",
      "r613",
      "r614",
      "r730",
      "r747",
      "r900"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "tlsi_AssetAcquisitionSalesMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionSalesMilestone",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Sales Milestone",
        "label": "Asset Acquisition, Sales Milestone",
        "terseLabel": "Sales milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "tlsi_ClassOfWarrantOrRightRedemptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRedemptionPrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Redemption Price",
        "label": "Class of Warrant or Right, Redemption Price",
        "terseLabel": "Class of warrant or right, redemption price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPotentialIncreasedAmount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Number of Shares Issued in Transaction, Potential Increased Amount",
        "label": "Sale of Stock, Number of Shares Issued in Transaction, Potential Increased Amount",
        "terseLabel": "Number of shares issued in transaction, potential increased amount (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price, per unit",
        "verboseLabel": "Price of shares sold",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentContingentEarnoutLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentEarnoutLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Earnout Liability",
        "label": "Derivative Instrument, Contingent Earnout Liability [Member]",
        "terseLabel": "Contingent earnout liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PreferredStockPercentageOfSharesCommitted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockPercentageOfSharesCommitted",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Percentage of Shares Committed",
        "label": "Preferred Stock, Percentage of Shares Committed",
        "terseLabel": "Percentage of shares committed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeiture (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "tlsi_ReverseRecapitalizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization",
        "label": "Reverse Recapitalization [Line Items]",
        "terseLabel": "Reverse Recapitalization [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AssetAcquisitionMaximumMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionMaximumMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Milestone Amount",
        "label": "Asset Acquisition, Maximum Milestone Amount",
        "terseLabel": "Maximum aggregate milestone payments per development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToOfficersAndStockholders",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due to Officers and Stockholders",
        "terseLabel": "Due to stockholders",
        "documentation": "The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "terseLabel": "Shares outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_GainLossOnWarrantExpirations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GainLossOnWarrantExpirations",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Warrant Expirations",
        "label": "Gain (Loss) on Warrant Expirations",
        "negatedTerseLabel": "Gain on expired warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StandbyEquityPurchaseAgreementMaximumAmountOfSharesAuthorized",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby Equity Purchase Agreement, Maximum Amount Of Shares Authorized",
        "label": "Standby Equity Purchase Agreement, Maximum Amount Of Shares Authorized",
        "terseLabel": "Maximum shares of common stock allowed under Purchase Agreement (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "tlsi_SeriesA6ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA6ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-6 Convertible Preferred Stock",
        "label": "Series A-6 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-6",
        "verboseLabel": "Series A-6 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "tlsi_PreferredStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockWarrantMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Warrant",
        "label": "Preferred Stock Warrant [Member]",
        "terseLabel": "Preferred stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ReverseRecapitalizationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization Disclosure",
        "label": "Reverse Recapitalization Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "tlsi_SeriesB3ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB3ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-3 Convertible Preferred Stock",
        "label": "Series B-3 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-3",
        "verboseLabel": "Series B-3 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r112",
      "r795",
      "r797",
      "r810",
      "r811",
      "r812",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r845",
      "r846",
      "r847",
      "r866",
      "r868",
      "r871",
      "r873",
      "r896",
      "r928",
      "r930"
     ]
    },
    "tlsi_NatureOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NatureOfBusinessLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business [Line Items]",
        "label": "Nature of Business [Line Items]",
        "terseLabel": "Nature of Business [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTables",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockTables",
      "http://trisaluslifesci.com/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding",
        "verboseLabel": "Schedule of warrant liabilities that are carried at fair value, the initial fair values recorded as debt discount at the time of issuance and amortized as additional interest expense",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r829"
     ]
    },
    "us-gaap_AccruedRentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRentCurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Rent, Current",
        "terseLabel": "Net of accrued rent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r891"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Aggregate purchase price",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r766"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Contingent Earnout Liability",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r590",
      "r602"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r203",
      "r1060"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)",
        "terseLabel": "Issuances (Settlements)",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability, noncurrent",
        "verboseLabel": "MTAC warrants",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "tlsi_ClassOfWarrantOrRightConversionDaysNotice": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightConversionDaysNotice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Conversion Days Notice",
        "label": "Class Of Warrant Or Right, Conversion Days Notice",
        "terseLabel": "Threshold number of business days before sending notice of redemption to warrant holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Fair value of warrant liability",
        "verboseLabel": "Proceeds from sale of private placements warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r680"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash (included in Other assets)",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r217",
      "r272"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Conversion of shares",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r81",
      "r145",
      "r183",
      "r466"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Net Transfer In (Out) of Level 3",
        "verboseLabel": "Net Transfer In (Out) of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "tlsi_AssetAcquisitionMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Milestone, Amount",
        "label": "Asset Acquisition, Milestone, Amount",
        "terseLabel": "Milestone amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ConvertibleNotesAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConvertibleNotesAndWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes and Warrants",
        "label": "Convertible Notes and Warrants [Member]",
        "terseLabel": "Convertible notes and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "verboseLabel": "Due to stockholders",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r926"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of preferred stock",
        "verboseLabel": "Net proceeds",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "tlsi_PurchaseAgreementOwnershipLimitation": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PurchaseAgreementOwnershipLimitation",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Ownership Limitation",
        "label": "Purchase Agreement, Ownership Limitation",
        "terseLabel": "Purchase agreement, ownership limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r891"
     ]
    },
    "tlsi_DerivativeInstrumentPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodThreeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period Three",
        "label": "Derivative Instrument, Period Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PreferredStockConversionPriceFloor": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockConversionPriceFloor",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Conversion Price, Floor",
        "label": "Preferred Stock, Conversion Price, Floor",
        "terseLabel": "Series A Convertible Preferred Stock, floor conversion price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommercialMilestone1000000AnnualSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestone1000000AnnualSalesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone, $1,000,000 Annual Sales",
        "label": "Commercial Milestone, $1,000,000 Annual Sales [Member]",
        "terseLabel": "Commercial Milestone, $1,000,000 Annual Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Trade payables, accrued expenses and other liabilities",
        "verboseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liability, current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "tlsi_DerivativeInstrumentPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period",
        "label": "Derivative Instrument, Period [Axis]",
        "terseLabel": "Derivative Instrument, Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsAssumedInReverseRecapitalization",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Assumed In Reverse Recapitalization",
        "label": "Adjustments to Additional Paid in Capital, Warrants Assumed In Reverse Recapitalization",
        "negatedTerseLabel": "Assumption of warrants to purchase common stock in connection with the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Preferred stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r460",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "negatedTerseLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tlsi_WarrantsLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsLiabilitiesTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Liabilities",
        "label": "Warrants Liabilities [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ReverseRecapitalizationTransactionCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationTransactionCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Transaction Costs Incurred",
        "label": "Reverse Recapitalization, Transaction Costs Incurred",
        "terseLabel": "Transaction costs incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from the issuance of preferred stock",
        "verboseLabel": "Proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails": {
       "parentTag": "tlsi_ProceedsFromReverseRecapitalizationTransaction",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SharePriceAsPercentageOfMarketPriceCommencingOnAdvanceNoticeDate",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price As Percentage Of Market Price Commencing On Advance Notice Date",
        "label": "Share Price As Percentage Of Market Price Commencing On Advance Notice Date",
        "terseLabel": "Purchase agreement, sales price, percentage of market price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds, net of issuance costs",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r123",
      "r124",
      "r343",
      "r883"
     ]
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period",
        "terseLabel": "Derivative instrument, contingent consideration, liability, earnout period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightConversionOfConvertibleSecurities",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant Or Right, Conversion Of Convertible Securities",
        "label": "Class of Warrant Or Right, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Retirements/Conversion (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Initial Fair Value",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTables",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities",
        "verboseLabel": "Schedule of changes in the level 3 fair value of warrant liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r123",
      "r124",
      "r343",
      "r762",
      "r883"
     ]
    },
    "tlsi_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Warrants Exercised",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "negatedTerseLabel": "Exercises (in shares)",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r21"
     ]
    },
    "tlsi_PurchaseAgreementExchangeCap": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PurchaseAgreementExchangeCap",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Exchange Cap",
        "label": "Purchase Agreement, Exchange Cap",
        "terseLabel": "Purchase agreement, exchange cap"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r503",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r537",
      "r538",
      "r539",
      "r540"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r123",
      "r124",
      "r343"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r86"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "tlsi_PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockNumberOfTradingDaysVolumeWeightedAveragePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Number of Trading Days, Volume Weighted Average Price",
        "label": "Preferred Stock, Number of Trading Days, Volume Weighted Average Price",
        "terseLabel": "Number of trading days, VWAP"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TemporaryEquityValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquityValueConversionOfConvertibleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Retirements / Conversions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Conversion price (in dollars per share)",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r84"
     ]
    },
    "tlsi_SeriesA3ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA3ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-3 Convertible Preferred Stock",
        "label": "Series A-3 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-3",
        "verboseLabel": "Series A-3 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r110"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Assumption of preferred stock in connection with the Business Combination",
        "verboseLabel": "Issuance of stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r145",
      "r146",
      "r185",
      "r776",
      "r850",
      "r878",
      "r937"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "tlsi_SeriesB2TrancheLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB2TrancheLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-2 Tranche Liability",
        "label": "Series B-2 Tranche Liability [Member]",
        "terseLabel": "Series B-2 Tranche Liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ShareBasedCompensationArrangementNumberOfPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedCompensationArrangementNumberOfPlans",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement, Number of Plans",
        "label": "Share-Based Compensation Arrangement, Number of Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrant and Tranche Liabilities / Contingent Earnout Liability",
        "verboseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r104",
      "r105",
      "r106",
      "r113",
      "r283"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss": {
       "parentTag": "tlsi_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r659",
      "r925"
     ]
    },
    "tlsi_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "verboseLabel": "Issuance of common stock upon closing of the Business Combination (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company's assets and liabilities that are measured at fair value on a recurring basis",
        "terseLabel": "Schedule of company's assets that are measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r196"
     ]
    },
    "tlsi_PreferredStockIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockIssuedPricePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Issued Price Per Share",
        "label": "Preferred Stock, Issued Price Per Share",
        "terseLabel": "Original issue price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCash",
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r734"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "First and second development milestone payments in R&amp;D",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "tlsi_CommercialMilestoneTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestoneTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone Type [Domain]",
        "label": "Commercial Milestone Type [Domain]",
        "terseLabel": "Commercial Milestone Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Cash paid for intellectual property and licenses",
        "negatedTerseLabel": "Cash paid for intellectual property and licenses",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)",
        "terseLabel": "Warrants outstanding (in shares)",
        "verboseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AssetAcquisitionRoyaltiesSalesThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionRoyaltiesSalesThresholdAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Royalties, Sales Threshold Amount",
        "label": "Asset Acquisition, Royalties, Sales Threshold Amount",
        "terseLabel": "Royalties, sales threshold amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PaymentsOfReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentsOfReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Reverse Recapitalization, Transaction Costs",
        "label": "Payments Of Reverse Recapitalization, Transaction Costs",
        "negatedTerseLabel": "Offering costs related to Business Combination",
        "verboseLabel": "Expenses related to business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r40",
      "r185"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "tlsi_PreferredStockConversionPercentageOfOutstandingShares": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockConversionPercentageOfOutstandingShares",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Conversion, Percentage of Outstanding Shares",
        "label": "Preferred Stock, Conversion, Percentage of Outstanding Shares",
        "terseLabel": "Percentage of then-outstanding preferred stock on an as-converted to common stock basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r40",
      "r185"
     ]
    },
    "tlsi_CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockSharePriceAverageDailyVolumeNumberOfTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Share Price, Average Daily Volume, Number Of Trading Days",
        "label": "Common Stock, Share Price, Average Daily Volume, Number Of Trading Days",
        "terseLabel": "Purchase agreement, number of days used for measurement of average daily trading volume"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from promissory note",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r275",
      "r454",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r470",
      "r474",
      "r603",
      "r853",
      "r855",
      "r882"
     ]
    },
    "tlsi_CommercialMilestoneFirstCommercialSaleOfProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestoneFirstCommercialSaleOfProductMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone, First Commercial Sale of Product",
        "label": "Commercial Milestone, First Commercial Sale of Product [Member]",
        "terseLabel": "Commercial Milestone, First Commercial Sale of Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "verboseLabel": "Transfers in or out of Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' DEFICIT",
        "verboseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period [Domain]",
        "label": "Derivative Instrument, Period [Domain]",
        "terseLabel": "Derivative Instrument, Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase Series B-3 preferred stock (in shares)",
        "verboseLabel": "Sale of private placement warrants (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuances (in shares)",
        "verboseLabel": "Issuance of preferred stock with PIPE financing (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r145",
      "r146",
      "r185",
      "r766",
      "r850",
      "r878"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "tlsi_MedTechAcquisitionCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MedTechAcquisitionCorporationMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedTech Acquisition Corporation",
        "label": "MedTech Acquisition Corporation [Member].",
        "terseLabel": "MedTech Acquisition Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PaymentsForAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentsForAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisition",
        "label": "Payments for Asset Acquisition",
        "terseLabel": "Payment for asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r428"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "ROU assets",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r963"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value",
        "verboseLabel": "Change in Unrealized (Gains) Losses",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Summary of net operating loss carryforwards",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRollForward",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Roll Forward]",
        "terseLabel": "Class of Warrant or Right [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionPotentialIncreasedAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received on Transaction, Potential Increased Amount",
        "label": "Sale of Stock, Consideration Received on Transaction, Potential Increased Amount",
        "terseLabel": "Consideration received, potential increased amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "verboseLabel": "Fair Value, liabilities measured on recurring basis, unobservable input reconciliation",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ValuationReverseRecapitalizationApproachEnterpriseValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ValuationReverseRecapitalizationApproachEnterpriseValueMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation, Reverse Recapitalization Approach, Enterprise Value",
        "label": "Valuation, Reverse Recapitalization Approach, Enterprise Value [Member]",
        "terseLabel": "Valuation, Reverse Recapitalization Approach, Enterprise Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "verboseLabel": "Financial Instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantLiabilitiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrant liabilities.",
        "label": "Warrant Liabilities [Member]",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TrancheLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheLiabilitiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for tranche liabilities.",
        "label": "Tranche Liabilities [Member]",
        "terseLabel": "Tranche liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r679"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r274",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r448",
      "r449",
      "r451"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds on sale of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_FairValueLiabilitiesTransfersBetweenLevelsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FairValueLiabilitiesTransfersBetweenLevelsAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis between various levels of fair value hierarchy.",
        "label": "Fair Value, Liabilities, Transfers Between Levels, Amount",
        "terseLabel": "Transfers between levels"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change in deferred tax assets valuation amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "tlsi_PutOptionLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PutOptionLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for put option liability.",
        "label": "Put Option Liability [Member]",
        "terseLabel": "Put option liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfThenOutstandingSharesOnAsConvertedToCommonStockBasisOffered",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the then outstanding shares on an as-converted to common stock basis, offered under the stock offering.",
        "label": "Percentage Of Then Outstanding Shares On An As-Converted To Common Stock Basis, Offered",
        "terseLabel": "Percentage of then outstanding shares on an as-converted to common stock basis, offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r679"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r679"
     ]
    },
    "tlsi_TrancheRightsAndObligationsAssociatedWithThirdTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheRightsAndObligationsAssociatedWithThirdTrancheMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for tranche rights and obligations associated with the third tranche.",
        "label": "Tranche Rights And Obligations Associated With The Third Tranche [Member]",
        "terseLabel": "Tranche rights and obligations associated with the third tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270",
      "r271"
     ]
    },
    "tlsi_TrancheRightsAndObligationsAssociatedWithSecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheRightsAndObligationsAssociatedWithSecondTrancheMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for tranche rights and obligations associated with the second tranche.",
        "label": "Tranche Rights And Obligations Associated With The Second Tranche [Member]",
        "terseLabel": "Tranche rights and obligations associated with the second tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "verboseLabel": "Offering costs related to IPO",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r185"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r545",
      "r1057"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r970",
      "r1033"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "negatedTerseLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r679"
     ]
    },
    "tlsi_BusinessCombinationAcquisitionExpensesDeferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BusinessCombinationAcquisitionExpensesDeferred",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of business acquisition cost deferred.",
        "label": "Business Combination, Acquisition Expenses, Deferred",
        "terseLabel": "Deferred expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Promissory Note",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r200"
     ]
    },
    "tlsi_CashPaidDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CashPaidDuringYearForAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid During the Year For [Abstract]",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PutOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PutOptionMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put Option [Member]",
        "terseLabel": "Put option",
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866",
      "r867"
     ]
    },
    "tlsi_WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantAndTrancheRightsAndObligationLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant and tranche rights and obligation liabilities.",
        "label": "Warrant And Tranche Rights And Obligation Liabilities [Policy Text Block]",
        "terseLabel": "Warrant and Tranche Rights and Obligation Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS",
        "verboseLabel": "PRIVATE PLACEMENT",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.",
        "label": "Concentrations Of Credit Risk And Other Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CumulativeIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CumulativeIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to cumulative income loss from issuance of securities.",
        "label": "Cumulative Income Loss",
        "terseLabel": "Cumulative net losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssets",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets",
        "terseLabel": "Increase in assets",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for preferred stock warrants.",
        "label": "Preferred Stock Warrants [Member]",
        "terseLabel": "Preferred stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash held in the Trust Account",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r734",
      "r787",
      "r813",
      "r926",
      "r938",
      "r955"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Net proceeds from issuance of convertible notes",
        "verboseLabel": "Proceeds from issuance of convertible notes and warrants",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "tlsi_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AccruedIncentiveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AccruedIncentiveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused incentive owed to employees based on the entity's incentive benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Incentive Current",
        "terseLabel": "Accrued incentives"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DeemedDividendIncreaseInNetLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeemedDividendIncreaseInNetLossPerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of per share increase in net loss from deemed dividend.",
        "label": "Deemed Dividend, Increase In Net Loss Per Share",
        "terseLabel": "Increase in net loss per share from deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r343"
     ]
    },
    "tlsi_PaycheckProtectionProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaycheckProtectionProgramMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Paycheck Protection Program .",
        "label": "Paycheck Protection Program [Member]",
        "terseLabel": "PPP"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MedtechAcquisitionCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MedtechAcquisitionCorporationMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to MedTech Acquisition Corporation.",
        "label": "MedTech Acquisition Corporation [Member]",
        "terseLabel": "MedTech Acquisition Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LongLivedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LongLivedAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Long-Lived Assets"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LongLivedAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LongLivedAssetsDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on long-lived assets.",
        "label": "Long-Lived Assets, Disclosure [Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuances",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfCustomer": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfCustomer",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customer.",
        "label": "Number Of Customer",
        "terseLabel": "Number of customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tlsi_BusinessCombinationWarrantsConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BusinessCombinationWarrantsConsideration",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of  consideration for the warrants.",
        "label": "Business Combination, Warrants Consideration",
        "terseLabel": "Warrants consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "verboseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r225"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1034"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit",
        "verboseLabel": "State and local taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1034"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "negatedTerseLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense, options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense, RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Closing price (in dollars per share)",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r450",
      "r469",
      "r602",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r746",
      "r905",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective federal tax rate",
        "totalLabel": "Effective income tax rate",
        "verboseLabel": "Income tax provision",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective income tax rate reconciliation, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1034"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r313"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain (loss) on disposal of fixed assets",
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r429",
      "r458",
      "r676",
      "r894",
      "r896"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r313"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate",
        "verboseLabel": "Statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r551",
      "r570"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "verboseLabel": "WARRANT LIABILITIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Recognized compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r542"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "negatedLabel": "Change in Unrealized (Gains) Losses",
        "documentation": "Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss": {
       "parentTag": "tlsi_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of ROU assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r659",
      "r925"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetails",
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Inventory, net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r889",
      "r926"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate amortization expense for intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock",
        "verboseLabel": "Class A common stock",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Redemption price per share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r76"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Final payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r133"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "verboseLabel": "Anti-dilutive securities attributable to warrants (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r249",
      "r250",
      "r251",
      "r276",
      "r307",
      "r308",
      "r311",
      "r313",
      "r319",
      "r320",
      "r381",
      "r416",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r455",
      "r456",
      "r460",
      "r463",
      "r471",
      "r630",
      "r766",
      "r767",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r805",
      "r827",
      "r850",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r941",
      "r967",
      "r975"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Basic and diluted net (loss) income per share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r284",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r646",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r968"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Total stockholders' deficit",
        "totalLabel": "Total stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r171",
      "r807",
      "r824",
      "r851",
      "r852",
      "r926",
      "r938",
      "r969",
      "r986",
      "r1045",
      "r1068"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "tlsi_InitialPublicOfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InitialPublicOfferingLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Initial Public Offering [Line Items]",
        "terseLabel": "PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of preferred stock warrants",
        "verboseLabel": "Proceeds from exercise of Series B preferred stock warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right-of-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense related to intellectual property",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r70"
     ]
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Borrowed aggregate principal amount",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareTables",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "verboseLabel": "Schedule of potentially dilutive securities (in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income per Share of Common Stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r646",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r968"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r139",
      "r140",
      "r200",
      "r203",
      "r284",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r646",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r968"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]",
        "verboseLabel": "Convertible Preferred Stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r116",
      "r117",
      "r194"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r81",
      "r85",
      "r125",
      "r126",
      "r128",
      "r132",
      "r182",
      "r184",
      "r284",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r646",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r968"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities",
        "verboseLabel": "Fair value of liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Aggregate Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Final net exercise",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liability",
        "negatedTerseLabel": "Loss on equity issuance",
        "terseLabel": "Gain (loss) on derivatives",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r333",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r483",
      "r484",
      "r713"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Options issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r76"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOffering",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r318",
      "r713",
      "r764",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r825",
      "r828",
      "r829",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r850",
      "r931"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Dynavax Purchase",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r223",
      "r233"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value per share (in dollars per share)",
        "verboseLabel": "Common stock subject to possible redemption, price per share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r76"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLossOnDerivative",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Loss on change in fair value",
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfer to level 1",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Short-term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_InventoryAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Adjustments",
        "terseLabel": "Reserve for excess inventory",
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r959"
     ]
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainOnDerivative",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain on Derivative",
        "terseLabel": "Gain on change in fair value",
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r887"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Accrued interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r1059"
     ]
    },
    "tlsi_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.",
        "label": "Condition For Future Business Combination Number Of Businesses Minimum",
        "terseLabel": "Condition for future business combination number of businesses minimum"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CurePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CurePeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cure period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Cure Period",
        "terseLabel": "Cure period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LossContingencyDamagesPaidValueNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LossContingencyDamagesPaidValueNumberOfInstallments",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of installments in which agreed damages is paid.",
        "label": "Loss Contingency Damages Paid Value, Number Of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r455"
     ]
    },
    "tlsi_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrants",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "verboseLabel": "Convertible preferred stock, issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "tlsi_DeferredOfferingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeferredOfferingCostsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails": {
       "parentTag": "tlsi_TransactionCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.",
        "label": "Deferred Offering Costs Noncurrent",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "tlsi_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.",
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TemporaryEquityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for temporary equity.",
        "label": "Temporary Equity, Policy [Policy Text Block]",
        "terseLabel": "Class A Common Stock Subject to Possible Redemption"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DynavaxPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DynavaxPurchaseAgreementMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dyvanax purchase agreement to purchase of in-process research and development (\"IPR&amp;D\").",
        "label": "Dynavax Purchase Agreement [Member]",
        "terseLabel": "Dynavax purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "verboseLabel": "Convertible preferred stock, authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r805"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "tlsi_AssetsHeldInTrustAccountPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assets held in trust.",
        "label": "Assets Held In Trust Account, Policy [Policy Text Block]",
        "terseLabel": "Cash and Investments Held in Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DynavaxPurchaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DynavaxPurchaseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Dynavax Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r805",
      "r824",
      "r1068",
      "r1069"
     ]
    },
    "tlsi_AggregateNumberOfSharesOwned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AggregateNumberOfSharesOwned",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares owned by the founders after the impact of the stock dividend.",
        "label": "Aggregate Number Of Shares Owned",
        "terseLabel": "Aggregate number of shares owned"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Number of shares subject to redemption",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "tlsi_NumberOfPatentsTestimonyLimited": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfPatentsTestimonyLimited",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patents for which testimony is limited.",
        "label": "Number Of Patents, Testimony Limited",
        "terseLabel": "Number of patents for which testimony is limited"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfPatentsSuitFiled": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfPatentsSuitFiled",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patents for which suit was filed.",
        "label": "Number Of Patents, Suit Filed",
        "terseLabel": "Number of patents for which suit filed"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PaymentsForInvestmentOfCashInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentsForInvestmentOfCashInTrustAccount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for investment of cash in trust account.",
        "label": "Payments For Investment Of Cash In Trust Account",
        "verboseLabel": "Payments for investment of cash in trust account"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EmployeeContributionBetweenFourAndFivePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EmployeeContributionBetweenFourAndFivePercentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for employees contribution between four and five percent.",
        "label": "Employee Contribution Between Four And Five Percent [Member]",
        "terseLabel": "Employee's contribution between 4% and 5%"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the ending (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "tlsi_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SponsorMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for sponsor.",
        "label": "Sponsor [Member]",
        "terseLabel": "Sponsor"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantsIssuedOn08262015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsIssuedOn08262015Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued on 08262015.",
        "label": "Warrants Issued on 08262015 [Member]",
        "terseLabel": "Warrants issued on 08262015"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash items:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r926"
     ]
    },
    "tlsi_ClassOfWarrantOrRightPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Price of Warrants or Rights",
        "terseLabel": "Price of warrant",
        "verboseLabel": "Price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TermLoanAndSupplementalTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TermLoanAndSupplementalTermLoanMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to term loan and supplemental term loan.",
        "label": "Term Loan and Supplemental Term Loan [Member]",
        "terseLabel": "Term loan and supplemental term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r455"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "tlsi_NumberOfSharesSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfSharesSubjectToForfeiture",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.",
        "label": "Number Of Shares Subject To Forfeiture",
        "terseLabel": "Shares subject to forfeiture"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B preferred stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r958",
      "r997"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "NOLs expiring between 2029 and 2037",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger",
        "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantsIssuedOn10272016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsIssuedOn10272016Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued on 10272016.",
        "label": "Warrants Issued on 10272016 [Member]",
        "terseLabel": "Warrants issued on 10272016"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "NOLs which do not expire",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days",
        "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "tlsi_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.",
        "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences",
        "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantsIssuedOn06302017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsIssuedOn06302017Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued on 06302017.",
        "label": "Warrants Issued on 06302017 [Member]",
        "terseLabel": "Warrants issued on 06302017"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "tlsi_PromissoryNoteWithRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PromissoryNoteWithRelatedPartyMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for promissory note with related party.",
        "label": "Promissory Note With Related Party [Member]",
        "terseLabel": "Promissory Note - Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_RelatedPartyLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RelatedPartyLoansMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for related party loans.",
        "label": "Related Party Loans [Member]",
        "terseLabel": "Related Party Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference (in dollars per share)",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r145",
      "r967",
      "r996"
     ]
    },
    "tlsi_WarrantsIssuedOn11202018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsIssuedOn11202018Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued on 11202018.",
        "label": "Warrants Issued on 11202018 [Member]",
        "terseLabel": "Warrants issued on 11202018"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes that each common share is entitled.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Common stock, votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Aggregate amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r714"
     ]
    },
    "tlsi_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual monthly amount to be paid for support services.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month",
        "terseLabel": "Expenses per month"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesA5PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA5PreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A5 Preferred Stock.",
        "label": "Series A-5 Preferred Stock [Member]",
        "terseLabel": "Series A-5 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "tlsi_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.",
        "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00 [Member]",
        "terseLabel": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights",
        "terseLabel": "Redemption price per public warrant (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesA6PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA6PreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A6 Preferred Stock.",
        "label": "Series A-6 Preferred Stock [Member]",
        "terseLabel": "Series A-6 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days",
        "terseLabel": "Threshold trading days for redemption of public warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesProvisionForFederalIncomeTaxStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Permanent differences tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for redemption of public warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Class of Warrant or Right, Number of Warrants Issued",
        "terseLabel": "Quantity"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumLoansConvertibleIntoWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumLoansConvertibleIntoWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.",
        "label": "maximum Loans Convertible Into Warrants",
        "terseLabel": "Loan conversion agreement warrant"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum borrowing capacity of related party promissory note.",
        "label": "Maximum Borrowing Capacity of Related Party Promissory Note",
        "terseLabel": "Maximum borrowing capacity of related party promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_RedemptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RedemptionPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of period of redemption.",
        "label": "Redemption Period",
        "terseLabel": "Redemption period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DeferredTaxAssetsFixedAssetsAndIntangible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangible",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from fixed assets and intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangible",
        "terseLabel": "Fixed assets and intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NetDeferredTaxAssetsChangeInValuationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NetDeferredTaxAssetsChangeInValuationPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying deferred tax assets change in valuation.",
        "label": "Net Deferred Tax Assets Change In Valuation Percentage",
        "terseLabel": "Deferred tax assets change in valuation percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r926",
      "r1066"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net (loss) income per common stock",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "tlsi_FirstInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FirstInstallmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for first installment.",
        "label": "First Installment [Member]",
        "terseLabel": "First installment"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of transaction costs incurred.",
        "label": "Transaction Costs",
        "totalLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r450",
      "r469",
      "r602",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r746",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "tlsi_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold  number of business days before sending notice of redemption to warrant holders.",
        "label": "Threshold Number of Business Days Before Sending Notice of Redemption to Warrant Holders",
        "terseLabel": "Threshold number of business days before sending notice of redemption to warrant holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedTerseLabel": "Undeclared dividends on Series A preferred stock",
        "terseLabel": "Undeclared dividends",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SecondInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SecondInstallmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for second installment.",
        "label": "Second Installment [Member]",
        "terseLabel": "Second installment"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AdministrativeSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AdministrativeSupportAgreementMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Administrative Support Agreement.",
        "label": "Administrative Support Agreement [Member]",
        "terseLabel": "Administrative Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EmployeeContributionBetweenThreeAndFourPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EmployeeContributionBetweenThreeAndFourPercentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for employees contribution between three and four percent.",
        "label": "Employee Contribution Between Three And Four Percent [Member]",
        "terseLabel": "Employee's contribution between 3% and 4%"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumNumberOfDemandsForRegistrationOfSecurities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of demands for registration of securities.",
        "label": "Maximum Number Of Demands For Registration Of Securities",
        "terseLabel": "Maximum number of demands for registration of securities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SaleOfStockUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SaleOfStockUnderwritingFees",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails": {
       "parentTag": "tlsi_TransactionCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of offering fees incurred and paid for underwriters.",
        "label": "Sale of Stock Underwriting Fees",
        "terseLabel": "Underwriting fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EmployeeContributionUptoThreePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EmployeeContributionUptoThreePercentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for employees contribution upto three percent.",
        "label": "Employee Contribution Upto Three Percent [Member]",
        "terseLabel": "Employee's contribution of up to 3%"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r73"
     ]
    },
    "us-gaap_PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount",
        "negatedLabel": "Deemed dividend related to Series B-2 preferred stock down round provision",
        "verboseLabel": "Deemed dividend to preferred stockholders",
        "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for convertible preferred stock."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r313"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Deemed dividend",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for convertible preferred stock."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r473"
     ]
    },
    "tlsi_IssuanceOfPromissoryNote2022ToSponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IssuanceOfPromissoryNote2022ToSponsorMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to issuance of promissory notes to sponsor.",
        "label": "Issuance of Promissory Note 2022 to Sponsor [Member]",
        "verboseLabel": "Extension Note"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of of maturities of operating and finance leases liabilities.",
        "label": "Schedule Of Maturities Of Operating And Finance Leases Liabilities [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities under noncancellable leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r334",
      "r338",
      "r340",
      "r902"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r201"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 and 0 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 4,015,002 and 0 shares at September 30, 2023, and December 31, 2022, respectively",
        "verboseLabel": "Preferred stock, par value $0.0001 per share; 1,000,000 shares authorized, none issued and outstanding as of June 30, 2023 and December 31, 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r735",
      "r926"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOffering",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r318",
      "r713",
      "r764",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r825",
      "r828",
      "r829",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r850",
      "r931"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal",
        "verboseLabel": "Federal:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "tlsi_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost on finance lease liability.",
        "label": "Finance Lease Cost",
        "terseLabel": "Total finance lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTables",
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "verboseLabel": "Schedule of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentOfDepositsIntoTrustAccountDrawnDown": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentOfDepositsIntoTrustAccountDrawnDown",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of deposits that are drawn down in Trust Account.",
        "label": "Percent of Deposits into Trust Account, Drawn Down",
        "verboseLabel": "Percent of deposits drawn down"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State and Local",
        "verboseLabel": "State:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r574",
      "r916",
      "r917"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Cost [Abstract]",
        "terseLabel": "Finance lease expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables",
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "verboseLabel": "Summary of cash, cash equivalents and restricted cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of components of right-of-use assets, short-term lease liabilities and long-term lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_StockOptionsAvailableForFutureGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockOptionsAvailableForFutureGrantMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock options available for future grant.",
        "label": "Stock Options Available for Future Grant [Member]",
        "terseLabel": "Stock options available for future grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "tlsi_StockOptionsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockOptionsOutstandingMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock options outstanding.",
        "label": "Stock Options Outstanding [Member]",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r916",
      "r917"
     ]
    },
    "tlsi_WarrantsToPurchaseSeriesB3PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsToPurchaseSeriesB3PreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants to purchase Series B-3 Preferred Stock.",
        "label": "Warrants to Purchase Series B-3 Preferred Stock [Member]",
        "terseLabel": "Warrants to purchase Series B3 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryTables",
      "http://trisaluslifesci.com/role/DisclosureInventoryTabless"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Components of Inventory",
        "verboseLabel": "Summary of components of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r152",
      "r153",
      "r154"
     ]
    },
    "tlsi_WarrantsToPurchaseSeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsToPurchaseSeriesBPreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants to purchase Series B Preferred Stock.",
        "label": "Warrants to Purchase Series B Preferred Stock [Member]",
        "terseLabel": "Warrants to purchase Series B preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r625"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r123",
      "r124",
      "r343",
      "r883",
      "r945"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r497"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and software",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r574"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Merger Agreement with MedTech Acquisition Corporation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "tlsi_ExercisePriceOf0.006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.006Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.006.",
        "label": "Exercise Price of $0.006 [Member]",
        "terseLabel": "0.06"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60",
      "r61",
      "r123",
      "r197",
      "r883"
     ]
    },
    "tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareRedemptionsRemovalOfTrustAccountToPayStockholdersAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of removal in Trust Accounts to pay stockholders.",
        "label": "Share Redemptions, Removal of Trust Account to Pay Stockholders, Amount",
        "terseLabel": "Amount removed from trust account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityTables",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "verboseLabel": "Schedule of key inputs into the monte carlo simulation for the private placement warrants",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate of operating lease",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r925"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ExercisePriceOf0.007Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.007Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.007.",
        "label": "Exercise Price of $0.007 [Member]",
        "terseLabel": "0.07"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "verboseLabel": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r185",
      "r738",
      "r756",
      "r761",
      "r770",
      "r806",
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "tlsi_ExercisePriceOf0.09To0.46Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.09To0.46Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.09 to $0.46.",
        "label": "Exercise Price of $0.09 to $0.46 [Member]",
        "terseLabel": "$0.09-$0.46"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate of finance lease",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r925"
     ]
    },
    "tlsi_ConvertibleDebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConvertibleDebtDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to convertible notes.",
        "label": "Convertible Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_EquityIncentivePlan2019AsAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EquityIncentivePlan2019AsAmendedMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2019 Equity Incentive Plan as Amended (the Plan).",
        "label": "Equity Incentive Plan 2019 As Amended [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DebtInstrumentConversionThresholdPercentageOfPricePerSharePaidByCashPurchasersOfStockIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of price per share paid by cash purchasers for the preferred stock issued in the qualified financing under the debt conversion arrangement.",
        "label": "Debt Instrument Conversion, Threshold Percentage Of Price Per Share Paid By Cash Purchasers Of Stock Issued",
        "terseLabel": "Threshold percentage of price per share paid by the cash purchasers"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_QualifiedFinancingMinimumProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "QualifiedFinancingMinimumProceeds",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum proceeds from the issuance of capital to be considered as qualified financing.",
        "label": "Qualified Financing, Minimum Proceeds",
        "terseLabel": "Minimum proceeds to be considered as qualified financing"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProbabilityOfOccurrenceOfQualifiedFinancingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProbabilityOfOccurrenceOfQualifiedFinancingPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of probability of occurrence of qualified financing under the debt conversion covenant.",
        "label": "Probability Of Occurrence Of Qualified Financing, Percentage",
        "terseLabel": "Percentage of probability of occurrence of qualified financing"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProbabilityOfConvertibleNotesConvertingAtMaturityPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of probability of convertible notes converting at maturity under the debt conversion covenant.",
        "label": "Probability Of Convertible Notes Converting At Maturity, Percentage",
        "terseLabel": "Percentage of probability of convertible notes converting at maturity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r494",
      "r942",
      "r943",
      "r974"
     ]
    },
    "tlsi_DebtInstrumentConversionDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DebtInstrumentConversionDiscountPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount on convertible notes.",
        "label": "Debt Instrument, Conversion Discount Percentage",
        "terseLabel": "Conversion discount percentage"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EliminationOfOccurrenceOfDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EliminationOfOccurrenceOfDiscountPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage on elimination of occurrence of discount rate.",
        "label": "Elimination Of Occurrence Of Discount Percentage",
        "terseLabel": "Percentage of discount modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss available to common stockholders",
        "verboseLabel": "Net loss available to common stockholders",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r169",
      "r206",
      "r240",
      "r258",
      "r259",
      "r263",
      "r276",
      "r289",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r309",
      "r321",
      "r334",
      "r338",
      "r340",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r614",
      "r630",
      "r745",
      "r826",
      "r848",
      "r849",
      "r902",
      "r936",
      "r993"
     ]
    },
    "tlsi_NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfBoardOfDirectorAboveWhichMajorityPreferredShareholdersVotingApprovalWillBeRequired",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockVotingRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of board of director above which majority preferred shareholders voting approval will be required.",
        "label": "Number Of Board Of Director Above Which Majority Preferred Shareholders Voting Approval Will Be Required",
        "terseLabel": "Number of board of director above which majority preferred shareholders voting approval will be required"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_March2021FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "March2021FinancingMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to March 2021 Financing.",
        "label": "March 2021 Financing [Member]",
        "terseLabel": "March 2021 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r494",
      "r942",
      "r974"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Allocation of net (loss) income",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r293",
      "r294",
      "r295",
      "r296",
      "r303",
      "r304",
      "r310",
      "r313",
      "r321",
      "r334",
      "r338",
      "r340",
      "r902"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareRedemptionsAmountNotRemovedAndHeldInTrustAccount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-removal in Trust Accounts to pay stockholders.",
        "label": "Share Redemptions, Amount Not Removed and Held in Trust Account",
        "terseLabel": "Remaining amount held in the trust account"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_Spring2021FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "Spring2021FinancingMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Spring 2021 Financing.",
        "label": "Spring 2021 Financing [Member]",
        "terseLabel": "Spring 2021 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred income tax assets and liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1029"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment and Disposal of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r176"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_Fall2021FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "Fall2021FinancingMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Fall 2021 Financing.",
        "label": "Fall 2021 Financing [Member]",
        "terseLabel": "Fall 2021 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommercialMilestoneTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestoneTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone Type",
        "label": "Commercial Milestone Type [Axis]",
        "terseLabel": "Commercial Milestone Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits accrued for interest and penalties",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Public warrants expiration term",
        "verboseLabel": "Public warrants, term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r548",
      "r549",
      "r555",
      "r556",
      "r561",
      "r563",
      "r765"
     ]
    },
    "tlsi_FairValueAdjustmentOfTrancheAndWarrantsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FairValueAdjustmentOfTrancheAndWarrantsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of tranche and warrant liability.",
        "label": "Fair Value Adjustment Of Tranche And Warrants Liabilities",
        "negatedLabel": "Change in fair value of tranche and warrant liabilities",
        "terseLabel": "Change in fair value of tranche and warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfConvertibleDebtToRemoveConversionDiscount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid-in capital from modification of convertible debt to remove conversion discount.",
        "label": "Adjustments to Additional Paid in Capital, Modification of Convertible Debt to Remove Conversion Discount",
        "terseLabel": "Modification of convertible debt to remove conversion discount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_GainOnPppLoanForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GainOnPppLoanForgiveness",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gains on forgiveness of PPP loans.",
        "label": "Gain On PPP Loan Forgiveness",
        "negatedLabel": "Gain on PPP loan forgiveness"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MilestonePaymentToDynavaxOperatingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MilestonePaymentToDynavaxOperatingActivity",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment to Dynavax, classified under operating activity.",
        "label": "Milestone Payment To Dynavax, Operating Activity",
        "terseLabel": "Milestone payment to Dynavax"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.",
        "label": "Increase Decrease In Operating Lease Right of Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromIssuanceOfStockOptionsAndWarrantsForCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options and warrants for common stock.",
        "label": "Proceeds From Issuance Of Stock Options And Warrants For Common Stock",
        "terseLabel": "Cash proceeds from the exercise of stock options and warrants for common stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TransferOfWarrantLiabilityToPreferredStockUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of warrant liability transferred to preferred stock upon exercise of warrants.",
        "label": "Transfer Of Warrant Liability To Preferred Stock Upon Exercise Of Warrants",
        "terseLabel": "Transfer of warrant liability to preferred stock upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Balloon payment",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PutOptionLiabilityTransferredToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PutOptionLiabilityTransferredToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of put option liability transferred to additional paid-In capital.",
        "label": "Put Option Liability Transferred To Additional Paid In Capital",
        "terseLabel": "Put option liability transferred to Additional paid-In capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "verboseLabel": "Other income and expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "tlsi_CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CarryingValueOfConvertibleNotesAndAccumulatedInterestTransferredToPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of convertible notes and accumulated interest transferred to preferred stock.",
        "label": "Carrying Value Of Convertible Notes And Accumulated Interest Transferred To Preferred Stock",
        "terseLabel": "Carrying value of convertible notes and accumulated interest transferred to preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FixedAssetPurchasesIncludedInTradePayablesAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of fixed asset purchases included in trade payables and accrued expenses.",
        "label": "Fixed Asset Purchases Included In Trade Payables And Accrued Expenses",
        "terseLabel": "Fixed asset purchases included in trade payables and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ValueOfWarrantsIssuedWithConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ValueOfWarrantsIssuedWithConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of warrants issued with convertible notes in noncash investing and financing activities.",
        "label": "Value Of Warrants Issued With Convertible Notes",
        "terseLabel": "Value of warrants issued with convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MilestonePaymentToDynavaxInvestingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MilestonePaymentToDynavaxInvestingActivity",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the milestone payment to Dynavax, classified as investing activity.",
        "label": "Milestone Payment To Dynavax, Investing Activity",
        "negatedLabel": "Milestone payment to Dynavax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r195"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total",
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_StockConvertedReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockConvertedReverseRecapitalization",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Converted, Reverse Recapitalization",
        "label": "Stock Converted, Reverse Recapitalization",
        "terseLabel": "Stock converted, reverse recapitalization (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Stock Price Trigger",
        "terseLabel": "Earnout shares vesting requirement, weighted average price per share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Loan received",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodVestingPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Vesting Percentage",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Vesting Percentage",
        "terseLabel": "Earnout shares vesting percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2022",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_DerivativeInstrumentPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodTwoMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period Two",
        "label": "Derivative Instrument, Period Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying amount",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "tlsi_CommercialMilestone500000AnnualSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestone500000AnnualSalesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone, $500,000 Annual Sales",
        "label": "Commercial Milestone, $500,000 Annual Sales [Member]",
        "terseLabel": "Commercial Milestone, $500,000 Annual Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_NumberOfProductLinesInDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfProductLinesInDevelopment",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Lines in Development",
        "label": "Number of Product Lines in Development",
        "terseLabel": "Number of product lines in development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_GainLossOnMilestonePaymentForAssetAcquistion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GainLossOnMilestonePaymentForAssetAcquistion",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Milestone Payment for Asset Acquistion",
        "label": "Gain (Loss) on Milestone Payment for Asset Acquistion",
        "negatedTerseLabel": "Milestone payments to Dynavax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IncomeLossFromPreferredStockConvertibleDownRoundFeaturePerBasicShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Preferred Stock, Convertible, Down Round Feature, Per Basic Share",
        "label": "Income (Loss) from Preferred Stock, Convertible, Down Round Feature, Per Basic Share",
        "terseLabel": "Increase in net loss per common share, deemed dividend (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r618",
      "r684",
      "r685",
      "r686",
      "r907",
      "r908",
      "r913",
      "r914",
      "r915"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusiness",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "verboseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r231"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214"
     ]
    },
    "tlsi_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Three",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_InitialPublicOfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InitialPublicOfferingTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about public offering.",
        "label": "Initial Public Offering [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "tlsi_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TrancheAndWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheAndWarrantLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche and Warrant Liability",
        "label": "Tranche and Warrant Liability [Member]",
        "terseLabel": "Tranche and warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightConversionStockPriceThreshold": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightConversionStockPriceThreshold",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Conversion Stock Price Threshold",
        "label": "Class Of Warrant Or Right, Conversion Stock Price Threshold",
        "terseLabel": "Warrant redemption condition, share price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Consideration payable",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r102",
      "r579"
     ]
    },
    "tlsi_PaymentsForAssetAcquisitionMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentsForAssetAcquisitionMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisition, Milestone Amount",
        "label": "Payments for Asset Acquisition, Milestone Amount",
        "terseLabel": "Payments for milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r673",
      "r674",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r823",
      "r825",
      "r857",
      "r1048"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Aggregate consideration payable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4"
     ]
    },
    "tlsi_DynavaxTechnologiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DynavaxTechnologiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dynavax Technologies",
        "label": "Dynavax Technologies [Member]",
        "terseLabel": "Dynavax Technologies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants Liabilities",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r620",
      "r621",
      "r626"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeemedDividendRelatedToSeriesBTwoPreferredStockDownRoundProvision",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deemed dividend related to Series B-2 preferred stock down round provision.",
        "label": "Deemed Dividend Related To Series B Two, Preferred Stock Down Round Provision",
        "negatedLabel": "Deemed dividend related to Series B-2 preferred stock down round provision",
        "terseLabel": "Deemed dividend to the preferred stockholders",
        "verboseLabel": "Deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightNumberOfWarrantsRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsRepurchased",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Repurchased",
        "label": "Class Of Warrant Or Right, Number Of Warrants Repurchased",
        "terseLabel": "Warrants repurchased (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesB2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB2ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-2 Convertible Preferred Stock",
        "label": "Series B-2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-2",
        "verboseLabel": "Series B-2 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ReverseRecapitalizationTransactionCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationTransactionCostsPaid",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Transaction Costs Paid",
        "label": "Reverse Recapitalization, Transaction Costs Paid",
        "terseLabel": "Transaction costs paid from proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Discount amortization and amortization of deferred financing costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r645",
      "r909",
      "r910",
      "r964"
     ]
    },
    "tlsi_BinomialTrancheModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BinomialTrancheModelMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Binomial Tranche Model",
        "label": "Binomial Tranche Model [Member]",
        "terseLabel": "Binomial Tranche Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169"
     ]
    },
    "tlsi_GainLossOnConversionOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GainLossOnConversionOfConvertibleNotes",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to conversion of convertible notes.",
        "label": "Gain Loss On Conversion Of Convertible Notes",
        "negatedLabel": "Loss on conversion of convertible notes",
        "terseLabel": "Loss on conversion of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of company's net deferred tax",
        "verboseLabel": "Schedule of significant portions of deferred income tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "tlsi_SeriesBTwoTrancheLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesBTwoTrancheLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of series B-2  tranche liability, due within one year or the operating cycle if longer.",
        "label": "Series B Two, Tranche Liability, Current",
        "terseLabel": "Series B-2 tranche liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the federal income tax rate to the company's effective tax rate",
        "verboseLabel": "Schedule of computation of federal statutory tax rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "tlsi_AssetAcquisitionRoyaltyPercentageUnderThresholdAmount": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionRoyaltyPercentageUnderThresholdAmount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Royalty Percentage, Under Threshold Amount",
        "label": "Asset Acquisition, Royalty Percentage, Under Threshold Amount",
        "terseLabel": "Royalties as a percentage of net sales, under sales threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesBThreeTrancheLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesBThreeTrancheLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of series B-3  warrant liability, due within one year or the operating cycle if longer.",
        "label": "Series B Three, Tranche Liability, Current",
        "terseLabel": "Series B-3 warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax provision",
        "verboseLabel": "Schedule of income tax expenses (benefits) from continuing operations",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryover",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities",
        "verboseLabel": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciess",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r408",
      "r409",
      "r884",
      "r989"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r625"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r673",
      "r674",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r823",
      "r825",
      "r857"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement with MedTech Acquisition Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Dynavax purchase agreement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Stockholders' Equity (Deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r204",
      "r739",
      "r926",
      "r969",
      "r986",
      "r1045"
     ]
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails": {
       "parentTag": "tlsi_ProceedsFromReverseRecapitalizationTransaction",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from MTAC trust account",
        "verboseLabel": "Capital Contribution by Sponsor",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)",
        "verboseLabel": "LIABILITIES, CLASS A COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Promissory note - related party",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Dividends, Shares",
        "terseLabel": "Share dividend",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r944"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Total expenses incurred",
        "verboseLabel": "Expenses incurred",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r673"
     ]
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Preferred stock available for future issuance (in shares)",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income and expense, net",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r426",
      "r427",
      "r437",
      "r438",
      "r439",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock",
        "verboseLabel": "Class B common stock",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r674",
      "r677",
      "r772",
      "r773",
      "r774",
      "r832",
      "r833",
      "r834",
      "r854",
      "r856"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r805"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Outstanding amount",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r203",
      "r1060"
     ]
    },
    "us-gaap_MeasurementInputInceptionDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputInceptionDiscountRateMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Inception Discount Rate [Member]",
        "terseLabel": "Discount rate",
        "documentation": "Measurement input using interest rate at inception of contract to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r830",
      "r831",
      "r834"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockTables",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Convertible Preferred Stock",
        "verboseLabel": "Schedule of Class A common stock subject to possible redemption reflected in the balance sheets reconciled",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r76"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r834"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Customer Concentrations",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average life of finance lease",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r925"
     ]
    },
    "tlsi_ProceedsFromRefundablePrepaymentsForPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromRefundablePrepaymentsForPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Refundable Prepayments for Preferred Stock",
        "label": "Proceeds From Refundable Prepayments for Preferred Stock",
        "terseLabel": "Refundable prepayments for Series B-2 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_GainLossOnEquityIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GainLossOnEquityIssuance",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Equity Issuance",
        "label": "Gain (Loss) on Equity Issuance",
        "negatedLabel": "Loss on equity issuance",
        "negatedTerseLabel": "Loss on equity issuance",
        "terseLabel": "Loss on equity issuance"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightConversionTermsThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightConversionTermsThresholdTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Conversion Terms, Threshold Trading Days",
        "label": "Class Of Warrant Or Right, Conversion Terms, Threshold Trading Days",
        "terseLabel": "Class of warrant or right, conversion terms, threshold trading days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates type of related party for liability classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "tlsi_A2009PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "A2009PlanMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2009 Plan",
        "label": "2009 Plan [Member]",
        "terseLabel": "2009 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Model",
        "label": "Black-Scholes Model [Member]",
        "terseLabel": "Black-Scholes Model"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeFinancialInstrumentsTrancheLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeFinancialInstrumentsTrancheLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Financial Instruments, Tranche Liability",
        "label": "Derivative Financial Instruments, Tranche Liability [Member]",
        "terseLabel": "Series B-2 tranche liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommercialMilestone250000AnnualSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestone250000AnnualSalesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone, $250,000 Annual Sales",
        "label": "Commercial Milestone, $250,000 Annual Sales [Member]",
        "terseLabel": "Commercial Milestone, $250,000 Annual Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "tlsi_PreferredStockConversionPriceAutomaticResetDurationFirstReset": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockConversionPriceAutomaticResetDurationFirstReset",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Conversion Price, Automatic Reset Duration, First Reset",
        "label": "Preferred Stock, Conversion Price, Automatic Reset Duration, First Reset",
        "terseLabel": "Conversion price, first automatic reset"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PreferredStockConversionPriceAutomaticResetDurationSecondReset": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PreferredStockConversionPriceAutomaticResetDurationSecondReset",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Conversion Price, Automatic Reset Duration, Second Reset",
        "label": "Preferred Stock, Conversion Price, Automatic Reset Duration, Second Reset",
        "terseLabel": "Conversion price, second automatic reset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Members of Board of Directors",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "tlsi_StandbyEquityPurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StandbyEquityPurchaseAgreementTerm",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby Equity Purchase Agreement, Term",
        "label": "Standby Equity Purchase Agreement, Term",
        "terseLabel": "Purchase agreement period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommonStockSharePricePercentageOfAverageDailyVolume": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockSharePricePercentageOfAverageDailyVolume",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Share Price, Percentage Of Average Daily Volume",
        "label": "Common Stock, Share Price, Percentage Of Average Daily Volume",
        "terseLabel": "Purchase agreement, maximum shares allowed, percentage of average daily volume"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r713"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r485",
      "r493",
      "r525",
      "r526",
      "r527",
      "r687",
      "r711",
      "r749",
      "r796",
      "r797",
      "r858",
      "r860",
      "r863",
      "r864",
      "r875",
      "r885",
      "r886",
      "r904",
      "r911",
      "r918",
      "r927",
      "r930",
      "r988",
      "r995",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about accounting policies.",
        "label": "Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Contractual term",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Other non employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "tlsi_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_IncreaseDecreaseInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IncreaseDecreaseInValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance.",
        "label": "Increase Decrease In Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r493",
      "r711",
      "r749",
      "r796",
      "r797",
      "r858",
      "r860",
      "r863",
      "r864",
      "r875",
      "r885",
      "r886",
      "r904",
      "r911",
      "r918",
      "r927",
      "r995",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "tlsi_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized start up and organization costs.",
        "label": "Deferred Tax Assets Capitalized Start Up And Organization Costs",
        "terseLabel": "Organizational costs/start-up expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r485",
      "r493",
      "r525",
      "r526",
      "r527",
      "r687",
      "r711",
      "r749",
      "r796",
      "r797",
      "r858",
      "r860",
      "r863",
      "r864",
      "r875",
      "r885",
      "r886",
      "r904",
      "r911",
      "r918",
      "r927",
      "r930",
      "r988",
      "r995",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "tlsi_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "INCOME TAX [Line items]",
        "terseLabel": "INCOME TAX"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentageOfChangesInFairValueOfWarrantLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfChangesInFairValueOfWarrantLiabilities",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Changes in fair value of warrant liabilities.",
        "label": "Percentage Of Changes In Fair Value Of Warrant Liabilities",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r493",
      "r711",
      "r749",
      "r796",
      "r797",
      "r858",
      "r860",
      "r863",
      "r864",
      "r875",
      "r885",
      "r886",
      "r904",
      "r911",
      "r918",
      "r927",
      "r995",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "tlsi_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about Income Tax .",
        "label": "Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r255",
      "r276",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r582",
      "r586",
      "r630",
      "r926",
      "r993",
      "r994",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "tlsi_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability, Current",
        "label": "Lease Liability, Current",
        "terseLabel": "Short-term lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average life of operating lease",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r925"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r912",
      "r998",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability, Noncurrent",
        "label": "Lease Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments",
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "tlsi_ScheduleOfReverseRecapitalizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfReverseRecapitalizationTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reverse Recapitalization",
        "label": "Schedule of Reverse Recapitalization [Table]",
        "terseLabel": "Schedule of Reverse Recapitalization [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ContingentEarnoutLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ContingentEarnoutLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Earnout Liability",
        "label": "Contingent Earnout Liability [Member]",
        "terseLabel": "Contingent earnout liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CapitalShareReservedForFutureIssuanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CapitalShareReservedForFutureIssuanceAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table relating to information on capital stock reserved for future issuance.",
        "label": "Capital Share Reserved for Future Issuance [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantLiabilitiesAndOtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantLiabilitiesAndOtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values of warrant liability, and other liabilities, classified as noncurrent, due after one year or the normal operating cycle, if longer.",
        "label": "Warrant Liabilities And Other Liabilities, Noncurrent",
        "terseLabel": "Warrant liabilities and other long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_FairValueDisclosureItemAmountDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FairValueDisclosureItemAmountDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Disclosure Item Amount [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest earned on marketable securities held in Trust Account",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest earned on marketable securities held in Trust Account",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r324"
     ]
    },
    "tlsi_CapitalSharesReservedForFutureIssuanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CapitalSharesReservedForFutureIssuanceDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table relating to information on capital stock reserved for future issuance.",
        "label": "Capital Shares Reserved for Future Issuance [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement.",
        "label": "Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Outstanding",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r797",
      "r810",
      "r811",
      "r812",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r838",
      "r839",
      "r840",
      "r841",
      "r844",
      "r845",
      "r846",
      "r847",
      "r866",
      "r868",
      "r871",
      "r873",
      "r928",
      "r930"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailsCal2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "tlsi_PercentageOfTransactionalFeePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfTransactionalFeePaid",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of transactional fee paid.",
        "label": "Percentage Of Transactional Fee Paid",
        "terseLabel": "Percentage of transactional fee paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1031",
      "r1033"
     ]
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation assumptions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "tlsi_ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareRedemptionsRemovalOfTrustAccountToPayStockholdersPerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of removal in Trust Accounts to pay stockholders.",
        "label": "Share Redemptions, Removal of Trust Account to Pay Stockholders, Per Share",
        "terseLabel": "Per share removal from trust account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "verboseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r930",
      "r932",
      "r933",
      "r934",
      "r935",
      "r971",
      "r972",
      "r1042",
      "r1064",
      "r1068"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r111",
      "r112",
      "r114",
      "r115",
      "r589"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r245",
      "r742"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r732",
      "r742",
      "r926"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r198",
      "r244",
      "r272",
      "r734"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred income tax assets and liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r202",
      "r558"
     ]
    },
    "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Capitalized Property Plant and Equipment [Member]",
        "terseLabel": "Other property",
        "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r226",
      "r229",
      "r740"
     ]
    },
    "tlsi_StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockholdersNumberOfPublicSharesHeldRedeemForProRataPortionOfFundsInTrustAccount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares held through shares redemption for Pro data basis of the funds in the Trust account.",
        "label": "Stockholders, Number of Public Shares Held, Redeem for Pro Rata Portion of Funds in Trust Account",
        "terseLabel": "Number of public shares held"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Business combination related costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentOfDepositsIntoTrustAccountFundedByAcquiree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentOfDepositsIntoTrustAccountFundedByAcquiree",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of deposits that are funded by Acquiree.",
        "label": "Percent of Deposits into Trust Account, Funded by Acquiree",
        "terseLabel": "Percent of deposits funded by TriSalus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilities",
      "http://trisaluslifesci.com/role/DisclosureAccruedLiabilitiess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShare",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded Derivative Financial Instruments [Member]",
        "terseLabel": "Embedded derivative",
        "documentation": "Derivative instrument embedded in host contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r258",
      "r259",
      "r268",
      "r276",
      "r289",
      "r299",
      "r300",
      "r321",
      "r334",
      "r338",
      "r340",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r581",
      "r584",
      "r585",
      "r614",
      "r630",
      "r731",
      "r744",
      "r775",
      "r826",
      "r848",
      "r849",
      "r902",
      "r923",
      "r924",
      "r937",
      "r960",
      "r993"
     ]
    },
    "tlsi_AmountDepositedIntoTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AmountDepositedIntoTrustAccount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deposits into the Trust Account.",
        "label": "Amount Deposited into Trust Account",
        "terseLabel": "Deposited into trust account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "tlsi_PercentageOfSharesCommittedSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfSharesCommittedSold",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares committed by the company sold during the period.",
        "label": "Percentage Of Shares Committed Sold",
        "terseLabel": "Percentage of shares committed sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "tlsi_Financing2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "Financing2022Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2022 Financing.",
        "label": "Financing, 2022 [Member]",
        "terseLabel": "2022 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Long-term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r136",
      "r137",
      "r138",
      "r141",
      "r276",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r583",
      "r586",
      "r587",
      "r630",
      "r993",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r246",
      "r741"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfSharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares outstanding.",
        "label": "Percentage Of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSU weighted average fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r834"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Damages settled value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Amount of convertible promissory note",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r426",
      "r646",
      "r907",
      "r908"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense for property and equipment",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r71"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life",
        "verboseLabel": "Useful Life (Years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureDebtTermLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r249",
      "r250",
      "r251",
      "r276",
      "r307",
      "r308",
      "r311",
      "r313",
      "r319",
      "r320",
      "r381",
      "r416",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r455",
      "r456",
      "r460",
      "r463",
      "r471",
      "r630",
      "r766",
      "r767",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r805",
      "r827",
      "r850",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r941",
      "r967",
      "r975"
     ]
    },
    "tlsi_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer one"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Loan forgiveness",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r1048"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss",
      "http://trisaluslifesci.com/role/DisclosureDebtPppLoanDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r834"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r679"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;D expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "tlsi_Financing2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "Financing2023Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2023 Financing.",
        "label": "Financing, 2023 [Member]",
        "terseLabel": "2023 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash items:",
        "verboseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r626"
     ]
    },
    "tlsi_FinanceLeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FinanceLeaseAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfRightOfUseAssetsShortTermLeaseLiabilitiesAndLongTermLeasesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Finance Lease [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash (included in Other assets)",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r956",
      "r965"
     ]
    },
    "tlsi_SeriesB3WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB3WarrantLiabilitiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series B-3 warrant liabilities.",
        "label": "Series B-3 Warrant Liabilities [Member]",
        "terseLabel": "Series B-3 warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1061"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "tlsi_SeriesB2TrancheLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesB2TrancheLiabilitiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series B-2 tranche liabilities.",
        "label": "Series B-2 Tranche Liabilities [Member]",
        "terseLabel": "Series B-2 tranche liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r244",
      "r888"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "verboseLabel": "Income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "totalLabel": "Total NOLs",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range of Exercise price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "tlsi_ScheduleOfActivityInConvertiblePreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfActivityInConvertiblePreferredStockTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of activity in convertible preferred stock.",
        "label": "Schedule Of Activity In Convertible Preferred Stock [Table Text Block]",
        "terseLabel": "Summary of activity in convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CopierEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CopierEquipmentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for copier equipment.",
        "label": "Copier Equipment [Member]",
        "terseLabel": "Copier"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Amount of matching contribution",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfAggregateLiquidationPreferenceOfConvertiblePreferredStockTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of aggregate liquidation preference of convertible preferred stock.",
        "label": "Schedule Of Aggregate Liquidation Preference Of Convertible Preferred Stock [Table Text Block]",
        "terseLabel": "Summary of aggregate liquidation preference of convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Exercise prices of options outstanding and exercisable",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ConvertiblePreferredStockDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConvertiblePreferredStockDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on convertible preferred stock.",
        "label": "Convertible Preferred Stock Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "tlsi_AnalyticalEquipmentInLaboratoryFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AnalyticalEquipmentInLaboratoryFacilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for analytical equipment in laboratory facility.",
        "label": "Analytical Equipment In Laboratory Facility [Member]",
        "terseLabel": "Analytical equipment in laboratory facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Options and RSU's outstanding (in shares)",
        "verboseLabel": "Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "negatedTotalLabel": "Deferred tax assets, net of allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease liabilities",
        "negatedTerseLabel": "Payments on finance lease liabilities",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r661"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Amount drawn on Second Extension Note",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r203",
      "r438",
      "r452",
      "r907",
      "r908",
      "r1060"
     ]
    },
    "tlsi_TemporaryEquityOriginalIssuePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquityOriginalIssuePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the original issue price for convertible preferred stock.",
        "label": "Temporary Equity, Original Issue Price",
        "terseLabel": "Convertible preferred stock, original issue prices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for Issue (in shares)",
        "verboseLabel": "Common shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "tlsi_TemporaryEquitySharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquitySharesAvailableForIssuance",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares available for issuance for convertible preferred stock.",
        "label": "Temporary Equity, Shares Available for Issuance",
        "terseLabel": "Convertible preferred stock, available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CopierInWestminsterFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CopierInWestminsterFacilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for copier in westminster facility.",
        "label": "Copier In Westminster Facility [Member]",
        "terseLabel": "Copier in westminster facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r243",
      "r252",
      "r400",
      "r401",
      "r402",
      "r712",
      "r898"
     ]
    },
    "tlsi_AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AutomaticConversionOfPreferredStockThresholdSharePriceOfCommonStock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold per share price of common stock for automatic conversion of preferred stock.",
        "label": "Automatic Conversion of Preferred Stock, Threshold Share Price of Common Stock",
        "terseLabel": "Threshold per share price of common stock for automatic conversion of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Fees Received",
        "terseLabel": "Aggregate fees received",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "tlsi_AutomaticConversionOfPreferredStockThresholdCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AutomaticConversionOfPreferredStockThresholdCashProceeds",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold net cash proceeds for automatic conversion of preferred stock.",
        "label": "Automatic Conversion of Preferred Stock, Threshold Cash Proceeds",
        "terseLabel": "Threshold net cash proceeds for automatic conversion of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PrincipalAdministrativeAndProductionFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PrincipalAdministrativeAndProductionFacilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for principal administrative and production facility.",
        "label": "Principal Administrative And Production Facility [Member]",
        "terseLabel": "Principal administrative and production facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeiture",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "tlsi_AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AutomaticConversionOfPreferredStockThresholdProceedsFromSpecialPurposeAcquisitionCorporationTrustAccount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockConversionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold proceeds received from the \"special purpose acquisition corporation\" trust account for automatic conversion of preferred stock.",
        "label": "Automatic Conversion of Preferred Stock, Threshold Proceeds From Special Purpose Acquisition Corporation Trust Account",
        "terseLabel": "Threshold proceeds received from the \"special purpose acquisition corporation\" trust account for automatic conversion of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LeaseForOfficeSpaceAtHalfDayRoadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LeaseForOfficeSpaceAtHalfDayRoadMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for lease for office space at Half Day Road.",
        "label": "Lease For Office Space At Half Day Road [Member]",
        "terseLabel": "Lease for office space at 2275 Half Day Road"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating leases.",
        "label": "Number Of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for excess or obsolete inventory",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r959"
     ]
    },
    "tlsi_TemporaryEquityDividendPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquityDividendPerShare",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the dividend per share of convertible preferred stock.",
        "label": "Temporary Equity, Dividend per Share",
        "terseLabel": "Per annum preferred dividend rates"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, weighted average fair value (in dollars per share)",
        "verboseLabel": "Grant date per share fair value of options",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSignificantPortionsOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1030"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "tlsi_B2PreferredStockFinancingSecondTrancheClosingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "B2PreferredStockFinancingSecondTrancheClosingsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closings.",
        "label": "B-2 Preferred Stock Financing, Second Tranche, Closings [Member]",
        "terseLabel": "B-2 Preferred Stock Financing, Second tranche, closings"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockFall2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r167"
     ]
    },
    "tlsi_NumberOfFinanceLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfFinanceLeases",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance leases.",
        "label": "Number Of Finance Leases",
        "terseLabel": "Number of finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at the ending",
        "periodStartLabel": "Options outstanding at the beginning",
        "terseLabel": "Options outstanding at the beginning",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "tlsi_B2PreferredStockFinancingThirdTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "B2PreferredStockFinancingThirdTrancheMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to B-2 Preferred Stock Financing, Third tranche.",
        "label": "B-2 Preferred Stock Financing, Third Tranche [Member]",
        "terseLabel": "B-2 Preferred Stock Financing, Third tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at the ending (in dollars per share)",
        "periodStartLabel": "Options outstanding at the beginning (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Upfront payment",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "tlsi_MeasurementInputFairValueOfUnderlyingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MeasurementInputFairValueOfUnderlyingStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using fair value of underlying stock.",
        "label": "Measurement Input, Fair Value Of Underlying Stock [Member]",
        "terseLabel": "Fair value of underlying stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r415",
      "r991",
      "r992"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetails",
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r167",
      "r272"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated life of the patents",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_InitialWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InitialWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial value of warrant liability.",
        "label": "Initial Warrant Liability",
        "terseLabel": "Initial value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumNumberOfSharesAgreedToSell": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumNumberOfSharesAgreedToSell",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares agreed to be sold by the company.",
        "label": "Maximum Number Of Shares Agreed To Sell",
        "terseLabel": "Maximum number of shares agreed to sell"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedPaymentArrangementsOptionExercisePriceRangeExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangements, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AggregateProceedsReceivableFromStockOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AggregateProceedsReceivableFromStockOffering",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds receivable by the company through stock offering.",
        "label": "Aggregate Proceeds Receivable From Stock Offering",
        "terseLabel": "Aggregate proceeds receivable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r429",
      "r458",
      "r676",
      "r895",
      "r896"
     ]
    },
    "tlsi_MaximumProceedsReceivableThroughSaleOfAdditionalShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumProceedsReceivableThroughSaleOfAdditionalShares",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum proceeds receivable by the company through the sale of additional shares under the stock offering.",
        "label": "Maximum Proceeds Receivable Through The Sale Of Additional Shares",
        "terseLabel": "Maximum proceeds receivable through the sale of additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage of matching contribution",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumNumberOfSharesAgreedToSellThroughSaleOfAdditionalShares",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares agreed to be sold by the company, through sale of additional shares.",
        "label": "Maximum Number Of Shares Agreed To Sell Through Sale Of Additional Shares",
        "terseLabel": "Maximum number of shares agreed to sell through sale of additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r499",
      "r530",
      "r531",
      "r533",
      "r919"
     ]
    },
    "tlsi_EnterpriseValueAllocated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EnterpriseValueAllocated",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of enterprise value allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock, and common stock on an as-if converted basis.",
        "label": "Enterprise Value Allocated",
        "terseLabel": "Enterprise value allocated"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantToPurchaseSeriesFivePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantToPurchaseSeriesFivePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants to purchase Series A5 Preferred Stock.",
        "label": "Warrant to Purchase Series A Five Preferred Stock [Member]",
        "terseLabel": "Warrants to purchase Series A5 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Convertible notes value converted",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "tlsi_WarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warrant issued during the period.",
        "label": "Warrant Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfStockOfferingClosingsEffectuated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfStockOfferingClosingsEffectuated",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of closings of stock offerings effectuated during the period.",
        "label": "Number Of Stock Offering Closings Effectuated",
        "terseLabel": "Number of closings effectuated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r415",
      "r991",
      "r992"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r427"
     ]
    },
    "tlsi_BusinessCombinationScenarioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BusinessCombinationScenarioMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to business combination scenario.",
        "label": "Business Combination Scenario [Member]",
        "terseLabel": "Business Combination scenario"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued upon conversion of notes",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "tlsi_ValueAssignedToTrancheRightsAndObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ValueAssignedToTrancheRightsAndObligations",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to value assigned to the tranche rights and obligations.",
        "label": "Value Assigned To The Tranche Rights And Obligations",
        "terseLabel": "Value assigned to the tranche rights and obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Number of Class A common stock issued upon conversion of each share (in shares)",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "tlsi_B2PreferredStockFinancingSecondTrancheClosingTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "B2PreferredStockFinancingSecondTrancheClosingTwoMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closing two.",
        "label": "B-2 Preferred Stock Financing, Second Tranche, Closing Two [Member]",
        "terseLabel": "B-2 Preferred Stock Financing, Second tranche, closing two"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantToPurchaseSeriesSixPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantToPurchaseSeriesSixPreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants to purchase Series A6 Preferred Stock.",
        "label": "Warrant to Purchase Series A Six Preferred Stock [Member]",
        "terseLabel": "Warrants to purchase Series A6 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Statements",
        "verboseLabel": "Summary of option activity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r276",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r583",
      "r586",
      "r587",
      "r630",
      "r804",
      "r901",
      "r938",
      "r993",
      "r1049",
      "r1050"
     ]
    },
    "tlsi_TrancheLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheLiabilityMeasurementInput",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure tranche liabilities.",
        "label": "Tranche Liability, Measurement Input",
        "terseLabel": "Series B 2 Tranche Liability, measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_FinanceLeaseLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FinanceLeaseLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease Liabilities Current",
        "terseLabel": "Short-term lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "tlsi_B2PreferredStockFinancingSecondTrancheClosingOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "B2PreferredStockFinancingSecondTrancheClosingOneMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to B-2 Preferred Stock Financing, Second tranche, closing one.",
        "label": "B-2 Preferred Stock Financing, Second Tranche, Closing One [Member]",
        "terseLabel": "B-2 Preferred Stock Financing, Second tranche, closing one"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentPeriodOneMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Period One",
        "label": "Derivative Instrument, Period One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r276",
      "r321",
      "r334",
      "r338",
      "r340",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r630",
      "r902",
      "r993"
     ]
    },
    "tlsi_RecapitalizationExchangeRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RecapitalizationExchangeRatio",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization Exchange Ratio",
        "label": "Recapitalization Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1039",
      "r1040"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOffering",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991",
      "r992"
     ]
    },
    "tlsi_ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightDaysFromWhichWarrantOrRightsBecomeExercisable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Days From Which Warrant Or Rights Become Exercisable",
        "label": "Class Of Warrant Or Right, Days From Which Warrant Or Rights Become Exercisable",
        "terseLabel": "Warrant exercise period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockMarch2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockSpring2021FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockWarrantExercisesDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B",
        "verboseLabel": "Series B preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Earnout Period, Threshold Trading Days",
        "terseLabel": "Earnout period, threshold trading days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "tlsi_SeriesA2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Convertible Preferred Stock",
        "label": "Series A-2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2",
        "verboseLabel": "Series A-2 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "tlsi_PaymentsForAssetsAcquisitionMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentsForAssetsAcquisitionMilestone",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Assets Acquisition Milestone",
        "label": "Payments for Assets Acquisition Milestone",
        "negatedTerseLabel": "Milestone payments to Dynavax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "tlsi_MeasurementInputFairValueSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MeasurementInputFairValueSharePriceMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Fair Value Share Price",
        "label": "Measurement Input, Fair Value Share Price [Member]",
        "terseLabel": "Series B-2, B-3 preferred stock fair value per share",
        "verboseLabel": "Series B-3 preferred stock fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AssetAcquisitionNumberOfCommercialMilestones": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AssetAcquisitionNumberOfCommercialMilestones",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Number of Commercial Milestones",
        "label": "Asset Acquisition, Number of Commercial Milestones",
        "terseLabel": "Number of commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "tlsi_SeriesA5ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA5ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-5 Convertible Preferred Stock",
        "label": "Series A-5 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-5",
        "verboseLabel": "Series A-5 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearPercentageOfTotalStock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Percentage of Total Stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Percentage of Total Stock",
        "terseLabel": "Percentage of fully diluted common stock determined in preceding year"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOffering",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "verboseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MeasurementInputExerciseSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MeasurementInputExerciseSharePriceMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Exercise Share Price",
        "label": "Measurement Input, Exercise Share Price [Member]",
        "terseLabel": "Series B-2 preferred stock exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommercialMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestoneMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone",
        "label": "Commercial Milestone [Member]",
        "terseLabel": "Commercial Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Accumulated interest",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r207",
      "r264",
      "r325",
      "r644",
      "r835",
      "r936",
      "r1067"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from the exercise of stock options",
        "verboseLabel": "Proceeds from issuance of exercise of stock option",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19"
     ]
    },
    "tlsi_ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightRepurchaseProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Repurchase Program, Authorized Amount",
        "label": "Class Of Warrant Or Right, Repurchase Program, Authorized Amount",
        "terseLabel": "Warrant repurchase program, authorized amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total Federal",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r550"
     ]
    },
    "tlsi_SaleOfStockAuthorizedAmountValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SaleOfStockAuthorizedAmountValue",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount, Value",
        "label": "Sale Of Stock, Authorized Amount, Value",
        "terseLabel": "Sale of stock, authorized amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r897"
     ]
    },
    "tlsi_A2023PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "A2023PlanMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2023 Plan",
        "label": "2023 Plan [Member]",
        "terseLabel": "2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total State",
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1027",
      "r1032"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r684",
      "r685",
      "r686",
      "r907",
      "r908",
      "r913",
      "r914",
      "r915"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "tlsi_ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightOutstandingWarrantsIssuedDuringPeriodNewIssues",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfWarrantsToPurchaseConvertiblePreferredStockRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Outstanding, Warrants Issued During Period, New Issues",
        "label": "Class Of Warrant Or Right Outstanding, Warrants Issued During Period, New Issues",
        "terseLabel": "Issuances (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r445",
      "r453",
      "r909",
      "r910"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r273"
     ]
    },
    "tlsi_SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SharePriceAsPercentageOfMarketPriceWithAdvanceNoticeOptionTwo",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price As Percentage Of Market Price With Advance Notice, Option Two",
        "label": "Share Price As Percentage Of Market Price With Advance Notice, Option Two",
        "terseLabel": "Purchase agreement, sales price, percentage of market price during three consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockActivityInConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockDividendsDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockLiquidationPreferencesDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockConvertiblePreferredStockRollforwardDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Convertible Preferred Stock",
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1",
        "verboseLabel": "Series A-1 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "tlsi_DerivativeInstrumentContingentConsiderationLiabilityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeInstrumentContingentConsiderationLiabilityShares",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Unvested",
        "label": "Derivative Instrument, Contingent Consideration, Liability, Shares",
        "terseLabel": "Shares unvested (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Warrants",
        "label": "Private Warrants [Member]",
        "terseLabel": "Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ClassOfWarrantOrRightThresholdNumberOfDaysForWarrantsToBeTransferable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Threshold Number of Days for Warrants to be Transferable",
        "label": "Class of Warrant or Right, Threshold Number of Days for Warrants to be Transferable",
        "terseLabel": "Class of warrant or right, threshold number of days for warrants to be transferable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeFinancialInstrumentsSeriesB3WarrantLiabilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsScheduleOfWarrantsOutstandingDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Financial Instruments, Series B-3 Warrant Liability",
        "label": "Derivative Financial Instruments, Series B-3 Warrant Liability [Member]",
        "terseLabel": "Series B-3 Warrant liabilities",
        "verboseLabel": "Series B-3 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r970",
      "r1033"
     ]
    },
    "tlsi_GuidelinePublicCompanyModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "GuidelinePublicCompanyModelMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guideline Public Company Model",
        "label": "Guideline Public Company Model [Member]",
        "terseLabel": "Guideline Public Company Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r71"
     ]
    },
    "tlsi_MTACWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MTACWarrantsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTAC Warrants",
        "label": "MTAC Warrants [Member]",
        "terseLabel": "MTAC Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r242",
      "r276",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r583",
      "r586",
      "r587",
      "r630",
      "r926",
      "r993",
      "r1049",
      "r1050"
     ]
    },
    "tlsi_ReverseRecapitalizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ReverseRecapitalizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization",
        "label": "Reverse Recapitalization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAmortizationAndAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "tlsi_TrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrancheAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche",
        "label": "Tranche [Axis]",
        "terseLabel": "Tranche [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePerYearNumberOfYears",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Number of Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Increase Per Year, Number of Years",
        "terseLabel": "Share reserve increase, number of years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares",
        "terseLabel": "Warrant liabilities",
        "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxes",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxess"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "verboseLabel": "INCOME TAX",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r546",
      "r552",
      "r555",
      "r562",
      "r568",
      "r571",
      "r572",
      "r573",
      "r771"
     ]
    },
    "tlsi_NatureOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NatureOfBusinessTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business [Table]",
        "label": "Nature of Business [Table]",
        "terseLabel": "Nature of Business [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonStockSharePriceMarketPriceNumberOfConsecutiveTradingDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Share Price, Market Price, Number Of Consecutive Trading Days",
        "label": "Common Stock, Share Price, Market Price, Number Of Consecutive Trading Days",
        "terseLabel": "Purchase agreement, number of trading days used for measurement of market price"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProceedsFromReverseRecapitalizationTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromReverseRecapitalizationTransaction",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Reverse Recapitalization Transaction",
        "label": "Proceeds From Reverse Recapitalization Transaction",
        "totalLabel": "Proceeds from transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Merger Agreement with MedTech Acquisition Corporation",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r575"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventory",
      "http://trisaluslifesci.com/role/DisclosureInventorys"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "tlsi_MedtechAcquisitionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MedtechAcquisitionCorpMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingencies",
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurements",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsTables",
      "http://trisaluslifesci.com/role/DisclosureIncomeTax",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxReconciliationOfFederalIncomeTaxDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxTables",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement",
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacementDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOffering",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactions",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEvents",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the information pertaining to MedTech acquisition corp member.",
        "label": "MedTech Acquisition Corp [Member]",
        "terseLabel": "MedTech Acquisition Corp"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProceedsFromExtensionNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromExtensionNote",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from extension note.",
        "label": "Proceeds from Extension Note",
        "terseLabel": "Proceeds from extension note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates type of related party for notes payable classified as current."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchase"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Dynavax Purchase",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "tlsi_PaymentForInvestmentOfCashInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentForInvestmentOfCashInTrustAccount",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment for investment of cash into trust account.",
        "label": "Payment for Investment of Cash in Trust Account",
        "negatedLabel": "Investment of cash into Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlowss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "verboseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_BusinessCombinationsOfWarrantToPurchase": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "BusinessCombinationsOfWarrantToPurchase",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of business combination of warrants to purchase.",
        "label": "Business Combinations Of Warrant To Purchase",
        "terseLabel": "Business combinations of warrant to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfHoldings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfHoldings",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of number of holdings.",
        "label": "Number of Holdings",
        "terseLabel": "Number of holdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityStockOptionActivityDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of options (in shares)",
        "verboseLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r145",
      "r146",
      "r185",
      "r509"
     ]
    },
    "tlsi_MtacClassCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MtacClassCommonStockMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for MTAC class a common stock.",
        "label": "MTAC Class A Common Stock [Member]",
        "terseLabel": "MTAC Class A Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r81",
      "r185",
      "r442"
     ]
    },
    "tlsi_ExtensionNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExtensionNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of extension notes payable due within one year or the operating cycle if longer.",
        "label": "Extension Notes Payable, Current",
        "terseLabel": "Extension Note"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_StockholderApprovalAfterDeliveringBusinessCombinationDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockholderApprovalAfterDeliveringBusinessCombinationDays",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of stockholder approval after delivering business combination.",
        "label": "Stockholder Approval After Delivering Business Combination Days",
        "terseLabel": "Period of stockholder approval after delivering business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of activity for options issued to employees, consultants, and directors",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "tlsi_TwoThousandTwentyOnePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TwoThousandTwentyOnePromissoryNoteMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Two Thousand Twenty One Promissory Note Member.",
        "label": "Two Thousand Twenty One Promissory Note [Member]",
        "terseLabel": "2021 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DueToSponsorForCertainReimbursableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DueToSponsorForCertainReimbursableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to due to the Sponsor for certain reimbursable expenses.",
        "label": "Due to Sponsor for Certain Reimbursable Expenses",
        "terseLabel": "Due to the Sponsor for certain reimbursable expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TwoThousandTwentyTwoPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TwoThousandTwentyTwoPromissoryNoteMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Two Thousand Twenty two Promissory Note Member.",
        "label": "Two Thousand Twenty Two Promissory Note [Member]",
        "terseLabel": "2022 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxIncomeTaxProvisionDetails",
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpensesBenefitsFromContinuingOperationsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "negatedTerseLabel": "Income tax benefit",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r230",
      "r299",
      "r300",
      "r326",
      "r550",
      "r569",
      "r748"
     ]
    },
    "tlsi_DerivativeWarrantLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DerivativeWarrantLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of derivative warrant liabilities.",
        "label": "Derivative Warrant Liabilities Disclosure [Text Block]",
        "terseLabel": "WARRANT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_OperatingBankAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "OperatingBankAccounts",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating bank accounts.",
        "label": "Operating Bank Accounts",
        "terseLabel": "Operating bank accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r85",
      "r182",
      "r184",
      "r185",
      "r249",
      "r250",
      "r251",
      "r319",
      "r455",
      "r456",
      "r458",
      "r460",
      "r463",
      "r469",
      "r471",
      "r766",
      "r767",
      "r768",
      "r769",
      "r911",
      "r941",
      "r967"
     ]
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "terseLabel": "Components of inventory"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_LegalFeesContingentUponConsummationOfMergerWithSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LegalFeesContingentUponConsummationOfMergerWithSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of legal fee which is contingent upon consummation of merger with subsidiaries.",
        "label": "Legal Fees Contingent Upon Consummation Of Merger with Subsidiaries",
        "terseLabel": "Legal fees upon merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "verboseLabel": "Outstanding warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r629",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r819",
      "r821",
      "r822",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r896",
      "r1065"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficit",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitPreferredStockDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' DEFICIT",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r319",
      "r455",
      "r456",
      "r458",
      "r460",
      "r463",
      "r469",
      "r471",
      "r766",
      "r767",
      "r768",
      "r769",
      "r911",
      "r941",
      "r967"
     ]
    },
    "tlsi_PercentageOfAmountDepositedInTrustAccount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfAmountDepositedInTrustAccount",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of amount deposited in trust account.",
        "label": "Percentage Of Amount Deposited In Trust Account",
        "terseLabel": "Percentage of amount deposited in trust account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "tlsi_ConvertibleNotesPayableRelatedPartyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConvertibleNotesPayableRelatedPartyNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for convertible notes payable, payable to related parties, which are due after one year (or one business cycle).",
        "label": "Convertible Notes Payable Related Party Noncurrent",
        "terseLabel": "Convertible Promissory Note - related party",
        "verboseLabel": "Convertible promissory note outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ProceedsFromRelatedPartyDebtConvertiblePromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromRelatedPartyDebtConvertiblePromissoryNote",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cash inflow from convertible promissory notes of the related party.",
        "label": "Proceeds From Related Party Debt, Convertible Promissory Note",
        "terseLabel": "Proceeds from convertible promissory note - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Series B-3 Warrants exercise price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendPaymentMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Payment [Member]",
        "terseLabel": "Dividend",
        "documentation": "Measurement input using expected dividend to be paid to holder of equity or financial instrument."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Estimated dividend yield",
        "verboseLabel": "Expected dividends",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "tlsi_ExtensionDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExtensionDeposit",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of extension deposit.",
        "label": "Extension Deposit",
        "terseLabel": "Extension Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (years)",
        "verboseLabel": "Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "tlsi_RaymondJamesAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RaymondJamesAgreementsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The information pertaining to Raymond James Agreements.",
        "label": "Raymond James Agreements [Member]",
        "terseLabel": "Raymond James Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_DeferredUnderwritingFeesUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DeferredUnderwritingFeesUponConsummationOfBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of  deferred underwriting fees upon consummation of business combination.",
        "label": "Deferred Underwriting Fees Upon Consummation Of Business Combination",
        "terseLabel": "Deferred underwriting fees upon consummation of business combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion prices of the Company's preferred stock",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Current stock price",
        "verboseLabel": "Stock price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2023FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio",
        "verboseLabel": "Exchange ratios",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "tlsi_ExtensionNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExtensionNoteMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for extension note.",
        "label": "Extension Note [Member]",
        "terseLabel": "Extension Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected share price volatility",
        "verboseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetails",
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r892"
     ]
    },
    "tlsi_PromissoryNote2022ThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PromissoryNote2022ThreeMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Promissory Note 2022 III.",
        "label": "Promissory Note 2022 Three [Member]",
        "terseLabel": "2022 Promissory Note III"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "verboseLabel": "Diluted net (loss) income per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r307",
      "r311",
      "r312",
      "r313",
      "r317",
      "r613",
      "r614",
      "r730",
      "r747",
      "r900"
     ]
    },
    "tlsi_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for merger agreement.",
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityNarrativeDetails",
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TrisalusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TrisalusMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://trisaluslifesci.com/role/DisclosureMergerAgreementWithMedtechAcquisitionCorporationDetails",
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for TriSalus.",
        "label": "TriSalus [Member]",
        "terseLabel": "TriSalus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureContingentEarnoutLiabilityShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDetails",
      "http://trisaluslifesci.com/role/DisclosureConvertiblePreferredStock2022FinancingDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsMonteCarloSimulationForPrivatePlacementWarrantsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "tlsi_ProceedsFromTrustAccountInConnectionWithRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ProceedsFromTrustAccountInConnectionWithRedemption",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash withdrawn from Trust Account for franchise and income taxes.",
        "label": "Proceeds from Trust Account in Connection with Redemption",
        "negatedLabel": "Redemptions of Class A common stock",
        "terseLabel": "Proceeds from trust account in connection with redemption",
        "verboseLabel": "Cash withdrawn from Trust Account in connection with redemptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureInventoryDetails",
      "http://trisaluslifesci.com/role/DisclosureInventoryDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r893"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share. Authorized 400,000,000 and 30,898,162 shares at September 30, 2023, and December 31, 2022, respectively; issued and outstanding, 26,316,681 and 347,926 shares at September 30, 2023, and December 31, 2022, respectively",
        "verboseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r736",
      "r926"
     ]
    },
    "tlsi_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Founder Shares.",
        "label": "Founder Shares [Member]",
        "terseLabel": "Founder Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r40",
      "r237",
      "r261",
      "r262",
      "r263",
      "r285",
      "r286",
      "r287",
      "r290",
      "r298",
      "r300",
      "r318",
      "r385",
      "r391",
      "r474",
      "r534",
      "r535",
      "r536",
      "r566",
      "r567",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r601",
      "r612",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r669",
      "r752",
      "r753",
      "r754",
      "r776",
      "r850"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from promissory note - related party",
        "verboseLabel": "Additional amount drawn on Promissory Note",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "tlsi_LegalFeeContingentUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "LegalFeeContingentUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of legal fee which is contingent upon consummation of business combination.",
        "label": "Legal Fee Contingent Upon Consummation Of Business Combination",
        "terseLabel": "Legal fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of aggregate amortization expense for intangible assets subject to amortization",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r776",
      "r971",
      "r972",
      "r973",
      "r1042",
      "r1068"
     ]
    },
    "tlsi_ExercisePriceOf0.005Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.005Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.005.",
        "label": "Exercise Price of $0.005 [Member]",
        "terseLabel": "0.05"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureBusinessCombinationsDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balances, end of period (in shares)",
        "periodStartLabel": "Balances, beginning of period (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r146",
      "r805",
      "r824",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r403",
      "r404",
      "r890"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U S Treasury securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r913",
      "r915",
      "r1058"
     ]
    },
    "tlsi_ConvertibleStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConvertibleStockConversionRatio",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.",
        "label": "Convertible Stock Conversion Ratio",
        "terseLabel": "Ratio to be applied to the stock in the conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r285",
      "r286",
      "r287",
      "r290",
      "r298",
      "r300",
      "r385",
      "r391",
      "r534",
      "r535",
      "r536",
      "r566",
      "r567",
      "r594",
      "r597",
      "r598",
      "r601",
      "r612",
      "r752",
      "r754",
      "r776",
      "r1068"
     ]
    },
    "tlsi_InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InvestmentAdvisoryFeeContingentUponConsummationOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Advisory Fee Contingent Upon Consummation Of Business Combination",
        "label": "Investment Advisory Fee Contingent Upon Consummation Of Business Combination",
        "terseLabel": "Investment advisory fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ExercisePriceOf0.004Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.004Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.004.",
        "label": "Exercise Price of $0.004 [Member]",
        "terseLabel": "0.04"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AccruedExpensesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Accrued expenses.",
        "label": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CashWithdrawnFromTrustAccountForFranchiseAndIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash withdrawn from Trust Account for franchise and income taxes.",
        "label": "Cash Withdrawn From Trust Account For Franchise And Income Taxes",
        "terseLabel": "Cash withdrawn from Trust Account to pay franchise and income taxes",
        "verboseLabel": "Cash withdrawn of interest income from the Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Options expiration term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "tlsi_NumeratorForCalculationOfEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumeratorForCalculationOfEarningsPerShareAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator For Calculation Of Earnings Per Share [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_SharePriceTriggerUsedToMeasureDilutionOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SharePriceTriggerUsedToMeasureDilutionOfWarrants",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.",
        "label": "Share Price Trigger Used To Measure Dilution Of Warrants",
        "terseLabel": "Share price trigger used to measure dilution of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ExercisePriceOf0.003Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.003Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.003.",
        "label": "Exercise Price of $0.003 [Member]",
        "terseLabel": "0.03"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrust",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSubsequentEventsDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held-in-trust",
        "terseLabel": "Deposited in trust account",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "tlsi_ExercisePriceOf0.001Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ExercisePriceOf0.001Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price of $0.001.",
        "label": "Exercise Price of $0.001 [Member]",
        "terseLabel": "0.01"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrustNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held-in-trust, Noncurrent",
        "terseLabel": "Cash and investments held in Trust Account",
        "verboseLabel": "Assets held in Trust Account",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureConvertibleNotesDetails",
      "http://trisaluslifesci.com/role/DisclosureNatureOfBusinessDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r237",
      "r261",
      "r262",
      "r263",
      "r285",
      "r286",
      "r287",
      "r290",
      "r298",
      "r300",
      "r318",
      "r385",
      "r391",
      "r474",
      "r534",
      "r535",
      "r536",
      "r566",
      "r567",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r601",
      "r612",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r669",
      "r752",
      "r753",
      "r754",
      "r776",
      "r850"
     ]
    },
    "tlsi_CommonClassaSubjectToRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommonClassaSubjectToRedemptionMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersDeficitCommonStockDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock representing ownership interest in a corporation that is subject to redemption.",
        "label": "Class A Common Stock Subject to Redemption [Member]",
        "terseLabel": "Class A common stock subject to possible redemption"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UponFirstOccurrenceOfAnnualNetSalesOf250000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UponFirstOccurrenceOfAnnualNetSalesOf250000Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to event of first occurrence of annual net sales of $250000.",
        "label": "Upon First Occurrence of Annual Net Sales of $250000 [Member]",
        "terseLabel": "Upon first occurrence of annual net sales of $250000"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WorkingCapitalLoansWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WorkingCapitalLoansWarrantMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for working capital loans warrant.",
        "label": "Working Capital Loans Warrant [Member]",
        "verboseLabel": "Working capital loans warrant"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UponFirstCommercialSaleOfProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UponFirstCommercialSaleOfProductMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to event of first commercial sale of product.",
        "label": "Upon First Commercial Sale of Product [Member]",
        "terseLabel": "Upon first commercial sale of product"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ConditionForFutureBusinessCombinationUseOfProceedsPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConditionForFutureBusinessCombinationUseOfProceedsPercentage",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold percentage of the assets held in the trust account funded by proceeds from the offering which must be used for purposes of consummating a business combination.",
        "label": "Condition For Future Business Combination Use Of Proceeds Percentage",
        "terseLabel": "Condition for future business combination use of proceeds percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsPropertyAndEquipmentTabularDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_ConditionForFutureBusinessCombinationThresholdPercentageOwnership": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConditionForFutureBusinessCombinationThresholdPercentageOwnership",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold percentage of voting interest to be acquired in a future business combination as specified for the use of proceeds from the offering.",
        "label": "Condition For Future Business Combination Threshold Percentage Ownership",
        "terseLabel": "Condition for future business combination threshold percentage ownership"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UponFirstOccurrenceOfAnnualNetSalesOf500000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UponFirstOccurrenceOfAnnualNetSalesOf500000Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to event of first occurrence of annual net sales of $500000.",
        "label": "Upon First Occurrence of Annual Net Sales of $500000 [Member]",
        "terseLabel": "Upon first occurrence of annual net sales of $500000"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityExercisePriceOfOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range of Exercise price",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "tlsi_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ConditionForFutureBusinessCombinationThresholdNetTangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.",
        "label": "Condition For Future Business Combination Threshold Net Tangible Assets",
        "terseLabel": "Condition for future business combination threshold net tangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UponFirstOccurrenceOfAnnualNetSalesOf1000000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UponFirstOccurrenceOfAnnualNetSalesOf1000000Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to event of first occurrence of annual net sales of $1000000.",
        "label": "Upon First Occurrence of Annual Net Sales of $1000000 [Member]",
        "terseLabel": "Upon first occurrence of annual net sales of $1000000"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_RedemptionLimitPercentageWithoutPriorConsent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RedemptionLimitPercentageWithoutPriorConsent",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The limit on the percentage of shares which may be redeemed with out prior consent of the reporting entity.",
        "label": "Redemption Limit Percentage Without Prior Consent",
        "terseLabel": "Redemption limit percentage without prior consent"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AggregateAnnualNetSalesLessThanOrEqualTo1000000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AggregateAnnualNetSalesLessThanOrEqualTo1000000Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to aggregate annual net sales less than or equal to $1,000,000.",
        "label": "Aggregate Annual Net Sales Less Than or Equal to $1,000,000 [Member]",
        "terseLabel": "Aggregate annual net sales less than or equal to $1,000,000"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss",
      "http://trisaluslifesci.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Total lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r925"
     ]
    },
    "tlsi_RedemptionPeriodUponClosure": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RedemptionPeriodUponClosure",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time in which the reporting entity must redeem shares issued pursuant to the offering.",
        "label": "Redemption Period Upon Closure",
        "terseLabel": "Redemption period upon closure"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AggregateAnnualNetSalesGreaterThan1000000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AggregateAnnualNetSalesGreaterThan1000000Member",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to aggregate annual net sales greater than $1,000,000.",
        "label": "Aggregate Annual Net Sales Greater Than $1,000,000 [Member]",
        "terseLabel": "Aggregate annual net sales greater than $1,000,000"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UpfrontPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UpfrontPaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment amount.",
        "label": "Upfront Payment Amount",
        "terseLabel": "Upfront payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.",
        "label": "Trading Period After Business Combination Used To Measure Dilution of Warrant",
        "terseLabel": "Trading period after business combination used to measure dilution of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumAllowedDissolutionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumAllowedDissolutionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount permitted to be paid for dissolution expenses if a business combination is not completed within the specified period.",
        "label": "Maximum Allowed Dissolution Expenses",
        "terseLabel": "Maximum allowed dissolution expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r925"
     ]
    },
    "tlsi_DenominatorForCalculationOfEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "DenominatorForCalculationOfEarningsPerShareAbstract",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator For Calculation Of Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PaymentOfUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PaymentOfUpfrontAmount",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of upfront amount.",
        "label": "Payment of Upfront Amount",
        "terseLabel": "Payment of upfront amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantExercisePriceAdjustmentMultiple": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantExercisePriceAdjustmentMultiple",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.",
        "label": "Warrant Exercise Price Adjustment Multiple",
        "terseLabel": "Warrant exercise price adjustment multiple"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantRedemptionPriceAdjustmentMultiple": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantRedemptionPriceAdjustmentMultiple",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.",
        "label": "Warrant Redemption Price Adjustment Multiple",
        "terseLabel": "Warrant redemption price adjustment multiple"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.",
        "label": "Restrictions On Transfer Period Of Time After Business Combination Completion",
        "terseLabel": "Restrictions on transfer period of time after business combination completion"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_UnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new units issued during the period.",
        "label": "Units Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of units, net of underwriting discounts (in shares)",
        "verboseLabel": "Number of units sold"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": {
     "xbrltype": "pureItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.",
        "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant",
        "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r554"
     ]
    },
    "tlsi_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after filing within which the registration statement filed with the SEC is expected to become effective.",
        "label": "Period Of Time Within Which Registration Statement Is Expected To Become Effective",
        "terseLabel": "Period of time within which registration statement is expected to become effective"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MinimumMilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MinimumMilestonePaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum milestone payment amount.",
        "label": "Minimum Milestone Payment Amount",
        "terseLabel": "Minimum milestone payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayments on term loan (including $254 balloon payment)",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "tlsi_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.",
        "label": "Maximum Period After Business Combination In Which To File Registration Statement",
        "terseLabel": "Maximum period after business combination in which to file registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Investments in money market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantExercisePeriodConditionTwo": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantExercisePeriodConditionTwo",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The alternate period of time after completion of an initial public offering before a warrant may be exercised.",
        "label": "Warrant Exercise Period Condition Two",
        "terseLabel": "Warrant exercise period condition two"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantExercisePeriodConditionOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantExercisePeriodConditionOne",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination before a warrant may be exercised.",
        "label": "Warrant Exercise Period Condition One",
        "terseLabel": "Warrant exercise period condition one"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumMilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumMilestonePaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment amount.",
        "label": "Maximum Milestone Payment Amount",
        "terseLabel": "Maximum milestone payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "tlsi_WarrantRedemptionConditionMinimumSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.",
        "label": "Warrant Redemption Condition Minimum Share Price",
        "terseLabel": "Warrant redemption condition minimum share price"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liabilities.",
        "label": "Warrant Liabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MilestonePaymentsMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MilestonePaymentsMade",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments made.",
        "label": "Milestone Payments Made",
        "terseLabel": "Milestone payments made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r673",
      "r674",
      "r675",
      "r676",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r823",
      "r825",
      "r857"
     ]
    },
    "tlsi_MaximumDevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumDevelopmentMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum development milestone payments.",
        "label": "Maximum Development Milestone Payments",
        "terseLabel": "Maximum development milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "WARRANT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfTrading": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfTrading",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of trading.",
        "label": "Number Of Trading",
        "terseLabel": "Number of trading"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_MaximumCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "MaximumCommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum commercial milestone payments.",
        "label": "Maximum Commercial Milestone Payments",
        "terseLabel": "Maximum commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_CommercialMilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "CommercialMilestonePaymentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payment amount.",
        "label": "Commercial Milestone Payment Amount",
        "terseLabel": "Commercial milestone payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfSharesNoLongerSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfSharesNoLongerSubjectToForfeiture",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of the company that were no longer subject to forfeiture.",
        "label": "Number Of Shares No Longer Subject To Forfeiture",
        "terseLabel": "Shares no longer subject to forfeiture"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_StockholderEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "StockholderEquity",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholder Equity",
        "periodEndLabel": "Balance at the ending",
        "periodStartLabel": "Balance at the beginning"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfCommercialMilestoneToBeMade": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfCommercialMilestoneToBeMade",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial milestone to be made.",
        "label": "Number of Commercial Milestone to be Made",
        "terseLabel": "Number of commercial milestone to be made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareDetails",
      "http://trisaluslifesci.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesDetails",
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationDetails",
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Stock options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationsss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfOperationss",
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r155",
      "r205",
      "r321",
      "r334",
      "r338",
      "r340",
      "r731",
      "r743",
      "r902"
     ]
    },
    "tlsi_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock shares reserved for future issuance.",
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of common stock reserved for future issuance in connection with the conversion of shares of Preferred Stock and upon the exercise of certain options and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedBalanceSheetss",
      "http://trisaluslifesci.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r248",
      "r276",
      "r321",
      "r335",
      "r339",
      "r381",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r582",
      "r586",
      "r630",
      "r733",
      "r818",
      "r926",
      "r938",
      "r993",
      "r994",
      "r1049"
     ]
    },
    "tlsi_AnnualNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AnnualNetSales",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual net sales.",
        "label": "Annual Net Sales",
        "terseLabel": "Annual net sales"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the information about the working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_AnnualRoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AnnualRoyaltyRate",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDynavaxPurchaseDetailss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual royalty rate.",
        "label": "Annual Royalty Rate",
        "terseLabel": "Annual royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Redemptions of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r342",
      "r903"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Share-Based Compensation Plan Balances",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r88"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r222",
      "r224",
      "r227",
      "r228"
     ]
    },
    "tlsi_AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedInvestmentPursuantToBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for investment pursuant to Business Combination.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Investment Pursuant to Business Combination",
        "negatedLabel": "Investment pursuant to business combination agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureFairValueMeasurementsChangesInLevel3FairValueOfWarrantLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails",
      "http://trisaluslifesci.com/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfOutstandingWarrantAndTrancheLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureLongLivedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments for repurchase of warrants",
        "verboseLabel": "Proceeds allocated to Public Warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "tlsi_NumberOfWarrantsIssuedPerUnit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants in a unit.",
        "label": "Number of Warrants Issued Per Unit",
        "terseLabel": "Warrant in each unit (as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r301",
      "r317",
      "r349",
      "r350",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r406",
      "r534",
      "r535",
      "r536",
      "r564",
      "r565",
      "r566",
      "r567",
      "r576",
      "r577",
      "r578",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r627",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r650",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r715",
      "r716",
      "r717",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureCashCashEquivalentsAndRestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r198",
      "r1061"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r186"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://trisaluslifesci.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r301",
      "r317",
      "r349",
      "r350",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r406",
      "r534",
      "r535",
      "r536",
      "r564",
      "r565",
      "r566",
      "r567",
      "r576",
      "r577",
      "r578",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r627",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r642",
      "r643",
      "r647",
      "r648",
      "r649",
      "r650",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r715",
      "r716",
      "r717",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763"
     ]
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionReflectedInBalanceSheetsReconciledDetails",
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://trisaluslifesci.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of shares of Class A common stock to redemption amount",
        "terseLabel": "Accretion of carrying value to redemption value",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PrivatePlacementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PrivatePlacementTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePrivatePlacement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about private placement.",
        "label": "Private Placement [Text Block]",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PrivatePlacementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PrivatePlacementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "PRIVATE PLACEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy on emerging growth company.",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://trisaluslifesci.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_NumberOfSharesIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "NumberOfSharesIssuedPerUnit",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares in a unit.",
        "label": "Number of Shares Issued Per Unit",
        "terseLabel": "Number of shares in a unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "tlsi_SaleOfStockOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "SaleOfStockOtherOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails": {
       "parentTag": "tlsi_TransactionCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of other offering costs incurred.",
        "label": "Sale of Stock, Other Offering Costs",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_InitialPublicOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InitialPublicOfferingTextBlock",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about initial public offering.",
        "label": "Initial Public Offering [Text Block]",
        "terseLabel": "PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosurePreferredStockFairValueMeasurementsDetails",
      "http://trisaluslifesci.com/role/DisclosurePreferredStockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "tlsi_InitialPublicOfferingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "InitialPublicOfferingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "tlsi_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trisaluslifesci.com/20230630",
     "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.",
        "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination",
        "terseLabel": "Obligation to redeem public shares if entity does not complete a business combination (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://trisaluslifesci.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.28)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//840/tableOfContent"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-12B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>207
<FILENAME>0001104659-23-126113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-126113-xbrl.zip
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M5=;]@N8X2*+1%X."VAE?B2.0U$<2R%;/WS7(,O(#K-T];FJ@K']1")^<_\V
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M\X!$+NR8A\&8&'\JLAGPEDY_+<I[W8S8N5S"ZP$.M8"WCI%N0O"4 MP&4.M
M388]*"I/CD=E+P/(>T4 %L?DG":4SY$98&D3N283=R8"1C8-^8!,[>'"##?X
M7[25/)MN?&*8$^@Z!Y/*XK/*Z4+F&P%RG%K7^-E[PX+_-4A&F9XS@I0V?3[
M65_P$6O=^,&A6LDQ>2  AG/J2[\=^KVA9D:P)_F*>9QB&>4W!$APSF(QD7PF
M^P&3]LG-Y5..BS!JF9]^ $N4GKDN';,(B(8$VD.G"\L#5Y>K_*/FKN<%"K.O
M#?KYT/URR06;$PB*0!#GL1YPD+SD$MQNB9"02MDW@-$NCYM<_C81-"V2[@T
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MIM62.DUKZ!H 0@*3R2N65"#A+71^[N>PW/TPVNY]+]HTM[YDB+')4V:'Z4T
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M1,R:*\4R=8F[$D@ +E*V%BPZML]H,Z;+[XX/A-7M>'D2P"\'+3KN"G0_:2
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MS5BY&MV-'JYOE/FO-S>+.=PU2IX/>OAE*Q.95W?A;B W+:#NDQ!K=HX2:3C
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MLR!A68%4C8KQS'\H@KB(VGBCDLB"WHDE%4V7_F>7NM ]6&[F%$DBYP\-2-D
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M9%GS%+3I)X5RI6A1LQ0K:E<'%C]B@9B8J9I^.I2&@1F9^ATIW6 T*D]!&&-
MV>+@C! %]"4>%*T3+$!#>S#8)6"*!A@3R@N']9U0FM68\E(!J!X3I--@I=4'
M#?F"X"B.Q'!1$TR 2_Q K0. DD,$*U<2/(W6V/8]FYH(9 X+4I( ."",@RO@
M?#DQM$$L\QXI106! '$"C>U$HB"+$\M. Z*SX<;W779+./Q\'AP7;#RBRI6E
M92M+O_KX'L0)6Z 0BKK@\^._ZH%?MR*FLA.8<F4R-CQZY#=MAL@^4"-[=;]7
MAV-DI#.)Q(RAI8:2X8P[\M3'!Y5=B6('SXDUHE#YZWWF%8,J1>Z3"DG) .++
M9"(@K[U'EF[-<*(FB?R#3'J[T6?2,*RWG#!M.ZIEGS2LJE@@OD4B@ML_GHLB
MGE49J-)%)>5TVJ+GZ^[51PA[<S$"19K\B.R5:I+&CO$R>%F+/@2G,0Y *Q;9
M=678F0P*G9,:NDL1/^;!SR9>8DTUW4?J0D-$,5V& V.4+G"R,7.<5*1V6R=%
MQSS;UBCKH#GTS$</&A3?>*G^=0QZ0\_HE(=+;-IAOYS.2M2262;2A.*WWGE9
MX(P,?!+R;"G"> !;UY*M3T8N*>*3FQ<.L:5I8S,OCQRV"OBC.>]";7[BOI-<
M!!7B9C/3_&W<$0+#>S-G:=EOJJT+<\TN :X""+ G0+TD\L9\%S,-G>#W\"(L
M691MG:'S%O/"F9,8S_R0)=UCMP;0 (]),X#(A_"[8"H*W_8(0\:HAG"7%RJL
M)_JQ R$ ],#,H(L>A1'5B2A#WWGG P5XVRP[;U&+E/#T3A/WG5,V2( 7Q'(T
MTGM(U:'/YB$B1/KDW1B](L/B/80B6TS?=: ,?/$K89!F_GA,>@(R=-#.#UI_
M;3G"&E1#57W7LEV)*-#$"\B:F'TCAI<4CB;(&_\*<4!Y)BEFVJ</_C$WM&6L
M]YG'D5+6>U)A>-W"?%9(*D?1XG5VRS8O:4Z1RMEVQV6W;;YY^A-I[L(B@QGV
MS\:JVXUR"DUVHO,6;[B6H+RD$4E4#%VP'K-1/ECN3I0HO]Q]U",)20#QYO4"
M_3ATW6.9?C08[YOD0WT2D]'P+.NXZ]=!8RA$U="C8X-^W:$G^3P8.6OTV/>U
MV)3C(9ARJLM- Z>S99H=67Z%V@QPA(VW^]9T$0WW$?0/QMC)R0&'*'%.LD.B
M+$#@K,YH(Z;+[X[_9DW\R1H!ACFYD\*X(,(X[SC;LF !'MALIV_&",M."(?/
MW&%6LN%=6H)(K4 RSFP]68'$.V)H'OD(@S..,W&+BI.W..;F-4C\*6"I8N#T
M6E$"6:-O:;3 )^ \7(5/_(KD[C?U/)  )UXA./RG>\7R[P'K3)@ /1Y$ /&?
MY!7*WG_6F2@!ND((X>$^I"J4/2F.SRV^&;(STEDH ?I+W"&R*43)[8? 0E4\
M&U \@@O7LL7!47)9@N/*7BMZ@ M:47S\A:UD*?NE&CS0 !>\4K X"U_I<O90
M*YBP 2Z(98!Q%L:RQ>R?5C!1 UPP2^%B+YQEB]E#I>CA@EHD-D6ILI*"NB2"
M:BM8<A/J40P=2&0*H3.3:]4X;O+<1"$5*L<_3D^:;+^,^01.7Z[-5L+KHY#V
MAKF-_V[JI+-9&].E'NKT/L1H1?\EPRFKC!YR+06UP[O!7AC')'6[5%EP='QG
M:Y,R.@]IW&/ $G*X 3AO5>%9!APHSYS)QB6?[[&)5YN5]U6$M(Q[<#:0=[C(
M]"M25GY-P2IS'=35 ?><),-)N;''=^%<K79=9KL*@JE)%9+H"\<T5O5%2QU=
MDDIV/R\%&?Q SD1U:R[>++J!9AV!29>S3SI1@!K@FE8<&+7/UZ,844E[IAI\
MW "/.82A43-]+;H1%;1?JL&'#?"L0QP9?JUGU(@*VC/-X,(&>. AB&SQ@FRD
M4FM]-<78EK-/>E& NMH9QR]'/A_!'NSO_P%02P,$%     @ ]:R.5[_I5\HY
ML0  #EL- !4   !T;'-I+3(P,C,P-C,P7V1E9BYX;6SLO>N3X[:2)_I](^[_
MH.O],#,1VW8_?,ZQ3\R9#95*9>M.54DKJ>V9_7*"14(EVA0A@V15RW_]!?@2
M*>+)9ZJ:L3O'W2T 1.8OD4@D,A/__K^_'+S)"R*!B_U_?//AV_??3)!O8\?U
MG__Q313NWOWPS?_^C__G?_S[__ONW7_=K.\G#K:C _+#B4V0%2)G\NJ&^\D6
M'X^6/WE A+B>-[DAKO.,)I,/[[_]R[?OO_UA\N[=?\1#W%@![8+]23S6QV\_
M9#_,TM&P__?)AX_???C+=Q_??_PT^?CW]]___?W'R?0A:_A I[9SE2T]U__]
M[^Q_GN@7)Y1&/_C[E\#]QS?[,#S^_;OO7E]?OWW]]"TFS[3[^P_?_=?#_<;>
MHX/USO6#T/)M],V$MO][$/_C/;:M,&90H?N7)^)E WSZ+O^6L 7[V[NLV3OV
M3^\^?'SWZ<.W7P+GFW2*[&>-CV3-OU3:IS1]^/'''[^+?\V;TH%<R= %LO/V
M3IAW*#;^RW?)C]_\Q_^83/Z=8 ^MT6X2?^WOX>F(_O%-X!Z.'ALJ_K<]0;M_
M?!-Z@?N.0?7^KY_>,YK_YR:DD#-9FF'?03Z5#/J' 'NNPT3AQO+8?#9[A,+@
MFPG[S.?U(I]02-S \J+ <W<HL-UO;7SXCK7YSFC4F%8MAG_7'[$KB]!V>Q2Z
MMN5U0_G%)Z"P(?\U6.Z61T3B1=<>^*+A(9(_VUO^,PH6_B;$]N][[#E41]^B
MG6N[82<,D7\0)(NL8'_GX==N!*0P>G_$W[J![>$@(NB6SINX1R:A5%C)L^6[
M?\;R.O6=FRAP?10$M99(_4\,P89-=#A8Y+3<;=QGGV[\MN6'4]O&D1]2"V5%
M@;-=5(]\W:&'('L5/='/+W<[1.A<:I%W.<0@9!#WA:ZHE6?9\;*J1TAED"%(
M62./:0BZ<8:G+;'\P++KKSSQ8$.0-L.'@QO&:H^N?*H/F?S30T#=A24=;Q E
MTF@+58PS!$&_6H1*37CO6D^NYX9U@>(-,P0Y"WK@/*"M]:46%87>0TS^SG+)
M+W2*Z %9[.^QW-<B1##2,-ON4X#^B.@$YB^UZ:D. M>"Z,&2&-:BT)OCUGKR
M.F5"]H%!U4P#*BMC@%$Y#8B2C@?_\'.+0LOU^C@#Y5^"SY1[]X_(==SPU!]W
MJI^$J^B:<,7P"W"9,/.L(&#6.DZ</G3#_@W9X1:O<!"X3VP:#CK$\-,)>?0G
MY"S\DB-QC6Q,+7L/.=USM)OI H;'\NS(LY+5=V,%KDV7W:WK192N1Q3>4ZJ3
M[6B%2($M/0#1<&+#>U2:\$@P$@3_2B.R1&-!\K;<44FDI^_-WB+-=+C9!R"Q
MH NJ!R54XBYJ0JO.L$"<42O:"1'"[A^:ZF_MP8&0WM:^I3<R#%]=$T(EHPUZ
MI+Y-A8S^<1H$U-)J0J3&J(,2F_]A1?"+RR)G6J%6,NR@Y&9&LYM:?'?4S":6
M5T"I!>*U/P+&X=*$;/F 8$A,%AW=/@OZ9KNWPBG)FCG3,.^YI,<N.R+,*F:'
M@O89U-)TP+#W@1HE:&81#V_<0WJ@NL/DTA)/=7[[_*S[?3 ,S&-6[M$+\CZ=
MH=^UN^NV]W$(ESG-' 2"L: $")7</1W%#0(BEQ_2UG7('% &%$\!\S^BV!/=
M7<"<Y&L0F9/'LW4<+C>0DGNT0OJ_RUUV+=%$R0G'&H*P=N\N@-U39!RFA_4G
MUV]^G2<=;Q"SA<Z"'FO8028(29PY$3PR\R!T7U CDT1K8"@DY_<*N=%4,)>6
M4<AR#UC*26HY41.?N2?M/6K+@.MZ3L,X3E.?9CBWB(^CW. \M2)A)L/#(C_V
MWL>I1E0/'.FVE=Q9,QB?X_WJIM!D99W8/TU?+>+D D!/FE%RDQC,OQSCF\1?
M,#L@L>'7=-?KAK%]3GQ 7VC 4JV<R#L?E8+">FO!/:KY@2%9T,H2%0\VS&UD
M\::A%0)50PY/YGD7P?X+(B&+0VCO/J?VMX9GC'".:^QY.TR8VFJ/-49?&YXY
M.9+9"M[B543L/?UHGW)4Y^O7R;Q.A*ZMB0S/TM8O.$R&'\1=D(0IK=)0C[.]
M,*6VF<-"F>@VLV'W!XW/'G4_-8BKF&N -G(8RT<$1V0'5 X5+WSRK1?K2Z:1
M&L4!"X8:QL^I],8V\_KJ#P\W=+29,!M^ HJ3J6T'$3@O&B#GV;7ZS.ZQ_WQ/
M]ULGB258$7RD9MJ)3I1=X1P9;5OK*?(LTH1C-;XR:(0/"JB1DE[OT9E3:V5&
M 3RE=FH[L5RZWX"S5;:Y5PZ6,_04KH['>VPU,N)XPPQ%SA:10QOT5,89R(>=
M'1,?<=@TX%DPUL"$M>?%@.F<$,YJ:M.3G1N>%GZ_W##Y+BB&M75MI3LZ*.)O
M*68.\IOMM@:C@R(^21V-#\W)#\BW6].&1I\"Q98'BQH1M-.'U 1O=CE6YS.@
MV+$YLF#>[ODA^PXHAMQ9GM<].\1? <6,],PY_X*([08=:0_A1T"Q@K;_V*U,
M\+\ C0F?.F<"YPM#9]8EL:@=)-:)!X9!<OPORSCX)3.!VR5=]@$8+,CTTHJX
M-O/()9% !<<<<T$E;5AYEW;94_?C,%C'G)A)N-4YA*I=_DB_ (,)4\=QV;R8
MKW>'R:'Y]9_A)P#<!;=XUSNLJQO1 8.[B,6R/[B^>X@.\3^E<8.-A%M[;)@%
M!;JJ*# 0P0^(/",R?28HR==SP_T#<D)D[Z<V77-!O-YFF!PQ:;R@:W_+E#$Q
M[1EW+B>ZLX*GN&L4O'NVK&,R2X2<PW?S+R'RXW) <S\ZI!E+]VX0UQ\L,)2-
M%/P]K6Q?&8]Q^CODA0'[%S9X$#,_9CS[S#=<P#1FKJ4SZ79I$8<)612$^##]
MX@:W^&"YE)L[*_(N29'K>.W!A+18Q,[(2?]8I(A!B8*#]2V*"#ZR_\0\_0X%
M:/==VOZ[5Y?N .]\>GK"KXA4D;@4"8^0O"\;_%WZ%TKFAQ_>??CP[F/\;L+_
MY(];DY+\ZZX??N>XAWP&] "LGG+A903VNL-?XOD5>K8]*?IG)NC8?^?$<-:<
MH6B8UJ<;C_[N@ Y/.@+ GRMOC+8GNJ?C$3MZ0N]RUM2<KF2D#H4A6=7-I:$\
MCG#"M!TU !(EZ_]>:HV8*G:0DXW!9MJV(F03R:;B8;NNBF?_<M;PZ3_\\QP6
MQ$K/I5% ;!(919[UA+Q_?*-L%[HA(UW=+N:;QYZ;P21E<V?4%2=Q6UK[*5GB
M!BD]D@820LX2,R5VJ3V5YFR 5+ ;2/Z.X(,.R[$&H><I_WTB''$2X@EOI"B@
M(^!C<NCY9H()W;+^\<V'GN!-/99+LG:?]R%'>)7MRF!+V@T@O.79R*18UE)&
M(5"Y5J.!34@O"KAPZ(* \X<<2-)9.,<Y-HTCXN(&*?F2!GT*=7D:C]8!<25:
MU8Q+%*<9%%F6<!]K4UN4X.J 3'3% ]63V^JQB_W+/V?6T0TM+W8 K>DAB+P@
MYPZ3Q%FR"(*(%1+AZ6'3?IG6,NYG(-(:- ;"C_+5<8VN'$JUNT(1<G.8<"-F
ME32Z[K=C#6_TS395?D#"@I:D?SMK2/J7?]*Y9*879_D(?DVY(?JUL7;7GS-W
M-0A_K\X;J%R+.(O5Q!5%]&(8)HB<[@,9&'-",)EA0E!2+Y<>2%?$Q62%Z/\Z
M4^<W>CJ-_<*%*=^<"G])&_K.],#2*#CBV^4G4G9W^HD^S:3"5*E>NB"+N\P,
M>J3,,ND!92EV"C"NP\7B"N]B=DQ-:,UJ(,61%MRF<W[$/BE4WV9.A"C@;F/:
M/?(M0K]'GZM4,2_!=FC01X]^H&O5!#5<CS'E[57YN63+U?I,J^>E0DXX9ST(
M?DU)%/W:_(23Y[454IFH&DI4#U=V#7JDLS?I 45N11S'=1A0E-"+@9DT:@TX
ME'<5TT.0'R;7RVLW^/WF=(-\>W^P".^&0+=Y=M+5;=ZKR[4RJ6Q*_(.^9G,A
MR8+F4%:"-D;8F!>EL[OB,_&173D\G%6RI7CH+9#+EN*U46DYZ+)@L]%;$=66
M(AHY+0&O@PH>O"4@)%XA_=G@7,$O#MJC:^K!^HV>.N([:D1X9KVX06;)B!MT
M[:-BGO#EKC0!KO@JVZ6DJ-M!$5T)T[$^O24KIC(B$U/)2 ,IYJPDP<I+RC3D
M=0F$"MJ@1\H7DQY]*FSAO(2*VZ"'BG; BMP$+UR'*<6%HO$QMG*T/C+0&DI*
M6^3A(/<,0894=>UHM$Q9I-.RS[4BF ]WE6BUE=,)=&7HH(+-&%!<"Y+AV1I0
M##N0]"?I/0O?05^0L\7L7O"<"91D>E07@EFGE%6&G?I<'K*I"7<3LTX:3 "\
MIQABAVMRI[B:]#[)%I;NIP;=7]C;=U&XQX2_HN2-2MI6V*C_#:4X%<E>(FXF
M) SH.E @@+4IKNX;EX.>MPS>8 /)\D\L6A AX;67\/>4;/'O?0IO:19<N96T
MX%$"5%K%W,8Z)!9EM#(4$T_N$ -))K]T:Q+]E*Z>/Y'S.7X5^IS_S<XCP4TY
MY7G-2B+RL@.Z^T*65]#A%_I<7PWHJ%+!79\=?J$Y%LHO0-$/7<H;[@.D4CY'
M^\0P'=<)$2WHR #9WS[CE^\<Y"9+DO[AO!+I7_YYCYXM;^Z'?(-3\&O*6-&O
M=;6(>K;)Q[B+G?=3%@O'^PG*\A(Q$4M)*LKTQ0A,'LL]A]ILHZ? =5R+G#86
M*X$O3*A3M<N4K;)=K]O7>0Z)QY\5/PXL<5BB?H>,7OT.4(19#1&NP8B2 A=]
M(5;#&B,/&QP8QU<59A6PH,?S+^(808..Y5 YDXX#1 S&DY"%!W(:< @$NAYJ
M8( U*.<$^VE\HA#S5QH:UHK07P+Z,@]"R%7[@U9;.9W7M0ID8F^R)4B&OQ1Y
M./O!AIX)XK+D<7ER_BV\M$U^ I6UZ?<\?S$3P9E<VDI$%5#)EG,?ZY);/J%R
MADS.F(*A!I)@]NY%*!=@69/L#"EKTJ?X7DZ$*[WR1@*2@,JNE/-8D];2.90S
M(!-<T4 #'DO1'Q%[D?<EC2T1'$HEK0I'4EFK7O5O=2Y\#:QJ)Z8-J"2K4,#Z
M1%\>-3G#QKI8/%R?.=*".PC1S4$'_GZ=&3Z4*G@5YUC^I3C+!T[5+P"2QO5@
MBTDI6:E%?W&IRT!Z\,;R6&[_9H^0+)Q-U2PE5=FL3U7(FPQ7%ZH;2L@#J@V5
M2& #NHL2+!J8";1LP('DF__BZOR+[44.<NXHK]A=313&<UWNYA;Q7?\Y+^=[
M<^(/P%DB/7PI2U3OX4N])O=SIR.LA:3;7,HMP+61^H 7&[.QJ ,ZG&&<WJ^<
MV5";912X/@J"0MUCWEXI;Y7M)8I6O>Z4G+FP/Q+$7X':[26T\MM#68,J=+ Y
M$TJ;*'_X> ]5#SO4D3D+1\]?!3EB/RZ-SCDXZ[2]+)$J;=OG>KB8"#_20-8F
M"SF0MH$BZWK\QWHD<\NF\@:. Q3X PY64Y*X+_%S@>>2@2S!E"/>.DWSDHP:
M3?L4[O.$V'L&Q++%3B*=IA4R)4VA2+P6)MB(_G(M2O'P255*V; ]NH[R!;JQ
MD6\1%\LT.:_-I0;GMNG:O91]]+,?')'M[ESD\%V>JG89-<IV4.18SG>L3S)7
M:Q<'C=V=XL$&TMAYM9B;4_['GUU$*/OVIWOT@CR.0)MUNJS;H]>I3WV>SZ=0
M3B>H3E)>P,BD[R5+C/I"63J&@.)FO"JN+[TOEXHAZ7UQ^$58F.<=B6]&;%XP
MFT&/ZO)3]AAZ[>6STEYQ@AZ2=2;J 7!U*?$2+"TY4P0+2O0QT6JJ?&2@-528
MTL(_1J+K:%6S:HD\?K,^EPAO,MR5H6XH(0_H.E B@0WH%I3.*PW,!%TVX%!%
MP:Q@SY[TH?]A9_X7RQ/XC=0-\\+PRH;]AGC2@YYKA\CA3XS_K_P[\1:&*I02
M;SP4E+6D@3ANE7OE<OJBCV=ER^M_="B[+7G&FCW**GE'1=$JLU$4K?I<BG%T
M[XZ5XO*=#2(O+GNJ>[GC3#%@FC'@_\3=HKH8.N5@)T-#6;HJ\<"=LK9D*_)G
MPA9QNS,8_C!V[UI/KL?\Z^S])ODQ3-RV>@"3M!WDZ)7-QT5!:ODX2W_-KHT)
M!?#&"MS@LX^?V*,F[ WRV"2B/V.*G.?&-]27-,D/;EU_[Y+CG7\/C);0DC'<
M/Q2"PV9UDJ5C9G>3Z_&&8,;J;B-R9&DS+ "#9[)+FN2U;25-.H\^1<>(V'LK
M0/D3UI?S$61B&?;+C6[3?E 6H!0F7)\CY>J^U6\D)K3VV -MK6S37^ZF[!'$
M9]'3!=(VF:4G;=-KW-UY#D'R_H-U_I=B%BGWG%JS=Q:55[,WE+4B1Q$W94]Q
MR7 _%<?)F7ZBU4<\>+?<Z7L]>@$3U<:2D E.8X.E8DR"(AQ"WEQ)!E#]K\EW
M;,P)57#$^2/E\ C1X*W*,5LH]IYGV7!^*9S6+W]I+H[IJ$+70^6W\FR 2A6/
M5UA.4$G[G;MGI_1"MX%L 6;@QR;Z%ME[W_TCXHF/O%%*JJ)1G^9 =2I<250U
M$Q(&5#X5"&!MBHM2RQ^4";!XL*$R9%XMX@@N'+F_918<][=^:PWPZJT5K:*;
MT[G-RCK%QA.;]GGNOL/JKPD/@5U^0EH]L*5/0%ED?&$1%OYKE<&ES)7B/,0U
M^YI^?Z@G/M)I<%8R[Z?LX0K>3WVN8^D*E$(+7.JYG,4*FDI/9A0&B-_&@"%G
MTR! H3P)2M8DVT!D37KU@UQ,A)]U*&TD( FH7$HYCS5I+:E5SH"QAT(P4*L'
M.*JX#ZQZJN4]N!X*0NPC@3FCT3+W6*M;-C_P";["E3^MMO+9 Y5&'5YC,P:4
M/<["X9/WY*3#RB7UW[^[8-<]_6O\ ^??2WQ$7T+D.\C))E[B9$6)Q6Q$R#E\
M-V?] O?)0W,_HA.WDM&#,/BFSU>!ID]!G+AR(:2*5OR7@"JM!KE&/K\IOMS]
M&OM10^&%N:SMY?6MM&U_2S 6YW>'DJ^9^])1!0UL1KCDE:-LZ-(U*7_(BV5W
M9*_&N^'I']^\[[&TV?D"]Q'[[-Y6+/A:;;/*8%IMF^\N]X@>6?(;Y/.G+J>N
M:):7^58T@R#+>JS%VD27"IO)QHXKG G';$&:!1BG*Z8P-WH:789[1+C3O8"^
M9N^4.75[7Y6@-&.1D?P8?TI#K#Z^U0+.K82&+'<[UT:$>[W-_2U[F8W[&P2Y
MEC 3RVD2U=)-1HG?3BOWAK!%%R<J"*87->!(W]7AJ:1.#2IO" AZ)?8<! )K
MB_]CT0=3_;'/0T6LM)-Y"/=>:9M,STC;0)!/ ;.Q'GT5%U)0W \%(T#0.X4-
M>:9[+A TK!X*1 W;/A',-(X#,XVSP&4;"'*IP<[**8!/J\"$FZGL_QDD>;VT
M(OG0*UH5E9*DU?7 KT>OO@ (QS/84,4>1:XSL<2ID+B!Y46!Y^Y08+O?VOB0
M> YS#\P,^P[RX\M./\">Z["]OUBU\\(U=>FE3%GRX<.'C^_??WC_?O+N7"Z$
M_GFV?+R=/V[FM^Q/F^7]XG:ZI7^YF=Y/'V?SR>;G^7R[H6,=/#_(9_WZ^OIM
MCC$=]E/,@2>ZEG*/)K;YPM7J&LD)V;)P_(NE(6KTW3!3C-,!Q&]I:;3/)M[N
MDMS3GL2.GM"[W.=?5'+%)2IG.UN>&E1<+*Q^T2A.AWOTE37LAO^%FY;T.YK,
M%PE4$0<>&<,"@ \'["?9-]S3GZQA1P"4]R0Y]\4"5&([9_)-V"ZYBTP_8VVB
MI]^0'6[Q&CGH$'^&RU^3CA#X+907QF\38J"(_8VNV-\, </'EL3^IG6V-WT1
ME=NB_RU5P&#QELJ==X]<G8M?;JW^/.P6*1&"C)-SV?NJ;>CD!^2$R-X7 FAF
MF!S%JEC>?D -+,(^U[ORF0^J;O/51(]=:$'_J+2V"PV[X;GE>=J676767-,Z
MU107C&83<,*_V]@/Z4EP[L5-__%-@)X/R3DY_=W#]$A)D211[T<BJ9]8U C
M)JB'S^7$SYZ##P.OBF1F<N>GHBT BU#LOE;,'0X0@LI$X<PBY.3ZSW&0C<A
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M@/$2X"N*O#&^)APC;\;(FS'RIO7(FS'R8_C(C_$&^*W= /^$?'J(\EB1->=
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M/?+H 7H;'B"ZW[.-=$7PBTMWS9O3YX 9[7FBY=0.W1?N.[A5:\AX( "'8.W
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M93P)*2J2]@"<-_6 D= $[TU9B5T@:=^_72!"J&.[0,(#>%A*#0)I#QB6@%)
ME<B , '2*4GUWD4; *: AD05V7]!0 =GR<O]+?UB(#Y-JGH X#)7-O)#I8J
MP8^5Q=+Z]%.*0R6W=?];AZ@X1 ]'2BX'H*$H/T>*V\/8-!1BJ4 $Q(9Q,2_I
MQB%H"T"U*25+ @48!5=Q1%3NM72<9_< 0FWTJ.'[P-I0B+T'S C,B!GVG9CO
M=YC<16%$4'9!-\.')]>/K^@>(R9_RUWV$PH>*%J'Z, S,YJ.",'CH"T<K5#<
M=77%SY2-P2(((N3<1NPF>87H%YTXQ39X1*_Q3]P\+-V>$)P19ICI4@8GHB.9
M6C)E:@G;*,N2%JE><7L L14U]*^8'C@@K0BV$7*".THLFZKEVVC!6&QYJ^C)
M<^WE;H>8N G=L-K](10X-P;1@#XXH'+/_ID^W[#PG#AD9T;-#N3<G+)C:=K0
MR']H,BJ$VNG& M"8ZJXW2^X$8WV3_Z,(V1K](=17-S1VC.B#LXAYFN<\8P-U
M7.P$H19[*SJX2%37*VQEG>(D1&HM)X>B^")HQYY6*)?OYSHQ]3M#J+YNMK8,
MB.O\#8/S5=X,!WQ55VT#HMZZ&<^K1'3-VL*T/ON4E%>VY?G/=XA_!I,V']"Q
M)163G+W2V7?-Z:Q 0V94QE-\Q#X+J$9\_:+L,G21"B7'E13T*-_+<,_LNL)$
M%!+.ZS!T>0@3&>?-OW.+5<?]%+\RE>W\].3,RK!;S]Q:7\W& _&J0P?^.R'!
M(.#=TB&"/?:<\\R6KSXBP=X]UL98/BB(ER$Z %I.-2RT'U&XM?QG]\E+$]N:
M8\T9$L3[$ETBS:&Y:YS7R$&'>,3$\?SY2'>7))N)AZ&T.8BW),SPD=+3'^_O
MW8,;GM?YKVZXQQ'S9F#"GBD5V(AF_4&\(%$7'1T"._<7G/7PD^<^)TL7LSFB
M0^(T3J\&=EE*"J+V;LBJ='DHY"U\KF.A@Z^ >'/"T 71 1NZ%I 'ZPN[2&5!
MQ:_(N76# 'L1^T!:DXV[*VITZA6^=KRS&E3!<<E2#?)"[2J790G'=!6O^#Y<
M@*;;J5?06O/)JJBZFF3N>_>/B)).%4.-K.Z/;61UOYOD<Q@SO,<,[[;#9<<,
M[S'#>\SP!IWAO4:>%2)G99'P5'#>!C>GXB^2Z'R3 ;Z:'' 3IH"!7QJ\SVL(
M(VK?7()%2(&(X"].2!J^SVL(('9?+%$BMG>8^+4Y4D' 1+RG7#0 QC]!;M?%
MI,&(:V'UF6\87UDVL)0+$!'5WAW 5@?1$%4-A#HTB%=TNLP+14Z/.(S]Q\K-
MP* ?,-TFK7]@0-; >0:8A%M$#K?H29G&RF_[]22Q\NF'A9\\@574&H9^DPJC
M%(D.==KV%6_W. HLW]F^(C\\+7U47MABO:;?%X!N4XC2.892FZ@^T*#_4!L-
M85\(68EUT1 2->83C_G$+><3IS=!K%JQ_WL:K<Z]?Q4TA+#.S*Y<!80 NF:U
M@OW4=]A_F.B\4*+H#*?AS"+D1.<=EYX6W;;J];VJ_%]#VKJ.7O@5D]]9L+!U
M=,-XZ5:6RF6+JTK?Y5+04T3(#28$OR8?MFSZO>6N>-PJ;XJ2(!'#<:XJ,[<!
MG7!4')M/L+).DFOP<I.KS)TMDP"'^\P>7?@!-2*8<?'9IY-Q*J(T/7!2^FJ-
M<%4YL[4HA -M'(849_<*_0?G!E>9#5LD  [?R^)R9]G(8/T4FU]5$JR:'#@(
MB3SO\42#4BU<PTLC[@C7E5E;B\0>4FM>$ E9ED=Q)RW.49X;:CC =6;"F5#8
M8^1_450L[PZAE>4Z/)#4?:XP<4U-5.>IU!':XO22_@Z3&9422NX:N8>GB 1,
M2&3!]B:]KS#;S(2\/M=,HF=OT1$'+EV_&M4U]#M?8=*9 74#QMMOHL.!^7EW
M&_?9=W>N;?G9O%B9.NRYMHMJ/)KVL?IHVN;SP\-T_=\LM'ZS^.EQ<;>831^W
MD^ELMOS\N%T\_C19+>\7L\6\^[?2!-)<)9P7ZBYO.H:LEU>/#F/'T/,Q]'P,
M/?_*'A'AE9O1T!,:M,##9'P,I,N@OSA16.-%"FX[ ($OFJ]]2(@87_S0NVPW
MXC3H]S]".C4VJY0BY;.2XO:#!XR;:GX)+1 T?SP='85?:@A#SRO%BJ/G2V0,
MG.%_.+#"+G1:4VGB#Z\AG'V (T#EY/WJY#OQ7^>?L3;1TV_(#I/*' ?Q0X(F
M'>'L!@)^FQ #+[3Q6IX8_K[A7C ^%3S87C$^%3P^%?QU9CS^I9G2&C,7>U=6
MX#,7SZ7QRW&/M.7'_+9/;'09=0>@P,SR&(VHZP"<ZMJ^%V2.J)OWGC.B2T'.
M;:$FZSWKHY5D!-$9,/YIZ/KJFKB4)PTG+*UVE@?0](ZZF/22T=$8K2T]M6)"
M#?8DIXO221";2?%$&T]ZZOP6)<^!"""L-=* B21U<*U%(UBP"R60-5[ST^T\
M8.Y)"Y *R8*#8E(@_&?D93%# L X[09,.JF##8>"SI\.8>=G5I$=D2![%*Y8
M=9A-)JE%?(<)M3S75FBM,&%36.[N(M\)U#%N[7]CP(048U.R?>H[EPDVK[-B
M"-;H@.G.SCPLYVEL\<HZ%6GCIDNT,-Z .2[F6#>B%":N@FVRE1$'S)7I"=L.
M-E1-=!.I>L1A/%'D3'VGL+/(U'6]@8;,EVD,IB:-<(RB9.]81F$06KXC?MZ8
MTV[(+)DZ5A&'A*[74B56/<2J5:/L,F02C+G_2T5-3TD5RUTZA^!R"K?$>O5O
M\:OL:1&MWD-FOQCC8D+8X! QXY4]*1V'#1/$M2!J##)D'DS[@%7I@[/)7/@*
M=/<<=;<A7VAJP6G2Y8[4_-GM]$GC]&X\NS?BO06JUV7(-Y7J@"6G!@Y0\]T.
MV:'[@A:^C0]H:WVA1W\Z349I1(D]/_$B@,UD@"%?5JH#H@EMT"%=(QO[MNNY
MR2,^X1T]=Q#+8X&F$9W#J=38"&O#D8=\J:D](3 D&HYT?/8)G?JS[_Z)'#J]
M&^13'(1*6=BZ5Q0;>$V4A(!')I>D%:*3"BFA4Y^=A1#=_9G]1B)T61&AE1%[
MO9%OX$IIA5@X4C"E%#LN>[WO!6V0'=%9T3G/O]A>1$WT.\H>]NAB%%J);WYN
M$9]R*'?Q2>L%M31VKY+1@N^F);(!R4A^T1UL\=1)GCRV/%829.&GU19SLQ,Y
M.M9WLR%[E8@6PG>:40M'$&[1#A&"G"6U40BK*"=!6-"V5^A:B/(1D &^<D><
MNI)DL20O?69)+"L<!&Y<;2F["%BCG4=_8A[/&\MC@K?9(Q0&F<V)G#IE0"JO
M;!J4 7DWB:<_F4[LF())P$B8! D-DQ!/CBD5$Y*30?^8TC%Q_4FX1Y.GA)I)
M$),S(3D]8YV1L<[(6&=DK#/2S?&QRLQKK3-RU=GF#>N,C-GFW640CMGF8[;Y
MV\LV%_%;*"]]9IN/&4YO*\/IXG8VRSU)G$?3D)XCGZ*0$<>B\SBEAAN,<V6Y
M4S4H[#R*A& ;(2=@OL!B7,2"FGZ^C^*4R.35QDP%<,-(:HQR)3E6M>F#XRL;
MDZZN)^E*L$SGS,/%[-HTCHFW"*MMKB0W2C![. LH"VFYPV2-CA&Q]U: \AIN
MJK >8:\K2X]2T@/?$VUY=N2EEUTW5N#:4]^Y9?=CR'E$X3T.TDO3%2(%AW4=
MG_.G9C[G\T0G>#=Y8E.=6+XS<9+)3GP43OZ5CAW\V\2-9SPY(E)V47?M6&[N
MTK'WR(E8%9F&UY0\SW57'QE]W@)'2B=@CM[RT5L^>LN_;F]Y]QIF]+./?O;1
MS]ZZG[U-MM_HLOUF"+;7*NXJF_PUQV&*O/;M#]^[E[\K#I4VH9:WN>N[3ZA$
MH3X%(;%LD4]2W!R "NA24L2$=^V-?(P.+/TG>?NMZ%/1A*[N( "V4A6%^>F@
M!GEP')Z/*$P<8<PE-GVQ7"^YE2HXQ=("&[$73; RC4<9$-]F<EUZM-R4ZLY?
MLD0^/KA^T_5::Q@ *EA[Q=8B$,Z:_16QEV20,WVA,OR,LEI7E61IV8HU'&/H
M]=I LHLKUI!J\)"G-QJZ]0*,1QDZZJ);V,5TPP'^DDS9FA:T'3K\HB40!=3!
MA2H5+TVP\M9#!U%T!%=.WX!WQTDUR"RKRORR]U/UG>'5YYO[Q6RRO+N;K]G5
M[D!)/@O&&\LK$RC,\Y&U'J\].6M"S=[Q_G*\OQSO+[^R]\1X)JN>JM @9WQ2
MK..+RO%)L?%)L5J\7M)CY-3S<!P1O!3G#&FT!^ UJX>%A"8($137^4H][_1L
MMI^,#]7WN(.,#]5WN4<T?Z@>CFOHJJ/T>$XB0RMW#+<;P^W&<+N.T]JY:_)>
MEEFMZC%,<K4>'>?W.B6JJ/>0* $TGWU6I3&NLW8;L?FMZ"QQ>O/TB%[CG[@0
MZ?8<^J;.$#1=L@!MX?'4DBGKO&HG:3_TA9P^5AK$]!"!5KBC3Z> "!,@0:R9
MN/G05VN&BT1*2U]\SXQJ;<X+.@R=H5R3]P)JX.@E[C$IEYP\$'5&=UWV^L7<
MLO?EMB;G;[-QA\YZ-M=S+1 -7#+F7^@YSPU0K,7/XIW^&GPPD0;U6'U* .\M
MA)8D0$WHD$$-Q'VA9\"59]FQ/6L>UO ])ZQAO?AENIU/5O?3V?QA_KB]@B3S
M_#YG29*"'@\HW&-GX;^@($2HX.>^.54;9\VD*>:M?F*,M%!=S+4'Y!B>,89G
MC.$97W=X1M?Z98SI&-X;_J9B.BXM.ZF'7-08@)>\7H2!B"!X9ZHK#2_H2Q^.
M,0EC3$)6@K2\I#6B$Q0] &@WHS@%!3EPG$?<G;3B.=&Q_NX!E''0HX9OQ+6A
M%*^O-(.A)_32)=:.4[DZ*H1X26-9:DQUUW<]W D*G)T\+6W6?\#K3W,,:] '
M1XD7BUEG[[NIB]DJ.@UXB5I_":J(@H/9>)_'N\+M3?F.5WJ KO3^VJD0@+[5
M6R./'A2<E47"4\%=$MSAR'?2X)O _*KO+]6KOO7\?KJ=WTY6T_7VOR?;]?1Q
M,YUM%\M'5IXZ_=PD^=X57 +F-=5$#+PYE7[1*BAM--9XK2=8M4V@&>_OQON[
M\?[.7!\*EIK$8RWM ><.KZDRT2(7(G12![6B#PP7M89,:B#4H>8JV5ABA<5M
M!L AK24XN?+B4@%1\"]6M+D*XPX YQ:N8XW&I1X,SMI:[2I4F41414B!"#@H
M3D@:;,!K"$SSB0,+>)/O8!?9'*D@8"+>/RX: ..?X-78BTF/6=4M956WO@V,
M.=?=19F]E9QKV&]MM)5S#>.MC:N.I!7=QK2FK,:0V3%D]BLNS=5JX"S4TEP"
M'5&YN-,[S=\#""O3I8C_ZH^1SKR^"+)8;$UK7IAV!A /5DL(-,F#$WD@F''\
M/'I-,"_[ H@+:Q'+2^K@0%E\[]I]<1WD.T$B>=*# +\#@&BP.J#)2.HZVG+Z
M_$S0,YWRQ?,CKW[EL0"-]@""LDP T*"HWXHRU/[]#=GA%M]ALD-N&%4J^NAV
M A 998R$!EG]PO&([['_C$@M6*2=!ZQ%T1(\4O*ZAFF-@I"XB86Z]./9[Q!)
M]CIZ,*&GSNDN1.0F"B@U04 5[!-[1"0.AC@</13&_H0J@NV,VR>X/[0$;CN4
M=XU[-J]I$+C/_I)LD.=-_5.JL4D6-1E/]3ROY2XMO<*9?;SKQD&76^(^/_,O
M1WKY;)]2\V-+4M,+8ZY/J+;T>P%[;9$.S=[PNK5.W%25OK[<J_?H/5C9XC/G
MBL5K1I4ULN-7?H>3--$D>A6Z%GQB0_&I<_G+)I!LYJ)M?.'_NG?M_>:(;'?G
MHN(:^=4-]Z[/V%#],1F4G6"1;_.KQO8\@5[EK@4WW! \ IA+4B=]Y*-!^LB8
M+3)FBXS9(F.VB,Z6.6:+P+VA';-%QFP1:"'6<+)%5G2Z;A!@<GK$(6(VH3*,
MVJ ?@"@4LWP2/;(Z<5"?/W./Z33%K!<VA1M.(."VD)+.+S&= ^40>_Z;G:XW
MT?&(23A])DA<J="@']Q0  $.>F1!"+Q^6Z4+V]K8QQJ%8XW"1+']BLGOKO\\
MLXYN:'FQ3DV_+59JZCX MG&3.H5J@N"$,[WQ=-&N\X3&=-'!SS)CNNCP!YLQ
M7?3MIXONJ4V^1>1PBY["+?V0+/N*W_8-9E[Q"84%E#S52M0:ALZ72IT4B0Z-
MW.TKWNYQ%%B^LWVE!]03_8>RXT:LA_3[ E!1"E$Z7P9K$]7^R@A(6%@5]&_G
M%4'_\L^UY3_S5-7%;_VK)E%UQJ:JZ8*P81C.E?_*K\.J&*YTE#@XF- ^6%_<
M0W00<O'B]P$UA0#QC(T7$QUT7[RQ/%:W>+-'*+QG7Y#?S8F;]Z\K! 'QK9DQ
M8EK!(28U9F0=8-@S*B%4H=*A53.U;1(A9_[E2"F256X3- 1@KZ@%YGSEP"<"
MC$=@3/&&GN(M"L5)MKP;3 A^3;S ENV&IS(Y9>N8&Z)3:QRX5[!<S!M0VGW&
M%I>,3&&PIQ"*,GEY5;]"Y('*WEYU@=YH:+@7O6*T6R,>_!W*]( C5A&_6'?$
M,!",.\*5)HT;T=CUZDYU3GPW-\/^"R*A2[>1A1]BP0,O^MVN,:=<B[#Q(:6A
M$\ZO]2DEYC]<^ &ULICU]=FGDW$J^WVB"00:TFB$*TM6KT4C''"9/1:LK),D
MO:/<Y,K2S?E$P.%_66SN+!L9K*1B\RM+Z%83-&#6&,M=<^,:<L'49ZF4(5W#
MR+?=.N\._;7Z[M!L^?"PV#[,'[>;R?3QEO[]<;MX_&G^.%O,KR!W;!GNXWS4
MC$>RW#!!VS'WB[^$I*P=<[O&W*ZAO+37G-N5I387YB:[.Q*U!I/3I5022E+
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M6KO&-KX(HO/)+W/#VJC6'@I [)\^GK6I[!K)A?^"@GCV4^?%93'%[<#:SK@
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M+Z/AF-AOR[W1?9W#T<LQ>CE&+\?HY?C*$V@'+$4_YM%^=7FT;?EQI*KPH@T
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MQ,WZ5R4"-[=*E8A)Z)WA:W2,B+VW C1]IGL*\XU?SHRK30S[#JM<5)*586)
M4 =Z9INZ_<4JYK+%@-JEENSDRN:2D$%W3Z84E[LI"U1^CHF0V#""MOUK'D%Q
M+ETC1D#'L*^XG&<3)-4FK/._Q#=OEAV'GDF/6<:CP+![I$)8>N3%E+Y.;A/(
M,R+YHI==(W ; K"*:@I;X9J!2QDDA^F](D=!W'RP/ ,5!3*W];7&^]/3O8V0
M$]Q13JR19X7(6;'MD]GK N3D72!X-@QPE!,#)PJ(G:,R9XWD:'UN B!XT02'
M\N3A\+WRJIEHXZ^V Q"19X( AX+>0XSRD-$9]AUJP2"'_B' GNNPA7EC>99O
MH\T>T8EJ1AM]?/_^P_OW++PH&YK5M,I&GQ2'GZ3C3Y(/@ TZR@B1AAM=-.IW
MT=RB.*'5?4$+/Z"[&IL(*U,N.=K(N\ )3.(RO[B,Y(0,JLO.4Z-B'[_EIG37
MRKO .+SH2!L?(1Y-'1Q8SA^\<WVJ85S+.\\T8.:^O<]C4OFOB#08!\!Q1T?P
M\K--/2I[AVU#?T7!S:>+@HRUX5.-!\"N;A%&%;4=P,GF[-(C-K6%+.+C2 <R
M=1\ 9K81+&J*>E]);:T@""M'8(>WN'*Z6#'MV:1*KP^GX7#^'N&L2YZ>"Y/O
M^GP\:8UEG9?G03TSKX?/Y<2A^0YFR1OH6NROM 5@O/&EIXI 9>YP@)A9P7[J
M.^P_\S\BJER]V/$>SJ@N/='=4%;Q0;,O&* $XE8*G],C"0Y^4]MF-[LL0PZY
M<<;<(PI30D7K2=H%@'+31DM."1R0%CYS,;(P06%R:;D) --9&X3RS.$P?470
MT7(=]GB<'R#YDA"T!6 >:\,@( $.'B5*=+9Z$(G1^KJH/'4X?%\1?$0D/*T\
M>C:B>QO;UX[,=!0K(WD7,#N$?#G(2("#SI+.TF)NAWMD!2BN,+K<?0Z2QU\$
M\"CZ@-D\9/@H:( #T!WC(;IW7UB]H=#RGUEJ14*?I%2$HA.8C44&D8H(.!@M
MPSTBZ<RP;TNW&$%;,%N-=-'PYPX'B&1NTLV]7U8+HC%U#^Z0>%NHS$+WLTV(
M[=_WV*-4!FQO"T\*+XI^=P#[AYY[2Y\DF"CJ P;)Z64JAR+$8(.CYYJ4=0 &
ME1XJ@#V5F;,GS6C=$LM1G.JE/6#!8^#LXE(#"B82(:=*FQ@D47L !TUCB$2T
MP 'H?(>JC9&\"P![P0PF.3FM(26X\8\/O/D=-9_QLH8 SHYZ[)81 6<YQ&<J
M[94@; W@_&BV"(24P(%&&Y6A 1&<,LT &5X7"7TGBK:P]FE-5033@<+=FI0^
M+64O6%NT\=X,$ZO"!-5Z"=J^K:F)(/%[BPY'3"QR2OP,64C&],".1=,P).Y3
M%,9'([RR)*NEQCC -)RIVZ4&Q7!@U_)N O1A-@$,KO]R18=!5!4G!,FBP[@M
M 7A=U-SGSAP.!#-\.&!?R?]J,P!:3,W\ZK3A<'[J.&[RY97E.@M_9AW=,(YT
MYGJV1*T!*"<U#L+9PX%CS6K@^\C)7@&:VG9TB.)$]5O*6ML5[18Z'0&8:VJ0
M= B!@U=U#Q3@PVL(P,&BQH,W<3C\5UDD-6^.0:R5MFXE^00"R_;/?PV6NS20
MBOZJG_;_43?M__RA"=Y-SI_Z9BP ,!8 & L C 4 &GN@TZ1UJG?U<UW5?0 <
M,XWR6M44C5G?'27C=YOU/:8/O^GTX35Z07Z$6(6T3-38 W:S* CQ 9'Y%_90
M+?.T!@&B_]_96E^$1](:(P%8:WI(UZ(.SL%IAH-PN?L)8R<^("#RXMHHV- S
M@M#W)NX P/NC!YJ,"#C8_$1P$*P(W@F]/:46 (ZJ>MPOS1H.N_.\G3314!7%
M+&D/P*.C!X6$!CC K%& * ]8]OHM>Z@7Q]ENZ8R%FXZT#P K6BENY5U&2@X<
MK#;(\]ANYSL/%OD=%>@3&7>2#@", ".49+3 @>@GY%.:/#K+J7.@?&7TL!.%
M'"=E+P";OQ%82H+@();3M?!M:E3>XT!T5.*V!! O:+@;%6</!P96#B((&17)
M_!;LV0DD+ XL;MXG(']K HB8!$BH)'.2JZ]*JSXQ^*$9!A<S[SIR]B=* 5MZ
M2S^Y(UH$0<0J)/.<9N*V??+WQSK\5<P?CH"??7[GV9[_39RIK]&O5S/X?9-5
MH$$,',3B!(1'[./R?B;74*I.O6+5R/FIH@0.4&<[(_/?N7Y$)WR^#KY!.TQ0
MTFYK?4'!_ NU$RF;7-\BIY@%+(2;>?YP;/PKC8(.O]BKB#3RFG;*!FCR1:>?
MROX-/7.(O7G"UKWBVLBQ*B0!#B9TKU >HR[:],K_1J[5BXG#X7HY\+CPE/,M
M?O77./*=.V2%$4&WR"8LFVGAEVC9XC1Z=F\1E(0P)3'^ @0[_%ZOTM#(N]LA
M$Z!*UJW[XCK(=X*$BIQ/B\-1[,DW&Z)7_!OY4\SH@@-I20BG+Y;K)1D\A0#Z
M-(KQQ@I<6T>)ZXS2*["-_#+&I,'!-HOG7B$2JQ49@H*VO>+4R'<C(  N&K>N
M%X5(=/<O;-TK(K6\/4H2X&#R*V(E(Y$SI;NU]8P>(T;^<A=/-UA&81!:/HLH
MD:T<PS%ZO6AKY <R) P\JJG\5>9OAJMXE%Z1;>0U,B8-<.9"-='B(FM+F<?P
MJ5X>0_'#_S))/CWYU_3C__;-F-O0>(IIGCD^'+$?/Z @3FY0]+FB[ 8%)0"2
MZ/,I2?,:!&UA)#1HB5@UE;Y"#:#3.#?:7MX40&265*+$YVL00?6%$Z"4^9QV
M **MM#G/F3[$]'DI!(H^ .*IM.%0D (JE5Z*B:@Q@-AJ;3!$-(S)/F.RC_B>
M,O;_G^\!JB>8-?:\.TQ>+2)R#QF/ F#'T;[6-*,,CM^A;*/H^AF4O0"8:36%
M5FS U?$QC!5&-!=:"VC!+D%2,$EU5YF\"P #L 70Y#3"@2^>(0O_1,YM1.CD
M5HC.+?4[QC\NXYD%\R^(V&X@O"2I,Q  \[*M]6E(.7@!B"NUM8"_;!P Z8+=
MP2\C' [Z4^>W*,ET"+98<)R-!9EYQQUV"D-^$$<JKA%E3N"&*$TC3JA>(QL_
M)UC**AEV_UD R3\MR%;W?((CBMI16U6^I@7!XABM#UJF?9/A :0QM7X&:,(/
M."(DW8D3$MG%Q')7('>#;-I44O*[Z:  ,JZZ-G(TN !>2&)]V+*,Z(X)(&FL
M8T.H3PD1Y/?I[*5IK:Y@2JDXL$=269D;$B"Z;R8-W#_CW?5"##H8'T**6@.9
MZ( C7<N'3'P-Q*#6,!"2W)JB78OP@4!-MJWFJ"K&@9"8UA&L"LHA*//"86>Y
MXY7-/!<*9*%EKI/FX.7E NMJ^18^#"'UK0_UWP*KP%N6R5)Y1*_Q3[6.&87.
M$)+RNCY/%,@%CVZ\O]4$][(OA!2[C@\"(*&%GAO;G8/1-'%VN-CRF17L[SS\
M:E 4__MZP>3L2Y/X4V/@^%@47QPZ,Q;%!Q-#/A;%'XOBCT7QQZ+X8YQL5_8Q
M,XI6!+-2"L[-Z7/ 7+5YW<JI3:60^PAMU8@V'@C 2M.N3F!,W'@&:K;]U)?,
MJR@?5'*A,5^9;[L>NBQ6T\K2[.93 !9O.R+2#7O@2-HM.A)DN[%SE=6&/F 2
M\N]#M'H 4 U=KIWR64+"!T@ OXERJH)%WA_8_=5C?3-UB@7W2UUC=C65CK,:
M2>4(3M$!2- 80"Q]7XM0Q (XB)ZE;F-Y:+FC!%,2P]/*LY(Z!\?T;,=#6+<S
M@/#YOA#794E_NO>!TAF$V$<KZ\2^?8<)>^HLG-HL[EH41F+6'T ,>\\Z6H<K
M<%9Y]?XMISH-;U"<N4P& !!UWM=J-V$+9&F8VC8+D0\HJQ"U$,57=7I= 9RI
MS"5>CBN/3,B(LH=A?/HA<22XH@^ HU+;&);H@PS>BJ"CY3JJ!W-4W0"<G-J&
M\))$R"CFE-ZSOXMB-6OT!W" :AM7(:V0 <[V!&H"L@V!N=1LFT3(R>9OHGSU
M!@-PDNIJ9Y43#D<.]+WTC:\60:CPUBZNM(D&CW7RZEYIUKP7<NI=,1L/#D!&
M&ET[&Q,,1S[2PS_+&F#G?H)*[AZJRE0>-),! )RJVET/I21O T9T[3O+YI+Y
M=(+$J1.S//?[\)QFFAT!'*W:!]*$ 8 7\,(/+?^99?PF!.BNVVH_ &JYQ^5:
MI1\.R/IL:+Q3@SB<=0>["2/ XW_G^I9O=V3%&0\.0&X:67'&!,.1#TJ*C9 3
MOW29W;JSF[MBV1EJ@23_@.B/\;^(=H::@\&U[FJNDW()GWI,Z=S2*\QKC7:1
M[S 71.QDS V9\BRY9E^-4>#:@ W@KLT-F+H@3?W(RN$);4%I%[AF8,OKNDIZ
MOZM7NT*&5C< VW$OZW.@JAC9^6&Y$TR!)6 %=/KTCS,<5,YA=0<!X#_O"E9S
M9L#1N@GQ*+[\61&7\N'(RF\D% G4KJ(/@)"D[O2N@G8XP!:5C4F-7HU^ ,*,
M^ME8P9?FU6=#XS,TB"*5W<%NP@@X^+,IL_]C+OH7RT-QF!0ETK5#Y+ ?Z-&N
M_ ^%EDG%E>JUL.U%K +]_(N]M_QGM+9"--_MD- /T_<D %@2>OZ:OAGS1N2R
M"S$#897T(#70A("5R'G$ODW_>'95^PY'K=ZZ 4M?CPA2N'V;#PO ?M$7A6:D
M=GV:G'E60 \^J0=B2=;LH>+XO+-C+Q2G_[[%:E=>W9$ >&_;$O1S(8Z:O.B]
M-->9EL>X#OQR=Q,%5**#X):]M.?IUN'Z_OV']Q\F[R;G\>A?DB%9M:UL4/9<
M<SQL5\\U"Z3\DCA>22U9PX'JI*1BE/CX-=YBKK8?O*"6FOW<*BI52H;="0O3
MD=;1XC6$43U+*52E?8M#!J!W0Z[SZ66Q$'7[[K*H:C9BV1PWGPJ5^C6X;-85
MP%6=G.MFY,"HGB5[0EVT,_#[]+\[?&QE=^!3,R@ZTA>,+U 1M 6V3\C$K(B*
M@)INBOQEZ_,1AR@XEQCD/WRMVPG WJ!\ %N7EF%55/04N(YKD5.2P:\T7,7M
M^U=-GQJI)C$EPR)RGLVC=:!_+%QE2G643D<@"DLE="6<-,CJY(42RW>>3LDJ
M7T7$WM.#[?29H%C32@PMK7X ])>^G!7>'-&A;7!]AOZ(V&;(TI]9Y56%-N.V
M[E^7?=]4EW'I@(:%7(&)V\/16Q+A4B "XE1^,2_IL5S0%H+N4DF6!(H.S^>7
MZ[5RT2#S6]X/6#A9;_;Y/B#02[T74!;!$#&$XVI43F3'USW!PK]%+\C#O/1$
MW4X#ND9, 5(3 ^?.\HT]X*-S*.$B9TC3&&]<*][8<"7U&S_<>"VMV5V=CQSV
MF "5G&!JV]$A\MAK.K>4U[8KNN'7Z3A@$)#Y*M(A" YN7UU2UE^;XCMXDM77
MG7SSMS;QZS"99HSIY@;W-L,+?(QV&K)W$:@W#6=4T$YT-XAM*4FLFT;?/L'[
ML2EXFC1U_NISP=L;A7OZK3\1*\P?^2$/$<T^O?HCWC>R)M7$ %I#^'# R<N5
M*XLL27S+F)Q"Z($DKO4M6D$Z/7M%K;:[PXBD[A]-E[G?MX@<S"\DDEZ]@M',
MM:%#3N<1N&=IB*%?$==F<F#3&5C/E(PI/2C2/]Q:KG?Z!7O1@:O::@W3*U2U
M?1GUZ1L$N^I$,@_:EE@L]>/6.G&=N$U&ZQ7)9EZ0)F0.JQ4?K"_N(3HD>RS=
M>N-WS,][;XT;7-6 O<):VTW2!J6=(WL6M:"H-AXL\CL*XQ^88*(XV'_I3YT7
MY@1XQ"']X9;NSUQP&X_9*[ZUW20M$0L XE_=<%^:67+PW+[BFOC*!NP5W-H^
ME#8H'62?+<PMVRO8@^_(CM@S777V6H,1>\6VMK^E%5([OQNZW"N6KSXBP=X]
MWKL'-Q1?#FGUZQ6HVKX5 X)ZAR/+5)Y91RT82NU[O>9NYD^1$S)@:EY:YIU=
MWF+/M5D*HF%RWL=J<MYYT$DV:N?9>2V4RW@M,(-@G_[11DGQ'C*+P<JKXL<M
MXOHN'N+E^[4T9@M^M("$!>+IW\Z$T[_\<\VFP(D[O/AM\%2_5D%BJ_*"P/8=
MF#J,YP:U57X=-J20*R4E#G873JO@X0-E!SWW";EX\?N X8 "Q#,V7DRT?T8F
M!V@Q(\N_#QA>IF)D>:+#%D^S7!+[W6].^1]_=A&A].Y/]RS"31+OK=MY\"R[
MUA6S*0=@8/R +&;[)(54*].5!I,;C@$CP-Q,N+FXZI$+ ]Z%?XS"(*;K@S02
M7=H#0#QZ+8'EPL<C$$(=A7)=%(F*E;0?/$&P,ZTJ(1H>>#K5,/@]8"A)I40J
MD>DP;? 6$??%8@ZYA1^$)(K+=\1U$9^9>\(B5-;"_,4_<1IAO7$ J$(-D<O=
M-_6('+CZ9SW54?%AM>32*(S;>]90ZSPI%P=MI*-[ST5J+%D/V$>GQ,=_%_F.
M9K2BLA> >BZ=R(>2<#B1=,+'W3X':!=Y]^Y.A*Y63Q!O+G2 L!;QW6=!%1,*
MDFH>S%8IWK@NJ<7.(BDH94F0!/?.I=Y (%YF:!'<)KSH&FNY.<+N6ETGK6N=
M&R5BP)N,!J#<<ONH-V$(1.A3^S3)SFQ+ BX&!5!!&88@7/ %SN:>A6+D;SMO
M$IM2:.B+VP.HD=R-*2\F&1Z.:W3$)&2'"$T@>1U /-O0(9(\F@>,ML@"16;X
M\.3ZR<,3IO$6GZKQ%GD)Y.*X0]5#WMA[Y$0L?4CTXI&H0+)N3P"NR6OQ*_/R
MB<P &KW'H_>XNL@?MM.9NCXFK]65>7YY)(S>^,Y**5^5-UX153-C%@LB1XN$
M)U:X4!!FQV\V>&!'S:U"3%'_(7;H>!EU>SDS[AYAV'?X\#R9H.61>OH$=;%=
M(&>+[/W4_B-R@YA',TRH91[+D&3_T.DV=%B?J92=MQ8=ZGK::Q)W!4=#:?48
M/%ZBIK+2(JY7!+@*2;//L(K(0+0T6-]SX$/RT:7/C\C6[S:@+C(2+ T$"E3U
M"L+V%=<!H=!MZ.J7+8)0H*I?$&B_6FNAU''H8I9M E&DJU<H[G!$ZB!1[#=T
M%<L6@2B2-4S2#L1L*1[3ZYW=QIRH,2>JQ\/3F!/U5>5$\?3ZV@UD[_C(N_2O
M:GF%;.K?J,BI X(5\ZVRIVB5[V+(N\"X5M$103Y"/)HZ-073]X$M[SS3('60
M&UT%F(P#X'I&1_ XEJ()E1W )ECY][*7-=1]AGE@0Y>6<XD?304(Y>&-R^EE
MU3C6[&]\I*0=AG8Y& .FH*?[4GAY.&V('(-'&S0[#NUY,%] >G0!>$JC\/@:
M#R#3$89V31@C94H@G,#!XLSCG=5]BJBPS9*Y"TPZ5:>AG]HPP4^7)IB0%=^.
M8"8/6GE6$B>I 9VL\]"O:32%4$9;YPK3.B61JD+#YZP+9CBHQ.C6'63H%S3,
MU:8YC0 VNYH[W/ O9G2QK76/B*9H+'P[8DE9!D<J\1!#/X]1PW0WI! (:BO+
M;8)8TGWP)S2Z@BLA#X[E<?:K9,X3%P6/.!$JH<FA[#7X8QIUC TE52!APT&P
M],]_5R-6Z3#X8QL-P:H0!!&GGR@SC'"J=AC\I8UF.%4)@H/397WKH)#M+4!*
MWF7PMS3J8"4G"0Y:\>1NK(">Y?'AB.@&FS"8,-<F.W[<G,Y-TA/)]-4B3I8N
MJ'AUH\/O#/X81QVYZ( /<(2)FY&BL?R5W09_EZ.6"E"2!0>YPN-U94%+WJI>
M2'S8]888_#&.6HO7B$20Z&;O=,G>^!,W'_R9C8:H79 #$J%2C0Q***+VG;,T
M6X Z8PS^$D=#+'5HA%A:YOJK"G$?]C#V\HPE@V"7#/K82I@+I'I 78']"PKB
M,BMYA;-.T.=\I5=Q:"6(I@LN@)>/L^FQ)>[S<YTR!/6^TJM\M!+4TP47P,L'
MRY0*]MAS%(_D=?2A7J6DE8"BCAAQ/8*B_[!B]]_L57R:NN%ZXLF ]=)X,=V/
MS 7%)FE:..W[:N&T?/Q)X0/TW_-OP'^V+G^08QH$* RFOE.XI$Q?^: G22I0
M$2$44]K@$?LD^^N-%;B![ F[%L?OV0L16F%2CB-Q7<:;J2312-)^\+IMG8%=
M<D>(&0#!$1]/1Z>H6ZDAC*0CI2QR7.TE,KJ(P:?:'P4WG]*H<Y=*1;G<M3BU
M2+LK@&PBL?2<@^]UR8&P#*ZS#J6@ZENG^FRL5CE6J\R>G7[R7%M=KY+?#HX2
MTZJ.R">BD_CI.-I>@ZW\AE=6=5) Q5=;7%7PPLJ0Q57'^@1"6#K=:<<J!GUO
MMV,5@[&*01>PU:DY?17UI8W@Z+:8=*T5PR)![#UJO&)$XP"P'%I<,2(J>X<M
M<RVTI?!4XP%XA:U%&%74=@!G*CG4_-&'3-T'P#-I1K"H*8+Q+GL#8[9RH];!
MO<?]@(5\.N45]T7XYB>+ZWL+]PVD27;HFI7*S15E5;Z)5) .'0-2G*\I<X0[
MU_D71&PW0'$@5OYCD/X:?#!!7ST6  MN&)%0LP:.G,2AV_%$1<$$A08 C+_.
M$2W2"P<F[A9CLB</6AQIV)T8/(XS<Q-K-H1])7C =AA49_",JW(A@,NB#8](
MC;"PWX!5F : 6<@&.%AS-_X\^Y01G4@I/=<BY^9T:0.86%HFHPY8 VI8F\N$
M27"DJ%BK+)UG9CR*1$3>9<BJ4KT)@)P%7:<+G)53_NVCFX2E<T/]Y>V'+"/5
M.6 :] ,+R=]$AX-%3LM=\EQ[L/!SYBQWA:-^2@KEQ,4%#>68>33_1]UH_G1Z
M$[R;I!.<N/Z$37$2SY']4)CE))WFA/YUDDYT4ICI%>4$R"4R%L'//GX*$'EA
M'MB%?XQ"^C.F7/3<I$Z=3FI :Y\9Z!KAYI3?;\3;I"3<1]$'7J9 RR+ ]?SS
M>0'CBJ@Y_9?428.'>O@NC @DK<7#E9;N.#,^S-Y^'%-O"VG Y]V_^A@VU1W@
M -@/' CWU4=C0<-^#.D"<"$(1!:ZC L;@Y/>9'!2:\>@ZXM1:I$',\NS(R\I
M4H<][PX35LVU^Z.0Z+N0;*0K$&$1&^&X]G-B4PK9(OK5#?<5PH(R9<'Z@J'I
MCA"/I9+/=K_UMLYL\A7/E=-VV0E0-C6XFOB9%_YGNM)9$1_D9 []%I2E;'!(
M&G$0Z6O(/X#B9KB>!,MI%1%[;P4H8%5G@^S--&I*AV%BM"@EL[]YO*WC;_<J
MM &KWZR\QZ63=X@$X@BB3K_XMH[M@\EPF:EO5EI[5\-@]6WGQZ@.^/=FQ3+?
M07JV#6"ISRL1R0+WWJQ QF^3]"2-V;>^AOR-CE@W8)R:^,:X=@'9'ZH%9,]?
MF:2?R2/%3M=51Y9WZQYDY^*;T\_(>::$KE%B! 9[]WAS6OB4\2@O;GG/)A;?
M\8C*T\BBR?J<P%A5JITHL_Z%9BP[-9:=>M/UB]HH)]5MM%3CQ5&P,6*;@E$B
MT87BYF#JV ZK!\4, @>S5 /*.L#0?RK)5:'2AN9K'9?YER.R0^3<NB^N0VW?
M-95(KK:L,P  U:F60QEL,N* F!@<G:,*(-+M/%ADD!EU*JNP*UW<>S#0^'2C
M2:E'7=&!\X3C6)!*HSQD?8T@H XB?%==#$%9&K(^A%=0Y: J;Z=+JT)['7)Z
M O!'M[D6.12"=!O'NO[&HCOW#!^.]-A@):PG+)B(3?ZFT&1EG=@_3=DM>=%Y
M'QUB0H+,JOP%,S.$#<_L2G.'="4'6N&0CF?X+I[BI$C&I$#'Y.E4:I?2,HF)
M^5_%O.D"0?]KDI$T.=,T843!=WV/3ZB]/4?-$ ^HC7Z8T0_3 )=S#3TC[TNU
MV]7[7*HD@0(JGMEYES-"2] 7P+&Y&60"ND#AQAPW=P11FS5$]-@>&CLZ90,
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M'G&@8+SYL4%^CH(E2ND7)I6. ,I*CE67?:) PG4=OH<!B@/EKXXW (!"E-/
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M:?OROW?QX;LEZ7JL$Y=$/P!!*FJ?B01-<(";^SX^VP5/)$]QFZ:(^98%K2&
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M[FV*V8A/'9B0V_ '^1,]OD"F P #V$!P>%39K6Q':E*2=^?OUILT>2^/PER
MN#T F'<&(L0ERRI$BWR%TNJ1T?#?*& 2R(5->10 =I"!4"J3:OQ5C2>2N\!X
MN:3Q&Y@J34/.YAU:[/"8^DGT?K7_.DE/(%H<M/C4SH]PO5TSN=CYW?+;)!3$
M#V_IM!9JGI&8'UQ&MG^W> H5,;*]4)AWZGM!E*),1VLQA_)4M<IY2&OHXXL,
M9%+T@&K+PDN6IY[/\FBJ# #Y LB5 !4BX3AEF*O^EJ'7;70?OK+LM5(](5M:
MF-(KA6J3RB. \TO*?E5>U GR)SD.Q(I ./C-?7^[)IXX%%RC38K\TGN&_QRA
M@O$QJ96;YN&_BW]G$L9 >KKA(9N"I&1B.E; D1X>1P9LS;#-2>.^?+FX'7T.
MY[L8_R-:>C\0"2':/TE#XC^+XMBOI0M^0 V'7\\^=MW-Y62S8C;\5SSA+*EG
MG.%6V<QOS@G?U<SF%\_#+.QE_)6F4@3FVWQ5R"''E\QJ#,9]+ E)YVDF*DVV
MW\[J+(KK'68WA^$2Y@L9'PT0KE^\")3EH7]%:CFE]%QT05L EQ"15#6!8%!A
MO[PKJ=B$1X_^9XOWMR#TR5*X> A[ ;A9J" CI,>NGXJI@47V.*F>U@QR"G2U
MO%"B#>GX#''759E4(JU%V"";QN?MR[^0GR^3FQ^;L'QPC*4T1PX*X!L>*"%C
M*8=S\5.@Y"')M<@&:UP A@+]XL$B_B@E9+PL@# <Z$?=J@&A>I"[3J:K;NPJ
MAH+?^G'IU:"S>E3XEH"#W^TJB;#$)@2K=S0GA6#>RB"BLHZHS_BYR.3RBE,<
MUWB@8R*S*H#8RA:OC15QS V,MF"L#?I@;^H"!A?L>@AZ)'ITJK@W,^518%@S
MN"+<LNZKTJ>AP%='0\_?4H2888)2/0 8,@:*W[Y4EXA$XY%!^\="GGV$:0D3
M1E@@HQW $$$=&I'# ?.(5=-_B[,-\L/7$ 54$ZV@K?V@0Z[H[;G.ID"#SOJV
M2>+;,,UR4AX=BV#H1:1*0Q'5%&Q]CNZ2[6DY1E$H/'M-)4N03A06?OGLNT]V
MO3C>>M$#RHNR&8O7BT]G^'\2@,@/8CGL<0 V\K39@JE8Q%B8VH-8-*EH@*E-
MFRV8SL^FP*DSBD4KB :@.L1I0&K^AH^#;X6/I3GU/<JRY<J+%R2WSHN6B1"L
M@0-93+E1PVL@?>8@^Y(B_&\I6<Q0L-A#6*R],0E,;,HL9_".OC>('(W33F'-
M(ZF#4_1D@NGN<L:]G<S=&/,RSA^]76&_8;Y\1F\'P-FH"WP.U=H?,"NG6[Q6
MT[-18;4$X.73B@N+;MW(U.E>(=XV\B1&PL]&T & 7TXK3@+RM<-5I3G*P\7O
M " '7"]<?/(-P75-7HM,RHSTSDJZ!QGY;@ *Q)F CL\$_>JQ,^57+^@Z<'D-
M38+TBQ5U2"5;-RP/6T(Y.;W6EM/]0I;))6*!)-7-)&2_6H!,B@FZ :1,+MS*
MQ'U,0O>;!>C$'-"-6]O.0#6V=%H8=<><60"E2["A,P5;%GA'"FXOHU 9MGQ(
M,\',%_24[+PHWSUY.76CHC0R"HX-RP2%9CC1K;5\+).Y_]<V).F5CVGBHRQ[
M0AG"W%QA%C2.J@SSI/HP1F$W;/@8SA6;8;'H)7_<;.X3+U9.G3T_HT3$XO%(
M<>;'QQD9$WY +%GPX:5V7D0KM:7IJ/3F$CCQJ+2&8()1.2QO1Y;W:;"<$]!<
MT(.WYA="9C>'$1S*%B8V"DTJ]!C6_17R_\3Z,D=^54?B+?7HA<CDN@ ( A4)
M3M-LSB<&0*KW/@J/9'46[!1EX3-Z@ D%E=1'7&(@ B.1B,_L T-%24B<!$(@
M\O*+(J_X>+DO)%(N]N;'!G.$7O=3K2L /2<EA[W*MT+* &WZO8,_=\^_!Q![
M(5@_>ZL_VJSOXK*%@NP6\Z%^+6_Q2HAC76,Y'0 $4"@@R*,$CO6A3= U\E-2
MR_P6CX)OW#%BUMV3Z <@KF+P!T<ER+)I8(G2]5#;P 7#-D#&=,8!9QQPQ@%G
M'% Q#M2Z:!X'S]O-ICQZ>%']SVP3@61'  =H:4.!)$EVXZ,C+\L6KW\4":_Y
M(GT*WU8\M<1I?VRF @XI\"#AZBEN#QBJ2BAG0F0T*JUJHN+9;O+,Z-FO%Y\O
MSLX_L;65J < -24A1GM-)2+' ,_/SRY^P5-^EN=YMP> 6^ 8GG?),2'G^%<\
MY2\*<M[I > J-TK..^28D//S"S+EKPIRWND!(=Q]C)QWR+%? I2<$BJ*GO/$
M_Y-S_.&T-W_\D;)M,(\_'%(@''^*Y<B<>EH-81QVA%)%.>RTR-"@AYY1&J)L
M_NDQK6K!%1.RM1"_/9SS#45.]JJ'3X,^)G]69#*C/9P#C023&30 ,O<XMQ!\
MMU";C$<L6DD0^E6PGA1NO3X OJ+!./:(@>,?JH]U\S@H3G_98IMGN1<'8?Q&
M+%P,L,3= %PI%/ 2TZ,]K85V%J\3;MJ';]H6I-0=P-5# AMUNN!\5M1EW_P@
MJ0,9>DQ#XBJN5U_]FITSOK6!8P'(SU7X  <2"0?Q>G&DW#;*\PB1O?LNOO*R
MU:T7IK][T18=/+0"M2H["(!$W@%*5I8ZB_[XJR1^1VD>X@7BU2+UIZ[.S_OQ
M^HU!9\6HSBD_Z6+OD_@MQYMU$4R!Y^$8@.A-C\TQ3Z?"JAKL+HEK^F$UAF'^
MX8D3#P40(; -74/6Q8UY9;0%8!SB2U/K_$"GP5FE[3CEG57Z9[1*'Z'!=+15
M&J+!M%S:I00:4CT F-[X>$A1 6,K((_\YKNK9+U)XB(/6F([H/<Y6D<EG1RK
M\'26Q-T9&&V!;0X\.6NBPJ#&[C,R01"6,S]Z84 ,!)LP]R+^HS'\/@"V%*Z,
MM=Z'X9-B^1U/,N]='* ?*%@FA>$US4K2RO_G*#39SN8UFY21FJG99.D"BYSP
MHB[;&8825!-2623!7.T?MWFY3JY"[+4"H +59+"5;->EQG) 0AJ^%S5K#MKA
M*<QX=WM^%_,:3\ICP\D(XE$#!)NK),Y3SQ>;(?E=8.@T&9&C(T2CR>YA&W_!
M08""PQ)OP]B+25&U VW\)P+5A@"@^62DLG4L5R+016>YZ"R5 T0C<[UC-V<=
M)G@] )B'!J;M]TB!$T[0IN@."U.*LIS4-BRN^,$CWME)&N*;G#^6/\!QQ6JI
M4 85T(;DE7\D1X$BS(45!:30_SC"NP80ICL&C[84,O\2]\I62=00+?+4(EX4
M_H?GE9<B8JFYW)%(EOKUV+0V5[-C]K1.=QSA7_KYH%MF_M_6BXIWMJH#6OQ6
MO?-1;S0TY"4Z'4=HERPUVE\)2I,7[R6,\!2+U^9#@?VU,7?.,0,!>*Q!%JV!
M%!I%L!M^5_\]?IOG7[U\2Q:B@*/J< #><1B$IBJ=<$Y'W94_>CM.K"&S-8!7
M'%1BGEEDP,&E/EU72[LJE$5>%>\N_\+ 2*HGA!<>% "3HLG6(96$&I.7//AZ
M4:4WA$<=QIXA:73!^;RXV2W/R"<:.\1ZW(LBA ^ZW00(?NS:\%$A/!@Q-G=$
MA5[@ G&Z>4.L9R..*'&(H:7O".N\J)KY/JS.:#25S&QJ%(F1>7I,(G0SNIJ1
M;67I-##*U)&&D<[2=;/R)@K7^.I'AFS?#.6.%DK=C<(PTKZA1)CV1Z""?VVS
MO'#_+1-6J%@2X(N\7ZVXX^58)D]HG;RC_AF)!JK6Z8P*P4BSB59&P#F '!S.
M^$I:K(#ZJJ*XN5%LAQM1Q(3 P::^?E8E^P47[WTKHTB,MXKTU@\'@,87W<XQ
M*)P151F";YLD/GSC8@N6_$A&'>WCK26#:-2]?7[!M-XG^,;0F+5O.*7MA+(]
MC:(TTFHB2Q.<3["C'3@Q*]261L$9;]F@T@"C+$+[DU:OCW#!KX^P'WY6C ^_
M4L(2K3=)ZJ55A/GEKIFRQBN<(-/1Y2V/K:@@#X]+8_[9TYC/F6I.F-$L[@H@
M&%D^N5E,CCX4+H:C(.X*(&95'@4Q.?I0^# <!7%7 '&G\BB(R=&'PL?A*(B[
M @@7E4=!3([&HLO#41!W!1"OJ5"*V2(*GX>C(.X*(.I2H?2(/10N!X,@[@D@
MEE(: S$U^B 8?DR5Z H@!%(>!(O'U,OAQU2)K@#B&>51L'A,O1Q^3)7H"B%*
M41X&O>?4J>UD/?,GWSIV#R!A5$1!TW A8W8ZO@32#E6/7KI(R]R[HH9OG9TC
M!RF[-X!+^@BLV73!\:9TEEPZYN;;?(77]^]>.)5T+P#W^A' ]>D!#A@U]DVJ
M!X"K_VB@X!7_IRZS\:"$"E*M;@!L!*/A:A$$%K,K+TUW)&^J" *:YWD:OFQS
MLE\O$ZS8V6DO \8!8',8@:H,A1 ]UG,_#]_QFN[B29W:%PI.[?^:>=4B9F$\
M\QL--_N&F?-^.^^W\WX[[[?S?COOM_-^.^^W\WX[[[?S?COOM_-^.^^W\WX[
M[[=N[[=S^#F'W\]B'9W>"3B)==2:X^)01_%ZFY;UX,*D]&8^H._%+Y*?L>10
M *Y$8QP<<D1"M(8_D$H3)/MYB,W[@Y+-.ZZG<E9M9]5V5FUGU796;6?5=E9M
M9]5V5FUGU796;6?5=E9M9]5V5FUGU78Y72ZGR^5TN9PNY^)QJ4"6W#<:4X$8
MNH^^@'<OC(A@W28I\2)XL4^MP*S0&< U70875;(,P[-(P[<0#UZX=HIB\Q*P
MT#H!N*\/A8-&#D07UW7X'@8H#K(A+J[/2BZN_53.Q>5<7,[%Y5Q<SL7E7%S.
MQ>5<7,[%Y5Q<SL7E7%S.Q>5<7,[%Y5Q<SL7E7%S.Q>5<7,[%-9E)OK:],HH0
MRG4!<,\>:H[O$P/1&'\?XL4&Q4.)Y0_D0<U!EOE?E"SSC7EGC8F=G=[9Z9V=
MWMGI3=CI3^C0!_O,]Y-<@,;:Z:U>@$[&&##63F_5&' B5K&Q5GJ+5K'3,0^/
M-M);- ^?CJMDM)'>IJOD9-R&8\WT5MV&)^-"'VNGM^I"/YEPDK%V>JOA)*<3
M6C763J\YMLK9Z8_?3N_>S]"9C*+G_8P33G>8./MD4+J#/?5'<;/(JD)J5P#W
M^1&?$(,HB!ZRKY@W*XSO^2V6MMC'G_L0[]BO2MZQ8LX9F72VG]6YQIQKS+G&
MG&O,B&OL1 S1HQUCL.]8S]N7+ Q"_$D_>Q&2T%+L]N:UE-RY7%9+L2FSB]!A
M-0_>&O]QF7IQ1EX;2V*NUI+I"$2+B82PA9,$61JT6O\,Q]9C[+8 -)>\/.TU
M&9L>6!<D9Q\Z.OO08YKX" 79+>9+7?IA\?J$ H36A";F[LD ><1X1V91&D&I
MZ<(G9-9^+?72!L8J/C]FH",V2<F2Z*R%QU$<Q9@BO48O>?G)DX-7O5;RK^5[
M%><,A2G1#T#(B8IBE* (*FR5SD;!79SAW9CLTLV'T>4P% \"('IE.*!B\B":
M@)\W1)F/M@'_IF0#+B=U1F!G!'9&8&<$=D9@9P1V1F!G!'9&X.%:K7^*XR@R
M=F, NFN &9A#D+,#.SNPLP,[.["S SL[L+,#PS YW>*-9ZS!Z?Q,R>!$IG3F
M)F=N<N8F9VZR86XZF1($HPU.P%.[G,7)69SL*[(CL#CU#G%L1<9L"D!Q#; V
M,<EQMB9G:W*V)F=K<K8F9VMRMB88MJ8_O!1OZ/G-#WQH#K-!U5_/SY5,3=6,
ML_V4SM#D#$W.T.0,328,3:=3XF_T^VSN!1C[55]AV_K<E?FTKLS=LY[$K;C?
M!<#W-?3BVR<&3CI))6S5$A?I4_BVRA^VA!U8!)&/KW<YUAA76.A1<+FKVF55
M0Q:4HT<]DLOQ9/1"O*)A6;D8%0IPH7 _P[^2^5P8@+N=N=N9NYVYU[/=Z]G'
M6^YX[/W,O9ZM\5QW'*6_3Z8,OGL]&P(*[O5L""BXU[/M8^!>SP8 @GL]&P(*
M[O5L""B<_.O9+G3;A6[;-SX=0^AV;?LFEG!.V#:M&0 CTY"0;1HI&CA[>=')
M=*SG?49^$@=DH?X*745)AO\M8[-^V#@ 3$\#L!E&JTGPEJLPK=<Q #-:=P#V
MJ2FAHI%H=:?YBCSB"R1>@+MXL\V7>"[.48#=W/Q)0,Y-+'D28!,&#A[N 8#7
M <;&+Y(X$2HZ*\1WIKOUPO1W+]KB;_Y;C&F*=D3;\J\TZF, ."F(Q>Q025Z9
M/E ?4)$2483A4R&4[P;@#"&'FCQ)H("J@[/4L:+V!'".& <7E2I0B!4K^SV)
MO#R,\,:KA!FC+P"_V#C4&'2!PNTIS/Z\31&ZBW.4HBQ_\G*U#XXW  "?VC@$
M><2!@O'FQP;Y.0J6*%TKZLM^1P!.N+'JLD\42+BNP_<P0''PZ.W(;X.08XP!
MP(LW#8@,^D#A>1?[J%@*"; ECQ0HJU'N" "<@>.PY%(W/9)9FC=0Q'\[((C_
M\L\G+WZCV3DZOYDW:LAE'PN,&ATJ['"7*ON]7^W:)*BBT.*@-0G]BMFQWM)W
M<LKO%HT(#,1K-G86:IZ1W@\^(]N_6[S7BQC97JAQ1N[#Q9]]%'MIF##T)Z.=
M>5TJ]Q*1A"YE4&0>@6KZ;W&&#T;A:XB/1C1CL*"M?9W+%:4]U]D4Z'!J;;,P
M1EEVE:Q?PKAXE+Y> ,>5)>YD63$+1>;@LQ+38O7 O3<T7^[N0^^EL*<47R['
M727H8UXER;VE)>FS$E ' ZUZ92'*JBM!L(B?2 8FJ5-TZ65A]BU.7C*4OA,Z
M2YL+<6C[N%<AA5WJN/XO _/"<*-)?0Y4:=''&0UJN<K,;:V9I8W9;0&XV(Q]
M$'N%SF:'QE#<*K9!"B]Q'P!.-O.XB=GBBH'\W,5 7 '%,15!0!10'!\BW'@Q
MM? RXA47_\;X#CGM ?C&53Y)#B5PX*'769VF+BV0:K0C"F4.I@\.P(H59FX\
M?]5NRX!\@G$!^-PUUNJA47RT8G&*Y9LF>"]<?_DFNP+1"N;:_[A?/^N5^(%C
M 8@#& V^F$K=M:TK]\M>"HM3R/PMQ?O7,GE&Y-K1/TE+= +@V9<^-4N0HQN&
M^1N>[LW+47UVP'=L%!97;G***,X)BU=\:,"'>!HB:OT!9/]*@Z-&F:'/I;^6
MY2I-MF^K,JMF'@1A.6LI2YQO2'DD"#G#JE^6,I'6M=Y0. >/:!36$1:D28B%
M<XYIW\0:5[3RC\1S07OA0;V[47Q'F)'4*3LJ,)^(R7HXF%5WHV!.8%N2ITRW
MXGW$YUT4Y]X;23A=H7BQS;/<BP.2754HAT4\SZH%$F5RE:S725PLN_!%%#O]
MH1)L4P-/-K11=,>^RS(9U=H?T6G[?7;=2%JJQ5[8QRA6(ZQ"DN3 T:7U570>
M!^5=M"%8 NB&#6$4R0F,.6K4Z?ZZ;D@>#YXD0X57=QX5G>F*DMW6* 8C;"H"
M,G0SNYPOR\*WF*C4ZK,NI0"+P^(E"M\*USCUIJ#2VR@@8\TH*H3!472-0(1]
M4,2AFCQ#M8DZ&<5MA(5%EA[=7]073-=]DN'#2KG8VFM&^W[8;8UZZL>:1MAD
MZ&;V'N%Y\*]MEI-=JJS^@K]6_)W6&UM#)F@P#!G%*$!CC1Q#" 3ZOL:'4>]K
M?%!^7^.#>U_#SOL:VY<,_;7%DGKSCO]/4/6(V?K8W]9@T66]/&5G5?R:A^SV
M,$*U!<(F0&2*X.JI,>'F-3/: HC!%DH6!PH0L;='_2R0G*W=/0MD75VY9X'<
MLT#N62#W+)![%L@]"^2>!8(03NV>!8(0P>R>!;(?2.R>!0(0+^R>!8(0&.R>
M!0(1XNN>!8+P+-"DCP&X9X'<LT#N\9I)'Q:"_W@-;2&+>,@[-H*1+ (X6GR'
MX=D@WC:BR^^\<FX#1[)HL[2$:(-XS>^N?6##16UFT7(Y'194RES5GY^[ZH^K
M3:#-X_.3UB9HEE^IUEGGV;/0YG<!X#8:6GZF3XSNZ-*]S#03L^N-X0;_W<^W
MK,P$^;X ?$C2@:3R5&G/P?J)2JF-3M:R7$I-(H&RG)QD](4YEI_G)!(F1E*[
M '!"#<IWI!(#<Q_:EP%+2RM#2:;$;L3J",!I-;HD6H<D2,B=8%6 $>E=KB@
ML*( $Z1\35@30%]22[&V%=;K>$$E38W\=?5<E@]GY]U<EN8,_SDKYRA27,@T
M54X+^!269W^%@NW>>EU=['FY*]P>4YQ3KKQ-F%<57YX0*1^-@MLDO=WFF._U
M#D!QPZEV!I.K(H'!_A"C0)^&(V1S]HPY/=7S-J"_70?<,%FD B4FU6Z(OE)
M@G0OVVZ=(<+:LFO9"QP\^;!^.?)<C+\YB^] 2%S OS[+[4!(7/2_/LOM0$A<
M*H ^L^Q 2%Q>@#Z3[$!(7)* MB2!08"XC %]MM.!B+CT 7TFT(&0Z#T!3U6-
MD7N5[[2Q';TW]N+>(4??(XS+Y'&;^BLO0Z4LW(;OTE^&\A  KNU46>H^KRA/
MD3E@GL,?(W%AC@#@ZCX(%B9!^E#)NFNX5 1%=@  =W<I3&3I,0G)A]&8,$8
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M88;8-,Q[7N$-?T )_?"1__7[&>V;'*@LY!D'3I)A6A='FG YI'8%D*98\FC
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MC='J2+&BZ83&J:7HL&*D6H\,UR_1>A<=$SIYKU]H0/&V"G%YMJB.#EOTA3E
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M^O; HPU3Z?L7;91WM=G.OLSP+DV/(V=ZCZ.V>B9,E78<#PRM](FV ZVJ9"&
MU5:R2T[UN(J]E_ J>JFK9F'6&S!*M;?":6$2@Z[ L:N#(CUWJ1B[$I:E.R_E
M]V)\Q@KYE-=9X.^D.,D81KDK#')5 O>2^C/$.2+&TL5]/S<&R4=(,3!&A$!V
M^HS]B[?YYM<CB;%V_[\+D2D#8I5-S''QE,+4X;%2G\%0<LLYHL<WE/$$!H[6
M36**D==GEG%6S,F-=?+!4HR1=4P>O.#HY'["G??&G"M9;?E!1'9I_#)*SM[N
M-NP"$SO;Z*MN)-6UA[NG9"1UY\$LB;/1S,FCO"0"9^!DKVE0C5?;+8[Y(XU#
MZ6=P?7%0#?,OR#1T@4,+:N)-2I[Q,MQ$>[SV7N^]E"K'[FT?J>GE8^116(5*
MK0C QJCVME 1R[PW7/SJH$/GTB49*R1X(<J,I>JR$S#VK4A //'*A)S$G<";
M$X-LL4^I!BBE%J'4AXG4V&,5X#0G8B@,J;@!XH^H^K)0^!!'SX35\H$S#90]
M<9Y>BX'Y0->$1RK#6ZEQ*V.VI3S%B:.3]9IGE%9DIS;5=%-N^#G(2Y$4!>6R
MG':".%.-:\_"-" 1W)4QLOF\?G8;!><_AS$UPE-(_H%]JN@%#O&65.XX5+>&
MC<<-6JH86]$4+FXV"=QUN*IT.:1EE)V@V2A:,D=\U&OITAES&+K#H1>D!"?S
MD!VF8VIIME,:'_'ILV=V*$[2J=M8R\#Q3<A-#AQ:*64=0&9JH)1+P!-9,QF0
M% (2UHQO-!6/6%X+X\!O,9/,3,QFATP<)[55Z!K8)\&1Q58/>'.,"9-D\2J*
M>UY3A[V,]H>C.#1<;1=>S#)U\PL6M6]HVZ(-&\:L6K!4]\4&8;C09E>]SGEW
MBA2H$ -E<HC[/HHD[+ FDZ6X&.7D/BM@2R:%)7')DINR)7%FR>)&WSL2RCH%
MWSA:;,*QYWN=0;TTC<GC49103B/TDCT.46VY<:82_^_').5':^MH[OM$O,[)
M7O]<AI?>@:1L:2Y/W+!O<D+>DR3PB<."O4KS10]Z@*<)&UIU]L&".?.T@CU_
M99<E;DH)9LH!/O9G(QSDF^"82].5C_I1+%^.IU9<WJU<P-,5I@+%V,\$J\.=
MJK:P :560Q4IM WA0D"]N-TO'PBJ*!^I[I)NAM&P-MNF1S9Q_DB)3/L[4:JJ
M#4SGJ=4H3_4];0 \D[=2W,['VFGQ&HAXV*BX^XWS-VMD2N:X*;K6=2W>X)$4
MQT^L'5VG45-DKZ/X'A^HQ794MM4V>_VM AN;>\$$EI9:ZW)E*[K G:E-!>^=
M,<LV40L.#(6&?//1.&EV%+WCDMXO ^K=(IEV,,WC:(.QGR OX* DEA#]WXWL
MGV!UNNOSF*2QMZG:"Z]I#AN^FO0LY3=5M(4+6(T2=YYPS[:(T9>,^+A/=PVN
MZH674%]D)UE\MY)Z:(A3]"Z(DN2;+$6FV-ZED$7_LJ>1""\'9&]5<DM#XIBU
MIE!TZ06;8U"U/ZOWU,Y$8/IO/YOD"Y_6%("OC+KKT[D(<R0>+R3BF<-GCP3C
M/U3H0.V,(Z(LD<(3K70':*[0T;5U?G01N]SB5"1#W%",GF<C<AU=<F!6"RER
M;*^84-I3@8F4/:VB!D M2<"-B[HJTMD?:,0@DXK>W?# (6?*XGW!]J0J*>?L
M))0:VSISL?:19^9GT963ZT0N1@A3^NSX6XTF)4=[0>45#J,]"?N&E=W(P(3+
MOG;)0\L.-( 'EWTTFG1XZ4)QA><$0DS'%NH29E9 XI(--2\06W#9$>.:C3F=
MWK6M 0-<LY8YCE4W!0Y7!H)W'GHDV=#9^B@V?$BXC>*]<$WO,3JFV7M$D60Z
M+EH-J+<DG6U0YR?P7SCY4]RQ[84W),3+%.]/C]+,>DS-&\^TK??(O/D4O?)<
M^*XCE%%"A)$J3O01C1^\<,,&KOP2K.:43-LEU&<1C[:_1>L=;5^T89/J,1%'
M,K[P>/90PB&*171>\OLDB2@'MCW\0M(=\B-6]1OM,7NB+!$QC. 640'I?+[W
MPC?DO6*>><=+@8\?UPS\+2K1@G\DSL-!J#*PTG>?+VZ6EVAU?;VX7][^Q>H!
M ']R3]2V%CF--*;Z'.HSE.J; P9# SW5[?NJML!AT$3RKD/POIS*=/;:)X>\
M8SAV)M.0*A=/0<K2[X(\7QTQ!DXVW4?0]O2+VH>;+ G!&'"J.DP <FIU/0,=
M;>N)P$Z][-:!)[_#XQAZAE&[<,>,/ASX&49C295]3NQM=OR+HG=>DE6[=7)!
MZS*@07BN\2J^)T^[-(?A_(+9I1<$K&CK@@I>;EMQ%&"#+DSPLVXY];"P-U&X
MQX?V5.OJ@%P"!7'8BI)35M\:5^[["E%8$6$FS%DO)\>,@*SX4M@C%E94@N;"
MBIO<BASU3GL!N-OKWJ;GL2F[=\>V2UB2G#09F.EA\4HG+)+@NYALE+Q>^6OR
ML8V9#6A-<!HPM5 C]#<1FAC<&ZLS ,1GO!%G7@H\LT9N+@JXL51NCD-FCE+-
M #\* B]6:C"  F>'UK&W67 =L4<*Q/EN\HGO>>L6)?IF,$&Q2:]\.T#3!O@F
M0)W$74?9>D<2>=J!^)N+XC*/9"5WY<9=] ^A9ED?]$60=7"*,;QR3EZC+<HU
M7!W9N<P=CDGD"X%N\0O_J>HFI7%GF(#3S0:EQVR->L*-LUK*W[W0;5'*! E&
M2'":H>Q)7,I-M' 31XUDB:PD2EUMI;&"HY%59G'0(<YJ9/#L6G%P?[>\6V0)
M W1@."XZ56&5G[S@B#OBX5G?2<*AW@(&:%CN.#DPK!!_""SDK*!"H64[S"F9
M_2&[@G *#!0#Z$@-68EVVH##!#O?NC@F),1TD7X9[1]9(NKY8QB.T=.RE53P
M['J]M?\^7G$#XXH\$Q_3M8:8):J6W74=8(-?LZZE;;?*UG!ASD#FSAMHRJTJ
ME!.?Z9<W(^V/#:>MN /@2ZKVMG;F3T\Q?O)27$YH6;V$9U7=3=K#]#=C3?-=
MG[K&P+=_C$3OO@^D23B+&&EV;,9FS:W894B0MZ7^PO]$]@=OPXMML7^).3<;
MR>/N&0UJFYQX=D:[RM/5.(/Q=Y%&4E<_((9*C7TX/OZ=AFKKZ#J*MYBDQUA[
M=<>D$V"T,M:Y(EE6TP,X;IG+/P)X)8(]2][?Y@(@(A",MWF)"<.WZ)F]I11$
MO% MBL0:@R0HC%*$Y=$,OQ? .A[BZ!"Q?SN]0#2\H<_P3S)!ZP@5;%PG[0ZA
MN=17.WR& L3;Z"8*GW#<"1CK.T\&( UL4 &4-3TG!9@F>EA+^I&A''L.@=US
M2G=>BEXP1<@P0@$70^\"+H%N! ,5@'<;(<$-)O0-:0MI@8:18 \,[W&2QH3O
MW26K<!U[84)G5;%!MMJNR1[/V4HDV\U3-O/8.Q@!KG(O2W0!0ZA-R^7H:H,H
M<."UJF*?8/; 67(TIDSEBGN3\V _>.@QV\;>%'(@7YP%O.S(1FQV9\">YW"B
MO??&H]A'C%*I8HQ'7J^#L+0J!%J%*!-#GJ0PU&>2("Z*]M0 %=*,C_SP;$@-
MDHTH_1#6#ME-E0U[S!V9->9)0I["5?R @V >OLEMDCC+UN,&*JRQVLI+QAJ;
M\<U?GNRWCLG3DSY1;ARV@&>>$>V>3TPC\ 0^;XUI@3[3FBBU*_)94^J_"2N,
M)A89^V/"9R1OLR/X659<B%E6&W]*C+TUQF:SN(";$MH4*Q@Y 7IY4[8K([!(
M8)!^XAQW^IO$!Y,RSI"0$JWHFH?*B:B@^?9W7&2PBUFRD)9-GUDE"=W<F;U-
M)7+AI=3CSZ)3^!3"4-)O!$U>?23_0I[X0C3(2]@78DOWL[CO='$_4PYRRJ$E
M/]J17TX[8QMEYX.:O=<9VE#2/L6'*^]-6XUH-,Z_J3F\SOH#3N,ZMK^YF;S6
M")WOD>\P>U:)"K$GK$B@!)%0O.7';Q!HIF:6@,6JK*F3>-V</#NI1N!3T5E<
M<+*XE<#((PC\RI[E$+\=\(9L"?V7>!-JZC/\(!]R^$D^%QM)N1$3_&N8YX?Y
M($58+,W%1[WJ4:7IW@NPNGU?S/;=I_=)S..74<@N>+-'B-U-Z95"_#9G]_IO
M,L9$KY?@MSOG-]AC6M/_IE"F#(Y9K<?H,<&QW"A0(H.O9N(?Z&N.&0,H*GR]
M\<!0WRFW8J4G3#1,R!039Q=5IQ;+\&<6^#]D<;UBVY\IM)"0?;[S'P51EL&-
MV94Y[5@860#(X8&+;U&$!F-RAQX6.+&%]5/KBG-JL887:_; .R08/6**7CR,
M2(C/7J%2<$A=YS?%&2-/]Q/[2MD4(H^X:XZVER'B,J-<KM*,C83<(DC0M<A8
MY-([F.,G^G%*YU5L_&M=J+03]OV'<B3P(KX..PGXH?131GQ3\5EZ)6P%K)#Z
MG1>G;S<1]<OJBC+530'/C0WZ*9E2VG; YYLFJ2U7F(D%.W1@_%# &(Z=@C2,
MOI(NXH01I^RPWLR(6EJ\N^BS?07VW!!;XCP<#^SIAOE3C#$;P=6H8M@/,,2T
MT;RXTVC0"3CXM%+!,A*5>2/)'.7<1[[).(8EFE1V"%A.],?Q,V'E='(^]K#L
MYRC^A89>E]Z!L*<K&5#*O:5J'#/H QC#3#7.\:NI W#L,A;?,FZ]"+YH(QB+
M&"K;V!L7M 8W@62 ) <95F455H=$JYHB+N.JKOW,U@JY)'&J%'&A_RH*N-!_
M_.V>RH[GK^1T^_3T-YBPI-6 P4_I!WC%5O3B=<\BI!"6I&1#!]$G[+%7$,5<
MSZB/.],[5&Q8%]'.Z>>_ G>3\WGZY"? KF()=2O'U!5_(-"1N[A1;C"7^>2]
MDOUQ7^DTI[_#=1NM)IGCE'Z$Z3IZ$;N.+TG-S2IR,'5<%,V[\ )6N.]AAW%Z
MPSC0-8@F##-H#M-W3/54R^55M87G6<82=QV9DC#BE%%&VG;@TW.\BDFEA6GR
M#M,;LV5=FT:M:#VM<7LBL^V1VST"J3I+V&SB(_87KP<<)G6/7%0UA#D(FW4K
MC@=TK8#OJ=7+W/W0JO3.I?H.^ ''J2>362,DV2,L^8]\!#"(\J<Z#7/NS],J
M/9[<F\E_30>L\F>>4Z%VN</QIRA,=TW'E_U( W9CR_;3YB'TH L<*FQKV2<#
MCG[I-*:,CG1AO6=4@S=Y^XRARB-&!X_X?/,^D4=NB3QZ<I?[X-)FY2P"A25[
M*TW(@IBCJ#^)W"94[LH>[.4BN<VP<&G+W&#L1O9>8XL>""]7P/QTXS(*G^ED
M21X#O S3*$N4UYG&K!M@9&ZA=XZZ!GV (VH;#?J@Y5YN$TF$%,F,'CI$*96.
MR*,NBJG'P$<[[YE5_^#XF>[BZ/BT$R^4AN6W\<;%T3$LE5E)''DJ7!!CDU_+
M&1_XQE#^1HP 1CSA]\7R#!6'+])F*<3SS:]'DI"F/;G*UC"!SU#+TMZ&OBG@
MC8T&@3OO:F1YV@IAE[MQ&C79?U(?JM^4,^@WO<&KU;QI&)<Z36M ZT6W.;1G
M*&,RP,;=.B:)%QQK=NS.6L <DS7:*'?BU9^!QX<5PEI.;Z-<'AB7L:]OV]5-
M*N$PH78@C4;+$2!A?8[ R>\P,:!2DSQ'0/T1WCQ3+6+G0W5!S6&.P!#J6-QR
M2;T-?WA>>7NL>BJL;0W3)0RU+/95*IL"GRX-!+<\=7Y:SR_1AK%$'K_H25<A
M_'6ND7='AE.<:\AIHSDJ/1CH;J)UH:[%0SSOC5+U_]W;XR2_!E-W@[>^/6#,
M,=&T.$.K:0P<=XQ$[[-_6WU^+EDCSKNX537V*=>0!JA2T>5=7Q?Z6C]DRAZT
MN<)[-J%=1_$]?I)W]5@!I@>\.<8D)?I2/EV( ,:JSC8Y/8XRIP <U;KK8REK
M*#N/4>K2"AED68-""EZ3)I?#R<G4B&;*DKZ+)[,D4_8\%E+9\N>T<L;.#JX<
MV*;MF+$'KE=8///S.7OBDL[4UQ@GGP_L.9@P.>[W4FU-@1R=$?L2! RZ5FR5
M W O:L#!V(YN?6)0F3M O8:ZE!"F>,:51:-;*@XZ'O@[0X5 K(/[9T#<FB_C
MCE3VB/%'3 "D2L @6U<E;'SP!F*S'F/,'JC?X"<OH,I3O9D<U%,[PWEW4H"!
MO*=]<@CO2 <X>/?5R@YL!TP*YD$R_XLD/(M6" 05N%V9CO-E$(T*SI#!VJV=
M&"S; ]ME^(P3_AK\W'\F212_V4%>2W0!P[!-R^68;(,H<("VJF)75RJ$0)D4
MH "H$J/_VWJ]X1N:";W,A':1/9NEDCK5/N'X"<?L]L;#\3$A/O'BBBWH?N0
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MUK5#>*1Y*9<FJ]^6Y<@P72]XPOX#YH<:MU'*M\<+VZTC:;N_\GK7VCG),GW
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M8(YUCP_42#LJR_R)+L;8E'"JIS9&;-L7K@NVMD#FE\8=83IK>_$MCG$7+P4
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MRN,,24JXZF+-D^F2_YHG3D][_7"2ZG:B(T_)[B@.04A/5\&3Z&<G)?@35O(
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M_3XC*?63-(#R&0GH<TZ",..7P4  5,K#/5<:9MG18V3$5UN\/6P:_R&J>4'
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M?!9PG[VV^<PT]5[B+Z?L\/I<&+_<>*?6M?U)TI9&Q*.\U,_'2J*62,OC@,W
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MA:P^,3?I<%6CWB*IZA*Y E/5E19+5"T0YHE84(2$IJQB1DE2!CU0<E3+]YU
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MGZ(D:3W6J%1KJ0S<0*W&LKS*DIFT"6#&P.>*\)#A\G%/X#,SX,M\S7V'!-@
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M? UTW>5,GZ3ILNTQBDZ$9^=AKI=OYI& ,L![-@\-X++#(:4^A<>">;>ZJ#7
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MT?FA<:&!QF>_>\3G/>8UOF_==!<<%F= YG 0FQ\^)TMRD<&+2=68*'M*UD'
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M99B=OH8"]'EXH'9X3'1?&L@KXX]5XLA)7^N;&.7]41H<,?7KV0$$^U>J'_T
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M&XQ#_J#"9\$@YJSD*P!(&2L]]S1"(6)#1\(@+=MH$4C5RA'P1QN+._J@LN?
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M+<(E#D.X=+VM$-^<0U %%JA4 35T:);D6GBA(,^&X\W07;%MD*^>:$R>.,<
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M2I$+5 H%08 VC5(VA'#1LH#XW_^UUHXLN/_^'_]0_J:H_A__'U!+ P04
M" #UK(Y7)&/9('W[  !Q-10 %0   '1L<VDM,C R,S V,S!?<')E+GAM;.R]
M:W/C.+8M^/U&S'_0U'PX?2(FN_Q*9V;'Z7M#EN4JS;$M74E9=<[]TD&3D(0N
MBE3Q8:?[UP_ AT2*! B H !0GCNGRVD#(-=>BQNOC8W_^%\_MN[@%00A]+V_
M_W3YUXN?!L"S?0=ZZ[__%$>K3U]_^E__\__Z'__Q?W_Z]%]W\\>!X]OQ%GC1
MP Z %0%G\ :CS6#I[W:6-W@"00!==W 70&<-!H/+B[]^_NO%7[\./GWZGTD3
M=U:(JOC>(&GKZJ^7^1]&66N^][?!Y=7/EY]_OKJXNAY<_>WBYF\75X/A4U[P
M";W:"C:6=*'WQ]_P_[R@)PX01B_\VX\0_OVG313M_O;SSV]O;W]]N_ZK'ZQ1
M]8O+G__KZ7%A;\#6^@2],+(\&_PT0.7_%B:_?/1M*TH,5*C^XR5P\P:N?]X_
MBU@"_^M37NP3_M6GRZM/UY=__1$Z/V6OB/_,\)"\./XKI)0O8$G+5]K/;'#Y
M[=NWGY.__O0__\=@\!^![X(Y6 V27_TM>M^!O_\4PNW.Q4TEO]L$8/7WGR(W
MA)^P_2]NKR\PD/_G/M-'_M^AYXR]"$;O$V_E!]O$C#\-</O?YY/]JT0!#"TW
M#EVX J$-_VK[VY]QF9_9FDO0,=GMYY;P%A&2*7Z1D>\YP$-J1C^$O@L=+-\[
MR\7F7FP B$(.E%RM:@EV9@6HW 9$T+;<;I ?/4(7,^S_&DY7TQT($DG*(Y_4
MO([P1QO+6X-PXBTBW_YCX[L.ZE?NP0K:,.K$(/0':FDB*]P\N/Y;-P(IM'XZ
M\/<PM%T_C -PC]X[@#NL4"368&UY\%^)7I'7OHM#Z($P%/I$Q!^AP@R+>+NU
M@O?I:@'7'AJLV!;JMVS;CU''Y:UGB#@; C'XK$VK@#V+7]#CIZL5"-"[",$[
M;D()C "^HB]JYEIV\EF) :DTH@+*'+C80Z".,WI?!I876K;XET=N3 6TD;_=
MPBAQ>^C+1_X0ZQ]-7$0_+&I[2IQ(JRZTH1T5@'ZW J2:Z!%:+]"%D2A1=<VH
M@#-!D^0M6%H_A% 4:JMX^0<+!K^A5P1/P,+_3G0O!(30DIIN]R4$?\;H!<:O
MPGBJC>@[@CC!2$+MB(+M'9?6B]NI$?('*'4S+5!6VM#&Y;0 16U/_\G//8@L
MZ)YB#K1_DOY&>81_QM"!T?OIK%-]I+Z.KHU5.)^@KQ%&KA6&>+3NIXL^J,/^
M)["CI3_SPQ"^X-=PP#:A'[V0B_X$G(E76DB< ]M'(WL7.-U;M)O7U9@>R[5C
MUTJ_OCLKA#;Z[.ZA&R-<SR!Z1*C3[F@&@H)93D!$RQ=3OZ+2QD:$EG187VD%
MB]263JLM#TB):/:]V%A!.Q_.]P"=3- %:J5 *<M%;;"R-*O)8M0,50)!@/<?
MVOIOYL8U@2ZKWV)K68^UNC9 *:TIG5+?9R)#/P[#$(VTVH!D:%4IV/T/L\!_
MA3C:1PI:2K-*X>:#9IB-^![0,#NPW )+$L S/T2;!9<VL.D-:@,Q_>A0]UGP
M-\N-%0V#O)@SC/8UIVC:9<<!'A7C28%\ TEZ'6W,^X0&)6!D!:Z_@-ML0O7@
M!\<C\<SGR[>GZ/.U,> ^9N41O +W^D#]2FZO*^_A.FSFM%L@(+2E2X!0:;FG
MH[A!7>&6HOHZPG[\#%T,41_;UW7LH*8&*$Z'QG_&R9)\=Y&#E*?I:)Q]8%_'
M<8.*O/VS%:'_G:[R_1DA-U]M1-]E\BY7NA4!S\T^\K<OT...\Z>WHV3TAIZ.
M9G=X/A=&0=PB1J:V(27+EN@[Q_^'/=ZKY6;KC'. 7@OBG2?\-[&%2Z:&U:P(
MX#&?'[P+3O7WM56\//JX@Q@X;6/FZII1LVJ>+6A'8ROP_'@_VQ CA]:<PE73
M5HNDJM?-VH88*0L^+^T8"&XFEIM0,A!*=Z)GV6Z>V#CHN TEPR#\Z.2T)^K'
M=VCP*3X@(#6E))[IW;->K1^S.+ W2=,B 4K';6BV@2E]ZU+KD?@I1N2*1^9U
MX\\VD9>4YG0=U+: R].\T@%NJPCAHS;T&.RV0$1N3*^!;QMA-C:J<A#< MAQ
M$^K'DRW U#>DP=BR!29"2_J,,]L<":$VJ,/B:)NM,&);BAR^Q AWS:+9:Y8Q
M6\&CMJ?+J/(9>^X(OH)6&]=,#>L">3\#V&^M%S;5IW&$$_#@9$I9IX:&CCB(
MU=X 6=O\7;^3KD/Z5G&V/.TK'=2WBU,[;D2/87U++T]J3:^!O117R-.\7O#K
MAU%#[&_6R:[S7:'(S'I/<GN]68&S]U3#,(S3@U'A^,<N.1CUFX_CO7#S<ROJ
MR+"G?'&5\S.<[<Z)W4/D5UCH&"1$>S,^0*4)I'RBY,84[^-(B7!6[%[+DV<I
M?#4UJ1[F8?3FHPX\B/ I47FG;82?I=XPQ'><^ZZ[\@/LA>69ANMIZHVS9W*_
M>N;G.TRGU)'(T\TT7B>BD_4BZDTJ_?@)3_,:+*\>AC]#--1T\$%SU,TL\.F.
MUI,@T4=I8!8I?7ACF_JL1+<ZMT!O43N0':!4E;:F'*+1*AT-H2DU4>92,U7K
ME:"ZN[S4&J>C[B8+M:;)IQL/<K0[,,+>O$;PV^:3UB>--/M;2?VF69Z@PZZO
MG/U>K4/QNCT5H]&>H;R=/HWWY[K;F5.])]=R-T[1ZS_ZWOH139*<-".!$(9*
M&WIL*,K:2E2_:-]ZN5Z/"9.4J9(J*.!%+--Z6E'1-FR^-/CL1^+AI$>-*(8B
MX4@/I375N<320^>M$X?ES6BPM"=E+4]5YPB$O59>5;=3//*/\2@"^02"-0B&
MZP"DF7U@M'D"3@3LS=!&Z@\A7I08^<'.#\0/F?$_1-]YU$GF4SK.J](H;=FG
MFC2>8[4!S-6^!@>;I)QLTF/NU>)X J$E/>9A;8BBM*9X3B;CY@VUQ\_PS*0%
MBF)UK>8$[0[/T=O48W[0YB 3L3$-Y@IM/ 6I*77SAC;^O-2 #AL-K3;SR8WI
M.UQN%[W ^0A=ALJRCQQI=RY+H^-89W *J_-C6*KG(*UPUK2BP2QD%O@[- 1Z
M1R;'!.RP5E%'%+M6T.8+$'B*IL:0$JLH]!P-##+QD'M:X_%Q^[L16)O6$/9P
MZZ-90GJ!'#[-Y;6+!FSQ-#VF^*W\(*TYQ9/\_3AN_[O,_N$=\, *1N%#X&_3
M]? 8==IR;G*4^P**3;B_ >3!#XYOPL!15C'N =L>W&SU/-4:.TP19O@[1]Q-
M5_EU,?MR=1=&R-)8^Q=0;$(T]\^$C_RH'X8CU'6^9X=?9%F)[1F*#3%TG&1+
M"FL>O=NV]6$#YK8U""]IU0D1VU*U,CO;[1Y]JQ5Y=<TH6V@&P58&GDH[.D36
MM,PY4-^65FOJDA!J=-23^%9#&TVZ8/0^\4YK#9[G:F4P63E-6%O7"GSZA[87
MY_$TKQ7\WWP\'IK#]:;=6@#? [0RP3WZ:AW@M1MH<K2N%?A'^&>,3\P@@:9_
M )XMK3_D>I169GFRT# 25;K,%O[;Y<X1>8Q6YECL\-6%W=N#]ARM#/)@N6[W
MYB _12MC9#M=XQ\@L&'8D?<@/D0K4Z#R5]UJHOX)NAGANG,CU#Q!C]B>D?QK
MQ,D-ZP$Y^<TTR8V73X+D0J<]0 \3Y'YI%D ;QP&DB0(+X0!X9S M@X."Y)I'
M].%ZF Z'3J39& \9%N7:A_H$/8P@?>&7]Q$:1 ]*S!VD$RSIU'*UKRY\$N?]
M\;TT!4,R_Y^NOH?9COABXP?I4C N6MB1POM3OK?>_RF4M%W6]2OI8>;D-^4(
M UGFJF]:6]C=H58)^B'&<;A/T(/;.!5CEJJX70 '>^,:0^\2N7;'0-O%9[*T
M:\*1T#;,"S^+US )]MPZQR]Z7/U;^IH>6.,D1H_6"W#+YJNKYP9!J=HGW-"G
MRZM/E[>)@>M:*Q/4^DU1YXCZ3*FO6VU2]CO[D>5*?N=*DW7OO M B"27R.H1
M%<J*XO89%.S;2?AY_E\\M4,?,-YVW _^R@\'/R+@.<#9_Q9&^$&7Z/^[0"@N
M!I\&>6/%']',<9"V/"@WS:I_C!4SY-NEUT'_MB(_J-H\1,TE387 _NO:?_W9
M ?!G["GP#XG+2$R-_O&/D?^*OMV7, HL.\I;<K'=__[3T=]^[O U<ELM48M'
M;W'\YW_<7G^]_HIJWUY??_UZ<WMS]>7P;D5!#(/R>UJ!G3>-?BQII&K[K,3/
MNR31V2=[ ]T][:O WU:LDSW)9WQA/T#3222=GP9QB-[#WZ7SCFZMG(IP#M80
MOS6.J][66;NNF!%69W[QS/I7"JS_ %T0C)"+6Z>7IM<;OU3*(-LWOW=F^FL%
MIE]L+=?-#]X135\J99#IF]\[,_V- M./MVB0B,;&OP3^6[3!\T++(ZN_MK1!
M5+"_?T;)9Q64_,"GZ=+1^0P$T'?(?%2*FD0&V\MG3-PJ8&*$P"6Q^0[X\9^
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M@Q_,P2X.[(T5@NFJD)"1I)K&BN>C'#%3M,T-H$'L#;M)6\][ST9-+4TB*>V
MNC45#![_'T[,\&JY^,.: V1!:"?>.-P,/:?\BT+)69(MH1H'8+LQOI=P_,-.
M[NV:HR]FO%H!XGK,:5]"-VT+K^5H8#;CUQ1;V; +.7^HDV@%20- U6DL-9<<
MHO/JZ]E++K-"/S)*Q;N=FQC4<O,<+A-OY0?;E%7Z9@EC[=Z(J U>6<-!E7&S
MA[ASZ*#1,3DF]JB@=@)HP6-5%8QXN]HSZ2(%V3T,;=</XP"-_D([@,F[3E?3
M8&UY\%^ID3PGS]V:!5WZ'GL>LLL+]/\&GP:'!^%_C!>C^62VG$R?<<JQZ?R7
MX?/D_PR3?P^?[P=WWQ>3Y_%B,9C.QO/DU]HF(RM:ZI"]+37;K,#,=)5-)W&B
MW#RQ&\'K2FKSU!W,2P@=: 7OTRP]XQ.(-GZ6"QB !>IALXO![MZKA?-BU.1H
M$A^ABZ>2JI]R%]:QL<R[>5B/'JEC6@Y*8+7&&:1R4\<[*PEEVAJ1G%,J-[7D
M-5)QM/_)C<OX$)N#ERHXK\>FM&[42F5#?;Z]N?Y\+EZ[A8%4A^"TW]RR(C1!
M0-./RCSC>!.K4E!?Q3#35[,QQ0:SNQQAW4XY%_%VB[^2U0*N/;B"MN7EP?+0
M6\_04-@N[&,R3#6OJE/-Q?>GI^'\O_$T<S'YY7GR,!D-GY>#X6@T_?Z\G#S_
M,IA-'R>CR5C;&6;5(H1I(ZW@B7L$>P.<&,M^B-['@6X<P5>P '8<)-NHXQ]X
MAPDX:>#'=A?G<YS\(M(9"))L[]39H-2'Z.(_FMDN=1+=V\#$:9X&[K][8C@F
M>G+["9TG>NJ89R6!=:*GGK.33_34DM=(A?!$3RZ5ZH;G+5U9TY105O.ZB$I)
M7W 28_8@@>N=%<)PNBHNL>.D2+2)R!+-/>Y<<GQNFR9UTVRG\JFJ5;KIS-R#
MG<4O"-QTA=X0(>68^%Y7)[ZS[W=H7HOFO0_C.9KF=C2[)8P1)A[2B^66\1"F
MK0UE#;ND2=VGRV1SUEN:U(\^3SMCO-4GQE+*C.]6^8T_IYKQJ6..E036&9]Z
MSDX^XU-+7B,5PC,^N53VX)8FP_PK)RSU\R&><1AI'L-00UM2Z?P<?<<"& V=
M3P3P%1EHYEHV*-XRSS"CN*F94<PGOPV7X\'L<3A*[HL][9SB& QA.D$N]A$/
MR1R5H.[+;F+Y-"&.35_]QTQ&2;!,[8#Z8QZDP5#Z8Q[T,0_J\SRHZQ#'L_+:
M+0RD[4SK>-Q"G601"^LK"F:&CGP%'U0SIUG%G&?+P/)"R^8])/>Y.MV:CQ_1
M;.M^,!O.E_\]6,Z'SXOA2.NS<"0[$&9JS<5512V2WNSNO?07IN!$CK;*G\27
MVYLK-3M)K#S61R*V!6SBI$L=5_+MSS&[:F*L/[,K=02SDL ZNU+/V<EG5VK)
M:Z1">'8EETIULRN"QVJ:7S55TT4$7;KH5K8P_KP8R8Z'<713S!Y'"[K)28AR
M9N4P6\#,*1O.% K3.Z.'GH.3ST)O#3S.\V:WU5G;:/KT-%GBW;%%DLID-$U.
MF8V?=3YB1K'& 1QA%L=9][0.8AIM0%!X0]J4K;:L+A^]$$/%SYP=W<?\2\0;
ML]OW8WY5,Q3^JF^"#L[YU=?S2]"AEKQ&*H3G5W*I5#=,/O9-31,K8GE=:&_C
M=,5 &C]58AI -,V6^!K172UTQJN*D8#>V$P=>-]OX[OH[<-[L((VY(DE_%*3
MEF,Y'?WGK]/'^_%\\6^#^_'#9#3I*IY00A3T 7VZVXWOLR',AYH*J]K3RG;N
M1ZX54J=!E!JZ?-!L?-3O3K&!,G$.I-[!\EJ98R:D?E3],1.JI^UC)J0->1\S
MH<91,'9(C.%[M65UH;N]R^6':?P<J'[<P#[]8:ZOFTK8.:X9.K4";>;NT.]6
M$%CX4)GU MW296H,LYVOU=G.[\/Y'&<=?)P,[R:/DV5W6T&$'B\#1(K$J_Y9
MB5O.7F,:S.%Z0\W 0*Y05N$WI,(K)9\>R>(UKI<5A3F#WY8S&76L"3+#,9$Q
MCDOAB8PZ%EE)8)W(J.?LY!,9M>0U4B$\D9%+I?*)3-E!,<YH")5T$4!K']P"
MKK;'B^Y!<HX&OM:,39LG,")-&"$'.IM'7D*& <R<S^PO+N.8QGRK3F,FSZ/I
MTWBP'/Z7KCLU>Z"-86O4DG)2KV0/J)O'U)30Y7MC,&$AD4HC G,&NL9.6EBI
M^)BE?,Q2>C5+N;Q D+_T;Y:2XU(]2VGJV4CS#4(I7;CC]Y<\@(S?):D9 #1M
MC-"JZ,DZG</J7)(;H:F17@\6#'Y#9< 3L/"_DW W]FG#Y45UVO PG,P'OPT?
MOX\'3^/AXOL\21ZG[6&8O04.($C[)O2BI_UL]^]2F-5F'#I3;XYSN.,TATFF
M]>^>_Q*"X!6[OHFWBR/T9]^S4:U$/K2=%]F/T<4]L+!>= @GL8,YX^]VDR>%
MO)^43_89F'D*$)V!*1[$LY# . /3@+./&1B).3-G8#J-"IIVE[IXE"YB4]1+
MG-RTQD]>ZX9Q3;-7:IT>*Y!W#LQO)U,GP3CM(?@S1BV-7SGGOY=U5Q#?+<;_
M^SN:\P[&O^D\\SV&33KA1"QV^J2LA?=HRI1^7+2LV$ME&02:K'Z<,94)ASGS
MAI8S1W6\<7/",?LSCD7AV9\Z_EA)8)W]J>?LY+,_M>0U4B$\^Y-+I=JTY077
MU#2#(Q77A?06'E<(HO&SH>.A1>,!)U)YS15 I[%1!0TXS8SY6\3;+<[/OZ+>
MHIO_EWF&@VQS<56=X3P]#>?_/9@^#!:37YXG#Y,1/NXT'(VFWY/T=X/9]'&"
M,^ -_I(_\=]UG055C428!]$*FG5KK<(ONMG:C%?6:C#^.KN93S,;'W.>CSG/
MQYSG8\ZCH"]LG.W0[PZ]O%*^UL_E7SEA29K;M':S(A0GFQO3U='0X3W]WZ8Y
M#EME;:5 9[4JAQ9PC7<%(]\+$4XG(8I-';0JO=$$-TC5"R&$3GZ\!<$:2?J7
MP'^+-B-_N[.\!B_ 7,]XLMLAS1B_-O;;_QZ"Z6H<1G"+[$8: I0+&4\Y!ZR,
MWQMC^1U9X09G847_P5F)7BT7+^0Q.GF6NKU1@SC:3"2?M3L-/PQ#$(6_ M>9
M>,L@#O.%399Q('\#QBM!$N1,#K>:C0*68+OS RMX3[.3,6N I5X_J!=&FC'^
MQ=A>XCY[S='&"M: L7N@5S)>$BU@9GKXJID'J*;S8/C\&RL93W0+F!G1WXS]
M\/?G-=D^>5)QXS4@!#!?^+DPEOZQ%7AHVAO.0+! [@VPJ:"A5ME6U_ILO_&*
M001GK@FC5P-M9*P@H6@.PS]&Z)UAA'\B+P:2:O1&"[P8<QTH3)$F[Y#(=/4
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M'OPS9ER;/LFS/Q2O@;TEN6LMSEQ*Z%%9OPN)C_KX#$YO7DGKK"<_\W6/_A#
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MK+O4E-:->46K+JR6D70IE9*,2#4XZ>LSI/(Z:H:50";Z13IO\P1 [?EKRQI
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MLE-R1",O-DU7J?*4H?F<*,'_['OX>"BH=\P-58QG5@2?ZO6GYN]U&FWPM*0
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M8.C ;R!-TZ=E\2SX5DGOC^R(<FUD7&W!,M(KA/2S)E)@YN7(6[##5-T[M ^
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MUX7C4PRON6P@Z>RDDA%V'5#J()M<03=]<''()@&C1MM#VPYBX(Q_[( 7TBY
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M]1=>7*IW"=K'%F2Y]PJ0:6$G]:7+IL&)_[X:YW!%($I:NE<35%*#$_\8 'H
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M1O6%=1.(='ZK$N(PA/%]V0/T+.2S\?8(LFN,ERHH'1FAM&X:4=2+\5A'TN:
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MY/FX6"](9@)EO L?.@Y,WWEF06?BC:P=C#" ^I7[^M*]X)L'F_$^?(XOKO:
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M@UDUS"WU03KMP'856G.B!'R<W<9MM=O8-Z5]KV!D/KZ#3O<O-4*C(?039T]
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MU@YDODM;[4^J0T)[&-W8DMK ILR[[\2I]J-#L<-X'_Z$G1;*M0V\:H-8PA"
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M(H(!8(T/PVC"OO$_? ^$'G(20MPNXN^=K=OH+VJ)0@9#-GXWKA]Y4N2<W:;
MNU]ONGE'1:IH&O%8N5]E%-UP0%?MCF4:5N"4*UI#5MS=?5_%>H\^N&"+6B*$
MP9!5.T^8!%!#@D;.+4(TA4IOLB(-]9T?)VG^&[HL."NT5RPR#*%IQ@D!H"_
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MT(T!NJ48?T&XE(IM$M)X!JEBZ71S_O*L'@6E)5ROI<J2:X]*6":'^]8=7\_
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M.2CY*VJVC4ME;9^%N=9@+@.I\6D*!T[GU!$NF4BNZ9XMY#=6V6@9'+I^ !K
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MT[#QCTW;I-O?06N[V.=U::0T^]>;)Q\8,]MA?BL#3^OK"2#:UJ%EBWL 20(
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M,ILT+;! 5=W/#U9$M529AUZ^R$D669JD3NCYX3O::L"(@E;,+ET(H94T4'R
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M=D)AUA#7SL9/RYS:SP!=#PJ\NRB^RU+8VJIY44_L#E]A76@6):^UM!B&6[^
MC3J>! NH-UR'N[PN4I! )$$50E8P.9,#7TPH8REMM2)$;\]FAP!\3<>1B4]_
M:S"&B'QNJ\<8@OQP%-Q")0@AUW8[:^)SX58I00CYX9"XA4H00JX^VD:/$^-6
M*4$(^>'X>&F/DXNS;VIS!LM3@A#RPUERVW0@!/QPL-Q"(0@A/YPRMU )0LC5
M'SF7=?L4T=W8>$87"8SE7*2#U?3X3?GAK]%3%KLK)P&%LN_\#^9>@+,*7:3
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M\+P2 *EF%G<>/^\%[T,7&L7_  C(R='QY3R9K_-) >%8/E-)7<DE,-6*G1R
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M&IGN\+4?"4DE?YJ#['80ZZ:U=OR;_ 902P,$%     @ ]:R.5WF%DXFU!0
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M[&*F7K9T:KRRWG8^VBUW1T_RH,1]P^1V_WHUY2'14FD;!BPP'93 <S1(-T%
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M;N^;"5^/\3E 7I 5X8]01" Z7<&I&08BEEOR-KV,P8)$0WE[3*5(<\R4#:!
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M@'?'W-.TI'=@=-04E+10NV4_B59'!?TI30K%7(Y05[!$HRQ:M#X@&VM-M&5
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M%R"<FMN:;GQ7T&:#T6PPFC4$'C88S0:CV6 T&XQF@]%L (5WQF@V(,T&I-F
M-/\9*)8::4\#TGP18FY FL]:8@U(\UF(R8(T8>)[V>*I\=KZ_B#-&J[);EB
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M*WCT5%I0S;^"R7RGT_G_ 5!+ P04    " #UK(Y7]\Z:<2!("@ =#6P %0
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MI59=B%T+."S?J@C_ 5=WO_\&6R_VLV_@X3&AN ^(B_8>'-J0?2A=3%G &PV
MG*0L7ESZ=65Q.&_DLU:C8\2JY1DZJX:>Y9E/&8K&3!:J]7X%5A.AU^\%(NW
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M?MY<E!OD+^Z2=VW)>[N+['O3T4NJDR'(D*:&$3=\;?M+>UO#-2U,#)U=;4:
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M/JM"0$<H^JP1GM]==,/'R\W_N^M>[L#Z\F0(G%L&Q5&M,)+1=I.IRWJW'8G
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MYHSLS3=P4%]UY\*06*]9956:]\2J'4<-X*P?@#A BA!,G(:#S:5G;D^@'G!
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MIMH /)"] 05=+=>;9$8EF'!2T<*CLK!(H8%390^KK;^03KB*QL^15_"HA0#
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M<OR2P%=SU>>3_K[*UF4SHEG%UG(E$D#0<1TM1#3M)8(?[7'?RM9>.$RAZ0G
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MI)\(;MG;F7GO5.Q5$P^&B_+-\NQ^L-$CT2+)6]F*F#73K?8H7X\3Q<"*IR>
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M5K[F#,(4[CFB[^C>QT9J$8M7*PF:R4K-Z*A/FSQ5"IRU=HM;_8&$=P@\7W5
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MC\<F4865/9A)VK_;7[M 6:255G*P5%=(>(*B Z'32H3UP,HL[WQ<#A],R+<
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M^Q%IMV^PH1]48_WK]RM?'R&NSH&6E"35L!^QUVQL.%I%$B606(HR'B;P1EU
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M,32>#F/Y0K(8]O^,^<]"\U*#J.O(=3M47^=+' 4W[FT%>_4V>K=WKB>D6=/
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M]UP_Y0_\,V3_'W?_L!_ AL8:&/[O7__1K)+PHSYEE;U'.G__451-9J7U;1?
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MUMZT'<K"-1ADFX%450E8H5*I%MQW1!&,B(9H3K#;IH5(YW:A=(")2D-YD1;
M2(6V#;PE5"B*P(82T$QX(NLF"JV;:!0)$PB"^"Z KQ6XSRI=D].IIBX%V<X+
M\$YR8 C-#EFV$6U7>=J?X8BIJ@,^I+,2@&K/J:B;.H=*WU$#^EF9DM%4.63
M)SMO;_]WG=M@;1D(IR/H6R_="<[IFXUJ(?@+#S@)FF-\" R'@+,]+C_\%W>.
M:/S<)//0%%0LFR<V"_1=/>, V$;C>@[ ?E<X"6=:&563U^%?. 5[]@,GTK 9
MP\+92:QE?]"<E*V@F*H)[\?J\.*IJ>FFG5>$US5,":QO%$&C(:?QA_,2GJ+*
M).? Q4Y%OX6X,>!$9\10E21U8;_?0%V^ASXNH@W9:"B80(C)AVA+AHS[;V<)
M)6(1PJ<E="W)#P@I;*I+(54V%+>-?7?/HI<MML7.*FN"VP0X05 "^WOPK_7?
MIPC[%II*@-7!*;HZ#H4$W^484TY@>^UU;- $H EC;X/:HOS49?:D'/BM\\_K
MJ;V''&F'_O-Y]D8"QUXV!.6=$=Y1 LY4X=>3=SA_FH_<13Z^&!AH!O(O!GX'
M R,[!BJ\G1,#H8'EDA8.%4.+,7!J%.QY>BI<'.9"=3R"/.4X(-F[E2 _;:YJ
M=E3EZ+<A157"1W[095:"?\#[3U7-L/D(31](!^LMM!;<D-SV6X]"(^A_&N/-
MS_96 N"\&0^&@N((?MWFHLT!#/GGU/LY/Z/_;(9=''#Z_38#;<RY@T^\ZV:D
MH'B CF*#,+:!W78?! 3JN[<T/ %AR'+Q09_#HGP_DH@1_02*X?TAAR-##AG&
ML0CNEH9[MJ#LU?TXK/]K<\<FUP=(=Q7A>'$ASII*A,ZG9@.K.^JC?<2]TW8D
MF]?[.9J.])GVM%(S2F:QO1S4[1*RPY%:*S\%D!(1L3T4S*)2UVN L>^)'8Y<
M"1C3)CIID2*S>+TPK .Z)=DC\<.1^49VF*R2V )IS\;9.+HLIK)DO8]]?+J0
M%_$XL4AE&*L1!V0ADHA357ODAZ<W1G50'\JY"F.IB\;0H%*%5'K1Q[<C[U6=
M]:G2JWCB/9%PBZ\VSW;OB:Z9=[)48!U>VE0+X._$IVJR/)CQ/$^%SQA"J;IQ
MHS:?PPN-G?X9:( 5PPM(FHO[O]S8E_,BFZ'L0%<ETP ^;P4[OV7C2E=QO;?+
M_??9BHT]-B3>8R\N/)P+GRZ=>;'!#S9@D?<$]F*#?VQPZI;.%NW>IB/N8HON
MJ</8^[:VW35/P^NO]DA5.F[!75$^=Y,POKOI?04&/N<<^"D#_9]]\E:&?EJ@
M/ E' [^.][;I?F(A'^Q*&=H;JXS__4N 5^F <]OU.%"P?="1JEE ^<N/S2L9
M^QFD^XR_M@Y)+JQDTZ \1>AA-8DF))+3E21T'I"3XGKM456.>;1;MA[9M/++
MI!;Q@Z06?2H,$'SIM<NJ7;EM['"!#E15&L#IJ\9 7?JR,!WJIDQ=4("N;Q>F
M28 JT-KCFDC+ DJ5F^&2,5S A8E_"HV'R_80FZ<6ZG/(XZ]4I^QB@5^I3@FR
M% L^20(HVZCC4<N79+N#9-O0-NN0EEQ3=BOAB%F[A3%H.2*"!3UN*'5:Z/63
M??P[)=QFQ\O:H_P^E_<[*S8^ .5\/NNLU>?D_T]E)>SRT:.I%&%XF$49LWH(
MFHZ<;3DJJI,%,_5U1@.^*(#OR8?LD>L016C=8=)).]G/DBS[X4YO);L:08%4
M4&WK!%+4L42= W)8R7:?55-Q#!;=W;1G;WU0[;9O^RDX&CA[4-?)B=C?[+_^
MQO[U=\K-Q+EIBOV,VON&1^?(%=H,>OA*7#:WU*PYQ/3L7A^7<KVI$D[6&9)H
MJ-E9J6OJC>3MBS!R=A'ZG>6[5)+3/$ DT !$K9.GU<]6Y-@?3&[L5BMISG]U
M>^>[S%IV=8L".&C(V=LX(+"<ZA9G&_PNJ>I<:.-2.EP6^ABBP'&E0FQH:&I.
M G*7.EZ,!?A<=X,]5$22M7XM^WU9X^Q+K^]LWP^L:XX& *XDX'DKP4E=JAK/
MVK6$SN+:6Q5QN"K.K(=-X8U-D8]S._HV'UYAC[*L?OB4$SW3WD+V"3T'Q2TZ
M*_ ?W__-X1$/( %D:&[?L8SJDI ]+5B/]F1ZEGYDWLGNMQ\[UE_,TW[L6'>R
M Y5DS_IR_[$/I/LLG7A!G\(U:LLG-[5Y-=$DB*&P&Z:_5O,C7PIV_W][07R6
M$Z'F-17>3LZJVI\- 3W-%]VWPAS&C4!XG2-PEOX?5EJPEK[Q4B GB/]T6?-G
MRP2GCZ33YS*T^].>U:>:9T;?X_'#YIGN=Y]NG@D7[(;6*'R;Z6'GCH^9D[TL
MQ_8YEZXB$/MIVQTB'],D3O>\R'M\^P;0^45P^&GE+(?E'RR*$M$X%D%./6!]
M\>X1!XO-"2)^?''[N<CNH>A[ C^5,[KTB..4N>8!VSO:;-^PXWA[ST/?9'-[
MQZZS3: _FFIKA+_1./*.\F#TKX,G+VRY#U]:5GGP9^M\:=(_85D/[_UH#.RO
M?6@ ,#%U0QA:7M"<L##<E3@<.BOQA+TA*&O3S]:&@EL@.X4$$^S6Q-!@@+:I
MK=T-4[?KC&S#V#%W@:T.H?)S#8RU!N3?X8P$QT)80*-C4Y$%),FQ=]=JTPJ-
MX=.!MC9.[!_M4?I>Z>Y%;7W0RO2*+J:"Q]QY#S4O3W-3H^JH[J-O:4^05^$?
M E0; (A[EPQ,Z^,5MD$#O8.]'C,+VP!R9K&^UM[09M>4NZ\QM>T" SHE.\M@
M+^/XX=^_OH>O1RH3,>1]K]JJC_$\$450O#_@AE@_$H7_B@^B\?X0(2(8A["1
M063PUYG6GC[V9CSF SL&!TY<7MBWM :FS<$$0M]&+;E>VXX)FW:2*!]:_][9
M0#UA9QZE0*U!E?+E?"79Z(9JC2I=H\@F0S]RV^<>?P09"CF-^]^_[+;@89M6
M"($C2QUE$01[GTRA$\Q*T,?.:NP4NDU_'9I[@N)8;P-)Y<2-M803[YC'L(C8
M?__U[\<T#[T>H#=#DIG::$3Q-PR-OJ$H%EH?J+J6&?9)HR'G#-)07H?NE2U,
MF"G\CEH"C1-T1[2T6<WV7_70^E8X\1:+86](!#EU*UMQK,=&W^S=&CAT'+<W
M@=_63 UJ%1WL7>5W(]=K*7\R+'*1^+85X.C"K?YS!"G0-YN:!)O$MO\]L$*F
M0S:[HG@T@IK9W1ME'C)+WU)8-9WPF.PH;TBOM]#_0][M0V-"4U8+S5G)!+:&
M6U\1^MM^GENZNU$)]\/4![[=0C2WA!BZ[\(&@N;4V6!DAPMW,%RX"'IS(R6<
MJNC0H'&( [U_EW:1+>+TX^!T@BDVB<X_;7>?S7-]IFE-$^8V"FH2Z^Z-VRR9
MNU$X- 82;X.O#/@F@"3T'.49<@\Z#I5*I%W3OND@&++M.EM[20*[]FHW 6&?
MZ>&^SQWAI4(7%9JH=F#-YOVZAR5K=\MQ"#_=$AY^#<&E ->JW)C&3BD^*[E[
M$W?;KB!:CA&4]#0Z_-LW,I6;2?)^ !DXEO;6K7 BBHZ8XD-_#S9++/Z&Q5&H
M Q(W+K'=?;YKB:T9=_]U=119ER #&7>"WN\70W[/J0Y925</=>+:4[,!9KMJ
M;Z'AX5[:MPV1:-?Y=3U4:T,T.QO">QSN[>/63K.@[1R_==;)WIX*_,;:B;>]
M(^:@UA,V2])CDYU8DZZV=,&WTY=8] W#8V]((O*%U0QO.H>36O=W=;Z)O"'0
M<H%&NN=N->CC LW>$KR^X<?5 M]#@'>"=HVFGQ+*WOB_,5;MO:I ,U@X&CI=
M.J<)4T?2)J$UY5S@NS#)URC7 +X?4VU*VW/G' 'Y_U#;PMM9=6\>(0P)36!O
M4>0DP_V=?49=[V"\-P&NUM&N^-A8+7" Z@2+;+&Z;81W2OSNDYG=-2F CW6L
M:L)+]%W;)/P-Q6QT(Z']^8?TG=]OP]AYAN*DM(= ,$R'==R&=>A;)(J])8CH
M*=;M+S2ORE1-P\EU.\MXNMX8Z*S/A1WY<J<+)S&R%1QP;#W[+'?."C4U@88^
M K2>G<FON0E'L' !LR/@ 1WV'D6]T[<GPL(WDM?WLZGN%GLX/ZUE@.%P"DYN
M^U:JO6(_NGD'ZQCL%JQS-VC]*FN#2AO!5_ 7Q.Y#MF]P1UN3=R(^K,/;BCIW
MXSZH$_?!WNP?G,3ONDU"$A)?"KE!H;=0F;5L%]#YY!"E8$*61C<_#]9T9R%)
M1P[<W]:VA#L;* W?0GF%>W=&;=@>JD[M4EX;-R5A"#9=971WJ'_VZ0'\[B<I
M_(5&T@5\=0WG.R+C;WYK1Q-O:"1^G1!81_\-0]JV38'7&'#-VC!SX@$A^V2\
MSTJ#3R[N$\]T/"3XV]05@>Y=3J_YPX6W<>F=]]Z\+9R'HL(WT+>7:8 3IH*C
MVS>>R?>@H$$S=X4 N#I:<5H5V!,_'3/X8$F@[U&/);'VZ(8[C01UFJ/7;O/H
M//;@UJ5SU?@9FQ%J7SNUI&J6G:8!FROL.(4MUPXTO5TFME UT2E47Q_=#H$!
MW6[--?OLJ4U9:[-.-E8B6$Z!HJ\S1X?>O=W0P<Z>V+;"P*W5ML,< _M,47N4
MXS>PZRM.^,A^1]RV5+N;^VI3Z@V2=[1NA;"-<YQ#E=U7TAZR[TF_A7R=_-T=
M]H^&]K'E(6S=J^C'8. I?VJWHB^0<6?*[U;?$2Z_A]IVO99D@YP#=AV5NV0X
M 'A][2[;TMJ[#.W/VV<Y996L/GX/Y=0%F-N-*1;N'>VDZ.:N]C7[=UVW %EG
M%T^(!7CK[7,N>.G[*F#/4;\<[KACE>Y/*R ZE=GU5ICAN[J/[]K_&Z0BJ'C\
M'8N<*()RZI5"NS\?6@3U.D'XD%QNJ0$^3 QX @SZPP0;[T?P >BS:(+O\Q$\
M-HP#CAVPJ+^E!N?"I<B92L9/14L/K.9UU[U-.[VA4P3O".0SLO22&%ZHIL3;
M6_W@K1R?>R_V$8V\$_^Y239Z8PW[Z5U'$6RK&>*NI_KWNO1X),SM*]850A\R
MGYO>@FM]<MZZW;<N6$]JQ6/6N7=R?M5.6Z8;'V<3GG "SGO^U&;$<1_G;6OZ
M'$[%$P>$)+!OLMY"N=7DK+&7"O#\<A#H^]>_WD-9"'S7VS,'-OF=:W:-O$XH
MX@\-&FVT[&Q:%S<0&U]0SV_'+($+,+/IZ?;1.GSW-S<N;UM;')CNJN6 LYT$
M&)MR]R_=W?93@<)O*\TVS^0<W L*ISEM#NV[SU5;SC@939>5[O.W;+%7P:&]
M ^]F2L8Z*JD+(\6IU8=TL]MX0GV_F8H;<81^@[-^3M[R/439#!?6O^P/AUSP
M/$&RJP,E=>&"Y6V7/=E=L>G<MG;+-Y+CNES4F_O>ZYC=FLIKKQRX-8"\FTYQ
MO#*7W/83/Y#)?>!13XH'=JQ^<#1C\W:6ZTZ-HV';K6/6,5AM=MH GX,MN^U7
MV2^9.%@F'.ON1+*V4^6]$HEUV:_O7-Y]'D ..&WC6&6/7INKIO;.!+@X[$>[
MA-YE-ESNP&EI3@C[,CC:8WNWR$;6;;=FG":0[>5JZX;13I="8=WHSRTOT8!A
M:LJZ>ZO-R?6K;7+>'\AE1RE=P+]Y4:T?>;#M2^P]7!>@YF.UX\_V5G(>,(,W
M'7;R@H->.T;IXLE.Y!U0>R.3]RCY;C=KA._"VO5W;W:OV4W#6DA)"9+D',D=
M:1RQLR['M=Q;:"OBV:UXV=95>.,4._Q<R@TXHX:F':FS!P#>7=MN*L2--&RX
M?Y!Y6"OT [9OY#Y<6D/!V!46'60Z(GO9I:W<]7)CFU>Y2H+8NX../0@EWK%H
M".)!\DC[7>'3W_\_>^_>%#>2I0]_%<5N[X8[0F8H+@:Z]]T(&G /L[;A!;R]
M\Y=#594%&JND&EV@:S[][UPS4[<" S9@:R-V&D-5*I5Y\N2Y/@\*SZUVPQ?$
MQ:Q3ZFW,_.>OX&?ZMN'&^MIHNR>;SN;AP=W.L4AUC #2,[B@N ,MI] 92#IH
M2HKJ>H:*57^YS7 WE$:<]YL.,-M4LF(4N94S@M,PDFI*/031HI3<L_2+P:6W
MA+]8M&NC9>U>B$_&_)6"*OP]_/4LSF&T*:@/]V5NO$OE[ND\M*WXLODG+ GI
M5[BK*(+QTVBC+MRO4)E-L>)?K",V[L"Y)^N._P6.2CS%%L$05M=G)J5?2+11
M?V6U3Q)_-C\+&/,2M(151_!B'!R78O7-]=?>G[3O5?#090<0AAF$9GN=5XF&
M:"Y.8TWAP;"L_KK6U_#&>(T&,%NPE*<1%R;/*1 ?VD J+X->^,U5<-2NJMS]
MN"BI#[XM.(F/ CGS;T+:"95RN,3QE2FNCUXE"K$^6"2VML<:QPK]N\-."$'D
M0>"7:T]VN"]N,UVD\:&-J][AX957>59=7@77$8@(>'5S4UYE*)91T;2@:$#>
M@+C$5@X-P\8=SCS)[P2K%R3/>H@M(?&XP@'^ZR_Q?Z\IH.L%-US 9&SK:X3-
M(G_RI4"I0S*6S'44TTO[UG.ARH0J>= ZI^(>9UUQ%=#4POUW#T/?@#58VN-?
MN/[.:?<S\!B606HNLS*F1_#WUH+CCK@_'$I^1?RZ)U:R(QC:I]MVM65*2308
MBCZ*K4OPRY!9E>"_XSS[;-CZFQIX&'I;$;8[Q0M.R,;2&%M;["EFQJ8"J2];
MZH^O^R3JA=P7$Z5R'3<Z>6K0^2[W[&++8U+@24+I-IBS39:0I6*ZLR9ELZF(
M'USKT_&K)R1->(GLNF7&.BEV_<C4DM0XW/+B8RQN+CY;M.$DNBFP\VA%G*/Q
M5MJ\Q&\TC0O"#L#I4;@<!8W/ 1D5+)5Q_@7Q;P?:_%6.XQ\](7N70O,B]YXT
MU>,M*^8?TM4)VJR9S(WFM%+ZU*D4KZ^TNTBPP%N-C>0K\(I,XJLLF_(UX7GR
M-7N-WM&.RGO@9B@7;FY 4_*X/#F*!\'5X)9!LN VW$53#YEN8V%(I;LXT1W\
ML L_G%3[G!\E^\/E/%LII= YTS+#.SQ8G)#ZS5_/G03G&?BD:#MTC=GMGA=@
M910%.['M>:H:J6T,FE BR?#&-F "QI\>2DHKZ9Y[^XN/K^_O& ,4)!%+OO1K
MVVTS;,0?0MM*="&DP)4'(]2+@_!$RO9<=5"A(9&IXVCTZC2BA3GOD*2F[+B4
M6*^O0>\V-1QA8I&Y)078D>Y3]>_FKW8/V3J][^+?V\WL+(V9I4G?P!8SA<X6
MB@?\D!(4S&U4 1IQ5'EQ>L9O5;FE:H#4U8U5'42Y(!.A[E&:SNO;YA+RK&N#
MM5?S#M+@AT*Q/P<-$YH\C#+G>"4)0VT:MS/6>-?N4]5U?ZU$!17N-62.6T?(
MVY(M_Q 5T^B?P>])-@9/XSV;>6[=P"#ZC$J(,&<*W:.+=^?''6P$^.L_[([)
M;06RD2S7@I.T(VI#EQ!Z5HQR*&Q3Q0K5>P,;UHR06(_OMI&<4L!1UM<VMF@4
MD<NO'(BX9>__X( 3[/_=J!W(Y9B1P<V[]1')YV<&?JS3$:%5QC4E44'G,.1(
MK4)!J<VW5!MC6DT(J8DD1[N*' RE7]5C^\QMHHO-1U/XMJA7!<3AM\6"[Q@,
M%F-5D83ED.9C!?V&K!!8KM+"P[Z6MD2M#>GW(?W^0Z3?G_:.>KP"LN-4(^^2
MYJ@!25QGR36ZNL$5? =T'5:E4L8B+L#T_WM6@?876_ ZAN=.0 =PN)Z#5\5G
M-N>J5&*N-.Y=PS0/JVEK.Y,=KW\&4PS>1A-,0CU^=9[>$RZ0C*EM4 D<CWR,
M%ZP_<.?QWZ'#LPIE3Z=>N//*D'-ET4<L>!L%*XH*KAN]?KJJW+X5'-DM)ZG^
MZ@HST[!=^\!?4@ESMZ(U+L9"^(^4 ;IFYL=I7+A_=L6(L%@A*@J_3#B:P)^Q
M5!V?-\4 _V39Z?_NL\W ]2Q2K9M)&@+3)?F26;W@,,XIG8;!O;3X.O!P_>2N
MI\YRX=X0/AV/^[\**_(-ZBCK.&W?%+YN*.X<K,O!NGSYUJ44=TXVL81S??HI
M>K.W_FEK,M[ZM#O;&'T:3_=V9Z.-G>V]W0;7';U1;['GPW&3;E'E%_N_O3L*
M3MX&!R<?+HX^7#PF;-*##]UCD?R) -,QB*HRTU_P(:#?U'D /1S"W&I%FLUK
M4+%9)5^J'X.[<Q#L;:YM;O5!L#\GI7=W5/DW:V^V_Z,!K#I:_-F+F_IUWO@V
M4OI5MN,IJ&:'I7</9@G957<C_/+ODXDQL]DWWFBK+?=_._EX<?'7XW,'BO9I
M>VOSS9N=^RE1&B_  6LP:PU%^L4RTUXO'WWW*66(SGY]=>/XH?+Q1,* VW6\
M_^[#R<71V='O^V>'QQ]^?WMR]@?\].[DY'_@7^<7^Q='[^\G&C)Z@,,'=OQ
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M'N[D,W"Z/WXXALN9$N?G;X_@E.[#R043[NAB___ '[^G-:"C!SP\)^;/ WE
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M2SPXW/-4Q1X?]C\>HAU^>G9"&X2)MB.PNP_!#/_M^,/1(>?@[ED HJ-C#4A
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M"V9*9TNVBM6"I4%J @RN\$.MKT8F+9Y#01UW89&G$?@_#"T-:2Q=]*A?@L!
M*#V(= M,Z3:F\YY"C3"=UC<G$QXO=I!RB8?T>F-A6^W6HJ,1R&U&=UY#%PMI
MREW.Q[W?KDEMWA-I],\/'1U2$0^@U_F#A O7X0"D\RUL>? >'<]C]] UY/>0
MJ_YI1.PD#?:KRZHH&3QRM*Y@Z>_,):)M7N3Q>93@94*,C[AA[XDO*CBOQD2
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MK*^]V6[Z _*[6_R![]7ZO]6=:JV+=!AI?]D:SII2:('*AGR"5GS%WWGY5WR
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MY0DPG,V'U;^+^<Q*0NV<4BU(;!.\C%#&ZQ_W,8AEFGIDR<?D' >=-F2P-X.
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MDE%*@?$B5%Q!SX*4HELXUSY7CB?&7 F&1\78$UN4<"8U>:F_+%%N69 E*+%
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M;8W>['S:G4W??-K9GD6SZ63+;$]-C>D!G*H38=W]M+NUO?YF[U%)'MJGW;_
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M#8-E5H$2IFJ<":ABKN?)330E$YIRI K7&:<SK'=D+%%3HK%<7FE9S'WB*R1
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M#ZLTNJR[_3J#X6G3G0M8\*W3/$E+S]RFS*MW\C 2AJZOC;1X\8S6:1M3%%^
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M2#JBL-1>4>TLKM4?A*N37PN@2:,PZ/8'2=2.FI_ %KJDJP!'(JVNJ0J.8JK
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MX<V^%VX<\ Y>W[0:G3S.?O*Z ST(-:+ :IA3G6>^K#\>FP[SUWQJ6[:PE+G
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M^:YR72AC/<4NO-"+QWF2-PC0($ B0'Z*LQ98T>HVB?6AJAWM_.HE#+5$0]F
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M\,I 26M@CG3AWD:1LF=W(;"UB!8W#:3.TBT ,]6V1%O$D;BT='<#B3OV017
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M"-"W2K@H6>>94$?6GY@%"60,;%0:7 :J'-%8NM(]RI?NN" <9=>G0)&'FS%
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M].C?-_&?5V0UC/ZC1#)F\_*_'#[#@X#X]8ZIF]//-P"ATI6*+#9JZEV#_>6
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M0]M=5T=W:UQ&J</>BCE3X1@5-9>9FP!PELK^\2&C-7(HDT[E[JR#H0(M-YQ
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M?N;0&QD$D(25M 'G.[BA!=53=J"HF\KL"8G6D]-P3II-Q!TEDUL4;UR%4R-
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M#AW34AY)') 3!29PY>2 _\O)'S<FF&LAK5#UA%Q%K=SO[S#%]QH,\_L%#+.
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M1U_<(N4XPI)D^VVL=BJLM"!ZO(AN>\WX$7KN-8V[O"8?1 ?'G@+&<>BB1D&
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MI2NA**K?;1R#@GS_M'=/>S="11/Z>83RA &CC3M)Y^]@\Y.L2Q3-,]&O*??
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M9M*.0JJ(N6ID+T5QM\>TA>]]-3T*\).PR2A2 \$QC[2=1 6L: /=/5LPHZY
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M4H\T_"'\3]I7PU]3F<9T.8J),ZIH8@;$@]_T@^O!W4S][:>Z#W/_DTIK4M[
M*YA3_>>5=0A\)L;TE\H)986WHAIR5R,-))P@Y(52>B9U$*3I0N- +ZWEULX9
M9,_+66\LST MX_ #6 <RWI0%UU>S%B H$+<HK'9E"+GW4>IP$>[#O?>0)".1
M#)1.> B*EARJ#IS,V:NR"U=R>+\7[];5 =G#NS;C'V!YSF=/T^I9]0X4!V3
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MNIK^Y:F:?JJF?_06WX^4M. L6+B#N 5R1UJ:[%-T9M-N;B^%0D<L+]T5U,\
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MJ*-%(PVSS]!1"=.BSX1C)<=ZS)S&$U?.PU"Y*C_V067H=] Z^Y4E$1\U>3S
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M&T_F6&948.1(X(;E.!0ZM5=Q0EWF."$$DY<7<ELT?7%XO6\P_P?V_$<G&2Q
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M4JB2@69JS*#\ 9WH#^(S7R7@IJ(1$T7CZ-H[#1'S:(&O+:2_?Y@4J9@30U)
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M.,B@/SX"!=7VVWRK38#7DX),5>+4 G\>BS]L9EJ -YP)+WC]]UZ8JIS:SJ1
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MD1;4'?#.'G!_BZ'1O3W@=CBC7.U*RA>?F.*\OQD+:.OT>X/.L[0O!U9CH[C
MP7 ;()5/R/'0FOO6'=C^WK=]DF]M=@Q1W"Q-//5G"7OA17E>!LFD<Q"UVOK8
MJMCLG$1/X) [/\*.'#)%VX:]X^VI4-VY[L*Y/K"BM;>'W!H?T?DL2"Z5%R7>
M-(@R[RJ(2X68]9A#-IDIRJ._#C+X5^'%44#[$ZDNAVE?+"5DS$>'G2]I?TZL
M\R6UZ?B.NB+/?3VZ_E:.;I_$7)L]2NL4'15D25H^C'*SM^IMFVV8T>EHF\UZ
MNB/>O2/N?$Q/X) '1T<=UEB[C[AS-[7-W?2AF*E,YR/Y7J*VA_FY'R?9WI98
MG$0QVIZCJ3WEK6T_]"W6S'6'OB^'?M@=^M,[]*W<]*[-X9ZXS=8!&HS5-,V4
M%.UY1?!7YS-[2EVOD!4,#[>)?- =^GX<>O]X:PI^YW/9EU,?G(ZV4W7?G?H>
MG3IB+9QL4=O;UU-OC>OMO='60']+U#0JO.?BB'MJD!KMM=(>.J.^-3;;DR&!
M_C:[M73'OW_'OT4\V^[X]^_XMW'[.X?=_CKL?E6%%Z/3+K@*HC@8QZ "IAZH
M@O,4]RZ=?)FE,9QKY\%[!*SBG38 ']K#MW/\Y/N__VUPW'_%_^W(XK%\@!U=
M["-=#$X/MXFUVM%%2^CBX?V(NT<7+?0>OE%JKD(OC*XB>";T,A4'!7P NN0%
MO ->_^/!T%MD:JJR3(6L67IA>IUX=%KP58JZ6)ITOL:O,#5W[FH_L*.Q#7S\
M"9[<MRY2?%HG1^)TM$WMNSNL?73$[9<RLP=N,WCS;_#5) XR1\<A #)1;E[7
M59O.6_:D.GLAZSWM_&%/[^"_?65I1P8[2 9X_T</#&_6'?P.'ORWKTC=/3)H
MFSOKQBAI4631N"R^1:#T:>AY%7(> 3F':8F;NP_.Z]'V>/Y*]IRS%6WC\/M\
MY-N.;W9GO@=G/GC &N;NS'?SS+<<E]R],Z^I;3^03K,SND7C-/[^9YD6KVZ=
M##^V?DJBW!FM_1_C>ZSY6B'U !G$(0QUGL[A,*,<=$)$R9TI[_,L4\K[!1Z=
MY=Y;4#E#[T(M"C4?J\P;]7UOV!^.? +2A;^&__AA_ @;X![0UYP[_O)E5,"-
MF#3MRB=UI9)2/>SYNCK]X/2AUFL6@^7-F0IR.,_QTGLVZ(T\&"*.\.3A8('5
M?^]-X2^D@8)H8,XTH-;30([VQ(*\S&!;;/K+80^(S,X',0PSF>,U#+G((M@)
M6)T7EF2SP-+-LT"D,/6!F3K\MDRB(L<O/F?1K\$5LN40IY:6F1<'93*9:=)>
M9&E83@K?&ZO+DGX+LX$Y96J2 I>$N5)K>WPT@F5-"OW#\_0J"@\&9QX<0ZCF
MT:3GO4\\9'D%3,+WKA6, <3T7Q@B@#_Q+3*[/(CA@,(HGX!5S/-\UN\-S0)@
MHO#K0F7S*.$,!'@?/,YF&YQ'<)EAK@+^MI@%!8S^9QEE]D$>M_=HO.B!K^)Y
MFM,Q_)2F8>Y=T-D"Z_DI0^OV8Y9.HZ(=UU0O])(62D0<*O?&]BW9^WAE!\>]
M_O?^M[VS>D9(V9/5"3=>7\MW8.7E%*Y5F8&JX*GI-)I$*IE@0"K,(N  N$Y]
MJX)8W]>(A9-<;Q@Q+Q>+-"OHAO/]NLS2ZV+VP)?@6U$"T_:":'N%:Q^Z7/MP
MV#O[GF7Q)?V(9^3\"';K%!3#[YFSG0Y[@T?D\I?NPI!6D$(LO<C@#7)AW5"R
MW(7*)G HP24+$*$E&!AH:Q'$,#3LW29DV%HN^@&V*"APN6^Y1#9OZTH_J5P%
M&<A\O!1O@'SB=('2LQVLX=/?@_GBU1N-.)C7V,-A[[@B(LX.>Z??6D286UH3
M!I;!>\]&#AMS;[4LBR:,S)U?.XFC! U8L#VC("85"K\,L_+2F\ Q1R$H3KYW
M\>9@T!\P-PQ07![=^H[0T@>.6F4,^( 9,T[AD^NHF)FQ<.^]F0I"4L!, JDY
M&9P&&,OP M'Y3O1T*ESFAS"Z^M<_X#^:)"8QT"]:Z3-MD/?[WS^(&P%YILHT
MJ0X/G4@"D^K)T)DB_??_N#.UP9Z#21JGV4OM"G&6,./+.207P:4Z&,/>?3D(
MIO#BET%\'2QS625(J>&A]CN\-.Z4$<[FJ'=Z^KUG_\3=6-FW>?#7@;-AE2 *
M_TI_1.X3_5F:D[;QDLX/2!3'=D9]B".H\8:1W?!_!!Y0_/2?W_WM\X?S)E;!
MW"])LWD05[B??/3=OSY3I <H[AR^1:O!$%MP.\'5][!I<]HD+"Y(><2;^DN0
M?5$H(-LA)^S"YGIAZV3&P#(F%!E'.RHR!KVS57:.LUP$RRR-8Y??FI6N6""6
M7\,-R1LV"?2D/$T2&*31SC!F2-/$@ZR(2-M,I]-<%3SQBC, 55^5YVS=P&%=
M11.UXA) ?\0T5A.:3YQ>:X!A,(O*#">,S).V.^8YUZ08SO9:C3VXN]SO*D\G
M,"]OKL(H\!9PDV';YNW5=7]2"2B[3!"OPSGH#GF1$?MJQ]UVUQ=4UK?NBA]9
M58@]!T<@;'?EDHN/#Y77TS4WO.G6^!7[#A^+U640^S#%)"]CNABT0R6Z$U!Y
M2[,O[+: Z\TWDO0Y7,:/91XE\ H0FO,Q^N%HIXPB>5)1(&]B.$X9D>O'T$RE
MM7?N/6J2*B\\1F5JQT4SBQ)@T.JE.CX!TDG+',G@\2Z27)\9' 8\&.D99VJB
M@"&X#NWD"KYP983Z:X(D/PGR&3FJ9R#J#M 1C=-02Q&*WK3$U'%X8*/%M9;"
M;;^E=]AOZ7]UOZ7/3F/)WZ6QY,]N[Z4VW 0DN\G7==8$4D1V#,0"OPPX*0T5
MGF&%V]_E]@C)UUV%-$(6A*3%92 B=/#F8SF&,]6'TUZ]9QV%OI6.8$^**NMM
MT)8U.KP,HH2#B6<5P^(K"=&-B^"_A7=6Z!#XJ,KB)=*GFX7Y>/3XD%D$OX(^
MU241M#F)X-FHYFP>G?4.':,B00KX&E5H@Q]N9%*(3L2&^U4:EW-E[7=X\QS]
M '@;X5E8C!-<9<6_8KG7 _A';@ _$.:BB3^?1=/""ZZ#)>M?/ 5XC1/7;[$<
M>L(1^ZJ)T*_=D,-^;_1(-^0.\7I\@]R=^JV1B#P+4<JH@;U(0]=7YOS:O7GM
M#\V/>OTZ._QFA]V0 F!S1SCR?PBSH6R P][P^TU"\R:(+M0!:VPZUY6TD,HL
M;AD)LZ[0)4NT67/IQ,$XS?8G5#;J0F5=J*S%H;(N@Z0=$NR6#))CZY9AE>60
M,LQV1JD/,)HQ;$SLR"E&!@2*5FB9U=-&_(8\8B.Q;\\&@0\J"2:UL1Q5SXT1
MZ&03SO*U6XWS,['(UEH"77@=_9S5V-L0LS%WXD*YT?5AA7R=V)L;Q:K2=-Z4
MGE])B;HMQ,XWR<V,PI\X;ZQ&U_PU$788P+J274UTY6RZR/I#1=:_D5*PNR'V
MLWIR?O]D5^ZY$9PGSD6K!+0;XNO>5"GS4WLC5V+LO@VR'U12(/6=@A>5!#,%
MJC-)YW*AEW9CU'W0E"+JY/OX=3YRM]R?R_4GW$7K]_+.WARM'PR&H.WI@#U?
MT<-OZ*'9[(I.[$5 (M7^EC);Q*5$ZL=!'"03NE@8T&=77$/ '@E[)2L KB=>
M#%)H-UUR:V\!M7Z%C7[[9XGQP?=Y7N+.MN,VO)9(>^(I7EXDRR-KY= QH9 4
ML0 R"ZU;=\.K4,.6H8B\\YH;@)2)86/2P(0N4T)14<D>H$C)H@0+'&^*&634
M.(A)N)(LA'0<1Y=T@<#@NYY%8,:#FJ<X,!QR_C^EO=B2T(E286XS9B234S]
M]>X!Q8'X#CMQ9AQ*X>Z841J=Z>Z>-*YQ2@FFLR#C9- ;EHR\"G32##3@1/%/
M;MEI_1)SMN^3")5H[Z-Y\((>? >,)YG .;3VPG<I/%M)X3&I$_V*/GD'QB%W
MPP18<Y,V <*QI#KLZOSD'MXP1[J;<!GHLB>IY0=9XXHVG^[PR5V'+E_HKOE"
M=Z+ZX%[)0IK,04H!E:_.NB/L[?9V>"2ZWP:IA[5MB"KIZ1NI D:%PC N#P<_
M'2LD8KM=;'U'EY=*PU( NXT.PB@NR9(QVPE624XN,YP#)=^CXE,[B)[WVF;4
M^#3<) 5;)\MY+%TR$\0($! !@\_Y4.&S^IF2--B;$/)A%T+N0LC[&4+^[E]!
M^)^2W!%Y.9DQ4@VE C'&J'>=EG&HC2R03)ER#)Z?U64P66*.T46 CHYSEGC,
MC,I%FK@< (9&-J"NHK3,XR4;9<PM4%JZCLV* KG"&QIXFF:5PA]K/]%K(154
MD=%\F0CF3S7])TF3 _+6\*Y0_*!6$A1$(?!^>&J!@NQ.3JB:$D ;[KSH*XSY
M1]0%MI>$_'/T9QF%J 3A 9W+QGY2.0B9">JP+<PQ_G"%[GIUW0X%_2)"+PG^
M9V%PM6;!E;)!A!PD:32-)FC/)8)Q+ %&=/Q/"L8XQKQ>X_X'%<-Y5%\T^%^5
M*T7\>UIBK*):6**KI2AP?PT7NS+L//A"'$9G4U P<#76R9&)U3#*#=$'RH3#
M=]KU\!HHSWC!M2SB-.MYOSM[XRR2"FQ&3I+RW=C+[[CM(?N;<8KT!_H1@:$J
MR8$.%J#6_17-09>+,<SMQFN ]S<-N_9XIZ1O8EH$)QFAINC  LU Z[F<K;C2
M:MS9%R%11'BD25JH7 )#6-(6IT&2T\K09987>* 1YXF /(:WY @?1"MS@[[D
M1<<I+A4=!1]<H30P40[<5_"#Z'OTO?-V3>/T.N?<2[NJGO<!3U)L-?V\D)^S
M>*9G-2GA301CEX(B1>L8ZYC9(H9[1F2'E*,NES[N;%QR!@QBIZ#C$N/1@>2P
MD^T)FY@%"P6*^2379.0S?0NP',MNE&]!A)DKEFJUK-('LA*O +V4LC:U_U6F
M!@0+RGK$80N<,I"P2G*JT$77S"7#V_%IN2?LO%N\V/#$#Y2I,RZT% 1>@-(;
M!"$8%V5&O]5+H'6A:!</-2])!*89>ZK-'727YS#Y'--^TFQ)I .']G[:M T1
M2M\"K(\)N:RN9RHQX'Q$V_-@"9>2]8L0=+HE>J/@X2*(8CHBY\2Q%"'FF2%-
MD"9CG=(TA6M:*[X26 -N56T(Q,S!X[W&-<HD@87K="A#.2DE:B-J(EI-8S4)
M2HQ(*2\&"\.E9QG#K_S<U]L5$$?D71%7/.I@#,]C9S4AQ6^,NP&[R=D;08C*
M'/*-8#H%)H<+K!A]FC' "Y"DR:IDA3)#'@"3',-]3<AX15Q:DYWA7"W#KHEQ
M7J;L2@'JR)@=XMN"'$X4:4/RV%%5!*&DS=XHIT@WZ(29T1+1[[X$EN%4UFJ*
M11@BK6W:38*)%DS@+<F!_[#Y/D>H8F,R )(3*?+I&*@_H:N_>J.HE-J$(8A7
M-NTC'#G=/.9WZ&U8.OJO>#FDL*>8*0WON=1G8Q1D8!BJH(M#7H88_DW*A>9G
M^*GK-28BG*/^11Q'82 I@''S&1$Y4.T8/7>VU\+:G2'\T"8D LJLF,\K4VC*
MD\!;_;J\A#5[ ^-AU$R;TA.=_7TV.G:<ELBH44(]1X4!79\-X 434"1TD+CI
M]2]J *AD2^63+!ICO!W$Y[6 HDI0[=EA!8V+)V"B9N8J@<S+)E&^/E)V0V@,
M1OV?$E@*Z1JO)9"VZH6]9MWF)O5%SZ])]>EY/W("9V)18?RZZ,[<#&)7G4"A
MG=,<A(1)=4L*F()6]Y#$*'MUK?(5K%^;B+L&G80=;>E_B-L"46M320067QRC
M)0(G 78ABB(H5L IZ4*M\ET0]V5Q!]8KRB7P]C'C4\Y@KSS0M>DH*&"-8GR^
MX-WD&P>2$WV(2ECP=98*N >*1+IZ*,%H$E<@6^G^:9Z2:?O/RU/@W1G[#_"'
MM:UG]4-T,?MK9WM,T#J$3]%A@2J*>2&G7= 1,,_#M<R1-[$VD;L*6C%+<^5<
M&3'5<V$'153$\"G"C _[KSY%^1?O'0]"'PU>\0\BJMC)<?8E4.:%@KG%>:I_
M]TX4B4_.(O3OZ8ZV1" !)_H FX-W@8NA+!]\=N;FLPO#,P);JH[6&1BWY"_<
MD4&AO@H'9EY )R4B+,1D"M'GA*$B+:2)D]BP[?EXSX5,-!%LSQ/CO%2C+I#W
MY3Z'+(3[@I@4YQ#6>/B)P\*?LP)GE,\*(.ZS@7'5O9!T0[A+F=EK.@P21[$R
MZ,/L$8 ;Z-Q5YWQ\?(:G!;)NM.%$CNP\MGZ^/G+K_Q!CPP@F&7C$*I#B4U$V
MP(BE(65-OZCL$F[1:PTYCNQE%HT90*D408T47%/@R 9B'<G)+J.,O&CN?63E
M&G4<%!:_?'Y]3GW'3E[E$L%!K0=>1\(A!9- QY%NV!$\_SC6>O\Z3RV?(^KT
M6IFZ->;E/<_4 B4X%X=7B>SLK#?\7K^T0(L/5H0BD1BM]F@GI'_E!^*0$)7*
M">.B\(OR%X_'?[? <O\G2$I4?C7W-,J7;YS^Z[2X0__D9. ?'PXW2WK26B'1
M1)39<2BTY&N,,-8E5UU39[:V@;367T@U,]J@(A.T),WW>?0"O1JB_.)0'MK*
MCBZ^RI4W(ZIK-%W'N$$G_M'AH&GAS;?^]@RY4U  !\<G&^TE5D XQ'W8_]YB
M%M"OD4JCHJBH)!4V1R%5*AXG(QKH_!*XQ26:OF9&)I/AV=#:':Q?/8]PBRO6
MB=YN2GG@N(L>R/0^,*KINIW>FR#O41?D[8*\^QKD7>5G@Q/_^.AXF^SLI.\?
M#P\WDPQW8T8.QFI[+)__*1/U:,+LZ 0D^=DV3W_@]T<#?S!H)*G;Q%E5\&.W
MU@<6;R.; ?NPXJWAXAT?^6?-4O]K]_[X>.2?'I\^Q-4;6I-H1Z^>B-OA:# %
MF_BK+N+&^N\9L+C!F3]J9IQW58#SVQ1@Q_?:RLU_G2R]!I>#C@)20GCA;")N
M%WE5Z;N@+%+TMT\H-(4NHEP5Y'[#YS9,4HKF5 -,^\TFK9C8YY;]KG7E<[27
M,Y-##M3:U[*=C@^K4 =LJ^^&1<I;6GFZ<+6LKYOO%QK?/Z9!)F[\*_$6Z-J-
M3\I<D(]9>ID%<TX2DY^4Q2S-.&W+Y5I.U6K%EU/%B* (;69>P'4'-[S9"U/%
M<6*I3%+H1W&9 9YG#:)4DDB6Z#"RG>%\%S\BJS8'*\SRL/M3P0WG,E5(-@:^
M YT@;240Q_TK>A"5/,IEPLWY=YI]N8)S1#A8V7CKY:+HFWG"-S)6AZ$I:,B^
MAG%9T&D6E5HS\JCE*J:N ?950D.COD-$"(I@+G?]'B-A8\@!BS7UF;D>-="+
M)7EGFL9Q>JT_YUP11[.[:;G&,4A>*87I"(D-Y>]JE/K>-%+IUB@)+YR-6JD#
M)!<G[KT;B\1_F\LIX<&>]S8 7J"O/JJ@!<$\FJQ7SE? $W&N>Z5NKW[^@:,R
M#0:]HSXF)O#CS&@LNV+X2LZ#DJD;)W.C>WQP-'2!<SB!GMB993N9:A"3Y)4=
MJSA2LE=Q] 7^-4M32<O0!58FUS<BE!#9/E99]#M\'44#%2?->#R[E&I8V&3Q
MN+G#?D-20=$$_8QWR=W?GG>14B(51B57?Z%;3E7%>N[%**TI9E@_$1_+U1)]
M!2N;*)$5"HWRA:0*;5]'WZ[MACJZ(K[>#*-CN65"VTUQU35[6HO%"\>#>T8!
M8!U07G/**"#T?''[:;WDGC:S;3BC^JDTA_"KU"6A499:3,X?L^@*B?EC'$R8
M%5=$X+G-^C:?BUALT.;P -<NIJ<70Z^MB5L<,TWB=0-3_0HG(4G^$7G^@238
MW,;UPZV4'$[R\4NJBGRL# -?P_HI*#@FB2'DO+*-U_:PIW8B*(HHJ2\YN&TN
M/L^Z,MCJ;FY #L#*,(19"/:/C8##*!RW9VJH3,-:OQ<V5O1ZPB$?F^I:BD)$
ML[0\&4Y"I\Q.TFR19F)F+E)2P=[8Q-TR$8E&N0V7H!$Y,M+LJ'MA*5O?<(Q;
M<R10L2IS4T]="<%SZH+2248J6A1:>MR<Z^+.IY7RE_-QWL">D!I_JC-66/2N
MX=A4X( :>$4,[H,PJE=TWBJ+*C^XNR@RJ2GWE4)WD#K,*@23!#FL][DF>-0Z
MF8, L/Q"L.6NX5[GLVAA84IDPRJ17#TQ*BIDE 87=9OXA4ZM@*G\ L>).7^^
MW$7,T[I!]=Z _UJ:$5<=-9U=:*6;GI%L,&2JG%2["2UP=C""%?(QZL[CU92J
ME63L2M+R-+@"GDAIAYRQC*E M?2.:!LW>;4HY;M_N>E)]-+!\)7W&^4S7W.Z
MO4Z(--GS;AF'R:1'-^)D1N3(.,1F^1)AEG;0>INM&L]YZVYR6E/6>JKK#.J)
MTY1EIU/6&B#?]'M-KU$N))!D;"!*;401CUB?76ZRT8W$1&+# W,/$(4@$1G:
M XASY6:0Q-$\6J$-;'Y-B_B/2A<H\?ZKUF;DU3+!]1[\XX=HF^S>:%LXJT>E
M0_PP]S[IS%:XCQ\,PX'CQ11CJY!L>1?T)B _IXK'4&'J_R-*^.T*]<_K%=JQ
M8J<GI_+@!@@/=I7'NO8D?JP+!28J_%K.95DO(96 3\V^/3KL'9O,'#<IIVIC
M-^HAWG-&?KR,KJ0CN*BC]8Q 1X6OBHSURB7I%!/@4!SW)<5"V(6,1-]FZ\4/
M*Y6AI 8RN]J;=(?C+MVA2W?8E72'^[$[#@MIQ4#?2M180;4K3+ ."ZNL9;'"
M/CZ^__C6N^";_YP&D>QX[>F0G,5((L%U[ OV#?;!*'KQHN>]*S,T7U"Z^!A#
M,NGERCOG6)')M RF4U ' BJ+9/]!D.E65V-0S+!B -['^CB^9<XF$6S?$3%6
M#"NXS%1K)D5ZJ7! TNFK,17XU:$_&I[Y9Z/!6K<W?;1:RU(KW2/O>@#:-'#\
M<EY]QXE_=#3RAR?KWN%[9J-)14//IP0,7XN3B:M&ZV'WF8I#J0*31$X34- 3
M24J2).MM"[8,A-5G&LR$WT>C55WYTSBE:"X>-0JZPA.1<'A2S-C[#WN<1$@4
M =<TU?9.D(DK]N4:]Q0&J/D,:Z*8<(S1'8U(>/"54^: Z=?HO_N)X*-)(CJ*
M]ZW;P9J!]HN)<K!(D=%$7*Z!:L)XN58-N$&#8&E;L_5NT2HH+R8&_J%6YMYD
MZE4AFPS,Q5>,3O8N8TT0;>MWLJ)O8"QP]*L4F2?I\MJ0O\VH9(T+K6."KW(-
M+FULZA8^[ R]W7_>5KBH<W1AO,-R[4=;8;2MY=VO%=\J+@A91(]NIGR-8>)P
M5:[P9:LAIPP/KM!W:O,1JH$K/ QJ@[7;$?WSBCW6S^G2,(AP_N+EK01S#\VN
MO@D(H<4&_<M9%,*VB879'[URI\&KU?HUZ<('5)>_R-5+_8?[UF-XE>C8J+Q-
M6.F3B;#RBRDR^@-6?>F3BH+<)_W<58_Q$]',6?<M,CTO>=^ 5UF$9HTH&"=!
M+.8%:)1%.I=!3OJ]P[/OW0V2U^G-<A129WST B(6@]XT_>^#ZRQ8O&1CXAJV
MZ58]GB?#+]:/!N,\17]DS<YRS)U__%"$&ZQP%A7J  YQ@JHYSDR/V#L]VH\U
M/S3Y.P_"EQM>AKL?A.SZX'@_=GV+E#;H'0V>VJ*'O=%^++EEMVM/>-IV;]>>
MKOF'(D/1O34QO1U21@OF0&]5;WBR$6V?WH&V'U1LWWL/3F_=@K__;7#<?[7Z
MW\KJ0!_$)?_SNZ/OOI:#GO2.C[33]4#H;+#X"TL#HM#3_MQOO15K?=2-J(-5
M>Q#M)=XK-IKX;[*<^$]C)O$_P58RV(+=C=G5&W._/5@ADSMNBKEHPZ^]:(-A
M[_CT]HLFWQ?I8L]O(7HEJM?J?EK>3FW,/3CUO0CH>,?VX9X$,MP&W[4QR)=_
MFTR4FDZ_/1NJ>%).>L.:>^R /ZKLS:_:C55*+J+Q9#G^JJTQYEW8I'N[QN[L
M 6A8]6-=GPVVY-DV3IN] #N_<(=QD+.QNA//#P?^X.SXQ=9DQ].C_N8[OUM$
M\"#4OP?KOH7XAX=^OS]ZL7?VR#:$H(GA/(00;/N=O]'GO=]+_&JO]^-<X8%_
M.!QL37RU]5 W\B;O]Q*_UI_\6&1[-#B\M^#9!6WK/K+(E N.EXU)!)U1]D!&
MV6-XGW>6.]QHQ>W.3MW 4;Q1)97\Z- _.CU^0)-NW=Y0(PUL^)T4K:6DC<R^
MW:&:';A?^[%1FU\OS*$^?"HVH\FN_<%[KA$)7FA@#[\!<C^I)/KC]YU5>0>1
M7;D6([@6V#P@5H\>M?K&7M7]VH;-><=@X)\=GVTY4K>Z34]-$.\7N3R4-W:_
M=N$V"_D$;LJ*;_8'2MK>F13RO2U]0+']FWB"/YAPZ&O'\GZ,:H;M(C#?H9&C
M;VL=;@H2"\S*P$%')I2DS7Y,#=*H\6\Z-2TH5QI0^I[I#XSU7J8_[F2&M5$(
MB(B'"",_&QS9-AZ^TP72:4X5>)=8/BUU<4[G6]U[+8BR:N]?AC^XQ&=4D"6(
MB*+[>BVYH/*L#E1_MY<TPKS685P9@]I!#,;J.NZ(ETZG6.HW7F*Y&&U@HEL>
MN@6DSP[M(?D(/),I[*8N=>4PN&VR146 6%)VP(V6$#I4);G[\*$];U2*G>/E
MOFC<JM&V/[.(D\]&E7F4RFW72:A0;AMF1!XNN3$;HN90@0IOL1ZQ\M0B6.(C
M.XJ#]( 7=GBG"SMTH$FW=&$/;:>,S2]LE:*;[FN%3NG@YXA#_M\;"!?O2Q/A
M2J\Z^=&HTM?#0< S[;$#6J$A1KKJO8';Z2V5]L"W43]OL4O6F_Z2.XUG5"Z+
M%[QZ.6!KL!>X[<+'<QQ5]J/I!O$6K' M]TIA3:?2]\G'4;)2.:^B)J)4NBW-
MT"K3KFW6X]5_/I2*\-X$BUNE(FP4%)?3/:R &V^N6!!),^J>@4(6+%*X#=*"
M'068 5)RNR^@Y%O.=2=I]QN2'A/&<T+4' 3R"V@)A8IC:FT0FY=HDH??8FNN
M1.EA97%]=]0WRR2X"OYJB52YRQE_51?P(9^QY>=W/NW#M:<]:,MI/P+/LHT@
M'IMG;8V$;XN7TOD>.;K)'7F557B FF'PA6C<#9B<<^Y_1ZT]CEW9NOKHAHTB
M<:@SE_,A$9O1]@;&Z:2#<>I@G'8%QNFNG&8K[:7Y(A_?;+P;S1KX3$D_=LR@
MM?T_OJVB_<U5E(WX^\G7L?>A7[5GR9IRE(UZ^XZ;&HHR>C C^]D&4=,4(;:\
M/TLX;A8-^-HJ&S<$IJ&'S&L&C70T^F8->1X/5:>I^70["/L#0<*B7KSDON,"
M%1WEMMNZ<0EHCF!A7(E:\4>Z2[Q?P9PE,-HX2C!08OF)PT;0[0",.ER%I?4N
MWAP,^@.M8R@SS()[T< D"#I7VLL@@I0[Q3JO0EA9H'R8Z><L^C6X0A0U[YI@
MV'(#QTXZ>3B'%S&\V)4RXQ%(+G:\)S4_O")M"0>N0>SJ63/B78%^K&NS.7HM
M!V8Q[J_5%"ZU>%QRI;XXJ^+.0(B_FS8A^!H\[[R<3( A3TODY#(V8>Q?8X,7
M,D<J0S4# G/3&0-C3^R?FLVAP($K\M^*^\I0@\#O.^A<OGL*8.> $(_R&347
MUN#2LD+\,RFQMSSWAYD$"^.[\1&FOLBB<6E\;N+G,5.".4ZS !XJ)]3R2#H4
MZ_DJ \&/*X6S?#V9I 2F'R\M]'*BA"9YH]8@,$^%%7";F41Z:E/3G92VB;")
M"3#6 !*C1V\:6Y=A%N4\A&"$9W2(N'\.S!EL, R6SJ,).<IR0DV\C-,QB^E,
M\_3?>A>]&JXR7B@*+0"G+B<:ZDT?=*A@K[%)>\6]9EL1:(QIIX=43D8#8O#!
M%I6)FB_B=,E]&.)@3)W%@'1!$\[]ZCN10Y1S.JMD"G(3;@TZ8Q'O#^ZD2A<I
MGO%$[MX\F&2I635":0M$.751B("I!>BEO)2KJ1\T[7YZWMN5SZC%39[.%>DX
MI@O9=9K!3E%#I+%2"?X[5PE1(ITED%Q6"D9MD3(7<I#K\)]N=X:(';4>[">\
MUH7<@J4QE>?N@7$/=)P#**9*CAUIPJIWA-M+\XUN)QYRZ.;*7;9=VY1Q->%
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M8Q*Z8U;][UK5M)YB%>?JFLD[J3M[-X@<M]:@_C"='OP8Q)0N>S%3JO!>.^E
MK>']8<0V#[F75G@-$H/*4;&5K->F7 S\J2_7:WHPECW+:<\<S! WF4K2[5D1
M BK"Z!$S@3*IQ"?0)\7IQVX,I1ITLEGRYFDL@"YH_0;! V4:Q9:X9CZTN= 9
M)]OAN&6VP&B+'L<W)1W()W2JO<@RVB7Y 2;'L].8,S]6-Z*^?%TC83SCL)$)
M/)1><PX:EZ#)^(]XR\;WN&*UL$<FI>^O&1 3]^DC'/1$UU>]E=+E_*5I#;R_
M5^M#K2(SL(M>F$63*W..('W_=6)V0RV#+N@[DEH7SE -^Z?%D\C=2K OQ-3
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M;JWPA@UM?E=[^U*?0ANV+1F3Q_L%K2'O/,CB%$'R2\&*)\0=^FN>@EYI'J]
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MF[)%E/ [2K_]CGQW@#-JL$TF0(='VEX]%('_K\K2*M^<FIX]&DZ!X:4(5,$
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M6.'S5>E,H1 =4.LNHCZP=)2"!T)BK=?L#Z0$RWKE=:Z)\I@"#58YF.S4?A*
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M$W^2%* MK1"7OWZSOE2\1Z\*@$\:-D4AD7<B/^Z6^*:Y7%>3-$71RWN'6T;
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MF,L%C&L@X:1Y))PT4A!/&)<\WQ*-$NKV_-\W+R*0D^[!?.5A40='T@5XB&Y
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MY-T&'.[?5;[[V_W4];4U;-0LT@L4G0(&*^52_QA6#+W/IR="FSWS^C;JZK&
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MB+JG4_F]S<_F1I Y$#A:*89\3,2=T6;RC%">">PU--PUB6B[_:7F03+?$ZC
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M*FPU5&XH#1C+FZ0SSO/A&BK1*"LJI<O.R&6,*68?U )AQ <UA55A:!S=QAS
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MU<_Q&^T+[OJMO$-8+G'HK#==FPMB>]E2EC==M%)7P#X$>!Y0S,(6S_9<4U1
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M;*^3DKN_<$,!\E0M%QUW!3>W)5Y=69N^HJO'L>ZOGD(5C0MR6Y!)A.QZ$M*
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MP;7MOHN)D9>V@;7I)JEC-71K0]U'T'1OD'$P89CFCI:9M)J)K0\?H6ARWP5
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M<3U$CD8T"H=R"K7ZSB-=$,:P2VP<<?Q[Q>)-"LQZ;_( )'H7BO*#97YB:*=
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M^7WY<Q 9F[9Z#[I]$!V707@'X1WR(D->9#CJ7S8O\C28K$->Y(YAQX":-RK
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MEWR59-T +@E$_"I!RT_O J4":-EFF@70\M2.6P M7R59 VC9_15N!VCY^<=
MJ0!:MIEF ;0\M>.V%: E1)IL(0Z)!EX_BGZO=W36.QZ$J)-=@1M!6'Z5V"1D
MY@0$$P[EEB&87_X9*+7M"*9WVNOUSH[..@_1ZIXZK3:/8-K4ZQ_UCX]"N9,=
M02G!@A+PQ],X;@%_[ JE-HP_#OO=?K][U.L-3CO=0*X=@"!!7GZM\"0840*(
M"8=RRT#,/X(;:.M!3+_;.SDZ[AWW@QMH%Q!,BWK'IV>#XVXH>+(C*"4840+^
M>!K'+>"/7:'4QO%'O]<]['5[AX%6NX<_3OJ#X\/302!=P!_;3+-MQQ]N?YY7
M^2AK\'U1<E=+'NS8L]S'QVO4\R/\!3X+_7IV";.$0O9;B%F^HT+V_?Y9?'H4
M@DUV :<$I>YKQ3";\O0,D]&'Z[)H\O'SOXU&2DTF.T)L C\'=3+,U-9,[#-R
M2IK#6^KG/;_)(^DHO;Y15-[/ 5J5ZKK)DKHH%U$RGY?%39)A.\1+ %'=7I3F
M43U5T?O.92>.;E6D/LZQ@7==1$,579<)L.(XFJ0W*MH[>L95L18J*2L<PAE9
M?03\5J4WL 7ND-'O@-FRJH#/:@78#8:%.60+@FQ%.9_"'H[+YCH:JPJ8DK$@
ML.1H&D?I1+\?)E8TV1A>PH-,E?>^.6Q3,:8A83AD21P&5EG?%M%>WYUU!X"F
M^44<-0_>GY?OUVX.M=&,]D[;NS-.ZF35OKQ\_[!M<7;$F<2ZO<&)(T*&\:*]
M7M>9S!V4JNJD)- \*8L9O0*+GU&S3-F)SF885V]^%8V:$ANEPMZ #%+E=8'3
M'65ICJ(LJLL4]C&"]<"G\U)555,"F7(\]F/-61EP+RS<TI1_?E6F;Y(;4BEP
MY?#/RP1V!CAD C^ 7;]<5+6:X>;?),!A\-6(E(HJIH?@\Y&CP=RF]32JZ)%T
M%(VF:O1A#I.MX7=3$ ZP]_@:D*^+3G19S&B7\;US:E9<L6IC>UU7R "C,AW"
M.FAH6)QFOH?./"DURZJQ,&VI,G4#C(/_Q&>!;KDJ([O?R7B6HE*E2L5+U%L]
M5C<J*^8SF"RO?UY4]3Z0\(,B%DHG[BC$/C#"<.&=KZ:>%B4</N ;GD]3J=4[
M^< U;H@_?V)JKIT6B5+<?OQ1561 [5O<9Z"Y+TNU$"%A*:P01Q7L-1SC$_G1
M'&0$;K'S(X]58I!T*L-A>_UG5F@7)8BFW##8W@BN<2(5[S/0](;+'1*[ 1%>
M-F4Q5\]HTR=%4T9[AZT9^&/Z_ H#7$R!AK&,$T>_%/#(/^$/9IA7,$:"',B*
M.C# *"N0_G4ZC\:+/,&# _\CP0.K 1:J@7=Q5X'YTA&,F-1ETLS@^5%4C%B.
M*3ETS#; 1W.0:<BE)$QG*D&10/^&S;])JA$P8VEEQ0AD[36,/%/ FGR)5'!&
MX+4T _[5_@@XI2PR%"I\B%6#<S"R1;/IVW?_>N4.M6J 4L'?@$@@K('**%96
M#=F)KF"\^YD%#W@*ZQ@JX %@&L <1[BU\-]3'N,AO+%J$%Q3OWO8[43G^<+\
M,H7U>#>&9HU5++$'6R!WURBI2.3-09*6>/?X# S2 T?&J>' DZ9&XN1%OD\7
M6\7\Z@U>3Y,:C]DDS9!G6[+NCA7U8N*5HH'9CLRA('(5N(84+Q95@AQ$L9=6
MHRP!N8&7NO,+N)"2FR3-\*;1:\>'0(#^T53$@/0 81:<?B5B?ZV\=P_&G6(=
M!&N9)7-F>%@';&R*0BN=I$Q:_3@*4#XY+"8/QNG-#]_#'UI<CC+ !Z@)3+6R
MT^U^^P5TFOZAM:?KQ(A>SYDC_?E?[E2M(@)G*2O*Y[KCJ;.&*7<T[Y-F<JWV
MAZ5*/NPG$WCS\R2[31:5+//TM-,_U+U4GYNNJ0.<SE'G]/3;R/X5MV-IXV;)
MQWUGQT0/VL_4I'[.3^F/2IJ2?%94!#R?,ZEO%([MC/H8-&C=80.[X]\GT;14
MD__YYF]7OUVT%!H>!/\.2F$Y2S(>5EK&RT??_'!%W ^G^J+(B:N-MI/\<"_'
MM?=PU>9\\8M='SK4WGHGW^F3/2_*>E)D:4'@QEQ6]F,21BCDT[QA<*-N"A"[
MG>A" UC"!$,0[W"YTPF%)[/B%D]\!H +_XOR<8UX@+LOP^N4#CT)-P9+"-@K
M.O1:MAL4@7=AF5;P-8@K''OUXNX112Q'XGO@SMN7+U[0.'@#<M%DTKW-\>6V
MQ7!T07)5ZKG^BTNJ8Z" '&'DC1'SE!"+S]9^M]/MGO6/3OLGK5/GF"/DS.$G
M_HFJ2ST=>4V/#\*]-A(V=9UUNH.[#$$.FSOCH[2> )VU94#_>Q]M+<]91-W"
M[MPK'7@R_&+]TV0(X+*IU:.([_7V#N>'\.5#S3)6LO]%TU3O'J-C(,27(D2O
M<W2G;310(AR)IT6(_J#3#Y38!DJ$([$MA#CM'!X&2FP#)3I'O4"(;2!$KQ-4
MB6T@1+<S. F$^'R$N#_F<)5.+=8!V8U>!XTRL GI.-)6OD<,.CA=VI:A-Z08
MO89%-D8#45IGZN"R&?Z!SKC725UCE.'P<T1<,&!9OQ=UF>3P6&F-(ENP'^R9
M6/[S<^T):Y@;9Y#[PG/NVJ(+=#&4B\ EC\8EHG3M-)><6P-L]*;H!&YY/)G"
M^LA.<\M;]DMH1KGKI]\/RX,?[OW5G@TI>O;9> ^UC<![R\!_IUGOI7$^?:8]
M80R^DWSB[\"G)-SXR!<^_])L<.8XS,B#=M+IMWRE^_R1MRDOQ/7YVL;IO+5Q
M.B\HVN OAUQO.*C<WZ0O$F+N@-P-\<*C9^@\-:KZH'1#5/6S>8X.3KN'\>G@
M+-#R$]?K0<:-T[)=5+8;G_8&\<GGH.O=!N*OCJXN'-LX66'(@>0J/Z0NT5^U
M;6XO,?\$D-K%90;9^PGH*,"?W2+;O8$0CX!O3@X&1\=Q_^0OUZ5]:L2ZUT7_
MU2WX20*=KVJ] ?Y\&?BS)&8O.&OK*IU'P1H4\$X@V\;PSN%!_^@L[I_]Y5)D
M3XU8CX]W[C38G,4G)]UXT OVFFV#,<MGK'MP@@:9HX!(M@:1;!M3/C7A&0#*
M+I)M,P!E,.C&AW^]?-Q3(];& <K9\6E\<O@9#&D!H 2 $@!* "@!H 2R;1]
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M07'0U[K<*MS_D<EPL#%R)B2.LY2TZ=-)9F(,E&7V'*#0V4?JP98@QMD'B>.
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M8^E+"QDX\XZ3GRST%ZW &@F71(IGS5Y5U]M#IP^Z0<PV?.+]<=&^/UP3"=O
M3::(+44D\7JT0L="X47SQZ():+V 8+7('[02+Y7BUAY>-[2-Z]RMB/CC<:GH
M+0])M0DQ(V4H46G):-2P:=#UBY!27=G*WES>/LOV^5P8!R2U.D!PG\O8$L"E
MLS(>3-XVM7Y,"[2F)B7L[&MK87P0M7Y\]?HWCUQS:B(YTTBM5%.#R^@+"IQ
M@RV&%=N*O+'L(_"7KI '-"]JOY J82)1VMJG;-GAS<=$ZY;B?1DKP$FL7_*V
M%K0OF"./-:M@ANBND:J$=C-<XN"S)OQM5*84N15C4"A<>%3  ).9Y'X"XKQ$
M+X'K]6+K6LO\OG3IM:)^?5^#F 1ES6; )9OK.O<(".DYV]Z^K'?D@F !WK%B
M,%T#U&+?=,$+(3L[F2IHX8["K]T&8EN-EU G5AQ#^[:4M+06_K8%PUKK]:G3
M4M=>W')Y,3TYV'>5156C$$PU] WW;0,R<15<6]0:944!22X<^3!*G+^L7$I0
MD2"% 4D:W+39 :F/4 *W=*:4OJEG2O>F@4.!$LQS/"6Z4"A',\V1$&*;P'>P
MZ/)B3RSN-W&V%#=JYL8.UG6S,TGW CRM@]_5SR<.Y:@DUEW1+W#3T,Y+Y=QE
M->4G5OEI]; X"M+6N0*D6FZHQ(<?D=)V.7 L;T:>PUK[VBB(#B6?AF,Z8+9]
M59# \*6,N2)S"=S1[:9PNFCVHI+]:L@^/BEU,ZWK^?.# SV4J%_P/'#D:K7&
M-AI*2M7F'2QC46'>MA2#GW*,L-OV0#[D' N89I;,8[X09D.,I2&S'?/0.,7(
MYC&''*-"*2''?,4"'Y1D&- .1V.P8N%<)G-1TBD !(:=8\HCAGZ35]\&@\A?
MQ?'9P,;5)J,9 S.]IB"M($YQ,-:WA2R,N8UKF6D_ MG\T8< BZW4<_V7[SZ#
MA7F?&T\^[]FFT?N@'Y OC":QGR4+X*3GD_2C&KLN%^V)8!#MM\C6?5CQNP/W
MB[\TXW:+4#Q+]S2"76J4^?>_G1V?G'W7[L;9ZJ:YY%?X#);4NYP2;Y'TK%;T
M5A@"K&)AX@J6%(R5=G.M<E"<3NR</8XMFB54\:AHYA2PY"DFVO+,KNQB!&='
M;.?\L'G,6/",CE"C09,J?WEGA/BE$]VY5FNP:P-R+X5+XS0X:2#G0$68+9O@
M))[>AG93;R%Z&O,=6&^OE@I\@_J#^BAI%$4EY4P)]H&@I2 /PG[7U$:$)(A)
MXL$<M5:\K+B6EOJ@AO/]5,]W_QZ>%]<8UFG1,(N#\40*8-@V.QLQDHY.<$4!
M!%8(R*'1WCN;FF-578Y>YY.EF[YIV4(JFJW#YMAPC"[9*@/FQ2KCJ=$Q4;8V
M?C&OR<K+WV*T1ZQS<ZZY+LKJ$G*1VV#1"8.V<9. A.\X:-L=/W <X@="_$!K
M<[[XU= --\-6W R#92W-TY#8TC\'7DDQ]*"\ WG82J9L M$VHQ:FNM85J=85
M\!0M<FWZB9=IZB$T1%OFNBC(_9E1<,.^!"S@G3))Q63J%9*RWISY=%&E ,YR
MIUJ)TXYO]=ZYNI98(\E" (/64D8@P0T ](BMXLA&&;,3?K\:)9EUUM\!;E=!
M6Z<1$V:08J\0;@=BB>39%"D6P'.5$%Y?JM?+KF LL ]KZOBKYAP\2CJD%&&.
M$BZU2\PK38YV#DVC2AP2AD1K24P);[1]L,06'G =AG?<P=XE8N0,(5)ST6RD
M.(!CG!1'IO64.<$_Y#3[Y- ?V'L=^<.7>"OR9Y*:0DJZ-H3P&AY3-JUA7TYI
MF(VMW'*N)$$7A"1QXY%R^B]7S8CK-8ER A(HN5XRN]H2CN+F<![+,$5Y]6-B
MU#,BA:Q[YC=.8TR3C<AI=N@BE([6.MS=KZP)*U%E3C<@R:<2A%RMJW#8^K1C
MN"47I@-:J5-O/-_!9C,;[O8EHNWRTB_UQR9XQZMXU0I2TG*Q8A,1".Q;=B^;
M\C(F>DG[_G'/N.07VTLIEAO?O:IA1?=H;WA'PPJJZ.U[>%JI9B8!TBM:N-04
M5BLQ'(6SNOC#RJH:I%NLJ IFY2.Y^>\LA&%^VTC) 4I6HQE2UH\T<J002:<2
MG].7BRL+HLD!YJ'R:_1%2+*Z1$4W9>H+<NU%2FK[?A-^K[,S)%%+IXG N:HH
MJM%>K&Y3\^@\8H+M]81F2%;SH'5RTB2H?ACV,J;@IM4%SI8C!C3:&"XD8'NH
MIDDV62XK@V'OTP2=OG!J_J.6Z^PL\<"&#N4*AM_KW\'SYL1AB(E()L]!*:?0
MN>^]0$(F.65F<1P)P!R;&8\4N^7<L#H"S0"-]VB;-MJ[J_J*N7]B"AY3+9:9
M3NG7E/0]*DPY1T((P?R"^/YW4VD(8>$B.ZPYJ59Z"F^NI3 %$E.M*/5A*6KS
M\L5^K]NS0J]]1E9<#YJ$L>N03<2'8"I7(MYBX#>:JM&'>9%2+#1E/Q0E5=0Y
M7_F,R=PCB=9NR" V'EUE""$INE!UN!*'*_! XL8G!X3CFC#HDR4Z^8FX38C>
M"\.9MJG"K:TWX/F1Z)3J@@-4QV:2 I+D>H3./&4N>FKIC/S/E8]I=68:N4]4
M4U.Q%0&N5SIT"PF( DF12XD9-:W,#&""/L1P2KM@[FA)!;O=0D+:?UF3MXJ3
M';4137ROG.SLL@ZFO:78,AWF:(L"27)F2RQ2[\(ZV4] /UI(70CS&UT5#7\E
MKEN@5Q;=%J6-F-J@(]&)+Y D5G&5"9D$]*8,TKQPI3WFIV>FN"O77[>]2KE<
M9;1W5:9ODIMGFG_AO-:DC]BR;*0_D&#1@67.P7'LB[A9S-:M[ 1;+TE]Q&I=
ME5]CCMK, VRD!=R(5NN4GZ50M:4W>IA<3I8>16I(4R$7G>WGE+*W,,C",5;@
M\N4=JC1?+LW /;=T2$W[],0T #!:V@69%.EU%&;OE.QF-"GQ/0\*(;AX\=+K
M@,GB@=HDP6F9(?CX U!-->9Z7$Z)07W,W[AQC&;M+2ZQ0D='KU2K=T+(CA[1
ME=ML&B'!B_;M!K>'B2-<F./K0N8C7+0RB,W=4J>-W[MDG)I0;NE$+<S]AOC2
M;:K",^,SP!*,TM=77RQFFK=*'X^U\M@I;B"C8W.#ER]>F.FO$M&N-)8+0:9N
M/'.H>VKF':I%H:WTNJ8,O;U58@&'6]T81=A!IJBK(7IQ3=A3^NV[?[URZD:,
MFK+D0IBL[#*:T;'K9K^(:OXRWKY\]^JW_>Y 9T"C8' '1S0CI:O':Z:L%5'=
M?8.K1W/4D3*5K2?D$]$B\4\+KI]$/+AS?"0VH5=L,Y,X>[#!LI"M'!R&Y=81
M9P#</%EHW.7W3(=E@]!0;N]CMY$,2H?*OR-<)]EJ_5?'N%OU^>'U'3F>U"D\
MZQ=<LXU%6SJN&( XL1>NC_+&4]X,"SU0 69>)X4&,Z'\P',ISNK5!\,0=0SU
M4@;>@R9+H;(FG\^MR4J)"55#19@RT#:EH9.C#3AZC>C,;O"0Q'I1C0]*1)+8
M3/\][2)F9I).YQM!-!5G[;?G.8)]1OU[P?9327K6?7N^5*@[1I&Y)26,'N0%
M^8ETP=HZ5%5_[%>FM)Y=*6GV#BLOM)#'Z]344+DD0\WUXF$@Y-W+UY<>"$G;
M7H7<#\36^8ZV'IP^+"9%DC(N*(_2E#AB#F'#J_,,*G X [D*N!V&MMJJ3(>C
MH[^:RA:R-L*Q7;18"C@E6Z1VMB>C#PF56P-J$7.2N=*R[^VTX((?)55V'VH7
MPESEE76=M-I:W3I@T&$]NU$:@)*TD,P,/9;;G?4M3#W!"JL6*[X$5J@7G! )
M]^8.9-V?!*]Y\)I_X:S[9,97K1/+_T[Y;5&D(52_VSN)3>#MK,B4#C4UP*K(
M1]Q?ELWU)EU8PLFT9.U$E[J<*?D[*?7 PJ\W[*7Z4?24*OH5,!4*D?-677@6
M><E(_"O7F*RB+2_)F%0C-+_ %-C/C$+>S%L[/-LUK@KQX3AUU=PK&3<)3N$M
MUQDF/ZQR<I[G1@Z-$!RBYXK3-'0;N!6[UGYF14$:H^&M5"!-?3 J"IY0PT3J
MZS-!8<HPP-R+'386H4(@"2QBS%U= YU-NJ[9&UNFV))CXY5WD?AG]'5+JK*4
M\>3BW+GG;I'IKRE*[B,^44U%G75;A5 0P%)REVACG-3UVAOJTS*[1C^_7I_:
MQ88D)W535_RM%E6M9@XB%8^]>/&UJZ:54X@S3QU#N5_^=T/ZQ6]<J=WOUR J
MAM4[<'NZO>\(8/>_DW^Q:;[ !+**SSLZ4=%XRPL]7BZ#MUQC^ U;-Y8&;UL^
MK@NI>,7%M8@_D11."PA3#P'HX':&999M=9:5L@A488PB$M)V$PC*.*30BVEQ
MBSGQ,<I372%)55+J;%TS67%W<"EH$ Z&T@#CI"1@:^;:-O4I!]5B?%-WDA2.
MQ!K3HTS5M=M BMIGF)A'^?9A1KAWOWJ'!4!LQBE+V@)A2@>*>N[6ED4JP CK
M6O'J;&@RBZ_LRNO\V'41%HX)G*LKO+Q1U!"!:Y2M"19"PR?Y<-V*Q;X.B"K0
MV('S="BH1)J)2;#925[6IZV;;U.+5@5,K0\\<.=AP@S$1Z/+1&=4^%]VFL-#
M.JM/36U/@*B+CJ2F-L):Z#N'BHZ$UV19CC&.=MS='V-G!@[R0"G"%>LW),>D
MA@LK3<:Z:W/J5OG5W 8PJRORQSJ263Q''TG-(>L;NG<<$PN<)^WL89,Z_I)T
M*-<AA,>V*)?L^%1RP_7(B\<,#A%)&E-*,[E)TLSIY^+&HAB_6V7-W+8EG]%$
MG?@$MEXNE<_U*P]5;CE.MUN ?U2P3"V'4MN6&$XTC%/4WFE@HB-YK _']JI8
M:NJ!5HUV43H](,HT;7XEWX5-,:/P)MO5X8Z.%SJ3F]D"3R<YDTN=8ZU-JDY,
MVZ'34U2^=9I>P 3U]_**#1V.M]Y6NA5:39$+O?O((E1S?D5;!,?$&CL5L=N]
MVQPTY\'.V)?\;GUH'=7O4$<7[%_1JF15?$BQY >-+>RW^9FL7>CF003S6#G1
MQ.<^EWJ2K@MV:VI6$35-M\5WQG:_00"I\[MC*WI;[6JU"U-?MSJ:SJLW:_R?
MK2*K17Y=M(2XC]/E)IVIFM@QG3@E&Y=X$Y3[6<6XU;G/-, J,;[!5&'&8^P+
M.C=J4K<\<4-,B2H';M=W[A^6N$*1N<S$!NIX32,VVE+8G8 G'ZWJ>-=!<%M8
M+!G+36Z^/=&^?#7^> G;NTU*O%*=/HZ))QET5>&9/F#Z82F@0HVDDSRYEDJM
M<-5QTQ2GV:73*VF?+"=<P\+<+;'D54O5:IR64-S%>$YT]786;+E#?_6JMY@*
M!2J_AGT;+S>IH7-G#AF3("U=GWZ[/H%;]Q75X&755X;;-[61W81T:0:T7*^9
MB>S K6M6";C0@J?%XUM-K;-D/)68[<*?BIM45937B6EJ3BBG%("'<8.JK(H\
M5QFF@:;9V#"I>P?AR,01MK C1UOH?2+XYNRF#EE4I8Y"+(1?'55?MHM52W%?
MQ4L=@O!7^C/3Q"06,[RN"FG"+NTX6,U(?^VW$7,*Q-F?V]J2VB]%':1<EQ]1
M1\PMQF+D;(V[8\[:5&5<J"VQRLFL%$3%=:&8$5MV)*X 'KM%\6_<FM9>,3W!
MY:8-E>T-X[_;F796:.,9V_&('GL8HPHTEO9*)>?$DMMOK+#Q-$F>HIP7!A2+
MLO<L]JN<.[>/Z=9H897O][:[K7ON\H[P*&5L&WQAK22N-E:J?2'&PVCAE_\P
MZ=:K@ILW)/[6]""[5_3X#<K:UROM-=RP5DM&%(NW['*+,KI?T55;P6%;JAJ%
M'4WP SB,VN\OUYL81O#V!!X%EE;  TR$-/^C,6/QW:U-6CYGFFY,>"ORW[F\
MG'./^6W37,"));73_S1<.0W.BK"Q#0:CC2HIOXJ.W/_/WKLVMVUD[:+?SZ]
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M5 8>#L"9*E3@+<-BZ4:C7L$/20FG1K*812]UBH,;$?[.P9$<90\>A71Z,N,
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M=:6GC.%]6C(JZ (-DP7:1?HG8QP ,2_@:ED1R)R[U#+4--34%Q:5X\$C_]C
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M=<5I$H3@)'F#1R6/Z(%2X0J% <8061)@FR\PML)1:\Y436S^1$(+($_*7-'
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MM*HF!@'R32G6:7 C'!2Z4/$Z;A"8 /MRWKPSU ]K$2W#C]K%(-H-F7I4_!T
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M!EV[23I=<OE7!=Z7F2"'^3A+KM U\4(,VA"XJ;BM&BCH!5:H@X(T[6;D"&R
MBZRL#FC\0?YN$XV_IB&YM; I6$''/F6B*XXV4+]F%V.P&0NRP+]&U/Z*J1K
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ME,VZZT]2)P$J2P-SPO,E>\$.Q$FBH1*/M $'25%&##9>Y7YF^VM$XMYPZ@>
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MDT:B=4LQ%V)U=VV2.6Y!E.5)-"O&*,N@R.'I$V-0SY-$PGK!&L7VL6"GX;U
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M&S:)) _W^$L27'KA6EW"".[XS/'5+F.Q2P>0 O3D 1"0F_ET1A\NBES H61
MNI: 1%@%MC$C!@7<)O,R:U5?@\B[2GP30+[8&!)&]6:BG&^3M5&0,? PL#>X
M\4LX.P!F!F0&%GMKCU#>?&<KB8,0\N*G#\CN*5_H:1 /K_RU'%H5F(ON@SS&
MG9T/!4QTG:1KN,%\K?W[+.Q6)5F!]%Q[H3,A+NV%"-4;$ XO^\.A.QX-Z!TI
MO!,_]$$5"01[2?RICR_#<_(2(,J)41%/BJ,U!1X])P,0^K"39;R&#?G_P9^N
M5[C$H/T#_F0!\LAXO4M_S. WP+B 2C,0N\XJB8'%>5SXZ@!GC#-\# 08O"Z
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MJR0^1.ZGXN>:-Z:V=XG)<![;+TVM6 H^J?SX[,TL<@Y7YY009DO>8O@UQ-F
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M1&*ZWSN-)!;T<?>9Q'G5SIQ/S&)];Q.*:;6=1A0K?>*^0XJYOH' =]<YQ7F
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MIV5=Y<",V&7=?*U?;ITZ#(#0;1#+DQV%LY!S'2L2' E0Q8G)#*$YM1.BF$3
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MUN@',X,LYZDVV(&Q/*99S $/KQ?!#&Z ^OL,G>.OF97?  RV<E$C.*!^ZDW
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MOA!EEB97X:GC#C>$'K?B:>@.SW=P!^V.)[!K1YWGDL/\,#Q]#G FZ@QCH0#
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M,$GP*R12V &@A-U9K-9%-!61<11.9;70/(#,CE,P2!K,^;MY(C7CP:K?"_#
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M]-99^>6_:9B\N7=NLJ\]P>,]86&1Q=U;_<7"E@B7D<SC\"Q?*:<XZ[XKC-M
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M3/_MPM%[7H&8'R%O+SXJ7-0M6Z K&\T)BV.23+AZ6K=);,/P>2GJ5!5"Z,_
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M]-R0@LG C2BM#^9>]XS_!N:&U>\8=L\!ZOHJ.K+^X.Z!.%0<@&ODR8$X5!R
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M-_1;$P\.P*'A !R5 ;6I#/A(HRMV0SY$C(F=,2@,T"2U:J,N0 ^ZP[(-Q[6
M9/U5$FP'Z@)0%P"=U 5*Q1PEH(16 DK4!>P]@F;1@+\ .6Z13_Q-XK#4&+KI
M"2'U,X!VJ27X3<=;_12_93O8OM\D!4>*'R0]2'KH-_1;$P\.P*'A !PD?7U(
M^I3%B1>3;^PJ'-*!S\B)=R7.BKB(TCBI9#-"V=W:&Z5 BJ5;2]UET"@@%:-
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M4(*;KR1\_NK'K-38N>E9(/73?CA[OEEY?9P]WRS]1EH?Q#R(>>@W]%L3!P[
MH>$ ',1\O8CY\Q8Y9<'(&WI!"')>C_RF@YWS>G .;<OHV#T@67^5!.4 <A[D
M/'12%R@5<Y2 $EH)*$'.5Q)"_[MH1'?J#2?,]QGY0F_(>_EL<A&E<2(#ZSB=
M;8I&ES]CX[X^2Q(628#%JQV8+8M_S?<"=C#)OF:9YL]ODG FQ[@VA?QC/K*7
M=N=7+ECI#"4#C4E(HO-^LQ@'=-YOF(*#<4#- &H&H-_0;TT\. "'A@-PU S4
MJ&8@H,F$8_ZN14XI'W; _D'9@!Z95Q=[^O5@0SJN875L(%E_E009@K(!E U
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MKY0@35!>@/("Z*0N4"KF*0$EM!)0HKQ@[^4%(KCWAA/*?/*6!C_(-W85#NG
M9Q4&\V[)P7S3$VOJ9U)1ZM HI@2E#LU2;Q E*'5 J0/T&_JMB0,'X-!P (Y2
MA]HT(3CQ^'T_\I_Y$&)R<G)426*CARH%;=*\*%+0A'HIMR-BHY!43"7!O*!&
M 34*T$E=H%3,40)*:"6@1(V"FML4SB<TXL^?,']$!C?D))P.:#0BGP(>MP<T
M\<* ^N0PCM.(!D-&SEN'K4IR 'T4-S0L=VH9;:=GF%8;D#>%'VD;W;YC]/LX
M:*$Q6NZZ)G1<[QH'N]5?W:C6*D._*S%E*UC__,M/5M=\D_W9"&4%G=DPAPS
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M!^ :.7$@#A4'X*@<J%'EP,7A$?D47+$XF;(@(2<G1Y54#[11/:!-TM4VT6=
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M@JO?>R!]0:<#%OG4"QCY2*/(B\'7-RD3B(WVS4KU8Z-]L_0;F7[P]4 <*@[
M-7+B0!PJ#L#!U]>'K[^8,'+H>T-&/K;(1QKX[(9\8U?AD Y\1BZB-$XJ:=+?
M0Y-^;1*O#GKTZT*'M*V.8?<<8%E_K00=@N(!8 FUU E*Q;PEL(1: DH4#U00
MU?/[Q>2X1<Z](4>7!B'Y'+500="DW&0;._X;13Y8O5(/SVLZX,KK-[@'5!
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MQ_SI+ZU?N:E)9Y"[ILG=1Q:QP4U%4F=#ZIHI=2O6#N #?( /\ &^[N O+38
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M< 2.P!$X5AZ"JUQ3<"0>0,EIE47_#NH*FI35ZKB&ZY96-0>P 3; 5@-LL!-
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MD?J^5TFK@6X;I09ZY/MZCF78_3KLB06.*#30'L9>VS1<U/W4'L=VJPX8HLV
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M$;+M\0&);_T?84I-,O-3/GW#893RVW*;Y'$K,HK%!2.:\*$$CQA8:Z[&&RX
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M:R\HR,=?>00:M?)[>;%\3+*Z8-_IJ6)FDDD:+]UM2F_(@/%XD,>7DAF4/G'
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M_( "K"$E-L)%<#S5'-N1E2P$"5L:=#1!&)IQ37<<IG4ZLD^::C<1,Y0J?:/
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MNG7@ CV3CU?'9&PQD"*1^[EJRIN<RN3H+,VW8TE@3*BR0/(+_,TA6/5507X
M5?=1\LVGM@67H]86KQV/UL)AIRR2./1AKY3R%I>:UHJ""5R"OVSZ%-<+TN0K
M+8:7_5@OL^ZF6_KOR9X!/QG-A 2J&8RJ5N/QIV:^\P8+TJ/7<"5BQ2-,!0<
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MU="M<"21H@WD8R7^+DI8,W2GR4-QXKZU)F=[ K?V4I+;-W9LA+9EML"&$/M
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M($:G5N4M>)S+:1<R.U @4KJ9DN5J[#UDZ)-2#0Q<]E5J[.JWXH5?BXF"UXD
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M;P-OVUUU^,/?WWP$C37XNQ)0\*O^V:1,C)QF0YYR3)M#3,V*<DS,4&P>EG%
M)/!-I2E%*0N@0Q/0QXB%RAMD^MWBI&:8CA9*T *$9V#IP>NR2/AP\DB85\QV
MR^A[DE03$%R,$:6A-#F=%;QF][4OQC2QDB  F!"88J@>]IS[^I"[(S I0?7
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MY2C>@Q.RM^>>D M8 ?C7*2IA J?C,SZ8<#2-ZB6)(H\#GO'L(#[>VXM>%VR
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M21C_1P*N8CF/S/OQ-8,,Y,\E,#0EJY)5M\OX_1R->VG!6X)HE%0E:L#A]NX
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MX<KO1$=J[M:=HW](C2&IJMZZA,R2AN^<VS<>[\D;K>^Y^)V_G_?I547CL)&
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M,.UA<+7A*>[8[-&9/Y%!?MH]CXX'SC(Q,<6<9K27 /F,@$S.I! D$R1'?NN
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MF0_6!AW; ;-_>>H$D$L(2,7=LZVXRW*Q),N0$NQ$!<Y6!;B8(+RM.4TT@&C
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M);3_1)=POM:P-^JPR#3?ZF[P3_0@V"MGH)K!)V$!XO"C'_\V>S@IS+!U:N@
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ME=:MWZB6>W3\WDVKUW=9]W$"G[H"3R+(UKLM\7'0?^H);OZNX#3ZE1IJNB2
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MRH]QD:.K?8E.-B9R/-YEF<S0:MKW-<1%*/$K%4,W*K+B)BXZHZCA6D!E[<'
M\- .K8NK<V=A$_@Z8&DX26R+]$T<^@T.?01)/'+QQ.CQ=P2$1O3K2/5K;]&R
M4U:;4PT'94W5=:DT--<& QM)QM;ZE!LD6Z':RD/;=7$RD#-/MXI]U#QT<?:5
M<G>E3_UIMNVU_'A72%FU]&U#2^_$6PUM.]0%#R>$X>%5.@TTK)=G9/%@\=_4
M>6+92SY9^##7OJXULWE;:,73EA/O7AOC##->-#>+Y?PG#,XF?+SMJ,Y4AEWW
MID%N6L7W7"0O.(MOK="RZCC*O3+M#70GQ4 [M'V7>KH3N;+=19D74I*+\>RR
M!8H-K)W/T%=M^*W.4 [X?.&1SV;ZT[0SFO2-D<::M3W/4$\9F0^ZZ[ER03+\
M0ER*9]1"#=VYCB+,*Z/,5"!W2O6HO];/5,X8&3K CE8X5^5&K6ZZJ7Y2OJIP
M]J0<?VR6XR>A3>S79ZJJ.A4'=U/'F9]5X.#)6SEAPM75O35^NK]H73V/)>8R
M9XCC=AJJ%)U@EE/+L3KM8Y:.1*/V-4L/K4*Z 9K)+#W(@#$OIGB%N0AF:95&
M#8$3:-7"0D6-T%LHU:7L#I4#&AXBQ3$Q"BD%GE@D]QC\BCN$\C!&P"3YK"1Q
M[9@3UZ*YB[#GE>0S8< W')6%W#.%<Y@>H-METI[G&&W?0UEO31ORU^K-YI%I
M"+JAQ:O]@MD;E.+/%=.XJ2DLOIF D6(BL@,XDB1+N(9PS<YW"?9L#^V;:\I3
M:70[J P5F66%<4%SLYPU'".N$9#/0;_K=)!=B;>[$HUF)7MU42GEY'H#)WRG
M_E Y.5_,%IMD3X(<*CV/0Z41D O1DNAJR>XW#TX#_*>Z/U!U9J>!\-9 #!WZ
M#>,J40Z*;4X5^5QD>"X&;$5^*I!5N)W<B3=R/=EB6X_M^N-]IBE=U. 41S?P
MNSGI;V_2NQ;92<X1"B69C5OWKES(5.O=[H]_41207G6'\[N!P3_1W139+5J#
M;8RT[_5L!S*#OE+.SR76TDO/TVOYUKUO%Y/MN]HHV=V$T@-N]>T6HQ^2F7QG
M%A\FXZ<D?66+=2LW86\NRGAO[GT?[+V=H/F;]K"[NC^8HL*/2.QCV]%=8'U$
MYD77]=^1M]T>-:1+FKF7"ZFV+J:ZSE593)\41K<KL(F<O!D+W%6CQ3Z5;+EB
M#3*W!0A0*"SP 6P:^,EXG\1^V03=N)]"HIHDJGF\4<VED_\$Q$<%XBT[K-'&
MYAE%<E<EJAV+-[IY2V+68F%7(AU^.1Z7V60OY]ZT!H[=T2Z8!Y#,?,,Y"%[Q
M>4^LD^8N>]EV.DX;VNTH]ZSX<=2/*/NQWY([S56G9OO)>Y)O\\9MRU*]>-Y/
M[U_N_&/M)M[A/(EF^R/:R5XX_-7EJ7G 4=60#_F!I8)9J8OLP&\9%67<Z]RD
ME9O+*/O.4=6+#TF[F19:YJAIM%JW-.B:4ZZ0?AR,46+8NKW/8_:[]ZP<&WS0
MI?E:XX#>7'2 \J ^]OM72OK9>4KG!)$GFK$+45^,7;EX*94<.MZK9+31Y/Z>
MH8_'UX_8MA?9_2-[Y-^[W48Q%2O^/"Y(,JBWKP>EO#>XNS[(]:1SKW$G5]L0
MQ$91<4][V_XK^LAVZ+R<RHW[+?]Q..$OKE.LJ411'T\UDR (X&3.)X"3";]\
M^_0X$%N5JM$:W ERLO+\^%Q*'2" 4_+']Z+5NJS*3X]C4QYW1Y+NC$\O@#.3
MNVE6#%[-7?-R0]!NKFIFLV04OW%^\ZMR%YVGD9KD&VSKJ3?H28_216\DD #.
M?C3D0R&%C)2=WO<?+X<MP\_<><KEI)>O1GEC.:IZ\2%IM[5+^T%.>XX\*"K.
MD*ZS%[TQ#N!\)WY#=..+L[4FIE!G"RGQ@F>Z\E-!3/I7E<=J=G)RX9N]Z<4:
M29OIZJ#)I^U+>IKF[JIEZ4(IYL?H*AKVW4JE[ZC$H2,YY^C]G=F8H[<S?K3G
M7K_%1Y\Y>[; 1MAD754SV5=' TN:L'2%5\?MVH0?5?M=A171,5:!39+SJZ?"
M&:><)'.TQU*_901NF0H&);MG7N080,='#9?NZ==/EY<U1 7")BHXHYRD-'P
M&KUJ4D/5T.$W*4T=&IYJDO#Z28?7R;[8.]R[[>Q9,N]1A/^9[2YMZS:X(UC0
M-,T?^,'MKCKH&)KA$1O_.WH;X4N4#K:&1?AJI24A43^C&5C8[K4<=>"IA@5T
M674L*&]W@09R 0M %P$*[)\?\16^0KU4JTHE32[TA6S<'F@WUQV%'RL<'5[;
MP0JI&,LL;W3](M1RHM2R;?N ,$;4+L_X'F,\9[)RALTVLO35]:U?=6O,XZ-<
M0XR!+M<08BDF%4NQXCK&.*,HPP=N;".5K [MCD7Z9J#CN.?MR(3ZN;I":Z];
M.@LC$\>;>W#$P'&#^H?KEHBFK<IR[R(_[*MUC4W>TOX0I,9H0#.C4H@E16'5
M$D'XCO!=A*Z,.S+9'0^M1<,2_ARMU9^]&TM(CE)R)3FI7P+#'Y?O:FA +Y8O
M0W.;:.U4XX^?NYPX1F5+Z4:#2E/9RO5UI1R8P52CE;F4LTVJ6:&JE4:CF"G)
M5%W.R=?59A$V2I=S>[.7SW*Q>,5N'"0PW?;1#4*1H+<OH^^O'5XD&C4A'<U-
MHA$]YOO%:TC3EKYR-7F[B%@7*:O;R,4+M#!U.^QEJ<3ED&V,[TEFZ1@CIF*I
MU+)M3*B-4!NAMB.AMH@6B]@QM?7+DJ^/X]T&77&?VN(PE7W.9FJ(VL+;#9(<
M%V-2TD?N7?X;7Z6P ^ \^JYG=*:+6/T:)VV]9QJ<;^"\LKH9\14UH)X:KUX;
M'%A%26N&AJSL'J!43;,'L)?H<@K*LCUTT,:!'UN4 9_?=7"^F^.A P5>#[@
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MH@6!;EKWH)6N/M4@R0@__N5B-$_'4@R_]3J?4;;;A,T6;<EV7:KCV /*'H(
M%>ZQ>#G1)=HHGX>.F, ^5! ILB=L/N<^;OT ^3%8BY6 5ZQNT=+L 4"$L^Y
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MT7 (C(4/GML>W[Q"?%,ZSUHRUA!E.(EH0>CDV^4F$$FCV&B7LO7R/2&9;+W
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M-L<XYD!6(M(GFHES)-"$CU8%-Y5W3<$_\WBGP!X10W-(9(#@!CPOG0C)XM:
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M!3IR,[=V(FCP#V6$]35QL<!JF^B]$X/4O^=J>8<U/'R5SLP)R<& ' =,>_!
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M\^G*098B82,(V+M%X!=<N]WSL6<FGMBX&Q*/'0R)^X>[WLZ:IB.->L3IS@#
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M!)<>?VB,F.Z!O_+*94:OU +&;[)T&K&Q6>AWZ-D _]_.E=^P2[MSHCIEO'X
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M"_7QS7(T!@2N>/P H*;'^(43#KD+9 "OM@G<I8&_O1$[R'=.Q4?8S=,;(M+
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MC0!93%,#6<0%2["]U"0J8\TH!7H*WEGGM/\06#!1!Y<!P?IBR""2#0!&HN"
MC(GO=WLCG.9FHHS/QY$M%.<E$,XI ,2!*D@!7[CZ$<6Y012ZQ\-R9*/F!*Z6
M+LZ%2,>R@Q0JD_=ZI;UYJKRK,EAL0YV6U#B&3]O"AR["5_8-3Z@FAQ5^>O;$
M\4NRL>8@*>#7XE[?#BQ9*#)>;XKEJ4K5*='>%'L/Z._"V'S5 30Z1 6>#T<(
M'@=&$GXAP=7#7Q+" \@>Q20H/PA3LP;4CNT*A@7E[>-T?$&_L4%*P(3#>PSE
M3)#IE+3!G_L21NE879_9D]C:%/@TY1F!)&:$'6U[E[:?9"SGKO1QELM5]-$
M&AX:S;2U07H@S0SMSR9\.C&O');Q0-RC&3WLM@T19D-. :UCB^U$<KV!YV&-
MP8?F=S@\,6&?15EN>_&PB 5"7&7,33<BE#YSX)I#=+S;PV($& %!6#(@SM>T
M;Z']D.B_ 10#>LR;X@:(T%92=61WBS,<N&'0'2G,$\"1Z2+<,.1I,A9]^$"E
MD,< HS>N_3C_,-"^L :(Y0)]^NY#H?L97K'_<43+TUG,R6F!85<-1IE:0G;$
MLR3,!9C#2*<WS;8ZV<JH\N:"%N-;"LU&87H%V%VW;,!D(NFIA<Z2LR">YNZ2
M3-_L^H;,O7F,D0I[CI<9=5RQV("&;GCZ%-]]/FP[]A+/"VQ/([%CV2CW:T\?
M$;A0;:\" 0039Y)E]T_QS2I\<#/H\A8@-$S6A)FTICTT9?N<@< HK8!K#4Q&
MO[@._#']@9?B6']"LA$BQ?\@HFN+509L[WB1..PW4]0R.G4;+\^_6GI"A!(+
M$"TQ;?N7.CRQ9F3IVYTD/?JAPXN@71&=>XQU(CP+RYS0CJX>''8=C:V9AP4H
M#XY!E28H(1I5TD/43)5)4P6*;P<6H&60MDSB2F/C]TCIRV2X1+E+BLLEQ>4=
M4EQ.DK22)6VBG5X)GE:VMEBC]@.YQ@QV>P5@K[T ,TBDW4V9 ]B'[^^'Z6:N
M51 ES GJ^&N#E,YC]<,^^>@F"J^\7F][[6LLL<*V0WNGPX97+/=9PU:&++V&
M;6*HFSXW&3%,CSWJ)9OGG[MOSNQ-%.82U ;1TSL%T/8(<J9KQ=AAOH.7^4[;
M<-]5=R#&^M2D_7OLA HA#")!I?C1EHJ*/5PE5>44G];17&"O[6SR<E.P/:(.
M18.+R-QZ+OCG=P'\Z=MF%GVC)O=S'P'P5>R'GE#"GI9P>/VLM:*R^F6G=-OX
MKD_<W)Y^:%0MV-%$AD@2+0/MTJ1#MG8,92>CP\ZP81^[G5^=7KG@&$30/E:1
M#/N '$<=?JI7C_&\F,5X3:JQN)Y8Y@&Q.PPSAP^=N^AB+MN!3V)2BBM1F5%)
MK^('4T9]JA.+J#JHJ4=]JD>?<DC=H3&YNC7'LDTZ8<J'/QB9PYJTT1@UL>X.
M21TDT*K*':P1D4"5:KH1D"9I2XZ,+IYW;H9E]P_[:LM&IT4A:C4D(:ELABF1
M[]T-DZW]O,W@<>0*C/X((4,2%Y!EHEOH WI'_'?H>X'?!5MO=(40_SO4Z=5J
MV?9=J%$,=<JE>KE8SF?KW5 VGV_TZMURO11J-JKE?%GH_/<_0ZH^G/4Y[YSF
MEOZY?Z*3*B_I]8A8F3:XV[ZA2,-9[;[U\6?T8M\Y62?(%B]%?P*@7MI2CTR9
ME@$Q!\1L)C)4Q  HWX!0IP?.FL7'9\AKR>/OL=6)'#GG<V;"OF4)W8I.=+.4
MS38=18F8?SN9FYXW4O!&.]9)>[ S_<&]J/;[DL,(I]TXEJ20@+&KN76$O#V+
MXYZVWXXO[3\^3CQ7QH0>WY@):>3L$#OJO7R_,!(GY6D?B:/L]29FH=Y[L>,[
M1[>:+EE2(\Q=_GGQJ>1,#3Q\04QKQUT\;+#7,=O.W5MC[6BVC6AK\(LZ_L2M
MTU(.PMJ00D3]?G5M1>VL#&O/$\H")K][+=-T&,D.A(HSYKH"1<=34^61&FBF
MT&Q NXS2W???GX!?2.ZI@.>"CV]<TK6U.6%;?(AI5DME();NUT,N4I$KJ**,
M1RGC,]QA]BI#=)DV*9V<.]PD1$A7L4UJ>[)C.ED[(&I;87[$F0XSF/B?XJ^
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M(E\"/<#X=)=:'D2J$"0'8<4JB,/*5DZPDXU.6'6WIMBN.B:L2V=D2PS*,'3
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M,JSIH#F)V'8#[4& 5ZJ+@ 3TO<8JGCE?8$,R:#,,J$74N$1[331#39T[GP?
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M"VC(JOOV$+P5$3Q4@$[TPJQ7+\1YJ&YOU6MUQ/,MTAM-OHDFW]*.XP!%8FB
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M2WR[%\]Y73! )+*/"KQ7?!3<?0VI/_I#$O^3M\3_6^+_N8G_QYT/;W!51+[
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M-.'F;#<3!!U$5<RW!\:"F9*H]!X)B:$N)8QE#!A5%+?'5VJ"9%1]NX;L2&@
MH/4(9ZK^@,&CD7Q7$!0$A!. #RF:O?LF!SSN+E :'5YCSX'R(0M*&N$:KG6B
M3N^?P+6$7>LC$)8]#/J%&=27-4LZNP$B$86.FL6TQ5I+YN+:5&K27C_SS[/N
M?*E..DLMJFE+2$Q@]MRM^PG%()Y36 (;$^KM).>7F\'?PM^XR2<!,^-<M$<Q
ML4>>EA>OC5E8%&NYL)&Y'W3#,&.?-4=AOG$^LUM-.4#7.-_?SR?][2"F( !W
M@YBZ04R=UT#RJ)/_\]WZ%#<?1_&(C%B#E>$Q$1PX8T L%7?.U-.\'G2.(OL,
MPD$W"N+,<_H$Z^\XW&9U@_8Q\JAA:T?\T+G5IJ'9Z"_N]Z_T;^NL\UIEOD%"
MYWD@L59H9AAJ'0YC?)']/<7J)[@6KD_I,6K?&K0%I-O8L;H:V4M 4.2]"^%=
M@0N9ZG70W#R*PKZ/U-O:&_R^1-G!SEZ8Q5[_D!UWT=]X;@;IUD@%)!9F(!QE
M;J&+?UN__/,!)&\=%3#-?UQ2"B\-#"(D<ULTW+]'TD84W%++$K%$OA@:^B=8
M(Z:7X8/[/^XOWC5B'+OG.9F>/'CGT%C_64\D0PPA8<2#!%MKW.(?UP"HN*8#
M_=__2B>2Z7_^[W\,P3TN[T5?WDQ,4JB+'@Y]X M)P8#"3H 7AOL?6.3_X%VY
M4<@/HQ!P,T :";$=+;+XZE%\2MW0YYA.NF8X66QMI*5RZ/!V[G6*3FVS2N^A
M@QWW_[3J$>JCW9Z+++B[]+K&;GA1%/1PZHYA/L#Q7BBLU$1MM4[-BK'!=!:_
M5W66:[ZUMRG)G/-[O3-;/#]GRO1[?_CZ9%QYJ3W,HQPK%;<+O2Z&MO7R&!?3
M^)727(8D<<6.]PR]2<V;U"3$@=T\<)XZV6L6;7RU*^>/D$>OC,RZQ TVF5PR
M95E\GG?%X>.H6XX,]7I"ZE52#\T+D(8=@J>BXI0GZI.'8\'4DH8%.R#^.#9B
MARW!5N)<\1EB5/T#NN,5"3[F)O<N:$^,@D[R#_Q!HFD Q0]]?ZB/U%8GC8GH
M[R_'=0XZ22'' N:F>?X027^&YDF?[,S/SL6I2@I$ O',\#1]U<V\65A4]$E+
M9KC9JC_F$QEUJ4!T#Z9Z7?HFP7K]!7%@G%AN]=,E""\+68*H'/E+P)2I"#I
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M'+*[<S;VEXO4P\6GSG(P:W69^;*3'$U&L>&J-OY0N#T/3I05392EN02:#"%
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MI7I@/1'1#5I ,@*2'IBK:)JR- .&-"9(1BFJ ;\82,0C,V:A:M9;.%D^\K+
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M;M8%DG)BZ#-UHF5Y!U/XZR+\5TJ,';@Q_6^[GCEXHPC^#!0 [!WFFZMTFX^
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MD?LLZ_S#Z\5GVJ^N#<O.RF-R!4..]K KK@/QE>Q7U(5JQHCV.SO7#:_Z4>O
M7.&BG\> B2#^ML4 /<8N=]%+MS#;*#S#_>L^*##^LU^OYD^WIP^OX,,KAU?%
M%_1.@X^&3W>SHE&,\-+#N0@I"SPNN"YFS7N5U@LL[Z.*-78IPMCC#/QK>P%L
M,1=TB6&FY";#;J&ZWC3, -SF'[]);;M-__>^@K'H+?@C5P$;7YP4GF"0_SC>
M)GYQEK0?4Z1=ZI[:-DDUO7KYL;#-" XC-V^2SU_:%,/4X+ !^O$C-SFO$!-S
MCCKW54M>'7[>3DOW)3]V\V#4+9)!>5Y"#;\Y3/-J<UB@I1^GM?_&/09XDYH5
M%S.%I7,(EG*K]%K-&HVU%MVY_^2F7(PR]XTR7YW>GQMEKOL*TRV 3-LC)[5T
M7BP: %(#E*HQJD_^]JW;GX&,*F=H&@N6@3$G^*%0FDLUH0Z)/>C/KTO=>E!M
MIQ3"_436S@^B'X;@KBGQX8RI#E<E 7LQ\?L.=ER?2%Q#5.]*IB+6CC@4>&T2
M<-Q0X,439#9%GA([IDTBO/&+_B?1\(>F+B<V38Y72O V%B^.&U[:H[\DV-Z>
MBQ\'$G]&4V)*KOM2Y*[NM.!H7I\18=\6^FXP/K H8\L))::7PJJ7U2=BM5!4
M2K\='^#'DJ.Z?,08WK:K<.T\VUF]LOGPJN>985?:JC-U=^H(1M\]$$88(C4=
MDXV2+*BU\6IJRT'37$!66O+7WQ1%/5%4ZAX#E3&LQ9'+DY$OW3FJS6QSU"V.
M1WV!TH<HKR 2WB*:5X5JYL!VF7X1:7%SFQDNZ5*N.^NP -7H7W\33SB.P__?
M76CT4S_"T1>P'D7#!.H-Y_+X+L6EAQ\'4;<S@<>!GWL+_!S1/;FN9,4$]LS<
MD\\2X>P+S)YNG\=/O<]/G&:Q(W>+281B%LC*6/DLW_[M%(J3[/,N.Q/HI=BI
M"W-M;@I#*U_M()#A'W@O.$.<UGNY-"3$V'A\'^?*L/&>W)[[ 4;$8.<#>6T+
M".6M2WE"Q!9I_[K".E23:-A9L6\*Y50%*:XQA2KF8$$3F!WR1%+D=QR@1Z\*
M^)X]&A*4;L4VXH26HB1M50GI9"7W#2FK;H5_=Q18&SMBQ&;Y3()&R22!A-G?
MD)=T0P +'@%;@.\$&R]N]U%VQ$H]E,SP6>Y853TW8DP]U/P3)E@II,=59Q'/
M+.C#(6K8IZBW<ECZ.QS(SA/V.APU>]?*'FU[]E(U,2R(&*6Z@[_:+Y4Z+\0%
M#B?O8Z\X6E\= *LNF>8JG"K7'[HA:'C@@W"82L)WP\J,B2H$UD1&<DP[P>M3
MWXS8<*NVHII@.L>Z/(;U'@'^NKJB.A$9[A"L1R+$K 2^.WG35_")%OF#IT_A
MTU^X@6<.@!=G!;8%&_33682$JB$=[RL#+UB*+0/OEAQ[GUOWDUG1(V9?=3D#
M8 6>M[!A5Z"J;K_\AN4==%:S]!'8AZU0[B )-5C/?P$HC'[\]U8X#CT1_$EW
M[<U8 ]LW%2"HKF]ZH6HEW-=G@_48@^U&=1+_,FVP<O_^=#8/O4MRMP,H1FN^
M/7FMCT9JJ!G*MISGJQ@ $7?!?(+I@@@ Z:9W9O[MR2U<'1D^QK9")GG)"1N%
MBT?]9PCTVDC*8U4V-LL9-;*@-D,U@WS0 "!U*-A@S%!\@&"K8$#L&^%P=X1#
M!5]3;-/65F$_?3=:?]7U=,@S_?'ROSUR#J$-**MN*Z O8Z@6EKT[4,^1(+,Z
M'* :ODE:2+H)__2T48]0^\&F]]',[W8O6JW?$<[G1&ZGISNK!#0-?A,(OB2/
MPZ]\--(M8S@TJ-R(&1[6 5(W@SOXM>W ==.$"AV.0]ICS([D2P4= #)LJ@OX
M12A1YV4?-]35EJ!;MS;3\@&VA/SHGX-!-*;/B+>C3?(6F;=92]D)HQ[@X08-
M:K;EO*'E[FQ9T-N@,Y8.I,\-*Y#NTW4/)JL^)<]H@JOW)X5@HK4IT3@C7??G
MHO*%-;;K)(W /PARV$"[7TIOYIG 'Y.(;[^6^%4Q)#XLP_>UKPOYH,25U[TN
MS#/%Q.MR?>N"/Z/QLES?LL0P=IWK$L/8=:X+_HS$ZW*Z=?EIEM)77LO%)N'.
MJ$ _R\[YT9S\Z:'N$<@$T5.G?GY%%GA@PBY'COR%7791!8J%Y>J$Y?/=[Y[
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MJL+PR0%4"3TH\#L_@PX"C*=HD@8&D%$=VTWD7AP%7G46NJRZ3\",DY_A9N_
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MV#/!IOV_[7KFH%1^R0#6#L$+($G&#JN@NR\R*7U'+M_.ZJ'I.O8<7&<(?(^
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ME/[]3N)$5%9)A):!*\7@DDC0#"I*N#H4,0I#5'6D,-B(WLC?YALTF2(91B&
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M5'@(%H>$XZ.ONP&AL_CZO&J:\-*]I52W2O0Q IDI,YM7\W3;T"LN.RW5S8:
M:"**;#)4X[NL\<'@ VCD:1WV'VDD[0WZA+DV:X;N36I+CEPTJN-0(\/$4^33
M#)AXC[S?,ZS'V"+/XG7_2"';3<^TF\FVB<P=/AEHYL"@F  J),PG19^(TVAD
M?*I\]1IYX5/ENW*=?Z22R[RH,(O ( 1L*<VY]AIC>8F%*@D=9_J)IH_L-]_>
MH7M>M51',D-G6E*FNJ6[GA.6V8V#^\<_=K_TM?$S'\M?>KA7 (KGN5P:*3$
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M678 ^49T)*++?3/19^K;3S(GP\@U^?K %-?&P7DD5:ZVI+#%<VO&7(U;2BO
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M4$$770^+ ;KL)&U3 YLR8" NVSQK:H@UEUEVZ(*MI#IHVB](C XO*O*"K90
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M!D;Y T9FQ:!>Q-"5'.*S49@[P[O2R7U6Y0WHY#Y7\OP#.;[OCBLB=\Q)I;[
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MV$'4>U_R5\'M5^K07@&QWZ( 9^)J^JCY_/FZW97AN2'IO00F.!?@#$0?;T6
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M"&?L79F%(\-1/ZS1X7;(+L,IBHJ#*=8'545K$'0GT6CJ(QI]DTC2?Y(RB/7
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MCV3D4$)&#AU-XB\]N->OZ-[S+$^.)/WSZ-O_\\]1!JA*(5A"DEH%T)=) L<
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M$D<DWG(05XA<RLE3<O*4//,V)T_)R5,NOW@90II<I]#>,WG*U9WD+Y!ZKIO
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MH@'H],IJ&A5]1\=^/F%0H1 \]_(Y&<(1(2V7'NE%R!".'/[3M8T*BVJMSRZ
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MUU&F;7580Z:*HBH.X-W@*SNCO[<'VZZ[;I8EH0:ND):P* =#E.IW(GL0WTA
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MPTV/'9-D1;%<X@<B,!W.=$;$V@OR\_<06._7"GO_5LD[K^V;W8"(V]D&8U@
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M+@*^*V[M%EWGY/PIJW;J!:TQSFE=*V.6@%L!.BB6*3['K9_-]5RS*.BYT7D
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M]996 MD 9E(L^VQNV.>(W7"S2'02EWZJO)?X7X!?"992C-E+T#!L3O<';H\
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M]4&A,P6L@,I#<02[83*VYC;2 %T8/KKT<T+ 'H ;T+]@5J D+0WG13>(>MS
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M =81\QVD8D>(7PLOH0))LU#3(%%#"<QS:H-I-NHC* WS* 5YE56$B-,.4%1
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M@%<0_UKDV[!\(&\#F3R=0.)I$"S;WV#, _"2I^8>RA$*:)2T,1$*9@OC,8'
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MBSGP,_W+@UVBU*$HKL5#WEN4J  20$(CZGJADQU]%B_7^7G$BE57F(\&P>]
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MMG!6=;\R+3+)9+!LN?/*0Z7;F8R35];J^%*M%Z&&)1=+)W.Q7&$_&O*YU-Y
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M!'+]8LE4=G_IH&L,*;$92GVB0'6P #7@&/5>^?#4A"MZN"FE>S4@&D"J2]K
M,Y4=2QL.V=4I]&=Q6&=IP(27H;']')MJ!BJ\O"816^%S7VN@!,XN;A/E;]6U
M #G]MT^.[T\#;]<"QZ;6W&5O-3Z[&,M/5P_W^C@7OTF6?E.F9#U1OY:;\SN#
M(@*G ?UN;-EO_Q=T==XD87YJ?S&%]0?%#%7@I#>ZN!SV1J>K<64RRBFK_%RI
M6\LW"IFM(H2=[_-BACU3-PB7*HM![?BIU3Q[&%_V3Y24?'ZOWA=#4B6Q3YD2
MHLQ;@@D<] ](G)*'T2:V42FNBK5D?]6)/Y3J1O[D\>KRD<J:U&8(Y#^[3#I_
M)B(*G3D$HJR@NG.>@(+=JDU#7R'<"I4S,4GU+[RC)@BL']>6\9&F4@/@[W/\
M3^\V/FEVX[-FM2,GYTU'M]35JC)\#\@)Z 7OMW7PN'TWK@Q>_X=N$CB3QWBQ
MN.XB-AM,"40[E0B44'P'9^-LR,RE9 P@-V3)<OH_C1^[4T;O/XWZAGE3-,=G
M&3L^B]N+HKQLOM4IW@VC^\YTF^G:2$:?YU3%:2<Z3^/4Y(',5N>%<X?.^-]D
M=F^^-/.@_VCU\TEO7E^UAL>UNU%E<G^I#.L#IS^'N_:WUA?=P'T"$@7\5=,,
M;>).^.FKB\3D/-YIYSJM>*UXGT['ZROG5Q'9?OO\VZ*M$O6T(>1](J^B[<K5
ML'DV2UVW1N-67$[?G5U=G-0P'6E/Y^^P^3#IID)G*M[21A:RZ<]&1_=&'/(R
M0!P9=SJ+=S3WM#,ICPN3=OU!?ZJ]/W' L^B'SLE+=&(TG=0L7BZ31*K5N"R/
M9[>7C1/P/_9$)XH_M4V: ?/RF]N7[87)::N5N%*,=#\_ZZSLJ^II0F\LC,GB
M(]N7Y?LY*5PNY%QEU3NQ4K6BD:UJI2]O7Z:,S'WMD>3ZG=2J>5><W#X61_+B
M8%\>[,O7,7IS7';:3_=INQ,O-8V+GJQ-[QIOOG3YD_;EJ&3?D<IY[;CB3N3N
MV4VV>W;: $=R?W<U!_OR8]F7Q[,'S8UKK9M.-S7OGS7:IW;E='BP+P_VY=JU
M[GFJHE\.S\SQ9:,ZCM]U"[/3PKO:E]_=P(0L7$Y>RF1:?;R\G50JVETB;MO'
MJVZG,OS()F9KMBK%NZESJY.:+N>]?.LD=='^<"',G;QYUV:J4XNG[E,WJV:G
M_E2^Z+NS6O6V?3!3#V;JJ\7%Y=A)*^/S\F/E[%@NEG/5.,GFAQ_94'UTM*=X
M)O'4J73/J[/C[ETB6YB!E7((A'X70W6@/5U<*;G2I.-VG]P3\^%REJH= J$'
M0W6-3F[UX_)MTBT_52;5RN7BZ:QW7"@WW\E0Q88%U%B=?V];]90J8V&J/NK=
MP7+\6!N?E1=&YW)LN*7>AXZ&JF?UI^)Y\K[1N6SEY9K<*B9G:O.CF:H[-S.U
MG&9-S'Y9KVB3X;V3L:]+P\GAMOU@9KZ6T\?9[M-Q?F78G<OCF3HL]^+32O9#
MAT/3BK5X2!6M=*>5KSS4)E=C^?8,5<?!ROPF5F9SWC(&B9Q3KM0[=^F<.1L[
M9S<'*_-@9:[1B5:XK ZJ2]E(Y-3YD[:XJD^5ZGN%0X^D$L=B@OXKL9!9L)88
MC-8!-PQX+;H&@$8^Y ><LV5Z;3Q$=Q7(A+>D/J%G0CYYSN]%UE):V?L+N:)U
M4H-FOG?9/+M9?,Z<7]:@AF&YV +8(8#\M6&>,)!K;''-C1B_>@I-%\@=-@$2
M#.T7V\/$"C23(IRF'-D:$@?(CQ((:UK-J.PY^Y1/> )YYGY^.G;(_MQD5:-3
M=)OG^?EXM1P5+A7K=/"4_X1DA2*B3T1I %$WX":#.'R '0A;T,L4"KE,.J_T
M"LF$W,N0;+(G9[/9GB*KV4(_*<L#&0#Y  XPHD_?WXE_MC;LV^B.]^8^=JG$
M43*[T<IN;U58S_4'I:_M_X;SQ'VC/F4F:,:7^>M__]OG!_-L4[Y/OU0/T$L*
M('J%%Q]J[[9=?KR (D3NTO-C-;^Z3[123F:XN*_-3TO#]1+*4UFS;@$7ZT2S
M%<HX+A5[;?J&8YT*V1\"G%*9II5FYGA22:Q.%BNU5SF[[7:X+449B*@EYYGG
M.(BE1*C],06)9;GD4T-:UMU@AS;-/T<T;S0; 14!?3[&,.C]YEIV3#37L+D&
M@U,.?#B55^P3Q9/>GIKRP!5C85".8/W_U"L 9[T4 T@/B*BNT!^M0#HB&)I0
MBC;9LIZ?O$LAM:K"V)< YZW0\70?&R[&P;I! Z/BI/K1QUW[*]B5*HC'1I_:
MBK,$;SJAVQ3X+HG?I1"YDR,,QU@7,GS:!Z#T7\&JOD2_/+HUKBUB)'[$1*'3
M&II05__WUP!TNB)SHO-:7BCR323_P29GJ7_X7U5CZM+3I+:X3B<GP619/9R"
M31<DULE,HM,;$XZHJL&L06-Y?=^L( 5\$2BLP,ZEGMLYS5!T5UW?.42>U>C+
M9"MZES;WEA&ZQD8-<%QX8#0XL>M;GTX5!8<'9<88(/ >*B.HS<,JMZF@<?05
M,X;%7U_OJ-+/'15LFVL$-HYO-MMW=HRVYK@<(6Z!#J7G5M+]=$ F4U>3NI Q
M?FSL$%'4\%,0^/7VB-"OJ0T'+6T=$0 AAGHD0>R.855&S\O#IO/ZX<(CH7Z>
MZQT+S841:/!#?]1'GR;4]D=0CY@Z@ W3B4RAQG)ANCK(1/)%: *T,]=5,4]/
MB<Z003VJ<<TP(3+8/6L*"[8;VU>ZEL7[^6KV%T.LSQ\0ZP^(]2\BUG/'N*#D
MY4$^4>QEDNE4+Y,HDEX_7TCV\ME<3DUD$RF2&G#'F/VBK?1D^;IX>G;^.*W,
MW.IIT3T_T9JE)O@KZT\^C!O3?N.R=#]>7<^U\5WZI'7I+.B3V?4G9_?G>K+F
MEHN=U%V5+.1^_D(9P9C)Y/JCP^1(5;3X_5UBEGN:*[55R[5=?#2S_J@ZNEV.
ME$DUVYEUS/[3\&YJWO46O50OL?YD,?G0/RDUT]6QEG93L]OVE:L^-NF3&VNZ
M[?6?%@KB0)2Z-\;\HDPFUR7ZY,::E+-LX4J=*_5$_*GD#).MF_M38TB?+*P_
M.5D>#XE6O;CK3!ZN3E+QI^2T8L/;-U=_FS*FN4(YE4S(QXD6(7JS=J'#DC97
M7YW;_=Q9RJV-M=*=:LUZ#\/%7;.7WES]K#:[O&DF>K>)67KQ<)>L7EUVSX?T
MR8W5=UOQ\:.6R2S&FELMM+.UTM,]6= G-U8_31TGBS>)JXO*6>^Q])#N/LR2
M9R7ZY,;J&\?#)T?7+AX3[DB[*I-Z[[QQ ?/<7/U<712TQUS'3=0O3M*+X]&M
MMDSCHQNK?]+OGBY.G>53PDTL3B;SB[.'^G#1RVRN_C1Y<K>XN$H-.]JX4>D>
M-P;SE5RB3VZL/CDOG33ZUMF\DE(?3I[R_<1UYZQ)G]Q8O94M*FXC4>YW+LG#
MXV6S8YX4["%]<F/UJ^KHX59/KBX[9*#>/2E5I7!?@S$W5]_-IA97IC$XJ72G
M_5*MKZ:N9I<PJ+?Z+7THGG?AW^#PI_88K=DW/%!DD$8J87 W"@[W"^ 'A8(#
M\@2B$5Y?]@#H)^]ISR,!04L*VO]\1$RR[X?"3YIV;IZNEOOCULGUS95L5^WV
M9+A/%/YG@CAK8:<@9?E4M1'A^H+4]"(JU%DBF;J52=GHR,KCI'/3</*%BS_;
M,^14;S>:Y4E#Z;C)P9VK&:?%Q:3YX]]BC*[U72C'WA:R%$(H)(,L,K7H3PSF
M_EJ$>W;8F\<Q@\X=D941/&Y:V#J"N^B>GXUQ!2DIW'3AE;-^//H*KZ[ID^&&
M).!CLA^F-GZXT2HH]--()O%6^EPH>'=+#H8A8A L8DM)Q_A:8CQL&@PJ3.@N
MP/VH:\=X&$4$5D6<(9A>M@$K#0^RE](IS$WP.'!-V*-X2JBR!?=SRC&+*95]
MG1ACR8E ^%WPD W9$MS_F$AZ'Q)E^^$\H\BSD3KKI,9*,WW3'M431NF]4+91
M#GR:],G=@NY&'E]E22Q%LPFF,GI?VOQ;.QEYIMW64W$Y/!O%$_+"U=*5>,Z=
M.@MZILFC?;52_VF'0%&+?QU)=7YCMIONY?MGQU<"6390M:WUDUFF)TGK:EZM
M=.+G<MY<Y;-*+OZG6;ETO:P\*E?U0848]?S#0[5\:EY3HZ002Z?3L51^3]C;
M$!GF:MY3^Z"TOM:I,[MD[=A'E6%\W*H.'\;E<KY=LA;D,CT8_N%COX\[I?-Q
MIG0SGCQ9J<>S^QOW*HZ]Q(KTV.G1[^_8N;5&#QSNL8^D;<HZ<*6\V;!.UO6@
MG8J:O+\;'7[H>_B,#Y.=6[5D64G==%;GG50U72GGR?EPGWT/P]=S"J>2SP>V
MOU]-\2:@?E@$V@:1HB';,AMUTC]SQMWRM%%*U\JKY8@><>(HN:<3WN8 ^@U?
MN<?XUQ?W3YX5>0@XON&A?AZY][+ANW?I-:S;-X6;[&TI4:[<MF4CH;L=2+Y-
M%6+%?35N]\27+-5@=Z2R;.DF)+&XNBRPXP<N@FOSG/U@LLNZ:[_>2:#PFD8"
M?RK-,7 2-7[M7X=^$>R2_QCN^#N!0 BFC]"OZ:'17^$\UK(CSR!"T;NU$^/E
M7;I>'\M.?]BPXHO3B\O%VGW)<X_V4N^;'[F+ZX- ^2'LG2W9[H2^ 9++_&ZL
M]F8[UO4[ADT1PNL!WM:FD0751)@P*@%DQ?H7 AZ\"*+]RIM2+\O\W\@86#^9
MN69K;/9_LT)7^@ F.Z7_"4XC(C<](B4]\%;(?>#9') 4H+!D@G">1<+//>=9
M%IN)+(XEWLI'2[(U;$U[9SDQ?)1,X2CUG^#J7Y/_O</=#3Q(OWSE7J^EK&]9
MW[:D_N11+O/MEISZ;J></\KDO]F2OR=A%[[9DO-'Q?0W6_*W).QD[ILM.7^4
M_'ZG_!T)^[LM.7^4^&Y*ZEL2=N;[2>S<)S5%L.3WV>+P#^HE%[X,!Q>>*Y]Y
M*4)6LC19IZ.>$WU.8%GP!MFPXUZ C$6,-O\_:H<44X</\<[DUW:K<)0KOOMN
MA8OFU\K@9<W"JO?HROJ7]C-B1+&=&V.&'\,H\+N\67:V81P<6&&/K%#<=ZSI
M=UFAC''Q=R%)S3B0Y)M)\B,[T&_>HC^KQ/^,2_W!-^$[\<HN+)D/+KZOB?,N
MLKMMT6$&Q#I(\'<Q*I+OOED'\_I9\_JCN=2;^1;/K887WWP6YOZS>O<;^,<"
M]>I=6"F=C!T([YMZHQW#(C( @JD'$MB7[$E_;..A:MLNX%C9!PKXICY-U7@7
MO?.S[CI_O<N;S<&!UK^GI^2E]+Z/I96([<!KX>F] L)XNI1L4]=42>"U?1RO
MQL^^/_#;/CV;=Z:(WV%(2*@_$,<^O8]/3!P_SV3-L-_'1K@R;?L@M_;K%7UF
MTFP10 E&;+"MW0P.5+(+S^D34PG&==_'U#S0Y!X]G$],DBG$=OM])\1#B_[[
M_RH*(8/!GTU0]/'U-NL\=T;V[[W(7ZD$W46IWGNO^W]V5H'W#BL),"<6S08Q
M&](A2'9I+P 'R50OC:7S*0_BPZN'/UYY,)0(^_%\;]07,2RSDTQ5-^NY5&*R
MO!\U[BOEIM5[%D'AB5BF*MNCK17[-1_0L*LYHXWJ?#M<GF^'B_F]">)8ZY +
M@#W=>;AP"W<7DW'NKKBZ.ZTHY_8,@)+3C)F2J7\B4!<.XN37Q4GA_=>]&W$"
M=8\?2YR "/FY8QGR O[&OB5*NOZ0'5R<S#.=;KRCEZ?Y<ZO\].MXRF\! F&)
MN57#OQ*%Z .$ 2+D"*D[B6QRT;#'DY/C]/BNQ_H'9'JY'_\FB[%B(K,A1OXZ
MR)'?3*=][W7O1HXDW^<$W\\L^:(BY8V6RA9#I<'1?NT6E3"V=Q<?B"Y%2)]*
M^:G36W6NKSJY4:I0:L^TXZM[Z$M1? 8ZZB!\?EWX?(!U[T;X)-[''#L(GU<+
MGUU[2%ODCL@GMZ_)!C0=E3"IYJ.2KDP2YQUMD:H,)YWNQ8T"$B:9.CA*>RO?
M?N]U[T;&Y#Z<H_1'XBY_3JB8QR-W;#S(D\1L.9AG1[W+R_+QKP-7_JG82[)[
MV3M=7I1GG=1R=6Q<Y<;)81EE2G9[SY'(+MGKK1@_B CX6OVO&I8&,+@F(B1^
MT398@>:A6QM=O[EIZ&M:($6ULX$F2*#]=X8[OQ\ W4!\N9^PZLO'RG"8:-UD
MG%E&<S*C:FFW"+K1N+GETVQ^4!G=5%)/DY4S<^;W#1-Z0^1BR<*>0*%_K7-Y
MC)*'/278 %I?O8HVHFCP\]'&KAJOM=ENK.O VOSV]O^S]Z7-J6K;VM_OK[#6
MO>>MO:LD%U!1U[ZUJVRP[Q6;?*$0$%$:I5'QU[]S3L"6)"N)71(^G+-7= JS
M&?T<XQF,56AW<6?5H(Q$)6MN6Q=NO)9[!;EY*;;(#M<VVHQ<S<2KB_*SA!6E
M7__&HTG\6BTJ+D6  5VVKM)7:M=*RF\OY<WL0RVF%H8^/I#)I@D,/0A+#E@"
M["AGV29LH Z.2M0X,*5=QZF%#H%MH7+SH?H]Z/(@E7;: 2;V]^Z!4?2C(_#S
M+EB[:+HCLUALWQKL+\"M@CA!N.EC4='7?T?L!7CZ'\P@^@+0NM<&_*6O@:$M
M&HKC8G6+P*^#N@KA<T<#NXCOVV]%$48WDD,&@GU'T,D;2#%P>T5#]=^!F@2+
ML(.ZSYS?!/W^&, \_1* N<<ZA^1JB$M;-F S>4F3)\!+ KLXLP4)\8W7(0(V
M7X=;"%[.22Y'H4;OO&4#H@2"G]?A#%7. ?\#^PU(57' >R?@%",30U?!4W3P
M7M&T9!4=P-@Y>-@W.8.R%JES!C]US\ 5:FL1IM4(!UVVCCF./*7UR!JX+6!G
MW?9QSH&A==Q9[91Q3Q\#V-<_-9?/@:83(IXF\KLDF$'MHC)61/9BN-'C?C#P
M8U=>_?$TIAP@DQ-F?US='_-4_^5ZKKK[DXV]T'MU56OI_5QZOJ67*D70TSZ[
M'@L7MCY?,P&ZS>F@4Y/I"C,H+(M8PAP,^D(;F@!4XOSZ[S(F "!#!&+/PS "
MD#C0(P':<)_[Y%J8/@T&:ZISOG$%THW8!O"RK;B*!,S\$0EZ%S2.'02-/T+?
MWMHSFO "#?<:B5R":#5Z>)&>;UBAF5MUEY>@8?_NNJGM/W-#O4!5@:<&4G1Q
MUF"Y97DX9);M176>&=NT,(!-N%)7HF= $B;4DU"-PL8/'ME^'YU6L?W.$J%*
M^WHJC;IX&_$W5%I=:/(IR4KGYT4VT^AT&P6B($JW4VE,>?:<'L^?RS@EYDFU
MG)_J#1QXM00>Q>-7ZD<4ZK3;ZC3J0*=]A,#?U&D+7,.W(X$<X6ILL**SO%*N
MI2]!Q!_2:=T^F31*PU%B+K:4:F.\Z*;G+4#2L6B<O%)7X&^NU515%&2W8>;B
M\(Y ]+K\GK1L?Q^_ ?XIB&/#Y@PGZGJ$T0,E"GFZ8BO.H4J%KP*"0^=EY!P?
M14VA6-D%LX3C2-9W.0[M;$>^7#?QY)EI#9YEH?"&UYVR"XEC+X-\-9K3-70]
M/5;$ED](:*AO7B^U$DT/68HANTR[K57+JX'1OG!KVX8-WP7F".^!7!7+*8HH
M9)W31M>![2UUJ3++K-:*3F/-@KCM&>F2*&5@!U,REH[&\/2U6Y>_Q9*(BWSF
M%F[5W/SC"BYYH."N1EGJ5!*2"WLR8')]O#Z=ER<F4_KX'7S+T'E1%,R"H:L>
MU?A-TX-OP/),FD_VAI4NDRLD$E/=2$PU2#7Q:")VG>[HWT1>!K0Z?3T>#SL[
MRQH&!F"JKHE.T#VN>WG\XGW JWHH&M%$"]OQ5Q02-20]=]R>30^;;L*_:Z+$
M\0XP1>4N>(P9]6\\@-VQ<9LONKRZ?X(_]/A1G+LAM/>C2 >N^RG2M"U,GQPL
M>[=4<;.0#3A1U^B%VX"L7@F89\CL@=_O.HD^M*C8-X,%LN*\-?*5O;UALZ7E
M))P>T3D2KRZU15DUG??+$#B1WWO;>"<^_%,P7S>0TWKA>4FH5G/>W2IQL21T
M]/(SD"17:J[L.G.GSEM@WH5BZCZQ^53ZIVQ[)*S@,KS6K)RW#D%>_?M_X/_\
M5?"*R!DPMVWJR1V_MC<&1<YQR\LKESR3\7VRFB?P"E@LY:X$S1O]_W\=3G^?
M;@>[?NK&;[\0^6!=7G].$N7?22(V-D1NCG$3\.K?G++F'-.OND\]D7&_QOGW
MKI@9[D0D\91*_2>R_R?<C[/-A U%#[;LJ*>H^ZOCKJ+>9^!DX>G\1O>,@*/@
MLX^>BL[%TA>_2>*)NM*QG&B=V/X0_H^+3 TH/?Z[U\P%UJ2CK"H-LJMR5+GO
M??3KWQZZ%0=D"U/\H(#842GW[\'YOD27Q[MZMETJV!V_"2OQE/ G#1F=3>/C
M=(I,4RR9)F)L7.#C[!CG$ZPHB!25$L;)5(KZY<Z#\_/U1IS-"9MV)<]4.:Y6
MX-?+/J:LH7%U.E+(-R944='G\V9G(LRP;#?!=3)@9.)T9 R7ID.-M7IT54L\
MB^DLSQFX!).SB=.A^&J,:5MG:M(8VVEG1O7EHDO#AQ+QTZ'SQ%A?:*/A=([-
M9Z-!W%#D7*S-DBQ^]OY$OQ1?;1<S!EM7J]O2BM/;M348>;8FBQVQ-,$T5)H;
M-O5G0N;[$Q(^\VQ-A7B)2&#@M?/!8%NL8VMUU.O#D:G3D=E10YC5U)$V+X[8
M8J,Z&NG+20:,/%]](34<LUH;R\V='E:O)RE\1)(2''JV^ER=,G4RU>O-<YEL
MHC:N6<ON9LW&SE=OU(EAW4R+\7FU02A#0C!,+-,&(\]6WRTWZ<)J7&.8II*C
MR5BM8Y-X!HP\6_T@9V8R&T'IXS+922SJ;'=FJ!(8>;9Z?EN1^1PQS3+8I-N4
M$],M2:[@R//5LY-BI3ZO3#%:[+:=OK,H#)<S-/1L]>-I4W=2VI2>8_5XC<E5
MZFJS"2OQSE9O)XNS@E.=3^<YIJ#6R02S[97;8.39Z@LBMY1B3J.*.T.":";3
M<J77AU7"9ZN7AZT>$4O-,KB32ZT4+BGD10V^_6SUK(-5,E:C),X'9KK8V0QY
M*I5'V:]GJ\^VL?6@B"\JC&BOC659T@:TCH8>KY[%"2(^(>)C-I$0!#:.BQ2;
MXB9Q5L0Y@N!B8X(4A-.'MWIV6B!->L(4,^WA4&L.Y!$;R-7=5)D?Y[)M:IX3
M^VO+F!H9\-\@KB;$98R>;_ Q3N*CP:I?5O)#K!W(U8L5%R/JTPU%+\E!@1'T
M52:F!'.UB#L45JOA\GQ0E2D%K_0[L78@5S^GZX6.L6+*=%,A&LWQ1"K*TT"N
M;G$$Q:8)JH(O&]UBDU]O]1'BP+,UL4Z?RI.F/L2I1IUC:)T9%4J9(*ZV%+%0
M3F($13>-F*8WVZ5^O[P.Y&IM,UQWZXLD/L\--JGZENVENZM,(%>/G_.<\CSN
MY<!&]0JC8HP0V$TFB*O3&[6[3"F#Y5RV,%7)YGIX0ED'<;652U:K9"7+T5UR
M+9?IN*Z8N7405R?73JN_:HK/=#>7(&AQE"QA1B!7;W+S_*99S.<92HPSS?@*
MVW!R,%>7<T1WTFI,ZG,N$6-4JRO/\K%,(%>S7$RO:YOX@!8M8JQPE6Y2UP.Y
M.FXL1D"4.SRS'/+QN5#3\"XA!7%U8FJGN.QS83TGB7QB+DT+O4Q['<35ULBQ
M6_WDO(@7Z2P]*Y,5?33,!'$U5:_%1Y8BK.:#A%U--Z;Q='DB!7+U#'<F=IU?
MCA@LN:5G!:V0C&_;YUP-*3^1J%N]Y6B&+Q.=0FR2Z)H*T)*)@-776FROIS?C
M#-?+)ZLQI[,@I P8>;;Z=4HW[54MUJ6;]:RXF$TSJ546CCQ;_5PVC*U$SHK,
MLE44YF0J->BK<.39ZB4SDZ"=THRCJ><87Q^D6GVHSQ(!JR]56LQDH>L*$%+\
M:#48IL?U 1IZMGJ)ZNLI9HRS.)?KQIN\L<@9K0Q+G:^>[%8VMJ5BPKP;,R:5
M07MJI"0X\FSUQ5B2)..;T1#GL+(LBVILH5%PY-GJ&TZV#1R0ZF1>U'G 2@M]
M35?:8.39ZG5NU+6T1"]!4TD>T\V<(:PG<"1Q+J (PBYL$Y5GQB[V2X5%.A^O
M !5-!6Q4JUTNYS%16#+=W";#QUOU!0L4/[7?J!-OQOWAF.47,;X=SZHT[N37
MCL#2Q?Z :;-P*/DK^%=%X#(LV+Z)SS?#6+,YYZRQU#*P=:%27:,]O&F8Y[.1
M'>A73G1%T=<H9Q3:VF;$M%7P!O!ZY"JZ(0X3QBN.[Z!UVPC,SW^I)F 7RG%3
M6+W^#5YB*WP\?)LF^_<6*EC*U(R(8-W"2TF\Z%TP8_?WFX&VVY>VH-W<>9LN
M^A7P-!5N88J__7\<OA7Z9YXS AT7WG5XCGW!@U(PSQ,\=[8MPW^K[]JX:WBQ
M/@WXAP_7-C-L?'M5B)D?MN+D4SQLZ/P#EDS^M%-V,99^U))_)&'?HBOD0RTY
M>9-NH ^UY)])V#]-?"6?\.LV5GN\)?](PB9_FOA*/J6^*"^_C>;\B!YRV([Y
M(1O?IIZHZSHA8>?;3W>^#5GA1CV@'[R+GXM?>Q>2E+60)-]-DH_L/=^L'\<C
M^],/O@D_B5<NTDKHN@;]9\5W0[3N(KM](-!0@M_%J'CL=JFA>?U8_O0[^Z^Z
M60E?A;._6B>PAW>.?4"X^S2@(Z(AX?U05W3?0B4D@6OV3WU@$MAUL@@IX(<Z
M-&7M+GKGKZ9MW:=CM#X):?UGNDF[C-[[6%IX]+,NRYW[V;[#I=GG8(?,=DVW
MYFMW."9"XKBFZ_&%B>,O")1@WL= @/@,H=RZKDOTE4GSH.G?WR&57--M^L)4
M@H*Z][$S0YJ\HGOSA4D2%BU^V@.Y<^N[P4E#)B=L9OBYDKQ[+_LRO0SC/ZU?
MZDD?)^)CS0R#P-!> $%3FXV$-.@MDG15-JR<N2WT[<''T8)OU<RP6"@SK>;S
MPIA3XJ+:H^>M,56#: XQH"C31-@;]=*5D/=>]V7D2?KA>J-"&?+7E9LNDX=-
ME\FKBQ1.4#OC1+)6G7<-BC'R3JDSUBX@4@Z"CYYT$9HG_97=)-RRMK\!]8$9
M V1(:K/-D W5D.<JEI):F73+:#8AS SUZU_B'/;W[U"&A#W<O=S7QY(A-^[A
M_O#BY$8]W%L>MKO9!8+%W-VX'X21 H2.TY\-8UECL:$'Q'-JHY;X4;P'A4XZ
M;.Q^M:+@>Z_[,H('UOJ&@B<4/(Z?,VZZW5=.10S..:5M9JL,<%'J6_IZL$DW
MGA$H'AG*F*O59]][W9>1,:F'<Y!N$G"YG5#9)I^9D2'.$@Q6ZN2<7JO8B3U_
MO''%K>(M^<2X7>Q9,DV3RJK!#+=ZLX2 =HG$KW]CR:"6VT?!Z/]%"'8/P_!?
M$D\/<.?/@[[XB6@?/VW)R9]XRC]PR3\0QB9]W<S9QULR\1/1,4-$O>^_Y =!
M:@KA]$(XO= .">V0$$[OD1WD$(7F(?$^4JC3W0.G<OY<P(]KO#9DKYO#Z3PV
M>]T?H^]1R?S*3OL?'-S+I/I%'/0'QZL+0?NN[L1?BLI_ #I%"+?W,^V#NV]6
M:'W?W/I^+!\^Q/![H-++AW?(0PR_[TEX#^^JGF#X_5"_\:N1U8_#!;S!K>B7
M.OX'=[O*6@0!]$5"L+P0+._K@>6YSD&(EA=RV[$#\:W 6T+BN*R1_X6)PT/+
MBUP8N2XTVD/DNM"P_WFP=6$<,X20>]$*B7W>+@\QY&Z197C#*K1[K_LR-<UW
M.L%[US3O0.2N7]0<%W&-;LHC!R\.J^U4+9>(DWKFX8N:VRJ7'579VHIIFBW!
MB8W2O96\]D#DJ',$J%">A!@)7DW?CY(GIS@LL4,<EMC5I0N=6?,F1B:$>=<P
MRP.6<)Q9ZG,X+)>&DEMLQ%&VUTQ.<"[;2X/MRG!9=>U"R5T5<>5. *EWER8A
MG-SUI,D_-X"D?'@1<A4#Y3- <N"DP"P#9 ^O5?-6GJI0N!PO9E:]18-S:FL7
M42[(BKD$CN4# $R'6'(AEMQW%D"/@27')7LYEJ5FZ[G:W\0G<6E 3+;K$$LN
M])-"++DWL.2N+U28$LLW]42=9\32JE5D,LF$J-Q4J+PWXC(K:J-I?$J6:,YQ
MB,FJ4>3YO@\C][8X>:Q,\G.^Z8(AX-=9C(Q8X,#XJ;@+1J,<D"]R\7)_&7CK
M15XNT/S=I=LUHLH]EU=.Q5NI(DZ8'-W,X;+"44I^T7G6C,>'RHQME8Q29%LB
MW6SE<"EI5<>%SII-P*AR/)K$7\/*# 7#@R&W7"YB' 9T+BD;A(Y1XS",5!D'
M$ZNE>C->;HTO(!LN'1A>R:W.9$M+ YP;IZOE:C+;69L9( RH7__&HB2.7ZG-
MR'U!^+XK[-[E(KZA-/@*TN 1PKO]'#?@IRMGBC>W0GN1[*T'6PJ:$^E?_Q+1
M1( Y<:$ [_<7'[?&1+M<Z/;[>AE?3I(\1IP6+#*V+&.CT5R<)$M%/<8;G80$
MI,1-XK3?7E1\4;_C%JB/]PY(W$XVX--TJ=^=9!T\EW=:B<1B7+;95[/<[AUN
M-94)7M[,]1)=':>:IC8<]LDDD@K7"K?>^^9B%X&-14[3@2\9@;WW,L.$X# A
M^"%"MRZ_96,OW%!9.)9DYILF2S>IA&'AC-!QOD"WHQ(N;].;14?"G59IJYA=
M,CE>9U@*AG")1#05T!TV%"WAG?=#Y@9_Y7#/&](E'\MD!TYILZ&+93J5R15R
M'3IW@;*#2P>!DYE$4J:D99')C?JXLLQBC<12 N($!H&)\V;UEPL!WYNIPM3@
M,#7XAPN31X@A8Y;",'+,3N'-1'ZP&O,SK)>& BB-[)D$GOJ^6<+V\5/1N.13
M GRKR)J(^6T887]&X,VBGP4XN;_^_8OX^P0AU5Z$6<5?+*LX%%V/%+3&A.TF
M4S'K&..TTTFG@V.\E&H#L10F%X>.5IA<?*-H]QO"!5.EH3..I2KSYM!.9RW3
MX9/UAXYZ5TL%MK"VVC2NXJQF-BL9=3N$T9MW1+W]?M6"O/H\W3SM><!'!SGX
MQ+<Z5/!OWQIY(M*B^L]"-V4XN=^&J*#C.VDF?3"Y/2O /M:Z\=L''3EH,WW^
M./3J)PJ\RC/8$D^XCV,"=T?<D7>$LRT]@D=P^-[_!2_V_S^@D_9O_)\76VK_
M>NM" ?(7NE5X48A13XG$'[+W_UO:NO7/FX?E#@L66J\<6! $S1_3!S(H7Q'M
M7WYYO:EL1C@5D*05D35>L07P"W/OKT3T2<1?_V?>\S^A37=[=_38[SP2P VP
M'G84BRUB4P.O,<5%0ZYNFUL\IZY__4LFHG$\*'C^>3J(1L!!1R9@IY6()EH1
M<2,:O&R*(9U]83K;A3T"J6RIS4V#&5(3ICNAR675&HZ5RAIFV:<"$FLO0V26
MY](8HA !&A&L 6DPJ 07ANA]85HZ/X\"RIL @1<9.Q'9#]A :OR?2\PDI,;;
M4R,,N[U BK.-GJW/,2<_[TI:'^OPRR$&29& %1_G$?[@/J>^T0E'P\.1-9MS
MAU_&>?%L"DP1)Q:THTC?H9$UX'%:OS'OLP.?!OZ/(/?QDV#,O?=T=3U;&X=V
MD15Q*B9,R!2;FG )-IY(\BQ'IGDV-IXD)Y/QF(Q/1&A[<G>P.4G\B;B#S4F0
M@599,&;WGQ'#"7!HXD6XT.^VU!QP2*,1'OQ_1%S:0$(IR B%-H,A O$D\Q80
MW/#[ !Q$GS$]4HT+,9)/Q>(L18U%-LY1"78L)L9L.HZG>"Z>) $=>Z3*^4[I
M2%;3&*_V99S+R\7B**,XUG,;"MO3D?7INI8J:3F.SC4*QK,SLMO4\QJ,3)R.
MQ%N;^;83+TYQL3,8MK%)3\[6,RQY_LS%M!ICF7DNCP^&-I;EAUD!7[3!R+-G
M+HQY6ZPN^.[<:225]',B9Q+RFHVQ^.E(MM5?D?D2.Y@73;.1:TWULCB!(\_>
MSE:<TCA?QR7<>5:'S5*_'9]D,V#DV=N-$9T0LC'9PN5*^[EE<9*9%20V?O[V
M5)_?IMC*F)G+PWF7LB;,5,_ PIJSD?B6;G,31QHP(CTH+OA"NE&OP 3ZLWDZ
MM8F>G/>W-<9N2WEM+.26Q3%,E_/GZ4KQ!E!E@%[>HS_%86R5%9+.".^25EQ:
MC^JK0D8Z55>01C.: /]#[VDT+YN\HD/UU0-ORRK M/!"'6-VFEED[4P^K=+D
M+#XI%#"MWU>!OA2!BEJ )P.U*_ZZ^KR[_%04;$5L3CH[5@I>R_D*\+58[R;(
M^8+!!#V-]Q:DI2?ON((7Y@WY_WSRB>?\.,LUY/2\V]P,;:O(S)32^>0O+SP/
MM39QWI3@,X;EGPM*X'&9T.@U(=JL )S\B#45(SD=3LL$'X!_(0!<#GX++%)K
M[_C#ET0*BKXVH_ P@9$%QX OX!,F0''K:ZA\#@V'!XG !]@> 2;'P5LI\"HO
M"*=R&PR1KK;3=<@4@[$U_P,4578_.3+7#NTW=PS\Q$.G=L.!EN'/ZR#H]^N/
MLG>3L2?JU13W@U#CP<-U\, )."M_Q_R_,6@[_1X;(C?'UF"/ D*/Q\_<?<^-
M <G8EKB[BSV.>%Z;"#YFTAZ$0S]Y8?YZ[Y@K'\)!*/#\/'[4.1!/B61X$ ]P
M$.FGY*OE1>%!A)+I1YT#D$SA.3S .:2?R%?+<,.#>-]!O%UJYI_(G]FKMULU
M]+[.XDTW2>=Y0R;?O:G(R\WE3T*.G^^_0A"/WGAUUW8Q<M8",22 "Q  _I2\
M+B["I3J)1\ZZ>H>R[_%(_Y,-J#Z[*1>3B-^J)U5(+5>C%E=\?FUJ(3_>P<R3
MJ7=(*#X*\B;/K^23)S?R7H0>Q>-/@_27XI3[YE6_R3PWRI6'(<#OD"OOQM!^
M=*[\7$X5VT1Y0S(.4R'Y]!3CK7K[PVE%P7>$&2O'&88#MO&EQ/1L@\[JR<1\
MP.1J7,+$Y\M<*BZQ,0@K0!+16"IVC6J7D*4/8V??@Z/)1R^TNSJ"R1@WFIL9
M+4EXMQ.WEG'9BD_+'\\4_"A+%ZK,4(O-E=G<UBO/J^VJU^!2,+6%^O5O.AHG
MXA>"5[J1T_<!:Z1SG!00^<M+]D<) 4UK"CQ>SC1%U)GZ:QCR1\OS(Q:7,BCN
M9V'_06W_[66R9YP\[JY\;4OE.!^KH6LPKQEP<H DPY.Q1;(KUS),<X+GK+KF
MF'+::X9*)H+2Z7\X-S\TV=Z)F<G[!A$>@IFO9Z2\@YLS9+\THM:IUCR7GQ?Y
MW,8H& /);4CZ.C=_V[!)3[<XQ4M<_)/TQH@YU=?:!],:O[#?=G\O+3CP<BQ7
M8D"N"+H-DS%O)5AN%YFY^U+O+4.O&KHY<?+.<M://S@8&132H99L5:RTDKAL
MQ#+=$A4SFC/);?9#$E$J]JU".O<7#8_)+K>+\-Q]J?>6#-<- 5U2-'2;0Z6N
MM>)=7(ZG&X6^I63J3MMM_9..4M2;H:'#<M!]\<OYWP_"VS>M<GF[,/4=)2^G
M(2S9?$C$@$=Q+U#!,_9<G!A$OY2;4\V..JO-DMO%7'K)N?C\9D:FHB+ 4GK=
M-B)C3IO#ZGO37BQTPT*?\;H!_@VL\0AOB()L@:,TA,C"T"6#4Y].2Y /^<>K
MZHS%8^,Q/^%8D8@GV'A<(-F42%+L)$ER,8**)\8)_K1B,#[*]B=<LI9BN*+5
M7=KY9YU9!E9UQE.#&4F7!7D^4&.=0K&R')OM=E!5IYPJ-2BA\&PS]K1*T&M^
MU9RDUD%5G3US4$^FDP-\3M)CH=.CQYOT*+"J<X-5BHS<+$SHJJ82=2<C]^-6
M8%5G<2HW-8P>-G"JG1YO5*Q<U9C JLZ-T)W-G([3Q;MJ8Y8L-7H=M;H.JNKL
M)8M,9?KL))E<;A;?CDE1'Y.9H*K.,DDGLEQAN\ I1YJ6AF:RJ-4#JSJU3D58
M#7*9(2[*K?BJ7N>S0#@$576RK7B.:1OQ)*/F:L.<E.>*6/.&59UE;0682#><
MUPHY^PM'JLV*I1K>%(I*,ZGG6HU:^ZR2,*Q\_["F.ZE\IWY,Y?N._EXI;+]9
M>>UN,CE7M[Q06"NW:C*SPKHR+3\+6V73QV+K[!<OK.U-@6K2U86N^>$BV=^,
M"&< KK95\#(()0[K:MTB6#,L@0U+8+]B/4=8:/;%SR$L@7V0@PA+8!_D($+)
M]!CG$); /L8YA"6PESV(L SL\3*(OE(%9%@"^X!K#DM@PQ+8+RK[OGY18U@"
M&U)+6 +[\+F<Q^4DW#JB<F#A,J>$691A^6I8OGKQ',C='1S@M;K/:@W10O"]
MHK$ZA[CO\6R%KB7+?'Z[H64P_8)(E^E$?NW5KJ:NT@_[Y[+N_9<=EJD^9(K6
MAUBW*M?P80IS-O,FWB_$4Z,6O>*\&M5DXK4$Y0>L4#VBTH*LR>94%"*2K@L7
MLQ:^OWQY@$+4ZY3EA>6DM[$<?,8K0KY[2_Y@C#"==2V,9.Q$J4$5QAVU/V^[
ME:5$-!;_)K6E][(4OBDCAZ6D-S$DWL7)A=7S>EDV&U7:KM62U)IJC?NX5U6:
M),Z;R'_=2(1_M!$*/7^W75'86S#T;<+BSK"X\X'-D^!V\T4V@6E)6V)H!UM,
M1[9:6^//:[=6DXA29!C$"$LU+QCEN/M2[\WG-[!>@AD]+>'9"F&FA_A@3%>+
MF9;15E$5$049/9X,ZL?Y1Y67#\*:7[?2\CA@X[4'-_W^X!$.8G! XQ.20D3<
M\*)I1L"_=)C7)5KB0<7$A;HZ/YJ"PTR1A[0/4^!,47N1\"$>G=>J-MA:1T6:
M3<YN62EUM68&=5O@.6(IV6WIU[^:K%RG2!/"J/S$TMEWG@O6L6-]O<#@.+D=
MM#L<V\P5M[!Q=5 P]A+'@LJ-=OE7KI<>PZ,12*1NXW0_-\?[CD#?D7]2-XNG
MR5AB#'OV"N,X&T_'4NR8$WE62*7(."\DDGP\>5J36:L\-[ F/6[3RWYR.\I-
M1'):6@?5S6YKB4:S01"%.4=/)M7.\V(<WP;6S3:L9DW-Q?-=VAG.#*8]CA'I
MD114-]O>EI6"Q%$:4S6-9()<-*L&M0ZJFQTYG55U0FPUFI,:SXVXRE?E22:H
M;K;!+ =J:4WU&8><5,0<E36H>6#=;%PTYE9UG,+F38VU2P97()5V8#?4[I(A
M*HMB7&,&O*&OMKF.&.?7076S77V4SPVXJ4WG1BJU60Y(NM,)K)NE-9'HQSK%
M+BZW#2[=K3ZGY\"%I\Y',LHR22SL_)S&B'HJ'T_0([PIL<GSD8IB%0G",-HX
M.5]DG^GMQN+*;3#R;.V9G-JD"\:J19,35A,WS8G0(-=@Y(UJ<3,\CS1.BW.@
MAL]H OC$L$7![_$MBZ_V6QT5)W(LD]SFZ1Q9V<Y&E4&[65B'9;I7*]--_I@R
M78\0(P>4^ @%N^?\\4+)+I6WV-4XOV;QP6"H]97<(E%SOGC);L"9^.UJS;!;
M;5BJ&Y;JAO4_]S^'L%3W00XB+-5]D(,()=-CG$-8JOL8YQ"6ZE[V(,)RM<=+
MR/I*E9IAJ>X#KCDLU0U+=;^H[/OZQ9=AJ6Y(+6&I[A=*D#V(CBN'-Q9APMR%
M,V._8$)<6+![V;Q6U$7Q_"(N]V+WIY4XH]*M?*M(VYUQ;)M*FFILW':+=6/1
M./Y:ZX&0<<-RW9_%M]=+"WLWX[:%@4 NY^IX;@]5<6+D''N5EMQ273*:QA-?
MN%C7-Q?&NF:'M;J7N=I[[!*^UV_#OH?PN)K2]]@E"[GE-9%1JXX8,Q73:#IG
M\@5%D6=689'Q^K9&DS@55M=>Y?+JL5GO]?N>[\%ZU]/;?\I[1IY?/=.BGF0H
M85$>&>EB41+:7I?5:"K]&N]]88=_Q?$HQ3!T&KZVMW]IV(V?YSI<6_OW/4Y[
M600)>KO?FW;L-DYMA9I3Y#+\<]PK:HTG7_,70I[]@H[^I0$V?A[+7MUJ>)MG
M"0USY#5=XW$,:YFU^7" ]4RO,VCLU3+TK^+C+SC'T!4E]#1"1*X0D>L&=D*7
M4SCCU<AB,R71HTEM+.*V95,)JS^K%/)KED+@%]<S$[X_Y]Z?N$,$KB]L+;S-
MN5ULHD\2^C+/=)_'[>?>8N[4I S@7!ADB">_48CA!'2KIUN<$N'"+(,0?^N2
M,8F[+_7>,NW:QL@?W71.L4&ZG!0J(WK0*F4+4WICE"6(+@#L$2I*X=<#!?V1
M7/^8G!""<7T?0^:/N+Z?ZFWG/46RZ>JH3HK3V39+93* ZRG(];'DF]:,CW_P
M*'QY HES:\"P#Y4SW6Y2Y)]/RJVN.B@:XQ61,R##3T^0.&+PE=>H&GLQH9>,
M']BF[H(+6"Q]6AOV7T<U;SL9! $7=..W+V@.UN75VI%(YD@BYI;4<1/PZM^<
MLN8<TX=,2#V1NRC*[YVP@CL123RE4O^)[/\)]^-L,R&6P\&6'6$UN+\Z1FOP
M/GNCKN\ #H4DGJ@K'<N)?Q#;'\+_<9&I 47<?_>:N4 BA/\&# DDF7*4M^Y]
M!'P,!)"A3R(Y'2%=F#N:Y/Z$+H]W-6B[/) LGB-2,8H@V/0X3;#Q,2&PZ0G'
ML8E4@B?&%)[FQ3.P)*N88NRDD>HQ))E]GI!])S'L9() LNJ4*4VZU%S&N5Q)
MY;++2:+66 >!9)429&K+<GT"IS0Z4^CW%U.96P>!9/&MY_P<+W6:=-?)J?QJ
MY P7JTP02%:';F^7YJI5H.551V=:-,EF:^T@D*Q:578V.<H8S8OI&94II7(I
M.QL(DO7,+KN$D1B;N)/O+A+K6'^K"NL@D"R";?!6AB1XW)8:6;.T+E.M3"8(
M)*N%%P02LUOM>6[&Y!1[P*?-'KRMCY^.3&+ Z:Z*(XFVV:ZQI@KM6*T%1YX!
MF8W;=*?UW&U/\$$KPVKU+=V'V/8!P%O96JT^LF.LC5/LUBRF!W)1SDA@Y-G;
M,R.!)35<K^-V*YW=YIDY7K<AF-?9V]-83RUV-27&R*T$-F/%53U;S 2!>9'8
M:FT/AWJ)&4Q;O-Q=\S([#@3SJG:R:[$[2K,XUMG4YR5'LE-HY-D\6PY!+^W*
MH$O;F\EF[8RR(RP&P;S\>5X9I"@/'KM"C%;63,L KP'\F]&$DB@ @2%E@ &Q
M>A/1BY347+O/JK-Y<R/&1O%\QNC$V_=']$)(1M\-X^JOU(^!\X+Z!*P'D&2$
MY@Q-MZT=BI3S"J[7UX5VS9C @3!Y0QZ+0D36(@W=$MU@-(D )O=_QZ+P>R .
M--%U<-:R-4586N)&Y&WTD0>N51<-230B&<D01<C>T4B]E\E%D'6&7F/I:%QW
MH6NF;D2Z]F*A&];^!_MG^T-*X'Q$PT1SJHD2QSN1GB%W.<4VHY&%;9@V!WX&
MG@M8DY]&;XDR:TXY0S39855P;"<WMA@;DZBDULX,NGSF5[  3;$$OI.@^S\\
M&<D&R<B.;,XS&]ED+<64V3VA>G2Z(],ZJ@!FVX,D/='%W#-39":*WIB*G08C
M';J+Y4;A#_Q%^+9 F;V?00YBJX'304O;S:.+MF7G3>('0*JJ7,P-8HGD!*]F
MT[5BNSU@&U@&%KD09"**!T:1+H"GZE&G>U[P+]TV@ 6IJN!LNQ90+Y&IJ B1
ML7-$>;*JBH+,6:+B1)"1C[[- <T$5A_)@R\B8Y$'>P7H8R6:%B!P2*2F/9X!
M1H$DN="AC2IS"MSMB2A;0*5%Y$F$!]J% SQE >L=\ M\G @!:0&5@P&:;D4X
M?BJ#CX2(8*.OX9M]N=0"O]"%IT@/<J#WF;<T^'->X4Q3GLAP.N"372#>0;-;
MBW *@(S!K,"Z5)&#>A8,M2(33C8B*\!8(OSK;*WHU[*BP 6:XM(&\P4/&(L1
M0SQ\"I(+8"C891&L GP+.1P^98'FO>=P?LH!*H*RY>#-WE'YZ]I/WA!YJ+V1
MK$)STZ&,-,$'D KA)1<'3P PIX4D"3KGYL(C3O/I38_Z44$-T3&;EJRB]9UO
ME86N7?B]_CK?.^]8>.\X =5G;,DV+5>^$SM@X34@F,>%@]Y+RTZNT5^8G-.F
ML<Q@8(K)='947'\X(K87<@=!L8:N\<%Q,23)-L/4,KOH)F),L\8WMV(# W;W
M&O;6C*;)H+#8!<38F(/D#K:3B]3A[D1RG*'H$5-6;051.2(,]U^J+HB**R/V
M= #/]X!;@822 9\<D]3CGO_>W[B@MBSB!-GGQ)S&</Q,93HM*YFJW):4:J)1
MDRL=?4CG8@9OQARSTXD#I9B.(HR"FP.,0ZJ1#P@%V65 N]B*M1>_KCA&TN0Q
M:69G<24#7=8+DM BL>[5]1EKSYN=:<%IK/%.)_GQ^/Q^1D5@(]1TTVQJ^\\"
M.F@@(IIP2M/"8OT!;7?6$ZPU(+OZ<_O7OT0ZF@ZL'[X %<&F#T@#38'UCNP#
M3=8\IP&85M;4A)8 5,HO(=D?VRHO&02OZK8/F@.1C&G:Z@+]$;'-/6'O12@T
MIO8NTEB$T&K?&#/XCP&!_7#Q9Q"!R:=DB A\=YQ!\HD, 1\?X2"(IWB(@/H(
M!Y%^PD..>(2#()_BJ? @'N @0M'T( <1BJ8'.0CB*1'"QE_P(-Z+4/J6[_ S
M$$I?M]PO@ICXJ%B\\>MB[#PF&//KYE!XWO<[;_<N)4)<[+#?4C!W.>S/H4J'
M,OL&,ONF>W QSO[:L,"7 Y&^LH /B>/K$L?5%<+MB.-=-:ZNUKAW 9A7'@,>
M##.%%H;,BQ?3!O=>VSV*V^(/4-1WF>(U_#XG>._:M/-;]/H^4Z"L+6RKYRQ$
M=(/^T@"4(]B"K.1=HF\'SW4*JV87<UM.24ZV7&7PZ5%I*_FI- SG= :G^8D]
MGDVU\:::R&-=G&(5LI&)FZ8I>3#<B2>"O$Z)*]3[]V:'4 R$8N 3^7B7$P-.
M>[C@VFJ].F^:<;,XZRSC$SES6S$0IZ5:8]O:B/-!=F$1C8:*#S-M%]0;-KZY
M"AJ_:^+=FQ\^+ <^8-;==&'T9B'R,"$()4J[1EQDI<, NUOA\>6]^QM*[:\*
MD/3Z_=FC"N4%$%?LM%*5V&G!F=/JE.*=Y(IO&IO,E8PS))#[.^;P1',O69/3
MTL)@\6+<BM/X/,>MJD=U)<351?,FG5_.9'M;88KB1.HWETLI1Z]=\'0J\70E
M$)*;1V;^<QQ3#]GV^[/M!8RI8+:UJOBJ-JP4\#E5KA/M<<O4":M]6[:5C/%*
M*4M3FK&70K94%/'G-9=Q<=>OQ;9WB)G]YTN'N6#6.S:!F=PR*M<TK8C!66&H
MZZO[N!>6Q-_"T;V]306YJP"8J^SQ5@>PEB>A\QEIUM'R&6PN%\NEHESN4&,[
M<UL)W<2+-5HJUG,X5LKBHYI&%^A>VX.E?[I23YI'B'Q=Q]2Z]ZI"GG\$@^P5
MGF=B]8D1K[;B.+>:5@6K6T^)N1L[4V5RTS$J^5QVGAN/[61FL1G$DAZL??SI
M*M'NQXAR?<Y.NT_<"E"0&OG+$3G#_#N,5H5N[Z-*V1%;+LYSQ#.A)NB<G!M*
M0F7K)"?7ND?T^:,'V,,3K0-[G#8QL=Z>YX:C)(:)Z::5^0#^R>>$J\A8(WJ9
M+L3QI:/$,^I"HU7,P^^//[W6,^0K!:I"G@YY^N)F4P!/*Q52LF.#C37G$J-I
MK457^HWA^M8\/6E2['9&E+*TW"1&34EH3#<CR47VOTI+CGOG?7WSQ"YZAZHC
MR"M9@*A%CBPJ0ACR"MW?G^[^7M VRWO,=>#^UF99WFBD-P9#<GPMI^=BO"F\
MENVU%0U=X,SIA8RS[BC6,+,E#7<JG::13A-U.I5QFQE EB#(?\*(5\CR/XSE
M+VBZ!;!\,MU9E\0,O9Q3M,%7>HK!==*O979=EN4GQ<9R6K-&')[;SN4TUJ=5
M?K%V.QE<D>4?,^#U8%T9OBZ([EO8C,?0>X((HWBR!H;:"(CQ3W'\=L,%V;0,
M>;S#W-T#C.JVQ>M@=B[DGPRYP,7,Y0YQKF!FP':/=07HF/=?:8A+6S;$"%@I
M)[F8;Y8>X18+Q8G,;$%"G\ 'JMQ\OV@3/(I7;$2_;X!2O0M_V^,>ZHD\99#_
M_1Q,=\ 3[X9>_1G*^XO[^Q6K_>NO3_0#W_LDS:@+\1R1S3T2)J3B*6 *W8!D
M$($T#)AM_QO$)/98D7E QI;!032ZA2@:0/VI8'8RF 9$L>/<^#KX.7B(AU$M
M'H7>3W!I72S;%[Q@7[R&3'!M)AC_$": ).B3_UH\)O]CDH3_01]S/J1Z2*1W
M)E+^>Q.I$9PWMB/78\-G#)&\)V"8QHN^I&6>NL!L,9 1[[@AN AO&RO111@%
M+_2(VX1B&]"T";%=Q<,^!&^+:FB[A)QP7TX0OC<G[,CP.)Q\(+A]LQE2_EB\
M9:^*#X?_WNXYBA_Y[9@I\O#R!6)9F:)V >\=X1MW<TIZ)+46--/,Q9U&MF)1
MO>GZU[\P2G!EM'4H3"8<[.@PY2QXBE,.B"9-!(P<67 R&&/ W5 XX^#HCQL.
M?*?&,<"_- \=0)5#72"\MA?@8*%WJ7&HUP7T%V4-F.,KV"3#:WL!(=$]3]*R
M8&L7(+"//$RPX4!'Z+"7!:?!;AAC\5"%(+$O;N")+ Q A28X\N/=/NGJZ/5T
MHQ)\,IU*B:Q(< DV3@DBFTI/2)9/X?%)0B1)CJ/ WASUS)K-)MQ03@THO+B6
M**LTPW"[%MC3K3\7.>69&JX94JTO-KEU;VE.84^WLSY<4EU-%I-)5<*;ZQQ'
M)A5YU.IE@GJZK7JY8DKM=\NXS2:%1&_9;L6?VV#DV3.S [DY$OBESF#:<%KM
MFR-]A4E!/=W4-;/L8/GABJY2HTZ?'8S,=!6./'LFD:"<2O9YQN-DW6H[O6Z2
MV;:EH$YMRPY#3(O93AVG2AK6[,D9@T\$=FK;)E;;8DE?9N9+J[8H9+G!K-'-
M!/5?:QB->&<N9?KS)5=*Y3N-R8:V87;:V2XY/;Q$I*?]/I,#PK?2F;&C)"D=
M=%6[4E\SU"!G (03IUGF =S_>=.R=55SY&2IM,)E=?U<G4JS7EGTY*ZLV:*0
ML5X9Q\)AQ/U;G)'X$Y%X&$/D@EW.TC^FRYE/K:]T-+MR$\ N/Q4%6Q&;$]1X
M:>IV]Z)1W :V'/-GV#0Z<.*GS%0T='O!YI>6[JAE3)]39E?-C<124EE*)_ST
MVE @1$[9Z4OU!/)W"89]36CBH?"P]7*C!:A6\R)_^!V!OB.CJ,\!!^-@BJ*O
MS>_<XL!C+=3A@+,MW?_ [7" /OGC+@BI#S9!.,7%"S%]]X^])]PX?L]^%.%!
M[((=Q!,5 K\_PDF$+/$@!Q&RQ-T!Q[\1;NMUA,'5(8G]1V8,F5/  TJBLA+A
M"N##.,W$7G9Z_ABL^DKL>7<DTNL DH<$\64)PO<$(\ )_"RN=R@:K\T)?[('
M[^*&.V^8QQ\AM'-(/3^5>LCW2MVCVJE[5Q;YJ>B1Q%,R@5[10BEVD7UX^4)\
M<>_$Z3L44'GD_1WJ#Q#6ILD.JX)C.[FQQ=B81"6U=F;0Y?^PZ"@'&P0W)QYA
M>9<"^][,+MWY9.=5&I2X)M&TVJT17EW61[(XKM;9_"<*P /GT-P'W@.J#7+J
M!"NW\,V8R16P+D'SSHHO9-@8O+Q,16.Q6)1,7@E..F2;AV6;79W)Q^7^784\
MRMP1(RT%;#]*UKBXO/^:)6/7=_B^KH!V:>9$0K-,3JIU%ZL*WFV(95/%TZQ3
MN:V$'L=7!L>9(WON#'F],)7,0G4+DUN A$Y$TT!" RE]/0D=$OK#B-0',Z6[
MX!?@85DL]OW,Z4L38L!Z[N@7?IIVP]/]1J=[+15,D&P,I5^1?ZJ#]RG7!5GC
M-%[FE+)F6H8-;3C3E3?9F/?K@ZQLUYE*K,6M7!],\:I2JSAX>U+G8Y] WOF
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M!0+)E7-KT\P=C7*'6>LOT>7QK@9M%R!SKQS2M>Y>+47V2XS?49!,WKIF\N+
M?:<28RTK2F0L0AB](SO%/YD/5\9^*IE%&M9U:TMH.$GQ?*>NL'%KD3E'W!!L
MXP1Q Y6G![XR#QB\8.CJ ,*2'']E9M'ZZ?WR#R2[5IX..R2]'=%J8FGB>2D3
M6U2D3YY$#'=5M@ FM>.!$QG]*<6 Q)H+=PC\%T5\R]=Q$11/B4/<+&3C3VCA
M%IE,;Q^^K\']!V8TP3W? ^T-\?4/3K?*;!D%SZ<*M&J7LV;%L"6LU?[DZ2;<
MPT5]:Q[B="%8"YB,(H-?V0N$>RF(+CXF_$J1E[8LN'3P/2!*FUHD8TO 7#XJ
M^XX=>_0360'..G@)(!X-8B0:H@2A1MTM P1CN8$1\$<!T)[[J"Y&1+B_N!T"
MC/_;"1 M+FH7Q/<"__U[C]35I7/>L\'\- E])INFS6G\#C35-9[/'$$T#,IC
M=&R>@-[]R+\^01$=),EM\*4,/AA#1#)Q G@&_ %FQ'/P&],&_ND+JT3@3*X:
MF$P\3!N$2Z.#I<H:Q+ !/BEO&P8<O3!T$^(^V6;$U;]P61#83#=?7(L-U*QR
M/&]/P$ P2O ?2)5@,D(45N;#Q\L3>8_;Z@===AA_WX96(2C<X:Z<J^-CPH6D
MY^X5PHKC.=.ELT-<A!-1?@V<VM1IX/Z3B&]GS_N2>&C<.0;6HT&K?&9Y@!G7
M4UUQ90.$J0(?+#CC1H";(<D%G<GX>Y/<<3#T?ZX?T?I8,/0._M#[8J,O^T:=
MG3F(0J.!$:[)3-ET3#)OSQV[FDX.UQV1J %+&7_"B>N%08_56"AD[L>%_/<6
M,LB^AOI,@;Z3-05/NF'H/,^NFDY7RM:'4UH=57FI.;'&JV[[71+&-"RVPVF2
MVZT$_E67-5FU_7YRGY% G5*]R_4:E3*M;GNY?G^43 R<#R3CO"R#<KH&6 O"
M6L)(34.W7A)$3K+)JLSS=$AWTZ/AFDU)M51*@C&5ZX@A&*-!6:O)?Z 6 @;W
MVI M2T3DXBFE W\:>$$BAR"@77?%!7N['1)S*+V"3E'XWM)+GKAH=[JF.!'X
M!W0'#7$!W'_@0/.*CEJI[&PHSYF$KCD")'1[0)@H3+3A15$P0S/K"F;67L2A
M74>V5F\*%@YE1#  =$W7*V/9V>)-O&9+69UN"P2\?$X]!2917?+R.0*C7.ZE
M,XQOZ887QC$7BFR94>^O'?1S%-";;DB<)F_1^: />&Z!DH^\CWR@XX@BS\6_
MW28DFO/E%.UU:>QRBA3&NLT=@?4,#DHYJ%T#:6VH<8[5D%LT[BS3C#0W%ZVU
M+,'*_>L0FN7.!^E7%"M% <:0%FY!"^!S4^1M&.1]BRR6*X%@F6;:F#MB;A6?
MB$I=[66N9VX=D(7?W45T0YK6%/;;&/OW&XANQBYD^F%TU(32"'WRDGUV&$WV
ML'B_+7!]>>)>#DQ%+3#([,:1D>DY=@[W\3SDO+M]@!<,!SN*DA@BX@J\09Z
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M):+[&E>151D*-)<,H7]_JH3^A(3&QWF'R,8X-BX0\8ZA.:]A!^8J,$@4'7:
M0&:2@WAF"KOH>7:L#*0@;!+LEUL8*+X%OI$-Z%BH,(8K[$A7A%V$RV]2_>%+
M3& _PQ(.':;;NU<&'WKO'^_3B[8ZVJ'#782S@[D^OK'GL;<)^,#?TT#C\KM4
M%GPG%5;"%[E1UXQ/F**@9J<2F6*>GZ^OPEZAQY>J#+ZNN3<XZK6&%"K,.3]D
MD<.BR<7YG@ /"2I#511=70P< )CMQWE-#[T>S3PD #>K#3X/Z!Q;$5S6AD8V
M_-@\M!N?(DT;QD@YQ8%,"P@=NC5@V+['NO](GO,X"/K-F6XNDB(2T;VZO5P1
MZ;Y"V97,)5$ 1R*A6M'/G$'4DTGF@8?ANG$B\G[T%6IZYYX.CS:.@\U[#ET7
M=";(F@'S\%P^0*S E/*4G689NG)P!>)&.M!90'GI_@3Z-? P@<RQ%93A!%32
M%-ZL(H<S\"%(<G+>3XXE.J*<$Y_Z17*!CN )L?#?*3,WXZU7T?=6YLO%MQ,.
M*,T5I]BN4QP4G7BUF-F\G*IZHX!RIZO@=59[/BY65*J9QL769E&@RK%YJ2#=
MLP0.B[U#39VW*P6BJ %DCYO\N]-2L0,MQ4_X(DXUEP;37:7&N+Y,U7D&WE1%
M$]>ZJ8(G_YU.-M $F=(2-N^6I>=Y+I?L98RU6(U-I)L>;3V>RW,8H2NT:.7B
MN0)34B?#-3Q:G$I=Y6AA^ VEEX-Y*LZ?&*7?7U+<"B;XZN04&_5XIRQDAK3Z
M7&]/-;M%)9<P?R=*4-1/E!0W<U:N?K3I[L:2%S&:8;IB)\TW2[;1IH&D(*-D
M(@@FZ?*2HG<D"EZ2!, M!T:WJ '["W7A%H[[7D,#"?RU2Y=!IN'.)O4&-3A3
MX):1HJ*/@;-?YXRY:+GO]UU[^--7Y TLZ=<<%$#P3%3W=D*%MS2PF'D!/P F
M&;RH0.DYZZF. A"!483(&IG$>YOUC:#"E%NANS=[#'TY&+%0G'V0 /I"+P<)
M>GZOZBCL#'[J.5EG9X 2XORY' )C $,7#/+*C]"/=Z./WGE6S'Y8Y?L5R]F)
ML)P]+&>_0CG[=0K4;X-.Y8*;N<;=,1+PET>A@FKAI>6YAB>\B_$NM'5M9FL'
M>%7[*_/C1Y! 0XE ^$/]Y5WH:)$F;^D[$]EM=0QT$S_=?1!#UE"=<_:?>,!%
MNP)+&%7Q[C+= /++J$6GBSJ=$0QG/#A\$7#3;HG15VGDBY8\IG&:&FTZB<DJ
M&Z_:#X!S5"/39:[1:=$T5YBS"X:7-9U97R>'U]WXF+?O?VSW?FK?V^Q\MJQG
M5@+#M6>=4KX2RU?)]OWWO9E<UFKKA9; JXV<TU*&S\]QOGW-?4_<=-\E8L3B
MX]:DSXBEE;1AM5XWWGB ?:]F&4[5!NG$7(U+W#./E[NUJH3JV8)<E;<_^+R0
M<]V'%_6$FVHC1#P3VP=T %+X2.@G4%@D%?5N'7?9_P(TOI&+X<6R49:1&\M&
M?H2[DJ=(!O@?T#*;BI@*A+VS=WW<G#&HK@Y+S5%VTJO/]'P3V&L>PB[RR->
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M.V5-0G!DH\TDKT5KJ<E@!>2FJZ ET.%GOONL^D(:^CLZ&Z.:([(+)].EL)G
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M^9[Z'UCBXUIE5\YPZ7 @^/*=&'%0D.6___:4/]QW6$_F/ZN)[JDI,($,2X7
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MTZTTF]7R=KI,M1JK;"7YD1D#2(C* V* 39?I#E<J#FPCF=T:O0)0TJF'"PU
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M#(*?$$ 5(DP[] U\Q'9@B/JB);+\?I6 A*R#364-!FUI2(Q_(/QD\*2+M+C
M[0JKC],;3=5M:;S)K3).!B8AQO%;=C*'1PSD>8#,#VPR9P;D#^H3VY67SK%^
M"W3?B:B'\PK0V(5@8@B1\@AH4]1EP8(!ZUD(A!P@GI%08-\":?-)9#,B>0A
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M[D(,5QN^>@EAI>V8L%SJ0+@$8!9/(,K"6O"E):]5T[5U'X@.// 1J,)#C(:
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MZP9DQOT#B6_B'H1MVXZ"$*%XW,NE?:\>U'D \K\Y_17[4PA\6NAWNTL@6<&
MI?^XN^_9F?8M1PQ:CCC!D\%O>]_AD7%XB(4%FW.L.@+_83GA%2&Q+?4X:E'H
M%SHS;2#1FS='Q1Y/ ;:JA&T=T/Q[P'ZV_5Z(%P-;I))*#S-N,LNYC9R@R0U#
MH"W@%V3CV(T\ U\,085F _<;*AJH"39F2!% ;'\9@DA?A1XL><=Y^&;E:JLJ
MF&-J59*G^?:KZ0$YE"&7%DWK\50NGG]NWEMH=F'.<\+(6C.V(V:T61MF5-_L
M_*^%-'R[-KW$]7E^3";&J_9L.]9*Y4ZCT*AG&T7A@\XX7\P5F>2BT\%JJW4)
M:V)5W;3:\);Z5F<<!\RLHFY^!T,='OLIQ+YONA_?FOP5C_TY"90%>!DP2Z'*
MV L&=QFT&Q/$&;1H0@4"; ;4LO#8]O6[^BT6,$P"K8#P:;:OW_\4@]=8IB?H
MP#S?O\1OK ->)"A FZ&0L6 8T'^ /7AML+NP,8XC[SV%(*IKQXH%.NADZ/>R
MF,C0+)*^B?Z'#00OG F*5/G>TGTS]<4(D&TY? >N /$P_*T!++^%NP@;=;R#
MY7,SFAQW66J.+?!Z?J%H[J;2?KV:_QW+-\(S>:9+=W&E"RE<&FO<P,65CDI/
M!^*P#>L9;Z?ES6]"#\+V2O30R>\H4LT9&V;E<CNZ;DXGT\3K+T.O00_+EI$E
MFUBZIM5:94[96*7A=(BBP3=4"<!?5!3D;$Z\4U%]D.:^FXAN>* #M[P6&;V0
MBO9[QY?KPPZ)C2HFEL]:/ M82)ZZ;[Q>> .M9#?K'J<T)Y@FY!J%*DVFRP5U
M\U:P[\<S")/=\GO]N%_X9:CO1G_0$>1>?<EY(Z+7G P*;;)!__'/U'2MVX@/
MH-" QX^NHOS>M<<$<T$-B4!'FTY,WHKRE7K;?+#DN2VUO%RRG(F30/Z]0*H,
MF3'+]@G)YDI;F6CH6\RKCP&5X.G;B144*T)M@!>"=-% N?< 0_;##9--=32K
M@9ET.;DVG+9F92>WTS[',!%$2QQT=,IDA(%.)S*+2GMN*3<U3)Z,^B&;/HC[
MA<'01Y''WP<5X\#C"5MRP>#?RY[[=#@1^BJTJ[BVLW\F^8IGGH56OX<O<M(
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M4E+'F239 00$X0L^5O;<ZT7NU:@'QVY /O;6JF:\I%3$5CS>&:^,*C?,?Z
M&I.ZE'8;B9U66EB3086MIK8LK(N+!%!$0B^20,N)4$VS^>( 6TTZ#76 U])"
M*[Q-_% 9]!"K'-W3^U5&%_U_6&R@Z[&O?47P9B*\ LGA2RWC*&9UA'4[8UP;
M5!Q7GUXK!/#R*X9!@W%+);-F:6Q7%,M%:2PM"_0?_V1N>,/PN/CD&*?![^UT
MU+)*U&7!@O @LT>I_R0,>]ZB9]634/]$\@CSRP^Z%A.P./ZT,]7_G73<V@.6
MP!(3T_H5HI(<K2OH]$6@4A%%3O@-O5!(^I>@;P3/#M:9R3P0R1!9[]<>V03N
M1"SUD,G\)W;X$>['V6;"GK%'6W;2-M;_UFGCV."SWW05.ZJ_(/ 'ZD;'\BCR
M31X.X7]";&9!=O]7C\U?[!X$?P9D!GA)/RGR"#[ZXY\>J@U"I5.HHZZ]IU'A
MN//84W1YNJN7MNM1C=7SA4Y! =-7OE 8!'<(J%087B $FL;/#H-%&4%=FA74
MI7WE<L>;W"J\N.3Q\>L[?@)>4+P(! HJ7NX!%K%GIBX]4@;'=PLN.T[56VN\
M@JVRF5$^4<YDABZ\;SY7!/^Y6DG^,UF!AV)8F,.R<OTLP"]H:-QK+D(GY$9D
MI#Y%(L?V0GM=-XRJLAABBTU^VNUAFY:ROU^^_Q3G2$)<E!#L^F4"HF0/QNV"
MF1,TEAZVI_AXGDG/X;W1.63'AP@(86*&95@"FO4WN8X?H"HY8.8A%7DA!P>X
M;D$%XAY8"]6?@>$>0AI0#101D [I/,!"@G6;J").MI]Z*GP?K'>!U6>H6@OP
MA"/O$W_R@CV+%75S _;>#@L=#<6OK_.++1$L!WI5X#T:#J0)>'#^^$50#0G_
MNB^D]'/2+LP)<OY92CE<H6].H=)*_VK1=0#7QN3U_FL(V&0*,4D.IL@DW%E8
MB&:?;IZ*"@>7ECGQ(2P061W-":)\3&0P,,BOE*!:0M\\LFK VR17_MP"^SS"
M=D%;11M2/MPH$4RPH-JB;MI@I\ZK[OF5)O)-><!QB>U,+VC,/(\IFZB._G9U
M]*D?4T=_1)*(-T^(\EL6U1=A!8<#/D6%V>#_*+$*PB<A<1R6V!R),5T5)D')
M^C$$#_S$KR6/!]7?@@4Q8P(1"OA.-6">FVBZ5E#*#JMN8 $RM)\/HAGI D$4
M 1L_\=JGY6 H7:&\E%3XL^U+U4F0* H/%0$GG0R!U<Y(Y JV:8"G>0?X$A1J
M1 M8J@:TQ<#$P58*/DQ+W)?>2)X:P(.4$<!N3-0%=>'GM/M;@1[@5T3#2<.7
M^SH.:B';U9&F 4(<O!'A$P@2$#]@E^3I%&HH^%J8Z7>L\:9@.PT4[@P]^7CP
M+*0"(>2!GT>-D+5$J!%A,W;[F]@>+4!%+D2G"O $:' <2%M"R#UP>FB/.K("
MZ]7]6$8',KH=H\-:Y1.LIY#.+1D!.!PD@.@"K;KP"=?P4P\#+"R(W /!')#"
M1G@U@!I51?%@, T\Z.C5EO]J'Z=A@6R%"W\.5K(4+-]"@90%@<@0 </@1#C)
MP!R "!"Z$) 1(NKCI_JO0]^%Q[$PU*EWZ?G < 7/A.E.P=./&>W9%_C&4+ -
MJ*-6^F_[=&7F1 ^$PG']^.O/RE^'#U0&36R$3!54$")\!0BJ(4",CW!5P<43
MPA-"H@'-WQ\# :Q,(%6L&'0D;/3M\/50E'1E8)7Z&_ G,*8D&?":+(62[/6S
M_\O?J3<L6S+!'.#M!12$_N$ ^O0%@"0L@!1"L"$^\!SB<>!".;K_Y2/X-%\P
M0-&$*O8D<*P>,J3]TP),%8"H/3Y->[\5WT1N#$)A#8WF@&1\^H$X@0@L!MX3
M0;@_GX&.QF\"X"HX.A#QT/$3??H.A3^"I$ 0()!H0NYR[;TF\964KV?A@?MG
M<JR#@3+R586Q-O6U3WH'_>IS)3HQ,YP'U+7[XT7 AN?Z-M2US]YLW!L"M:3:
M$'\%SE'^^W5STL%J$\&MQ?.3.LP>_O&%4_QZ=T!X= <4W0']]@Y(0(XV3TC9
M%"Z($I_.9%-\<DH*O##!,[PL81-2D+.9I(C]X;_5_T;/4FE7ZLA+TW+,:06(
M<B@1P0P[@8Z1I98+[('@2S?F@$MZX[GNY_Z\X;X>S3QVF'H,S5V,T:(((WA0
MUA95:['W"6\@-WN^/8CP$:&A$@*O^F"N8*8%8*F*$*+J)C-XO'W@?+N"[MJQ
MNCH%LP(>L0&AHOSZI(HA/OSZD&G\3[W ,*H#:$"$>,*AEW8A1EC<>TR':"'0
M?]<\OU=8,6' 4P#N<Q#NA%ZO;W\A)_)X[A-!1TAU]DR6?0?OM\<1^+H36Y54
M8!Y 8_;(POL+QA4A#9U <Y XZI1 H._Z]7'H]C-P TZF9)^$7(_]3?N(8@-+
M$AG1HNKXE6T';S1$\/)?[P%!A1P3X.- 4_D !1S. -AA<"$P;'> 7 \"N)=\
MX\,D_T+V%S*-?!IYX?=B 58<PC&%;X.>.G!&]KYZX(8$7N&Y6Q[6C>S]Q9?M
M^V'E>Y\>!DP.^^SCE:$:Z)?NIA_(@;<Q$)D0.5'<0_<AI@!3U0*+\B %PB))
M"9%B(.>6P#L0U:6.?(!/Y_"2"><$&!OXJ\;GL6_O67:]2$B(W5%D'I 4<#U0
M;-]V%[[O%20:A%2"'-X02#:&8" 5,W@/7/E#C+8A&I_HVK;O(#0!:_@'CX>A
MA-_.Z322 6\.;'<Z1?K.@IX?\@MUTX;!!M^U."6_&9H8O.D2A24\HH#/@2SR
M_#59 @P"!E";#L+>--V) ^_$7 >1KQ]M0&[8L^MM[*-N>^\4> 9&Z,9"G>@O
M&]X:"0["AX<.6P #;XN6.CG;*=\S__W9229R ?UPIX_O*4ASUPYBQ6BIOC,7
MQ/-\G^XH[(>D@ K#($&@Q?'N@9UR@JWZ<B-0G9_*4O9+S@(>:B 9EQ#S+J"?
M4S&[IY%#L-;O#_#H6RJ*N\E;A" *01_-$POB11/:0T=![8+T>1#$AM076_J&
MXY% G0+#<1]Y"7'6X=P#&S/DQR-;$UY]VXB^?.OO3Y@)$-Y[VG_%_FSE:387
M@)Q:<AC'E (\*O7(IGT<.SN6 %"WB?#>$1D;^WDA)3&5(;B@?A02BNG"9G^'
M>0RK;[E 61S@O\!27?T41/\HQ 9',%MQA@"ET 6,#8-6^^>BE3W#*E\E[ 3C
MQRZ*^A_(Y*D-MX,4C_U^^9L A)5I'_\U..8 6U%& M$'5Y4MJ.:#=@_@5:C_
MQ22(<0?7'#+2/Q9ZM2^/-S,YZ&'Q4D:<6K+LWXD$YA \OG!(?/] R47!+=FR
M8+C2 E\#L_(9<K\32+3NI^Y;'J8H2^B*!@;IH!KR.UA8JJW93[XVW+07J+]G
MYQ<_WLK'\T'*#<F20._ DT'S>HAU4:SY,'B_-GDKP.8EAA)'2',QP+L.%!\J
MF(J\5B54&^$KLS BZV>,!)<'^VOQ?1;$;]=XLLE(%QYFXZ/I[M]TR>2+N780
MLH8-3U2@W.&E2W@]9ONW:A/OY$X,:.\-1".&F0NGKS#7R,X,;6KAV#Y^P4H>
M@QH?,1(*=D/-?$S>D[UR.[+[;QS(OI$ ^:_]WUBMU2C%ZO76;Q=P1>LA=%/!
M]]9^,LHE)8L. 6RSK4("#M"/;Q,5*<@&(*(XF()N6H)D?JUCI %GZ3$"#QL2
MPJH4\&1(HM JC1$"8A\@4 X7Q^@."]!QZ#+&\*3_]8^D@RB(?R=!?"(*XD=!
M_)<&\5-9')M24YPGIP+))ZE4BL^DA"F/R40:_$%,DQ)VG_'X7J?2I>M<-U:O
M%)E8-U]AFGFF&X8WF_F'?>3]^/8ASS:[;+U2H'M,(4?7:?B=,L/TNF G""*;
M_;"U_FYYQQ.-!3.-^5.]\I7">V;YFR#E!\[T5;3S)[*-3=<&$[7W.M;O.Q58
M],%O0+4*?SVB)%Z@DE,9I[)\BA I/DDFD_R$( B>PE(825!I(24\NOD2^=U(
MK8B9 5_A\KMM&M_6V'E)V,#DV,<CR3HK]AIYB61<TATNAE9_06;:8&3J\<C:
M0C)+N5IZIPF)(9NL-?)NK;WA"?[L[>.ZV2Y)O#S@%M.JU!FZW0Z5H'GR?.0N
MU5\.AXWVBJ'L?*W%&V1)(A0^>3ZRF^V(C7E>)IF$(,Q6@RHFNOH&C#Q;D;?8
ME?)RR>MSLE0;*>W.+,<FVF#DV8K*>K7;[4YZ3:;4QFLEI>4Z_>6&3YV_W=UJ
MCEFWG0G'#M.SLJT2_173YJGSD3([K=0&*B=C,MGLKUL*V4UZ"I^^\,SF1&;:
M8K' U0:C8J-=SN95K,UGSD<N2[4Q65LH1<TM32H5P9AKM-/FL^<CRYE9?9S=
MF2Q&>/-!-;5;2ITU.'?L?"B]FE'9OEK;<H*BY9>D/%79(@V'4H^'YI-8(E?$
M1YK6'6X[EI>M=68*H!'\_*F5Q78[M=F4P,E:4:8GDPFMTQL(7W\V=-%KN$I.
MUPV&J):7.9JF."H+)G"!3 1FE)R:E)S3\GV'%Q-J@1AE-W#HV>E71D*Q;B;K
M+:ZDU!N5W9JR:A(:>G;\"27%V,TU23"U23^)L\Y2576%QR]07ZL_D)UEP\&Q
MQ:1:[.#E;7O#@+E>(!7-*A:L7G:D:)YN+KJ%9:G8DL%3+]#*II*K#!QOW-"$
M$4.VN^,&Y7IM./1L6<ZLMN@.Z"3++?A-JY5GFEJVB(:>+:O%K\B::6@9+2]F
M5%?'6^4L!B9P@02[WF"@)WDWK5%].K>TF0(^'X!E7:#!<D&BAFTJCVFUT=QA
M!IU=?B2TX= S<@$24!PF-=EBV,QR4ENPN%%UP5,OT.M\:F =1RY-M3Q><VR\
MI?-2 PT]>^HBH1,2IF5*C)H:+%9-NR6N\@I/7"#M99-OK7K9UIBC.O7IR&QU
MC-X$#3U[:L>H;5*$Y<TY 2OQ6J;)S$V<YHD+I#W8T)9>-)<L)MM;-\$TBD.W
M (9>(&UK5^ZM]?ELP=1PKU1V6C.Z9P!1>8&TU8*3HTJU2H.I.?-$-E>?%G.*
M H>>S;7!]OIE>M3$-:^=[#-&U5+T&7CJ!7HMLO/^T/7F92#_&8)GG*&1JH"Y
M7J#736G9ZN0<-<^I*\^B-^(ZV1'!!"[0:[+*."E[EF>Q/)M2J!$W'G=W8 (7
M*$NHK>H;>3MH,X)76O>:2RNCEL$$+E!6+]>I#P3)6#"E E\JZ75K,IR"IUX@
METHA45BQVF3*E;8U)2'W,=M**W H><:&9I+O]3@&%H*9_4XZ9R[5% V'GNUK
M%<,KUH9DLDS)X7FI:E6H1%F!U2-G$S!)I<G-.7R"4:)5RR^WCHA-VK UQ_FR
MM'YZK*;('M:54CTWZ21WK2E0@A?(9;-14RY9S168[G!MM7$O4P.\QI,7R(5H
MIQ9:<V6,,6I$\YNVEQ:;$S3T3&34";R_['=&<VU17]:;G"*2V3D:&HJ,"S4I
M%TI1CLPBZ-P$[AJT^D7?6P@]4^1'":YCAA_X7A3ZY,37P@YE*<&8<V?6L<*)
M!2_$?4/KZ8H8,ZQ\29/(;SNR*U]2%_)>CPQ[P%+/!&7\[[TB$G!:V?)HL7X0
MX)GBGP<R^;-W '](_G :R*)HR4_>@8@+(BX 7$!\BQU !7[/UX1^ 0T([[3/
M0B3?0QA<N*X_W9'G8D1^2.O\W[-*5V"6P1WY?W\0?[Q5)F /:2(,H^]+69?;
MH'EJ&*&_\4[]-KKV\KV#0<"G*H(C(GD[D7PS&L$O%$R_3IX>;K-^_4L497DZ
MO;F(/?&;T@_$Q5TYSAI*^(/>O%$(]<2^*CM]PK:]D\6NM'S?^KJWY9\IY@]7
MQ;YG\@G[<L0Z*.YP'5$<,4O$++=V8+XIL]RA4_.4QGVY?LTC5&D')8@Z]J^O
M8);^EA'"P_MN$8EO%(E[%;^>LF1$H#^>0#\@2'8% OW:3MM+5 CEJQ!80[DO
M3855%6M!]Q/SOJF=^>$T?Y?VYK^_JW=%/EYI[":M,G "WL7#@" _P2QV.V<4
M!>MVDLXJJ3K)685^-0+P'AT2,"*$A03_8P[L2#MYP;)@P6U?T-VS/A4PR\O*
MKYM56U]S7J&Q9!I-36(%F+=&_O%/-I[$DQ>@?R,6CUC\Z_F$'\WB.*_N,!+G
M&D4&\[9.T1M7\R+F?3R+XW5==BA]3&$K@LJ,MX6$G%,ABU.HG1&)X<_P^#?S
M@'WS):@4A@6AH@PV<J++W\+)^"P1]BT<J\_W@K^\$1+R56?/5DW9"<)-%P03
M.<R9%;ZPK&(L6ZOU,JV5W*@K? K:'G@\E4K?SO:(N/3K<NDGAP*^O!WQ2BY5
MF.9,<F168CQ[5!C3;;Y&ZY!+*<BEY+-<^E/B(14#-B@P+2\.T7TB#^E;>TA7
MMCA^N)MT=2-DSXM JET09\MUSF)Z2\=F!@.Y,Z5Z^5V+W_"4;W0DT\\Y0Q$[
M1^P<13T^UEKY#3L/LHO)-HD90ZW&)US!S> Y84D#=D;6"9$][V'US6,;+0B6
MJ$K[K@>1R_0>4?5Y":8?;H9\\E+O28A=W28)F)+Q>?*9B$AGXN&JQ[2U1&';
M7'9Z_7QN1O-I:)PDX^GT<](L8N^(O9\Q2R+VOIV-\E+V;BDE7 !/X[5$.=_/
MJ/UQ;<=!\ U@K!!Q/'/EBY@O%DI![>H@CC\$1A9/DA0C%RQRP:*(RJ==ZR >
M?%JL.01;T5=2V^5J7B79R ECM:9#I" 84DG'B2B))&+H**9R1_;*[QC:K:7P
M?"&%T=QJ5K:6DCU:LWV%1UA*9"J.DS\H8P0+HBJPE8/CH:17F.^Z]+&;KWG;
M\Q/EUG<14E'FR'L#)#Y_M73!<&A#8D(6NQSUW6WU=#W='1%:OFO/"Y6:-TY6
M(.(@"1TIXEGY%''IC^72*'/DO7&.5W'IN*=F*XUB#V<2:0O?]=.MW$2@^:Q_
M-Y/._NS,$7\BJ(=QPIPF7%N.@AV1;Q0%.S[9$F']EFV&4I<%6T;LR4XY6T8^
MTP4A5YFL,:DKS6;,@FHG='6=SA2V"L0I1@DEY+-!W8C!(P;_\L$/U-:&>%\5
M[/TKZHH!))6B!FW 9-@-*W+^([<B<OZOD;$9LI8?F 3>!+.%3=? -I9,4X+-
M72]H7C5+,)CN3-*:L%MVM^G68K!D% C[#S1O!HMR)2)FC6( -\C'?!.S$IM2
M>3?*-E.,6Q"%G5->$4,),2OUQS_I[',WA#\E%,"BUII1#."#7(3/SHCZW!C!
M9Z_^53+RB]DSB)$#Z6@:XI/7K%6^)=!)8[CCU%*B/1BWUYG,$C4C @8,2=VP
M_#62"C]=*EP.+'SVZK^UY?12L3 5U-0L(RL=QFWM%J-F+2F4IC2<&+PWP5,_
M)_?B)"/TRH;1CY1W)^Q- O:63!=&M.Y!NET16^RSEWE/8NQ&V:"7DC*:]%22
M^<Z(ZU+>KJVP:4>%[0))E)6!Q[/9YT17Q,X1.[^D=.6'L_.-<D$OL/.F6M3,
M&H:E&7G)TIT)0VBB@-@99H&FXQGR^^9OW*Q]15T5D'!093L.NYFC/8&TW++D
MJ0PL0BG6=4Q10WFFZ*<9^*)LV>B2+?UWK"!/55%UOC6F_^>#VM_EO?+']3JX
MR\R2M^S'#VB $3'+YS/+_65I7(M9OEE P9](V !#/RCC[]$%([H;_M*)'$^L
M[1MUP8@(]$LG+[R00+^V[_=RJ*6>)4AR;"EX$$,SNK+_W@9EU/KB;@/2 9YM
MRV?$I\N::;*@>%BI/><6_<JV9_6*C?:*YG'*AU?*)J,;]XBIOX?_]_7#TB]E
MZI0R]YJ9(C9@U'Z:6;&)WISH*9"I?7QJ#/LY]^7[[A:6*TO'[FWD/$3.PV=[
MM]_!SH!\=72%\[14VI).FZ@.FT5MP X'8T[H+K(V,#40DB,5)]-1;XN(1^_/
MP?\.9L.+>33)NJ.IV!ZPG-<S&&G4&TWGP@;R*(7< 2K[;>^W7VY,=,%S9=LG
M\5R"B#F68(@S^2;&Q9TY!Y&/= L3Y(<[2E>S2AS=5G_YW)GK;<R>SY>AX/.>
M%GNS96J"Y]-4GEFEJ*)7EY=\DFKS>"8 F;YEX>2=D7;$X;<P8.Z>P[\[8,$E
MS4W&-H(%9(03A04BER,*"UQ; <\L67ZY"AX:<F[!87):6S6:VXXS28JU/E#!
M"+\03\4S^'.N1\2K/Y97[RX\< U5^C7]XIEI.0E'MA8Q'0*%10YQ9"Y'#O&G
MZV,$VO<"#>QULJNNN9@V-94J9'(KI3C!AVTP'U1ZGW[NSC#BZ8BG(Q?X2[C
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MFOJQPX]P/\XV<R%L$T=;=F*X^]\*/T*2*OS,M-%-]B]+U@68, R???)4="[
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MUL-=;3P@K6%/-MLK5-+[;+:G<I'&I-;(F[GX!BXA<8I=IC'*Q1=,ML,G66Z
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M,J=-HP(O2D"[@1?E_56,%VFW+O7V>;-QKS-H(!L#MK8W*H,LT"Y)0DC'G_6
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MIRQ+(".F3.!-,#]=_Q%J6;K_M;(1PH]7,*:Y)W)WAW>NP6K_+H@C3EK(JFR
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MF)^C$ATXJ;L(ZF>)W,4+)30VJ9[GBQO"AS]"/9G(9A5,.1]*.]JFHZ Z.%)
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M#\#B?YH=S/M,G"N8?)1O<7Q$2@_8JAK![("-A>.9TZYI($N(3/#K&WXIA55
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M&Z*V)!!EPX)H[_@28#1SV/8JX.>2@Q%!Z"GZ$-_]+.VYY5,]O!T!W3@N>9G
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MAM?[2<4)B'LIK*5LMNWDL-J9J+^V0T<K->VO$J%ZE*%')"@X4&<:"3ULP.X
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MX2FL/G%*N"7H6.\$OU"$!%4=;N_'."H@C@Q'KZ,I.(.6=H$A,>LTQ6;'_H?
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MEO?#ZG%GJYJVKM+!RIZOZH6W!SCG0*T%8.#\+$BAV*>$AUG@3Y=D80AR9V1
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M;0[CD.<C"U(VTTJFQ0I"K'J;3KZPGG6'"AAYLJ9FNNY.?3I7952TPH[<2:/
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ME1F.,.U;P8EY%6;J17P8MRSHW6:FG&:EA>X7VQ2@0)D.@?>AD78!<)A8 \7
M^]<W:V+TZHO4^MT8&;X/''O,S['7^8YBO%MGYPM[G><Q"+,565<GK<("\2DA
M@SC4TF7J],U[G964.,)QI=% U!Z/TWT_DUNO]FCLQ&O=EFXK$?:W\M(%OP /
MRR:QA .V4)A*^_A<<*-^^R'J6U6,7T +WAJF7(QT>-^P0U\#$/RN0C6A?L]B
MO5"YGY[0<PSM5[))365R?'7"SOW:QIC>#+3OQT(V \SOL,EBI8P,U)PFYDET
M(9M*"!&./A!X^H)1F^^F4ZX-XO0U8,(_O<G ]U4I;T(+?ZY16HZ:E@Q_RK-=
MKB-3B)Z7,ZUV"!)./*3PTYZ'L4+Y@QC9_2N4FX,)CVWGV*/[%)"INPUB_?9<
M([5I6C5;K1R+-82AD1^LFMW\[0>S<F6^TE^)-955T_/>*CFN+#M5#YQ=,)B%
M/Y#(Z27F5TH[VT>X4@GO60;:.2-<-[;J^#;@>^6@Q9=;<?K3':<_W:'_FWHY
MU;*-UZJ+^G2M)8O\<&QL*)US[B,+ZKGMT+'K[:9OYF5$Q952MY2LK]JLPA$P
MDI9ZH-*I. $S3G_ZFNE/L0:ZJ0B<.O*:^7(![R+$8%@ &R<PW2'41)D?OU#T
M(4,0L2J*,]>^9N;:V5O\W=A.QLYJG+IVY:C?RV>IUZF@*C[ %XC?[I2RZ=%J
M4LS>?M1/=_&![A?'),/W6OTVDZEJ)N>!\Q)&_=#T X7^-HOMO+T:#SCP13"@
M=W0;$-75GT_K\6EBNZKA@T\<<Q'^$_R]:W?XB&:D^3\+TU8AQ7Y:D@YV9R4]
M:Y-X,+DG680=&DWKYZX8^:"!XNGC@E<_$N!5VW;!Z4=D5]\,MTS:DS/!NXZ9
M0!((?.]_P(MW_[V(PD*Q:*4MJO9"Y_V?JJ&KAI2<Z*:@'?6]A+_9THAZ@0,^
M.L7PG_!!@#) "O4C/*GM1S]^_87^O>>?X'^]J6HG^#G8&B>AALZPG;"?C-"$
M*2?^]W:;=;^HL,3!*,>6NX.TIHIVT\P:U#!CWLSU.S3WI1,#OP$6PYF%><O&
M^^LZ(E%]J:@UN"1?\V"@(94YO6!_2%B2Z J2F)CX"77G1,2;=HE->\4U"W:.
MV(Q2DN%/1DS5(RN32K9%=0<T.&=.FZ<_AH=,^&G#G0.1%L)_0Y*KALN'1Q$?
M/)W+B"ER0B($1TDXPN&4A'"\A A<&I%YF92E5)J:0,7'[WX!CCX^[W5Y@F!Z
MFM\II5DTZR;7&07NW?.1M)3R,DJGQ2 8,VF:2HV55YH'1J:?CU2YA5K/2YT\
MDMN8ZY:0;A>JDS:'G3Z3X4OU=E))D4BQRZ_7<Z'275MPY,DSB11%3T5^B&O+
MDDTNS*;FXAV%2W'(\Y$S<\E;Q1J307ASTU1[1I<:H'#DR=NG%;TWG$Y\CBG6
M-UQWI2RS:],#(T_>[C18UI0 H[!8.]6<UCN352D/ZQI/WCY Y:39R8@%QA>=
M:I/((<1\U0XK((]';F1J9);G4YS-T6UL6NXVIP("KQI/YME-]I=C:IC"V>1Z
MA(ESK#Y8^#08N9OG$8.\*Y"2RO;33&,F=S5WG)Y33;^N;+#V<PG)\?:4-D3X
M/V;IJBO TX"[\ZHMZ":4F!YX718>8UN+:L+E46[*#KR6Q?KF<#@>$I-ED]FJ
M"L"WDD@[KXSCX##T1T("XK, \W L8+;=_BD]^80C>@>FA&\AE,)#^M6>)F#7
M'A("^&]">MJ\!-#KX%"P'< Q#C@7X/=[$)6+M_)^3OFWS_$AP=N)!?@0@L:(
MP!9).%,ID3/A:VSP ?@KP+'AX;?@]'*>[!/XDD1!-SW[ ?(AT-EP#/@"/D$V
M=? -=/4""EQ:HKK"%!S(NM24HV6K!P^=4[$2>MI(*K>K&1:3:BU2'_&N#4_@
MRPC*DRE_:/R_[I4@;_=*SM68?>N!!'W9H8&_^R#LRQY\\N;>[=0?MVXG4X_4
M-^]:C3UBZ>]- ?3QFQ,@<VF,\9NG !""6\K\C(7@*D+P)0CPGKS&VSW^/JW=
MVN<<?W_:^.EZG9Q0Y)&Z;(;XG?2Q^9PCXKX9Y:XZE9RQTT"L1R^O1^\%L'>K
M,+\R8N_MZM![8I(OA1=_VH'B _KS"MD=1[$F\A%[%@E-AA^]1I8@4 ECG\\#
MHF=3JC>6S7.-G*;;H\(Y<IK"N,NWSVF:(%9S/6,4!>EV<&>)JPX^+7\\#RDZ
M1D\[.=ZR?$#*E_**U"6=E2W7*;(YW=+(7+&TZ4W@563JQZ_, X[BETC##4_$
M&^/M6,+/*.'?7L!13MT@*92M%QC$7SL%?US)"8C_^0(^[,X=O3X5%,UOX;+'
M^C6MS+2!@,.2'^0AA;P&NGZ#[N"?VRZ=X^O:Q%_;;+'@JK;I3"4KP=NV%+0
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MS:JY=JI8PO)-JA59)5JVJSS15 E.JW:Z_6HCO?0H18FJ$N7:4Z=)SH@<T^T
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M,KH*?60)_A;L#?R%* %),T/%#AXO 'X 7 (?*DA0G!Z@  @FL)O4IV>LX(S
MY,+WP,<$[THX)IC8'!RG0!_ ],1P@KPEP>=-X*D+WR&[$"LA <38,.>JD)A(
MAB2KCOV8:!TN#A#!A'H%2&[PFL64!WPN2&Y@P 4KT76@*ESPCZ>3"CXX/,)$
M\ 0P2G M*_S[I?<&/X*:192D.1@*5C%YFO%CXG1CX ^@&K*@6N'#"0>D@5_P
M800.? .I%E '$!S((UR)KLH!#>"GX58"HDYX.%LSW!!^ 3<4K"DX=-<+-501
M"1&,MN&W@)D#2H)I2KPPW3[FL#D&MFN.X?@+2"O .>\IPGG)AXLHD/$ "6S)
M>*YH"BI0AU(-*''QB7B!B$6VKK"SY*HX0I8&XV/5%%T5Z,F"@T<F<J#$7^L&
MLE^P"36W[5@\9,>DKAH2)*X*6.LP+KHW<H!0!;L"2!G-3O L.3HDOH()<TB*
MIOQL@T[2,H(=<OVA-&']\0!19^6%HKGEI$U[,(7W-(?W*Q@U'R!1WZ@:TP7E
M,2S63=I9R5B+S R8.2AR6MGYW,P92$?6C26^8-ILS]-$R)5H:!\]*1=>42Q)
M 7_N=-"I2:^>Z#+;G<S 3* ,'/T*C@[TRU9;R6"N8#"\YX$.+O@W),*AE:7:
M@98U==WT[)_!(?JRUODHS[]5T=B'6\B$%.A!O=D#,\CJIJ!M/<H)EVTMAB3*
MMM:,U'$KN59SO.'K@'<DL, %>)ECN=+Y(A:JD9R&5@CPVE_U%Y]^";]\H_<8
M^+:[)VP#%P+8$GYA2S]W?QQ.B@#/WDYHSJ^3P1X9NVF%>4J\ZYB[#X*#/OSD
M*)?I,+DI' ,_V491D'_#M3G6;E[;]Z'AFG\;G0D?@C]F/N%"X<UAMH/?O7UW
M_C302&2^-P70S[A3NFD"((\$]B5(\/L[XRCQO\N437"@I<XF_C>6>7/!?L;H
ME7(U;^RF)93X;P[1>/:;Q?=9C@TPK9XGZ2NI#N8XC<I=3ZXW?&I063%(,=6<
M)EMK;^!X;6#<IG[\(EX#:/V8(KP+K8=_":/GO KM6VJO6%5]FJH: 5^\YYD1
M&LH@QZ0^1$IEIEC19DV^S/@BJG#8A334O9IJZ:]MJL6&66R8?3%M-[4D*4K?
MY9F:[+;9+KN<K<B-N:!SCD!SJ>]LD1&Q119;9+%%]NDZJF"Z5H2*TE?C<D;N
M"PHSX+H-J3W/94<L[.47FV2'6HN,3;+8)(M-LCM2=V!LA+HCUWX^Q]B+@I:<
MNQY=1-.I >-QZ6]KD?6FDB7QLB-9L5UVJLYNN)+V>KKMA@MLOYFBHZ'<OJ+M
MZ'(&W>3% <5@'CE:S685;)%7. )J.YS\;9G"/5AWMR4B-VGB7:,V*YH9KE[&
M=.EJK9?-OZLO_;NJS>@:KG[)-IJ4DJUK@Z:<M<U6<E'*MSD2:D;JU1;V1P5<
MER[8^EARRW-4_]NL,ON/J*Y^_1?\9_<[00<G&12QZ2[5;R<M\"4[ 0LS^2Y<
MNX_A.PVQ%XE"DL /YAW\]W\.I_\D]##=T;1^[B3[8%W;M$,L$')%2DZ [:TE
M _/[)Z][O&_O#E3J$<-WMM;/O7: E$BD'RGJWXFG/R$]3H@),RD/2';D*(2_
M.LZ5W'YFVBKD]Y]!7CH0)_CLHZ<&^^*8BY\8^DA<:%N>:>G4TR;\ET],+:A0
M_M5KYEXNN#&@WM"/"FZV'P&'9U<$D@OS3)]*;OBW\.4Q5:/(Q>]TS(BH(6ZZ
MZ_68014IEKJ2Z3-]F(^!_0C?MA^9HHSQD,!2"I+K+N93"J=F$@+O14]&3AI#
MV2<P<L1(FM8KVQQ>\/@V&)E^/A)UEAUNM"C6V62;JDW%_LKL@&>F..3Y2%W1
M*;FH^C*2;#4IHJJG.P3>!B-/WEY,UORN8ZLNHB9%H8W(?*$L>F#DR=L;E7QG
ML\;5!>)J:UJ9K4MIK4%S>,3;)Q67'4JK&3-(Z44O+Y9GU2'L%'HR$BD1S*CI
MIL<:YB?[JTIO51TCL'O1R4C4PG6R1W \4Q73Z\5@DET16#OL>G(\LJ]-/3N3
M5GV&=[-U;-)+.YSCA?T)@I&7SA^G!0&H#,=N\3YD3(B?(PB6*XDUE0^4J"K9
M>=46=--VK8C4<:^7EOS.:K4":H0;\3F90HNPI=1E4L??5OH&"Q9UWO^I&K#^
M)3F!$SZ*2QSH<RK\^>0L\WM=!6QK[OXB__[O?R:_=F)__.;CH=NM2!SL1?C3
M:U3G[2:C/TUF5Y]G[TLD@M(':#M^2O%#5YA*H@L+.4^9]H52!V[3S#7H,JFR
M?*V>T7.-EJ*3[;C4X>JE#D_X6&3J\=4HWL'1>/!L6&HH ^;;$6SW[R1TCWZ&
MA@XLUONMC;'_GI_8INXZTC_0W+B4"7CA//,G6_&/(PNI5R%>+KPI6TL\>/')
M_GSG?4$?\5>QY.)]N<Z^9!ZQ6%YN<%]B/7:;^Q+KL=O<%Z#'7LV5BO?EC_;E
M/;BQO[.+KT8 ZAT$N*CROB<* /<,?OA_/](_/DJ-U"-)7/4^G'HMAAU-O]?"
M'2?P5/M@1RPKMR<K$=&B]]?%[J4 ^Z@4H,@C>8)0><]2 .-?QXP?\\ ;>."+
ML0#ZI[KO+C.=(V+,9Q.#."LF<+%NC SGR'H)8RUQSO-Y<UJ"1LNG]RHYB"88
MV4 #-]!: 5W+#%OM8\YL*/<:HYP25IMA#QGDM?3F6+9CV7XE_O#-9?OLB./O
MENV:(%>I$CGLL;[%%7UVT=2]*LR\( +9CH"^O66_[7R&BFI 6T]=G=%.^8Z*
MZTN4;/SNRN?KZ:6SV1R.;JL_MS)5WHG4R]H(6==F63+;6+%^VJJ//+DW3*[I
ML&@4>Z R%^IF'4OG?4OG-ROZ/IO5\$[IM)2B6YA/NZ1&-&QV,-1TSB?:0#H)
MV)XD3?PVN_W[Q#E6O'"^KM6Q(W2KCM"938QO[@U=HD,QE,;^5AA?UFS$H$OX
MNM[V&%\KD^OVBDHQ[6WU=@H[;1 :BW4LUG&0XXJ]@M\FUI6B*=*SH>H@*E?J
MS"NY>;F1@24@,+A!OM8Q\2N'-A:\;YFZ'GM.?Z*P;AC X=Q&20S+<'$+I16*
M9(]?OQ:K;2R:C6Y++76UY;(WSO6R.-5RVB'J H:_AKH02W@LX:_8)[&$7]Q8
M>9N$%Q9"G:E;:$WS=9[LXSECU!%@)2HT6+#7HI]W$5^Y+3F//;#7/;"K(XM<
M+;WDZBN_)8UX*9OG3=?3&)%=KWET92*YAFKJM9J7S6E>"*="/*1>A9J*%4.L
M&,X<MKGZRF]),5S*5'J38EC3>7F=D_,T,J<KZ:))*[F910/% "PE_"%#O!:S
MC9&6SH2T%**=<),43N$I2N9X'IP6>#J5X2AI(G*9C"2F,B*:IK#)<WP4-9-E
M<(1E6<9%-Y,"GIJ/%4>)PK"IM.Q5=Y5I]=AN;=1H$@S)5TMPY"DRC3(HKJV9
M44#FNK?.M--9A4M"#)L3')>*F$X-:F1QQBS;\PV>*^6*PH".PK!I%+T%-BT)
M'E)L.?ENLEORR5$DAHU!8H:W\IBLELSW2O,V.*;$8&3J^4B)R&='Y7Z[Q_H#
MM<^RX\8@Q=-1:#>L4F+2ML/QS"#=6-O#7K*I++?96<<C\7R]@Q&9E:%)C459
M2 KR9(2VHW!QZ,&(R)N=P@B1BKW9JJ65EB:US;%XA@DT%KK90M9O:6Z7;;6J
MM6R[4E;"^][CD03::RM2SIFPN46MIQ,&EFNMZ/#^Y'BDF\QL>"')&RQAE)WR
M7&P4:7<;DCT>F6TOB4ZY55RPJH1WIGZGV6OEVE&H/(6Y(!@>*Q>88FO5\^SE
M@"ET%* +3D:R:J_C&*Y;8J7LO-7-^'.U32@<%8'TPTBJ)G3\LJ:.\JA=+M5[
MK -'GJRH)AAKL2U3$I-L%RFDZ)/>K.:!D2<KFBXM4>?+V(09*,N*/]1(S6Q[
M'(J<OGY0TFK#VMP=:\E%=ESPARMFW5+@T!.^:PS6=&J\P4A-Q7 V[=JM>L]H
MPZ''[,11&7#0D6F>2R$RP>$\B7'\A.>Y"2K(O(SCO(2*SQ_>6\@R-_.S362)
M9 93?42.,S@=):;]59IJBEFGB70S:FDZJ]&KW!B**?Y\9*=<$OQ2=BJS2[4F
ML1HY%=.,%R6FP\Q<)HB^@FD^XE<'G+=1*LMM6Y_CD52_,QN8E6%'(Z1E#148
MKHWI=!1\U3 )-@D9C1:(6J*\2KHN6%@G4O2IQG"Q6F?U$;/,KY)N"ENSLXT2
M)5)U,=EKMW%[A6 :W9X4W,)4GM!14%/I&9;;^,R:8Y=]?L1W-DAQ,XF$FE*X
M9K,AY_M9;5!-LK,I,QX82#345+JK8<4ALT"ZU6*OD??+3*F[A1Q\QM2I/BK8
M_70;\2V)=YS<(*,7X*%YLD>F2X]R?:6I,IC1V@R+S1D_G"B?"%]5-@1S+O7X
M]6L854-%2<IRV6JPQ6E221:-D>LR6Z-%-8 I03NOC./@,#1&M'H%T8IZ,Z)5
MN%^)(+ZUKW#Z/)BHG#E?F 9$W8,]S;>LLP4SSDJ&)*O."[A1+70]SI87@YKF
MERN(,T!'6(GT+L05[T#E@OW/U9"H#K_>=3JW$W]-PN78?R=DRYSO>!WV+3<7
M4DA5.VAQ[DREPQ[F$GBMF#@IQ4T$;==A8WMHTC\D> OV0I^#B8%9BR=MSV-D
MJAB9*D9T^=;[$B.ZW.:^Q,A4M[DOL1Z[S7V)]=AM[DN,3!4C4_V. #':3HRV
M$Z/MQ&@[,=I.%%4*$MA!7O\9YT)\Z3*5SR?#39:IW0!=8BF)I>3&J[[.1Y?;
M<R#^Y,0D@HEL$XWNP5B\08:_/IK$^=*!;RJ##^X4BIVCTB-FRSMFRUO#-SEA
MRR_O5X6G1%Z2)7!.B+'%^,DYYE^W_.XM!2@W7I%W[D,J%HKO+A1O*;ZX-Z&X
M/:_IMI@^-E#O76ICYRGFS5OES=B#NK8'%4ZDZ_".%-]+Q1'W^%XJOI>*I22^
MEXKOI>)[J1C)*\;J.P,\Q4=K"C^(5K$5S<"BI0VQ9H+-.BDZC$"N<$<F0O%E
MJ:95AX9+HJ2C%G$E+->](-)P+/E?5_*_.X;?<\E'CR0?Y4BRB]:JK%]FJO46
MR4WE,9MM*I\N^<EQ6>WKV<F '1 UTFA0Z2ZR4$+,FM2]8_O%MZLWJP5OBPS?
MK&="?#L:,_6]^^CQ[69L@\<V>.Q]WY#W?61\OX#XDS-WT#C-/3).A%G.,W+?
M; U)1RLV%39%6&U&U-I<)G;(8V40.^3WX)"?41FH591;U:V-SU3=/#_FV&E:
M&=% &7QW'QU"DX&9]$R'/U_KH!NSXF_(F;DZTO3G5-O<XLIO2G->V(QZ05E&
M*$9T,"GC%49TM"JO5),KH3U)KP.8V<N:2;&*^,XJ(H;AO[IQ]78588VQ5A[M
M>!4DEQW.Z5(YH]>:@8IXB_&T ^2_4:S[S\.R9619$B PU9[R'6#>=B3P3@',
M,WC7"V"VM1JUP*N90H9M9I'^7,_8S7F1O@TPVX5E0E(#_H?@M$_0MN"=H@J6
M;-DAH.W1-^#/A>M '%H'XMDFY!#9!,R?=US'M/P '!?07_H3S%O1!>\SPQ<$
M8+<031<HI?G7!KW% \BGEW5EC'I[%;1(A(S1[VYO7S*/2(P6>8/[DGJ\I@Z+
MMR46E[O:%_0Q@\?[<K%]>5<8^'?VUW= 5WW=V+DU1,F7@3C/ C0:*LTO!<!Y
M+@S6WQSS%X=@C=GBDKBL%SO.;H$O_@""-CPA[NRF,)Q(=Q^A@=&9LYT5-W8=
M<,:D >0Z68T7"64O7$OBII6JPDT+OL;,IX3@DRNA::WI<U]WO2>4_9;(*NUL
MT9/W#'PT>!_V3F+[N#=ISI&YOI%19% TQ%FCI9;;$FP^B %=ASXBE[@<"\[#
M&Q.&?[^(31[+Q!_(Q/OO=VY )LKE:G^!#QT6&<P$W)6LL=?%8.M._'(R$1H#
MMR84?W3TW\<Y+P5W*3K,O@KO;>[!-?SLL_U[*:WK'^3128&2':6M1GV<G<^$
M2E\KCMU2BITN#3[GA5V^L0L>X#%[WRE[7_],?@][%Y;#33*E99MLLL63U;R7
M&[@-!; W/(P?TY<[BV\FMGDQ')$[]M!S4]Y08)/AQ(K7W8"I$CS,?N -(7;8
M[](Y.5ENXJ^O?]"'?%PV=O7C8!!MVY)C]W=L3>^X&BA'0#>@&Z.TI%*=3?DB
M-4!8K.75]1XIMEH]C\.A$8!F(JR O[^H'Q_+R)>S%LXE(WT$99NM+E5%<A/,
M]<1D8];B:" CT)) +B0C-^G7?Z9Y<?NV1-.92E;L]7]WM^CZQD# B+0X<VUG
M#G@WTAVB7:/6JXRK8V;)-RI">MXHZAK-I8.#/O;V;YVMO^4!'L'7+Y_2G4S:
MR;'F1&2;0UG7';9(6[@'&!R<TL@C>L%#^KN<R'?I\+<DP) &&+PMN)" M7>^
M4/V-V6>7=V)NN<+_RP0"'-U6WZ0@]\R=?^)M\!G,57I55YI&@U_WR9'%^ Q?
M2V[F5&.=;W,$- ;2L=,?R\M]V107EQ?*ZM%51&EHFI]):^I85_(%VP/R FR+
MU",>!P#N,0!P6Q7O7RX(<&?UZN>#K+RZVWNAE+3ONI_7=_*>IU/=.&K \VF%
MI4('!5&"+O$6I/MT5PR^XRKXTDM41+V8R(_A.X+OJ5U($NGGA4[_<U3/M3^3
M84&\:?W<2<#!NK9U9%C +HJ4#,O%>!F\^B>O>[QO[TK:J4<,WTG7S[T404HD
MTH\4]>_$TY^0'B?$A+7V!R0[\IC#7QU7TV\_^TW-VG9?8'$ZACX2%]J69TR?
M>MJ$__*)J04MR'_UFKG(FBWX-V S8-#I_QR6(6P_^O$K@(M(F'(B%R(1V'L>
MY0\+V5[BRV.J1I&+#\Q#+H-,)M($H[@TF@(6(2;QW&1"$!R)(7(FQ:,9*B7_
M"-_*[PS*)F,E'169E)%NCTLKVJ0V-'P:VLC/1Q+5R7HH+1I=Q&VL/&'9MU"4
M;(.1Z><CQ?EB8]NT,V+=3;%0D'/ESKCN<1B'/!\Y$-V^F9D-4&:YP%S;JVPR
M_1I,C3D9R7?Y:KY<KS:8HKRDFAXYUIHD'>:('8],^GPAC::U'J+ZF10J2$Y#
MW<!LLI-YMDF'K$YX;,I*GJTW-RO3;HP4#C]]^Y@:^_V.M*EH:K-0DTKC>95O
MPICUR4AGQ552G=("19+^RA*IAJ[IF@(,]).1DX52W&R<-<KZ)9%HX]RXDC$\
MCCP=Z?9F&ZN4'N&,BRFS5(5OCK@D'2+7'X\L,+ZE%4FUS/A=Q\&RP^:JT/0X
MZO29!9HV#=+2%+8XK*]73;Y59Z@V&'GRS#J:JFQ2M-C6B.&F)#8K2J[4\+A,
M!)6XZ<*;Z/2:5?4.61C;OD\@ 0+-R=!^15TN:3=K:-VIEW31>MIO9A0.14^'
MIGMJMSE?YJK:,E4D2TM$=#W (V@$.^7SA-C',1E')-O2_!9E9&LUP,P1_"1J
MQ3GKSE,K=MG++EN;7K''C<'0B,UOC:M^OLAE5DRS+O CC)4<E )#(W9_+5.M
M)<X1E*8B+6?4S&=DB53@T!,VK9;1D>0C2!4A"I:2DS#%XYG@J:GG0U?#@EA2
M.Y;#)KM%7=$I:;#H!T-/6#HG3A8^RB!E=I"=4\EJ9Y2?KX()G.QK:[W1.#U=
M;K$Y<C$<\TNKR2<C)7_6FXF,1]6[R'*1JJ:7HQJC#;VPPN+9HDH+>9;%J":C
M3DS/;MF%=%B+<3)1</ P-7E536K%A:,A<RVKSWM>E.0OL=:8+4\V,M,=Y/I5
MHN'V/*\=)?EB1_5=E*)TQL\3TYJ2RO K+%+RN8PXK*,YK\<6=<+(CEJ+JK.)
ME/SAV.P6YK6"H$F-K,;/6SIIF)&2WUY12HJJ%7G&[=GE7FZR%%:6QT5L?7]0
M9T6SF,:88IJT<R6M0'=$.'(W3V"VP-B%:FSSPK;X0D-%2<IRV6JPQ6E221:-
MD>LR"@>'HC\^$R/I)(\!9D*J?&"1J9+] CQ2KC>;X9E2UF6:IFTO,LDF/B*4
MVX!'>H(]2DA!^,:&Y[4CS1>FQ5O^8<@^X4QY)Z& HS=AJ78 700#-JH,+'G#
M28 ?!.BFP>_!D\4MK0Y?P0=$"]/VG\@&499^"Y;$6Q#+2;*A[2@F)A*$!?C*
M*$F_0:N/09*N I+T.H)VC&)Q+721UYM&Q_MR+32>U[NSQ_L2Z[%X7V(]=NO[
M$B("Q_MR"^A5M]7%Z1BQY02+Y6LT>?H<D"+@JD&*_-\/[,='U2<2)LE])<2B
M<P%9Q4QRP"1?C$?0/X!ZNL>>,.%$=K&X@\#2S[C]PY=N=_GY9+C)9J\W0)=8
M2F(IN?'NL>>CR^WY)W_>];S1K"4$WK)\V;0\WA+/4Y#Q71M,7G/-Y^N*=EOI
M@V=N7T3;7%,^O/N=(%9S/6,4!>EV<&>)JPX^+=,?[E=T<C6\[?=H*#73MG.'
MHA;1PVA4YS>YUJH[9J6*D!Y.INNDW8+Y0*D?OU+( XZ=5L_% ON]!?;5B.37
M$UB44S=("F7K!0;QUT[!'U=R N)?2V M8U ;,ZM%A\FUT)+$X8W:M 33\@C@
MDI,/"()]YZZMH8U14->PA=93SH=J "90U(E^IOK/V >Y51_DW"WN;\NUN%MC
M)2C3.U%\@9SN\]G*>R&-4'OK&E8MI=KK/.(N<MU.#7,;) .!>("=@CVDR N:
M*3?&X;&@GUW0;R^&<+=&SA\+^KS<IS/52<%#NAJ1R^C-2G+3@*AT1"#H"'%6
M\^;V;1E:$"P7T#_VNN[4ZSJS1?*=M-+E8R7@C]UGVW;/'0G0925!/;43O0@M
MQ687V9S/U$8(9N1<9ZT4*XUBFPM*22CT(@C#L?3>N_3&@9,S!TX^++WY;'K8
MYW 9*:KR.#4V2[E" 988 1L#1:@X@%(V5F"D:?FQ$Q4[47&TY&;,E;U<1BBU
M?)9:Y==2"]>(^4PDL3[>M!NP#AJ8).1K7E,LV;%DQ^&1*YLRKTGVJ)!=4?2,
M-)EYM=JCJ&ZWWYA#R#X8$L$RWRP@<C[H[>_J3UT;F/ S+9(;QF#\>N9)()H1
M"JR76R""2LH+EN#7F=6BF''Z2PB\ J,E9!PLB87[8T;)70GW"2K=-XDEY/B%
MZH#U;"0QT?E__'SQ3SXAA=&:.!GC\D[(M87DNN&':Z_^>YW_9:-EF8)DVS ,
MRUO"E#;$O+22=',Q#W&6GUL&S0G+:LIF8VM-V?&K0";4<8_F*&@9X \$FHKC
M%K'*^-RXQK57_^E6Q>V;$%W'%+3DA+<E6(@[A[9#"-.VM2-BAR%V&.)HP*U9
M Z>WL[D#V06F058R)%EU[.Z4MZ0LE.[# 3G3CK(85JTR1LN=4961FBY;HK+Y
M]*8/P5$O?,T1JX:OJQKN+I9P[[<=EU$-K;2M%!ITW=(&MI!KU3.>GT^V@6H@
M?OPB7O,DODDDIF<ZO/X*/&KL6L57PG&RQ\W83T7+M*.RUR:9FI9J362;[0I8
MN\X[J_P80IXC0<TN]8"G7[L2CD4[%NTXV^/*]L]+HNU71LJ04_(IS2>[76?6
M,MGNU(.B#5,],@_DF9-3;]EF"2=R!+9U -U^/L2M[ZB^OHJNNG(]S MK.]L*
M8P:]=P:]<LG'&QGTF_B_+4M:\*H89Q_$5XEQ]L$).=[< ?H&'>:#5DA;(=^&
M%:.,;-.G^XOUJ"*R&)-#D)%>U%#5"R8*R[].D23.T=(Y5A2QHKC/G(-/5Q27
M=+_?I2AXM)%RE9)MLKFRP#(#=^A@91I.%'CCY*DG_O=7=<5AZ[8WW!\\;Z\6
M>T"Q!W1M%_W+7 N4 VD[5F$1.DM6S$UU#G07VRQAO;9CC91,JPT;LH:7 ZGT
M:Q'$6$Z_K9S&X!3G,3+>**>4/L5D;J,H["#?U?+U:C(KY!0HIV&DGT@AWSEA
M(9Q(3;+MGXD5KV^[\O*Z;GJ\(9POX3-VR+Z[0Q9';FX@U:$A1>5SX7.[T>5I
M::"I4WLD^A.OH]7:L&/\R[9,'*N)54,<J_D2L9K75(-?DG,K?D9E&;XI;'QF
MLD;F50^JAI?-IZ\>G@&4BH,SUTB,3P$=()KN1)=N0@6>KR_+U9?YA[5P,6?'
MG/V6<H_[X^S@ /N/PX,I_]H== UW#EXEG'\C/LB.9R34]A1$(WJ]PL-O2Z:R
M$9QUM@UV*^%,I80E0=R)\,CS$Z:<,%WKZ8A\.AL?$IX$K1Q;!4R1\*82Q+%)
MJ$Y"M1-STY+ N:E)N@^>"8A@F [\PP%F'SA@%Z85F%6F!:,3\!WPQ1'O2'@J
M^![^>+*;F"0^)GI@M*L[P!1R]O,-'RA'/@7,2)064D"/A+L  ^'[%,D(6LB$
MOY-=Q[6"LQ_RQ\X4$%UK1Y<%H+0I@H<98+&J, 4?FC;X@30'R^$M/R&J,GBU
M9 A@JR92^'-)=($=!1[XF!@<4 L^SQ:FX%L=S-22@#C:O'XR_0/+XR&QL,R9
M)#C@J\BI/@2V"OS50N<- \[:=L#R) 7\&DYZSFOA4@ UPAV'\ */"=J&&RF:
M 9FG_$H"#_(38)1C6E!%G+QG.Q% -_MEPL'VZ2^1+7JK>>N07N%R>-D!C]F1
M;;]7\!'A!$,&W;4"2N@F7-C#P8(FDJX"\OZ6+\$O E[;,EGPBLFVGFKW2N/0
M5CPV$L%T!0&H1S )W7\(R2C94-6H]A2VU8D*R"6DI0OI:[XU;+L A.:FE:K"
M30N^QLRGA."3*Z%IK>ECAR/OAL3B4&X;C.B9AZ&)5+:?9AHSN:NYX_2<:OIU
M98.U#_T/[*UM"X !?>)^Y !I%:EL]'=K;DD6[)S,*T_-"Y)8Z)<T>,OB-';5
M4*O42F1<9XB6I36O35D%)I:<>B3_AMOQPE:$JD$(7@\Y#NY:%.'!TN!WH=_K
M2[QE)Z!V$!-Y29#F$\D*OTFA#PE(KX 7H>.6\'@[\;]G]@[_?+/>Y2SN-X7>
MD>/Y_NVVCYX#'_[$D0PVK+O*J.L5RQDLL>"M5L--&_5&^\<OZH'$3N-+ ?TN
M33;TB&PH1Y)=M%9E_3)3K;=(;BJ/V6Q3N2[92$TK>[EQP6.7I?9LUDC5!RD!
MD"W]0)*G]4</0!O9"ZAJ5T!A/5['/J #]1<M%X&BG?)B(([/M7#B+VC>8,@_
MC6;-#OY$__D;R"D@.:0@^!Y*)_QR>S!L-;:T7JA 2\/CP'8G\*2!&A+H:G"J
M077I.NK^O-?5N>KLCP4*"73#\4GT=UCT<&3MG47\CMFCZ\X!#?VF_')?NAYX
M8U8W!6T;D)EP_6$!]T0C*VA8D7(:5J&>&2X!BTJ =190P5JN=#X?0362T[ 9
M/;"37[55GWX)OWRCY1K8U;LG;%T% 6PUO["EG[L_#B<%\XNW$YKSZV2P)\9N
M6F%,AW<=<_=!8/&'GQS%?0X#0>$8^$GHMP".@&MSK-V\MN]#PS6?(9 EJJN(
M9T/K1P9,OB/8[M])Z%/]G  C0TMZ@$3_+$Q;A<SWTY)T'LKYLV?NO^<GMJF[
MCO0/F-K! L$!^>\K^-8'OWL[@_P'K&O_WXM&&BZ\*5L'.'CQR?Y\YWWY77)'
MO"_7V9??993%^Q+KL7A?8CUVZ_ORNXR[>%_^:%]N[X+W P2@WD& KW3=]4<4
M .X9_/#_?J1_?)0:J4>2N"HB&'5\003CC9+U.OTF1^_T0I4Q,77Q'XBA\"SB
M$?X!0P+__<_DI@$DOK741$2S7BSF?A%Y8"\/V$?E 44>2?0KR4-!@C<P^C'O
MQVSP!C;X2ES0=7A'^E/]=Y=I]4&@.HA-PQ#W1'(\23)@%#RSO1U*D7$6[9?&
M"SMCBMCWA@K#N.VM";>O^Z%=9VI:@*GHM6KOO\Z#+VU WAR\4+/\>F"0<9.V
M.9I-VK;*$E,[G2]-FSS7/F=#IA=O<+KA?53/9* >"&Z-(M)LE;662E<]7-.Z
M_5'66KC-]E*@N:"8$$\]9% L1AJ,-4<,,GA)S1'8*;0AUDQ X8IKJ;:H!A/:
MZA!ZR5=T;2RFV;FX<<4U8BEC\^,Y%6?7(5E4YX;&*F]JR04[1W2%L#RTS06%
MC@3YD*+.6^AX)^971)[ /?@BMZLFOTE-4MS%XFO87PW3>9OZQ(;NJND/7)S)
MR32YR3?()F^UN: &DL(>$.2"8,^Q(OFZBB3N>?'5S+$WJQ1AW"/IEMZ<(M7V
M<J"QF^*\M?:XH'82I1Y2F?."3-]9C.RP5P8TU6*']I,+RK]FT=E;<"9NO@[M
M1G3PK1ES$3JVZ&0&$WWJ><@2F_+Z9IF>8^TVEPXP1K'T0P8[Q1F--4VL:3X)
MMB+6-/=N[47H')OTEG1W-,XCRQ2W0:A-;N!J4.?\?_:^LSEU)6OW^_LK7/N]
M<^M,E?$H(= ^<T^5 )$SB/1%I8002J! ^O6WNR4R-K8W-MAF:F:/ 87NU:N?
M7GD!N2X)\W+.RG7WC.+]C"&8@E> ;F8;"(--=:;:@?J0=A24_^J+NNW!%%(X
M>IA!BK(O+7'Y, Q<E$&,<GHV^9;[644/,EQ-&,#G/8@S43=1SHGOP/3@P$,5
M/%#VJF/OY/8]Z,,'&0 ">/,#' U,Z)3EP'V$&4)FH*!46;##]"& #-N/T@=1
MQJHSM\&K1OH$?  3 N>G]_3 [R0@1:F(!Z-<9^+*@"O!7.1=%CQ*;((?/+ U
M?1V0*\IQVLEK4@(T04B/[6BB#,?M9=X#8'RX9?P1''<KS,^-8I>2Q#J#%:T"
M')T'[C1%F!8#4ZBWRX'2E">PR"],K 2\=GHAX2-%\.W2TSTX.D4%5UFZ'>;-
M'DT"$-Q&:>0PDQ=JRR),8WYN>=>4>GI@P^1P>"?*\?1]5Y<"7STFHGW\TJ>'
M5B"/3@U&=@(39EU[@>FOLT35C>ZWF^W[EG65U"',+MY)3[O!C+U-)FN8(ZTK
MMU<Q,N:I,@1\&)+KJ?8AVO.VJ\H.V*TKA/CKGI>GTRW=4@];)"=3SLK79WUV
M//-=3OOUS\U5?KO@G/%EHB3EQ.* LY:3='H4'U9X!<S9=DZ<8P=?[.3_!SNO
M1#R_28:''*0X@'DC)PS:@A#$T=9'N:^0_YY_ ,JSCQ!L!W?-)?C%'T7[T0;$
M!4P=<J\%B#T">% #0 #S[,$KX)Z< "B1EP\A!('OW4#=X#0:YD0%& 6K)SR@
MB&XX$.>EF8'_HE;IX/@()[%3$"KJ?W*E/0UG/@PC\$+\]L/2%W[@VAY*9Q=-
M<S>=W54M>-X! +/AI-4%&*,=XINT#-$TDMT ><))06Z ;*W;8:+SQR?-IF%6
M*)"Q4; ]Z[J0)6!1BHSNR0!P U<]SIDM%!M,M9F3$IA%&7V!S"^M:2W:D&#D
MJL+Z+UPGP,OPC\JP?7;Y]N0V1?<FIKC\K=LF.#%C$IS>'B_ >R*5+'DJ).^]
MXPL_P@>!90788_Y](L+O+^;?87Q?*$&^&"*]M($0MGBH!R[8SMXV+O##MT=8
MMZ88F,M-5#:&3K1)-!1EM[ ,Q 33!#@%!0$@ZX!#W5^&A[D+A2[%#;2U%!85
MAVAE8CB&/PQ=QWI83[.MRB/;,1U44&6=W![]N,YO1_(3/%8A.(KR-$"I[ !/
M5? G>"G8DM$=C^ 2%_T$1H2JGH"M.13EJ-X+K(T#QNDYMJV:?X=56^8(H-93
M#/$I!NZ650]N> ]L?"3P 'P&PIKI3.!>VHRT4&_^7]&:_)W9CC6<)2RU IXT
M@]8A#>UJ"#(:O!<,=^=1CQ!J10 GIAF#153 .V5UXH.1,INWM,M-9IOLKSFV
M#K X]-OKWKH:"\)A2;>5M60+[]H\#>(94,*AS.@%$R",>IX.*[A85@ $3!DL
MI;<CN5M+,#Q=B0%LU.&3U[> 4867;K!M5S<+LUYV<GMD$U /&@I&ZWSSM=*_
MLQLOFMSS;%0N0:WM'!O\R,9H^C!GYW_V4I,VM@N8<^^XO]<&BIUY12E1!+)5
M: !X4.83*K'S6S3GXM);9\TGGPAJ[>GZO3%R0$H\Q)^2R7\];/^$]#@B)DSG
MWR'9GF,AO&L_83_Z[DSZ5;0N, &>P)_H#UJ6 Q GMXOP7_%AY,+#[W_;M?3)
M3(KGH#7Z"JC&2%\%&S<=%COP-HJZN)N3]1Q?[E/U%+D.CO"7#\WH,/SXXV\-
M#I5,*[U3"@06> )C!4@3@UM6#:6ZW7W^]- ^ AL/%K@"\/U@J,L'US$WA7YT
MVX9"472_M_1\U4(O >H:_$%\D%Q=T9 Z+2KBQ-^@"D#FIX>"OX]04*2%<O$L
M5  11$U<1),]* )/ QAL.? -8 8Q/[  ]K31KP_#P)9#9;2K;FI1H4>OL7<^
M4B'(FF P4.4.4!TVJ/'6N4P&HJ\NPXI6,L1H"RKJ2,=V@?0"-$T9G#5>J!3#
MU09#"9W1: RAJ+Z^R0E\*,N&PB)ZVX.E^B(X\V"M%B0M@],/4@J*>O @=-&@
M=4 ='<G.0#8& @LJ">;Y@;)$<F5874G=')AA825PL(('69$4'<Q4<(\%V-0&
MC'3\<F2PF/@[ZFJHH:+A;U\/='P &M'YA$;PB-X'%P767PN?&TX=VG8>*O \
MW*9M74ETKXM+"QF= #A'-='6$L7F*!<U5T62;UCKS(-D^_WPE_CO</1 'WD(
M)D 8 1=,PL=!NGY81:5$*-1C4*A/1#(]MC'OMI<3M3;<$=>1\1<6 Q.BB:T%
M0G8]K<CP.UNT*0G#^PTNJ,BU:<XE*V[S[2694-TQ/J1'1-T7:BYAJVPWQ925
M+*8'BIWSW3Z=S#1^_<,\8B>JBT75X("D!81T6#3.AB+*W%G3'4A^/YKL$;UK
MPXC^+Q!>;?K3N6/+!!\KC?11M9Y>%N@Y+'9UDO ?6R.,V*'M1D^]!''+[#!9
M8ZBTQZNUS"06=WI<,_GQQ.5+*:6M8#,14QV''[E53?8U]M<_U$GB/CZ@'J[Z
MKLX$Z;UO) RUJ-V:8_]^?/A+BD ( "70$" 4;;;"II2F*(_@R;8&IK6U?5<-
M00>Q8P'Y6X8ZU^9I7HCS?\G1:UQG*9I 4]J\1$+J'"S?IP'2:^@D#VVZT$+K
M <IX49W(Z R"@@(8O?>0S; /X@0>?V&514F%QZ-RI7, ND5.T!!Q7*AH?G9A
MP3]G_GZ<5"8UF>URJMPKY9=CF2B-WLG\%7#46X%569/H/+(/4YDETQ@O**/4
MS-/S5F>8S93 'L"?07;GIU-87+R1PJ/%?*4,AD:>G])S)=TPI@,C@^IR/@,S
M0!;5-"3(2LO][;]%B% $5<$W2#B<P(490HD7[",@7?JA'ZJ-RL1N'W!BZP I
M-;1!RZKZ\?4EO\3:9K84.USFT^X"IM$?+#J]F&B(M4FJ6#3X1=F'>RAQ>HF1
M3F")T(UXO"0?*I0R.V4^&8'$P@]_O@JFC_.3AL&6N998'_2DUCS5&,S?BV$'
M-*\ 2IVDNQ9/U2?85/$,E6PI?8MEA$I]_BQVG5:1HG,OTI'6BN.!EG9> =M9
MTST=Z\.6DM[9472TE)?84&Q\T/1S6&6"E3*C:4[Q2K-E_>W!;&]<2J'8F7J*
M9IM&;>2D,".A#W.3QK-+>;QKD%BVCE@(O;2O6-?G5-\KB3>%+>L\;JII(W>B
MCY2G".A?R5(Z8'5!2;5+08T0+$Q4,_IT:C-F0KI!E"Y4LZ_QYH;EL@/XT-HP
MO1&%-XS6=E+J'I-ANWA1=/-XADS4^66B15JE0=9I9P%.PX/SF,>>$;0_^XCT
M7#\,!H/D;,FJ+;JZLR4\#]2'K.YZ_I88+3#QVK >>D2B!?CS)10</^=7]<R4
M;Y&9&%$HLJ58[^T!9V@!3RS<*R353*I<I\9R%Z-C3&TV47!_/&:?E:-"Q6H(
M2;.[E%#76?NT(J?1WS>[IC488H6Z(8 U0_I:5?7A\GJU(1&'OHF++6]S4?0J
MW+"@&+6*Z] 5J]2<M]XI1[UK>6FJGAOH&5,P6OEQRIP%O;P]!H<Y\=+RPE4,
ME]C9D.I#!:B?N:#[0SV]?#&,7JS*!&'H*ZLX3SK-F$3"Y8L_LWZZ?62"^)H;
M$2W;Y=9MV:>)0EUG&2S6;$T7P7*DV>IG;D3?SHCR3.II7*M4B"V[W3&9CFD_
M:"/>\(*^8B/F,Y[4LX->D1>QH=,L<.EV?P3;(V!OV8B?T6SB(]8.QRZ[>.,>
M5TDW.Q+&M3JE;J)4'SL2]IF[L670Q=HJ;Y6Y()UJU0)^J,Z*8#>2/V4WWO**
MOF([UFIQP>JG*E6#MFIV6^%[Q6YMK=B^>D,^/11V;/>/:(%/ZB</WDB,NGW=
M37I;D][S6^_TJA6R?FK>%$@1([22A-&X8I8G0)I)/F/0NXZYH!M9" !-0O-
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M6 V6_8#JY(D2>=_-X;KVLY+85L-,?%<SW<]RN-)WA^O=X?K)#E>:Q"" O.O
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M5AW79CIY=-'E=MWDQHTFEHO'R7S*7>8XMP$#SBC\8XZN*#X45CIT[ ,F/&;
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M*X_&6?;,&84KY1D6Y&,SH1=D.MF$!JX\&N?"D])$KK>8<BHV2=O^E!LPTX:
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MQ=&,9Q,J1M?2=8<;6*8BNQ<\_%BMVFY4]46>I8MN0ALRQ;E<8<YY^">S6OZ
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M%OC<68"?H$4(@@,FIPMHK@+8.E[6(](*'"2XF69$D$W!T2P;NAZL:,1RP-+
MG?67 BZ);(-/M[.&1$'@%PA[&T1_P4?AH()A0L(&=M(V>=WR:9'E>[_"9T19
M=2!%V;H[P/>R+J@.C#U$$PZ_@--]U:5VZ)70??H#/18]0"]YN+R_P4)$:0)N
M.-AF"="E?YXB;P/,E0&5@_OKV "A*.)2]0XQ]SPO_^CV$0@_ __78V!TZ.*!
M*SLX2'##_=7(FB:),M@U\")P\M!GX\-/4 T+_A2\A8],9%-#+Y)MR,P G ",
M75.V;>@* FQ4!CA=.&- $L /P)K@+Q>."??2AB."*RF!SQ$Y!X<XE2W;9Z!@
MW@&'!"]1(73@T('C"& '# W;; @VG B>(LDHQ =@9SI$+SA2=R:#+?V;#]8#
M?[@  _A[[%^:8QL%;IMNV!%5LBSP)9C>CQ4UWH\I_[!LP(2X>R;J]<F^0-*9
M@7E#,H;<GTA@J$\R:&?1]\?-A>6N("YBW$+I)=KQH55TNP7!/:OT^/<SC0*8
MAO30/_<=6@+P, 8$-B 3(;$!3Q\0F7_0!?][O(,Q?CH%,(;41I?LB,!;,P V
M0Y D0%LA\GB(+=ZR+X&K6TU3^#2F,F ;&\$NOHQ6]BV/V;)(I'HNJ]#>2*L2
M^*+4JP$U)/Y:4:]3"*)_R_+.P8-]M!Q-XT.VSN^R&X@>RR^H ;XR)96'"-SE
M1Y#A:I(YE<PH&@IFLZ*QH@')DM8"($=3R/]]-[PK6Y(?!<H')!:0:C DI'\P
M_IG _H6"LD^! 0L$3_,"D.TM&<TH9(O@[^AI_%\X,H Z8+9C2P:TW_2>Z>@!
MG31"4AI<"<07(9<&%!NH#\]C"8"96E Z\3\W)0TP7"NBRO 21O??\'QYMG<&
M(,!1;<@VD$R!7O&IC=UEY/"Z ]*_0F]0><'G+^&& D:C Q:/./[.&^ 5WYF.
M( %6%4HX8,Y?VVK;!$0(/"3 H'Q$&+8R'MPY'1XW9$%@47=**.AS$(J02.3
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MQ"C\E$%:"GZ4/S/5N#N:RFV!]0:,53/E<C.Q=J&O/HKCR?.@]&]9%U0'*0H
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M#+0$GZG0C0"#*Y\#V !]T_T((0$Z6%!-.]]H;\],2=KNXS\1:2W,>'T*>XV
M%5@7]G<O'%,:S4KEZ6B6\Q16F]&"EU@)=7-]3R;]SU4X>A>K+7A2QVVO94<%
M*F_.4GH;JR;V2X6ATX>2W!-^KM)& %+XY>SZ-P:KZYKT+P:K\EI8](=]N8:5
M>_WV9M6MQ4;"%,$J<28:^ JLSF37OS%87=>D?S%8*:N&.="6>975ZJD:15*3
M!5ER$:SH,^F=K\#J3';]&X/5=4WZ%X/5@&RW3,%U%IS6MAIXG,U6I;C/!.G+
M,L$SV?5O#%;7->E?#%:X-I$7V4E^R;:G R<E<&L1'_E,\%SA$J_ ZDQV_1N#
MU75-^A>#E2L-4Z(EYRE63N->;6!7=-[P894Z5R;*<5B=R:Y_6["ZKDG_<L2J
MS@[30GEN*75N7O!FI*LG-5^T.E=YL:.H.F+7OT-,7=><?S%0Y7M3@DID=8[3
MN*F]S-5X)U\)Y/4S.;6/@^K/L"Y<V72/70I6MK<NU:N23K)YS"HWS'F13J2@
MO'Y12)W/=G]CJ+JNV?YBJ,HD*=:1"L)46:JF:X^9.#_NNI=&U6'ZSNG[D+Z1
M"P)FUH,9!A.8N?"1; WD1O"S=V -VVV7C1>/!?TV(G^;$OC& F\^TCCAMF#_
M+C'=5(=L(3'7/86>>GV;9-LC._5I1HL2U1N2*8#Y\%-P:SHS2:\[M@77"PLU
M(?=<76>L8#ZPI$(&)0ZAR:1Y2[;J_H%M<1TC=H#=:RS<3E+D.UQF0:KV:"QZ
M#%084JFG0Z/9?\*3!&>OQXSG>6S3LG14D\.*">%T#M*FQG!*_P0)4."@'>1L
MFL N27!D8R'YB2O6BQ;:"TF PX&O94-$=P/F :D2P@K*6G$L69<L"Z:@C $U
M03#YVY*D2,VP@U:Q./U/-*BM#'\&1]4M,._M\& J?IT1!\'SE;R9HZ^"!-Z4
M>!$E)H&E6)*ZDJQ@1#ZR<,:J+$2"Y*6G2-H >(UH""U6%/8(%QQ;AK] :4<P
MJ2XB@04:GB2]7OWI[2K2H@QNF!&!WKJP*)0&MELR-? 6*W@).. 8( 4KF X-
M;AQT_9J1X$H^11@+9>9%=Y-[X)[XY:DCB/! F 2'R0<T4)17O_\+_@A)DJ!*
MO/EK#-X8T),8^+MM:+](2%=<6;1G@/Q@_X$,[H1TC%?EJ?X+WA[)# D90059
M;=@VJ2T72Q#^2M"\T9__;W?Z8UY0ILCM"9"M&N:O_\'0__[=6=?,;\%,@!$7
MX*[&Q@ ,2HR?@%?_XE67]ZQ@G<GD$T']Y]^Q88(M_H6%\X([$8D_)9/_B3S_
M%>['P69J_#JVLV4+6/=!G\94:6+_\G\5?H3RQL+/# M5A_B%7+P :7#LO5'1
MN=C&XA>!/]%G.I87F87D\R'\EX_,3$B:_Z=3S[S>]5J'-%/=ZWH=?/37[PXL
MWP%I5 92>MVVMNR1_[USOJ_A<G]7CVW7"Z C,MH9CZ3&8+T9S.<&ERD4BOU$
MDI7I97,$'Z7^VM(YD;'?>SI^KGW>R>!\GVS #$68_PMI%:"/O&V8GI]&Z'\.
MZ6"8#RP @@UWG&EG(AUC 2A< D]&?6K[7_G(^05=R__ZG0E'!QL)TP4Q_%^4
M-4C\&_S+G];N8X#2_'ZZC*SS<M<Z7\WT_1NNAL#^??E<F#Z.OL;__2>R%7XB
M$Q.0_)"S!BW+>!60?,LV'2B:0-[(VX#IAH6Q3$DPICI8EPCI.A]197XLJ[+M
MP7_N4FYP@J:T=&33YW6BI )DFV UMHWN3L#'G84!NQSZE1;"U,YP^6&TB,9[
M\-V.:H="FB79MBH%W)FW9A'1Y^Y^KFG, BJ C=)<P>L!;]O-H(W"F8J2)9CR
M&*YB;*RDITA;!@<+&PN&6:>0W8*OCR?H/M<^?"6QU_J0IG;\Q(A(4'T@4@DW
M]_#HX-Z_>WHO#T^ @J8\D0\/SV?<\&I120Q\&7U.GX7+A,(B2L%%'>R"PT+I
M]<%,P6E#(0UP]/ ,(9$Q#?5%MB[:_% *_T!J_3-4>8""N6'"R0:B(8,:563"
M1A5!#;<HO# PT]L.\?#<(I.'I<!\6(<'^(Y8(T$1!DI@ (D2$F*@. DUC<,:
M!?]$7T1H?N,Z"$Y8EW-GEZU7T\7?NR90N@2W!,J"@6#Y&I'8IJR_B\D(+-ZT
MCZ@03W(@6\(G@O,##Q@^(1_S*KJ9UDR2[* 2J0PD4,N?-;C3//CGBE<=.(KM
M1X,!'!@F$L!%&"6&6,1.Y00_&Q[LJ[]@A/VM#.V7 8"_#2+&P&X\OV.7HJ'8
M,U.'-6C?(/X_H@!"![5_W2[R:,V#W5-'MS$K"4A+\!\@\6@D:*R**&9P%<2(
MX[<;A#+\. !#(""!+[<*#J '@(I*$<T 8(?7!Y7N0!?24%7#1=J4"XX,",V\
M"4/X4*+^T4''J!2C<;PH@?]&/KPP""^& /4J\(I?D;_QX#K"@DR  U@1<##;
MM^Y-++RL04V04&M$M#)L[!FH5?Y5)YZ'WAOO==TM&%HU+,!TN&=UZ7!FT3=/
M;%>YW)46QE)8%&)'%WN-247]+4<0"8\5S5P%6DBL+0!"#7"&#M!O)?0>HHZ1
MB5? DY9U0X/L*OQ%U7\-HE#HE=9.?8G "O2,' NH6Z@2!60-8,$^C[=^!7V/
M=Z>)-D)%RO)[[.9'%NFJ2KP%Y!I(](HZ8"@=;R$]FY%>?IL#>].%6U.?<-N-
M.6I&/8T+2?<LT>ZP^HKS2IY6S\_[G0KQZ2PTOY.PCY0MM%XN[:@]-1Y/*"(I
M)W'6297T>'QH-2J$>]:,QIV*7&%3WX](@P_P?19\[]I&YQM3[)2Y:D/A2X-5
MH5?O.HG*IQ,]O@Z^13K'-ZHI9J/DRZE*.5$I#)8N<ZG&P)\@A8?:Y .-GT7C
MNPXJ A_J YI(IS%^);>PD4?7VOBG:Q9^'8W%)).HKCN5-.80DWQ&ENK)5 W6
M,GXBSA1;L4L)=]3\9YKXY;)F]P7/UQ[8*T%Y'E"VTFXB6:^EVEQ>[<2GH[8C
MLI<DD8XS6 GM<K;/T0DE7<V(6I-BFA<JF(E &>@K*P-:7]7 P/ C'.B6:8]:
M4*5%QP[_595U6&KZ!52VA"[M;0\'H>:0H[XX0_#9B[$^C6&$W>YV<\/F+N,2
M7YOIS$PI&YJ566M4FY7V8(>?%782S3;E B>(7'Y)\^M<0Y)BS/2OWW'LZ3!Z
M\3^QGPH'O_+X[<,!HX58NIL==KEV1UE[DV6KN6A,+P>';'[:3B_&$TIQ&%Y9
M3"O2L!H'@AH=/P:'4Z !Z@:F;"G(B@LT7: @2Y8-LQDOW6#BSNE/"VQR#NQQ
M,=CB%MCA8$RE.U!2LH:GV+RTSN08K2MGELSE4!?#/;6WZ0H,MLPFJ*'-VL,B
M#1N=/&C0M2"Q*%8Z5JQ@ AFYV:YVS%@63^@7A 0QK98JZ?1JP&G)4C\U;!*"
M:S4A) Z-%:>B0SM"$#3379C\#$;%O)+!A[@69S-RIC\52QLO,3G>0H3X6;2'
M#?:U [8U&$O-#V;T:CJL*3UCB7?=JMOM7A)@DKN<$.QD[K*Q]# YSK6S*@TY
M'78D"NN2).=T,+@]>G,$!I;<( ?&P!YR1$6N5E8]L9987U#^W63K*:VH"SFE
M/NJ6*:HL9S"S"6%P'E. K\E[$F\^^UX_X&*\;"CS]4E1X-XY+_;RR2XESOD,
MJV1<WDOUK7J5RGZ:!(71SJ%'BM%%OSW!3M3HAZ"(T2Y1=!.;-E<?F7F#2U7&
M?1NJ8D^'/0O^+(IT$33T%[KJ4@I64YPZ;M5*$YFQ4I^F1"=# YYQI3C77M&L
MQ]5$/K&NQ>HZ0 -]1":^#&%Z$1QQ001^N[_:E_'A&SYUL<%[\+L *AV7YH:I
M3K^E$%9^44T8.6:8V=/27S1%>Z4QU.?8UF[_LZK>Y;B%:@X4 FLG6UHST6YO
MW+]^Z\9Y;(5BL _6:_[O'8_*!1J&.-8V(-N20B\Y\N&#6<@K&#QC&MHVEN;5
M7@DP$@FPUYWE/#O_\XX,HY-T*=+P \G#J(BJ9,\,,1JQ $20ZUU5O8@IK208
M(Z'!$)N%ZK\2Q4B8**YI+Q@=-:6 LPV>#OJY'9LA )$D\*AC T TB;8,_(4*
M7^B?!YS[-O#CU5O[' EQ-"1C&[JQ$VY@(:THV,9P%]\\_7>/;A&$KZ#8CVT#
MC&,3^E&^#<C@MJZ(=K"5.VV6@@7NK"]\Z+N\#*6D['I&JNG$HA.7*Q/,R8VZ
MJ;F6:/0W7R[K]VU.UBW;<[*LCZN85&C+Y*;%,UG;1>5)4^=W;?@A@;(5Q$YM
MX8<R%!8F=,/Y4(:A1\]I'IID3L$@VTC)"X'Q^RSOVSA<CT5K*B3)#!>;:1F,
M:E:3Z33S!G-[0R5CMYN,)#Q&50W8,T<\RM/TV3+6L"D*8VE!6ALR,6VO1-@R
MCCBGQ ,>5U$R43BW;0K=D62KR9$Z?L?XU]%BN'M)6=N\+7D2]J7RX_MD*PJX
MK248#@H6Y>V?8P*_#OD#RKN$@MZRP:[M6#&U#=<D2+I4QW@]Y\3GFR)!V%_.
MDOXV)2QWW72?V\@F5QZUU<6L'A>%%0/[R)_'INE+07O9?$<9;=B-"L84^P+%
MVP+"VU&R* Q1>KOA%Y!_P+U#N2UC:1L0(8:=PASKAM4+XG2@]X3JK%IO\PX7
M6V:M43\7MYK)YA<5"9_$6C B%":E!GJ%CU0 V?ISH/Q1\EL8<L5N?C,D%:+%
MI!+=Q**8;C+G4RE\KBO#F&M_RF&>PGL]X5XDV/B1Q!!)V[@:V0Y2!-[(4KAL
M(O>QY*8/AZ6_, 1^,-P8ZA?/R02 CURLF_EW+#I6%1-3\QS=X?+&:F95^<U4
M)=Y2K=\FV3LOV,X*\@E \ "U/GH/.M6I:_ 9MZLX3&-#$&QREJO @DYX-$4?
M!BNB([FEK7W7?$]IM=B827$;S'-B[<PZKLTGU%M$Y^1;/([CKNA1F1ZFU0=6
MD^K7;7(#HPRB)'7HWHO"S!7(OH!B#_/2D @?IJ(_)P=MTYM\#B:M!<B_@B]W
M,G("U7HOO<97U)])T")H40^38B1D3PC;J()-M8(S]O-I_.]XF%,#- 8X %@X
MRLL/C O;?IO!$."<+4.5170MK9![H)GNI.*#?YT:5%G''WR$CP)4=8Q=;D:F
MNW&V-I^T%6<8UY)UKSK=$)_'!>)%>5[6*V ?ZCJ+=J$8;,)?*&$!C'04%Z8J
M.3K62)2QWHCGXCUR4\KT 2Z241(_],KYYQS(WWL)F)8AR&A[M[E/K]I$8%8&
M%-N0](;.'S*/?=)\IMM-G)1PIDL351XW<@O,2PHIS$XN';;Z>;7M&[>ZX.%
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MK_0AV.03U45GY@TY+=\<9?.QHCN< 2I*G2L8,90<?# *X0Q#S]*^1!&49+3
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MKPNW[BPR%SBC^%O-D-#O/GXZ_V>+'UCO3+:E&/B1 "56U^07P1803R3^9^\
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M$!<.^+7[Y7!1#)P[7-!<7,?Q29J[907N7M%SK=T'V"8)/CER"1_ZB(,QZ)/
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MRK8WXWRQS<491RM-Q0D])C_:9^-V!IPN4=MF)@_JA)B9=TL]J:VSB0PD/V3
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M7W0@SKG05-9,,(EY#J3$F OGR!K07(MWY:EE "=>ATP TD7P%)X%8W=L;DV
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MN [3<N$7%@KZB(DQ&XB.9>*SA.P"Y\CC1Q7/A>SR:5[$!E90$\=?@OG"L#8
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M%Q7)R)\K(Q5%D^'9H^T@!*(H-ADKB094O\0-?*TX>8AE1=.$UH'DV>9#K&Q
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MK$F/+QJED9::L^EIO8V&GAQHSC?*8YTV&SJE"&9QK:Y2OHV'[D[TA;YUKX>
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MZT]%5DPS8XJVAG .VHVC1<7$9UTI@\]DO&WT@.79L8/-QY1P]P\Q>!;1@;W
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MO$-W"K4<)4AZQ(GV$PW]#@=KT *1T)XF ).ZX\'%'0V1143),91##Y5 R=A
MRQ_" E7)>8364;"!!;1# MX"CT!4,9/&Y6E0*J2-*D;$%F':I&R(VCQ(L@Q
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MCKV9:0QRKHJ:/#V_3HO#^5 M18!@ B=Y>'YP>^9U"+.)ANAY#S9,W]HYA$?
M?,)TI+F=8OICK&E" \"6I\%SY+ZVQG,<VFE%AN@?*4:>L].'>%><!EB)M6O$
MIO?*D!@HHX$N:ENFJGC&?A6A/GN$?](&S8SUY!#O+:3C[ECV [*O( ^/P^6$
M>NXI:H8*PHG$1DHN_ ^[5:_JFJ=1P?H=QCW](<351'N1;&UT,:%FV)H$-G;O
M _7)+,=YNLS:Y(-==O'F^Y#?G=QC8S2=;@@BW<Q6@$X)\\5ZT%+'E 71E$V>
MEL^%/ ZQS9W4V$L,!83ZS_YL-*!@E&I S'RB?S+Y5+%E+\^@2 *N:X0$OBO
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M S7___:NM+EM(VE_?W\%RMG=LG=)"@!O.9LJ69(3V;*M%>5DLU]4(# 4$8$
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MS+G'A%@>!A;)-Y@V:%EVQEWUX\Z$CSJNCPT"?.95\U->X[L0O,\3XC?QHH0
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M>CSI@JN/U"-=MSJ-S+<^FP)-6+8!G21$#7-7T+62N6VX;523!69#Z4/C5@(
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M3V73_27N[I&%B,Q7F8'?VPX35/T<X=&E(@V^OI:VQ,.;H7/GB7AH?VDL?=6
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M A:%-?Y^0N(2;PC.XK/>%Q',S0@('Q ^("^$\$%5E[,L^(#:>!,^('RP%_B
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MH.KG"...11I\?2UMB8<W0^?.$_'0_M)8^JH!Z=^J\:[<DZDR\X("AN$(PIX
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M?>4/&&Q@V<DA786?QN4S&C.^PDM9%-XH]I:>SJ@Q=\8!P!L/])TK1A\?6G1
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MJD@F.=:A9\W@GW$X<7[Z?U!+ P04    " #UK(Y7,_WS;Z<>  !H'P  &
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MG]S#CQS"\]"7[SG)!H[3W$\2W6U]<'&S7'B)P>UGRH9*_\DV,_<H^1?B;J"
MAC55+PF(3,!!T6%5Z(UO3#8#G&F3FB-.F@U@P]A]4/AB378*>EY\L4. 17^!
M!??DX[M9"YFD]V9D,$8!OL<"FE,*TKI99H.3/8?8(]D97X<HZU&$F(W4K@34
M,^E(;'G33I(X-CL.P2TN$=,XN9()",>]\+:RL6YXK6AG*.6BQ^<?B2Q;1B'E
MKF=*=T9U>W.7GIL-+XC^;M8+Q<'1O0D7=DP5DPKS#NZM&4U@^QJ3T\OZLSHH
M,_.(Q;I\RJ%*M.U)@ID5ZQ<.R1_9":UF8P?."^J.CP(3NV5F>ML6V5?.G]1]
MBQAOZW"[&V^?%<J(GN(_+:OJ/9NL09, *C>EJ*C#O-(MK'8KW95SE;%LK; ,
MI#36;O?MDDU@6!_2]EYXS<]6JP1E"TTZH9-.IG<2KOT<JQF8Y\4.1K!XOK_5
M)P'G:;47(+5Q(D6(!5[DU5EZ9PZO#2P.4DM8=E&:&FZA$GF:+7_8'>S<)A#_
M- 2*O:HT^R<TDBC&/7DVK+CO;-<LO_F.^FR2*H$$0&6B^-E&5K,7N^XV_LTU
M8S_S_[00,J:XD2OS)#ASD)#83/$#!D83$<70VL).8QQ[P=WOQZ]N/]?NF1"J
M:!M2W>:T5&!U;0$YL&_9OV8N_? NX>%H7)U$VDGCML=Z*\>59NBR0/> ':.;
MV-<L-09+4?T%3=DVVB"RO846GIX%L3IL0)3TD?([ZAC&KF%IPL<P!9QHM%]3
M@K-A8VNCCTAW9P9?8C$Q%1=BD@4A>W+?#;28ODH"KFZCXS.<%&S<!N82,21@
MB6^^"\[0;%O_X>]>Q[U>O!/_JZN$8%!_N8H&5K3+ZT_-0IP((D;2JUX/H4_G
M0!BS#0STBC^P\(+5&6%WVW+TQZ4E;]IJ6OTT/O5##F./L/C/H?:Q*-@&<1<E
M='06:'L/5,;8FC, #@P])SJ9Q>0UCTKSTYU;[!0:A_-U.8*VK=40P5.9)]1@
M-U6;78/TN#NA\CVF?+)P:@OUX]?@ L.F6CP73JJM;KQ&)HK[6SB_S<^#G9/0
MP+:+1Z%/>&3R55V>$"':1.T"B'SW<Q*P6#ZT. @*#/V#K,<J@UG=^'DF2H^D
MY/Y:26P[@UBQM5P0?+!94\%B) K:(N7N83G6"69WQW3)"R0OFM.J;1["QX-C
MUU1,SF_@,0L]-I!.[\V%^Z-1-T(95VTN^X/Z)SX[-,BKDSM'<&JW ;:CTK6$
MHC9TJG-"7BJGK]!]Q1.V(Y@NVZWS9-OMV[]DN<(<**+;)W6K_:':FR(MS1G3
M,.WN[)N$S##9F2T.?^/IK<R'1)O=]_F4+CPQ0B?TS>%CU[D);[")L=5[W#!G
MO:D[&=V3GXNL"@:;._%)D5JAO9H;&LA!$'V('A:Y"\F=P0MA_.8L!3Y<AXAJ
MXI*>7AV\N#UWR/N%_E M]^@8-5W2G2V,EUD.-5NRZ^)D2,"DM_YV\K\I$;%]
MXT%OI/')%!\C5@NZN6&\\N&S0+07I>"RFWBJR7=M[;6F_-TV'TWZ>"/!GU^U
MJ2-BVL@5%2IPD?[IZ%VP5MJ6E<0M*9%&N)Q3S)4,GHD6 U?:7FQOG&\BY[1.
M\->MVV[^2;^.=Q6:/ QO\"JMC_,SF$_5$,"=W(\FB[_;/GJ!F,U+AF;\<=/*
M;U"-T+?_^B/)R#NEN8YNGK;W*:JVM;XZ$MKTZE1>Z=W(>MG8+))1O#6KZ,_6
MY&W;6?UT]JK<9#$'13,C.6JUR.;SKIQJ>*< -=0LZ$G5<A:+_G@IS\OCNGL:
M+Q-:J'<?Q%I^ P=9>CJ,(-Y*VR>+L:IXBYF:;FALB=>F?+/8\#><F;9ZY.PJ
M,!?)-ENR^-;(]2RBMO@%Q>JW/B]W)<DD Z[^QJ1_- X55J<$:A([Z*!]4H[X
MN%QM+][(FS%EY>WM[9R]UB/]R,%Q#GD#J41SL7H!3>N>)FQ=AZWH/ZVEZ!:9
MISY]P7'/G"Y^#OI=^RD<?UOY[0K3G'$"H]A?)3\WHX#WF6&6O&$QV,3V;)Y/
M>@5X.YV*C[PQ@M7JG;ANOSCV.8?8Y68?7'[;(H/'[FZ(,:9%5*.AGN=KY-FJ
M0P!_KE]OB^\L?PL"GV(0;CB*+#WBH8M89!O\\>[Q"G]>%&6FKC)CJ6Y-Z%8"
MR@AM,V<FA@&])X)P)E.S"G#ZS:#4WD /=\,O1&&G7-Q)C]W5D-MIU!<FF"P9
MC;0P^P_'2T+U1W13_/BR\$ZU6Z,J+[YU?G?)S"HK1?R2YQO\4B+L?G@C,F7.
M=]TT;KUP]L"2+41U208$T_'?:!2)_$C=?B[2V'OVUC0?.Y1!62.-Y(NH=$ON
MN9&,L^?WR=TH:$S:-4SD=!G$1&(Q6Z;KUE9>OI,\)"!$4)3L^,PY?DS%<=D&
MU,9-/SL<7:/G+J#W_GM?@/^YPX->NI2_+CI2[[>>?6[^[)YYH)[2@7N<M^PG
MWA]T#7:CZN(>.D&T@]MM\^QNEGO!M(1\:<N/%]>8O9]0>4.3L-J[9-@]C%8#
M(0F=R+G)O5:P>F?1L;)^\69WCQ5_N-!!&:)[X?9(,]W7@9+MLX*RI,*'_94V
M\ZT_QRMH<W.\U;_VG]S<UTNQ">)>\;AJ"HIN%<#[="\Q>&J.'5G[WO/?%A2(
M8=UU[CGCB'(_G#F2LASMY]-UV?VQDJ;.CC$[CXUJ\)BH%UY*=G%5[>4:2ED+
M=SUU\>$7P%NA!6@-UEV(/*.'?:CU@IKO0F'/G:K]/&DVN7=7$R;S$%:V<].H
M#'?)D4@7JPF=#>@_S82O1*YIV"=\V')O$"OWSY3^NXE!>>&'LQ#UT"K;]S<9
M.)/,Y9C^Z?Q'NU2$L^!E7);E:+K*RM[\G/]P.ML0+ 5=%ZGR$G2\]A;AABC<
M+O'SOU2G5YU C5V'LL&C'1%\1&YW4/*I%/G\B_!U'J\/#9@6([KWV6RIG'+W
MZ7\H70LR=E4=D<W2E<F40ISPPJ-:Z?%"'0$27OEX,YVQOV0_TWB>,8(J>J"5
M#Z?O(\$-A%PBCR4L%^\-YW6YO6T/$9YNV:<A7^>!W!^"=7O \C&0R!"V  =H
MV7::I4WW9G=S@-RNG$]\XJND/DQR[(?.8J-2LZ"$NO7B@\5=.AQ3B$99 O_H
M\TEVJG5Q6&!P3N[FT2 L=/6WXDJ8W_2V'>[$AP38\)Q.@?TFB#47BQ]*5<+D
M_+9:K(A)!,&4%ZY+Y1\WC2VM<,X"10MO>/YA\+8LP M?=!Z4'9B4V9* $K/B
M]P4\^=N;CP]VGYP&=H*&&DK^E/\*>Y%8&L1W@C/E6YQ7.#8W%VI4>%6KZ,[1
M:[D8[JDVD;M]+U.UK7W1\?7(^G9X.'[JAVM.[7JT] _,6-AU6/ #?$+!K=F!
M[W_$K7>/4[7D_SX*3-U;^*$\O&T'#3?5,]XO$WP&O:<X9K97=3[LG*Y/R"#>
MEOS::3$9QKCM[5V^I7<\>+\N]U4RU40Z;M-.YT(2[[.L/,CQ $L"8CVK24 ,
M/\_8FEXB0X@ZM@4S&)JOBUA9X/SK@@>6 [@8DN+#_'..$(39LP$BS2 )$&'T
MQ OL*QPR)TKZ@GFZ#Z !<./#LKZ75K!)9XN;M.25TA-2'Q[S108;(\'+DYXG
MH'V$YHEK'1RW*W...#637?93>TWX1\43/0]N"S@SF&PI^.-6"8MZ2N.@L*.G
MS"+;QI0VY_,G=@_EY@%W1O+EG$6"#]A./R\)G"H;R!-[_$G R*!=(;SFWL7G
MX0\D8(>3!/QZ&F#VK7C"-#A+ID,2%+' 1@+*'5'$-Q)K,O0N_*H31(40:SC-
MIAK-^*LI6T-E_%<N6Q-/*5CB<R'.HSV[)Q<W2$"R%=KNG%*#!.32'@C,G!-U
MD3VH<TXS$O"PE/*VOP_T;/Q$CSJ;[I90DD/"Q#.Y![??X#H2=?'RQ[!QA6 X
MHQ9+EP#MCF_$E(Q^;:N0"7&,B5!ZLF].G^V_XML=>IA%$<8!&R9JASH346N7
M )'A^72063&A$ZTK],_+:+,U^&1GT_3=UPO,1E$K/% 28)U" C38G""-+BK;
MYOC>Y8C"1'=<55>8&'8JX8*9*%(Y)E0U<2&U;/ZQ"U<DW6I<2YL,PJZUG!R[
MXTISNF3";?DF?]SA#%& JNB7%,Z^$8PON1;23/915#@4BA[&BT$N4N$,EX4(
M:@BEWLH$[U/ ]A+"\R[[5A?EK=X3IG2?]45@$2:A?IEZHHDQ1IO^V;?J&W3N
MS#0_,#0\)'RAYK9+!]:O^]B>8#\<M 40>;(]HZ+TW!G*"A9F'U"\+9P_2'H;
M/NS5'9)# BBD2< _VI&H;>01L@#E!#\5XN<F 4C'W,QRPFAQZ)#T,!&2<MD5
M5VB!"7P00N. S,Y1\4>7I,A\!!I! DQ!L\84J)FCXT&Y_]WQ":$9M3+;K'F9
MJKOP0^_?^FQ;[4$L(93C"CK-)G>">E#83N-YE[!A4/B[TB7W3A&BO:[[D-<B
M&\?NE"O?I6B.BJWTF_)R#,<P?D-RI7Z<X#QD''PI*V??^V[.,6T34<_N%?$/
M"=C7\/CWRKN0!&Q:^W*/1U5UW5JL.,A)+,11=5RV7# J-"B:H2</,8TOZWV*
M':JZ+CI<OJ"IODO QY$=]M:$5N \&&R7T8FQ0K_UPRW<U;R@J[S@C.IEUR/D
M%4(5?.4U7H@$..B#?YI-R(7VTW]O*M([FSN57T)&JP'3%U=&)8\:+F0]1GHJ
MMB8S?\;MYK@/[ZET>2YP+,[1GGWO*_VL%SVS<RX8$9(C^<+?_=1K-]YLK;<+
M=*HFX7EV;DF0A. /2< ;N"Z5+6]MP!Q>>\F=6$61-1WU'ZV.(&T\ZW W9([3
M%E7^KI2OD  0?^J)?MU3R\U2+\FBM)&NEX&L%WE75I(^3!\BNW+X24 ?9!*\
M(TX"SI10;H?@4W9)\/8HF  \M17G+9,^S[G2CMP 4^S<F#CD<VZS8U>A@2,E
M!PIM'\8@K?HD9RAH!I2%? X8)XYRNE$SZSKXL2+7H(3C_$#$9T?U$?7HA[%-
M_03T?CGSSP8N3I_VZTQ8JDCP"N&R&B_/(]JCS!S.JT%,04_D(,:DF?\"4$L#
M!!0    ( /6LCE=-:3,(5MP  "[E   8    =&QS:2TR,#(S,#8S,'AS,6$P
M,#,N:G!GI+MG6%-/]S:Z 2%(%0R]JB@=1'H'D2Z]25=0JC21(BT4 0E-N@("
M2@E(D]Y[%S%TI$."5,&$9H"0G/A[GG\YU_5^..=Y)YD/.WO-K/M>.]>:>TTF
M^!_X->":CH:V!D!$# !$A!> 7P34 !)BXK]O0KM">).2DY)>N4)* 0*1D5-1
M4%%14E!24M/07Z.FH:.AI+S&>(WN.IB!@8&*EHF9$<Q,#V8 _YV$B(0PY@KI
M55+2JV!J2FKP_^^&[P;HR(FIB"])B&X"Q'1$)'1$^'Z BX"3E.B?!OR[$1$3
M,)*!R*]24!(,&JX!Q$0D),172/ZB)MP-)=P'KM"1TM\04R6[;O0$=-,'?"\B
MY2/YK?LU/0S&$R@><8<7D5<I&)F865AOW^'EXQ>0D)22EI&54WN@KJ&II:UC
M8FIF;O'(TLKQZ3,G9Q=7-]^7?OX!@:^"HEY'Q\2^B8.FIJ5G9&:]>Y_]J;"H
MN 166O:YMJZ^H;&IN:6UMZ]_8'!H>.3KY-3TS.S<C_F%=01RX^?FUO;.+OKP
MZ/CD] _F[/PO+R* A.B_VO^1%QV!%_&5*R170']Y$1$'_#6@NT)Z0XR,7M4(
M],3G^LU[$>3@^RD?:WJNWA(W1C$XO)B@8.216+^-_DOM'V;_WXA%_D?,_IO8
M__!: *A(B @/CX0.4 8NKZ%%H7Z*TA9YE,'A*2++!8,P%I)I<V]TU1=-;*@(
M9"\5#T1K(D7/F#W#XO!  71H<=]>32-16D\:''+BUL"@4>7)Q>K.=72L_'N2
M8$HR:-6#![)2\$!8%E:0\LHI3!3$O&?5"N[*8!&847Z?TS<HUV3?0'MQVK6N
MSRDV ]G:X+IPZEI_%.ZC0VKP!88M56S0_[6$!UZ/FN&!_(A_YN%77A>;2<:V
M)_\=]:BE@$3SKV'8 NQ(W"?$OCQW<QNRVH '*.PQNB?V9V=<?_8AO37JHE9V
MO?F''R_<\K]YT#+MPG!VIGA@49)@%X"]O5"-Q59?7MBC*AXZI!.[!K-"OL:4
MF^(<GP<VF2EZ,N$NJS%&>."J9QD>4";Y>V6N)*9Q=5^SAN"XVEUI<QCM5):/
MP?SC*AU3;:I\B.KZQ^TT:]#'D^)?KGA @-;#I*6BD\!Z:QWR>X$0'"Y4QFXL
MSNZ?V<W-O<54MAH,_IG00VFS&GM;[J,R&J7\CZ5LB!'!,]S;X"(>QY#)F$YS
M'"P ^<JY$#IFC]$^$3J2PP.KE#@PI->@S#ENZ!\>M7S?^?\:B;J;M, (T)6*
M\T0 /-#HC@/_1&L4)V,P(-P\P:\6"\R_^%?9J>#"]($[I->HE.#'AQ#F.2Q_
M%RK=[0%:!@]TN1.\DBKX_*7[<?]S@ 0>6+\SW?;]7^!$L3RM;_! )O(?'O9K
M_)IGB&1'@R_!KG\D07%^M_" \#^0"G'TMFJXX'^%^:L87"=+)]\AP[*SI!3-
M^3'_!(G#_&.C1[!)OEB']-:!=%1:SDTO9/PEMK)\#3%IAG@@[Q\K&*17/0QT
MCL8#(:(8\T?V;MY6BNGRU/JV8Z(8K1.N,\)SZ/T7,*N('0+^3B:LH#1(XI=#
M\C.:GOW;2Q.<-Z9IL8TL>,"'\+@"HPRW_O3A,%SKEMT^^A3WQ#5K8Q^?UAZX
MB+X1A6,;F?& MTE74W4=KAFR2FG9337)FN],T_U9[T0BJ0N"!Q1C+U'*O1'5
MJX3 /<G_ \*8>Q</57)^YXB%*VTFG^[C 99WD%42+#^DR0NR]86 AF#BZ:J6
MAP0'R_C3NBIM1LQYQ6(;\< 0"&,H>;%R& E9(F Y@SOJ-BE0*.;*@Q0NLF_9
M=NQM)E]L&$,\5^G%[OXSBQEW\YX^ $G1K(M]O)7_XO?IS/8.'_PB,NOBQ077
M'@3=8]H%UU&&Z]A]YXC*"QWM6LQ:/9K# ^Q@B,<* 2SA"QU"48P+,L*$I7?\
MXR4KIBD0\O,O1'6033OH\K$RBLY44P%Y7$ 3[)#L3--GDO5B9TY4>:OTKXGH
MZ?(6]H001&\S$452WG7=^;X:'=\#.[F9-:X]S4L4/UE#4-!7Y=\1ICOW4UU.
M?7ZQ'Q[8XN;;]^_^:_38;^P)"$<L$,<LT5PX/_3%=[3%VUWZPT^N/]T%>Q;Y
M1].05>(RM";XA>;?6[X7GD>XH.2+-?.5%)_;8U]>T6S";1Q:?*$[+Y6$IH/G
M% -+AQYX:>@;F+M K?BJQ+_P?8("_VD_K&8EI)JK#"L@E?QS\@H5.>@BN@F;
M$/#NV.#RBCDWE[3D\;1R-)?:IB >H+<K#$?D@< 1$ 'O':LZ'A$?W21,$>6
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M;6]>]3^Y3;)I@N.<06;#(JOJK?OK.[/-KN4N?GW]VNN^(JYAQYZM71]'B[%
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MR[AEEJ@R., ,! =;Y.P>XH'>&;38^/ZCIIB796J[ 11AUN]C!3V+0G]R6*/
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M""SL$,@U3203U]7P50&#P875.OH8V/Z?,@#4*&8L+.:HZ&M G6+B\+8(*3F
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MA_+YG[M#_GL*[]_=Z8_-N+OXCZ$.+'+K_[1K /W^G9A5Y@,@GFEYC?TQ<1%
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M]:N.)&>=DT9&FV+3"O"8%9 !T(DNN_)]B"B5OJ/1F1)!OQ+#_/!B-^-04S7
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M>^%@N6H!+'+;Q.;G26&+WO(7A<^_O[3?ES_BE(YM MZ7!3G6**M(SU>^CWX
MT$XH*9$9LG_MVB*0NRUI/"0;Z#K#_A[R"RBDF(QD?P P$[P.F3V$.%4>+/C+
MI/Q-AP@LF7:W;6?:+D7+J-5P;Z2C0KWX;^[\]P(=?CPR69!P\/-(G(MF&N>/
M5'R&PAP^F,XJZ#3YV.V\FY.$R#FM)4:P7<5WU7.EA@S.W P&8&GT>PQ?HU#\
M/-)@[O'-<<GIHT!^IW>>RU(M!H4'*MYO8CL"P8/DN>"3;P^ 2OJ=4&Y'JBEC
M,VT/-ZX^ER?"OW[OXD9CJK%/H9FT4G84(PLUHW1G^-_--5Q'[IWP;A&"+D3,
M8!Q#8=*::=WW8RU#=S>.UX4;D.@L:&T8G[!QF%D.4+-I3OBG^*KP>IN7[CKP
MR=!2J.S75F0R5(I!2J^S&8&91U&2(_>GEEV(X)O&W: ,"*P"/8WM)$+8_FBD
ME8MNN'N%^-8<3A/LK3L7ZI8=8#0**N:+@)\/M?H..J$L'#]?\;8(W>QTI%^E
M*45!)T!E_:\<%_SC"WYF& GRQ'53Z$,2LQ,NT/;6.)!?H2",<7+:DS:[$@W!
M--63%WW$4ANV8!Z18RF#&9MY7I?J&L\_-N=Z)Q)HT:4UI^H(?3L8D#_ZG@5A
M%+8[U:[O(]).N93V)4#(S%Q1L@S LZRJ&Y=42E/#W9_[;$;$!=W>-*@IJ@@.
M3NGDU9 CWM=FVUMXM?S=^6EX7#_C2XE]>28%WQ!8^F?IMQ4$<LH(QIPRRR,^
MYG"7[V7BK(2"@@%&YI@R&&ZYDM/2K*W.B5XPS,:?X%F^0B!-_?:U8#*80I7>
M3GQYZL90;C"/PC&8:390IM3^;]Z?OZ8GI82Y(@0%2ZMT:1_U>ZS%GUX<RC-,
M0SPA$,)O_._NYU2#IQ8"HC*?3Z"3[.=>!KG->5X,!'; CC7>(A410@-+=?,G
M[0IN6)$DU1\ZE1QTX_()!IY$ LZG_ V'(MN=8!WL^O#+,8@E^]PQ_P^ON8FN
M$EYP$<'/UG&R4&S=.(KK&/HIK*FCEYN)#P!(E=0#@-XW1#WV1*/:>F*-6VUA
M#5KT'8V\*MC Y@^H.'#9YU%Q7%WYBT5773(1.XI")%,$M'UXVT5OI!.'GUGQ
M8:_@F(7UH9^:KW^],,NRPD,9)WH!][\C2[!3S'])GIR3Q[PD#US%,G]GP[ ?
M=O7#*1&=TYPD>RX&1S\;[?304@P:<.S3QT15+2W@!<-;#=#LFL9X *#>O***
M?&M=:L-5.Q)$I&UZ]1U"$J:*Z?<Z3]M?*;32+B%@/I8#K1F6KVKL36$;"PCM
M5?;%_/9*8;_G@&N ',UJF/ENRJ_8.#8;+4Q_6AX;DT.&TX%(';#=R1;R.[XB
MI#7OAG:ND_A1WM,S*: J^&/RSE@<NTY*[R/!_!$/@"T<K*D0+L!N^R,S>K;\
M_U;U31 Y _4'F,X86OY34R/D%83!#^V_/JC\&T<<ESF"8&S.Y/UQIME?5&4O
ME>UU@SM/[V&I@F#7;>A<J'7B+SE;6B57H'=&;Z*+8;),A:C3GZME4U?D3B0#
M/:3T%GCXCUU8.EMCR85H#'5D;66 >;;3D#>>3J_HL)W5K)W>/U'K6(S=#-2M
M,=FC%:VK.B!],=ZL<.7[MGG%;R+(=]]*[#"/N-9+HR%W:L(D :DC^[MW%QE5
M'#!=ZG621SVWU5(4I.]R%Y._"I[(JSIP\,0,O*2;15"\PKETTG_;/._\QEN@
M7XBQN%?%7:;GU-+GA^^Y\?Q107V&#?%GK*/&H[+2.>G(4@@*R!\#N<65:@NX
M145<:8@2,.0S>7E,S9TMCISY&U^ " (59R:* [!2Z@ZTVK#IQ;1P\T+4+UTB
M.@728%>G:NT9Q81KG]@,1VM4N$\/" ++G4H=]%95'^7*K_D"G1\'E(-NL\\[
M]*%39KS*,Y?\N8<V%3Q9ZAD2ATT%+"5 6D1<>5O.(N>$R(_3NLM:EG /[0E
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M7XH]2\R[Z,N 0VX7I)K+L2<29^VJL<+RM6QH8MC-PMI"-L5IR]>"F$K[#I[
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MD V69[(^M]:;]=J4W>DXN 7LYJ\(X.HTUVOB.>=XX3LC7&UBX[?E:8#Y5;:
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M$+C. [X%0)3YVVFK,\YD>'60F;> A\6YMP 9XYOSO =WKJE#^2[*@%==7U-
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M;?E7B;G/?VV B/EO&A]#*ZF*Y#">AL(PV(,C#^K:G_NB"[%1E*\L]4EJH@_
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MH'$)XK[&/))F1W 7_R13[#I_W%.GDK<W,:3?!DBA!HAY[(;=I(3R=U4[,=5
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MRSX2"E^K&S)S%[V,JMU?4VQI*((")+TU#$=\AQGX>)W3=V 8,S/>)?J$?#2
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M;ZGJ6H@;!H-6MBT1\2%>Q3A!][49<88FW#X0\2!36.0Y899^4?H[444VL3M
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MDL'Q2\>&_Z)+1O3VX^4KK7_V+B)J>-ZH>'Q$D_]+KE@UJWC-!_VZ*TY PQI
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MS?>?\TH.5C7,=;"PQ=D<M#B6[^C> G2"8/V*@W<U4=V4I*7W.7!8@97*<8&
M\R-TM*63<MUCJ,9V4T$)UG"&/U9!FBVWR4V\)Z'XM_1-YC8K8PSC>B0U>#47
MMF^CZD5-\8++#:4[M/0!FE$8NZ9[&&Y?T6)<[C'5=Z79=D4,GVS]%20>^MH
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MD>,'FY'@K+D4R_GVU/O^5.C3G$[2M6EY"M+.["K5Z,OX4SG/_I?$0Z=>YBO
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MD\8/>$^'6#%B2LA9PN)JC7W#]C3S.NE$GJ[_8G_D&UYAB'1?:8[#18J_&JO
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M-XQ'";& ALNF:$S/"5\:0I#PB\4J%2CW#9]AYB33W@!]ALKIR:HD9Q]4VF%
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MR=2S=L_;.E"R?PN?*L""N@W$=Z2PI;#U%BW?UB3'(P=1Z/;H0+WUTX38>F)
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M6 @-V3^]\=*,Q"JGRC0/Z<**.5.QH]2J0Q5==26U*(#U5913J.IK5YTL%GL
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M;)#I)O9[3G(6.RR'%P,HT)G\SU$O_=<;I22",<>F6GSTVH).571F2#Y*"N7
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M^B\BWIOK1Q5R@,\D%<6-_LH:K_\/^R!8/>TC>U[1Z\QT;V+8XY S3UD1=YW
MU4?ETQ^5O^MZI'\ 7!:6T8P$[=*8.0?9F@?M[(N6(B\<K\KFD$0/@,]M?W7^
M\WC;4D"P/P#P(3=>D<B[!\"!U@- 7\#L%B-IL>M.'^T! -3L.7Z<HJ#_3%$&
MG/9Q)B%P;233 R##6P'Q_'_'#82^!)Y?4AG>4IC R\81M'^U^K<J!?\:E/K-
M]:.4['N3$3-$U]#QN_OBT$<F!>O7?L@:Q[&@V2;@?_C^^]_[JUK&OU3+1999
MM5W@\39 [O31_ZK5ZRB8VE)<_<A7:AUXLX9W?ZD<B >/I]VG?YSHO0= <4/1
M R#Y7UHYFSUJI2< DJ9R@F?LU1\Y_PS,:@3"=6B8QA!^?Q5,@68CV$[1TTLM
M)2NZ&<&6GEV;&T)+H?T"BN]M5,?CC(?R?XR8"72,1DT6E$U);;%0DL9.S8)+
MJ&4 @SJWOIIFLR\@C66!DLNY^0$%!E?D)49=C8MXZYX#I49SF&A!T)[WB\+,
M?=?>I9F??Z@95*?W";T^%2Z4*@:I8<RE]$XO<D ]\J[$F*[%[,8=>=]]#B(,
M+S>;RC;@HHOV?A:L'VLSG]JMEUU&T6)[O.; -1P9Q:,P6]WM_B47-_6ET$W@
M5$'1\]<>1<N:F-_89T\%CZ>D7?N$!'A0+DH9LRH)])LX5D][.,K%A!CI.P2+
M\LF+&K[UJM[77Q:D$T?[O2_EWTD)#Z$6GW!^+?>,(QL 3E>4,3CA=WL;+"WO
MJQO1_^%B1$58K=_WS4LXU7HV+?O !G& S+/NYRZZ@:=:+AH_^YK>WJRL WO;
MOB!IX->Y<)$N(%Y0G:2$E^.'>-WOX@RMP)TRSS(I/*%%6>M3+P. 4J&W6U<%
MC61]:4Y],M[U=<+8FFD>)I:\]R_^XA"UWL6#RNTX?_(9Z#C>YT Z.Z\'P*'A
MC6?Q!;H.1?6[.TDX0^<[P5E2\;0N),A6I$I-?54-J'S1'\(Y(N%H1Z=E)?QC
MC9M4/@H7J%A1N;%U)U5$CU D'C?85@EH"N:<>[+^:R&C,Y%<,C587?Y DSES
M@]4MXW2KE2%"$\&]!R[,%>4K"^#TZN/S21%CA*O9I4QDN+*-F=IE9;2_TX7I
MB_L93,0?(Z'YCIDHAK51S]%M?[6O5\4WV-#71@[5)_"EG7&<E%Q)FPP"RY_6
MD.:ZM8R&5]1HRM$G_ '.0$I]VKK_T)K"G^Q=XW<0S7KAG%8Z+R2JYN2)[:JA
M^TJM+-*".D]I(]Q7B.=S\_(!#2',AJ^]%O/I9KB#3TJ--O2:RFU>#."6ML3G
MQ/8PYIU66>%V=+F34>GAA2/IX%>C*G[5!?,KJ0'B*C\V&J)K10E0VG&>B?XQ
M/5G!;N8?'WHV-:.E4E[+_W1U*,H1453[\R2HLQ&TB.V'^N2DAM\Q/HMO  T"
M,G<!DOG[%=C<TH8+<9*G+_&BQ!EH5E 18]A(^<ZHLFYX5B0FSK*,SEPR_;_F
MWCJJK>Y;% U.6PJEN 8*Q=TI6L$=BKL5:XJ[!$K1XA0I[E(<$H)#<2E.H00G
M% @4"1+28H_O^\D][XS[SGCWCG/?>'_,D;WFFK[WVFO.-?9:T?]<#%IT"2Z%
M;36K(&H"(IN.]^51%+D1\==)>:L#8CW9-^N#DHB9S_;'W7T&M-],<FAMGE[Y
M1 [8LR>R7T*PMBC7($K1M9#VR_Z9 C>KQTMJ3ZL;^O/%Q)HH^^@#;-J[:?T0
M_7F4QT=1#]N<8,^Z:D3<)?V67[1G2 [^NH%6@8Y->PWJ5WK; B&^+UT43[8X
M)MR*Z3U-_\ ^>(U[BWSO")_0D%4(M,[!M1(@^2G/*%A^%8!Z&IIN;M.G%6AO
M^DG',;X]Z%7<R=!/">1\HVN(H%]WOP\EZM63V:U+<TC1Z2^//O*&UFVYSZU,
MO@04!P)77,?C[3SA&H!P;I##,)OZT>0"6V7?L6%OLE.JT76"+5$C3]2W#)X2
M^@J]'R2E #?A((^%#90#^K6VD;,:1[)5 OS><^+P\NR6JL!08>. J/XURGVU
M B'G9\$EX7H)4IG%S>EL<$759U*/ 3<7+^&=?, P"Y*$@_)+W(@+82[(&M<[
MZJ>*$N,:=S.)96^#4[[M)?VLT@[OX.^GWR(R#J]^[,IPX$Q:8XXV*5&B$Y]!
MH/*]Q??&H(&:CBI(X= :SZO\8UJ?0M2.:>,,B$G0:+S:7-UFU&B\F8=ODY%A
MZ72IKM.7$HP31 ,2SV7,Y\_43_/D_U._XH,:,'8-9Z0,9KF4@*OV@3,=A&ZN
MQ-6/ALJA +?C*P<4;W\6SPER'JZ0.UJ1=@0J_;WD0_BPA? :YE 36"FI+]LB
MVCMV[-)[:F8LG>Z!Y0PPFK=,[I&D&Y3<09H/]_3LX,0Z$A"?Y2*55N[\>A<"
MZ8\@(! I!Y#-9_^>V=F7GU ;6".&U-$JUP6+;O'"QL!-9B+6LY?5PN^YMK/7
MS8&J<T\ZFT+[I,5ZYZ7)H-J! 0O/-0E^BE2SA,]U49I@8K_U53E3-<EEW@)$
MH7T*F3_N)H2W]*0F?RS#1(+IM*&=33#'TN;F2]:7[O"&/X'7+L7C-'^FK7,L
M\H^;7M:C).9G#U*6JS+BV7/S)#+/N>[UU,Z=EUSM3LYGR?,Y&5:6[22<=0*8
MIK#1)?MKL698+_(@ "_D:BHF@BT$XK O3\P$K+'SJ^J;[^*=>@?)'OS,^\[0
M+O*>.BCQ(NH)U/.\6,X$UW\SB'(J555#8KQ"C5Z=<1&^?A0:%E=X,&#2B+&V
M+H</E+\Z] (_1>3-O&SY9EHEQ7ASOGSC16M LS-_"\#K$,9/\[1B;G>7BI&=
MNB":Y;1LHYAD(3</(C\>6,UPL-U:>=7\ZUN3DA3/A.D1P=NKGM.L,\;-3T33
M5IQ.;5ZT^B64Z17,L CL)\2A]]N?7SE)3 98\>\H\"D5EMU%_[[L?C#W)Y3<
M/T[ ,(E+/:O5ZU_>4[M9+V<83=@V+,7/H-Y,HEUITJ[@ Z7OB<=JVGIS(<J>
M'V3EBSB@2@B8G?X:^5W4&?(W$\9>%\2"$B1,RQX^#3_!]UM=US48ES1F?K'
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MMP >Y5M &!!5M&&-73 AETMG*-/]S+T!0GV]P-A^QVHR,<47E!-L=@N(IWH
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MXDG-;N=;!WUS,R3DMR_7Z3R,V4T>NU6#-OBX&">%( #)LR1Q4541'5-%C1N
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ME[K?#-9'<GYGAUW..1)07?+X)4.513ME@STMNMJA]@ZS':H%*_ MS].M0]T
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MO9I5V([GFSY5?!5^6@NA3];W=M'/6RFV3O-FNIS]^#-MB-?6=K)#T,.N.9&
MP)%]WSR^RN.A^S-RL$UKUF(8OB3A4+-+?9.-_%GMER@>_608 3L%!W7[GQI#
MF)Q E5!\DV)@'G>LDIT8.PX!4K.LLOPU+9Z_X9!K3!NLSUQ.-9A*-=&P:XYO
M_COO5L88;EZ4A.@>=#,? NM;L=UDS-ZXE&&C61ZH&&*=-1UE\=,&=MUC*06X
MAZ-+%B#C_#HSYZY$2B3Q5AUJ'&^M6U9PJV\!7K^S%0GJR%?TT)]16E$B,AX+
MAL>=G=T?15H+XZN+6M=P/W+V)ETJ_8S=^W4+L$]\F$BT^L/"^5G:3:6_1"OH
MG3]XIC@Y!*DKL=E*$B/79/;'MV]_GX$8H8/B:ZVT>'$1$'&VCXY4>%<8 [#2
MQOEY77:E4["X[W,W[B)!U= #&>L6Y:*V-?JD83=94'$R,E;K(Y#A?/<)2C.M
MS$&MI;X>VI'PA^IZ74A@=#U1%0GI7G1X_@R_!E2Y!V^NK'"N'TQ96QDEFL(#
M<KR0Z!'%2_SUN<C4Q!FUXI=H,K<SMY%P[YTKJX%;Q7/JJP9YZE7^ZT)IO76U
M7+Q\]5FHQF._FI3-#5>5MM4](57<GOV5" ]XQI!6M,&?\D0^/A "1*:11[AA
MZE+'ITS1Y@G983H]JU/X?I=/3)+LM96.KZ'13:ZN;O6?>8H^^6NB0BF&#_WH
MO:I"F*\SSN+!.G.'MX#F<U,_*$7,N[<(NY/,H0NC.._-]PFFNM=ETJJISE0F
M[!&(N2"I0IZ7^AUY1V]+ZG%_N\"VAV33E"RN*X-T14'69R1$2VN.;>80*AB5
ML/E;[YA;P.+2"'K<!S[YJVICQ<'8!?K]_".=6C)P"7+I_[XOL E 0X"Q@3Z]
MSI66O@4<IY;X4AD<[Z=/PU5H0?T<N6*W@/-=BO$#-81X9(?P!HC=?.$<=P8D
M2OB]6(@%QNH Y!#E#P\1P*AMTK0S,LS;SF5-2X_HLWC#Y=95N6W5CRT^.VQ<
MRRFW0!.UFQOC;:-7!H%AJW7&?KZJL[CYUK,'->*)^</1;$>U'*2;(0P8) )(
M@<G:#I;J59$+9VX/9.\R36(WM*BI3VS'S F$3/_):7N8=@M O^8ZW8]2Y6)%
M6-F(AR=T?>^VOQ3:36?D!]D\=#5*U H,]X'3+H,@0GG5[I,;QE%HC2FYC2<:
M&M[73J#B[IOI1/7'..]2=MAQ9D(ELQ/AAH,Q#IO7%G)$BV)1A6:B7]3?W0("
MA<,'J1QP4-5KE#?SC-S'^I')E)4;UT)+AEW1J_X:/M\^DEBGQ>7NS +C V!7
MPH?QMP#"[N@STF!_M+G'KU4-]K%6^N3>2W<51/[B@B(*AA8IUNV<<84,RTYD
MI <^& %>6#+% M:ADW#/_H59IWL;<@]-]_C]2W)5%3KR1P4/+OO2)'==Q"81
M0XE!YJ@'/9S%<%-3)"VT2</=\=0JA8XD%09S/I_$Z#R3_'YP3A;LXQ"E!N)W
MQ142^&H[M%K]T7*Q3K7^%O!!I_H\5W/4E<35R"[B$XU^MKLANH#$.M1^4,D$
M"M%W\>;J<9 M^?X%H'Y?0.:O(W1ZSHJQTV,!&L4BD/^T._D_ .GD3?79E4LL
M)M5WLU/NI6G=O>M(E]VG)$^;B]G3Z!M\M3%2&CXG1'4U'L!''3@.*!*51-7N
MUO;W/:.-ZNF>U'$]8!RA)'=Y1OXO(5--F+4>1I'9MXB,/@N>F5^,*@PE#^\S
M*HUPK.?)< _=//+;O@7(Y_>+!_!55D?;'%^:FYFZI.2>K-A>V\DGO Y8F&N;
M['&];Q8D-]?!7HJLWYTW;*"&J[VFN_"Q"4C--]F4)KD46ANJ,EOS&^LO[^<3
M&9P!44KH"E*T4G^%%[.Z:Z[[[_0:>[L28"XW!H[0VZ65X%Y;!YZV'/'4=W$M
M>&$Z2S.=5.BTCJ[Y(+7U?(*!RA5DUKL&K]Z#7ULG6][ZP]H_-E-[@$T^Y>MK
MI'!G."QF:[Y&1)DU7 $B4'')U1R")J>4D#E5;\-8;D[&KA+->C_4,\U00T5^
M#N:!AQ3-[WY02@'XH1'4Z!*"Q'&$ZV,3#&?'HZQSU%UB_"$)J8@9N4E%@]9\
MP;7XPBK5F,E^,$F0.$*.P.G/^57Z/#R',GW!4ZW-L2@IJ$>6>U'K%XP^G_@6
MT)AM_KE#"WUT\+R&0EMCXM=6K2!LB3P=W CQ#;F_P.-]X /2Z@^HWO=FJZWX
MHJL/9-8'  AF0B6.(O.$6S#\"$OR75]?^$1G@0G\I3]#ZRU I44II## SFY^
MIX<?'K*S21)]KD%GW#CW-/DH3XJ3>1:M0/ZR:'2IQ?F@BSB(M ,#KMX+..RN
M%8\.>AY016;^B;"*]DQ?'Q"2MHIAN9M.UVTKFQ.=T3LZK2Y5N3--ATGGTGER
M]WUQ2C\D_1@D>.<<8#-(X!S\/T]*_A=!<!/(O'/\1>^$&LM$5[%A\-MA;*A=
M$SW6Z_&*EN'XS9 K,;_SVLP1LZ_]6^>(9G;$?"W&54OL&;;=H]F1SI9]O;U5
MZO9V@&+%<SDQC;=#;YY&<A0X;AGA#Q$N?J70S8+&Q-'Z<G]AZ'!(1FKJ)"^<
M52GVFB60!SN%?&62&*[8-@!R,^G3T)]5<2R2%_5J*[%DN3<G$:5(E(Z[_;1U
MX^SP3."R;.A:G8M<#A4:%>[9J:%Z^9.C,4V"-81\77)_W"20\IW?9+FJ54-2
MWIKFN=GFEBVIYVK96:FI"H$D,$+"=&3OH<94J]&WV4^^Y<&?)TN%K'B3(#,E
M*K.>S?A@6KZHX3Y?J'@J/#>"AUPU(E%B>/*G;@FQE(/L)W,";A9<U("$0U;2
M*U-IG%@*232Z:%?2:&:-7U7;0UB%)UE^./$)2STKMP#N-9YAE.'LMEGI01-@
M2>BI92?RO/I05[V=9H1\/VWM 5"UYKK4GMK'I0*[$#[TC1[X\DA/S?_=!Q8-
MVL^RZPXXOK/SJ?:ERQOGIG(-F ]=Q(NOQ1&F8I9>MB(KSJL,BFK^UFW-RS5-
M;#HC9U7S67:HQ&PG.9-=3PWN3 ^I=)#18\DM?60BX6IDU9#C;@ 'A7T1F[1M
MOO.@@5AL P?]#CQ77=OOC]Z^L'R=-*8.]<B/T''(1W8M(+U[+RXWT)OZST*A
M \7V&G47S5J0$NWC18N7CB*76^VIXP0[./4]TE,$]T"79H["?GDRK+NT_6ZB
M%^C /462,[N,>MXC8^!C.1>M7\&Z&N)])C(#"\G!##E9-=]P%]-Y(^5[SBF\
MN]_$VV'>(M?@\V_TZFIK35ULK?9RA;,&402_FA!2*YKH,4V48CY!Q,[<@AYE
MTXM5O^"ESVIX2,SL%'$6&&[3]SS*/%4;UMJ=/H_B.?CUZR ZQ<GX.;SC=!Y*
MA8Z'9O0(^:6L]6:=STU-6+7,4BY=/WDL53^)W6INB+9&D2\\RRLN=YGW:6N8
M0\R=_695M(O_A-7\/$&)\=S!!$.%$C:?_K5Z.D3I2]N[\KF6R8_:2-K.UC4C
M,9MQ,QXP,=_M@GCFIXOH6Z6>X^<]=TE_[\X*[HBN[&/"P52]FT47SAY(2WD'
MNML&5^[Q5LKFNY0NFB2[LP"(Q;;.SJL? !==!IZ)1WI)F3X,5#,W5/O.VJU2
M$M919BC)#7-E"'B-[FZ\!<2<?12L0(8P-\!0&EU5;(6NT@W"IFEN0G&"><7U
MQ?+/Z+KA8WWSJQ30[XK)7]1\11<;,]24P3/6V4"ONHV7(?//<"UPP8^ZXK\\
M';4$.S!P]-TDL=T@:1 U]D[=36Q-6#/0!RO.,_MFM"W?13D-A)*5%4.,%NB]
MCV); R_E,#%>8)HE8XO=U+':O?A@>I.TNNS[+  !Q=E(1 6Y(T&Y'_LF#R/O
M<>&"PZRKEU%O4V?GR=LD@*3$69WT5+<+"8E+ULDB [M!8T-NGI2,P>;#Y@O-
MUM%B7Z2I'($LD3,C !-<@0$;?:>\,46P_0Q-QKW?1V=#0&W98TA0'#+6Q7D*
M6>$V08FFK45X^;/F:S6_QVXZ>KNN_(.>",V61!="=5WC94GA@FXS>T9999>A
MJX9+&S$G 7/2DS3[\]TR"@R91-=,-Z$H,A8/V;*VGGN_B["RC\[_E!*PKNN4
MWV105^YX0P]-U6_R%QE7-%UDT(_*!!8E9E34R6"JCIUW7ASS9D1&+%E@$DX-
M_0_R9JBX&H;7!'CCB$EJ ,$RQT>#Z%L Z94@J-9T2</%U6W\9TD?D3RKPZZ[
MN67RD,Z!40CQ5&J?+.VLR'"H/C2,!;E,##;950 H6B-/W35<@GOL$@/R8@$Q
M-ER+#P?4%,@!.O\O8,%\+.'3)+N,AIH"X#G:,V=+!PU&MU;N%A#*3KA?U <K
M8"]MCS$,S9<7A3*)]>01XW' < HK*PKN;__8>K266?GDXRA!SMRG_[P0'+H=
M2AG+48#]OP%$0/+=6\!2V\.?231"@Z\?#OC_F0=&>+ETBIM%,+(GT 4_D_)G
M94U+D:=*/J,/H0@<\FTT]G/>>ZTVPKJ.U[#Y0NOE+V[QK[X7:_#ZQ65S->^;
M]XWJ3\W\M9($?^O6,P3? O)X=B@W3-8+[[47RE2-:/7543FE:[C:A]3M:&;H
M=GB QFX!CR1W"-A+ [8+W4#5/S.YE74>X#Y/"4G[26E2GE -<H@T]3<X-+XZ
M2WE-_"6"^M.@HF1/&>[\#2T*FE#N[V5/I3/2;><J]V4=:P) OBC]8+.8%7;O
MRVB&9H*MK(^^W3#<?;;LD),_R!)1Y<\4+X+Y+(\[.D6OK!H.HT'0#,@N](<(
M-']2\<72X5)B:?O:PNUY6?_YVE.>HN:*!&&D42Q6+C+ U]_(VE1A8!9W=G!@
M3N=H\911QEQ>ZR>2^?ZGQW:,!%(AK;7.0!K,WI_M#3U-,52D0WPI["L7_HOK
MPY+8U7E7UUI1.B=7_'**[D5;/X,>T#5:\[@/"<,.Y5CQT^H_,6NO4A^=:5?Y
M6"#][7J0_JH@P+<,V46$>N87R9W[ EE[4)S%B25LA8I?)I9QKN[B1W6N0MU=
M7.VLFI:7V%*6B,("@=DY?V;KI&T1ST%=4H(/9P44(PY.&MCDYM^MK,V2 RX3
MB?U@>JT+&IT# SD>8TP1<.O3,L-W4R%'(2YZ?:ND*(K<R#ITC:(Q/]L')>=)
M#E QXW*(J,VD#HJMN&3/PQ(?VL_%K.98?]DZQCGYI#67O3^/8Q9$Y+9DIL;H
MD:(%_+R=?YB@.+WG7V"?NCY)M>5OR$^JC4WFWCXF-Y#G/XG42OV:Q],=MKIY
MHN:?(JW(E//P&[Z09N"<;P@?*N4K0[_80]Z)1:+D3)\AK)Z>/=^;3S6;=13(
M29"GY\]A!P6MIU:]]M%84;(E;T+MX 0?I*TI:\J6+?=T_1\5&,8_Q=.2(=S3
MZE2HNI)#43:!)5I:A$Q$A[(NRS9ZF"H>Y&?0SR]\K!7M5-*8L9OF8^!+!Z^]
M-6/F_JY\QDK[\VV')<+05%GVJ^<#]8,=FLV1.,9L4VD$L 9;'-H-<#;LXFJ=
M SWU([5=>;=I TCB(Z>85)_WAH4%62R4'GD;;\67/.2J_JK?@J#>\H07?!P(
M$6Y4P3;N^ 8X^99^"]C/+AQ9&7PV!X_Z> 6R=4[*E1CS^,:ZW+S&J7=%L+T^
MA?^6D0S58=+AKB7:]Y7%U4 MKEJIE5VNL+:J[X]#=-DL%)*.UA(A<[7G*7:R
MIT\?6I"^YN*NA'J6.D5>[=W#61Y#YS?EKT9\A<M^'K!W[N)#>><5XN6EE2^/
M.]5SI)P [':*R=ISM/'S8M8UE)V3U_;85&BE_&T2.-E7#7T$A$A"_&M]53"!
MF]Q2]WXM*3>?/&WGNY<6U/]RP>G\8M\49L&)"BZM2FSB-GM5;D6Y].%@R"+$
M+$2T<(/7=< $.@!#AT9*@3FS%!,>B].O8TV28TVJ'"^8"/4],7TQX@I,L7;R
MR]G:5-PY(@EQ7JU:KW$Q3EA]&MUO'<-T^7+DE%GWGO<?!#">RV55I+'>J?CC
MY,FBK='.1T]9-?NFO!\,7W+:CN+Y:XH_W3LHMV,=K+=^';:4YRE/F$]T_M5O
M-O,)U]A/PJNO)\#?>Y*#8)/S?1P.F [76RO ?@[*XL6-,"H'9?*;4K>XC_+-
M"LECE1_>R%G153\2@^_>,@(,UB]6#MD%"_67EECF0Y_U(S7+RN]SL&KC5)01
M=^6;^#ABTT4F&PH.=7:U?-F760>B]B<O-VO)CL8Y)"6'"^Z#'3MN ?F65]$<
MEPIK5W_ 6\\-[][/LL'_N%:"\]T"=F9O 4_N=RH =/Y%HLKW%WKA%@"D\(D%
ME*(_=O\^OP4,#3#^Q78+0&S63LN3=TW[W@)DNS&8X@,J\.G^+2 QMET!X* B
M,\+B7?>3J0*N,B%N3"#;/F=[6O,"Z^ Y4!4P3K;, =SM%B_;B'O=_;=A6E?1
M7(=8I07WY?[5O+-SY]]V_B?L+> ?:(M_V9%Z()[_#]7_,'_GGU[QR_U'I_X_
MP"[\$ZM[>OC/R)'G_]O!<W(LI0.J_%/D+2 9#_C?CE;[9_R3\?YO]R=^8.T?
M$9-O^<<C$*0/Y\!._E=#-[CH]"88?,)4-:>-!X18@"?+;UZ1_XV4^Y\A_T4I
M>W1WC4+I/N<Y>?PT?(RQ/:SJM38V\:?_8NWAOP+ZA?AW6XU3?$\C-TW] ;\M
M6-<F)*BK^;'V?;,BSA[X1F4%XN6]'8)^#WL0OI8\.=/<X;EIB5'T>O!Q^&#\
M6P\H7E\<X)YD%.!N+'L/]6 /-C^CG@2!907YLBEGX#X"V+/,2A80EUMDN00S
MGA]\/9VGY S+"TG;"K#LMWS\JOG$W%2#QV">+Y6J^:V&[!GA,K$$>RS:="GZ
M %26]?*# A_X_DFN\&8IIBEGV>F]6GJ^ET#]21.6[N*.Y* @9@JW$J5E:FKD
M:C>-7OKP@(MPB\^LP2PL(>?-%S54E&&BRJ5Z5I"V>O6Z$E>]$SH)N[Q0\@AI
M>"@K0&=<% :1S'/#&:X8J^>DBY386C_[ C[.-=G+F%*K<$R.45RT.EWF>E4N
MO4,/(\<2K>M?(S-_<7_7,4ZMB] #.U1S-L$3GN^*DNM_O)>\V!Q=[(BM$F(%
ME+[JQ!SI#*%J^ [YGD"FO]60-;TS!)#KI'@F=-#^F._0YYPK(+58<M+^^+K-
MH#4:EF64I&W+(#B[&LKMYSOXY_RF'0]ZD-4'@ D)*&?Z5RNN?U%>3TC+9A\(
M]@=MI4&8*OCN$Q'PD--;5>R("EW9F^:J[DTLJ F/TZ7%]T40%=#GY3!R&<OR
M?S'*SH2X"@>]9XUNBQ&_X!'LN2AX^_&&;)*TI/&+26G_>P6L.,U'?"0PD\BC
MS4&8JTQG'5HRQ>;%Z!AYMMM84@\"ZO4(,X_0G_9VVFRB#31]\MM5BNA(<IB%
M<<6%1!U3R M-@6X)KJI&><7A?^,OVI&*Q^9>"M)'49M&@&CL3UCD))<?".S^
M.+L%W&^M]EO3RYOLRPJ%FJEE9-WC7:M Q,6%*^P,E,!BZ5)+/S]^SJQLP]2%
M+P!,S.B47=C\5N=&>ZI,*C]@DR#3TS8<X)#P">L%8G.UCF)\V:>-1G (.I=I
M9T%B(9CB/)X_8.YSO'PTG3[/%WM8JQ[D-E&<0[N*&HIQ/0ODY0+QP>D^O\F\
M5\B=SB5I15*G8S80->CID?3$2$GD0A.9 _I!P.+&\F,*'XY9,VP\ODD3:=[G
MN<#*,O1;QE92T"; 1;/5.#)R?H>.5;6;MK^TIF]HZN-Q7DK%R4G]*OJ1:F 0
M-CNCUBEB]O9WCF+?Y0\L+/J9Y2L'VN"LZV(U3B\CTD=N8)\ <<VN.2PBDXL8
MD1I17?&\&Q6+EZRI_;Y/.'ON4\5E%3J@"$QF3#:-:5W0CC#%,GQ"DD+J8=&I
M9;_!&Q"_AIQCN!:5X>/!"V%FKK#G++&3<UT"+PM7^ZQXBN?*O #+IJ$51V=,
M.2$B6)8*F*IJ#9GEA3:O$3K3F"?1O8C'=@\+$%U@U97I$&;G@,C\:@W9=.N\
M67R)T:X9$L\;3^WE*UU*= TK7#4J3$V--/DEHSR=Q$Z-Q?%0(CN*85D ;!^<
M9A>SE1P7&C&$$^<I3U]M20'=#\QONHY>A30U^E>Z/OG"AR^8/$P_O_:AB]4Y
MH+F;.-O31EUQN6F%T$Y=@D::=')#QVGM\3OF\/%\U<M7'*\4E8<-^-2L0"SE
M% 9KFP.K!399J[W4+%YO69);! C"A[!#*=<V(]LK]@TI*>'*V@D_WSV-E8]X
M[2%X-WI:2_Q.3;Y#SQ^^ 8$B("ET!C$P.Z^1H9#>3%EN,GI9_0^*.TP3[4.C
M4N@]Y\-\Q.+YY$-G&!K]H&P2'UNF#YN:;(\ /U0H>Q,< [*.WYEY5)+PB!J1
MNK4LW!+G@%T\'\*^CW0BA<W"VI0+/L2<NA%[PEC"SK],H@AT,YVTKTMMA521
M/'DJ= U39-?.I1?]&C84\XPTR27-8#Y" YX_7E>[V'-KY%<:M J^UVD17_&?
M*MI+GT\()R/-96M0#W0;3=DCAX7&[H_J(-PFAC#R0P3[^T9J"!D;.8(5#0_4
MHKF2/SVCW?%Z4>J(?;GX0(Q71"Q\D_K<*6Z;M?5C:%^35;@\K2>FKC\C  ]E
M]'C^8E3%VDN1^26P[?DA=WX#)F8S7F@//J\A<WA1L28R_4E?<H>:/E77>8VF
MO$GYP+8Q;E6Y6"CJ(6V## D]D7Y58KR;/*@8Q#'.3)ULZR8/1OMM.73BR.CV
MGKO6S"@@F.P>*3XTF7BVD+8+ILEX/7? 2Z:<Q\P"2C=PAY+\' \(TJTN$,H=
M#9QZXOS?L-;X?Q*XR(D)K:@]Y_1-@Y],S/]1:RF\Y[9+7O^K.(YD-)8#>RN9
M9SJIAYPE*7 .9$\45SU=:;_^6!)G2D<!H,3V^>T6 2P&31\_-O5G-CZW:5,L
M[#Z?0*D?NB@68#5;8_LT'?Z4];%;<?+431HKFG(!*^B'[G,@%[7#W91*9"[T
M7;]YJ;_6,^61Y[XR7"8[G1=$]0T;-C;G<\>>9/*57)'Y\6^']V%^3[+:%#)?
MQ9GT5]'A:Y-;:U7<]2O.\AS? G:G-V)X3Q*"G6N&(G_QLT;DK;R4WYABYBIM
M?RPUK8!C7R$RYN+7[]X;^V7@/9I(4Z7 B=+Y,@+R?-*M0$<!FQ22K964[5C?
M[0;:U>!&&J1NR4"T8 TZ"N18/.F4%P+1/R-8XQQ^VA]I-Z<Z$MJZDKJ'$G^=
MB>7 FBQ;DEN%1:=-W+,T":+4-N%[$F,#  ,&R+5Q3'J7"WFQ2;]*>XN$JT$4
MJ9NC*=8?=>*1:V/SI;U)$5LRBCQ4^2%92JM?GZ#<+_@!W%'H1K>O0/[PX<U@
M U=#MG(L/U=[R-%,LI<+QT_B]*0H JGF4P5RPA1SV0?1RRI$'MPGHV-)6IT"
M3NE5/\- CQ8O0BS;S^[B8;N+5O\6,D:I1< A62Z6^L:G$OKQ)X"(__DN1U$2
ML3G7N.HMH%CAZ_K!EGY+,>F7+Q7:4L1S.NKW_HHEQ_^/X7;Q_P)02P,$%
M  @ ]:R.5\79OY7)F   X*4  !@   !T;'-I+3(P,C,P-C,P>',Q83 P-2YJ
M<&><MV= 4UO7+1Q$1*E*D4Y4FG3IG:@<0$1$0.E%0*2#]$Y$I'=04$"*4H6
M2),:Z5)##X02 @C2$VD!0G(C>L[QG.=YW^_>;T-^9&?/-<<8<\RYUR),$.8
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M?8Y'&-]16W8;X\[C<DQ$>S MQCP!O=_23*?U6"='-< %4;VM(G2;Y,NKA61
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MV()B @5=&J?A^(V8+$;LP7P#E-$1SX&A#;U4,;8A6;X1(.@HB.%[ [2;F:*
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MY$8IWW[SCKS)/&(NOL+'$@6YB?B.6-"$N[+V"%;'C9I\LGK_2&4;,,$=;.8
M>XH71/A:?%ZXGN7*8"AN7CU1AU[*YRA.9*"L:.,?$$L?1$.[*E!*%JJ^DKTQ
MQP+#YR";$-="]>1OD@5_)'Y@IKO<,K-V]VXU4O2;P+W/[FT(!3-!Q'[3V"%B
MO+D[<+*G&UVH']'"%,PK/I6A&;!4>23+-^!E,#%"0@ HMIV7V#*C@:#/?&_)
MBZ8]/S%KVB)597 O0R'RM++W3+X9_-&G:?'S2V4)""J>8?NUW/9 [G%1&^FL
M[G/U;EQ,/MM[BW2+TO*!;ZNJ71'2G5L#ONN!-P+VPFOZ4TN*NX3?E+^L7:J-
MY7TP,'!.\=%HG95H[:(CA9]53&-U=?T6!%&KMEY]E+J<;@^F+=NUN+"&4/3Q
M7I&.3^D6*BW5OT'_,*R+2ZG2!$$ ?&X"MR&:"RW=I!K#1[2U;K*\H]+%L+ST
M+GQW:N+23@DMAJ_UT">R&F*M-K1;G6T0OB2W &T,&V/5RRSH8"==,\C>>_JF
MM%'/\3BM3HKE-,(S^5:!)OF!3.S"DMK$.=)F@>D2Z=(JL3A%JH=C&@%P;X>]
MZC?U_H&X,@]S;JPM><2ET<O@B]_@\IOI(5N>C[;I_EBITU4CX?&""4##W4S%
MY,K-QY6E[&7\92*'>U5'(5NXZ[&NP@6-43O8)<OP+*GON/ZN(K(/$N:JL;3#
MU7G+KD'LAI\&=2T,?,P-#ES'IW:^WWQX.!P27T5S=?4&9-/OD,)>(MM!7S;G
M8>PPRPK^%);>;0%)LW+XUC=#<]AFU)6[XN/'QF>/_994N]D2S]=Q]&L"UY?G
M^49Q("N7RS,E'6Z7WUQZ.5]]+9GET1.QE/AK#EDQ&)@INK!-T(("Z[]WI%IG
M,EDF(NJ<?X\O#DXB%OM,R3$/O;\A!LY105'>@M\W4[A5F87 #PC.%1<I/D]<
MM&9AP0O!J9H_9#@Z.P4Q\KSLOBDE\N;E;,.,F>N0^9&?6>8+,)E7%];$;R%)
MJF)DH] NKE Y0 U2G4]:\-G1Q.@X:U>8O,W;^"4R4O+5YJ95^)S]P,=WK[Y>
M$NF^?> N(R=0*#58OB'A2N5FA_'5A>,O2(T [R9/MK*-(Y/[>+^1>#2X*.AQ
M';_UC &>5HZP1/6K*DY8A4!$O$ *VA'6IVS"><F251),'PTOM<O46@C'W/]8
M!8&!O1';@69CJ3"82Q<_AFNN%2=5]<DQ@='(06;P5D73"U:O:76^+![/"YFD
MDR4"1ZB[Y04XR=!.N*Z)2J&I*:3Q8DN;UB4GU!>@I]O@=\<R;!.F4A.;46#:
MQ: L]&S>2/?6QM9N5;;V\Z<D4P!S>3<88]N4[[@@.-P SW#$]MJE^NH6?IS=
M^=Y[M>$F#YCQ.$VYP-+LX2'[J\BYE_;O+6@%OU;OKP3,X&]]U4 $V7LO);K=
MIB'SXKQ6F*2EJ+LX3'\P2+71S(X3)P">'\*,&C,L*M"[J2\JJN!,@[U7%:8<
MGG*=WMV#(.F"!YJYT=,2"C"R@X1[X>V4S#9I3UZ<JO3\8LIY@X4Q!3TU/_L.
MW?8'1K@Y<?]B>ED)@P;9<4.1])$)W^60 75V_<ZHHYN^,>KHKQUO5_TKQEVJ
M?7?9WN@J]"<H.ERS<L'A'W2#7 >FO97J@9,#L=;&N#WGZN#-7O#=F/Z$80+
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M)\@6_/LE<$_S-DK\&K]_]%$YGN, 17O(XD4 M/_0_ML)544"H.]/6:NN'1,
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M7=?(0B:K?:[!@@41US^_3Y57BG\MU3>>JK_W<?J#WRSS2U9]4D %Z=(E@'C
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MF0H*E526,71J\A[7$XC'@$/IAF(+\RFCF0Y7ZIEVO5:7:WGEET/N"[W+='[
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MU])/T 29\-),I'4Z!SH0A@%.SB1D%W.$,L]PYS' _/HZF?H3.'=[YD'_.0;
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MMUU[;"S,^,.#G4CPB.D ^309?6U82J%L)L6^_'G2W*Z8(^X,\ 6/?.FIPZE
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MY#%ID=L(J@)Y2]$Y"66<](5FI$L)9;R"*N2<<KR;#VRXY+YF 0PZ7&+4YDT
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MY]=J130B#/N(4ALY(EGG;9ZND% 4>D)"G!^^W>$H1B^^T^6[AV([\[S M8?
M*6614-E*H6W(USO?,0 .%8JS<M?O" .0J)T_L,X;@_[:*>-#3]CVW@J^EI R
M\XJ<D-]7]R$B.MS5V0("L?(Z"PU[R(7_]68*X;T,RP +-JF=+5,5B)E-RR$Q
MUCE;'V* )1OE\*J],_Q)R,)="$(HQ&_(8KG6*OZ866=XQM!4^98Z;_I59><D
MAVD8J.GUS_%4Y%K'?A>$M6;4?F\MRB%^<S;;2I_&(^0[Z'WF$MLZ][K\XH4H
M.NB9*?)*)DK]YJ#0$ ;@+^%#X6NB[P3*6,%KFFP*;:[G??[8:^=+MJ_<B'>_
M7('SI*W/9L/T>NF.PTI-/0RJ7V 7M4_)5)JC3,I?T=;-+U^1K1%4D'D::A!
M&X$!.K$DKZ"AD%\T%A@@\+)BI)*%S@F1-,;QOJ^P^H<FIY%*;^UT+)Z2<R#Q
M70HF"L/5*@Q !\8 =G94F[@0MJ=*T<I5<0^'<.6-ZY8#@2Y_R4N":;+_$!RZ
M""K  (-_(,< $3FM?L<8@++JR\KCRDVEI7XN5E@TN#I>7+OU-)\C?:XC>M00
M];@JVD&Y+WAUL3$1O/K!LS/C60>, Z<A>NP0]$>;I2V_M6F*5#[<.R,P@"S<
MPN*M3Y&V%\ Z69/N\-R&>3!L'.P2/W#_-#[O94(+4?$ 7BP7M.FBN>&E_6'%
M_<VMIZ/0#9X(LGOF]#B?NE4YX#2'$"QI:PR0HIN,QN7  %0ZX/5CC\_$K",[
M6>_=O,K&] -8+=_B]/@)(BV(@G<4QP95CS[HK<6Z5+Y&D5RH>[*.!%=N.Q_F
M_834SR=* F[4H +KG[-MJ&*/3VA:5#'_-5*&*WV,IK)8S\@&GQ?N%^":4P>Z
M%]I#L'$O*FH=<O<93L[K\61S\DC(71$!--7I$X#IJL;[G8K+F*6+C59W8QG4
M@:5D<Q\!%"?6APKW/^)(;[AV,8+/"Z)BHD,"J/7Q.61&Z[H8Z5GD4<5=V(A8
MA)-NC0=]]3O(_9S$L@ >"*HH"^V7RH:@E6)SG?<SOXX&#O+;R'5Q/MLMW!=J
M8+R4"T^1A]X)*U2"'0; "CM(:"U]&4>$&D#G9:<,<K<RTP-R(K7>&0<\&?7(
MB65T$8N^M;9;Q+Y<YB)S'0E;=*+WLGHTX>"N[V!_)#QKG[Q_[WHM[U!,7+2W
MA9FTL[%#^PV'/,5N@T?OSB.1%QC@)<4U$Z^;5=.C@X[5^E),;FI<JQ[.3K['
M&QS7N:F_1;TC7.QWX891:$0]'#-P::AH */##I>)^;RGS3>B9)<*0XXDFQRO
MN&_=]F?8VQ8ML!F_'6D6]&WU33_.IMC7YZ-,?)$!G%Y.[5!>6+&Q;:P&5#B[
MJ:GF2YQE;32K8,/W)PVQ2M*N)C0<VUW%MB:BM5 ,H Q?'0A?1=C+W'Q?-WO[
MQZV^'"\301;RVZ?=JD2^+)('#!/;9<OI3SHS.)I(%J>?%TUNB0BHV?%-C@UO
M4,NG)%W3<QRJ_2+.$1<H8.S<L6B4N&EC!^U.OX-FVYPV9;06K>?>["V9))-@
M)9W@<0FZR8X7;K^HR19L:X/2S9GJQ7>U'1=0?76M/=ZHNT . [A:<Z3_%.LQ
M&3O@BX!8D-G,&Z"[WBI7CV1@ *71F\//8^5IAJIKO KU?FA$_OA!+Z",7_&#
M^^VHK"4&N&Z\-;#(Z$^D7!\GQ>STPEU=P\ B1CUNS])E?(0>[?F.,O248K:;
M"#^:BD):U_3[]X&LQ+M..Z 76RP2\.,081!L2^390"&X>G:&1^*TLCWW]B3.
M#*%T"4<'A!8EOI24N%V>9J!<*/\18JV1(VF.WU"3OK+,9C-#+C#7[#_18C%/
MBPQ?DBG\.(L!GJM9")IVPGR#>^\)3GI3WKA%:9&GAY,.51I@E.M2=CKG]6HV
MI:AR 7OY$"<\'LQ"_S"8+7-<J80J)W%I)LEZ<IJYOCZ@BK76M^>[VV3L=FH4
MT)_8S*-96G7Q:$*W.G+SVR_N!AL]-U>YQ:&>(C,5MHUG=J^1PHO8.$2(E-V6
MB$[.7H==GYTQAE@A_>D-6S_++&35B(J6 %D9@7K>)D^'WT'?UHLSJ$Y>(>2R
MP2$2JL;%.BJ7=19N[+MA1]RH]D ZZUSKO!DB']%@GT'<.*C(\) <"\Z2Z:ET
MS.57GLR/&&!#L<SWF+O53PT#<'RZW.H[,KW@K*[PNP^HK"P/6@:"5".=4@0R
MYFJ7DKVF,T:!JB<//_I>>&T\8A)HQ4Z362^"!=4>\T7WP D#F6L"!50;/096
M;*3:,EQDL@;Q:@8)N42#G0>6N#RO H98_S728J**/@0:K*?E%_02O=X>!X](
MB9?-V<1OZ'U1L^-(ZG^7JK]<U'N21:$[K32%R$3:-+&A \_"+XY 2&RT)Q//
M@PPR:F& 9FPJRT!D/KEQI<]K "4T%X,!Y/P5T&<Q*&P0#$L=EETG*X+,:V.
M*%SI%%+M=Q-1H"DG%= !X:CL7A$&Z$Y ,]BIR/ZW&"B=\FZ0D+L;LEAPZ(R=
MI_SE(*V7'.3/-:W[1E2:V2:7__!K[<*W;+1",SC]JW/R)2T,D"63C0'\E=%"
M5XZ-JQPJ;OR5@^*O'"#X"%0,&Z"E3[&+RAZT$'G/%YS(O]+'8:5W^,M2^US=
MA@AM]F?(@[32T$A$S!\4)C# R2AD6?EOA[_#)6'YH60];7)?]G>;J=_=AC%
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M2I?O+O*U1.CZ:R0^2]D)"[ @R['#*!W-JQM.138"R@11W\'!<'9SRB+9;0Q
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MI&S@+VNX9B$\OS\A93_]F6VD@"#M)S16O+)J;?6+_;%=77E,[NCD"L>J8:_
M RFC=>&YO)UD9H3'Q'T?41.&XU9^K_P]%28MQLH6Y.0V;%M/)Q6;VO&.*=KD
MI,81[C!GDFC2TK.PEL2J6'X5%2UC"^Q+\ .$35]:.=0+PNWA;<!K; @/G32@
M4XT46+IA!*L$1.C8$5E;'9 Z /I98M;SJ<.&JEO#U@8JOO2-XBE[LVD4^EE
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M%B(Q_-E=-;)!?/  2$XDS6\5,?9&H[N6R6W+H3&J$:1;W3V:C?-AE\A"/_"
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MQS=V-1^>&=KCK@GV5GV(&I&0V'P\H6<YJ9;/EG]_2V G4<.9:1L8E\C3#?E
M\_UWC(3^QK/IK\S0R+2/_RN!KH@J8N\ESV6RS:P%+1 %[Z6Z""0%%T1./,L>
M&DV"ZAR5-O)"+P\KED\S.P7Z,=NY*>KUZ-9U2&+>]>@81/4IK>@+.OW+,65^
MF5HT\T_VK$X'X8AX8Y0BYR0>]HT,7 ^Y[L8K3N.6%):;0/5 4V SH"C$!3>!
M-WB'_UFO&(@JYUO1K$CRBYB8D(UN-GK!^FX>%3HV^U]>^QL 2JR0@?^DQUHR
M "::_&@4P-_ 1]G7G79SO&-Y+/O*@9N0^Z,]26M+9Y^JT\9:PAW'CW$3.!+U
M$3*_:I CQ2I$'0BEH( HU2/?ZT_R=ZRLC2CKE+1!W9$O/_W00.]UOZW_Q'N6
M;PY4!BE"D5>#,DV!;<B_XI*&DOKE)W\'![NU$Q:$*HG2$W+%">;5!(E]::B/
MZ3SF+-36(][*IKN67]44NK"=XOH]UY^Q*GYLK\L6V$XF@(D\6YC?Y>ZW8.=^
M&_IW=$:R\K\#B?Z*OK_+T>WG) K8OOUM?\5SB7/.7UF #+0\F&7Y*W>$$_Y5
M(&_DO@,)_SON97YM>1_>_2==_8Y !"7L/_PI]#3<OY.T 1E(^I,&'KWZ>Y-_
M D/V=RUXC/\O-B)_]OTK%/\W-6SV5Q9L([G]B@06>#SXWP7H3W4@ W3!Q'\R
M!8SYGQIVZM_MQ+]S^^S?N?UW*H'\2>UAJ7]2TQ^\;G7(_ZD?H(.\_RKWE_[&
MMR$AF2+%+.:_RY;TOQ,:I01!*P@&I&^9C.6*87IGAE3)0%0::^Y&9:+O*94.
M=YI.E+(!PTC,'GS"%=X)@9XE Y]/S))B52_3.ZU#X6A^F  9&.,$+3AV.)XA
M@.'=I5 5"HDD^%M#PA,FF??_6NQOKWB)9N^4R!Y];#SE2.3$\Z'@?"N5V*E5
M]=/O)R6;'II(Q@J6!5./$^6Z&P7QS&C$4S5SAG:MK0X"G'<E*+W Y).;8$3.
MP\)35A+K=P/G<*I4>S"DP4TY)&2\#=>(?2HH'2E/],UR=)]P;$!I3_."N'H"
M!9)[;81Z+,18U@%GOR!)2.6UO<S. C"-AQZ+N=ZH575-96E][(U(E"<FZWX/
MTYW.0@8!RK9&2"/DJAQZE@XVK57RK+A>/O@C43/3!)/14 R)0HWP73&Y4,/2
MS,$N5 G-ETJ'$WS<?](.KS<*34WA3Z*=R,#3H%'[$$/V^E8+^>FLS@7[)88&
M("2,7] <U:@;16+BRK+ VN-OZW*J4#I6CWCV5>?+%A4AV:%-Z]73"P_0CSU^
MD@%7BVAK43KL5FLLHX*?7,!>D6=1KIE HL0+QNY)F9MFBI\[@."QF[ 7=1'0
MB+G,R=AK6*D"Y+@:*"K9S9%_9*^FG-$/L<&=V#B0\*VIED;[TDS%:J803'L:
MJCBJ<P:) .%]+'@#VMJ5-4L'#;]-&I?2.\Q<IY7AIMH0BJ![LBF']HJ!EVMT
M;"AV93(\6E.D [&EPPY=_72E<"0)R5SN]#!]1N;0ZM-K<=8I*T$EG>D>S4T<
M>K)N30)^'M[(=-L59\ST0N&5<3,6:2GEL2EE91F:7:\ ''&9#92_Y)1N11J;
MT?REI B#=7V:"]X3CBQ@;KC>CY S3YKSUE-Z2S^7><X!% EQF^4:AWUM%,>>
MZ'^6008Z;*.>*3SRY,3=NW(MPS.18Y*)#1;V1&^7A;%7J.L#<6TQ<ZP,55F#
MMCB&CVIM5!P9=,1&/:W@RI]9/;DZZVYT>45&(KRETSC7#7H2.]-41!H$<Q-U
MX9\L?-^O7,<A7.[AQX_=WY18TP>??9#[M22)I$F:T3)N58Q.BWI:M*NYYYS=
MQGU8..@N>W^YY.?-^% 5]3/-!;9D8*/&^3V\U9 #0T3X>WFY^+_7']SPM)5+
MHF97>B&>P(A[!_KD3V6$)9E#W5!;>)E[+Y&*HGI1D$AT2E^K1[##%33!G!<E
ML-"Y$$.M8<J><:'0BN"P!F=1LXBKS2M,=90=W)WEM%FI-<_Y\NQF><*-T)[N
M\%)E'Y-WH!K_&+] XV9P[ [1%6/ED;R2,G$U6EO?N6Q(HC$"2S0Y_M!@OZ7D
M&F*3"?#CMM2G^[]:5WB!;6]]9D.IN>"!'U2&4H'9#_?>T;V/D0$HBPID.J\G
ML^Q/DL+[HQRD+_J*9@?>4N7=>'MK_((PKKCU>0Q Q."UL8BSF,RV+6:H5!W>
M\*,'G.-^R<C,DFGM(-/90O!BG<:)Q\[XVL4:B"!1TZ4>CT8S%JG9>;&OD%3*
M//7,W*0,!(EO8CYAVI*.M90,^C0<,*R9,T+J1DNXJ0X\"88!&>AK^'3Y>:U+
M9=D!!>9#JDB1/H6EI%5J:^C'JGU+XWZ))/>M=C) .[W&#@W"QK)Z5QQQ71^<
M_YD7Z39D9!+K>YQ-2.PMUBD_5W,IS2N%40Q0V= 'I\++'88>>C3Q*D"#9B2=
M.. NMMU(@<(X%)770O$V"USLH.K!=/@-DNH@T: (/VF&:'>4SFQ33UH.NH59
M($[X+2PZN6^>?L5&L[3E5=*@)P[K=J3#IZ*"I[VN"P[YS*X30M(S"E354^OT
MMMZP:UM<&NL-VDS--<BY83MN>UZLHC+>.482::G?3(-Y!TJCI F\7ZS3>+A%
M@M";@FE+/Q$9$U\/H8)NPL+4I+&8:%[C??P;S&&(#P&]%+WDX+87SXOK,Q=!
M9OC=>,.QD*W_L"LY@Q665ALIC.A+DZ 55<ET!PZ\< 68J&B8..E;FOO*8ZXU
M:UQ>EV7]X&"TPGN$QX57NI>H-#_!&?3T LS0H/9^5K<,=KQ+T-+%00<_,+N[
MUJTOI*_WJ7!^,^^^WMB;\':RX>BZ)'N:X>,[?SU]S%*4@O11=:/L*5Y/6M^
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M1XL4#!"/S<6;M5&\"B;FH:%D*)I>:.&*@]E17TA@CZ\)AC8/NS9"\ ^\A,E
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MSFO;KXURP0KC(\##D.$WER+Q:^NY21R'LYM\:9>2Z.=TLZTFE'Y;'[%$*BW
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M793B-5=WMJ>?W&9F*!X1+I-\E%GK>0_I)L^L_-5"E2=IDWLG- !!GWATC,V
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M8IL!A-90N],L.2SW?#*274ZP/C(L<Z0V?.%\J4^QNY=_L-+45*?8P?DW3^\
MGMPC%@KZE9Y<,%I,TP*%'O3CX+V(TRL8[E91&Y*#ML1.V^'1CBVJW-"WNGF=
MV\]H-/PW'#HNBM\AOB%D51'D9/*\:K9(>GLF>5?'AGO0@TE-D"_Y]D6H+34
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M/[J0R.;EXE,K45X8^?Q&ON-V9[Z!82C995 \ZECXP'N?D5J YOI<I5FXVRE
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M,M5C8"<XQV_H87_7H4Y].=1]_?T]KYHC.8NL(>DK#S[H335]%<F9P,/7R[!
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M_4?T!)R40S"/AE1KESZ-. N[_4M+#VM_TE3>;NSXV/.XL0M7]3^S'^_M0WD
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M952Z]HD&(,@]G8]":;HQ]J+^K+A &]U$!OQ'<MVO'$F#\+<@D<C=*_)41OH
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M!MF:&Q9,)-[)#(G30Z@S0THX_5"ET7R@!&NCKJR AJH4\;TOCL0.?<* "S9
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MUX*"20L>)[K?2MZW\K[BV%NJ=WF;Y\QXM#)@S^6JP7YI?P,@;6K,ORTI^LV
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MBT>5")4)#L#9W9^ N?!G2JJ.O@- X$J3>A2X!/_4/?C);(/ER;S[F%.,KZY
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M_5T[L"U.RCO!Q5K>5E$0)W5: 38:<?\/#1X1;-R^8<=!!)CP"'-#1($:726
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MX$@L76+=7'LD1*.!4DC39Q/I]M%8\)PKVI/CT3?_HDK4!P@<Z]6E9(\F.9K
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M%_)E_6B]C@%LUWM1U-K= S'(<4ML7B\_M"Q_>G-2"MO3<^/X_D<]>Y1N<&)
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M'X)\) 7:<3+#^X<_^M/D2(2B./,W#]1^!+R8?V1K\.5Q"Y(>5>(OIR_%TA\
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M&%5S F)'AZCQMR&3K_!BJV5L)<&YLIL7G9+T3%0S36-=K72ESDW2MN5VE1C
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MY650]UYB)DK#IF/M0$5]S;-\^G0%-YNTQFZ-MO[3^BADXGLO7[46QS5C=PF
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M9'&C^_;1;$#PWK]:9NP3H.U5@<I%GTOK2L5;&=#5F)SFCIRVO>BDQ%1E[3W
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ME#X> RA9/?)N_$U4\=&!D2%R]RM ?+(A;/UB[$FSY(D"HUNIO7_DMVU87$L
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M#!7[F.X!/HW&_1WB0@[ 3W%2\\W7,)I=CF^#[]+^+ TS]*EM-1Z'H0H8%8[
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ME?!<^*+X_?P>:$/OK93#E02#A^MY_H9N'T-+^^SJ?+/_&33J'D!GBU".DN$
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MH'RVSRK776[=/>#I_M3\TIZX?XOQ5RIQL?+09\L89@L7PZA2PZ<:2#T/K'O
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M01$H93=8*YE+Z3RKS>-HQ9T=]8+XW- !(KEZQ_5[P!&!?'2@B]-/"X>D [Z
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M8HHIB0[.>*0<D"BBD,9L D*CI][\:D( 7/>BBF!$.9">X&*>Z@8..3Q1130
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M^Y[GWOO__W-FYL@S1N887WW'-[YO!OL=NP2XKJZLI@S NP( X.$^ .PLX"$
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MVBEHAD#.*L>>2QQD27*\>XD<I(HJ*%R0>B7\//1T>=L1Z%)?HZP1L*9E:#C
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MAXQ??*"DER42<4#]\4"9&7B8))3:\;IE6H8^8G)<J""?K5U@[%;@-TI%XMJ
M0EQ <&,-"]LFYRFF-A_J[Y192%ZUH@L41L7D;Q6O6E&CKF$!]K@M"HT16+Q0
M*&(@?6X\&;?'J/ AT8(GIMW^_V+EJ^.B[+IV1T&ZNT'I%J135+H$Z51IAJ%C
M: 4!:0$!">F&H;NENW/H;I@AASX\;SWO=UZ?<[X3?\P?]PS[7GNM=:UK79O?
MWON6T4L;'L!Q@TH[X[N"6^W-^F$\\KN=J\ :&A*-[<M>XZ23DLH:LQH2AJN8
M0<I[ /36VEVI*5H"$Q&Y C$VB!A7F1"C=3G?@'%F5V7OP/83LR?W[[2''S>D
M<DVD[\Y@'XTUT'Y90G_7:4PF1N^^NH2IZOWAPS(FLCR_HJY8WI&Z$@C4BO0L
M##8?45M2>N%R&2GNGNE+MI#:%:%6H#=_2;OBVZ9HAW?#@NA>MO(2E@@J6MB-
M+R&JV.E:8 BK [ZF^M%>4+[^Z&?=1;&=THB7<:$7-B)\+1(?S+6G#I> 8,>%
MU1/O\QZ2Q/W"7V?)-OSU\9@8=1,SY-K)[=K VW(>?<C];) J?7]X>'099%A9
M$F:59:GW?4HD-0"DWIL&Z[?B,>PK#V]C-T-EP#DXH5%VO0>02I C<I8ZS^O=
M@IR!->,2])8>/I%%\W-MKC.]Z)$#T0:XWW_4<*DZA%QSNUV_2850-MT#](1?
MS])B>NDBS*':'4N4>D ]B5R)2-\/5F8K.S9B+/RII^!5]/7VIR[7?"'MPFO,
MR=,3-+@(U=S>%4XJH&+>@G4J+*(XR(G_M($9Z-I.'*412V"*]4V%9ZJ)3N!%
M(+VXO<?8(=F>,CL.WYB;4"J&%R6LQJ]J:\HY23BMQ8$WWC/(I2-),#PW\M*\
M]G1K8MI.OO8/N(WS*T"?_@.\5F%_ZQ6\N![(P[)_U=.RZ];^CWJ:X&N#P+)L
MJW>[[WH=D ]XZ!UTG^/2Q,YH,Q9M72MXF0BOB8M@Y"6.SP_?=8[< [:@6W?W
M +7;T/1[P'#5\.U=R7!H28@$UQA_TF6C"URTRQ?SCKZX?'5Q26]LMI$%U#$3
MP9&!IY:YYB"NXK38U-_>0NMEA]J5&IKHD[UR616)C0 J5#57E(\5T[GS]N@J
M>3V^\UVD3+HP.=*<7TJXL!AKF4EDOKE^Z&!+NY)E?*J7YW7W@);)$\G %EML
M 1GX%Q]6V+Z>V!W5B.Q74PJ)"I2"Z%>&)L>*W9]B#EV>X#BD5-DIW);PL],2
M;%-HA]]1&X%Y.8UE&Z?7FD *[+530VA>\RLH7FTH&%3O8_<2N3>I%BU&_\*D
M<;ODG%Y_-\T+6'54 =AQZ4TI',B[[:9U=5!UUK6<'<MUL'8)F9TP14IV%N(_
M;14F,K"JF8B\)GQS#T@%IE[?RIXS!=\#)*8E+ZZR,WX<7I=S[RL3WGD7^QZ=
MT?YI,2[D\5'#L[N.4<E_ACHXP_=OD<ZW3./ZVR \W_X_G@NA,@G9O\2ZT)BU
M+'5U*A,N5?4@VLZI9^.^TTQ9YTS:U9OO1YV5<$^!40_M/]_W3T_X7I+3HZ:_
MYT%,#TAB^7" C[?:/&02LMJS]RC\=8 435W9J^P)O>@HV0SR>/AAU=H JD_I
MGJ>9:B?\DZE*OA\M4T\.G.X!OGEW'?\"A+:_ESIB&J<%1MH1LZ.^6\_]U1Q6
MOYO/05*1H>\>17]WN/<^K/QH#3M%1)MPC?;K'=>$%^KR3P).K2T5.$IHONP]
M )UQLC' -('S<*5:FKEX=F"T[HPR/_0! 9/W@-_F8]7J^J6U[*I+<? YZ-F)
M3/.D'5]MJBJINKSM2#=]8:_]VY>=84I8<FY<'M'8CAXE!X]6E5'V?M$\FSJ=
M YJL8M,<*E*S]:UJ58:G**IAU500=R@DS52L84 ^1UOB6"S\I:.!B-3SSU.G
MN"2['C8BFN$W%,2=D)1,.^RJO?F%_F<RQU45#.8,&@2LCV7ZW]\NHN\V/T;X
M=Z0\&Q53XPZVX[2SJ()+Y)O8G/]JEON8G)$^CXH9QNWELOEITWMVA_:W?G(2
M$;LM1/V7V?P3&QJ5;TF]9TG_Q%7DOQ"E*/WH?S>*ZY^C2ICBLXM#&5XM^E8D
M^/,F2(!FEC<+-2?N =_$6LXF?-F4XGTV[?[\\S^-N%\<D!<N;DL^OG'(VZEQ
MTEF:LW+L?S+8\#U:@*R=E1K;<0<>U#FR.ZX"E0B_!Z!5Q7\]N!'F@#CPM/SH
M>VHL_I*2%*C$F\OXB<&D84(XU=53]=\],<3]NQ&O:?C%:E=NGORRYS#2PBY,
MV:38H&DA.2YF]K8.=,"0D,;^K.1'&-XG&1F'=_->[UI:$&O,7_==/MUA5(W8
M9527)FY+68C!I;#[!^F/']%X.1QNV5*$OWX UE_5^53"M1PBSGFJ*# \:S>Q
MJ5+$]#Q:GW/C9]$2L.XY$9,SSBO\5!Z9*>K/A4;4B";(@[ F:Y1:[H<C7V4N
MZ@_S'9/'JU8'\"&R4MC594QC?U1PN*-2)C2A40TWB!]=D[[^DPV"_N%KLV7,
M>21<-L2+NF!QQY5$(#_/4OLJ(L'E2=.RMW!&<%;D 2[#1T&.M&\F0EB RR#^
M(V,<.Q=JQ58:BL;)K!"0RI925<JFG-3,L9A"9Z#[EK#$^@B&\IGYT>]Q\<3P
MPM3X+Y#V9,E5^E]\D_DG=:F/OOS_,\KY0=EQ_9T!/S4<]E-$Q&<K/OD6ASZK
MSB%#HO3!:6DJ_T_,%BJ^?1!^GMQ7&[? ;HGGB(*'574*%TRY,VO,'6 =,VQ-
M5>1&H_FE_%FSR*<^W"J&5R#.8;6'+M5]T_ ?9+&(C]@J85SP!X_+C1<5N4CB
ME'P%^98^&5R'Y2!B,Z($8NA]+N5X(CI,PJ:%F3NM3GVA)%LZ=5/<&3#^KG@S
MZ_/X$+BT'</HO")5ER"@:R-MQO'1Y:>,?:_A!HFP_T+6_^J+<7=4#YI-)3(;
MG''^4'0U26\G7?:L0,^FE8XAL4V=:;4ZZ7Y/>.4T,6Y"PPCDZ3#V^)8B)-CA
M/^/\@3F6]2!(5_J'_'EK4E)> ^GS#U9" 6%JL;AU)[':O]Y=U+][8*@4^.]B
M;LSC)7*;<^2[HB1;5)70".*:5A['M XT:VAHJ84B#Z4K8OHF/6TU=X14.@S-
M(%H>1-CN'7591:A2&;A1&?3!#5Q]\0VZ*S#63O^90L%/FBX3!54L@&XYZJ53
M\_X5YF^;6=:[J$0]C(;#GI9_Q7OBSR06Z+%@-N^'_D4;_/3_8]BDZ[CBV+AR
M<X00,UZM&AVO:0KXUX'F[D'JC7])<^C-#J_I0LT+F=\$RT"V.USE2 ;!O\9^
MC9E@<P0Z[<T*7$5A@Y<:842-3&,ZP;L[746:;@XR+ =70((=KLW4B:\=>)I_
M##RE<<2R,80\[Q$>PN%Y>?G 79&_Y:X#^-JJX5T%;D N3"6ST.I"B^(T<%/8
M9JN2]".F>[:E0D_AILRB+I6I(]O/X<Z%U[J(:Q.(56(FMQ_D5'][M2INJZ^B
M_B>G^D:VZ[: >UG.X1(_1>A_J")GR7]2UV3-P=-5-9.B[MO(+.OZGXUZSN?A
M-O%QKF.W!6L]+'HK2 +CPS_\K:@#:' 0W<4Z7L9P9G]^*:RK"N.L$Y6#YZ75
M?J)\[A^K.'B/>?HYW*ELS4]S\YPD]J](?YN'9E#-;9:8VNH@SB:(6[&T)E)C
M[*BX<N_K<N-"+I]:19>M829^\]D[?_)6&]P?3D8'L.,+]0DO])6YIH]RYI-<
M?-?NQ0PU"V4_,[48;+>2_;Q/H)_4[0H%)?\"#VS_.UWT?R6F_M\&U?_[H+H1
ML.W4U%COU)A@!.]Z%+VM<$;JRA+BV.YBD#AF?BV^8U"/)2/JZ7]#E#\RB*M,
MKT+_M2Z(>DP\-<U<Y-NC8)=W]ZI ]$&(7P(-;Z-OM"$(.PV86"IIE? =I?6[
MRAH*Z;L$XLFKKC$[2P+XG+W2*8.I*X26_*ZG?]5;O]M\N/."0B9X]0!C6KI^
M?*R3 >PS\/E]%",'.IEQ MIEN0QP.X1M<-\KU_>:)EQ0":Z27V3-N1K8#/-'
M.!IBMGN(-_^@X8\R"X>4(@@"W_IX'3+GD1%OM6 UDR R5ULZ6[ $@RF[$DL"
M3GVQC+<O:HS81TW&L-#%C!3T7^6I)C&A<W*I+ABK^!QF7:W?6I;6J9W\\1_2
M6;=W"(<22P)#\-B2QDBC1* H)KLOCIZ>H8K @6J5(5O\][0NC -F<J;F3TB/
MXT(P]/ZYJ[HMA"5-ZI]:MT#33?X>8"AXZVA-SCN3E96O+N*'5JSZ$J&]XHO%
MAOU"D>07IRU'/$'#1_+-%WV-J:O?XH;5DG'8"ZE9+5FV2KR0TJTED"6P:\M/
MQ 1LIE4%F&2ZOQ40,>UOI5%M\?]T@/FW">K%5?DR19(W3NF-EF03"+V@_)B#
M<P-BRPVSH-IL8&/!I/&U@S'_FJJ'5*=3QZ[V6WES95J1GH=M8LJO+VW^R%BH
M0KJ,K'OY:Q[XT3C0B#RE;:P+Q,2Z?^!<YVR9%ILPON^(C(N/?-/Z=3QFF!J8
ME_&IK.TA/-]AN7.<6R0UZ2:*+M$SUB\N28U>/B9)$;\V-\5(>['^,U.XM3BH
M/05_[(;IJM#*7KQ^UZW<6I#%S.*U6'+/;M:WI*^]2(!H99O1ESK_T\T&*,0N
MDNNXW+<NM'WY?]=YJ7_H/'0+T=5(+*OF%[#S]/0]DK83Q9:OOQP>?6P8.2-'
MQD=HHB#<5\XK4V9F<)F\%<2-I$\HD[)8U%6:PJRZ542TY:61>/E+,*Q\GDZ<
M>LNJ55\K;T;QQ9.HOR@]_KEF.;-,197Y_->PWB;''3*8H+W]'$I%0QO 5PCF
MYLRL/J'*B]@.K*7U9'9 BNEI[>(Q/"-ZU+JSA-3(F&N-[7L.O.Z_B$#+JF^9
MR*V-T_13XW@Z.[-E I#-I:^#@!17<@///&=+N"I7&.?KPRC*DA5V]UPPT-9B
MY219T=+EJ/"_2?469X0\[EFI7/);)!C'[NLV<> OFAK7S8X=/!V;TW\M>#6S
M')QDHS#["P.5"@N'/7^$3U05:]N50OEKK$W1>T4PB96>ML[$!RE7AFH $L,Y
M!(,%\W>[_?_ I?3@ZUOI^%NGNZI^1.@O#\%0YHHDS0I2==VB'212LQFFX(SX
M]"V6 >&=%/:\"<D)7=]IR3V-G6<F9?XY"$KIT3-JKKNAX=Z&<;ZU+*@<@\F&
MW@9N?._6C[]!0[33&%V,><UT*L9@=&U"6U?1\NA+N>31&RP]FJ --IWD,,(4
M8$E&@BQIX0TMK+G"F_,$:C"[2V#(N#7'=ST+RM$EH:4C=GZO0=;\*M./U4OX
M =LIA.RW";EB3^GK Y#F^YDZ:EW<)VQ-/@VD-]>=\<\^8&?%'$&_7+>_4@4B
M0_LXGC'VEN&8E00N!(Y_6E$O\"CJ[CAY^=A:1P(784TIM&)I5\RDB*AZX>V0
M-\@X-]_U/)JOLX:*2YN\"YUL?1HH_>@#H)/S/_GN>6&U[S%.\Q7W28&FZ_"=
MU/22])US2H>B"6J'$4TIW#S -].ZU+M0N3D@K?93F>$VF)X^"J'%MX0EQN\
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M4;+S,V<(R:%MZ"!=Y.7?)ISXYX3MPU;Y..0TD1A2)C>NM#N'\8!Q6HM/2V'
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M+$9S0G6#WDY$)-%W'9!7.R#'>&WW40J%V;]<^9Q=ANA?\<_=5K?V@.1$^19
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M*Z?_VFMX.?RX"7---OAL& U,?RW;#I^3]^&&/'VV<\[4R_S&;L56SL9Y3?C
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M/XGY-#^.;-<Z7Z0N%U%)MBFR&U/EU:]H4M%V-M5'D1:M]4WVA^99W0,PQ"Q
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M;E#,8<!,)E0T\U7)L2T^0,$$>3WD#%V"=_>914M0^VC_BLMDQ->:>P"HL]\
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M-"XAE!SRZ_> FA[A%4."9$^:BQ7N *BL/S?HD./0A75L;+9H'W3$-5 Z^W*
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M/_U'ZG 6_'\Y),MA+MR.S-DG"5001M<OD/A/L51_G#=[U_@(J(8\:$7^%;
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MBU'7F+1SZ^=]>VB8\8N/XY@ET\=+2JF&1.DC*::_GG3LYQM4T;EQXWG]EX^
MU/_)!$()*PJM$^O$:T]<LU6 (&"KW(,5?Y*^HN!Y8N$%8YR[8UF>SDZD!#H
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M'@ UN?=M$H2?W%Y._@T)DFZN "=$6;KOMP!CHU23NN9.2)_I%S7]QJ&W>S$
MU,'T94U!W;?KL$].)7W3BTO+2\]GQ*L9F_CH&NO'1? !'/F:^\[<.KI\;4T'
M'P\%V9JZG!>5@#\#*^BW=AQ?)']G6J*]H-RB8GYR:[U96<#HFL^/8LKTW)S"
MGHR\E)=[YM/:%K=<4E)THP)F::7IG90_6 %-^9Z\US_(41^@QY[;C@^Q^GTJ
M'4<.:J%(Q!<["Z^<DCYX\:*\]C9P-D2D)%G; 'D55^U6W'03NI)I6A)N']%F
MZ$3$LC) M&;F_K8SBY%WY0% >PZ#U?C<"(@9=[= V^E\VB>Z"H-I:GX$P[C
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MJVBPN/'^-/S]W($[V0.*Y* U;@]B=-2DF O=9:RHCN<;QN1>:B(>APSN$E]
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M7'-PJ,=F"#RLZEJ^>2K.SKSUA7GGXD33Y,L_#$2=J19,\]/JR-3-VZL@P_T
M:S5(*"O9VM";>//#_5CNJ,^,)=O8D[.SE-,'9L2)B/'@UW.'1Q(FMGF"&^2/
M6#3U=QQ>W6T$)SP>GH(Q,W5:0-G\('P'C*_4YBZT\1QG(#-8-[(>\44*+A"3
MD>\";#5!23[5].OQ5@HQR\;O.I6*EJR<\VD2!_S%5EP^QNR5$1M18C\S$#]%
M6I --)S_#I7217,BKW3:,_:G>N'BU(2G<MJ,=9.66B-BBT]^X*?( (WE48H;
M>=D#2^!R2W6M6-V8T2I#]Z:O'@H_/O4&!Q*0"+2@SMQ?1OA%<E-^ZE='30T'
M5>3?Z,[>CH-%!<3UW/C93@6M$+BE:5W]/\J8+SX^HTBJE9GD:T(S>]>LH]6'
MN1X YL$'32BN2@^0I[B,Y'[2XYJ985;-$8L(6>/78>1H^J-VM0KOS3O17?V9
M?[80S0G:&V6(QS]+@OP>#&#YO/$YR>CR4Y%S/D/^M3F]G+RLI='ND93 D]=2
MK[( ;?=G3W#:"EUW)Q0(4#V)YR<D>]@S($;00 -:BQ8Q)_C3()!@_4^8R1D'
M'CL6Q[=Z^EQGKO97J%?#QNT.?D&A U>RR5D7 [(?]4@&VJL;^#50,?6!D=+C
MMU,$4F.OWV6 YA\ F\8!5')R>=QH#W5ST%<KF6I"7LQT\7S[Y+;)U0> %",)
MT%BL!$V^:9WH8RFD-GO+X_35^;G.5[,?D(S0/$OKL;1/#30:&D-XX[SYA?I\
M"KNB"@JN7@'T0V9SQCD61Z5[</#$AW%WE#I']J/^'8;C7M_OKT9D&&;!W:(!
M"R]1R3]:@EQ"\9<'"A8%G"\].1R%QVJ%X#DV:QX3K6KDF#9>NJ"9XWNR )P!
M\B6KE0#CYST9,UC-+1^7V>,0UNV)*<*=&WY'"9WKA)T<]T),O![$+L,#]C1S
M/S F1^A5G,HVI%>3%[?$B7_LU4<E[3+NB4P&S_Q44K8Q^/D?XVH^84P/@-2_
MGS H ?@?WL:?+XW!GS-6YK\D\)#]?PVZ_6O@[5]&1OO8]D7J'SP==#BK(>.$
MR_&K+PF\DQ'_4T_A_Z'W:$C5\P% <,\T@5Q6[IQ]@Q)L1$!:>_)OCH*V[]WJ
MX^G9..73@TEV+"/VM)74_..:8+!.Q6\NHT\SKB"9YOP%*X))A?>T$X'J[SI?
M(A*%\-$JO7L; EJSIK/%C;,7]-6ZBT2":S2OV:<H-NL%E3'HODZ:N!-$6?4'
M!Q+GO?'T]T+P!0? 72S.7^N;IFX\JI6+W;+*JES<NZ+2M]Y+#/2V8<DVG.4P
M.=YH^ZB62L!G<SPIJFO,TH!X)S;4-!4K^[/N)_@PA+%B+TRD,<KX ? ^VPK"
MF/@-#[QK^-*SX+Q 4CWZ0SCV^N80KX#YI5>R>)ZA )"*+AQM_*3?X_V?7'.#
MO[$F,#%"'QX09B,]$;2>\ !P)F)_GFK5()G3$E^YUV[17I%M_'-'F -W$SB$
MN\3Z<5--R=US&C80SM I\32N9 93ML9NOJ>N=(XX'S$F-_/(Y,6JJ)>PFIH&
M9J0SUPCR1I%@M :=.3"*$RTA5\!0F^"S $4)I9GQD5(V)^JU;_D?1S Y.S\
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M'7IPP+;*6)WB=%*4DK&D\W_^]VG[&OZUX2_KA,,JYB=4[E3_GYX@W0PN.:Q
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M)NQ-[L>A,+_VJ__%V'='-;5M[T:E5T7IO2M5Z26 =!#ITIO2 X1>0A>0WHF
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M'7TI*KNF?K_]2X> 07G&BWCE>A.GE[Y?H]XEI]ROXIFE_G!_3KM'D>9 %JE
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M[@#5$3D B)MNS1@LHT7L4FXLMKEVU,NY<IAT-6KI)5^)(M?K=< PI8A(_V[
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M0&LX>C;[1[E4;!N_8OH-8-EI:'R@=S_';:SM'RW&?\5[W0" O;].I7J:LV\
M/6*ZJ0A"3IFF:::Z&4&=Y'V'Q;ZD%;FFO,?B!Q@/#9?L;P#^;4>YBIS$EI?9
MH7]?_/@?0S+UW6R[F#\1\![]=7XU3%,J 3WT(?_?#$S="6"LG"7QFJRA<)K
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M,V"@4R*"83J7I60Z2_T3B^9_8948E7O)M/<O 3E*8Y?B1XUJ2R=IQJ1A^=@
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MF!E,59S5$Y#03IAN[N"HM8-'18$@K<SRB\E#)\?U^_!YN4E51HQW\AB5:]D
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MT@SBMFRT&HFI4B"5\J NY8C1=%5WY3>3N2U:?MJ\8ZR!:F8K+>V:5<]+.Q%
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M/O)FJ>5!'Q'$$IO.:!BOE9B.L,)R\ ]78U$(T#L]O+?JT)]Z/CX6 O5C@AH
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MNY.]!IM"6^[;!*/HR/RZ)DXVN'H@7OO&4"GQKD2G".G=Q[%3X7MYMB_T/3Q
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ML7>W9ITWSDM [V8](P7T1ET4#<4]ZF5]Y9)R]^#99NS;BJ+6:%A]^_MG0.A
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M#^,/MRX@A7U2UK;L:$$H2W.!<TFV02&9Z<7KV!&Z^S_T#\M.7'566K?IJ>V
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M>0F &FUP54@ANDN#HK\<A\:[1ZY:L57QP3'B9L?'O*T_O#;:#.F(8 K>%N*
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M28K(85PK=P?>O7LW+-%CR^A?ZLTYX@*1"!69,^CC*1/J;$1DOJ@R)L!@-0_
MO1651]I7XNG;!L-5>Z?.,%C,?0E 1I4)UE$%*\0M+AY8S"JN&(E:;&R$[Q45
MFAGK>/RL;.,E;BL$%PPYE-K0JD\M5]6-[?%.+]3X]_8_RB(PPR+H2I$%D!I>
M4)YZ62P:&9[I@']JZXSO904CO5JTM@9=HUFZA>@!?"V-1$[Q\0,N@IKF],7T
M4G7MJHQ#AA>CX'0U<R.Y(Y>Q@F:0-2_=W<'IZ)MW[UA92RY)COO>:F6L"[1
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M%-ZD^[C;9ZA7[F?306(_QIM2X#-6_/.WCYAP"BJ)BF"[<PS/H-4#)3::AAT
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M4;3H,A_U(_J#F6G1NM,EP$KVAW'3FCP=Z[H=B( S.EK'3L,H=,%<A*7I7JN
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M,C R,S V,S N>'-D4$L! A0#%     @ ]:R.5QJAM8[Q(   @28" !4
M         ( !NS<  '1L<VDM,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M /6LCE>_Z5?*.;$   Y;#0 5              "  =]8  !T;'-I+3(P,C,P
M-C,P7V1E9BYX;6Q02P$"% ,4    " #UK(Y7\Y!!$T\> 0 O_!( %0
M        @ %+"@$ =&QS:2TR,#(S,#8S,%]L86(N>&UL4$L! A0#%     @
M]:R.5R1CV2!]^P  <344 !4              ( !S2@" '1L<VDM,C R,S V
M,S!?<')E+GAM;%!+ 0(4 Q0    ( /6LCE<-=7R+H@,  -0*   8
M      "  7TD P!T;'-I+3(P,C,P-C,P>&5X,C-D,2YH=&U02P$"% ,4
M" #UK(Y7>863B;4%  !A&@  &               @ %5* , =&QS:2TR,#(S
M,#8S,'AE>#(S9#(N:'1M4$L! A0#%     @ ]:R.5]H>)0ZH%@  #^,  !<
M             ( !0"X# '1L<VDM,C R,S V,S!X97@U9#$N:'1M4$L! A0#
M%     @ ]:R.5T>/H'@V"P  J6H  !X              ( !'44# '1L<VDM
M,C R,S V,S!X97AF:6QI;F=F965S+FAT;5!+ 0(4 Q0    ( /6LCE?WSIIQ
M($@* !T-;  5              "  8]0 P!T;'-I+3(P,C,P-C,P>',Q82YH
M=&U02P$"% ,4    " #UK(Y7,_WS;Z<>  !H'P  &               @ 'B
MF T =&QS:2TR,#(S,#8S,'AS,6$P,#(N:G!G4$L! A0#%     @ ]:R.5TUI
M,PA6W   +N4  !@              ( !O[<- '1L<VDM,C R,S V,S!X<S%A
M,# S+FIP9U!+ 0(4 Q0    ( /6LCE?YO&(#//(  ,'\   8
M  "  4N4#@!T;'-I+3(P,C,P-C,P>',Q83 P-"YJ<&=02P$"% ,4    " #U
MK(Y7Q=F_E<F8  #@I0  &               @ &]A@\ =&QS:2TR,#(S,#8S
M,'AS,6$P,#4N:G!G4$L! A0#%     @ ]:R.5S1/902 RP  <MX  !@
M         ( !O!\0 '1L<VDM,C R,S V,S!X<S%A,# V+FIP9U!+ 0(4 Q0
M   ( /6LCE=D0H+7<(\  $Z9   8              "  7+K$ !T;'-I+3(P
M,C,P-C,P>',Q83 P-RYJ<&=02P$"% ,4    " #UK(Y7;GQ-?!>L 0!(U $
M&               @ $8>Q$ =&QS:2TR,#(S,#8S,'AS,6$P,#@N:G!G4$L%
3!@     1 !$ E00  &4G$P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
